LINZ'S

Comprehensive Respiratory Diseases

Sindee Karpel

Anthony Linz

LINZ'S

Comprehensive Respiratory Diseases

Sindee Kalminson Karpel

Anthony Linz

World Headquarters
Jones & Bartlett Learning
5 Wall Street
Burlington, MA 01803
978-443-5000
info@jblearning.com
www.jblearning.com

Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

77653-4

Production Credits
VP, Product Management: Amanda Martin
Director of Product Management: Cathy L. Esperti
Product Specialist: Rachael Souza
Project Specialist: Daniel Stone
Senior Production Editor, Navigate: Leah Corrigan
Marketing Manager: Michael Sullivan
VP, Manufacturing and Inventory Control: Therese Connell
Composition and Project Management: S4Carlisle Publishing Services
Cover Design: Scott Moden
Rights & Media Specialist: Maria Leon Maimone
Media Development Editor: Troy Liston
Cover Image (Title Page, Chapter Opener): © TairA/Shutterstock
Printing and Binding: LSC Communications
Cover Printing: LSC Communications

Library of Congress Cataloging-in-Publication Data
Names: Karpel, Sindee K., author.
Title: Linz's comprehensive respiratory diseases / Sindee Karpel.
Other titles: Comprehensive respiratory diseases
Description: Burlington, Massachusetts : Jones & Bartlett Learning, [2020] |
Includes bibliographical references and index.
Identifiers: LCCN 2018058170 | ISBN 9781449652715 (pbk. : alk. paper)
Subjects: | MESH: Respiratory Tract Diseases--diagnosis | Respiratory Tract Diseases--therapy | Respiratory Therapy--methods | Case Reports
Classification: LCC RC731 | NLM WF 141 | DDC 616.2--dc23 LC record available at https://lccn.loc.gov/2018058170

6048

Printed in the United States of America
23 22 21 20 19 9 8 7 6 5 4 3 2 1

To my husband, Larry, for all his love and support. To my children, Brad and Jordan, for challenging me daily. In memory of my parents, Herman and Bertha Kalminson.

Brief Contents

Contents

Preface

The profession of respiratory care is continuously evolving. The respiratory therapist (RT) of today is quite different from the RT of 38 years ago, when I started out in the profession. Back then RTs did little more than deliver oxygen and turn some knobs on mechanical ventilators. We are now called upon to utilize clinical critical thinking to share in the development, assessment, and revision of patient care plans, protocol administration, patient education, and disease management. RTs are becoming more involved in home care, outpatient care, private office practice, end-of-life and palliative care, and smoking cessation programs, as well as case managers for pulmonary disease patients. With these expanded roles, RTs rely heavily on their knowledge of pulmonary diseases and with this knowledge are expected to make and defend their clinical judgments. The goal of this text is to assist respiratory therapy students in gaining the pulmonary disease knowledge base necessary to pass the National Board for Respiratory Care's (NBRC) Registered Respiratory Therapist (RRT) credentialing exams and function as competent, confident respiratory therapists.

Audience

The target audience for this book is students enrolled in respiratory care programs. Others who may find the content germane to their practice include respiratory therapists, physician assistants, nurses, nurse practitioners, and medical school students.

Organization

This book is designed to provide a comprehensive overview of the pulmonary and cardiac disorders that are covered on the NBRC board exams and most frequently require an RT's care in clinical settings. Each chapter includes the following elements:

- **Chapter objectives** and **key terms** to understand the chapter learning objectives.
- A **case study** is then presented to introduce the topic.
- The reader is then given the most up-to-date information on the **diagnosis, etiology, epidemiology, pathophysiology, diagnostic testing, treatment, and management of each disorder**.
- **Knowledge check questions** are included in every chapter.
- Illustrations, tables, and figures support concepts in each chapter.
- Student learning is enriched with a **chapter summary, key points,** and **NBRC-type questions** at the conclusion of each chapter.

Instructor Resources

Qualified instructors will receive a full suite of instructor resources, including the following:

- A comprehensive chapter-by-chapter PowerPoint deck
- A Test Bank containing questions on a chapter-by-chapter basis, as well as a Midterm and a Final
- Answers to the Knowledge Check questions and the end-of-chapter review questions
- Additional Case Studies with questions and answers

Sindee Kalminson Karpel, MPA, RRT, AE-C

How to Use this Book

Chapter Features

- Each chapter of the book begins with a list of **Chapter Objectives** to help you focus on the most important concepts in that chapter.
- Each chapter contains **Tables** that highlight important information, such as **Table 3.5** Determining Optimal PEEP.

TABLE 3-5
Determining Optimal PEEP

Method	Use	Explanation
Static compliance method	For volume control ventilation	Keep V_T setting constant, measure and record exhaled V_T and $P_{plateau}$ or C_{STAT} at different PEEP settings. The optimal PEEP setting produces the highest C_{STAT}.
Equal pressure method	For pressure control ventilation	Keep the PIP–PEEP (ΔP) constant (15–25 cm H_2O) while making changes to the PEEP. (This means changes to the PIP to keep the ΔP constant.) Record the exhaled V_T at each change. The PEEP setting that gives the largest V_T represents the optimal PEEP.
Tissue oxygen delivery	For patients with Pulmonary Artery Catheters	O_2 Delivery = Cardiac Output × Ca_{O_2}. At each change of PEEP, use the pulmonary artery catheter to measure the cardiac output while drawing an ABG. Calculate the Ca_{O_2}, and then determine the O_2 delivery. Optimal PEEP produces the highest O_2 delivery.
P_{flex} or low inflection point	For ventilator graphics	Examine the pressure–volume curve. The intersection point between the slopes of the high-compliance segment and the low-compliance segment is the low inflection point or the P_{flex} point. The optimal PEEP is 2–3 cm H_2O above the P_{flex} point.

- This text is **highly illustrated** with diagrams and photos demonstrating a variety of concepts.



FIGURE 6-5 Intrathoracic and extrathoracic airways.

- Each chapter includes a **Case Study** to put the concepts discussed within the chapter in real-life scenarios.

Case Study 3

A 39-year-old man comes to the hospital for his preoperative evaluation prior to gastrointestinal bypass surgery for his obesity. He weighs 465 lb and is 5 foot 11 inches tall (body mass index 194 kg/m^2). He has been morbidly obese for more than 20 years. A baseline ABG was drawn on room air. The results are pH 7.46, $Paco_2$ 72 torr, Pao_2 53 torr, Sao_2 81%, HCO_3^- 28 mEq/L (he is the patient mentioned in Box 3-5). This is a fully compensated respiratory acidosis with moderate hypoxemia. As shown in Box 3-6, the hypoxemia is due to the hypoventilation (hypercapnia).

- **Knowledge Check Questions** appear throughout the chapters to help students test what they have learned.

KNOWLEDGE CHECK QUESTIONS

1. Respiratory failure due to increased ventilatory demand may be caused by:
   a. sepsis
   b. obesity
   c. neuromuscular disease
   d. upper airway obstruction
2. True or False: Metabolic acidosis can lead to respiratory failure due to a decrease in ventilatory demand.

- Each chapter concludes with a **summary, Key Points** and **Chapter Questions** as a review of the important concepts within the chapter.

Chapter Summary

Overall, patients who suffer from a neuromuscular disease process may show different signs and symptoms upon presentation to the physician's office or the acute care facility. It is always important to start with obtaining a patient history and physical examination, if appropriate, then begin with more in-depth assessment and testing, if needed. In some of these cases, the end outcome of the disease process is terminal, while in others it is resolvable, and the patient may maintain a relatively normal lifestyle after the event. It will all begin with determining the correct disease process and then being able to provide the appropriate treatment for these patients.

Many tests are available for the physicians' offices and at the hospitals to identify the type of neuromuscular disorder and its severity. Hopefully, this will occur as promptly as possible, to expedite the treatment. In some cases, the patient may remain in the hospital setting for an extended period. Treatment may involve noninvasive and invasive life support depending on the severity of the disease process and the patient's overall health.

Key Points

1. Neuromuscular disorders consist of a variety of process that affects voluntary muscles of the body. These include central nervous system disorders, drug overdose, spinal cord disorders, peripheral motor nerve disorder, neuromuscular junction disorders, and muscular disorders.
2. This chapter covered poliomyelitis and PPS (central nervous system disorders); ALS and spinal cord injury (spinal cord disorders); Guillain–Barre syndrome (peripheral motor nerve disorder); MG, botulism, and tetanus (neuromuscular junction disorders); and DMD (muscular disorders).
3. The etiologies of neuromuscular disorders include genetic mutations, viral infections, bacterial infections, autoimmune diseases, and metabolic disorders.
4. Any neuromuscular disorder that affects the muscles of ventilation can cause acute and chronic respiratory failure.
5. Chronic respiratory failure due to a neuromuscular disorder may cause failure to liberate the patient from noninvasive mechanical ventilation. Invasive mechanical ventilation is an option to be considered at this point.
6. Therapies available for the treatment of neuromuscular disorders may improve the quality of life for many of these patients. The MIE (Cough-Assist®) is one such therapy.
7. Treatment for chronic neuromuscular diseases requires a team approach with numerous healthcare practitioners and family members.
8. The prognosis for neuromuscular disorders depends on the extent of the cardiopulmonary involvement.

Chapter Questions

1. The _____ nerve has **no** effect on the upper airways.
   a. glossopharyngeal
   b. vagus
   c. lumbar T8
   d. spinal accessory
2. Receptors for _____ and _____ drive the response of the brain to breathe.
   a. $Paco_2$; HCO_3^-
   b. Pao_2; $Paco_2$
   c. Sao_2; Hb
   d. HCO_3^-; Pao_2
3. A/An _____ is not a useful test to assess a patient with a questionable neuromuscular disease process.
   a. arterial blood gas analysis
   b. pulmonary function testing
   c. urine output
   d. chest radiograph
4. _____ is a central nervous system disorder.
   a. Amyotrophic lateral sclerosis (ALS)
   b. poliomyelitis
   c. botulism
   d. Guillain–Barre syndrome

About the Author

Sindee Kalminson Karpel, MPA, RRT, AE-C, has been a respiratory therapist since 1980 and is currently professor of cardiopulmonary sciences and respiratory care and chair of the Bachelor of Science completion program in cardiopulmonary sciences in the School of Health Professions at Florida SouthWestern State College in Fort Myers, Florida. She is the author of several textbook ancillaries, continuing education books, and peer-reviewed articles. Sindee served on the founding Board of Directors of the National Asthma Education Certification Board and on the Board of Directors of the New York State Society for Respiratory Care and is currently on the Board of Directors of the Lambda Beta Society. She is the recipient of the 2003 NYSSRC Samuel Runyon Memorial Award, the 1990 NYSSRC Practitioner of the Year Award, and the 1988 NYSSRC-SEC Award for Excellence in Respiratory Care.

Sindee was born and raised in New York City, New York. She received her bachelor of arts degree in anthropology from Queens College of the City University of New York (1974), a 2-year certificate in Respiratory Care from New York University Medical Center—Bellevue Hospital (1980), and a Master of Public Administration degree in healthcare administration from the C.W. Post Campus of Long Island University (1986). Before relocating to Florida, Sindee was associate professor of allied health sciences at the Borough of Manhattan Community College of the City University of New York, where she taught for 10 years. She began her career in respiratory care at Queens Hospital Center in New York, where she was promoted from staff respiratory therapist to day supervisor to assistant director. Sindee also worked as adjunct faculty of the respiratory care program at the Borough of Manhattan Community College from 1982 to 1993. She was also assistant director of respiratory care at Long Island Jewish Medical Center before becoming a full-time educator. Sindee is a Certified Asthma Educator, certificate number 13. She has spent numerous hours volunteering with the American Lung Association of Florida and New York City, the Southwest Florida COPD Community Team, the Asthma and Allergy Network, and at local asthma and COPD events. She is a passionate educator and has mentored numerous respiratory therapists over the past 38 years.

Acknowledgments

I am honored and privileged to be able to complete the work of Anthony James Linz, DO, MPH, the original author of this text. It was his love of pulmonary medicine and teaching respiratory care students that led him to proposing this book and authoring several of the chapters before his death. I share Dr. Linz's love of teaching and vision to have a pulmonary disease textbook that embodies a student-centered pedagogical approach to pulmonary disease.

Thank you to the ancillary contributor, Jean Newberry, for her ability to take my thoughts and put them into action. Finally, a special thanks to Cathy Esperti and Rachael Souza for giving me the opportunity and assistance to make this book a reality.

Sindee Kalminson Karpel, MPA, RRT, AE-C

Contributors

A project of this magnitude is never completed without assistance. I would like to thank all the contributors:

Sharon Connelly-Merdian, RRT
Director of Clinical Education
New York City, NY

Amanda M. Dexter, MS, RRT, RCP, CHSE
Clinical Assistant Professor
University of North Carolina at Charlotte
Charlotte, NC

Dan Fisher, MS, RRT
Director, Respiratory Care/PFT
Boston Medical Center
Boston, MA

Donna (De De) Gardner, DrPH, RRT-NPS, FAARC, FCCP
Associate Professor
Texas State University
San Marcos, TX

Hossein Gharanfolib M.A, RRT-NPS-ACCS, RPFT
Instructor
Bowling Green State University
Norwalk, OH

Marnni Elaine Hutchins
Instructor
Central Piedmont Community College
Charlotte, NC

Raymond Lenius, A.S.
Professor
Florida SouthWestern State College
Fort Myers, FL

Heather O'Connell, MS, RRT, CPFT
Professor, Respiratory Care
Director of Clinical Education
Florida SouthWestern State College
Fort Myers, FL

Jeffery Ruiter, MSHI, BSRT, RRT, RCP
Program Director
Central Piedmont Community College
Charlotte, NC

Nicole Smith, RRT
Respiratory Care Supervisor
HealthPark Medical Center
Lee County, FL

Charley Starnes, BS, RRT, RCP
Instructor
Central Piedmont Community College
Charlotte, NC

Reviewers

Kira M. Anderson, MSA, BHS, RRT
Director of Clinical Education
Baptist College of Health Sciences
Memphis, Tennessee

Lea M. Endress, BS, RRT, RPFT, RCP
Professor
San Joaquin Valley College
Visalia, California

Linda M. Lair, MS, RRT, CPFT
Director of Clinical Education
University of Missouri
Columbia, Missouri

Mary P. Martinasek, MPH, RRT
Professor
Hillsborough Community College
Tampa, Florida

Kathe Rowe, BS.Ed., RRT-NPS
Respiratory Therapist Program Director
Rose State College
Midwest City, Oklahoma

CHAPTER

1

Cardiopulmonary Assessment

"It is only by the methodical examination of every system and organ that we get those comprehensive facts from which we can draw reasonably safe inductions."

—William Osler, MD, Unpublished draft of an address to medical students at the University of Pennsylvania, 1885.

OUTLINE

OBJECTIVES

1. Outline the essential components of a medical history.
2. Explain the main categories of the review of symptoms.
3. Describe normal vital signs and explain common causes of vital sign alteration.
4. Understand the terminology associated with breathing patterns.
5. Describe each of the elements of a pulmonary assessment.
6. Describe the commonly found adventitious breath sounds and their causes.
7. Review the elements of a basic cardiac examination.
8. Summarize normal and abnormal heart sounds.
9. Describe different neurologic assessment scoring systems often used in the acute care setting.
10. Utilize the Glasgow Coma Scale to assess a patient's neurologic status.

KEY TERMS

Adventitious breath sound
Atrial gallop
Biot respiration
Bradycardia
Bradypnea
Bronchovesicular breath sound
Capillary refill time
Cheyne–Stokes breathing
Chief complaint (CC)
Crackle
Cyanosis
Decerebrate posturing
Decorticate posturing
Diastolic blood pressure
Dyspnea
First heart sound (S_1)
Fremitus
Gallops
Glasgow Coma Scale (GCS)
Grunting
Heart murmur
History of present illness (HPI)
Hyperpnea
Hypertension
Hyperthermia
Hypothermia
Jugular vein distension
Kussmaul respiration

Kyphoscoliosis
Kyphosis
Lordosis
Mean arterial pressure
Nasal flaring
Orthopnea
Paradoxical breathing
Pectus carinatum
Pectus excavatum
Pedal edema
Platypnea
Point of maximal impulse
Pulse pressure
Pursed-lip breathing
Pyrexia
Resonance
Review of system
Rhonchi
Scoliosis
Second heart sound (S_2)
Smoking history
Sternal retraction
Stridor
Systole
Systolic blood pressure
Tachycardia
Tachypnea
Tracheal (bronchial) breath sound
Vesicular breath sound
Wheeze

Introduction

Patients with respiratory problems consult with healthcare practitioners because their family or friends have noted some departure from normal health. Patients may be suffering from mild symptoms or may be apprehensive and fearful of a severe illness that may lead to their incapacitation. Understandably, the patient expects a clear and satisfactory explanation provided in simple terms.

Patients are not a collection of symptoms, assessment data, dysfunctional organs, and abnormal physiology with imbalanced homeostasis. The patient is human with feelings, emotions, fears, and hopes. Healthcare professionals interacting with a patient should use their scientific knowledge and clinical skill as well as their human attributes, sympathy, kindness, and tact. Developing a harmonious and sympathetic relation and demonstrating compassion are imperative for successful patient care.

Proper and quality care of the patient with lung disease requires recognizing the etiology and functional abnormalities presented with the disorder. Obtaining adequate and reliable information from various sources will achieve this task. Taking a history, performing a physical examination, evaluating radiographic studies, assessing other system functions, and other diagnostic tests are methods utilized to provide the necessary information.

Assessment is, without a doubt, the most important skill required to initially evaluate the patient with a respiratory disease and recognize the health problems facing the patient. The patient's perception of the respiratory care practitioner's (RCP) competence is of utmost importance. Therefore, it is imperative that any healthcare provider's affect be genuinely caring toward the patient; skill and a caring attitude must coexist to ensure professional and trustworthy relationship.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Developing a sympathetic relationship with the patient is imperative for successful patient care.
2. True or False: Obtaining adequate and reliable information from various sources will help identify a patient's functional abnormalities.

Taking a History

The medical history provides a comprehensive picture of a patient's health and health problems. It is a detailed record that contains pertinent facts about the patient's disease process. The medical history provides data regarding variables affecting a patient's health so as to develop an individualized plan. This is an essential part of the entire process of patient assessment performed by the respiratory therapist.[1] The characteristics of the chief complaint (CC) and associated symptoms need ascertaining. The information gathered while taking the patient's history is the basis for the extent of the assessment. Obtaining a comprehensive history is time consuming, and the acuity of the patient's condition may limit the practitioner's ability to assess all the body systems. Therefore, many practitioners perform a focused assessment of the body systems of concern. Understandably, the cardiopulmonary system is of primary importance for respiratory care professionals. A list of the components of a patient medical history appears in **Table 1-1**.

Providing a Therapeutic Climate

The patient's impression of the healthcare practitioner's competence is of the greatest importance. When the RCP is perceived of as being uncaring and incompetent, the patient may remember that attitude most vividly.[1] Even worse, that uncaring attitude and perception may define (characterize) for that patient other members of the profession. Clinicians must dress appropriately because a professional appearance conveys respect for the patient. A patient's opinion of the healthcare provider often is based on the physical appearance. At the core of successful history taking is skilled and patient-centered communication through which the respiratory therapist and the patient establish a rapport.[2] A healthcare provider can communicate a caring attitude and competence by displaying the attributes listed in **Table 1-2**.

Components of the Patient History

The first step in diagnostic thinking is to carefully and thoroughly review the patient history. This entails identification of the who, what, when, and where of the patient's current respiratory condition. Obtaining a patient's history requires a systematic approach and includes identification of the patient's CC, history of present illness (HPI), past medical history (PMH), medication history, social history, occupational and environmental history, family history, and a review of symptoms (ROS).

TABLE 1-1
Example of Components of the Medical History

Demographic data	Patient name Address Age Gender Race/ethnicity Education Marital status Religion Languages spoken Admitting diagnosis (if available) Patient's physician Brief description of reason for medical care
CC	The particular reason for this visit made by patient or family member List of complaints in order of acuity
HPI	Specific details regarding the presenting illness in chronologic order
PMH	Previous hospital admissions Past operations Major illnesses Accidents Injuries Pregnancies
Medication history	Current prescription medications Over-the-counter medications Allergies
Social history	Birthplace Marital status Living arrangements Smoking history Alcohol use Drug use Sexual activity
Family history	Relatives and causes of death Family diseases
Occupational/environmental history	Occupation Work environment and exposure Military service
Review of symptoms	General symptoms Skin and nails Head, eyes, ears, nose, and throat (HEENT) Endocrine Respiratory Cardiac/cardiovascular Hematologic Lymph Gastrointestinal (GI) Genitourinary Musculoskeletal Neurologic Mental status

TABLE 1-2
Attributes Supporting a Caring and Professional Climate

Professional in appearance
Professional in conduct
Caring demeanor
Eye contact
Respectful
Active listener
Honest
Nonjudgmental
Unhurried

Case Study: Patient History

An RCP is asked to assess a 66-year-old woman complaining of rapid onset of shortness of breath (SOB). She states, "I cannot catch my breath." She is coughing up a yellowish sputum, is diaphoretic, and feeling feverish, although she has not taken her temperature.

Questions

1. **What other important questions should be asked by the RCP?**
2. **What possible pulmonary problems (working diagnosis) are suggested by the symptoms at this point?**
3. **What is the significance of the patient complaining of sweating?**

Answers

1. **The RCP should ask the patient if she has chest pain, nausea, dizziness, or blood in her sputum. The RCP should also ask about any history of lung disease or cigarette smoking.**
2. **The pulmonary problems based on interview suggest pneumonia, acute bronchitis, asthma, and acute exacerbation of chronic obstructive pulmonary disease (COPD).**
3. **The sweating is significant because it is consistent with a fever that may be caused by infection. Fever may be a contributing factor to SOB because of an increase in oxygen consumption, increased CO_2 production, and an increase in the drive to breathe.**

Chief Complaint

The **chief complaint** is the problem or group of symptoms that brings the patient to the physician or hospital for health care. To elicit information about the CC, start with an open question, for example, "What is the problem?" or "Tell me about the problem."[3] The CC is a subjective statement made by the patient (patient's description of the problem) and should be documented using the patient's words. For example: "I am short of breath." Documentation of more specific details is in the HPI.

History of Present Illness

The **history of present illness** describes the detailed information pertinent to the CC. Once the patient has completed his or her answer to the initial CC question, the practitioner moves on to clarify and focus using specific questions. Closed questions provide extra detail and sharpen the patient's story.[3] This clarification includes a description of the onset of the problem, the date the symptoms were noted, and whether the symptoms developed gradually or suddenly. Also included is the setting in which the signs and symptoms developed. Past medical problems, hospitalization, symptoms, and treatments are noted as well as whether the problems are resolved, ongoing, or recurrent. The variables included when taking an HPI are summarized in **Table 1-3**.

A focused pulmonary history is a specialized version of the HPI that focuses on symptoms related to cardiopulmonary disease. A complete pulmonary history should include questions regarding the presence or absence of a cough, sputum production, hemoptysis, wheezing, chest tightness, chest pain, and breathlessness.[4]

The most common complaint by patients with pulmonary problems is the feeling of SOB or breathlessness. **Dyspnea** is the term used to describe the uncomfortable awareness of difficult or labored breathing associated with feeling short of breath. Dyspnea is a subjective symptom influenced by the patient's reaction, sensitivity, and emotional state. Not all patients with SOB use similar terms to describe their dyspnea. Patients with asthma tend to use the phrase "my chest feels tight," patients with fibrosis state "my breathing is too fast," and patients with congestive heart failure (CHF) express their dyspnea with the statement "I feel like I am suffocating." Dyspnea is due to an increase in the work of breathing out of proportion to the level of activity.

In assessing for dyspnea, it is important to determine whether it is chronic or acute. In the acute episode, the event is recent and often severe. The circumstances in which a patient's dyspnea develops should be determined and evaluated. Dyspnea may occur with certain body positions. **Orthopnea** indicates dyspnea in lying down position, which is a characteristic symptom associated with heart failure. In reclining position, there is an increase in venous return to the failing heart; this additional fluid may accumulate in the lungs and lead to dyspnea. Many patients with an advanced pulmonary disease must assume an upright position to breathe well. **Platypnea** is dyspnea in the upright position, which improves by lying down.

TABLE 1-3
Items to Include in the History of Present Illness

Component	Elements
Onset	Date, time, sudden, or gradual
Location	Where is the problem? Did it spread?
Duration	Symptom duration
Character	Quantity and quality of symptoms
Associated manifestations	The setting in which the symptoms began
Relieving factors	Factors that diminish or aggravate symptoms
Treatment	Medications, remedies that relieve or exacerbate symptoms

Hess, Respiratory Care Principles and Practice 3rd edition, 2016

Past Medical History

The PMH gives an insight into the health status of the patient up to the point of the present illness. This section contains information about the patient's past illnesses and treatment, including previous hospital admissions, prior surgeries, major illnesses (such as diabetes, hypertension, or heart disease), and accidents. When taking a PMH, it is important to ascertain the diagnosis, dates, sequence, and management of each diagnosis.[3] Other information documented here include childhood diseases and development, allergies, and immunizations.

Neglecting the PMH can cause inadvertent discontinuation of essential medications, prescription of incorrect dosages of chronic medications, duplication of diagnostic testing, neglect of an earlier prescription, or disruption of plans made by previous clinicians.[5] Problems may become further compounded given that some of the most difficult patients to treat are also those with the most complex medical histories.[5]

Medication History

Medication information is crucial. Current medications serve as a reminder of other existing conditions that the patient may have forgotten to mention earlier in the interview. Medications taken may contribute to the current problem or influence the choice of medications for the current problem. It is important to ask about over-the-counter medications as well as herbal remedies because all these can have adverse reactions or drug interactions. Numerous drugs affect gastric pH,

enzyme quality, normal renal excretion, intestinal bacteria, and blood chemistries. Drugs may also confuse the significance of certain signs and symptoms.

Medication adherence is an important part of taking a medication history. Finding out the level of adherence and any reasons for nonadherence can be of significance in the future treatment of the patient.[3] Also, an enquiry into drug allergies and sensitivities is necessary.

Social History

A patient's health and well-being are affected by social, personal, and occupational factors. Knowledge of the patient's background is useful, not only for diagnosis but also for disease management. How patients think, live, and behave influence how they cope with illness.[6] Social history includes getting to know how the patient's illness impacts the patient at home, as well as at work. Information obtained from the social history include leisure interests, physical exercise, living arrangements, children, sexual relationships (or lack of them), tobacco use, drinking alcohol, and recreational drug use.[6]

Smoking harms every organ in the body and causes many diseases that reduce the individual's general health. The **smoking history** is an essential part of the patient interview.[4] The practitioner documents the type of substance the patient smokes or uses: cigarettes, cigars, pipe, snuff, chewing tobacco, marijuana, or other recreational drugs. The length of time of lung exposure to tobacco smoke is vital information and quantifies smoking in pack-year: the number of cigarette packs smoked per day multiplied by the number of years smoked. Occasionally, a patient will smoke less than one pack per day. Each pack has 20 cigarettes. Therefore, 10 cigarettes per day make half a pack per day, and so on (**Box 1-1**).

Inhalation of other substances, such as marijuana or crack cocaine, is associated with pulmonary symptoms such as a cough, sputum production, and wheeze.[4] Illicit drug inhalation has cardiovascular effects as well. The amount and frequency of drug use are relevant information to ascertain in social history.

Smoking cessation and assistance with drug use are valuable in the improvement of the patient's overall health. For those patients who are willing to try and quit, the clinician should offer assistance and follow-up care.[4]

Excessive drinking has immediate effects that increase the risk of many harmful health conditions, including alcohol poisoning. Over time, chronic alcohol consumption use can lead to an increase in long-term health risks such as hypertension, cardiomyopathy, stroke, liver diseases, and digestive problems.[7] Alcoholics are prone to the development of aspiration pneumonia, as well as many other health issues.[4] When quantifying alcohol consumption, one drink is usually 5 oz of wine, 12 oz of beer, or 1.5 oz of 80-proof distilled liquor.[8] For women, four or more drinks in a day are excessive; for men, five or more.[8] Past and present patterns of drinking alcohol are often assessed, in the hospital situation, by using the CAGE system, which uses four questions to elicit a view of alcohol intake.[3,6] These items are shown in **Box 1-2**. Scores of two or more positive answers indicate a significant alcohol problem.[3,6]

Occupational and Environmental History

Taking a patient's history needs to include information about previous and current employment. This is important because aspects of employment other than the job itself can influence social well-being if illness precludes a return to work.[3] Patient management and prognosis are affected significantly by the knowledge of this information. For example, patients with occupational asthma or hypersensitivity pneumonitis often cannot be managed adequately without cessation of exposure to the offending agent.[9]

Exposure to inorganic, as well as organic dust, is associated with the development of respiratory diseases. Inorganic dust includes asbestos, silica, coal, beryllium, aluminum, chromium, cobalt, nickel, and tungsten. Organic dust includes cotton, grain, fungal spores, vegetable products, insect fragments, animal dander, bird and rodent feces, toxic chemicals, biomass smoke, diesel exhaust, and others.[9] These exposures occur in mining, farming, construction, ship repair, and a variety of industries.[9]

BOX 1-1 Examples of Tobacco Smoking History

1. A patient who currently smokes two packs per day for 35 years has a (2 packs/day × 35 years =) 70 pack-year history of smoking.
2. A patient who smokes five cigarettes per day (5 cigarettes/day ÷ 20 cigarettes/pack = ¼ pack/day) for 25 years has a (¼ pack/day × 25 years =) 6.25 pack-year history of smoking.

BOX 1-2 CAGE Questionnaire

C	Have you felt the need to ***C**ut* down on your alcohol intake or drinking?
A	Have people ***A**nnoyed* you by criticizing your drinking?
G	Have you ever felt ***G**uilty* about your drinking?
E	***E**ye*-opener: Have you ever had a drink to steady your nerves in the morning?

Reproduced with permission from Lloyd H, Craig S. A guide to taking a patient's history. *Nurs Stand.* 2007;22(13):42–48. doi:10.7748/ns2007.12.22.13.42.c6300.

Environmental exposure history is also necessary. Environmental exposure to contagious diseases, travel, and the home environment also have an impact on the development and course of cardiopulmonary disease.[4] Indoor, as well as outdoor, exposure exacerbates existing pulmonary problems and increase the risk for cardiopulmonary diseases.[9] Exposure to secondhand tobacco smoke, radon gas, wood smoke, and other biologic agents generated indoors need consideration.

Pets may also play a significant role in the development of certain types of lung disease. For example, pet shop employees, bird fanciers, and veterinarians may develop a particular bacterial infection associated with pet birds and poultry.[4] A careful environmental history is imperative in identifying asthma triggers. Hobbies may also impact pulmonary diseases, such as woodworking and gardening.

Family History

Some disorders are considered familial or hereditary. Obtaining a patient's family history can reveal the presence of a genetic predisposition to certain diseases. For example, the presence of cerebrovascular disease or dementia in a close blood-related relative might help guide the management of the patient.[3] The family health history needs to include parents, siblings, and grandparents. The major diseases included in the family history are hypertension, cancer, heart disease, lung disease (including asthma, COPD, pneumonia, and tuberculosis [TB]), diabetes, stroke, kidney disease, thyroid problems, and Alzheimer disease.[4] People who have a close family member with a chronic illness may have a higher risk of developing that illness than those without such a family member.

Review of Symptoms or Review of Systems

The review of symptoms (ROS), also known as a **review of systems**, provides an opportunity for the RCP to collect data verbally. The focus of the ROS is on the system or systems that are affected by the present illness and relate to the patient's complaint. Documentation of only pertinent information makes this problem-focused. This review is based on a list of questions, arranged by organ system. It is designed to uncover dysfunction and disease. Unfortunately, there is no gold standard for ROS. However, the systematic analysis of any symptoms is best achieved by a detailed assessment of its timing, influences, nature, and associated features (TINA).[6]

The timing of a symptom relates to its onset, duration, pattern, and progression. Onset may be sudden, gradual, or insidious. Influences refer to things that aggravate the symptom and relieve the symptom. The nature of the symptom includes its characteristics, such as description, and its severity. The associated features include a description of other symptoms that may have occurred at the same time and the relationship of these other symptoms to the primary symptom. **Table 1-4** shows the main categories and examples of findings in each category. The following box is a case study demonstrating the importance of the ROS.

Vital Signs

Vital signs are the four signs of life: temperature, pulse, respiratory rate (RR), and blood pressure (BP). These are the most frequently made clinical assessments because they are easy to obtain and provide useful information about the patient's clinical condition.[10] Most acute medical problems cause abnormal vital signs that become more irregular as the problem increases

TABLE 1-4
Review of Systems: Main Categories and Examples

Categories	Examples
General symptoms	Weight loss, weight gain, fatigue, difficulty sleeping, fevers, chills, sweats, chronic pain
Skin and nails	Color, temperature, appearance, skin eruptions/rashes, itching, clubbing
HEENT	***H****ead*—dizziness, loss of consciousness, fainting, head injury, concussion ***E****yes*—Blurred vision, double vision, eye discharge, red eye, pupillary reaction ***E****ars*—Pain, hearing loss, tinnitus, vertigo ***N****ose*—Nasal discharge, sneezing, nasal flaring, sinus pain, postnasal drip, nosebleeds ***T****hroat*—Vocal cord pathology, voice change, sore throat, tooth pain, bad breath, appearance of gums
Endocrine	Diabetes, thyroid enlargement, thyroid tenderness, polyuria, weight gain, weight loss
Respiratory	Chronic or past pulmonary disorders, SOB with or without exertion, chest pain, cough, hemoptysis, wheezing, snoring, chest deformity, chest trauma
Cardiovascular	Chronic cardiovascular disorders, chest pain or pressure, SOB at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, syncope, palpitations, leg pain or cramps with ambulation, foot ulcers that are difficult to heal

Categories	Examples
Hematologic	Chronic or past hematologic disease, fevers, chills, sweats, weight loss, abnormal bruising or bleeding
Lymph nodes	Tender, enlarged, swollen
GI	Chronic or past GI disorders, heartburn, abdominal pain, difficulty swallowing, nausea, vomiting, abdominal swelling or distension, jaundice, hematemesis, tarry stools, use of caffeine
Genitourinary	Urine output
Musculoskeletal	Known disease, trauma, joint swelling, restricted motion
Neurologic	Known disease, weakness, tremors, seizures, paralysis, balance problems, headache
Mental status	Depression, restlessness, anxiety, mood swings, sleep disturbances, known mental health disorder

Case Study: Review of Symptoms

Mr. Brown, a 59-year-old Caucasian man, presents to the emergency department (ED) with a CC of SOB and chest pain. The chest pain began 8 hours ago while Mr. Brown was working in his yard. His SOB started while resting in the reclining position about an hour before he presented himself to the ED. The ED physician is busy and asks the respiratory therapist to assess and evaluate the patient.

The RCP enters the patients room and introduces herself and explains what she is about to do. She asks the patient about the nature of his chest pain. (Chest pain could be pleuritic or nonpleuritic in nature. Constant chest pain under the sternum with a heavy pressure feeling on the chest is consistent with inadequate oxygen delivery to cardiac muscles from low perfusion and is called ischemia. Pleuritic pain is localized posteriorly or laterally and worsens with coughing or deep breathing.)

The RCP asks the following questions about Mr. Brown's chest pain:

1. **Does the chest pain increase with deep breath?**
2. **Does the pain radiate to the arms and shoulders?**
3. **How severe is the pain?**
4. **Is the chest pain associated with nausea, indigestion, weakness, and profuse sweating (diaphoresis)?**

Next, the RCP assesses the severity of Mr. Brown's SOB. The severity of the SOB is assessed by asking the following questions:

1. **Does it occur at rest or only with exertion?**
2. **Has SOB occurred before this incident?**
3. **Does the SOB occur in reclining position (orthopnea)?**
4. **Does the SOB improve when sitting upright?**

After gathering information about Mr. Brown's chest pain and SOB (CCs), the RCP asks about other possible symptoms such as fever, cough, sputum production, hemoptysis, and swollen ankles. (Additional information to enquire about include heart disease, family history of heart disease, and the patient's stress levels. Social habits need to be identified as risk factors for heart and lung disease.)

Mr. Brown explains that the chest pain is centrally located and radiates to his left arm and jaw. The chest pain started when he started pushing the lawn mower (exertion increases cardiopulmonary workload and oxygen requirement). The pain decreased with rest and is not affected by breathing. Mr. Brown has not taken any medication for his chest pain. He describes his SOB as severe and says it awakens him after going to bed. It improved when he sat upright. He describes his SOB as a feeling of suffocation.

Mr. Brown denies any other symptoms except for having some diaphoresis, weakness, and nausea, but denies vomiting. He has been smoking two packs of cigarettes a day for the past 43 years.

Case Review Assessment

Upon completing the interview and information gathering, the respiratory therapist's evaluation is as follows:

Chest pain: Mr. Brown's explanation of his chest pain is the classic description of cardiac pain. The pain is probably due to narrowing of coronary

(*Continues*)

Case Study: Review of Symptoms (*Continued*)

vessels that prevents adequate perfusion to the heart muscle and inadequate blood flow to the heart muscle results in an ischemic myocardium. Exertion requires more blood flow to the heart muscle and, in this case, the inability of deliver more oxygen to meet the additional demand causes the chest pain to worsen.

SOB: This is most likely due to pulmonary edema (patient feels as if he is suffocating). The pulmonary edema is caused by left ventricular failure and increase in pulmonary capillary hydrostatic pressure (pulmonary capillary filtration pressure).

Respiratory Therapist's Recommendations

The respiratory therapist's report to the physician includes a strong suspicion of heart failure. The respiratory therapist recommends oxygen therapy, diuretics, a 12 lead electrocardiogram (ECG), and chest radiograph. The respiratory therapist ruled out pneumonia, because Mr. Brown did not have any fever, chills, cough, and sputum production.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A patient who smoked 2½ packs of cigarettes a day for 25 years has a 62.5 pack-year smoking history.
2. True or False: The CAGE questionnaire is used to investigate illicit drug use.

in severity.[11] Chronic conditions may not result in abnormal vital signs as compensatory mechanisms take effect.[11] The fifth vital sign is blood oxygen saturation or pulse oximetry. Although it is not always considered a vital sign, the patient's oxygen saturation is often included with the vital sign assessment.

A comparison of the measurements obtained during the initial assessment of a patient's vital signs is made with the normal values (**Table 1-5**). After documentation of several vital sign measurements, these data are then used as a baseline for subsequent measurements and trending.

TABLE 1-5
Normal Vital Sign Values for Adults

Temperature	37°C or 98.6°F
Pulse	60–100 beats/minute
RR	12–20 breaths/minute
BP	Systolic 90–140 mm Hg Diastolic 60–90 mm Hg
Pulse oximetry	≥95%

Infants and children have a higher RR, higher pulse rate, and lower BP values than adults.

Temperature

The human body has a narrow temperature range within which it operates. Body temperature measurement is an indicator of a patient's physiologic state; it varies from person to person and is an important measurement for decisions in medical diagnosis, bedside care, treatment, and the need for laboratory tests. Thermoregulation is the body's mechanism to maintain body temperature within its narrow operating range and is carried out by the hypothalamus. The body's operating range normally varies because of diurnal variation and cellular metabolism and results will vary depending on the assessment location. The core temperature, the most accurate body temperature, is assessed using a rectal or tympanic measurement; however, oral temperature measurements are very common.

Under normal conditions, the body can maintain a normal temperature of 37 ± 0.5°C (98.6 ± 1°F).

The purpose when measuring body temperature is to estimate changes in core temperature. A site that quantitatively and rapidly reflects changes in arterial temperature and is independent of local blood flow or environmental changes would appropriately estimate core temperature.[12]

Elevated body temperature, also known as fever or **pyrexia**, can arise from disorders affecting every body system. In most patients, a fever is a temperature of >38.3°C (101°F).[4] Fever is one of the ways the immune system attempts to combat infection from viral, fungal, or bacterial organisms. However, in the absence of other signs, fever usually has little diagnostic significance. Fever causes an increase in metabolic rate, resulting in an increase in oxygen consumption and carbon dioxide production. This results in an increased RR and heart rate to accommodate the increased carbon dioxide production and oxygen requirement of the cells.[11] A persistent high fever (>40.6°C or >105°F) represents an emergency.

Hyperthermia is an elevated body temperature due to excessive heat production or inadequate heat dissipation from heavy exertion in a hot, humid environment.

A body temperature below normal is **hypothermia** and is most often caused by prolonged exposure to cold. This occurs in patients with head injuries that damage the hypothalamus and in drowning victims.[11]

There are also some medications that increase the patient's risk of hypothermia. Hypothermia reduces oxygen consumption and carbon dioxide production and may cause a patient to breathe shallow and have a low pulse rate.[10] The hypothalamus is the suspected cause of hypothermia when there is a significant neurologic incident (stroke or head trauma) or the development of a tumor.

Heart Rate

A pulse results from the force of ventricular contraction (**systole**) required to move the blood forward in the vascular system. It is a measurement of the heart rate that may be assessed by taking the patient's pulse, using pulse oximetry, auscultating the heart, or by electrocardiography.

The pulse rate and rhythm are a quick and easy assessment via the palpation of any accessible artery; the radial artery is the most common assessment site for this purpose. A practitioner may count the pulse for 15, 30, or 60 seconds and then mathematically calculate to the rate per minute. The 30- or 60-second count is most accurate, allowing for assessment of the quality of the pulse as well as the rate. The normal heart rate for adults is 60–100 beats/minute. See **Table 1-6** for normal and abnormal rates.

Quantitative pulse assessment reveals normal, rapid (tachycardia), or slow (bradycardia) rates. **Tachycardia** is a normal physiologic response to vigorous activity, such as running or climbing stairs.[13] It is an abnormal physiologic response associated with many pathophysiologic conditions such as hypoxia, anemia, hypotension, cardiac disease, uncontrolled pain, and fever. Certain drugs, such as epinephrine, atropine, caffeine, nicotine, and cocaine, may cause tachycardia. **Bradycardia** is less common than tachycardia but can occur with hypothermia, as a side effect of medications, with certain cardiac arrhythmias, and with traumatic brain injury.[10]

Qualitative pulse assessment, taken during pulse rate assessment, includes rhythm and strength. The rhythm and strength or amplitude need to be noted using common terminology for describing pulse quality[13] (**Table 1-7**).

Cardiac arrhythmias cause pulses to be irregular. An ECG will determine the type of arrhythmia. An absent or a weak pulse may be bilateral or affect only one extremity. When bilateral, an absent pulse is a vital indicator of life-threatening conditions such as cardiac arrest, shock, or arrhythmia. Diminished blood flow causes a weak, thready pulse and is usually due to hypovolemia, hypotension, shock, myocardial infarction, CHF, poor blood flow, or blood clots.[13] In a healthy person, a bounding pulse develops because of exercise, pregnancy, and periods of anxiety. However, this sign also results from fever and certain endocrine, hematologic, and cardiovascular disorders that increase the basal metabolic rate.[14]

The heart rate is higher in infants and children than in adults. The normal heart rate range for infants, especially newborn to 3 months of age, varies widely between an awake rate and a sleeping rate. The normal heart rate becomes that of an adult after the age of 10 years (**Table 1-8**).

Respiratory Rate

A normal range for RR for an adult is 10–20 breaths/minute. An RR greater than 20 breaths/minute is **tachypnea**, and slower than 10 breaths/minute is **bradypnea**. As with pulse, the RRs in children vary with age and slow down as children grow (**Table 1-9**).

Tachypnea may result from reduced arterial oxygen tension or arterial oxygen content, decreased perfusion, or increased oxygen demand.[14] The causes of increased oxygen demand include anxiety, exertion, fever, pain, or as a compensatory mechanism for a metabolic acidosis, pulmonary irritation, stretch receptor stimulation, or a neurologic disorder of the respiratory center.[14] Tachypnea and shallow breaths are the hallmarks of restrictive breathing disorders such as atelectasis, pulmonary edema, pneumonia, pneumothorax, and pulmonary fibrosis.[11]

Bradypnea is usually due to central nervous system (CNS) depression from an overdose of CNS depressants

TABLE 1-6
Heart Rate in Adults

Classification	Rate (Beats/Minute)	Common Causes
Normal	60–100	Normal
Tachycardia	>100	Hypoxia, cardiac disease, fever, exercise, and anxiety
Bradycardia	<60	Very severe hypoxia, cardiac disease, arrhythmia, and vagal stimulation. Well-trained athletes may have a "normal" resting heart rate in the 50s

Reprinted with permission from Shelledy D, Peters J, eds. Respiratory Care Patient Assessment & Care Plan Development. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016.

TABLE 1-7
Qualitative Assessment of the Pulse

Rhythm	Regular or Irregular		
Strength	4+	Bounding	Very strong
	3+	Full, increased	Strong
	2+	Normal or expected	Normal
	1+	Diminished, thready, barely palpable	Weak
	0	Absent, not palpable	Absent

Reprinted with permission from Shelledy D, Peters J, eds. Respiratory Care Patient Assessment & Care Plan Development. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016.

TABLE 1-8
Heart Rate in Infants and Children (Beats/Minute)

Age	Awake Rate	Sleeping Rate
Newborn to 3 months	85–205	80–160
3 months to 2 years	100–190	75–160
2–10 years	60–140	60–90
>10 years	60–100	50–90

TABLE 1-9
Normal Respiratory Rate by Age (Breaths/Minute)

Age	Normal Respiratory Rate
<1 year	30–60
1–3 years	24–40
4–5 years	22–34
6–12 years	18–30
>12 years	12–18

such as opiates, benzodiazepines, barbiturates, and alcohol. Other causes of bradypnea include hypothermia and severe hypoxia.[13]

Assessing the respiratory pattern provides additional important information about the patient. The respiratory motions (inspiration and expiration) are apparent over the chest and abdomen. Under normal conditions, inspiration is shorter than expiration, the normal I:E ratio is 1:2. The change in respiratory pattern associated with respiratory disease is due to changes in breathing rate, tidal volume, rhythm, and the ratio of inspiration to expiration.

The diaphragm is the primary muscle of inspiration. A respiratory cycle includes an inspiratory phase and an expiratory phase. Inspiration is an active process that requires the expenditure of energy and the use of oxygen to produce that energy (adenosine triphosphate [ATP]). During inspiration the diaphragm contracts and causes the intrathoracic pressure to decrease. This decrease in intrathoracic pressure, in turn, produces a subatmospheric pressure that causes airflow through the airways and alveolar expansion. At the end of inspiration, the diaphragm relaxes, and the lung recoil causes an increase in alveolar pressure relative to atmospheric pressure. This passive process that causes the air to flow out of the lung is the expiratory phase of respiration.

Breathing Patterns

A breathing pattern that is fast and deep is **hyperpnea** and usually results in hyperventilation (a lowered $Paco_2$). **Kussmaul respiration** is rapid and deep breathing associated with metabolic acidosis, usually diabetic ketoacidosis.

Cheyne–Stokes breathing is a pattern of slow, shallow breaths, which increases in depth and rate followed by periods of apnea. This breathing may be normal in young children and the elderly. However, this pattern of breathing is common to individuals with cerebral disease and CHF.

Biot respiration is a pattern of a burst of uniform, large tidal volume followed by periods of apnea. Biot respirations are symptoms of increased intracranial pressure and meningitis. **Figure 1-1** shows various patterns of breathing.

Blood Pressure

Arterial BP is the force exerted by the circulating intravascular volume of blood on the wall of the arteries. This pressure occurs during ventricular contraction and pushes the blood forward into the aorta and pulmonary arteries. BP assessment includes four arterial pressure measurements. **Systolic blood pressure** (SBP) is the pressure measured during ventricular contraction. **Diastolic blood pressure** (DBP) is the pressure measured during ventricular relaxation and is a result of the elastic recoil of the arteries and arterioles. **Pulse pressure** (PP) is the difference between the systolic and diastolic pressures and is dependent on stroke volume and arterial wall elastic properties. Lastly, the **mean arterial pressure** (MAP), or perfusion pressure, drives the blood through the systemic vasculature from the arteries to the arterioles, capillaries, venules, veins, and back to the heart. It can be calculated by the following formula: $MAP = (SBP + 2[DBP]) \div 3$.

The normal BP varies with age, body size, and underlying pathology. Normally, BP values rise from birth and reach the normal adult values of 120/80 mm Hg around age 18 to 20 (**Box 1-3**). An SBP continuously ≥140 mm Hg or a DBP continuously ≥90 mm Hg is **hypertension** (**Table 1-10**). Numerous medical conditions cause elevated BP, including myocardial infarction, kidney disease, Cushing syndrome, anemia, and essential hypertension.

A sustained BP of less than 90/60 mm Hg is hypotension. It occurs from a decrease in cardiac output, peripheral vasodilatation, or hypovolemia. A hypotensive crisis exists if the patient's SBP is less than 80 or 30 mm Hg below the patient's known baseline. Shock is most likely, and quick action is necessary.

PP normally increases during exercise. It abnormally increases in patients with atherosclerosis of the larger arteries. Heart failure or hypovolemia causes a decrease in PP.

Normal MAP is 80–100 mm Hg. An MAP of >60 mm Hg is necessary to perfuse the vital organs of an average individual under most circumstances. An MAP <60 mm Hg could lead to underperfusion of tissues and organs and hence compromised oxygen delivery to those organs.



FIGURE 1-1 Patterns of respiration.

Modified from Mosby's Guide to Physical Examination, Seidel HM, Ball JW, Dains JE, et al., Copyright Elsevier (Mosby) 1999.

BOX 1-3 Normal Average Blood Pressures (mm Hg) by Age

- Newborn 80/60
- Infant 90/60
- Children 110/70
- Adult 120/80

TABLE 1-10
Stages of Hypertension

Category	Systolic Blood Pressure (mm Hg)		Diastolic Blood Pressure (mm Hg)
Prehypertensive	120–139	or	80–89
Hypertension stage 1	140–159	or	90–99
Hypertension stage 2	≥160	or	≥100
Hypertensive crisis	>180	or	>110

Data from U.S. Department of Health and Human Services, National Institutes of Health, NHLBI. JNC 7 Express, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003. NIH Publication No. 03-5233, December 2003.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Cardiac arrhythmias are identified using pulse rate.
2. True or False: A patient with a BP of 145/95 mm Hg has a normal MAP.

Essential Elements of a Pulmonary Examination

Performing a directed physical examination enhances the already gathered history and focuses the diagnostic process by searching for specific signs that either confirm the findings or differentiate between various conditions that might explain the current symptoms.[15] The pulmonary examination requires only a stethoscope; eyes, ears, and hands of the clinician; and the clinician's skill in eliciting and recognizing abnormal findings.[16]

There are five components to the pulmonary examination. These components are observation, inspection, palpation, percussion, and auscultation. The primary focus of this discussion is not to elaborate on the details of a chest examination but to examine a few of the basic principles; the primary focus is on selected aspects of the examination and the mechanisms that produce abnormalities.[16]

Observation

Observation of the patient begins when the respiratory therapist walks through the door to the patient's room. It includes a quick review of the patient and the patient's environment. The environment includes observing for equipment being used, as well as for any safety issues. The equipment can be as simple as a nasal cannula, intravenous solutions, or as sophisticated as life support equipment and a dialysis machine. A patient's facial expression can reveal distress or pain, alertness, mood, and mental status. Body position can reveal respiratory distress if sitting upright or leaning forward with elbows on the knees or on the arms of the chair in the "breath saver" position.

The respiratory therapist needs to be able to identify signs of respiratory distress such as nasal flaring, pursed-lip breathing, cyanosis, and diaphoresis (excessive sweating) during observation (**Table 1-11**). **Nasal flaring** occurs when the external nares flare outward during inhalation. This occurs most often in infants with respiratory distress, indicating an increased work of breathing. Patients with COPD adopt the **pursed-lip breathing** technique to create resistance to exhalation flow. This creates an increased resistance, which acts as a mechanism to keep the airways open and allow for a complete exhalation without airway collapse. The presence of pursed-lip breathing, especially while at rest, could mean the patient is in distress. Central cyanosis is present in patients with respiratory disease that reduces oxygen saturation and arterial oxygen content. This cyanosis is often due to severe hypoxemia and requires immediate further assessment to determine the cause. Respiratory therapists must be aware that lack of cyanosis does not indicate adequate oxygenation. **Cyanosis** occurs when the concentration of desaturated hemoglobin is 5 g or more. Excessive sweating (diaphoresis) while at rest is an early sign of disorders that can be life-threatening. Diaphoresis is known to accompany heart failure, myocardial infarction, shock, and pneumonia.

TABLE 1-11
Elements of Observation

Observation	Reveals
Facial expression	Distress Pain Alertness Mood Mental status
Nasal flaring	Respiratory distress, especially in infants
Patient position	Inability to breathe in reclined position or distress
Pursed-lip breathing	Patient with COPD in distress while at rest
Central cyanosis	Serious, life-threatening situation
Diaphoresis	Serious, life-threatening disorder when it occurs while at rest

Inspection

Inspection is the use of our eyes and looking closely at the patient to gather information; this is the most informative phase of the physical examination. Inspection reveals valuable information about the patient's degree of illness and distress. An in-depth knowledge of anatomical structure and function is imperative to the interpretation of physical examination findings regarding underlying pathologic process. **Table 1-12** shows a review of the elements of inspection.

Jugular Vein Distension

The most common cause of **jugular vein distension** (JVD) is right-sided heart failure (cor pulmonale) secondary to increased pulmonary vascular resistance as a result of chronic hypoxemia. Right-sided heart failure may be secondary to chronic left-sided heart failure. JVD may be present because of hypervolemia or increased impedance to venous return to the right atrium. **Figure 1-2** shows how to estimate JVD.

Tracheal Position

Inspection of the neck is a valuable tool in evaluation of the tracheal position. The trachea is located anteriorly,

TABLE 1-12
Elements of Inspection

Inspection	Reveals
JVD	Right heart failure, hypervolemia, decreased blood return to right heart
Tracheal position	Air or fluid in the pleural space (e.g., pneumothorax, hemothorax) on the opposite side, atelectasis on affected side
Accessory muscle use	Increased work of breathing
Paradoxical breathing	Flail chest and/or weakened diaphragm
Chest configuration	Barrel chest from obstructive lung disease Restrictive lung disease from pectus carinatum, pectus excavatum, kyphosis, kyphoscoliosis, lordosis, or scoliosis
Pedal edema	Right heart failure, hypervolemia, decreased blood return to right heart



FIGURE 1-2 Jugular vein distension. To estimate jugular vein pressure (JVP), position the patient supine at a 45° angle. Visualize the internal jugular vein as it ascends the side of the neck between the two heads of the sternocleidomastoid muscle. Measure the height of the distension as a vertical column of blood in relation to the sternal angle. Normal JVP ≤ 3–4 cm above the sternal angle. JVP may increase because of right heart failure (e.g., cor pulmonale), left heart failure, constrictive pericarditis, pleural effusion, obstructed vena cava, and other cardiopulmonary disorders.

in the midline of the neck. Check the centrality of the trachea by inserting the tip of the index finger into the suprasternal notch. Allow the finger to slip to either side of the trachea. If the finger slips more easily to one side or the other, the trachea is not midline.[6] The trachea will shift toward an area of the collapsed lung and away from areas of increased pressure, from fluid or air in the pleural space (e.g., tension pneumothorax, hemothorax, large pleural effusion).

Accessory Muscle Use

When the diaphragm is severely depressed by the increase in residual volume and functional residual capacity, or air trapping, the accessory muscles of inspiration are activated. Normally, accessory muscles of inspiration are prominent during exercise. The use of accessory muscles, at rest, is an indication of respiratory distress, increased work of breathing, and oxygen consumption. The major accessory muscles of inspiration include the scalene, sternocleidomastoid, pectoralis major, and the trapezius.

The accessory muscles of expiration are often used to overcome significantly increased airway resistance due to increased airway narrowing, loss of elasticity, and airway collapse associated with chronic obstructive pulmonary disorders. The major accessory muscles of exhalation include the rectus abdominis, external oblique, internal oblique, and the transversus abdominis.

Sternal retractions are the inward movement of intercostal spaces and are caused by conditions that impede inspiration. They may occur anywhere along the respiratory tract. These conditions are characterized by increased resistance or decreased compliance. These inspiratory barriers are overcome by more negative pressure generation during inspiration, resulting in an inward movement of the intercostal spaces, suprasternal spaces, and subclavian spaces.

Paradoxical Breathing

Paradoxical breathing occurs when chest movement is the opposite of the normal chest motion. One common cause of paradoxical breathing is flail chest. A flail is the result of two or more rib fractures in two or more places, causing instability of the isolated piece of the chest wall. In this situation, the affected side moves inward on inspiration and outward during expiration. A flail chest causes a restrictive lung disorder because of rib instability, lung volume restriction, atelectasis, lung contusion, and possible pneumothorax.

The chest and abdomen move in synchrony during the respiratory cycle. The paradoxical motion of the abdomen during inspiration indicates diaphragmatic weakness associated with paralysis. Paradoxical inward movement of the chest wall during inspiration indicates paralysis of the chest wall muscle, as may occur in high thoracic spine injury or low cervical spine injury.

Finger Clubbing

Chronic hypoxia can lead to digital clubbing, where the fingers appear like a small club (**Figure 1-3**). Digital clubbing is due to chronic diseases such as bronchiectasis, congenital heart disease, cystic fibrosis, GI disease, liver disease, and lung tumors.

Chest Configuration

Inspection of chest configuration is important to identifying abnormalities of the chest that impact on pulmonary mechanics and reveal information about the progression of lung disease. Barrel chest is a common finding in many patients with obstructive lung disease



FIGURE 1-3 Digital clubbing. Normal finger **(A)**, mild digital clubbing **(B)**, and severe digital clubbing **(C)**.



FIGURE 1-4 Normal chest configuration **(A)** and a patient with an increased anteroposterior diameter **(B)**.

Data from Wilkins RL. Physical Examination of the Patient with Cardiopulmonary Disease. In: Wilkins R, Krider S, Sheldon R, eds. Clinical Assessment in Respiratory Care. 3rd ed. St. Louis: Mosby-Year Book; 1995: 47-77.

(e.g., emphysema) where the lateral diameter of a normal chest is twice the anteroposterior diameter. **Figure 1-4** shows the comparison of a patient with a normal chest to a patient with a barrel chest.

Other abnormalities of the thorax may cause restriction lung expansion and are restrictive lung diseases (**Figure 1-5**). One such abnormality is **pectus excavatum**, which is a sternum that is depressed and deviated like a funnel. **Pectus carinatum** is a chest that bows out at the sternum, similar to that of a pigeon. **Scoliosis** is a lateral curvature of the spine. **Kyphosis** is the forward curvature of the spine. **Kyphoscoliosis** is a combination of kyphosis and scoliosis. **Lordosis** causes posterior curvature of the spine.

Pedal Edema

Edema is an excessive accumulation of fluid in the interstitial space. Chronic lung disease can cause pedal edema because of right heart failure or cor pulmonale. Chronic hypoxemia causes pulmonary vasoconstriction that increases the right heart workload to push the blood through the constricted vasculature. This results in right ventricular hypertrophy and decreased venous return to the right heart. The reduced blood return to the right heart increases venous hydrostatic pressure and fluid accumulates in the interstitial space of the ankles, causing **pedal edema**. The patient with left heart failure also often presents with pedal edema; and edema of the feet, legs, and arms is not uncommon in patients with multisystem organ failure.[13] Pitting edema occurs when there is enough fluid in the interstitial space to cause an indentation in the skin when compressed under the fingertips.

Palpation

Palpation is the art of touching and feeling the surface of the body to assess the underlying tissue. For chest assessment, this involves touching the chest wall of a patient to find areas of tenderness or subcutaneous emphysema due to trauma, determine chest expansion, and assess for tactile fremitus. Palpation uses the fingertips, palms, or the ulnar part of the hand with light pressure. **Table 1-13** shows a review of the elements of palpation.

Peripheral Skin Temperature

Palpation of the patient's feet and hands provides information about perfusion; cool extremities may indicate inadequate perfusion. When cardiac output and blood flow are not sufficient, compensatory vasoconstriction of the extremities shunts the blood to the vital organs. The peripheral vasoconstriction and reduced perfusion result in the loss of warmth in the extremities.

Capillary Refill Time

Capillary refill time (CRT) is the amount of time required for the return of color after the application of blanching pressure to a distal capillary bed, and is used



FIGURE 1-5 Abnormal chest configurations. Pectus excavatum **(A)**, kyphosis **(B)**, scoliosis **(C)**, and pectus carinatum **(D)**.

(A) © Dr P. Marazzi/Science Source; **(B)** © Dr P. Marazzi/Science Source; **(C)** © Ralf Geithe/iStock/Getty Images; **(D)** Reproduced with permission from Hock, András. Minimal access treatment of pectus carinatum: a preliminary report. *Pediatr Surg Int.* 2009; 25(4):337–342 (Web. February 14, 2016; Figure 2, p. 340).

TABLE 1-13
Elements of Palpation

Palpation	Reveals
Peripheral skin temperature	Perfusion to skin, decreased skin temperature due to decrease in cardiac output, ambient temperature, or poor circulation
Capillary refill time	Decrease in perfusion to finger may be due to a decrease in cardiac output or poor circulation
Tactile fremitus	Increase due to solidlike or liquid substances (e.g., atelectasis) Decrease due to excessive air (e.g., COPD)
Subcutaneous emphysema	Air under skin due to trauma, esophageal rupture, bronchial tube rupture
Chest expansion	Right or left lung expansion problem

to assess the adequacy of blood flow to the extremities.[17] Capillary refill is assessed by pressing the fingernail and counting the number of seconds it takes for the color to return to the finger nail. When cardiac output is low, and perfusion to the extremities is inadequate, capillary refill is slow. Normal CRT is less than 3 seconds. However, ambient temperature and patient temperature have a profound effect on CRT. A quick and easy bedside test to perform, CRT is done at any place and under any conditions. Unfortunately, its results cannot be interpreted with any degree of confidence in the adult population.[18]

Tactile Fremitus

Normal lungs transmit palpable vibrations to the chest wall. This is **fremitus** and requires the examiner's hands to be placed on the chest wall to feel the vibrations that occur while a patient is speaking. The patient is asked to repeat the word "ninety-nine" or

"one-one-one," while the examiner places the ulnar aspect of both hands firmly against either side of the posterior chest wall between the scapula and the spine. The hands are moved downward and laterally to assess the lower lobes.

Sound waves move through gas, liquids, and solids. The movement of sound vibrations through a liquid and a solid are more effective than through gas (air). This is the basis for using tactile fremitus to assess the lungs. Some disease processes increase the transmission of sound and augment the intensity of the vibration felt. These disease processes include pneumonia (consolidation), pulmonary fibrosis, atelectasis, alveolar consolidation, pulmonary edema, and lung tumor. Other conditions diminish the transmission of sound and decrease the intensity of the vibrations. These disease processes include pneumothorax and hyperinflation (air trapping). Another reason for a decrease in tactile fremitus is obesity, overly muscular chest, and pleural effusion. These increase the distance between the chest wall and the air-filled lungs.

It is important to note that if the area of consolidation or atelectasis is not in contact with an open airway, tactile fremitus decreases or is absent. This occurs with atelectasis caused by complete bronchial obstruction. Fremitus is relatively subtle and is difficult to note when the increase or decrease is bilateral. Tactile fremitus can be supportive evidence used in addition to all other elements of assessment.

Subcutaneous Emphysema

Subcutaneous emphysema is the presence of air under the skin. The air may be present in subcutaneous tissues of the neck, chest, and face. This condition may be painful, and the tissues may swell. Subcutaneous emphysema may be detected by placing the stethoscope over the tissue and listening for crackling or popping sounds or by palpating bubbles as the examiner's fingers move along the surface of the affected area. The possible causes of subcutaneous emphysema include chest trauma, rupture of the esophagus, a rupture in the bronchial tube, or as a result of invasive procedures such as intubation, bronchoscopy, and central line insertion.

Chest Wall Expansion

The chest wall is palpated to determine if the lungs are expanding symmetrically. Lung disorders such as atelectasis, pneumothorax, pneumonia, lung resection, and right main stem intubation can cause asymmetrical chest expansion. To assess for asymmetrical expansion, the practitioner places the tips of each thumb on the patient's posterior chest so that they are touching at approximately the eighth thoracic vertebra. The thumbs are placed after the patient exhales fully, before a full and deep breath. The palmar surface of the hand and fingertips are spread out across the lower chest wall. At the end of the full, deep breath, the practitioner should note the distance each thumb moves outward from the midline. Under normal conditions, each thumb moves equally (symmetrically) a distance of approximately 3–5 cm.

Percussion

Percussion or tapping with a finger is used to evaluate the underlying lung tissue by the transmitted sounds. During percussion of the chest, the clinician firmly places the middle finger of the nondominant hand over the area to be evaluated. With the flip of the nondominant wrist, the tip of the dominant hand middle finger is used to strike the finger on the chest. Symmetrical and orderly chest percussion is essential to compare the sounds generated over the percussed areas of the chest (**Figure 1-6**). A normal air-filled lung creates a resonant sound on percussion. **Resonance**, or resonant percussion note, is the natural frequencies of vibration through normal air-filled lungs. Alterations in the lung tissue cause changes in the resonance heard during percussion.

Dull Percussion Note

A dull percussion note heard over the areas of high density or areas with little or no air is due to pleural effusion, atelectasis, and pleural thickening. It is also heard over the liver and a tumor. A dull percussion note has a flat or soft, high frequency (high pitch) and short duration. When there is an increase in tissue density, the sound vibrations generated by percussion do not freely transmit through the lungs.

Hyperresonant Percussion Note

A hyperresonant note is loud, has a high pitch, and is of long duration. This note is heard over the areas of low tissue density or areas with increased air. These areas occur in patients who have emphysema, pneumothorax,



FIGURE 1-6 Percussion technique.

Case Study: Dyspnea Associated with Septic Shock

The respiratory therapist is called to evaluate a patient with symptoms of septic shock. The patient is complaining of SOB and elevated body temperature. His level of consciousness (LOC) has been deteriorating for the past few hours; he is alert but confused. Physical assessment of the patient reveals the following:

- Heart rate = 106 beats/minute
- RR = 26 breaths/minute
- BP = 84/62 mm Hg
- Auscultation = bibasilar fine crackles
- No pedal edema or JVD
- Extremities cool to touch with peripheral cyanosis
- Positive for central cyanosis
- Capillary refill = 5 seconds

Briefly, explain the assessment parameters that may suggest this patient has hypoxia. Until the physician arrives at the hospital, what recommendations are appropriate for this patient?

Case Review Assessment

Septic shock or any type of shock could be detrimental to the patient if not treated promptly and appropriately. Shock is generally defined as the inability of the cardiovascular system to deliver adequate oxygen to the tissues. The objective data obtained from patient assessment indicate cardiopulmonary inefficiency to meet the body's metabolic demand. The patient is in a hypermetabolic state because of the fever. This increases CO_2 production and increases oxygen demand. Both the heart rate and the RR are increased to attempt to meet that high demand.

The feeling of dyspnea is the patient's perception of increased effort beyond normal to get air into his lungs. Auscultation revealed bibasilar fine crackles, which may be due to atelectasis. Cool extremities are a sign of compensation for hypotension due to vasoconstriction of superficial blood vessels, diverting the blood flow to the organs with high metabolic demand. A capillary refill of 5 seconds is indicative of poor peripheral perfusion. Cyanosis of the lips and mucous membrane indicates central cyanosis caused by tissue hypoxia. Low pulse pressure (PP) and hypoxia can account for the patient's confusion by causing cerebral hypoxia. Lack of pedal edema and JVD may rule out right heart failure and could be the result of hypotension.

Respiratory Therapist's Recommendations

The respiratory therapist recommends that the patient be started on oxygen therapy and monitored by pulse oximetry to maintain a saturation of greater than 92%. Vasopressor medications are indicated to increase the patient's BP. It is imperative that hemodynamics be restored to ensure adequate oxygen delivery to the tissues. Continuous ECG monitoring is necessary to monitor for tachycardia and cardiac arrhythmias. This patient needs to be monitored continually until the physician arrives.

an asthma exacerbation, or dynamic hyperinflation due to mechanical ventilation.

Auscultation of Breath Sounds

Breath sounds are generated in the large airways because of high air flow in the trachea and large bronchi. The bulk flow of air and its velocity produce turbulence in the large airways, creating audible sounds. Gas movement in the alveoli is due to simple diffusion, not bulk flow. Therefore, there are no audible lung sounds produced in the alveoli.

Listening to the breath sounds is the respiratory therapist's most important physical assessment technique. Breath sounds provide valuable information about a patient's lungs and their condition. Auscultation requires the use of a stethoscope and a quiet environment. The best position for the patient is sitting up. The anterior, posterior, and both lateral chest walls require breath sound assessment. Placing the stethoscope against bare skin eliminates distortion caused by clothing. The tubing should not be in contact with or rub against any objects during auscultation. The sounds created by the tubing rubbing against objects may be erroneously interpreted as adventitious lung sounds. Auscultation of breath sounds must be symmetrical with a comparison of the same spot over each lung segment. At each location on the chest wall, the patient inhales slightly deeper than normal and exhales passively. The auscultation of breath sounds should begin at the base of the lungs over the posterior chest (**Figure 1-7**).

There are four major characteristics of a breath sound that require assessment. The pitch is the physical property of vibrational frequency. The higher the frequency, the higher the pitch. Intensity, or amplitude, is the degree of change in pressure (positive or negative) during breathing and is directly proportional to the depth of breath, duration of inspiratory or expiratory sounds, and location of the sounds. **Table 1-14** shows the characteristics of the normal breath sounds.



FIGURE 1-7 Suggested sequence for systematic auscultation of the chest. For chest auscultation, always move from side to side (e.g., 1 to 2, 3 to 4, 5 to 6) to compare breath sounds on the left versus the right side. The suggested sequence for auscultation for a complete chest examination is numbered. The respiratory care clinician should listen to breath sounds on inspiration and expiration and move in sequence from position 1 through 25.

TABLE 1-14
Normal Breath Sound Characteristics

Breath Sound	Pitch	Intensity	Duration	Location
Vesicular	Low	Soft	Throughout inspiration until early in exhalation	Most lung fields
Bronchovesicular	Medium	Moderate	Throughout inspiration and expiration	Main bronchus area and upper right posterior lung field
Tracheal	High	Loud	Throughout inspiration and expiration	Trachea

Normal Breath Sounds

Tracheal breath sounds, also called bronchial breath sounds, are heard over the trachea and are high pitched with loud intensity as a result of turbulence created by the bulk flow in the trachea. The inspiratory and expiratory tracheal breath sounds are equal in length. If this breath sound occurs over lung fields, it is indicative of consolidation.

Bronchovesicular breath sounds are heard anteriorly over the upper part of the sternum between the first and second intercostal spaces. This is a combination of tracheal breath sounds and vesicular breath sounds. If this sound occurs over lung fields, it is indicative of consolidation.

Vesicular breath sounds, low pitched with a soft intensity, are heard over the lung periphery (parenchyma) where alveoli are located. The inspiratory phase is longer than the expiratory phase.

The differences in these breath sounds are explained by the role that healthy lung tissue plays in "filtering" or muffling the harsh sounds produced by turbulent flow in the trachea and large airways.[13] **Figure 1-8** shows an example of a normal versus abnormal (adventitious) breath sound heard during auscultation.

Adventitious Breath Sounds

In addition to normal lung sounds, other sounds may be produced in the lung when the underlying tissue is abnormal. Different lung pathologies produce sounds that do not occur normally; these lung sounds are **adventitious breath sounds**. Adventitious lung sounds are either continuous or discontinuous. The continuous sound maintains a uniform pattern for at least one-tenth of a second.[13] The discontinuous sound does not hold that pattern.[13]

Crackles or rales are discontinuous (becoming stronger and weaker during the respiratory cycle) adventitious breath sounds. Crackles are brief and explosive, and are usually heard during inspiration (sometimes during late inspiration). Depending on their site of origin, crackles have different qualities. They are often divided into fine, medium, and coarse.

Fine crackles occur when terminal airways and alveoli pop open during a deep breath when the inspiratory effort is sufficient enough to overcome the forces that collapsed the airways or the alveoli (atelectasis). Medium crackles occur when air is passing through fluid-containing bronchi. Coarse crackles are present in CHF when fluid accumulates in the interstitial space between the capillaries and alveoli. In the initial stage of CHF, coarse crackles are heard in the base of the lungs. As CHF worsens, crackles ascend higher up the airways. Medium and coarse crackles are also present in pneumonia over the involved lobe. In general, the common causes of crackles include atelectasis, pulmonary edema, interstitial lung disease, acute respiratory distress syndrome, and respiratory infections.

Rhonchi are deep rumbling sounds that are continuous and more pronounced during expiration. Rhonchi occur because of air passing through partially obstructed always or a tumor. Low-pitched rhonchi occur because of the presence of thick secretions in the larger airways. These rumbling rhonchi may be palpable through the chest wall. The Latin word rhonchus means wheeze; occasionally, rhonchi are called sonorous wheezes.

The term **wheeze** is used to describe the musical lung sounds from the lungs with intrathoracic airway obstruction. Wheezes occur because of rapid airflow through narrowed (obstructed) airways. The wheeze is indicative of increased airway resistance and work of breathing under conditions such as asthma and CHF. Wheezes are usually high pitched and most commonly heard during expiration. As airways narrow, wheezes may be heard on expiration as well as on inspiration.



FIGURE 1-8 Abnormal and normal breath sounds.

Airway diameter reduction and wheezes are indicative of bronchospasm, bronchitis, lung tumors, foreign body obstruction, and pulmonary edema.

Stridor is produced by airflow with high velocity through a narrowed larynx and trachea. The diameter of larynx and trachea are decreased because of infections such as croup or epiglottitis or from postextubation edema as a result of tissue injury. Stridor is a life-threatening sign because ventilation is compromised in patients with stridor. Close monitoring is imperative, and an emergency intubation or tracheostomy may be needed. Treatment for the causes of stridor includes cool humidity or aerosolized racemic epinephrine, depending on its cause.

Grunting is a lung sound heard in newborns with respiratory distress. It occurs when the newborn exhales against a partially closed glottis in an attempt to maintain lung volumes and prevent alveolar collapse. Grunting may be loud enough to hear without a stethoscope. Grunting improves gas exchange by increasing the functional residual capacity.

When pleural membranes become inflamed and rub against each other, a creaking or grating sound is produced and called a pleural friction rub. A pleural friction rub is localized and limited to the areas of pleural irritation, and may be intermittent. Pleural rubs usually occur in patients with pneumonia, pulmonary fibrosis, pulmonary embolism, pleural effusion, or post thoracic surgery.

A decrease in airflow into the lungs will cause diminished breath sounds. Little or no air flow will cause an absence in the production of breath sounds. This emergent situation occurs because of atelectasis, pneumothorax, consolidation, or severe asthma exacerbation.

Voice resonance, like breath sounds, reflects changes in lung density and airway patency and can help identify the underlying disease. Voice resonance increases with consolidation of the lung and decreases in lung collapse.[6] Voice sounds are normally muffled when auscultated during patient speech. When the practitioner auscultates over an area of suspected consolidation and has the patient say ninety-nine, if heard clearly it is bronchophony.[1] Similarly, egophony is elicited when the patient is asked to say the letter *e*. Over normal lung fields, the *e* would sound like *e*. Over areas of consolidation, the letter *e* sounds like the annunciation of the letter *a*. This "*e* to *a*" phenomenon occurs over areas of consolidation.[1] Whispered pectoriloquy refers to a distinct increase in transmission of vocal sounds associated with early pneumonia, pulmonary infarction, or atelectasis.[13] With this voice sound, the whispered numbers "*one, two, three*" are heard clearly through the stethoscope.

Case Study: Postoperative Atelectasis

The respiratory therapist is called in to evaluate a patient who is postoperative 3 days for upper abdominal surgery. She is afebrile, alert, and oriented, but complains of SOB. She is 62 years old, 5 feet tall, and weighs 190 lb. Her respiratory pattern is rapid at 36 beats/minute and shallow. Heart rate is 112 beats/minute and regular. The patient indicated that her SOB has increased for the past few hours and gets worse with any activity. Auscultation reveals diminished breath sounds with fine, late inspiratory crackles. The review of other body systems was unremarkable.

Issue: What is the most likely explanation of the patient's dyspnea and inspiratory crackles?

Case Review Assessment

Pulmonary complications are not uncommon following upper abdominal surgery. There are many factors that contributed to this patient's postoperative dyspnea.

1. **The surgical operation was in proximity to the diaphragm. The diaphragm is the major muscle of inspiration and any operation that might limit its contraction and relaxation will compromise the patient's tidal volume, as evident by an increase in RR and shallow breathing. The increase in RR is proportional to the degree of volume loss.**
2. **The late inspiratory crackles are caused by the sudden opening of peripheral airways during inspiration.**
3. **The patient weight is another contributing factor to her inability to breathe deep; her estimated ideal body is about 105 lb.**

These findings suggest atelectasis and loss of lung volume as the cause of dyspnea. Atelectasis causes arterial desaturation and hence low arterial oxygen content. The patient's inability to provide the increase in oxygen demand leads to worsening of dyspnea on exertion.

Respiratory Therapist's Recommendations

There may be other reasons for the patient's dyspnea besides postoperative atelectasis. CHF and pulmonary embolism are also concerns that need to be ruled out. The respiratory therapist recommends a chest radiograph and lung expansion therapy if atelectasis is confirmed.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Restrictive lung disease causes a barrel chest.
2. True or False: Bronchial breath sounds indicate lung consolidation.

Essential Elements of the Cardiac Examination

The cardiac examination is a systematic examination that begins with the clinician's first clinical impression, through observation or the view from the door. A closer look at the patient involves the inspection of the periphery as well as the chest. This inspection requires visualization of the patient's chest. Care must be taken to ensure privacy and comfort during the cardiac examination. Chest palpation identifies the heart's point of maximal impulse (PMI) and auscultation over the heart identifies abnormal heart sounds.

Observation

Examination of a patient's cardiovascular system begins, in earnest, with the observation of the patient, vital sign assessment, observation of JVD, finger assessment for clubbing, and ankle assessment for pedal edema.

Jugular Venous Distension

The primary visual inspection of cardiac assessment involves observation of the right internal JVP. Fluctuations in the right jugular vein reflect pressure changes in the right atrium and provide an indication of right heart hemodynamics. Distension of the right jugular vein suggests increased volume in the right ventricle and often suggests right ventricular failure. Normal jugular venous oscillation should not exceed 3 cm above the sternal angle (angle of Louis; Figure 1-1).

Inspection

With the patient in the supine position and the head elevated to 30°, inspection of the anterior chest wall is done to check for scars, an implanted pacemaker, and visible pulsations. Be sure to explain what you are doing and why before beginning. Expose the minimum amount of bare skin necessary. Ask for the patient's assistance to raise and cover the breast area if the patient is a female. The patient's age, size of the chest, and state of health influence this inspection. Obesity, large breasts, and a muscular chest can make the precordial examination more difficult. Apical pulsation or the **point of maximal impulse** occurs because the apex of the heart bumps against the chest wall with each heartbeat.[19] The PMI occurs in the midclavicular line in the fifth intercostal space and is due to left ventricular contraction (systolic thrust). If the PMI is visible, its location and size need to be noted.

Palpation

Because the apical impulse is not always visible, the clinician can palpate the PMI (**Figure 1-9**). The PMI may shift to the right or left with shifts in the mediastinum. Patients with COPD (emphysema) and air trapping with flat diaphragms may have the PMI shifted toward the epigastric area. Also, the left ventricular hypertrophy may cause an enlarged PMI.

Auscultation

Auscultation of the heart sounds provides valuable information that is significant in evaluating the critically ill patient. There are five auscultatory sites to assess during a cardiac examination (**Figure 1-10**). Normal heart sounds are primarily created by the closure of mitral, tricuspid, pulmonic, and aortic valves during the cardiac cycle (systole and diastole). The normal heart sounds are S_1 and S_2 (the "lub-dub" sound).

Normal Heart Sounds

The **first heart sound**, S_1, is produced when the mitral and tricuspid valves snap shut simultaneously at the beginning of systole. The first heart sound is the "lub." Normally, S_1 is a single sound; any delay in right ventricular systole may cause S_1 to split into its two component sounds. Right bundle branch block (RBBB) is the most common cause of S_1 splitting.

The **second heart sound**, S_2, is caused by the closure of the aortic and pulmonic valves during ventricular relaxation (diastole). The second heart sound is the "dub." This sound is heard best at the aortic and pulmonic listening positions. Splitting of S_2 occurs when pulmonic and aortic valves do not close simultaneously. A narrow splitting of S_2 that occurs during inspiration



FIGURE 1-9 Palpation of the apical pulse.



FIGURE 1-10 Use a systematic approach to auscultating heart sounds. Listen to each area for the S_1 and S_2. The sound of the aortic valve occurs over the "aortic area." The pulmonic valve closure occurs over the "pulmonic area." Erb's point is a common listening area, which lies halfway between the apex and the base of the heart. The mitral valve is heard over the PMI or the "mitral area."

TABLE 1-15
Normal Heart Sounds

Sound Name	S_1	S_2
Sound heard	"Lub"	"Dub"
Cause	Closure of mitral and tricuspid valves	Closure of aortic and pulmonary valves
Timing	Beginning of systole or ventricular contraction	Beginning of diastole or ventricular filling
Best heard over	Apex of heart (PMI or mitral area)	Base of heart (aortic and pulmonic areas)

is a physiologic phenomenon and is the result of a decrease in intrathoracic pressure and increased venous return to the right side of the heart. A significant delay of pulmonic and aortic valve closure will produce a wide splitting of S_2 and is indicative of pulmonary hypertension, RBBB, pulmonary embolism, and right-sided heart failure. **Table 1-15** summarizes the normal heart sounds.

Listening to cardiac sounds takes concentration and practice.[19] See **Box 1-4** for an outline of the steps to the cardiac auscultation. Extraneous noises need to be reduced, and the stethoscope must be placed directly on the skin. If the heart sounds are difficult to hear, the practitioner can ask the patient to change position. Sitting upright and leaning forward or lying down in the left decubitus position brings the heart closer to the chest wall.

Abnormal Heart Sounds

Extra heart sounds, S_3, and S_4, are generated by atypical blood flow mechanisms. These sounds, if present, are heard over the mitral area. Both S_3 and S_4 occur during diastolic filling and are due to blood striking the left ventricle.[13] These rhythms are commonly called **gallops** because of their resemblance to the sound of a horse galloping.[1] The S_3 heart sound is often a sign of systolic heart failure. However, it can be a normal finding in children, pregnant females, and well-trained athletes. The S_4 heart sound is always abnormal, and goes by the name "**atrial gallop**." The S_4 sound occurs during active left ventricular filling when atrial contraction forces blood into a noncompliant left ventricle. The S_4 sound is indicative of diastolic heart failure and may also occur with atrial fibrillation. **Table 1-16** summarizes the abnormal heart sounds.

BOX 1-4 Steps to Cardiac Auscultation

1. Begin with the aortic area, located along the right sternal border. Palpating for the right second intercostal space along the right sternal border will ensure the appropriate stethoscope location.
2. Next, move the stethoscope directly toward the patient's left sternal border at the left second intercostal space. This is clinically called the pulmonic area or left upper sternal border.
3. Moving down the left sternal border, next auscultate the tricuspid area. This area is at the left lower sternal border at the left fourth intercostal space.
4. The final auscultatory site is the mitral area, which is at the apex of the heart. The mitral area is anatomically at the fifth intercostal space in the midclavicular line. To auscultate the mitral area, use the bell of the stethoscope and have the patient lie in the left lateral decubitus position.

TABLE 1-16
Abnormal Heart Sounds

Sound Name	S_3	S_4
Sound heard	"Bub" in "lub-du-bub"	First "dub" in "dub-lub-dub"
Cause	Can be normal in healthy young athletes Distended or floppy left ventricle Systolic dysfunction Congestive heart failure	Atrial contraction or atrial kick Noncompliant left ventricle Diastolic heart failure Atrial fibrillation Active myocardial ischemia
Timing	After S_2	Late diastole, just before S_1
Best heard over	Apex of heart with stethoscope bell with patient in left lateral decubitus position	Apex of heart with stethoscope bell with patient in left lateral decubitus position

Abnormal heart sounds occur from turbulent blood flow within the heart. These "whooshing" sounds are **heart murmurs**. Murmurs occur when blood travels backward through a leaky valve (regurgitation), is forced through an abnormally tight area (stenosis), or is forced through a congenital anomaly between chambers. Causes of systolic heart murmurs include aortic stenosis, pulmonic stenosis, atrial septal defect, mitral regurgitation, tricuspid regurgitation, and ventricular septal defect. Causes of diastolic murmurs include aortic regurgitation, pulmonic regurgitation, mitral stenosis, and tricuspid stenosis.

The description of a heart murmur uses timing in the cardiac cycle, intensity, location, quality, pitch, configuration, and the response to specific maneuvers. Using those features will accurately characterize the nature of a murmur.[20] The timing of murmurs is early, middle, or late systolic—that is, occurring between S_1 and S_2. Others are diastolic, coming between S_2 and S_1.[1] Furthermore, systolic and diastolic murmurs are divided according to their duration within the cardiac cycle.[20] Systolic murmurs that are present throughout all of systole are holosystolic. Systolic murmurs can also be mid-systolic, early systolic, and mid-to-late systolic. Diastolic murmurs can be early diastolic, mid-diastolic, and late diastolic.

The intensity of a murmur is also classified by the intensity on a scale of 1 through 6. **Box 1-5** provides the grading system for intensity; the higher the grade, the louder the intensity.

The location where the murmur is loudest helps identify the origin of the murmur. For example, the murmur of aortic stenosis is loudest over the aortic area, and the murmur of pulmonary stenosis is loudest over the pulmonary area (Figure 1-10).

BOX 1-5 Timing and Grades of Heart Murmurs

Grade 1: Very faint murmur only appreciated by an expert in optimum conditions.

Grade 2: Faint murmur recognized by nonexpert in optimum conditions.

Grade 3: Loud murmur without an accompanying thrill.*

Grade 4: Loud murmur with an accompanying thrill.

Grade 5: Loud murmur heard with stethoscope partially off the chest.

Grade 6: Loud murmur heard with stethoscope off the chest.

*A "thrill" is a tremor or vibration felt upon palpation of the chest wall.

The quality of a murmur is harsh, blowing, musical, or squeaky. The pitch is either low, medium, or high. A high-pitched murmur is due to a large pressure gradient across a pathologic lesion. A change in the intensity of the murmur throughout the cardiac cycle is the configuration of the murmur. Configuration can be crescendo (increases progressively in intensity from start to finish), decrescendo (decreases progressively in intensity from start to finish), crescendo-decrescendo (increases then decreases in intensity), diamond-shaped decrescendo-crescendo (decreases then increases in intensity), plateau (constant intensity), and rectangular shaped (holosystolic or pansystolic).[20] Lastly, some murmurs respond to changes in position as a result of changes in preload, afterload, and chamber size that affect the characteristic of a murmur.

Many murmurs are classified as functional, innocent, or physiologic, meaning that they are clinically insignificant.[1] Others are significant in that they suggest a progressive pathologic process that may eventually require surgical intervention.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Left ventricular hypertrophy may cause the point of maximum impulse to shift to the epigastric area.
2. True or False: The S_3 heart sound is commonly normal in athletes and pregnant women.

Neurologic Assessment

Nervous system injuries often affect a patient's respiratory function. Familiarity with the basic components of the neurologic examination and common neurologic

abnormalities are essential to the respiratory therapist. The respiratory therapist needs to be able to assess a patient's LOC using the appropriate terms and assess and understand the commonly used neurologic scoring systems, such as the GCS, Ramsay Sedation Scale, the Richmond Agitation–Sedation Scale, and the Confusion Assessment Method for Assessing Delirium in the Intensive Care Unit. Other important aspects of the neurologic assessment include posturing and pupillary response.

Level of Consciousness

The most sensitive indicator of neurologic change is consciousness, which is the state of general awareness of oneself and the environment. It is difficult to measure consciousness directly. However, observation of a patient's response to certain stimuli supplies an estimation of consciousness. Assessment of LOC begins at the initial patient encounter. A patient with intact and normal functioning CNS will be awake, interacting, and communicating with others. If asleep, the patient can be easily aroused to an awake and alert state. If the patient does not respond to verbal stimuli but moves spontaneously in a purposeful manner, the patient is localizing. Localizing is purposeful and intentional movement intended to remove the stimulus. The terms in **Table 1-17** are used to describe deviations from the normal LOC.

Glasgow Coma Scale

When a patient experiences an alteration in the LOC because of trauma or some other hypoxic or metabolic event, the **Glasgow Coma Scale** (**GCS**, **Table 1-18**) is commonly used.[1] This scale decreases the subjectivity of responses by assessing and quantifying the patient's neurologic impairment. The GCS is used to evaluate the best motor response, best verbal response, and eye opening. The scale goes from a low of 3 to a maximum of 15. A score of 3 points is consistent with a deep coma or brain death. A score of 15 points indicates full consciousness (Table 1-18).

TABLE 1-17
Terms to Describe Levels of Consciousness

Term	Description
Coma (comatose)	The patient does not respond to any stimuli, even painful stimuli. The patient is unconscious.
Confusion (confused)	Patient has difficulty understanding directions. The patient is not oriented to person, place, time, or situation.
Delirium (delirious)	The patient is confused, restless, agitated, incoherent, and is often having hallucinations.
Lethargy (lethargic)	The patient is drowsy, but can be aroused.
Obtunded	The patient is difficult to arouse but responds appropriately.
Semi-coma (semi-comatose)	Patient is unconscious but responds to pain.
Stupor (stuporous)	Patient has reduced responsiveness when attempts are made to arouse.

Ramsay Sedation Scale

In patients who are critically ill, sedation and decreased LOC are often pharmacologically induced.[1] In delivering prescribed sedation, the use of valid sedation assessment tools promotes safe practice, and the repeated use of sedation scores helps ensure that documentation is kept up to date and that the cumulative effects of sedation on patients' cognitive states are minimized.[21] This scale has two defined groups of scores: those of 1, 2, and 3 are given in assessing degrees of wakefulness, and those of 4, 5, and 6 are given in assessing degrees of sleep (**Table 1-19**). The use of this type of scale can prevent over- and undersedation of patients who are acutely or critically ill.[21]

TABLE 1-18
Glasgow Coma Scale

Observation	Score
Eye Opening Response	
Spontaneously	4
In response to voice	3
In response to pain	2
None	1
Verbal Response	
Oriented response	5
Confused response	4
Inappropriate words	3
Incomprehensible words	2
None	1
Motor Response	
Obeys commands	6
Localizes	5
Withdraws	4
Flexes (decorticate)	3
Extends (decerebrate)	2
None	1

Data from Center for Disease Control: Glascow Coma Score. Last updated May, 2003. http://www.bt.cdc.gov/massacasualties/pdf/glasgow-coma-scale.pdf

Richmond Agitation–Sedation Scale

Agitated behavior frequently occurs in patients in the intensive care unit (ICU). Structured assessment of sedation and agitation is useful to titrate sedative medications and to evaluate agitated behavior.[22] RASS is a 10-point scale, with four levels of anxiety or agitation (+1 to +4 [combative]), one level to denote a calm and alert state (0), and five levels of sedation (−1 to −5) culminating in unarousable (−5)[22] (**Table 1-20**).

TABLE 1-19
Ramsay Sedation Scale

Observation	Score
Patient is anxious and agitated, restless, or both	1
Patient is cooperative, oriented, and tranquil	2
Patient responds to commands only	3
Patient exhibits brisk response to light glabellar tap or loud auditory stimulus	4
Patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus	5
Patient exhibits no response	6

Reproduced with permission from Dawson R, Fintel N, Nairn S. Sedation assessment using the Ramsay scale. *Emergency Nurse.* 2010;18(3):19 (Table 1, page 19)

Confusion Assessment Method for Assessing Delirium in the Intensive Care Unit

Conventional treatment of mechanically ventilated patients in the ICU has included deep sedation and, in some cases, muscle relaxation.[23] Prolonged ICU and hospital stays are associated with an increase in the diagnosis of delirium.[23,24] The diagnosis of delirium is particularly problematic in intubated patients because of problems of communication and the common use of sedative and analgesic drugs. Recent guidelines recommend that all adult patients in the ICU need regular assessment for delirium.[25] One of the methods recommended is the CAM-ICU monitoring tool (**Figure 1-11**).

TABLE 1-20
Richmond Agitation–Sedation Scale[22]

Score	Term	Description
+4	Combative	Overtly combative, violent, immediate danger to staff
+3	Very agitated	Pulls on or removes tube(s) or catheter(s) or aggressive toward staff
+2	Agitated	Frequent nonpurposeful movement or patient–ventilator dyssynchrony
+1	Restless	Anxious or apprehensive, but movements not aggressive or vigorous
0	Alert and calm	
−1	Drowsy	Not fully alert, but has sustained (>10 seconds) awakening, with eye contact, to voice
−2	Light sedation	Briefly (<10 seconds) awakens with eye contact to voice
−3	Moderate sedation	Any form of movement (but no eye contact) to voice
−4	Deep sedation	No response to voice, but any movement to physical stimulation
−5	Unarousable	No response to voice or physical stimulation

Procedure

1. Observe patient. Is patient alert and calm (score 0)? Does patient have behavior that is consistent with restlessness or agitation (score +1 to +4 using the criteria listed, under *Description*)?
2. If the patient is not alert, in a loud speaking voice state patient's name and direct patient to open eyes and look at the speaker. Repeat once if necessary. Can prompt patient to continue looking at the speaker. Patient has eye opening and eye contact, which is sustained for more than 10 seconds (score −1).
   Patient has eye opening and eye contact, but this is not sustained for 10 seconds (score −2).
   Patient has any form of movement in response to voice, excluding eye contact (score −3).
3. If the patient does not respond to voice, physically stimulate patient by shaking shoulder and then rubbing sternum if there is no response to shaking shoulder. Patient has any form of movement to physical stimulation (score −4).
   Patient has no response to voice or physical stimulation (score −5).

Reprinted with permission of the American Thoracic Society. Copyright © 2019 American Thoracic Society. Sessler C, Gosnell M, Grap M et al. The Richmond agitation–sedation scale. *Am J Respir Crit Care Med.* 2002;166(10):1338–1344 (Table 1, page 1139). doi:10.1164/rccm.2107138. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.



FIGURE 1-11 Confusion Assessment Method for assessing delirium in the Intensive Care Unit (CAM-ICU).

Reproduced from Guenther U, Popp J, Koecher L, et al. Validity and reliability of the CAM-ICU flowsheet to diagnose delirium in surgical ICU patients. *Crit Care.* 2010;25:144–156. © 2010, with permission of Elsevier.



FIGURE 1-12 **(A)** Decorticate posturing. **(B)** Decerebrate posturing.

Posturing

Patients with neurologic injury may demonstrate decerebrate or decorticate posturing (**Figure 1-12**). **Decorticate posturing** (Figure 1-12A) is characterized by adducted arms, flexed elbows, wrists, and fingers flexed on the chest, and legs stiffly extended and rotated internally. This type of response to painful stimuli occurs when the comatose patient has a lesion in the mesencephalic region of the brain. **Decerebrate posturing** (Figure 1-12B) is characterized by internal rotation and extension of the arms, with the wrists pronated, fingers flexed, and the legs extended. This type of response occurs when the comatose patient has a low-level brain stem compression.

Pupillary Dilation

Examination of the eyes, pupils, and eyelids is important in the search for clues about the patient's condition. Bilaterally dilated pupils (**Figure 1-13A**) that are fixed at 4 mm and nonreactive can be caused by severe midbrain damage, cardiopulmonary arrest due to hypoxia, and anticholinergic poisoning. Bilaterally constricted (**Figure 1-13B**) or pinpoint pupils can be caused by lesions of the pons, usually after hemorrhage. Unequal or unilaterally dilated (4 mm), fixed and nonreactive pupil (**Figure 1-13C**) can be caused by brain stem compression, increased intracranial pressure, or head trauma with a subdural or epidural hematoma.



FIGURE 1-13 **(A)** Bilaterally dilated pupils. **(B)** Bilaterally constricted (pinpoint) pupils. **(C)** Unequal pupils.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A patient who opens his eyes only in response to pain, uses inappropriate words as verbal response, and withdraws from touch has a GCS of 9.
2. True or False: Low-level brain stem compression causes decorticate posturing.

Chapter Summary

The respiratory therapist must be able to utilize the patient's medical history and physical examination to determine the need for immediate, life-saving techniques and further diagnostic testing. This process initiates as soon as the respiratory therapist walks through the door of the patient's room. Elements of cardiopulmonary assessment include determination of the patient's CC; taking the patient's medical history; assessing vital signs; observing, inspecting, palpating, percussing, and auscultating the patient's chest, lungs and heart; and a brief neurologic examination.

Key Points

1. The essential components of a patient medical history include the patient's CC; HPI; PMH; medication history; social, occupational, and environmental histories; family history; and an ROS.
2. The ROS includes assessing the patient's general symptoms, skin and nails, HEENT, endocrine system, respiratory system, cardiovascular system, hematologic system, lymph nodes, GI tract, genitourinary system, musculoskeletal system, neurologic status, and mental status.
3. Vital signs include body temperature, heart rate, RR, and BP. Disease states or changes in metabolism cause changes in vital signs.
4. Various abnormal breathing patterns are clues in the identification of underlying disease states.
5. Chest physical assessment includes observation, inspection, palpation, percussion, and auscultation. General observations about the patient include the identification of pursed-lip breathing. The inspection includes looking for JVD or accessory muscle use. Palpation can identify changes in tactile fremitus or locate broken ribs. Percussion of the chest can reveal pneumothorax (hyperresonant), pleural effusion (dull), or consolidation (dull). Auscultation of the chest identifies areas of the lungs with adventitious breath sounds.
6. Adventitious breath sounds include wheezes (bronchospasm), crackles (fluid or alveoli popping open), rhonchi (mucus), and stridor (upper airway obstruction).
7. Examination of a patient's cardiovascular system includes patient observation, vital sign assessment, observation of JVD, finger assessment for clubbing, ankle assessment for pedal edema, and listening for heart sounds. Listening to heart sounds involves notation of the rate and rhythm, extra heart sounds, and murmurs.
8. Normal heart sounds are S_1 and S_2; abnormal heart sounds are S_3 and S_4. Heart murmurs are characterized by their timing in the cardiac cycle, intensity, location, quality, pitch, configuration, and response to specific maneuvers.

9. In addition to the LOC, basic neurologic assessments made in the acute care setting include the GCS, Ramsay Sedation Scale, Richmond Agitation–Sedation Scale, and the CAM-ICU.
10. The GCS is used to evaluate the best motor response, best verbal response, and eye opening. The scale goes from a low of 3 to a maximum of 15. A score of 3 points is consistent with deep coma or brain death. A score of 15 points indicates full consciousness.

Chapter Questions

1. Demographic data include which of the following?
   a. Past surgeries
   b. Patient's physician name
   c. Major illnesses
   d. Living arrangements
2. The part of the patient's medical history that describes detailed information pertinent to the chief complaint is the:
   a. past medical history.
   b. social history.
   c. history of present illness.
   d. review of systems.
3. Factors that aggravate or diminish a patient's symptoms are documented in which section of the patient's medical record?
   a. History of present illness
   b. Past medical history
   c. Review of systems
   d. Chief complaint
4. A patient informs the respiratory therapist that she smokes 1½ packs of cigarettes each day for the past 30 years. This patient has a _____ smoking history.
   a. 15 pack-year
   b. 20 pack-year
   c. 30 pack-year
   d. 45 pack-year
5. A patient who smokes 10 cigarettes a day for 10 years has a smoking history of:
   a. 100 pack-year.
   b. 5 pack-year.
   c. 10 pack-year.
   d. 50 pack-year.
6. During the review of systems, the respiratory therapist finds out that the patient is suffering from dizziness and occasional fainting. Documentation of this information goes in which section of the review of systems?
   a. Mental status
   b. General symptoms
   c. HEENT
   d. Respiratory
7. Timing, influences, nature, and associated features (TINA) may be used to assist in the gathering of information for:
   a. history of present illness.
   b. review of systems.
   c. past medical history.
   d. occupational history.
8. The questionnaire system used to assess past and present alcohol intake is the:
   a. TINA questionnaire.
   b. Ramsay questionnaire.
   c. CAGE questionnaire.
   d. Glasgow questionnaire.
9. Which of the following patients has **all** normal vital signs?

	Heart Rate (Beats/ Minute)	Respiratory Rate (Beats/ Minute)	Blood Pressure (mm Hg)	Temperature (°C)
a.	68	14	98/65	37.5
b.	75	24	85/58	39
c.	105	18	142/95	38.7
d.	88	12	450/90	37

10. An elevated body temperature due to a disorder affecting the body is:
    a. hyperthermia.
    b. pyrexia.
    c. hypothermia.
    d. hyperpnea.
11. Central nervous system depression from a drug overdose causes which of the following?
    a. Bradypnea
    b. Tachypnea
    c. Hyperpnea
    d. Biot breathing
12. The patient with which of the following blood pressure readings (mm Hg) has underperfusion of the tissues and organs?
    a. 135/70
    b. 90/60
    c. 85/45
    d. 70/40
13. A patient with diabetic ketoacidosis is expected to have which breathing pattern?
    a. Cheyne–Stokes
    b. Kussmaul
    c. Biot
    d. Apneustic
14. Patient information gathered via observation includes which of the following?
    a. Pedal edema
    b. Tracheal position
    c. Pursed-lip breathing
    d. Jugular vein distension

15. The chest configuration most indicative of chronic obstructive pulmonary disease is:
- **a.** lordosis.
- **b.** scoliosis.
- **c.** kyphosis.
- **d.** barrel chest.

16. Which of the following combination of patient findings is associated with areas of lung consolidation?

	Palpation (Tactile Fremitus)	Percussion	Auscultation
a.	Increased	Tympanic	Bronchovesicular
b.	Decreased	Hyperresonant	Vesicular
c.	Increased	Dull	Bronchial
d.	Decreased	Resonant	Vesicular

17. A patient presents to the emergency department with shortness of breath, central cyanosis, bilateral lower lobe dull percussion, and bilateral coarse crackles of rapid onset. The most likely cause of these signs and symptoms is:
- **a.** an asthma exacerbation.
- **b.** congestive heart failure.
- **c.** lobar pneumonia.
- **d.** interstitial lung disease.

18. The point of maximal impulse is located at the:
- **a.** fifth intercostal space left midclavicular line.
- **b.** fourth intercostal space left sternal border.
- **c.** fifth intercostal space right midclavicular line.
- **d.** third intercostal space left sternal border.

19. The heart sound caused by the closure of the aortic and pulmonary valves is:
- **a.** S_1.
- **b.** S_2.
- **c.** S_3.
- **d.** S_4.

20. A patient who opens her eyes only to vocal stimuli, has a confused response to verbal stimuli, and withdraws from painful stimuli has a Glasgow Coma Score of:
- **a.** 6.
- **b.** 8.
- **c.** 11.
- **d.** 14.

References

1. Simmons P. History and physical examination. In: Hess D, MacIntyre N, Galvin W, Mishoe S, eds. *Respiratory Care: Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:2–21.
2. Gask L. ABC of psychological medicine: the consultation. *BMJ*. 2002;324(7353):1567–1569. doi:10.1136/bmj.324.7353.1567.
3. Lloyd H, Craig S. A guide to taking a patient's history. *Nurs Stand*. 2007;22(13):42–48. doi:10.7748/ns2007.12.22.13.42.c6300.
4. Shelledy D, Peters J. Patient history. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:87–135.
5. Redelmeier D, Tu J, Schull M, Ferris L, Hux J. Problems for clinical judgment: 2. Obtaining a reliable past medical history. *CMAJ*. 2001;164(6):809–813.
6. Ford M, Hennessey I, Japp A. *Introduction to Clinical Examination*. 8th ed. Edinburgh, UK: Elsevier, Churchill Livingstone; 2005.
7. Center for Disease Control and Prevention. Alcohol and public health. Fact sheet. Updated December 17, 2015. http://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm. Accessed January 10, 2016.
8. National Institute on Alcohol Abuse and Alcoholism. A pocket guide for alcohol screening and brief intervention. Updated 2005 Edition. http://pubs.niaaa.nih.gov/publications/Practitioner/PocketGuide/pocket.pdf. Accessed January 10, 2016.
9. Balmes J, Speizer F. Occupational and environmental lung disease. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Medical; 2013:93–104.
10. Kallet R. Bedside assessment of the patient. In: Kacmarek R, Stoller J, Heuer A, eds. *Egan's Fundamentals of Respiratory Care*. 10th ed. St. Louis, MO: Elsevier Mosby; 2013:329–355.
11. Wilkins R, Gold P. Introduction to patient assessment. In: Wilkins R, Dexter J, Gold P, eds. *Respiratory Disease: A Case Study Approach to Patient Care*. 3rd ed. Philadelphia, PA: F.A. Davis Company; 2007:1–34.
12. McCarthy P, Heusch A. The vagaries of ear temperature assessment. *J Med Eng Technol*. 2006;30(4):242–251. doi:10.1080/03091900600711415.
13. McCarthy M, Shelledy D. Physical assessment. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:137–186.
14. *Professional Guide to Signs and Symptoms*. 6th ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams and Wilkins; 2011.
15. Hanley M. The history & physical examination in pulmonary medicine. In: Hanely M, Welsh C, eds. *Current Diagnosis & Treatment in Pulmonary Medicine*. 1st ed. New York, NY: Lange Medical Books/McGraw-Hill; 2003:16–25.
16. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. Philadelphia, PA: Elsevier Saunders; 2014.
17. Gorelick MH, Shaw KN, Baker MD. Effect of ambient temperature on capillary refill in healthy children. *Pediatrics*. 1993;92:699–702.
18. Lewin J, Maconochie I. Capillary refill time in adults. *Emerg Med J*. 2008;25:325–326. doi:10.1136/emj2007.055244.
19. Atitesting.com. "Physical assessment (Adult)." N.p. 2016. https://quizlet.com/271477628/ati-physical-assessment-adult-flash-cards/. Accessed August 19, 2018.
20. Etoom Y, Ratnapalan S. Evaluation of children with heart murmurs. *Clin Pediatr*. 2013;53(2):111–117. doi:10.1177/0009922813488653.
21. Dawson R, Fintel N, Nairn S. Sedation assessment using the Ramsay scale. *Emerg Nurse*. 2010;18(3):18–20. doi:10.7748/en2010.06.18.3.18.c7825.
22. Sessler C, Gosnell M, Grap M, et al. The Richmond agitation–sedation scale. *Am J Respir Crit Care Med*. 2002;166(10):1338–1344. doi:10.1164/rccm.2107138.
23. Svenningsen H, Egerod I, Videbech P, Christensen D, Frydenberg M, Tønnesen E. Fluctuations in sedation levels may contribute to delirium in ICU patients. *Acta Anaesthesiol Scand*. 2013;57(3):288–293. doi:10.1111/aas.12048.
24. Haenggi M, Blum S, Brechbuehl R, Brunello A, Jakob S, Takala J. Effect of sedation level on the prevalence of delirium when assessed with CAM-ICU and ICDSC. *Intensive Care Med*. 2013;39(12):2171–2179. doi:10.1007/s00134-013-3034-5.
25. Barr J, Fraser G, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. *Crit Care Med*. 2013;41(1):278–280. doi:10.1097/ccm.0b013e3182783b72.

CHAPTER

2

Diagnostic Testing and Monitoring

"Not everything that counts can be counted and not everything that can be counted counts."

—Reproduced from Cameron, W. *Informal Sociology: A Casual Introduction to Sociological Thinking*. New York, NY: Random House:1963:13.

OUTLINE

OBJECTIVES

1. Discuss methods for examining a sputum sample.
2. Explain the indications, contraindications, and complications for bronchoscopy.
3. Identify parameters commonly measured during spirometry.
4. Explain the correlation among sleep apnea, snoring, and excessive daytime sleepiness.
5. Describe the normal components of capnography.
6. Discuss the need for fractional exhaled nitric oxide measurements.
7. Label arterial blood gas results using conventional and alternative clinical interpretations.
8. Analyze a complete blood count, a comprehensive metabolic panel, and cardiac enzyme results.
9. Systematically evaluate a chest radiograph for normal anatomic structures.
10. Identify the advantages and disadvantages of using computed tomography, magnetic resonance imaging, and positron emission tomography to diagnose pulmonary diseases.
11. Differentiate between diagnostic ultrasound techniques and their clinical indications.
12. Explain cardiopulmonary exercise testing, its indications, and contraindications.
13. Describe the clinical importance of hemodynamic monitoring.
14. Discuss the roles of arterial blood pressure, central venous pressure, and pulmonary artery pressure in hemodynamic monitoring.

KEY TERMS

Anemia
Anion gap
Basic metabolic panel (BMP)
Berlin Questionnaire
Bronchoalveolar lavage (BAL)
Bronchoscopy
Capnography
Cardiac catheterization
Cardiac enzyme
Cardiac troponin
Cardiopulmonary exercise testing (CPX)
Central venous pressure (CVP)
Clinical chemistry
Complete blood count (CBC)
Comprehensive metabolic panel (CMP)
Computed tomography (CT)
Co-oximetry
Creatine kinase (CK-MB)
CT pulmonary angiography
Dyshemoglobins
Dyslipidemia
ECG telemetry
Echocardiography
Electroencephalogram (EEG)
Electromyogram (EMG)
Electrooculogram (EOG)
Electrophysiologic test (EP)
End-tidal carbon dioxide ($ETCO_2$)
Epistaxis
Epworth Sleepiness Scale (ESS)
Erythrocyte
Excessive daytime sleepiness (EDS)
Fick method
Flow-directed pulmonary artery catheter
Fractional exhaled nitric oxide (FE_{NO})
Hematology
Hemodynamics
High-density cholesterol (HDL)
Lateral decubitus
Leukocytes
Low-density cholesterol (LDL)
Magnetic resonance imaging (MRI)
Mainstream capnography sensor
Maximum oxygen uptake (Vo_{2max})
Metabolic equivalent (MET)
Nonrapid eye movement (NREM) sleep
Percutaneous coronary intervention (PCI)
Polycythemia
Polysomnography (PSG)
Positron emission tomography (PET)
Pulmonary artery pressure (PAP)
Pulmonary capillary wedge pressure (PCWP)
Pulmonary function test (PFT)
Pulmonary vascular resistance (PVR)
Pulse oximetry
Radiolucent
Radiopaque
Rapid eye movement (REM) sleep
Sidestream capnograph sensor
Six-minute walk test (6MWT)
Sleep-disordered breathing (SDB)
Spirometry
Systemic vascular resistance (SVR)
Thermodilution method
Thrombocyte
Thrombocythemia
Thrombocytopenia
Transesophageal echocardiography (TEE)
Transthoracic echocardiography (TTE)
Tuberculin skin test (TST)
Ultrasonography

Introduction

A comprehensive evaluation of patients with a suspected or known cardiopulmonary disease requires a thorough history, physical examination, and diagnostic testing. The proper use of diagnostic testing confirms or rules out the presence of a disease. It is the patient interview and physical examination that drive the need for diagnostic testing. These tests include biologic specimens, cardiac catheterization, cardiopulmonary exercise testing, direct visualization of part of the respiratory system, echocardiogram, electrocardiogram, electrophysiology studies, imaging studies, measurements of gas exchange, and pulmonary function testing.

Case Study: Diagnostic Testing and Monitoring

A 27-year-old man arrives in the emergency department unable to speak because of shortness of breath. His wife states that this shortness of breath came on suddenly 2 days ago and is progressively worse. His wife states that he has a history of asthma with no known allergies. She also says that before 2 days ago, her husband was in good health.

Physical examination reveals a well-developed, well-nourished man in obvious respiratory distress. He is alert, oriented, but very anxious. He is sitting forward in the bed, gasping for air. His vital signs include a respiratory rate of 28 breaths/minute, pulse 125 beats/minute, blood pressure (BP) 112/75, temperature 37.9°C, and pulse oximeter reading of 92%. His trachea is midline with accessory muscle use. Lung auscultation reveals bilateral inspiratory and expiratory wheezes.

Questions

1. **What type of continuous monitoring is appropriate for this patient?**
2. **What diagnostic tests are appropriate for this 27-year-old man in respiratory distress?**

Answers

1. **Continuous monitoring of his oxygen saturation, pulse, heart rhythm, and BP is appropriate at this time. This will identify any life-threatening alterations in his cardiopulmonary status. Immediate administration of supplemental oxygen is necessary for this patient because he is in respiratory distress even though he is maintaining his oxygen saturation for now. The patient's past history of asthma with his current presentation points to an acute asthma exacerbation**

Case Study: Diagnostic Testing and Monitoring (*Continued*)

necessitating an aerosol treatment with a short-acting beta-agonist. A peak expiratory flow rate (PEFR) measurement is appropriate before and after each aerosol treatment. A pre-treatment PEFR <50% of predicted or personal best is indicative of a severe asthma exacerbation.

2. **Arterial blood gas is needed to assess the patient's ventilatory status and confirm his ability to oxygenate. A chest radiograph is appropriate to rule out other causes of respiratory distress such as upper airway obstruction, pneumothorax, or pneumonia. A complete blood count (CBC) is appropriate to find evidence of infection. A 12-lead electrocardiogram (ECG) will rule out any cardiac causes of respiratory distress or identify any cardiac response to hypoxemia.**

KNOWLEDGE CHECK QUESTIONS

1. True or False: It is appropriate for a patient with shortness of breath to have continuous oxygen saturation monitoring.
2. True or False: The patient history and physical examination determines the need for diagnostic testing.

Pulmonary Diagnostic Tests

Pulmonary diagnostic tests are a series of examinations that are specific to the diagnosis of lung diseases. These tests include visual inspection and microbiological testing of sputum and of specimens acquired by invasive biopsy techniques, including bronchoscopy and bronchoalveolar lavage. Pulmonary function tests (PFTs) can assist in the diagnosis of a pulmonary disease, the assessment of severity, and monitoring the treatment. Polysomnography is the gold standard for the diagnosis of sleep-related respiratory disorders.

Sputum Examination

Coughing and sputum production is a manifestation of many respiratory disorders and may be necessary for the diagnosis and management of such disorders. Laboratory examination of sputum is helpful in the evaluation of respiratory tract infections.

Proper sputum collection is imperative for sputum examination; a good specimen will have few squamous epithelial cells and many polymorphonuclear leukocytes. Sputum can be obtained by expectoration, airway suctioning, or bronchoscopy. **Table 2-1** shows the different ways of sputum sample examination.

Factors that can alter the result of sputum culture include the recent use of antibiotics, contamination of the sputum sample, an inadequate sample, and delivery delay to the laboratory.

TABLE 2-1
Examination of Sputum

Evaluation Technique	Use
Gross examination	• Indicate further microbiological evaluation
Culture and sensitivity	• Diagnose bacterial infections • Select and evaluate the effectiveness of antibiotic therapy
Gram stain	• Classify bacteria into gram negative and gram positive • Guide therapy until the culture and sensitivity are available
Acid-fast smear and culture	• Determine the presence of acid-fast bacilli via a series of three early-morning sputum samples
Cytology	• Identify the presence of abnormal malignant cells via microscope

Skin Testing

Skin tests are performed to evaluate allergic reactions or exposure to *Mycobacterium tuberculosis*. Skin tests require the injection of the antigen into the dermal layer of the skin. A positive allergy test indicates that the individual had exposure to the tested antigens. A positive **tuberculin skin test (TST)** shows an individual has been infected with *M. tuberculosis* but does not have the disease.

Bronchoscopy

Bronchoscopy is one of the most common methods of evaluating the respiratory tract and can be used to perform both diagnostic and therapeutic procedures. The bronchoscope is an instrument that allows the visualization of the airways beyond the larynx. **Figure 2-1** shows the view of a normal trachea and carina. The standard flexible bronchoscope is less than 0.5 inches wide and is about 2 feet long.[1] **Table 2-2** lists the indications and contraindications for bronchoscopy.

Hazards and Complications of Flexible Bronchoscopy

Complications from bronchoscopy include the adverse effects of the medications used before and during

bronchoscopy. Also, cardiac arrhythmias, hypoxemia, hypercarbia, bronchospasm, increased airway resistance, hypotension, and vagally mediated phenomena or death can occur. Mechanical complications include **epistaxis**, pneumothorax, and hemoptysis.[2] The patient can also suffer from nausea and/or vomiting and fever and chills. There can be cross-contamination of specimens or bronchoscopes.[2]

Bronchoalveolar Lavage

Bronchoalveolar lavage (BAL) uses the suction channel of a fiberoptic bronchoscope to withdraw the instilled sterile normal saline solution. The withdrawn fluid then undergoes chemical, cytologic, and/or microbiologic assessment. Common tests include gross observation, cell count and differential, cultures, and stains.[3] **Table 2-3** list the indications and complications/adverse reactions for the BAL procedure.

Pulmonary Function Testing

Pulmonary function tests (PFTs) range from simple bedside assessment of PEFR measurements to complex computerized lab studies.[4] PFTs are the primary diagnostic tool for evaluating patients with respiratory symptoms and for guiding the management of such patients' diagnosed lung disease. PFTs provide



FIGURE 2-1 **(A)** Normal-appearing main carina with sharply defined bifurcation. **(B)** Tumor infiltrating the proximal right mainstem bronchus.

TABLE 2-2
Indications and Contraindications to Bronchoscopy

Indications	Contraindications	Relative Contraindications
Evaluation of airways Infection Lung mass or nodule Hemoptysis Unexplained cough Removal of foreign body	Inability to maintain adequate oxygenation Operator inexperience Inadequate facilities Lack of informed consent Status asthmaticus	Active ischemic heart disease Active cardiac arrhythmia Refractory hypoxemia Bleeding diathesis Uncooperative patient Active or uncontrolled bronchospasm hypo- or hypertension

TABLE 2-3
Indications, Diagnosis, and Adverse Reactions for Bronchoalveolar Lavage

General Indications	Diagnostic for	Adverse Reactions
Nonresolving pneumonia Diffuse lung infiltrates (interstitial and/or alveolar) Suspected alveolar hemorrhage Infiltrates in an immunocompromised host Exclusion of diagnosable conditions by BAL, usually infection Research	Alveolar hemorrhage Malignancies Infections (mycobacterial, pneumocystis, bacterial, fungal, viral)	Cough Transient fever (2.5%) Transient chills and myalgia Transient infiltrates (resolves in 24 hours) Transient fall of lung function Bronchospasm (<1%) Transient decrease in baseline Pa_{O_2}

an objective assessment for the determination of the presence or absence of pulmonary disease. They provide data about the presence of ventilatory defects, gas exchange defects, lung disease severity, and patient response to therapy. **Spirometry** is that part of pulmonary function testing that measures how an individual inhales or exhales volumes of air as a function of time.[5] Spirometry is useful as a screening test of general respiratory health.[5] The goals of pulmonary function testing are to detect airflow limitation, lung restriction, gas transfer abnormalities, and ventilatory muscle weakness.[6] **Table 2-4** lists the indications and contraindications for PFTs.

A variety of tests may detect functional impairment of the respiratory system at a relatively early stage of pulmonary disease. Commonly performed pulmonary function studies are measurements of lung volumes, forced expiratory flow rates, and diffusion capacity. There are three locations where PFTs are usually performed: at the bedside, in a physician's office, or in a pulmonary function laboratory. Bedside and physician offices utilize spirometry, as do screenings during health fairs. Full PFTs may be hospital based or freestanding. **Table 2-5** lists types of tests included with screening or laboratory testing.

PFTs are an important tool in the assessment of patients with suspected or known respiratory disease. Interpretation of the tests, which requires knowledge of normal values and appearance of flow-volume curves, must be combined with the patient's clinical history and presentation.[7]

Polysomnography

Polysomnography (PSG) is the technique of creating a continuous record of physiologic variables, including respiratory, cardiac, brain, and muscle activity, during sleep. Multiple sensors are used to create a diagnostic polysomnogram montage. These sensors measure brain activity with an **electroencephalogram (EEG)**, eye

TABLE 2-4
General Indications and Contraindications for Pulmonary Function Testing

Indications	Contraindications
Diagnose • Investigate symptoms and signs that suggest pulmonary disease • Identify pulmonary disease in at-risk individuals • Identify respiratory complications in at-risk individuals Monitor/evaluate • Monitor the progression of known pulmonary disease • Evaluate response to therapy • Monitor the effect of occupational or environmental exposure • Preoperative evaluation • Monitor lung transplantation • Evaluate the degree of disability	• Recent MI (within 1 month) • Unstable angina • Recent eye surgery • Thoracic or abdominal aneurysm • Recent abdominal or thoracic surgery • Current pneumothorax

TABLE 2-5
Common Pulmonary Function Tests

Pulmonary Function Test	Lung Function Test Included
Screening spirometry • Patient bedside • Physician office • Health fair	• Slow vital capacity • Forced vital capacity (FVC) • Forced expiratory volume 1 second (FEV_1) • FEV_1/FVC • Forced expiratory flow 25–75% (FEF_{25-75}) • PEFR • Flow-volume loop • Pre- and post-bronchodilator therapy • Dynamic lung volumes (tidal volume, inspiratory reserve volume, expiratory reserve volume, minute volume)
Laboratory pulmonary function testing • Hospital lab • Physician clinic/lab	• Same as bedside pulmonary function spirometry • Maximum voluntary ventilation (MVV) • Static lung volumes (residual volume, functional residual capacity, total lung capacity) • Diffusion capacity (DL_{CO}) • Bronchoprovocation test • Airway resistance

activity with an **electrooculogram (EOG)**, and muscle activity with an **electromyogram (EMG)**. The assessment of adult sleep looks at changes in these three sets of parameters.

Normal adult sleep consists of two states: **nonrapid eye movement (NREM) sleep** and **rapid eye movement (REM) sleep**. These sleep states alternate throughout the night.[8] A sleep cycle is a combination of NREM and REM sleep. Sleep normally begins with NREM and progresses to REM. The brain activity diminishes during NREM, suggesting a resting or restorative state. The REM period is characterized by increased brain activity, dreaming, and partial paralysis of skeletal muscles. Throughout the night, REM episodes increase in duration and normally account for 25% of the total sleep period. NREM occupies about 75% of the sleep period and includes restorative sleep known as slow-wave sleep. **Table 2-6** shows both normal and abnormal physiologic changes that occur during sleep.

Patients with **sleep-disordered breathing (SDB)** often have nonspecific and unremarkable physical examinations. Assessment of snoring and excessive somnolence issues occurs during the medical history and the interview portion of the physical assessment. Evidence of **excessive daytime sleepiness (EDS)** may be evident during the interview. In some cases, the loss of sleep can produce lethargy or inability to concentrate on tasks and questions. Two instruments can provide additional information about and insight into EDS and SDB. The **Epworth Sleepiness Scale (ESS)** is a tool used to assess daytime sleepiness (**Figure 2-2**). The **Berlin Questionnaire** is a survey instrument used to identify risk factors associated with sleep apnea (**Figure 2-3**).

The main scoring categories during PSG include sleep stages, respiratory events, leg movements, and arousals. Other parameters, such as pulse oximetry, ECG, snoring, continuous positive airway pressure titration, and effects of posture, are assessed and documented. The main components of laboratory PSG are listed in **Table 2-7**.

Simple, inexpensive devices are available to screen or case-select patients with SDB. The portable devices offer several potential advantages compared with in-laboratory PSG. Home sleep testing might provide a more realistic appraisal of SDB than can be obtained in the PSG lab. The reduced number of monitors with portable devices may also help with a better approximation of the patient's usual sleep habits. The home sleep test may be performed by a technician or by the patient. These systems often record only the airflow, respiratory effort, ECG, and Spo_2.[9]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Malignant cells can be identified in the sputum using gram staining.
2. True or False: Skin testing determines exposure to *M. tuberculosis*.
3. True or False: One of the goals of pulmonary function testing is to detect impaired gas diffusion across the alveoli.
4. True or False: A diagnosis of SDB occurs during a physical examination.

Noninvasive Monitoring

Monitoring patients with cardiopulmonary diseases is a crucial responsibility of the respiratory therapist. In the practice of respiratory care, several noninvasive patient monitors are available. In addition to vital sign

TABLE 2-6
Physiologic Changes During Sleep

Normal Occurrences	Abnormal Occurrences (SDB)
Alterations in neurochemical reflexes	Decrease in airflow ≥90% of baseline for ≥10 seconds (apnea)
Increased airway resistance	Reduction in airflow by ≥30% for ≥10 seconds and of O_2 by ≥4% (hypopnea)
Reduction in upper airway muscle tone	Apnea with continued ventilatory effort (obstructive apnea)
Reduction in ventilatory muscle tone	Absent ventilatory effort with apnea (central apnea)
Reduction in ventilation (rate and volume)	Apnea with initial absence and then resumption of respiratory effort (mixed apnea)
<10 cortical arousals (non-sleep stage change in EEG activity) of at least 15 seconds/hour of sleep	>20–25 cortical arousals (non-sleep stage change in EEG activity) per hour of sleep

HEALTH ANALYSIS

Epworth Sleepiness Scale (ESS)

The following questionnaire will help measure your general level of daytime sleepiness. You are to rate the chance that you would *doze off or fall asleep* during routine daytime situations. Each action is rated from 0 to 3; never *dozing or falling asleep* in a given situation (0) and the very high chance of *dozing or falling asleep* in that situation (3). In contract to just feeling tired, how likely are you to *doze off or fall asleep* in the following situations? If you haven't done some of the activities recently, think about how they would have affected you in the past.

Use this scale to choose the most appropriate number for each situation:

0 = would never doze
1 = slight chance of dozing
2 = moderate chance of dozing
3 = high chance of dozing

SITUATION	CHANCE OF DOZING			
Sitting and Reading	0	1	2	3
Watching Television	0	1	2	3
Sitting Inactive in a Public Place (Theater/Meeting)	0	1	2	3
Riding in a Vehicle for an Hour or More	0	1	2	3
Lying Down to Rest in the Afternoon	0	1	2	3
Sitting and Talking to Someone	0	1	2	3
Sitting Quietly After Lunch (No Alcohol)	0	1	2	3
Waiting in Stopped Traffic	0	1	2	3

Total Score _____

Name: _____

Date: _____

NAVY AND MARINE CORPS PUBLIC HEALTH CENTER
PREVENTION AND PROTECTION START HERE

FIGURE 2-2 The Epworth Sleepiness Scale is a short questionnaire designed to determine a patient's subjective level of daytime sleepiness. The patient and physician can compare the patient's score with the following key[9]:

0–5 Normal daytime sleepiness
6–10 Mild daytime sleepiness
11–17 Moderate daytime sleepiness
18–24 Severe daytime sleepiness

Reproduced from Johns, M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*, 14(6), 540–545.

BERLIN QUESTIONNAIRE

Height (m) _____ Weight (kg) _____ Age _____ Male/Female

Please choose the correct response to each question.

CATEGORY 1

1. **Do you snore?**
   a. Yes
   b. No
   c. Don't know
   If yes:
2. **Your snoring is:**
   a. Slightly louder than breathing
   b. As loud as talking
   c. Louder than talking
   d. Very loud - can be heard in adjacent rooms
3. **How often do you snore?**
   a. Nearly every day
   b. 3-4 times a week
   c. 1-2 times a week
   d. 1-2 times a month
   e. Never or nearly never
4. **Has your snoring ever bothered other people?**
   a. Yes
   b. No
   c. Don't know
5. **Has anyone noticed that you quit breathing during your sleep?**
   a. Nearly every day
   b. 3-4 times a week
   c. l-2 times a week
   d. l-2 times a month
   e. Never or nearly never

CATEGORY 2

6. **How often do you feel tired or fatigued after your sleep'?**
   a. Nearly every day
   b. 3-4 times a week
   c. 1-2 times a week
   d. 1-2 times a month
   e. Never or nearly never
7. **During your waking time, do you feel tired, fatigued or not up to par?**
   a. Nearly every day
   b. 3-4 times a week
   c. 1-2 times a week
   d. l-2 times a month
   e. Never or nearly never
8. **Have you ever nodded off or fallen asleep while driving a vehicle?**
   a. Yes
   b. No
   If yes:
9. **How often does this occur?**
   a. Nearly every day
   b. 3-4 times a week
   c. 1-2 times a week
   d. 1-2 times a month
   e. Never or nearly never

CATEGORY 3

10. **Do you have high blood pressure?**
    a. Yes
    b. No
    c. Don't know

SCORING

CATEGORY I
* Item 1 is assigned 1 point if the answer is a.
* Item 2 is assigned 1 point if the answer is c or d.
* Item 3 is assigned 1 point if the answer is a or b.
* Item 4 is assigned 1 point if the answer is a.
* Item 5 is assigned 2 points if the answer is a or b.

Category 1 is positive if the total score is 2 or more points.

CATEGORY 2
* Item 6 is assigned 1 point if the answer is a or b.
* Item 7 is assigned 1 point if the answer is a or b.
* Item 8 is assigned 1 point if the answer is a.
* Item 9 is noted separately.

Category 2 is positive if the total score is 2 or more points.

CATEGORY 3
Category 3 is positive if the answer to item 10 is a or if the patient's BMI is 30 or higher

HIGH RISK: If there are 2 or more categories with a positive score.

LOW RISK: If there is only I or no categories with a positive score.

FIGURE 2-3 The Berlin Questionnaire for sleep apnea. The questionnaire consists of three categories related to the risk of having sleep apnea. Patients are classified into high risk or low risk based on their responses to the individual items and their overall scores in the symptom categories.

Adapted from Spriggs W. *Essentials of Polysomnography*, 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015:37–38.

monitoring, other noninvasive monitoring of adult patients includes ECG telemetry, pulse oximetry, capnometry, and exhaled nitric oxide.

ECG Telemetry

In the critical care setting it is common to place and keep monitoring leads directly on the patient's chest in a simple three-lead ECG configuration to show continuous wireless cardiac electrical activity (**ECG telemetry**). These include Lead I, Lead II, and Lead III. This placement forms Einthoven's triangle, presented in **Figure 2-4**. Other continuous monitoring electrode placements include a 5-lead system, a 6-lead system, and a continuous 12-lead system. The choice of monitoring lead systems relies on the goals of monitoring for specific patient population and the patient's clinical situation.[10]

An ECG tracing has waves, complexes, segments, and intervals that represent the electrical activity of the heart. **Figure 2-5** displays a normal ECG tracing showing all of the components of the tracing.

Each of the three leads provides information about different areas of the heart muscle. Changing the relationship of the positive, negative, and ground leads provides a few different bipolar electrical views of the heart.

- Lead I: LA is positive (+), RA is negative (−), and LL is the ground. This contains information about the left lateral wall of the myocardium.

TABLE 2-7
Components of Polysomnography

Activity Monitored	Polysomnography Component
Brain activity, sleep stages, arousals	EEG
Eye movement (REM vs. NREM)	Right and left EOG
Cardiac activity	ECG
Chin muscle activity	Chin EMG
Airflow through mouth and nose	Airflow sensor
Chest and abdominal movement	Respiratory effort belts
Snoring	Snore microphones or snore sensors
Leg movement	Leg EMG
Oxygen saturation	Pulse oximeter



FIGURE 2-4 The placement of ECG chest leads for three-lead continuous cardiac monitoring. The most frequent monitoring lead is Lead II.



FIGURE 2-5 The normal ECG tracing showing waves, complexes, intervals, and segments.

- Lead II: LA is the ground, RA is negative (−), and LL is positive (+). This provides information about the inferior wall of the myocardium and is the most common monitoring lead (**Figure 2-6**).
- Lead III: LA is negative (−), RA is the ground, and LL is positive (+). This provides information about the inferior wall of the myocardium.[11]



FIGURE 2-6 Normal ECG tracings for Leads I, II, and III.

Figure 2-6 shows normal ECG tracings for Leads I, II, and III. **Table 2-8** summarizes normal and abnormal waves and complexes seen in ECG telemetry.

Pulse Oximetry

Pulse oximetry is a noninvasive technique that uses optical sensor (spectrophotometry) to estimate the functional arterial oxygen saturation (Spo_2). Pulse oximeters use LED wavelength of 660 nm (red light) and 905–940 nm (infrared) because these wavelengths correspond to the absorption characteristics of oxyhemoglobin and reduced hemoglobin. The deoxygenated hemoglobin absorbs more light than oxyhemoglobin at a wavelength of 660 nm. Conversely, oxygenated hemoglobin absorbs more light at 905–940 nm than does deoxyhemoglobin. Pulse oximeter determines pulse by relating cyclical changes in light transmission that occur during ventricular systole and diastole.

The benefits of pulse oximetry center on its ease of use, noninvasive design, and rapid assessment of hypoxemia.[12] Pulse oximeters can provide either a spot-check measurement or continuous trending of the patient's

TABLE 2-8
Basic Normal and Abnormal Components of Lead II ECG Telemetry

	Normal		Abnormal	
Component	Morphology	Duration (seconds)	Morphology	Duration (seconds)
P wave	Positive (upright), smooth, rounded	0.12–0.20	Widened—left atrial enlargement Tall—right atrial enlargement	<0.12 or >0.20
Q wave	Negative (downward) or absent	<0.03	Pathologic Q—height ≥1/3rd the height of the R wave—MI	>0.03
QRS Complex	Positive (upright), narrow, sharp pointed	0.06–0.11	Widened QRS complex Premature ventricular contraction—conduction disturbance due to myocardial ischemia or infarction, hypoxemia, electrolyte imbalance Narrow QRS complex with a rapid rate—supraventricular tachycardia Wide QRS complex with a rapid rate—ventricular tachycardia	≥0.12
T wave	Positive (upright), slightly asymmetrical, rounded	0.10–0.25	Symmetrical—sign of pathology	
ST segment	Slightly elevated and flat	≤0.20	Elevated—myocardial ischemia, MI, coronary artery spasm, pericarditis Depressed—ischemia, nontransmural MI, left ventricular hypertrophy, digitalis effect	
U wave	Small (<2 mm in height), positive (upright), symmetrical, rounded		>2 mm in height—sign of hypokalemia	

oxygenation.[12] It is used across the spectrum of patient ages and in all aspects of healthcare from the emergency department to home care.

Pulse oximetry is relatively safe. However, it may be a source of cross-contamination of the patient.[13] Disposable single-patient sensors (finger, toe, and foot probes) are available. Additionally, latex may be used in the construction of some non-disposable sensors.

It is apparent that the accuracy of a pulse oximeter reading is dependent on the arterial pulse. In conditions where low perfusion exists, such a hypovolemia, the pulse oximeter may not be able to accurately identify a pulsatile signal. Pulse oximeters are accurate for oxygen saturations greater than 80%. Pulse oximeter saturations less than 80% should be confirmed with arterial blood gas analysis. Factors that affect pulse oximeter performance and accuracy appear in **Box 2-1**.

Pulse oximetry is an important clinical diagnostic tool and it is a standard of care. To many clinicians, it is the fifth vital sign. However, it is critical to understand that the pulse oximeter is only an oxygenation monitor. It does not provide any indication of ventilation, pH, or $Paco_2$.[12] Thus, even with an adequate Spo_2, there is still a need for blood gasses or ventilation monitoring with capnography.[12]

Capnography

Monitoring respiratory and metabolic function by using **capnography**, to measure **end-tidal carbon dioxide ($ETCO_2$)**, is standard practice in anesthesia and is more common now in intensive care units, during procedural sedation, and to assess the effectiveness of cardiopulmonary resuscitation.[14] Capnography monitors ventilation, whereas pulse oximeters monitor oxygen saturation. During periods of apnea, capnography immediately reflects the lack of breathing. Pulse oximetry has a lag time during breath-to-breath changes. **Table 2-9** compares capnography with pulse oximetry.

Capnography uses infrared technology to produce $ETCO_2$ values and capnography waveforms. Another form of $ETCO_2$ expression is the partial pressure of CO_2 ($PETCO_2$). Depending on the location of the carbon dioxide–measuring device, there are two sensor types: sidestream and mainstream. The **sidestream capnography sensor** aspirates exhaled gasses through a small sampling tube and brings it to the capnograph for measurement. This is used with non-intubated as well as intubated patients. The **mainstream capnography sensor** is connected directly to the patient's endotracheal tube and sends an electronic signal to the capnograph. **Figure 2-7** compares the sidestream and mainstream capnography systems. The mainstream sensor has a faster response time and less damping effect than the sidestream system, but it imposes a mechanical dead space that can affect total minute ventilation, particularly with small tidal volumes.[15] The sidestream system works well with

BOX 2-1 Factors That Affect Pulse Oximeter Performance and Accuracy

- Hypotension
- Hypovolemia
- Hypothermia
- Vasoactive agent administration
- Motion artifact
- Ambient light
- Poor pulse amplitude
- Carboxyhemoglobinemia
- Methemoglobinemia
- Dark skin pigmentation
- Severe anemia (Hb <5 mg/dL)
- BP cuff on same extremity

TABLE 2-9
Capnography versus Pulse Oximetry

	Capnography	Pulse Oximetry
Measures	End-tidal carbon dioxide	Oxygen saturation of hemoglobin
Effect of supplemental oxygen	No effect on capnography	Increases
Additional data provided	Respiratory rate	Heart rate
Data provided	Immediate indication of • Hypoventilation • Apnea • Airway obstruction	An indication of changing oxygen saturation of the blood
Cannot provide data on	Oxygenation status	• Ventilation status in the presence of supplemental oxygen • Actual delivery of oxygen to the tissues • Real-time changes in oxygenation or ventilation

Reproduced from Casey G. Capnography: monitoring CO_2. *Nurs N Z.* 2015;21(9):20–24 (Table 1, page 21).



FIGURE 2-7 **(A)** Mainstream CO_2 monitor; the sensor is in the patient circuit. **(B)** Sidestream CO_2 monitor; the sensor is inside the monitor rather than in the patient circuit.



FIGURE 2-8 Nasal cannula for sidestream CO_2 monitor.



FIGURE 2-9 Normal time-based capnogram. Phase I, dead space emptying with no CO_2; Phase II, an abrupt rise in CO_2 as anatomic dead space changes and terminal airways and alveoli begin emptying (the CO_2 increases rapidly in healthy lungs); and Phase III, an alveolar plateau that ends in an $ETCO_2$ measurement.

BOX 2-2 Clinical Applications for Capnography

Capnography can be used to assess/verify:

- adequacy of mechanical ventilation
- adequate reversal of neuromuscular blockade
- asthma/COPD exacerbation severity
- asthma/COPD intervention effectiveness
- blocked or kinked endotracheal tube
- cardiac output (CO) changes
- CPR effectiveness
- dead space
- endotracheal intubation success
- futility of resuscitation
- Non-operating room deep sedation, conscious sedation
- presence of pulmonary embolism
- patient-controlled analgesia (PCA) use
- shock development
- ventilator circuit disconnect
- ventilator management

COPD, chronic obstructive pulmonary disease.

non-intubated patients. **Figure 2-8** shows a particular nasal cannula used to deliver oxygen and sample exhaled carbon dioxide.

Most commonly seen in clinical practice is the time-based capnogram (**Figure 2-9**). This displays a steady increase in CO_2 after exhalation begins, progressing to a slightly sloped plateau as the $ETCO_2$ is reached.[14]

Capnography has a variety of clinical applications. **Box 2-2** lists these clinical applications.

There are three sources of clinical information in capnography: numerical value of $ETCO_2$ ($PETCO_2$), the difference between the $PETCO_2$ and $PaCO_2$, and the shape of the capnograms.[16] Normally, the $PETCO_2$ is 2–5 mm Hg less than the actual $PaCO_2$. Numerical values are a useful tool for differential diagnosis.[16] **Figure 2-10** shows various conditions that may cause increases or decreases in $PETCO_2$.

The difference between $PETCO_2$ and $PaCO_2$ is the $PETCO_2$–$PaCO_2$ gradient. This gradient is directly proportional to the degree of physiologic dead space (V_D).[17] The alveolar CO_2 concentration is normally slightly greater than the arterial blood concentration, due to the mixing of CO_2-containing alveolar gas with exhaled gas devoid of carbon dioxide from the anatomical dead space. In a patient with lung disease, the addition of alveolar dead space further dilutes $PETCO_2$ relative to $PaCO_2$.[18]

The shapes of the capnograms offer more specific diagnostic clues than the numerical value and the $PETCO_2$–$PaCO_2$ gradient.[16] **Figure 2-11** shows various capnogram shapes and their interpretations.

Monitoring $PETCO_2$ can provide insight into the metabolic process, perfusion, and alveolar ventilation. It provides continuous information about the patient's minute ventilation and respiratory status and can prevent harm from drugs that cause respiratory depression.[14]

Exhaled Nitric Oxide

Nitric oxide (NO) is another exhaled respiratory gas that is measured noninvasively. Nitric oxide, which is produced in the lungs and is present in exhaled breath, is implicated in the pathophysiology of lung diseases, including asthma. It acts as a vasodilator, bronchodilator, neurotransmitter, and inflammatory mediator in the lungs and airways. **Fractional exhaled nitric oxide (FE_{NO})** is a noninvasive marker of airway inflammation in asthma. FE_{NO} levels are raised in people with asthma and can be



FIGURE 2-11 Examples of various capnographic shapes. **(A)** Apnea. **(B)** Bronchospasm or airway obstruction. **(C)** Tachypnea leading to hyperventilation. **(D)** Hypopnea leading to hypoventilation. **(E)** Return of spontaneous circulation (ROSC) after a cardiac arrest. **(F)** Curare cleft due to patient attempting to breathe during partial muscle paralysis.

Modified from Kodali B. Capnography Outside the Operating Rooms. *Anesthesiology*. 2013;118(1):192–201. doi:10.1097/aln.0b013e318278c8b6.



FIGURE 2-10 Causes of $PETCO_2$ Increases and Decreases

Modified from Kodali B. Capnography Outside the Operating Rooms. *Anesthesiology*. 2013;118(1):192–201. doi:10.1097/aln.0b013e318278c8b6.

lowered by effective treatment with corticosteroids.[19] Common reasons for measuring FE_{NO} appear in **Box 2-3**.

FE_{NO} values are high when they are greater than 50 parts per billion (ppb) for adults and greater than 35 ppb for children.[20] They are considered to be acutely rising when they vary more than 40% from a predetermined baseline.[21] **Table 2-10** shows the general outline for FE_{NO} interpretation when monitoring patients diagnosed with asthma.

KNOWLEDGE CHECK QUESTIONS

1. True or False: ECG telemetry uses only a three-lead configuration.
2. True or False: A 3-mm U wave on an ECG is normal.
3. True or False: Carboxyhemoglobinemia is identified with a pulse oximeter.
4. True or False: Capnography responds faster to apnea than pulse oximetry.
5. True or False: The FE_{NO} is a noninvasive marker of bronchospasm in asthma.

Diagnostic Laboratory Tests

The diagnostic laboratory plays an essential role in the assessment of a cardiopulmonary patient.[22] These tests include, but are not limited to, arterial blood gasses, hematology, clinical chemistry, serum electrolytes, and cardiac enzymes.

Arterial Blood Gas Studies

The main function of the respiratory system is to sustain arterial blood oxygen and carbon dioxide within a physiologic range. It is also essential for acid–base balance. Acid–base balance is the physiologic mechanism that regulates the hydrogen concentration of blood and body fluids within a range compatible with cellular function. Measurement of the arterial blood for pH, carbon dioxide, and oxygen is the most logical approach to the assessment of respiratory function. Additional clinically useful variables are the concentration of total hemoglobin, oxyhemoglobin saturation, saturations of the **dyshemoglobins** (carboxyhemoglobin and methemoglobin), and other calculated or derived values, such as plasma bicarbonate and base excess/deficit.[23] The indications for collecting arterial blood for analysis are listed in **Box 2-4**.

BOX 2-3 Common Reasons for Measuring FE_{NO}

- To assist in assessing the etiology of respiratory symptoms
- To help identify the eosinophilic asthma phenotype
- To evaluate potential response or failure to respond to anti-inflammatory agents, notably inhaled corticosteroids (ICS)
- To establish a baseline FE_{NO} during clinical stability for subsequent monitoring of chronic persistent asthma
- To guide changes in doses of anti-inflammatory medications: step-down dosing, step-up dosing, or discontinuation of anti-inflammatory medications
- To assist in the evaluation of adherence to anti-inflammatory medications
- To assess whether airway inflammation is contributing to poor asthma control particularly in the presence of other contributors (e.g., rhinosinusitis, anxiety, gastroesophageal reflux, obesity, or continued allergen exposure)

TABLE 2-10
General Outline for FE_{NO} Interpretation When Monitoring Patients Diagnosed with Asthma

	FE_{NO} < 25 ppb (adults) FE_{NO} < 20 ppb (children)	FE_{NO} 25–50 ppb (adults) FE_{NO} 20–35 ppb (children)	FE_{NO} > 50 ppb (adults) FE_{NO} > 35 ppb (children)
Symptoms* present	Possible alternative diagnoses Unlikely to benefit from increase in ICS	Persistent allergen exposure Inadequate ICS dose Poor adherence Steroid resistance	Persistent allergen exposure Poor adherence or inhaler technique Insufficient ICS dose Risk for exacerbation Steroid resistance
Symptoms* absent	Adequate ICS dose Good adherence ICS taper	Adequate ICS dose Good adherence Monitor change in FE_{NO}	ICS withdrawal or dose reduction may result in relapse Poor adherence or inhaler technique

*Symptoms refer to cough and/or wheeze and/or shortness of breath.

The typical arterial blood gas study includes measures of oxygen tension, carbon dioxide tension, pH, oxygen saturation, calculated plasma bicarbonate, and base excess/base deficit. The addition of hemoximetry results in actual oxygen saturation, hemoglobin (Hgb), carboxyhemoglobin, and methemoglobin.[13] The normal arterial blood gas values are listed in **Table 2-11**.

Interpretation of Acid–Base Balance

Interpretation of the acid–base balance entails assessing the pH, $Paco_2$, and HCO_3^-. Acid–base imbalances involve a primary abnormality of one component of acid–base balance, either $Paco_2$ or HCO_3^-. Acid–base disorders can also involve compensatory responses by which the non-primary component is altered in an attempt to return and maintain the pH within its normal range. Acid–base abnormalities caused by only one component, $Paco_2$, or HCO_3^-, are *pure conditions*. Those that are produced by both $Paco_2$ and HCO_3^- are *mixed conditions*. The presence of near-normal pH may indicate a compensatory response to a primary acid–base disorder. **Boxes 2-5** to **2-8** show the causes of acid–base imbalances.

In many critically ill patients, respiratory and metabolic disturbances coexist. With combined respiratory and metabolic conditions in the same direction, acidosis

BOX 2-4 Indications for Arterial Blood Gas Analysis

The need to:

- evaluate the adequacy of ventilation ($Paco_2$), acid–base (pH and $Paco_2$), and oxygenation (Pao_2, SaO_2)
- assess the patient's therapeutic response to intervention and diagnostic evaluation
- assess early goal-directed therapy measuring central venous oxygen saturation in patients with sepsis, septic shock, and after major surgery
- monitor severity and progression of documented disease processes
- assess inadequacy of circulatory response

TABLE 2-11
Normal Arterial Blood Gas and Hemoximetry Values

Analyte (units)	Description	Normal Value	Normal Range
pH	$-\log [H^+]$	7.40	7.35–7.45
$Paco_2$ (mm Hg)	Arterial carbon dioxide tension	40	35–45
Pao_2 (mm Hg)	Arterial oxygen tension	95	80–100
SaO_2 (%)	Arterial oxygen saturation	97.5	95–98
Plasma HCO_3^- (mEq/L)	Plasma bicarbonate	24	22–28
BE/BD (mEq/L)	Base excess or deficit	0	−2.0 to +2.0
Hb (g/dL)	Hgb	15	Men: 13.5–16.5 Women: 12–15
COHb (%)	Carboxyhemoglobin		0.5–1.5
metHb (%)	Methemoglobin		0.5–1.5

BOX 2-5 Causes of Respiratory Acidosis (Hypoventilation)

Respiratory acidosis is also known as hypercapnia, hypoventilation, ventilatory failure, and hypercapnic respiratory failure. Common causes of respiratory acidosis include the following:

- Increased work of breathing—↓ lung compliance, ↑ airway resistance, ↓ chest wall compliance
- Decreased ventilatory drive—sedative or narcotic drugs, brainstem lesions, morbid obesity, head trauma, sleep apnea, metabolic alkalosis
- Neurologic disease—spinal cord injury, amyotrophic lateral sclerosis, poliomyelitis, Guillain-Bare syndrome, myasthenia gravis, botulism, muscular dystrophy, critical care myopathy

BOX 2-6 Causes of Respiratory Alkalosis (Hyperventilation)

- Hypoxia/hypoxemia
- Anxiety/pain
- Early sepsis
- Hepatic encephalopathy
- Other neurologic disorders—trauma, infection, stroke
- Pulmonary emboli
- Metabolic acidosis
- Iatrogenic hyperventilation

BOX 2-7 Causes of Metabolic Acidosis[13, Box 8-15, p.332]

Increased Anion Gap Acidosis

- Lactic acidosis
- Ketoacidosis
- Renal failure (most patients have an increased anion gap)
- Salicylate overdose
- Ingestion of methanol, ethylene glycol, large quantities of propylene glycol, or toluene
- Accumulation of pyroglutamic acid

Normal Anion Gap Acidosis

- Diarrhea
- Pancreatic fistula
- Distal (Type 1) renal tubular acidosis
- Proximal (Type 2) renal tubular acidosis
- Hypoaldosteronism (Type 4 renal tubular acidosis)
- Post-treatment ketoacidosis
- Ureteral diversion
- Ingestion or administration of ammonium chloride
- Administration of carbonic anhydrase inhibitors
- Intravenous hyperalimentation
- Ingestion of toluene (late finding or with good kidney function)

Data from Beachy W. Clinical assessment of acid-base and oxygenation status. In: Beachy W, ed. Respiratory Care Anatomy and Physiology. 2nd ed. St. Luis: Mosby-Elsevier;2007:214–235; Post TW, Rose BD. Approach to the adult with metabolic acidosis. In: Basow DS, ed. UpToDate. Waltham, MA; 2013.

BOX 2-8 Causes of Metabolic Alkalosis

- GI tract loss of hydrogen ions—vomiting, nasogastric tube suction, unusual cases of diarrhea with potassium loss
- Renal loss of hydrogen ions—loop or thiazide diuretics, genetic renal tubular disorder, post-hypercapnic increases in HCO_3^-, excess mineralocorticoid, hypochloremia, hypokalemia, hypercalcemia
- Intracellular shift of hydrogen ions—hypokalemia
- Contraction of blood volume—hypovolemia due to fluid loss, loop or thiazide diuretics
- Administration of base—sodium bicarbonate, ingestion of base, crack cocaine or freebase cocaine

BOX 2-9 Commonly Encountered Mixed Acid–Base Disturbances

- Chronic respiratory acidosis with chronic metabolic alkalosis
- Acute respiratory acidosis with chronic respiratory acidosis
- Acute respiratory acidosis with metabolic acidosis
- Metabolic acidosis with chronic respiratory acidosis

or alkalosis, the pH may reach extreme values.[13] **Box 2-9** lists commonly encountered mixed acid–base conditions.

In addition to the traditional blood gas classification system of respiratory and metabolic acidosis and alkalosis, there is an alternative approach to the clinical interpretation of acid–base balance. This terminology appears in **Table 2-12**.

Interpretation of Oxygenation Status

Some oxygen transport measurements are available to assess the oxygenation status of a critically ill patient. Arterial blood gas studies allow for the direct measurement of a patient's Pao_2. Combined with **co-oximetry** (which also measures COHb and metHb), SaO_2 and Hb

TABLE 2-12
Alternative Approach to Clinical Interpretation of Acid–Base Balance

Label	Description
Acute ventilatory failure Acute respiratory failure Acute hypercapnic respiratory failure Type II respiratory failure	A sudden rise in $Paco_2$ with corresponding decrease in pH
Chronic ventilatory failure Chronic respiratory failure	A chronically elevated $Paco_2$ with a normal or near-normal pH (due to compensation)
Acute-on-chronic ventilatory failure	A sudden rise in $Paco_2$ in a patient with chronic ventilatory failure
Acute alveolar hyperventilation	A sudden fall in $Paco_2$ with a corresponding increase in pH
Chronic alveolar hyperventilation	A chronically decreased $Paco_2$ with a normal or near-normal pH (due to compensation)
Acute alveolar hyperventilation superimposed on chronic ventilatory failure	A sudden decrease in $Paco_2$ in a patient with chronic ventilatory failure

TABLE 2-13
Acceptable Pao_2 Ranges for Adults in Supine Position at Seal Level

Age (years)	30	40	50	60	70	80	90
Pao_2 (mm Hg)	>90	>85	>80	>75	>70	>65	>60

Values are calculated with the equation of Sorbini CA, Grassi V, Solinas E, Muiesan G. Arterial oxygen tension in relation to age in healthy subjects. Respiration. 1968;25(1):3–13.

levels can be measured. This allows for arterial oxygen content (Cao_2) to be calculated.

Pao_2 is a simple indicator of the patient's pulmonary oxygenation status. It reflects the lung's ability to transfer O_2 across the alveolar capillary membrane. The normal range for Pao_2 is 80–100 mm Hg when breathing "room air" or 0.21 oxygen. Mild, moderate, and severe hypoxemia correspond to Pao_2 values of 60–79, 40–59, and <40 mm Hg, respectively.[24] It must be noted, however, that normal values of Pao_2 decrease with age. The definition of hypoxemia in adults depends on the age of the individual and the altitude. See **Table 2-13** for the acceptable Pao_2 ranges for adults.

Calculated indexes of oxygenation status include the alveolar–arterial tension gradient, the arterial blood oxygen content, the Pao_2-to-FiO_2 ratio, the arterial oxygen tension ratio, and the oxygenation index. These are discussed in Chapter 3.

Adequate O_2 delivery depends on both adequate arterial blood oxygen content and CO. Increases in the delivery of oxygen to the tissues are accomplished more efficiently through the increases in Hgb concentration and CO than by an increase in oxyhemoglobin saturation. A complete assessment of patient oxygenation must take into account the adequacy of blood flow; clinical signs of an inadequate CO include hypotension, cool extremities, weak peripheral pulses, reduced urine output, and depressed levels of consciousness.

Hematology

Hematology is the study of blood in health and disease. The **complete blood count (CBC)** is an overall assessment of the kinds and numbers of cells in the blood. These cells include **leukocytes** (white blood cells, or WBCs), **erythrocytes** (red blood cells, or RBCs), and **thrombocytes** (platelets). The CBC is one of the most frequently used laboratory diagnostic tests.[25] The CBC test includes the total WBC count, a WBC differential, an RBC count, hematocrit (HCT), Hgb, platelet count, and mean platelet volume (MPV). The CBC provides valuable data about the patient's diagnosis, prognosis, and therapeutic response. **Table 2-14** shows the components of the CBC along with their description and normal ranges.

For practical purposes, the variables of interest to a respiratory therapist are specific. The Hgb is a general indicator of **anemia,** when Hgb is low, or **polycythemia**, when Hgb is high. The platelet count can show **thrombocytopenia**, decreased platelet count that can lead to excessive bleeding, or **thrombocythemia**, excessive platelets. The WBC count gives important clues to leukopenia, or decreased WBCs, and leukocytosis, or increased WBC.[25] The WBC differential gives the specific cause of the increases and decreases in WBC. The CBC is an excellent screening test for identifying many different hematologic disturbances as well as for evaluating blood homeostasis. The CBC can provide the respiratory therapist with the tools needed to identify blood cell abnormalities and monitor the stability of the patient.[13]

Chemistry Panels

Chemistry panels are groups of tests that are routinely ordered to determine a person's general health status.[26] An understanding of blood chemistry is a significant part of patient assessment. **Clinical chemistry** analyzes the non-cellular components, reporting the concentration of atoms and molecules present in the plasma.[22] These chemicals are in the intracellular and extracellular fluid. For proper functioning of cells, a normal concentration of these chemicals must be maintained within both the intracellular and the extracellular fluid.

The number and type of tests contained in specific panels, and the names of the panels, have been standardized nationally.[26] Examples of common chemistry panels include the **basic metabolic panel (BMP)**, the

TABLE 2-14
Complete Blood Count Components

Component	Description	Reference Range
WBC count	A count of all the different cells that respond to microorganisms and play a vital role in the defense of the body	4,500–10,000 cells/μL
Neutrophils (WBC differential)	Primary defense WBCs that phagocytize microorganisms and release enzymes that kill microorganisms	50–70% of WBCs Or 2,000–7,000 cells/μL
Lymphocytes (WBC differential)	Immune system cells that take part in cellular immunity (T lymphocytes) and produce antibodies (B lymphocytes)	20–40% of WBCs Or 800–4,000 cells/μL
Monocytes (WBC differential)	WBCs that become macrophages to kill and remove microorganisms and cellular debris	2–10% of WBCs Or 80–1,000 cells/μL
Eosinophils (WBC differential)	Immune cells that release enzymes during infection, allergic reactions, and asthma	2–4% of WBCs Or 80–400 cells/μL
Basophils (WBC differential)	Immune cells that release enzymes in response to allergic reactions and asthma, causing an inflammatory reaction	0–1% of WBCs Or 0–10 cells/μL
RBC count	A count of the number of erythrocytes in a blood sample; RBCs carry oxygen to the tissues	Male: $4.8–6.2 \times 10^6$/μL Female: $4.4–6.2 \times 10^6$/μL
HCT	The volume occupied by RBCs in a volume of whole blood expressed as a percentage	Male: 40–50% Female: 37–47%
Hgb	A measurement of the iron-containing protein present in all RBCs	Male: 14–16 g/dL Female: 13–15 g/dL
Mean corpuscular volume (MCV) (RBC indices)	The size of the RBCs	MCV: 80–100 fL
Mean corpuscular hemoglobin (MCH) (RBC indices)	The amount of Hgb in an average RBC	MCH: 27–31 pg/cell
Mean corpuscular hemoglobin content (MCHC) (RBC indices)	The percentage of the RBC count that is hemoglobin	32–36%
RDW	Measurement of the variation in RBC size or RBC volume	<12%
Platelets	Repair tissue after injury and stop bleeding after injury by clot formation	$165–415 \times 10^3/mm^3$
MPV	A measure of the average volume of platelets	9.00–12.95

comprehensive metabolic panel (CMP), electrolyte panel, lipid profile, liver profile (hepatic function panel), renal panel (kidney function panel), and diabetes tests. **Table 2-15** lists the most common analytes, their reference ranges, and the type of chemistry panel that reports them.

The **anion gap** is a measurement of the difference between the sum of the positive electrolytes and the sum of the negative electrolytes routinely measured in BMP and CMP. The anion gap formula is $(Na^+ + K^+) - (Cl^- + HCO_3^-)$. However, the potassium is usually ignored in the formula, and the anion gap is $(Na^+) - (Cl^- + HCO_3^-)$. This entity is useful in the detection and analysis of acid–base disorders, assessment of quality control in the chemical laboratory, and detection of such disorders as multiple myelomas, bromide intoxication, and lithium intoxication.[27]

Diabetes mellitus is a common and serious group of disorders that involves insulin and the inability to maintain normal levels of circulating glucose.[22] A fasting blood glucose level greater than 100 mg/dL is a common finding among patients. An elevated glucose level is indicative of diabetes mellitus, but also of other endocrine disorders.[22] A patient who has, on more than one testing occasion, had a fasting glucose level ≥126 mg/dL is very likely to have diabetes. The patient with diabetes is susceptible to a series of chronic complications and is at a risk of premature death.[28] These complications include coronary artery disease (CAD), cerebrovascular accident, peripheral vascular disease,[28] and a restrictive

TABLE 2-15
Common Chemistry Analytes

Analyte	Adult Reference Range*	Panel
Bilirubin	Total: 0.3–1.9 mg/dL	CMP
Calcium (Ca^{+2})	8.5–10.2 mg/dL	BMP, CMP
Creatinine	0.6–1.3 mg/dL	BMP, CMP
Electrolytes	Sodium (Na^+): 135–145 mEq/L	BMP, CMP
	Potassium (K^+): 3.7–5.2 mEq/L	BMP, CMP
	Carbon dioxide (tCO_2): 23–29 mEq/L	BMP, CMP
	Chloride (Cl^-): 96–106 mEq/L	BMP, CMP
Glucose (fasting)	70–100 mg/dL	BMP, CMP
Liver enzymes	Alkaline phosphatase (ALP): 44–147 IU/L	CMP
	Alanine aminotransferase (ALT): 10–40 IU/L	CMP
	Aspartate aminotransferase (AST): 10–34 IU/L	CMP
Proteins	Total protein: 6.0–8.3 g/dL	CMP
	Albumin: 3.4–5.4 g/dL	CMP
Urea nitrogen (BUN)	6–20 mg/dL	BMP, CMP

*Reference ranges presented in the table are for general information purposes only. Individual laboratories link test results to their particular reference intervals, which should be used to interpret a particular test result.

Data from Updated by Laura J, Martin A. Comprehensive metabolic panel: MedlinePlus Medical Encyclopedia. *Nlmnihgov*. 2016. https://www.nlm.nih.gov/medlineplus/ency/article/003468.htm. Accessed March 27, 2016.

TABLE 2-16
Diagnosis of Diabetes

The presence of one or more of the following test criteria is consistent with a diagnosis of diabetes		
Test	**Description**	**Critical Value**
Hemoglobin A_{1C}	Percentage of glycated Hb, which reflects average blood sugar and blood sugar control over the past 2–3 months	≥6.5%
Glucose (fasting)	Fasting plasma glucose level (FPG)	≥126 mg/dL
2-hour plasma glucose	2-hour plasma glucose level during oral glucose tolerance test (2-h OGTT)	≥200 mg/dL
Random plasma glucose	Elevated plasma glucose in the presence of symptoms of hyperglycemia or hyperglycemic crisis (e.g., increased thirst, headache, difficulty breathing, diminished concentration, drowsiness, blurred vision, vomiting, abdominal pain)	≥200 mg/dL

Data from American Diabetes Association. Standards of medical care in diabetes-2013. *Diabetes Care*. 2013;36(suppl 1):S11–S66.

pattern of respiratory abnormality.[29] **Table 2-16** shows the criteria for the diagnosis of diabetes.

CAD laboratory tests are available for risk assessment, the diagnosis of myocardial infarction (MI), and the evaluation of congestive heart failure (CHF).[22] These tests include total cholesterol, **low-density cholesterol (LDL)**, **high-density cholesterol (HDL)**, and triglycerides. The term **dyslipidemia** describes a disorder of lipoprotein metabolism, either overproduction or deficiency. CAD risk is high when the total cholesterol level is ≥240 mg/dL. Elevated levels of circulating LDL correlate with an increased incidence of atherosclerosis and CAD and is the "bad cholesterol."[30] Conversely, elevated HDL appears to protect against atherosclerosis and has earned the moniker "good cholesterol."[30] **Table 2-17** lists these CAD laboratory tests, called adult treatment panel (ATP III), with the guidelines for classification.

The chemistry panels performed by the clinical chemistry laboratory encompass a diverse array of analytes that are performed on serum and help the respiratory therapist to determine if the patient has an abnormality in almost any body system.[22]

Cardiac Enzyme Studies

Enzymes are chemicals substances (proteins) that speed up the rate of intracellular chemical reactions. Some of these enzymes are present in low concentrations in serum under normal physiologic conditions. However, under pathologic conditions such as cellular injury, metallic abnormalities enzyme leak from damaged cells, resulting in elevated serum enzyme concentrations. The distribution of enzymes in the cells are relatively organ specific, and the change in their concentration, when tissues are damaged, is clinically significant.

Cardiac enzymes are a group of proteins that are found in myocardial tissues and are released in the serum when cardiac cells are injured. The elevated cardiac enzymes in the serum, the clinical presentation of the patient, and other diagnostic tests such as ECG are used to diagnose acute MI. The initial cardiac enzymes (chemical markers) include **creatine kinase (CK-MB)** and **cardiac troponins**.

TABLE 2-17
Classification of Total, LDL, and HDL Cholesterol and Triglycerides (mg/dL)

Total Cholesterol	
<200	Desirable
200–239	Borderline high
≥240	High
Low-Density Lipoprotein (LDL)	
<100	Optimal
100–129	Near optimal/above optimal
130–159	Borderline high
160–189	High
≥190	Very high
High-Density Lipoprotein (HDL)	
<40	Low
≥60	High
Triglycerides	
<150	Normal
150–199	Borderline high
200–499	High
≥500	Very high

Creatine kinase is made up of three types: CK-MB (present in heart muscle), CK-BB (found in the brain), and CK-MM (found in skeletal muscles).[30] The myocardial-specific kinase (CK-MB) is the standard chemical marker for evaluating myocardial injury. The CK-MB concentration in plasma begins to rise after 3–8 hours of myocardial injury and peaks at 24 hours and returns to normal within 48–72 hours.[30] Clinical manifestations and the ECG are helpful in recognizing patients with MI.

Troponin is a regulatory protein that controls the interaction of actin and myosin in muscle cells. The cardiac forms of troponin are structurally unique and highly specific for the heart muscle. These cardiac troponins are troponin I (cTnI) and troponin T (cTnT). The cardiac troponins are released into the blood after cardiac muscle cell damage. An increase in cardiac troponins may be detected after 3–4 hours of the onset of chest discomfort; they peak between 18 and 36 hours, and then decline slowly, allowing for detection up to 10–14 days after a large MI.[30]

Table 2-18 lists the cardiac enzymes and their laboratory reference ranges in healthy adults.

TABLE 2-18
Cardiac Enzyme Reference Ranges for Healthy Adults

Cardiac Enzyme	Reference Range
Creatine kinase (total)	Male: 51–294 U/L
	Female: 39–238 U/L
Creatine kinase-MB	Mass: 0–5.5 ng/mL
	Percentage of total CK: 0–4%
Troponin I (cTnI)	0–0.04 ng/mL
Troponin T (cTnT)	0–0.01 ng/mL

Data from Loscalzo J. Harrison's *Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Medical; 2013.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A sudden rise in $PaCO_2$ in a patient with chronically elevated $PaCO_2$ is an acute-on-chronic ventilatory failure.
2. True or False: Acceptable PaO_2 levels vary inversely with age.
3. True or False: Thrombocytopenia is an excess of platelets in the blood.
4. True or False: Blood sugar control over the past 2–3 months can be assessed using HbA_{1c}.
5. True or False: CK-MB can be detected in the blood for as long as 2 weeks after a massive MI.

Diagnostic Imaging

Diagnostic image studies are important tools in diagnosing and monitoring patients with respiratory disorders. Diagnostic imaging includes diverse modalities such as radiographs, magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and nuclear medicine scans.[31]

Chest Radiography

Chest radiography aids in the diagnosis of lung disorders, the severity and location of the disease, and the evaluation of the progress of the disease. Of all the viscera, the lungs are the best suited for radiographic examination.[32] The lungs provide an excellent background against which abnormalities can stand out.[32] Radiography produces an image of internal organs by passing x-rays through the body to an x-ray film. Radiographic images are created when electrons interact with matter and convert their kinetic energy into electromagnetic

radiation. Because of differences in the density of its various structures, the x-ray beam transmitted through the patient will vary in intensity and produces **radiolucent** (black) or **radiopaque** (white) areas. When there is low-density tissue, such as air-filled structures, radiolucent areas are created. High-density tissues and structures such as heart and bones block the x-ray beam and create radiopaque areas.

It is more and more common to have radiographs available digitally than on an x-ray film. A detailed description of chest radiography is beyond the scope of this text. However, the following is a brief overview of this commonly used diagnostic test.

Chest radiographs usually are taken in two standard views: either posteroanterior (PA) or anteroposterior (AP) and lateral. The PA chest radiograph is taken standing up and is not commonly performed on patients in the intensive care units or emergency departments. In those hospital units, portable x-ray machines are used to take the AP chest radiographs while the patient is in bed. The lateral chest radiographs can be done in the upright position. A patient can have a **lateral decubitus** (right and/or left) taken by a portable machine while in bed. Lateral x-rays of the neck can identify upper airway obstructions such as croup and epiglottis.

The first step in examining the chest radiograph is to determine the technical quality of the image. An assessment of the adequacy of exposure is done by looking at the vertebral bodies. If it is easy to see the vertebral bodies, the image is probably overexposed, and the lungs will appear black. Underexposure makes the identification of the vertebral bodies more difficult and the lungs appear more radiopaque than on a properly exposed chest radiograph.

The respiratory therapist must be able to determine the normal anatomic structures to be able to identify abnormalities on a chest radiograph. Normal anatomy is relatively easy to describe. However, it is important to understand that "normal" actually encompasses a broad range of sizes and measurements.[31] Small differences in techniques such as minor rotation of the patient and tiny changes in the patient's inspiratory effort can significantly alter the appearance of a chest radiograph in the absence of a real pathology. **Figure 2-12** illustrates average lobar anatomy as seen from anterior and lateral views.



FIGURE 2-12 Radiographic anatomy showing lung lobes and fissures.

1. Mediastinum (trachea, heart, lymph vessels, blood vessels)
    a. Trachea position, patency
    b. Carina; endotracheal tube position, if present
    c. Aorta
    d. Heart size, borders (cardiophrenic angles, cardio-thoracic (C/T) ratio)
2. Hilum—pulmonary arteries, veins, bronchi
3. Lung fields (vascular marking, infiltrates, air bronchograms, and silhouette sign [if present])
4. Dome of diaphragm (shape, flattening)
5. Pleural surface
    5a. Costophrenic angles
6. Bones (humerus, clavicles, scapulae, vertebrae, ribs [position, fractures, intercostal spaces, deformities])
7. Skin and soft tissue (neck and chest wall)
8. Sub-diaphragm (observe for stomach bubble on left)



FIGURE 2-13 Normal anatomy as seen on the chest radiograph.



(A)



(B)

FIGURE 2-14 Normal chest radiograph. **(A)** PA view. **(B)** Lateral view.

A. Structures include:
1. Trachea
2. Right main stem bronchus
3. Left main stem bronchus
4. Aortic "knob" or arch
5. Azygos vein emptying into superior vena cava
6. Right interlobar pulmonary artery
7. Left pulmonary artery
8. Right upper lobe pulmonary artery (truncus anterior)
9. Right inferior pulmonary vein
10. Right atrium
11. Left ventricle
12. Labeled structures (clavicle, scapulae, sternum, right costophrenic angle, breast shadow, ribs 11 and 12, stomach, etc.)

B. Structures include:
1. Retrosternal airspace
2. Ascending aorta
3. Aortic arch
4. Brachiocephalic vessels
5. Trachea
6. Right upper lobe bronchus
7. Left upper lobe bronchus
8. Right pulmonary artery
9. Left pulmonary artery
10. Confluence of pulmonary veins
11. Labeled structures

Figure 2-13 shows the normal anatomy as seen on a chest radiograph. **Figure 2-14** shows a normal PA chest radiograph and a normal lateral view with the identification of significant structures.

After assessing the image quality, type of view (AP, PA, lateral), patient position, and whether the patient took a full inspiration, a systematic image review is performed. **Box 2-10** provides a checklist for inspection of the AP or PA chest radiographs.

The following is a case study using a chest radiograph to identify a cardiopulmonary emergency. Use the checklist in Box 2-10 to evaluate the chest radiograph in the case study.

Computed Tomography

Compared with the plain chest radiography, **computed tomography (CT)** of the chest provides greater anatomic detail but is more expensive and exposes patients to a significantly higher dose of radiation.[32] However, CT offers several advantages over routine chest radiography. First, the use of cross-sectional images allows distinction between densities that would be

BOX 2-10 Checklist for Chest Radiograph Evaluation

A checklist for evaluation of the chest x-ray (CXR) should include the following:

Quality of the Film

- Is the image PA, AP, or lateral?
- Is the film overpenetrated, underpenetrated or good exposure?
- Is the patient upright and flat or twisted in position?
- Is there anything outside of the chest such as jewelry that might be misinterpreted?
- Verify right side as opposed to left side as follows: observe stomach bubble and shape and position of left border and aorta; note identifying differences in ribs and parenchyma; note marker on film.
- Was film taken at full inspiration, or is it a full or partial expiration film?

Review of the Chest Film

- Trachea: position, patency, normal narrowing at larynx and normal slight deviation to right at aorta
- Carina: note endotracheal tube position, if present
- Aorta: size, shape, calcification, tortuosity
- Hila: pulmonary arteries, main and branches; enlarged nodes; calcium; eggshells; relationship right versus left; left hilum normally slightly above right
- Heart: size, shape, straight left border, calcified valves, prostheses, mediastinal air, cardiophrenic angles, double contour, enlarged atrium, CT ratio
- Hemidiaphragms: right hemidiaphragm normally slightly above left, scalloping, "adhesions," calcific plaques
- Costophrenic angles
- Obliques: posterior ribs can be identified as horizontal; anterior ribs run diagonally; abnormal shadows can be located as anterior or posterior by the tendency to remain in relationship to one or the other in two different views
- Bones and joints: old or recent fractures, degree of calcification, notching of upper and under margin of ribs, moth-eaten areas, cervical ribs, deformities
- Parenchyma: character of abnormal shadows, that is, mottling; stringy, homogenous, clear, or vague margins; calcific, specular radiations; air bronchogram; silhouette sign; interstitial as opposed to alveolar infiltrates; vascularity or bronchovascular markings
- Soft tissues of neck and chest wall: air, foreign objects, calcifications, sinus tracts

Specific abnormalities on CXR

- Tracheostomy and endotracheal tube position with respect to the carina
- Position of a central lines (CVP) or pulmonary artery (Swan–Ganz) catheter
- Chest tube placement
- Interstitial or alveolar infiltrates
- Pleural effusion
- Pneumothorax
- Rib fractures and chest trauma
- ARDS and pulmonary edema
- Hyperinflation and COPD
- Fibrotic lung disease
- Deviated trachea
- Enlarged heart
- Pulmonary arteries

Most modern x-ray departments today use digital imaging; however, we will use the term "film" loosely to mean the digital image or film image.

Data from Radiology Masterclass 2007–2013. http://radiologymasterclass.co.uk/tutorials/chest/chest_pathology/chest_pathology_page2.html

Case Study: Chest Radiograph

A 10-year-old boy presents to the emergency department complaining of right-sided chest pain after being in a motor vehicle accident. The boy complains that the pain is sharp, and he is very short of breath. He has tachycardia and tachypnea, and is diaphoretic. His trachea deviates to the left, and he has no breath sounds over the right lung. A non-rebreather mask is placed on the patient, and a STAT chest radiograph is taken.

(*Continues*)

Case Study: Chest Radiograph (*Continued*)



© Mediscan/Visuals Unlimited, Inc.

Questions

1. Review the quality of the film using the checklist.
2. Review the chest radiograph using the checklist.
3. What is the most likely cause of this patient's respiratory problem?
4. What does the chest radiograph show?

Answers

1. The image is an AP view. The image has good exposure. The patient is in a flat position. There is no jewelry. Air bubble is noted.
2. Trachea: Marked deviation to the left. Carina: shifted left. Aorta: shifted left. Right lung is collapsed. Heart: shifted to the left. The right hemithorax is black with no vascular markings. Right hemidiaphragm: depressed. Left costophrenic angle is visible. No fractures noted. Specific abnormalities noted: right-sided tension pneumothorax and deviated trachea.
3. This patient has a right-sided tension pneumothorax and is in need of an emergent needle decompression. Once the tension is decompressed, a chest tube can be placed.
4. The chest radiograph shows the right hemithorax has no vascular markings due to air in the pleural cavity. The right lung is completely collapsed. The trachea is pushed to the opposite side due to the buildup of tension on the right side. The heart is shifted to the left along with the right heart border.



FIGURE 2-15 Normal lungs on CT.
© kalus/istock/Getty Images.

superimposed on plain radiographs. Second, CT characterizes tissue density better than radiography, distinguishing subtle density differences between adjacent structures and providing accurate size assessment of lesions.[33]

The tomographic image is a picture of a slice of the patient's anatomy. CT scanning shows the slices in 1- to 2-mm thickness so that fine details are visible. **Figure 2-15** shows a CT scan for normal lungs.

Intravenous injections of radio-contrast agents enhance CT images or produce images that would not otherwise be visible. Contrast agents make areas within the body more distinguishable by temporarily changing the way imaging tools interact within the body.[34] A pulmonary emboli diagnosis is made using **CT pulmonary angiography**, a combination of helical CT scans and intravenous contrast media.

Magnetic Resonance Imaging

The role of **magnetic resonance imaging (MRI)** in the evaluation of respiratory system disease is less well defined than that of the CT.[33] Unlike CT, MRI uses no ionizing radiation, but a powerful magnetic field to align the nuclear magnetization of (usually) hydrogen atoms in water in the body. MRI is useful for the examination of the heart, aortic arch, and great vessels without the complications of iodinated contrast media.[31]

Because the magnetic resonance imager generates a strong magnetic field, the magnetic force generated can interfere with the normal function of pacemakers and most ventilators. MRI is particularly useful in the evaluation and diagnosis of neurologic conditions, disorders of the muscles and joints, tumors, and abnormalities in the heart and blood vessels.

Positron Emission Tomography

A **positron emission tomography (PET)** is a nuclear medical imaging technique that produces a three-dimensional image that shows both the anatomic structure and the metabolic activity of the tissues and organs scanned. PET is an excellent tool for the assessment of thoracic pathologic processes and tumor imaging.

PET scanning uses a solution of glucose that is tagged with a radioactive isotope F-18-FDG (18-fluoro-2-deoxyglucose). F-18-FDG, or FDG, is a glucose analog that is taken up by high-glucose-using cells such as brain tissue, kidney tissue, and cancer cells. This is a unique aspect of the PET scan that can detect cancerous cells in the tissues before morphologic changes develop. Before scanning, the patient fasts for several hours and is injected with the FDG while in the supine position and quiet for an hour. Cancer cells rapidly consume and metabolize glucose at high rates. As glucose molecules break down, they emit positrons (an antiparticle of an electron). The positrons collide with electrons that emit gamma rays. The gamma rays convert to dark spots on the PET scan and are "hot spots." The presence of hot spots on a PET scan is indicative of a rapidly growing tumor.

The limited anatomical definition of radionuclide imaging was improved by the development of hybrid imaging that allows the superimposition of nuclear medicine and CT images, a technique known as functional-anatomical mapping.[33] This allows direct correlation of specific lesions visible on a CT scan with their corresponding FDG uptake. This PET-CT thoracic imaging can detect structure and function simultaneously, with greater detail and a higher level of accuracy.[33]

Ultrasonography

Ultrasonography or diagnostic ultrasound uses the ability of different types of tissue to transmit sound and of tissue interfaces to reflect sound. This has made ultrasonography useful for evaluating a variety of body structures.[32] Ultrasound produces images using the echoes or reflection of the ultrasound beam from interfaces between tissues with differing acoustic properties.[33] Ultrasound images are produced in real time, allowing the clinicians to assess functional processes as they occur.[34] Bedside availability makes it valuable in the intensive care setting.[33] Ultrasonography is safe for use in fetal imaging because it does not use ionizing radiation. Ultrasound imaging is an alternative technique for those who cannot tolerate CT or nuclear medicine and for those with metal implants.[34] Commonly used ultrasound techniques include bedside ultrasonography, Doppler ultrasound, echocardiography, and endobronchial ultrasound. The different types of diagnostic ultrasound techniques appear in **Table 2-19**.

Ventilation–Perfusion Scan

Injected or inhaled radioisotopes readily provide information about pulmonary blood flow and ventilation.[32] Imaging of the gamma radiation from these isotopes produces a picture showing the distribution of blood flow and ventilation throughout both lungs.[32] This test involves two separate imaging exams: one for ventilation with inhaled radioisotopes, and one for perfusion

TABLE 2-19
Indications for Diagnostic Ultrasound

Type of Ultrasonography	Uses
Bedside ultrasonography (focused)	• Abdominal pain • Evaluate pregnancy and placental status • Guide for needle biopsy • Trauma • Unexplained hypotension • Visualize pleural effusion
Doppler ultrasound	• Identify blood clots • Evaluate vasculature • Guide radiofrequency ablations • Assess umbilical cord blood flow
Echocardiography (ECHO)	• Assess myocardial structure • Evaluate myocardial function • Evaluate myocardial perfusion
Endobronchial ultrasound (EBUS)	• Identify bronchial lesions • Allow transbronchial needle aspiration

with intravenous radioisotopes. Indications for a ventilation–perfusion scan (VQ scan) include the diagnosis of a suspected pulmonary embolus and the assessment of regional lung function.[35]

KNOWLEDGE CHECK QUESTIONS

1. True or False: An upper airway obstruction may be apparent on an anteroposterior neck x-ray view.
2. True or False: The lungs appear more radiopaque than normal when the CXR is underexposed.
3. True or False: CT scan slices are 1–2 mm in thickness
4. True or False: Ultrasonography cannot be used on patients with metal implants.
5. True or False: A pulmonary embolus may be identified using a VQ scan.

Cardiac Diagnostic Tests and Monitoring

Most cardiac diagnoses use a careful patient history backed up by a thorough physical examination. The next step is to perform low-risk noninvasive tests first followed by direct further investigations and monitoring.

12-Lead Electrocardiogram

One of the first tests to be carried out following the physical examination of a patient is the 12-lead ECG. It is recommended to screen for heart disease (e.g., CAD, left ventricular hypertrophy), rule out heart disease in surgical patients, evaluate patients with chest pain, follow the progression of patients with CAD, and evaluate heart rhythm disorders. The three-lead ECG is a common configuration for continuous bedside monitoring or transport monitoring. A 5-lead ECG is often used in the intensive care unit to monitor patients, and the 12-lead ECG is used for patient assessment.

The 12-lead ECG allows the electrical impulse and conduction to be viewed from 12 different positions to produce a better and more complete picture of the heart's electrical activity. The 12-lead ECG tracing is created using 10 leads placed on the patient. The limb leads, or extremity leads, are put on the limbs no less than 10 cm from the heart. The chest lead location is specific on the anterior chest. **Figure 2-16** shows the location of the leads for the 12-lead ECG.

A normal ECG consists of the following waves: P, Q, R, S, and T. The Q, R, and S waves together produce a QRS complex. Each wave represents impulse conduction system for each cardiac cycle of contraction and relaxation (systole and diastole), as shown in Figure 2-5. Table 2-8 includes a description of the normal and abnormal morphology of each wave.

Figure 2-17 shows a standard 12-lead ECG with a normal sinus rhythm. A basic knowledge of 12-lead ECG interpretation is necessary for the respiratory therapist. However, this is beyond the scope of this text.

Echocardiography

Echocardiography is a specific type of ultrasonography to assess information about cardiac structures and valvular function. During echocardiography, sound waves are emitted and travel through the ventricular wall in a



FIGURE 2-16 Lead placement for the 12-lead ECG.



FIGURE 2-17 An example of a normal 12-lead sinus rhythm electrocardiogram.
Modified from 12-Lead ECG: The Art of Interpretation, Courtesy of Tomas B. Garcia, MD.

straight line. As the tissue density changes, the direction of ultrasound signals changes and is recorded by the receiver. The change in the direction of ultrasound waves enables the physician to differentiate one structure from another (myocardium vs. blood). Echocardiography can be helpful in (1) ruling in or ruling out MI when the ECG is normal; (2) identifying causes other than ischemia responsible for the patient's chest pain; (3) identifying and quantifying the mechanical complications of MI such as mitral or aortic valve dysfunction; and (4) providing information about left ventricular function.[36] **Figure 2-18** shows an example of the images seen using echocardiography.

Echocardiography is useful for diagnosing impending MI and for assessing left ventricular function in patients after MI. However, resting echocardiography alone does not have high sensitivity or specificity for the diagnosis of coronary heart disease in patients who do not have ischemia or infarction.[37] The guidelines of the American College of Cardiology Foundation and the American Heart Association for cardiovascular risk assessment recommend echocardiography for the detection of left ventricular hypertrophy in hypertensive adults with no symptoms or signs of heart disease.[37] Echocardiography is not routinely recommended for patients who do not have hypertension.[37]

Two types of echocardiography exist: **transthoracic echocardiography (TTE)** and **transesophageal echocardiography (TEE)**. TTE looks at the heart from the anterior chest. The sound waves must pass through bones, muscles, and the lungs, which can alter the quality of the image. TEE looks at the heart from within the esophagus, which sits just behind the left atrium. The sound waves do not have to pass through the bones, muscles, and the lungs. Also, the posterior portion of the heart is clearer compared to the TTE. The TEE is helpful in assessing possible valvular abnormalities and in detecting aorta dissections involving the thoracic aorta.[36]



FIGURE 2-18 Echocardiography display screen. A middle-aged patient undergoing an echocardiography. A transducer (held against his chest) emits ultrasonic sound waves and detects the reflected echoes. The change in frequency is used to build images of the heart structures and to assess the velocity and direction of the blood flow.
© Vendome Card/Astier/AgeFotostock.

Cardiopulmonary Exercise Testing

Exercise tests are commonly used in clinical practice for both functional and diagnostic assessment.[38] **Cardiopulmonary exercise testing (CPX)** measures physiologic reserve and functional capacity, which cannot be determined from resting measurements.

CPX involves the analysis of heart and lung function during incremental levels of work. The standard workload measure for exercise testing is the

metabolic equivalent (MET). One MET is the average resting oxygen uptake of 3.5 mL of oxygen per kilogram body mass per minute.[39] The parameters monitored during CPX are listed in **Box 2-11**.

Indications for clinical exercise testing fall into three general categories: (a) diagnosis, (b) prognosis, and (c) evaluation of functional capacity.[39] CPX provides the most comprehensive and objective assessment of functional impairment and yields information about the metabolic, cardiovascular, and ventilatory responses to exercise.[40] In addition to assisting in the diagnosis of dyspnea and exercise intolerance, CPX can be used for a broad range of other applications such as determining disease severity, exercise prescription for rehabilitation, assessing the effectiveness of pharmacologic agents, or assessing for lung transplant.[40] **Box 2-12** lists the indications for cardiopulmonary exercise testing.

The most basic pulmonary response to exercise is an increase in ventilation. Ventilation increases linearly with the amount of work and oxygen consumption up to the anaerobic threshold (AT), after which minute ventilation increases exponentially relative to the increase in oxygen uptake.[41]

BOX 2-11 Parameters Measured During Cardiopulmonary Exercise Testing

- ECG
- Respiratory rate
- BP
- Oxygen saturation
- Oxygen uptake ($\dot{V}O_2$)
- Carbon dioxide output ($\dot{V}CO_2$)
- Arterial blood gasses (as needed)

The primary parameter for evaluating cardiorespiratory fitness is **maximum oxygen uptake (Vo_{2max})**.[39] Vo_{2max} is a representation of the functional limitation of the cardiovascular system as well as aerobic fitness. Test results are normal if patients can reach their predicted Vo_{2max} and a heart rate at or near their predicted maximum heart rate (HR_{max}) at peak exercise capacity. The maximal heart rate of a patient is calculated by subtracting the patient's age from 220. Variations resulting from age, gender, and fitness level are noted in Vo_{2max} and result primarily from differences in maximal CO.[39]

The most commonly used CPX protocols involve incremental exercise on either a treadmill or a cycle ergometer continued to symptom limitation.[38] The most common measured variables obtained during CPX appear in **Table 2-20**.

BOX 2-12 Indications for Cardiopulmonary Exercise Testing

- Evaluation of unexplained dyspnea
- Evaluation of disease severity
- Development of an exercise prescription of pulmonary rehabilitation
- Identification of gas exchange abnormalities
- Preoperative assessment: lung cancer surgery, lung volume reduction surgery, heart or lung transplantation
- Evaluation for lung/heart transplantation
- Objective evaluation of exercise capacity

Stickland M, Butcher S, Marciniuk D, Bhutani M. Assessing exercise limitation using cardiopulmonary exercise testing. *Pulm Med*. 2012;2012:824091. doi:10.1155/2012/824091.

TABLE 2-20
Common Cardiopulmonary Exercise Testing Variables

Variable	Normal Value	Clinical Relevance
Vo_{2max} (mL/minute)	>84% predicted, based on gender, age, height	Conventional expression of aerobic exercise capacity; reflects cardiovascular function
AT (ventilation threshold)	>40% Vo_{2max} predicted; wide range of normal (40–80%)	A measure of fitness
Maximum heart rate (HR_{max})	>90% age predicted	Cardiac response to exercise
Oxygen pulse (Vo_2/HR)	>80% predicted (~15 mL/beat in men; ~10 mL/beat in women)	Reflects cardiovascular function
Breathing reserve (ventilatory reserve)	MVV–V_{Emax}: >11L; (V_{Emax}/MVV) ×100: <85%	Reflects ventilatory function
Respiratory exchange ratio (Vco_2/Vo_2)	Rest: 0.6–1.0 Peak exercise: >1.15	Estimate of metabolic events Ensures good patient maximal effort

Contraindications for cardiopulmonary exercise testing include acute MI (3–5 days), unstable angina, uncontrolled arrhythmias causing symptoms or hemodynamic compromise, syncope, active endocarditis, acute myocarditis or pericarditis, uncontrolled heart failure, acute pulmonary embolus, uncontrolled asthma, $SaO_2 \leq 85\%$, suspected dissecting aneurysm, and pulmonary edema.[42] Criteria for the early termination of CPX include chest pain suggestive of ischemia, ischemic ECG changes, complex ectopy, second- or third-degree heart block, hypertension (systolic >250 mm Hg; diastolic >120 mm Hg), fall in systolic blood pressure (SBP) >20 mm Hg, $Spo_2 \leq 80\%$ when accompanied by symptoms and signs of severe hypoxemia, signs of respiratory failure, mental confusion, loss of coordination, dizziness, or faintness.[42]

A simpler form of exercise often used to assess functional limitation is the **six-minute walk test (6MWT)**.[32] This test can also be used to assess response to either cardiac or pulmonary therapeutic interventions.[43] Walking is an activity performed daily by all but the most severely impaired patients. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.[44] This test does not distinguish limitation due to lung disease from that attributable to other medical problems such as heart disease, peripheral vascular disease, or muscle weakness. However, it does provide an easily performed objective measure of a patient's exercise tolerance and can be used to follow how a patient is doing over time, with or without treatment.[32] The primary indications for the 6MWT appear in **Box 2-13**. Reasons for immediately stopping a 6MWT include chest pain, severe dyspnea, leg cramps, walking instability, and signs of respiratory distress.

Examining the cardiopulmonary responses to CPX can provide additional clinical data that is not available through resting tests of lung and cardiac function and can assist clinicians to determine mechanism(s) for exercise intolerance and/or dyspnea.[40]

Cardiac Catheterization

Cardiac catheterization, also known as a Heart Cath, is the process of inserting a catheter into the heart. This technique can evaluate the heart structure, patency of the coronary arteries, and cardiac function. A "right heart" catheterization, performed through a venous route, obtains hemodynamic measurements and is also used for electrophysiologic studies. A "left heart" catheterization, performed through an arterial route, can evaluate coronary artery anatomy, left ventricular function, and valvular heart disease.

BOX 2-13 Primary Indications for the 6MWT

- Assess functional status
- Measure response to therapeutic interventions
- Predict mortality and morbidity

Percutaneous Coronary Intervention

Coronary artery anatomy is delineated using contrast medium injected through the heart catheter during a "left heart" catheterization. This is diagnostic coronary angiography. It is the gold standard for assessing the coronary anatomy in patients with angina and may be used to guide angioplasty and to determine whether to conduct coronary artery bypass graft surgery (CABG).[34] When used to guide angioplasty and/or stenting, this process is known as **percutaneous coronary intervention (PCI)**. PCI is effective in restoring coronary perfusion (reperfusion) in the case of an ST-segment elevated myocardial infarction (STEMI) when carried out on an emergency basis in the first few hours of MI.[45] **Figure 2-19** shows an example of a coronary angiography identifying an area of stenosis.

Electrophysiology

An **electrophysiologic test (EP)** is conducted to study the electrical activity of the heart to recognize the nature of cardiac arrhythmias. There are two parts to an EP. One part assesses the electrical function of the heart, and the other paces the heart to bring about certain arrhythmias to observe under controlled conditions. The electrophysiology study results are used to decide the type of treatment needed to stop an abnormal heart rhythm. This treatment may include medication, pacemaker, implantable cardioverter defibrillator (ICD, used to control the heart's rhythm and speed and to stop fatal arrhythmias), radiofrequency ablation, or cardiac surgery.

Hemodynamic Monitoring

Hemodynamics is the branch of physiology dealing with the study of the circulation of blood through the body. **Figure 2-20** provides a brief schematic of blood circulation through the body.

Hemodynamic monitoring often plays an important role in the assessment of critically ill patients with the signs and symptoms of a compromised cardiovascular function. Invasive hemodynamics includes measurement and/or continuous monitoring of arterial blood pressure, CO, central venous pressure (CVP, to evaluate intravascular volume), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP, a surrogate for left atrial pressure), pulmonary vascular resistance (PVR), and systemic vascular resistance (SVR). To detect changes in hemodynamics, it is important to compare measured values to normal ranges.[21] **Table 2-21** shows the normal values for hemodynamic measurements. Indications for hemodynamic monitoring appear in **Box 2-14**.



FIGURE 2-19 Coronary angiograms. **(A)** Normal coronary angiogram visualizing the morphology of the left coronary arteries. **(B)** Coronary artery stenosis. The arrow is pointing to an area that has a pinched artery that has become narrowed due to deposits of fatty plaque on the walls of the artery. This may cause chest pain (angina) to occur. A complete block may cause an MI (heart attack).



FIGURE 2-20 Hemodynamic cycle. IVC, inferior vena cava; SBP, systolic blood pressure; SVC, superior vena cava.

TABLE 2-21
Approximate Normal Values for Hemodynamic Measurements

Variable	Normal Range	Use
Arterial blood pressure	Systolic blood pressure (SBP): 90–140 mm Hg	Assess for cardiac function and adequacy of perfusion
	Diastolic blood pressure (DBP): 60–90 mm Hg	
	Mean arterial pressure (MAP): 80–100 mm Hg	
CO	CO: 4–8 L/minutes (varies with size of patient)	Assess for shock and its treatment
	Cardiac index (CI): 2.5–4.0 L/min/m^2	
CVP	4–8 mm Hg	Assess for fluid balance
PAP	Pulmonary artery systolic pressure (PASP): 20–35 mm Hg	Assess for fluid balance
	Pulmonary artery diastolic pressure (PADP): 5–15 mm Hg	
	Mean pulmonary artery pressure (MPAP): 10–20 mm Hg	
PCWP	6–12 mm Hg (<18 mm Hg)	Assess for left ventricular failure
PVR	100–250 dyne-second/cm^5	Assess right ventricular afterload
SVR	800–1200 dyne-second/cm^5	Assess left ventricular afterload

BOX 2-14 Common Clinical Indications for Hemodynamic Monitoring

- Acute respiratory distress syndrome (ARDS)
- Chest trauma
- Complicated MI
- Heart failure
- Pulmonary hypertension
- Post-cardiac surgery
- Severe burn injury
- Shock

Arterial Blood Pressure Monitoring

The arterial catheter (A-line) is the most common method of invasive hemodynamic monitoring. An arterial catheter may be inserted in the radial, brachial, axillary, or femoral arteries. Indwelling arterial line placement is for patients with significant hemodynamic instability. The arterial catheter placement allows for continuous measurements of systolic, diastolic, and mean arterial blood pressure. Arterial lines overestimate the systolic pressure and underestimate the diastolic pressure, but are usually very accurate for monitoring the MAP.[21] It is important to monitor the appearance of the arterial waveform for damping because this indicates that values may be inaccurate.[21] Arterial pressure monitoring reveals information regarding fluctuations in BP and is a guide in regulating therapeutic interventions. The A-line is also useful in patients who require frequent arterial blood gasses.

Cardiac Output

Placement of a pulmonary artery catheter (PAC) provides a wealth of hemodynamic measurements, including invasive CO using the **Fick method** or **thermodilution method**. The Fick method requires the analysis of both arterial and mixed venous blood withdrawn from the PAC and oxygen consumption measured via indirect calorimetry. CO is calculated using the equation

$$CO = Vo_2 \div (Cao_2 - Cvo_2)$$

where Vo_2 is the oxygen consumption, Cao_2 is the arterial oxygen content, and Cvo_2 is the mixed venous oxygen content.

Thermodilution CO uses a special thermistor-tipped PAC. This method uses the injection of a cold solution of saline with a known temperature into the right atrium. The thermistor on the PAC located in a major vessel branch downstream records the temperature change over time. The attached monitor displays a temperature–time curve. The area under this curve is inversely proportional to the flow in the pulmonary artery, which is equal to the CO in the absence of intracardiac shunt.[46]

Cardiac index is the volume of blood pumped out by the heart divided by the patient's body surface area (square meters). Because body size affects overall CO, the cardiac index is a more precise measurement of heart function and allows the practitioners to compare the value to patients of different sizes.

Central Venous Pressure

Central venous pressure (CVP) is the pressure exerted by the blood in the right atrium. A single lumen or multi-lumen catheter is positioned in the superior vena cava via the subclavian or internal or external jugular vein.[46] The catheter can monitor the CVP, infusing medications, and venous blood sampling. Assuming a competent tricuspid valve, the CVP waveform reflects both venous return to the right atrium (during ventricular systole) and right ventricular end diastolic pressure (RVEDP).[46] The CVP is used to assess right ventricular preload and as a guide for fluid and blood replacement in hypovolemic or bleeding patients. The central venous catheter is also used to obtain venous blood samples to assess for the saturation of hemoglobin (Svo_2). If the Svo_2 is low, it indicates that the tissues are extracting more oxygen from the blood than normal. This indicates that the CO is not high enough to meet tissue oxygen needs.

Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure

The **flow-directed pulmonary artery catheter** (Swan–Ganz catheter) assesses left ventricular function and hemodynamic performance. PACs allow for **pulmonary artery pressure (PAP)** measurement and blood sampling from the pulmonary artery and can also facilitate pressure monitoring and blood sampling from the right ventricle and right atrium. PACs enable left atrial pressure to be estimated from **pulmonary capillary wedge pressure (PCWP)**, also known as pulmonary artery occlusion pressure (PAOP). PCWP determines left ventricular preload and is important in the differentiation between CHF and acute respiratory distress syndrome.

Observation of pressure waveforms permits the evaluation of mechanical events within the atria and ventricles and offers important diagnostic information in a wide variety of cardiopulmonary disease states.[46] Each anatomic position within the heart produces a characteristic waveform.[46] **Figure 2-21** shows the waveforms and normal pressures indicative of the right atrium, right ventricle, pulmonary artery, and pulmonary capillary wedge pressure.



FIGURE 2-21 PAC waveforms and normal pressures.

Modified from Longnecher D, Brown D, Newman M, Zapol W. *Anesthesiology*. New York, NY: McGraw-Hill. © 2007 The McGraw-Hill Companies, Inc. Used with permission of The McGraw-Hill Companies, Inc.

Vascular Resistance

With a PAC in place, **pulmonary vascular resistance (PVR)** calculation is possible. PVR provides a measure of right heart afterload.[21] PVR is calculated using the following formula:

$$PVR = (MPAP - PCWP) \div (CO \times 80)$$

where MPAP is the mean pulmonary artery pressure, PCWP is the pulmonary capillary wedge pressure, and CO is the cardiac output.

Systemic vascular resistance (SVR) provides a measure of left heart afterload. It is calculated using the following formula:

$$SVR = (MAP - CVP) \div (CO \times 80)$$

where MAP is the mean arterial pressure, CVP is the central venous pressure, and CO is the cardiac output.

Chapter Summary

The identification of pulmonary diseases and the evaluation of their functional effects can be narrowed down using history taking and physical examination. However, definitive diagnoses are made only after diagnostic testing using appropriate tests including sputum testing, skin testing, bronchoscopy, PFT, polysomnography, noninvasive testing, laboratory testing, diagnostic imaging, and cardiac diagnostic testing. The use of these tests is needed to arrive at a definitive diagnosis, accurate functional assessment, and close monitoring.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The 12-lead ECG is created using 10 leads placed on the patient.
2. True or False: A patient with non-ischemic coronary heart disease can be diagnosed using echocardiography.
3. True or False: The primary pulmonary parameter for evaluating cardiopulmonary fitness is the MET.
4. True or False: Hemodynamic measurements are obtained via a left heart catheterization.
5. True or False: The PCWP is used to determine left ventricular preload.

Key Points

1. Laboratory examination of sputum is helpful in the evaluation of respiratory tract infections.
2. Skin tests are performed to evaluate allergic reactions or exposure to *M. tuberculosis*.
3. Bronchoscopy is one of the most common methods of evaluating the respiratory tract and can be used to perform both diagnostic and therapeutic procedures.

4. PFTs are the primary diagnostic tool for evaluating patients with respiratory symptoms and for guiding the management of such patients' diagnosed lung disease. PFTs provide an objective assessment for the determination of the presence or absence of pulmonary disease. They provide data about the presence of ventilatory defects, gas exchange defects, lung disease severity, and patient response to therapy.
5. Polysomnography is useful for the diagnosis of SDB. Sleep testing may be done with portable technology for the home or in an overnight sleep laboratory.
6. In the critical care setting, it is common to place and keep monitoring leads directly on the patient's chest in a simple three-lead ECG configuration to show continuous wireless cardiac electrical activity (ECG telemetry).
7. Capnography monitors ventilation by measuring exhaled carbon dioxide and producing a time-based capnogram waveform.
8. Airway inflammation can be monitored by noninvasively measuring the FE_{NO} level. This is especially helpful with patients who have asthma.
9. A patient's ventilatory, acid–base, and oxygenation status is evaluated using arterial blood gas sampling.
10. The CBC is an overall assessment of the kinds and numbers of cells in the blood. The CBC test includes the total WBC count, a WBC differential, an RBC count, HCT, Hgb, platelet count, and MPV. The CBC provides valuable data about the patient's diagnosis, prognosis, and therapeutic response.
11. Chemistry panels are groups of tests that analyze the non-cellular components present in the plasma.
12. Cardiac enzymes are a group of proteins that are found in myocardial tissues and are released in the serum when cardiac cells are injured, elevating their levels during an acute MI.
13. Diagnostic image studies are important tools in diagnosing and monitoring patients with respiratory disorders and include radiographs, MRI, CT, ultrasound, and nuclear medicine scans.
14. The 12-lead ECG is recommended to screen for heart disease (e.g., CAD, left ventricular hypertrophy), rule out heart disease in surgical patients, evaluate patients with chest pain, follow the progression of patients with CAD, and evaluate heart rhythm disorders.
15. Echocardiography is a specific type of ultrasonography to assess information about cardiac structures and valvular function.
16. CPX measures physiologic reserve and functional capacity of the heart and lungs that cannot be determined from resting measurements.
17. Cardiac catheterization, also known as a Heart Cath, is the process of inserting a catheter into the heart and is used to evaluate the heart structure, patency of the coronary arteries, and cardiac function.
18. An EP is conducted to study the electrical activity of the heart by assessing the electrical function of the heart and pacing the heart to bring about certain arrhythmias to observe under controlled conditions.
19. Hemodynamic monitoring helps in the assessment of critically ill patients with the signs and symptoms of a compromised cardiovascular function. Invasive hemodynamics includes measurement and/or continuous monitoring of arterial BP, CO, CVP (to evaluate intravascular volume), PAP, PCWP (a surrogate for left atrial pressure), PVR and SVR.

Chapter Questions

1. _____ is helpful in the detection of malignant cells in a sputum sample.
   a. Cytology
   b. Gram staining
   c. An acid-fast smear
   d. Culture and sensitivity
2. A bedside spirometry test provides data about the patient's _____.
   a. MVV
   b. Forced expiratory volume 1 second/forced vital capacity (FEV_1/FVC)
   c. static lung volumes
   d. airway resistance
3. Nonrapid eye movement sleep accounts for _____ of normal sleep each night.
   a. 25%
   b. 45%
   c. 75%
   d. 85%
4. Lead II from ECG telemetry shows a negative or downward deflection for the _____.
   a. P wave
   b. Q wave
   c. T wave
   d. U wave
5. Pulse oximeters are accurate for saturations greater than _____.
   a. 60%
   b. 70%
   c. 80%
   d. 90%
6. P_{ETCO_2} is decreased with _____.
   a. shivering
   b. hypoventilation
   c. pulmonary embolism
   d. malignant hypothermia

7. _____ causes a normal anion gap acidosis.
   a. Diarrhea
   b. Ketoacidosis
   c. Lactic acidosis
   d. Salicylate overdose
8. _____ are the most prevalent white blood cells during allergic reactions and asthma exacerbations.
   a. Monocytes
   b. Eosinophils
   c. Neutrophils
   d. Lymphocytes
9. Coronary artery disease risk is elevated when the total cholesterol level is greater than or equal to _____.
   a. 130 mg/dL
   b. 190 mg/dL
   c. 240 mg/dL
   d. 260 mg/dL
10. A rapidly growing tumor is most easily identified with an(a) _____.
    a. magnetic resonance imaging
    b. computed tomographic scan
    c. positron emission tomographic scan
    d. Ultrasound
11. The simplest test to establish a pulmonary patient's functional limitation is a(an) _____.
    a. six-minute walk test
    b. FEV_1/FVC
    c. 12-lead electrocardiogram
    d. pulmonary angiogram
12. A blocked coronary artery is identified using _____.
    a. hemodynamics
    b. angiography
    c. ultrasonography
    d. electrophysiology

References

1. Arora A, Diaz K, Peters J, Malave A. Bronchoscopy and other diagnostic studies. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:543–552.
2. Volker E, Treece A, Wahidi M, Shofer S. Interventional pulmonary procedures. In: Hess D, MacIntyre N, Galvin W, Mishoe S, eds. *Respiratory Care Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:171–203.
3. American Thoracic Society—Bronchoalveolar Lavage. *Thoracic.org*. 2016. https://www.thoracic.org/professionals/clinical-resources/critical-care/clinical-education/critical-care-procedures/bronchoalveolar-lavage.php. Accessed March 9, 2016.
4. Scanlan C, Heuer A. *Comprehensive Respiratory Therapy Exam Preparation Guide*. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015.
5. Miller M. Standardisation of spirometry. *Eur Respir J*. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805.
6. Haynes J. Pulmonary function testing. In: Hess D, MacIntyre N, Galvin W, Mishoe S, eds. *Respiratory Care Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:144–170.
7. Ranu H, Wilde M, Madden B. Pulmonary function tests. *Ulster Med J*. 2011;80(2):84–90. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229853. Accessed March 10, 2016.
8. Chaudhary B, Mishoe S. Polysomnography. In: Hess D, MacIntyre N, Galvin W, Mishoe S, eds. *Respiratory Care Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:204–215.
9. Spriggs W. *Essentials of Polysomnography*. 2nd ed. Burlington, MA: Jones & Bartlett Learning.
10. Jacobson C. Optimum bedside cardiac monitoring. *Prog Cardiovasc Nurs*. 2000;15(4):134–137. doi:10.1111/j.0889-7204.2000.080402.x.
11. Siddall V, Shelledy D. Cardiac assessment and the electrocardiogram. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:385–426.
12. Toben B. Blood gases and associated technologies. In: Wanger J, ed. *Pulmonary Function Testing a Practical Approach*. 3rd ed. Burlington, MA: Jones & Bartlett Publishing; 2012:281–332.
13. Scott JB, Walsh B, Shelledy D. Blood gas analysis, hemoximetry, and acid-base balance. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:281–346.
14. Casey G. Capnography: monitoring CO_2. *Nurs N Z*. 2015;21(9):20–24.
15. El-Khatib M. Patient monitors. In: Volsko T, Chatburn R, El-Khatib M, eds. *Equipment for Respiratory Care*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:175–210.
16. Kodali B. Capnography outside the operating rooms. *Anesthesiology*. 2013;118(1):192–201. doi:10.1097/aln.0b013e318278c8b6.
17. Fletcher R. The arterial—end-tidal CO_2 difference during cardiothoracic surgery. *J Cardiothorac Anesth*. 1990;4(1):105–117. doi:10.1016/0888-6296(90)90457-q.
18. McSwain SD, Hamel D, Smith PB, et al. End-tidal and arterial carbon dioxide measurements correlate across all levels of physiologic dead space. *Respir Care*. 2010;55(3):288–293.
19. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | 3-Clinical-need-and-practice | Guidance and guidelines | NICE. *Niceorguk*. 2014. https://www.nice.org.uk/guidance/dg12/chapter/3-Clinical-need-and-practice. Accessed March 21, 2016.
20. Dweik R, Boggs P, Erzurum S, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602–615. doi:10.1164/rccm.9120-11st.
21. Vines D, Jendral K, Wilson J, Kaur R. Acute and critical care monitoring and assessment. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:557–591.
22. Flaws M, Radtke J, Castillo D. Laboratory studies. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:347–383.
23. Davis M, Walsh B, Sittig S, Restrepo R. AARC clinical practice guideline: blood gas analysis and hemoximetry: 2013. *Respir Care*. 2013;58(10):1694–1703. doi:10.4187/respcare.02786.
24. Wettstein R, Wilkins R. Interpretation of blood gases. In: Wilkins R, Dexter J, Heuer A, eds. *Clinical Assessment in Respiratory Care*. 6th ed. St. Louis, MO: Elsevier-Mosby; 2010:142–165.
25. Tefferi A, Hanson C, Inwards D. How to interpret and pursue an abnormal complete blood cell count in adults. *Mayo Clin Proc*. 2005;80(7):923–936. doi:10.4065/80.7.923.
26. Chemistry Panels. *Labtestsonlineorg*. 2016. https://labtestsonline.org/understanding/analytes/chem-panel. Accessed March 27, 2016.
27. Kraut J, Madias N. Serum anion gap: its uses and limitations in clinical medicine. *Clin J Am Soc Nephrol*. 2007;2(1):162–174. doi:10.2215/cjn.03020906.

28. Kaparianos A, Argyropoulou E, Sampsonas F, Karkoulias K, Tsiamita M, Spiropoulos K. Pulmonary complications in diabetes mellitus. *Chron Respir Dis*. 2008;5(2):101–108. doi:10.1177/1479972307086313.
29. Anandhalakshmi S, Manikandan S, Ganeshkumar P, Ramachandran C. Alveolar gas exchange and pulmonary functions in patients with type II diabetes mellitus. *J Clin Diagn Res.* 2013;7(9):1874–1977. doi:10.7860/jcdr/2013/6550.3339.
30. Lilly L. *Pathophysiology of Heart Disease.* 5th ed. Baltimore, MD: Wolters Kluwer/Lippincott Williams & Wilkins; 2011.
31. Ray C Jr, Fielding L. Diagnostic imaging. In: Hanley M, Welsh C, eds. *Current Diagnosis & Treatment in Pulmonary Medicine*. 1st ed. New York, NY: Lange Medical Books/McGraw-Hill; 2003:26–38.
32. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine.* 6th ed. Philadelphia, PA: Elsevier-Saunders; 2014.
33. Fuhlbrigge A, Choi A. Diagnostic procedures in respiratory disease. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Education; 2013:36–44.
34. Vasquez L, Shelledy D, Peters J. Cardiopulmonary imaging. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development.* 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:427–501.
35. VQ Scan | Inside Radiology. *Insideradiologycomau*. 2016. https://www.insideradiology.com.au/vq-scan/. Accessed August 20, 2018.
36. Heramba P, Jonathan S. Acute coronary syndrome. In: Richard A, ed. *Essentials of Emergency Medicine.* 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2011:101–121.
37. Greenland P, Alpert J, Beller G, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults. *J Am Coll Cardiol*. 2010;56(25):e50–e103. doi:10.1016/j.jacc.2010.09.001.
38. Arena R, Sietsema K. Cardiopulmonary exercise testing in the clinical evaluation of patients with heart and lung disease. *Circulation*. 2011;123(6):668–680. doi:10.1161/circulationaha.109.914788.
39. Swain D. *ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription*. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2014.
40. Stickland M, Butcher S, Marciniuk D, Bhutani M. Assessing exercise limitation using cardiopulmonary exercise testing. *Pulm Med*. 2012;2012:824091. doi:10.1155/2012/824091.
41. Balady G, Arena R, Sietsema K, et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation*. 2010;122(2):191–225. doi:10.1161/cir.0b013e3181e52e69.
42. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med*. 2003;167(2):211–277. doi:10.1164/rccm.167.2.211.
43. Hirst K, Walsh B. Adult pulmonary function. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development.* 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:503–542.
44. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med*. 2002;166(1):111–117. doi:10.1164/ajrccm.166.1.at1102.
45. Antman E, Loscalzo J. ST-segment elevation myocardial infarction. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine.* 2nd ed. New York, NY: McGraw-Hill Education; 2013:321–340.
46. Hess D. Hemodynamic monitoring. In: Hess D, MacIntyre N, Galvin W, Mishoe S, eds. *Respiratory Care Principles and Practice.* 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:42–55.

CHAPTER

3

Respiratory Failure

"Breathing is truly a strange phenomenon of life, caught midway between the conscious and the unconscious, and peculiarly sensitive to both."

—D.W. Richards, MD, 1953

OUTLINE

OBJECTIVES

1. Identify the clinical manifestations of respiratory failure.
2. Discuss the differences between the types of respiratory failure.
3. Describe the underlying pathophysiologic causes of the types of respiratory failure.
4. Utilize patient data to differentiate the types of respiratory failure.
5. Discuss the management of respiratory failure.

KEY TERMS

Acute hypercapnic respiratory failure
Acute hypoxemic respiratory failure
Acute-on-chronic respiratory failure (ACRF)
Alveolar dead space
Alveolar-to-arterial oxygen tension gradient [$P_{(A\text{-}a)}O_2$]
Anatomic dead space
Anatomic shunt
Anemic hypoxia
Arterial blood oxygen content (C_aO_2)
Arterial-to-alveolar oxygen tension ratio (Pa_{O_2}/P_{AO_2}, or a/A ratio)
Chronic respiratory failure (CRF)
Dead space
Diffusion
Histotoxic hypoxia
Hypoxemic hypoxia
Intrapulmonary shunt
Oxygenation index (OI)
Physiologic dead space
Ratio of arterial oxygen tension to oxygen concentration (P/F ratio)
Respiratory failure
Shunt
Stagnant hypoxia
Type I respiratory failure
Type II respiratory failure
Ventilation-to-Perfusion ratio ($\dot{V}/\dot{Q}$)

Introduction

Respiratory failure is a syndrome rather than a single disease, in which the respiratory system fails in one or both of its primary functions: oxygen absorption and carbon dioxide elimination. The respiratory system handles oxygen supply to the blood for aerobic metabolism and removes the body's major waste product carbon dioxide. The respiratory system accomplishes these functions using three distinct mechanisms of ventilation:

1. The delivery of ambient air to the alveoli
2. **Diffusion**, the movement of oxygen and carbon dioxide across the alveolar air sac and capillary wall
3. Circulation, the method by which oxygen moves from the site of gas exchange to the cells, where active metabolism occurs

This process is called respiration. Conceptually, the lungs handle two of the three vital components: oxygenation and ventilation. Respiration depends on the vital links of various anatomic subcomponents, seen in **Figure 3-1**.

The lungs achieve ventilation through the "pumping" action created by the chest wall and the respiratory muscles. The central nervous system (CNS) respiratory centers control the respiratory muscles through the spinal cord and nerves connecting the CNS to the respiratory muscles. The thorax, pleura, and upper airways need to be intact for ventilation to occur. A failure of one of the components of the "pump" leads to **Type II respiratory failure**, also known as pump failure or hypercapnic respiratory failure. The principal problem in Type II respiratory failure is hypoventilation, which subsequently leads to hypercapnia. Despite the concurrent presence of hypoxemia observed in patients with Type II respiratory failure, an elevated $Paco_2$ is considered the primary characteristic of ventilatory failure. Hypercapnic respiratory failure may occur either gradually in a subtle manner or acutely imposed upon chronic carbon dioxide retention.

The failure of gas exchange function as a result of lung disease typically results in hypoxemia (low blood oxygen level) with normal or reduced carbon dioxide levels (hypocarbia). This situation is commonly referred to as **Type I respiratory failure**, lung failure, or oxygenation failure. Type I respiratory failure (hypoxemia) and Type II respiratory failure (hypercapnia) may coexist in the same patient. Mixed Type I and Type II respiratory failure is common in patients who have severe chronic obstructive pulmonary disease (COPD). Typically, these individuals initially develop hypoxemia followed by hypercapnia as the disease persists or progresses.

If flawless oxygen and carbon dioxide gas exchange were to occur naturally, blood flow and ventilation would be perfectly matched. This perfect match would create a **ventilation-to-perfusion ratio ($\dot{V}/\dot{Q}$)** of 1 (**Figure 3-2A**). This perfect match would result in no alveolar–arterial Po_2 difference. However, even in normal lungs, not all alveoli are ventilated and perfused perfectly. For a given perfusion, some alveoli are inefficiently under-ventilated, while others are over-ventilated. In the same way, alveolar ventilation results in some units being under-perfused while others are over-perfused. Alveoli that are well ventilated but not well perfused have high $\dot{V}/\dot{Q}$ units (**Figure 3-2B**). These units physiologically act like an



FIGURE 3-1 These are the vital links that are necessary for normal respiration to occur. A break anywhere in this chain causes respiratory failure.

Data from Bone R. Acute respiratory failure: definition and overview. In: Bone R, ed. *Pulmonary And Critical Care Medicine.* 1st ed. St. Louis, MO: Mosby; 1997.



FIGURE 3-2 Ventilation–perfusion relationships in health and disease. **(A)** An ideal situation where the V̇/Q̇ is 1. **(B)** The capillaries are under-perfused creating a mismatch between ventilation and perfusion such that the V̇/Q̇ is greater than 1. **(C)** The alveoli are over-ventilated creating a situation where the capillaries are shut by the over-distended alveoli. **(D)** Perfusion is normal, but there is little ventilation creating a low V̇/Q̇. **(E)** There is perfusion of the capillaries, but no ventilation, creating a shunt. **(F)** A silent unit has neither ventilation nor perfusion.



FIGURE 3-3 The lung zone model shows the influence of position on the perfusion and ventilation characteristics of normal lungs. Gravity has its greatest effect on the lungs in the standing position. In the upright position, blood flow is highest within the base of the lungs and decreases toward the apex. In zone 1, the pressure in the alveoli is greater than the pulmonary artery or venous pressures, so the vessels are relatively compressed. There is more ventilation than perfusion, giving a high V̇/Q̇ ratio. In zone 2, the pulmonary artery pressure is greater than the alveolar pressure, which is greater than the venous pressure. Ventilation and perfusion are considered matched in this zone in the upright position. In zone 3, the alveolar pressure is less than both the pulmonary arterial and the venous pressure, so the pulmonary veins are distended, and airway pressure does not influence perfusion. P_A, alveolar pressure; P_a, arterial pressure; P_v, venous pressure.

added **dead space** (**Figure 3-2C**). In contrast, perfused alveoli that are not well ventilated have low V̇/Q̇ units (**Figure 3-2D**). These units act as a shunt mechanism (**Figure 3-2E**). Areas of the lung that have no perfusion and no ventilation are called silent units (**Figure 3-2F**). Normal lungs have some degree of V̇/Q̇ mismatch and a small quantity of right-to-left shunt. This normal mismatching and shunting, seen in **Figure 3-3**, results in alveolar P_{O_2} (P_{AO_2}) being slightly higher than arterial P_{O_2} (P_{aO_2}).

The general term *respiratory failure* is used to describe a patient situation in which the heart and lungs are unable to supply adequate tissue oxygenation and/or remove carbon dioxide.[1] The cells of the body demand oxygen delivery and carbon dioxide removal. The respiratory system both supplies oxygen and removes carbon dioxide. Normally, the respiratory system is capable of exceeding tissue demand, creating our pulmonary reserve, which is used during times of exercise and illness. A state of respiratory failure exists when the respiratory system is unable to keep up with the demands of the tissues. There can either be an increase in tissue demand (increased ventilatory demand), or a decrease in the ability of the respiratory system (diminished ventilatory supply), or both. See **Box 3-1** for some examples.

There are four basic types of respiratory failure: **acute hypoxemic respiratory failure**, **acute hypercapnic respiratory failure**, **chronic respiratory failure** (CRF; hypoxemic and/or hypercapnic), and **acute-on-chronic respiratory failure (ACRF)**. The clinical presentations of patients with acute and CRF are usually quite different. Acute respiratory failure is a life-threatening abnormality in oxygenation and/or ventilation. CRF is more latent and may be clinically unapparent.

The overall incidence of respiratory failure in the United States, as well as worldwide, is difficult to estimate due to the multiplicity of its many underlying causes. Because the ability to sustain normal respiration depends on the integration of the many systems involved in breathing, disruption in any one or a combination of these systems can induce failure. As many underlying causes may contribute solely or in combination to the development of respiratory failure, this disorder represents a common and major cause of illness and death. Respiratory failure is the leading cause of mortality from pneumonia and COPD, which together comprise the third leading cause of death in

BOX 3-1 Ventilatory Supply-and-Demand Causes of Respiratory Failure

Factors that decrease ventilatory supply:

1. Airway obstruction
2. Bronchospasm
3. Drug overdose
4. Neuromuscular diseases
5. Obesity
6. Respiratory muscle atrophy
7. Respiratory muscle fatigue
8. Upper airway obstruction

Factors that increase ventilatory demand:

1. Acute asthma exacerbation
2. COPD exacerbation
3. Fever
4. Hepatic failure
5. Hypoxemia
6. Metabolic acidosis
7. Pulmonary emboli
8. Sepsis

the United States today. This disorder is also the leading cause of mortality in many neuromuscular diseases that weaken the respiratory muscles, rendering them incapable of sustaining normal breathing. The incidence of respiratory failure does appear to increase significantly for each decade of life until 85 years of age with a particularly high incidence observed in patients over the age of 65 years.

KNOWLEDGE CHECK QUESTIONS

1. Respiratory failure due to increased ventilatory demand may be caused by:
   a. sepsis.
   b. obesity.
   c. neuromuscular disease.
   d. upper airway obstruction.
2. True or False: Metabolic acidosis can lead to respiratory failure due to a decrease in ventilatory demand.

Acute Hypoxemic Respiratory Failure

Definition

Hypoxemic respiratory failure is also known as Type I respiratory failure, lung failure, or oxygenation failure. Hypoxemia is a decreased Pao_2 in the blood, below the normal range.[2] Hypoxemic respiratory failure can be either acute (minutes to hours) or chronic (several days or longer). The American Association for Respiratory Care (AARC) Clinical Practice Guideline for Oxygen Therapy for Adults in the Acute Care Facility[3] defines a Pao_2 of less than 60 torr or an Sao_2 of less than 90% while breathing room air as hypoxemia. Additionally, a person with a Pao_2 and/or Sao_2 below a desirable range for specific clinical situations is regarded as having hypoxemia. The severity of hypoxemia may be classified by using either Pao_2 or Sao_2 (**Box 3-2**).

Hypoxemia is a very dangerous situation because it can lead to tissue hypoxia and death. The organs of the body that are at greatest risk due to hypoxemia are the CNS and the heart. Tissue hypoxia causes cell injury by adenosine triphosphate depletion, intracellular acidosis, the build-up of metabolic byproducts and free radicals, and the induction of inflammation. The assessment of adequate oxygenation depends on more than just a simple evaluation of Pao_2 and Sao_2. Tissue oxygenation depends on four factors: the ability of the respiratory system to bring in oxygen (ventilate), the ability to diffuse the oxygen across the alveolar-capillary membrane, the presence of enough hemoglobin in the blood to carry the oxygen to the tissues, and the ability of the cardiovascular system to bring the oxygen to the tissues. Other factors involved in oxygenation include perfusion of the tissues, extraction of oxygen by the tissues, and utilization of the oxygen by the cells.

Causes

The underlying pathophysiologic causes of acute hypoxemic respiratory failure include problems with various processes that bring oxygen into the lungs, across the alveolar–capillary membrane, and to the cells of the body. These causes include ventilation–perfusion mismatch, alveolar hypoventilation, decreased fraction of inspired oxygen, a diffusion impairment across the alveolar–capillary membrane, intrapulmonary shunting, and a reduction of oxygen in mixed venous blood.

Ventilation–Perfusion Mismatch

Ventilation–perfusion mismatch or inequality is the most common pathophysiologic cause of acute hypoxemic respiratory failure. It causes the development of hypoxemia. Hypoxemia can occur by a decrease in ventilation to adequately perfused regions of the lung, a reduction in perfusion to adequately ventilated regions

Case Study 1

A 40-year-old police officer presented to the emergency department with a 10-day history of slight fever followed by rapidly progressive dyspnea for 3 days prior to admission. He indicated to the attending physician that he had always kept himself in good health and "very fit." He did admit to a loss of his usually good appetite and was unable to work for the past few days due to shortness of breath, overall weakness, and a slight sore throat. A nonsmoker, he denied the use of alcohol and had no prior history of any medical illness other than borderline high blood pressure. He is 6 feet 2 inches and weighs 195 lb.

On observation: The patient appeared to be in moderate-to-severe respiratory distress with mild central cyanosis. Vital signs showed a temperature of 101.0°F, resting respiratory rate of 30 breaths/minute, and blood pressure of 100/65. Breath sounds revealed extensive fine inspiratory crackles. Physical examination of the heart revealed a resting tachycardia of 120 beats/minute. The patient was immediately given supplemental oxygen via a nasal cannula at 4 L/minute, and pulse oximetry revealed a saturation of 86%.

An arterial blood gas (ABG) test while receiving oxygen at 4 L/minute showed a pH of 7.48, $Paco_2$ 23 torr, Pao_2 48 torr, HCO_3^- 20 mEq/L, and Sao_2 85%. A complete blood count (CBC) drawn in the emergency department revealed a hemoglobin level of 14.4 g/L. The patient had a white blood cell count of 30,000/mm^3 with 84% neutrophils, 9% lymphocytes, 5% monocytes, and 2% eosinophils. A portable chest x-ray taken in the emergency department revealed diffuse bilateral alveolar infiltrates with normal cardiac size.

After the ABG test, the patient received a non-rebreather mask at 12 L/minute and broad-spectrum intravenous antibiotics (erythromycin and levofloxacin). Because no significant improvement was noted clinically or with ABG measurements over the next 12 hours, the patient was transferred to the intensive care unit (ICU), with the anticipation of the need for mechanical ventilation. In the ICU, the patient was placed on continuous positive airway pressure (CPAP) with an initial setting of 5 cm H_2O and an FIO_2 of 60%. Within 1 hour of starting CPAP, there was a drastic improvement in the respiratory rate (falling from 30 to 18 breaths/minute) in addition to a significant improvement in ABGs. There were additional CPAP adjustments, with maximum CPAP of 8 cm H_2O administered during his hospital stay. Gradually, clinicians brought the level of CPAP down over several hours, as the patient's clinical condition and ABGs showed progressive improvement. He was discharged after a 12-day hospital stay, achieving a satisfactory ABG result on room air and advised to continue erythromycin for an additional period of 3 weeks. On 1-month follow-up, the patient was asymptomatic, with complete clearing of the previously noted infiltrate on standard chest x-ray.

BOX 3-2 Assessment of the Severity of Hypoxemia

Value	Normal Range*	Mild	Moderate	Moderate to Severe	Very Severe
Pao_2 (mm Hg)†	80–100	60–79	50–59	40–49	<40
Sao_2 (%)‡	96–98	91–95	85–90	75–84	<75

*Expected Pao_2 declines with age. For subjects >60 years, the expected "normal" Pao_2 can be estimated as follows:
Supine normal $Pao_2 = 109 - (0.43 \times \text{age}) \pm 8$ mm Hg
Standing normal $Pao_2 = 104 - (0.27 \times \text{age}) \pm 12$ mm Hg

†Many authors list the range of Pao_2 for the assessment of hypoxemia as follows:
Mild: Pao_2 = 60–79 mm Hg
Moderate: Pao_2 = 40–59 mm Hg
Severe: Pao_2 <40 mm Hg

We believe, however, that Pao_2 <50 mm Hg represents a medical emergency that should be treated as moderate-to-severe hypoxemia.

‡Actual Sao_2 will vary with pH, Pao_2, and temperature.

of the lung, or a reduction in both ventilation and perfusion. Regions of the lung with low $\dot{V}/\dot{Q}$ ratios (caused by inadequate ventilation) can result in both arterial hypoxemia and hypercapnia. Regions of the lung with high $\dot{V}/\dot{Q}$ ratios (caused by inadequate perfusion) lead to hypoxemia and probably to hypocapnia. **Figure 3-4** shows how disturbances in ventilation or perfusion can change the $\dot{V}/\dot{Q}$ ratio.

Alveolar Hypoventilation

Alveolar hypoventilation is a relatively common cause of acute hypoxemic respiratory failure. Pure alveolar hypoventilation is an acute reduction in an individual's effective alveolar ventilation, in which lung parenchyma is essentially normal. This reduction results in arterial carbon dioxide retention (hypercapnia), with a concurrent decrease in oxygen that is absorbed from the lungs, resulting in a decrease in arterial oxygenation (hypoxemia). Less oxygen in the alveoli results in less oxygen in the blood. Because this pathophysiologic mechanism combines characteristics of hypercapnia and hypoxemia, alveolar hypoventilation can be considered a "mixed form" of respiratory failure. Causes of acute hypoxemic respiratory failure from alveolar hypoventilation include neuromuscular dysfunction, CNS depression from anesthesia or an opiate overdose, and COPD exacerbation.

Decreased Fraction of Inspired Oxygen

Decreased inspired oxygen is an uncommon cause of acute hypoxemic respiratory failure that usually occurs as a result of a decrease in barometric pressure as in breathing at high altitudes. At high altitudes, the partial pressure of inspired oxygen falls, decreasing the amount of oxygen being inhaled. Less oxygen in the alveoli (decreased P_IO_2) means less oxygen in the blood. For this reason, passenger airplane cabins are usually pressurized to between 6,000 and 8,000 feet. At this level, most "normal" people have little or no problems or discomfort. Individuals with cardiopulmonary diseases may require supplemental oxygen during their flights. In the acute care setting, insufficient delivery of supplemental oxygen (F_IO_2) to patients with cardiopulmonary disease can contribute to hypoxemic respiratory failure. This type of hypoxemic respiratory failure usually responds to the delivery of supplemental oxygen administration.



FIGURE 3-4 Common causes of $\dot{V}/\dot{Q}$ mismatch are bronchospasm, mucus plugging, airway inflammation, premature airway closure, or heart diseases, which cause inadequate tissue perfusion.

Adapted from Bone R. Acute respiratory failure: definition and overview. In: Bone R, ed. *Pulmonary And Critical Care Medicine.* 1st ed. St. Louis, MO: Mosby; 1997.

Diffusion Impairment

Diffusion impairment is a relatively uncommon cause of acute hypoxemic respiratory failure occurring primarily in emphysema and severe interstitial lung disease (ILD). The alveolar–arterial oxygen tension gradient in pure diffusion impairment is usually small and responsive to supplemental oxygen therapy. Increasing the alveolar P_O2 with supplemental oxygen increases the driving pressure for oxygen across the alveolar–capillary membrane and can easily correct pure diffusion impairments.[4] Individuals with acute respiratory distress syndrome (ARDS) frequently develop diffusion impairments that play a role in their hypoxemia, though intrapulmonary shunting is considered the primary pathophysiologic derangement in this disorder.

Intrapulmonary Shunting

Intrapulmonary shunt, also known as physiologic or right-to-left shunting, occurs when unoxygenated blood passes by airless, nonventilated alveoli and enters back into the arterial system. **Shunt** is wasted work for the heart because the shunted blood remains venous in its configuration. The normal 2–5% **anatomic shunt** occurs due to bronchial veins, Thebesian veins, pleural veins, and drainage of coronary venous blood directly into the left ventricle. Anatomic shunt is also called venous admixture. Only certain pathologic disorders cause increases in anatomic shunt. These include persistent fetal circulation and congenital cardiac defects.

Intrapulmonary shunting is an extreme form of $\dot{V}/\dot{Q}$ mismatch. This mismatch can be due to consolidation, pneumonia, atelectasis, or pulmonary edema. In any of these cases, the pulmonary capillary blood passes next to the completely collapsed alveoli or alveoli filled with edema fluid or inflammatory cells. The differentiation of shunt from $\dot{V}/\dot{Q}$ mismatch depends on the response differences to the inhalation of 100% oxygen. Pa_O2 levels in patients with intrapulmonary shunting who receive 100% oxygen will not significantly improve, whereas

an appreciable rise in Pa_{O_2} with oxygen therapy occurs in disorders causing ventilation–perfusion mismatch. Pulmonary diseases that cause intrapulmonary shunt include consolidative pneumonia, large pneumothorax, atelectasis, acute lung injury, ARDS, and complete airway obstruction.

Reduced Oxygen in Mixed Venous Blood

Reduced oxygen in the mixed venous blood is an *uncommon*, isolated cause of acute hypoxemic respiratory failure. Normally, the lungs fully oxygenate the pulmonary arterial blood, and mixed venous oxygen tension (Pv_{O_2}) does not substantially affect alveolar oxygen tension. A decrease in Pv_{O_2}, however, can precipitate significant lowering of Pa_{O_2} when other factors such as intrapulmonary shunting or $\dot{V}/\dot{Q}$ mismatch are present. Factors that can contribute to low Pv_{O_2} include anemia; inadequate cardiac output, as occurs in cardiogenic shock; and increased oxygen consumption. Improving oxygen delivery to tissues by increasing hemoglobin or improving cardiac output should result in decreased oxygen extraction, improved mixed venous oxygen tension, and improved arterial hypoxemia.

Table 3-1 shows the causes of hypoxemic respiratory failure, their pathophysiologic mechanisms, and some clinical examples.

Assessment

Hypoxemia should be suspected when a patient shows signs and symptoms of inadequate oxygenation, meaning that the tissues are becoming or have become hypoxic. Recognition of progressive global hypoxia can be difficult in the early stages because the clinical features are often nonspecific. Hyperventilation due to stimulation of the carotid chemoreceptors becomes obvious when the Pa_{O_2} falls to 40 torr.[5] Clinically, the patient exhibits nonspecific abnormal vital signs such as tachypnea, tachycardia, and hypertension. Some patients may exhibit cyanosis; however, if the patient has anemia, cyanosis is not usually apparent. **Table 3-2** reviews clinical manifestations at different levels of tissue hypoxia. Often after the development of hypoxemia, hyperventilation and respiratory alkalosis follow. If not, this situation is not treated, hypoventilation due to respiratory muscle fatigue (see Acute Hypercapnic Respiratory Failure) will occur.

While reduced Pa_{O_2} and Sa_{O_2} define a state of hypoxemia, hypoxemic respiratory failure results from abnormal oxygen transport secondary to pulmonary parenchymal disease. Oxygen delivery to the tissues is dependent on Pa_{O_2}, Sa_{O_2}, hemoglobin concentration, and cardiac output. Arterial oxygen saturation and Pa_{O_2} remain the principal clinical measures of arterial hypoxemia; however, these values may be normal despite tissue hypoxia in low cardiac output states and anemia.[5] Most clinical manifestations caused by oxygen exchange dysfunction do not occur unless the Pa_{O_2} and Sa_{O_2} are significantly affected. Although a diagnosis of acute hypoxemic respiratory failure often begins with a clinical suspicion of its presence, confirmation is established by ABG analysis.

An overall assessment of a patient's oxygenation status can be determined by calculating the **arterial blood oxygen content (Ca_{O_2})**, the **alveolar-to-arterial oxygen tension gradient [$P_{(A\text{-}a)}O_2$]**, the **ratio of arterial oxygen tension to oxygen concentration (P/F ratio)**, the **arterial-to-alveolar oxygen tension ratio (Pa_{O_2}/PA_{O_2} or a/A ratio)**, and the **oxygenation index (OI)**. **Table 3-3** shows the normal and critical values for these oxygenation assessments. **Box 3-3** demonstrates how to calculate these values.

TABLE 3-1
Common Mechanisms of Hypoxemia in Respiratory Failure

Causes of Type I Respiratory Failure	Pathophysiologic Mechanism	Clinical Example
Ventilation–perfusion mismatch	Continuous perfusion of nonventilated portions of the lung	COPD, asthma, emphysema, chronic bronchitis, cystic fibrosis
Alveolar hypoventilation	Reduced ventilation results in an increase in $P_{A}CO_2$, which in turn decreases PA_{O_2}, causing arterial hypoxemia despite a normal $P_{(A\text{-}a)}O_2$	Reduced respiratory rate (hypoventilation) caused by CNS depression (such as in an opioid drug overdose)
Low inspired oxygen concentration	Reduced amount of oxygen in the alveoli	High-altitude breathing, inhaling high concentrations of gases other than oxygen, inappropriately low inspired FI_{O_2} in a disease state
Diffusion impairment	Abnormal diffusion of oxygen across the alveolar-capillary membrane into the capillary blood	Pulmonary edema, diffuse ILD
Intrapulmonary shunt	Intrapulmonary shunting of blood to the systemic circulation, passing by collapsed alveoli	Atelectasis, pneumonia, acute lung injury, ARDS, complete airway obstruction

TABLE 3-2
Signs and Symptoms of Hypoxia

Degree of Hypoxia	Respiratory	Cardiac/Cardiovascular	Cognitive/Neurologic
Mild	Shortness of breath Increased respiratory rate Respiratory distress	Increased heart rate Mild hypertension Peripheral vasoconstriction	Overconfidence Restlessness Anxiety Excitement Euphoria Lightheadedness Nausea Dizziness Fatigue
Moderate	Increased respiratory distress Tachypnea Increased minute volume/hyperventilation Accessory muscle use Intercostal retractions	Tachycardia Arrhythmias Hypertension	Agitation Impaired judgment Confusion Decreased night vision Disorientation Listlessness Headache Tingling Loss of coordination
Severe	Severe dyspnea Slowed, irregular breathing Cyanosis Respiratory arrest	Hypertension followed by hypotension Tachycardia followed by bradycardia Cardiac arrest	Confusion Somnolence Severe headache Unconsciousness Vision disturbances (blurred vision, tunnel vision) Slowed reaction time Coma

TABLE 3-3
Normal and Critical Oxygen Assessment Values

Assessment	Formula	Normal Value	Critical Value
Ca_{O_2}	$(Hb \times 1.34 \times Sa_{O_2}) + (Pa_{O_2} \times 0.003)$	16–22 mL O_2/dL	<16 mL/dL
$P_{(A\text{-}a)O_2}$	$[FI_{O_2} \times (P_B - 47) - (Pa_{CO_2} \times 1.25)] - Pa_{O_2}$	On room air, 5–10 torr	>10 torr
		On 100% O_2, 25–65 torr	>65 torr
P/F ratio	$Pa_{O_2} \div FI_{O_2}$	>400	200–300 mild disturbance 100–200 moderate disturbance <100 severe disturbance
a/A ratio	$Pa_{O_2} \div PA_{O_2}$	>0.75	0.35–0.75 $\dot{V}/\dot{Q}$ mismatch <0.35 intrapulmonary shunting
OI*	$(MAP \times FI_{O_2} \times 100) \div Pa_{O_2}$	Not assessed unless receiving mechanical ventilation	>8

*Used to assess the oxygenation status for patients receiving mechanical ventilation to assess the intensity of ventilatory support needed to maintain oxygenation.

MAP, mean airway pressure.

The term *hypoxemia* defines a state of low oxygen in the blood as opposed to hypoxia, the condition of low oxygen levels in the body tissues.[6] Hypoxemia is only one of the several causes of hypoxia and, as seen earlier, may be caused by several pathophysiologic mechanisms. There are four mechanisms that cause tissue hypoxia (**Table 3-4**), including hypoxemia (**hypoxemic hypoxia**), anemia (**anemic hypoxia**), cardiovascular dysfunctions (**stagnant hypoxia**), and cellular dysfunction (**histotoxic hypoxia**).

Evaluation for an underlying cause and concurrent treatment must begin early. The cause of hypoxemic respiratory failure may become evident after a careful history and physical examination. Cases of cardiogenic

BOX 3-3 Evaluation of Oxygenation for the 40-Year-Old Police Officer Suffering from Type I Respiratory Failure

ABG while breathing with 4 L/minute nasal cannula (estimated $F_{IO_2} = 0.36$)

$P_B = 700$ torr

pH = 7.48

$P_{aCO_2} = 23$ torr

$P_{aO_2} = 48$ torr

$HCO_3^- = 20$ mEq/L

$S_{aO_2} = 85\%$

1. Assessment of the severity of hypoxemia = uncorrected moderate-to-severe hypoxemia. Uncorrected because the patient is receiving supplemental oxygen that has not corrected his hypoxemia. It is important to note that this patient is hyperventilating, has tachypnea, and tachycardia with supplemental oxygen. ABG analysis = partially compensated respiratory alkalosis with uncorrected moderate-to-severe hypoxemia.
2. $C_{aO_2} = (Hb \times 1.34 \times S_{aO_2}) + (P_{aO_2} \times 0.003) = (14.1\ g/dL \times 1.34 \times 0.85) + (23\ torr \times 0.003)$

   $C_{aO_2} = (16.06\ g/dL + 0.14) = 16.2\ mL/dL$. This value is at the low end of the normal range.
3. $P_{(A\text{-}a)O_2} = [F_{IO_2} \times (P_B - 47) - (P_{aCO_2} \times 1.25)] - P_{aO_2} = [0.36 \times (760\ torr - 47) - (23\ torr \times 1.25)] - 48\ torr$

   $P_{(A\text{-}a)O_2} = [(0.36 \times 713\ torr) - (23\ torr \times 1.25)] - 48\ torr = [257\ torr - 29\ torr] - 48\ torr$

   $P_{(A\text{-}a)O_2} = 228\ torr - 48\ torr = 180\ torr$. This gradient for F_{IO_2} is wider than normal.
4. P/F ratio = $P_{aO_2} \div F_{IO_2} = 48\ torr \div 0.36 = 133.33$. This is a critical value suggestive of a moderate disturbance of oxygenation.
5. a/A ratio = $P_{aO_2} \div P_{AO_2} = 48\ torr \div 228\ torr = 0.21$. This is suggestive of an oxygenation problem due to intrapulmonary shunting.
6. The OI is not applicable to this patient because he is not receiving mechanical ventilation.

This patient was managed by changing the 4 L/minute nasal cannula to a non-rebreather mask. When there was no improvement, the patient received a CPAP mask.

TABLE 3-4
Mechanisms of Hypoxia

Mechanism	Explanation	Examples	Response to Oxygen Administration
Hypoxemic hypoxia	Insufficient oxygen at the tissue level due to low P_{aO_2}	Lung diseases, high altitude	Good, except in the case of intrapulmonary shunt
Anemic hypoxia	Normal P_{aO_2}; however, there is less Hb available to carry O_2	Anemia, carbon monoxide poisoning, methemoglobinemia, hemorrhage	Poor
Stagnant hypoxia	Inadequate blood flow to maintain oxygenation to the tissues	Cardiac failure, cardiac arrest, hypovolemia, persistent hypotension	Poor
Histotoxic hypoxia	Inability of cells to metabolize oxygen	Cyanide poisoning	Poor

pulmonary edema usually develop in patients with a history of cardiac disease (left-ventricular dysfunction or valvular heart disease), recent symptoms of chest pain, paroxysmal nocturnal dyspnea, and orthopnea. Cases of non-cardiogenic pulmonary edema or ARDS occur in a variety of clinical backgrounds including sepsis, trauma, aspiration, pneumonia, pancreatitis, drug toxicity, and multiple transfusions.

Management

Suspected or documented hypoxemia is treated initially by administering supplemental oxygen via nasal cannula or air entrainment mask. The underlying cause for acute hypoxemic respiratory failure is a major factor in the response to the administration of supplemental oxygen. Supplemental oxygen delivery is most likely to correct hypoxemia associated with diffusion impairments, alveolar hypoventilation, $\dot{V}/\dot{Q}$ mismatch, and low inspired oxygen. Nonpulmonary causes of hypoxemic respiratory failure, such as cardiogenic shock, low cardiac output, anatomic shunt, and anemia, need to be treated medically or surgically and may require both oxygenation and ventilatory support.

Intrapulmonary shunt is the only pulmonary cause of hypoxemia that does not respond significantly to the administration of supplemental oxygen. Even 100% oxygen does not elicit appreciable changes in the oxygenation

status. This occurs because the unoxygenated blood in the pulmonary capillaries passes by collapsed alveoli containing no oxygen in them. Patients with P/F ratio below 200 and/or a/A ratio below 0.35 have intrapulmonary shunting. These patients do not respond significantly to supplemental oxygen alone. Another indicator of shunting is refractory hypoxemia or a Pao_2 rise of <5 torr following an increase in $FIO_2 \geq 0.10$.[1] To improve oxygenation in this situation, these collapsed alveoli must be reopened. Patients with acute hypoxemic respiratory failure who are spontaneously breathing may benefit from the administration of noninvasive CPAP. However, the use of CPAP may only be a temporary measure. Patients most likely to benefit from noninvasive CPAP would be those with postoperative atelectasis.[7] The strongest evidence for the use of noninvasive CPAP is for patients with acute cardiogenic pulmonary edema.[8] A European study has shown that helmet CPAP can rapidly improve oxygenation, better than oxygen therapy, in patients with community-acquired pneumonia with moderate acute hypoxemic respiratory failure.[9,10]

If the hypoxemia is not responding to noninvasive CPAP, noninvasive positive pressure ventilation (NPPV) could be another alternative, especially if the P/F ratio is below 200. Initial settings for NPPV should be inspiratory positive airway pressure (IPAP) 10–15 cm H_2O, expiratory positive airway pressure (EPAP) 5 cm H_2O with an FIO_2 of at least 0.50. The tidal volume delivered should be 6–8 mL/kg of the predicted body weight (PBW). Use IPAP adjustments to maintain pH and $Paco_2$. Use EPAP and FIO_2 to maintain Pao_2 and Sao_2. Keep the pressure support (IPAP–EPAP) at ≥5 cm H_2O. Contraindications for the use of NPPV include (1) hemodynamic instability; (2) the presence of life-threatening dysrhythmias; (3) the existence of life-threatening severe hypoxemia; (4) a substantial risk of gastric aspiration; (5) a diminished patient mental state; and (6) poor patient tolerance. Invasive ventilatory support would be necessary if there is a contraindication to NPPV or if NPPV does not reverse the patient's hypoxemia.

In the situation of acute hypoxemic respiratory failure, refractory to supplemental oxygen , CPAP, NPPV or invasive ventilatory support should be used to increase the patient's Pao_2. The FIO_2 needs be sufficient to raise the Pao_2 to a minimum of 60 torr. This will avoid high FIO_2s, which increase the risk of oxygen toxicity and atelectasis.[4] Patients with P/F ratios <200 will most likely require high levels of positive end expiratory pressure (PEEP) to reduce shunting and to keep the FIO_2 levels as low as possible. The level of PEEP used in a given clinical situation is determined by one of the methods reviewed in **Table 3-5**.

For conventional invasive ventilatory support, the target tidal volume is 6–8 mL/kg of PBW to keep the $P_{plateau}$ <30 cm H_2O. With patients who have severely reduced lung and/or chest wall compliance, use 4–6 mL/kg PBW for the volume and allow for slightly higher plateau pressures.

TABLE 3-5
Determining Optimal PEEP

Method	Use	Explanation
Static compliance method	For volume control ventilation	Keep V_T setting constant, measure and record exhaled V_T and $P_{plateau}$ or C_{STAT} at different PEEP settings. The optimal PEEP setting produces the highest C_{STAT}.
Equal pressure method	For pressure control ventilation	Keep the PIP–PEEP (ΔP) constant (15–25 cm H_2O) while making changes to the PEEP. (This means changes to the PIP to keep the ΔP constant.) Record the exhaled V_T at each change. The PEEP setting that gives the largest V_T represents the optimal PEEP.
Tissue oxygen delivery	For patients with Pulmonary Artery Catheters	O_2 Delivery = Cardiac Output × Cao_2. At each change of PEEP, use the pulmonary artery catheter to measure the cardiac output while drawing an ABG. Calculate the Cao_2, and then determine the O_2 delivery. Optimal PEEP produces the highest O_2 delivery.
P_{flex} or low inflection point	For ventilator graphics	Examine the pressure–volume curve. The intersection point between the slopes of the high-compliance segment and the low-compliance segment is the low inflection point or the P_{flex} point. The optimal PEEP is 2–3 cm H_2O above the P_{flex} point.

It is important to note that the impairment of oxygenation can lead to hypoxemic respiratory failure. When the hypoxemic respiratory failure becomes severe, carbon dioxide elimination becomes impaired and leads to the development of hypercapnic respiratory failure.

KNOWLEDGE CHECK QUESTIONS

1. Tissue hypoxia causes:
   a. intracellular alkalosis.
   b. an induction of inflammation.
   c. a depletion in metabolic byproducts.
   d. an increase in adenosine triphosphate.
2. True or False: Pulmonary edema can lead to acute hypoxemic respiratory failure by causing a diffusion impairment.

Acute Hypercapnic Respiratory Failure

Case Study 2

A 43-year-old female was found unresponsive on a bed in her apartment by her husband when he came home from work. He found empty bottles of diazepam (anti-anxiety) and venlafaxine (antidepressant) along with numerous empty beer cans near the bed. The husband immediately called emergency medical services (EMS), which arrived within 10 minutes. At the scene, the patient's blood pressure was 100/60, pulse 68 beats/minute, and respiratory rate 10 and shallow. Her Glasgow coma score was 10 on the scene. The EMS took the patient to the emergency department at the local hospital. During the transport, the patient required ventilatory assistance with a manual resuscitator bag because her breathing dropped to 6 breaths/minute and remained shallow.

Upon arrival at the emergency department, the patient received a non-rebreather mask. An ABG was drawn, showing a pH of 7.26, $Paco_2$ 56 torr, Pao_2 50 torr, Sao_2 60%, HCO_3^- 24 mEq/L. Her Glasgow coma score was 3 in the emergency department. She was then intubated; an oral gastric tube was inserted, and an IV started. The patient was given intravenous Flumazenil, and a gastric lavage was completed. The patient's Glasgow coma score increased to 13 within 12 hours, and she was extubated within 18 hours of admission.

Definition

Hypercapnic respiratory failure is also called Type II respiratory failure, ventilatory failure, or pump failure. Hypercapnia is an increased $Paco_2$ in the blood above the normal range and can also be called respiratory insufficiency. Hypercapnic respiratory failure can be acute (minutes to hours), chronic (several days or longer), or acute on chronic. A $Paco_2$ of greater than 50 torr, in otherwise healthy individuals, is considered hypercapnic respiratory failure. Acute hypercapnic respiratory failure is a sudden increase in $Paco_2$ with a corresponding acidotic pH. Chronic hypercapnic respiratory failure is a consistently high $Paco_2$ with metabolic compensation resulting in a pH within normal limits. A chronic hypercapnic respiratory failure that is complicated by an acute superimposed hypercapnia is acute-on-chronic hypercapnic respiratory failure. Hypercapnic respiratory failure can be life threatening because it has toxic effects on both the brain and the circulation. Hypercapnia causes an alteration in brain chemistry causing depression of consciousness and it raises intracranial pressure by increasing cerebral blood flow. Elevated blood CO_2 levels also depress myocardial contractility and cause coronary as well as systemic artery vasodilation. If not quickly recognized, the patient can become comatose, suffer hypoxemic respiratory failure, and die.

The body's metabolic production of carbon dioxide and its effective removal via alveolar ventilation by the lungs normally maintain the arterial $Paco_2$ within a physiologically normal range (35–45 torr). Elimination of CO_2 by the lungs is important in the maintenance of the body's acid–base balance. Control of carbon dioxide stability connects both alveolar ventilation and hydrogen ion regulation through sensitive hydrogen chemoreceptors. These chemoreceptors maintain the arterial blood pH within a relatively constant narrow range (pH 7.4 ± 0.05) by the elimination of CO_2 produced during metabolism and local production of H^+. Alveolar ventilation effectiveness is inversely proportional to arterial blood CO_2, and therefore, consequently, an increase in $Paco_2$ is indicative of inadequate alveolar ventilation with regard to the body's metabolic production of carbon dioxide. If significant retention of CO_2 above the normal level occurs, it is usually accompanied by significant hypoxemia unless a high concentration of oxygen is administered simultaneously. This is called hypercapnic/hypoxemic respiratory failure.

The relationship between alveolar ventilation and $Paco_2$ may be understood using the equation in **Box 3-4**. From this equation, it becomes clearly evident that the $Paco_2$ increases with either a decrease in alveolar ventilation or an increase in CO_2 production.

Activity and metabolic rate vary the rate of CO_2 production. Alveolar ventilation is that part of ventilation that participates in gas exchange and is sometimes called effective ventilation for this reason. Alveolar

BOX 3-4 The Relationship Between $Paco_2$ and Alveolar Ventilation

$$Paco_2 = (k \times \dot{V}co_2) \div \dot{V}_A$$

The constant k converts liters to torr and mL/minute to L/minute and is equal to 0.863. $\dot{V}co_2$ is the rate of CO_2 production and $\dot{V}_A$ represents alveolar ventilation.

BOX 3-5 The Relationship Among Alveolar Ventilation, Minute Ventilation, and Dead Space

$$\dot{V}_A = \dot{V}_E - \dot{V}_D \text{ physiologic}$$

$$\dot{V}_D \text{ physiologic} = \dot{V}_D \text{ anatomic} + \dot{V}_D \text{ alveolar}$$

$$\dot{V}_A = \dot{V}_E - (\dot{V}_D \text{ anatomic} + \dot{V}_D \text{ alveolar})$$

ventilation is equal to the minute ventilation minus the physiologic dead space ventilation. **Box 3-5** shows this relationship.

Physiologic dead space is of two types. The dead space that is due to the conducting airways (conducting zone) is **anatomic dead space**. The normal anatomic dead space varies directly with a person's height and is equal to approximately 1 mL/lb or 2.2 mL/kg of PBW. The dead space that is due to ventilated alveoli with no blood circulation to their capillaries (no perfusion) is **alveolar dead space**. This type of dead space can vary with disease states that reduce perfusion to the alveoli, such as pulmonary embolus, pulmonary artery thrombosis, hypotension, or hemorrhage. The total functional or physiologic dead space consists of the addition of the anatomic dead space and the alveolar dead space. The equations in Box 3-5 show that alveolar ventilation can be decreased either by a reduction in total ventilation (V_E) or through pulmonary ventilation–perfusion mismatch causing an increase in alveolar dead space ventilation. Because the $Paco_2$ and pH are linked, an acute increase in CO_2 causes a respiratory acidosis, leading to tissue dysfunction and clinical symptoms. The elimination of CO_2 by the lungs and fixed acids by the kidneys determine blood pH. The blood pH is inversely proportional to the $Paco_2$ and directly related to the bicarbonate (HCO_3^-). Also, not only can a reduction in alveolar ventilation cause hypercapnia, but increases in CO_2 production secondary to increases in metabolism without increases in alveolar ventilation can also lead to hypercapnia.

Causes

A failure of the lungs to remove carbon dioxide from the blood results in acute hypercapnic respiratory failure, otherwise known as "pump failure." This is a failure to move air out of the lungs and replace it with "fresh air."

Impairment of the CNS

An impairment of the CNS directly reduces minute ventilation by blunting the respiratory center. This can occur as a result of the effects of opioid and sedative drug overdoses (intentional or accidental), alcohol overdose, head trauma, anesthesia, or diseases of the medulla. Anything that interferes with the respiratory center's output causes hypercapnia via a decrease in minute ventilation. Severe hypercapnia, or hypoxemia, can also depress the respiratory center, leading to a downward spiral of clinical deterioration. Factors that depress the respiratory center also tend to depress the cerebral function globally, leading to decreased consciousness, the inability to protect the airway, and increased risk of aspiration.

Impairment of the Spinal Cord

If motor output emanating from the CNS does not reach the respiratory muscles, hypercapnia occurs. The degree of respiratory involvement due to spinal cord impairment depends on the level at which the spinal cord is affected. High cervical spine injuries, particularly C1–C4, increase the likelihood of hypercapnic respiratory failure.[11]

Impairment of the Neuromuscular System

In the case of neuromuscular impairment, the CNS and the spinal cord may be intact but are unable to signal the muscles of inspiration due to transmission problems at the nerves, neuromuscular junctions, or muscles. Many neuromuscular diseases produce progressively worsening impairments in which respiratory insufficiency occurs slowly and follows a predictable rate of worsening; these include amyotrophic lateral sclerosis (ALS), post-polio syndrome, and Duchenne muscular dystrophy. Others may have a seemingly faster onset, such as Guillain–Barre syndrome, myasthenia gravis, and phrenic nerve damage. Botulism, organophosphate poisoning, and paralytic drugs can also result in inadequate ventilation.

Impairment of the Thorax

Impairments of the thorax interfere with the mechanics of ventilation, predisposing the patient to the risk of respiratory failure. Fractured ribs can lead to hypoventilation if not treated with adequate pain medications. Other thoracic impairments include kyphoscoliosis, obesity, and flail chest.

Impairment of the Pleura

The presence of gas or liquid in the pleural space interferes with the integrity of the pleura, contributing to the development of acute hypercapnic respiratory failure, leading to acute hypoxemic respiratory failure. Examples of these impairments include pneumothorax, hemothorax, and pleural effusion.

Impairment of the Upper Airway

The upper airways lie above the carina and are subject to obstruction by a foreign body, trauma, infection, spasms (laryngospasm), edema, collapse (as in obstructive sleep apnea), and tumors. There are both acute and chronic causes of upper airway obstruction. The acute causes include foreign body aspiration, bilateral vocal

cord paralysis, and trauma to the cartilages. Bacterial causes of upper airway obstruction are more common in children than in adults. Chronic or slowly progressive causes of airflow obstruction include vocal cord polyps or granulomas and tumors.[12]

Fatigue

When a patient's work of breathing is high for prolonged periods of time, the inspiratory muscles can become fatigued, leading to hypercapnic respiratory failure. In other words, the respiratory muscles are unable to continue to generate enough pleural pressure to ventilate adequately although the CNS and the thoracic cage are intact. When the energy supply to the respiratory muscles is unable to meet the demands, fatigue sets in. Fatigue that plays a role in CO_2 retention may occur either acutely or chronically. Fatigue and hypercapnia of acute onset are usually due to a combination of increased work of breathing, a reduction in muscle strength, a decrease in efficiency, and a reduction in energy supplies to the inspiratory muscles.[13]

Table 3-6 shows the causes of hypoxemic respiratory failure, their pathophysiologic mechanisms, and some clinical examples.

To simplify the classification of hypercapnic respiratory failure, the causes of decreasing alveolar ventilation fall into three broad categories: (1) CNS depression, (2) mechanical defect, and (3) fatigue.[13]

Assessment

The most common symptoms of acute hypercapnic respiratory failure in conscious patients are shortness of breath and anxiety. These typically occur with rapid and shallow breathing. When the central drive is affected, as with drug overdose or stroke, it is typical to have a lethargic patient. These patients are not able to provide any past or present medical history. As with hypoxemic respiratory failure, clinical clues to the presence of hypercapnia are nonspecific and include headache, diminished alertness, bounding peripheral pulses, and flushed warm skin. It is very likely that a patient with an elevated $PaCO_2$ also has a low PaO_2. Therefore, clinical signs of hypoxemia may be evident as well.

Other clinical signs of hypercapnic respiratory failure include tachycardia, tachypnea, accessory muscle use, and diaphoresis. Accessory muscle use and/or paradoxical movement of the chest and abdominal wall (opposite directions) indicates that there is an increased work of breathing. Intercostal retractions and nasal flaring, especially in infants and children, may accompany the accessory muscle use. Without intervention, a patient with these signs and symptoms can deteriorate to respiratory failure and very likely to cardiac arrest. **Figure 3-5** demonstrates an uninterrupted progression of ventilatory failure.

An assessment of respiratory rate, rhythm, and depth is imperative in identifying hypercapnic respiratory failure. Usually, tachypnea is accompanied by low tidal volumes, which essentially means ventilating little more than the patient's anatomical dead space. Respiratory rates >30–35 breaths/minute with diaphoresis, inability to speak between breaths, and accessory muscle use usually signal an impending respiratory arrest, which would require ventilatory support.

A patient with a decreased respiratory drive due to a CNS impairment would present with a respiratory rate

TABLE 3-6
Common Mechanisms of Hypercapnia in Respiratory Failure

Causes of Type II Respiratory Failure	Pathophysiologic Mechanism	Clinical Example
CNS impairment	Decreased ventilatory drive	Drug overdose, stroke, head trauma, obesity hypoventilation, central sleep apnea
Spinal cord impairment	Lack of communication from central drive to respiratory muscles, leading to an absent ventilatory drive	High spinal cord injury
Neuromuscular impairment	Motor neuron deficit, motor neuropathies, neuromuscular junction disorders leading to respiratory muscle fatigue and a decreased or absent ventilatory drive	ALS, post-polio syndrome, myasthenia gravis, Guillain–Barre syndrome, botulism, nerve gas, Cobra snake bites, bilateral phrenic nerve injury
Impairment of the thorax and pleura	Alteration of the integrity of the chest wall and pleura or change in pressure within the pleural space, impairing the lungs' ability to move air	Flail chest, diaphragmatic rupture, penetrating chest wound, pleural effusion, pneumothorax
Upper airway impairment	Obstruction of the upper airways prohibits the movement of air into the lungs	Obstructive sleep apnea, foreign body obstruction, post-extubation laryngospasm, bilateral vocal cord paralysis
Fatigue	Increased work of breathing, reduction in muscle strength, reduction in energy supply	Asthma, neuromuscular diseases, kyphoscoliosis, atrophy due to mechanical ventilation



FIGURE 3-5 Progression of ventilatory failure. Ventilatory failure often progresses over time in a typical fashion, often in a few hours to days; Time 0 provides an example of a patient with normal Pa_{O_2}, Pa_{CO_2}, and pH. Beginning at time 1, the patient's Pa_{O_2} starts to decline due to lung disease. When the Pa_{O_2} decreases to about 60 torr (Time 2), the patient starts to hyperventilate due to hypoxemia (e.g., the peripheral chemoreceptor stimulation). As the patient's Pa_{O_2} continues to decline (Times 2 to 3), the patient continues to hyperventilate and pH rises (e.g., acute respiratory alkalosis). By Time 3, the patient begins to tire, and Pa_{CO_2} rises with a corresponding decrease in pH (Times 3 to 4). As the patient's condition worsens, Pa_{O_2} continues to fall, Pa_{CO_2} continues to increase, and an acute respiratory acidosis ensues (Times 4 to 5). At this time, the patient has developed acute ventilatory failure (Time 5).

Data from Shelledy DC. Initiating and adjusting ventilatory support. In: Wilkins RL, Stoller JK, Kacmarek RM. *Egan's Fundamentals of Respiratory Care.* 9th ed. St. Louis, MO: Elsevier-Mosby; 2009:1045–1090.

TABLE 3-7
Signs and Symptoms of Acute Hypercapnia

Major Disorder (Causing Hypercapnia)	Respiratory	Cardiovascular	Neurologic
Decreased ventilatory drive	Bradypnea, decreased respiratory effort, declining tidal volume, respiratory acidosis, hypoxemia	Tachycardia, peripheral vasodilation	Headache, lethargy, obtundation, confusion, coma, miosis (opiate drug overdose)
Increased work of breathing (increased ventilation demand)	Tachypnea, increased respiratory effort, accessory muscle use, retractions, nasal flaring, respiratory alkalosis, adventitious breath sounds	Tachycardia, hypertension, arrhythmias, diminished heart sounds, pulsus paradoxus	Anxiety, agitation, tingling, fatigue
Respiratory muscle weakness	Bradypnea, decreased respiratory effort, declining tidal volume, respiratory acidosis, hypoxemia, impaired gag reflex, abdominal paradox	Tachycardia	Lethargy

<12 breaths/minute and would most likely have an altered mental status. Time is important in this situation. Immediate ventilatory support is necessary.

Patients with respiratory muscle fatigue due to a reduction in muscle strength may present with drooling, dysarthria, weak cough, weak gag, lower extremity weakness, or ocular muscle weakness. These patients usually have neuromuscular diseases such as ALS, Guillain–Barre, or myasthenia gravis.

The one test that identifies hypercapnic respiratory failure is the ABG. If the ventilatory failure had a rapid onset, the ABG would show an uncompensated respiratory acidosis. If the hypercapnia has been present for a long time, this would give the kidneys the opportunity to compensate for the respiratory acidosis and the ABG would show a partially or fully compensated respiratory acidosis. **Table 3-7** summarizes some of the pertinent signs and symptoms of acute hypercapnic respiratory failure.

KNOWLEDGE CHECK QUESTIONS

1. Respiratory failure due to a thoracic or pleural impairment may be caused by:
   a. diaphragmatic rupture.
   b. obstructive sleep apnea.
   c. high spinal cord injury.
   d. ALS.
2. True or False: A patient with an increased ventilatory demand may present with tingling extremities, tachypnea, tachycardia, and pulsus paradoxus.



FIGURE 3-6 This figure shows the difference between Patient A and Patient B. The hypoxemia in Patient A is most likely due to V̇/Q̇ mismatch or shunt due to the high alveolar–arterial oxygen gradient. The hypoxemia in Patient B is due to alveolar hypoventilation because the Pa_{O_2} is reduced even though the alveolar-to-arterial oxygen gradient is normal.

Differentiating Hypoxemic and Hypercapnic Respiratory Failure

The $P_{(A\text{-}a)}O_2$ can be used to help differentiate between hypoxemia due to ventilation–perfusion mismatch, shunt, or diffusion defect from hypoxemia caused by hypoventilation. **Box 3-6** shows a comparison of two different patients' cases. Patient A's arterial oxygen tension gradient is at the critical level, while Patient B's gradient is within normal limits. This shows that Patient B's cause of hypoxemia is elevated $PaCO_2$. However, the cause of Patient A's hypoxemia is one of the other mechanisms, most likely V̇/Q̇ mismatch. Therefore, the treatment of hypoxemia and hypercapnia in these two patients should be different. The patient with critically high $P_{(A\text{-}a)}O_2$ requires high levels of supplemental oxygen to start the treatment. The patient with normal $P_{(A\text{-}a)}O_2$ and elevated $PaCO_2$ requires mechanical ventilation and may respond positively to NPPV with low-to-moderate levels of supplemental oxygen.

In **Figure 3-6**, each alveolus represents the lungs from both patients in the example in Box 3-6. Both patients are breathing atmospheric oxygen at a barometric pressure of 760 torr. Patient A has moderate-to-severe hypoxemia with a critically high alveolar–arterial oxygen gradient. The oxygen in the alveoli is not able to diffuse across the alveolar–capillary membrane. When this patient is given supplemental oxygen, if the Pa_{O_2} does not rise as expected, the cause of the hypoxemia is an intrapulmonary shunt. Patient B, on the other hand, has a normal alveolar–arterial oxygen gradient. The elevated CO_2 reduces the available O_2 in the alveoli, as evidenced by the P_{AO_2} of 60 torr, when it should normally be approximately 100 torr. This identifies the cause of this patient's hypoxemia as being hypercapnia.

BOX 3-6 Differentiating Causes of Respiratory Failure

Patient A	Patient B
FIO_2 = 0.21 P_B = 760 torr	FIO_2 = 0.21 P_B = 760 torr
ABG Results pH = 7.36 $PaCO_2$ = 46 torr Pa_{O_2} = 41 torr Sa_{O_2} = 74% HCO_3^- = 24 mEq/L	ABG Results pH = 7.46 $PaCO_2$ = 72 torr Pa_{O_2} = 53 torr Sa_{O_2} = 81% HCO_3^- = 28 mEq/L
$Pa_{O_2} = FIO_2 (P_B - 47\text{ torr}) - (PaCO_2 \times 1.25)$ $P_{AO_2} = 0.21(760 - 47) - (46 \times 1.25)$ $P_{AO_2} = 150 - 57.5$ P_{AO_2} = 92.5 torr	$P_{AO_2} = FIO_2 (P_B - 47\text{ torr}) - (PaCO_2 \times 1.25)$ $P_{AO_2} = 0.21(760 - 47) - (72 \times 1.25)$ $P_{AO_2} = 150 - 90$ P_{AO_2} = 60 torr
$P_{(A\text{-}a)}O_2 = P_{AO_2} - Pa_{O_2}$ $P_{(A\text{-}a)}O_2$ = 92.5 torr − 41 torr $P_{(A\text{-}a)}O_2$ = 51.5 torr	$P_{(A\text{-}a)}O_2 = P_{AO_2} - Pa_{O_2}$ $P_{(A\text{-}a)}O_2$ = 60 torr − 53 torr $P_{(A\text{-}a)}O_2$ = 7 torr
$P_{(A\text{-}a)}O_2$ > 10 torr on room air = CRITICAL	$P_{(A\text{-}a)}O_2$ = 5 to 10 torr = NORMAL

KNOWLEDGE CHECK QUESTIONS

1. In acute Type II respiratory failure, a patient's hypoxemia is caused by:
   a. V̇/Q̇ mismatch.
   b. diffusion impairment.
   c. increase in dead space.
   d. intrapulmonary shunt.
2. True or False: A patient with a $P_{(A\text{-}a)}O_2$ of 94 torr with a Pa_{O_2} of 60 torr and $PaCO_2$ of 45 torr while breathing room air has Type I respiratory failure.

Chronic Respiratory Failure

Case Study 3

A 39-year-old man comes to the hospital for his preoperative evaluation prior to gastrointestinal bypass surgery for his obesity. He weighs 465 lb and is 5 foot 11 inches tall (body mass index 194 kg/m^2). He has been morbidly obese for more than 20 years. A baseline ABG was drawn on room air. The results are pH 7.46, $Paco_2$ 72 torr, Pao_2 53 torr, Sao_2 81%, HCO_3^- 28 mEq/L (he is the patient mentioned in Box 3-5). This is a fully compensated respiratory acidosis with moderate hypoxemia. As shown in Box 3-6, the hypoxemia is due to the hypoventilation (hypercapnia).



FIGURE 3-7 Mechanisms of CRF.

Redrawn from Hanley ME, Welsh CH, eds. *Current Diagnosis & Treatment in Pulmonary Medicine*. Lange Medical Books/McGraw-Hill; 2003 (Figure 26-1, p. 269).

Definition

Chronic respiratory failure (CRF) typically involves inappropriate levels of minute ventilation or an increase in dead space. Manifestations of CRF, also called chronic ventilatory failure, in contrast to those of acute respiratory failure, are commonly less clinically dramatic or apparent. The onset of this type of failure is insidious. In CRF, slow development and long duration of disturbances of lung function allow for the intervention of various compensatory mechanisms, which prevent, or at least diminish, the harmful effects on body homeostasis. These compensatory mechanisms include changes in the respiratory pattern and the utilization of accessory muscles to overcome the increased airway resistance or reduced compliance. Hyperventilation occurs to increase CO_2 elimination and improve alveolar oxygen tension, circulatory adjustments improve oxygen transport, increases in hemoglobin facilitate oxygen delivery to the tissues, and renal compensation improves acid–base derangements. Individuals with CRF typically reduce their physical activity to cope with respiratory insufficiency.[14]

Causes

CRF, therefore, is a long-standing insufficient alveolar ventilation caused by a decreased CNS respiratory drive to breathe, impaired neuromuscular competence, and excessive respiratory load (**Figure 3-7**). The most common cause of CRF is COPD.

Examples of some CNS impairments that cause CRF include morbid obesity, primary alveolar hypoventilation (Ondine's curse), brain stem infarction, or neoplasm. Respiratory muscle impairment or weakness occurs due to neuromuscular diseases such as post-polio syndrome, myasthenia gravis, muscular dystrophies, quadriplegia, and phrenic nerve damage. Chest wall dysfunctions include kyphoscoliosis and thoracoplasty. Lung diseases causing CRF include COPD, tracheal stenosis, and obstructive sleep apnea.

Assessment

CRF is a problem brought on by conditions that predispose a person to respiratory failure. Identification of the underlying cause is central to the treatment of CRF, and the patient interview is essential to uncovering this cause. Also, disease-specific clues may be found on physical examination.

The symptoms of CO_2 retention vary widely and do not correlate well with $Paco_2$ levels. Using central cyanosis for the sole identification of hypoxemia is very dangerous, due to its appearance close to the Pao_2 and Sao_2 levels that cause tissue damage. Hypoxia does produce neurologic manifestations, from mild confusion to coma, but because the differential diagnosis of confusion is very broad, its clinical recognition is difficult.[15] These facts make it impossible to use physical assessment to estimate a patient's Pao_2 and $Paco_2$. Therefore, it is vital to perform both oxygen saturation and an ABG.

Because long-standing respiratory insufficiency leads to right heart problems, the identification of jugular venous distention and lower extremity edema not due to venous stasis, cirrhosis, or cardiomyopathy is a clue to cor pulmonale. Other physical signs include tachypnea, abdominal paradox (inward abdominal movement during inspiration), respiratory alternation (alternation between abdominal and rib cage breathing), and accessory muscle use.

Diagnostic studies are important in identifying CRF. The ABG is used to determine the presence and degree of respiratory failure. The CBC identifies the presence of polycythemia, suggesting chronic hypoxemia. The pulmonary function tests (PFTs) identify the presence and degree of obstructive or restrictive respiratory problems. Other tests include serum levels of

thyroid-stimulating hormone (TSH), which evaluates the possibility of hypothyroidism, a potentially reversible cause of chronic hypercapnic respiratory failure, and a chemistry panel.

Management

The reversal of CRF is rare (CRF due to hypothyroidism can be reversed). The main goals of managing CRF is to ensure oxygenation and adequate ventilation. Low-flow supplemental oxygen treats chronic hypoxemia. Ventilatory support may be noninvasive, invasive (via tracheostomy), round the clock, nocturnal, full, or partial. The level of support is purely dependent on the patient's situation (**Table 3-8** for some examples).

TABLE 3-8
Examples of Respiratory Support for Different Causes of CRF

Cause of CRF	Type of Respiratory Support
ALS	Tracheostomy full invasive ventilation
COPD	Supplemental oxygen nocturnal NPPV
ILD	Supplemental oxygen
Obesity hypoventilation syndrome	Nocturnal NPPV
Respiratory muscle weakness (e.g., post-polio)	Nocturnal NPPV
Restrictive thoracic disease (e.g., kyphoscoliosis)	Nocturnal NPPV

Another goal of CRF management is to treat the underlying cause of the condition. Bronchial hygiene therapy should be used to mobilize excessive mucus. The administration of supplemental oxygen to treat hypoxemia will also treat the patient's polycythemia and pulmonary hypertension. Phrenic nerve or diaphragm pacing is a potential therapy for patients with CRF from high cervical spinal cord lesions or respiratory drive disorders. Medications may be used to treat or maintain the underlying disease state.

One of the cornerstones in the treatment of CRF due to COPD is pulmonary rehabilitation. Pulmonary rehabilitation is an evidence-based, multidisciplinary, and comprehensive intervention for patients with chronic pulmonary disease who are symptomatic and often have decreased daily life activities. The goal of pulmonary rehabilitation is not to improve lung function, but rather to reverse the systemic consequences of the disease such as dyspnea, exercise tolerance, and quality of life.[16] Pulmonary rehabilitation is successfully used in the management of CRF due to severe persistent asthma, bronchiectasis, cystic fibrosis, and restrictive lung diseases.[17–19]

KNOWLEDGE CHECK QUESTIONS

1. Which of the following is vital to identify CRF?
   a. Central cyanosis
   b. ABG
   c. Accessory muscle use
   d. CBC
2. True or False: Full invasive ventilation is necessary to treat CRF due to ILD.

Acute-on-Chronic Respiratory Failure

Case Study 4

A 71-year-old man with a past medical history of COPD and cor pulmonale presents to the emergency department with progressive shortness of breath. He had been able to walk as much as 20 feet without difficulty until about 2 weeks ago when his dyspnea progressed to shortness of breath at rest. His current home medications include fluticasone furoate and vilanterol (Breo®), furosemide, theophylline (low dose), continuous oxygen via nasal cannula at 2 L/minute, and albuterol/ipratropium bromide as needed.

Physical examination reveals a temperature of 37.6°C, pulse 102 beats/minute, respiratory rate 28 breaths/minute, positive accessory muscle use, blood pressure 155/87. His breath sounds are diminished at the bases with bilateral basilar inspiratory crackles. His cardiac assessment revealed a regular rate and rhythm with jugular vein distension (JVD), and a right-sided S_3 is noted. He has 3+ pedal edema and is alert and oriented.

ABG results with 2 L/minute nasal cannula: pH 7.25, $PaCO_2$ 90 torr, PaO_2 42 torr, SaO_2 59%, HCO_3^- 38 mEq/L. A CBC reveals 13,500/µL; hematocrit 57.2%. A chest x-ray reveals extensive hyperinflation, some blunting of both costophrenic angles, and flattened diaphragms (**Figure 3-8**).

Definition

Acute-on-chronic respiratory failure (ACRF) is also known as acute-on-chronic ventilatory failure. ACRF is present when an acute increase in the $Paco_2$ with a corresponding decrease in pH complicates a patient's fully compensated respiratory acidosis (CRF). Most often it is seen in patients with severe COPD but is also found in patients with other diseases. Usually ACRF is used to describe a patient with COPD who develops acute respiratory failure at the time of an upper respiratory tract infection or another acute respiratory insult usually known as an acute exacerbation of COPD (AECOPD).



FIGURE 3-8 Chest radiograph of a 71-year-old male with a past medical history of COPD.

Causes

Relatively few patients develop ACRF from a decrease in respiratory drive; most often the ACRF is due to inadequate neuromuscular function, or excessive respiratory load, or both.[20] **Figure 3-9** shows that the balance between the burden on the respiratory system and the strength of the system determines the progression to and resolution of ACRF. The figure also gives examples of the causes of ACRF.

Assessment

An essential part of the initial patient presentation is the history of present illness and past medical and social histories, especially if this is the first time medical assistance is being sought by the patient. The physical assessment of the patient may reveal a variety of nonspecific clinical manifestations stated earlier in this chapter. The most important assessment in determining the presence of ACRF is the ABG.[21] Having a baseline ABG to compare with the patient's current ABG assists in the distinction between CRF and



FIGURE 3-9 The balance between the load on the respiratory system and the strength of the system determines the progression to and resolution of ACRF. The central component of the respiratory drive is an important co-regulator.

Redrawn from Douglas IS. Acute-on-chronic respiratory failure. In: Douglas IS, Schmidt GA, Kress, JP, eds. Principles of Critical Care, 4th ed. New York, NY: McGraw-Hill; 2015. http://accessmedicine.mhmedical.com/content.aspx?bookid=1340&Sectionid=80033029. (Figure 54-2).

ACRF. Remember that what appears to be a lack of compensation, on an ABG, may be an acute process superimposed on a chronic process. The typical patient with CRF has a fully compensated respiratory acidosis with mild-to-moderate hypoxemia. An acute exacerbation on top of the chronic situation can increase the patient's $Paco_2$ to a point where the HCO_3^- is not enough to keep the pH within the normal range and the patient's typical state of hypoxemia worsens. If there is no baseline ABG to assess, the patient's ABG looks like a partially compensated respiratory acidosis. This is precisely what Case Study 4 ABG looks like: pH 7.25, $Paco_2$ 90 torr, Pao_2 42 torr, Sao_2 59%, HCO_3^- 38 mEq/L. Without knowing the patient's history, this ABG is interpreted as a partially compensated respiratory acidosis with uncorrected moderate hypoxemia. However, knowing the prior acid–base status, it would be most correct to say this patient has an ACRF. The AECOPD has led to an increase in the $Paco_2$ without any further increase in the HCO_3^- because the kidneys have not had time to compensate for the acute change in the patient's condition. See **Table 3-9** for examples of CRF and ACRF ABGs.

Each of the CRF ABGs in Table 3-9 shows fully compensated respiratory acidosis with mild hypoxemia. In each case of CRF, the pH is within normal limits due to the elevated HCO_3^-. In all of the ACRF cases, the HCO_3^- remains relatively unchanged, because metabolic compensation for primary respiratory abnormalities usually take several days, while the $Paco_2$ is higher than the patient's baseline.

Without a reference baseline ABG, primary respiratory acidosis and secondary metabolic alkalosis are two major clues for the diagnosis of ACRF. Other clues include polycythemia, positive smoking history, malnutrition or morbid obesity, peripheral edema, JVD, hepatic enlargement, and hypophosphatemia (caused by many drugs used to treat CRF, such as beta-adrenergic agents, corticosteroids, diuretics, and methylxanthines). Some patients may exhibit signs of respiratory failure, such as dyspnea that has worsened over days, with increased cough and sputum production, purulent sputum, inability to clear sputum, fever, and leukocytosis. Other signs are diminished breath sounds, reduced diaphragm excursion, and hyperresonance on percussion. Most often, physical examination demonstrates accessory muscle use, prolonged expiratory time, recruitment of expiratory muscles, and wheezing. It is important to realize that the absence of respiratory distress is not necessarily reassuring, and when there is somnolence, it is a grave and ominous sign of an impending respiratory arrest.[20] Electrocardiography (ECG) may show a cardiovascular cause for the ACRF or may detect dysrhythmias resulting from acidosis or severe hypoxemia. A chest radiograph is often abnormal and reflects the chronic lung disease, but only in 15–20% of cases, it reveals an acute finding (e.g., pneumonia, pneumothorax, pulmonary infarction, pulmonary edema) that results in a change in patient management.[22] **Box 3-7** shows a list of common causes of ACRF.

The prevalence of ACRF is the greatest in patients over the age of 60 years as exacerbations of COPD are the most common cause. Younger ACRF patients, however, tend to have neuromuscular diseases and cystic fibrosis.[23]

To analyze ACRF in a way that facilitates management, it is important to dissect the very complex real-life patient into the simple components of inadequate neuromuscular function and excessive respiratory load[20] (Figure 3-9).

Management

The goals of management in patients with ACRF who are not yet intubated are to avoid invasive mechanical ventilation when possible and to recognize progressive respiratory failure when it is not. The proven efficacy of NPPV to avert the need for intubation, reduce

TABLE 3-9
Comparison of Examples of ABG for CRF and ACRF

	Patient 1		Patient 2		Patient 3	
Value	**CRF**	**ACRF**	**CRF**	**ACRF**	**CRF**	**ACRF**
pH	7.35	7.25	7.45	7.34	7.36	7.22
$Paco_2$ (torr)	55	65	72	95	75	100
HCO_3^- mEq/L	32	33	48	49	41	40
Pao_2 (torr)	70	59	68	52	65	40
Sao_2 (%)	94	90	93	86	92	75
Fio_2	0.21	0.21	0.28	0.28	0.24	0.24

BOX 3-7 Common Causes of ACRF

Bacterial respiratory infection
Pneumonia
Pneumothorax
Postoperative period
Pulmonary edema
Pulmonary emboli
Retained bronchopulmonary secretions
Sedatives
Viral respiratory infection

complications, and shorten the length of hospital stay makes this therapy one of the most significant developments in the management of these patients.[20] Current guidelines conclude that NPPV improves outcomes compared to supportive care alone for patients with COPD-related ACRF.[24] Patients with chronic neuromuscular–related ACRF may also benefit from NPPV[23,25] along with a mechanical insufflator-exsufflator.[23] Oxygen therapy should be administered to relieve hypoxemia with a target Pa_{O_2} of 50–59 torr with a S_{AO_2} of 88–90%. This avoids oxygen-induced ventilatory depression and increased $\dot{V}/\dot{Q}$ when the Pa_{O_2} exceeds 60 torr.

In addition to ventilatory support, the management of ACRF includes eliminating or controlling the precipitating cause. This may, for example, require antibiotic therapy, bronchodilator therapy, corticosteroids, cardiac medications, and, if not caught early enough, invasive mechanical ventilation.

KNOWLEDGE CHECK QUESTIONS

1. A patient with ACRF would most likely have which of the following HCO_3^- level?
   a. 15 mEq/L
   b. 20 mEq/L
   c. 25 mEq/L
   d. 30 mEq/L
2. True or False: The most common underlying disease in young patients with ACRF is neuromuscular disease.

Prognosis for Respiratory Failure

The overall prognosis for patients with respiratory failure depends chiefly on its primary cause. Respiratory failure is not in itself a particular disease but represents an end product of a comorbid disorder often accompanied by at least one precipitating factor (such as respiratory infection, among others). An estimation of mortality associated with respiratory failure, therefore, generally varies according to the primary etiology. Significant mortality is known to occur in individuals admitted with hypercapnic respiratory failure mostly because these patients most often have a chronic respiratory disorder and other comorbidities such as cardiopulmonary, renal, hepatic, or neurologic disease. These patients also may have a poor nutritional status.

If the underlying disease is managed and the precipitating factor is effectively treated while the patient's breathing is supported, the outlook is usually good in respiratory failure. Careful attention is considered necessary not to expose the patient to potentially harmful factors while recovering from respiratory failure because this could tip the balance against recovery. If it is not possible to provide sufficient oxygen to the body tissues, complications involving either the brain or the heart are likely to prove fatal. Prognosis markedly deteriorates when kidneys fail, previously diseased lungs become infected, or the primary disorder responsible for the lungs failing is irreversible. Once acute respiratory failure is present, treatment should occur in an ICU, where a close supervision of the treatment by highly skilled personnel and using the potential equipment is available, which helps to minimize additional complications.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The overall prognosis for a patient with respiratory failure depends chiefly on the type of respiratory failure.
2. True or False: The more comorbidities a patient has, the worse is the prognosis for respiratory failure.

Chapter Summary

Respiratory failure represents a syndrome rather than a single disease, in which the respiratory system fails in one or both of its gas exchange functions. It is said to occur when the respiratory system, composed of those components involved in alveolar–arterial gas exchange or in the delivery of oxygen or elimination of CO_2, can

no longer function sufficiently to maintain a normal physiologic gas exchange status, regardless of its underlying cause. The pace at which respiratory failure develops is dependent upon the nature of the precipitating condition as well as the presence of preexisting respiratory disorders.

Respiratory failure is classified as hypoxemic or hypercapnic and may be either acute or chronic or acute on chronic. There are many potential causes of respiratory failure, including inherent lung disorders, neuromuscular diseases, and abnormalities causing central neurologic depression. The ultimate outcome following acute respiratory failure appears to be more dependent on dysfunction on other vital organs than on the degree of severity of the respiratory failure. The various vital organ systems affected by respiratory failure are impacted most by damage and subsequent consequences of hypoxia to the tissues and not the hypercapnia (though the elevation of $Paco_2$ and the resultant acidosis further enhance the harmful effects of hypoxemia). Hypoxemia may also produce direct effects on the myocardium, causing left-ventricular impairment and reduced cardiac output, with resultant cardiogenic pulmonary edema as well as right-sided heart failure (cor pulmonale). Hypoxemia and hypercapnia jointly affect respiratory muscles and diaphragm function, which can often lead to additional worsening of respiratory failure and ultimate mortality if appropriate treatment and immediate reversal are not secured.

The first principle in managing patients at risk for respiratory failure is to prevent the progression of the underlying disease or precipitating factors responsible for its development. Because respiratory failure is the consequence of many other primary conditions, its successful treatment is dependent, for the most part, upon effective therapies for the primary conditions.

Key Points

1. Respiratory failure is a syndrome rather than a single disease, in which the respiratory system fails in one or both of its gas exchange functions: tissue oxygen delivery and carbon dioxide elimination.
2. Respiratory failure is classified as either hypoxemic or hypercapnic and is ordinarily subdivided into either acute or chronic forms.
3. The clinical features of acute respiratory failure include a combination of clinical features of the underlying disease process (as occurring in persons with COPD), precipitating factor(s) (as with superimposed infection), along with manifestations of hypoxemia and/or hypercapnia.
4. The acute deterioration of usual arterial Po_2 and Pco_2 in persons with established CRF leads to ACRF.
5. The effectiveness of alveolar ventilation is inversely related to arterial blood CO_2, such that an increase in $Paco_2$ is indicative of insufficient alveolar ventilation with relation to the body's metabolic production of carbon dioxide.
6. Appropriate tissue oxygenation, which is dependent upon arterial blood oxygen content, cardiac output, and tissue perfusion, is of major concern in the management of individuals with respiratory failure.
7. Hypoventilation, $\dot{V}/\dot{Q}$ mismatch, and shunt are the most common pathophysiologic mechanisms resulting in acute respiratory failure.
8. The distinction between acute and chronic hypoxemic respiratory failure is made on the basis of ABGs, and the clinical manifestations of chronic hypoxemia such as polycythemia or cor pulmonale.
9. Acute hypercapnic respiratory failure develops over minutes to hours usually causing the pH, in pure respiratory failure, to be less than 7.3. CRF typically develops over several days or longer, allowing time for renal compensation and an increase in bicarbonate concentration.
10. Although a diagnosis of respiratory failure usually begins with a clinical suspicion of its presence, confirmation is established by laboratory means with ABG analysis.

Chapter Questions

1. Which of the following arterial blood gas (ABG) results is most consistent with Type I respiratory failure? (The barometric pressure is 760 torr)

	pH	$PaCO_2$	PaO_2	SaO_2	HCO_3	FIO_2
a.	7.15	68 torr	60 torr	91%	23 mEq/L	0.21
b.	7.36	76 torr	50 torr	88%	42 mEq/L	0.24
c.	7.32	34 torr	43 torr	79%	17 mEq/L	0.5
d.	7.32	95 torr	45 torr	81%	48 mEq/L	0.28

2. The laboratory results of a patient in the intensive care unit are as follows: ABG while receiving 100% oxygen with $P_B = 760$ torr: pH 7.43, $Paco_2$ 37 torr, Pao_2 216 torr, Sao_2 100%, HCO_3^- 24 mEq/L. The patient's hemoglobin is 6.9 g/dL. The respiratory therapist can conclude that in this patient:
   a. the content of arterial oxygen is within the normal range.
   b. the alveolar-to-arterial oxygen gradient is critically elevated.
   c. the P/F ratio shows a severe disturbance.
   d. the a/A ratio shows intrapulmonary shunting is present.

3. Chronic respiratory failure is reversible if it is due to:
   a. post-polio
   b. interstitial lung disease
   c. hypothyroidism
   d. amyotrophic lateral sclerosis
4. The laboratory results of a patient in the intensive care unit are as follows: ABG while receiving 35% oxygen with P_B = 760 torr: pH 7.30, $Paco_2$ 55 torr, Pao_2 60 torr, Sao_2 91%, HCO_3^- 26 mEq/L. The patient's hemoglobin is 14 g/dL. The respiratory therapist can conclude that in this patient:
   a. the a/A ratio shows intrapulmonary shunting is present.
   b. the content of arterial oxygen is in a critical range.
   c. the P/F ratio shows a severe disturbance.
   d. the alveolar-to-arterial oxygen gradient is within normal limits.
5. A patient with acute hypoxemic respiratory failure due to intrapulmonary shunting has a Pao_2 of 45 torr and $Paco_2$ of 38 torr while receiving 50% supplemental oxygen. The most appropriate action to take at this time is to:
   a. administer NPPV with 100%.
   b. increase the oxygen concentration to 100%.
   c. perform intubation and initiate mechanical ventilation.
   d. administer noninvasive continuous positive airway pressure with an Fio_2 of 50%.

References

1. Shelledy DC, Peters JI. *Respiratory Care Patient Assessment & Care Plan Development.* Burlington, MA: Jones & Bartlett Learning; 2016.
2. Pierson DJ. Pathophysiology and clinical effects of chronic hypoxia. *Respir Care.* 2000;45(1):39–51; discussion 51–53.
3. American Association for Respiratory Care Clinical Practice Guideline: oxygen therapy for adults in the acute care facility-2002 revision and update. *Respir Care.* 2002;47(6):717–720.
4. West JB. *Pulmonary Pathophysiology: The Essentials.* Baltimore, MD: Lippincott Williams & Wilkins; 2013.
5. Leach RM, Treacher DF. Oxygen transport—2. Tissue hypoxia. *BMJ.* 1998;317(7169):1370–1373.
6. Pruitt WC. Ventilation and oxygenation. In: Hess DR, MacIntyre NR, Galvin WF, Mishoe SC, eds. *Respiratory Care Principles and Practice.* 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016: 532–553.
7. Wilkins RL, Dexter JR, Gold PM. *Respiratory Disease: A Case Study Approach to Patient Care.* Philadelphia, PA: FA Davis; 2007.
8. Hess DR. Noninvasive ventilation and continuous positive airway pressure. In: Hess DR, MacIntyre NR, Galvin WF, Mishoe SC, eds. *Respiratory Care Principles and Practice.* 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:532–553.
9. Consentini R, Brambilla AM, Aliberti S, et al. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. *Chest.* 2010;138:114–120.
10. Brambilla AM, Aliberti S, Prina E, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. *Intensive Care Med.* 2014;40:942–949. doi:10.1007/s00134-014-3325-5.
11. Vazquez RG, Sedes PR, Farina MM, Marques AM, Velasco MEF. Respiratory management in the patient with spinal cord injury. *BioMed Res Int.* 2013;2013:168757. doi:10.1155/2013/168757.
12. Balkissoon R. Obstruction of large airways. In: Hanley ME, Welsh CH, eds. *Current Diagnosis & Treatment in Pulmonary Medicine.* New York, NY: McGraw-Hill; 2003:105–108.
13. Roussos C. Respiratory muscle fatigue and ventilatory failure. *Chest.* 1990;97(3):89s–96s.
14. Farzan S, Farzan DA. *A Concise Handbook of Respiratory Diseases.* Stamford, CT: Apple & Lange; 1997.
15. Fernandez E. Chronic ventilatory failure. In: Hanley ME, Welsh CH, eds. *Current Diagnosis & Treatment in Pulmonary Medicine.* New York, NY: Lange Medical Books/McGraw-Hill; 2003.
16. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med.* 2006;173(12):1390–1413.
17. Madhusudhan B, Rao M, Krishnaswamy U, Ravindra S. Prospective study of an outpatient-based pulmonary rehabilitation program in patients with chronic pulmonary diseases. *Trop J Med Res.* 2015;18(1):20–30.
18. Bradley J, Moran F. Physical training for cystic fibrosis. *Cochrane Database Sys Rev.* 2008;(1):CD0002768.
19. Rewall C, Stockley RA, Hill SL. Exercise training and inspiration muscle training in patients with bronchiectasis. *Thorax.* 2005; 60(11):943–938.
20. Douglas IS. Acute-on-chronic respiratory failure. In: Hall JB, Schmidt GA, Kress JP, eds. *Principles of Critical Care.* 4th ed. New York, NY: McGraw-Hill; 2015. http://accessmedicine.mhmedical.com/content.aspx?bookid=1340&Sectionid=80033029. Accessed August 04, 2015.
21. Menzella F, Facciolongo N, Lusuardi M, et al. Clinical audit on diagnostic accuracy and management of respiratory failure in COPD. *Respir Care.* 2012;57(12):2067–2073.
22. McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. *Chest.* 2001;119:1190–1209.
23. Goldring JJ, Wedzicha JA. Managing acute on chronic respiratory failure: a guide to non-invasive ventilation. *Br J Hosp Med.* 2008;69(8):444–449.
24. Williams JW Jr, Cox CE, Hargett CW, et al. *Noninvasive Positive-Pressure Ventilation (NPPV) for Acute Respiratory Failure* [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2012. (Comparative Effectiveness Reviews, No. 68.) http://www.ncbi.nlm.nih.gov/books/NBK99179. Accessed August 05, 2015.
25. Flandreau G, Bourdin G, Leray V, et al. Management and long-term outcome of patients with chronic neuromuscular disease admitted to the intensive care unit for acute respiratory failure: a single-center retrospective study. *Respir Care.* 2011;56(7):953–960.

CHAPTER

4

Neuromuscular Diseases

OUTLINE

OBJECTIVES

1. Understand the basic relationship between the neuromuscular system and the respiratory system.
2. Define each type of neuromuscular disease process.
3. Identify the causes of the various neuromuscular disease process.
4. Assess a variety of neuromuscular patients and identify their main problems.
5. Suggest therapeutic interventions and management for a particular neuromuscular patient.

KEY TERMS

Amyotrophic lateral sclerosis (ALS)
Ataxic breathing
Becker muscular dystrophy
Botulism
Central nervous system
Cheyne–Stokes breathing
Duchenne muscular dystrophy (DMD)
Guillain–Barre syndrome
El Escorial criteria
Muscular dystrophy (MD)
Myasthenia gravis (MG)
Neuropathy
Peripheral nervous system
Plasmapheresis
Ptosis
Single-fiber electromyography (SFEMG)
Tetanus
Thymectomy

Case Study

A 19-year-old female noticed an onset of symptoms approximately 2 months ago. The young woman began to realize that she had a hard time swallowing, had a generalized weakness in her upper arm region, and some visual distortions. The patient stated that as the day went along, she noticed that the symptoms began to get worse than when she first woke up. At this time, her general practitioner referred her to a neurologist to determine the root of the symptoms.

Upon scheduling her appointment, the neurologist requested that she be seen when her symptoms are at their worse, so the patient planned her visit to the neurologist's office for the afternoon. Upon physical examination, the patient had disconjugate eye movement and bilateral ptosis. She had deterioration in her upper limb strength with repeated testing. At this time, the patient was further questioned about any other visual disturbances or weakness that she had noticed. She stated that she feels tired while chewing her meals but seems to resolve after she is done eating.

The neurologist felt that the patient may have myasthenia gravis (MG). The neurologist performed a Tensilon test with an intravenous injection of edrophonium. The test proved positive by completely abolishing all the neurologic signs. However, the patient's eye movements deteriorated 30 minutes after the injection. The neurologist concluded that the patient should undergo a diagnosis for MG. Subsequent blood tests showed high levels of antibodies against the acetylcholine receptor. The patient received a prescription for an oral cholinesterase inhibitor, and a 1-month follow-up appointment was made. If the patient experienced a worsening of symptoms, she was instructed to return to the neurologist's office.

At her 1-month follow-up, her symptoms were about the same as before. A CT scan was ordered to investigate her thymus gland. No signs of a tumor were noted, and a thymectomy was done to relieve her symptoms.

Following the thymectomy, the patient's symptoms dissipated and the neurologist discontinued the oral cholinesterase inhibitor with instructions to monitor herself for signs. At her postsurgical follow-up, a baseline pulmonary function test result was within normal limits. However, blood work revealed a slight elevation in acetylcholine receptor antibody levels. At this time, the patient is considered stable.

Introduction

The signals for voluntary breathing originate in the cerebral cortex. The parietal cortex can signal for inspiration and expiration to occur. The automatic breathing system is a complex one that includes the respiratory centers in the pons and medulla of the brain. Nerve tracts and chemical and mechanical feedback mechanisms are part of the automatic breathing system[1] (**Figure 4-1**).

The spinal cord and the motor nerves conduct the nerve impulses from the cortex of the brain and the brainstem to the anterior horn cells of the motor neurons that supply the respiratory muscles. The fibers in these tracts project to the lower portion of the spinal cord, where they synapse with the lower motor neurons.[1] The lower motor neurons have their cell bodies, anterior horn cells, within the spinal cord and are considered the spinal nerve roots. These are the nerves that supply the respiratory muscles. These nerves reach the muscle membranes of the respiratory muscles at the motor end plate junctions. Here, acetylcholine is the neurotransmitter between the nerve ending and the muscle. The respiratory muscles include inspiratory muscles, expiratory muscles, and accessory muscles.[1]

The diaphragm, the primary muscle of inspiration, is innervated by the phrenic nerve, which originates from cervical nerve roots three through five. The external intercostal muscles expand the rib cage during inspiration, and the internal intercostal muscles function during expiration. The intercostal muscles are innervated by the intercostal nerves that originate from the thoracic spinal



FIGURE 4-1 Schematic of the neurorespiratory system.

Reproduced with permission from Benditt J. The neuromuscular Respiratory System: Physiology, Pathophysiology, and a Respiratory Care Approach to Patients. *Respir Care*. 2006;51(8):829–836 (Figure 1).

nerve roots.[1] Other muscles used for ventilation include the abdominal muscles, the accessory muscles of ventilation, and the upper airway muscles.[2]

When the neuromuscular disease process begins, it can affect one of two components of the patient's breathing. The disease process may affect the movement of the respiratory muscles, the expansion of the rib cage, or the neurologic control of breathing. The severity of respiratory impairment depends on the neuromuscular disease process that is occurring and its severity. Considering the variety of neuromuscular diseases, the impairment of the respiratory function may begin at the central nervous system and can take place anywhere throughout the respiratory system. These can include the spinal cord, peripheral nerves, and neuromuscular junction. Within this chapter, each disease process will consider the etiology, assessment, and management of patients with neuromuscular diseases.

Neuromuscular diseases may affect the body in several ways. However, they can present with very similar clinical assessments. With many of these neuromuscular patients, the clinician may record reoccurring pulmonary infections, weakness, and an inability to adequately clear secretions or a cough. Neuromuscular diseases may also be looked at in two pathologic groups for disease processes, as seen in **Table 4-1**. When discussing the upper and lower motor neurons, it is best to understand what these mean and how these areas affect the respiratory system.

Neuromuscular Disease and Its Effects on the Respiratory System

The respiratory changes that occur with neuromuscular diseases become worse as the disease process progresses. The fundamental alterations observed in patients with neuromuscular disorder involve such issues as muscle weakness leading to a decrease in tidal volumes, decreased functional residual capacity, poor cough, and the inability to protect one's airway (**Figure 4-2**).

TABLE 4-1
Levels of Pathologic Injury in Neuromuscular Diseases

Level	Disease
Upper motor neuron Spinal cord	Spinal cord injury
Lower motor neuron Anterior horn Peripheral nerves Neuromuscular junction Muscular disorders	Poliomyelitis Amyotrophic lateral sclerosis (ALS) Guillain–Barre syndrome MG Botulism Tetanus Muscular dystrophy

Hess, Dean. (2016). Respiratory Care: Principles and Practice, 3e. Burlington, MA: Jones & Bartlett Learning.



FIGURE 4-2 The pathophysiology of respiratory failure in patients with neuromuscular disease.

Reproduced from Hill NS, Braman S. 1999. Noninvasive ventilation in neuromuscular disease. In: Cherniack NS, Altose MD, Homma I, eds. *Rehabilitation of the Patient with Respiratory Disease*. McGraw-Hill, New York. (© McGraw-Hill Education).

Some patients may also show signs of sleep disorders such as nocturnal hypoventilation, which could lead to atelectasis and increased work of breathing. Many of these symptoms may become apparent rather quickly or may be very subtle in neuromuscular compromised patients. When looking at patients with neuromuscular diseases, the diagnosis may not even occur until the patient is being invasively ventilated and is unable to be liberated promptly.

To have a better understanding of how the respiratory system is affected by this variety of neuromuscular disease, it is essential to review how the respiratory system functions in a healthy person. In healthy people, the relationship between oxygen saturation and ventilation is linear, such that a fall in oxygen saturation by 1% will trigger an increase of approximately 1 L/minute in ventilation.[2] There exists a relationship not only between oxygen saturation and minute ventilation, but also between hypercapnic breathing and minute ventilation. For each 1 mm Hg rise in $Paco_2$, ventilation increases by 2.5–3 L/minute.[2] Changes in the levels of $Paco_2$ and Pao_2 drive the brain's response. Alterations in either of these two values can happen with neuromuscular patients, and they may be unable to adjust their breathing adequately.

Different muscles are used for ventilation, including the muscles of the upper airway, chest wall, abdomen, and the diaphragm. The body employs inspiratory and expiratory muscles to perform the act of breathing. In the inspiratory muscle group, the diaphragm is considered the major muscle of inspiration. Additionally, muscles such as the scalene muscles, sternocleidomastoids of the neck, the intercostal muscles, and other muscles of the rib cage may help with inspiration.

The muscles of expiration include the rectus abdominis, transversus abdominis, and internal and external oblique muscles during strenuous exercise or heavy breathing. Typically, exhalation is a passive process due to the elastic energy that is built up during inhalation (**Figure 4-3**).

Some neuromuscular disorders affect the muscles of ventilation, which in turn can compromise the respiratory drive of the neuromuscular patient (**Table 4-2** and **Figure 4-4**).

Each neuromuscular disorder may produce a slightly different effect on the respiratory muscle drive. A variety of tests may determine the extent of the respiratory muscle involvement.



FIGURE 4-3 Muscles of the chest wall involved in ventilation.

TABLE 4-2
Muscle Groups and the Nerves That Control Them

Muscle Groups	Nerves
Upper airway Muscles of the soft palate and pharynx Genioglossus muscles	Glossopharyngeal nerve Vagus nerve Spinal accessory nerve Hypoglossal nerve
Inspiratory Diaphragm Scalene muscles Parasternal intercostal muscles Sternocleidomastoid muscle Lateral external intercostal muscles	Phrenic nerve Cervical (C4 through C9) nerve Intercostal (T1 through T7) nerve Spinal accessory nerve Intercostal (T1 through T12) nerves
Expiratory Abdominal muscle Internal intercostal muscles	Lumbar (T7 through T11) nerve Intercostal (T1 through T12) nerves

Cordova F, Mullarkey J, Criner G. Neuromuscular dysfunction. In: Hess D, MacIntyre N, Galvin W, Mishoe S. *Respiratory Care: Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:993–1032.

Assessing Patients with Neuromuscular Disease

As with any respiratory patient, assessment usually starts with the patient history and physical examination. Arterial blood gas measurements, chest x-ray, and pulmonary function test are helpful with the assessment of neuromuscular patients. Other tests include maximum voluntary ventilation, total lung capacity, maximum inspiratory pressure, and maximum expiratory pressure.

When investigating the patient's history, it is essential to note the onset and severity of the patient's symptoms as well as the symptom location. Often the symptoms of neuromuscular disorders are similar.



FIGURE 4-4 The three main components of neuromuscular respiratory failure.

Reproduced with permission from Benditt J. The neuromuscular respiratory system: physiology, pathophysiology, and a respiratory care approach to patients. *Respir Care*. 2006;51(8): 836 (Figure 5).

A neuromuscular disease that predominantly affects the pump function of the respiratory system will present as dyspnea, weak cough, and recurrent respiratory tract infections. Neuromuscular disorders that primarily affect the limb muscles present as impaired patient mobility early in the disease evolution.[2]

Respiratory failure is a real possibility with any of the neuromuscular disorders, either due to the severity of the disorder or with its progression. In some cases, there may be a rapid decline in the patient's respiratory status. In other cases, the decline is slow, and hypercapnic respiratory failure develops as chronic respiratory failure. Overall, one of the critical factors to monitor is the patient's overall muscle strength.[3] See **Figure 4-5**. When the respiratory deterioration is caught early enough, invasive mechanical ventilation may be avoided. In many cases, the early use of noninvasive mechanical ventilation is successful in avoiding invasive mechanical ventilation.[3]

Following a thorough interview of the patient, the physical exam can begin. With many of the neuromuscular disorders, a routine examination may not yield a conclusive diagnosis. Patients need to present with current symptoms of muscle weakness or with another symptom that demands more energy from the patient. Signs of limb muscle or respiratory muscle weakness may not appear until the patient makes multiple attempts at a particular activity. If the patient presents with acute neuromuscular exacerbation, visible signs of respiratory distress may be present.

Once the patient is in respiratory distress, intervention is necessary to avoid respiratory failure. Some neuromuscular patients may present with abnormal breathing patterns such as **Cheyne–Stokes breathing**, or ataxic breathing.[1] Cheyne–Stokes breathing is a repeating pattern of breathing where both the rate and the depth of breathing increase to a peak, then decrease followed by a period of apnea.[2] **Ataxic breathing** is entirely irregular with pauses and increasing periods of apnea.



FIGURE 4-5 Assessing for neuromuscular respiratory failure that requires mechanical ventilation.

Modified from Makker H, Mangera, Panesar. Practical approach to management of respiratory complications in neurological disorders. *Int J Gen Med*. 2012:255. doi:10.2147/ijgm.s26333.

Other portions of the physical examination include the overall muscle strength of the patient. In specific disease processes, patients may present with **ptosis**, or drooping of one or both eyelids.[4] The physical examination includes a test for reflexes, coordination, and sense of touch. The patient history is of great value for the differential diagnosis.

Some neuromuscular disorders deteriorate acutely within days to weeks, such as Guillain–Barre syndrome and MG. Muscle disorders including Duchenne muscular dystrophy (DMD) progress more slowly, while ALS has a more rapid progression.[3]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Neuromuscular disease processes can affect the movement of the respiratory muscles and lung function.
2. True or False: The respiratory impairment depends on the type of neuromuscular disease process and its severity.
3. True or False: Cheyne–Stokes is a repeating pattern of breathing, which includes increases and then decreases in the respiratory rate and depth of breathing, followed by a period of apnea.
4. True or False: The body uses more the inspiratory and expiratory muscles to perform the act of breathing.
5. True or False: The two pathologic groups of neuromuscular diseases include only upper and lower motor neurons.

Central Nervous System Disorders

Central nervous system disorders comprise disease processes such as poliomyelitis, post-polio syndrome (PPS), drug overdose, ALS, and spinal cord injury. The central nervous system is the part of the nervous system that consists of the brain and the spinal cord. Sensory impulses travel to the central nervous system, and motor impulses pass out of the central nervous system. The central nervous system coordinates the activity of the entire nervous system.[5] With each of these types of the disease process, the pulmonary system may be affected directly or inadvertently, and the patient may require some measure of pulmonary support. These disease processes can consist of poliomyelitis, PPS, and drug overdose.

Poliomyelitis

In the early 20th century, for decades, polio was one of the most feared diseases. Polio is a highly contagious viral illness that occurs in the gastrointestinal tract. It enters the body through the mouth and multiplies in the intestines and targets the nervous system.

Definition/Diagnosis

Poliomyelitis is a term that refers to the disease process of polio. Between the late 1940s and early 1950s, polio crippled around 35,000 people each year in the United States.[6] Three polioviruses exist. Of the three strains, one strain was eradicated in 1999, and a second strain has not been reported since 2012.[7] In 2017, only 37 cases of polio were reported.[7]

Etiology

The poliovirus infects only humans. It is highly contagious and spreads through person-to-person contact. The virus enters the body through the mouth and spreads through contact with the feces of an infected person and less commonly through droplets from a sneeze or a cough.[8]

Clinical Signs and Symptoms

Typically, small children, under the age of 5 years, are at a higher risk of developing polio as they are more likely to place contaminated toys and other objects into their mouths. However, travelers to areas that still have active cases of polio and do not currently have immunity either due to a lack of immunization or incomplete vaccinations need to take precautions.

The poliovirus causes an inflammatory response in the central nervous system, which affects the anterior horn cells of the spinal cord and the brainstem. In some cases, this inflammation will decrease, and the patient may show complete recovery or some minor paralysis. The World Health Organization (WHO) reports that 1 in 200 infections leads to irreversible paralysis (usually in the legs). Among those paralyzed, 5–10% die due to their breathing muscles becoming immobilized.[7]

Initially, patients may present with flu-like symptoms such as fever, headache, nausea, vomiting, fatigue, pain in the limbs, and a stiff neck. These symptoms may appear within 3–14 days depending on the degree of the illness. Patients who present with a minor degree of the polio infection may have symptoms that dissipate 24–72 hours after their initial onset.[8] Other patients who present with a significant degree of polio illness will experience symptoms in the latter time frame of 7–14 days. Severely affected patients have similar symptoms along with deep muscle pain, areas of increased sensitivity, and paresthesia.

Treatment and Management

There is no cure for poliovirus; it can only be prevented. The polio vaccine protects children by preparing their bodies to fight the polio virus. There are two types of vaccines: the inactivated poliovirus vaccine (IPV) and

oral poliovirus vaccine (OPV). The United States uses the IPV, but much of the world uses the OPV.[8]

In those who acquire polio, recovery is possible. The management of these patients is a lifelong process. Polio patients have a risk of developing post-polio complications later in life. With strong efforts from the WHO, a Global Polio Eradication Initiative (GPEI) was launched in 1988.[7] In 1994, the WHO Region of the Americas was certified polio free followed by the WHO Western Pacific Region in 2000, the WHO European Region in 2002, and the WHO South-East Asia Region in 2014. Today 80% of the world's population lives in certified polio-free regions.[7]

Post-Polio Syndrome

PPS was first identified more than 10 years after the first outbreak of polio. Up to three quarters of polio survivors are affected by PPS, with new onset of muscle weakness or deterioration of previously affected muscles, muscle atrophy, pain in the joints and muscles, and functional deterioration.

Definition/Diagnosis

According to the Mayo Clinic, PPS refers to a cluster of potentially disabling signs and symptoms that appear decades—an average of 30–40 years—after the initial polio illness.[9]

Etiology

The cause of PPS is not fully understood at this time. Some believe that once the initial infection occurs, the destroyed motor neurons get replaced by other motor neurons that enlarge and sprout additional fibers to compensate for the ones that are destroyed. As time progresses, these enlarged motor neurons cannot maintain this extra capacity. The new weakness of PPS appears to be related to the degeneration of individual nerve terminals in the motor units.[6] The slow deterioration of the neurons leads to loss of muscle strength. Restoration of nerve function may occur in some fibers a second time, but eventually, nerve terminals malfunction and permanent weakness occurs.[6]

Clinical Signs and Symptoms

An assessment of these patients reveals general fatigue, muscle atrophy, progressive muscle and joint weakness, and breathing or swallowing problems. A comprehensive medical history and physical examination are necessary. All other causes of the presenting symptoms and signs require elimination before a diagnosis of PPS is made. Also, certain criteria are necessary when diagnosing PPS, including prior paralytic poliomyelitis with evidence of motor neuron loss. Other criteria include a period of partial or complete functional recovery after acute paralytic poliomyelitis. The patient currently needs to have a slowly progressive and persistent new muscle weakness or decreased endurance (with or without generalized fatigue, muscle atrophy, or muscle and joint pain). These current symptoms must be present for at least a year. Lastly, no other causes can explain the patient's symptoms.[6]

Treatment and Management

There are no effective treatments for PPS. There are, however, recommended management strategies. Patients with PPS are advised to participate in physical activities and exercise as tolerated and utilize assistive mobility devices or aids if needed. No pharmaceutical treatments show statistically significant improvement following therapy.[6]

Patients with PPS need to be cautious with falls, malnutrition, and dehydration. Some of the post-polio patients may develop chewing and swallowing problems, which can lead to aspiration pneumonia. Patients and caregivers need to be aware of any muscle deterioration because the diaphragm may be involved, leading to respiratory insufficiency. If this occurs, the patient may require assistance with deep breathing and coughing. Continued deterioration can lead to the development of chronic respiratory failure requiring mechanical ventilation and/or a permanent airway.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Certified polio-free areas exist around the world.
2. True or False: PPS results in rapid deterioration of the muscles.
3. True or False: The main method to combat the polio virus is through prevention and containment.

Drug Overdose

An overdose of drugs such as opiates like fentanyl, heroin, or morphine; some benzodiazepines; and barbiturates depresses the central nervous system. This depression leads to alveolar hypoventilation, acute hypercapnic respiratory failure, and possibly death.

Definition

A drug overdose can occur by a few different methods. Overall, it is an inappropriate use of a pharmacologic agent by an individual. In some cases, this can be accidental on the patient's part due to the inability to comprehend the types of medications they are taking, or they may not be able to fully remember if they have already taken their pills or not. In other cases, it is intentional by the patient and is considered abuse of pharmacologic drugs.

Certain drugs can affect the respiratory system in certain ways. These include direct suppression or stimulation of the respiratory center, alteration in the response of chemoreceptors to changes in P_{CO_2}, impaired mechanics of respiratory muscles from muscular weakness, and increase in metabolic demands leading to an increase in total body consumption.[10] Unfortunately, drug overdose is a widespread occurrence.

Etiology

The causes of an overdose may vary from patient to patient, but the overall results may be the same. The effect of a drug overdose depends on the number and types of medications consumed by the patient. In some cases, the patient may exhibit minor effects of the overdose, and in others, the patient may require more invasive therapies to avoid death. Life-threatening issues include respiratory failure and multisystem organ failure.

Clinical Sign and Symptoms

When a patient presents with a possible overdose, a few common characteristics lead to the suspicion of overdose. The patient's vital signs, history, and physical exam may infer an overdose, especially when severe respiratory depression is present with the current history. However, restoration of ventilation and oxygenation takes precedence over obtaining the history of the present illness or performing a physical examination or diagnostic testing.[11] The patient may present with an altered level of consciousness, irrational behavior, or even a coma-like state. Other typical characteristics include tachypnea, cardiac arrest, respiratory arrest, hypoxemia, hypercapnia, or even kidney injury and imbalances. If any of these are present, the patient requires immediate intervention.

The typical presentation of patients with opioid analgesic intoxication is respiratory depression, miosis, and stupor. However, miosis and stupor occur in poisoned patients. Hypoxemia or ingestion of drugs that are co-formulated with acetaminophen can cause hepatic injury; acute renal failure can result from hypoxemia or precipitation of myoglobin due to rhabdomyolysis. Opioid analgesics also decrease intestinal peristalsis. Patients in a motionless stupor often have compressed fascia-bound muscle groups, causing compartment syndrome. These patients can also have hypothermia, due to environmental exposure.[11]

Treatment and Management

In many of these cases, the patient may not be able to adequately protect their airway or perform a normal function to maintain homeostasis. In this case, it will require intervention such as mechanical ventilation. A study showed that approximately 77% of the patients who participated required mechanical ventilation in an acute overdose setting.[12] During the stabilization of the patient, a drug screen test should be performed to verify the type of medication that was consumed by the patient. In many cases, some of the common drugs found include opioids (heroin, fentanyl, oxycodone, morphine, methadone, and hydrocodone), cocaine, benzodiazepines, methamphetamine, and alcohol.[12]

This type of patient requires an intensive care unit (ICU) admission. Some of these patients require medications to stabilize their hemodynamics. The length of stay in the ICU and hospital may vary from patient to patient. Some patients may require an extended stay due to the previous history of drug abuse, alcohol abuse, or other reasons that may put them at risk if they are liberated too soon. In the case of an unintentional overdose, the patient may be in the hospital only for a brief period.

Unfortunately, in many of these cases, preventable occurrences may happen repeatedly. Services can be provided to the patients for support or counseling to determine the underlying cause. In some cases, it may mean that the patient is supervised, or receives assistance while at home with their prescriptions.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Drug overdose can be life threatening and may result in the patient suffering from respiratory failure, multisystem organ failure, and even death.
2. True or False: All drug overdoses are preventable.

Spinal Cord Disorders

Spinal cord disorders can include a few specific processes. ALS and spinal cord injury are two common spinal cord disorders that both lead to a compromised respiratory system. In each of these types of conditions, the spinal cord is affected by different methods.

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a devastating neuromuscular disease that begins in the muscles of the mouth, throat, chest, or abdomen, and works its way down and out. The relatively worse form of ALS is the bulbar form. This type of ALS is associated with more widespread brain tissue loss.

Definition

By definition, ALS is a disease process that involves progressive degeneration of nerve cells that control muscle movements.[13] ALS is considered the most common lower motor neuron disorder in developed countries. It damages the anterior horn cells of the spinal cord and brain stem.[14] ALS is also known as Lou Gehrig disease.

Etiology

Currently, the cause of ALS is partially unknown. Numerous studies have attempted to identify genetic or environmental processes that cause ALS. Currently, more than 25 genes have an association with ALS.[14] It appears that men have a higher likelihood of having ALS than women. ALS appears later in life between the ages of 50 and 70.

Clinical Signs and Symptoms

ALS most frequently presents as progressive distal muscle weakness and wasting in an older adult.[14] The different phenotypes have various clinical presentations (**Table 4-3**). ALS has both lower and upper motor neuron involvement. The **El Escorial criteria** are used to determine the diagnosis and degree of progression for this process. See **Box 4-1**. In the case of ALS, there

TABLE 4-3
Clinical Presentations of ALS[14]

Classifying Feature	Name of Phenotype	Description
Motor neuron involvement	ALS	A mixture of upper and lower motor neuron signs on clinical examination. The degree of certainty of diagnosis based on El Escorial criteria. May involve up to all regions.
	Primary lateral sclerosis or upper motor neuron predominant ALS	Clinical signs limited to upper motor neuron features. Slow progression but involving all regions. This phenotype is usually confirmed if there have been no lower motor neuron signs after 4 years.
	Progressive muscular atrophy or lower motor neuron predominant ALS	Clinical signs limited to lower motor neuron features. Slightly slower progression but can involve all regions. This phenotype is usually confirmed if there have been no upper motor neuron signs after 4 years.
Site of onset	Bulbar onset Spinal onset	The site of onset may be included in the description of ALS, as different disease-onset patterns have different rates of progression. The two categorized are bulbar and spinal.
Disease focality	Progressive bulbar palsy	A condition involving the bulbar region and predominantly lower motor neurons. May progress to other regions.
	Pseudobulbar palsy	A condition involving the bulbar region and predominantly upper motor neurons. May progress to other regions.
	Flail arm	Predominantly lower motor neuron proximal symmetrical involvement in the upper limbs. Some upper motor neuron signs may be seen in the lower limbs.
	Flail leg	Lower motor neuron distal symmetrical involvement restricted to the lower limbs. May affect one side only.
Cognitive involvement	ALS with cognitive impairment	ALS with some cognitive involvement below the threshold criteria for frontotemporal dementia.
	ALS with frontotemporal dementia (ALS-FTD)	ALS with frank frontotemporal dementia.

Martin S, Al Khleifat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis? *F1000Res*. 2017;6:371. doi:10.12688/f1000research.10476.1.

BOX 4-1 Criteria for Diagnosis of ALS

The diagnosis of ALS requires:

1. The presence of
   - Neuropathologic, clinical or electrophysiologic evidence of lower motor neuron degeneration
   - Clinical evidence of upper motor neuron degeneration
   - Patient history or clinical examination revealing a progression of the motor syndrome within a region or to other regions
2. The absence of
   - Electrophysiological, pathological or neuroimaging evidence of other disease processes that might explain the upper and/or lower motor neuron signs and the observed and electrophysiological signs

Data from Oliveira A, Pereira R. Amyotrophic lateral sclerosis (ALS): three letters that change the people's life forever. *Arq Neuropsiquiatr*. 2009;67(3a):750–782. doi:10.1590/s0004-282x2009000400040.

is a progression of degeneration of the motor neurons. Once this process begins, the muscles that are affected start to weaken, resulting in paralysis and eventually death due to respiratory failure.

Treatment and Management

More than 50% of patients die of complications, such as aspiration and pneumonia, within 3 years of diagnosis. Serial pulmonary function testing in such patients reveals a progressive decline in vital capacity and total lung capacity and an increase in residual volume caused by the widespread loss of respiratory muscle function that will eventually lead to respiratory failure.[14]

There are a few different methods of treatment for patients with ALS. None of these treatments can reverse the process of ALS. However, they can improve the quality of life. These can consist of nonpharmacologic and pharmacologic methods of treatment. According to a recent study, masitinib and edaravone show enormous potential but have no approval in the U.S. and European markets.[15]

As for the nonpharmacologic treatments, many studies with stem cell therapy do not have U.S. Food and Drug Administration (FDA) approval. Other methods of treatment are focused on managing pain, improving cognitive impairment, avoiding respiratory failure and fatigue, and providing adequate nutrition. Respiratory failure is managed by either noninvasive mechanical ventilation or invasive mechanical ventilation. Tracheostomy can prolong life substantially but does not affect the disease progression.[15]

Spinal Cord Injury

Most often spinal cord injury leads to impairment of the pulmonary system. The higher in the spine the injury, the more likely the injury will affect ventilation. The main cause of mortality and morbidity following spinal cord injury is respiratory insufficiency.

Definition/Diagnosis

A spinal cord injury is one that causes damage to a portion of the spine that influences cardiopulmonary actions of the body.[16] In many of these cases, the spinal cord injury is a result of trauma due to a motor vehicle accident, sports injury, shooting, or work-related accidents and, in other cases, diseases such as polio or spina bifida, which can result in a spinal cord injury. These types of injuries can be complete or incomplete spinal impact. An incomplete injury to the spinal cord will result in the patient having some function below the injury site. With a complete injury, the patient will no longer have voluntary movement below the injury site.

Clinical Signs and Symptoms

A traumatic spinal cord injury causes spinal shock resulting in flaccid paralysis of the muscles below the level of damage.[16] The flaccid paralysis may last for a period of weeks to months. Flaccid paralysis of the intercostal muscles creates an unstable chest wall during inspiration. The negative intrathoracic pressure causes paradoxical inward depression of the ribs, creating a mechanical imbalance that increases work of breathing and causes microatelectasis. Airway secretions can accumulate in the lungs due to increased production or decreased clearance secondary to impaired cough. It is during this time that intubation and ventilation for respiratory support are very likely.[17] Patients who have suffered a spinal cord injury present with bradycardia and hypotension, along with minimal or no movement to the affected area. Most patients that show bradycardia and hypotension will require pharmacologic intervention. Along with cardiac complications, the bronchopulmonary functions may be affected. Such complete injuries that occur at the level of C3–C5 may result in loss of the voluntary movement of the diaphragm.

Many patients with spinal cord injury will not be able to maintain respiratory function on their own. Usually, patients who have complete injury above the level of C5 have diaphragm function impairment[18] (**Table 4-4**).

Treatment and Management

The management of patients who have had a spinal cord injury will depend on the location and the type of injury that has occurred. If the injury causes impairment of respiratory muscles, there may be a reduction in vital capacity, ineffective cough, reduction in lung and chest wall compliance, and excess oxygen cost of breathing due to the distortion of the respiratory system.[19] If any of these complications occurs, it will help to determine the type of treatment and therapies that may be needed for the patient. Patients who have had a loss of voluntary function to control breathing may require the use of mechanical ventilation. Others may require only partial ventilatory support or other means of treatment.

Many of the other patients will require monitoring of their respiratory status. Follow-up of these patients can include trending the patients' vital capacity, and muscle strength for exhalation and inspiration. In some cases, patients may qualify for procedures such as phrenic nerve pacing or pacing of the external intercostal muscles, to maintain respiratory function. Patients may also be able to try respiratory-muscle training and abdominal binders to improve their respiratory function.

With patients who have suffered a spinal cord injury, the leading cause of death has been noted to be septicemia, pneumonia, cardiovascular complications, and suicide. It is highly critical that these patients be monitored very closely with respect to not only their respiratory function but also their skin integrity and cardiac and urinary function. A large group of tetraplegics, paraplegics, and quadriplegics suffer from urinary tract infections and are at a higher risk for respiratory tract infections.[19]

TABLE 4-4
Neurologic Level for Complete Spinal Cord Injury, Typical Respiratory Impairment, and Support[17]

Level of Impairment	Respiratory Dysfunction
C1 to C3	Severe diaphragm weakness or paralysis leading to full-time ventilatory support. May be able to tolerate brief periods of self-ventilating using the guppy-breathing technique. A potential candidate for diaphragm pacing.
C3 to C4	Impaired diaphragmatic function leading to reduced tidal volume and vital capacity. Periods of unassisted ventilation likely and may be adequately supported with nocturnal ventilation alone. If unassisted ventilation produces high enough tidal volumes while seated, noninvasive ventilatory support may be adequate.
C5	Diaphragm function intact, but intercostal and abdominal muscle paralysis may decrease lung volumes, and cough strength and effectiveness. Initial ventilatory support is common with independent ventilation in the long term.
C6 to C8	People with lesions caudal to C7 typically can augment inspiration and cough with accessory muscles, particularly pectoralis major and minor. In the long term, patients can breathe independently.
T1 to T4	Inspiratory capacity and forced expiration are supported by intercostal activity. Cough efficiency remains reduced secondary to abdominal (expiratory) muscle weakness.
T5 to T12	Minimal disruption to autonomic dysfunction affecting the cardiovascular system below T6.
T12	Respiratory function is essentially comparable to that of a non-disabled person.

KNOWLEDGE CHECK QUESTIONS

1. True or False: 10% of ALS patients die from complications of the disease.
2. True or False: The location of the spinal cord injury can affect how the patient's respiratory function will occur.
3. True or False: Cardiovascular complications are a leading cause of death in patients with spinal cord injuries.

Peripheral Motor Nerve Disorder

The **peripheral nervous system** consists of various parts of the nervous system that is outside the brain and the spinal cord system. Many disease processes and syndromes are peripheral motor nerve disorders. These disorders can consist of diverse types of peripheral nerve disorders, including infectious, hereditary, inflammatory, or ischemic types. They include, but are not all inclusive to, carpal tunnel syndrome, radial nerve palsy, hereditary sensory and motor neuropathies, hepatitis C, herpes, Lyme disease, syphilis, choric inflammatory demyelinating polyradiculoneuropathy, Guillain–Barre syndrome, and vasculitis causing multiple mononeuropathies.[20] This section covers the Guillain–Barre syndrome.

Guillain–Barre Syndrome

The Guillain–Barre syndrome is a rare condition that causes a person's immune system to attack the peripheral nervous system. In doing this, the affected person has muscle weakness that begins in the lower extremities and progresses upward. The person may have temporary mild weakness or become entirely paralyzed.

Definition/Diagnosis

Guillain–Barre Syndrome is a peripheral motor nerve disorder in which the immune system is evoked to demyelinate the peripheral motor neurons. The syndrome includes several pathologic subtypes, of which the most common is a multifocal demyelinating disorder of the peripheral nerves in close association with macrophages.[21] There are three common forms of Guillain–Barre syndrome, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP), Miller–Fisher syndrome (MFS), and acute motor axonal **neuropathy** (AMAN) and acute motor-sensory axonal neuropathy (AMSAN).[22] Under the general heading of neuropathy, Guillain–Barre syndrome is an abnormal and usually degenerative state of the nervous system.[23]

Etiology

Guillain–Barre syndrome is considered an autoimmune response due to the postinfectious disease process. The infection can be either bacterial or viral and may even be triggered by a surgical procedure or vaccination in some cases.

Clinical Signs and Symptoms

The first symptoms of Guillain–Barre syndrome include weakness or tingling sensations, which usually begin in the legs and can spread to the arms and face, and an

ascending symmetric paralysis of the lower extremities. These symptoms can lead to paralysis of the legs, arms, or face muscles. In 20% to 30% of people, the chest muscles are affected, making breathing difficult.[24] One-third of the patients with Guillain–Barre develop acute respiratory failure.[2] The diagnosis of Guillain–Barre syndrome rests on the presence of progressive weakness of more than two limbs, areflexia (lack of neurologic reflexes), and progression for no more than 4 weeks. The patient must also meet criteria for exclusion of other disease processes such as lead poisoning, botulism, vasculitis, and porphyria.

Treatment and Management

In patients who present with a confirmed diagnosis of Guillain–Barre, the treatment includes close monitoring in the ICU with adequate respiratory support always available. Intubation for airway protection is indicated when bulbar muscle weakness increases the risk of aspiration. Indications for ventilatory support include a forced vital capacity less than 12 mL/kg, hypercarbia, hypoxemia, and the inability to handle oral secretions.[2] Deep vein thrombosis prophylaxis is essential to prevent pulmonary emboli. Also, patient movement, when possible, is vital to maintain good skin integrity and minimize the effects of atelectasis. The use of plasma exchange (the discarding and substitution of plasma) and intravenous immunoglobulin therapy in the earlier stages of the disease processes shortens the recovery time for patients with Guillain–Barre syndrome.

The prognosis for these patients is relatively good. Approximately 65% of patients in whom diagnosis was confirmed were able to return to normal function within 1 year of onset. Of the other group of patients (approximately 35%), 8% had passed away from cardiac or pulmonary complications such as a pulmonary embolism or cardiac arrhythmias.[25]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The types of peripheral nervous disorders include infectious, inflammatory, hereditary, and dehydration.
2. True or False: Approximately 65% of patients with a confirmed diagnosis of Guillain–Barre syndrome return to normal function.

Neuromuscular Junction Disorders

When a patient suffers from a neuromuscular junction disorder, there is a lack of communication at the neuromuscular junction itself. These junction sites, the motor end plates, contain the receptors that are responsible for picking up acetylcholine. Acetylcholine is the neurotransmitter responsible for transmitting the electrical impulse from the nerve to the muscle causing the muscle to contract. If nerve impulse transmission cannot proceed, the muscles will not contract properly. In neuromuscular diseases such as MG, botulism, and tetanus, this transmission is blocked.

Myasthenia Gravis

Myasthenia gravis (MG) is a neuromuscular disease that is caused by a breakdown in the communication between muscles and nerves. Typically, the paralysis caused by MG begins in the facial area and descends to the extremities.

Definition

MG is the most common disorder of the neuromuscular junction.[14] It is considered an autoimmune disorder. Patients who have this disorder may show onset at various ages in their life. MG is a disease characterized by progressive weakness and exhaustibility of voluntary muscles without atrophy or sensory disturbance and is caused by an autoimmune attack on acetylcholine receptors at the neuromuscular junction[26] (**Figure 4-6**).

Etiology

Patients with this disorder lack the appropriate amount of acetylcholine receptors. In MG, antibodies block, attack, or destroy the acetylcholine receptors needed for muscle contraction.[27] Without the proper amount of acetylcholine, these patients cannot contract the muscles that are being affected.

Clinical Signs and Symptoms

Patients who are suffering from an MG exacerbation present with a history of a recent infectious process. Their symptoms begin to develop and progress very rapidly over a few days. These patients will typically present to their primary care practitioner, clinic, or hospital with fluctuating weakness that is fatigable, worsening with repetitive activities, and improving with rest. Weakness worsens with exposure to heat, infection, and stress.[28] Approximately 10% of these patients who present with MG crisis will have respiratory muscle involvement.

The distribution of weakness may range from ocular muscle weakness to bulbar, neck and proximal extremity weakness, and, in more severe cases, the respiratory muscles. The effect of respiratory muscle weakness is seen after the first few years of diagnosis of the disease process. Diagnosis of MG can be done by performing the Tensilon test (edrophonium chloride test). During this test, the patient receives an edrophonium chloride injection. Edrophonium chloride is a short-acting acetylcholinesterase inhibitor. Following the injection, the patient is monitored for improvement in muscle strength. The injection of edrophonium chloride increases the duration of action of acetylcholine at the



FIGURE 4-6 Comparison of a healthy motor end plate and one with MG. Notice the receptors at the neuromuscular junction are blocked.

neuromuscular junctions. A positive response to this test occurs with an improvement in the ocular muscles. Eyelid ptosis and extraocular muscle movements improve. Eyelid ptosis is one of the more commonly seen signs of MG exacerbation.

Another method of diagnosis of MG is with an electrophysiologic test. Two kinds of tests can be performed depending on the specific patient symptoms. These include the repetitive nerve stimulation study and the **single-fiber electromyography (SFEMG)** test. The repetitive nerve stimulation test is performed by stimulating the nerve supramaximally at 2–3 Hz. A 10% decrement between the first and the fifth evoked muscle action potential (AP) is diagnostic of MG. In the absence of the decrement, exercise can be used to induce exhaustion of muscles and document decrement.[28] In SFEMG, a selective EMG recording technique allows the identification of APs from individual muscle fibers. This test is the most sensitive test for MG. The procedure uses a special needle electrode that allows the identification of APs from individual muscle fibers. The procedure simultaneously records the APs of two muscle fibers innervated by the same motor axon. The variability in time of the second AP relative to the first is called "jitter." In MG, the jitter will increase because the safety factor of transmission at the neuromuscular junction is reduced.[28]

Treatment and Management

A patient with MG can have a full recovery from an MG exacerbation. The first step in treatment is to increase the amount of available acetylcholine for binding to the receptors. The next step is to open the acetylcholine receptors for more binding opportunities. Treatment includes the administration of an acetylcholinesterase inhibitor, intravenous immunoglobulin treatment, long-term glucocorticoid agents, other immunosuppressive drugs, plasmapheresis, and lastly surgical treatment.[28]

The most commonly used acetylcholinesterase inhibitor drug for MG treatment is mestinon (pyridostigmine). This medication has an onset of action of 15–30 minutes and a duration of 3–4 hours. Side effects include, but are not limited to, increased salivation, increased bronchial secretions, bradycardia, nausea, sweating, diarrhea, and abdominal cramping.

Plasmapheresis is a process that directly removes acetylcholine receptor antibodies (AChR) from the circulation and promotes quick improvement for the patient. Plasmapheresis has side effects such as hypotension, thrombotic complications, and possible bleeding disorders. The intravenous immunoglobulin therapy has a rapid onset as well. However, these side effects are short lived and temporary.

For the long-term treatment of MG, corticosteroids and immunosuppressive drugs are used. The corticosteroid of choice is prednisone in combination with other immunosuppressive therapies. The nonsteroidal immunosuppressive medications used include azathioprine, mycophenolate mofetil, cyclophosphamide, tacrolimus, and etanercept.[28] If all other treatments are unsuccessful, the treatment of last resort is surgical intervention. The surgery is a **thymectomy** (removal of the thymus gland). In patients who present with thymoma, this intervention is strongly encouraged.

Botulism

Poisoning by the bacterium *Clostridium botulinum* can be deadly because this bacterium releases a neurotoxin that causes flaccid paralysis. Botulism is not contagious but is spread most commonly by consuming contaminated food.

Definition/Diagnosis

Botulism is a potentially fatal neuromuscular disease that occurs when *C. botulinum* releases neurotoxins A–G. Neurotoxins C, D, and E do not affect humans.

Neurotoxins A, B, E, and rarely F cause human botulism. These neurotoxins prevent the release of the acetylcholine from the presynaptic terminal axon that affects both the nicotinic receptor site and the muscarinic receptor site synapses[29] (**Figure 4-7**). The diagnosis of foodborne botulism depends on the patient history and physical examination. It is confirmed by the presence of the toxin in serum, stool, or food. Botulism can also be confirmed via culture of *C. botulinum* in the food, stool, or wound.

Etiology

There are three variations of botulism: foodborne, infant botulism, and wound botulism. Foodborne botulism occurs when a person ingests *C. botulinum*, which can be present in canned vegetables or meat. The *C. botulinum* grows and produces toxins before the food consumption. Infant botulism occurs when an infant, usually less than 6 months of age, ingests *C. botulinum* spores. These spores germinate and colonize the infant's intestines and release toxins. Wound botulism is rare and occurs when the *C. botulinum* and its spores contaminate traumatic or surgical wounds.[20]

Clinical Signs and Symptoms

Typically, early symptoms of botulism poisoning comprise diplopia (visual disturbances), dysphagia (difficulty swallowing), dysphonia (voice change), and dysarthria (slurred speech).[29] Foodborne botulism begins to show signs and symptoms of abdominal cramping and vomiting between 12 and 72 hours of ingestion of the bacteria. It is not the bacteria that cause botulism, but the toxins released by the bacteria. Wound botulism will present with the same symptoms along with cellulitis around the affected area.

Treatment and Management

Treatment for botulism consists of antitoxin administration, hospital admission, close monitoring, respiratory support, and debridement plus antibiotics in the case of wound botulism.[29]

Tetanus

Tetanus is a nervous system disorder that is characterized by the presence of muscle spasms brought on by the toxins of the anaerobe *Clostridium tetani*. One of the cardinal signs of tetanus is trismus, or lockjaw. Trismus is painful intense spasms of the masseter muscles.

Definition

Tetanus is a rare disease process now and occurs in many undeveloped countries. The vaccine to prevent this disease has been around since 1923. **Tetanus** is caused by *C. tetani*, a gram-positive bacillus bacterium that can result in respiratory paralysis, opisthotonos (muscle spasms causing severe hyperextension of the spine), and rigidity of the voluntary muscles (**Figure 4-8**). This bacterium secretes two toxins: tetanospasmin and tetanolysin.[30] The main toxin that yields the clinical symptoms of tetanus is tetanospasmin.



FIGURE 4-8 Opisthotonos (muscle spasms) occurring in a boy with tetanus. Tetanus is caused by *C. tetani*, which enter the body through a small wound or puncture of an infected object.



FIGURE 4-7 Comparison of a healthy neuromuscular junction with one exposed to the botulinum toxin.

Etiology

Tetanus is an infectious disease caused by wound contamination with *C. tetani* or the spores they produce. The bacterium produces the toxin tetanospasmin. Tetanospasmin binds to motor nerves that control muscles. The toxin prevents the release of neurotransmitters. "The toxin has a predominant effect on inhibitory neurons, inhibiting release of glycine and gamma-aminobutyric acid (GABA)."[30] Following an injury, tetanus is typically picked up from rusty metal, manure, or the soil.

Clinical Signs and Symptoms

A patient with tetanus will show a clinical triad of muscle spasms, rigidity, and autonomic dysfunction.[31] The tetanus toxin causes hyperactivity of voluntary muscles in the form of stiffness and spasms. The muscle spasms can occur in the jaw, causing rigidity of the temporal and masseter muscles, which leads to trismus (lockjaw).[31] Masseter muscle spasms may be the primary symptom of tetanus. A patient with tetanus may also show the characteristic "risus sardonicus," or the bared teeth and contracted facial muscles causing dysphagia. The muscles of the head and neck are usually affected first with the progressive caudal spread of rigidity and spasm to affect the entire body. Severe tetanus is associated with marked autonomic instability causing tachycardia and hypertension, vasoconstriction, and pyrexia. These "autonomic storms" occur with marked cardiovascular instability, including cardiac arrest.[30] The muscle spasms and rigidity of the chest wall, diaphragm, and abdomen lead to a restrictive defect. Pharyngeal and laryngeal spasms can cause respiratory failure or life-threatening airway obstruction. A weak cough from rigidity, spasm, and sedation leads to atelectasis, and the risk of pneumonia is high.[30] Before the introduction of mechanical ventilation, many patients with severe tetanus died from acute respiratory failure.

Treatment and Management

Because muscle rigidity and spasms are common occurrences with tetanus, they have an impact on the patient's respiratory function. The focus on the treatment for tetanus is to neutralize the toxin, remove the source of infection, and control the patient's symptoms. To neutralize the toxin, 3 to 6,000 units of human tetanus immune globulin are given intramuscularly.[30] For removing the source of infection, surgical removal and debridement of the area may be required. The antibiotic of choice is metronidazole, but penicillin, erythromycin, tetracycline, chloramphenicol, and clindamycin are all acceptable alternatives. Sedation with a benzodiazepine is the mainstay of treatment. When sedation by itself is inadequate, a neuromuscular blocking agent, an artificial airway, and mechanical ventilation may be necessary for a prolonged period.

The mortality for this tetanus varies with the treatment available to the patient. In highly developed countries, the mortality is substantially lowered than in underdeveloped nations. With the use of critical care treatment, mortality rates have dropped. Mortality also depends on the patient's age at the time of infection. Many other factors contribute to mortality when the patient has this type of infection. Elderly patients who develop tetanus have a higher chance of generalized sepsis, thrombosis, gastrointestinal bleed, and pneumonia.[31]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The Tensilon test diagnoses Guillain–Barre syndrome.
2. True or False: Neurotoxins C, D, and E secreted by *C. botulinum* cause botulism.
3. True or False: Plasmapheresis and intravenous immunoglobulin treat MG.
4. True or False: The toxin that occurs in a tetanus infection predominantly affects the inhibition of neurons, inhibiting the release of glycine and GABA.
5. True or False: When tetanus infection is present, the first area of the body to show signs of the infection is the legs.

Muscular Disorders

Muscular disorders that cause progressive skeletal muscle atrophy may also cause the respiratory muscles to weaken. Respiratory failure is the main cause of death among patients suffering from muscular dystrophies.

Muscular Dystrophy

Muscular dystrophy (MD) is one of a group of 30 genetic diseases characterized by progressive weakness and degeneration of the skeletal or voluntary muscles, which control movement.[21] The two primary conditions are Duchenne and Becker muscular dystrophies. Both of these muscular dystrophies are progressive myopathies due to mutations in the dystrophin gene on chromosome Xp21.[32] **Duchenne muscular dystrophy** (DMD) is a lethal form of MD caused by mutations in the dystrophin gene that result in absent or insufficient functional dystrophin, a cytoskeletal protein that enables the strength, stability, and functionality of myofibers.[33] Duchenne is more likely to occur in boys. **Becker muscular dystrophy** is a less severe form of MD, with dystrophin present but in smaller quantities than in a healthy individual. Becker MD is less common than DMD. Unfortunately, with both diseases, respiratory failure, due to weakened muscles, will result in death.

Etiology

These disorders are inherited through the X-link gene, with DMD being more common than Becker MD. With both disease processes, patients may present with wasting or deteriorating muscle strength. Because of this loss of muscle strength, it is essential to monitor the progression of muscle wasting in these patients. Ultimately, the loss of muscle strength will affect the respiratory and cardiac systems.[33] As with most neuromuscular diseases, this will cause a restrictive respiratory concern.

DMD is reported in approximately 1 in 3,500 boys worldwide. The expected lifespan of these patients is into the mid-20s.[33] At various stages in their lives, the progression of the disease is noted. Typically, the beginning of the disease process is observed around the time the patient begins to walk. Other observable characteristics of a child with DMD include the gate, stability, and strength with walking. The weakness of the lower limb muscles of children with DMD is demonstrated by their inability to get up from a squatting position. Children will use their hands and arms to help lift themselves. The action of lifting oneself up with hands and arms is the Gowers sign (**Figure 4-9**).

Once the patient is diagnosed with MD, it is just a matter of time before the muscle wasting takes over and the patient becomes wheelchair bound. Typically, between the ages of 15 and 20 years, respiratory muscle weakness sets in and causes the patient to require assistance with their respiratory function.[34] Many of these patients will also develop cardiac symptoms with cardiomyopathy.[35]

Clinical Signs and Symptoms

Many methods are used to assess the respiratory dysfunction of patients with DMD. Respiratory impairment is evaluated by using vital capacity and mouth pressure generated during a maximum inspiratory maneuver.[36] Other routine evaluations of respiratory function include gas exchange, lung volumes, assisted cough peak flow, and maximum insufflation capacity.[36] These other measures will take into consideration the muscle strength to generate the flows through the airways. As time progresses and the patient's respiratory muscle strength waivers, carbon dioxide levels need monitoring to detect the presence of alveolar hypoventilation.

Treatment and Management

Managing these patients will depend on the severity of the disease process at a particular time. Following the diagnosis, a classification of the severity of the disease is needed. Patients need to be able to perform some of the basic therapies, such as airway clearance. The inability to adequately clear secretions leads to respiratory viral infections or pneumonia. A patient unable to generate an effective cough can benefit from the use of a mechanical insufflator–exsufflator (MIE) device (Cough-Assist®).[37]

In the next stage of management, noninvasive ventilation (NIV) is usually necessary during sleep. Many patients with DMD develop elevated levels of CO_2 in their bloodstream while they sleep. Once this begins to occur, patients require assistance while they are sleeping. A high level of carbon dioxide during daytime hours necessitates ventilatory support in the daytime as well as at night. There are many options for ventilatory support for these patients. See **Box 4-2**.

If NIV is required 24 hours a day, the patient and families may need to consider invasive ventilation. In this type of situation, a surgically placed tracheostomy allows for mechanical ventilation. The chronic



FIGURE 4-9 The sequence of movements of a boy with DMD with Gowers sign.

BOX 4-2 Types of Ventilatory Support for Patients with DMD[37]

- **I.** Positive pressure ventilation
  - **A.** A. Noninvasive positive pressure ventilation (NIPPV)
    - **1.** Pressure-supported ventilation (patient's inspiratory flow triggers mechanical breath)
      - **a.** Bilevel positive airway pressure (BPAP)
      - **b.** Continuous positive airway pressure (CPAP) (for obstructive sleep apnea without hypoventilation)
    - **2.** Volume-supported ventilation
  - **B.** Invasive positive pressure ventilation via tracheostomy
- **II.** Negative pressure ventilation
  - **A.** Iron lung or tank
  - **B.** Cuirass
  - **C.** Pneumo-suit
- **III.** Other support
  - **A.** Insufflator–exsufflator (Cough-Assist®) if coughing is impaired
  - **B.** Pneumatic belt respiratory assistance
  - **C.** Quad coughing

Modified from Wagner K. Approaching a new age in Duchenne muscular dystrophy treatment. *Neurotherapeutics*. 2008;5(4):583–591. doi:10.1016/j.nurt.2008.08.013.

use of corticosteroids is a part of the standard of care for DMD. This type of treatment may lead to side effects, and rapid withdrawal of corticosteroids can result in life-threatening complications. Prednisone and deflazacort are the two corticosteroids of choice. Deflazacort is an anti-inflammatory and immunosuppressant that slows the loss of muscle strength and function, preserves cardiac and respiratory function, and reduces the incidence of scoliosis. Compared with prednisone, deflazacort causes less unwanted side effects, such as weight gain, loss of bone mass, glucose intolerance, and behavioral issues.[37]

Many patients with DMD do not live past age 25 years. Fifty to ninety percent of DMD patients succumb to respiratory failure, 13% from heart failure or severe rhythm abnormalities, and 12% from infections or septicemia.[34] Unfortunately, MD is fatal in all cases. No patients are reported to live into their 30s. Researchers are studying novel approaches to the treatment of DMD. These studies include the evaluation of the therapeutic potential of a protein called PTEN in DMD and the study of exon-skipping drugs (targets genetic instructions at the RNA stage) in DMD.[34] Researchers are also looking at regeneration and stimulation of muscle growth and evolving therapeutic advances.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Once NIPPV is required 24 hours a day to maintain adequate respiratory function, it is time to consider a tracheostomy.
2. True or False: Respiratory impairment in patients with DMD is measured by vital capacity, monitoring gas exchange, lung volumes, and peak flows.
3. True or False: MD is considered a terminal disease

Prognosis for Neuromuscular Diseases

The prognosis for patients with neuromuscular conditions has improved since the days of the polio epidemic in the mid-20th century. The improvement is largely due to the availability of NIV. Successive large cohort studies have shown that NIV can extend survival in patients with nonprogressive conditions such that these individuals are likely to have a nearly average life expectancy.[38] The prognosis for neuromuscular disorders depends on the extent of the cardiopulmonary involvement. In situations such as a drug overdose, the patient is likely to make a full recovery and resume a normal lifestyle. In other cases, such as DMD or ALS, respiratory failure is inevitable and chronic. In these chronic situations, it is crucial to understand the appropriate time to intervene. Interventions can range from monitoring the maintenance of current pulmonary status to invasive mechanical ventilation.

With chronic neuromuscular conditions, it is important that the patient's care team involve not only the physicians but other healthcare practitioners as well. Team members may include the respiratory therapist, specialized nurses, nutritionists, physical therapist, social workers, and support groups for both the patient and the family members. Although a vast majority of these patients with neuromuscular conditions will not be able to improve function, it is possible to maintain the function they currently have. Therapies that help to maintain and possibly improve the quality of life include respiratory muscle training, MIE, diaphragmatic pacing, and NIV.[38,39] Therefore, in the absence of disease-modifying treatments, the management of respiratory failure with support is necessary to improve the quality of life and prevent secondary complications.[39]

KNOWLEDGE CHECK QUESTIONS

1. True or False: NIV does not normalize the life expectancy of a patient with neuromuscular disorders.
2. True or False: Quality of life for patients with neuromuscular disorders may improve with the use of an MIE.

Chapter Summary

Overall, patients who suffer from a neuromuscular disease process may show different signs and symptoms upon presentation to the physician's office or the acute care facility. It is always important to start with obtaining a patient history and physical examination, if appropriate, then begin with more in-depth assessment and testing, if needed. In some of these cases, the end outcome of the disease process is terminal, while in others it is resolvable, and the patient may maintain a relatively normal lifestyle after the event. It will all begin with determining the correct disease process and then being able to provide the appropriate treatment for these patients.

Many tests are available for the physicians' offices and at the hospitals to identify the type of neuromuscular disorder and its severity. Hopefully, this will occur as promptly as possible, to expedite the treatment. In some cases, the patient may remain in the hospital setting for an extended period. Treatment may involve noninvasive and invasive life support depending on the severity of the disease process and the patient's overall health.

Key Points

1. Neuromuscular disorders consist of a variety of process that affects voluntary muscles of the body. These include central nervous system disorders, drug overdose, spinal cord disorders, peripheral motor nerve disorder, neuromuscular junction disorders, and muscular disorders.
2. This chapter covered poliomyelitis and PPS (central nervous system disorders); ALS and spinal cord injury (spinal cord disorders); Guillain–Barre syndrome (peripheral motor nerve disorder); MG, botulism, and tetanus (neuromuscular junction disorders); and DMD (muscular disorders).
3. The etiologies of neuromuscular disorders include genetic mutations, viral infections, bacterial infections, autoimmune diseases, and metabolic disorders.
4. Any neuromuscular disorder that affects the muscles of ventilation can cause acute and chronic respiratory failure.
5. The differential diagnosis of neuromuscular disorders depends on the muscle and nerve groups that are affected, age at onset, the rate of progression, genetic predisposition, blood tests, physical examination, and possibly a biopsy. The Tensilon test, using edrophonium, helps diagnose MG. A positive test demonstrates improvement in muscle strength following its administration. However, SFEMG is a more sensitive test for MG.
6. Noninvasive mechanical ventilation is becoming more commonly used with neuromuscular patients.
7. Chronic respiratory failure due to a neuromuscular disorder may cause failure to liberate the patient from noninvasive mechanical ventilation. Invasive mechanical ventilation is an option to be considered at this point.
8. Therapies available for the treatment of neuromuscular disorders may improve the quality of life for many of these patients. The MIE (Cough-Assist®) is one such therapy.
9. Treatment for chronic neuromuscular diseases requires a team approach with numerous healthcare practitioners and family members.
10. The prognosis for neuromuscular disorders depends on the extent of the cardiopulmonary involvement.

Chapter Questions

1. The _____ nerve has **no** effect on the upper airways.
   - **a.** glossopharyngeal
   - **b.** vagus
   - **c.** lumbar T8
   - **d.** spinal accessory
2. Receptors for _____ and _____ drive the response of the brain to breathe.
   - **a.** $PaCO_2$; HCO_3^-
   - **b.** PaO_2; $PaCO_2$
   - **c.** SaO_2; Hb
   - **d.** HCO_3^-; PaO_2
3. A/An _____ is not a useful test to assess a patient with a questionable neuromuscular disease process.
   - **a.** arterial blood gas analysis
   - **b.** pulmonary function testing
   - **c.** urine output
   - **d.** chest radiograph
4. _____ is a central nervous system disorder.
   - **a.** Amyotrophic lateral sclerosis (ALS)
   - **b.** poliomyelitis
   - **c.** botulism
   - **d.** Guillain–Barre syndrome

5. _____ is an acetylcholinesterase inhibitor used during a myasthenia gravis (MG) exacerbation.
   a. Pyridostigmine
   b. Prednisone
   c. Cyclophosphamide
   d. Etanercept
6. The most common clinical sign of tetanus is _____.
   a. hypertension
   b. muscle rigidity
   c. ptosis
   d. sepsis
7. The respiratory muscles are weakened in a patient with Duchenne muscular dystrophy around ages _____.
   a. 5–7
   b. 7–9
   c. 10–13
   d. 15–20
8. Plasmapheresis is a therapy used in the treatment of _____.
   a. MG
   b. Guillain–Barre
   c. botulism
   d. ALS
9. The most sensitive test to confirm a diagnosis of MG is the _____.
   a. Tensilon test
   b. pulmonary function test
   c. maximum inspiratory pressure
   d. single-fiber electromyography
10. _____ of patients with ALS die due to complications of the disease.
    a. 10%
    b. 30%
    c. 50%
    d. 70%

References

1. Benditt J. The neuromuscular respiratory system: physiology, pathophysiology, and a respiratory care approach to patients. *Respir Care*. 2006;51(8):829–836.
2. Cordova F, Mullarkey J, Criner G. Neuromuscular dysfunction. In: Hess D, MacIntyre N, Galvin W, Mishoe S. *Respiratory Care: Principles and Practice*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2016:993–1032.
3. Mangera Z, Panesar G, Makker H. Practical approach to management of respiratory complications in neurological disorders. *Int J Gen Med*. 2012;5:255–263. doi:10.2147/ijgm.s26333.
4. Mayo Clinic. Myasthenia gravis—Symptoms and causes. 2017. https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/symptoms-causes/syc-20352036. Accessed December 27, 2017.
5. Merriam-webstercom. *Definition of Central Nervous System*. 2017. https://www.merriam-webster.com/dictionary/central%20nervous%20system. Accessed December 7, 2017.
6. Post-Polio Syndrome Fact Sheet | National Institute of Neurological Disorders and Stroke. *Nindsnihgov*. 2012. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Post-Polio-Syndrome-Fact-Sheet. Accessed February 25, 2018.
7. CDC Global Health—Polio—What Is Polio? *Cdcgov*. 2018. https://www.cdc.gov/polio/about. Accessed February 25, 2018.
8. World Health Organization. *Poliomyelitis*. 2018. http://www.who.int/mediacentre/factsheets/fs114/en. Accessed October 30, 2017.
9. Mayoclinicorg. *Post-polio Syndrome*. 2018. http://www.mayoclinic.org. Accessed November 9, 2017.
10. Hua A, Haight S, Hoffman R, Manini A. Endotracheal intubation after acute drug overdoses: incidence, complications, and risk factors. *J Emerg Med*. 2017;52(1):59–65. doi:10.1016/j.jemermed.2016.07.114.
11. Boyer E. Management of opioid analgesic overdose. *N Engl J Med*. 2012;367(2):146–155. doi:10.1056/nejmra1202561.
12. Orsini J, Din N, Elahi E, et al. Clinical and epidemiological characteristics of patients with acute drug intoxication admitted to ICU. *J Community Hosp Intern Med Perspect*. 2017;7(4):202–207. doi:10.1080/20009666.2017.1356189.
13. ALS | Conditions & Treatments | UCSF Medical Center. *Ucsfhealthorg*. 2017. https://www.ucsfhealth.org/conditions/als. Accessed December 27, 2017.
14. Martin S, Al Khleifat A, Al-Chalabi A. What causes amyotrophic lateral sclerosis? *F1000Res*. 2017;6:371. doi:10.12688/f1000research.10476.1.
15. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? *Front Aging Neurosci*. 2017;9:68. doi:10.3389/fnagi.2017.00068.
16. Soden R, Walsh J, Middleton J, Craven M, Rutkowski S, Yeo J. Causes of death after spinal cord injury. *Spinal Cord*. 2000;38(10):604–610. doi:10.1038/sj.sc.3101080.
17. Berlowitz D, Wadsworth B, Ross J. Respiratory problems and management in people with spinal cord injury. *Breathe*. 2016;12(4):328–340. doi:10.1183/20734735.012616.
18. Kelly B, Luce J. The diagnosis and management of neuromuscular diseases causing respiratory failure. *Chest*. 1991;99(6):1485–1494. doi:10.1378/chest.99.6.1485.
19. Brown R, DiMarco A, Hoit J, Garshick E. Respiratory dysfunction and management in spinal cord injury. *Respir Care*. 2006;51(8):853–865.
20. Rubin M. Overview of peripheral nervous system disorders. *Merck Manual*. 2016. https://www.merckmanuals.com/professional/neurologic-disorders/peripheral-nervous-system-and-motor-unit-disorders/overview-of-peripheral-nervous-system-disorders. Accessed November 9, 2017.
21. MedicineNet. *Definition of Muscular Dystrophy*. 2017. https://www.medicinenet.com/script/main/art.asp?articlekey=11682. Accessed December 17, 2017.
22. Newman T, Stacy Sampson D. Guillain-Barré syndrome: symptoms, causes, diagnosis, and treatment. *Med News Today*. 2017. http://www.medicalnewstoday.com/articles/167892.php. Accessed December 6, 2017.
23. Merriam-webstercom. *Definition of Neuropathy*. 2017. https://www.merriam-webster.com/dictionary/neuropathy. Accessed December 14, 2017.
24. WHO. Guillain-Barre Syndrome. 2016. http://www.who.int/en/news-room/fact-sheets/detail/guillain-barr%C3%A9-syndrome. Accessed December 9, 2017.
25. Wilner JB. Guillain-Barre syndrome. *Mol Pathol*. 2001;54(6):381–385.
26. Merriam-webstercom. *Definition of Myasthenia Gravis*. 2017. https://www.merriam-webster.com/dictionary/myasthenia%20gravis. Accessed December 24, 2017.
27. Robinson J. Understanding Myasthenia Gravis—the Basics. *WebMD*. 2016. https://www.webmd.com/brain/understanding-myasthenia-gravis-basics#1-2. Accessed January 01, 2018.
28. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. *Autoimmune Dis*. 2012;2012:874680. doi:10.1155/2012/874680

29. Jeffery I, Karim S. Botulism. *Ncbinlmnihgov*. 2018. http://www.ncbi.nlm.nih.gov/books/NBK459273/?report=printable. Accessed November 16, 2017.
30. Cook T, Protheroe R, Handel J. Tetanus: a review of the literature. *Br J Anaesth*. 2001;87(3):477–487. doi:10.1093/bja/87.3.477.
31. Hassel B. Tetanus: pathophysiology, treatment, and the possibility of using botulinum toxin against tetanus-induced rigidity and spasms. *Toxins (Basel)*. 2013;5(12):73–83. doi:10.3390/toxins5010073.
32. Benditt J, Boitano L. Pulmonary issues in patients with chronic neuromuscular disease. *Am J Respir Crit Care Med*. 2013;187(10):1046–1055. doi:10.1164/rccm.201210-1804ci.
33. Birnkrant D, Bushby K, Bann C, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. 2018;17(3):251–267. doi:10.1016/s1474-4422(18)30024-3.
34. Duchenne Muscular Dystrophy (DMD)—Medical Management | Muscular Dystrophy Association. *Muscular Dystrophy Association*. 2018. https://mda.org/disease/duchenne-muscular-dystrophy/medical-management. Accessed February 22, 2018.
35. Finsterer J. Cardiopulmonary support in Duchenne muscular dystrophy. *Lung*. 2006;184(4):205–215. doi:10.1007/s00408-005-2584-x.
36. Finder JD, Birnkrant D, Carl J, et al. American Thoracic Society consensus statement. Respiratory care of the patient with Duchenne muscular dystrophy. *Am J Respir Crit Care Med*. 2004;170(4):456–465. doi:10.1164/rccm.200307-885st.
37. Wagner K. Approaching a new age in Duchenne muscular dystrophy treatment. *Neurotherapeutics*. 2008;5(4):583–591. doi:10.1016/j.nurt.2008.08.013.
38. Simonds A. Recent advances in respiratory care for neuromuscular disease. *Chest*. 2006;130(6):1879–1886. doi:10.1378/chest.130.6.1879.
39. Pfeffer G, Povitz M. Respiratory management of patients with neuromuscular disease: current perspectives. *Degener Neurol Neuromuscul Dis*. 2016;6:111–118. doi:10.2147/dnnd.s87323.

CHAPTER

5

Disorders of the Chest Wall and Pleura

"Healing is a matter of time, but sometimes it is a matter of opportunity"

—Hippocrates

OUTLINE

OBJECTIVES

1. Describe the etiology of chest trauma and pathophysiological changes that occur.
2. Identify common pathophysiologic conditions in chest trauma patients.
3. Describe the components of primary and secondary surveys in a chest trauma patient.
4. Explain the treatment and management priorities with a chest trauma patient.
5. Relate how chest wall deformities impact the respiratory system.
6. Recognize common characteristics, manifestations, and anatomic features of the pleura and pleural space.
7. Compare common disorders involving the pleura and their management.
8. Discuss diagnostic testing used in identifying pleural effusion.

KEY TERMS

Abdominal paradox
Ankylosing spondylitis (AS)
Beck triad
Blunt force trauma
Cardiac tamponade
Cobb angle
eFAST
Empyema
Empyema necessitans
Exudative
Flail chest
Glasgow Coma Scale (GCS)
Hemopneumothorax
Hemothorax
Kyphoscoliosis
Kyphosis
Mesothelium
Open pneumothorax
Paradoxical chest movement
Parapneumonic effusion
Parietal pleura
Pectus carinatum (PC)
Pectus excavatum
Pleural effusion
Pleural space
Pleurodesis
Pneumomediastinum
Pneumothorax
Primary spontaneous pneumothorax
Primary survey
Pulmonary contusion
Sclerotherapy
Scoliosis
Secondary spontaneous pneumothorax
Secondary survey
Simple pneumothorax
Spontaneous pneumothorax
Tension pneumothorax
Thoracentesis
Tracheal deviation
Transudative
Traumatic pneumothorax
Urinothorax
Visceral pleura

Case Study

A 54-year-old woman with a long-standing history of disabling rheumatoid arthritis was admitted to the hospital with pleuritic left-sided chest pain along with progressive shortness of breath. She had no allergies, prior surgeries, or other serious medical illnesses to her knowledge, but admitted to a 30-pack-year history of cigarette smoking, which she had discontinued 3 months earlier. She had no known exposure to asbestos or other occupational/environmental dusts and no recent history of chills, sweats, or sputum production. She did admit to a weight loss of approximately 10 pounds over the past 2 months attributed to "just not feeling hungry." Her only current medication was prednisone taken daily for her rheumatoid arthritis.

On physical examination, her temperature was 99.2°F, pulse was 108, and respiratory rate was 20. Her blood pressure was 135/75 mm Hg. On physical examination, the patient appeared relatively comfortable at rest though became noticeably dyspneic with minimal exertion. Prominent rheumatoid deformities involved the hands, ankles, and knees. No skin rash or cervical lymphadenopathy was found. Soft, bilateral axillary lymph nodes were palpated with nodes identified on the right side as being noticeably more enlarged. Lung auscultation revealed diminished sounds in the left base. Dullness was noted to chest percussion over this area with inspiratory crackles heard above the area of dullness. Breast examination was not remarkable. The cardiac and abdominal exams were also considered normal. There was slight lower extremity peripheral edema bilaterally though no overt signs were present suggestive of deep venous thrombosis.

A standard chest radiograph taken on admission showed a moderate left-sided pleural effusion. A patchy opacity was suggested involving the left lower lobe. The heart was felt to be of normal cardiac size. A ventilation–perfusion scan revealed a low probability of pulmonary embolism.

Shortly following her hospital admission, a diagnostic thoracentesis was performed revealing cloudy pleural fluid, which contained 120,000 red cells and 97,400 white cells per cubic millimeter; of the white cells, 78% were neutrophils, 7% lymphocytes, 9% monocytes, and 6% eosinophils. Specific gravity of the pleural fluid was 1.030 with a fluid glucose level of 47 mg/dL. The total protein level of the pleural fluid was 4.6 g/dL with an amylase level of 31 U/L and an increased lactate dehydrogenase level (LDH) of 1,565 U/L. Microscopic examination of the fluid showed no acid–fast bacilli, fungi, or other microorganisms; anaerobic, fungal, and mycobacterial cultures were sterile. The pH of the pleural fluid was 7.20. Cytological examination of the pleural fluid was consistent with a diagnosis of adenocarcinoma. A chest x-ray taken following thoracentesis showed a decrease in left-sided pleural effusion along with a persistent area of increased density involving the base of the left lung.

Introduction

The chest wall and the pleura are vital parts of the respiratory pump. Disorders that affect the structure of the chest wall and the pleura affect the function of the lungs and can lead to respiratory failure. These disorders are characterized by a reduction in the vital capacity and sometimes resting lung volume with little change in airway resistance. These disorders do, however, alter the ability of the lungs to stretch, thus decreasing compliance.

The visceral and parietal pleura are a single continuous membrane that folds over itself to form a double layer that covers each lung. The inner layer, the visceral pleura, is attached to the lung's surface. This layer doubles back around the hilar region to form the outer layer, or parietal pleura. The parietal pleura is attached to the inner chest wall surface (**Figure 5-1**).

The thoracic cage is formed by the ribs, their muscles, the sternum, the vertebrae, and the diaphragm. The thoracic cage protects the lungs and assists in the enlargement of the chest cavity during inspiration. The ribs and the intercostal muscles create a semiflexible chest wall (**Figure 5-2**).

KNOWLEDGE CHECK QUESTIONS

1. True or False: Disorders of the respiratory pump increase airway resistance.
2. True or False: The visceral and parietal pleura are two separate structures.
3. True or False: The thoracic cage is formed by ribs, sternum, muscles, vertebrae, and diaphragm.



FIGURE 5-1 The thorax showing the pleura. The pleural cavity is the interpleural space, which is extremely small and is filled with a thin layer of serous pleural fluid, which lubricates the membranes allowing for the almost frictionless movement of the lungs.



FIGURE 5-2 Muscles of the chest wall involved in chest movement for ventilation and protection of the lungs.

Disorders of the Chest Wall

The chest wall is a critical component of the respiratory pump. Diseases and disorders that alter the structure of the chest wall affect the function of the respiratory pump and can result in respiratory compromise or failure. The components of the chest wall include the bony structures, ribs and spine, respiratory muscles, and nerves connecting the central nervous system to the respiratory muscles. Forces that act on the mechanical structure of the chest wall play a major role in determining lung volume. Chest wall pathology may be a significant contributor to restrictive physiology of the respiratory system.[1] The disorders discussed in this chapter are not all inclusive but represent those commonly seen in two main categories: chest trauma and chest wall deformities.

Chest Trauma

The chest wall protects the internal thoracic organs (heart and lungs), mediastinal structures (esophagus and trachea), and major vasculature (aorta and vena cava). Damage to the chest wall may coincide with significant injury to some of these internal structures.[2]

Definition/Diagnosis

It is critical that a trauma patient receive pre-hospital triage prior to transport to a trauma center. Minimizing time between critical injury and definitive care has long been a hallmark and metric of trauma systems.[3] When considering the time to treat a trauma case, there are generally three phases. The first lasts from the point when a patient is injured to the time when 911 is notified. The second phase lasts from the time of 911 notification to the delivery of the patient to the hospital. The third period is the interval between arrival at the hospital and actual medical intervention in the emergency center.[4] Rapid identification, stabilization, and timely transportation to the hospital is of utmost importance. Pre-hospital trauma triage criteria typically adopt a combination of physiologic, anatomic,

and mechanism of injury components tailored to meet individual trauma system needs, generally adapted from early criteria developed in the United States.[5]

In the emergency department, life-threatening injuries must be addressed immediately. Patients are assessed, and their treatment priorities established, based on injuries, vital signs, and the mechanism of injury. In severely injured patients, logical and sequential treatment priorities must be established based on overall patient assessment.[6] It is not a matter of whether certain procedures are needed, but it is more a matter of when they need to be performed. A primary example of this is in the case of a tension pneumothorax. The clinical identification of a tension pneumothorax is enough evidence to perform a needle decompression. Waiting for a chest radiograph for confirmation of the pneumothorax causes potential life-threatening delay. All trauma patients need assessment and management in accordance with Advanced Trauma Life Support (ATLS) guidelines.

The primary survey facilitates the identification and treatment of immediately life-threatening conditions. This process constitutes the ABCDEs of trauma care. See **Box 5-1**.

The primary survey is designed to assess and treat any life-threatening injuries quickly. It needs to be completed very rapidly. The main causes of death in a trauma patient are airway obstruction, respiratory failure, shock from hemorrhage, and brain injuries.[6] Therefore, these are the areas targeted during the primary survey. **Box 5-2** identifies specific injuries that may be found during a primary survey and may be potentially life threatening.

Clinical Signs and Symptoms

The initial evaluation follows a protocol of **primary survey**, resuscitation, **secondary survey**, and either definitive treatment or transfer to an appropriate trauma center for definitive care.[8] The objectives of the initial evaluation of the trauma patient are as follows: (1) to rapidly identify life-threatening injuries, (2) to initiate adequate supportive therapy, and (3) to efficiently organize either definitive therapy or transfer to a facility that provides definitive therapy.[8] All life-threatening situations must be addressed at the time they are identified.

Chest trauma patients typically present with chest pain and shortness of breath but can also present in shock (altered mental status) or in traumatic arrest. Presenting vital signs tend to range from slightly abnormal to very unstable. See **Box 5-3**. A simple algorithm for rapid assessment can help determine some issues that cause respiratory distress (**Figure 5-3**).

The primary survey guides the practitioner's initial assessment of the patient. It is important to follow the ABCDEs of trauma to assure that no critical or life-threatening injuries are overlooked.

The patency of the patient's airway can be assessed by asking the patient a question. If the patient can speak, the patient is responsive and has an open airway. If not, either a chin lift or a jaw thrust can be used. In the case of a cervical spine injury, the jaw thrust is

BOX 5-1 The ABCDEs of Trauma Care

Airway maintenance with cervical spine protection

Breathing and ventilation

Circulation with hemorrhage control

Disability

Exposure/environmental control

Advanced Trauma Life Support. Chicago, IL: American College of Surgeons; 2012. Planas J, Waseem M. Trauma, primary survey. In: *Statpearls*. Treasure Island, FL: StatePearls Publishing; 2017. https://www.ncbi.nlm.nih.gov/books/NBK430800. Accessed June 11, 2018.

BOX 5-2 Potential Life-Threatening Injuries Identified During a Primary Survey

- Airway obstruction
- Tension pneumothorax
- Massive internal or external hemorrhage
- Open pneumothorax
- Flail chest
- Cardiac tamponade

Data from Planas J, Waseem M. Trauma, primary survey. In: *Statpearls*. Treasure Island, FL: StatePearls Publishing; 2017. https://www.ncbi.nlm.nih.gov/books/NBK430800. Accessed June 11, 2018.

BOX 5-3 Chest Trauma Primary Survey Signs

Breath sound abnormalities

Chest wall deformity

Hypoxemia

Percussion abnormalities

Respiratory distress

Tachypnea

Tracheal deviation

Data from Nadir N. Chest trauma. *CDEM Curriculum*. 2018. https://cdemcurriculum.com/chest-trauma. Accessed June 17, 2018.



FIGURE 5-3 A simple, rapid assessment of patients with thoracic trauma and respiratory distress during the primary survey.

From the MSD Manual Professional Version (Known as the Merck Manual in the US and Canada and the MSD Manual in the rest of the world), edited by Robert Porter. Copyright 2018 by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Kenilworth, NJ. Available at http://www.msdmanuals.com/professional.

preferred. Other issues to look for during the airway assessment are foreign bodies, secretions, facial fractures, or airway lacerations. During these evaluations and possible interventions, caution must be used to ensure that the cervical spine is immobilized and maintained in-line. Airway protection is required in many trauma patients. Patients with airway obstruction require immediate ventilation.[7]

The first inspection of the patient reveals whether the patient is breathing. The clinician needs to look for tracheal deviation, chest wounds or an open pneumothorax, flail chest or paradoxical chest movement, and asymmetrical chest wall excursion. Auscultation of the lungs may also identify decreased or asymmetric breath sounds. Decreased breath sounds and decreased chest wall excursion can be a sign of a pneumothorax or hemothorax. These combined with either **tracheal deviation** or hemodynamic compromise can be a clinical sign of a tension pneumothorax requiring immediate needle decompression followed by chest tube placement. Open chest wounds need to be covered immediately to prevent the entry of air into the chest. If a flail is present and is causing respiratory compromise, positive pressure ventilation may need to be provided.[6]

Adequate circulation is a requirement for oxygenation to all the vital organs. Evaluate the circulation by identifying hypovolemia, **cardiac tamponade**, and external sources of hemorrhage. Inspect extremities for the quality of perfusion and determine whether the heart tones are auscultated and whether the external hemorrhage is identified and controlled. Initiate treatment of hypovolemia by rapidly infusing a lactated Ringer solution via two large-bore, peripheral, intravenous catheters placed preferentially in the upper extremities.

The disability of the patients is determined using gross mental status and motor examinations. The patients' conscious state and neurologic signs are assessed using the **Glasgow Coma Scale** (GCS) (**Figure 5-4**), pupil size and reaction, and lateralizing signs.

The final step in the primary survey includes patient exposure and control of the immediate environment. Completely remove patient clothes for a thorough physical examination. Simultaneously, initiate treatment to prevent hypothermia, a condition that is frequently iatrogenic in the exposed patient in an air-conditioned emergency department. Treat prophylactically with the administration of warmed IV fluids, blankets, heat lamps, and warmed air-circulating blankets as needed.[8]

The secondary survey includes a more methodical examination of the respiratory system. Secondary survey utilizes all aspects of a physical exam



FIGURE 5-4 The Glasgow Coma Scale (GCS). The GCS is scored between 3 and 15, with 3 being the worst and 15 the best.

Reproduced with permission from Laureys S, Majerus S, Moonen G. Assessing consciousness in critically ill patients. In: Vincent JL ed. 2002 Yearbook of Intensive Care and Emergency medicine. Heidelberg: Springer-Verlag, 715–727.

BOX 5-4 Secondary Assessment Survey for Chest Trauma

- Inspect the anterior, lateral, and posterior chest wall for signs of blunt and penetrating injury, use of accessory breathing muscles, and bilateral respiratory excursions.
- Auscultate the anterior chest wall and posterior bases for bilateral breath sounds and heart sounds.
- Palpate the entire chest wall for evidence of blunt and penetrating injury, subcutaneous emphysema, tenderness, and crepitation.
- Percuss for evidence of hyperresonance or dullness.

Advanced Trauma Life Support. Chicago, IL: American College of Surgeons; 2012. Planas J, Waseem M. Trauma, primary survey. In: *Statpearls*. Treasure Island, FL: StatePearls Publishing; 2017. https://www.ncbi.nlm.nih.gov/books/NBK430800. Accessed June 11, 2018.

including inspection, palpation, percussion, and auscultation. See **Box 5-4**. The secondary survey can identify bruising, deformity, or paradoxical chest motion, chest wall tenderness or crepitations, diminished breath sounds, muffled heart sounds, and mediastinal crepitations. Specialized diagnostic tests may be performed during the secondary survey to identify specific injuries.

Etiology

Chest trauma can be distinguished by the mechanism of injury. Blunt chest trauma refers to mechanisms causing increase intrathoracic pressure. This occurs with motor vehicle accidents and falls. By comparison, penetrating chest trauma refers to gunshot wounds, stab wounds, and impalement. Crushing chest injuries occur when the elastic limits of the chest and its contents are exceeded. There is considerable overlap among the various traumatic disorders experienced in penetrating, blunt chest trauma.[9] The mode of injury is very important. **Blunt force trauma** to the chest is an acceleration or deceleration injury. These injuries are a result of a motor vehicle accident or a fall. Blunt force trauma to the chest wall can occur in one of three directions: anterior–posterior, lateral compression, and trans-diaphragmatic. See **Figure 5-5**.

Crushing chest injury typically occurs from anterior–posterior forces, causing **flail chest**, shock, pneumothorax, cardiac and aortic injuries, and rupture of the diaphragm. Penetrating injuries are caused by low-velocity, medium-velocity, or high-velocity penetration (**Table 5-1**).

TABLE 5-1
Etiology of Penetrating Chest Trauma

Velocity	Possible Injuries
Low velocity (knife wounds, impalement)	Disrupts only the structures penetrated
Medium velocity (handgun bullet, shotgun, pellet gun)	Disrupts only the structures penetrated Can cause cavitation of surrounding tissue
High velocity (military weapons)	The higher the velocity, the more the damage Fragmentation weapons cause extensive disruption and thermal tissue damage

Modified from Shahani R. Penetrating chest trauma: background, anatomy, pathophysiology. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/425698-overview. Accessed June 11, 2018.



Lateral view

Possible injuries
- Disruption of the aorta at the legamemtum arteriosum
- Laceration of left and/or right mainstem bronchus
- Cardiac injury (contusion, destruction of valves)
- Sternal fracture
- Flail chest

Anterior view

Possible injuries
- Fracture of ribs 7–10
- Laceration of spleen, liver and kidneys
- Long contusion
- Laceration of lung parenchyma

Anterior view

Possible injuries
- Rupture of diaphragm, especially the left hemidiaphragm

FIGURE 5-5 Types of forces that cause blunt chest trauma.
Based on Blyth A. Thoracic Trauma. *British Medical Journal*. 2014;348. doi:10.1136/bmj.g1137.

Life-threatening chest trauma includes flail chest, **pneumothorax** (**traumatic pneumothorax**, **tension pneumothorax**, and **open pneumothorax**), massive **hemothorax**, and cardiac tamponade. Other important injuries include rib fractures, **pulmonary contusion**, **simple pneumothorax**, simple hemothorax, and blunt aortic injury and blunt myocardial injury.[12]

Epidemiology

Injury is the number one cause of death for people aged 1 to 44. In the United States, there were 199,756 trauma deaths in 2014, about two-thirds being accidental. Of intentional injury deaths, more than 70% were due to self-harm. In addition to deaths, injury results in about 41 million emergency department visits and 2.3 million hospital admissions annually.[12] Estimates of thoracic trauma frequency indicate that injuries occur in 12 persons per 1 million population per day. Approximately 33% of these injuries necessitate hospital admission. Blunt chest wall trauma accounts for over 10% of all trauma patients presenting to emergency departments worldwide.[13] Overall, blunt thoracic injuries are directly responsible for 20–25% of all deaths, and chest trauma is a major contributor in another 50% of deaths.[14]

Pathogenesis/Pathophysiology

Rather than list the various types of injury to organs and describe the pathophysiologic consequences, a discussion of three common problems arising from chest wall trauma is addressed in this section.[15] These problems are hypoxemia, hypotension, and inflammation.

Chest trauma can compromise breathing by directly damaging the lungs or airways or by altering the mechanics of ventilation. Direct injury to the lungs or airways includes pulmonary contusion and tracheobronchial disruption. Injuries that alter the mechanics of ventilation include flail chest, hemothorax, and pneumothorax. The pain associated with these injuries can cause ventilatory compromise as well. Hypoventilation occurs and, if severe enough, causes hypoxemia. Areas of atelectasis may occur because of hypoventilation. The atelectatic areas form areas of ventilation–perfusion mismatch and contribute to further worsening.[15]

Damage to the lung parenchyma, tracheobronchial tree, or esophagus may allow air to enter the soft tissues of the chest, neck, and mediastinum, causing subcutaneous emphysema. Subcutaneous emphysema is not a particularly harmful issue. However, the underlying injury is the problem.[16] Pulmonary contusion usually occurs because of blunt chest trauma, although it may also occur with high-velocity penetrating chest injury. Pulmonary contusion is characterized by hemorrhage into alveolar spaces and variable disruption of alveolar-capillary membranes.[15] The degree of hypoxemia initially caused by the pulmonary contusion depends on the size of the contusion.

Blunt chest trauma can cause air, or blood, or both to enter the pleural space (pneumothorax, hemothorax, **hemopneumothorax**), interfering with oxygenation and ventilation by compressing lung parenchyma. The occurrence of a pneumothorax during trauma is called a traumatic pneumothorax. The thorax may be injured in such a way as to create a one-way valve. This allows air to enter the pleural space each time an inhalation is attempted. Eventually end-expiratory pleural pressure exceeds atmospheric pressure and the lung becomes compressed.[15] The tension pneumothorax is of special concern because as air leaks out of the lung parenchyma into the pleural space, it will eventually compress the underlying lung and shift the mediastinal contents toward the opposite side (**Figure 5-6**). Progressive



FIGURE 5-6 (**A**) A drawing of a pneumothorax. (**B**) A chest radiograph showing a right-sided pneumothorax. As the air collects in the pleural space, the lung on the affected side collapses because the pressure in the pleural space is greater than within the lungs. If left untreated, the pneumothorax will begin to push the trachea to the opposite side.

(**B**) © meenon/iStock/Getty Images.

ventilation–perfusion mismatching occurs, and hypoxemia worsens.[15] Distortion of the superior vena cava by this mediastinal shift can result in decreased blood return to the heart, circulatory compromise, and shock.[17] Heart failure and conduction abnormalities can result from blunt cardiac injury that damages the myocardium or the heart valves.[16]

An open pneumothorax (sucking chest wound) occurs when an object penetrates the chest wall, leaving a hole. It involves air in the pleural space, but it differs from other pneumothoraces due to the unsealed opening and communication with the atmosphere. When a patient with an open pneumothorax inhales, air is entrained into the chest cavity through the opening in the chest. The larger the opening, the more the air brought in this way. Once the size of the hole is more than 0.75 times the size of the trachea, air preferentially enters through the thoracic cavity instead of the trachea due to the lower resistance of the hole. Movement of air in and out of the open pneumothorax, during inspiration and expiration, can cause mediastinal shifting with each breath. This causes inadequate oxygenation and ventilation, and a progressive buildup of air in the pleural space.[12]

Flail chest, the existence of two or more ribs broken in two or more places, indicates the application of a significant amount of force resulting in rib fractures and damage to the underlying structures. This results in a free segment of the chest wall that can move independently of the remainder of the chest during ventilation.[18] A flail produces both mechanical and physiologic abnormalities. The severity of the pain from the flail and muscle spasms causes splinting by the patient.[18] **Paradoxical chest movement** is a sign of patient exhaustion. Flail chest and pulmonary contusion are inherently linked as a complex injury in patients suffering from blunt chest trauma.[18] Other mechanical effects from the flail are typically due to the underlying hemo- or pneumothorax that frequently accompany the flail (**Figure 5-7**).

One of the hallmarks of the chest trauma patient is hemorrhage, because the thoracic cage contains many structures filled with blood, some under high pressure. Many times, the source of bleeding is not immediately apparent. The easiest patient to evaluate is one who arrives lying in a pool of blood and is hypotensive.[18] Internal bleeding into the pleural space or pericardial space can occur, causing hypotension and hypoxemia. When air accompanies blood in the pleural space, there may be a hemopneumothorax, which can also cause progressive atelectasis and ventilation–perfusion mismatching. The pericardium surrounding the heart serves a similar function as the pleura surrounding the lungs. The pericardial space is also a potential space, which can fill with blood from adjacent structures following either penetration or blunt chest trauma. When pericardial pressure exceeds the pressure in the right atrium and ventricle (lower pressure system), venous flow decreases, stroke volume is depressed, and cardiac output drops. Cardiac tamponade, a life-threatening emergency, requires immediate attention.

Blunt chest trauma can cause myocardial contusion and laceration. Due to its anterior position, the right ventricle is the most commonly contused region of the myocardium.[18] Fractured bones, including the sternum and/or ribs, can cause a contusion or laceration. Posterior myocardial contusions can occur with crushing chest injuries.[19] Other



FIGURE 5-7 (**A**) Drawing of a left-sided flail segment. (**B**) Chest radiograph showing a large left-sided flail segment with small hemothorax and apical pneumothorax. The flail segment moves in the opposite direction of the remainder of the chest, paradoxical chest movement, causing air to be shunted back and forth from one lung to the other, pendelluft. The lung under the flail segment is compressed and atelectasis occurs, causing intrapulmonary shunting.

injuries to the heart include chamber rupture or great-vessel injury (such as thoracic aortic disruption). An aortic disruption frequently results in death prior to hospital arrival from exsanguination or loss of cardiac pump function.[17]

Penetrating chest trauma to the heart can cause cardiac tamponade physiology or hemorrhagic shock, depending on whether blood can escape the pericardial space. As little as 50 mL of blood in the pericardial sac can cause tamponade.[20] The right ventricle is the most commonly injured chamber in penetrating trauma due to its anterior position within the chest cavity.[20] A penetrating cardiac injury or great-vessel injury leads to massive hemorrhage, causing a traumatic arrest. These types of patients typically expire in the field.

Hypovolemia can lead to a hypovolemic traumatic cardiac arrest, which is known to have a poor outcome. The initial cardiac rhythm for most patients in survivable traumatic cardiac arrest is pulseless electrical activity (PEA). Traumatic cardiac arrest PEA is often a very low cardiac output state, rather than a true cardiac arrest as understood for medical patients with a ventricular fibrillation (VF) arrest (when there is no output at all).[21] Understanding the difference between a medical cardiac arrest and traumatic cardiac arrest is important because the treatment rationale is different.

At the molecular level, after blunt chest trauma a local inflammatory response occurs. Severe injury or multiple trauma evokes a systemic inflammatory response, excessive immune reaction, subsequent priming of neutrophils in the circulation, and mobilization of new young neutrophils from bone marrow.[22] Surgical intervention can worsen the inflammatory response, thereby increasing the risk of posttraumatic inflammatory complications and posttraumatic organ failure.[22] Persistent elevation of pro-inflammatory cytokines in the lungs with subsequent suppression of the immune system is associated with an enhanced risk for acute lung injury progression and is known to increase mortality.[23] This process can go on to cause acute respiratory distress syndrome (ARDS) and multiorgan failure.[24]

The many types of injuries that can occur with chest trauma are listed in **Table 5-2**.

TABLE 5-2
Some Possible Chest Trauma Injuries[2,7,9,15,21,25]

Blunt Chest Trauma	Penetrating Chest Trauma
Aortic and cardiac injury	Diaphragmatic rupture
Blunt cardiac injury	Hemothorax
Blunt esophageal rupture	Hemopneumothorax—open
Cardiac contusion	Pneumomediastinum
Costochondral fractures	Pneumothorax—open, tension
Flail chest	Rib fractures
Fractures—ribs, sternum, clavicular, and scapular	Sternal fracture
Hematomas of the lung	Traumatic cardiac arrest
Hemopneumothorax	Thoracic wall lacerations
Hemothorax	
Lung contusion	
Pneumothorax—simple, tension	
Pulmonary contusion	
Traumatic cardiac arrest	
Traumatic diaphragmatic injury	

Risk Factors

Risk factors for mortality in patients sustaining blunt chest wall trauma are age 65 years or above, three or more ribs fractures, and the presence of preexisting disease, especially cardiopulmonary disease.[26]

Risk factors for motor vehicle accidents revolve around inexperience, distractions while driving, having teenage passengers, excessive speeds, following too close, drinking and driving, drugs and driving, driving at night, and being male.[27]

Complications

Although there are a wide range of complications following chest trauma, respiratory failure, pneumonia, and pleural sepsis are the most common potentially preventable complications. Respiratory failure and pneumonia are directly related to the severity of the injury and the age and condition of the patient.[28] Pleural sepsis can develop when there is a retained hemothorax, which becomes contaminated with bacteria. The most common source for this contamination is from the placement of the chest tube (tube thoracostomy).[28,29]

Pulmonary contusion occurs quite often with chest trauma. It is sometimes considered a direct injury from chest trauma and other times as a complication of chest trauma.[15,30,31] However it is considered, it contributes to the development of ARDS by way of diffuse systemic inflammatory mediators. This inflammatory network leads to alveolar and interstitial edema, reduced alveolar fluid clearance, impaired surfactant production and function, and lung fibrosis, which finally results in respiratory failure.[32] The release of inflammatory mediators from the damaged lung tissue triggers systemic inflammation and promotes multiple organ failure, which represents a major cause of late deaths after severe trauma.[33,34] ARDS may also be a complication of pneumonia. Other complications of chest trauma include decubitus ulcers, deep vein thrombosis, and other systemic sepsis.[35]

Diagnostic Testing

Patients with chest wall trauma are at significant risk for intrathoracic or intraabdominal injury. This risk is based on the mechanism of injury or the initial clinical assessment and may warrant further diagnostic imaging unless they require immediate surgery. Depending on the clinical scenario, initial imaging typically includes an extended focused assessment with sonography for trauma (**eFAST**). The FAST exam, per the ATLS protocol, is performed immediately after the primary survey of the ATLS protocol.[36] Ultrasonography has recently emerged as an essential point-of-care device in the trauma bay.[37] Ultrasound is the ideal initial imaging modality because it can be performed simultaneously with other resuscitative cares, providing vital information without the time delay caused by radiographs or computed tomography (CT). The concept behind the FAST exam is that many life-threatening injuries cause bleeding. Although ultrasound is not 100% sensitive for identifying all bleeding, it is nearly perfect for recognizing intraperitoneal bleeding in hypotensive patients who need an emergent laparotomy and for diagnosing cardiac injuries from penetrating trauma.[38] eFAST is an extension of the practitioner's hand and allows for the assessment of the pleura, brain, heart, and stomach. It facilitates vascular access and other invasive procedures. However, eFAST does not replace radiography in the initial management of trauma.[36]

Advancements in CT have changed the management of trauma patients and permitted the detection of blood in bronchi and interstitial air or blood with greater accuracy.[39] However, studies have shown that the use of WBCT does not reduce in-hospital mortality compared with the standard radiological work-up, and WBCT increases the amount of radiation the patient is exposed to.[40,41] Additionally, hemodynamically unstable trauma patients are difficult to scan due to the resuscitation equipment required and the increased risk for transport to the scanning room.[39]

The NEXUS CT Chest Decision Instrument identifies blunt trauma patients with clinically significant thoracic injuries. The instrument can be used to determine whether a blunt trauma patient requires a CT chest scan to be done or whether it may be avoided.[42] This decision-making tool is available at https://www.mdcalc.com/nexus-chest-ct-decision-instrument-ct-imaging.

Every patient with chest trauma has a chest radiograph. The chest radiograph is systematically reviewed for evidence of hemothorax, pneumothorax, pulmonary contusions, fractures, and cardiac and aortic injury (**Figures 5-8** through **5-12**). The chest radiograph is the most common diagnostic tool in the detection of pulmonary contusion, but the presence of hemothorax or pneumothorax might complicate the diagnosis.[43] Typically, the identification of pulmonary contusion is not possible for the first 6 hours after injury.[44] CT chest scan



FIGURE 5-8 A chest radiograph of cardiac tamponade. This patient requires immediate treatment with a pericardiocentesis, which can be done at the bedside in a life-threatening situation.
© Santibhavank P/Shutterstock.



FIGURE 5-9 A chest x-ray of a blunt chest wall injury.
© Sopone Nawoot/iStock/Getty Images.



FIGURE 5-10 Fracture of the left clavicle. Clavicle fractures are commonly associated with blunt chest trauma.
© stockdevil/iStock/GettyImages.



FIGURE 5-11 Right-side tension pneumothorax with chest tube in place.



FIGURE 5-12 Chest radiograph of a trauma patient with a fracture of the eighth rib, pulmonary contusion, and right hemothorax.

is the most accurate diagnostic tool for pulmonary contusion and can detect the lesion right after the injury.[45] However, ultrasonography has been found to have better screening performance characteristics when compared to radiography in the detection of pulmonary contusion.[43]

The presence of blunt aortic injury is not easily found. However, there are certain findings on chest radiography that increase the likelihood of blunt aortic injury. See **Box 5-5**. If chest radiography shows any of the possible findings, a CT of the chest is warranted.

Other imaging tests that may be used to scan for injuries include aortography, transesophageal echocardiography (TEE), magnetic resonance imaging (MRI), and nuclear medicine study.[39] These imaging techniques have no role in the initial treatment of a critically ill and hemodynamically unstable patient.

Laboratory and other tests that are helpful in the assessment of chest trauma patients include complete blood count (CBC), arterial blood gas (ABG), cardiac markers, and electrocardiogram (ECG). The CBC serves as a baseline for the detection of ongoing hemorrhage. ABG results monitor patients for hypoxemia and hypoventilation. Cardiac markers (e.g., troponin and CPK-MB) can help exclude cardiac injury. Cardiac injury may cause arrhythmias, conduction abnormalities, ST segment abnormalities, or a combination of these.[16] These can be identified via ECG.

BOX 5-5 Chest Radiography Findings That Indicate the Likelihood of Blunt Aortic Injury[2]

- Wide mediastinum
- Obscured aortic knob; abnormal aortic contour
- Left "apical cap" (e.g., pleural blood above the apex of left lung)
- Large left hemothorax
- Deviation of nasogastric tube rightward
- Deviation of trachea rightward and/or right mainstem bronchus downward
- Wide left paravertebral stripe

Reproduced with permission from Legome E. Initial evaluation and management of blunt thoracic trauma in adults. Post TW, ed. *UpToDate*. Waltham, MA: UpToDate Inc. http://www.uptodate.com (Accessed on September 19, 2018).

Treatment and Management

The primary survey of patients with chest trauma begins with the airway, followed by breathing, and then circulation. Major problems should be corrected as soon as they are identified. Apart from patients with very superficial lacerations, superficial contusions, and solitary rib fractures, most patients warrant admission for observation.[9] Treatment of the chest trauma patient depends on the nature of the injury.

Important, yet often subtle, signs of chest injury or hypoxia include an increased respiratory rate and change in the breathing pattern, which is often manifested by progressively shallower respirations. Cyanosis is a late sign of hypoxia. However, the absence of cyanosis does not necessarily indicate adequate tissue oxygenation or an adequate airway. The major thoracic injuries that affect breathing and must be recognized and addressed during the primary survey include tension pneumothorax, open pneumothorax (sucking chest wound), flail chest and pulmonary contusion, and massive hemothorax.[6]

The presence of a tension pneumothorax is an emergency, and treatment should not be delayed waiting for radiologic confirmation.[6] A tension pneumothorax requires immediate decompression and can be managed initially by rapidly inserting a large-bore needle into the second intercostal space in the midclavicular line on the affected side. Definitive treatment requires the insertion of a chest tube into the fourth or fifth intercostal space, along the anterior axillary line (**Figure 5-13**). A simple pneumothorax is also treated with chest tube placement.



FIGURE 5-13 Left-sided chest tube placed into the fifth intercostal space along the anterior axillary line.

Initial management of an open pneumothorax may be accomplished by placing a sterile occlusive dressing over the wound and taping it securely on three sides.[6] This provides a flutter-like valve, so the air can escape, but cannot enter the pleural cavity through the wound. The definitive treatment is the placement of a chest tube.

A flail chest is initially managed by insuring adequate ventilation and oxygenation and providing fluid resuscitation. Analgesics must be given for pain control and must be provided judiciously as not to cause respiratory depression. Local anesthetics may be administered via intermittent intercostal nerve block(s) and intrapleural, extrapleural, or epidural anesthesia.[6] Prevention of hypoxemia is vital in the management of trauma patients, and a short period of intubation and mechanical ventilation may be necessary until the full patient assessment is complete.

Treatment for a hemothorax is drainage with a chest tube. Evacuation of more than 1,500 mL of blood immediately after the chest tube is placed is considered a massive hemothorax.[6] A massive hemothorax also requires restoration of blood volume through large-caliber intravenous lines and rapid crystalloid infusion. The blood from the chest tube can be collected in a device suitable for autotransfusion.[6] A simple hemothorax (<1,500 mL) must also be evacuated with chest tube placement. If not fully evacuated, the blood retained in the pleural space can clot or develop into an **empyema**.[6]

Cardiac tamponade may develop slowly, allowing for a less urgent evaluation, or may occur rapidly, requiring rapid diagnosis and treatment. The diagnosis of cardiac tamponade can be difficult in the setting of a busy trauma or emergency room because the initial assessment for it relies on the presence of **Beck triad** (elevation of venous pressure, decline in arterial pressure, and muffled heart tones).[6] Also, other problems can mimic cardiac tamponade. The blood in the pericardial sac requires evacuation. This can be done with percutaneous pericardiocentesis, surgically, or with a video-assisted thoracoscopic (VAT) procedure. The method used depends on the patient's hemodynamic stability[44] (**Figure 5-14**).

Pulmonary contusion occurs in 25–35% of all blunt chest traumas.[46] Most pulmonary contusions resolve spontaneously within 14 days, provided no secondary insult occurs.[30] Most pulmonary contusions require no specific therapy. The management focuses on supportive care while waiting for the contusion to heal.[47] Most importantly, it focuses on the prevention of respiratory failure and maintenance of adequate oxygenation. However, large contusions may affect gas exchange and cause hypoxemia. If this occurs, tracheal intubation and mechanical ventilation are necessary. Once the pulmonary contusion heals, mechanical ventilation may not be necessary unless ARDS develops. At that time, ventilator strategies to protect the lungs from over-inflation are needed (lung protection strategy). Some additional strategies include independent lung ventilation,[48] extracorporeal membrane oxygenation (ECMO),[46] and prone positioning.[49]

Prognosis

The outcomes of patients with penetrating chest trauma directly depend on the extent of the patient injuries and the timeliness of initiation of treatments. Blunt thoracic trauma is a common form of injury and a frequent cause of mortality and morbidity in severely injured patients.[50] In the United States and Europe, the mortality rate in patients with blunt chest trauma can be as high as 60%.[51]

Chest Wall Deformities

The thorax is a critical component of the respiratory pump. Normal breathing is done by the respiratory muscles by synchronously expanding the rib cage with piston-like movements of the diaphragm. Anything that limits the mobility of the ribs impedes the movement of air into the lungs.[52] Therefore, disorders that change the structure of the chest wall affect the ability of the pump to function, resulting in respiratory compromise or failure.[51] Any anatomical or functional abnormalities of the bony thorax increases dead space ventilation and the work of breathing, whether congenital or acquired, acute or chromic, and whether its cause is infectious, traumatic, environmental, iatrogenic, or unknown.[52]

Definition/Diagnosis

Chest wall deformities are caused by anomalous skeletal development and/or formation of the thoracic cavity.[53] These anomalous deformities develop while in utero. The most common of these are **pectus excavatum** (PE) and **pectus carinatum** (PC). PE or funnel chest is



FIGURE 5-14 Access site selection for percutaneous pericardiocentesis is based on the detection of the shortest distance to the largest fluid pocket within the pericardial space detected by echocardiography. This site selection can be achieved after careful bedside scanning from multiple directions. Needle and catheter insertions are performed while avoiding the intercostal and internal mammary artery structures. (**A**) The anterior view of the rib cage with the internal mammary arteries and intercostal arteries in red and pericardial fluid in yellow. The small green squares mark the location of the safe access sites. (**B**) A sample of short-axis echocardiographic views to help select the shortest distance to the largest fluid pocket. (**C**) A close-up view of the needle and catheter insertion site. Insertion must avoid the intercostal and internal mammary arteries.

El Haddad D, Iliescu C, Yusuf S, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. *J Am Coll Cardiol.* 2015;66(10):1119–1128 (Figure 2). doi:10.1016/j.jacc.2015.06.1332.

characterized by variable depression of the sternum and lower costal cartilage.[53] PC or pigeon chest is characterized by the protrusion of the sternum and adjacent costal cartilages.[53]

Spinal deformities can also alter the structure of the chest cavity. These deformities include **scoliosis**, **kyphosis**, and **kyphoscoliosis**. Scoliosis is a lateral curvature of the spine. Kyphosis, "dowager's hump," is an anteroposterior curvature of the thoracic spine. Scoliosis is complicated by an abnormal kyphosis, whereas kyphosis can be present without scoliosis when acquired in adulthood due to vertebral compression, infection, tumor, or injury.

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that can affect the axial skeleton. This inflammatory process can cause fusion of spinal vertebrae, which limits the mobility of the thoracic cage and causes a restrictive-type pulmonary impairment.

Obesity is a chronic disease characterized by excessive accumulation of body fat that is harmful to individuals. In obese individuals, structural changes in the thoracic-abdominal region lead to limited diaphragm mobility and rib movement, both essential for appropriate ventilatory mechanics.[54] Excess body fat is classified in categories according to severity or by the distribution of the fat, either gynoid (pear shaped) or android (apple shaped).[54] Because obesity affects the function of the ventilatory pump, it is included in this chapter.

Clinical Signs and Symptoms

Disorders of the chest wall and spine include an array of conditions that share pulmonary function abnormalities consistent with restrictive lung disease. The hallmark of any chest wall deformity is the appearance of the thorax. The more severe the deformity, the more likely the patient will have dyspnea with exertion and symptoms of nocturnal hypoventilation.[55]

Patients with abnormalities in ventilatory pump function typically have limited exercise capacity, reduced respiratory system compliance, and an increased work of breathing. Patients may exhibit significant alterations in their breathing patterns. Typically, individuals with significant thoracic abnormalities and those with abdominal distention take on a rapid shallow breathing pattern consisting of low tidal volumes, shortened inspiratory time, and increased respiratory rate.[55] See **Box 5-6**. Dyspnea appears to be an early manifestation of ventilatory pump abnormalities.

BOX 5-6 Common Respiratory Signs in Patients with Ventilatory Pump Abnormalities[52,55,56]

- Abdominal paradox
- Accessory muscle use
- Dyspnea on exertion
- Exercise intolerance
- Fatigue
- Hypopnea
- Nocturnal hypoventilation
- Orthopnea
- Tachypnea



FIGURE 5-15 The paradoxical inward movement of the abdominal wall during inhalation is due to the upward movement of the fatiguing diaphragm in response to negative intrathoracic pressure generated by the inspiratory action of the accessory muscles.

Adapted from Medicine Specifies, 2018. http://medicinespecifics.com/paradoxical-breathing-abdominal-paradox-mechanism/.

Inspection and palpation demonstrate accessory respiratory muscle use. Intense respiratory efforts are associated with visible activation of the neck accessory muscles, interosseous intercostals, and abdominal expiratory muscles.[56] Patients with AS typically complain of chest pain that is accentuated by inspiration.[52]

Breathlessness in the supine position is characteristic of isolated diaphragm dysfunction or increased hydrostatic pressure imposed by the abdominal viscera (obesity).[56] Normally, in the supine position, the anterior abdominal wall moves prominently outward during inspiration. With impaired diaphragm function, the abdominal wall may move inward on inspiration. This is called abdominal paradox (**Figure 5-15**). **Abdominal paradox** reflects cephalad movement of the contracting diaphragm in response to the negative intrathoracic pressure generated by the inspiratory action of the neck and intercostal muscles. Abdominal paradox may also be present in patients with marked derangements in lung mechanics, in whom inspiratory intrathoracic pressure swings exceed 30% of maximum.[56]

The severity of obesity is commonly assessed by calculating the body mass index (BMI), defined as body weight (BW) in kilograms divided by the square of height in meters (BW/Ht^2). An individual with a BMI between 18.5 and 24.9 kg/m^2 is normal, a BMI between 25 and 29.9 kg/m^2 is overweight, and a BMI greater than 30 kg/m^2 is obese; BMI greater than 40 kg/m^2 is morbidly obese.[55]

Etiology

Scoliosis is most frequently idiopathic. However, it can be caused by neuromuscular diseases, such as cerebral palsy, poliomyelitis, Duchenne muscular dystrophy, vertebral diseases, Marfan syndrome, or thoracic cage abnormalities. The severity of scoliosis is quantified by Cobb's method of measuring the angle, **Cobb angle**, between the upper and lower portions of the spinal curve.[57]

Kyphosis can be caused by any process that affects the supporting structures of the spine. Deformities that result in anterior wedge-shaped vertebra will accentuate the angle of kyphosis. As with other age-related conditions, kyphosis occurs because of multiple contributing factors. These factors include vertebral fractures, low bone density, short vertebral height, degenerative disc disease, postural changes, and loss of elasticity of the intervertebral ligaments.[58] If kyphosis occurs early in life, it is often related to inherited genetic conditions including Marfan syndrome, cystic fibrosis, and osteogenesis imperfecta. Other causes include spinal tuberculosis, spondylolisthesis, and other complications from spinal surgical procedures. Kyphosis tends to progress with age.[58]

Kyphoscoliosis acquired in adulthood is usually a complication of neuromuscular disease or injury, including thoracoplasty. Otherwise, most are idiopathic in etiology. Kyphoscoliosis is believed to be a multigene condition, with autosomal or sex-linked inheritance with variable phenotypic expression.[55]

PE is a congenital chest wall deformity with a family history present in 15–40% of the cases.[55] It is believed to result from an abnormal growth of cartilage around the sternum due to a defect in collagen formation.[59] The sternal depression may be minimal or prominent. In extreme cases, it is usually apparent at birth and progresses as the child grows.[55] PC is less common than PE and can be associated with congenital heart disease, severe childhood asthma, and rickets. This chest wall deformity has less physiological consequence than PE.[57] As with PE, there is a genetic

component in PC and an association of this anatomic variant with numerous conditions such as Marfan disease, Noonan syndrome, prune belly, Morquio syndrome, osteogenesis imperfecta, mitral valve prolapse, and homocystinuria.[60]

The etiology of AS is unknown, but a combination of genetic and environmental factors works in concert to produce this disease. There is a strong association with genetic predisposition. The heritability of AS is estimated to be greater than 95%.[61] However, not everyone with the genes develop the disease. Nongenetic factors, such as microbial infection, play a role in its development.[61]

Almost all obesity in children is strongly influenced by environmental factors, caused by either a sedentary lifestyle or a caloric intake that is greater than needs. There is strong evidence that genetic factors play a permissive role and interact with environmental factors to produce obesity.[62] People can become overweight at any age. However, there are certain times when weight gain tends to occur, which vary between men and women. There is increasing evidence that environmental and nutritional influences during critical periods in development can have permanent effects on an individual's predisposition to obesity and metabolic disease.[63] The increasing prevalence in adults, adolescents, and children has made it a global epidemic.[63]

Epidemiology

Adolescent idiopathic scoliosis (AIS) is called "late-onset" idiopathic scoliosis. AIS accounts for 80–85% of cases of idiopathic scoliosis.[64] The prevalence of AIS with a Cobb angle greater than 10 degrees (minimum to define scoliosis) is approximately 3%. Males and females are affected equally. However, the curve progression (and therefore the need for treatment) is 10 times higher in females than in males.[64]

Because there is no widely accepted definition of kyphosis, the prevalence is unknown. Some estimates range between 20% and 40% in individuals 60 years or older. The prevalence increases with age, with the greatest change in the angle of kyphosis occurring among women age 50–59 years.[58] In the United States, kyphoscoliosis affects approximately 2% of the population. This 2% is mostly young children who are going through a growing spurt. Kyphoscoliosis rarely develops in adults—unless it is a worsening condition that started in childhood and was not diagnosed or treated.

PE occurs in an estimated 1 in 300–400 births, with male predominance (male-to-female ratio of 3:1). It comprises approximately 90% of all chest wall deformities.[65] PC is much less common. The incidence for PC is 1:1,500 live births[60] with an estimated overall prevalence of 0.06%.[66] Internationally the percentage of chest wall deformities by PC are greater in reports from Brazil and Argentina.[66]

The prevalence of AS is estimated between 0.1% and 1.4% with higher occurrence in men 6.0:1.[61,67] AS is an underrecognized form of chronic arthritis. The disease predominantly strikes men between the ages of 20 and 40 years, in their peak productive years, leading to significant loss of work productivity and decreased quality of life.[61]

Obesity affects about 93.3 million adults in the United States, with a prevalence of 39.8%. Broken down by age, the prevalence among young adults (20–39 years) is 37%, 42.8% among middle-aged adults (40–59 years), and 41% among older adults (60 and over).[68]

Pathogenesis/Pathophysiology

Each disease has its own pathogenesis. However, the commonality here is that each of the diseases discussed can lead to respiratory insufficiency. This insufficiency is due to failure of the ventilatory pump. Any deformity of the chest wall can create an abnormal anatomical arrangement (**Figure 5-16**). The thoracic cage is mostly covered by muscles that do not belong to the thorax, but to the shoulder, neck, back, or abdominal wall.[69] Chest wall deformities not only limit rib mobility, but also cause some of the muscles to be overstretched and others to relax, reducing the patient's ability to inflate the lungs. The changes in the length and orientation of these muscles cause ineffective coupling between the respiratory muscles and the thoracic cage, leading to weakness of the diaphragm.[56,70] In childhood, these chest wall deformities rarely cause physical discomfort because of the elasticity of the thorax. However, as the individual grows, more physical interferences occur. As stiffness of the bony elements of the chest wall increases, the diaphragm becomes overworked. The direct consequences are fatigability and reduced oxygenation of the body.[71]

Obesity imposes a stress on the respiratory system both by altering lung mechanics and by the work of breathing. The mass loads applied to the thorax and abdomen by excess fatty tissue decrease chest wall compliance, causing an increase in the elastic and resistive work of breathing. Additionally, the excessive body mass results in increased carbon dioxide production and oxygen consumption. Increases in metabolism may be two to three times normal in morbidly obese individuals.[56] Compliance of the lungs is decreased more than chest wall compliance in morbid obesity due to pulmonary vascular engorgement and a decrease in operating lung volume. Chest wall compliance is decreased due to adiposity of the chest wall and within the abdomen.[57]

Individuals with chest wall deformities, including obesity, breathe against increased elastic resistance (elastance) caused by their increased elastic load. These individuals tend to breathe with smaller tidal volumes and reduced inspiratory and expiratory times, demonstrating a rapid and shallow pattern of breathing. This



FIGURE 5-16 Cross-sectional views of various chest wall deformities.

is the body's attempt to diminish the elastic work of breathing.[56] Those with AS can also have interstitial lung involvement causing decreased lung compliance.[52] Continuous breathing against an increase elastic load due to the decrease in chest wall compliance results in hypoventilation. Eventually, muscle fatigue, alveolar hypoventilation, hypoxemia, and sleep-disordered breathing may occur. Sleep-related changes in chemosensitivity underlie the recurrent patterns of apnea, hyperpnea, and exaggerated hypercapnia that occur in some patients with chest wall diseases.[56]

With limited ability to expand the lungs, the consequence is typically abnormally low total lung capacity (TLC) and inspiratory capacity (IC) depicting a restrictive defect. Functional residual capacity (FRC) and residual volume (RV) may not be reduced, at least to the same degree as TLC and IC. The RV–TLC ratio is often abnormally high[52] (**Figure 5-17**). Unique among the disorders of the thoracic cage, about half of patients with AS have an elevated FRC,[57] as seen in Figure 5-16.

Exercise or stress increases minute ventilation in individuals with chest wall deformities, with further rapid shallow breathing rather than increase in tidal volume. The work of breathing increases more, for these individuals, due to dead space ventilation. The more severe the deformity, the less the exercise tolerated due to oxyhemoglobin desaturation.[72] Some individuals with milder forms of chest wall deformities may have exercise intolerance due to deconditioning or cardiovascular disease;[52] others may also have obstructive lung disorders.

Risk Factors

Risk factors for the development of chest wall abnormalities are varied. Some are due to genetics and others are the result of other disease processes. Disease processes responsible for the development of chest wall deformities include osteoporosis, degenerative disk disease, arthritis, connective tissue disorders such as Marfan syndrome, muscular dystrophy, polio, spina bifida, spinal tumors, spinal tuberculosis, Paget disease, and neurofibromatosis. Other risk factors for the development of these chest wall abnormalities include trauma; thoracoplasty; poor posture, especially in teenagers (kyphosis); genetics; or congenital anomaly.

Complications

The most important complications from chest wall deformities are physiologic and typically do not develop unless the chest deformity is severe or the individual is elderly. Chest wall compliance decreases with age, further increasing the work of breathing and risk of respiratory muscle fatigue in older adults.[1]

Atelectasis and excessive airway secretions are the main issues that develop as chest abnormalities worsen. These lead to chronic hypercapnic respiratory failure and chronic hypoxemic respiratory failure. Pulmonary hypertension and cor pulmonale may also develop in these individuals.[52,57] The inability to take deep breaths and cough reduce the individual's ability to clear secretions. Upper respiratory infections can prove to be challenging for these patients and often lead to pneumonia and acute-on-chronic respiratory failure. See **Box 5-7**.

Morbid obesity can lead to obesity hypoventilation syndrome. Severe chest wall deformities can also cause progressive sleep apnea and sleep fragmentation. Kyphoscoliosis is associated with nocturnal hypoventilation and obstructive sleep apnea. Although daytime respiratory symptoms are more common



FIGURE 5-17 TLC and its subdivisions in normal persons and in patients with kyphoscoliosis and AS.
Reproduced from Donath J, Miller A. Restrictive Chest Wall Disorders. *Semin Respir Crit Care Med.* 2009;30(03):275–292. doi:10.1055/s-0029-1222441.

BOX 5-7 Manifestations Associated with Acute-on-Chronic Respiratory Failure in Patients with Chest Wall Disorders[55,56]

- Tachypnea, more than baseline
- Tachycardia
- Cyanosis
- Digital clubbing
- Pitting edema
- Jugular vein distension
- Loose, nonproductive cough
- Dull percussion notes
- Bronchial breath sounds over lung fields
- Whispered pectoriloquy
- Adventitious breath sounds
- Abdominal paradox
- Accessory muscle use (more than normal)

when the angle of the thoracic spinal deformity approaches 100 degrees, nocturnal oxygen desaturation is not directly correlated with the degree of scoliosis or with either lung volumes or ventilatory responsiveness.[73] Individuals with daytime hypoxemia and hypercarbia often have further deterioration of gas exchange during sleep. Therefore, individuals with even mild abnormalities in daytime blood gases are at risk for significant disruption of nocturnal gas exchange.[52,73] The more severe nocturnal oxygen desaturation is seen and should be suspected in individuals with cor pulmonale, polycythemia, and daytime systemic hypertension.[73] Advanced chest wall deformities can also compress the heart.

Diagnostic Testing

Chest wall deformities can go unnoticed in their mildest forms. Unfortunately, when these deformities are severe enough to cause respiratory compromise, they are very noticeable when visually inspecting the patient. Conventional chest and anteroposterior spine radiographs can help identify and characterize many thoracic cage abnormalities (**Figure 5-18**). CT is useful for determining the severity of PE, PC, and scoliosis in selected patients[1] (**Figure 5-19**).

In the case of acute respiratory failure, ABG measurements are needed to determine the severity of the respiratory failure. These measurements typically show hypoxemia more than baseline and acute hypercapnia superimposed on chronic hypercapnia. These measurements determine the need for ventilatory assistance and supplemental oxygen.

For patients who can perform them, pulmonary function tests (PFTs) help to determine the degree of respiratory impairment caused by a chest wall abnormality and whether other respiratory diseases are contributing to the patient's symptoms. Complete PFTs for this type of patient include upright spirometry, lung volumes, diffusion capacity for carbon monoxide (DLCO), supine spirometry, maximal inspiratory pressure (MIP), and maximum expiratory pressure (MEP). The maximum inspiratory and expiratory pressures reflect respiratory muscle strength. Among patients with severe scoliosis or kyphoscoliosis, MIP is decreased, approximately 50% normal in eucapnic patients and 25% normal in hypercapnic patients, due to either intrinsic muscle weakness or mechanical disadvantage caused by the rib cage distortion.[1] Weakened



FIGURE 5-18 Chest deformities seen on chest radiography. (**A**) scoliosis, (**B**) kyphoscoliosis, (**C**) PE, (**D**) AS causing kyphosis.
(A) © real444/iStock/Getty Images; **(B)** © Puwadol Jaturawutthichai/Shutterstock; **(C)** Published with permission from LearningRadiology.com; **(D)** Published with permission from WikiFoundry.



FIGURE 5-19 A CT scan of a 14-year-old male with severe PE.

inspiratory muscles coupled with a stiff, poorly compliant respiratory system not only leads to profound decrements in vital capacity but also predisposes these individuals to respiratory failure.[55] Decreases in these patients' vital capacities to less than 40% of predicted is a sign that monitoring for hypercapnia is appropriate.[1]

Exercise testing is appropriate when the patient is not acutely ill. Exercise capacity may be reduced, but oxygen desaturation with exercise is uncommon, contrary to what is frequently observed in patients with interstitial lung disease. However, in some conditions (e.g., scoliosis, obesity), atelectasis may be present and associated with hypoxemia.[1] For those individuals with complaints relating to sleep, a sleep study is appropriate.

Treatment and Management

Treatment of the acute respiratory failure can be accomplished with supplemental oxygen and/or mechanical ventilation, suctioning of the airways, and airway clearance therapy. The seriousness of the acute respiratory failure determines the amount of supportive treatment. Nutritional, rehabilitational, and psychological care also provide important ancillary help.[52]

Once back to the patient's own baseline health, a determination of the need for long-term treatment and management may be assessed. The treatment depends on the severity of the chest wall deformity. Surgical considerations are appropriate for certain chest wall disorders.

The traditional approach to the treatment of chest wall deformities was complete or partial sternotomy. Currently, PE repair can be accomplished using a minimally invasive technique to safely position a convex metal bar from one side of the chest to the other side. This bar is then inverted 180 degrees, exerting upward pressure on the concave sternum. Bilateral thoracoscopy may be necessary if the pectus is severe.[74]

PC can be treated nonoperatively with a brace that provides anteroposterior compression results in progressive remodeling of the chest. The brace must be worn 14 hours per day for at least 2 years. Surgical correction is often reserved for those who fail conservative management or in nonadherent patients. The surgical treatment of PC is like that of PE.[53]

Like PC, the primary treatment for kyphosis is nonsurgical and consists of exercise, physical therapy, and pain medication. However, treatment options depend on the type of kyphosis. Some types of kyphosis, like Scheuermann kyphosis, may require surgery.

The treatment for kyphoscoliosis depends on the etiology, onset, and state of the disease. Brace therapy is sometimes used, and its goal is to prevent disease progression. However, it is inconvenient and has limited efficacy. Surgery may include the traditional Harrington rod insertion to prevent further progression of the curvature, spinal arthrodesis, vertebral fusion with metal hardware or bone implants, thoracoscopic scoliosis surgery, and/or thoracoplasty. The outcome of surgical correction is many times cosmetic in nature with little improvement in vital capacity.[52] For patients with chronic respiratory failure, nocturnal mechanical ventilation can reverse cor pulmonale, improve gas exchange and maximum inspiratory and expiratory pressures, and reduce hospital admissions.[57] However, both exercise limitation and dyspnea usually become persistent and impair health-related quality of life (HRQL). Pulmonary rehabilitation in patients with chronic respiratory failure due to kyphoscoliosis improves exercise capacity, muscle strength, dyspnea, and HRQL.[72,75]

No definite disease-modifying treatment exists for individuals with AS. Early diagnosis is important, and treatment measures include pharmacologic, surgical, and physical therapy. Disease progression can be monitored by following laboratory values, including the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level. Any surgical treatment is focused on the resolution of complications related to AS, such as correcting spinal deformities or repairing damaged peripheral joints.[76]

Dietary changes combined with exercise and behavioral modifications can lead to weight loss in some obese individuals. However, these modalities are usually not successful in maintaining long-term weight loss. Bariatric surgery is a common intervention that can produce not only weight loss but also long-term maintenance of weight loss. In patients with obesity hypoventilation syndrome and acute or chronic hypercapnic respiratory failure, nocturnal noninvasive ventilation may improve gas exchange, daytime somnolence, and HRQL.[55]

Prognosis

Depending on the cause, these disorders can manifest from birth to adolescence, with a very variable prognosis ranging from death during infancy (e.g., severe congenital chest wall deformity) to milder functional abnormality later in life (e.g., adolescent kyphoscoliosis).

Mild defects do not shorten life expectancy. Patients debilitated with severe advanced disease often die of respiratory failure at times of intercurrent acute illness. Life expectancy and quality depend mainly on disease severity, comorbidity, and timely therapy.[52]

KNOWLEDGE CHECK QUESTIONS

1. True or False: A pneumothorax can push the contents of the chest away from the affected side.
2. True or False: The primary survey for chest trauma consists of observation, inspection, palpation, percussion, and auscultation.
3. True or False: A large open pneumothorax will allow more air to flow through the opening in the chest than through the trachea.
4. True or False: A tension pneumothorax must be confirmed by chest radiograph prior to treatment.
5. True or False: Beck triad is a sign of a traumatic pneumothorax.
6. True or False: Chest wall deformities can decrease compliance by limiting chest expansion.
7. True or False: The most common chest wall deformity is scoliosis.
8. True or False: Chest wall deformities cause restrictive patterns on PFTs.

Disorders of the Pleura

The potential space between the **visceral pleura** and **parietal pleura** surfaces is separated by about 10 mL of glycoprotein-rich fluid, which serves as a lubricating film. While the protein is qualitatively like plasma, the albumin content is slightly higher and fibrinogen content is slightly lower than that of plasma.[77]

The lymphatic anatomy of the visceral pleura and parietal pleura is important in the homeostasis of pleural fluid volume in a normal individual. In disease, excess production or decreased absorption of lymph plays a significant role in the generation of effusions. Naturally occurring pores (stomata) in the caudal portions of the peripheral parietal pleura and lower mediastinal parietal pleura transfer particulate matter and cells directly into lymphatic channels for removal.[78] Fluid that abnormally accumulates within the pleural space is derived from the lung through the visceral pleura and absorbed almost entirely through the parietal pleura system (**Figure 5-20**). Protein content and increased cellular components in the accumulated pleural fluid are often useful in determining disease etiology.[79]

The normal pleura is a thin translucent membrane consisting of five layers: (1) the **mesothelium** composed of flattened mesothelial cells joined primarily by tight junctions; (2) a thin layer of submesothelial connective tissue; (3) a superficial elastic tissue layer, (4) a second loose subpleural connective tissue layer rich in arteries, veins, nerves, and lymphatics; and (5) a deep fibroelastic layer attached to underlying lung parenchyma, chest wall, diaphragm, or mediastinum.[80] Long slender microvilli present on the mesothelial surface facing toward the pleural space provide an increased surface area for the release of hyaluronic acid into the pleural fluid and do not appear to play any resorptive role.[80] Visceral pleura mesothelial cells have more microvilli than mesothelial cells of the parietal pleura at similar intrathoracic levels.

The **pleural space** plays a vital role in ventilation. In healthy individuals, the pleural space conjoins the natural outward movement of the chest wall to that of the natural inward movement of the lungs via two mechanisms. First, the potential space's relative vacuum sustains the visceral and parietal pleurae's extreme uninterrupted adherence. Second, the minute amount of pleural fluid serves as the lubricant to facilitate the normal physiologic sliding motion of both pleural surfaces against each other during inspiration and expiration. The small volume of fluid is maintained via a delicate balance of hydrostatic and oncotic pressure and peripheral sulcal lymphatic drainage.[81] Primary disease of the pleura is relatively uncommon compared to secondary involvement affecting the pleura, yet most disorders manifest by fostering fluid accumulation.

Fluid in the Pleural Space

A **pleural effusion**, an excessive accumulation of fluid in the pleural space, indicates an imbalance between pleural fluid formation and removal. Accumulation of pleural fluid is not a specific disease, but rather a reflection of underlying pathology. Pleural effusions accompany a wide variety of disorders of the lung, pleura, and systemic disorders.[79] Hemothorax results from blood in the pleural space typically caused by either a blunt or a penetrating chest injury. It is distinguished by a hematocrit of at least 50% that of the individual's blood.

Diagnosis/Definition

In the normal individual, resorption of pleural fluid maintains pace with pleural fluid formation, so fluid does not accumulate. An abnormal accumulation of



FIGURE 5-20 Schematic diagram of normal filtration and resorption of fluid in pleural space. The solid arrow shows the filtration of fluid from parietal pleural microvessels into the pleural space. The arrowhead indicates the removal of fluid through stomata and into parietal pleural lymphatics. Dashed arrows indicate a minor role for filtration and resorption of fluid by visceral pleural microvessels.

Adapted from Pistolesi M, Miniati M, Giuntini C. Pleural liquid and solute exchange. *Am Rev Respir Dis.* 1989;140:825–847.

fluid within the pleural space caused by an intrinsic abnormality of the pleura (associated with exudative effusion), an imbalance in oncotic or hydrostatic pressures (associated with a transudative effusion), or extravascular fluid such as cerebrospinal fluid, urine, bile, chyle, or blood enters the pleural space. Not only should chest disease be considered a cause of pleural effusion, but diseases of organs below the diaphragm (splenic infarction), systemic diseases (systemic lupus erythematosus), and diseases of the lymphatic system must be considered in the appropriate clinical setting. Effusions, therefore, represent a common manifestation of both intrathoracic and systemic diseases.

Changes in hydrostatic and oncotic forces in the chest favor the accumulation of ultrafiltrates of plasma within the pleural space.[82] This fluid is **transudative**. Transudative pleural effusions can also be caused by the movement of fluid from peritoneal spaces or by iatrogenic infusion from misplaced or migrated central venous catheters or nasogastric feeding tubes. **Exudative** pleural effusions primarily result from structural breakdown or increased vascular permeability.[82] This occurs in malignant effusions resulting from tumor invasion of the pleura, infection, and a multiplicity of inflammatory conditions that often require extensive evaluation and treatment. Increased pleural permeability may result from pleural or lung inflammation, impaired lymphatic drainage of the pleural space, or trans-diaphragmatic movement of inflammatory fluid crossing the peritoneal space. Recognition of manifestations of disorders in patients who present with pleural effusions may be helpful in narrowing the differential diagnosis of an exudative effusion.

In many patients with pneumonia, a sterile simple **parapneumonic effusion** develops in the pleural space. If this pleural effusion becomes infected, it is labeled a complicated parapneumonic effusion, whereas the presence of frank pus in the pleural space defines an empyema.[83] An empyema represents the end stage of a complicated parapneumonic effusion and essentially always requires chest tube drainage. Contamination of the pleura and pleural space can occur from disease arising in the ipsilateral lung from trauma and vascular dissemination. Direct pleural contact with other structures also directly affects contiguous susceptibility to infection. Every class of infectious organism (or contagion) can cause pleural infection as well as produces a fiber-filled exudate. Parietal pleura overlying the diaphragm and chest wall is relatively resistant to infection penetration, whereas the parietal pleura that overlies the mediastinum is easily penetrated by invading organisms.[84]

Clinical Signs and Symptoms

Individuals who develop pleural effusion may be asymptomatic with the chest radiograph comprising the only clue. Dyspnea and discomfort are the most common symptoms associated with pleural effusion and predominately attributed more to the distortion of the diaphragm and chest wall occurring during respiration rather than to hypoxemia.[81] These complaints generally begin abruptly and are more likely to be expressed in persons with a large effusion and normal lungs, and in individuals with small- to moderate-size effusion coupled with underlying lung disease.

While drainage of the pleural fluid often alleviates or partially relieves symptoms in many individuals, limited benefit may be seen in gas exchange. Underlying lung or heart disease, obstructing endobronchial lesions, or diaphragmatic paralysis can also cause or increase dyspnea, especially after coronary artery bypass surgery. These comorbidities may be recognized following pleural fluid removal on follow-up chest radiographs.

Less common symptoms of pleural effusions include mild nonproductive cough. A more severe cough accompanied by production of purulent or bloody sputum suggests underlying pneumonia or endobronchial lesion.

The chest pain associated with pleural effusion is caused by pleural inflammation of the parietal pleura resulting from movement-related friction between the two pleural surfaces. Pleuritic chest pain may be localized or referred. The pain is typically sharp and is exacerbated by movement of the pleural surfaces, as with deep inspiration, soughing, and sneezing. The pain eases with strapping of the chest.[79] Pleuritic chest pain suggests an inflammatory pleural process or the possibility of pulmonary embolism, whereas systemic manifestations presenting as fever, weight loss, and inanition are by and large more suggestive of infection such as empyema. Continuous chest wall pain may reflect chest wall invasion by bronchogenic carcinoma or malignant mesothelioma, especially when combined with a compatible history.[85]

Pleural effusions with less than 300 mL typically manifest no clinical signs or symptoms. Physical findings usually manifest after pleural effusions exceed 300 mL (**Table 5-3**).

Symptoms of empyema may vary in severity and are often quite nonspecific and confounded by host factors. Features such as host immunity, concurrent medical treatment, and associated disease processes may affect the clinical presentation. Signs and symptoms that are considered common but not always present with pulmonary empyema include fever usually not more than 102°F, cough, pleuritic chest pain, sweating, and shortness of breath.[83] Empyema may also subacutely present with anorexia, fatigue, weight loss, malaise, and low-grade fever.[83] Chronically ill patients, as well as individuals on steroids or other immunosuppressive agents, may remain afebrile despite the presence of infection.

TABLE 5-3
Physical Findings for Pleural Effusion/Empyema[81,83]

Assessment	Findings	Indication
Inspection	Peripheral edema	CHF Nephrotic syndrome Pericardial disease Yellow nail syndrome
	Distended neck veins	CHF
	Digital clubbing	Long-standing empyema
Palpation	Asymmetrical or delayed chest expansion	Delayed expansion on the side of the effusion
	Mediastinal shift away from the effusion	Effusion >1000 mL
	Trachea and mediastinal shift toward the side of the effusion	Lobar bronchial obstruction (malignancy or foreign body obstruction)
	Decreased tactile fremitus	Location of pleural effusion
Percussion	Dullness to percussion	Fluid surrounding the lungs Location of pleural effusion
Auscultation	Diminished or inaudible breath sounds	Either fluid or air around the lungs Location of pleural effusion
	Pleural friction rub	Pleural inflammation
	Egophony (E-to-A change in voice sound on auscultation)	Enhanced transmission of high-frequency sound through fluid

Etiology

Patient history provides information about the possible etiology of pleural effusion and guidelines for necessary investigations. For example, a history of pneumonia suggests parapneumonic effusion, empyema or uncomplicated. Fever indicates an infective etiology. A history of cardiac, renal, or liver impairment can suggest transudative effusion. See **Box 5-8**.

Common causes of empyema include a parapneumonic effusion that has become infected (about 50% of all empyemas); penetrating chest trauma; undrained hemothoraces, including those secondary to blunt chest trauma; and contamination of a wound during procedures such as needle decompression, chest tube placement, **thoracentesis**, or thoracic surgery.[83] See **Box 5-9**.

Epidemiology

The estimated incidence of pleural effusion in the United States is 1.5 million cases per year, with most effusions caused by congestive heart failure (CHF), bacterial pneumonia, malignancy, and pulmonary emboli.[81] Malignant pleural effusion (MPE), a sign of advanced cancer, affects an estimated 150,000 people each year in the United States and over 100,000 people in Europe.[87]

The estimated prevalence for pleural effusion is 320 cases per 100,000 people in industrialized countries.[81] Overall rates of parapneumonic empyema in the United States are estimated at 6 cases per 100,000.[83] The rate for individuals at the extremes of age is higher.

Nearly two-thirds of MPEs occur in women, which are associated with breast and gynecological malignancies. Because pleural effusion is usually the manifestation of an underlying disease process, racial differences most likely reflect racial variation in the incidence of the causative disorder.[81] Pleural effusions associated with systemic lupus erythematosus is specifically more common in women than in men. In the United States, the incidence of pleural effusion in the setting of malignant mesothelioma is higher in men.[88]

Most empyemas are complications of pneumonia, but up to 20% are secondary to iatrogenic causes, including but not limited to thoracic surgeries, chest tube insertion, or thoracentesis. Three percent of empyemas are estimated to occur as complications of chest trauma.[83]

Pathology/Pathophysiology

Factors determining the accumulation of fluid within the pleural space include: (1) increased oncotic pressure of pleural fluid, pleural microcirculation

BOX 5-8 Causes of Pleural Effusion[79,81]

Transudative Pleural Effusion

- Ascites
- Cerebral spinal fluid leak to the pleural space
- CHF
- Hypoproteinemia
- Nephrotic syndrome
- Superior vena cava obstruction
- Urinothorax (retroperitoneal leakage of urine into the pleural space)

Exudative Pleural Effusion

- Connective tissue disorders
  - Rheumatoid arthritis
  - Systemic lupus erythematosus
- Infectious
  - Bacterial
  - Parasitic
  - Tuberculosis
  - Viral
- Malignancy
  - Primary cancer
  - Metastatic cancer
- Immunological
  - Post-cardiac injury syndrome
  - Sarcoidosis
  - Wegener granulomatosis
- Gastrointestinal related
  - Abscess
  - Complicated amebic abscess of liver
  - Esophageal perforation
  - Hematoma
  - Hepatitis related
  - Infarction
  - Pancreatitis
  - Spleen related
- Inflammatory
  - Asbestos related
  - Meigs syndrome
  - Post-abdominal surgery
  - Postpartum
  - Pulmonary embolism
  - Trapped lung
- Iatrogenic
  - Drug induced (e.g., amiodarone, nitrofurantoin)
  - Enteral feeding tube misplacement
  - Esophageal sclerotherapy

BOX 5-9 Common Microorganisms Causing Empyemas[83,86]

Aerobic gram-negative bacilli
Bacteroides species
Clostridium
Enteric gram-negative bacilli
Escherichia coli
Fusobacterium nucleatum
Peptostreptococcus species
Prevotella species
Pseudomonas species
Staphylococcus aureus
Streptococcus pneumoniae

permeability, and lymphatics; (2) pleural microcirculation permeability; (3) systemic and pulmonary venous pressures; (4) any process obstructing lymphatic drainage; (5) diaphragmatic defects as well as enhanced trans-diaphragmatic lymphatic flow; and (6) increased negative pressure in the pleural space (with pulmonary atelectasis).[79] Fluid can accumulate in the pleural space under pathologic conditions that disrupt the process that typically allows around 90% of accumulated fluid in the pleural space to be drained by the vascular system. The remaining 10% is absorbed by the lymphatics. An abnormality in the delicate balance that exists between the oncotic and hydrostatic pressures of the pleural space will alter the filtration and drainage of pleural fluid.

Lymphatic drainage from the parietal pleura can significantly exceed the rate of fluid filtration in the pleural space.[89] Abnormal chest wall and diaphragmatic movements can impair the absorption of pleural fluid by the vascular and lymphatic vessels. Excessive filtration of fluid can overwhelm these efficient absorptive mechanisms and lead to the formation of pleural effusion. Diseases that adversely affect the filtration of pleural fluid result in transudate formation that is observed in disorders such as in CHF and nephrosis.[79] The systemic nature of the causative disorders such as inflammation or injury, on the other

hand, increases pleural membrane permeability to proteins and various types of cells, leading to the formation of exudative effusion.[89]

In 5–10% of patients with a pleural effusion, the effusion becomes infected and neutrophils build up.[83] This inflammatory response also causes the production of chemokines, cytokines, oxidants, and protease mediators.

This more complicated parapneumonic effusion requires both antibiotics and some form of surgical drainage or alternative treatment modality to remove the purulent effusion. In these more complicated effusions, decreased fibrinolysis and activation of the coagulation cascade lead to the production of fibrin with subsequent adhesions and loculated fluid collections. This process ultimately can cause pleural fibrosis and a permanent impairment of lung expansion.[83]

Complications

Pleural effusions compromise lung function by preventing its full expansion for breathing. If the effusion is long-standing, associated lung scarring can occur, resulting in a permanent decrease in lung function. Pleural fluid that remains present within the pleural space for a prolonged period is also at risk for becoming infected and forming empyema.

An untreated empyema can spontaneously burrow through the parietal pleura and present with a spontaneous abscess. This rare complication is known as **empyema necessitans**. This complication was more common in the pre-antibiotic era.[90]

Complications arising from diagnostic thoracentesis as well as chest tube placement include mispositioning of the catheter or chest tube in the lung parenchyma often within the lobar fissure, under the diaphragm, or subcutaneously. Bleeding, as well as hemoptysis, from lung puncture may sometimes occur along with risks associated with anesthesia. Clotting, kinking, or dislodgement of the chest tube may require replacement. Patients may develop reexpansion pulmonary edema or hypotension after rapid removal of large volumes of fluid. Subcutaneous emphysema can occur with tube manipulation as well as infection of residual pleural fluid or recurrent effusion. Pulmonary or diaphragmatic laceration is a possibility with an invasive procedure as well as the rare injury or perforation of other structures such as liver or spleen. Vasovagal syncope causing a sudden loss of consciousness from decreased cardiac output, peripheral vasodilation, and bradycardia associated with vagal activity may also complicate pleural fluid removal.

Diagnostic Testing

The presence of an effusion is usually confirmed by standard chest radiographs. Freely flowing pleural effusions of approximately 200 mL are usually apparent as blunting of the costophrenic angle[79] (**Figure 5-21**) or as a crescent-shaped attenuating area[79] (**Figure 5-22**) in the dependent portion of the hemithorax on upright posteroanterior chest radiographs. This occurs because the lung-effusion interface has an upward concave configuration due to the recoil tendency of the lung.

Chest radiographs taken in the patient's supine position in contrast to upright films generally display significant pleural effusions as a homogenous increase in density over the lower lung fields (**Figure 5-23**). Elevation of the hemidiaphragm, lateral displacement of the dome of the diaphragm, or an increased density between the left hemidiaphragm and the gastric air bubble suggest a subpulmonic positioning of the effusion. Loculated effusions as well as underlying lung disease may also alter or displace the typical chest x-ray pattern of fluid layering. A lateral decubitus view of the chest obtained with a horizontal x-ray beam is the most sensitive radiographic projection for detecting smaller pleural effusions as little as 50 mL.[79] Layering of an effusion



FIGURE 5-21 Chest radiograph of a left-sided pleural effusion showing the blunting of the costophrenic angle (yellow arrow).



FIGURE 5-22 A right-side pleural effusion showing the crescent-shaped attenuating area.





FIGURE 5-23 (**A**) Upright chest radiograph showing a right pleural effusion (arrows). (**B**) Right lateral decubitus film of the same patient in (A) shows that the effusion is free flowing and provides better quantitation of the size of the effusion.

Reproduced from Erkonen W, Smith W. Radiology 101: The Basics And Fundamentals Of Imaging. 3rd ed. Philadelphia: Wolters Kluwer; 2010:24 (Figure 2-17).





FIGURE 5-24 (**A**) Frontal chest radiograph of a patient with an empyema. (**B**) Lateral view of the same patient.

Case courtesy of A.Prof Frank Gaillard, Radiopaedia.org, rID: 15390.

reliably defines a freely flowing effusion, and a fluid accumulation approximately 1 cm thick generally indicates an effusion of greater than 200 mL. The inability of an effusion to layer on lateral decubitus films suggests the possibility of loculated pleural fluid or some other etiology causing the increased pleural density.

A chest radiograph of an empyema can resemble that of a pleural effusion and can mimic a peripheral pulmonary abscess. Generally, empyemas form an obtuse angle with the chest wall and, due to their lenticular shape, are much larger in one projection (e.g., frontal chest radiograph) compared to the other (e.g., lateral)[91] (**Figure 5-24**).

Ultrasonography or CT can confirm a pleural effusion or empyema especially in cases where the fluid is loculated, there is complete opacification of hemithorax, or when associated lung parenchymal or mediastinum abnormalities (such as the presence of a mass or lymphadenopathy).[79] These modalities can also detect thickened pleura or signs of invasion of underlying or adjacent structures. CT scanning in empyema with contrast material enhances the pleural surface and thereby assists in delineating pleural fluid loculations. The chest CT may also aid in detecting airway or parenchymal abnormalities such as endobronchial obstruction or the presence of lung abscesses. Ultrasound has a major role in enabling targeted thoracentesis.

Patients with pulmonary effusion usually present with dyspnea and chest discomfort that may cause mild

tachypnea and hyperventilation. Hypoxemia with or without increased PCO_2 may be seen on ABG analysis associated with pleural effusion results from an intrapulmonary shunt caused by compression of the lungs, V/Q perfusion mismatch, and underlying lung disease. The drainage of a pleural effusion unfortunately does not always improve gas exchange. Pleural fluid pH can be useful diagnostically with various exudative fluids when combined with additional diagnostic testing as well as when determining therapeutic strategies in parapneumonic effusions. A low pleural fluid pH of <7.30 in the setting of a normal arterial pH essentially narrows the differential diagnosis of exudative effusions to include empyema, complicated parapneumonic effusion, chronic rheumatoid pleurisy, esophageal rupture, malignancy, tuberculous pleurisy, and lupus pleuritis. In cases where the pleural fluid pH is less than 7.0, drainage of the pleural cavity is necessary, and pleural lavage is needed if the purulence is strong.[82]

Laboratory testing of pleural fluid rarely provides a specific diagnosis; however, when combined with a detailed patient history, physical examination, and appropriate chest x-ray or CT scan studies, the diagnostic value of pleural fluid testing is significantly enhanced. Initial pleural fluid analysis may be definitively or presumptively diagnostic in 80% of patients with effusion and is valuable clinically in about 90% of cases. Thoracentesis followed by pleural fluid analysis is performed on new and unexplained pleural effusions when sufficient fluid is present to allow a safe procedure and no other contraindications exist.

Initial pleural fluid characteristics may be extremely valuable in determining the appropriate testing. Most transudates are non-odorous, clear, non-viscous, and straw colored. While the gross appearance of some exudates may be clear, straw colored, and non-viscous, generally most cases involving exudative fluid may be odorous, turbid, milky, colored, viscid, or sometimes bloody in appearance. Putrid-smelling effusion is suggestive of anaerobic bacteria and purulent fluid should prompt Gram stain and appropriate culture studies. An ammonia odor suggests **urinothorax**, whereas a very viscous fluid (either clear or bloody) is characteristic of mesothelioma. Bloody fluid, on the other hand, suggests many potential causes, including malignancy, trauma, pulmonary embolism with infarct, and asbestos.

The differentiation between pleural fluid transudates and exudates is an important laboratory diagnostic starting point in the analysis of pleural fluid. Causes of transudative effusions represent hydrostatic and oncotic pressure imbalances in persons with normal pleural membranes, and characteristically have a low specific gravity, protein content, and cell count. Exudates occur more frequently and are associated with a multitude of diseases, including infection, inflammation, malignancy, and lymphatic abnormalities. Exudative fluids, in contrast to transudates, involve abnormal pleural membranes and are associated with a high specific gravity, protein content, and cell count. Light's diagnostic criteria are most commonly used to differentiate between transudative and exudative effusions. According to this method, an exudative effusion is diagnosed if one or more of three criteria are satisfied[82] (**Table 5-4**).

Pleural fluid pH can be especially helpful in parapneumonic effusions because a low pleural fluid pH level is more predictive of complicated effusions than a low pleural fluid glucose level. Other factors are helpful in the differential determination of the type of fluid in the pleural space. See **Box 5-10**. There is increasing

TABLE 5-4
Light's Criteria for Exudative Effusions[82,92]

Parameters	Normal	Criteria for Exudative Effusion
Protein		Pleural fluid protein/serum protein >0.5
Total serum protein	6–7.8 g/dL	
Pleural fluid protein	1–2 g/dL	
Lactate dehydrogenase (LDH)		Pleural fluid LDH/serum LDH >0.6
Serum LDH	60–160 U/L	
Pleural fluid LDH	0–1,000 U/L	
Upper limits of normal Serum LDH	222 U/L	Pleural fluid LDH >2/3 serum LDH upper limits of normal

Note: At least one or more of the findings needs to be met to be considered an exudative effusion.

BOX 5-10 Pleural Fluid Findings Suggestive of an Empyema or Parapneumonic Effusion[83]

- Grossly purulent pleural fluid
- pH <7.2
- White blood cell count >50,000 cells/μL (or polymorphonuclear leukocyte count = 1,000 IU/dL)
- Glucose <60 mg/dL
- Lactate dehydrogenase >1,000 U/mL
- Positive pleural fluid culture

Modified from Ward M. Empyema and abscess pneumonia: background, pathophysiology, epidemiology. *Emedicinemedscape-com*. 2015. https://emedicine.medscape.com/article/807499-overview#a5. Accessed June 17, 2018.

evidence that tumor necrosis factor (TNF)–alpha may be used to help determine whether a pleural effusion is a complicated parapneumonic effusion or an empyema.[93]

In 25% of cases, pleural effusion results from malignant disease. In another 20–40% of cases, biochemical testing, bacteriological examination, and pathological cytology of the pleural fluid fail to identify any underlying cause of disease. In such cases, either cytology is repeated, or a pleural biopsy is performed.[82]

Additionally, helpful tests to assess the patient include pulse oximetry, to assess oxygenation, and ABG analysis, to assess oxygenation and ventilation. Tissue sampling via closed pleural biopsy for histological assessment is performed in some cases and can reveal granulomas of tuberculosis or tumor cells from malignant processes.[94]

Treatment and Management

Treatment of the underlying disease is the principle therapy for fluid in the pleural space. Emergency procedures are required when there is a large amount of fluid, when breathing is impaired, when cardiac function is compromised, or when pleural bleeding resulting from external injury cannot be controlled. Drainage of the pleural space is instituted promptly in cases of acute thoracic empyema.[82] If the initial thoracentesis reveals a complicated parapneumonic effusion with pleural fluid pH <7.20 or a glucose level ≤ 40 mg/dL, an immediate chest tube thoracostomy placement is required. Chest tube insertions for complicated effusions must be done under imaging guidance as the added cost for the procedure is expected to be more than compensated by the increased success of drainage.[84]

Only in few specific circumstances is a thoracentesis not warranted; for example, if there is a strong suspicion of heart failure as a cause of the effusion(s), then a trial of medical therapy for heart failure can be done prior to a thoracentesis.[84]

The palliation of dyspnea in persons with recurrent malignant fluid accumulation is an important therapeutic goal. The instillation of agents such as talc, tetracycline, doxycycline, or bleomycin into the pleural space (**sclerotherapy**) following chest tube drainage may be effective in fusing the pleura (**pleurodesis**) and preventing the recurrence of the effusion. The type of malignancy involved, however, directly influences the success of pleurodesis regardless of the sclerosing agent used with mesothelioma and lung cancer particularly prone to failure.[82,95]

Prognosis

Prognosis varies in accordance with the underlying disorder and subsequent response to directed therapy. The outcome in malignant effusions invariably carries a very poor prognosis with survival typically measured in months. While management in malignant effusion is primarily palliative, therapeutic options including thoracentesis, tube thoracostomy, chemical pleurodesis, and thoracoscopic powder poudrage can result in a significant response.[85] Parapneumonic effusions, on the other hand, when recognized and treated promptly, normally resolve without significant consequence. Most patients recover, but the mortality rate for parapneumonic effusions and empyema remains at approximately 10%. Approximately 15–25% of patients require surgical intervention, including decortication and/or open drainage procedure.[96]

Air in the Pleural Space

Pneumothorax is a relatively common disorder involving the abnormal presence of air or gas within the pleural space. Pneumothorax is traditionally referred to as spontaneous when it occurs in the absence of indirect or intentional trauma in an individual with or without the presence of pleural or lung disease. Normal intrapleural pressure is negative (less than atmospheric pressure) because of inward lung and outward chest wall recoil. In pneumothorax, however, air enters the pleural space from outside the chest or from the lung itself via a virtual check-valve-like mechanism through mediastinal tissue planes or direct pleural perforation causing intrapleural pressure to increase and lung volume to decrease.

Definition/Diagnosis

Spontaneous pneumothoraces can be divided into primary or idiopathic form that occurs in persons without a previous underlying lung disease and a secondary form occurring in individuals with a known underlying lung disease.[97] Other forms of pneumothorax that are sometimes separately described include catamenial, iatrogenic, traumatic, and tension pneumothorax.

A spontaneous **pneumomediastinum** refers to the presence of free air (extraluminal gas) in the mediastinum that happens without traumatic injury or known underlying disease, resulting from alveolar rupture. A secondary pneumomediastinum, on the other hand, refers to free air introduced into the mediastinum following medical procedure complications or trauma, commonly occurring following perforation of the tracheobronchial tree or esophagus, or gas leaking into the thorax from the neck, chest wall, or abdomen.[98]

Clinical Signs and Symptoms

The main symptoms of pneumothorax and pneumomediastinum are chest pain and dyspnea, which usually begin abruptly. Pneumomediastinum can manifest with variable signs and symptoms. The severity of the symptoms depends on the volume of air and the degree of the underlying disease. **Box 5-11** shows

BOX 5-11 Common Physical Signs of Pneumothorax (Non-tension) and Pneumomediastinum[97,98]

Pneumothorax

- Respiratory distress
- Tachypnea
- Asymmetric lung expansion (less expansion of the affected side)
- Distant or absent breath sounds of the affected area
- Hyperresonance on percussion (over the affected side)
- Adventitious lung sounds
- Tachycardia
- Pulsus paradoxus

Pneumomediastinum

- Dyspnea
- Fever
- Dysphonia
- Throat pain
- Jaw pain
- Subcutaneous emphysema
- Hamman sign (crunching, rasping sound, synchronous with the heartbeat, heard over the precordium)

some common physical signs of pneumothorax and pneumomediastinum.

A small amount of air in the pleural space may not manifest with any symptoms and have a normal physical exam. The triggering factors for pneumomediastinum include precipitating factors such as the Valsalva maneuver, illicit drug ingestion, vigorous vomiting or cough, or activities leading to barotrauma (e.g., scuba diving, flying). A forceful cough from asthma is one of the most common triggers of spontaneous pneumomediastinum.[99]

Etiology

In some cases of pneumothorax, air enters the intrapleural space without preceding trauma and without an underlying history of lung disease. This type of pneumothorax is commonly referred to as **primary spontaneous pneumothorax** (PSP). There are times when a pneumothorax is diagnosed as PSP; however, the patient has subclinical lung disease that can be detected only by CT scanning. These patients are typically between the ages of 18 and 40 years, tall, and thin and often smoke tobacco.[97]

Secondary spontaneous pneumothorax (SSP) occurs in people with a wide variety of parenchymal lung diseases. These lung diseases cause structural alterations that allow air to enter the pleural space via distended, damaged, or compromised alveoli. Iatrogenic pneumothorax is a type of traumatic pneumothorax resulting from pleural injury.[97] In this type of pneumothorax, air enters the pleural space because of a diagnostic or therapeutic medical intervention. Pneumomediastinum may occur spontaneously or because of trauma.

Epidemiology

Pneumothorax is estimated to occur in more than 20,000 individuals in the United States and cost over $130 million annually in added healthcare expenses. The estimated annual incidence of PSP is between 7.4–18 cases per 100,000 persons in men and 1.2–6 cases per 100,000 persons in women, while the incidence estimate of SSP is 6.3 cases per 100,000 persons annually in men and 2 cases per 100,000 persons annually in women.[97] While difficult to accurately determine, it is likely that the incidence estimates for spontaneous pneumothorax are underestimated. PSP occurs less commonly in children than in adults. Chronic obstructive pulmonary disease (COPD) involving primarily emphysema is the most common cause of SSP and carries an estimated incidence of approximately 26 cases per 100,000 persons.

Spontaneous pneumomediastinum typically occurs in young, healthy individuals with no serious underlying pulmonary disease who are between 20 and 40 years of age. There is a slight predominance for males.[97]

Pathology/Pathophysiology

Spontaneous pneumothorax occurs mostly from the rupture of blebs and bullae. This is thought to be related to increased shear forces in the apex (apical pleural blebs), especially in tall, young people without parenchymal lung disease. Spontaneous pneumomediastinum occurs when air leaks through small alveolar ruptures to the surrounding bronchovascular sheath.[98] Air escapes into the surrounding connective tissue and dissects further into the mediastinum. Less commonly, pneumomediastinum results from air escaping from the upper respiratory tract, intrathoracic airways, or gastrointestinal tract (e.g., esophageal perforation). Esophageal trauma or elevated airway pressures may also allow air to dissect into the mediastinum. Air may then travel superiorly into the visceral, retropharyngeal, and subcutaneous spaces of the neck, and can then continue throughout the body.

Risk Factors

Risk factors for PSP, SSP, and pneumomediastinum are listed in **Box 5-12**.

BOX 5-12 Risk Factors for Pneumothorax and Pneumomediastinum[97,99]

Primary Spontaneous Pneumothorax

- Smoking
- Tall, thin stature in a healthy person
- Marfan syndrome
- Pregnancy
- Familial pneumothorax

Secondary Spontaneous Pneumothorax

- COPD
- Asthma
- Human immunodeficiency virus/acquired immunodeficiency syndrome
- Necrotizing pneumonia
- Tuberculosis
- Sarcoidosis
- Cystic fibrosis
- Bronchogenic carcinoma or metastatic malignancy
- Idiopathic pulmonary fibrosis
- Inhalational and intravenous drug use
- Interstitial lung diseases associated with connective tissue diseases
- Lymphangioleiomyomatosis
- Langerhans cell histiocytosis
- Severe acute respiratory syndrome (SARS)
- Thoracic endometriosis and catamenial pneumothorax
- Collagen vascular disease, including Marfan syndrome

Pneumomediastinum

- Acute generation of high intrathoracic pressures
- Asthma
- Respiratory tract infection
- Parturition
- Emesis
- Severe cough
- Mechanical ventilation
- Trauma or surgical disruption of the oropharyngeal, esophageal, or respiratory mucosa
- Athletic competition

Complications

Complications can take place in all forms of pneumothorax and are usually categorized as being either acute or long term. Acute complications include air leaks due to continued leakage of air from the lung into the pleural space or air leaking around the chest tube insertion site, and are more common in secondary than in PSP. Failure of the lung to reexpand may complicate pneumothorax from a persistent air leak, an endobronchial obstruction, a trapped lung, or a mispositioned chest tube. Reexpansion pulmonary edema may occur when the lung is rapidly expanded following a relatively extended collapse. Other associated difficulties include bilateral pneumothorax, hemothorax, empyema, or acute respiratory failure. Problems that more likely occur for a long term include persistent pneumothorax (failure of the lung to reexpand) and pneumothorax recurrence. In most cases of complications for pneumomediastinum, the movement of air into the subcutaneous tissues prevents the buildup of pressure in the mediastinum. Occasionally, air leaks into the pericardial space, causing pneumopericardium.[98]

Diagnostic Testing

Standard radiographic findings in pneumothorax are dependent on the presence or absence of coexisting lung disease and tension pneumothorax. The chest x-ray examination in pneumothorax uncomplicated by underling pulmonary disease or adhesions typically reveals the margin of the lung as a thin outwardly convex line separating the collapse lung from the chest wall (**Figure 5-25**).



FIGURE 5-25 Red arrows point to the thin white visceral pleural line, which is the single best sign for pneumothorax.
Published with permission from LearningRadiology.com.

Patients with mild pneumothorax usually present with mild hyperventilation causing ABGs to commonly display a lowered Pa_{O_2} and Pa_{CO_2} with an increased pH consistent with acute respiratory alkalemia. Mild-to-moderate hypoxemia (reflecting an increased V/Q shunt) is usually dependent on the extent of physiologic impairment. Acute ventilatory failure can result from inadequate alveolar ventilation and abnormal gas exchange, especially with life-threatening tension pneumothorax or with significant secondary pneumothorax.

ECG findings in pneumothorax characteristically reveal decreased QRS amplitude and electrical axis shift in addition to tachycardia.[100] Electromechanical dissociation may occur in extreme cases, as with tension pneumothorax.

Left-sided pneumothoraces greater than 30% are often associated with right-axis deviation, diminution of the QRS complex amplitude, T-wave inversion, and loss of R waves in the precordial leads.[100] Rarely, 12-lead ECG findings may be suggestive of acute myocardial infarction. Right-sided pneumothorax less often produces diminution of precordial chest R waves, inversion of precordial T waves, diminution of QRS amplitude, and rightward shift in the frontal QRS axis.[100] In general characteristic changes encountered in pneumothorax return to normal with the resolution of pneumothorax.

Treatment and Management

The management options are dependent on the severity of the pneumothorax or pneumomediastinum, the predisposing state, and the underlying disease. Persons that present with a small, uncomplicated, asymptomatic pneumothorax or pneumomediastinum with no underlying lung disease present may (1) be monitored by careful observation in either the inpatient or the outpatient setting only; (2) undergo small-catheter pleural aspiration; (3) undergo small chest tube placement attached to a flutter valve (for pneumothorax); or (4) undergo chest tube drainage to evacuate the air (for pneumothorax).[101]

More complicated presentations generally require chest tube insertion attached to negative pressure evacuation and underwater seal. Because recurrences of PSPs are common after the initial evacuation treatment additional therapy may include chemical pleurodesis, open thoracotomy with pleural abrasion, or VAT in which blebs are stapled.[101] A pleurodesis may be necessary with pleural abrasion, parietal pleurectomy, or talc insufflations after recurrence of pneumothorax. The use of supplemental oxygen in all cases (spontaneous pneumothorax and spontaneous pneumomediastinum) causes an increase in the gradient between nitrogen in the pleural space and nitrogen in the pleural capillary blood, promoting the movement of nitrogen out of the pleural space.[97,98] When no evidence of re-accumulation of air is confirmed on chest radiograph following an adequate period of observation, the catheter can be removed.

Uncomplicated spontaneous pneumomediastinum is managed conservatively with analgesia, rest, and avoidance of maneuvers that increase pulmonary pressure (Valsalva or forced expiration, including spirometry). Asthma or another underlying lung disease is treated as indicated.[98]

Prognosis

SSP is associated with a higher mortality and morbidity than PSP. The presence of pneumothorax in patients with HIV is thought to be an ominous sign and is associated with poor outcome. Pneumothorax occurs in 1–2% of hospitalized HIV patients and is associated with 30–34% mortality.[102] Pneumomediastinum is generally considered a benign entity of little clinical importance with good prognosis.[103]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Decreased absorption of lymph fluid can cause a pleural effusion.
2. True or False: The pleura consists of five layers of cells.
3. True or False: CHF typically causes an exudative pleural effusion.
4. True or False: Empyemas are caused by infection.
5. True or False: A spontaneous pneumomediastinum is caused by either chest trauma or an underlying pulmonary disease.
6. True or False: Trauma to the esophagus can cause a pneumomediastinum.

Chapter Summary

The thorax is a body cavity that contains the lungs, heart, great vessels, esophagus, trachea, nerves, and blood vessels that supply blood to these vital organs. Surrounding and protecting these organs is the chest wall made up of the rib cage, sternum, spine, respiratory muscles, and diaphragm. The lungs are covered by a thin, transparent double membrane that is in close contact with each other and cover the lungs and inner chest wall. Between these two thin flexible layers, there is normally about 10 mL of fluid surrounding each lung. Alterations of any of these structures can have major effects on the ability of the respiratory system to operate effectively, leading to respiratory distress and possibly

failure. These alterations may come from direct trauma to the chest wall, chest wall deformities, infectious diseases, CHF, cancer, and other systemic diseases. The effects on the respiratory system may be immediate, as with chest trauma; may take days or weeks to develop, as with infectious diseases; or may take years to develop, as with chest wall deformities. The pulmonary effects depend on the severity of these disorders.

Key Points

1. The primary survey for chest trauma consists of assessing the airway, breathing, circulation, disability, and exposure (ABCDEs of trauma care) of the trauma patient looking for life-threatening injuries and addressing them immediately upon discovery.
2. The secondary survey for chest trauma is a methodical examination of the respiratory system looking for injuries that may have been missed with the primary survey.
3. Chest trauma comes in several forms, but the majority are blunt injuries, or penetrating injuries, or a combination of both.
4. Chest trauma causes a local inflammatory response, and severe or multiple trauma evokes a systemic inflammatory response that can lead to ARDS and multiorgan failure.
5. Chest wall deformities can lead to respiratory insufficiency by limiting the ability of the chest to expand while overworking the diaphragm.
6. Obesity is a form of chest wall deformity because it limits chest expansion, decreases chest compliance, and increases the work of breathing.
7. Limited movement of the chest wall manifests in reductions of lung volumes and appears on PFTs as a restrictive defect.
8. Once the type of pleural effusion (exudative, transudative, parapneumonic, empyema) is determined by the drainage and evaluation of the fluid, the underlying disorder causing the disrupted physiologic condition can be treated.
9. Transudative pleural effusions are caused mostly by CHF.
10. One-quarter of all pleural effusions are due to a malignant process; many more go undiagnosed.

Chapter Questions

1. A(An) _____ can cause the trachea to shift away from the affected side, dull percussion over the affected side, decreased chest expansion of the affected side, and absent or decreased breath sounds over the affected side.
   a. tension pneumothorax
   b. open pneumothorax
   c. massive hemothorax
   d. pleural effusion
2. Hemorrhaging into the alveolar spaces and disruption of the alveolar–capillary membrane is typically caused by a _____.
   a. hemothorax
   b. hemopneumothorax
   c. flail chest
   d. pulmonary contusion
3. Shifting of the mediastinum away from the affected lung during inspiration and back to midline during expiration is caused by a(an) _____.
   a. open pneumothorax
   b. tension pneumothorax
   c. flail chest
   d. pneumomediastinum
4. A chest radiograph that shows a wide mediastinum, obscured aortic knob, a left apical cap, and tracheal deviation to the right is indicative of a _____.
   a. pneumomediastinum
   b. pneumohemothorax
   c. blunt aortic injury
   d. flail chest
5. The presence of elevated venous pressure, with a decline in arterial pressure and muffled heart tones are signs of _____.
   a. pulmonary contusion
   b. pericardial effusion
   c. pleural effusion
   d. cardiac tamponade
6. The anteroposterior deformity of the spine is _____.
   a. kyphosis
   b. scoliosis
   c. ankylosing spondylitis
   d. pectus excavatum
7. Transudative pleural effusions can be caused by _____.
   a. metastatic lung cancer
   b. congestive heart failure
   c. connective tissue disorders
   d. sarcoidosis
8. Blunting of the costophrenic angle on chest radiograph from a pleural effusion requires a minimum of approximately _____ mL of fluid.
   a. 50
   b. 100
   c. 150
   d. 200
9. A primary spontaneous pneumothorax occurs _____.
   a. during a Valsalva maneuver
   b. without preceding trauma or lung injury
   c. because of different types of parenchymal lung disease
   d. from pleural injury

10. A recurring spontaneous pneumothorax can be treated using _____.
- **a.** permanent chest tube placement
- **b.** pleurodesis with talc insufflation
- **c.** rest and Valsalva maneuver avoidance
- **d.** pneumonectomy

References

1. Schwartzstein R. Chest wall diseases and restrictive physiology. In: King T Jr, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. https://www.uptodate.com. Accessed June 10, 2018.
2. Legome E. Initial evaluation and management of blunt thoracic trauma in adults. In: Moreira M, Grayzel J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018.
3. Kotwal R, Howard J, Orman J, et al. The effect of a golden hour policy on the morbidity and mortality of combat casualties. *JAMA Surg*. 2016;151(1):15. doi:10.1001/jamasurg.2015.3104.
4. Berger E. Nothing gold can stay? *Ann Emerg Med*. 2010;56(5):A17–A19. doi:10.1016/j.annemergmed.2010.09.012.
5. Cameron P, Gabbe B, Smith K, Mitra B. Triaging the right patient to the right place in the shortest time. *Br J Anaesth*. 2014;113(2):226–233. doi:10.1093/bja/aeu231.
6. *Advanced Trauma Life Support*. Chicago, IL: American College of Surgeons; 2012.
7. Planas J, Waseem M. Trauma, primary survey. In: *Statpearls*. Treasure Island, FL: StatePearls Publishing; 2017. https://www.ncbi.nlm.nih.gov/books/NBK430800. Accessed June 11, 2018.
8. Dries D. Initial evaluation of the trauma patient: overview, triage and organization of care, initial assessment. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/434707-overview. Accessed June 11, 2018.
9. Nadir N. Chest trauma. *CDEM Curriculum*. 2018. https://cdemcurriculum.com/chest-trauma. Accessed June 17, 2018.
10. Blyth A. Thoracic trauma. *BMJ*. 2014;348(2):bmj.g1137-bmj.g1137. doi:10.1136/bmj.g1137.
11. Shahani R. Penetrating chest trauma: background, anatomy, pathophysiology. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/425698-overview. Accessed June 11, 2018.
12. TRAUMA.ORG: Thoracic Trauma. *Traumaorg*. 2004. http://www.trauma.org/archive/thoracic/CHESTopen.html. Accessed June 13, 2018.
13. Bellone A, Bossi I, Etteri M, et al. Factors associated with ICU admission following blunt chest trauma. *Can Respir J*. 2016;2016:1–5. doi:10.1155/2016/3257846.
14. Jordan J. Approach to the trauma patient. In: *Merck Manual Professional Version*. Kenilworth, NJ: Merck & Co, Inc; 2018. https://www.merckmanuals.com/professional. Accessed June 12, 2018.
15. Kramer J. Pathophysiology of thoracic trauma. *Semin Cardiothorac Vasc Anesth*. 2002;6(2):57–61. doi:10.1177/108925320200600202.
16. Weiser T. Overview of thoracic trauma. In: *Merck Manual Professional Version*. Kenilworth, NJ: Merck & Co.,Inc; 2018. https://www.merckmanuals.com/professional. Accessed June 12, 2018.
17. Mancini M. Blunt chest trauma: background, anatomy, pathophysiology. *Emedicinemedscapecom*. 2016. https://emedicine.medscape.com/article/428723-overview. Accessed June 13, 2018.
18. Qasim Z, Gwinnutt C. Flail chest: pathophysiology and management. *Trauma*. 2009;11(1):63–70. doi:10.1177/1460408608101344.
19. Cox W. *Blunt Force Traumatic Injuries of the Chest*. Doylestown, PA: Forensicmd.wordpress.com; 2012. https://forensicmd.files.wordpress.com/2012/01/blunt-force-traumatic-injuries-of-the-chest.pdf. Accessed June 12, 2018.
20. Mayglothling J, Legome E. Initial evaluation and management of penetrating thoracic trauma in adults. In: Moreira M, Grayzel J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www.uptodate.com/. Accessed June 12, 2018.
21. Smith J, Rickard A, Wise D. Traumatic cardiac arrest. *J R Soc Med*. 2015;108(1):11–16. doi:10.1177/0141076814560837.
22. Nasreldin E, Khairy M. Activation state of the circulating neutrophil in isolated chest trauma patients: characterization of surface receptor expression. *J Trauma Treat*. 2017;6(1):363. doi:10.4172/2167-1222.1000363.
23. Ehrnthaller C, Flierl M, Perl M, et al. The molecular fingerprint of lung inflammation after blunt chest trauma. *Eur J Med Res*. 2015;20(1):70. doi:10.1186/s40001-015-0164-y.
24. Ayan E, Koksel O, Polat A, et al. The role of thoracic trauma in inflammatory responses, apoptosis and bacterial translocation following multiple trauma. *Ulus Travma Acil Cerrahi Derg*. 2013;19(6):491–499. doi:10.5505/tjtes.2013.29660.
25. Turkalj I, Petrovic K, Stojanovic S, Petrovic D, Brakus A, Ristic J. Blunt chest trauma: an audit of injuries diagnosed by the MDCT examination. *Vojnosanit Pregl*. 2014;71(2):161–166. doi:10.2298/vsp1402161t.
26. Battle C, Hutchings H, Evans P. Risk factors that predict mortality in patients with blunt chest wall trauma: a systematic review and meta-analysis. *Injury*. 2012;43(1):8–17. doi:10.1016/j.injury.2011.01.004.
27. What risk factors do all drivers face? 2016. https://www.nichd.nih.gov/health/topics/driving/conditioninfo/risk-factors. Accessed June 17, 2018.
28. Stewart R, Corneille M. Common complications following thoracic trauma: their prevention and treatment. *Semin Thorac Cardiovasc Surg*. 2008;20(1):69–71. doi:10.1053/j.semtcvs.2008.01.006.
29. Menger R, Telford G, Kim P, et al. Complications following thoracic trauma managed with tube thoracostomy. *Injury*. 2012;43(1):46–50. doi:10.1016/j.injury.2011.06.420.
30. Alisha C, Gajanan G, Jyoth H. Risk factors affecting the prognosis in patients with pulmonary contusion following chest trauma. *J Clin Diagn Res*. 2015;9(8):17–19. doi:10.7860/jcdr/2015/13285.6375.
31. Zhang J, Chu X, Liu Y, Wang Y. Treatment of 336 cases of chest trauma. *Chin J Traumatol*. 2012;15(3):180–182.
32. Horst K, Andruszkow H, Weber C, et al. Thoracic trauma now and then: a 10 year experience from 16,773 severely injured patients. *PLoS ONE*. 2017;12(10):e0186712. doi:10.1371/journal.pone.0186712.
33. Fröhlich M, Lefering R, Probst C, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma. *J Trauma Acute Care Surg*. 2014;76(4):921–928. doi:10.1097/ta.0000000000000199.
34. Dewar D, Tarrant S, King K, Balogh Z. Changes in the epidemiology and prediction of multiple-organ failure after injury. *J Trauma Acute Care Surg*. 2013;74(3):774–779. doi:10.1097/ta.0b013e31827a6e69.
35. Senn-Reeves J, Jenkins D. Examining the relationship between preinjury health and injury-related factors to discharge location and risk for injury-associated complications in patients after blunt thoracic trauma. *J Trauma Nurs*. 2015;22(3):136–147. doi:10.1097/jtn.0000000000000124.
36. Hamada S, Delhaye N, Kerever S, Harrois A, Duranteau J. Integrating eFAST in the initial management of stable trauma patients: the end of plain film radiography. *Ann Intensive Care*. 2016;6(1):62. doi:10.1186/s13613-016-0166-0.
37. Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. *Intensive Care Med*. 2012;38(4):577–591. doi:10.1007/s00134-012-2513-4.
38. Reardon R. Ultrasound in trauma—the FAST exam focused assessment with sonography in trauma. *Aceporg*. 2008. https://www.acep.org/sonoguide/FAST.html#fastref9. Accessed June 13, 2018.
39. Khan A. Thoracic trauma imaging: overview, radiography, computed tomography. *Emedicinemedscapecom*. 2015. https://emedicine.medscape.com/article/357007-overview. Accessed June 13, 2018.
40. Lang P, Kulla M, Kerwagen F, Lefering R, Friemert B, Palm H. The role of whole-body computed tomography in the diagnosis of thoracic injuries in severely injured patients—a retrospective multi-centre study based on the trauma registry of the German trauma society (TraumaRegister DGU®). *Scand J Trauma Resusc Emerg Med*. 2017;25(1):82. doi:10.1186/s13049-017-0427-4.

41. Sierink J, Treskes K, Edwards M, et al. Immediate total-body CT scanning versus conventional imaging and selective CT scanning in patients with severe trauma (REACT-2): a randomised controlled trial. *Lancet*. 2016;388(10045):673–683. doi:10.1016/s0140-6736(16)30932-1.
42. Rodriguez R. NEXUS Chest CT Decision Instrument for CT Imaging—MDCalc. *Mdcalccom*. 2018. https://www.mdcalc.com/nexus-chest-ct-decision-instrument-ct-imaging. Accessed June 13, 2018.
43. Hosseini M, Ghelichkhani P, Baikpour M, et al. Diagnostic accuracy of ultrasonography and radiography in detection of pulmonary contusion: a systematic review and meta-analysis. *Emergency*. 2015;3(4):127–136. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608349. Accessed June 13, 2018.
44. Wanek S, Mayberry J. Blunt thoracic trauma: flail chest, pulmonary contusion, and blast injury. *Crit Care Clin*. 2004;20(1):71–81. doi:10.1016/s0749-0704(03)00098-8.
45. Soldati G, Testa A, Silva F, Carbone L, Portale G, Silveri N. Chest ultrasonography in lung contusion. *Chest*. 2006;130(2):533–538. doi:10.1378/chest.130.2.533.
46. Ganie F, Lone H, Lone G, et al. Lung contusion: a clinico-pathological entity with unpredictable clinical course. *Bull Emerg Trauma*. 2013;1(1):7–16.
47. Sutyak J, Wohltmann C, Larson J. Pulmonary contusions and critical care management in thoracic trauma. *Thorac Surg Clin*. 2007;17(1):11–23. doi:10.1016/j.thorsurg.2007.02.001.
48. Cinnella G, Dambrosio M, Brienza N, et al. Independent lung ventilation in patients with unilateral pulmonary contusion. Monitoring with compliance and EtCO2. *Intensive Care Med*. 2001;27(12):1860–1867. doi:10.1007/s00134-001-1149-6.
49. Baron R, Levy B. Recent advances in understanding and treating ARDS. *F1000Res*. 2016;5:725. doi:10.12688/f1000research.7646.1.
50. Huber S, Biberthaler P, Delhey P, et al. Predictors of poor outcomes after significant chest trauma in multiply injured patients: a retrospective analysis from the German Trauma Registry (Trauma Register DGU®). *Scand J Trauma Resusc Emerg Med*. 2014;22(1):52. doi:10.1186/s13049-014-0052-4.
51. Veysi V, Nikolaou V, Paliobeis C, Efstathopoulos N, Giannoudis P. Prevalence of chest trauma, associated injuries and mortality: a level I trauma centre experience. *Int Orthop*. 2009;33(5):1425–1433. doi:10.1007/s00264-009-0746-9.
52. Donath J, Miller A. Restrictive chest wall disorders. *Semin Respir Crit Care Med*. 2009;30(3):275–292. doi:10.1055/s-0029-1222441.
53. Blanco F, Elliott S, Sandler A. Management of congenital chest wall deformities. *Semin Plast Surg*. 2011;25(1):107–116. doi:10.1055/s-0031-1275177.
54. Melo L, Silva M, Calles A. Obesity and lung function: a systematic review. *Einstein (São Paulo)*. 2014;12(1):120–125. doi:10.1590/s1679-45082014rw2691.
55. Tzelepis G, McCool F. Nonmuscular diseases of the chest wall. In: Grippi M, Elias J, Fishman J, et al, eds. *Fishman's Pulmonary Diseases and Disorders*. 5th ed. New York, NY: McGraw-Hill Education; 2015. https://accessmedicine.mhmedical.com. Accessed June 15, 2018.
56. Kelsen S. Pump failure: the pathogenesis of hypercapnic respiratory failure in patients with lung and chest wall disease. In: Grippi M, Elias J, Fishman J, et al, eds. *Fishman's Pulmonary Diseases and Disorders*. 5th ed. New York, NY: McGraw-Hill Education; 2015. https://accessmedicine.mhmedical.com. Accessed June 14, 2018.
57. Laghi F, Tobin M. Disorders of the respiratory muscles. *Am J Respir Crit Care Med*. 2003;168(1):10–48. doi:10.1164/rccm.2206020.
58. Kado D. Overview of hyperkyphosis in older persons. In: Schmader K, Sullivan D, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 13, 2018.
59. Jaroszewski D, Notrica D, McMahon L, Steidley D, Deschamps C. Current management of pectus excavatum: a review and update of therapy and treatment recommendations. *J Am Board Fam Med*. 2010;23(2):230–239. doi:10.3122/jabfm.2010.02.090234.
60. Baez J, Lee E, Restrepo R, Eisenberg R. Chest wall lesions in children. *Am J Roentgenol*. 2013;200(5):W402–W419. doi:10.2214/ajr.12.8883.
61. Tsui F, Tsui H, Akram A, Haroon N, Inman R. The genetic basis of ankylosing spondylitis: new insights into disease pathogenesis. *Appl Clin Genet*. 2014;7:105–115. doi:10.2147/tacg.s37325.
62. Klish W. Definition; epidemiology; and etiology of obesity in children and adolescents. In: Motil K, Geffner M, Hoppin A, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 14, 2018.
63. Bray G. Obesity in adults: etiology and natural history. In: Pi-Sunyer F, Martin K, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 14, 2018.
64. Scherl S. Adolescent idiopathic scoliosis: clinical features, evaluation, and diagnosis. In: Phillips W, Torchia M, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 14, 2018.
65. Hebra A. Pectus Excavatum: Background, Pathophysiology, Epidemiology. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/1004953-overview. Accessed June 14, 2018.
66. Cataletto M. Pectus carinatum: background, pathophysiology, epidemiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/1003047-overview. Accessed June 14, 2018.
67. Dean L, Jones G, MacDonald A, Downham C, Sturrock R, Macfarlane G. Global prevalence of ankylosing spondylitis. *Rheumatology*. 2013;53(4):650–657. doi:10.1093/rheumatology/ket387.
68. Adult Obesity Facts | Overweight & Obesity | CDC. *Cdcgov*. 2018. https://www.cdc.gov/obesity/data/adult.html. Accessed June 15, 2018.
69. Mirilas P, Halkos M, Symbas M, Symbas P, Skandalakis L. Applied anatomy of the chest wall and mediastinum. *Basicmedical Key*. 2018. https://basicmedicalkey.com/applied-anatomy-of-the-chest-wall-and-mediastinum. Accessed June 16, 2018.
70. Gonzalez C, Ferris G, Diaz J, Fontana I, Nuñez J, Marín J. Kyphoscoliotic ventilatory insufficiency. *Chest*. 2003;124(3):857–862. doi:10.1378/chest.124.3.857.
71. Gzik-Zroska B, Wolański W, Gzik M. Engineering-aided treatment of chest deformities to improve the process of breathing. *Int J Numer Method Biomed Eng*. 2013;29(9):926–937. doi:10.1002/cnm.2563.
72. Cejudo P, Lopez-Marquez I, Lopez-Campos J, et al. Exercise training in patients with chronic respiratory failure due to kyphoscoliosis: a randomized controlled trial. *Respir Care*. 2013;59(3):375–382. doi:10.4187/respcare.02484.
73. Kramer N, Millman R, Hill N. Evaluation of sleep-disordered breathing inpatients with neuromuscular and chest wall disease. In: Shefner J, Badr M, Eichler A, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed June 15, 2018.
74. Demmy T, Dexter E. Overview of minimally invasive thoracic surgery. In: Friedberg J, Collins K, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed June 15, 2018.
75. Ghanbarzadeh M, Mehdipour A. Study and influence of exercise program on respiratory function of adults with kyphosis. *Acta Bioeng Biomech*. 2009;11(1):11–17.
76. Brent L. Ankylosing spondylitis and undifferentiated spondyloarthropathy treatment & management: approach considerations, pharmacologic therapy, guideline-directed therapy. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/332945-treatment. Accessed June 14, 2018.
77. Michailova K, Usunoff K. Serosal membranes (pleura, pericardium, peritoneum) normal structure, development, and experimental pathology. In: Beck E, Christ B, Korf H, et al, eds. *Advances in Anatomy Embryology and Cell Biology*. Berlin, Germany: Springer-Verlag; 2006.
78. Lai-Fook S. Pleural mechanics and fluid exchange. *Physiol Rev*. 2004;84(2):385–410. doi:10.1152/physrev.00026.2003.

79. Karkhanis V, Joshi J. Pleural effusion: diagnosis, treatment, and management. *Open Access Emerg Med*. 2012;4:31–52. doi:10.2147/oaem.s29942.
80. Wang N. Anatomy of the pleura. *Clin Chest Med*. 1998;19(2):229–240. doi:10.1016/s0272-5231(05)70074-5.
81. Boka K. Pleural effusion: background, anatomy, etiology. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/299959-overview. Accessed June 16, 2018.
82. Sato T. Differential diagnosis of pleural effusions. *Jpn Med Assoc J*. 2006;49(9–10):315–319.
83. Ward M. Empyema and abscess pneumonia: background, pathophysiology, epidemiology. *Emedicinemedscapecom*. 2015. https://emedicine.medscape.com/article/807499-overview#a5. Accessed June 17, 2018.
84. Koppurapu V, Meena N. A review of the management of complex para-pneumonic effusion in adults. *J Thorac Dis*. 2017;9(7):2135–2141. doi:10.21037/jtd.2017.06.21.
85. Thomas R, Francis R, Davies H, Lee Y. Interventional therapies for malignant pleural effusions: the present and the future. *Respirology*. 2014;19(6):809–822. doi:10.1111/resp.12328.
86. Strange C. Parapneumonic effusion and empyema in adults. In: Bartlett J, Broaddus V, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed June 18, 2018.
87. Penz E, Watt K, Hergott C, Rahman N, Psallidas I. Management of malignant pleural effusion: challenges and solutions. *Cancer Manag Res*. 2017; 9:229–241. doi:10.2147/cmar.s95663.
88. van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. *J Thorac Dis*. 2013;5(6):E254–E307.
89. McCauley L, Dean N. Pneumonia and empyema: causal, casual or unknown. *J Thorac Dis*. 2015;7(6):992–998.
90. McCague A, Bowman N, Navarro R, Kong L. Recurrent left chest mass: a case report. *Transl Lung Cancer Res*. 2012;2(3):E25–E28. doi:10.3978/j.issn.2218-6751.2012.11.01.
91. Weerakkody Y. Thoracic empyema | Radiology Reference Article | Radiopaedia.org. *Radiopaediaorg*. 2018. https://radiopaedia.org/articles/thoracic-empyema-1. Accessed June 17, 2018.
92. Light R. Light's criteria for exudative effusions—MDCalc. *Mdcalccom*. 2018. https://www.mdcalc.com/lights-criteria-exudative-effusions#evidence. Accessed June 17, 2018.
93. Rezaeetalab F, Parizadeh S, Esmaeely H, Akbari H, Akbari F, Saberi S. Tumor necrosis factor alpha, high sensitivity C-reactive protein in diagnosis of exudative pleural effusion. *Clin Biochem*. 2011;44(13):S187. doi:10.1016/j.clinbiochem.2011.08.958.
94. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. 6th ed. Philadelphia, PA: Elsevier/Saunders; 2014.
95. Bielsa S, Hernández P, Rodriguez-Panadero F, Taberner T, Salud A, Porcel J. Tumor type influences the effectiveness of pleurodesis in malignant effusions. *Lung*. 2011;189(2):151–155. doi:10.1007/s00408-011-9283-6.
96. Limsukon A. Parapneumonic pleural effusions and empyema thoracis: background, pathophysiology, etiology. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/298485-overview#a2. Accessed June 17, 2018.
97. Daley B. Pneumothorax: practice essentials, background, anatomy. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/424547-overview#a2. Accessed June 17, 2018.
98. Saadoon A, Janahi I. Spontaneous pneumomediastinum in children and adolescents. In: Redding G, Hoppin A, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed June 18, 2018.
99. Carolan P. Pneumomediastinum clinical presentation: history, physical, causes. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/1003409-clinical. Accessed June 17, 2018.
100. Sevinç S. Electrocardiographic changes in primary spontaneous pneumothorax. *Turk Gogus Kalp Dama*. 2014;22(3):601–609. doi:10.5606/tgkdc.dergisi.2014.9034.
101. Light R. Primary spontaneous pneumothorax in adults. In: Broaddus V, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 18, 2018.
102. Sarkar P, Rasheed H. Clinical review: respiratory failure in HIV-infected patients—a changing picture. *Critical Care*. 2013;17(3):228. doi:10.1186/cc12552.
103. Kouritas V, Papagiannopoulos K, Lazaridis G, Baka S, Mpoukovinas I. Pneumomediastinum. *J Thorac Dis*. 2015;7(S1):S44–S49. http://dx.doi.org/10.3978/j.issn.2072-1439.2015.01.11. Accessed June 17, 2018.

CHAPTER

6

Upper Airway Obstruction Disorders

"Listen, are you breathing just a little, and calling it a life?"

—Mary Oliver, *Have You Ever Tried to Enter the Long Black Branches?*

OUTLINE

OBJECTIVES

1. Recognize common characteristics, manifestations, and diagnostic features of upper airway obstruction (UAO) disorders.
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of UAO disorders.
3. Compare vocal cord dysfunction and vocal cord paralysis.
4. Discuss the management objectives for UAO disorders.
5. Identify common complications associated with UAO disorders.

KEY TERMS

Angioedema
Bronchoplasty
Central airway obstruction (CAO)
Cryotherapy
Deglutition muscle
Endobronchial electrocautery
Endobronchial laser therapy
Endobronchial ultrasound (EBUS)
Extrathoracic airway
Fixed obstruction
Glottis
Heimlich maneuver
Infraglottic
Intrathoracic airway
Laryngeal re-innervation
Laryngopharynx
Medialization laryngoplasty
Nasopharynx
Oropharynx
Papillomatosis
Photodynamic therapy
Stenosis
Stridor
Subglottic
Supraglottic
Tracheal stenosis
Tracheomalacia (TM)
Type I LM
Type II LM
Type III LM
Upper airway obstruction (UAO)
Urticaria
Variable extrathoracic obstruction
Variable intrathoracic obstruction
Videolaryngostroboscopy

Case Study

A 41-year-old woman presented to her primary care physician for an assessment of progressive breathlessness with activity. She is taking inhaled bronchodilators and corticosteroids for several years now without noticeable improvement. Her medical history is notable for a 1-week of endotracheal intubation and mechanical ventilation 9 years earlier following a severe head injury. She denies a previous history of smoking as well as family or personal history of allergy or asthma. Her work and environmental exposure history is noncontributory. She is complaining of mild nocturnal coughing but denied symptoms suggesting gastroesophageal reflux.

On physical examination, the patient appears to be in no respiratory distress at rest. Her temperature is 97.5°F, pulse is 94/minute, resting respiratory rate is 18/minute, and blood pressure is 128/90, and the patient weighs 140 lb. Her ear, nose, and throat are normal. A chest examination reveals a biphasic wheeze with deep breathing, but her anterior–posterior chest radiograph is normal. The abdominal exam is noncontributory. Upper and lower limbs are normal. Office spirometry reveals a mild airflow obstruction.

The patient receives a referral for full pulmonary function testing. The pulmonary function testing including maximum expiratory–inspiratory flow–volume loop studies displayed marked limitation of the inspiratory and expiratory flow rates, consistent with a fixed upper airway obstruction (UAO). Her static lung volumes are normal as is her diffusion capacity. High-resolution computed tomography (HRCT) imaging of the trachea revealed a narrowing of the trachea 2.8 cm below the vocal cords. Fiberoptic bronchoscopy confirmed a circular fibrous tracheal web located 2 cm below the vocal cords. The patient received a referral to a thoracic surgeon for surgical consideration.

Introduction

The upper respiratory tract or upper airway consists of the segment between the nose or mouth and the carina. This part of the respiratory tract includes the conducting nasal passage, pharynx, larynx, and central airway. The central airways refer to the trachea and the main-stem bronchi. Unlike the lower conducting airways, such as the main, lobar, and segmental bronchi, the upper airway has no collateral ventilation. Therefore, the obstruction of the upper airway or central airway is unique in that any obstruction, whether acute (occurring within minutes) or chronic (developing over weeks or months), may be catastrophic. Clinically significant obstruction may occur at any site along the upper airway and result in asphyxia and death; recognition and treatment can be lifesaving.[1]

The nasal pathway is considered a part of a dual airway conduit along with the oral cavity. Because of their parallel arrangement, the mouth and the nose are rarely the sites of obstruction except in massive facial trauma.[2] The pharynx has three distinct continuous areas. These areas include the **nasopharynx** region, which occupies the portion below the nasal passages and above the soft palate of the mouth; the **oropharynx**, consisting of the area between the soft palate and the epiglottis; and the **laryngopharynx**, which extends below the epiglottis to the level of the cricoid cartilage (**Figure 6-1**). The larynx has three separate areas, including the **supraglottic** region, the **glottis,** and the **subglottic** region.



FIGURE 6-1 Upper airway anatomy.

Upper airway obstruction (UAO) includes obstruction of the mouth through the trachea at the level of the carina. The term **central airway obstruction** (CAO) refers to the obstruction of airflow through the trachea and main-stem bronchi.[1] Lower airway obstruction

relates to airflow obstruction in the smaller bronchi and is not associated with UAO or CAO.

Definition/Diagnosis

UAO disorders limiting airflow exchange can occur subacutely, as a persistent yet slowly progressive process over several months. One such subacute UAO is tracheal tumors. UAO can also present as an acute event that is potentially fatal. Acute UAO requires immediate evaluation and treatment to assure adequate ventilation and oxygenation, as with foreign body aspiration. UAO disorders can occur anywhere within the upper respiratory tract. However, the larynx has a predilection for obstruction because the glottis in adults and the subglottic region in infants are normally the narrowest part of the upper airway. Slowly progressive upper airway narrowing may be tolerable and symptom free until a critical boundary is reached. In an acute situation, however, rapid identification of warning signs and symptoms is necessary to secure sufficient time for evaluation and treatment of the precipitating condition. The timing for any medical or surgical interventions is based on the clinical status of the affected individual and the assessment of the circumstances.

In the unconscious apneic person, airway obstruction requires immediate determination of airway patency. In this situation, airflow must be quickly established. The initiation of appropriate resuscitation efforts is determined by the absence of airflow and is caused by the termination of cardiopulmonary function or airway obstruction. In the absence of associated cervical spine injury, an airway obstruction resulting from backward displacement of the jaw and tongue can be corrected by tilting the head backward. This backward head tilt extends the neck, separating the posterior pharyngeal wall from the base of the tongue. Moving the mandible forward with a chin lift opens the pharyngeal airway. This sniffing position allows air passage and removal of secretions or other substances. If unconsciousness persists, endotracheal intubation establishes, protects, and maintains airway patency (**Figure 6-2**). A surgical airway, such as tracheostomy, cricothyroidotomy, or needle cricothyrotomy, may be necessary under certain circumstances.

A diagnosis of complete UAO in a conscious person, caused by a foreign body or food bolus lodged in the hypopharynx, is often made by an observer witnessing the event. In this case, witnesses observe that the affected person stops breathing during the process of eating. This event is shortly followed by the affected person becoming pale, anxious, and agitated. This situation is accompanied by the obvious inability of the victim to voice complaint or a cough. The cause of the acute respiratory distress, in the outpatient setting, points to an obstruction of the larynx from a foreign body. For this reason, techniques such as the **Heimlich maneuver** (abdominal thrust), a jaw-thrust technique in suspected neck trauma, chest thrust, and back blows may be sufficient (especially when repeated if not initially dislodged) to create an artificial cough to expel the foreign substance from the airway (**Figure 6-3**).



FIGURE 6-2 The sniffing position to open the upper airway with the neck slightly flexed and the head extended. This position is used for intubation.

FIGURE 6-3 The Heimlich maneuver or abdominal thrust is done to clear a foreign body obstruction from the upper airway.

A diagnosis of a partial or incomplete UAO in an awake and breathing patient is suspected when an impediment of airflow during breathing is accompanied by a history of foreign body aspiration, trauma, or infection to upper airway structures. These types of situations cause somewhat less dramatic features than those displayed in complete airway obstruction.

Clinical Signs and Symptoms

Acute UAO typically presents with stridor and dyspnea. These patients require immediate assessment so that they can be managed expediently with appropriate interventions to secure a safe and stable airway.[3] **Box 6-1** lists other clinical signs and symptoms of UAO, both acute and subacute.

Symptoms and signs of shortness of breath, cough, wheeze, stridor, and voice hoarseness, along with intercostal and supraclavicular muscle retractions, indicate at least partial airflow movement. Stridor is an abnormal, high-pitched sound produced by turbulent airflow through a partially obstructed airway at the level of the supraglottis, glottis, and/or trachea. Stridor is associated with partial obstruction of the upper airway, and represents turbulent airflow involving the upper airway, glottis, and trachea. It implies a reduction in airway diameter to less than 5 mm in an adult. Stridor may be inspiratory, expiratory, or biphasic depending on its timing in the respiratory cycle. Inspiratory stridor suggests a laryngeal obstruction, whereas expiratory stridor implies tracheobronchial obstruction. Biphasic stridor suggests a subglottic or glottic anomaly. A triad of choking, cough, and wheezing is suggestive of foreign body aspiration in children.[4]

Etiology

The upper airway can be affected by either acute problems or those following a more subacute or chronic course. The causes of UAO disorders are varied. They include congenital abnormalities, trauma, infections, inflammation, foreign bodies, vocal cord paralysis (VCP), tumors, angioedema, and neuromuscular, and may be inadvertently caused by medical treatment (iatrogenic) (**Table 6-1**).

Epidemiology

The epidemiology of UAO depends on the cause. Some of the well-known UAO disorders include laryngeal or glottic **stenosis**, angioedema, vocal cord dysfunction (VCD), Ludwig angina, and foreign body aspiration. Approximately 15% of patients who are intubated for more than 10 days develop some degree of glottic stenosis. The reported incidence of subglottic stenosis after intubation is 1–10%. The duration of intubation is the most critical factor in the development of stenosis. Congenital glottic stenosis is a rare disorder, as is congenital laryngeal webs.[5] The World Allergy Organization states that **urticaria** (hives) and angioedema affect up to 20% of the population and estimates that approximately

BOX 6-1 Clinical Signs and Symptoms of UAO

Acute UAO	Subacute UAO
• Throat constriction • Panic • Inability to speak • Muted or weak cough • Salivation • Patient grabbing at throat • Stridor or no audible breath sounds • Tachycardia • Hypertension • Hypercapnia • Hypoxemia	• Progressive dyspnea • Dry chronic cough • Sore throat • Voice changes • Orthopnea • Shortness of breath related to position • Asymmetrical neck bulge • Paroxysmal nocturnal dyspnea • Gastroesophageal reflux symptoms

TABLE 6-1
Etiologies of UAO in Adults[4]

Category	Causes
Angioedema	Anaphylactic reactions (e.g., allergic, hereditary, drug induced)
Congenital	Laryngeal web Laryngomalacia (LM) Macroglossia (large tongue) Micrognathia Vascular ring VCD
Foreign bodies	Chicken bones, etc.
Iatrogenic	Mucous ball from transtracheal catheter Tracheal stenosis postintubation Tracheal stenosis post-tracheostomy
Infections and Inflammation	Diphtheria Laryngitis Ludwig angina Pharyngitis Relapsing polychondritis Retropharyngeal abscess Sarcoidosis Suppurative parotitis Tonsillar hypertrophy Wegener granulomatosis
Neuromuscular	Guillain–Barre polyneuritis Hypocalcemia Laryngospasm Myasthenia gravis Obstructive sleep apnea Recurrent laryngeal nerve interruption Stroke Tetanus
Trauma	Acute laryngeal injury Airway burns Facial trauma (mandibular or maxillary fractures) Hemorrhage Laryngeal stenosis (LS) Tracheal stenosis
Tumors	Laryngeal papillomatosis Laryngeal tumors (benign or malignant) Tracheal stenosis
Others	VCP Exercise-induced laryngeal obstruction

10–20% of the world population may experience at least one episode of angioedema during their lifetime.[6] Angioedema affects people of all ages. Individuals who are predisposed to angioedema have an increase in the frequency of attacks after adolescence, with the peak incidence in the third decade of life.[6]

VCD is observed in up to 10% of patients seeking referrals for asthma that is unresponsive to aggressive therapy. VCD is predominantly found in females, with a female-to-male ratio of approximately 3:1, and in people aged 20–40 years.[7] Most patients who develop Ludwig angina, a life-threatening, soft tissue infection of the floor of the mouth and neck, are between the ages of 20 and 60 years. This UAO disorder has a male predominance, with a male-to-female ratio of 3:1 to 4:1.[8] Foreign body aspiration has a bimodal age distribution. Most incidences occur with children ages 1–4 years, and then the frequency rises again with people over the age of 75 years.[9,10]

Pathology/Pathophysiology

The sites of UAO include supraglottic, above the true vocal cords; intraglottic, involving the true vocal cords; or **infraglottic**, between the vocal cords and the carina. UAOs are also divided into intrathoracic and extrathoracic locations. There are a variety of causes of UAO, but fundamentally all lead to an increase in airway resistance and work of breathing and cause breathing to be ineffective.

Nasal Passage

Nasal obstructions infrequently cause significant airflow limitation and ventilatory impairment due to the combined airway pathway through both the nose and the mouth. The nasal passages primarily participate in nearly all modifications of inspired air, including a warming and humidifying function resulting from aerodynamic patterns of airflow proximal to the nasal mucosa. When abnormalities exist, nonemergent airway obstructions are far more commonly seen. Those disorders that can produce nasal airflow obstruction include nasal passage or sinus allergies and infections, nasal polyps, nasal tumors or lymphoma, adenoidal hypertrophy, and trauma. Any process causing obstruction of the nasal passageway and cavities not only compromises the air modification processes but also affects the cellular defense mechanisms of the nasal mucosa and impairs normal drainage from paranasal sinuses.

Pharynx

The muscles of the pharynx are central to efficient lung airflow and ventilation because they are responsible for helping to maintain open upper airspace for the unrestricted passage of air into and out of the lungs. The oropharyngeal and hypopharyngeal regions of the pharynx serve as a common pathway for both food and inspired air. Respiratory control regulates and maintains the tone of **deglutition muscles** (swallowing muscles), including the tongue, which prevents the collapse of pharynx during inspiration. In unconscious patients, the tongue may fall backward, causing UAO.

The oropharynx region of the pharynx is especially crucial in obstructive sleep apnea because this area is more vulnerable to airflow obstruction during inspiration. An interrupted loss of pharyngeal and tongue muscle tone, especially during periods of rapid-eye-movement (REM) sleep, causes a fundamental modification of pharyngeal muscle tone and reflex responses that, in healthy individuals, leads to predictable airway narrowing and hypoventilation. In persons with already anatomically narrow upper airways, the effects of sleep are compounded, thus predisposing these individuals to inspiratory flow limitation (hypopneas), airway closure, and obstructive sleep apnea (Chapter 7). Pharyngeal obstruction is caused by various infections presenting as abscesses, neoplastic lesions, tonsillar enlargement, salivary tumors, traumatic injury, and macroglossia.

Larynx

The larynx is that region of the upper airway that connects the pharynx with the trachea. It is composed of three single cartilages (thyroid, cricoid, and epiglottis) and three paired cartilages (arytenoid, corniculate, and cuneiform), which are connected by ligaments and moved by various muscles (**Figure 6-4**). Because of the small size opening of the larynx, especially in children, this upper airway structure is commonly obstructed from infectious causes of inflammation such as those responsible for causing epiglottitis and croup. Other causes of laryngeal obstruction include foreign body aspiration causing partial or complete obstruction; allergic mechanisms (as in angioedema); trauma to the larynx; congenital defects; neoplastic changes in the larynx, including **papillomatosis**; and vocal cord anomalies. Post-extubation laryngeal edema may immediately result in airway impingement or obstruction following removal on an endotracheal tube. Vocal cord movement disorders can cause abnormal laryngeal closure and opening, resulting in airway obstruction. This can be due to the failure of or the augmented activity of the vocal cord adductor muscle function which can disrupt normal glottic opening during inspiration and narrowing during expiration. VCP or palsy is generally a much more severe disorder, especially with bilateral cord involvement.

Trachea

The trachea is the longest section of the upper airway, which begins at the inferior portion of the larynx and extends to the main bifurcation, the carina. The trachea has a "D" shape, with 18–22 elliptical-appearing or "C"-shaped cartilaginous rings in the human trachea occurring approximately two rings per centimeter. The



FIGURE 6-4 Anatomy of the larynx. (**A**) Anterior view. (**B**) Posterior view.

cartilaginous "C rings" are present throughout the entire trachea as well as the large- and medium-sized airways, which function to maintain airway patency during expiration, including coughing. Posterior to the trachea is the esophagus, which sits next to the straight membranous wall of the trachea. The diameter of the trachea varies from 2 to 2.5 cm, and the length ranges from 10 to 13 cm. Tracheal obstructions result from intrinsic disorders such as infections, inflammatory disorders, trauma, and malignancy or from extrinsic compression from adjacent structures such as carcinomas and lymph nodes.[11] Obstructions in the trachea, as well as in the main-stem bronchi, are CAOs and are divided into malignant and nonmalignant etiologies.[1]

Fixed Versus Variable and Intrathoracic Versus Extrathoracic UAO

UAO is either fixed or variable and either intrathoracic or extrathoracic. Inspection of the flow–volume loop obtained during a pulmonary function test helps to determine which type of UAO is present.[12] The **extrathoracic airways** include the upper portion of the trachea, the glottis, and the structures superior to the glottis. The **intrathoracic airways** include the lower portion of the trachea and all the conducting airways inferior to the trachea (**Figure 6-5**).

During normal deep inspiration, the intrathoracic airways slightly increase in diameter due to the negative pressure maintained in the intrapleural space and the airways. The extrathoracic airways slightly decrease in diameter during deep inspiration. During forced expiration, the intrathoracic airways slightly reduce in diameter due to the positive pressure surrounding them and the extrathoracic airways increase in diameter because the tracheal pressure is higher than the atmospheric pressure.

An obstruction of the upper airway causes a change in the flow–volume loop, which is characteristic depending on the location and type of obstruction. See **Box 6-2**. **Figure 6-6** presents a flow–volume loop that shows a **variable intrathoracic obstruction**. The forced expiratory flow rates cause the airways to collapse due to the increased pleural pressure. During the forced inspiration, flow is normal.[13]

Figure 6-7 shows a flow–volume loop with a **variable extrathoracic obstruction**. The forced expiratory flow rates are normal and higher than those achieved during the forced inspiration. During the forced inspiration, flow rates are reduced because the pressure in the extrathoracic airways is less than atmospheric pressure, causing collapse.[13]

Figure 6-8 presents a flow–volume loop that shows a **fixed obstruction**. The airway is minimally affected by the airway pressure because of an intrathoracic or extrathoracic blockage. Airflow during forced inspiration and expiration is equally reduced, and the flow–volume loop appears rectangular.[13]



FIGURE 6-5 Intrathoracic and extrathoracic airways.

BOX 6-2 Examples of Fixed and Variable UAO[12]

Fixed UAO, which may be extrathoracic or intrathoracic, includes the following:

- Tracheal stenosis (postintubation or post-tracheostomy)
- Tracheal tumors or lesion (firm)
- Angioedema
- Goiter (enlarged thyroid gland) compressing the trachea

Variable UAO, which may be extrathoracic or intrathoracic, includes the following:

- Extrathoracic UAO
  - Laryngeal abnormalities
    - Glottic strictures (stenosis, swelling)
    - LS and tumor
    - LM
    - Subglottic stenosis (SGS)
    - VCP and dysfunction
  - Extrathoracic tracheomalacia
- Intrathoracic UAO
  - Intrathoracic tracheomalacia
  - Tracheal tumor

Data from Shelledy D. Assessment of Oxygenation. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016 (Box 6-7, page 197).



FIGURE 6-6 **(A)** Flow-volume loop displaying a variable intrathoracic large airway obstruction (e.g. airway tumor). **(B)** Schematic of lungs, with a variable intrathoracic airway obstruction in the thorax, during a forced expiratory maneuver. The positive pressure in the pleural space during the forced exhalation causes the airway to collapse, reducing the expiratory flow.



FIGURE 6-7 **(A)** Flow-volume loop displaying a variable extrathoracic large airway obstruction. The extrathoracic airway obstruction increases during an inspiratory maneuver when the atmospheric pressure is less than the pressure in the upper airway. **(B)** Schematic of lungs during an inspiratory maneuver with a variable extrathoracic obstruction. During a forced expiration the airway normalizes in size.



FIGURE 6-8 **(A)** Flow-volume loop displaying a fix airway obstruction, either intrathoracic or extrathoracic. Both the forced expiratory and inspiratory maneuvers demonstrate similar flow limitations. **(B)** Schematic of lungs, with either an extrathoracic or intrathoracic airway obstruction.

BOX 6-3 Stridor Versus Wheeze[2,15]

Stridor	Wheeze
• Occurs usually during inspiration • Heard loudest over the neck • Accentuated by voluntary panting • Intensity changed with neck flexion (thoracic outlet obstruction) • Inspiratory and expiratory stridor may be intrathoracic obstruction • Worrisome sign of UAO	• Predominantly during expiration • Loudest at end expiration • Diffuse wheeze (lower airway narrowing) • Focal wheeze (e.g., foreign body in lower airway, endobronchial tumor) • Polyphonic wheeze (dynamic compression of large, more central airways) • Monophonic wheeze (suggestive of bronchospasm when over lower airways)

Diagnostic Testing

It is difficult to detect the sound signals from the asthmatic wheeze and **stridor** because they are of similar frequency. This explains why errors in diagnosis may be made and why UAO due to a tumor or foreign body is often mistakenly treated as asthma.[2,14] See **Box 6-3**.

The character of a patient's voice may be a clue to UAO. Hoarseness may be a sign of a laryngeal abnormality, and muffling of the voice without hoarseness may represent a supraglottic process.[2] The direct observation of a visible pharyngeal abnormality such as infection, cyst, tumor, and tonsillar enlargement can provide evidence of incomplete airway obstruction. Most other subacute or chronic causes of UAO and severity may be suspected by obtaining a complete history and physical examination, appropriate use of radiographic imaging, and pulmonary spirometric studies, and may be later confirmed with endoscopic visualization of the suspected region. When an acute UAO is suspected, immediate treatment is necessary because a delay may be dangerous for the patient.

Investigational options in UAO include several studies that can assist in identifying the presence, location, and usually the cause of an apparent UAO.

Symptoms, spirometric findings, and specific risk factor exposures may suggest the need for chest and neck radiologic screening. These tests identify tracheal deviation, extrinsic airway compression, or the presence of radiopaque foreign bodies when the diagnosis remains in doubt, and there is no immediate threat of worsening obstruction. Diagnostic imaging plays an essential role in the evaluation of disease processes that affect the upper airway. Imaging allows for the localization and characterization of various conditions that are often not identified on physical examination.[16] Plain radiography maintains a limited role in airway evaluation, whereas advanced imaging modalities, including computed tomography (CT) and magnetic resonance imaging, have emerged as indispensable tools in patient evaluation[16] (**Figure 6-9**). CT scanning is the standard imaging modality for the evaluation of chronic UAO because it is highly accurate for identifying focal abnormalities in the large upper airways.[1] The use of multiplanar CT techniques, coupled with three-dimensional reconstructions, provides precise anatomic delineation of the trachea and larynx.[1,17] Virtual bronchoscopy offers excellent anatomical images of airways, thereby overcoming the limitations of conventional axial CT images. The advantage of virtual bronchoscopy is the ability to produce images of the airway surfaces beyond the site of stenosis, through which conventional bronchoscopes cannot pass.[17]

Pulmonary function studies, including spirometry with flow–volume loop determinations, may assist in assessing the individual who displays symptoms of nonemergent UAO. The flow–volume loop tracing is useful for identifying the anatomic location, as well as functional severity, of UAO (Figures 6-6 to 6-8).

No definitive laboratory tests are currently available and capable of aiding in the diagnosis of UAO disorders. Endoscopic findings via direct visualization provide the most successful means of diagnosing and often treating suspected UAO (Figure 6-9). Rigid bronchoscopy is useful and recommended in securing the upper airway by permitting direct passage through incomplete stenotic regions of obstruction below the larynx. Flexible bronchoscopy, with a thin bronchoscope, is a useful tool for evaluating narrowed airways during therapeutic



FIGURE 6-9 Medication-induced angioedema of the upper airway seen in two patients. Diffuse mucosal and submucosal edema is seen in these contrast-enhanced axial and sagittal CT images through the upper airway. Mild narrowing of the airway is seen in the first patient (top left and right), and complete occlusion of the airway is seen in the second patient (bottom left and right).

bronchoscopic procedures. A thin bronchoscope, with a 1.7-mm working channel, can pass through a stenosed airway when a standard-sized bronchoscope has failed.[17] Bronchoscopes, both flexible and rigid, are useful during the visual examination to establish a diagnosis and also to deliver treatments such as **endobronchial laser therapy**, **cryotherapy**, **photodynamic therapy**, **endobronchial electrocautery**, **bronchoplasty** (balloon dilation), or tracheal stent placement[18] (**Figure 6-10**).



FIGURE 6-10 Bronchoscopic view of a lobulated mass lesion located in the mid-portion of the trachea, causing 65% of the lumen obstruction.

Reproduced from Yıldırım F, Türk M, Demircan S, Akyürek N, & Yurdakul AS. (2015). Tracheal papilloma treated with cryotherapy and interferon-α: a case report and review of the literature. Case reports in Pulmonology, 2015.

Fixed UAO

Tracheal obstruction results from both intrinsic disorders (infections, inflammatory diseases, trauma, and malignancy) and extrinsic compression from adjacent structures. These disorders manifest mainly as obstruction via narrowing or stenosis.[11] However, a process that causes flaccidity of the supporting tracheal cartilage, **tracheomalacia**, causes the trachea to collapse during inspiration or expiration. Tracheomalacia (TM) presents as a variable intrathoracic UAO.

Tracheal Stenosis

Clinically significant stenosis typically occurs when the original diameter of the trachea is reduced by approximately 50%.[19] Clinical recognition of **tracheal stenosis** is usually complicated early in its course because features of airway obstruction are late and nonspecific. If tracheal narrowing is less than 50%, the pressure drop across the narrowing is like that which occurs through the normal

glottic opening and, therefore, is unlikely to cause symptoms.[19] CT imaging and the use of multidetector computed tomography (MDCT) enable early diagnosis.

Tracheal stenosis is mainly related to endotracheal intubation, tracheostomy, and postinfection, transplant-related, and idiopathic stenosis.[19] The incidence of postintubation tracheal stenosis (PITS) is estimated to be up to 21% and is more common in females.[11]

Tracheal stenosis has several morphologies. Circumferential tracheal stenosis is concentric in nature and is due to a cuff-related injury from an endotracheal or tracheostomy tubes and autoimmune disorders. Simple circumferential tracheal stenosis is less than 1 cm in the vertical extent. Complex circumferential tracheal stenosis is longer than 1 cm and occurs with chondritis. Triangular tracheal stenosis is "A" shaped and develops from tracheal wall injury after tracheostomy and chondritis. Eccentric tracheal stenosis is oval or elliptical in shape and occurs after intubation or after thermal injury (inappropriate use of laser or electrocautery). Eccentric tracheal stenosis is often complex stenosis with cartilaginous damage. The complex tracheal stenosis is a scar stenosis with an hourglass-like contraction that is usually greater than 1 cm long with tracheal wall injury or associated chondritis. Complex tracheal stenosis occurs most commonly after intubation and tracheostomy (**Figure 6-11**). Simple tracheal stenosis is a web-like membranous stenosis without cartilage damage and is less than 1 cm in vertical length.[11,19] Iatrogenic tracheal stenosis is due to tracheal mucosal ischemia, inflammation, and erosion of the mucosa leading to necrosis, then fibrosis at the site of the endotracheal tube or tracheostomy tube cuff and at the location of the tracheostomy.[11]

The assessment of airway stenosis, particularly tracheal stenosis, requires that several factors be considered. These factors are considered for individualizing treatment and follow-up strategies in patients with tracheal stenosis. The factors include the severity of the airway narrowing, extent, cause (origin), morphology (shape of the stenosis), voice characteristics, swallowing, and overall functional impairment.[19] The severity categories include mild, less than 50% reduction in tracheal diameter; moderate, 51–70% reduction in diameter; and severe, 71% or greater reduction in diameter.[19]

FIGURE 6-11 Three-dimensional reconstruction CT scan of tracheal stenosis.

Reproduced from Saenghirunvattana, S, et al. Different approaches on various cases of tracheal stenosis. *Open Journal of Respiratory Diseases.* 2014:4, 90–100. Doi: 10.4236/ojrd.2014.43013.

Surgical reconstruction is the "gold standard" for the management of tracheal stenosis.[20] However, stenosis resection in the subglottic area is much more difficult to repair surgically. Conservative treatments are possible for stenoses smaller than 1 cm in length without circumferential scarring and no loss of cartilaginous support.[21] Noninvasive techniques are available for those patients who are not candidates for surgical repair. These include techniques that can be applied through the bronchoscope such as bronchoscopic dilatation, intralesional corticosteroid injection, laser therapy, photodynamic therapy, cryotherapy, external beam radiation, and brachytherapy. Airway stents are useful for palliative relief of airway obstruction in selected, inoperable, and histologically benign tracheal stenosis.[11,19]

Tracheal Tumors

A variety of malignant and nonmalignant tumors can obstruct the trachea. The nature of the malignant tumors is further classified as primary endoluminal, metastatic carcinoma of the airway, extraluminal, or mixed. Primary tracheal tumors are relatively uncommon, with an estimated 600–700 cases per year. Most of the primary tracheal tumors (70–80%) are due to lung cancer, either squamous cell carcinoma or adenoid cystic carcinoma[22] (**Figure 6-12**). Carcinoid tumors account for most of the primary airway tumors distal to the carina.[22] Metastatic tracheal tumors are mostly from thyroid, breast, or colon cancer; melanoma; or renal carcinoma.[19]

The clinical signs and symptoms of tracheal tumors are nondefinitive, often manifesting like a variety of common respiratory conditions. If the airway obstruction is mild, it may have little effect on airflow, and therefore, patients may be asymptomatic. The inflammation associated with even mild respiratory tract infections can cause mucosal swelling and mucus production, which may further occlude the tracheal lumen. That is why patients are sometimes misdiagnosed with exacerbations of chronic obstructive pulmonary disease (COPD) or asthma, especially because wheezing and dyspnea may improve with therapy aimed at treating the superimposed infection.[22]

An initial insidious presentation typically involves slow progressive shortness of breath after activity. Evidence of acute respiratory difficulty does not emerge until the airway is almost completely occluded. Because of the dramatic loss of airway diameter before the development of symptoms, patients can present with respiratory



FIGURE 6-12 Tracheal squamous cell carcinoma: 2 cm in size, located 2 cm above the carina, obstructing about 90% of the trachea.

distress.[22] Tracheal tumors are very likely to be found during the work-up for more common pulmonary conditions such as pneumonia, adult asthma, or lung cancer.

The flow–volume loop in the case of a tracheal tumor, either intrinsic or extrinsic, demonstrates the characteristic "clipping" of both expiratory and inspiratory sides. Because of the possibility of inducing respiratory failure, spirometry should not be undertaken in patients with respiratory distress.[22] In a stable patient or in one who is stable following the initial airway management, a thorough patient history, imaging studies (chest radiography and CT scan), and pulmonary function tests (in nonintubated patients) are needed. These tests will provide enough evidence to narrow the differential diagnosis to one or a few diagnostic possibilities.[23]

Direct visualization allows the nature and extent of the obstruction to be determined and provides useful treatment planning information such as the relative amount of intraluminal and extraluminal disease.[22] In most cases, flexible bronchoscopy with or without **endobronchial ultrasound** (EBUS) is sufficient for the diagnostic evaluation of a tracheal tumor. EBUS is extremely sensitive for determining the degree of tracheal invasion and is useful in planning therapeutic interventions.[22] EBUS is useful in selecting proper airway stent size, guiding tumor debridement, and selecting patients for endoscopic therapy versus surgical therapy.[22] If cancer is suspected, a tissue sample is necessary for therapy. In some cases, brief therapeutic interventions can be performed simultaneously with the initial bronchoscopy. If cancer is not suspected, as with extraluminal nonmalignancies (vascular ring or enlarge goiter), a CT scan may be sufficient.[23]

The immediate goal for the treatment of airway obstruction due to a tracheal tumor is to stabilize the airway and ensure adequate ventilation and oxygenation. In emergencies, airways may be dilated with the barrel of a rigid bronchoscope or via sequential balloon dilation.[22] Surgical resection of the tumor in patients with lung cancer is considered curative and is, therefore, the standard therapeutic approach. In all other patients, the goal of management is to restore airway patency to improve symptoms or prevent postobstructive pneumonia, respiratory insufficiency, and sepsis.[19,24] Endobronchial treatment with or without airway stenting is commonly used as a tumor-debulking method for malignant tracheal tumors.[25] Other effective treatment options for symptomatic obstruction relief include laser therapy, argon beam coagulation, contact electrocautery, cryotherapy, photodynamic therapy, brachytherapy, and airway stenting[19] (**Figure 6-13**). No one endobronchial therapy is superior to another for debulking tracheal tumors.[19,22,24] Frequently, the best therapeutic approach appears to include a combination of several treatment approaches.[24] Interventions need to leave options for further therapy open, and the most comprehensive assessment and therapy are generally provided by centers with a multidisciplinary airway team specializing in compromised airways.[22]

Angioedema

Angioedema manifests as episodes of localized swelling in the dermis, subcutaneous tissue, mucosa, and/or submucosal tissues because of vascular leakage.[26] Angioedema is typically nonpitting and nonpruritic, with either no change in color or a slight redness. Different types of angioedema are recognized. Hereditary



FIGURE 6-13 Contact electrocautery of an airway tumor.

Stratakos G, Gerovasili V, Dimitropoulos C, et al. Survival and quality of life benefit after endoscopic management of malignant central airway obstruction. *J Cancer*. 2016;7(7):794–802 (Figure 7, p. 801). doi:10.7150/jca.15097.



FIGURE 6-14 **(A)** Edema of the face and neck due to angioedema. **(B)** Resolution of edema.

angioedema (HAE) is a rare genetic disorder occurring in approximately 1 per 50,000 persons.[27] HAE due to a C1 inhibitor deficiency (HAE-C1INH) results from gene mutations. Two subtypes of HAE-C1INH exist. Type I results from the inability of the mutated C1 inhibitor protein to be secreted into the blood and accounts for 85% of cases. Type II HAE results from the secretion of dysfunctional C1 inhibitor protein and accounts for the remaining 15%.[28] Types I and II usually appear early in life, most often by age 13 and may increase in severity with age. The third type of HAE (HAE-nl-C1INH) results from a mutation in coagulation factor XII. With HAE-nl-C1INH, the C1 inhibitor gene is normal. But like HAE Types I and II, there is a hereditary factor. This type of HAE occurs more frequently in women.[28] Two very rare types of acquired angioedema (AAE-1 and AAE-II) appear in the fourth decade of life or later and are not genetic in origin. Nonhistaminergic angioedema (INAE) occurs in about 1 out of every 20 cases of angioedema and occurs without urticaria (hives).[28] The most common form of angioedema is allergic angioedema. Allergic angioedema is a reaction to an outside influence such as food, bee sting, cold, heat, latex, or drug, which provokes a histamine reaction.[28] If urticaria persists past 6 weeks, it is called chronic idiopathic angioedema and not allergic angioedema. More than 40% of chronic angioedema is idiopathic.[6] About 4–8% of people with angioedema have the angiotensin-converting enzyme (ACE) inhibitor type. The ACE inhibitors that are known to cause angioedema include captopril, enalapril, benazepril, quinapril, and ramipril.[28]

Pathophysiologically, angioedema develops mainly because of the release of two different vasoactive peptides: histamine and bradykinin. The clinical presentation of angioedema may be similar.[29]

Whatever the etiology of the angioedema, the priority is to ensure that the patient has a patent airway. Recognition of airway involvement is of primary importance in receiving appropriate early care (Figures 6-9 and **6-14**). Facial and lip edema is regarded as an important "initial" symptom because upper airway edema is preceded by facial/labial edema in 15–30% of cases.[30] Edema of the soft palate, pharyngeal arch, uvula, and tongue is easy to assess using a tongue blade. However, the assessment of laryngeal angioedema requires endoscopy or indirect laryngoscopy. Assessment of the physical signs and symptoms of UAO is vital because acute laryngeal edema due to angioedema is a potentially life-threatening emergency. See **Box 6-4**.

BOX 6-4 Signs and Symptoms of Angioedema of the Upper Airway[29,30]

Aphonia	Loss of consciousness
Anxiety and agitation	Odynophagia (painful swallowing)
Cyanosis (rapidly progressive)	Resonant, "barky" cough
Diminished respiratory effort	Rough voice
Dyspnea	Stridor
Hoarseness	Throat tightness
Intercostal and supraclavicular retractions	Voice changes

The challenge of this condition is whether to observe the patient or immediately secure the airway, either by intubation or via surgical airway. Airway edema may become so severe and extensive that tracheotomy may not be successful in providing a patient airway.[26] This difficult airway situation requires videolaryngoscopy,[26] fiberoptic bronchoscopy,[26] or nasopharyngeal[30] intubation.

Pharmacologic treatment depends on the type of angioedema. Antihistamines are beneficial in histamine-mediated angioedema but have no role in the treatment of bradykinin-mediated angioedemas, such as HAE.[28] Epinephrine is appropriate for acute airway edema, anaphylaxis, and histamine-mediated angioedema.[29] Glucocorticosteroids are beneficial in the treatment of patients with acute urticaria and angioedema.[29] Bradykinin-mediated angioedema can be treated with plasma-derived C1 inhibitors, bradykinin receptor antagonist, plasma kallikrein inhibitor, or recombinant C1 inhibitor.[28,29]

The long-term prognosis for patients with angioedema depends on the etiology and on whether the trigger can be identified and subsequently avoided. With

idiopathic angioedema, there is tremendous variability in the clinical course. HAE requires lifelong treatment.[6]

Variable Extrathoracic UAO

A variable obstruction elicits varying degrees of obstruction during the respiratory cycle. A variable extrathoracic airway obstruction creates increased turbulence during inspiration and a decreased intraluminal pressure (below atmospheric pressure). During inspiration the already partially obstructed airway becomes narrower. The positive pressure during expiration decreases the obstruction because it is located outside the thorax. VCP, VCD, LS, and LM are common causes of variable extrathoracic obstructions.

Vocal Cord Paralysis

Vocal cord paralysis (VCP) can be caused by a lesion anywhere on the neural pathway to the larynx.[31] Vocal cord (fold) paralysis is typically classified by the site of the lesions (supranuclear, bulbar, peripheral nerve, myoneural junctions, or laryngeal muscles) or the nature of the disorder (inflammatory, neoplastic, traumatic, postsurgical, systemic, or idiopathic).[32] VCP may be bilateral or unilateral, congenital or acquired (**Figure 6-15**). The disorder generally involves either the vagus nerve or its recurrent laryngeal branch between the jugular foramen and its arrival at the larynx. Unilateral VCP is most common. About one-third of unilateral paralysis is neoplastic in origin, one-third traumatic, and one-third idiopathic.[31] However, it is the bilateral VCP (BVCP) that can be life threatening.

VCP ultimately results from a disturbance of the vagal nerve and the recurrent laryngeal nerve supply to the laryngeal muscles.[32,33] The primary outcome of VCP is the loss of sufficient vocal cord abduction and adduction that can influence phonation, ventilation, and deglutition.



FIGURE 6-15 A comparison of normal vocal cords, unilateral VCP, and BVCP during respiration and phonation.

Unlike the immobile vocal cord that is paralyzed and constant in location, conditions such as recurrent laryngeal nerve paralysis may permit the cord to move with phonation but not with inspiration. Although the voice may be hoarse in character, the airway usually remains unobstructed because the normal cord is capable of abducting sufficiently. In BVCP, which is nonfixed, both cords are generally positioned near the midline (2–3 mm),[31] with a narrow glottic aperture.[34] While the voice usually remains of good quality in contrast to the hoarseness of unilateral paralysis, the intensity of the voice typically becomes diminished. The obstructed airflow pathway becomes insufficient, resulting in inspiratory stridor and shortness of breath as both vocal cords are drawn closer to the midline by an inspiratory Bernoulli effect.[31]

Unilateral and bilateral VCP are different entities with an assortment of presenting symptoms, causes, and treatments. In unilateral VCP, the left vocal cord is affected twice as often as the right and occurs more often in females than in males (3:2).[31] Clinical presentation of unilateral VCP includes coughing, choking, dysphonia, and aspiration. Around 40% of unilateral VCP is caused by surgical injury.[33] Stridor and other symptoms of airway obstruction are less frequent and are often relatively mild. Treatment for unilateral paralysis is directed at improving voice quality and preventing aspiration through augmentation, medialization, or re-innervation. Injection augmentation of materials such as autologous fat, gel foam, collagen, and silicone can bring the cords closer together to improve the voice and prevent aspiration.[31] **Medialization laryngoplasty** shifts the vocal cord toward the midline by inserting an adjustable spacer laterally to the affected cord.[31,35] **Laryngeal re-innervation** is a surgical procedure that aims to bring a new nerve supply to the injured vocal cord.[35] Symptom resolution often occurs over a period of several months depending on the treatment performed.

BVCP presents a far more significant clinical challenge. BVCP in adduction is characterized by inspiratory dyspnea, due to the paramedian position of the vocal fold with narrowing of the airway at the glottic level. The condition is often life threatening and therefore requires surgical intervention to prevent acute asphyxiation, or pulmonary consequences of chronic airway obstruction.[36] Symptoms range from minimal dyspnea or inspiratory stridor to severe respiratory distress.[34] Four to fourteen percent of patients with BVCP tolerate the condition and do not require any surgical treatment.[36] However, over the course of several years, these individuals may decompensate and inevitably need surgery. Most patients undergo some form of surgery to enlarge the glottis.

BVCP can be iatrogenic, secondary to neck surgery or tracheal intubation. Neurologic disorders such as amyotrophic lateral sclerosis, diabetic neuropathy, myasthenia gravis, stroke, and head injury may also

be the cause.[34] Treatment for BVCP is based on the severity of symptoms, functionality, and patient priorities. For some, optimal vocal quality is worth living with a tracheostomy, but for most, decannulation of their tracheotomy, or improvement of their airway obstruction symptoms is the primary goal of treatment.[37] Treatment options for BVCP include nocturnal CPAP[37] for those not opting for surgery, posterior laser cordotomy,[31] arytenoidectomy,[31] endoscopic lateralization,[38] and possibly re-innervation of the recurrent laryngeal nerve.[37]

Vocal Cord Dysfunction

VCD, or paradoxical vocal fold motion disorder, is a disorder characterized by inappropriate closure of the vocal cords during inhalation and sometimes during exhalation.[39] VCD can cause extrathoracic airway obstruction and asthma-like symptoms by producing a partial upper airflow obstruction at the level of the larynx.[40] The vocal cords normally abduct with inhalation and partially adduct during the early phase of expiration (**Figure 6-16**). This causes unobstructed movement of air into the lungs and outward from the lungs to the atmosphere while maintaining alveolar patency. Normal vocal cord adduction also occurs during swallowing, phonation, the Valsalva maneuver, and the early compressive phase of coughing.[41] In this way, the larynx functions as an upper airway valve to maintain ventilatory performance and lung expansion in addition to its role in voice production and swallowing.

The disorder predominantly occurs in females compared to males in an approximate ratio of 3:1.[42] While the condition is seen mostly in people aged 20–40 years,[41] it can occur in people from infancy to 82 years, with an increase among children and adolescents.[42] VCD is frequently misdiagnosed as having refractory asthma and is often treated with high-dose inhaled or systemic corticosteroids and bronchodilators.[43,44]

Patients with VCD typically present with episodic and recurrent attacks of dyspnea. The distressing sensation of having to struggle to take a breath constitutes the predominant complaint.[41] Patient-reported symptoms include air hunger, sensations of choking, chest tightness, chest pain, difficulty swallowing, globus sensation, intermittent aphonia or dysphonia, neck or chest retractions, fatigue, and throat clearing. Many of these sensations can elicit fear, panic, and anxiety, which can further worsen respiratory symptoms.[44] The severity of respiratory distress is quite variable, reflecting the degree of airway obstruction. Often, dyspnea is relatively mild. In other cases, it can be very severe. The dyspnea often occurs suddenly without warning signs. Dyspnea is accompanied by stridor heard loudest over the larynx and upper trachea.[41] Typically, these symptoms do not respond to routine asthma therapy. Fortunately, most of these episodes are self-limiting and subside spontaneously in less than 2 minutes.[41]

Although the underlying cause of VCD is unknown, inflammation and/or irritation of the vocal cords secondary to gastroesophageal reflux disease (GERD), rhinitis with postnasal drip, cold air, exercise, or inhalational irritants are potential triggers.[43] Physical findings observed during symptoms may be unremarkable except for the detection of harsh stridor over the laryngeal region at the time of an acute attack. A history or presence of postnasal drip and/or gastroesophageal reflux is common.[42]

Pulmonary function testing is particularly useful in differentiating VCD from asthma because bronchospasm produces an impaired expiratory loop that is different from that seen in VCD.[39] Flow–volume loop studies obtained during symptomatic periods show inspiratory loop flattening suggestive of variable extrathoracic obstruction[39,42] (**Figure 6-17**). Routine laboratory tests are usually not helpful, and only severe episodes of VCD are associated with arterial blood gases that show hypoxia with desaturation.[41] Chest radiographs do not typically show any abnormalities. The gold standard for confirmation of VCD is **videolaryngostroboscopy**. This visualizes and documents the vocal cords adducting paradoxically during inspiration.[41]



FIGURE 6-16 Images taken during laryngoscopy showing (**A**) paradoxical adduction detected during mid-inspiration in a patient with VCD and (**B**) appropriate movement of the vocal cords during mid-inspiration in the same patient following speech therapy.

Dunn N, Katial R, Hoyte F. Vocal cord dysfunction: a review. *Asthma Res Pract.* 2015;1(1) (Figure 1, p. 5). doi:10.1186/s40733-015-0009-z.



FIGURE 6-17 (**A**) Normal flow–volume loop in an asymptomatic patient. (**B**) Example of flattening, early truncation, and saw-tooth pattern of inspiratory limb of the flow–volume loop in a patient with VCD.

Dunn N, Katial R, Hoyte F. Vocal cord dysfunction: a review. *Asthma Res Pract.* 2015;1(1) (Figure 2, p. 6). doi:10.1186/s40733-015-0009-z.

An acute severe episode of VCD can generally be managed with sedation and/or Heliox (80% helium and 20% oxygen) administration.[39,41,42] The use of anticholinergic inhaled agents (such as ipratropium bromide) may be helpful in patients with exercise-induced VCD.[39] An invasive and rarely used treatment modality is a laryngeal injection of botulinum toxin type A, which prevents acetylcholine release at nerve endings, leading to chemical denervation and paralysis of the vocal fold in the open position.[44] Tracheostomy represents another invasive procedure option that carries the risk of potential morbidity and like botulinum, toxin should be considered only as a final option in cautiously selected cases.[39,42,44] The primary long-term treatment for VCD involves teaching the patient vocal cord relaxation techniques, breathing exercises, and speech therapy. These speech therapy procedures along with a multidisciplinary approach including patient education, supportive counseling, psychotherapy, and control of comorbidities are effective in controlling VCD even in severe cases.[41,42]

Laryngeal Stenosis

Laryngeal stenosis (LS) is the partial or circumferential narrowing of the supraglottis, glottis, or subglottis area, or multiple sites caused by an acquired or congenital disorder that results in airway compromise[45] (**Figure 6-18**). Adult LS is a complex disease caused by several etiological factors. The primary etiology, however, is postintubation stenosis.[46] LS can also occur after external trauma or thermal injury, in granulomatosis with polyangiitis (GPA; formerly known as Wegener disease), in idiopathic subglottic stenosis (ISS), and due to other causes.[46]



FIGURE 6-18 Laryngeal stenosis. (**A**) Normal glottis. (**B**) Posterior glottic stenosis. (**C**) SGS.

Reproduced with permission from Pacheco-Lopez P, Berkow L, Hillel A, Akst L. Complications of airway management. *Respir Care.* 2014;59(6):1006–1021 (Figures 3A, 4, and 5A, p. 1012). doi:10.4187/respcare.02884.

Supraglottic stenosis is a rare disease, which is usually difficult to manage.[47] The most common causes of supraglottic stenosis are iatrogenic and include supraglottic surgery, prolonged intubation, trauma, radiation therapy, caustic ingestion, and autoimmune disease.[47]

Glottic stenosis is the narrowing of the larynx at the level of the glottis caused by scarring most often in the posterior glottis and interarytenoid regions, where the endotracheal tube rests.[48] Glottic stenosis characteristically presents as anterior or posterior webs, interarytenoid adhesions with or without VCD, or rarely as a fusion of the true vocal folds. Congenital glottic stenosis is rare. The most common form of LS is acquired posterior glottic stenosis, which typically results from trauma due to prolonged endotracheal intubation.

The subglottic area of the larynx is the most common site of involvement in LS. The subglottic area extends from the inferior margin of the vocal cords to the lower border of the cricoid cartilage. The subglottic area within the laryngeal region of the upper airway is particularly unique in being the narrowest passageway for air because of its complete, non-expandable, and solid ring of cartilage, unlike the trachea and the larynx. SGS is generally nonmalignant and may be due to a variety of diseases, but postintubation injury is the most frequent cause.[49] Such damage may be produced by either translaryngeal intubation or tracheostomy.[49]

LS with airway compromise causes significant morbidity to the patients and is a difficult condition to treat. The successful outcome of treatment entails adequate airway patency with the maintenance of airway protection and phonation.[45] The presence of comorbidities, such as diabetes mellitus, gastroesophageal reflux, and immunosuppression, predisposes patients to the development of stenosis.[50] The duration of intubation correlates significantly with the incidence of laryngeal pathologies, including the development of subglottic edema and narrowing when intubation time exceeds 7 days.[50] Inflammatory changes in the posterior glottis occur as early as 2–5 days after intubation.[50] Pressure from the endotracheal tube can cause localized tissue ischemia when the pressure on the tissue exceeds the capillary pressure. The excessive pressure can lead to vascular damage, edema, granulation, and ulcers.[50] Patients who progress to granulation formation are at risk of interarytenoid adhesion formation or early posterior glottic stenosis.[51] As the granulomas mature and proliferate, the deposition of collagen eventually leads to scar formation and tissue contracture.[50] This causes progressive narrowing of the lumen leading to airway compromise.[45]

Treatment for LS is difficult with the requirement of multiple interventions and is based on the patient, the type, the site, and the severity of the stenosis. The interventions can be endoscopic or open and include intralesional injections, balloon dilation, excision with CO_2 laser or cold steel, microdebrider excision, and open surgery. The success rate of endoscopic procedures ranges between 44% and 68%.[50] The literature shows that uncomplicated stenosis including cases of thin web-like stricture or granuloma can be removed definitively by dilation, laser treatment, or laser-assisted mechanical dilation. However, the benefit of their use in more complex lesions is generally temporary, with frequent recurrences, consequent need for repeated procedures, and risk of extending the diseased segment.[49] Open procedures, such as laryngotracheal reconstruction with anterior and/or posterior cartilage grafting and cricotracheal/tracheal resection with anastomosis, are possible options for stenoses longer than 2 cm or for patients in whom multiple endoscopic procedures have failed.[50] Stenosis resulting from infections or inflammatory disorders typically requires treatment with antibiotics, or corticosteroids, or both.

Prevention of LS as a complication of endotracheal tube insertion is of paramount importance for the reduction of postintubation patient morbidity. Several key facts can aid the prevention of this complication. See **Box 6-5**.

Laryngomalacia

Laryngomalacia (LM) is an abnormality of the laryngeal cartilage, which represents the most common congenital lesion of the pharynx and cause of congenital stridor.[52] It characterized by a dynamic obstruction of the upper airway caused by an inward collapse of supraglottic structures during inhalation, resulting in

BOX 6-5 Techniques to Prevent Postintubation Laryngeal Stenosis LS[48,50]

- Maintain the endotracheal tube tip close and parallel to the video-laryngoscope blade until it is viewed on the monitor.
- Directly visualize the endotracheal tube tip during intubation until it is out of site; then look at the monitor.
- Insert the endotracheal tube in the midline with the proximal portion oriented to the right and then rotate counterclockwise 90 degrees to bring the tip into view.
- Whenever possible, have a capable assistant during difficult or emergent intubation.
- Monitor and keep cuff pressures between 20 and 30 cm H_2O and limit prolonged intubation.
- Ensure the endotracheal tube is rotated regularly and its position maintained.
- Consider patients with comorbid conditions at higher risk of long-term airway complications and manage accordingly.
- Seek early otolaryngology evaluation for patients with severe acute soft tissue injuries, for those with severe symptoms after extubation, and for those whose symptoms (hoarseness, dysphagia, aspiration) persist beyond 1 month after extubation.
- Choose a supraglottic airway device that is adequately sized for the patient and monitor cuff pressures.



FIGURE 6-19 Morphological types of LM classified: Type I LM: prolapsing supra-arytenoid floppy tissues; Type II LM: shortened aryepiglottic folds associated with a long, omega-shape epiglottis that curls on itself; Type III LM: overhanging retroflexed epiglottis collapsing posteriorly during inspiration.

Reproduced with permission from Reinhard A, Gorostidi F, Leishman C, Monnier P, Sandu K. Laser supraglottoplasty for laryngomalacia; a 14-year experience of a tertiary referral center. *European Archives of Oto-Rhino-Laryngology*. 2016;274(1):367–374 (Figure 1, p. 368). doi:10.1007/s00405-016-4252-6.

inspiratory stridor.[53] In infants, the inspiratory stridor is exacerbated by feedings, agitation, and when lying in the supine position. Most forms of congenital LM are minor (70–90%), presenting in the form of isolated and intermittent stridor without alteration of crying or coughing, no dyspnea, and no swallowing disorders. The stridor usually appears in the first 2 weeks of life, with an incidence peak around 6 months and spontaneous resolution in 90% of the cases by the second year of life.[52] These minor forms do not have any consequences on the infant's growth and simply require observation. Only 10–20% of infants have severe enough LM to require surgical management.[54]

Acquired airway obstruction in adults is rare[55] and is typically caused by excessive hypotense, hyperactive, or floppy supraglottic tissue (LM).[56] Adult LM may be secondary to trauma, surgery, neurologic lesion, degenerative disease (Parkinson disease, amyotrophic lateral sclerosis), or it can be idiopathic.[55] There is an increasing attention to physiological laryngeal dysfunctions as a cause of respiratory difficulties during sports in young, otherwise healthy, individuals. In general, this issue is exercise-induced laryngeal obstruction, and one of the conditions that can lead to the laryngeal obstruction is exercise-induced laryngomalacia (EIL), where the arytenoid regions collapse into the airflow, obstructing the flow and creating turbulence.[57]

LM is categorized into three types depending on the supraglottic morphology. **Type I LM** is due to collapse of the bodies of the arytenoid cartilages over the laryngeal inlet. In **Type II LM**, the anteroposterior dimension of the airway is significantly reduced by abnormally short aryepiglottic folds. The **Type III LM** form involves abnormal degrees of posterior deflection of the epiglottis during inspiratory aerodynamics, which results in pronounced narrowing of the laryngeal lumen[56] (**Figure 6-19**). There is a predominance of LM among male patients

LM is consistently associated with several specific anatomical abnormalities. These include shortened aryepiglottic folds, redundant arytenoid mucosa prolapsing into the glottis, or an elongated curled epiglottis. Usually, these conditions require surgical intervention when simultaneously present. Severe cases of LM are associated with a higher incidence of gastroesophageal reflux, as well as other difficulties such as choking or gagging, life-threatening apneic episodes, neuromotor disease, and obstructive apnea, and failure to thrive for infants.[53] Infants affected by LM who develop clinically significant hypoxemia (defined as a resting oxygen saturation $<90\%$) require supplemental oxygen because they are more likely to develop pulmonary hypertension. Noninvasive positive pressure mechanical ventilation can also be used to maintain a patent airway in cases of airway collapse. If airway patency cannot be sustained by noninvasive positive pressure mechanical ventilation in individuals with impending respiratory failure, intubation with mechanical ventilation is necessary.[54]

Radiologic imaging studies including fluoroscopy of the airway may be used to diagnose this disorder as cartilages may be observed collapsing on inspiration on a lateral view of the airway. A more effective evaluation uses endoscopy under general anesthesia or a systematic dynamic airway endoscopy to confirm the diagnosis and exclude an associated respiratory tract lesion.[54] In most infants, conservative management without surgical intervention is the only treatment necessary for LM because the cartilage abnormality gradually improves as it matures with typical inspiratory noise disappearance by 2 years of age. In severe cases in which the LM impedes ventilation sufficiently to impair normal eating, growth, and development, a surgical approach may be warranted, involving simple tracheotomy or laser supraglottoplasty. Patients with Type III LM have a more limited success rate than those with morphological Types I and II.[53] The kind of LM varies by age and initial presentation. The outcome of surgical treatment seems to be poorer for males and in the presence of neurologic diagnosis.[58]

Variable Intrathoracic UAO

A variable airway obstruction in the intrathoracic airways causes a decrease in maximal expiratory flow but preserves the maximal inspiratory flow. This relationship occurs due to the high intrapleural pressure during forced expiration, which causes dynamic compression of the intrathoracic airways. During inspiration, the obstruction decreases because the intrapleural pressure is markedly negative.

Tracheomalacia

Tracheomalacia (TM) is an upper airway condition characterized by weakness of the supporting structures of the trachea, resulting in expiratory collapse, leading to symptoms of airway obstruction.[59] There are two distinct anatomical forms: the cartilaginous malacia characterized by softening of the cartilage and the membranous malacia with excessive forward displacement of the membranous wall (also known as excessive dynamic airway collapse [EDAC]).[60] TM classification is either congenital (primary) or acquired (secondary) (**Table 6-2**). TM is the most common congenital anomaly of the trachea and is more commonly seen in premature infants than in healthy infants.[61] Congenital TM occurs in approximately 1:2,100 children. In adults, TM is more commonly acquired than congenital.[60]

The diagnostic evaluation of TM may be challenging because patients often have pulmonary comorbidities such as COPD, asthma, or sleep apnea with overlapping symptoms. The diagnosis of TM is often overlooked because the admitting chest radiograph is unremarkable, and therefore, the patient's respiratory failure is often attributed to the pulmonary comorbidities.[59] The mainstays of diagnosis are dynamic CT and dynamic bronchoscopy with forced expiratory maneuvers[62] (**Figures 6-20** and **6-21**). Dynamic CT has the advantage of showing the distal extent of the TM. This is important for treatment decisions. If the TM extends into the segmental and subsegmental bronchi, neither airway stenting nor surgical intervention can correct the distal disease.[60] Bronchoscopy provides information about the ease of navigation into and within the airway, which is useful for planning future interventions. Both tests are necessary to evaluate the degree of TM.[60,62] The diagnosis of TM is made when the diameter of the trachea exceeds the upper limits of normal by three or more standard deviations. TM is also defined as mild, if the lumen narrows to 50% of its initial size; moderate, if it narrows to 25% of its initial size; and severe, if the anterior and posterior walls touch.[63]

Patients with mild TM may be asymptomatic. When the severity of airway narrowing progresses, the symptoms and signs of airway obstruction become more obvious. This typically occurs when the patient has an infection, is under general anesthesia, is extubated, or has progressive hypercapnic respiratory failure from a pulmonary comorbidity. The main symptoms of TM in adults are dyspnea, cough, and sputum production.[60,61,63] When TM coexists with pulmonary comorbidities, the symptoms may seem out of proportion to the severity of any condition alone, or some patient may remain symptomatic despite maximal medical therapy for the condition being treated.[60]

Treatment for TM depends on the extent of the airway collapse and if the patient is symptomatic. Patients with coexisting diseases need their medical regime optimized. Then the patient has a functional assessment.[60]

TABLE 6-2
Classifications for Adult TM[60,61]

Appearance of the trachea	Crescent—anteroposterior tracheal narrowing (scabbard shape)	
	Lateral—lateral tracheal narrowing (saber-sheath or fissure shape)	
	Circumferential—both anteroposterior and lateral narrowing	
Distribution of tracheomalacia	Segmental or diffuse	
	Tracheal, bronchial, or both	
Etiology	Congenital (Primary)	Genetic—such as polychondritis
		Idiopathic—such as Mounier–Kuhn
	Posttraumatic	Postintubation
		Post-tracheostomy
		External chest trauma
		Post-lung transport
	Emphysema	Chronic infection/ bronchitis
	Chronic inflammation	Relapsing polychondritis
	Chronic external compression of the trachea	Malignancy
		Benign tumors
		Cysts
		Abscesses
		Aortic aneurysm
	Vascular rings, previously undiagnosed in childhood	



FIGURE 6-20 Dynamic, flexible bronchoscopy. Left: During forced inhalation. Right: At exhalation.

Reproduced with permission from Majid A, Sosa A, Ernst A et al. Pulmonary Function and Flow-Volume Loop Patterns in Patients with Tracheobronchomalacia. *Respir Care*. 2013;58(9): 1521–1526 (Figure 1, p. 1522). doi:10.4187/respcare.02277.



FIGURE 6-21 Dynamic CT. Left: During forced inhalation. Right: At exhalation.

Reproduced with permission from Majid A, Sosa A, Ernst A et al. Pulmonary Function and Flow-Volume Loop Patterns in Patients with Tracheobronchomalacia. *Respir Care*. 2013;58(9): 1521–1526. (Figure 2, p. 1522). doi:10.4187/respcare.02277.

This assessment typically includes pulmonary function testing, 6-minute walk test, quality-of-life assessment, and dyspnea scores.[60,62] This functional assessment assists in establishing a baseline from which the response to therapy can be objectively measured.[60] Treatment options include surveillance, noninvasive medical treatment, minimally invasive intervention, and surgery (**Figure 6-22**).

Chapter Summary

The upper airway is considered to represent the portion of the conducting passageway extending from the nose and mouth to the tracheal bifurcation. UAO is any disorder that impedes the process of breathing when the remainder of the respiratory system is functioning normally.

The dynamic and severe nature of UAO typically precludes little, if any, time for an investigative work-up. In cases of severe UAO, a secure airway, endotracheal tube, or tracheostomy needs to be in place prior to establishing a definitive diagnosis. The life-threatening potential of a majority of acute UAO cases poses a medical emergency requiring rapid evaluation and simultaneous treatment precluding any radiologic, laboratory, and arterial blood gas testing. An emergent presentation mandates that all efforts and resources be directed toward securing a patent airway and preventing cardiopulmonary arrest. Components of effective UAO treatment, as well as management, are dependent on several factors, including the associated symptoms, the extent or amount of obstruction, the potential for progression, characteristics of the specific disorder, associated conditions, and the location of the obstruction. While therapeutic strategies (**Table 6-3**) used in various UAO may differ, the immediate goal in any UAO remains the same: the establishment and maintenance of adequate airflow and airway patency to allow adequate oxygenation and ventilation.



FIGURE 6-22 Sample algorithm for the evaluation and treatment of tracheomalacia. 6MWT, 6-minute walk test; CPCP, Continuous positive airway pressure; PFT, pulmonary function test; PEP, positive expiratory pressure; TBM, tracheobronchomalacia.

Adapted from Buitrago D, Wilson J, Parikh M, Majid A, Gangadharan S. Current concepts in severe adult tracheobronchomalacia: evaluation and treatment. *J Thorac Dis*. 2017;9(1): E57-E66 (Figure 2, p. E61). doi:10.21037/jtd.2017.01.13.

TABLE 6-3
Endobronchial Therapy for UAO[18,22,23]

Therapeutic Strategy	Method of Operation	Indication for Use
Airway stents	Tube-shaped tracheal prosthesis placed via bronchoscope, made from silicone (requires rigid bronchoscope) or self-expanding metal set via flexible bronchoscope	Lifesaving therapy in fragile patients who cannot tolerate surgery with either intrinsic or extrinsic tracheal tumors following debulking
Argon plasma coagulation (APC)	Immediate-acting noncontact, nonpenetrating, thermal ablation technique through a flexible bronchoscope	Superficial vascular lesions, granulomas at surgical anastomosis, respiratory papillomatosis
Bronchoplasty	Endoscopic airway dilation with a rigid or flexible bronchoscope; a rigid bronchoscope can be advanced through the stenotic airway opening, which has a "coring" effect instead of balloon dilation	Sequential rigid bronchoscopy causes less mucosal trauma than balloon dilation; sequential rigid bronchoscopy is useful for severe obstruction; balloon dilation is useful for less-severe obstruction
Cryotherapy	Local ablation using repeated freeze–thaw cycles via bronchoscopy	Foreign body removal, treatment of extrinsic airway lesions and is frequently combined with other therapies; can be useful for post-transplant anastomotic strictures
Debridement	Forceps removal of damaged tissue in the trachea using a rigid bronchoscope; can be combined with "coring" for severe obstructions; microdebriders, with rapidly a rotating blade, can also be used	Severe UAO
Electrocautery	Contact electrical thermal injury administered via a flexible bronchoscope	Alternative to laser therapy or APC for the acute treatment of intraluminal tumors
Endobronchial brachytherapy (EBBT)	High-dose or low-dose radiation seed delivered directly to the airway through a flexible bronchoscope	Palliation of obstructive symptoms caused by large inoperable airway tumors
External beam radiotherapy (EBRT)	Delivery of targeted radiation from outside the body	Non-life-threatening inoperable intraluminal or extraluminal obstruction due to non-small-cell cancer of the airway
Laser therapy	Thermally ablative noncontact technique performed using a rigid or flexible bronchoscope	Useful for debulking intraluminal short (<4 cm) airway tumors; not for extraluminal tumors
Photodynamic therapy (PDT)	Nonthermal light modality administered via bronchoscope following intravenous administration of a photosensitizing agent	Palliative or adjunctive therapy to relieve non-life-threatening airway obstruction due to malignant or benign conditions

Key Points

1. UAO disorders can clinically present as a subacute slowly progressive and persistent process or as an acute life-threatening emergency.
2. The oropharynx region is vulnerable to airflow obstruction during inspiration and is the primary cause of obstructive sleep apnea.
3. Tracheal tumors are classified as primary endoluminal, metastatic carcinoma of the airway, extraluminal, or mixed.
4. Pulmonary function studies, including spirometry with flow–volume loop determinations, may assist in assessing the individual who displays symptoms of nonemergent UAO. Flow–volume loop testing can identify whether the UAO is fixed or variable and intrathoracic or extrathoracic.
5. Clinical recognition of tracheal stenosis is usually complicated early in its course because features of airway obstruction are late and nonspecific.
6. LM is consistently associated with several specific anatomical abnormalities, including the collapse of the bodies of the arytenoid cartilages over the laryngeal inlet, abnormally short aryepiglottic folds, and abnormal degrees of posterior deflection of the epiglottis during inspiratory aerodynamics.
7. Unilateral VCP is more common than BVCP and ultimately the result of a disturbance of the vagal nerve and the recurrent laryngeal nerve supply to the laryngeal muscles.

8. VCD causes an extrathoracic airway obstruction that mimics asthma symptoms but can be differentiated by flow–volume loop determination.
9. LS is a postintubation complication that is often difficult to treat. Prevention is the key to reducing LS.
10. Glottic stenosis is caused by scarring, usually in the posterior glottis and interarytenoid regions, where endotracheal tubes typically rest.

Chapter Questions

1. In an adult, the narrowest part of the upper airway is the _____.
   a. oropharynx
   b. subglottis
   c. glottis
   d. trachea
2. Foreign bodies tend to lodge in the _____ of adults, causing a complete upper airway obstruction (UAO).
   a. pharynx
   b. larynx
   c. trachea
   d. hypopharynx
3. Glottic stenosis occurs in approximately _____ of patients intubated for more than 10 days.
   a. 5%
   b. 10%
   c. 15%
   d. 20%
4. A flow–volume loop that shows reduced airflow during both forced expiration and forced inspiration is typical of _____.
   a. tracheal stenosis
   b. supraglottic stenosis
   c. laryngomalacia (LM)
   d. extrathoracic tracheomalacia
5. Muffling of the voice without hoarseness may be a sign of _____.
   a. vocal cord dysfunction (VCD)
   b. tracheal stenosis
   c. a subglottic process
   d. a supraglottic process
6. The gold standard treatment for tracheal stenosis is _____.
   a. cryotherapy
   b. surgical resection
   c. intralesional corticosteroid injection
   d. laser therapy
7. Histamine-mediated angioedema can be treated with _____ to help relieve acute UAO.
   a. recombinant C1 inhibitor
   b. captopril
   c. epinephrine
   d. plasma kallikrein inhibitor
8. _____ is often misdiagnosed as asthma.
   a. Unilateral vocal cord paralysis
   b. VCD
   c. Bilateral vocal cord paralysis (BVCP)
   d. LM
9. Tracheomalacia is diagnosed using _____.
   a. chest radiography and flow–volume loops
   b. dynamic CT and dynamic bronchoscopy with forced expiratory maneuvers
   c. bronchoscopy and flow–volume loops
   d. endobronchial ultrasound and dynamic CT with forced expiratory maneuvers
10. The inhaled anticholinergic agent, ipratropium bromide, is helpful in the treatment of _____.
    a. BVCP
    b. exercised-induced VCD
    c. subglottic stenosis
    d. LM

References

1. George G, Lippmann M. Disorders of the central airways and upper airway obstruction. *Clinical Advisor*. 2017. https://www.clinicaladvisor.com/pulmonary-medicine/disorders-of-the-central-airways-and-upper-airway-obstruction/article/625312. Accessed February 11, 2018.
2. Braman S, McCool F. Upper airway obstruction. *Clinical Advisor*. 2017. https://www.clinicaladvisor.com/critical-care-medicine/upper-airway-obstruction/article/585129. Accessed February 11, 2018.
3. Choudhury N, Perkins V, Amer I, Bhagrath R, Ghufoor K. Endoscopic airway management of acute upper airway obstruction. *Eur Arch Otorhinolarygol*. 2014;271:1191–1197.
4. Swami H, Hawthorne M. Upper airway obstruction. In: Thomas W, Reed M, Wyatt M, eds. *Oxford Textbook of Fundamentals of Surgery*. 1st ed. New York, NY: Oxford University Press; 2016:440–444.
5. Gerber M. Laryngeal stenosis: background, problem, epidemiology. *Emedicinemedscape.com*. 2016. https://emedicine.medscape.com/article/867177-overview. Accessed February 17, 2018.
6. Li H. Angioedema: practice essentials, background, pathophysiology. *Emedicinemedscape.com*. 2017. https://emedicine.medscape.com/article/135208-overview. Accessed February 17, 2018.
7. Buddiga P. Vocal cord dysfunction: background, pathophysiology, epidemiology. *Emedicinemedscape.com*. 2016. https://emedicine.medscape.com/article/137782-overview. Accessed February 17, 2018.
8. Lemonick D. Ludwig's angina: diagnosis and treatment. *Hosp Physician*. 2002;38:31–37.
9. Tariq S, George J, Srinivasan S. Inhaled foreign bodies in adolescents and adults. *Monaldi Arch Chest Dis*. 2005;63(4):193–198. doi:10.4081/monaldi.2005.620.
10. Shepherd W. Airway foreign bodies in adults. In: Parsons P, Mathur P, eds. *UpToDate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed February 17, 2018.
11. Al-Qadi M, Artenstein A, Braman S. The "forgotten zone": acquired disorders of the trachea in adults. *Respir Med*. 2013;107(9):1301–1313. doi:10.1016/j.rmed.2013.03.017.
12. Shelledy D. Assessment of oxygenation. In: Shelledy D, Peters J, eds. *Respiratory Care Patient Assessment & Care Plan Development*. 1st ed. Burlington, MA: Jones & Bartlett Learning; 2016:196–198.
13. Wanger J. *Pulmonary Function Testing*. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2012:43–47.

14. Nunn A, Nouraei S, George P, Sandhu G, Nouraei S. Not always asthma: clinical and legal consequences of delayed diagnosis of laryngotracheal stenosis. *Case Rep Otolaryngol*. 2014;2014:325048. doi:10.1155/2014/325048.
15. Irwin R. Evaluation of wheezing illnesses other than asthma in adults. In: Barnes P, Hollingsworth H, eds. *UpToDate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed March 5, 2018.
16. Kuo G, Torok C, Aygun N, Zinreich S. Diagnostic imaging of the upper airway. *Proc Am Thorac Soc*. 2011;8(1):40–45. doi:10.1513/pats.201004-032rn.
17. Oki M, Saka H. Thin Bronchoscope for evaluating stenotic airways during stenting procedures. *Respiration*. 2011;82(6):509–514. doi:10.1159/000330838.
18. LoCicero J, Murgu S. Endobronchial photodynamic therapy in the management of airway disease in adults. In: Mathur P, Finlay G, eds. *UpToDate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed March 6, 2018.
19. Murgu S, Egressy K, Laxmanan B, Doblare G, Ortiz-Comino R, Hogarth D. Central airway obstruction. *Chest*. 2016;150(2):426–441. doi:10.1016/j.chest.2016.02.001.
20. Park J, Kim J, Song H, Shin J, Ko H. Management of benign tracheal strictures caused by tracheostomy. *Cardiovasc Intervent Radiol*. 2013;37(3):743–749. doi:10.1007/s00270-013-0727-7.
21. Sarper A, Ayten A, Eser I, Ozbudak O, Demircan A. Tracheal stenosis after tracheostomy or intubation. *Tex Heart Inst J*. 2005;32(2):154–158.
22. Ernst A, Feller-Kopman D, Becker H, Mehta A. Central airway obstruction. *Am J Respir Crit Care Med*. 2004;169(12):1278–1297. doi:10.1164/rccm.200210-1181so.
23. Herth F. Clinical presentation, diagnostic evaluation, and management of central airway obstruction in adults. In: Mathur P, Finlay G., eds. *UpToDate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed March 6, 2018.
24. Stratakos G, Gerovasili V, Dimitropoulos C, et al. Survival and quality of life benefit after endoscopic management of malignant central airway obstruction. *J Cancer*. 2016;7(7):794–802. doi:10.7150/jca.15097.
25. Dalar L, Özdemir C, Abul Y, et al. Therapeutic bronchoscopic interventions for malignant airway obstruction. *Medicine (Baltimore)*. 2016;95(23):e3886. doi:10.1097/md.0000000000003886.
26. Orlewicz M, Choromanski D, Wood A. Intubation of patients with angioedema: a retrospective study of different methods over three-year period. *Int J Crit Illn Inj Sci*. 2013;3(2):108. doi:10.4103/2229-5151.114267.
27. Thomas M, Shah S. New treatment options for acute edema attacks caused by hereditary angioedema. *Am J Health Syst Pharm*. 2011;68(22):2129–2138. doi:10.2146/ajhp100718.
28. The US HAEA Angioedema Center. *Angioedemacentercom*. 2014. http://www.angioedemacenter.com/patient-resources/angioedema-types. Accessed March 7, 2018.
29. Pedrosa M, Prieto-García A, Sala-Cunill A, et al. Management of angioedema without urticaria in the emergency department. *Ann Med*. 2014;46(8):607–618. doi:10.3109/07853890.2014.949300.
30. Farkas H. Management of upper airway edema caused by hereditary angioedema. *Allergy, Asthma Clin Immunol*. 2010;6(1):19. doi:10.1186/1710-1492-6-19.
31. Sasaki C. Vocal cord paralysis. In: *Merk Manual Professional Version*. Kenilworth, NJ: Merk & Co.; 2018. https://www.merckmanuals.com/professional/ear,-nose,-and-throat-disorders/laryngeal-disorders/vocal-cord-paralysis. Accessed March 8, 2018.
32. Afsah O. Approach to diagnosis of vocal fold immobility: a literature review. *Egypt J Otolaryngol*. 2015;31(2):78. doi:10.4103/1012-5574.156088.
33. Dankbaar J, Pameijer F. Vocal cord paralysis: anatomy, imaging and pathology. *Insights Imaging*. 2014;5(6):743–751. doi:10.1007/s13244-014-0364-y.
34. Bruch J, Kamani D. Hoarseness in adults. In: Deschler D, Sullivan D, eds. *UpToDate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed March 8, 2018.
35. Paniello R, Edgar J, Kallogjeri D, Piccirillo J. Medialization versus reinnervation for unilateral vocal fold paralysis: a multicenter randomized clinical trial. *Laryngoscope*. 2011;121(10):2172–2179. doi:10.1002/lary.21754.
36. Sapundzhiev N, Lichtenberger G, Eckel H, et al. Surgery of adult bilateral vocal fold paralysis in adduction: history and trends. *Eur Arch Otorhinolaryngol*. 2008;265(12):1501–1514. doi:10.1007/s00405-008-0665-1.
37. Brake M, Anderson J. Bilateral vocal fold immobility: a 13-year review of etiologies, management and the utility of the Empey index. *J Otolaryngol Head Neck Surg*. 2015;44(1):27. doi:10.1186/s40463-015-0080-8.
38. Oysu C, Sahin-Yilmaz A, Uslu C. Emergency endoscopic vocal cord lateralization as an alternative to tracheotomy for patients with bilateral abductor vocal cord paralysis. *Eur Arch Otorhinolaryngol*. 2012;269(12):2525–2529. doi:10.1007/s00405-012-2076-6.
39. Deckert J, Deckert L. Vocal cord dysfunction. *Am Fam Physician*. 2010;81(2):156–159.
40. Low K, Ruane L, Uddin N, et al. Abnormal vocal cord movement in patients with and without airway obstruction and asthma symptoms. *Clin Exp Allergy*. 2016;47(2):200–207. doi:10.1111/cea.12828.
41. Truong A, Truong D. Vocal cord dysfunction: an updated review. *Otolaryngology*. 2012;S1:002. doi:10.4172/2161-119x.s1-002.
42. Kenn K, Balkissoon R. Vocal cord dysfunction: what do we know? *Eur Respir J*. 2010;37(1):194–200. doi:10.1183/09031936.00192809.
43. Traister R, Fajt M, Petrov A. The morbidity and cost of vocal cord dysfunction misdiagnosed as asthma. *Allergy Asthma Proc*. 2016;37(2):25–31. doi:10.2500/aap.2016.37.3936.
44. Dunn N, Katial R, Hoyte F. Vocal cord dysfunction: a review. *Asthma Res Pract*. 2015;1(1):9. doi:10.1186/s40733-015-0009-z.
45. Nair S, Nilakantan A, Sood A, Gupta A, Gupta A. Challenges in the management of laryngeal stenosis. *Indian J Otolaryngol Head Neck Surg*. 2015;68(3):294–299. doi:10.1007/s12070-015-0936-2.
46. Halmos G, Schuiringa F, Pálinkó D, van der Laan T, Dikkers F. Finding balance between minimally invasive surgery and laryngotracheal resection in the management of adult laryngotracheal stenosis. *Eur Arch Otorhinolaryngol*. 2014;271(7):1967–1971. doi:10.1007/s00405-014-2901-1.
47. Ramadan O. Adult supraglottic stenosis: etiology and management. *Otolaryngol—Open J*. 2016;2(5):132–140. doi:10.17140/otloj-2-129.
48. Hyzy R. Complications of the endotracheal tube following initial placement: Prevention and management in adult intensive care unit patients. In: Manaker S, Finlay G, eds. *UpToDate*. Waltham, Mass.: UpToDate; 2018. https://www/uptodate.com. Accessed March 9, 2018.
49. D'Andrilli A, Venuta F, Rendina E. Subglottic tracheal stenosis. *J Thorac Dis*. 2016;8(suppl 2):S140–S147. doi:10.3978/j.issn.2072-1439.2016.02.03.
50. Pacheco-Lopez P, Berkow L, Hillel A, Akst L. Complications of airway management. *Respir Care*. 2014;59(6):1006–1021. doi:10.4187/respcare.02884.
51. Howard N, Shiba T, Pesce J, Chhetri D. Photodocumentation of the development of type I posterior glottic stenosis after intubation injury. *Case Rep Surg*. 2015;2015:504791. doi:10.1155/2015/504791.
52. Pinto J, Wambier H, Mizoguchi E, Gomes L, Kohler R, Ribeiro R. Surgical treatment of severe laryngomalacia: a retrospective study of 11 cases. *Braz J Otorhinolaryngol*. 2013;79(5):564–568. doi:10.5935/1808-8694.20130101.
53. Reinhard A, Gorostidi F, Leishman C, Monnier P, Sandu K. Laser supraglottoplasty for laryngomalacia: a 14-year experience of a tertiary referral center. *Eur Arch Otorhinolaryngol*. 2016;274(1):367–374. doi:10.1007/s00405-016-4252-6.
54. Ayari S, Aubertin G, Girschig H, et al. Management of laryngomalacia. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2013;130(1):15–21. doi:10.1016/j.anorl.2012.04.003.
55. Bartolomeo M, Bigi A, Pelliccia P, Makeieff M. Surgical treatment of a case of adult epiglottic laryngomalacia. *Eur Ann Otorhinolaryngol Head Neck Dis*. 2015;132(1):45–47. doi:10.1016/j.anorl.2013.10.004.

56. Rutt A, Dworkin J, Stern N. Supraglottic obstruction in an adult with inspiratory arytenoid cartilage prolapse. *Otolaryngology*. 2014;4(2):165. doi:10.4172/2161-119x.1000165.
57. Christensen P, Thomsen S, Rasmussen N, Backer V. Exercise-induced laryngeal obstructions objectively assessed using EILOMEA. *Eur Arch Otorhinolaryngol*. 2010;267(3):401–407. doi:10.1007/s00405-009-1113-6.
58. Erickson B, Cooper T, El-Hakim H. Factors associated with the morphological type of laryngomalacia and prognostic value for surgical outcomes. *JAMA Otolaryngol Head Neck Surg*. 2014;140(10):927–933. doi:10.1001/jamaoto.2014.1843.
59. Kandaswamy C, Bird G, Gill N, Math E, Vempilly J. Severe tracheomalacia in ICU: identification of diagnostic criteria and risk factor analysis from a case control study. *Respir Care*. 2013;58(2):340–347. doi:10.4187/respcare.01866.
60. Majid A. Tracheomalacia and tracheobronchomalacia in adults. In: Mathur P, Finlay G, eds. *UpToDate*. Waltham, MA: UpToDate; 2016. https://www/uptodate.com. Accessed March 12, 2018.
61. Carden K, Boiselle P, Waltz D, Ernst A. Tracheomalacia and tracheobronchomalacia in children and adults. *Chest*. 2005;127(3):984–1005. doi:10.1378/chest.127.3.984.
62. Buitrago D, Wilson J, Parikh M, Majid A, Gangadharan S. Current concepts in severe adult tracheobronchomalacia: evaluation and treatment. *J Thorac Dis*. 2017;9(1):E57–E66. doi:10.21037/jtd.2017.01.13.
63. Malvi K, Padmanabhan A, Hari T. An undiagnosed cause of chronic cough. *J Family Med Prim Care*. 2015;4(4):598. doi:10.4103/2249-4863.174303.

CHAPTER

7

Sleep-Related Breathing Disorders

"Sleep is that golden chain that ties health and our bodies together."

—From 'The Gul's Horne Booke.' Warner, et al., comp. 1917. The Library of the World's Best Literature. Bartlebycom Great Books Online. 2018. Retrieved from: http://www.bartleby.com/library/prose/1607.html. Accessed January 28, 2018.

OUTLINE

OBJECTIVES

1. Relate the common characteristics, manifestations, and diagnostic features of sleep-related breathing disorders (SRBDs).
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of SRBDs.
3. Compare and contrast the three types of SRBDs: obstructive, central, and mixed central apnea.
4. Discuss the testing methods used in the diagnosis of SRBDs.
5. Understand the surgical management used for SRBDs.

KEY TERMS

Adaptive servo-ventilation (ASV)
Apnea
Apnea threshold
Auto-titrating positive airway pressure (APAP)
Average volume-assured pressure support (AVAPS)
Bi-level positive airway pressure (BPAP)
Body mass index (BMI)
Central sleep apnea (CSA)
Circadian rhythm
Congenital central hypoventilation syndrome (CCHS)
Continuous positive airway pressure (CPAP)
Electroencephalogram (EEG)
Electromyogram (EMG)
Electrooculogram (EOG)
Epworth sleepiness scale (ESS)
Excessive daytime sleepiness (EDS)
Home sleep apnea testing (HSAT)
Homeostatic sleep regulation
Hypopnea
Loop gain
Mandibular advancement devices (MADs)

Nonrapid eye movement (NREM) sleep
Obstructive sleep apnea (OSA)
Polysomnography (PSG)
Positive airway pressure (PAP) therapy
Rapid eye movement (REM) sleep
Respiratory events
Sleep-related breathing disorders (SRBDs)
Stage N1 of NREM
Tongue-retaining devices (TRDs)
Treatment-emergent CSA
Uvulopalatopharyngoplasty (UPPP, or U3P)

Case Study

A 32-year-old overweight man is referred to a pulmonologist for the evaluation of sleep apnea following a recent visit to his primary care physician for a routine follow-up visit for persistent hypertension and "diet-controlled" type 2 non-insulin-dependent diabetes. The patient's medical history reveals marginal treatment control over his ongoing hypertension. The patient mentions that he noticed feeling progressively and unusually sluggish and sleepy during the day, and when lying down, he would fall asleep quickly. The patient believes that he sleeps well, but his wife complains persistently about his loud snoring and irregular breathing during his sleep. His only prescription medication is a daily thiazide-calcium blocker antihypertensive.

On physical examination, the patient is 5 feet 10 inches and weighs 284 pounds, resulting in a **body mass index (BMI)** of 40.8. The patient's temperature is normal, his respiratory rate is 22 breaths/minute, and he has a seated blood pressure of 165/94. The patient has swollen nasal mucosa with thick secretions. Chest auscultation reveals normal breath sounds throughout all lung fields. His heart examination is unremarkable other than a mild tachycardia of 118 beats/minute. The patient's abdomen and upper and lower extremities are all normal. Pulse oximetry while breathing room air at rest is 90%.

The patient completes a sleep questionnaire in the pulmonologist's office. His score on the **Epworth Sleepiness Scale (ESS)** is 15. The patient's sleep history, obesity, hypertension, and results from the ESS are strongly suspicious of a sleep-related breathing disorder. The pulmonologist recommends a diagnostic sleep study.

Introduction

Sleep-related breathing disorders (SRBDs) refer to several conditions that cause brief and cyclical cessations in breathing rhythm (**apnea**) or transient or sustained decline in the breath amplitude (**hypopnea**) that occur during the sleeping state. These events are typically sufficient enough to cause significant hypoxemia and hypercapnia. The International Classification of Sleep Disorders defines four significant categories of SRBDs: **obstructive sleep apnea (OSA)** syndrome, **central sleep apnea (CSA)** syndrome, sleep-related hypoventilation (SRH) disorders, and sleep-related hypoxemia disorder.[1] Further categorization is according to their etiology. See **Box 7-1**.

BOX 7-1 Sleep-Related Breathing Disorders

Disorder

- **I.** OSA disorders
  - **A.** OSA, adult
  - **B.** OSA, pediatrics
- **II.** CSA syndromes
  - **A.** CSA with Cheyne–Stokes breathing
  - **B.** CSA due to a medical disorder without Cheyne–Stokes breathing
  - **C.** CSA due to high-altitude periodic breathing
  - **D.** CSA due to a medication or substance
  - **E.** Primary CSA
  - **F.** Primary CSA of infancy
  - **G.** Primary CSA of prematurity
  - **H.** Treatment-emergent CSA
- **III.** SRH disorders
  - **A.** Obesity hypoventilation syndrome (OHS)
  - **B.** Congenital central alveolar hypoventilation syndrome
  - **C.** Late-onset central hypoventilation with hypothalamic dysfunction
  - **D.** Idiopathic central alveolar hypoventilation
  - **E.** SRH due to a medication or substance
  - **F.** SRH due to a medical disorder
- **IV.** Sleep-related hypoxemia disorder

Reproduced with permission from American Academy of Sleep Medicine, International Classification of Sleep Disorders, 3rd ed. American Academy of Sleep Medicine, Darien, IL 2014.

Normal Respiration during Sleep

To understand the pathogenesis of SRBDs, the basic knowledge of normal sleep patterns is necessary. Most adults typically sleep between 7 and 8 hours per night, although variation in the pattern of sleep architecture does occur among healthy individuals. Age may alter sleep patterns. Both infants and the elderly experience frequent interruptions of sleep. The normal control of respiration during the dynamic physiologic state of sleep significantly differs between sleep and wakefulness. Significant changes in several processes controlling breathing occur with sleep onset. The normal sleep time consists of a complex sleep architecture composed of several stages of **nonrapid eye movement (NREM) sleep** alternating with periods of **rapid eye movement (REM) sleep**. Each sleep stage in a typical sleep cycle has a characteristic electrophysiologic pattern, identified by waveforms seen during **electroencephalogram (EEG)** readings (**Table 7-1** and **Figure 7-1**).[2]

The stages of sleep begin with Stage W (wake), progress to Stage N1 (light sleep), then to Stage N2 and Stage N3 (deep sleep), and finally to Stage R (REM sleep) (**Table 7-2**).[2] Each stage in the sleep cycle has characteristic waveforms identified by EEG. These waveforms are used in **polysomnography (PSG)** to identify the stages of sleep. PSG is a continuous multifunction physiologic recording system used to distinguish two states of sleep. PSG uses the characteristic patterns in the EEG to measure brainwave activity, the **electrooculogram (EOG)** to measure eye movement activity, and the surface **electromyogram (EMG)** is placed on the chin and neck to measure muscle movement activity. This procedure enables the identification of specific states of sleep, REM and NREM stages. About 75–80% of the night is spent in NREM sleep, which is further divided into three stages characterized by identifiable EEG patterns that are capable of demonstrating increasing arousal thresholds and slowing of the cortical EEG. **Stage N1 of NREM** sleep presents as the initial stage of "light sleep" transition between wake and sleep, in which a low-voltage mixed-frequency pattern emerges. In this stage, individuals often drift in and out of sleep and can be awakened easily. During Stage N1 sleep, eyes usually move very slowly and muscle activities slow down, and if awakened, the individual often remembers fragmented visual images. Other significant physiologic changes in the processes controlling respiration occur with the onset of sleep. These changes include a fall in minute ventilation in response to a decline in the metabolic rate and a diminished chemosensitivity to O_2 and CO_2.[3] Sleep onset causes a gradual decrease in sympathetic activity, resulting in a slowing of heart rate and drop in blood pressure, which progresses with deeper stages of NREM sleep.[4] Stage N2 of NREM sleep is recognized by the presence of spindles and K-complexes on EEG and may be the first true sleep stage. During Stage N2 sleep, eye movements stop and brain wave fluctuations of electrical activity slow down and there are intermittent bursts of rapid waves called sleep spindles. Stage N3 of NREM sleep, which is also referred to as slow-wave or deep sleep, is distinguished by high-amplitude slow delta waves interspersed with smaller, faster waves. During Stage N3 sleep there is no eye movement or muscle activity (Table 7-2).

REM sleep is characterized by rapid eye movements and low-frequency sawtooth waves. The complete sleep cycles that occur at the beginning of each night contain relatively short REM periods lasting only a few minutes

TABLE 7-1
EEG Waveforms in Sleep

Waveform	Type	Characteristics
Alpha	Fast	8–13 Hz Occipital EEG channels Relaxed wakefulness Associated with EEG arousals
Theta	Low voltage Mixed frequency	4–7 Hz Stage N1 Background of Stage N2 and REM
Sleep Spindles	Brief bursts of high frequency Activity	11–16 Hz Central EEG channels Associated with Stage N2
K-complex	Unique waveform	Sharp negative wave followed by slower positive component Associated with Stage N2 Often immediately followed by sleep spindles
Slow waves	Low frequency Low amplitude	0.5–2 Hz Frontal regions of the brain Mostly associated with Stage N3

Data from Spriggs W. *Essentials of Polysomnography*. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015:157–187.



FIGURE 7-1 EEG waveforms indicative of different stages of sleep.

TABLE 7-2
Sleep Stages Seen on PSG of Normal Healthy Adults

Stage of Sleep	Waveforms	Characteristics
Stage W	Alpha waves	Awake Physically active (body movements) or inactive (no body movements) or relaxed wakefulness Eye blinks High-amplitude chin EMG
Stage N1	Alpha waves disappear Low-voltage, mixed-frequency EEG	First stage of sleep or transitional stage of sleep Light sleep NREM Makes up <10% of the total sleep time
Stage N2	Sleep Spindles K-complexes	Begins at the first set of sleep spindles or the first K-complex NREM Makes up about 50% of the total sleep time
Stage N3	Slow waves	Begins when the EEG waveforms contain a minimum of 20% slow waves NREM Human growth hormone is emitted Makes up about 20–25% of the total sleep time
Stage R	Sawtooth waves (2–6 Hz)	REM sleep Typically occurs 90–120 minutes after sleep onset Core temperature drops Respiratory patterns may vary slightly Makes up about 20–25% of the total sleep time Transitions to wake or Stage N3

Data from Spriggs W. *Essentials of Polysomnography*. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015:157–187.

and long periods of deep sleep. REM usually alternates with NREM periods in 90- to 120-minute average complete sleep cycles. REM periods with added sleep time increase in length while deep sleep decreases as the night goes on. Most adults spend approximately 20–25% of their sleep time in REM sleep, whereas infants typically spend about 50% of their sleep time in REM sleep. A variety of physiologic and behavioral changes occur during NREM and REM sleep. **Table 7-3** sums up the differences between the two types of sleep.

As the complete sleep cycle sequentially transitions through the NREM phases into the REM stage, respirations become variable, that is, more rapid, irregular, and shallow. Eye movements begin to occur rapidly in various directions, while limb muscles become temporarily inactive. Heart rate and blood pressure increase during REM sleep. Changes in respiratory rate, rhythm, and depth of breathing result in variations in alveolar ventilation. Other alterations known to occur during REM include a reduction in mucociliary clearance as well as diminished protective reflexes of the airways and decreased arousal responses to noxious stimuli. Individuals who awaken during REM sleep frequently experience strange dreams. A partial loss of the ability to regulate their body temperature during the REM stage of sleep will cause abnormal changes in environmental temperature to result in a reset in the normal sleep cycle progression. In such cases, subsequent sleep typically begins with the REM sleep stage rather than beginning with Stage N1 and goes through extended periods of REM until a "catch-up" has occurred. Ventilation during NREM sleep normally demonstrates a characteristically more regular respiratory pattern than wakeful breathing, without a sizable reduction in average respiratory frequency. Significant physiologic changes occur with the onset of sleep, including a fall in minute ventilation along with a decline in metabolic rate and diminished chemosensitivity to O_2 and CO_2, resulting in a reduction in the respiratory drive during sleep[3] (**Table 7-4**).

The lowest frequency of minute ventilation during NREM sleep occurs during Stage N3 sleep (also known as slow-wave sleep) with concurrent declines in tidal volume. As a result of the physiologic changes occurring during NREM sleep, end-tidal carbon dioxide ($ETCO_2$) increases by 2–3 mm Hg compared with the waking state.[6] During REM sleep, on the other hand, respiratory patterns and control vary more significantly compared

TABLE 7-3
Differences between NREM and REM Sleep

Characteristics	NREM	REM
Eye movement	Slow eye movement	Rapid eye movement
Type of sleep	Restful sleep	Not restful sleep
Metabolism	Decreased metabolism	Increased metabolism
Vital signs	Decreased	Irregular
Muscle tone	Maintained	Depressed
Dreams	Not vivid	Dreams occur

Reproduced with permission from Burepalli S, Punuru P, Gottiganti G, Badhvel J, Gopinath C. Review on Sleep and Sleep Disorders. *Scholars Acad J Pharm*. 2017;6(9):372–377. doi:10.21276/sajp.2017.6.9.1.

TABLE 7-4
Normal Physiologic Changes during Sleep

Physiology	NREM Sleep	REM Sleep
Heart rate	Slow and regular	Irregular
Blood pressure	Stable	Transient increases and decreases
Cardiac output	Decreases	Decreases further
Respiratory rate	Decreases	Increases
Ventilatory drive	Decreased tidal volume; decreased response to hypoxia and hypercapnia	Significant decrease in ventilatory drive; decreased response to hypoxia and hypercapnia
Autonomic nervous system	Increased parasympathetic tone	Unstable, brief surges in sympathetic and parasympathetic activity
Gastric motility	Decreases	Decreases
Muscle tone	Similar to wakefulness	Absent
Blood flow to brain	Decreases	Increases
Temperature regulation	Decreased hypothalamic temperature set point	Reduced thermoregulatory mechanism

Reproduced with permission from Burepalli S, Punuru P, Gottiganti G, Badhvel J, Gopinath C. Review on Sleep and Sleep Disorders. *Scholars Acad J Pharm*. 2017;6(9):372–377. doi:10.21276/sajp.2017.6.9.1; Benca R. *Sleep Disorders*. New York, NY: Oxford University Press; 2012.

to that observed during NREM sleep, with increased respiratory frequency and diminished regularity.[3] Tidal volume in REM sleep is additionally reduced to that seen during NREM sleep, resulting in the lowest level of normal minute ventilation. Subsequently, the onset of REM sleep will exhibit an increase in $ETCO_2$ (an additional 2–3 mm Hg), which is typically accompanied by a decrease in oxygen saturation.[7]

A fall in sleep-related alveolar ventilation may also be attributed to sleep-related changes in the upper airway mechanics. Upper airway muscles are normally active during inspiration when awake, functioning to maintain patency and prevent the collapse of the upper airways during inspiration. See **Box 7-2**. The activity of the genioglossus muscle during NREM sleep seems to mirror its action during wakefulness except that its response to CO_2 during sleep appears to be blunted[8] (**Figure 7-2**). At the onset of sleep, a partial pharyngeal collapse causes an increase in inspiratory resistance. The increased inspiratory resistance can cause hypoventilation if the added resistive "load" is not compensated for by increased respiratory effort. Upper airway muscle activity is at its lowest during REM sleep.[7] There is a higher degree of sleep-related reductions in muscle activity of the upper airway compared to that of the diaphragm.[7] Other factors that negatively affect upper airway

BOX 7-2 Muscles That Determine the Patency of the Upper Airway

Muscles regulating the position of the soft palate

- Alai nasi
- Tensor palatine
- Levator palatini

Tongue

- Genioglossus
- Geniohyoid
- Hyoglossus
- Styloglossus

Hyoid apparatus

- Hyoglossus
- Genioglossus
- Digastric
- Geniohyoid
- Sternohyoid

Posterolateral pharyngeal walls

- Palatoglossus
- Pharyngeal constrictors

Ayappa I, Rapoport D. The upper airway in sleep: physiology of the pharynx. *Sleep Med Rev*. 2003;7(1):9–33. doi:10.1053/smrv.2002.0238.



FIGURE 7-2 Upper airway anatomy. There are more than 20 upper airway muscles surrounding the airway that actively constrict and dilate the upper airway lumen. These groups of muscles interact in a complex fashion to determine the patency of the airway. Soft tissue structures form the walls of the upper airway and include the tonsils, soft palate, uvula, tongue, and lateral pharyngeal walls.[9]

patency include position, especially the supine position, the presence of excessive upper airway soft tissue, and retroglossal narrowing of the upper airway during sleep. Subtle increases in vascular congestion of the airways in response to positional changes may also increase upper airway resistance. Skeletal muscle inactivity associated with normal REM sleep causes ventilation to be accomplished solely by the diaphragm.[3] Because of the combined effects of decreased sensitivity of the respiratory drive to hypercapnia and hypoxia and reduced respiratory mechanical capacities, REM sleep is normally associated with relative hypoventilation. Hypoxia and hypercapnia may trigger arousals from sleep, resulting in a return to the more tightly regulated ventilatory control associated with wakefulness. The waking state is also associated with an increased ventilatory response to both elastic and airways resistance, prompting compensatory changes that preserve appropriate ventilation and prevent the development of hypercapnia.

Regulation of the sleep–wake cycle is modulated by two separate biologic mechanisms: **homeostatic sleep regulation** and **circadian rhythm**. The homeostatic factor refers to an increased propensity for sleepiness with longer periods of prior wakefulness, while the circadian factor relates to clinical variations in physiologic alertness and sleepiness with the time of day.[4,10] Homeostatic drive gradually increases as the day progresses, and by the end of the day, this drive results in the onset of sleep.[9] Sleep and wake states are produced by the interplay of centers in the brain stem, the hypothalamus, thalamus, and forebrain. Two mutually inhibitory groups of these centers, a wake-promoting group and a sleep-promoting group, result in a flip-flop circuit that provides sleep–wake control.[11] The circadian control is active during the day, while the homeostatic drive to sleep increases. When one system inhibits the other, the result is a switch between wakefulness and sleep.[11] The homeostatic sleep drive dominates over the circadian waking signal at the end of the day. When a person wakes spontaneously, in the morning, the homeostatic sleep drive is essentially zero, and the circadian wake signal is dominant. The circadian clock is normally synchronized with environmental cues, such as lighting and noise level, and external influences can affect the sleep–wake balance.

Several neurotransmitters promote wakefulness or sleepiness. These neurotransmitters include acetylcholine, adenosine, gamma-aminobutyric acid, glutamate, histamine, hypocretin, noradrenaline, and serotonin.[4,10] Because sleep and wakefulness are influenced by different neurotransmitter signals in the brain, foods and medicines can change the balance of these various neurotransmitter signals, affecting alertness and the quality of sleep. Underlying abnormalities in the function of the sleep–wake cycle, or outside interferences, such as environmental, drug-, or illness-related disorders, may alter either system's normal expression, leading to a clinically recognizable sleep disorder.

KNOWLEDGE CHECK QUESTIONS

1. True or False: There are four major categories of SRBDs.
2. True or False: Theta waves are normally present in K-complexes.
3. True or False: Stage R sleep usually occurs about 30 minutes after sleep onset.
4. True or False: Unstable, brief surges of parasympathetic and sympathetic activity occur during NREM sleep.
5. True or False: Neurotransmitters play a role in the daily sleep–wake cycle.

Definitions

The American Academy of Sleep Medicine promotes the use of standardized language. The terminology in **Tables 7-5** and **7-6** appear throughout this chapter.

TABLE 7-5
Sleep-Disordered Breathing (SDB) Definitions

Respiratory Event	Definition
Apnea	Cessation of airflow for at least 10 seconds, though may last for 30 seconds or longer. Airflow decreased by >90% is considered an apnea.
Hypopnea	A respiratory event characterized by a reduction in airflow (>30%) at least 10 seconds with >3% oxyhemoglobin desaturation. Hypopnea may occur during any sleep stage though tends to be more severe during REM sleep when ventilation is more irregular.
Respiratory effort–related arousal (RERA)	Arousal seen on EEG caused by a decrease in airflow that does not qualify as either an apnea or a hypopnea.
Obstructive apnea	A respiratory event characterized by continued thoracoabdominal effort in the setting of partial or complete airflow cessation.
Central apnea	A respiratory event characterized by the lack of thoracoabdominal effort in the setting of partial or complete airflow cessation for a minimum of 10 seconds during sleep.
Mixed apnea	A respiratory event including both obstructive and central features.

TABLE 7-6
Measurements of SDB

Indices	Definition
Apnea index	The average number of apneas per hour of sleep.
Apnea threshold	The $Paco_2$ level below which respiratory output ceases primarily, resulting in a central apneic event. This generally occurs 2–6 mm Hg lower than normocapnic sleep $Paco_2$ levels observed during spontaneous breathing.
Hypopnea index	The number of hypopnea events occurring per hour of total sleep time.
Apnea–hypopnea index (AHI)	The number of complete airflow cessation (apnea) and partial obstruction (hypopnea) events per hour of total sleep time, used to assess the severity of sleep apnea. AHI = (apneas + hypopneas) ÷ total number of minutes of sleep. The AHI can be used to classify the severity of disease (mild as 5–15, moderate as 15–30, and severe as greater than 30 episodes per hour of sleep).
Respiratory disturbance index	The average number of respiratory disturbances, including apneas, hypopneas, and RERAs per hour of the total sleep time. This index, like the AHI, is commonly used to assess the severity of SDB.
Central apneas	The number of complete cessations of airflow and respiratory effort events per hour of the total sleep time.
Central hypopneas	The number of hypopneas due to reduced effort during sleep.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A decrease in airflow of 95% is considered an apnea.
2. True or False: Apnea is defined as cessation of airflow for at least 20 seconds.
3. True or False: The apnea–hypopnea index and the respiratory disturbance index are the same.

Obstructive Sleep Apnea

OSA is the most common type of SDB. OSA is caused by the collapse of soft tissue in the pharynx.

Definition/Diagnosis

OSA represents an abnormal condition characterized by recurrent episodes of complete (apnea) or partial (hypopnea and RERA) interruption of airflow resulting from upper airway collapse and obstruction during sleep despite continued efforts in breathing. Clinically, the patient has loud snoring, daytime sleepiness, witnessed breathing interruptions, or awakenings due to gasping or choking in the presence of at least five obstructive **respiratory events** (apneas, hypopneas, RERAs, or mixed apneas) per hour of sleep. The occurrence of 15 or more obstructive respiratory events per hour of sleep in the absence of sleep-related symptoms is also sufficient for the diagnosis of OSA.[12] These respiratory events are often accompanied by fluctuations in heart rate, an abrupt fall in oxygen saturation, and brief arousals. Typically, these occurrences are concurrent with loud and harsh breathing sounds or snoring as air is exhaled when the airway reopens. Clinical manifestations of hypopnea can be similar to those of apnea, though a more significant decrease in oxygen saturation is generally associated with apnea compared to hypopneic events.

A diagnosis of OSA is based on the presence or absence of related symptoms, as well as the frequency of respiratory events during sleep, as measured by PSG or **home sleep apnea testing (HSAT)**.[13] The diagnosis of OSA in adults is confirmed if either of the two criteria developed by the American Association of Sleep Medicine exists (**Box 7-3**).[1]

BOX 7-3 Criteria for the Diagnosis of OSA

- ≥5 predominantly obstructive respiratory events per hour of sleep (for PSG) or recording time (for HSAT) in a patient who has ≥1 of the following:
  - Waking up with gasping, choking, or breath holding
  - Habitual snoring, or breathing interruptions, or both noted by a bed partner or observer
  - Fatigue, sleepiness, nonrestorative sleep, or insomnia symptoms
  - Atrial fibrillation, cognitive dysfunction, congestive heart failure (CHF), coronary artery disease (CAD), hypertension, mood disorder, stroke, or type 2 diabetes mellitus
- ≥15 predominantly obstructive respiratory events per hour of sleep (for PSG) or recording time (for HSAT), regardless of the presence of associated symptoms or comorbidities

American Academy of Sleep Medicine. *International Classification of Sleep Disorders*. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.

Clinical Signs and Symptoms

Manifestations of OSA usually begin insidiously and are often present for years before the patient is referred for evaluation. As clinical signs and symptoms eventually become apparent, the patient with OSA typically displays nocturnal symptoms, including loud, persistent snoring that is bothersome to others; witnessed apneas, which

frequently interrupt snoring; gasping or choking that awaken the patient from sleep; restless sleep with nocturnal awakenings and excessive body movements; and more.[13,14] See **Box 7-4**. These manifestations all tend to result in poor sleep quality. Daytime symptoms include **excessive daytime sleepiness (EDS)**, which typically begins during quiet activities (such as when reading or watching television) and progressively worsens.

Eventually, these individuals extend their sleepiness into activities that require alertness (such as during school or work, or when driving). EDS is one of the most debilitating symptoms associated with OSA syndrome because it reduces the quality of life, impairs daytime functioning, and causes neurocognitive deficits, such as memory loss. EDS is typically assessed using a subjective sleep questionnaire, such as the ESS. The ESS is a validated self-administered eight-item questionnaire that measures subjective daytime sleepiness[15] (**Figure 7-3**). Although the ESS is not specific for apnea, and apnea severity is not always correlated with the degree of perceived sleepiness, the scale is used to identify patients with EDS who may require further screening for sleep apnea or other causes of sleepiness.[5] Another helpful screening tool is the Berlin Questionnaire, which has been demonstrated to have good sensitivity in

BOX 7-4 Symptoms of OSA

Awakening with choking
Cognitive deficits
Daytime sleepiness or fatigue
Diaphoresis at night
Dry mouth upon awakening
Gastroesophageal reflux
Insomnia with frequent awakenings
Lack of concentration
Loud snoring
Mood changes
Morning headaches
Nocturia
Nocturnal restlessness
Nonrestorative sleep
Witnessed apneas by bed partner

Modified from Benca R. ***Sleep Disorders***. New York, NY: Oxford University Press; 2012; Kline L. Clinical presentation and diagnosis of obstructive sleep apnea in adults. In: Finlay G, Collop N, ed. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 29, 2017.

THE EPWORTH SLEEPINESS SCALE

Name: _____

Today's date: _____ Your age (years): _____

Your sex (male = M; female = F): _____

How likely are you to doze off or fall asleep in the following situations, in contrast to feeling just tired? This refers to your usual way of life in recent times. Even if you have not done some of these things recently try to work out how they would have affected you. Use the following scale to choose the *most appropriate number* for each situation:

0 = would *never* doze
1 = *slight* chance of dozing
2 = *moderate* chance of dozing
3 = *high* chance of dozing

Situation	Chance of dozing
Sitting and reading	_____
Watching TV	_____
Sitting, inactive in a public place (e.g. a theater or a meeting)	_____
As a passenger in a car for an hour without a break	_____
Lying down to rest in the afternoon when circumstances permit	_____
Sitting and talking to someone	_____
Sitting quietly after a lunch without alcohol	_____
In a car, while stopped for a few minutes in the traffic	_____

Thank you for your cooperation

FIGURE 7-3 The ESS is a subjective measure of a patient's sleepiness.
Reproduced with permission from Johns M. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14(6):541 (Table 1).

TABLE 7-7
Physical Findings Frequently Identified with OSA

Sign	Criteria/Comment
BMI	>30 kg/m^2
Crowded oropharyngeal airway	Mallampati classification of 3 or 4
Large neck	>17 inches for men, >16 inches for women
Large waist circumference	>102 cm (40 inches) in men or women
Elevated blood pressure	50% of patients with OSA have coexisting hypertension
Signs of pulmonary hypertension or cor pulmonale	Common sequelae when OSA exists with daytime hypoxemia due to other chronic illnesses

Epstein L, Kriste D, Strollo P, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263–276; Kline L. Clinical presentation and diagnosis of obstructive sleep apnea in adults. In: Finlay G, Collop N, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 29, 2017; Qasrawi S, Al Ismaili R, Pandi-Perumal S, Bahammam A. Chapter 13 Sleep-related breathing disorders in adults. *Synop Sleep Med*. 2016:213–232. doi:10.1201/9781315366340-14; Davidson T, Patel M. Waist circumference, and sleep disordered breathing. *Laryngoscope*. 2008;118(2):339–347. doi:10.1097/mlg.0b013e3181587d7c.

identifying individuals at risk for OSA.[5] Other methods of quantifying EDS and fatigue include the multiple sleep latency test (MSLT) and the maintenance of wakefulness test (MWT). The MSLT is an objective test of physiologic sleepiness using a nap study to measure how quickly a patient falls asleep in quiet situations during the day.[16] The MWT measures a patient's ability to stay awake in a calm, nonstimulating situation for a given period of time.[16] These tests are not routinely indicated in the initial evaluation and diagnosis of OSA.[17]

The physical examination for individuals suspected of OSA is frequently normal except for the presence of obesity (BMI >30 kg/m^2), a significantly enlarged neck circumference, and a crowded oropharyngeal airway.[12] The upper airway of all patients displaying symptoms suggestive of OSA needs evaluation, even if they are not obese (**Table 7-7**).[18]

Numerous conditions can cause the crowding in the oropharyngeal airway. These conditions include retrognathia (lower jaw setback from the upper jaw), micrognathia (small lower jaw), macroglossia (large tongue), tonsillar hypertrophy, elongated uvula, high arched or narrow palate, nasal septal deviation, and nasal polyps.[13,14] The Mallampati classification is a common evaluation method for quantifying upper airway narrowing. This simple scoring system relates the amount of mouth opening to the size of the tongue. It is typically used to assess the space available for oral intubation by direct laryngoscopy[13] (**Figure 7-4**).



FIGURE 7-4 Mallampati classification of airway crowding. A classification of 3 or 4 is considered positive for a crowded oropharyngeal airway.

Etiology

The most common cause of OSA in adults is obesity associated with disproportionate amounts of soft tissue in the mouth and throat. Because sleep represents a period of time muscles of the upper airway are normally more relaxed, the presence of additional soft tissue can block the oropharyngeal airway. Certain naso-oro-pharyngeal parameters are significantly associated with OSA. These parameters include enlarged adenoids, a large tongue, greater neck circumference, and a narrow oropharyngeal inlet.[19] Contributing factors may also include metabolic disturbances, such as hypothyroidism, acromegaly (abnormal growth due to excess production of growth hormone), allergies, and a deviated nasal septum.

Epidemiology

OSA is the most common SRBD. Prevalence estimates vary according to the way in which OSA is defined and the distribution of risk factors in the population being studied.[20] The prevalence of OSA is two times higher

in men than in women in the general population.[21] The prevalence of OSA increases with age through midlife but then decreases in both men and women.[21] The number of adults in the United States with OSA is at least 25 million.[22]

The prevalence of OSA also varies by race and ethnicity. OSA is more prevalent in African Americans who are younger than 35 years compared with Caucasians of the same age group and independent of body weight.[20] Given the rising obesity rates in the United States, it is likely that the prevalence of OSA will also continue to increase.[5]

Pathology/Pathophysiology

Most individuals who develop OSA demonstrate recurrent upper airway obstruction above the level of the larynx. Upper airway size in patients with OSA is typically small. This is often due to increased body mass or eccentric facial bone structure. Retropositioning of the maxilla and mandible can also predispose patients to a narrow pharynx caused by posterior displacement of the tongue and soft palate. The obstruction can result in substantially reduced (hypopnea) or complete cessation (apnea) of airflow despite ongoing breathing efforts (**Figure 7-5**). Disruptions in breathing produce intermittent blood gas disturbances (hypercapnia and hypoxemia) and surges of sympathetic activation. The frequent occurrence of loud snoring is usually interrupted in most cases by the culmination of a respiratory event associated with a brief awakening from sleep (arousal). A cyclical breathing pattern and associated fragmented sleep events continue to reoccur as the patient fluctuates between wakefulness and sleep. In severe cases of OSA, respiratory events can occur more than 100 times/hour, with each event typically lasting from 20 to 40 seconds.

OSA has long been recognized as a heterogeneous pathophysiologic disorder with potentially multiple contributing causes that may vary considerably between patients. The site of upper airway collapse during sleep is typically between the hard palate and the larynx. The collapse occurs during inspiration due to the limited space, negative pharyngeal pressure, and the decreased tone of the genioglossus muscle.[23] REM sleep is often associated with the most frequent or prolonged obstructions, possibly because of the generalized muscle atonia and reduced chemoreceptor sensitivity to changes in $PaCO_2$ and PaO_2.[5] The occurrence of an anatomically compromised collapsible airway associated with sleep-induced loss of the compensatory tonic input to the upper airway dilator muscle motor neurons leads to further collapse of the pharyngeal airway. **Box 7-5** lists the abnormal physiologic contributing to and perpetuating OSA.



FIGURE 7-5 A normal upper airway during sleep versus OSA. The obstruction is caused by the reduced muscle tone of the genioglossus muscle of the tongue, the soft palate, and the uvula.

BOX 7-5 Abnormal Physiologic Factors Causing or Perpetuating OSA

Decreased arousal threshold (ability to wake from increased respiratory drive)

Decreased upper airway dilator muscle responsiveness and activity

Decreased upper airway opening

Sleeping in the supine position can worsen apnea, as gravity allows the tongue and related soft tissues to fall back toward the posterior wall of the pharynx, decreasing airway diameter. The ability of the individual to compensate for the airway obstruction thus controls the degree of cycling of these events (**Figure 7-6**).

Despite multiple physiologic sleep-related changes in respiratory mechanics and a rise in $PaCO_2$, not all individuals develop complete upper airway obstruction. Individuals with favorable upper airway anatomy and lung mechanics are able to sustain rhythmic breathing and normal gas exchange, whereas those with highly compromised upper airway may develop complete obstruction.[24]

Risk Factors

Risk factors for OSA are advancing age, male gender, menopause, obesity, neck circumference, and nasal and pharyngeal anatomy, nasal congestion, smoking, and alcohol consumption. Several medical conditions increase a person's risk for OSA. These medical conditions include endocrine abnormalities, such as acromegaly and hypothyroidism. Other risk factors include polycystic ovary syndrome and testosterone therapy because they cause increased tissue deposition in and around upper airway along with effects on respiratory centers. See **Box 7-6**.

Complications

Patients with OSA are at a higher risk of developing complications that include postoperative hypoxemia, respiratory failure, unplanned ICU transfers, and longer



FIGURE 7-6 **(A)** Schematic representation of the typical pathophysiologic sequence that occurs in OSA and the associated physiologic processes that occur throughout the cycle. Factors that are protective/restorative are located on the outside of the circle. Factors that are perpetuating are located on the outside of the circle. **(B)** Schematic representation of the possible sites where each of the various pathophysiologic traits either predisposes or tends to worsen OSA. These factors are located inside the main circle.

Modified from Eckert D, Malhotra A. Pathophysiology of adult obstructive sleep apnea. *Proc Am Thorac Soc*. 2008;5(2):144–153 (Figure 2A, p. 148). doi:10.1513/pats.200707-114mg.

hospital stays.[25] OSA is associated with EDS, inattention, and fatigue, which may impair daily function, induce or exacerbate cognitive deficits, and increase the likelihood of errors and accidents.[20]

Moderate-to-severe untreated OSA puts an individual at a high risk for a broad range of cardiovascular morbidities, including systemic hypertension, pulmonary arterial hypertension, CAD, cardiac arrhythmias, heart failure (HF), stroke, and sudden cardiac death.[20,26,27] Patients with OSA who develop coronary heart disease are a high-risk group because of the increased likelihood of apnea-associated silent myocardial ischemia and electrical instability of the myocardium. The occurrence of serious cardiac arrhythmias, such as premature ventricular contraction, second-degree heart block, and ventricular tachyarrhythmia is linked to OSA due to intermittent hypoxia.[26] Increasing evidence has also demonstrated that OSA is an independent risk

BOX 7-6 Risk Factors for OSA

Advancing age
Alcohol use
BMI >25 kg/m^2
Craniofacial and upper airway abnormalities
Family history of OSA or snoring
Male gender
Menopause and postmenopause
Neck circumference >17 inches for men, >16 inches for women
Pregnancy
Smoking
Medical conditions
- Acromegaly
- Depression
- Diabetes mellitus
- Down syndrome
- Hypertension
- Hypothyroidism
- Neuromuscular disorders
- Polycystic ovary syndrome
- Renal failure
- Stroke

Medications
- Anesthetics
- Barbiturates
- Benzodiazepines
- Growth hormone
- Narcotics
- Testosterone

factor for ischemic stroke.[28] Patients with untreated severe OSA have a two- to three-fold increased risk of all-cause mortality compared with individuals without OSA, independent of other risk factors, such as obesity and cardiovascular disease.[28-30]

Diagnostic Testing

The clinical history and physical examination indicate which patients are at a higher risk for OSA. However, the diagnosis of OSA requires a sleep study. PSG is considered the "gold standard" when considering the possibility of SRBD. However, for patients who are strongly suspected of having OSA without any medical comorbidities, the HSAT may be an acceptable alternative. Routine laboratory and radiologic testing are usually not particularly helpful in the diagnostic evaluation of OSA unless a specific indication is clinically present or suspected.

Polysomnography

PSG entails the recording of multiple physiologic parameters during the night in a sleep laboratory attended by a specialized sleep technologist. It is a multichannel recording of both sleep and breathing. Numerous measurements are continuously monitored (**Table 7-8** and **Figure 7-7**).

A diagnostic, or baseline, PSG report contains much information from the study. The data from the PSG are reported to the physician to assist in the determination of an accurate diagnosis. The information on the PSG report includes, but is not limited to, information such as patient demographics; results of screening tools such as the ESS; sleep time summary, including total sleep time; respiratory summary; EEG arousal summary; limb movement summary; ECG summary; AHI; and oxygen saturation summary (**Figures 7-8** and **7-9**).

Home Sleep Apnea Testing

HSAT is useful for the diagnosis of OSA in patients with a high pretest probability of moderate-to-severe uncomplicated OSA. This means patients who do not have medical comorbidities, such as cardiopulmonary disease or other significant disorders, may be tested with HSAT. The risk of moderate-to-severe OSA is high when the patient exhibits daytime hypersomnolence and at least two of the following three criteria: habitual loud snoring, witnessed apnea or gasping/choking, or diagnosed hypertension. Additionally, environmental or personal factors may influence the choice of the testing site.[13] HSAT is a considerably less complicated diagnostic modality, is less difficult to perform, and is less time consuming and less expensive. Portable studies offer greater convenience and more closely replicate the patient's usual night of sleep. At a minimum, HSAT must record airflow, respiratory effort, and pulse oximetry.[5,12] These unattended tests typically do not include standard sleep-staging parameters, so no sleep data are obtained.[5]

Treatment and Management

OSA is a chronic disease that requires long-term, multidisciplinary management. The goals of OSA therapy include resolution of signs and symptoms of OSA, improving sleep quality, and normalizing AHI and oxygen saturation levels during sleep. The potential benefits of

TABLE 7-8
Parameters Measured during PSG

Parameter	Placement	Function
EEG	Multiple electrodes placed on head using the International 10/20 System for EEG electrode placement	Records various brain waves generated while awake and during sleep
EOG	At least two electrodes placed above or below the outer canthus of the eye	Records eye movements for identification of REMs that occur during Stage R (REM) sleep
EMG	Three electrodes placed on the chin	Records activity in the chin to determine the level of muscle tone
ECG	Two standard ECG electrodes placed in a lead II format	Records the heart rhythm
Upper airway sound recording	Snore sensor or microphone placed over the trachea or on the side of the neck	Detects snore bursts for determining and verifying the nature of arousals
Airflow sensor	A thermistor, thermocouple, or pressure transducer placed directly in front of the nose or mouth	Records air movement from both the nose and the mouth
Respiratory effort belt	Snug fitting (not tight) respiratory inductance plethysmography belts around the chest and abdomen	Records respiratory effort
Leg EMG	Two electrodes placed on the anterior tibialis muscle on the outside of the lower half of each leg	Records leg movement during sleep
Pulse oximetry	Finger sensor placed on the tip of any three middle fingers	Records arterial oxygen saturation during sleep
Body position	Observation by sleep technologist during the study or body position monitoring device	Identify body positions that exacerbate apnea during sleep
Video recording	Recording of behavior during sleep with the least disruption	Observe the patient's normal sleep pattern in an environment that resembles a bedroom or hotel room

Spriggs W. *Essentials of Polysomnography*. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015:157–187; Benca R. *Sleep Disorders*. New York, NY: Oxford University Press; 2012; Epstein L, Kriste D, Strollo P, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263–276; American Association of Sleep Technologists. *Sleep Technology: Technical Guideline*. Darien, IL: American Association of Sleep Technologists; 2012:2–8. https://www.aastweb.org/hubfs/Technical%20Guidelines/StandardPSG.pdf?t=1510785704439. Accessed January 3, 2018.



FIGURE 7-7 Example of electrode and sensor placements during PSG.



Diagnostic Sleep Report

Patient: Jane Doe
Date of Birth: 12/1/1962
Referring Physician: Dr. Sleep, MD
Date of Service: 2/18/2008
Place of Service: Sleep Lab
Interpreting Physician: Dr. Sleep, MD

Patient History: Jane Doe is a 45-year-old Female who is 65 inches tall, weighs 195 pounds and has a BMI of 32.4. Sleep Complaints include drowsiness, fatigue, snoring, morning headaches, and witnessed apnea. Current known medical history includes hypertension, diabetes, CHF, seasonal allergies, and sinus problems. Known current medications include Lexapro and Diovan, which were taken on the day of the test. The patient does not smoke. Patient had 7 hours of sleep the previous night and indicated that this was not adequate. The patient consumed 1 caffeinated and 0 alcoholic beverages on the day of the test. The patient did not take a nap on the day of the test. Epworth Sleepiness Scale = 11, which indicates moderate daytime sleepiness.

Symptoms Consistent with OSA

Protocol: This sleep study included recording and monitoring of EEG, EOG, EMG, ECG, respiratory effort and flow, snoring, pulse oximetry, and position. Video recordings were obtained as needed. A qualified sleep technologist continuously monitored the patient throughout the night. Data was digitally stored and tabulated using Sandman software. Sleep staging and respiratory events were scored manually using AASM standards.

Test Information:
Lights Out: 9:47:29 PM Lights On: 5:18:16 AM Pre-B/P: 131/80 Post-B/P: 138/88

PSG

Sleep Architecture

Total Study Time:	450.8 minutes		REM Latency:	108.0 minutes	
Total Sleep Time:	361.8 minutes		Sleep Efficiency:	80.3%	Normal: >90%
Sleep Latency:	12.0 minutes		Awake after Sleep:	77.0 minutes	

Decreased Sleep Efficiency

			Normal
Stage 1:	5.4%	19.5 minutes	5%-10%
Stage 2:	57.4%	207.5 minutes	55%-62%
Stage 3+4:	11.9%	43.0 minutes	5%-20%
Stage REM:	25.4%	92.0 minutes	21%-25%

Respiratory Events

Obstructive Apneas:	10	Apnea / Hypopnea Index:	18.9	Normal: <5 per hour / sleep
Hypopneas:	97	N-REM Event Index:	9.8	
Central Apneas:	7	REM Event Index:	45.7	
Mixed Apneas:	0	Supine Event Index:	24.9	
Total Events:	114	REM / Supine Index:	61.8	

Increased AHI

AHI Elevated During REM

SpO_2 Statistics

SpO_2 Baseline:	94.3 %	SpO_2 Minimum:	81.0 %	
Time below 90%:	12.5 min.	# of Desaturations:	123	

Decreased Oxygen Saturation

PLMS Events

# of PLMS:	73	PLMS Index:	12.1 per hour / sleep

Arousal Statistics

PLMS Arousals:	11	PLMS Arousal Index:	1.8
Resp. Arousals:	9	Resp. Arousal Index:	1.5
Snore Arousals:	0	Snore Arousal Index:	0.0
Spontaneous Arsls:	24	Spontaneous Arsl. Index:	4.0
Total Arousals:	44	Total Arousal Index:	7.3

Increased Number of Leg Movements

FIGURE 7-8 Sample PSG report page 1.

successful treatment of OSA include clinical improvement (e.g., less daytime sleepiness), reduced healthcare utilization and costs, and, possibly, decreased cardiovascular morbidity and mortality. OSA should be treated early because the overall outcome is dependent on avoiding potential long-term complications.[32] There are medical and surgical options, as well as lifestyle modifications, for the treatment of OSA. Adjunctive therapies are used as needed to supplement the primary treatment options.[12] The patient must take an active role in the treatment decision and receive education about the risk factors, causes, and consequences of OSA.

The sleep specialists who evaluate the PSG or HSAT results typically make their treatment recommendations for OSA patients based in large part on the severity of the SDB. Individuals presenting with mild apnea have a greater variety of options, including behavior modification programs and medical



FIGURE 7-9 Sample PSG report page 2.

treatment, while those with moderate-to-severe apnea typically require additional measures ranging from **continuous positive airway pressure (CPAP)** to surgical interventions.

Lifestyle Modifications

Treatment of OSA often includes lifestyle modifications, such as weight loss, which can improve or possibly cure OSA in cases where apnea is caused by obesity.[5] A majority of patients with OSA are obese, and the incidence of OSA in adults is also high. Evidence shows that intensive weight loss interventions help reduce AHI scores and improve OSA symptoms.[33] Other health benefits are associated with weight loss. After a 10% change in body weight, reassessment of OSA severity is recommended.[5] Lifestyle counseling is an essential component in the comprehensive care of patients with OSA. This counseling not only addresses weight loss but also promotes adherence to other therapies that may be prescribed.

Many patients have what is called positional OSA. This form of OSA occurs when a person experiences more respiratory events while sleeping in the supine position as opposed to the non-supine position. Positional

OSA is defined as an AHI at least twice as high in the supine position as in other positions.[34] For these patients, avoidance of the flat position may be enough to control their OSA. There are several commercial products available that can be worn to prevent a person from rolling onto their backs during sleep. Alternatively, self-made devices utilizing tennis balls sewn into the backs of pajamas can also prevent patients from moving onto their backs. Unfortunately, long-term adherence to positional therapy is low.[34]

There are also specially designed pillows for the treatment of snoring and mild OSA that may effectively maintain the patient's head and neck positions during sleep to optimize upper airway patency. Other lifestyle modifications that help to reduce OSA symptoms include smoking cessation, elimination of exposure to secondhand smoke, avoiding the use of alcohol, and elimination of or decrease in the use of sedating medications, especially at bedtime.

Positive Airway Pressure Therapy

The "gold standard" treatment for sleep apnea is **positive airway pressure (PAP) therapy**.[5,12,14,33] PAP therapy provides pneumatic splinting of the upper airway by maintaining positive pressure to the upper airway structures during both inspiration and expiration. As a result, the patient experiences fewer apneas and hypopneas due to airway collapse.[14] Patient ESS scores improve, and there are reductions in AHI and patient symptoms.[33] PAP therapy is recommended for patients with moderate-to-severe OSA (AHI $\geq$ 15) and considered for mild OSA accompanied by daytime sleepiness or associated comorbidities.

The three ways to deliver PAP include CPAP, **auto-titrating positive airway pressure (APAP)**, **bi-level positive airway pressure (BPAP)**, and **adaptive servo-ventilation (ASV)**. CPAP is generally considered the preferred treatment option for OSA. CPAP can quickly reverse OSA with appropriate titration of a fixed airway pressure typically between 5 and 24 cm H_2O. This pressure is applied to the airway by means of a nasal mask, nasal prongs, nasal pillows, or facemask. **Figure 7-10** shows a nasal mask. CPAP dilates the airways within the retropalatal and retroglossal regions, increases the lateral dimensions of the upper airway, and causes thinning of the lateral pharyngeal walls. The appropriate pressure setting for a patient is identified via titration during the second half of the sleep study (split-night titration) or during a full-night titration. The pressure is increased until the respiratory events and snoring disappear. The higher the CPAP, the less tolerable it is. However, because CPAP is the standard of care for the treatment of OSA, all reasonable interventions to improve the tolerance for CPAP therapy are needed before deciding to terminate treatment for a particular patient.

APAP (or auto-CPAP) represents a more recently developed mode of PAP delivery designed to act in response to changes in upper airway resistance. PAP with this mode automatically increases or decreases in response to changes in pressure, airflow, or reflections of snoring sounds. APAP automatically varies the level of pressure administered to the patient during each use. This action permits delivery of the lowest pressure that overcomes airflow limitation between minimum and maximum pressure determined by the provider. APAP is particularly valuable in patients who experience difficulty tolerating a fixed, higher level of CPAP. APAP is not recommended for patients with certain comorbidities, including HF, chronic obstructive pulmonary disease, OHS, and daytime or nocturnal hypoxemia.[5] **Figure 7-11** shows a summary of the approach to initiation, management, and follow-up of CPAP for OSA.

FIGURE 7-10 CPAP delivered by nasal mask.

BPAP provides two different pressures, an inspiratory positive airway pressure (IPAP) and an expiratory positive airway pressure (EPAP). IPAP is set higher than EPAP and prevents the collapse of the airway during inspiration. Because EPAP is lower, it can make PAP easier to tolerate because the overall lowered mean airway pressure tends to provide a more comfortable option. BiPAP's overall delivery often reduces the feeling of excessive air pressure or the sensation of exhaling against positive pressure. BPAP and APAP are considered in the management of OSA for CPAP-intolerant patients.[12] BPAP is the treatment of choice for patients who have hypoventilation, such as those with OHS or chronic obstructive pulmonary disease, and in those with a component of CSA.

ASV is a type of PAP therapy that adjusts the airflow to maintain a preset minute ventilation. The device performs a breath-by-breath analysis of the patient and adjusts the airflow according to the patient's respiratory effort. This form of PAP therapy is useful for the treatment of CSA with various etiologies, including Cheyne–Stokes respiration (CSR-CSA). ASV is useful for the treatment of OSA that coexists with CSA, especially in patients with HF.[35]

Because adherence rates for PAP therapy are low, increasing adherence with PAP therapy is probably the most important issue in the treatment of OSA.[5] Patient education and supportive interventions that encourage



FIGURE 7-11 Approach to initiation, management, and follow-up of CPAP treatment for OSA in adults.

Modified from Epstein L, Kriste D, Strollo P, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med.* 2009;5(3):263–276 (Figure 2, p. 269).

BOX 7-7 Some Problems Leading to Decreased Adherence to PAP Therapy

Equipment issues
- Mouth leak
- Mask leak
- Claustrophobia

Patient issues
- Dryness of upper airways
- Eye irritation
- Nasal congestion
- Sinusitis
- Skin irritation/pressure sores
- Epistaxis
- Aerophagia

people to continue to use their CPAP machines are essential to improve adherence.[36] Close follow-up for PAP usage and problems by appropriately trained healthcare providers is indicated to establish effective utilization patterns and remediate issues, if needed.[12] Problems that may cause decreased adherence to PAP therapy are listed in **Box 7-7**. It is the multidisciplinary care team, which typically includes a sleep specialist, a referring physician, nursing personnel, a respiratory therapist, and a sleep technologist, that work with each patient to select the most appropriate therapy and provide education and supportive interventions to improve the adherence to treatment.[12]

Alternative Therapies

Although CPAP is the gold standard for OSA, there are some patients who do not or will not tolerate CPAP. Alternative therapies may be used for those patients for whom CPAP is not an option for treatment of mild-to-moderate OSA.

Oral Appliance Devices

OSA treatment is generally predicated on the premise that supportive measures should begin with those methods that are least invasive and effective, then advance to more invasive treatments as necessary. Most experts believe that all patients requiring more than lifestyle modifications need to be initially offered PAP therapy. Oral appliances (OAs) are generally indicated for patients who have mild-to-moderate OSA decline and do not respond to or fail to adhere to PAP therapy.[14] OA devices are not considered first-choice treatment for patients with OSA.

There are several types of OA devices. **Mandibular advancement devices (MADs)** or mandibular repositioning appliances (MRSs) cover the upper and lower teeth and reposition the lower jaw forward and downward during sleep (**Figure 7-12**). The treatment aims to widen the upper airways in order to improve the upper airway patency and reduce snoring and OSAs.[37] Candidates for a MAD require adequate healthy teeth upon which to seat the OA, no important

FIGURE 7-12 One type of mandibular advancement device (MADs).

temporomandibular joint (TMJ) disorder, adequate jaw range of motion, and adequate manual dexterity and motivation to insert and remove the OA, as determined by a qualified dental professional.[12] For MADs to operate properly, they need to be custom-made and evaluated and need to advance the mandible by at least 50% of the maximum protrusion.[37] **Tongue-retaining devices (TRDs)** work by keeping the tongue in place, thereby preventing it from occluding the upper airway at the level of the oropharynx or laryngopharynx. TRDs are not recommended for OSA.[14,37]

OAs may be better tolerated than PAP therapy. However, these devices are less efficient.[5] Side effects of oral devices include jaw, TMJ or tooth pain, dry mouth, changes in bite, excessive salivation, and discomfort. Persistent TMJ pain and changes in occlusive alignment may necessitate cessation of treatment.[14]

Pharmacologic Treatment

Supplemental oxygen is not recommended as a primary treatment for patients with OSA.[38] Supplemental oxygen is appropriate as an adjunct to other primary therapies to treat hypoxemia. However, supplemental oxygen alone may prolong apneas and may potentially worsen nocturnal hypercapnia in patients with comorbid respiratory disease.[12]

Pharmacologic therapy with agents such as acetazolamide, medroxyprogesterone, fluoxetine, protriptyline, and xanthines was investigated for the management of OSA. However, these agents are not considered a part of the primary treatment recommendations.[12,14,37,38] Although pharmacologic therapy is not considered useful for OSA, modafinil (a wake-promoting medication) and armodafinil (a derivative of modafinil) appear to effectively enhance alertness in patients with residual daytime sleepiness despite optimal use of CPAP.[12,14,38]

Surgical Treatment

Patients with therapeutically resistant OSA or those who are nonadherent with first-line therapy (CPAP,

BiPAP, APAP, and ASV) or with alternatives such as OAs are then offered alternative surgical options.[12] **Figure 7-13** lists common surgical procedures for OSA.

Tracheostomy is an effective surgical procedure for treatment of OSA and may be considered when other treatments fail or are refused.[5] It is virtually 100% effective because it completely bypasses the obstruction. While its therapeutic effectiveness is noteworthy, tracheostomy is primarily reserved for the most severe cases because of the potentially substantial surgical and psychosocial complications that may arise following the procedure. Unfortunately, tracheostomy is a disfiguring procedure that often results in a decrease in quality of life. Tracheostomy may be used as a temporary or permanent option in patients presenting with critical oxygen desaturation or who develop cardiac dysrhythmia precipitated by OSA when CPAP therapy is refused, poorly tolerated, or unsuccessful.

Uvulopalatopharyngoplasty (UPPP, or U3P) is one of the more common surgical procedures used in the surgical treatment of OSA. This procedure normally entails resection of the uvula, as well as excess retroglossal soft tissue, and palatine tonsillar lymphoid tissue involving the soft palate. The success rate of this procedure is about 50%.[37] This degree of effectiveness is despite preselection of patients with upper airway obstruction evidenced by using radiographic imaging and endoscopic studies. Predicting which patients will likely benefit from UPPP is problematic especially because patients with initial treatment success when following the treatment over a long term often have a recurrence of symptoms. Laser-assisted uvulopalatoplasty (LAUP) uses radio frequency waves to heat and remove tissue. However, LAUP is not recommended for the treatment of OSA,[12] except in carefully selected patients.[37]

Nasal surgery for patients with OSA include septoplasty, nasal turbinate reduction, polypectomy, and rhinoplasty may in certain circumstances be useful adjuncts to other procedures or improve insufficient CPAP adherence. Nasal causes of obstruction are caused by boney and cartilaginous distortion or from soft tissue changes. Nasal surgery by itself, however, is rarely effective for the treatment of OSA. Nasal surgery is recommended for reducing high therapeutic CPAP pressure due to nasal obstruction.[37]

Surgical procedures may be considered as secondary therapy when there is an inadequate treatment outcome with PAP therapy and an OA or when the patient is intolerant of these therapies. Surgery is appropriate as an adjunct therapy when obstructive anatomy or functional deficiencies compromise other therapies to improve tolerance for other OSA treatments.[12]

Prognosis

Although a common clinical disorder with increasing awareness of its potential to cause serious disease, OSA remains underrecognized by most primary care physicians with an estimated 75–80% of Americans remaining undiagnosed.[39] OSA is important for physicians to consider because of its strong association with several medical conditions, including hypertension,[40] cardiovascular disease,[26] CAD,[41] insulin-resistance diabetes,[42] depression,[43] and sleepiness-related traffic accidents.[44]

The short-term prognosis of OSA patients has been shown to be good to excellent with the regular use of



FIGURE 7-13 Anatomical sites and the surgical procedures used to treat OSA.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Individuals with OSA continue breathing efforts with little or no airflow during apnea episodes.
2. True or False: A Mallampati classification of three or more is associated with a crowded oropharyngeal airway.
3. True or False: During polysomnography, respiratory effort is monitored with an airflow sensor.
4. True or False: The most effective treatment for OSA is the use of PAP therapy.
5. True or False: The success rate of uvulopalatopharyngoplasty is higher than 75%.

BOX 7-8 Common Symptoms Associated with CSA Syndromes[46,47]

EDS
Inattention
Insomnia
Memory loss
Mood disorders
Morning headaches
Nocturnal angina
Paroxysmal nocturnal dyspnea
Poor concentration
Poor subjective sleep quality

CPAP.[45] CPAP treatment for OSA reduces the risk for CAD by normalizing serum concentrations of biomarkers associated with CAD. Cardiovascular disease, primarily stroke, is related to OSA, and subjects under the age of 70 run an increased risk of early death if they suffer from OSA.[21]

CSA Syndromes

Unlike OSA, CSA has a neurologic cause. CSA occurs because the central nervous system (CNS) fails to signal the respiratory muscles. Therefore, with CSA there is no effort to inhale by the person.

Definition/Diagnosis

CSA is not a single abnormal condition but comprises a heterogeneous group of distinct SRBDs in which airflow ceases due to an absence of respiratory effort.[14] CSA represents the cessation of breathing during sleep, resulting from failure of stimulation of the respiratory apparatus by medullary respiratory centers. It is characterized by impaired airflow caused by a lack of ventilatory effort or drive. The inability and temporary cessation of CNS controller mechanisms to activate inspiratory muscles ultimately lead to daytime symptoms, nocturnal hypoxia, and ventilation/CO_2 changes. CSA is far less common than OSA and tends to occur in those with congestive HF, neurologic disorders, and stroke. It is also more common in patients taking opioid narcotics, and it is exacerbated at high altitudes.[5]

Clinical Signs and Symptoms

Common symptoms associated with most CSA syndromes are similar to the clinical features of OSA. See **Box 7-8**.

Other commonly experienced nighttime symptoms include bed partner–witnessed apneas, erratic snoring, sleep disruption with nighttime awakenings, and nocturnal breathlessness. Many of these symptoms are similarly seen in patients with OSA. Daytime symptoms frequently include unusual or atypical irritability in an otherwise easygoing individual, lack of ability to concentrate, and an overall reduction in quality of life. Patients also experience coexistent symptoms pertaining to their underlying primary diseases, such as symptoms of HF, stroke, renal failure, Parkinson disease, or multiple system atrophy. Physical findings in CSA are generally not helpful in predicting its presence or absence in contrast to OSA because CSA patients usually have a normal body habitus.[48]

Etiology

Central apnea is due to an abnormality in the regulation of breathing in the respiratory centers of the brainstem.[49] This causes a loss of ventilatory effort, and if it is sustained for 10 seconds or more, it is defined as central apnea. During central apnea, the instability of the CNS controller mechanisms causes a lack of brainstem inspiratory neural output that ultimately results in the temporary cessation of nerves innervating the inspiratory thoracic pump muscles. This action may be clinically observed as central apnea by the absence of naso-oral airflow and thoracoabdominal excursions. CSA exists in various forms and therefore has multiple etiologies. Refer back to Box 7-1. The adult etiologies include CSA with Cheyne–Stokes breathing (CSA-CSB), CSA due to a medical disorder without CSB, CSA due to high-altitude periodic breathing, CSA due to medication or substance, primary CSA, and treatment-emergent CSA.

Patients with CSA-CSB usually have predisposing factors such as HF, stroke, or renal failure, as well as a lower resting $PaCO_2$ than normal.[48] The medical disorders that can cause CSA without CSB appear in **Box 7-9**. CSA due to high-altitude periodic breathing occurs only with a recent ascent to altitudes of 5,000 m or more. Drugs commonly used for pain control, including morphine, fentanyl, and methadone, can cause CSA.[50] The cause for primary CSA is not apparent and is essentially a diagnosis of exclusion.[50]

BOX 7-9 Medical Disorders That May Cause CSA without CSB

Acromegaly
Arnold–Chiari malformation types I–III
Cervical cordotomy
Diabetes mellitus
Familial dysautonomia
Hypothyroidism
Idiopathic cardiomyopathy
Medullary respiratory center damage
Multiple system atrophy or Shy–Drager syndrome
Muscular dystrophy
Myasthenia gravis
Parkinson disease
Post-polio syndrome
Prader–Willi syndrome
Stroke

Becker K. Central sleep apnea syndromes. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/304967-overview. Accessed January 21, 2018.

Treatment-emergent CSA (TECSA) may also emerge during the titration of CPAP in patients with OSA and may also appear on exposure to virtually any treatment modality used to treat OSA.[48,51]

Epidemiology

Central apnea is relatively uncommon and occurs in less than 10% of patients with sleep-related disordered breathing presenting for PSG and less than 1% of the general U.S. population. The prevalence of CSA associated with Cheyne–Stoke breathing (CSA-CSB), however, has been reported in 25–40% of patients with HF and in 10% of patients who have had a stroke.[48]

Primary CSA mostly affects middle-aged or elderly individuals. CSA-CSB shows a striking male preponderance, while gender distribution in other subtypes of CSA syndromes is not known. CSA does appear to be uncommon in premenopausal women. Many sleep experts feel that differences may be due to the presence of a lower apneic threshold of $PaCO_2$ in women compared with men, requiring a more significant reduction in their $PaCO_2$ to initiate apnea. CSA primarily affects middle-aged or elderly individuals, with CSB-CSA increasing in prevalence among individuals older than 60 years.[48]

Pathology/Pathophysiology

During wakefulness, ventilation maintains levels of PaO_2 and $PaCO_2$ within narrow ranges. Wakefulness ventilation relies on two systems. One, the autonomic system utilizes peripheral and central chemoreceptors, intrapulmonary vagal receptors, the respiratory control centers, and the respiratory muscles. The other is the behavioral system, which can influence ventilation through signals from cortical areas of the brain. Many nonchemical stimuli, which include pulmonary mechanoreceptors and behavioral or awake stimulation, are known to modulate this phenomenon.[48]

Ventilation during sleep relies on automatic control only. Sleep is characterized by elevation of $PaCO_2$, a higher **apneic threshold**, the $PaCO_2$ below which ventilation stops, and loss of the behavioral system. A few mm Hg reduction of $PsCO_2$ below the apneic threshold can result in apnea.[48] The chemoreflex response to increases in $PaCO_2$ depends on the apnea threshold and the sensitivity of the ventilatory response.

The engineering concept of **loop gain** is helpful in the understanding of the pathogenesis of central sleep apnea syndromes (CSAS)[50] (**Figure 7-14**). Loop gain refers to the ratio of a corrective ventilatory response, the ability to increase ventilation by the lungs and respiratory muscles, to a disturbance, change in $PaCO_2$ and the feedback between the two.[52,53] As with any system that is regulated by feedback loops, the respiratory system is vulnerable to instability.[52] The occurrence and perpetuation of ventilatory instability in the pathogenesis of CSA can be visualized in the context of loop gain.[48] With ventilation, loop gain is the ratio of the controller gain (e.g., ventilatory response to CO_2), the plant gain (e.g., blood gas response to a change in ventilation), and feedback gain (e.g., the speed [cardiac output] of the



FIGURE 7-14 Loop gain is the measure of the propensity of a negative feedback control system to oscillate. Loop gain = response/disturbance. When loop gain is less than 1, the response to a disturbance is lessened. When loop gain is greater than 1, the response to respiratory disturbances is vigorous, resulting in the continuous oscillation between the events and the corrections. This results in an unstable periodic breathing pattern.[48]

White D. Pathogenesis of obstructive and central sleep apnea. *Am J Respir Crit Care Med*. 2005;172(11):1363–1370.



FIGURE 7-15 A schematic representing the pathophysiology of CSA syndrome. See text for explanation.
Modified from Kohnlein T. Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature. *Thorax*. 2002;57(6):547–554 (Figure 1, p. 547).

feedback signal [CO_2] back to the controller).[53] During sleep the respiratory system regulates $PaCO_2$ via chemoreceptors. Under normal NREM sleep conditions, small (<2 mm Hg) changes in $PaCO_2$ are promptly recognized by the chemoreceptors, maintaining stable ventilation.[53] Individuals with very effective CO_2 excretion are more likely to develop marked CO_2 fluctuations than individuals with less efficient CO_2 excretion.

There are two broad pathophysiologic patterns that cause CSAS, either hyperventilation (ventilatory instability) or hypoventilation (depression of the brainstem respiratory centers or chemoreceptors)[48,54,55] (**Figure 7-15**).

The hyperventilation causes of central apneas are more common than the hypoventilation causes.[54] The hyperventilation causes of CSA include HF, high altitude, and idiopathic. Initiation of a central apnea may be as a result of a variety of stimuli. However, the most common trigger is hypoxia. Once this occurs, the apnea it causes will repeat throughout the night (**Figure 7-16**).

Patients with HF and CSA have an augmented ventilatory response to change in $PaCO_2$ compared to patients with HF and OSA.[56] In contrast to OSA, CSA is typically considered a consequence rather than a cause of HF.[49] HF patients have significant alterations of sleep due to changes associated with their disease. Three main factors interact and lead to ventilatory instability in HF: hyperventilation, circulatory delay, and cerebrovascular reactivity. Alterations in these three factors destabilize normal breathing, leading to respiratory instability and the rhythmic pattern of breathing referred to as CSB.[57] CSB occurs primarily during NREM sleep.

Hypoxia augments the ventilatory response to changes in $PaCO_2$ and predisposes to instability in ventilation, as in Figure 7-16. Ambient hypoxia occurs at high altitudes and leads to high loop gain, resulting in hyperventilation and hypocapnia. These individuals do not have this periodic breathing at sea level. Eventually, at an altitude (other than extreme elevations), the periodic breathing resolves.[58]

The last type of CSA that is caused by hyperventilation is idiopathic CSA. This is a relatively uncommon disorder seen at sea level in individuals with high loop gain. Idiopathic CSA is typically diagnosed by exclusion. Patients with idiopathic CSA tend to have low $PaCO_2$ levels during wakefulness. During NREM sleep these individuals exhibit central apnea because of ventilatory instability.[58]



FIGURE 7-16 The pathogenesis of CSA due to hyperventilation.
Modified from Badr M. Central sleep apnea: Pathogenesis. In: Eichler A, Chervin R, eds. *Uptodate*. Waltham, MA: UpToDate; 2017.

CSA due to hypoventilation (hypercapnia) is a less common cause of central apnea.[54] Ventilatory depression during wakefulness is a well-known effect of opioid drugs and other CNS depressants. The daytime hypoventilation caused by chronic use of these agents is generally mild, but sleep apnea tends to become somewhat prevalent particularly with opiate use. CSA that develops as a result of drugs or substance abuse is more common during NREM sleep in contrast to REM sleep.[48] Breathing patterns associated with CSA resulting from drug effects are both periodic and nonperiodic with the cycle length typically being short.

Narcotic respiratory depression from drugs such as heroin, morphine, and methadone results from stimulation of the opioid Mu receptors located on neurons present in the medullary respiratory complex.[48] CNS tolerance may develop for many adverse effects of opioids especially in individuals receiving long-term opioids.

Brainstem, as well as spinal cord, disorders constitute several heterogeneous pathologic processes that can cause severe hypoventilation and central apnea during sleep. Because central chemoreceptors and respiratory centers are located in the brainstem, pathologic processes such as compression, edema, ischemia, infarct, tumor, encephalitis, and neurodegenerative disorders (e.g., Parkinson disease) are associated with CSA.[52]

Individuals with **congenital central hypoventilation syndrome (CCHS)**, also known as Ondine's curse, have relatively normal ventilation during wakefulness but a very diminished or absent ventilatory response when they fall asleep. CSA results as the wakefulness stimulus for respiration is lost. Patients with CCHS exhibit the most severe hypoventilation in deep NREM sleep, during which automatic control of breathing usually predominates. Historically, CCHS was diagnosed in the newborn period, yet we now know that cases can be diagnosed later in infancy, childhood, or adulthood.[59]

Patients with chest wall disorders can have significantly compromised chest wall compliance and subsequently lower tidal volumes while awake and during sleep. These restrictive pulmonary disorders can arise from major thoracic surgery or those impacting the bellows function of the respiratory system (e.g., kyphoscoliosis, ankylosing spondylitis, nonsurgical chest trauma, or pleural disorders). The changes in control of breathing and respiratory mechanics increase physiologic dead space, making it difficult for the patient to sustain adequate gas exchange during sleep, eventually causing daytime and nocturnal hypercapnia, as well as hypoxemia as their condition worsens. These patients are also subject to the development of atelectasis, further deteriorating hypoxemia, and pulmonary hypertension. These events are accentuated during sleep as hypoventilation results in reduced arterial oxygen saturation and a rise in end-tidal P_{CO_2}.

Neuromuscular disorders represent an assorted group of conditions affecting both adults and children characterized by dysfunction of respiratory motor innervation causing respiratory muscle impairment. Neuromuscular disorders may affect respiratory muscles, the neuromuscular junction, or the phrenic and intercostal nerves. Diseases include Duchenne muscular dystrophy, idiopathic diaphragmatic paralysis, amyotrophic lateral sclerosis, post-polio syndrome, and myasthenia gravis. These maladies often have additional risk factors that may predispose them to a specific pathophysiologic SDB. These factors may include CNS involvement, chest wall deformity with restrictive lung disease, diaphragmatic weakness, increased upper airway resistance, and impaired respiratory chemosensitivity, especially during sleep.[60] Other comorbidities associated with CSA appear in Box 7-9.

Treatment-emergent CSA, previously referred to as complex sleep apnea, is detected in approximately 5–15% of patients who undergo PAP titration for OSA. Treatment-emergent CSA is the persistence or emergence of central apneas and hypopneas during the initiation of CPAP therapy for OSA, despite significant resolution of the obstructive respiratory events.[52] The conversion from OSA to CSA can occur with the use of CPAP, an OA, or tracheostomy.[61,62]

There are a few potential mechanisms by which treatment of OSA may induce central apneas. Patients with OSA frequently exhibit ventilatory instability (high loop gain), which is augmented by PAP therapy. This results in minor ventilatory disturbances causing a ventilatory overcorrection that brings the P_{aCO_2} level below the apneic threshold. The central apnea, in turn, prompts a reciprocal corrective response, establishing a pattern of periodic breathing.[52] Chronic intermittent hypoxemia, common in OSA, is associated with increased peripheral chemoreflex activity, making patients with OSA more susceptible to the development of CSA due to hyperventilation.[61] Also, PAP therapy activates stretch receptors, which inhibits central respiratory output and causes central apnea.[52]

Risk Factors

Certain factors are known to increase the risk of developing CSA. These factors include male gender, increased age, comorbidities, HF, atrial fibrillation, stroke, and chronic opioid use.[46,48] The treatment of OSA increases the risk for treatment-emergent CSA. Risk factors for high-altitude CSA include the inherent presence of a greater intrinsic hypoxic ventilatory drive, being at extremely high altitudes above the sea level, and rapidly ascending to higher altitude.

Complications Associated with CSA

The overall morbidity and mortality associated with primary CSA remain unknown although most individuals with CSA are unlikely to develop significant hypercarbia or hypoxia that will adversely affect the pulmonary circulation or result in cor pulmonale.[48] Those individuals who develop HF associated with CSA-CSB have a higher mortality rate than those without it. The likelihood of atrial fibrillation or complex ventricular ectopy appears to increase with the severity of SDB in patients with both OSA and CSA-CSB. Various forms of SDB are associated with different types of arrhythmias. However, CSA is strongly associated with atrial fibrillation/flutter.[48]

Diagnostic Tests

An overnight in-laboratory, fully attended PSG is the standard for the diagnosis of CSA.[5,46,56] HSAT has not

TABLE 7-9
Diagnostic Criteria for CSA Syndromes

I. Primary CSA A. PSG shows ≥5 central apneas and/or central hypopneas per hour of sleep B. No evidence of CSB C. No evidence of daytime or nocturnal hypoventilation D. EDS E. Awakening short of breath, snoring, witnessed apneas, or insomnia
II. CSA with CSB A. PSG shows ≥5 central apneas and/or central hypopneas per hour of sleep B. At least three consecutive central apneas and/or central hypopneas separated by crescendo-decrescendo breathing C. The number of central apneas and/or central hypopneas is >50% of the total number of apneas and hypopneas D. EDS E. Awakening short of breath, snoring, witnessed apneas, or insomnia
III. CSA due to high-altitude periodic breathing A. Recent ascent to at least 5,000 m (for some less) B. EDS C. Awakening short of breath, snoring, witnessed apneas, or insomnia D. Symptoms clinically attributable to high-altitude periodic breathing (PSG reveals recurrent central apneas or hypopneas during NREM sleep at a rate of ≥5/hour) E. Disorder not better explained by another current sleep disorder, medical or neurologic disorder, or medication use or substance use disorder
IV. CSA due to a medication or substance A. Opioid or other respiratory depressant being used by the patient B. EDS C. Awakening short of breath, snoring, witnessed apneas, or insomnia D. PSG shows ≥5 central apneas and/or central hypopneas per hour of sleep E. The number of central apneas and/or central hypopneas is >50% of the total number of apneas and hypopneas F. The disorder is not better explained by another current sleep disorder

Reproduced with permission from Boiing S, Randerath W. Chronic hypoventilation syndromes and sleep-related hypoventilation. *J Thorac Dis*. 2015;7(8): 1273–1285. doi:10.3978/j.issn.2072-1439.2015.06.10.

been validated for the management of CSA.[46] Monitoring respiratory effort is critical for distinguishing between CSA and OSA. Findings on PSG for CSA typically display more than five central apneas per hour of sleep, each apneic period lasting 10 seconds.[5,46] The diagnostic criteria for CSA vary according to the type of CSA[1] (**Table 7-9**).

Treatment and Management

If present, the treatment of an underlying medical disorder often improves CSA. This is especially true in such cases as high-altitude periodic breathing where descending to a low altitude may be sufficient. Optimizing medical treatment for HF helps improve the CSA associated with HF. This therapy may include angiotensin-converting enzyme inhibitors, beta-blockers, diuretic agents, and cardioversion.[57]

Positive Airway Pressure Therapy

CPAP therapy targeted to normalize the AHI is indicated for the initial treatment of CSAS related to CHF.[63] CPAP has been shown to improve cardiac function in patients with congestive HF associated with CSA-CSB and can also improve their survival.[64] Patients with CSAS related to CHF can benefit from nocturnal oxygen.[63] Supplemental oxygen may help to prevent hypoxemia and reduces hypocapnia in patients with increased sensitivity to CO_2.[5] Other types of PAP therapy include BPAP and ASV. BPAP provides two levels of pressure: IPAP and EPAP. The IPAP setting is higher than the EPAP setting. The change from the lower pressure to the higher pressure delivers a volume to the patient, augmenting alveolar ventilation. BPAP can be more effective in treating CSA-CSB and improves left ventricular function in HF.[64]

ASV is a form of closed-loop mechanical ventilation, pressure present, and volume or flow cycled. It can be delivered at default settings or with variable inspiratory and expiratory pressure (to ensure upper airway patency). ASV alleviates CSA-CSB by providing dynamic (breath-by-breath) adjustment of inspiratory pressure support with a backup rate to normalize breathing patterns relative to a predetermined target. Specifically, ASV mitigates hyperventilation and associated hypocapnia by delivering preset minute ventilation.[63] However, an American Academy of Sleep Medicine 2016 update states that patients with symptomatic congestive HF and reduced left ventricular ejection fraction (LVEF ≤45%) using ASV for treatment of CSAS are at an increased risk of cardiovascular mortality.[65] An overview of the treatment of CSAS in adults appears in **Box 7-10**.

BOX 7-10 Treatment of CSAS in Adults

- Treat underlying medical problems
- Weight loss for obese patients
- Eliminate medications that may be contributing to apnea
- Trial of PAP therapy (CPAP, BPAP, ASV)
- Nocturnal oxygen therapy
- Pharmacotherapy with respiratory stimulants (acetazolamide, clomipramine, theophylline)
- Other therapies: phrenic nerve stimulation, CO_2 administration, atrial overdrive pacing

Data from Benca R. *Sleep Disorders*. New York, NY: Oxford University Press; 2012; Aurora R, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep*. 2012;35(1):17–40. doi:10.5665/sleep.1580; Momomura S. Treatment of Cheyne–Stokes respiration–central sleep apnea in zpatients with heart failure. *J Cardiol*. 2012;59(2):110–116. doi:10.1016/j.jjcc.2011.12.008.

Prognosis

The mortality and morbidity associated with primary CSA remain unknown; however, these individuals are unlikely to develop significant hypercarbia or hypoxia to the detriment of pulmonary circulation or cor pulmonale.[48] CSA is now recognized as an important, independent risk factor for worsening HF and poor prognosis in patients with HF.[57,66]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The physical findings in CSA are very helpful in predicting its presence or absence.
2. True or False: CSA with Cheyne–Stokes breathing is indicative of HF.
3. True or False: Hypoventilation is a more common pathophysiologic mechanism of CSA.
4. True or False: Patients with CSA experience the central apneas during NREM sleep.
5. True or False: An overnight, in-laboratory, fully attended polysomnography is the standard for the diagnosis of CSA.

Sleep-Related Hypoventilation Disorders

There are six subtypes of hypoventilation sleeping disorders. See Box 7-1. Three subtypes are rare. These include CCHS, late-onset central hypoventilation with hypothalamic dysfunction, and idiopathic central alveolar hypoventilation. In contrast to these rare disorders, the OHS and chronic hypoventilation due to medical disorders or pharmaceutical influences represent the considerable majority of chronic and SRH.[67]

SRH due to a medical disorder is diagnosed in patients with underlying diseases of the lung parenchyma or the airways, the pulmonary vessels, or neurologic or musculoskeletal disorders. In addition, SRH can be induced by drugs that depress ventilatory drive or impair muscle function. These drugs include long-acting narcotics, anesthetics, sedatives, muscle relaxants, and alcohol.[67] SRH refers to a more significant than normal increase in $PsCO_2$ during sleep. A $PsCO_2$ >55 mm Hg for 10 minutes or more during sleep or an increase of 10 mm Hg or more above the awake supine $PsCO_2$ to one over 50 mm Hg for 10 minutes or more is the definition of SRH.[68] With obesity on the rise to pandemic proportions, this section reviews OHS as the representative disorder in the SRH disorders group.

Obesity Hypoventilation Syndrome

OHS was historically called the Pickwickian syndrome. The syndrome is named after Joe, the heavy, red-faced boy in Charles Dickens's the *Pickwick Papers*.

Definition

OHS, which historically has been described as the Pickwickian syndrome, consists of the triad of obesity with a BMI >30 kg/m^2, SDB, and chronic alveolar hypoventilation that is typically worse during wakefulness. This disorder by definition occurs in the absence of other known pulmonary, thoracic, metabolic, or neuromuscular diseases accounting for hypercapnia and subsequent marked nighttime hypoxemia (**Table 7-10**). Decreased ventilatory responsiveness reflecting a defective central respiratory control to both hypoxemia and hypercapnia is further compromised by a diminished total lung capacity, an increased work of breathing, and an increase in carbon dioxide production.[16,69,70]

Clinical Signs and Symptoms

About 90% of patient with OHS have coexisting OSA; therefore, symptoms and many of the physical findings in OHS patients are similar to those in patients with OSA, such as EDS, snoring, choking during sleep, morning headaches, fatigue, mood disturbance, and impairments of memory or concentration.[14,67] About 10% of patients with OHS have AHIs <5 events/hour of sleep.[67]

On examination, obesity is the most obvious feature. Many OHS patients have a crowded oropharynx and an increased neck circumference.[14] These patients might display signs of cor pulmonale and secondary

TABLE 7-10
Characteristics of OHS

Definition Criteria	Description
Chronic hypoventilation	Hypercapnia in wakefulness and sleep ($Paco_2$ ≥45 mm Hg)
Obesity	BMI ≥30 kg/m^2
Absence of other causes of hypercapnia	Lung parenchymal disease; airways; pulmonary vessels; neuromuscular, musculoskeletal, or idiopathic disorders; congenital central alveolar hypoventilation syndrome; medications; or drugs
SRBDs	OSA with or without coexisting SRH (present in 90% of OHS patients) Nonobstructive (AHI <5 events/hour) SRH (present in about 10% of OHS patients)

Data from Piper A, Yee B. Clinical manifestations and diagnosis of obesity hypoventilation syndrome. In: Badr MS, Finlay G, ed. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed February 1, 2018.

pulmonary hypertension, including polycythemia, eye redness, peripheral edema, and a prominent pulmonary component (P2) of the second heart sound.[14,70,71]

Etiology

Patients with OHS have a higher incidence of restrictive ventilatory defects when compared with patients who are obese but do not hypoventilate. Studies have shown that patients with OHS have total lung capacities that are 20% lower and maximal voluntary ventilation that is 40% lower than patients who are obese who do not have hypoventilation.[72]

Epidemiology

The prevalence of OHS varies significantly due to differences in disease definition, population studied, and the methods of sample acquisition. Because most OHS patients have coexisting OSA, most prevalence studies have focused on patients referred to sleep centers for evaluation of SDB, and a reasonable prevalence estimate among OSA patients has emerged. The overall prevalence of OHS can be estimated using severe obesity (BMI >40 kg/m^2) and OSA prevalence data. This estimate is likely conservative because it does not take into account the roughly 10% OHS patients who do not have OSA. Estimated by this method, the rate of OHS in the United States is approximately 1 in 160 adults. OHS may be more prevalent in the United States because of the higher prevalence of severe obesity than in other countries.[72]

Pathology/Pathophysiology

Obesity increases the demand (mechanical load) on the respiratory system, leading to its restriction, and triggers compensatory mechanisms to maintain adequate ventilation. Eventually, OHS develops due to the failure of these compensatory mechanisms, resulting in hypoventilation, hypercapnia ($Paco_2$ ≥45 mm Hg), and hypoxemia[73] (**Figure 7-17**).

Reduction of minute ventilation is the common characteristic of all chronic hypoventilation disorders. However, the underlying pathomechanisms differ



FIGURE 7-17 The pathophysiology of OHS simplified into an algorithm.

Adapted from Al Dabal L Bahammam A. Obesity hypoventilation syndrome. *Ann Thorac Med.* 2009;4(2):41 (Figure 1, p. 43). doi:10.4103/1817-1737.49411.

substantially between the entities and can be complex in individual cases.[67] The pathogenesis of OHS results from a series of complex interactions that involve SDB, altered pulmonary mechanics, impaired ventilatory control, and increased carbon dioxide production.[73]

The role of SDB is supported by the fact that a majority (90%) of individuals with OHS also have OSA and that treatment of the OSA with PAP therapy also eliminates OHS.[73] Also, although other obesity-related mechanisms play a role in promoting hypoventilation during wakefulness, changes in gas exchange are most prominent during sleep, further emphasizing the contribution of SDB to the pathogenesis of OHS.[73]

Obesity leads to a reduction in chest wall compliance and respiratory muscle endurance with increased airway and chest wall resistance.[70] Individuals with OHS adopt a pattern of rapid shallow breathing. The low tidal volume leads to decreased alveolar ventilation and increases CO_2 accumulation. Obese individuals poorly ventilate the lower lung lobes due to reduced respiratory muscle strength, decreased lung compliance, difficulty moving the ribcage and diaphragm, and

atelectasis.[70,73] The final result is hypoxemia, especially in the supine position; impaired pulmonary function; and progressively worse disability.[70]

Individuals with OHS demonstrate reduced hypoxemic and hypercapnic ventilatory responses, especially in the supine position. Resistance to the protein leptin is one proposed mechanism that contributes to OHS through decreased ventilatory responsiveness to CO_2. Leptin is produced by adipose tissues and acts on receptors in the hypothalamus to suppress appetite and also on the central respiratory pathways to increase ventilation. Obese individuals have serum leptin levels significantly higher than non-obese individuals.[70] Clearly, if these high leptin levels were biologically active, there would be reduced eating and subsequently weight loss. This is apparently not the case in human obesity, and the problem instead is "leptin resistance."[74]

Excess CO_2 production is associated with increased body surface area.[73] This plus the decreased ventilatory responsiveness to CO_2 leads to hypercapnia. In addition, hypoxic and hypercapnic ventilatory responses are blunted during REM sleep, leading to insufficient reactions to changes in blood gases. Respiratory derailments during REM as well as NREM sleep trigger arousals, resulting in sleep fragmentation and diminished sleep efficacy.[67]

TABLE 7-11
Complications Associated with OHS

Body System	Complications
Cardiovascular	CAD Congestive HF Endothelial dysfunction
CNS	Cognitive deficit Decreased neural drive
General	Decreased physical activity Increased morbidity and mortality Peripheral edema
Metabolic	Chronic inflammation Central (abdominal) obesity Insulin-like growth factor 1 (IGF-1) deficit Metabolic syndrome
Respiratory	Pulmonary hypertension Restrictive lung function
Upper airway	OSA Increased intubation risk

Piper A, Yee B. Clinical manifestations and diagnosis of obesity hypoventilation syndrome. In: Badr MS, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed February 1, 2018.

Risk Factors

Morbid obesity (BMI >50 kg/m^2) is a major risk factor for OHS.[74] Although all OHS patients are obese, not all patients with obesity, or even morbid obesity, develop OHS.[72] The severity of concurrent OSA is a significant risk factor for OHS. No gender-specific, race-specific, or ethnic-specific risks are currently known. It has been speculated, however, that due to the higher prevalence of morbid obesity in African Americans, they might have a higher risk for OHS.[72]

Complications

Numerous complications are associated with OHS due to the overlap with obesity alone. Approximately 66% of patients with OHS have pulmonary hypertension. Conditions such as hypertension, congestive HF, and insulin resistance are all more common in patients with OHS than in patients with eucapnic obesity and may be present 3 or more years prior to the diagnosis of OHS[71,72] (**Table 7-11**).

Diagnostic Tests

OHS is a diagnosis of exclusion that can be made when the patient has a BMI >30 kg/m^2; has awake alveolar hypoventilation, as indicated by a $Paco_2$ >45 mm Hg; and alternative causes of hypercapnia and hypoventilation have been excluded.[71] Diagnostic tests include arterial blood gas (ABG), pulmonary function tests, chest radiograph, laboratory tests, electrocardiograph, and PSG.[14] The primary competing diagnosis for the symptoms of OHS is OSA. Apart from the presence of chronic respiratory acidosis with compensatory metabolic alkalosis, both disorders are often clinically indistinguishable from each other.[71]

For those in whom OHS is suspected, a serum bicarbonate level is a useful test in screening patients. An elevated serum bicarbonate level >27 mEq/L should prompt an ABG.[14,71,74] Usually, the ABG reveals the indicatively elevated $Paco_2$ with a high bicarbonate level, which reflects the chronic nature of the disease.[14] Similarly, Pao_2 is generally <70 mm Hg in OHS, particularly in those with a more severe disease. Therefore, a pulse oximetry reading of <94% suggests the need for an ABG to clarify the diagnosis.[74] For those with suspected OHS in whom a diagnosis of OSA does not already exist, in-laboratory PSG should ideally be performed based on the rationale that 90% of patients with OHS have coexistent OSA and the remainder have SRH.[71] Once diagnosed, all patients with OHS need to have assessments for common complications, including pulmonary hypertension and cardiovascular disorders (**Table 7-12**).

Treatment and Management

The optimal management of patients with OHS requires multidisciplinary approach combining experts in obesity, sleep, and pulmonary medicine. Initially, PAP therapy together with weight loss is the first-line therapy for patients with OHS.[14,69,70] Losing at least 10 kg of original

TABLE 7-12
Typical Diagnostic Test Results for OHS

Test	Results
Serum bicarbonate	>27 mEq/L
$Paco_2$	>45 mm Hg
Pao_2	<70 mm Hg
Pulmonary function tests	Mild-to-moderate restrictive pattern due to obesity
Chest radiographs	Rules out other causes
Electrocardiogram	Right heart strain Right ventricular hypertrophy
Transthoracic echocardiogram	Right ventricular hypertrophy Right atrial enlargement Pulmonary artery hypertension
PSG	Oxygen desaturation and hypercapnia during sleep not related to apneas and hypopneas Hypoventilation more prominent during REM sleep compared to NREM sleep

Data from Qasrawi S, Al Ismaili R, Pandi-Perumal S, Bahammam A. Chapter 13 Sleep-related breathing disorders in adults. *Synop Sleep Med.* 2016:213–232. doi:10.1201/9781315366340-14.

body weight leads to improvement in pulmonary physiology and function as evidenced by improved vital capacity and forced expiratory volume.[70] In patients with combined OSA and OHS, weight loss leads to a reduction in AHI and desaturation severity.[69,70] Severe obesity is refractory to dietary management with or without behavioral or drug therapies, and in these cases, bariatric surgery is the most effective modality of reliable and durable treatment for severe obesity.[70] Weight loss is just part of the initial treatment.

The application of PAP therapy is the mainstay of therapy for OHS because 90% of these patients have OSA and 10% have SRH. CPAP is the initial mode of choice. However, for patients who have acutely decompensated OHS, BPAP is usually the initial mode of choice. Patients with OHS and OSA who fail or do not tolerate CPAP are also treated with BPAP. For those who fail or do not tolerate BPAP, a hybrid mode (**average volume-assured pressure support [AVAPS]**) or, less commonly, volume-cycled ventilation may be chosen.[75]

The therapeutic goals for OHS patients receiving PAP therapy include normalization of $Paco_2$ during wakefulness and sleep, elimination of oxyhemoglobin desaturation during wakefulness and sleep, relief of daytime hypersomnolence, and treats underlying OSA. The PAP therapy also prevents some complications, including polycythemia, pulmonary hypertension, and right HF. Sleep architecture and quality also improve.[75]

Weight loss and PAP therapy are the first-line treatments for OHS. Second-line therapies are reserved for patients with OHS who fail or do not tolerate first-line therapies (**Table 7-13**). In any case, all comorbid conditions need to be identified and treated.

TABLE 7-13
Summary of Treatments for OHS

Therapy Type	Description
First line	Weight loss + PAP therapy (CPAP, BPAP, or AVAPS) + Supplemental oxygen, if necessary
Second line	Bariatric surgery Tracheostomy Pharmacotherapy—medroxyprogesterone acetate, acetazolamide
Additional therapy	Treat comorbidities

Prognosis

The mortality of severe OHS patients is high and substantially worse than that of OSA patients, even when properly managed and treated from a respiratory perspective.[69,76] OHS tends to be progressive if left untreated in many patients developing cardiovascular complications, including pulmonary hypertension and right HF. The impact of therapy, particularly PAP therapy on cardiovascular complications and mortality, is uncertain and appears limited based on extrapolated data from patients with OSA.[69]

Individuals with OHS have considerably worse health status and access more healthcare resources compared to the general population, with differences apparent up to 8 years before a diagnosis is made.[69] A few factors are able to predict a poor prognosis in OHS. These independent predictors include a clinical history of diabetes, baseline diurnal oxygen saturation <83%, EPAP <7 cm H_2O after titration, and adherence to NIV <4 hours.[76]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Congenital central alveolar hypoventilation syndrome is a common type of SRH disorder.
2. True or False: About 90% of all OHS patients also have OSA.
3. True or False: Obesity causes an obstructive ventilatory defect.
4. True or False: Respiratory issues due to OHS occur during both NREM and REM sleep.
5. True or False: First-line treatment for OHS includes PAP therapy and weight loss.

Chapter Summary

The sleep process represents an active, complex, and dynamic state that greatly influences our waking hours. The diagnostic approach to SRBDs begins with a comprehensive sleep evaluation that includes a complete sleep history, and a physical examination focused on the upper airway. If the evaluation suggests an SRBD as the cause of the patient's symptoms, appropriately directed diagnostic tests are performed. While several diagnostic approaches may be helpful when screening for the presence of a particular SRBD, such as dynamic magnetic resonance imaging, airway fluoroscopy during sleep, fiberoptic endoscopy, and pneumography recording the movements of the thorax in respiration, the PSG remains the "gold standard." The approaches to the management of SRBD include the use of medical and surgical treatments that are dependent on the specific respiratory abnormality and its etiology. Management of patients with SRBD may be extremely gratifying because even current treatment modalities often result in significant improvement in people's lives, especially when applied early in the disease course.

Key Points

1. OSA representing the most frequent sleep-related breathing disorder is a common health problem worldwide with increased prevalence associated with advancing age and male gender.
2. It appears likely that OSA and CSA increase the risk of death in patients with HF from different hemodynamic effects that develop during sleep.
3. Health complications in untreated OSA and OHS along with increased mortality include an increase in cardiovascular disease and neurocognitive difficulties.
4. The predominant symptoms associated with OSA include loud snoring, restless sleep, and daytime hypersomnolence. Polysomnography is required for diagnosis.
5. Patients with OSA may develop CSA after beginning PAP therapy. This is called treatment-emergent CSA.
6. Uvulopalatopharyngoplasty is currently the most commonly performed surgical procedure for OSA, yet is often unsuccessful as the first line of surgical therapy for OSA. The presence of coexistent patient factors such as obesity, retrognathia, and additional sites of obstruction often results in treatment failure of OSA in unselected patients.
7. Central apnea is relatively uncommon and occurs in less than 10% of patients with sleep-related disordered breathing presenting for PSG and less than 1% of the general U.S. population.
8. There are two broad pathophysiologic patterns that cause CSAS, either hyperventilation (ventilatory instability) or hypoventilation (depression of the brainstem respiratory centers or chemoreceptors).
9. The underlying cause of CSA typically determines its specific treatment.
10. Individuals with OHS have an excessive increase in arterial Pco_2 during sleep, ordinarily have hypercapnia during wakefulness, and typically have a very high BMI. The pathogenetic processes leading to this disorder include mechanical mass loading by the chest wall and alterations in ventilatory control.

Chapter Questions

1. Slow-wave sleep is characterized by _____ sleep waves.
   - **a.** low-frequency, low-amplitude
   - **b.** unique, sharply negative
   - **c.** low-voltage mixed-frequency
   - **d.** brief bursts of high-frequency
2. How much of a normal night's sleep is spent in NREM sleep?
   - **a.** 15–20%
   - **b.** 25–30%
   - **c.** 55–60%
   - **d.** 75–80%
3. The $Paco_2$ level below which respiratory output ceases is the _____.
   - **a.** apnea index
   - **b.** hypopnea index
   - **c.** apnea threshold
   - **d.** respiratory disturbance index
4. A physical finding frequently identified with obstructive sleep apnea is a _____.
   - **a.** small neck size
   - **b.** BMI >30 kg/m^2
   - **c.** Mallampati classification of 2
   - **d.** waist circumference of 35 inches

5. _____ is not monitored during home sleep apnea testing.
   a. Airflow
   b. Respiratory effort
   c. Pulse oximetry
   d. Sleep waveforms
6. The most common surgical treatment for obstructive sleep apnea is _____.
   a. bariatric surgery
   b. uvulopalatopharyngoplasty
   c. epiglottoplasty
   d. tracheostomy
7. _____ tends to occur in patients with congestive heart failure, neurologic disorders, and stroke.
   a. Central sleep apnea
   b. Obstructive sleep apnea
   c. Obesity hypoventilation syndrome
   d. Congenital central alveolar hypoventilation syndrome
8. High-altitude central sleep apnea occurs following a recent ascent to altitudes of _____ or more.
   a. 2,000 m
   b. 3,000 m
   c. 4,000 m
   d. 5,000 m
9. A diagnosis of sleep-related hypoventilation requires the following during sleep:
   a. $Paco_2 > 40$ mm Hg for at least 5 minutes
   b. $Pao_2 < 80$ mm Hg for at least 10 minutes
   c. $Paco_2 > 55$ mm Hg for at least 10 minutes
   d. $Pao_2 < 70$ mm Hg for at least 10 minutes
10. A majority of patients with obesity hypoventilation syndrome also have _____.
    a. late-onset central hypoventilation
    b. central sleep apnea with Cheyne–Stokes breathing
    c. obstructive sleep apnea
    d. primary central sleep apnea

References

1. American Academy of Sleep Medicine. *International Classification of Sleep Disorders*. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
2. Spriggs W. *Essentials of Polysomnography*. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2015:157–187.
3. Piper A. Nocturnal hypoventilation—identifying and treating syndromes. *Indian J Med Res*. 2010;131(February):350–365.
4. Burepalli S, Punuru P, Gottiganti G, Badhvel J, Gopinath C. Review on sleep and sleep disorders. *SAJP*. 2017;6(9):372–377. doi:10.21276/sajp.2017.6.9.1.
5. Benca R. *Sleep Disorders*. New York, NY: Oxford University Press; 2012.
6. Brillante R. Hypercapnia in obstructive sleep apnoea. *Austin J Sleep Disord*. 2017;4(1):1031–1036. http://austinpublishinggroup.com/sleep-disorders. Accessed December 27, 2017.
7. Krimsky W, Leiter J. Physiology of breathing and respiratory control during sleep. *Semin Respir Crit Care Med*. 2005;26(1):5–12. doi:10.1055/s-2005-864197.
8. Pillar G, Malhotra A, Fogel R, et al. Upper airway muscle responsiveness to rising PCO2 during NREM sleep. *J Appl Physiol (1985)*. 2000;89(4):1275–1282. doi:10.1152/jappl.2000.89.4.1275.
9. Ayappa I, Rapoport D. The upper airway in sleep: physiology of the pharynx. *Sleep Med Rev*. 2003;7(1):9–33. doi:10.1053/smrv.2002.0238.
10. Markov D, Goldman M. Normal sleep, and circadian rhythms: neurobiologic mechanisms underlying sleep and wakefulness. *Psychiatr Clin North Am*. 2006;29(4):841–853. doi:10.1016/j.psc.2006.09.008.
11. Neurobiology of Sleep—Sleep eBook. *Sleepdisorderssleepfoundationorg*. 2017. http://sleepdisorders.sleepfoundation.org. Accessed December 27, 2017.
12. Epstein L, Kriste D, Strollo P, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263–276.
13. Kline L. Clinical presentation and diagnosis of obstructive sleep apnea in adults. In: Finlay G, Collop N, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 29, 2017.
14. Qasrawi S, Al Ismaili R, Pandi-Perumal S, Bahammam A. Chapter 13 Sleep-related breathing disorders in adults. *Synop Sleep Med*. 2016:213–232. doi:10.1201/9781315366340-14.
15. Johns M. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14(6):540–545. doi:10.1093/sleep/14.6.540.
16. Sullivan S, Kushida C. Multiple sleep latency test and maintenance of wakefulness test. *Chest*. 2008;134(4):854–861. doi:10.1378/chest.08-0822.
17. Littner M, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. *Sleep*. 2005;28(1):113–121. doi:10.1093/sleep/28.1.113.
18. Davidson T, Patel M. Waist circumference, and sleep disordered breathing. *Laryngoscope*. 2008;118(2):339–347. doi:10.1097/mlg.0b013e3181587d7c.
19. Priyadarshan S, Kamath PS. Etiology of obstructive sleep apnoea syndrome. *Int J Otorhinolaryngol Head Neck Surg*. 2017;3(4):952. doi:10.18203/issn.2454-5929.ijohns20174313.
20. Strohl K. Overview of obstructive sleep apnea in adults. In: Finlay G, Collop N, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 30, 2017.
21. Franklin K, Lindberg E. Obstructive sleep apnea is a common disorder in the population—a review of the epidemiology of sleep apnea. *J Thorac Dis*. 2015;7(8):11311–1322. doi:10.3978/j.issn.2072-1439.2015.06.11.
22. *Rising prevalence of sleep apnea in U.S. threatens public health*. American Academy of Sleep Medicine—Association for Sleep Clinicians and Researchers. 2017. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health. Accessed December 30, 2017.
23. Eckert D, Malhotra A. Pathophysiology of adult obstructive sleep apnea. *Proc Am Thorac Soc*. 2008;5(2):144–153. doi:10.1513/pats.200707-114mg.
24. Badr M. Pathophysiology of obstructive sleep apnea in adults. In: Finlay G, Collop N, eds. *Uptodate*. Waltham, MA: UpToDate; 2017.
25. Vasu T, Grewal R, Doghramji K. Obstructive sleep apnea syndrome and perioperative complications: a systematic review of the literature. *J Clin Sleep Med*. 2012;8(2):199–207. doi:10.5664/jcsm.1784.
26. Kendzerska T, Gershon A, Hawker G, Leung R, Tomlinson G. Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study. *PLoS Med*. 2014;11(2):e1001599. doi:10.1371/journal.pmed.1001599.
27. Gami A, Olson E, Shen W, et al. Obstructive sleep apnea and the risk of sudden cardiac death. *J Am Coll Cardiol*. 2013;62(7):610–616. doi:10.1016/j.jacc.2013.04.080.
28. Yaggi H, Concato J, Kernan W, Lichtman J, Brass L, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. 2005;353(19):2034–2040.
29. Punjabi N, Caffo B, Goodwin J, et al. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med*. 2009;6(8):e1000132. doi:10.1371/journal.pmed.1000132.

30. Young T, Finn L, Peppard P, et al. Sleep disordered breathing, and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep*. 2008;31(8):1071–1078. doi:10.5665/sleep/31.8.1071.
31. American Association of Sleep Technologists. *Sleep Technology: Technical Guideline*. Darien, IL: American Association of Sleep Technologists; 2012:2–8. https://www.aastweb.org/hubfs/Technical%20Guidelines/StandardPSG.pdf?t=1510785704439. Accessed January 3, 2018.
32. Kryger M, Malhortra A. Management of obstructive sleep apnea in adults. In: Finlay G, Collop N, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 22, 2017.
33. Qaseem A, Holty JE, Owens DK, et al. Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2013;159(7):471–483. doi:10.7326/0003-4819-159-7-201310010-00704.
34. de Vries G, Hoekema A, Doff M, et al. Usage of positional therapy in adults with obstructive sleep apnea. *J Clin Sleep Med*. 2015;11(2):131–137. doi:10.5664/jcsm.4458.
35. Tomita Y. Effectiveness of adaptive servo-ventilation. *World J Respirol*. 2015;5(2):112. doi:10.5320/wjr.v5.i2.112.
36. Wozniak D, Lasserson T, Smith I. Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. *Cochrane Database Syst Rev*. 2014;(1):CD007736. doi:10.1002/14651858.cd007736.pub2.
37. Randerath W, Verbraecken J, Andreas S, et al. Non-CPAP therapies in obstructive sleep apnoea. *European Respiratory Journal*. 2011;37(5):1000–1028. doi:10.1183/09031936.00099710.
38. Morgenthaler T, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. *Sleep*. 2006;29(8):1031–1035. doi:10.1093/sleep/29.8.1031.
39. Kapur V, Strohl K, Redline S, Iber C, O'Connor G, Nieto J. Underdiagnosis of sleep apnea syndrome in U.S. communities. *Sleep Breath*. 2002;6(2):49–54. doi:10.1007/s11325-002-0049-5.
40. Parati G, Ochoa J, Bilo G, et al. Obstructive sleep apnea syndrome as a cause of resistant hypertension. *Hypertens Res*. 2014;37(7):601–613. doi:10.1038/hr.2014.80.
41. Arzt M, Hetzenecker A, Steiner S, Buchner S. Sleep-disordered breathing and coronary artery disease. *Can J Cardiol*. 2015;31(7):909–917. doi:10.1016/j.cjca.2015.03.032.
42. Punjabi N, Shahar E, Redline S, et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the sleep heart health study. *Am J Epidemiol*. 2004;160(6):521–530. doi:10.1093/aje/kwh261.
43. Schröder C, O'Hara R. Depression and Obstructive Sleep Apnea (OSA). *Ann Gen Psychiatry*. 2005;4(1):13. doi:10.1186/1744-859x-4-13.
44. Knauert M, Naik S, Gillespie M, Kryger M. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. *World J Otorhinolaryngol-Head Neck Surg*. 2015;1(1):17–27. doi:10.1016/j.wjorl.2015.08.001.
45. Downey, III, R. Obstructive sleep apnea: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/295807-overview#a6. Accessed January 11, 2018.
46. Badr S. Central sleep apnea: risk factors, clinical presentation, and diagnosis. In: Eichler A, Chervin R, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed January 16, 2018.
47. Singh J. *Basics of Central Sleep Apnea*. American College of Cardiology. 2018. http://www.acc.org/latest-in-cardiology/articles/2014/07/22/08/25/basics-of-central-sleep-apnea. Accessed January 16, 2018.
48. Becker K. Central sleep apnea syndromes. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/304967-overview. Accessed January 21, 2018.
49. Pearse S, Cowie M. Sleep-disordered breathing in heart failure. *Eur J Heart Fail*. 2016;18(4):353–361. doi:10.1002/ejhf.492.
50. Muza R. Central sleep apnoea—a clinical review. *J Thorac Dis*. 2015;7(5):930–937. doi:10.3978/j.issn.2072-1439.2015.04.45.
51. Nigam G, Pathak C, Riaz M. A systematic review on prevalence and risk factors associated with treatment-emergent central sleep apnea. *Ann Thorac Med*. 2016;11(3):202. doi:10.4103/1817-1737.185761.
52. Parthasarathy S. Treatment-emergent central sleep apnea. In: Eichler A, Badr M, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed January 25, 2018.
53. Naughton M. Loop gain in apnea. *Am J Respir Crit Care Med*. 2010;181(2):103–105. doi:10.1164/rccm.200909-1449ed.
54. Badr M. Central sleep apnea: Pathogenesis. In: Eichler A, Chervin R, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed January 25, 2018.
55. Kohnlein T. Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature. *Thorax*. 2002;57(6):547–554. doi:10.1136/thorax.57.6.547.
56. Chowdhuri S, Badr M. Central sleep apnoea. *Indian J Med Res*. 2010;131(Feb.):150–164.
57. Costanzo M, Khayat R, Ponikowski P, et al. Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. *J Am Coll Cardiol*. 2015;65(1):72–84. doi:10.1016/j.jacc.2014.10.025.
58. White D. Pathogenesis of obstructive and central sleep apnea. *Am J Respir Crit Care Med*. 2005;172(11):1363–1370. doi:10.1164/rccm.200412-1631so.
59. Weese-Mayer D, Rand C, Zhou A, Carroll M, Hunt C. Congenital central hypoventilation syndrome: a bedside-to-bench success story for advancing early diagnosis and treatment and improved survival and quality of life. *Pediatr Res*. 2016;81(1–2):192–201. doi:10.1038/pr.2016.196.
60. Aboussouan L. Sleep-disordered breathing in neuromuscular disease. *Am J Respir Crit Care Med*. 2015;191(9):979–989. doi:10.1164/rccm.201412-2224ci.
61. Orr J, Malhotra A, Sands S. Pathogenesis of central and complex sleep apnoea. *Respirology*. 2016;22(1):43–52. doi:10.1111/resp.12927.
62. Javaheri S, Smith J, Chung E. The prevalence and natural history of complex sleep apnea. *J Clin Sleep Med*. 2009;5(3):205–211.
63. Aurora R, Chowdhuri S, Ramar K, et al. The treatment of central sleep apnea syndromes in adults: practice parameters with an evidence-based literature review and meta-analyses. *Sleep*. 2012;35(1):17–40. doi:10.5665/sleep.1580.
64. Momomura S. Treatment of Cheyne–Stokes respiration–central sleep apnea in patients with heart failure. *J Cardiol*. 2012;59(2):110–116. doi:10.1016/j.jjcc.2011.12.008.
65. Aurora R, Bista S, Casey K, et al. Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses". *J Clin Sleep Med*. 2016;12(05):757–761. doi:10.5664/jcsm.5812.
66. Bodez D, Guellich A, Kharoubi M, et al. Prevalence, severity, and prognostic value of sleep apnea syndromes in cardiac amyloidosis. *Sleep*. 2016;39(7):1333–1341. doi:10.5665/sleep.5958.
67. Böing S, Randerath W. Chronic hypoventilation syndromes and sleep-related hypoventilation. *J Thorac Dis*. 2015;7(8):1273–1285. doi:10.3978/j.issn.2072-1439.2015.06.10.
68. Budhiraja R, Siddiqi T, Quan S. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. *J Clin Sleep Med*. 2015;11(3):259–270. doi:10.5664/jcsm.4540.
69. Martin T. Treatment and prognosis of the obesity hypoventilation syndrome. In: Badr MS, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed February 1, 2018.
70. Al Dabal L Bahammam A. Obesity hypoventilation syndrome. *Ann Thorac Med*. 2009;4(2):41. doi:10.4103/1817-1737.49411.
71. Piper A, Yee B. Clinical manifestations and diagnosis of obesity hypoventilation syndrome. In: Badr MS, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed February 1, 2018.

72. Balachandran J, Masa J, Mokhlesi B. Obesity hypoventilation syndrome. *Sleep Med Clin*. 2014;9(3):341–347. doi:10.1016/j.jsmc.2014.05.007.
73. Piper A, Yee B. Epidemiology and pathogenesis of obesity hypoventilation syndrome. In: Badr MS, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed February 1, 2018.
74. Piper A, Grunstein R. Obesity hypoventilation syndrome: mechanisms and management. *Am J Respir Crit Care Med*. 2011;183(3):292–298. doi:10.1164/rccm.201008-1280ci.
75. Martin T. Noninvasive positive airway pressure therapy of the obesity hypoventilation syndrome. In: Badr MS, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed February 1, 2018.
76. Castro-Añón O, Pérez de Llano L, De la Fuente Sánchez S, et al. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. *PLoS ONE*. 2015;10(2):e0117808. doi:10.1371/journal.pone.0117808.

CHAPTER

8

Asthma

"Asthmatics escape death, but in the intervals between severe attacks or even when they are walking on ground level, they bear in mind the symptoms of the disease."

—Aretaeus. The Extant Works of Aretaeus the Cappadocian. Adams F, editor-translator. London: The Sydenham Society; 1861. Ch. XI, pp. 73–75

OUTLINE

OBJECTIVES

1. Identify the common characteristics, manifestations, and diagnostic features of asthma.
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of asthmatic disorders.
3. Describe the underlying pathophysiologic mechanisms in asthma.
4. Utilize diagnostic testing to establish a diagnosis of asthma and classify the disease severity.
5. Identify common risk factors and complications of asthma.
6. Discuss the four major components of effective asthma management.

KEY TERMS

Anticholinergic bronchodilator
Asthma–COPD overlap syndrome (ACOS)
Bronchial challenge
Bronchial hyperresponsiveness (BHR)
Bronchial thermoplasty
Cytokine
Eosinophil
Exacerbation
Forced expiratory volume in 1 second (FEV_1)
Fractional exhaled nitric oxide (FE_{NO})
Heliox
Heterogeneous
Histamine
Immunoglobulin E (IgE)
Immunomodulator
Inhaled corticosteroid (ICS)
Leukotriene receptor antagonist (LTRA)
Leukotrienes
Long-acting beta-agonist (LABA)
Mast cells
Methacholine
Methylxanthine
Nonsteroidal anti-inflammatory drug (NSAID)
Peak expiratory flow rate (PEFR)
Phenotype
Prostaglandin D2
Pulsus paradoxus
Short-acting beta-adrenergic agonists (SABAs)
Systemic corticosteroid
T lymphocytes
Trigger

Case Study

A 48-year-old white stockbroker is seeing his primary care physician for a routine office follow-up. The patient is complaining of increasing difficulty in controlling his "asthma." He admitted to a life-long history of recurrent episodes of breathing difficulty primarily with upper respiratory infections. He described frequently missing school as a child because of "asthmatic attacks." He experienced a noticeable improvement in his asthma while away at college and after returning home, but feels that his asthma has seemed to have "gotten progressively worse" in the past few years. When acutely symptomatic, he experiences a minimally productive cough, chest tightness, as well as wheezing. He reports using a "rescue" short-acting beta-agonist inhaler "more often" in addition to his regular doses and frequently awakens from sleep during the middle of the night with wheezing, shortness of breath, and cough.

The "**triggers**" that appear to initiate this patient's asthma symptoms include moderate exercise, exposure to cats, and strong odors, which can sometimes cause his symptoms to persist for several days. He denied ever smoking or using illicit drug. He lives in an older house with a "damp basement" following heavy rain. There is no apparent change in his respiratory symptoms whether he is at work or home. There are no pets in his house, and he denied any known food allergies. He takes no medications other than his **inhaled corticosteroid (ICS)** once daily and a short-acting albuterol inhaler two to three times daily. He does not take aspirin or any **nonsteroidal anti-inflammatory drugs (NSAIDs)** since this was advised by his family physician many years ago. He continues to experience seasonal allergic rhinitis during the spring and fall seasons manifested by itchy eyes and nasal congestion. He does complain of frequent nocturnal cough; he denies symptoms suggesting gastroesophageal reflux. Although he began his ICS inhaler about 6 weeks ago, he has not noticed any significant improvement in his symptoms.

On physical examination, the patient appears in no obvious respiratory distress while at rest. His temperature is 98.5°F, pulse 96/minute, resting respiratory rate 20/minute, blood pressure 140/90, and weight 200 lb, with a body mass index (BMI) of 31. His nasal mucosa and turbinates are pale and swollen with a watery discharge. Chest examination reveals scattered expiratory wheezing with an increase in anterior–posterior diameter. Abdominal exam is noncontributory. Upper and lower limbs are normal. The patient's **peak expiratory flow rate (PEFR)** reading is low compared with his baseline values. Office spirometry reveals a mild airflow obstruction. His forced expiratory volume in 1 second (FEV_1) improved by approximately 20% following short-acting beta-agonist inhalation (**Figure 8-1**). A chest x-ray, taken 2 months ago, during a severe asthmatic episode treated in a local hospital emergency department, is essentially normal.



FIGURE 8-1 Pre- and post-bronchodilator spirometry results.

Introduction

Asthma is a complex genetic disorder in which multiple genes contribute to its development as well as a multifactorial disease involving various environmental factors that influence disease characteristics.[1,2] While recognized as a chronic respiratory disorder causing inflammatory changes and bronchoconstriction of the airways, its severity can be widely variable in any one individual and characterized by episodic **exacerbations** that may be frequently mixed with symptom-free intervals. Asthma has significantly increased in prevalence over the past several decades and is a significant cause of disability, medical expense, and preventable death.[3]

In the United States, the growing problem of asthma is the focus of the National Asthma Education and Prevention Program (NAEPP). This program is administered by the National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI). The NAEPP released its third asthma guideline report (Expert Panel Report 3 Summary Report 2007: Guidelines for the Diagnosis and Management of Asthma[4]) following two previous successive reports published in 1991 and 1997. Expert panels develop these clinical practice

guidelines by conducting systematic evidence reviews.[5] While asthma is not yet curable, NAEPP guidelines emphasize that formal patient and family education, objective measurement of airflow obstruction, and an individualized treatment plan, designed for daily and disease exacerbation use, are necessary components of successful management.

Asthma is not just a public health problem in the United States. Globally, the World Health Organization (WHO) recognizes this and coordinates international efforts to reduce disability and deaths related to asthma. The WHO and the NHLBI collaborate their efforts to help healthcare professionals and public health officials around the world to reduce the prevalence, morbidity, and mortality due to asthma with the Global Initiative for Asthma (GINA).[6] The GINA guidelines update was published in 2017.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Asthma has a genetic component.
2. True or False: Asthma is caused mainly by episodes of bronchospasm.

Definition/Diagnosis

Asthma is a complex, **heterogeneous** disease usually characterized by reversible and variable recurring symptoms, reversible airflow obstruction, **bronchial hyperresponsiveness (BHR)**, and underlying inflammation.[4,6] Asthma may manifest as any single symptom or a combination of symptoms that include wheezing, chest tightness, shortness of breath, and cough. Exercise, allergen exposure, or viral infections often precipitate the symptoms of asthma due to airway inflammation and obstruction. Symptoms characteristically vary over several minutes, within a single day, and from day to day. In general, symptoms also tend to worsen at night or during early morning hours. Extensive yet irregular airflow obstruction occurring during exacerbations often reverses spontaneously or following treatment. The inflammatory processes also heighten BHR to a variety of stimuli or "triggers."

The hallmarks for the diagnosis of asthma include physical examination, history, and spirometry. The diagnosis is confirmed by a history of respiratory symptoms, including wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation identified using spirometry.[4,6] Initial diagnostic criteria for asthma in adults, adolescents, and children ages 6–11 years are listed in **Table 8-1**.

Recurrent episodes of cough and wheezing most often are due to asthma in both children and adults; however, other significant causes of airway obstruction leading to wheezing need consideration in the initial diagnosis and if there is no clear response to initial therapy.[4] **Box 8-1** shows several possible differential diagnoses of asthma in adults.

TABLE 8-1
Diagnostic Criteria for Asthma in Adults, Adolescents, and Children Ages 6–11 Years

Diagnostic Feature	Diagnostic Criteria
History of variable respiratory symptoms	
• Recurrent wheeze • Recurrent shortness of breath • Recurrent chest tightness • Recurrent cough	• Symptoms vary over time, worse at night or on waking. • Symptoms vary in intensity. • Symptoms are commonly triggered by allergens, cold air, exercise, or laughter. • Symptoms often appear worse with viral infections.
Confirmed variable expiratory airflow obstruction	
• Spirometry showing reduced FEV_1/FVC • Significant reversibility of airflow obstruction following short-acting beta-agonist inhalation • In the setting of normal spirometry, confirm airway responsiveness via bronchoprovocation	• Spirometry results compared with referenced values based on age, height, gender, and race • Obstructive pattern that shows reversibility as evidenced by FEV_1 increase ≥0.2 L or ≥12% over baseline spirometry measurements 15 minutes after inhaled bronchodilator • Methacholine, histamine, cold air, or exercise challenge useful to identify airway responsiveness if FEV_1 drops by 20% after bronchoprovocation

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017 (Box 1-2, p. 17). www.ginasthma.org. Accessed October 24, 2017.

The differential diagnosis of chronic obstructive pulmonary disease (COPD) can be difficult with adult-onset asthma. The demarcation between childhood-onset and adult-onset asthma is somewhat arbitrary, but adult-onset asthma has been defined as occurring from as young as 16 years.[7] Sometimes the distinction between adult-onset asthma and COPD is clear. At other times, however, the difference is less clear. Recognition of these overlapping features of both asthma and COPD in some patients has led to the description of the **asthma–COPD overlap syndrome (ACOS)**.[6,8] COPD typically presents in patients with a smoking history of more than 20 pack-years who demonstrate less pronounced reversibility in post-bronchodilator spirometry.[8]

The diagnosis of asthma in adults requires a stepwise approach. This approach begins by identifying whether a patient is at risk of having or currently has a chronic airways disease. To determine this, a detailed history, physical exam, and other tests are necessary. Next, a comparison of features is required to distinguish asthma from COPD. If there are features of both asthma and

COPD, then ACOS is very likely. Spirometry is essential for any patient suspected of having a chronic airways disease. **Table 8-2** compares the spirometry results for asthma, COPD, and ACOS. One-time spirometry is not always confirmatory of a diagnosis, and results need consideration in the context of the patient's clinical presentation, and whether treatment has started.[6] In the case of a patient with normal spirometry that does not meet the guidelines for FEV_1 changes required for bronchodilator reversibility, a bronchial challenge test with methacholine may be necessary.[9]

BOX 8-1 Differential Diagnosis of Adult-Onset Asthma

- Chronic obstructive pulmonary disease (COPD)
- Congestive heart failure (CHF)
- Pulmonary embolism (PE)
- Mechanical obstruction of the airways due to benign or malignant tumors
- Pulmonary infiltration with eosinophilia
- Cough secondary to medications such as angiotensin-converting enzyme inhibitors
- Gastroesophageal reflux
- Vocal cord dysfunction (VCD)

National Heart, Lung and Blood Institute (NHLBI). *Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma.* Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed October 24, 2017.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Wheezing is the only sign of an asthma exacerbation.
2. True or False: The signs and symptoms of asthma are variable.

Clinical Signs and Symptoms

No clinical feature is unique to asthma, and no clinical feature is universal in all patients with asthma. The symptom triad consisting of wheezing, chest tightness (a sensation of a heavy weight on the chest), and shortness of breath is commonly considered the classic presentation for asthma. While one or more of these symptoms occur in most patients during an asthma exacerbation, none of these findings are diagnostic. See Table 8-1. Patients with several disorders, including those with COPD and heart disease have the same complaints.

TABLE 8-2
Spirometry Measurements for Asthma, COPD, and Asthma–COPD Overlap Compared

Spirometry Variables	Asthma	COPD	ACOS
Normal FEV_1/FVC pre- or post-bronchodilator	Compatible with diagnosis	Not compatible with diagnosis	Not compatible unless there is other evidence of chronic airflow limitation
Post-bronchodilator FEV_1/FVC <0.7	Indicates airflow limitation but may improve spontaneously or with further treatment	Required for diagnosis (Global Initiative for Chronic Obstructive Lung Disease [GOLD] criteria)	Usually present
Post-bronchodilator FEV_1 $\geq 80\%$ predicted	Compatible with diagnosis (good asthma control or interval between symptoms)	Compatible with GOLD classification of mild airflow limitation if post-bronchodilator FEV_1/FVC <0.7	Compatible with diagnosis of mild ACOS
Post-bronchodilator FEV_1 $<80\%$ predicted	Compatible with the diagnosis; risk factor for asthma exacerbations	An indicator of the severity of airflow limitation and risk of future events (e.g., mortality and COPD exacerbations)	An indicator of the severity of airflow limitation and risk of future events (e.g., mortality and COPD exacerbations)
Post-bronchodilator increase in FEV_1 $\geq 12\%$ and 200 mL from baseline (reversible airflow limitation)	Usual at some time in the course of asthma, but may not be present when well controlled or on controller medication	Common and more likely when FEV_1 is low	Common and more likely when FEV_1 is low
Post-bronchodilator increase in FEV_1 $>12\%$ and 400 mL from baseline (marked reversibility)	High probability of asthma	Unusual in COPD, consider ACOS	Compatible with the diagnosis of ACOS

Reproduced with permission from Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. www.ginasthma.org. Accessed October 24, 2017.

The typical presentation of asthma includes a pattern of respiratory symptoms that occur following exposure to triggers such as allergens, exercise, or viral infection, and resolve with trigger avoidance or asthma medication. Although the symptoms of asthma are also seen in several other respiratory diseases, it is the presence of certain historical features that increases the probability of asthma. These features include symptoms that worsen at night or those triggered by exercise, cold air, and exposure to inhaled allergens; work-related exposures that worsen symptoms; family or personal history of atopy; and history of asthmatic symptoms as a child.[8]

An acute exacerbation of asthma is a medical emergency that needs treatment and diagnosis urgently.[10] Exacerbations represent an acute or subacute worsening in symptoms of shortness of breath, cough, wheezing, or chest tightness and a progressive decrease in lung function from the patient's baseline status or, in some cases, the initial presentation of asthma.[6] The severity of asthma exacerbations ranges from mild to life threatening. Symptoms can develop following viral respiratory tract infections, after exercise, or from exposure to aeroallergens or irritants, or can be persistent in severe or uncontrolled asthma.[11]

The interaction of underlying airway inflammation, airflow obstruction, and BHR effectively determines the clinical presentation, degree of severity, and response to treatment. Manifestations of asthma during an acute exacerbation usually reveal expiratory wheezes with a prolongation of exhaled breath and accessory muscle use. Rapid labored breathing and tachycardia typically present. Since airway obstruction occurring with acute asthma exacerbations cause significant alterations in intrathoracic pressure, **pulsus paradoxus** (a pulse that weakens abnormally during inspiration due to an unusually large decrease in systolic blood pressure during inspiration) may also occur during moderate-to-severe exacerbations. On the other hand, when asthma is quiescent, a patient with asthma may show no abnormal findings on physical examination. Since the presentation of asthma is variable, any given patient may or may not exhibit a variety of the clinical signs and symptoms depending on the severity of asthma when evaluated[7,12] (**Table 8-3**).

A cough associated with asthma is typically nonproductive, tends to worsen at night, is often chronic, and at times reoccurs persistently for several years. Asthma cough also tends to worsen with exercise, inhalation of cold air, allergen exposure, and upper respiratory infections. When attempting to distinguish asthma symptoms from other causes of cough, supportive factors associated with asthma, such as a personal or family history of asthma, allergic rhinitis, atopic dermatitis, or eczema, increase the likelihood of diagnosis.[4] Identification of other health conditions that may mimic asthma is needed to eliminate them as the cause of the symptoms. See Box 8-1.

TABLE 8-3
Signs, Symptoms, and Severity of Asthma Exacerbations: General Guidelines

	Mild	Moderate	Severe	Life-Threatening, Respiratory Arrest Imminent
Symptoms				
Breathlessness	While walking can lie down	While at rest, prefers to sit	While at rest, needs to sit upright	
Speech	Able to speak in full sentences	Able to speak in phrases, breathless with complete sentences	Able to talk a few words at a time (chipped speech) without becoming breathless	
Level of consciousness	Alert and oriented	Alert, usually agitated	Alert, agitated	Drowsy or confused
Signs				
Accessory muscle use, suprasternal retractions	Usually not	Commonly	Usually	Paradoxical thoracoabdominal movement
Pulse rate	60–100 beats/minute	100–120 beats/minute	>120 beats/minute	Bradycardia
Respiratory rate	Tachypnea	Tachypnea	Often >30/minute	
Pulsus paradoxus	Absent <10 mm Hg	May be present 10–25 mm Hg	Often present >25 mm Hg	Absence may be due to respiratory muscle fatigue

Modified from Camargo C, Rachelefsky G, Schatz M. Managing Asthma Exacerbations in the Emergency Department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations. *Proc Am Thorac Soc*. 2009;6(4):357–366. doi:10.1513/pats.p09st2.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Wheezing, chest tightness, and shortness of breath must be present to make a diagnosis of asthma.
2. True or False: Pulsus paradoxus may be absent in life-threatening asthma due to respiratory muscle fatigue.
3. True or False: The interaction of underlying airway inflammation, airflow obstruction, and bronchial hyperresponsiveness determines the clinical presentation of asthma and its degree of severity.

Etiology

Asthma is a complex heterogeneous disease that is affected by numerous genes[12] and environmental factors.[13] It is the interaction of genetics and the environment that determines the eventual expression of the asthmatic **phenotype** (**Figure 8-2**). Genetic factors associated with the pathogenesis and expression of asthma are involved in a variety of biologic processes. Some of these processes include the **immunoglobulin E (IgE)** response of B cells, Th2 cytokine inflammation, and HLA locus/immunity, which contribute to the development of acute and chronic allergic inflammation.[2] Genetic association studies have identified and replicated susceptibility genes.[2] The three main strategies currently used to determine the genetic factors that predispose to the development of asthma are linkage analysis in families with asthma, case-control or family-based association studies, and animal models of asthma traits. Despite recent advances in the genetics of asthma, there is currently no established clinical utility for these findings.[14] However, knowing the genetic signature of asthma-associated genes with altered expression during the peak of asthma exacerbations may help predict the severity and response to therapy.[15]

Factors that provoke symptoms of asthma are not necessarily those that are responsible for its inception, and gene–environment interactions may modify the expression of asthma according to different levels of exposure.[16] Infectious sequelae of viral causes are implicated as a predisposing factor in the development of asthma. Research findings suggest that children who experience severe respiratory syncytial virus (RSV) bronchiolitis at an early age are more likely to develop a subsequent asthma diagnosis.[17–19]



FIGURE 8-2 Etiology of asthma. Both environment and genetic factors contribute to the phenotypical expression of asthma. *Gene identification from association studies and genome-wide association studies.

Ober C, Yao T. The genetics of asthma and allergic disease: a 21st century perspective. *Immunol Rev.* 2011;242(1):10–30. doi:10.1111/j.1600-065x.2011.01029.x.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Asthma is a homogeneous disease that is environmental in etiology.
2. True or False: The factors that provoke asthma symptoms are those responsible for its cause.

Epidemiology

Asthma is a common respiratory disorder that affects an estimated 235 million people worldwide.[20] The Centers for Disease Control and Prevention (CDC) estimates that around 25 million Americans are currently living with asthma[21] (**Figure 8-3**). Asthma prevalence varies around the world. Since the year 2000, a rise in prevalence has occurred in some countries, while in other countries there has been a plateau.[22–25]

Asthma occurs more commonly in urban than in rural populations, has a higher incidence among minority populations, and is the most common chronic disease among children.[21] Asthma can develop at any age, though most cases develop early in childhood and among boys younger than age 18. In contrast to patients



FIGURE 8-3 Current asthma prevalence percentage by age, gender, and race/ethnicity, United States, 2015.

National Health Interview Survey, National Center for Health Statistics, Centers for Disease Control and Prevention. https://www.cdc.gov/asthma/asthmadata.htm.

who develop adult-onset asthma later in life, children with asthma often have remission as adults. Ethnic differences among people with asthma often translate to healthcare disparities. Urban areas with prevalent poverty and large minority populations have a very high rate of asthma, with those below 100% of the federal poverty threshold having the highest asthma rate.[21]

Fortunately, mortality rates associated with asthma have decreased over the last decade, probably at least in part secondary to advances made in diagnosis and medical management. More adult women, however, die from asthma compared with men. These deaths may be attributable to hormonal differences among other things. Ethnic differences in mortality rates are conspicuously striking. African American men between the ages of 25 and 35 years are at the highest risk of dying of asthma, which is 2.5 to 3 times higher than in whites.[21] Differences in mortality rates among racial and ethnic groups, however, likely reflect composite differences in access to care, tobacco use, genetic influences, environmental exposures, as well as social and cultural influences among different population groups. The number of deaths due to asthma in 2014 was 3,651, or 1.1 deaths per 100,000.[21]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Asthma is more commonly found in rural areas of the United States.
2. True or False: The highest prevalence of asthma is among African Americans.

Pathology/Pathophysiology

Pathologic findings usually are the result of multiple processes within the airways that ultimately lead to obstruction of the airways, limiting airflow and causing lung hyperinflation. These are the findings described by autopsy studies and therefore represent the consequences of the severe disease. In these cases, marked overdistention of the lungs is seen, and thick, tenacious mucus plugs occlude the airways. Microscopic examination of the airways demonstrates similar findings in both mild and more severe disease, the only difference being severity[26] (**Table 8-4**).

The NAEPP defines asthma as "a complex chronic inflammatory lung disease characterized by variable and reoccurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation."[4] It is the interaction of these features that create the clinical presentation of the patient, thereby defining the patient's treatment and management. The underlying inflammation in asthma contributes to the recurrent episodes of shortness of breath, coughing, wheezing, and chest tightness in susceptible individuals.
The characteristic inflammatory changes due to asthma include infiltration of **eosinophils**, **mast cells**, macrophages, and **T lymphocytes** into the airway walls, mucosa, and lumen. Bronchial smooth muscle contraction occurs secondary to release of several mediators. These mediators, including **histamine**, **cytokines**, **prostaglandin D2**, and **leukotrienes**, contract the airway smooth muscle directly (**Figure 8-4**).

TABLE 8-4
Airway Microscopy Findings for Asthma

Area of Airway	Findings
Bronchial wall	Edema and cellular infiltrates (eosinophils and lymphocytes)
Epithelium	Detachment of surface epithelial cells from basal cells, increased deposition of collagen in a layer
Smooth muscle	Hypertrophy and hyperplasia
Mucous glands	Hypertrophy
Goblet cells	Increased number

Modified from Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. Philadelphia, PA: Elsevier/Saunders; 2014:74–90.

The immediate, or acute phase, response to an asthma trigger is short lived. This phase involves bronchospasm with airway narrowing that responds to bronchodilator therapy. During this phase, the cells that mediate this response are recruited into the airway. Over several hours, these cells become activated and cause persistent inflammation with a cycle of cell damage and repair.[4] Six to eight hours after the acute phase, the late-phase reaction occurs. This phase manifests as a more severe reaction that is difficult to treat. The late-phase response is characterized by recruitment of inflammatory and immune cells, particularly the eosinophil, basophil, neutrophil, and T cells to the sites of allergen exposure.[27] Other cells, including monocytes and dendritic cells, are also recruited to inflammatory sites and may play roles in mediated or modulating the response to allergen exposure[28] (**Table 8-5**).

Eosinophils present in the airways of people with asthma have a destructive impact on the airway epithelium, leaving the airway walls denuded.[4] It has been proposed that patients with significant epithelial destruction present with persistent rather than intermittent asthma.[29] Permanent airway structural changes, airway remodeling, may occur over time and limit the patient's asthma from being fully reversible[4] (**Figure 8-5**). These histopathologic structure changes are characterized by the damage to or loss of normal pseudostratified airway epithelium, increased number of goblet cells, fibrotic thickening of the subepithelial reticular basement membrane, increased numbers of myofibroblasts, angiogenesis, increased airway smooth muscle mass, and increased extracellular matrix[30] (**Figure 8-6**). BHR to direct stimuli seems to be a



FIGURE 8-4 Asthma inflammatory cascade. Acute-phase inflammation is triggered when inhaled allergens are captured by epithelial cells and macrophages and presented to T cells. Activated Th_2 cells trigger B cells to become antibody-producing plasma cells. Plasma cells release antigen-specific IgE, which binds to IgE receptors on mast cells. Activated mast cells degranulate releasing histamine, which binds to receptors on airway smooth muscle cells, triggering contraction and airway narrowing. Repeated bouts of acute inflammation can lead to chronic inflammation with persistent airway eosinophilia and/or neutrophilia. APCs, antigen-presenting cells.

Reproduced with permission from Wadsworth S, Sin D, Dorscheid. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. *J Asthma Allergy*. 2011:77 (Figure 3). doi:10.2147/jaa.s15081.

TABLE 8-5
Examples of Cells Involved in Airway Inflammation and the Mediators They Produce in Asthma

Cell Type	Mediators Produced
Basophils	Cytokines Histamine Interleukin-4 (IL-4) Interleukin-13 (IL-13) Leukotrienes
Eosinophils	Cytokines Interleukins Leukotrienes Platelet-activating factor (PAF) Toxic granule products Transforming growth factors (TGFα and TGFβ)
Mast	Histamine Prostaglandins (some) Tumor necrosis factor (TNFα)
Th2 lymphocytes	Granulocyte-macrophage colony-stimulating factor (GM-CSF) Interleukin-3 (IL-3) Interleukin-4 (IL-4) Interleukin-5 (IL-5) (increases extracellular matrix proteins) Interleukin-13 (IL-13)



FIGURE 8-5 Schematic representation of the major events underlying asthma pathophysiology.

Reproduced from Youssef M, Kanagaratham C, Saad M, Radzioch B. Genetics of allergic asthma and current perspectives on therapeutic management. In: Pereira C, ed. *Asthma—From Childhood Asthma To ACOS Phenotypes;* 2016 (Figure 2). https://www.intechopen.com/books/asthma-from-childhood-asthma-to-acos-phenotypes/genetics-of-allergic-asthma-and-current-perspectives-on-therapeutic-management. Accessed November 21, 2017.



FIGURE 8-6 Airway remodeling (abnormal half of figure) involves almost all elements of the airway wall and occurs throughout the bronchial tree.

Shifren A, Witt C, Christie C, Castro M. Mechanisms of Remodeling in Asthmatic Airways. *J Allergy*. 2012;2012:1–12 (Figure 1). doi:10.1155/2012/316049.

function of airway remodeling and airway inflammation.[30] However, airway remodeling is not a prerequisite for increased bronchial responsiveness to direct stimuli as exposure to organic material can induce a substantial increase in bronchial responsiveness in healthy, non-asthmatic subjects.[31,32] Traditionally, airway remodeling was thought to be indicative of adult asthma with a slow progression from a reversible to an irreversible state. However, airway remodeling has been shown to be present as early as 3–6 years of age.[33,34]

The airway geometry that results from airway remodeling and inflammation creates BHR. BHR makes the airways susceptible to numerous exogenous or endogenous stimuli or triggers.[35] The degree of BHR usually correlates with the clinical severity of asthma. The common exogenous triggers are divided into categories: allergens, medications, infections, irritants, and others (**Table 8-6**).

Airway obstruction increases airway resistance, decreasing expiratory flow rates, leading to hyperinflation. Uneven changes in airflow resistance, the resulting unequal distribution of air, and alterations in circulation from increased intra-alveolar pressure due to hyperinflation all lead to ventilation–perfusion mismatch,[36] alterations of pulmonary mechanics, and increased work of breathing. These changes are evident during acute exacerbations and in severe persistent asthma.

TABLE 8-6
Examples of Asthma Triggers

Category	Triggers
Allergens	Animal allergens Cockroach antigen Dust mite antigen Mold Pollen
Medications	Aspirin Certain beta-blocker medications NSAID
Infections	Flu virus Respiratory tract infections Sinus infection
Irritants	Air fresheners Burning wood Cooking oils Indoor chemical use Outdoor air pollution Perfumes Tobacco smoke Volatile organic compounds
Other	Cold air Exercise Menstrual cycle Strong emotions

Asthma Phenotypes

Asthma is a heterogeneous disease comprised of several distinct phenotypes.[37,38] See **Box 8-2**. Phenotypes are a cluster of characteristics that define a disease or a subset of a disease that results from the interaction of genes with the environment.[39,40]

The identification of an asthma phenotype assists the clinician in understanding the pathophysiology better and utilizing appropriate treatment unique to the control of a patient's asthma. For example, a patient with nonallergic asthma phenotype will not respond favorably to immunotherapy. A patient with the allergic asthma phenotype will respond favorably to immunotherapy.[38] A patient with allergic asthma phenotype

BOX 8-2 Representative Asthma Phenotypes

Asthma Phenotype	Major Characteristics of the Phenotype
Major Asthma Phenotypes	
Allergic	• Positive allergy test • Younger patient • Early onset • Seasonal variation • Allergy triggers (grass, dust, cat, dog)
Nonallergic	• Negative allergy test • Normal or low IgE • Late, adult onset • No family history
Aspirin-exacerbated respiratory disease (AERD)	• Asthmatic response to aspirin or another NSAID(s)
Infection induced	• Causes of new-onset infection-induced asthma: RSV, rhinovirus, parainfluenza, metapneumovirus • Causes of exacerbations: rhinovirus, RSV, influenza/parainfluenza, coronaviruses • Causes of persistence: adenovirus, chlamydia, mycoplasma
Other Asthma Phenotypes	
Exercise-induced bronchospasm	• Occurs 3–5 minutes after cessation of exercise • Peak bronchoconstriction at 10–15 minutes
Cough variant	• Cough is the main or only symptom • No atopy • No diurnal variability

responds favorably to trigger avoidance and environmental modification. However, a patient with cough-variant asthma will not.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The late-phase response is characterized by bronchospasm.
2. True or False: Eosinophils present in asthmatic airways damage the airway epithelium.
3. True or False: Airway inflammation and remodeling create bronchial hyperresponsiveness.
4. True or False: The allergic asthma phenotype has a late onset.

Risk Factors

Several risk factors are associated with the development of asthma (Table 8-7). Major risk factors include a genetic link, including a family history of asthma, or atopy.[2] Atopy is the "genetic propensity to develop immunoglobulin E (IgE) antibodies in response to exposure to allergens."[41] In childhood, gender is a risk factor. Boys have a higher risk for asthma than girls. However, after age 20, the prevalence of asthma for male and female is approximately equal. After age 40, the disease is more common in women.[42] Exposure to environmental tobacco smoke is also a risk factor for the development of asthma in children.

Occupational exposure increases the risk of new-onset asthma, including exposure to industrial spills, fires, and mixing cleaning agents.[42] Additionally, individuals with an increased BMI have a higher risk of developing asthma than those with a healthy BMI. This risk may be more significant for the nonallergic asthma phenotype than the allergic asthma phenotype.[43]

TABLE 8-7
Common Risk Factors for the Development of Asthma

Genetics	Family history of asthma Family history of atopy
Age/gender	Boys <20 years old Women ≥40 years old
Exposure	Cigarette smoking Cleaning agents (occupational) Chemical fumes (occupational) Environmental tobacco smoke Exhaust fumes (occupational) Fires (occupational) Industrial spills (occupational)

Occupationally related asthma may be induced in some patients from workplace exposure to airborne dust, vapors, or fumes. It may be traced to high-molecular-weight allergens (e.g., flour, latex, and animal proteins) with classic IgE-mediated allergic reactions versus low-molecular-weight antigens, most often such chemicals as isocyanates or acid anhydrides, where the precise mechanism is not as clear. Potential triggers are diverse, and therefore, diagnosis is dependent on obtaining a complete and accurate occupational and environmental history and documenting a temporal association between workplace exposure and the onset of asthma.

Although occupational asthma usually refers to a new onset of disease caused by some exposure at the workplace environment, an exacerbation of preexisting conditions that is not asthma can occur at the workplace that is work aggravated rather than work caused. Management of occupationally related asthma includes utilizing standard asthma therapies in combination with instituting preventive strategies such as appropriate avoidance of environmental triggers. Preventive measures often involve providing specific work restrictions as well as using environmental controls and individual respiratory protection.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Women under the age of 40 have a higher risk of developing asthma than men of the same age.
2. True or False: A family history of atopy is a risk factor for the development of asthma.

Complications

Asthma complications occur most often when asthma is not well controlled and during acute exacerbations. These complications include, but are not limited to, interference with activities of daily living, respiratory failure from severe acute asthma, and death. Several distinctive circumstances are identified as increasing the risk of death in patients with asthma.[44–50] See Box 8-3.[51] Identification of the conditions that increase the risk of death due to asthma is vital to the survival of the patient.

Life-threatening asthma is a medical emergency in which acute asthmatic symptoms are persistently nonresponsive (refractory) to bronchodilator therapy. The bronchodilator therapy typically begins at home and is later continued in the hospital emergency department. Individuals with this more severe form of asthma frequently describe having chest discomfort and tightness, display rapidly accelerating shortness of breath, manifest a dry or minimally productive cough, and produce

BOX 8-3 Circumstances Increasing the Risk of Death from Asthma

- Prior intubation and mechanical ventilation due to severe asthma
- At least one ICU admission as the result of severe asthma
- Two or more hospitalizations for asthma in the past year
- Three or more emergency department visits in the past year for asthma
- Comorbidity with another serious disorder such as cardiovascular, psychiatric, or other chronic lung disease, especially in the older asthmatic
- Poor patient adherence to treatment or under-treatment with ICSs
- Use of >2 metered-dose inhaler (MDI) canisters of SABA per month
- Difficulty perceiving asthma symptoms or severity of exacerbations
- Low socioeconomic status or urban residence (lack of access to medical care)
- Sensitization to the aeroallergen *Alternaria alternata*

Modified from National Asthma Education and Prevention Program Expert Panel Report 3. *Guidelines for the Diagnosis and Management of Asthma.* Bethesda, MD: National Institutes of Health; 2007.

inspiratory along with expiratory wheezing despite the frequent use of short-acting bronchodilators. These individuals may present over a few hours or a few days after the onset of a viral respiratory illness, following exposure to a potent allergen or irritant, or after exercise in a cold environment. Frequently, these patients have underused or may have been underprescribed anti-inflammatory therapy.[6] Occasionally, patients with life-threatening asthma do not perceive the severity of their asthma and may appear better than their lung function.[52]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Lack of access to medical care increases the risk of complications from asthma.
2. True or False: Life-threatening asthma responds to bronchodilator therapy.

Diagnostic Testing

The diagnosis of asthma is maybe apparent from the symptoms of variable and intermittent airways obstruction but is confirmed by objective measurements of lung function.[53] Variable airflow obstruction means that the obstruction is not necessarily present at all times, varying with time, exposure to asthma triggers, and treatment.[54] It is the intermittent nature of and wide variation in asthma symptoms that make diagnosing the condition a challenge.[55] The medical history is an essential part of diagnosing asthma (Figure 8-7).



FIGURE 8-7 Examples of items for the medical history of an asthma patient.
Based on Clark M. *Asthma: a clinician's guide.* Sudbury, MA: Jones & Bartlett Learning; 2011.

Pulmonary Function Testing

Pulmonary function testing or spirometry is recommended for all patients to confirm the diagnosis of asthma before initiation of therapy. Spirometry can demonstrate obstruction and assess reversibility in patients 5 years old or older. It is an essential objective measure to establish the diagnosis of asthma because patients' perceptions of airflow are highly variable.[4] Spirometry is also a critical factor in the classification of asthma severity, which in turn determines treatment.

Spirometry in asthma commonly shows an obstructive pattern demonstrating a reduced ratio of **forced expiratory volume in 1 second (FEV_1)** and FEV_1/forced vital capacity (FVC). These reductions indicate the presence of airflow limitation. The clinical diagnosis of asthma is supported by an obstructive pattern in which the FEV_1 increases more than 12% and at least 200 mL from baseline following administration of an aerosolized short-acting bronchodilator. The improvement in FEV_1 verifies reversibility. Bronchodilator responsiveness provides the quickest support for diagnosing asthma when suspected on clinical grounds (**Figure 8-8**). Lack of airway obstruction or reactivity, however, does not rule out asthma. In such cases, the diagnosis can be made by demonstrating heightened airway reactivity after graded **bronchial challenge** usually with **methacholine**. A positive bronchial challenge test reflects a fall in FEV_1 from baseline of 20% or more with a standard dose of methacholine or histamine.[6] A positive test is consistent with asthma, and a negative bronchial challenge test may be more helpful to rule out asthma.[4]

Generalized gas exchange is measured by diffusion capacity (DL_{CO}) and is either normal or slightly elevated in patients with asthma. Lung volumes typically show normal or elevated total lung capacity (TLC) and functional residual capacity (FRC) with markedly elevated residual volume (RV). **Table 8-8** shows a summary of pulmonary function testing.

TABLE 8-8
Pulmonary Function Test Findings in Asthma

Test	Findings
FEV_1 (pre-bronchodilator)	Normal or reduced
FEV_1 (post-bronchodilator)	Increased from pre-bronchodilator FEV_1
FVC	Normal or reduced
FEV_1/FVC ratio	Normal or reduced
Flow–volume loop	Scooped-out shape
TLC	Normal or increased
FRC	Normal or increased
RV	Normal or increased
DL_{CO}	Normal or increased
Bronchial challenge with methacholine	FEV_1 reduction more than 20%





(C)

Spirometry measure	Predicted	Before Bronchodilator		After Bronchodilator		
		Best	% of Predicted	Best	% of Predicted	% Change
FVC, L	3.70	3.30	89	3.95	107	20
FEV_1, L	2.94	1.80	61	2.76	94	53
Ratio FEV_1/FVC, %	80	55	NA	70	NA	NA

Note: NA = not applicable.

FIGURE 8-8 Spirometry results for a patient with asthma: **(A)** data table, **(B)** flow-volume loop, and **(C)** volume-time graph. The FEV_1 before the administration of a bronchodilator is 77% of predicted and the FEV_1 following the bronchodilator is 96% of predicted. This improvement demonstrates reversibility of airflow limitation. The FEV_1% before the bronchodilator is 83% of predicted and increases to 100% of predicted. This is redrawn from the author's spirometry results from 11/18/16.

Clinicians need to correlate the patient's medical history, the physical examination, and the pulmonary function test results to ensure that the diagnosis is accurate.[7]

During an acute exacerbation of asthma, the measurement of expiratory airflow with a peak flow meter is typically the most appropriate method for objective assessment of the severity of the exacerbation in patients who can perform the test. The normal values for PEFR depend on gender, height, and age. However, a PEFR below 200 L/minute indicates severe obstruction for most adults except those who are very short or elderly.[4]

Allergy Tests

Because there is currently no definitive diagnostic laboratory test for asthma, differentiating asthma from many other respiratory disorders (especially COPDs) can be challenging. Laboratory tests provide only supportive evidence of asthma. The presence of atopy increases the probability that a patient with respiratory symptoms has allergic asthma, but this is not specific for asthma nor is it present in all asthma phenotypes.[6] Elevation in serum immunoglobulin E (IgE) levels and positive skin prick tests to common antigens may support an allergic susceptibility associated with asthma but does not confirm a diagnosis of asthma.

Exhaled Nitric Oxide

A less-invasive diagnostic method of examining airway inflammation and oxidative stress associated with asthma is to measure the constituents of exhaled air, including nitric oxide (NO). **Fractional exhaled nitric oxide (FE_{NO})** measurement is a biomarker of airway inflammation and appears to be clinically promising for diagnosis of certain asthma phenotypes and for improving asthma management.[56] FE_{NO} measurements assist in assessing the etiology of respiratory symptoms, help identify the eosinophilic asthma phenotype, and assess response to ICSs. Also, they serve as a guide to the use of anti-inflammatory medications, assist in the evaluation of adherence to anti-inflammatory medications, and help to assess whether airway inflammation is contributing to poor asthma control.[57]

Chest Radiograph

Chest radiography is not diagnostic for asthma. A chest radiograph in patients with asthma may be entirely normal or may show signs suggesting over-inflation of the lungs, including hyperlucency, depressed diaphragms, and increased retrosternal airspace. A chest radiograph is often obtained to evaluate other diagnoses, including pneumonia or pneumothorax.

Pulse Oximetry and Arterial Blood Gas

Pulse oximetry is particularly valuable in the symptomatic asthma patient. Decreased oxygen saturation, less than 90%, present while breathing room air is usually associated with the need for hospitalization, signals the need for aggressive therapy,[6] and necessitates arterial blood gas (ABG). Oxygen administration should be titrated against pulse oximetry to maintain oxygen saturation at 93–95% (94–98% for children 6–11 years).

ABG analysis is essential in assessing asthma exacerbation severity, assure adequate oxygenation, and substantiate the necessity for more aggressive management. ABG measurements are helpful for evaluating $PaCO_2$ in patients with suspected hypoventilation, those in severe distress.[13] An ABG determination is considered mandatory when the PEFR or FEV_1 is less than or equal to 25% of the predicted value[13,58] or when the patient shows evidence of fatigue or progressive airway obstruction despite treatment. At the onset of an exacerbation, ABG values are typically normal, but as exacerbation severity increases, hyperventilation causes a decrease in $PaCO_2$ and a corresponding respiratory alkalosis. Without intervention or response to therapy, a widened alveolar–arterial oxygen gradient develops, causing PaO_2 and SaO_2 to drop. Eventually, the $PaCO_2$ begins to falsely normalize and pH decreases in a person with a persistent severe asthma exacerbation. At this point, fatigue and impending respiratory failure are more likely to be clinically seen. The final and more severe stage is consistent with respiratory and ventilatory failure as well as profound respiratory muscle fatigue, which is characterized by a low PO_2, low pH, and a high PCO_2 (**Table 8-9**). The respiratory muscle insufficiency mandates ventilatory support.

Laboratory Blood Tests

Most patients with an asthma exacerbation do not require laboratory studies. However, if ordered, these lab tests must not delay treatment. A complete blood cell (CBC) count is rarely needed but might be appropriate in patients with fever or purulent sputum.[13] The CBC count and differential may demonstrate a bacterial infection, such as pneumonia. Leukocytosis, however, may be caused by treatment with glucocorticoids and beta-agonists.[13,59] Glucose levels need to be checked and monitored for hyperglycemia from glucocorticoid administration, especially in patients with diabetes. Electrolyte assessment during an acute exacerbation can reveal hypokalemia associated with the use of beta-agonists and systemic corticosteroids. Reduced serum levels of magnesium and phosphate may also be identified.[58]

Classification of Asthma Severity

It is crucial to determine the degree of an individual's asthma severity since current guidelines for asthma treatment recommend a "stepwise" treatment approach to asthma management, matching treatment intensity to disease severity. The NAEPP guidelines[4] classify asthma severity intensity as (1) intermittent, (2) mild persistent, (3) moderate persistent, or (4) severe persistent. Asthma severity classification is based on the level of impairment and the number of asthma exacerbations requiring oral systemic corticosteroids. Impairment is based on the number of days with symptoms, the frequency of nocturnal awakenings, short-acting beta-adrenergic bronchodilator use for controlling symptoms, interference with normal activity, and lung function, including FEV_1 and FEV_1/FVC. The NAEPP guidelines make specific recommendations per age group for each of these classifications of severity.[4] The age groups include children 4 years of age and under, 5 to 11 years, and 12 years and older. There are classifications for asthma severity and recommended therapy for the initial visit and follow-up visits.[60] These classifications are used as a guide to assist with decision making for treatment (**Table 8-10**).

TABLE 8-9
ABG Progression during Acute Asthma Exacerbations*

Stage	ABG	Comments
I	$Paco_2$ = hyperventilation Pao_2 = normal	An ABG at this point is usually not warranted because the patient's PEFR or FEV_1 is greater than 25% of the predicted value. Monitoring the pulse oximeter is most appropriate. Mild exacerbation.
II	$Paco_2$ = hyperventilation Pao_2 = hypoxemia	The presence of hypoxemia (Pao_2 <60 mm Hg, Sao_2 <90%) suggests possible complications such as atelectasis due to mucus plugging or pneumonia. Moderate exacerbation.
III	$Paco_2$ = false normal Pao_2 = hypoxemia	Ventilation is decreasing from Stage II due to respiratory muscle fatigue. Severe exacerbation.
IV	$Paco_2$ = hypoventilation Pao_2 = hypoxemia	Increasing airflow obstruction and fatigue lead to respiratory muscle insufficiency and respiratory failure. Life-threatening exacerbation.

*Treatment can stop the progression to the later, more severe stages.
Data from Camargo C, Rachelefsky G, Schatz M. Managing Asthma Exacerbations in the Emergency Department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations. *Proc Am Thorac Soc*. 2009;6(4):357–366 (Table 2, p.359). doi:10.1513/pats.p09st2.

TABLE 8-10
Initial Visit: Classifying Asthma Severity Ages 12 Years and Older

Component of Severity	Intermittent	Mild Persistent	Moderate Persistent	Severe Persistent
Symptoms	≤2 days/week	>2 days/week but not daily	Daily	Throughout the day
Nighttime awakenings	≤2 times/month	3–4 times/month	>1 time/week but not nightly	Often 7 times/week
Short-acting beta-agonist use for control (not to prevent exercise-induced bronchospasm)	≤2 days/week	>2 days/week but not daily and not more than once on any day	Daily	Several times per day
Interference with normal activity	None	Minor limitation	Some limitation	Extremely limited
Lung function FEV_1*(% predicted) FEV_1/FVC*	>80% Normal for age	>80% Normal for age	60–80% Reduced by 5%	<60% Reduced >5%
Asthma exacerbations requiring oral systemic corticosteroid	0–1/year	≥2/year	More frequent and intense events usually indicate greater severity	
Recommended step for initiating therapy	Step 1	Step 2	Step 3	Step 4 or 5

Data from U.S. Department of Health and Human Services, National Institutes of Health. *Asthma Care Quick Reference Diagnosing and Managing Asthma*. Bethesda, MD: National Heart Lung and Blood Institute; 2012:5.

KNOWLEDGE CHECK QUESTIONS

1. True or False: PEFR measurements are a key factor in the diagnosis of asthma.
2. True or False: A positive bronchial challenge test shows a minimum of a 20% drop from the baseline FEV_1 measurement.
3. True or False: A 150 mL increase in post-bronchodilator FEV_1 is indicative of the reversibility of airflow obstruction in asthma.
4. True or False: An eosinophilic asthma phenotype may be identified utilizing the measurement of FE_{NO}.
5. True or False: The classification of asthma severity depends on symptoms, nighttime awakenings, use of short-acting beta-agonists, interference with normal activities, lung function, and use of systemic corticosteroids.

After the initial assessment and classification, therapy is recommended. On follow-up visits to the primary care practitioner, the NAEPP guidelines recommend a similar assessment. This evaluation establishes the level of control based on the same impairment and risk criteria as the initial assessment plus the use of validated questionnaires for the patient. The follow-up assessment is also used to adjust therapy.

Treatment and Management

There are two main focuses for the treatment and management of asthma. One focus is on the treatment of acute exacerbations, and the second on the long-term management of asthma. The key short-term, quick relievers for the treatment of acute exacerbations are the **short-acting beta-adrenergic agonists (SABAs)** such as albuterol and levalbuterol. The inhaled **anticholinergic bronchodilator** ipratropium bromide can provide additive benefit to SABAs in moderate-to-severe acute exacerbations and may be used in patients unable to tolerate SABAs. All short-term, quick-relief medications increase airway caliber by relaxing airway smooth muscle. **Systemic corticosteroids**, while not short-acting, are effective in moderate-to-severe asthma exacerbations when used adjunctively with short-acting beta-agonists. The most effective and most used long-term controllers are ICSs, which primarily produce improvement through their anti-inflammatory action and are considered first-line therapy in all age groups. Alternative long-term control medications include **leukotriene receptor antagonists (LTRA)** such as montelukast. Another long-term control alternative is the **methylxanthine** theophylline, which produces mild-to-moderate bronchodilators in addition to mild mucosal anti-inflammatory effects. Two **long-acting beta-agonists (LABAs)** such as salmeterol and formoterol are effective in improving asthma control when regularly taken with ICSs. Safety concerns of LABAs, however, have been questioned because trial results showed an increase in asthma-related deaths in individuals who received salmeterol compared to placebo. LABAs should *not* be used without simultaneous use of ICSs. Combination of two drugs in a single delivery device can be used to increase individual compliance and convenience as well as provide a safety factor. **Immunomodulator** treatment of asthmatic patients older than 12 years of age with a recombinant DNA-derived humanized IgG monoclonal antibody can be useful in treating moderate-to-severe allergic, corticosteroid-dependent asthma. Their excessive cost limits their use. These medications are summarized in **Table 8-11**.

Acute Exacerbation Treatment

An acute exacerbation is an acute or subacute episode of progressively worsening shortness of breath, cough, wheezing, and chest tightness or some combination of these symptoms.[6] Signs of an acute exacerbation may include tachypnea, tachycardia, use of accessory muscles, pulsus paradoxus, and inability to speak in full sentences. Exacerbations are characterized by decreases in expiratory airflow that can be documented and quantified by simple measurement of lung function, either FEV_1 or PEFR.[61] The principal goals for treatment of asthma exacerbations are to reverse airflow obstruction, correct hypoxemia (if present), and reduce the likelihood of future exacerbations.[61] At the onset of the exacerbation, early treatment by the patient at home is the best strategy for managing asthma exacerbations.[4] When the patient has an asthma action plan, most often a mild asthma exacerbation can be managed entirely at home with a possible visit to the patient's primary care practitioner. Individuals with asthma must be able to recognize their early indicators of an exacerbation and adjust their medications by increasing the use of their short-acting beta-agonist. In some cases, these patients need to add a short course of oral systemic corticosteroids and remove the allergen or irritant from their environment.[4]

In the emergency department, the severity of the asthma exacerbation determines the intensity of the treatment and the frequency of patient monitoring. In general, primary treatment with the administration of oxygen, inhaled SABAs, and systemic corticosteroids is the standard for all exacerbations, but the dose and frequency of administration and the frequency of patient

TABLE 8-11
Commonly Used Medications in the Treatment and Management of Asthma

Medication	Use	Comments
Inhaled short-acting beta-agonist	Acute care management Relieves acute bronchospasm	Albuterol and Levalbuterol are used in the United States
Inhaled short-acting anticholinergic	Acute care management Used in addition to inhaled albuterol for patients with severe exacerbations in the emergency department	Ipratropium bromide mixed with albuterol for continuous bronchodilator therapy (CBT)
Systemic glucocorticoids	Acute care management Anti-inflammatory to reduce airway inflammation that causes persistent airflow obstruction	Oral glucocorticoids—prednisone, prednisolone (used for acute exacerbations and to gain control of persistent asthma when ICSs are not effective) Intravenous glucocorticoids—methylprednisolone (used for impending or actual respiratory arrest, or when a patient is intolerant of oral glucocorticoids)
Magnesium sulfate	Acute care management Has bronchodilator activity in acute asthma	Given via intravenous route, it is helpful in a subgroup of patients with severe asthma
ICSs	Long-term management Anti-inflammatory, used to prevent future severe exacerbations	Low-dose, medium-dose, and high-dose ICS; use depends on severity of persistent asthma
Inhaled LABAs	Long-term management Used in combination with ICS for long-term control and prevention of asthma symptoms	Formoterol, Salmeterol Not to take the place of SABA; not for long-term monotherapy; always use in combination with ICS
Combined long-term control medications	Long-term management Used for the long-term control and management of asthma symptoms	Combinations of LABA and ICS Not to take the place of short-acting beta-agonists
Leukotriene modifiers	Long-term management Alternative treatment option for long-term management of persistent asthma	Available in oral tablets LTRAs—montelukast, zafirlukast 5-Lipoxygenase pathway inhibitor—zileuton
Methylxanthines	Long-term management Alternative therapy for management of persistent asthma	Bronchodilator and mild anti-inflammatory
Immunomodulators	Long-term management Additional therapy for moderate-to-severe persistent allergic asthma	Injection Anti-IgE therapy—omalizumab Anti-IL-5 therapy—reslizumab, benralizumab

monitoring differ depending on the severity of the exacerbation[13] (**Figure 8-9**).

Use of intravenous magnesium sulfate (a smooth muscle relaxant) is another adjunct medication in addition to beta-adrenergic agonists and systemic steroids for severe asthma exacerbations. [62] Another adjunct treatment includes the administration of **heliox** (a mixture of helium and oxygen) to patients with asthma to help decrease the work of breathing and improve ventilation.[62]

A small proportion of asthmatics have progressive respiratory failure despite aggressive pharmacologic therapies.[53] The decision to intubate and initiate mechanical ventilation during a severe asthma exacerbation is clinical. Slowing of the respiratory rate, depressed mental status, inability to maintain respiratory effort, worsening hypercapnia and associated respiratory acidosis, or failure to maintain an oxygen saturation greater than 92% despite high-flow supplemental oxygen suggest that the patient requires intubation.[62] The use of noninvasive ventilation for asthma patients with respiratory failure may be beneficial, but the results of several studies did not show a clear benefit for noninvasive ventilation.[63,64] Intubation of the asthmatic patient is best accomplished in a semi-elective manner and before respiratory arrest. Current invasive ventilation strategies aim to improve gas exchange, maintain adequate alveolar ventilation (permissive hypercapnia may be necessary),[13] minimize air trapping, and avoid ventilator-induced lung injury.[53]

Long-Term Management

Successful management of patients with asthma includes four major components of effective asthma management: (1) use of objective pulmonary function measures to assess asthma severity and monitor therapy outcomes; (2) control of environmental events that avoid or eliminate "triggers" contributing to asthma severity and give rise to symptoms or exacerbations; (3) patient and family education in partnership with his or her healthcare provider that addresses expectations of asthma control; and (4) use of a pharmacologic regime designed to reverse and prevent the airway inflammation with least amount of adverse effects.[4] Addressing each of these components helps to maintain normal pulmonary functions and activity levels, averts chronic symptoms as well



Key: PCO_2, partial pressure carbon dioxide; PEF, peak expiratory flow; SaO_2, oxygen saturation

FIGURE 8-9 Management of asthma exacerbations in the emergency department and hospital-based care.

National Heart, Lung and Blood Institute (NHLBI). Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma. Bethesda: U.S. Department of Health and Human Services, National Institutes of Health; 2007 (Figure 21, p. 55).

as recurrent exacerbations, and results in the optimal use of treatment with least number of side effects.

The assessment of severity determines the recommendation for therapy for the initial visit to gain control over asthma symptoms and for the follow-up visits to maintain that control (Table 8-10 and **Figure 8-10**).

A minimally invasive surgical treatment called **bronchial thermoplasty** has been reported to significantly improve quality of life and reduce asthma exacerbations and respiratory-related emergency department visits in patients with severe asthma by reducing the amount of excess smooth muscle in the airway. This procedure uses a standard flexible bronchoscope that allows the introduction of the tip of the small-diameter catheter to be placed in contact with the walls of targeted airways. Thermal energy is administered to airway walls, decreasing airway smooth muscle that usually narrows the airways in asthma patients who are experiencing a bronchoconstrictive attack.[65]

KNOWLEDGE CHECK QUESTIONS

1. True or False: LABAs are useful in the treatment of an acute asthma exacerbation.
2. True or False: LTRA are first-line control medications for asthma.
3. True or False: In the emergency department, the primary treatment for an acute asthma exacerbation includes the administration of short-acting beta-agonists, systemic corticosteroids, and oxygen.
4. True or False: A patient with intermittent asthma requires low-dose ICSs.
5. True or False: All asthma patients ≥12 years with a persistent type of asthma require an ICS.



* Abbreviations: EIB, exercise-induced bronchospasm.
Treatment options are listed in alphabetical order, if more than one.
† If alternative treatment is used and response is inadequate, discontinue and use preferred treatment before stepping up.
‡ Theophylline is a less desirable alternative because of the need to monitor serum concentration levels.
§ Based on evidence for dust mites, animal dander, and pollen; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for
** immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults.
Clinicians who administer immunotherapy or omalizumab should be prepared to treat anaphylaxis that may occur.
†† Zileuton is less desirable because of limited studies as adjunctive therapy and the need to monitor liver function.
‡‡ Before oral corticosteroids are introduced, a trial of high-dose ICS + LABA + either LTRA, theophylline, or zileuton, may be considered, although this
§§ approach has not been studied.

FIGURE 8-10 Stepwise approach for managing asthma long term for those ≥12 years of age. This approach tailors the selection of medication to the level of asthma severity or asthma control. It is meant to help, not replace, the clinical decision making needed to meet individual patient's needs.

Modified from U.S. Department of Health and Human Services, National Institutes of Health. *Asthma Care Quick Reference Diagnosing and Managing Asthma*. Bethesda, MD: National Heart Lung and Blood Institute; 2012:7.

Prognosis

Asthma is not curable, but it is controllable. The natural history of asthma is variable and often difficult to predict for any one individual.[66] Children with asthma are more likely to experience long periods without symptoms and remission more frequently than adults.[67] The prognosis for asthma depends on several factors, most importantly its severity. In mild-to-moderate cases, asthma can improve over time, and many adults even become symptom free.[68] The worse prognosis is for those new-onset adults with a history of cigarette smoking.[69,70] Other factors that worsen the prognosis of adult-onset asthma include current persistent rhinitis,[8] hormonal influences,[71] and elevated BMI.[8,71] Good control over asthma allows most individuals with asthma to lead normal lives.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Remission of asthma symptoms is more likely with children than with adults.
2. True or False: People with asthma are unable to live normal lives.

Chapter Summary

Asthma is a chronic inflammatory disease of the airways affecting probably greater than 25 million persons in the United States and is one of the most common chronic diseases of childhood. Asthma is also a complex genetic disorder in which the underlying pathology, clinical manifestations, natural course, and responses to treatment manifest considerable heterogeneity. Approximately 80% of children with asthma begin wheezing before 5 years of age, and 50% will have their first episode within their first year. It has become recognized as a major cause of disability and economic costs. While on the increase in developed Western countries, the prevalence of asthma also appears to be escalating in non-Western societies that adopt aspects of Western culture.

Periodic assessment is necessary to know whether successful asthma management is being achieved. Asthma not sufficiently controlled is associated with significant economic burden, reduced quality of life, and increased healthcare utilization. The key goal of management, therefore, is to control asthma by lowering impairment as well as risk. Current therapies available can be very effective in controlling asthma if appropriately and optimally applied, yet efficacy is also dependent on the patient's full engagement and adherence to care. Modification of existing categories of therapeutics that include the development of safer and longer acting ICSs, LABAs, improvements in agents that inhibit leukotriene pathways, and new therapies that block the IgE pathway or IL-5 pathway is now available. Eventually, it should become possible to target anti-inflammatory treatments to various specific aspects of this disorder as well as various proinflammatory cytokines or inflammatory cells, thereby improving individuals who have inadequate responses to currently available medications. Until more specific and curative treatments become available, only the combined use of anti-inflammatory and bronchodilator therapies, coupled with measures that reduce or eliminate environmental exposures, reduces the enormous burden of asthma on those affected.

Key Points

1. The NIH Expert Panel recommends that clinicians attempting to establish a diagnosis of asthma in a suspected patient should determine whether episodic symptoms of airflow obstruction are present, evidence of airflow obstruction is at least partially reversible, and other diagnoses can be excluded.
2. ICSs are probably the most effective long-term therapy available for mild, moderate, or severe persistent asthma.
3. Poor compliance with anti-inflammatory therapy (such as corticosteroids), as well as ingestion of certain substances (such as aspirin or NSAIDs) or illicit drugs (heroin, cocaine), is frequently associated with fatal or near-fatal asthma.
4. It is essential for patients to distinguish pharmacologic differences in asthma medications. Long-term control medications are normally used to prevent symptoms usually by reducing airway inflammation. These agents must be taken daily to maintain asthma control and are not expected to give immediate or "rescue-type" relief.
5. Quick-relief medication such as SABAs primarily cause relaxation of airway muscles to provide prompt relief of symptoms and is not expected to provide lasting asthma control.
6. Most acute wheezing episodes in asthmatic children result from viral infections, which may be accompanied by fever. Antibiotics are not required and may be ultimately detrimental.
7. The overall incidence of life-threatening attacks of asthma can be significantly decreased if individuals remain vigilant regarding treatment compliance and avoid any factors known to trigger an attack.
8. Individuals with asthma should be assessed for risk factors and disease impairment in determining their level of asthma control.
9. Education of individuals with asthma regarding environmental controls and appropriate pharmacotherapy are key components in helping individuals achieve asthma control.

Chapter Questions

1. How many people in the United States are estimated to have asthma? _____
   a. >10 million
   b. >15 million
   c. >20 million
   d. >25 million
2. Asthma symptoms are most often worse at what time of day? _____
   a. Morning
   b. Afternoon
   c. Evening
   d. Night
3. Significant alterations in intrathoracic pressure during an acute asthma exacerbation can cause _____.
   a. pulsus paradoxus
   b. tachycardia
   c. hyperventilation
   d. hypotension
4. Which immunoglobulin binds to mast cells to facilitate the release of chemical mediators?
   a. IgA
   b. IgD
   c. IgE
   d. IgM
5. Asthma is the most chronic disease among _____.
   a. infants
   b. children
   c. young adults
   d. adult
6. Microscopic examination of an asthmatic airway may find _____.
   a. smooth muscle hypertrophy
   b. mucous gland atrophy
   c. a decrease in goblet cells
   d. a decrease of collagen deposits in the epithelium
7. _____ cause denuding of the airway walls in asthma.
   a. Basophils
   b. Eosinophils
   c. Mast cells
   d. Th2 lymphocytes
8. The acute-phase response to an asthma trigger is_____.
   a. mucous plugging
   b. persistent inflammation
   c. epithelial damage
   d. bronchospasm
9. The medication type used for the long-term maintenance of persistent asthma is the _____.
   a. inhaled corticosteroid
   b. short-acting beta-agonist
   c. long-acting beta-agonist
   d. immunomodulator
10. A high-dose inhaled corticosteroid together with a long-acting beta-agonist is the recommended medication for the initial treatment of _____.
    a. intermittent asthma
    b. mild persistent asthma
    c. moderate persistent asthma
    d. severe persistent asthma

References

1. Koppelman GH. Gene by environment interaction in asthma. *Curr Allergy Asthma Rep.* 2006;6:103–111.
2. Ober C, Yao T. The genetics of asthma and allergic disease: a 21st century perspective. *Immunol Rev*. 2011;242(1):10–30. doi:10.1111/j.1600-065x.2011.01029.x.
3. Akinbami L, Moorman J, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. *NCHS Data Brief, U.S. Department of Health and Human Services*. 2012;94. http://centerforplainlanguage.org/wp-content/uploads/2012/05/CDC_Asthma_Infographic_BEFORE1.pdf. Accessed October 24, 2017.
4. National Heart, Lung and Blood Institute (NHLBI). *Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma*. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed October 24, 2017.
5. About Systematic Evidence Reviews and Clinical Practice Guidelines—NHLBI, NIH. *Nhlbinihgov*. 2017. https://www.nhlbi.nih.gov/health-pro/guidelines/about. Accessed November 21, 2017.
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. www.ginasthma.org. Accessed October 24, 2017.
7. Torén K, Hermansson B. Incidence rate of adult-onset asthma in relation to age, sex, atopy and smoking: a Swedish population-based study of 15813 adults. *Int J Tuberc Lung Dis.* 1999;3(3):192–197.
8. Fanta C. Diagnosis of asthma in adolescents and adults. In: Barnes P, Bochner B, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed November 6, 2017.
9. Kaicker J, Dang W, D'Urzo A. The challenge of objective confirmation of asthma diagnosis in primary care. *NPJ Prim Care Respir Med*. 2014;24(1):14032. doi:10.1038/npjpcrm.2014.32.
10. Urso DL. Treatment for acute asthma in the Emergency Department: practical aspects. *Eur Rev Med Pharmacol Sci*. 2010;14:209–214.
11. Boulet L. Asthma control, education, and the role of the respiratory therapist. *Can J Respir Ther*. 2011;47(4):15–21.
12. Camargo C, Rachelefsky G, Schatz M. Managing Asthma Exacerbations in the Emergency Department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations. *Proc Am Thorac Soc*. 2009;6(4):357–366. doi:10.1513/pats.p09st2.
13. Peterson M, Gaeta T, Birkhahn R, Fernández J, Mancuso C. History of symptom triggers in patients presenting to the emergency department for asthma. *J Asthma*. 2012;49(6):629–636. doi:10.3109/02770903.2012.690480.
14. Barnes K. Genetics of asthma. In: Barns P, Raby B, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed November 21, 2017.
15. Youssef M, Kanagaratham C, Saad M, Radzioch B. Genetics of allergic asthma and current perspectives on therapeutic management. In: Pereira C, ed. *Asthma—From Childhood Asthma To ACOS Phenotypes*; 2016. https://www.intechopen.com/books/asthma-from-childhood-asthma-to-acos-phenotypes/genetics-of-allergic-asthma-and-current-perspectives-on-therapeutic-management. Accessed November 21, 2017.
16. Granell R, Sterne J, Henderson J. Associations of different phenotypes of wheezing illness in early childhood with environmental variables implicated in the aetiology of asthma. *PLoS One*. 2012;7(10):e48359. doi:10.1371/journal.pone.0048359.

17. Bacharier L, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. *J Allergy Clin Immunol*. 2012;130(1):91–100.e3. doi:10.1016/j.jaci.2012.02.010.
18. Lu S, Hartert T, Everard M, et al. Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood. *Pediatr Pulmonol*. 2016;51(12):1382–1392. doi:10.1002/ppul.23461.
19. Edwards M, Bartlett N, Hussell T, Openshaw P, Johnston S. The microbiology of asthma. *Nat Rev Microbiol*. 2012;10(7):459–471. doi:10.1038/nrmicro2801.
20. WHO | Asthma. *Whoint*. 2017. http://www.who.int/respiratory/asthma/en. Accessed November 21, 2017.
21. CDC—Asthma—Most Recent Asthma Data. *Cdcgov*. 2017. https://www.cdc.gov/asthma/most_recent_data.htm#modalIdString_CDCTable_0. Accessed November 21, 2017.
22. Maio S, Baldacci S, Carrozzi L, et al. Respiratory symptoms/diseases prevalence is still increasing: a 25-yr population study. *Respir Med*. 2016;110:58–65. doi:10.1016/j.rmed.2015.11.006.
23. Backman H, Räisänen P, Hedman L, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. *Clin Exp Allergy*. 2017;47(11):1426–1435. doi:10.1111/cea.12963.
24. de Korte-de Boer D, Mommers M, Gielkens-Sijstermans C, et al. Stabilizing prevalence trends of eczema, asthma and rhinoconjunctivitis in Dutch schoolchildren (2001–2010). *Allergy*. 2015;70(12):1669–1673. doi:10.1111/all.12728.
25. Kim B, Kim J, Kang M, et al. Allergies are still on the rise? A 6-year nationwide population-based study in Korea. *Allergol Int*. 2016;65(2):186–191. doi:10.1016/j.alit.2015.11.002.
26. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. Philadelphia, PA: Elsevier/Saunders; 2014:74–90.
27. Liu M, Hubbard W, Proud D, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics: cellular, mediator, and permeability changes. *Am Rev Respir Dis*. 1991;144(1):51–58. doi:10.1164/ajrccm/144.1.51.
28. Jahnsen F, Moloney E, Hogan T, et al. Rapid dendritic cell recruitment to the bronchial mucosa of patients with atopic asthma in response to local allergen challenge. *Thorax*. 2001;56(11):823–826. doi:10.1136/thorax.56.11.823.
29. Barrios R, Kheradmand F, Batts L, Corry D. Asthma pathology and pathophysiology. *Arch Pathol Lab Med*. 2006;130:447–451.
30. Liu M. Pathogenesis of asthma. In: Bochner B, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed November 24, 2017.
31. Strandberg K, Ek A, Palmberg L, Larsson K. Fluticasone and ibuprofen do not add to the effect of salmeterol on organic dust-induced airway inflammation and bronchial hyper-responsiveness. *J Intern Med*. 2008;264(1):83–94. doi:10.1111/j.1365-2796.2008.01928.x.
32. Sundblad B, Palmberg L, Larsson K. Bronchial responsiveness to eucapnic hyperventilation and methacholine following exposure to organic dust. *Chest*. 2002;122(1):363–368. doi:10.1378/chest.122.1.363.
33. Barbato A, Turato G, Baraldo S, et al. Epithelial damage and angiogenesis in the airways of children with asthma. *Am J Respir Crit Care Med*. 2006;174(9):975–981. doi:10.1164/rccm.200602-189oc.
34. Yoshihara S, Yamada Y, Abe T, Linden A, Arisaka O. Association of epithelial damage and signs of neutrophil mobilization in the airways during acute exacerbations of paediatric asthma. *Clin Exp Immunol*. 2006;144(2):212–216. doi:10.1111/j.1365-2249.2006.03058.x.
35. Pascoe C, Wang L, Syyong H, Paré P. A brief history of airway smooth muscle's role in airway hyperresponsiveness. *J Allergy*. 2012;2012:768982. doi:10.1155/2012/768982.
36. Morris M. Asthma: overview, diagnosis and management. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/296301-overview#a4. Accessed November 27, 2017.
37. Wenzel S. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med*. 2012;18(5):716–725. doi:10.1038/nm.2678.
38. Chung K. Personalised medicine in asthma: time for action. *Eur Respir Rev*. 2017;26(145):170064. doi:10.1183/16000617.0064-2017.
39. Lockey R. Asthma phenotypes: an approach to the diagnosis and treatment of asthma. *J Allergy Clin Immunol Pract*. 2014;2(6):682–685. doi:10.1016/j.jaip.2014.09.008
40. Kiley J. *Asthma phenotypes task force goals and objectives*. Presented at the World Allergy Congress, Buenos Aires, Argentina; 2009.
41. Arshad S, Tariq S, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort Study. *Pediatrics*. 2001;108(2):E33. doi:10.1542/peds.108.2.e33.
42. Litonjua, A. Risk factors for asthma. In: Bochner B, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed November 20, 2017.
43. Chen Y, Dales R, Jiang Y. The association between obesity and asthma is stronger in nonallergic than allergic adults. *Chest*. 2006;130(3):890–895. doi:10.1378/chest.130.3.890.
44. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. *Am J Respir Crit Care Med*. 1994;2(3):604–610. doi:10.1164/ajrccm.149.3.
45. Sturdy PM, Victor CR, Anderson HR, et al. Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study. *Thorax*. 2002;57:1034–1039.
46. Turner MO, Noertjojo K, Vedal S, Bai T, Crump S, FitzGerald JM. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. *Am J Respir Crit Care Med*. 1998;157:1804–1809.
47. Pumphrey RSH, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. *J Allergy Clin Immunol*. 2007;119:1018–1019.
48. Alvarez GG, Schulzer M, Jung D, Fitzgerald JM. A systematic review of risk factors associated with near-fatal and fatal asthma. *Can Respir J*. 2005;12:265–270.
49. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. *Eur Respir J*. 1994;7:1602–1609.
50. Roberts G, Patel N, Levi-Schaffer F, Habibi P, Lack G. Food allergy as a risk factor for life-threatening asthma in childhood: a case-controlled study. *J Allergy Clin Immunol*. 2003;112:168–174.
51. National Asthma Education and Prevention Program Expert Panel Report 3. *Guidelines for the Diagnosis and Management of Asthma*. Bethesda, MD: National Institutes of Health; 2007.
52. Lugogo N, MacIntyre N. Life-threatening asthma: pathophysiology and management. *Respir Care*. 2008;53(6):726–739.
53. Barnes P. Asthma. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw Hill Education; 2013:66–84.
54. Kaplan AG, Balter MS, Bell AD, Kim H, McIvor A. Diagnosis of asthma in adults. *CMAJ*. 2009;181(10):E210–E220.
55. Clark M. *Asthma: a clinician's guide*. Sudbury, MA: Jones & Bartlett Learning; 2011.
56. Chiappori A, De Ferrari L, Folli C, Mauri P, Riccio A, Canonica G. Biomarkers and severe asthma: a critical appraisal. *Clin Mol Allergy*. 2015;13(1):20. doi:10.1186/s12948-015-0027-7.
57. Dweik R, Boggs P, Erzurum S et al. An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. *Am J Respir Crit Care Med*. 2011;184(5):602–615. doi:10.1164/rccm.9120-11st.
58. Papiris S, Manali E, Kolilekas L, Triantafillidou C, Tsangaris I. Acute severe asthma. *Drugs*. 2009;69(17):2363–2391. doi:10.2165/11319930-000000000-00000.
59. Abramson N, Melton B. Leukocytosis: basics of clinical assessment. *Am Fam Physician*. 2000;62(9):2053–2060.
60. U.S. Department of Health and Human Services, National Institutes of Health. *Asthma Care Quick Reference Diagnosing and Managing Asthma*. Bethesda, MD: National Heart Lung and Blood Institute; 2012:1–11.

61. Urso D. Acute asthma exacerbations in emergency department. *Rev Health Care*. 2015;6(4):127. doi:10.7175/rhc.v6i4.1210.
62. Fanta C. Management of acute exacerbations of asthma in adults. In: Bochner B, Hockberger R. eds. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 15, 2017.
63. Pallin M, Hew M, Naughton M. Is non-invasive ventilation safe in acute severe asthma? *Respirology*. 2014;20(2):251–257. doi:10.1111/resp.12428.
64. Lim WJ, Mohammed Akram R, Carson KV, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. *Cochrane Database Syst Rev.* 2012;12:CD004360. doi:10.1002/14651858.CD004360.pub4.
65. Wensel S. Treatment of severe asthma in adolescents and adults. In: Bochner B, ed. *Uptodate*. Waltham, MA: UpToDate; 2017. http://www.uptodate.com. Accessed December 15, 2017.
66. Bisgaard H, Bønnelykke K. Long-term studies of the natural history of asthma in childhood. *J Allergy Clin Immunol*. 2010;126(2):187–197. doi:10.1016/j.jaci.2010.07.011.
67. Ernst P, Cai B, Blais L, Suissa S. The early course of newly diagnosed asthma. *Am J Med*. 2002;112(1):44–48. doi:10.1016/s0002-9343(01)01033-6.
68. Asthma in adults. *University of Maryland Medical Center*. 2017. http://www.umm.edu/health/medical/reports/articles/asthma-in-adults. Accessed December 16, 2017.
69. Westerhof G, Vollema E, Weersink E, Reinartz S, de Nijs S, Bel E. Predictors for the development of progressive severity in new-onset adult asthma. *J Allergy Clin Immunol*. 2014;134(5):1051–1056.e2. doi:10.1016/j.jaci.2014.05.005.
70. Tuomisto L, Ilmarinen P, Niemelä O, Haanpää J, Kankaanranta T, Kankaanranta H. A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study. *Respir Med*. 2016;117:223–229. doi:10.1016/j.rmed.2016.06.017.
71. Tuomisto L, Ilmarinen P, Kankaanranta H. Prognosis of new-onset asthma diagnosed at adult age. *Respir Med*. 2015;109(8):944–954. doi:10.1016/j.rmed.2015.05.001.

CHAPTER

9

Chronic Obstructive Pulmonary Disease

"Smoking is hateful to the nose, harmful to the brain, and dangerous to the lungs."

—King James I. Born June 19, 1566; died March 27, 1625

OUTLINE

OBJECTIVES

1. Define chronic obstructive pulmonary disease (COPD) based on the World Health Organization (WHO) parameters.
2. Explain the signs and symptoms of COPD.
3. Explain the relationship of symptoms with activities of daily living.
4. Explain the etiology and epidemiology of COPD.
5. Understand the pathophysiology of COPD and how it relates to symptoms seen in COPD.
6. Understand the importance of spirometry and other pulmonary function tests in the diagnosis and ongoing disease process.
7. Explain the importance of eliminating risk factors that can lead to COPD.
8. Understand the importance of treating the patient's symptoms as it relates to the quality of life.

KEY TERMS

Acinus
Airflow limitation
Alpha-1-antitrypsin (AAT) deficiency (AATD)
Anterior–posterior (A–P) diameter
Biomass fuel
BODE index
Cachectic
Centrilobular emphysema
Chronic obstructive pulmonary disease (COPD)
COPD Assessment Test (CAT)
Dyspnea
Forced expiratory volume in 1 second (FEV_1)
Forced vital capacity (FVC)
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Lung volume reduction surgery (LVRS)
Modified Medical Research Council (mMRC) Dyspnea Scale
Neutrophil elastase (NE)
Panlobular emphysema
Pulmonary vascular resistance (PVR)
Spirometry
Ventilation/perfusion ratio (V/Q)

Case Study

Mr. HJ is a 71-year-old male who presents to the pulmonologist's office, with his wife, complaining, for the first time, of shortness of breath and fever. He has never been to this physician before despite having the referral from his primary care physician. Because of his current symptoms, his wife has insisted he see the pulmonologist at this time. Mr. HJ has a past medical history of heart failure secondary to his myocardial infarction (MI) at the age of 65. Mr. HJ has a 30 pack-year smoking history. He quit smoking after the MI. He is a retired schoolteacher. He is supposed to use 2 L/minute of oxygen via a nasal cannula at home but admits he does not like to wear it. His history also includes hypertension and an appendectomy. Cigarette smoking, hypertension, and heart failure are also a part of his family history.

His home respiratory medications include home oxygen, salmeterol/fluticasone 500/50 dry powder inhaler (DPI) twice a day, tiotropium DPI once a day, albuterol/ipratropium metered dose inhaler (MDI) or solution for a small-volume nebulizer every 6 hours as needed, and levalbuterol MDI every 4–6 hours. He explains that he is confused about when and how to take these medications. His last **spirometry** results reveal a **forced expiratory volume in 1 second (FEV_1)** of 35% of the predicted value, with little improvement after he receives a bronchodilator.

On physical examination, Mr. HJ is unable to speak in complete sentences due to shortness of breath, and he has a productive cough of yellowish-gray sputum. There is audible wheezing, and he has clubbing of his fingers. His oxygen saturation is 86% on room air. His chest radiograph reveals hyperinflation and right lower lobe pneumonia. Mr. HJ is sent by ambulance to the emergency department by the pulmonologist. In the emergency department, his arterial blood gas (ABG) results on room air are pH, 7.31; $Paco_2$, 65 torr; Pao_2, 49 torr; HCO_3^-, 31 mEq/L; Sao_2, 85%. The patient's vital signs show a blood pressure of 128/74; heart rate of 68 beats/minute and regular; respiratory rate of 32 breaths/minute. The patient is 5 feet 6 inches tall, weighs 122 pounds, and, moreover, has an oral temperature of 101.5°F. The patient receives treatment with the antimicrobials amoxicillin and doxycycline. He is placed on a 31% air-entrainment mask, and receives oral prednisone and albuterol/ipratropium medication nebulizer treatments every 6 hours.

Over a 3-day period, the patient significantly improves and is weaned back to the 2 L/minute of oxygen as he uses at home. He can now switch from small-volume nebulizer treatments to inhalers. Discharge planning will continue.[1]

Introduction

According to the World Health Organization (WHO), **chronic obstructive pulmonary disease (COPD)** is a lung disease characterized by chronic obstruction and **airflow limitation** interfering with normal lung function that is not fully reversible.[2] COPD is the fourth leading cause of death in the United States.[3] The two diseases most commonly associated with COPD are emphysema and chronic bronchitis (**Figure 9-1**).

Tobacco and tobacco-related products have a long history that stretches back to 6,000 BC in North and South America. Native Americans have been smoking for over two millennia for both medicinal and religious purposes. Tobacco products gained a strong foothold in the United States around the time of the Revolutionary War. It was the cash crop that financed the war. Cigarettes came into popularity after the invention of the cigarette-making machine in 1881.[4] Cigarette smoking is the primary causative agent for COPD. Smokers find it difficult to quit because tobacco contains nicotine, which is a highly addictive substance. Cigarette smoking is an addiction and a chronic relapsing disorder, making it difficult, but not impossible, to overcome. Tobacco dependence is a chronic condition that warrants repeated treatment until long-term or permanent abstinence is achieved.[5] In the United States, legislation has curtailed the advertisement of tobacco and emphasized the detrimental effects of cigarette smoking. With the establishment of smoking-cessation programs and older smokers dying from lung and heart diseases, the tobacco companies shifted their target to the youth of America. Younger Americans are rapidly becoming the population most at risk for future COPD.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Tobacco is relatively new to North and South America.
2. True or False: Tobacco financed the Revolutionary War in the United States.
3. True or False: Smoking tobacco is an addiction.



FIGURE 9-1 COPD comprises subsets of individuals that may have the dominant features of the three main obstructive lung diseases: chronic bronchitis, emphysema, and asthma. The red box focuses on areas of disease overlap with the other obstructive diseases. Patients with COPD typically have the symptoms of chronic bronchitis and emphysema but may have some reversible airflow obstruction. The airflow obstruction due to COPD is not fully reversible. Patients that exhibit symptoms of both asthma and COPD have asthma–COPD overlap syndrome (ACOS).

Modified from Mosenifar Z. Chronic Obstructive Pulmonary Disease (COPD): Practice Essentials, Background, Pathophysiology. Emedicinemedscapecom. 2017. https://emedicine.medscape.com/article/297664-overview. Accessed April 30, 2018.

Definition/Diagnosis

COPD is common, preventable, and treatable, and is due to abnormalities of the airways and alveoli.[6] The definition of COPD and its subtypes (emphysema, chronic bronchitis, and chronic obstructive asthma) and the interrelationships between the closely related disorders that cause airflow limitation provide a foundation for understanding the spectrum of patient presentations.[7] See **Box 9-1**. For many years, cigarette smokers who had a chronic cough were said to have "smoker's cough." A chronic cough is one of the primary symptoms of COPD, and most people with COPD are either current or former cigarette smokers. However, a small number of COPD patients have never smoked. Some of these individuals have had long-term exposure to lung irritants, such as air pollution, chemical fumes, or dust. Other individuals with COPD have **alpha-1-antitrypsin (AAT) deficiency (AATD)**, a rare genetic condition. AATD can cause COPD.[8]

When diagnosing COPD, practitioners must be mindful that in recent decades women smoke as much as or more than men. Historically, COPD was a male dominated disease because it was socially unacceptable for women to smoke. Today, the rates of COPD among women are equal to that among men. COPD is underdiagnosed in women and possibly misdiagnosed with asthma.[9] Practitioners need to objectively assess symptoms and risk factors with no regard for the patient's gender. COPD patients are significant consumers of healthcare services, even before diagnosis. It is estimated that half of all COPD cases are undiagnosed. Undiagnosed and underdiagnosed COPD is a tremendous burden on the healthcare system.[10]

BOX 9-1 Definitions for COPD and Its Subtypes[6]

- "COPD is a common, preventable, and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation that characterizes COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person. Chronic inflammation causes structural changes, small airways narrowing, and destruction of lung parenchyma. A loss of small airways may contribute to airflow limitation and mucociliary dysfunction, a characteristic feature of the disease."
- Chronic bronchitis is defined as a chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of chronic cough (e.g., bronchiectasis) have been excluded. It may precede or follow development of airflow limitation.
- Emphysema is a pathologic term that describes some of the structural changes sometimes associated with COPD. These changes include abnormal and permanent enlargement of the airspaces distal to the terminal bronchioles that is accompanied by destruction of the airspace walls, without fibrosis.

KNOWLEDGE CHECK QUESTIONS

1. True or False: COPD is not preventable.
2. True or False: Cigarette smoke is the only cause of COPD.
3. True or False: Abnormal and permanent enlargement of the airspaces is caused by chronic bronchitis.

Clinical Signs and Symptoms

Any patient presenting with a cough, sputum production, **dyspnea**, or a history of exposure to risk factors needs further assessment to rule out COPD as the cause. The triad of symptoms, cough, sputum production, and dyspnea, is indicative of COPD (**Figure 9-2**).

Although symptom assessment leads to the suspicion that the patient has COPD, spirometry is the gold standard for the diagnosis of COPD (**Table 9-1**). A post-bronchodilator FEV_1/**forced vital capacity (FVC)** of $\leq 70\%$ confirms that airflow limitation exists.

Patients with COPD usually present in one of three ways. Some patients lead an extremely sedentary lifestyle and do not complain much because they avoid dyspnea by limiting their activities. These patients typically mistake shortness of breath for fatigue. Some patients with COPD present with respiratory symptoms and complain of shortness of breath and a chronic cough. The dyspnea is progressive and becomes noticeable at rest. The chronic cough produces sputum, typically <60 mL, early in the morning. During exacerbations, the sputum becomes purulent. Other patients with COPD present with exacerbations of increased cough, purulent sputum, fatigue, shortness of breath, and wheezing. These patients may or may not be febrile.[5]



FIGURE 9-2 These three symptoms combined in any patient should lead the clinician to suspect possible COPD.

Modified from Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive pulmonary Disease; *Am J Respir Crit Care Med.* 2013;187(4):347–365.

TABLE 9-1
Symptoms and Risk Factors of COPD[6]

Spirometry: Required to Establish a Diagnosis	
Symptoms	**Risk Factors**
• Chronic cough • Shortness of breath • Sputum production	• Host factors • Indoor/outdoor pollution • Occupation • Tobacco

The severity of COPD is defined by both the patient's spirometry and their reported symptoms. Visual observation of these patients typically reveals either a thin and underweight or a **cachectic** appearance, typical of emphysema, or a stocky and overweight appearance, typical of chronic bronchitis. Other findings include a barrel-shaped chest, prolonged expiration, and increased resonance on percussion. Digital clubbing is not a characteristic finding with COPD (even with associated hypoxemia). However, the presence of digital clubbing suggests comorbidities such as lung cancer, interstitial lung disease, or bronchiectasis.[7] Lung auscultation can reveal decreased breath sounds, wheezing, bibasilar crackles, and distant heart sounds.[7]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The criteria for establishing airflow limitation are based on FEV_1.
2. True or False: Fatigue can be mistaken for shortness of breath in patients who lead sedentary lives.
3. True or False: Emphysema can cause a patient to look cachectic.

Etiology

It is estimated that 16 million people in the United States have COPD. When you take into consideration all those who are undiagnosed, that number could be millions more. It is the third leading cause of death in the United States, causing 120,000 deaths annually.[11] Cigarette smoking is the primary cause of COPD, but not the only cause.

AATD also contributes to the incidence of COPD. AAT is synthesized primarily by the liver and then released into the bloodstream. Its function is to protect the lungs by blocking the effects of **neutrophil elastase (NE)**. NE is secreted by neutrophils in response to infection or irritants to digest damaged tissue in the lungs. AAT binds to the excess NE, which results in inactivation of the protease. Without AAT, the lungs are left vulnerable to NE. Patients with AATD who smoke or are exposed to tobacco smoke typically present with respiratory problems at an earlier age due to the accelerated appearance of symptoms and damage to the lungs.[12]

Oxidative stress may also play a role in the development of COPD. Cigarette smoke and other particulates that are inhaled chronically generate oxidants that activate inflammatory genes and stimulate mucus secretion.[6] Nonsmokers can develop COPD due to chronic exposure to organic and inorganic dusts.

The etiology of acute exacerbations of COPD (AECOPD) is complex and includes mucous plugging, regional atelectasis, inhalation of environmental irritants, changes in temperature, discontinuation of medications,



FIGURE 9-3 Common causes of acute exacerbations of COPD.

Reproduced with permission from Anzueto A. Primary care management of chronic obstructive pulmonary disease to reduce exacerbations and their consequences. *Am J Med Sci.* 2010:340(4):309–318. doi:10.1097/MAJ.0b013e3181e40cd1.

deviation from diet, viral infections, atypical bacteria, and common bacterial infections[13] (**Figure 9-3**). The most common bacteria that cause AECOPD include *Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis*, and *Pseudomonas aeruginosa*.[14] Common viruses with the potential to cause AECOPD include human adenovirus, human coronavirus, human metapneumovirus, influenza virus, human parainfluenza virus, human rhinovirus, and respiratory syncytial virus.[15] Exacerbations of COPD are associated with significant morbidity, mortality, decreased quality of life, and increased healthcare resource utilization.[16]

KNOWLEDGE CHECK QUESTIONS

1. True or False: NE inactivates AAT.
2. True or False: Air pollution plays a role in the etiology of acute exacerbations of COPD.
3. True or False: Exacerbations of COPD have no effect on the overall quality of life of patients with COPD.

Epidemiology

COPD is a leading cause of morbidity and mortality worldwide, and results in an economic and social burden that is both substantial and increasing.[5] It is the fourth leading cause of death in the United States.[3] According to WHO estimates, 65 million people have moderate-to-severe COPD.[17] Irrespective of world region and independent of prevalence within a world region, COPD is substantially underdiagnosed,[3] with only about 10–15% of all cases identified. A contributing factor to underdiagnosis is the failure of clinicians and patients to recognize the significance of symptoms.[18]

A significant portion of the total cost of this disease is associated with exacerbations.[10] An estimated 29 million (15%) Americans ages 20–79 years are living with obstructive lung disease, but only 13 million, or 6.5%, of these adults are aware of their diagnosis.[3] Many people who know their diagnosis are unaware of the specifics of their disease and the severity of it. In 2012, COPD exacerbations accounted for 1.8 million emergency department visits, with an estimated 20% subsequently admitted to the hospital.[3] The Centers for Medicare and Medicaid (CMS) have instituted mandates that require healthcare institutions to manage COPD patients in such a way as to diminish readmissions and improve the quality of life of the patient. The goal is to reduce the readmission rate and the financial burden of the disease on the healthcare system in the United States.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Underdiagnosis of COPD is a significant issue worldwide.
2. True or False: Diagnosis of COPD does not necessarily mean the patient understands the disease process.

Pathology/Pathophysiology

The pathophysiologic changes of COPD occur in the central and peripheral airways, lung parenchyma, and pulmonary vasculature. Inhaled tobacco smoke and other irritants cause inflammation, an ordinarily protective mechanism, to become chronic, leading to tissue destruction and impairment of pulmonary defense mechanisms. The repeated exposure to tobacco smoke and other irritants causes repeat injury and an increase in inflammatory cells resulting in small airway fibrosis. Lung inflammation can persist after smoking cessation or elimination of occupational exposure. The extent of inflammation, fibrosis, and luminal exudates in the small airways correlates with the decrease in FEV_1 and FEV_1/FVC that is characteristic of COPD.[6] This inflammation is different from the inflammation indicative of asthma. The inflammation in COPD involves neutrophils, oxidative stress, and an excess of proteinases.[6]

Destruction of small airways caused by inflammation and narrowing of the airways leads to airflow limitation demonstrated by a reduction in FEV_1. The added destruction of lung parenchyma by excess proteinases and loss of support of the small airways results in the air-trapping or lung hyperinflation characteristic of COPD (**Figure 9-4**). Lung parenchyma destruction and pulmonary capillary apoptosis reduce the surface area for gas exchange and create **ventilation–perfusion ratio (V/Q)** mismatch. Consequently, hypoxemia develops. The reduced airway caliber, due to mucosal edema, airway fibrotic remodeling, and mucous impaction, increases airway resistance. The weakening of elastic tissue generates inadequate inward lung elastic recoil pressures to cause movement of air out of the lungs.[19] Together, the increased airway resistance and the lack of elastic recoil prolong the removal of carbon dioxide from the lungs. The chronic hypercarbia that develops causes the normal chemoreceptor response to carbon dioxide to recalibrate and breathing becomes a response only to low levels of oxygen (hypoxic drive).

Mucus hypersecretion is a feature of chronic bronchitis, which is caused by hypertrophy of the submucosal glands and an increase in the number of goblet cells of the airway. This hypersecretion alone does not necessarily result in airflow limitation but does contribute to a chronic cough.

Several types of emphysema have distinct pathologic features, dependent on the location and distribution of the destruction. The two most important types are **panlobular (panacinar) emphysema** and **centrilobular (centriacinar) emphysema**.[20] In both, there is weakening and enlargement of alveoli distal to the terminal bronchioles. The entire **acinus** is affected with dilatation and destruction. Panlobar emphysema typically occurs in the lower parts of the lung and is common with AATD. Centrilobular emphysema affects the proximal respiratory bronchioles, particularly in the upper portions of the lung. The most common form of emphysema is centrilobular emphysema, which has a strong association with cigarette smoking.

Due to the chronic alveolar hypoxia of COPD, hypoxic vasoconstriction of the pulmonary vasculature develops. Pulmonary vasoconstriction increases **pulmonary vascular resistance (PVR)**, causing elevation of pulmonary artery pressures resulting in pulmonary arterial hypertension (PAH). The continuous backup of pressures and resultant persistent increases in right ventricular pressure leads to the characteristic sequelae of right heart failure, or cor pulmonale. Most moderate-to-severe COPD patients develop some degree of mild PAH (25–35 mm Hg) over the course of time, and rarely severe PAH (>45 mm Hg). PAH is a known independent prognostic marker of COPD.[19] Each COPD exacerbation increases pulmonary arterial pressure and can cause full-fledged PAH on recurrent episodes.



FIGURE 9-4 Pathophysiologic changes occurring in the lung of patients with COPD.

Brashier B, Kodgule R. Risk factors and pathophysiology of chronic obstructive pulmonary. *J Assoc Physicians India.* 2012;60(Suppl):17–21 (Figure 3, p. 19) https://www.ncbi.nlm.nih.gov/pubmed/23155808. Accessed May 9, 2018.



FIGURE 9-5 Summary of the pathophysiology of COPD and its physical consequences for the patient.

Reproduced with permission from Cooper C. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. *Am J Med.* 2006;119(10):21–31. doi:10.1016/j.amjmed.2006.08.004.

Exacerbations of COPD are usually triggered by bacterial and viral infections, or environmental pollutants, or a combination of these factors. However, up to 30% of AECOPD is of unknown etiology.[21] However, each acute exacerbation causes an increase in inflammation, hyperinflation, air trapping, and dyspnea. The classifications of AECOPD include mild, moderate, and severe. Severe exacerbations can cause acute respiratory failure. A history of earlier treated exacerbations is the best predictor of future frequent exacerbations.[6]

Systemic features of COPD include skeletal muscle wasting, increased cardiovascular disease osteoporosis, anemia, and depression. Having moderate-to-severe shortness of breath makes it difficult to breathe and eat. Shortness of breath is not conducive to eating. Failure to eat causes further muscle wasting and poor nutrition, leading to an increase in the work of breathing and further muscle weakness. As the patient's condition worsens on a day-to-day basis with shortness of breath, an inability to carry out the activities of daily living ensues, the patient suffers from depression (**Figure 9-5**).

KNOWLEDGE CHECK QUESTIONS

1. True or False: Fibrosis and small airway exudates, along with chronic inflammation, decrease lung function in COPD.
2. True or False: The inflammation associated with COPD is the same as the inflammation associated with asthma.
3. True or False: Reduction in lung elasticity plays a role in hyperinflation.
4. True or False: Submucosal gland hypertrophy and goblet cell proliferation are indicative of chronic bronchitis.
5. True or False: Centrilobular emphysema is common with AATD.

Risk Factors

Risk factors for the development of COPD include tobacco smoke and indoor and outdoor environmental exposures. See **Box 9-2**. However, smoking is the most critical risk factor for the development of COPD, amounting to almost 85% of the COPD cases; the remaining 15% are nonsmoking related.[19] The nonsmoking risk factors for COPD include the burning of **biomass fuel**, such as wood, cow dung, and crop residuals, which releases an array of air pollutants. Chronic exposure to pollutants like sulfur dioxide, carbon monoxide, nitrogen dioxide, formaldehyde, and particulate matters smaller than 10 μm in size leads to COPD.[19]

Genetics plays a role in the development of COPD due to AATD. Although AATD is one of the most common inherited conditions[22] affecting about 1 in 2,000–5,000 individuals, it is underdiagnosed and accounts for a small percentage of COPD cases.[12]

KNOWLEDGE CHECK QUESTIONS

1. True or False: 10 years of exposure to biomass fuel burning is a risk factor for COPD development.
2. True or False: Men are at higher risk for developing COPD than women.
3. True or False: Chronic exposure to aerosolized particulate matter of less than 10 μm in size increases the risk of developing COPD.

BOX 9-2 Risk Factors for the Development of COPD[3,7,19]

- Tobacco smoke (≥10–15 pack-years)
- Indoor air pollution from heating and cooking with biomass fuel in poorly ventilated homes (≥25 years of exposure)
- Occupational exposure to organic and inorganic dusts found in fertilizer manufacturing, explosive manufacturing, petroleum refining, farming, food product manufacturing, welding, cement industry, granite industry, and more
- Outdoor air pollution, especially when an individual has reduced lung volumes from previous tuberculosis, early childhood recurrent lower respiratory infections, or poor nutrition
- Female gender
- Old age
- Low-socioeconomic status

Complications

Patients with COPD are at an increased risk of developing perioperative complications and have increased mortality.[23] These patients are at higher risk for the development of postoperative pulmonary complications such as pneumonia, reintubation following extubation, and prolonged intubation. Poorly controlled COPD carries a higher risk for perioperative complications than controlled COPD.

Cor pulmonale was once considered a common complication of COPD, causing an increase in right ventricular mass and right ventricular dysfunction. However, contemporary literature on cor pulmonale in COPD demonstrates that the more severe COPD is associated with smaller right ventricular volumes. The finding of reduced right ventricular volumes contradicts the classical paradigm of cor pulmonale in COPD, defined as an increase in right ventricular mass and volume in the setting of lung disease with or without right ventricular dysfunction. The reduced right ventricular volume appears to be the more common right ventricular phenotype in COPD in the U.S. general population without overt cardiovascular disease and is better known as cor pulmonale parvus.[16] The reasons for cor pulmonale parvus may include impaired venous return to the right heart due to gas trapping, diaphragmatic impingement on the inferior vena cava due to pulmonary hyperexpansion, right heart stiffness and distortion, right ventricular diastolic dysfunction, and reduced blood volume.[16]

COPD patients are at a higher risk for the development of cardiovascular diseases because airflow limitation is a predictor of future risks of hypertension and cardiovascular events. COPD worsens over time no matter the level of patient care.[24] Other complications that affect patients with COPD include respiratory infections (including pneumonia), pneumothorax, lung cancer, and depression.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Perioperative complications and surgical mortality are higher in patients with uncontrolled COPD.
2. True or False: Reduced right ventricular volume, commonly seen in the COPD population in the United States, is called cor pulmonale parvus.
3. True or False: COPD patients usually develop hypotension.

Diagnostic Testing

When diagnosing a patient who presents with dyspnea, cough and sputum production, spirometry, lung volumes, diffusing capacity, and chest radiograph aid in the diagnosis of COPD. Spirometry plays a major role in the diagnosis and assessment of the severity of airflow obstruction for prognosis and follow-up assessment of patients who have risk factors for COPD or present with the signs and symptoms of COPD.

Chest radiography is obtained during the evaluation of a patient with COPD to exclude alternative diagnoses or evaluate for comorbidities such as lung cancer, pneumonia, pneumothorax, or heart failure. Imaging is not required to diagnose COPD. However, advanced COPD typically reveals a flattened left and right hemidiaphragms due to hyperinflation. The heart silhouette appears elongated because the heart rests predominantly on the left hemidiaphragm. The intercostal spaces appear widened due to hyperinflation, along with an increase in the **anterior–posterior (A–P) diameter**. The patient's retrosternal space can be increased because of air trapping[7] (**Figure 9-6**).

Pulmonary function testing is the cornerstone of the evaluation for patients who are suspected of



FIGURE 9-6 Chest radiograph of a patient with COPD. Hyperinflation is evidenced by the widened space between ribs, increased radiolucency, and a long, narrow heart shadow.

TABLE 9-2
Classification of Airflow Limitation Severity in COPD in Patients with FEV_1/FVC <0.70 (Based on Post-bronchodilator FEV_1)

GOLD Classification	Severity	Spirometric Cut Points
GOLD 1	Mild	FEV_1 ≥80% of predicted
GOLD 2	Moderate	50% ≤ FEV_1 <80% of predicted
GOLD 3	Severe	30% ≤ FEV_1 <50% of predicted
GOLD 4	Very Severe	FEV_1 <30% of predicted

Data from Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 Report; 2018.

having COPD. Patients with COPD have pulmonary function test findings that reveal decreases in all expiratory flow rates and increased total lung capacity (TLC). When performing spirometry, an FEV_1/FVC ratio of <70% of the predicted value establishes that the patient has airflow limitation. The post-bronchodilator FEV_1 establishes the severity of the airflow limitation. **Table 9-2** shows the **Global Initiative for Chronic Obstructive Lung Disease (GOLD)** guidelines for COPD diagnosis and classification of airflow limitation severity. Airflow limitation that is irreversible or only partially reversible with bronchodilator is the characteristic physiologic feature of COPD.[7]

To further determine whether the airflow limitation is irreversible, a pre- and post-bronchodilator flow–volume loop (FVL) is also performed. Patients



FIGURE 9-7 An FVL from a patient with severe emphysema (COPD).

with COPD show the characteristic dug-out expiratory limb of the FVL (**Figure 9-7**).

Lung volumes can be increased due to hyperinflation from expiratory airflow limitation, particularly the TLC, residual volume (RV), and functional residual capacity. Emphysema destroys lung tissue, leading to loss of elastic recoil, allowing the lungs to be stretched to abnormally large volumes. The loss of elastic recoil increases the TLC. RV can also be increased in COPD when disease progression destroys the elastic tethers that help hold small airways open during exhalation. The loss of elastic tethers leads to premature closing of the airways and causes abnormal amounts of air to be trapped in the lung.[25]

The diffusing capacity of the lung for carbon monoxide (D_LCO) measures how easily carbon monoxide molecules cross the alveolar–capillary membrane. In COPD, the D_LCO decreases with increasing severity of the disease due to the lower amount of surface area available for diffusion.[25] This is due to the destruction of the alveolar walls and pulmonary capillary bed. An ABG can quantify the amount of hypoxemia the patient has, as well as determine the level of hypoventilation the patient is experiencing.

The alveolar hypoxemia associated with COPD causes specific changes in oxygenation indicators but is not necessary for the diagnosis of COPD. There is typically an increase in pulmonary shunting (Q_S/Q_T) due to ventilation–perfusion mismatch and a decrease in total oxygen delivery (DO_2) due to the reduction in oxygen crossing the alveolar-capillary membrane. Oxygen consumption (VO_2) is normal because the tissue cells

do not change oxygen requirements. There may be an increase in the oxygen extraction ratio (O_2ER) because the oxygen available to the tissues has decreased. The decreased availability of oxygen reduces the mixed venous oxygen saturation (SVo_2) because the tissues continue to have the same requirements with less available oxygen (**Table 9-3**).

Measurement of symptoms is subjective; however, it is necessary for the assessment of the patient's overall health status and guiding therapy. One of the tools used for this type of evaluation is the **Modified Medical Research Council (mMRC) Dyspnea Scale**. The mMRC Dyspnea Scale assesses patient perception of "shortness of breath"[6] (**Table 9-4**).

TABLE 9-3
Typical Pulmonary Function Test Results for COPD[26]

Parameter	Value
FEV_1	Decreased
FEV_1/FVC	Decreased
TLC	Increased
RV	Increased
D_LCO	Decreased
Q_S/Q_T	Increased
DO_2	Decreased
VO_2	Normal
O_2ER	Increased
SVo_2	Decreased

TABLE 9-4
The mMRC Dyspnea Scale

Description	Grade
"I get breathless only with strenuous exercise."	0
"I get short of breath when hurrying on the level or walking up a slight hill."	1
"I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level."	2
"I stop for breath after walking about 100 yards or after a few minutes on the level."	3
"I am too breathless to leave the house" or "I am breathless when dressing."	4
Grade	

Data from Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary Disease, 2018 Report; 2018.

Shortness of breath can be very subjective, as is pain, but how the patient feels is vital in the treatment of symptoms. How the patient feels about his/her symptoms determines the level of activity the patient is willing to undertake. The mMRC Dyspnea Scale is best utilized to establish baseline functional impairment and is a component of a multifaceted assessment and treatment approach to patients with COPD (https://www.mdcalc.com/mmrc-modified-medical-research-council-dyspnea-scale).

Another assessment tool used as part of the multifaceted assessment is the **COPD Assessment Test (CAT).** The CAT is an eight-item unidimensional measure of health status impairment in COPD. **Figure 9-8** shows the items assessed in the CAT. The role of the CAT is to supplement information obtained from lung function measurement and assessment of exacerbation risk.[27]



FIGURE 9-8 Items used to measure the status of COPD.



FIGURE 9-9 The refined ABCD assessment tool for COPD. Step 1 in this process is the confirmation of the diagnosis of COPD by post-bronchodilator $FEV_1/FVC < 0.7$. Step 2 is the assessment of airflow limitation and classification of severity using the post-bronchodilator FEV_1. Step 3 is the assessment of symptoms using either the mMRC Dyspnea Scale or the CAT. Step 4 is the classification of exacerbation history. The symptom assessment and exacerbation history classify the patient in one of four boxes or groups, A, B, C, or D. These groups are used to determine treatment.

Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease. 2018 (Figure 2.4, page 33). http://goldcopd.org.

BOX 9-3 Example of the ABCD Assessment Tool for COPD

Spirometry confirms that a patient has a diagnosis of COPD based on a 35 pack-year smoking history, the presence of a chronic cough, and post-bronchodilator FEV_1/FVC of 0.58. The patient's post-bronchodilator FEV_1 is 51% of the predicted value, which establishes the patient with a GOLD 2 classification of moderate airflow limitation. This patient has a CAT score of 12. The patient has had three exacerbations in the past year. Utilizing the ABCD assessment tool in Figure 9-9, this currently classifies the patient into the GOLD grade 2, Group D.

The assessment of symptoms is combined with the risk of exacerbations and the evaluation of airflow limitation to create the ABCD assessment tool.[6] The risk of exacerbations is based on the history of exacerbations and exacerbations leading to hospital admissions (**Figure 9-9** and **Box 9-3**).

There are no diagnostic laboratory tests for COPD. However, specific criteria are sometimes used to exclude other causes of shortness of breath and comorbid diseases. These tests include hemoglobin because anemia is a cause for dyspnea. However, patients with COPD can have polycythemia as a compensatory mechanism for chronic hypoxemia. Measurement of the plasma brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) concentrations identifies heart failure as a differential diagnosis. Other laboratory tests used for differential diagnoses include blood glucose levels, urea nitrogen, creatinine, electrolytes, calcium, phosphorous, and thyroid-stimulating hormone.[7] Any patient diagnosed with COPD should have the test for the AATD, especially if the patient is 45 years old or younger.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Chest radiography is necessary for the diagnosis of COPD.
2. True or False: A patient with a post-bronchodilator FEV_1/FVC of 0.70 and FEV_1 of 60% of the predicted value has moderate airflow limitation.
3. True or False: COPD does not affect oxygen consumption (VO_2).
4. True or False: The mMRC Dyspnea Scale assesses the health status of patients with COPD.
5. True or False: COPD patients younger than 45 years should be tested for AATD.

Treatment and Management

Once a patient receives the diagnosis of COPD, the next step is to relieve the symptoms of airflow limitation, sputum production, and cough, and improve exercise tolerance and health status. Additionally, the goal of treatment is to reduce risk by minimizing exacerbations, preventing disease progression, and reducing mortality.[6] Treatment, therefore, should decrease emergency department visits and hospitalizations.

Long-Term Treatment

Inhaled medications, including long-acting beta$_2$-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), and inhaled corticosteroids (ICSs) in combination with LABAs, are the mainstay of maintenance therapy for COPD. See **Box 9-4**. Other medications that are added to combinations of LAMAs, LABAs, and ICSs include methylxanthines, oral glucocorticoids, and phosphodiesterase-4 (PDE4) inhibitors. These treatments improve the airflow limitation and reduce airway secretions, thereby decreasing dynamic hyperinflation at rest and with exercise.[6]

Based on the ABCD assessment tool (**Figure 9-10**), the treatment for patients in Group A is based on the treatment's effect on breathlessness. These patients require either a short-acting beta-adrenergic agonist (SABA) or a LABA. Initial long-term maintenance treatment for patients in Group B consists of monotherapy with either a LABA or a LAMA and, if symptoms persist, combination therapy with LABA/LAMA. No evidence exists that recommends one class of long-acting bronchodilator over another for the initial relief of symptoms in Group B patients. Group B patients typically have comorbidities that may add to their breathlessness and impact their prognosis. Initial long-term therapy for Group C patients consists of a LAMA. If symptoms persist for Group C patients using only a LAMA, conversion to combination therapy is recommended. This combination can be in the form of either a LABA/LAMA or LABA/ICS, with the LABA/LAMA being the primary choice due to the increased risk of pneumonia with the use of ICSs. Group D patients need to begin initial therapy with a LABA/LAMA combination and not a LABA/ICS combination because these patients have a higher risk of developing pneumonia when treated with ICSs. If the Group D patient has asthma–COPD overlap, the LABA/ICS can be the first choice for initial therapy. Persistent symptoms in Group D patients may require the addition of an ICS to the LABA/LAMA combination (triple inhaled therapy). When a Group D patient is receiving triple inhaled treatment and is still experiencing exacerbations, a PDE4 medication, roflumilast, or a macrolide, azithromycin, can be considered for use.[6] This tool helps the clinician to determine initial therapy and steps to take if symptoms persist.

In addition to COPD maintenance therapy, patients with AATD and an FEV$_1$ of 30–60% predicted typically receive AATD augmentation therapy.[28] This therapy may slow down the progression of emphysema by replacing the deficient protein. This therapy does not restore lost lung function. There are four augmentation drugs available in the United States: Prolastin-C®, Aralast NP™, Zemaira®, and Glassia®. These drugs are administered by infusions.

Nonpharmacologic measures for the treatment of patients in Groups A to D include smoking cessation

BOX 9-4 Commonly Used Medications for the Long-Term Management of COPD[6]

LABAs

- Arformoterol (liquid for nebulization)
- Formoterol (DPI)
- Indacaterol (DPI)
- Olodaterol (soft mist inhaler)
- Salmeterol (DPI and MDI)

LAMAs

- Aclidinium bromide (DPI and MDI)
- Glycopyrronium bromide (DPI)
- Tiotropium (DPI and soft mist inhaler)
- Umeclidinium (DPI)

LABAs/LAMA Combination Inhalers

- Formoterol/aclidinium (DPI)
- Formoterol/glycopyrronium (MDI)
- Indacaterol/glycopyrronium (DPI)
- Vilanterol/umeclidinium (DPI)

LABAs/ICS Combination Inhalers

- Formoterol/beclomethasone (MDI)
- Formoterol/budesonide (DPI and MDI)
- Formoterol/mometasone (MDI)
- Salmeterol/fluticasone (DPI and MDI)
- Vilanterol/fluticasone furoate (DPI)

LABAs/LAMA/ICS

- Vilanterol/umeclidinium/fluticasone furoate (DPI)

PDE4 Inhibitors

- Roflumilast (pill)

Methylxanthines

- Theophylline slow release (pill)



Preferred treatments are indicated by blue boxes and arrows

In patients with a major discrepancy between the perceived level of symptoms and severity of airflow limitation, further evaluation is warranted.

FIGURE 9-10 Pharmacologic treatment algorithms by GOLD grade. See text for explanation.

Reproduced with permission from Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 Report. 2018 (Figure 41, p. 83). http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.

(**Box 9-5**), physical activity, flu vaccination, and pneumococcal vaccination, and for patients in Groups B to D pulmonary rehabilitation. Pulmonary rehabilitation can improve the patient's symptoms and activities of daily living and can reduce the number of future exacerbations.

Patients in all groups need to become active partners in their ongoing care through self-management education. COPD self-management intervention is typically structured but personalized and often multifaceted, with the goals of motivating, engaging, and supporting patients to positively adapt their health behaviors and develop skills to manage their disease better.[30] Self-management intervention is based on frequent interactions between disease management clinicians and patients. The goal of these patient-centered interactions is to identify patient needs, health beliefs, and motivations; identify personalized patient goals; formulate appropriate management strategies to achieve the goals; and evaluate and readjust plans.[30] Patients with moderate-to-severe COPD who receive a self-management education with supervision and support of a case manager have better outcomes than patients receiving standard care. The benefits are on patients' health status and healthcare utilization with markedly decreased hospitalizations and emergency department and unscheduled physician visits.[31]

Long-term oxygen therapy (LTOT) is commonly used for stable COPD patients who have Pao_2 at or below 55 mm Hg or oxygen saturation below 88%, with or without hypercapnia confirmed twice over a 3-week period. LTOT has been shown to increase the survival of patients with severe chronic resting arterial hypoxemia. Noninvasive positive pressure ventilation may be used with stable, but very severe COPD patients, especially if they have daytime persistent hypercapnia ($Paco_2 \geq 52$ mm Hg).[6]

In some cases, **lung volume reduction surgery (LVRS)** can be useful especially in patients with low exercise

BOX 9-5 Pharmacologic and Nonpharmacologic Methods for Treating Tobacco Dependence[29]

Pharmacologic Methods

- Nicotine replacement
  - Patch
  - Gum
  - Lozenge
  - Inhaler
  - Nasal spray
- Non-nicotine replacement
  - Varenicline (pills)
  - Bupropion SR (pills)

Nonpharmacologic Methods

- Behavioral counseling
  - Individual counseling
  - Group counseling
  - Telephone quit-line counseling
- Physician counseling
  - Brief advice
  - Brief counseling

BOX 9-6 Commonly Used Medications for the Treatment of Acute Exacerbations of COPD[6]

Short-Acting Beta$_2$-Agonists

- Albuterol (DPI, MDI, and liquid for nebulization)
- Levalbuterol (MDI and liquid for nebulization)

SAMAs

- Ipratropium bromide (MDI and liquid for nebulization)

Short-Acting Beta$_2$-Agonist/SAMA Combinations

- Albuterol/ipratropium (soft mist inhaler and liquid for nebulization)

Systemic glucocorticoids

capacity before surgery. LVRS is a surgical procedure in which parts of the lungs are resected to reduce hyperinflation, making respiratory muscles more effective pressure generators by improving their mechanical efficiency. LVRS increases elastic recoil pressure of the lungs, thus improving expiratory flow rates and reducing exacerbations.[4] This surgery is not undertaken lightly as these patients already have significant pulmonary dysfunction.

Treatment of Exacerbations

Acute exacerbations are treated with SABAs and short-acting muscarinic receptor antagonist. See **Box 9-6**. Antibiotics in COPD should be used only if an infection is present. Patients with COPD are generally older than asthma patients and have comorbid conditions; therefore, the risks of adverse reactions to medication therapy increase.

Acute COPD exacerbations are triggered most commonly by respiratory infections, with viral and bacterial infections being the most common cause. However, environmental factors such as pollution and ambient temperature may also initiate or amplify these events.[4] Physical findings frequently include wheezing, tachypnea, inability to speak in full sentences, accessory muscle use, and paradoxical chest wall motion. Patients with hypercapnia or hypoxemia may present with altered mental status. High oxygen concentrations are typically not required to correct the hypoxemia associated with most exacerbations of COPD. The target oxygen saturation for these patients is 88–92%.[6] The inability to correct hypoxemia with up to 4 L/minute nasal cannula or 35% air-entrainment mask may be due to pulmonary emboli, acute respiratory distress syndrome, pulmonary edema, or severe pneumonia as the cause of the respiratory failure.[32]

Acute exacerbations' classification includes mild, moderate, or severe. Mild exacerbations can be treated with a SABA and can often be taken care of at home. Moderate and severe exacerbations require the addition of antibiotics and systemic glucocorticoids, noninvasive positive pressure ventilation (NIPPV), or invasive mechanical ventilation. Each exacerbation, whether mild, moderate, or severe, has a significant impact on the health status of the patient.[6] This impact is why exacerbation prevention is of utmost importance. The need for hospitalization during a COPD exacerbation is dependent on the patient signs and symptoms, and the clinical presentation of COPD exacerbations is heterogeneous.

Antibiotics are used in the treatment of exacerbations of COPD only if the patient presents with increases in dyspnea, sputum volume, and sputum purulence or requires NIPPV or invasive mechanical ventilation. NIPPV is preferred over invasive mechanical ventilation because NIPPV improves many clinical outcomes for patients with exacerbations of COPD. See **Box 9-7**. Failure of NIPPV is an indication for the use of invasive mechanical ventilation. See **Box 9-8**.

BOX 9-7 Indications for NIPPV for COPD

At least one of the following clinical findings:

- Respiratory acidosis (pH ≤7.35 with $Paco_2$ ≥45 mm Hg)
- Severe dyspnea with clinical signs suggestive of respiratory muscle fatigue, or increased work of breathing, or both, such as the use of respiratory accessory muscles, paradoxical motion of the abdomen, or retraction of the intercostal spaces
- Persistent hypoxemia despite supplemental oxygen therapy

Data from Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 Report. 2018.

BOX 9-8 Indications for Invasive Mechanical Ventilation for COPD[6]

- Inability to tolerate NIPPV or NIPPV failure
- Status post respiratory or cardiac arrest
- Diminished consciousness, psychomotor agitation inadequately controlled by sedation
- Massive aspiration or persistent vomiting
- Persistent inability to remove respiratory secretions
- Severe hemodynamic instability without response to fluids and vasoactive drugs
- Severe ventricular or supraventricular arrhythmias
- Life-threatening hypoxemia in patients unable to tolerate NIPPV

KNOWLEDGE CHECK QUESTIONS

1. True or False: ICSs are the first-line medications for the long-term maintenance of COPD.
2. True or False: The ABCD assessment tool helps determine initial therapy for the long-term management of COPD.
3. True or False: Lung augmentation therapy restores lung function to patients with COPD due to AATD.
4. True or False: COPD patients confirmed with oxygen saturations less than 88% benefit from LTOT.
5. True or False: NIPPV is preferred over invasive mechanical ventilation for the treatment of acute respiratory failure due to COPD.

Prognosis

There is no cure for COPD. However, the progression can be slowed down to give the patient the chance to live a long life while maintaining activities of daily living as much as possible. Each exacerbation of COPD is associated with increased mortality.[6] The mortality rate within the hospital ranges from 3% to 9% and estimates for death within 3 months of admission are 14%.[32]

A multidimensional index, the **BODE index**, is an assessment tool that may be used to assess an individual's risk of death from COPD and can predict hospitalization.[33] This index is based on four factors, including (B) body mass index (BMI), (O) airway obstruction severity (FEV_1), (D) dyspnea (mMRC Dyspnea Score), and (E) exercise capacity (6-minute walk distance) (**Table 9-5**).

TABLE 9-5
The BODE Index for COPD Survival

Factor	Measurement	Score
Body mass index values	BMI >21 kg/m^2	0
	BMI <21 kg/m^2	+1
Airway **o**bstruction values	FEV_1 ≥65% of predicted	0
	FEV_1 50–64% of predicted	+1
	FEV_1 36–49% of predicted	+2
	FEV_1 ≤35% of predicted	+3
Dyspnea Scale (mMRC)	Dyspnea when hurrying or walking up a slight hill	0
	Walks slower than people of the same age because of dyspnea or stops for breath when walking at own pace	+1
	Stops for breath after walking 100 yd (91 m) or after a few minutes	+2
	Too dyspneic to leave house or breathless when dressing	+3
Exercise tolerance (6-minute walk distance)	≥350 m (383 yd)	0
	250–349 m (273–382 yd)	+1
	150–249 m (164–272 yd)	+2
	≤149 m (163 yd)	+3
TOTAL		Total the points and place patient score here

Data from https://www.mdcalc.com/bode-index-copd-survival.

TABLE 9-6
Four-Year Survival Predictions Using the BODE Index

Calculated BODE Index (Points)	COPD 4-Year Survival (%)
0–2	80
3–4	67
5–6	57
7–10	18

Data from Marin et al. Prediction of risk of COPD exacerbations by the BODE index. *Resp Med.* 2009;103:373–378.

The BODE index is used to approximate a COPD patient's 4-year survival rate (Table 9-6).[34]

The BODE index is a better predictor of the number and severity of exacerbations in COPD than FEV_1 alone.[32] It can be a useful tool when looking at future COPD exacerbations or COPD survival. It should be used as a tool and not a steadfast predictor of patient outcomes. Outcomes can vary a great deal for each patient. The use of medications and therapies can improve these scores and the patient's quality of life.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The BODE index can help predict hospitalizations in patients with COPD.
2. True or False: The higher the BODE index, the worse the prognosis for the patient.
3. True or False: Outcomes for patients with COPD are variable and therapy can change the BODE index score.

Chapter Summary

Despite COPD being preventable, both the global and the national burden of COPD remain high. COPD is characterized by airflow limitation and obstruction that is not fully reversible. The two diseases associated with COPD are emphysema and chronic bronchitis. However, there may be overlap between COPD and asthma. Today, COPD affects as many women as men. Cigarette smoking is a leading cause of COPD, but not the only cause. The genetic condition AATD, air pollution, and chemical fumes and dust can also result in COPD.

Spirometry and lung volumes are essential in the diagnosis, along with the symptoms reported by the patient. Treatment may be guided by both spirometry and symptoms. Changes to the patient's alveolar–capillary membrane, if untreated, can lead to cardiac problems. As the disease progresses, treatment needs to address the pulmonary dysfunction and patient symptoms to maintain as much of the activities of daily living as possible.

It is essential to educate the public on the hazards of cigarette smoking and indoor/outdoor air pollution to protect public health from this debilitating and costly disease.

Key Points

1. Cigarette smoking is the leading cause of COPD and is an addiction.
2. "Smoker's cough" is a serious sign of underlying pulmonary disease.
3. Airflow limitation, sputum production, and cough are hallmark signs of COPD.
4. Untreated and undertreated COPD can result in right heart dysfunction.
5. The COPD patient's symptoms must be appropriately treated to maintain their activities of daily living.
6. Systemic issues such as skeletal muscle wasting, increased cardiovascular disease, osteoporosis, anemia, and depression need to be addressed.

Chapter Questions

1. Chronic obstructive pulmonary disease (COPD) is the _____ leading cause of death in the United States.
   a. second
   b. fourth
   c. sixth
   d. eighth
2. Which of the following is the leading risk factor for COPD?
   a. Cigarette smoking
   b. Outdoor air pollution
   c. Biomass fuels
   d. Household cleaning solutions
3. Which medications are used regularly for the patient with COPD?
   a. Methylxanthines
   b. Corticosteroids
   c. $Beta_2$ agonists
   d. Antimicrobials
4. Which tool is used to assess the potential risk for exacerbations of COPD?
   a. Modified Medical Research Council (mMRC) Dyspnea Scale
   b. Global Initiative for Chronic Obstructive Lung Disease (GOLD)
   c. Centers for Medicare and Medicaid (CMS)
   d. World Health Organization (WHO)

5. In COPD patients, chronic hypercarbia causes the normal chemoreceptor response to react to _____.
   a. nitric oxide levels
   b. carbon dioxide levels
   c. carbon monoxide levels
   d. oxygen levels
6. In the presence of alveolar hypoxia, the lungs ____ _____.
   a. decompensate because they cannot handle the problem
   b. build new alveoli
   c. constrict the pulmonary capillaries
   d. dilate the pulmonary capillaries
7. The pulmonary function tests of a 63-year-old male reveal an increased total lung capacity (TLC) and increased residual volume (RV) with a decreased forced expiratory volume in 1 second/forced expiratory volume (FEV_1/FVC). These findings are indicative of _____.
   a. pneumonia
   b. COPD
   c. interstitial lung disease
   d. lung cancer
8. Lung volume reduction surgery is useful in the treatment of _____.
   a. COPD
   b. interstitial lung disease
   c. diseases of the chest wall
   d. diseases of the diaphragm
9. _____ is not typical of COPD.
   a. A cough
   b. Sputum production
   c. Shortness of breath
   d. Chest pain
10. According to the combined COPD assessment tool, patients most at risk for an exacerbation are in _____.
    a. Group A
    b. Group B
    c. Group C
    d. Group D

References

1. Galet N. Case Study: Patient with COPD. 2015. https://www.slideshare.net/aaaa-2012/case-study-patient-with-copd. Accessed May 8, 2018.
2. WHO | COPD: Definition. Whoint. 2018. http://www.who.int/respiratory/copd/definition/en. Accessed April 18, 2018.
3. Criner R, Han M. COPD care in the 21st century: a public health priority. *Respir Care*. 2018;63(5):591–600. doi:10.4187/respcare.06276.
4. History of Tobacco in the World—Tobacco Timeline. Tobacco-Free Life. 2018. https://tobaccofreelife.org/tobacco/tobacco-history. Accessed May 10, 2018.
5. Celli B, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J*. 2004;23(6):932–946. doi:10.1183/09031936.04.00014304.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2018 Report. 2018. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed May 11, 2018.
7. Han MK, Dransfield MT, Martinez FJ. Chronic obstructive pulmonary disease: definition, clinical manifestations, diagnosis, and staging. In: Stoller JK, ed. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed May 10, 2018.
8. COPD | National Heart, Lung, and Blood Institute (NHLBI). Nhlbinihgov. 2018. https://www.nhlbi.nih.gov/health-topics/copd. Accessed May 11, 2018.
9. Tsiligianni I, Rodríguez M, Lisspers K, LeeTan T, Infantino A. Call to action: improving primary care for women with COPD. *NPJ Prim Care Respir Med*. 2017;27(1):11. doi:10.1038/s41533-017-0013-2.
10. Akazawa M, Halpern R, Riedel A, Stanford R, Dalal A, Blanchette C. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. *Respir Med*. 2008;102(12):1744–1752. doi:10.1016/j.rmed.2008.07.009.
11. NIH Fact Sheets—Chronic Obstructive Pulmonary Disease (COPD). Reportnihgov. 2018. https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=77. Accessed May 11, 2018.
12. Kaplan A, Cosentino L. Alpha-1 antitrypsin deficiency: forgotten etiology. *Can Fam Physician*. 2010;56:19–24. http://www.cfp.ca/content/56/1/19.long. Accessed May 16, 2018.
13. Dal Negro R, Micheletto C, Tognella S, Visconti M, Guerriero M, Sandri M. A two-stage logistic model based on the measurement of pro-inflammatory cytokines in bronchial secretions for assessing bacterial, viral, and non-infectious origin of COPD exacerbations. *COPD*. 2005;2(1):7–16. doi:10.1081/copd-200050680.
14. King P, MacDonald M, Bardin P. Bacteria in COPD; their potential role and treatment. *Transl Respir Med*. 2013;1(1):13. doi:10.1186/2213-0802-1-13.
15. Frickmann H, Jungblut S, Hirche T, Groß U, Kuhns M, Zautner A. The influence of virus infections on the course of COPD. *Eur J Microbiol Immunol (Bp)*. 2012;2(3):176–185. doi:10.1556/eujmi.2.2012.3.2.
16. Kuwal A, Joshi V, Dutt N, Singh S, Agarwal K, Purohit G. A prospective study of bacteriological etiology in hospitalized acute exacerbation of COPD patients: relationship with lung function and respiratory failure. *Turk Thorac J*. 2018;19(1):19–27. doi:10.5152/turkthoracj.2017.17035.
17. WHO Burden of COPD. WHO. 2018. http://www.who.int/respiratory/copd/burden/en. Accessed May 9, 2018.
18. Soriano J. An epidemiological overview of chronic obstructive pulmonary disease: what can real-life data tell us about disease management? *COPD*. 2017;14(suppl 1):S3–S7. doi:10.1080/15412555.2017.1286165.
19. Brashier B, Kodgule R. Risk factors and pathophysiology of chronic obstructive pulmonary. *J Assoc Physicians India*. 2012;60(suppl):17–21. https://www.ncbi.nlm.nih.gov/pubmed/23155808. Accessed May 9, 2018.
20. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. 6th ed. Philadelphia, PA: Elsevier/Saunders; 2014.
21. Ko F, Chan K, Hui D, et al. Acute exacerbation of COPD. *Respirology*. 2016;21(7):1152–1165. doi:10.1111/resp.12780.
22. Greulich T, Nell C, Herr C, et al. Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003–2015. *Orphanet J Rare Dis*. 2016;11(1):75. doi:10.1186/s13023-016-0453-8.
23. Lumb A, Biercamp C. Chronic obstructive pulmonary disease and anaesthesia. *CEACCP*. 2014;14(1):1–5. https://academic.oup.com/bjaed/article-abstract/14/1/1/336087. Accessed May 13, 2018.
24. Imaizumi Y, Eguchi K, Kario K. Lung disease and hypertension. *Pulse*. 2015;2(1–4):103–112. doi:10.1159/000381684.

25. Bailey K. The Importance of the assessment of pulmonary function in COPD. *Med Clin North Am*. 2012;96(4):745–752. doi:10.1016/j.mcna.2012.04.011.
26. Fletcher E, Levin D. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. *Chest*. 1984;85(1):6–14. doi:10.1378/chest.85.1.6.
27. Jones P, Harding G, Berry P, Wiklund I, Chen W, Kline Leidy N. Development and first validation of the COPD assessment test. *Eur Respir J*. 2009;34(3):648–654. doi:10.1183/09031936.00102509.
28. Sandhaus R, Turino G, Stocks J, et al. α1-Antitrypsin augmentation therapy for PI*MZ heterozygotes. *Chest*. 2008;134(4):831–834. doi:10.1378/chest.08-0868.
29. Rigotti NA. Pharmacology for smoking cessation in adults. In: Stoller JK, Aronson MD. eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed May 12, 2018.
30. Effing T, Vercoulen J, Bourbeau J, et al. Definition of a COPD self-management intervention: International Expert Group consensus. *Eur Respir J*. 2016;48(1):46–54. doi:10.1183/13993003.00025-2016.
31. Bourbeau J. Self-management interventions to improve outcomes in patients suffering from COPD. *Expert Rev Pharmacoecon Outcomes Res*. 2004;4(1):71–77. doi:10.1586/14737167.4.1.71.
32. Stoller JK. Management of exacerbations of chronic obstructive pulmonary disease. In: Barnes PJ. ed. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com. Accessed May 12, 2018.
33. Ong K, Earnest A, Lu S. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. *Chest*. 2005;128(6):3810–3816. doi:10.1378/chest.128.6.3810.
34. Marin J, Carrizo S, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. *Respir Med*. 2009;103(3):373–378. doi:10.1016/j.rmed.2008.10.004.

CHAPTER

10

Cystic Fibrosis and Bronchiectasis

"Remember that life is not measured by the number of breaths we take, but by the moments that take our breath away!"

—Vicki Corona

OUTLINE

OBJECTIVES

1. State the working definition for both cystic fibrosis and bronchiectasis.
2. Define and discuss the clinical manifestations associated with both cystic fibrosis and bronchiectasis.
3. Explain the diagnostic testing used for both cystic fibrosis and bronchiectasis.
4. Summarize the recommended disease management for both cystic fibrosis and bronchiectasis.
5. Identify common complications associated with both cystic fibrosis and bronchiectasis.
6. Define the prognosis for both cystic fibrosis and bronchiectasis.

KEY TERMS

Active cycle of breathing
Adenosine triphosphate-binding cassette (ABC)
Allele
Alpha-1 antitrypsin (AAT)
Ciliary dyskinesia
Cystic fibrosis transmembrane conductance regulator (CFTR)
Cytokines
Dittrich plugs
Gamma globulin
High-frequency chest wall oscillation
Homozygous
Hypertonic saline (HTS)
Immunoreactive trypsinogen (IRT)
Meconium
Mucociliary escalator
Mucolytic
Mucopurulent
Neutrophilic proteases
Pilocarpine
Sweat chloride test
Tenacious
Trypsin

Case Study

A 13-year-old female with cystic fibrosis is directly admitted to the hospital from her pulmonologist's office. The patient is complaining of increased cough and shortness of breath over the past 3 days. The patient's pulse oximeter oxygen saturation (Spo_2) upon admittance is 89% on room air; she is given supplemental oxygen with 2 L/minute nasal cannula, which increases her Spo_2 to 96%. The pulmonologist increased the patient's home regimen, and ordered a posterior–anterior (PA) radiograph, lateral chest radiograph (CXR), and sputum induction for culture and sensitivity. PA radiograph and CXR are positive for hyperinflation, mucus plugging, and bronchial wall thickening. Sputum is positive for gram-negative rods, *Pseudomonas aeruginosa*. The treatment plan includes increasing home nebulizer and vest therapy and adding a broad-spectrum antibiotic (**Table 10-1**).

After 1 week of no marked improvement, the patient's physician decides that a flexible bronchoscopy is needed. The bronchoscopy results show inflammation in the airway suspected to be from the excessive thick, sticky mucus plugs throughout the right and left lung fields. Bronchial washings are performed, and samples obtained. After 3 days, *P. aeruginosa* and methicillin-resistant *Staphylococcus aureus* organisms are isolated. Inhaled tobramycin 300 mg is added twice daily. Oscillatory positive expiratory pressure is added to coincide with nebulizer treatments. High-frequency chest wall oscillation is increased from 15 to 20 minutes four times daily to mobilize retained secretions.

TABLE 10-1
Home Medication Regimen for Case Study Patient

Medication/ Therapy	Home Frequency	Hospital Frequency
Albuterol 2.5 mg	Twice daily and prn	Four times daily and prn
7% NaCl 4 mL	Twice daily	Four times daily
Dornase alfa 2.5 mg	Twice daily	Twice daily
Pulmicort 0.5 mg	Twice daily	Twice daily
Tobramycin 300 mg	N/A	Twice daily
Vest therapy × 15 minutes	Twice daily	Four times daily

Cystic Fibrosis

Although cystic fibrosis (CF) is a systemic disease process, it is the effects on the lungs that continue to be the primary cause of patient morbidity and mortality. The development of respiratory tract infection with certain bacteria is widespread. The rate of progression of this disease is varied, depending on factors such as genetics, environment, and adherence to a daily maintenance plan.

Introduction

European folklore references CF as follows: "Woe to the child which when kissed on the forehead tastes salty. He is bewitched and soon will die."[1] CF is a life-limiting autosomal recessive genetic disorder caused by a mutation in the **cystic fibrosis transmembrane conductance regulator (CFTR)** located on the long arm of chromosome 7.[2] CF was first identified as CF of the pancreas by Dorothy Anderson, MD, a pathologist, in 1938.[3] While conducting an autopsy on a child, who died from what was thought to be celiac disease, the physician noticed a pancreatic lesion. Anderson and her team began extensive medical research, including reviews of past autopsy records and the medical literature. The findings concluded that there was a clear disease pattern, and they named it CF.[2]

The next breakthrough discovery was a result of the New York City heat wave of 1948.[4] Paul di Sant'Agnese, MD, a pediatrician, observed that infants with CF were presenting to emergency departments with hyperthermia and a white powdery substance on their skin. Dr. Sant'Agnese hypothesized that the sweat from these infants was abnormally high in sodium and chloride. This singular discovery leads to the correlation between CF and abnormally high concentrations of salt. Sweat chloride testing is used to this day in the diagnosis of CF.[5] Positional cloning identified the defective CF gene and its protein CFTR in 1989. This development led to better understanding of the disease and more effective treatments, and has improved patient outcomes.[6]

Definition/Diagnosis

CF is a multisystem genetic disease affecting the exocrine glands, respiratory and gastrointestinal systems, and reproductive tract.[7] CF patients inherit two mutated CFTR genes, one **allele** from each parent.[8] The parents are carriers of the mutated gene, and most are asymptomatic. One of the functions of CFTR is to open

the sodium chloride channels.[9] CF causes viscous mucus that builds up in the lungs and blocks the airway, making it difficult to breathe, a breeding ground for bacteria, leading to chronic infection. Mucus normally has a slippery, watery consistency, keeping the lining of certain organs from dehydration and infection. Repeated serious infections over time will scar the lungs and lead to bronchiectasis.[4] The viscous mucus blocks pancreatic ducts, making it difficult for digestive enzymes to reach the small intestine. Pancreatic enzymes aid in breaking down food particles. Without them, fats and proteins are unable to be absorbed through the intestines, causing malnutrition, vitamin deficiency, and failure to thrive.[10]

Clinical Signs and Symptoms

CF manifests in severity and symptoms differently in each person and is progressive. One of the earliest signs is the salty taste of an infant's skin when kissed. Digestive issues can also be noticed within the first few hours after birth. The **meconium** is more viscous in newborn infants with CF, blocking the ileum and causing the infant not to pass stool. Infants with CF may vomit green bile and have swollen hard stomach.[11] CF patients have a strong chronic cough producing viscous sputum and hemoptysis. The build-up of thick, sticky mucus makes it a breeding ground for bacteria and virus to grow, leading to chronic infection, obstruction, and inflammation. When auscultated, breath sounds can demonstrate wheezing or poor aeration. Visual signs include clubbed fingers, which is associated with low arterial oxygen levels and malabsorption in the gastrointestinal tract. The sinus passages are also affected by chronic sinusitis and rhinitis. Frequent pancreatic blockages prevent enzymes needed to break down and absorb fats and proteins in the intestines, causing failure to thrive. The body's inability to absorb fats and proteins creates a foul-smelling, bulky, greasy stool. This stool can block the intestine and cause severe gas and constipation.[12] In males, the dehydrated thickened secretions obstruct the development of the vas deferens (congenital bilateral absence of the vas deferens [CBAVD]), making them sterile.[13] In females, the cervical mucus is thicker than normal, resulting in irregular menstruation, making it difficult to become pregnant.[14] See **Box 10-1**[15] and **Figure 10-1**.

BOX 10-1 Signs and Symptoms Related to CF

Genetics

- Family history
- Two copies of the faulty CFTR gene

Respiratory

- Persistent cough
- Thick, sticky sputum
- Wheezing
- Hemoptysis
- Dyspnea
- Chronic lung infections
- Chronic sinusitis and rhinitis

Digestive

- Meconium ileus (neonatal)
- Greasy, bulky, foul-smelling stool
- Severe gas
- Chronic diarrhea
- Failure to thrive

Reproductive Male

- Sterility

Reproductive Female

- Thick cervical mucus
- Irregular menstruation
- Infertility

Data from Cystic Fibrosis Background and Epidemiology. *Pediat Clin N Am*. 2016;(63):567-584. doi:10.1016/j.pcl.2016.04.001.



FIGURE 10-1 Signs and common disorders of CF. These symptoms are different in different patients. Patients may have one or more of these symptoms.

Reproduced with permission from Farnia P, Mirtajani S, Hassanzad M, Ghanavi J, Farnia P, Velayati A. Geographical distribution of cystic fibrosis; the past 70 years of data analyzis. *Biomed Biotechnol Res J*. 2017;1(2):105 (Figure 1). doi:10.4103/bbrj.bbrj_81_17.

Etiology

A defect in the CFTR gene causes CF. Researchers have identified over 1,900 CFTR mutations. Less than 150 of those known mutations cause CF.[16] It is an autosomal recessive disease, manifesting only when both parents pass on the faulty CFTR allele (**Figure 10-2**). F508del is the most common mutation accounting for approximately 70% of the CF population.[16] The CFTR mutations have been divided into five classes, depending on where the mutation occurs, which organ is affected, and the severity of disease.[17]



FIGURE 10-2 The diagram illustrates how CFTR genes are inherited. People inherit one copy of the CFTR gene from each parent. If the parent is a carrier of the gene (has one normal copy "R" and one mutated copy "r"). Each child has a 25% chance of inheriting two mutated genes causing CF; a 50% chance of inheriting one normal gene and one mutated gene, making them a carrier; and a 25% chance of inheriting two normal genes.

National Heart, Lung, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services. https://www.nhlbi.nih.gov/health-topics/cystic-fibrosis.

Epidemiology

CF is the most common autosomal recessive gene among Caucasians, affecting approximately 1 in every 3,000 white births worldwide. Most of these individuals are born in Europe, North America, and Australia.[1] Approximately 30,000 adults and children are living with CF in the United States, and 40,000 more worldwide. The disease is less common in other ethnicities, affecting 1 in every 7,000 Hispanics, 1 in every 17,500 African Americans, and 1 in every 31,000 Asian Americans[15] (**Figure 10-3**).

Pathophysiology

CF is caused by mutations or changes in the CFTR gene. The CFTR gene provides a code that is needed to produce the CFTR protein. The CFTR protein is a member of the **adenosine triphosphate-binding cassette (ABC)** membrane transporter superfamily.[18] The CFTR



FIGURE 10-3 The difference in the distribution of CF in different continents. Accordingly, the highest rates are in Europe and the lowest rates are in East Asia.

Reproduced with permission from Farnia P, Mirtajani S, Hassanzad M, Ghanavi J, Farnia P, Velayati A. Geographical distribution of cystic fibrosis; the past 70 years of data analyzis. *Biomed Biotechnol Res J.* 2017;1(2):105 (Figure 4). doi:10.4103/bbrj.bbrj_81_17.

gene encodes a CFTR protein channel that is made up of 1,480 amino acids organized into five functional domains: two membrane-spanning domains (MSD1 and MSD2), two nucleotide-binding domains (NBD1 and NBD2), and one cytoplasmic regulatory domain (R)[18]. MSDs are also known as transmembrane domains (TMD1 and TMD2). CFTR mutations can occur in the gene sequence that encodes any of the five protein domains. CFTR acts as a cyclic adenosine monophosphate-dependent chloride ion channel and plays a role in chloride transport across apical epithelial surfaces.[18] The CFTR protein controls salt, fluid, and pH in the intestines, pancreas, lungs, and other organs (**Figure 10-4**).[10] CFTR gene mutations are categorized into six classes based on the way the mutations affect the CFTR protein.[18] Classes one through three are more severe, and four through six are mild[18].

Class I mutations are the most severe altering CFTR protein synthesis. The prevention of stable protein biosynthesis results in a truncated protein caused by a premature termination codon. These truncated proteins are unstable and degraded in the endoplasmic reticulum (ER), resulting in no mature CFTR protein formed. The mutations include Gly542X, Trp1282X, and 1717-1G→A.[4]



FIGURE 10-4 Cystic fibrosis, major affected organs.

Class II mutations affect CFTR protein processing and trafficking. CFTR protein is created but cannot correctly fold in the ER. The misfolded protein is targeted for cellular degradation and keeps the protein from reaching the apical membrane. The most common Class II mutation is F508del.[4]

Class III mutations affect chloride ion channel regulation. The mutated gene in this class creates the CFTR protein as it reaches the cell surface but does not function correctly. The mutation is located within the NBD folds, affecting the binding of cyclic adenosine monophosphate (cAMP), thus preventing channel activation. The CFTR on the cell surface is nonfunctional. Mutations include G551D, V520F, and R560T.[4]

In Class IV mutations, the CFTR protein is encoded, traffics through the cell to the apical membrane, and responds to cAMP stimulation. A decreased chloride ion current is generated and impairs protein function. Class IV mutations are located in the MSDs. Mutations include R117H, R334W, and R347P.[4]

Classes V and VI are the least severe of the faulty CFTR genes. In Class V, a normal CFTR protein is produced and moves to the apical surface but in insufficient quantities. Mutations include A455E, D565G, and 3272-26A>G. Class VI mutations decrease CFTR expression by aiding the channel removal from the plasma membrane, decreasing CFTR stability. Mutations include 4326delTC, Gln1412X, and 4279insA.[4]

Risk Factors

Only one risk factor is associated with CF. If both parents are carriers of the abnormal CF gene, each child has a 25% chance of inheriting both the genes and having CF. Being of European descent may also be considered a risk.[15] The type of mutation a person has impacts the severity of the disease.

Complications

CF affects the pulmonary, digestive, endocrine, and reproductive systems. Pulmonary manifestations vary with severity. Respiratory failure is the leading cause of death in persons with CF. Respiratory failure is brought on by thick, **tenacious** sputum, which blocks the airways, causing inflammation, chronic infection, and hemoptysis. Over time this chronic injury to the lungs causes tissue damage, inflammation, scarring, and bronchiectasis.[4] Individuals with CF are prone to suffer from recurrent bouts of pneumonia due to the abnormal mucus and reduced water content in their airways. Some individuals with CF develop cor pulmonale due to increased pulmonary vascular resistance, especially when pulmonary symptoms are primary (**Figure 10-5**).



FIGURE 10-5 The vicious cycle of CF.

Reproduced with permission from Kreindler J. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. *Pharmacol Ther*. 2010;125(2):219–229 (Figure 2). doi:10.1016/j.pharmthera.2009.10.006.

Chronic sinusitis and rhinitis lead to the formation of nasal polyps, that is, soft, painless growths in the lining of the nose. Surgery may be needed to remove polyps if the nasal cavity is obstructed.[19] The mucosal lining of the pancreas and intestines is dehydrated in people with CF. Pancreatic dehydration may lead to pancreatic insufficiency, which causes CF-related diabetes. Annual testing is usually required starting at the age of 10. Other nutritional deficiencies include blocked bile duct, intestinal obstruction, and distal intestinal obstruction. Oral enzymes are taken to aid in nutritional absorption. Electrolyte imbalances occur because large amounts of salt are lost during sweating. This causes dehydration, tachycardia, fatigue, weakness, hypotension, and heat stroke.[10] See **Box 10-2**.

BOX 10-2 Common Complications Caused by CF

Pulmonary

- Repeated pneumonia
- Bronchiectasis
- Pneumothorax
- Cor pulmonale
- Nasal polyposis

Gastrointestinal

- "Failure to thrive"
- Distal intestinal obstruction
- Hyperglycemia
- Rectal prolapse
- Liver cirrhosis

Reproductive

- Delayed puberty
- Male infertility
- Female infertility

Data from Cystic Fibrosis Background and Epidemiology. *Pediat Clin N Am*. 2016;(63):567-584. doi:10.1016/j.pcl.2016.04.001.

Diagnostic Testing

Genetic and sweat chloride testing are the only two tests that accurately confirm a CF diagnosis. Bronchoscopies with bronchoalveolar lavage and pulmonary function testing help clinicians effectively treat, recognize, and manage disease progression.

Genetic Screening Test

Genetic testing is voluntary and costly, but an integral part in diagnosing CF.[1] The chance of being a CF carrier depends on ethnic background unless there is a family history. Many Caucasians are carriers of the mutated CFTR gene. When one parent, typically the mother, has a positive CF-carrier test, the other parent should be tested. Genetic testing is minimally invasive. Cells are extracted from the blood, tissue, or saliva to examine deoxyribonucleic acid (DNA). The American College of Obstetrics and Gynecologists recommends parents who are pregnant or planning to become pregnant have CF-carrier testing. Although there are over 1,900 known CFTR mutations, this exam looks for the 23 most common mutations. A positive result means the person is a CF carrier, and genetic counseling is encouraged.[20]

Sweat Chloride Test

The **sweat chloride test** is the gold standard in CF diagnosis. When an infant has a positive **immunoreactive trypsinogen (IRT)** test, the physician may order sweat chloride testing at 2–4 weeks of age for further analysis. The sweat chloride test is typically ordered if a patient has signs and symptoms related to CF.[20] The sweat chloride test is noninvasive and may be done on the patient's arm or leg. This test is performed in three stages. See **Box 10-3** and **Figure 10-6**.

Two positive sweat chloride tests are sometimes needed to confirm a diagnosis of CF (**Table 10-2**).

Immunoreactive Trypsinogen

Early diagnosis is paramount to disease management and patient outcomes. All newborns in the United States undergo newborn screening to diagnose

BOX 10-3 Stages of the Sweat Chloride Test for CF

Stage I

- The site of choice is cleansed with distilled water and dried. Transdermal **pilocarpine** and electrical stimulation are applied for 5 minutes to promote sweating.

Stage II

- Sweat is then collected for 30 minutes near the site using either filter paper, gauze, or a plastic coil. The sweat is sent to the laboratory for analysis.

Stage III

- The sweat is analyzed, and the amount of chloride in the sample is measured. This exam generally takes 1 hour.

Data from Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic Fibrosis Center. *Hopkinscforg*. 2018. http://www.hopkinscf.org/what-is-cf/diagnosis/testing/sweat-test/. Accessed October 10, 2017.



FIGURE 10-6 The sweat chloride test for CF. An elevated chloride level in the skin can be used to diagnose CF.

Reproduced with permission from Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic Fibrosis Center. *Hopkinscforg*. 2018. http://www.hopkinscf.org/what-is-cf/diagnosis/testing/sweat-test/. Accessed June 20, 2018.

TABLE 10-2
Sweat Chloride Test Results Interpretation

Age	CF Unlikely (mmol/L)	Intermediate (mmol/L)	Indicative of CF (mmol/L)
Birth to 6 months	0–29	30–59	≥60
Infants older than 6 months, children and adults	0–39	40–59	≥60

Data from Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic Fibrosis Center. *Hopkinscforg*. 2018. http://www.hopkinscf.org/what-is-cf/diagnosis/testing/sweat-test/. Accessed October 10, 2017.

specific health conditions. While in the hospital the infant's heel is punctured, a small blood sample is extracted and sent for analysis. The newborn CF screening evaluates the IRT levels. Trypsinogen is manufactured in the pancreas and transferred to the small intestine to be converted into **trypsin**. Trypsin is the enzyme responsible for breaking down proteins found in food into peptides. Individuals with CF may have thick mucus plugs that lodge in the ducts of the pancreas, blocking trypsinogen from reaching the small intestines. This blockage increases trypsinogen values in the blood. Infants with an increased IRT level may be referred for sweat chloride testing. False positives may be seen in preterm infants and those with pancreatitis. IRT is not used for screening only or for a definitive diagnosis. If the IRT is positive, further testing is necessary.[21]

Pulmonary Function Tests

Most individuals with CF have a progressive obstructive pulmonary component to their disease process. Pulmonary function testing is used to monitor the progression of the pulmonary component of CF. The percentage predicted forced expiratory volume in 1 second ($\%FEV_1$) is commonly used to monitor lung function and to describe disease severity in CF.[22] $\%FEV_1$ is also utilized to make clinical decisions as to when to increase the intensity of treatment and as an outcome measure.

Pulmonary function tests are available and performed on infants. At a very young age, PFT results may not show any signs of the disease. However, these results may begin to deteriorate by age 6 months. This decline in pulmonary function is associated with inflammation and infection. As CF progresses, PFT results decline. The $\%FEV_1$ correlates with survival in CF patients.[22] Significantly low $\%FEV_1$ can be used to determine the need for lung transplantation.

Bronchoalveolar Lavage

Bronchoalveolar lavage is the gold standard for detecting pathogens in the lower airways in CF.[23] A few pathogens are recognized in CF airway disease. These include *P. aeruginosa*, *S. aureus, Haemophilus influenzae*, and the *Burkholderia cepacia* complex.

Treatment/Management

There is currently no cure for CF. The treatment for CF focuses on disease and symptom management and focuses on several strategies, relief of airway obstruction, treatment of airway infection, suppression of inflammation, and nutritional repletion.[5] A pulmonary regimen of aerosolized bronchodilators, mucolytics, steroids, and antibiotics used concurrently with airway clearance therapy is needed to improve the quality of life and increase life expectancy. See **Box 10-4**. In the past few years, gene modification therapy has been at the forefront of CF research.

Medications

Beta-adrenergic bronchodilators aid in the relief of airway obstruction by relaxing smooth muscles. The most commonly prescribed bronchodilators, in the United States, include albuterol sulfate (1.25 and 2.5 mg dosages)[29] and levalbuterol (0.31, 0.63, and 1.25 mg dosages).[30] These are commonly prescribed via aerosol delivery. **Hypertonic saline (HTS)** is used in 3% and 7% concentrations nebulized in 4–5 mL vials. HTS aids with mucociliary clearance by impacting the hydration deficiency, and by stimulating the patient to cough, mobilizing the patient's sputum up and out the tracheal-bronchial tree.[31] **Mucolytics** help to thin the thick, tenacious secretions indicative of CF and loosen the secretion to enhance airway clearance. Dornase alfa (Pulmozyme®) is the mucolytic of choice for CF. Unlike other mucolytics, it breaks down the extracellular DNA found in the CF respiratory tract and decreases the viscosity of purulent sputum indicative of patients with CF. Dornase alfa (2.5 mg) is delivered via inhalation and cannot be mixed with any other aerosolized medication.[32] Inhaled corticosteroids (ICSs) are administered for their anti-inflammatory effects. One commonly given ICS is budesonide (Pulmicort®) via inhalation in dosages of 0.25, 0.5, and 1 mg.[33]

Inhaled antibiotics allow for providing high antibiotic concentrations in sputum while minimizing systemic adverse effects.[5] The three most commonly prescribed inhaled antibiotics include tobramycin solution (TOBI®), colistin, and aztreonam lysine (Cayston®). Tobramycin belongs to the aminoglycoside class of antibiotics and was the first aerosolized antibiotic approved for the treatment of *P. aeruginosa*.[5] The medication disrupts protein synthesis, altering the cell permeability and cellular envelope disruption, leading to the cell's death. Tobramycin is administered at the 300 mg dosage, twice daily for 28 days. Tobramycin should be given as close to every 12 hours as possible for maximum efficacy.[24] Colistin belongs to the class of antibiotics called polymyxins and is a cationic peptide used in the treatment of *P. aeruginosa* and *S. aureus.* Colistin acts as a cationic detergent and damages the bacterial cytoplasmic

BOX 10-4 Summary of Treatment Regimen for CF[5,12,24–28]

Treatment of Airway Obstruction

- Beta-adrenergic bronchodilator (aerosolized)
  - Albuterol
  - Levalbuterol
- Mucolytic (aerosolized)
  - Hypertonic saline
  - Dornase alfa (Pulmozyme®)
- Anti-inflammatory agents (aerosolized)

Treatment of Airway Infection

- Antibiotics (aerosolized)
  - Tobramycin solution (TOBI®)
  - Colistin
  - Aztreonam lysine (Cayston®)

Airway Clearance Therapy

- High-frequency chest wall oscillation
- Positive expiratory pressure
- Oscillatory positive expiratory pressure
- Postural drainage, percussion, and vibration

Exercise

- Pulmonary rehabilitation
- Upper body exercises

Reverse the Defective CFTR Protein

- CFTR Potentiators
  - Lumacaftor (Kalydeco®)
  - Lumacaftor/ivacaftor (Orkambi®)
  - Tezacaftor/ivacaftor (Symdeko®)

Aid in Digestion

- Pancreatic enzyme supplements
- Vitamin supplements (including vitamins A, D, and K)
- Nutritional supplements
- High-fat, high-energy diet

membrane, causing leaking of intracellular substances and cell death. The adult dosage is 150 mg administered every 8–12 hours. Both tobramycin and colistin are licensed for administration via PARI® nebulizer.[34] Aztreonam (Cayston®) is an inhaled antibiotic used only in the treatment of *P. aeruginosa.* Aztreonam is used only with the PARI Altera® nebulizer and is given three times a day at least 4 hours apart in a 75 mg dosage.[35]

The newest medications are aimed at modifying the specific genetic defect. Ivacaftor (Kalydeco®) is a CFTR potentiator increasing the effect of epithelial cell Cl^- transport of faulty G551D mutant cell-surface CFTR protein, improving the management of salt and water absorption and excretion in the gastrointestinal and respiratory tracts. Patient's using ivacaftor have shown an increase in FEV_1 and a decrease in sweat chloride within 2 weeks. Lumacaftor is a CFTR corrector that works by improving the conformational stability, increasing the processing and trafficking of mature CFTR protein to the epithelium. Lumacaftor/ivacaftor combination therapy known as Orkambi® is used for the treatment of patients who have double copies of the F508del mutation. It is the only medication currently on the market that works inside the cell to target the actual protein defect. Orkambi® is given in tablet form every 12 hours and is available in two different dosages; lumacaftor 100 mg and ivacaftor 125 mg and lumacaftor 200 mg and ivacaftor 125 mg.[26]

Symdeko®, a synergetic combination of tezacaftor and ivacaftor, is approved by the Food and Drug Administration for children and adults over the age of 12 who are **homozygous** for F508del mutation. Tezacaftor increases the number of fully developed CFTR proteins delivered to the cell surface by aiding cell processing and trafficking of normal and specific mutations of CFTR. Ivacaftor is a CFTR potentiator, increasing chloride transportation by activating the channel-open probability of the CFTR protein. Ivacaftor can activate the protein delivered to the cell surface by tezacaftor, increasing chloride transport.[36]

Airway Clearance

Chronic bronchial infection and airway obstruction requires aggressive pulmonary hygiene to mobilize retained secretions. Postural drainage, percussion, and vibration (PDPV) was the standard CF therapy. Postural drainage is performed concurrently with percussion and vibration. The patient is placed in numerous body positions to assist in the drainage of the mucus. The body positions help to drain the affected parts of the lung.[37] The percussion is administered using cupped hands, a pneumatic device, or a percussive cup over the lung fields. **High-frequency chest wall oscillation** (HFCWO) consists of an inflatable vest or wrap connected to an air-pulse-generating device using hoses. Pressure pulses within the vest or wrap oscillate the thoracic wall, transiently increasing airflow within the lungs. High oscillatory volumes at the mouth and high peak expiratory flow rates mimic that of a cough. These forces physically vibrate the mucus, altering its consistency and thereby mobilizing the mucus by the change in inspiratory and expiratory flow and velocity.[27]

Many medications are involved in the routine therapy for CF. The aerosolized medications should never be mixed and needs to be administered in a specific sequence. The appropriate sequence for therapy is (1) bronchodilator, (2) mucolytic, (3) airway clearance therapy, (4) anti-inflammatory agents, and (5) aerosolized antibiotic. The airway clearance therapy may be used during the administration of the bronchodilator and mucolytic.

Nutritional Support

CF is a complex and multisystem disease that requires many different types of therapies. The maintenance of adequate nutrition is a vital part of CF therapy because relative underweight is a negative prognostic indicator.[5] Therefore, to try to keep up with high-energy needs, nutritional support is encouraged.

Physical Activity

In addition to nutritional support, regular physical activity is encouraged. Exercise aids in controlling diabetes, which can be caused by CF; improving lung function; and reducing the risk of cardiovascular disease.

Lung Transplantation

CF is the second most common reason for lung transplantation.[5] Only one in every five lungs from deceased donors is viable. Patients must meet physical and psychosocial factors to be eligible for lung transplantation. To be eligible for a double lung transplant, the person must have a poor prognosis, with survival being predicted at <2 years. A person's physiologic, not chronologic, age must be 60 years or younger, and the person must have no other life-threatening systemic disease. Lifetime regimen (medications, airway clearance, enzyme supplementation, and others) compliance, emotional stability, and social support are also deciding factors.[37] After successful transplantation, the donor's lungs are recognized as foreign tissue, and patients must take immune suppressants the rest of their life, so the body does not reject the lungs. The survival rate is 90% at 1 year, 55% at 5 years, and 33% at 10 years. The leading cause of death in the first year of transplantation is infection.[37]

Prognosis

CF, once a childhood death sentence, is now a manageable disease, with the number of adults outnumbering the pediatric population.[5] The median age of survival

is nearing 40, with the leading cause of morbidity and mortality being obstructive lung disease and respiratory failure. Adherence to treatment regimen creates better patient outcomes. However, CF remains a life-limiting disease.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The sweat from an individual with CF is high in sodium and chloride.
2. True or False: Inheriting one mutated CFTR gene causes CF.
3. True or False: The pancreas is involved in CF.
4. True or False: CF causes a restrictive-type pulmonary disease.
5. True or False: The newest medications for CF modify the CFTR protein.

Bronchiectasis

Bronchiectasis is an uncommon chronic pulmonary condition characterized by bronchial inflammation and permanent bronchial dilation secondary to an infectious process. One or both lungs may be affected. Bronchiectasis can be categorized as a chronic obstructive pulmonary disease (COPD) manifested by airways that are inflamed and easily collapsible, resulting in airflow obstruction with shortness of breath, impaired clearance of secretions (often with disabling cough), and occasionally hemoptysis.[38]

Diagnosis

Bronchiectasis most commonly presents as a focal process involving a lobe, segment, or subsegment of the lung. It is much less common for an individual to have a diffuse process involving both lungs.[38] There are two broad categories to classify bronchiectasis: CF-associated bronchiectasis and non-CF-associated bronchiectasis (**Table 10-3**). Most cases are not associated with CF.[39] CF can cause diffuse bilateral bronchiectasis due to chronic pulmonary infection, increased viscous sputum, and mucus plugging. Non-CF-associated bronchiectasis is common in immunocompromised patients with chronic infection or people with connective tissue diseases, like **ciliary dyskinesia**. In ciliary dyskinesia, the cilia are impaired and unable to move secretions up the **mucociliary escalator**, creating an opportunistic environment for infection.

Diagnosis is usually based on a compatible clinical history of chronic respiratory symptoms, such as daily coughing and viscid sputum production, and characteristic radiographic findings on **computed tomography (CT)** scans, such as bronchial wall thickening and luminal dilatation.[38-40]

TABLE 10-3
Representative Categories and Causes of Non-cystic Bronchiectasis

Category	Causes
Post-infectious	Viral
	Bacterial
	Fungal
	Atypical mycobacteria
Allergic bronchopulmonary aspergillosis	
COPD	
Idiopathic traction	Post-tuberculosis fibrosis
	Post-radiation fibrosis
	Fibrosis (e.g., sarcoidosis)
	Collagen vascular diseases
	Twisting or displacement of the airways after lobar resection
Inhalation/aspiration	Inhalation of corrosive substances
	Aspiration of foreign body
Obstruction	Benign bronchogenic tumors
	Broncholithiasis
	Enlarged lymph nodes
Amyloidosis	Nodular pulmonary amyloidosis
	Secondary amyloidosis
Immunologic abnormalities	Both primary and secondary immunologic abnormalities
Congenital abnormalities	Anatomic—scoliosis, pectus excavatum, Marfan syndrome
	Secondary—chemotherapy, immunosuppressive therapy, cancer
Ankylosing spondylitis	

Data from Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. *Postgrad Med J.* 2010;86(1018):493–501. doi:10.1136/pgmj.2009.091041.

Clinical Signs and Symptoms

Bronchiectasis is a morphologic diagnosis and therefore may exist with relatively few symptoms.[38] The classic clinical manifestations of bronchiectasis are cough and the daily production of **mucopurulent** and tenacious sputum lasting months to years.[39] Other

signs include dyspnea, wheezing, weakness, malaise, weight loss, and hemoptysis. During an exacerbation, patients have increased viscous sputum production.[41] Occasionally, the sputum has a foul odor caused by infections, such as *P. aeruginosa*. Increased baseline dyspnea, pleuritic pain, and fatigue are also clinical manifestations during a flare-up. Physical examination includes a head-to-toe analysis. Hypoxic patients present with cyanosis and polycythemia. Auscultation typically reveals crackles, rhonchi, and wheezing. Approximately 3% of moderate to severe patients have digital clubbing. The chronic sinusitis leads to the formation of nasal polyps.[41]

Etiology

The cause of bronchiectasis involves pulmonary insult. Diseases that affect the formation of the lungs or that are correlated with increased pulmonary infection are the most likely to cause bronchiectasis. See **Box 10-5**. Patients who had an acute pulmonary infection, respiratory syncytial virus, or adenovirus during childhood are also at higher risk. Aspiration and bronchial obstruction damage the lung tissue and parenchyma, causing edema and scarring leading to focal bronchiectasis typically seen in the right middle lobe.[41]

Epidemiology

Approximately 110,000 people are living with bronchiectasis in the United States.[39] The prevalence of diagnosis increases with age, but the disease is diagnosed in all age groups. Evidence suggests that non-CF-related bronchiectasis is more common and more virulent in women, particularly slender white women older than 60 years.[38] The prevalence of bronchiectasis increases with age after 60 years (300–500/100,000) as compared to ages <40–50 years (40/100,000 to 50/100,000).

Pathophysiology

The pathophysiology of bronchiectasis is not well defined.[42] The clinical changes in the lungs are a result of other conditions and diseases. Factors such as infectious pulmonary insult, chronic airway obstruction leading to inadequate pulmonary drainage, and an autoimmune impairment cause permanent pulmonary scarring and dilation.[40] Three important elements lead to bronchiectasis: inflammation, infection, and damage.[41] The tissue damage is, in part, a result of the host response of **neutrophilic proteases**, inflammatory **cytokines**, nitric oxide, and oxygen radicals.[38] Inflammation protects against the invasion of foreign material, but when this response fails to eliminate the aggressor, the inflammation may turn chronic, inducing bronchial wall damage and irreversible dilatation.[41]

Three observed phenotypes are used to classify the bronchodilation associated with bronchiectasis (**Figure 10-7**). These phenotypes are cylindrical (tubular), varicose, and cystic.[42] The most commonly seen phenotype is cylindrical, which is also the mildest form of bronchiectasis.[43] The varicose phenotype is more severe than the cylindrical phenotype, and the cystic phenotype is the most severe type.[43] Cylindrical bronchiectasis is characterized by mucosal edema with straight dilated bronchi that end abruptly and are square. Varicose bronchiectasis has a rounded appearance, the bronchus is dilated, and obstructive scarring can be seen. Cystic bronchiectasis shows a balloon-like

BOX 10-5 Causes of Bronchiectasis

Primary infections
Bronchial obstruction
Aspiration
CF
Primary ciliary dyskinesia
Allergic bronchopulmonary aspergillosis
Immunodeficiency states
Congenital anatomic defects
Connective tissue disorders
Alpha-1 antitrypsin deficiency (AATD)
Autoimmune diseases
Idiopathic inflammatory disorders
Autosomal dominant polycystic kidney disease
Traction from other processes
Toxic gas exposure



FIGURE 10-7 Morphologic types of bronchiectasis.
Source: https://radiopaedia.org/articles/bronchiectasis.

appearance on chest radiography. Neovascularization and ulceration are also present.[41]

Risk Factors

Risk factors for bronchiectasis include infections and diseases that cause injury to the lungs. See **Box 10-6**.

Complications

The most common complications include recurrent pneumonia requiring hospitalization, empyema, lung abscess, progressive respiratory failure, and cor pulmonale.[38] Additional complications include chronic bronchial infection and pneumothorax.[44]

Diagnostic Testing

Diagnosing bronchiectasis includes an array of testing to include the presence of bronchiectasis and the underlying cause. A detailed pulmonary history is vital to disease diagnosis.

Chest Radiograph

Chest radiography is not usually a definitive factor when diagnosing bronchiectasis. Chest radiographic findings are usually abnormal and may include increased pulmonary markings, honeycombing, atelectasis, and pleural changes. Dilated bronchi, linear hyperlucency, and parallel markings emanating from the hila are seen in cylindrical bronchiectasis. Alternating areas of constriction and dilation are noticeable in varicose bronchiectasis and clustered cysts in cystic bronchiectasis (see **Figures 10-8** and **10-9**).

Computed Tomography

The gold standard for diagnosing bronchiectasis is high-resolution computed tomography (HRCT). A multislice, multidetector-row, helical computed tomography (MDCT) is also used for diagnosis. Airway dilation is noted as parallel lines (tram lines) or end-on ring shadows. There are three key markers on CT scan: there is absence of bronchial tapering as it reaches the periphery of the lung, the bronchial internal diameter's width is greater than the adjacent vessel, and the bronchi are visualized in the peripheral 1–2 cm of the lung field(s)[42] (**Figures 10-10** and **10-11**).

Alpha-1 Antitrypsin Level

Alpha-1 antitrypsin (AAT) blood testing is recommended for patients with idiopathic bronchiectasis.[43] AAT is

BOX 10-6 Risk Factors Associated with Bronchiectasis

Extreme age
COPD
Mucociliary dysfunction
Post-infectious insult
Immunocompromised patients
Rheumatic diseases
Alpha-1 antitrypsin (AAT)
Aspiration
Malnutrition
Obstruction

Data from King P. The pathophysiology of bronchiectasis. *Int J Chron Obstruct Pulmon Dis.* 2009;4:411–419. doi:10.2147/copd.s6133.



FIGURE 10-8 Cystic bronchiectasis.
Case courtesy of Dr Ian Bickle, Radiopaedia.org, rID: 34599.



FIGURE 10-9 Cylindrical bronchiectasis and tram-track opacities in a CF patient.
Reproduced with permission of the © ERS 2018: Perera P, Screaton N. Radiological features of bronchiectasis. *Bronchiectasis.* 2011:44–67 (Figure 1b). doi:10.1183/1025448x.10003510.



FIGURE 10-10 HRCT scan showing cylindrical bronchiectasis.
Case courtesy of A.Prof Frank Gaillard, Radiopaedia.org, rID: 2587.



FIGURE 10-11 HRCT coronal section showing cystic and cylindrical bronchiectasis.
Case courtesy of Dr Alexandra Stanislavsky, Radiopaedia.org, rID: 13187.

a protein made by the liver and aids in protecting the body from other proteins. People who are AAT deficient have deformed AAT proteins. These malformed AAT proteins are unable to move out of the liver into the bloodstream efficiently. AATD is a genetic disorder. Low levels of AAT in the blood cause an increased risk of lung disease. Recent studies have shown that as much as 95% of patients with AATD with normal sputum cultures present with bronchiectasis on radiography.[43]

Immunoglobulin Level

Hypogammaglobulinemia is considered a differential diagnosis for bronchiectasis. It is a disorder where the body produces insufficient amounts of **gamma globulin**. These individuals are immunocompromised; often the initial presentation is a chronic infection, like bronchiectasis.[44] If hypogammaglobulinemia is suspected, diagnostic testing is performed specifically for IgG, IgM, and IgA. This includes quantitative measurements of immunoglobulin levels in the blood.[43]

Pulmonary Function Tests

Pulmonary function testing is used to assess pulmonary obstruction and severity. Pulmonary tests may be normal or abnormal.[44] Spirometry, including forced vital capacity (FVC), FEV_1, and FEV_1/FVC, are examined. Patients do not typically show reversibility following bronchodilator administration.[39]

The most common abnormality is an obstructive airway defect, which may even be found in patients without a prior smoking history. Also, patients with bronchiectasis have higher rates of yearly decline in FEV_1 than patients without bronchiectasis.[38] In patients with non-CF bronchiectasis, risk factors for a more rapid decline in FEV_1 include colonization with *P. aeruginosa* and higher concentrations of proinflammatory markers. The 6-minute walk test may provide additional information about spirometry.[39]

Sputum Analysis

Sputum analysis may reinforce the diagnosis of bronchiectasis and add significant information regarding potential etiologies. Once sputum settles in the collection cup, the examination may reveal **Dittrich plugs**, small white or yellow concretions.[38] Bedside analysis of the sputum checks for consistency, color, and odor. Most often, three layers of sputum form in the collection cup: at the top, there is a frothy saliva layer; in the middle, there is a sero-mucus liquid layer; and settled out at the bottom is a layer of cellular debris, including pus and necrotic tissue.

A Gram stain and culture result may reveal evidence of microorganisms, including mucoid *Pseudomonas* species and *Escherichia coli*, which suggest CF but are not diagnostic.[38] *H. influenza* is the most commonly isolated non-CF-associated bronchiectasis.[39] *Mycobacterium avium* complex (MAC), also known as noncontagious tuberculosis, is another identified microbe. MAC is a highly opportunistic microorganism, requiring intensive antibiotic therapy for 24 months. *Pseudomonas* is found in both CF-related and non-CF-related bronchiectasis and contributes to decreasing lung function, disease progression, and increased morbidity and mortality.[44]

Treatment and Management

The goal of treatment from bronchiectasis is to improve the symptoms of a cough, sputum production, and dyspnea, and to prevent the progression of airway

damage.[41] Early recognition is essential in bronchiectasis and associated conditions. Additionally, management of underlying conditions, which may include the use of intravenous immunoglobulin or intravenous AAT therapy, is essential to the overall treatment of the patient.[38]

Pharmacologic Management

Pharmacologic management is similar to that of CF. Bronchodilator therapy, mucolytics, antibiotic therapy, and anti-inflammatory therapy are used. See **Box 10-7**.

Antibiotic treatment is the mainstay of bronchiectasis treatment. Oral, parenteral, and aerosolized antibiotics are used depending on the situation. Antibiotics can be used prophylactically and for treatment of acute exacerbations of bronchiectasis. Severe infections require high-penetrating antibiotics—macrolides, quinolones, and azalides.[45] Mucolytics are administered to stimulate a cough and improve pulmonary clearance by targeting the physiochemical makeup of sputum.[45] Anti-inflammatory agents reduce inflammation, and systemic corticosteroids target the bronchial wall, making them more effective.[45] Patients present with shortness of breath; bronchodilator therapy is prescribed, but not indicated unless the underlying cause is COPD or asthma.[45]

BOX 10-7 Treatment Modalities for Bronchiectasis

Antibiotic Therapy
- Oral
- Parenteral
- Aerosolized

Aerosolized Bronchodilator Therapy
- For patients with underlying bronchospasm

Anti-inflammatory Therapy
- Aerosolized
- Oral

Mucolytic Therapy
- Hypertonic saline (especially for CF-related bronchiectasis)
- Dornase alfa (especially for CF-related bronchiectasis)

Airway Clearance Therapy
- HFCWO
- Oscillatory positive expiratory pressure
- Positive expiratory pressure
- Intrapulmonary percussive ventilation
- Active cycle of breathing
- PDPV

Surgery
- For advanced or complicated diseases with focal disease poorly controlled by antibiotics

Lung Transplantation
- Especially for CF-related bronchiectasis

Nonpharmacologic Management

Nonpharmacologic management is an essential treatment option. Airway clearance therapy and exercise training have proven to be effective in decreasing exacerbations and increasing exercise tolerance.[45] Airway clearance therapy aims at clearing out the excess secretions. It includes PDPV, positive expiratory pressure, oscillatory positive expiratory pressure, HFCWO, and active cycle of breathing. **Active cycle of breathing** is an effective method to assist in clearing out excess secretions.[46] This procedure does not require any equipment. It consists of several breathing techniques, including breath control with abdominal breathing, thoracic expansion exercises with deep breathing, and forced expiratory technique with breath control and huff coughing (**Figure 10-12**).

Surgical Management

Surgical resection is an option for patients having frequent exacerbations not easily controlled by antibiotic therapy. The afflicted lung segment or segments are surgically removed. By removing the diseased portion, a reduction in chronic infection and sputum production improves the patient's quality of life.[41]

Prognosis

There is currently no cure for bronchiectasis. Regular physician visits, higher body mass index, and yearly

KNOWLEDGE CHECK QUESTIONS

1. True or False: Bronchiectasis is a reversible obstructive airway disease.
2. True or False: COPD can be an etiology for bronchiectasis in some patients.
3. True or False: Foul-smelling mucopurulent sputum is indicative of *P. aeruginosa*.
4. True or False: Inflammation, infection, and airway damage are the three important elements of bronchiectasis.
5. True or False: The gold standard for the diagnosis of bronchiectasis is chest radiography.



FIGURE 10-12 **(A)** Lung volumes during active cycle of breathing technique. **(B)** Active cycle of breathing technique. **(C)** Three active cycles of breathing routines.

Reproduced with permission from Fink JB. Forced expiratory technique, directed cough, and autogenic drainage. *Respir Care.* 2007;52:1210–1223.

vaccinations decrease mortality.[38] Prognosis is based on age, patient compliance, and disease progression. Patients with CF-associated bronchiectasis have an increased mortality rate.[41] Exacerbations decrease lung function and quality of life and increase hospitalizations and mortality. Two systems are utilized by practitioners to predict mortality: bronchiectasis severity index (BSI) and FACED. FACED was designed as a prognostic score. F for FEV_1; A for age; C for *Pseudomonas* colonization; E for extent of bronchiectasis (counting lobar involvement on a CT scan); and D for dyspnea, using the Medical Research Council (MRC) dyspnea score.

The BSI combines age, body mass index (BMI), FEV_1 in previous hospitalizations, exacerbation frequency, colonization status, and radiologic appearance. This score was designed to predict future exacerbations and hospitalizations, health status, and death over 4 years[47] (**Table 10-4**).

TABLE 10-4
Comparison of Two Bronchiectasis Assessment Indexes

Bronchiectasis Severity Index	FACED
Advanced age	Age >70 years
Lower FEV_1	FEV_1 <50% of predicted
Dyspnea (MRC dyspnea score >3)	Dyspnea (MRC score ≥3)
P. aeruginosa colonization Colonization with other organisms	*P. aeruginosa* colonization
Radiologic severity (≥3 lobes involved or CF-related bronchiectasis	Extension of bronchiectasis (≥2 lobes)
Lower BMI (<18.5)	
Prior hospitalization	
≥3 Exacerbations	

Data from https://www.aboutbronchiectasis.com/en/diagnosis-classification/assessment-of-disease-severity/

Chapter Summary

CF is a progressive, genetic disease that causes a mutation in the genes that control the CFTR protein. The CFTR protein, in turn, controls the salt, fluid, and pH levels in the intestines, pancreas, and lungs. These mutations cause a thick, tenacious, chronic build-up of mucus in the lungs. The dysfunctional or missing CFTR protein prevents the release of digestive enzymes, causing numerous gastrointestinal problems. The most common CFTR mutation is F508del. CF requires lifelong adherence to a complexity of routine therapies, including medications, airway clearance therapy, diet, exercise, and nutritional supplements. The prognosis is better now than it was in the past, with the median age of survival nearing 40 years.

Bronchiectasis is an uncommon chronic pulmonary condition that is characterized by chronic and persistent mucus production. It is caused by an infectious insult, impairment of mucociliary clearance, and airway obstruction. There is permanent damage to the airways. This damage may be seen on chest radiography. However, HRCT is the gold standard for diagnosis. There are three phenotypes: cylindrical, varicose, and cystic. The etiology of bronchiectasis can be categorized as either CF related or non-CF related. The management of bronchiectasis is very similar to that of CF. The prognosis for bronchiectasis is based on several factors, including age, FEV_1, dyspnea, bacterial colonization, and the number of lobes affected by the disease.

Key Points

1. CF is an autosomal recessive genetically inherited disease that requires the inheritance of two recessive mutated genes, one from each parent. The parents are carriers of the gene, and most are asymptomatic. The CF gene mutations are categorized into six classes (I, II, III, IV, V, and VI), with Class I being the most severe.
2. CF is a multisystem disease that affects the exocrine glands, respiratory system, gastrointestinal tract, and reproductive tract. It causes sterility in males and infertility in females. In the pulmonary system, the mucus is thick, tenacious, and copious.
3. Complications of CF include repeated pneumonia, bronchiectasis, pneumothorax, cor pulmonale, nasal polyps, failure to thrive, and distal intestinal obstruction. CF increases the chances of airway colonization with a variety of microorganisms, including *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Haemophilus influenzae*, and *Burkholderia cepacia* complex.
4. Infant screening is done with the IRT test. If the IRT is positive, further testing is necessary. Two positive sweat chloride tests are necessary to diagnose CF.
5. The treatment and management of CF are complex, requiring numerous therapies throughout the day. These therapies include the administration of bronchodilators, mucolytics, anti-inflammatories, aerosolized antibiotics, airway clearance therapy, nutritional supplementation, diet, and exercise. These therapies improve the quality of life and the longevity of the individual with CF.
6. Bronchiectasis is typically seen secondary to an infectious process that results in abnormal and permanent airway damage, causing a build-up of mucus. The diagnosis of bronchiectasis is based on a compatible clinical history of chronic respiratory symptoms, including daily coughing and sputum production.
7. Bronchiectasis shows up on HRCT as bronchial wall thickening and luminal dilation, demonstrating three forms: cylindrical, varicose, and cystic.
8. Pulmonary function testing results show that bronchiectasis is an obstructive lung disease with no reversibility. The treatment of bronchiectasis is similar to that of CF.

Chapter Questions

1. The 1,480 amino acids of the CFTR protein channel are organized into _____ functional domains.
   a. 2
   b. 3
   c. 5
   d. 7
2. The cystic fibrosis (CF) Class ____ mutations result in having no mature CFTR proteins.
   a. I
   b. II
   c. V
   d. VI

3. Two sweat chloride test results for a 4-month-old baby read 75 mmol/L. These results indicate that the baby _____.
   a. probably has bronchiectasis
   b. most likely has CF
   c. does not have CF
   d. has pancreatitis
4. Lung transplantation for CF is considered when _____.
   a. the *Burkholderia cepacia* complex colonizes the airways
   b. the patient has bronchiectasis
   c. the chest radiograph worsens
   d. the $\%FEV_1$ becomes significantly low
5. The most appropriate sequence for the administration of treatments to a patient with CF is _____.
   a. aerosolized antibiotic—bronchodilator—mucolytic—inhaled anti-inflammatory—airway clearance.
   b. mucolytic—aerosolized antibiotic—bronchodilator—inhaled anti-inflammatory—airway clearance.
   c. bronchodilator—aerosolized antibiotic—mucolytic—inhaled anti-inflammatory—airway clearance.
   d. bronchodilator—mucolytic—airway clearance—inhaled anti-inflammatory—aerosolized antibiotic.
6. _____ is a CFTR potentiator medication.
   a. Budesonide (Pulmicort®)
   b. Ivacaftor (Kalydeco®)
   c. Aztreonam lysine (Cayston®)
   d. Dornase alfa (Pulmozyme®)
7. _____ can be used for patients with CF who have *Staphylococcus aureus* in their sputum culture.
   a. Tobramycin (TOBI®)
   b. Colistin
   c. Tezacaftor/ivacaftor (Symdeko®)
   d. Lumacaftor/ivacaftor (Orkambi®)
8. The mildest form of bronchiectasis is _____.
   a. cylindrical
   b. CF associated
   c. non-CF associated
   d. varicose
9. The diagnosis of bronchiectasis is made with a(an) _____ test.
   a. sweat chloride
   b. chest radiograph
   c. high-resolution computer tomography
   d. immunoglobulin blood level
10. _____ are the only type of medication used to treat CF, but not routinely used in the treatment of non-CF bronchiectasis.
    a. Mucolytics
    b. Inhaled anti-inflammatory agents
    c. Bronchodilators
    d. Inhaled antibiotics

References

1. Reference G. CFTR gene. *Genetics Home Reference*. 2017. https://ghr.nlm.nih.gov/gene/CFTR#. Accessed December 6, 2017.
2. Changing the Face of Medicine. Dorothy Hansine Andersen. *Cf-medicinenlmnihgov*. 2017. https://cfmedicine.nlm.nih.gov/physicians/biography_8.html. Accessed October 16, 2017.
3. Volsko T. Cystic fibrosis and the respiratory therapist: a 50-year perspective. *Respir Care*. 2009;54(5):587–594. doi:10.4187/aarc0439.
4. Elborn J. Cystic fibrosis. *Lancet*. 2016;388(10059):2519–2531. doi:10.1016/s0140-6736(16)00576-6.
5. Davis P. Cystic fibrosis since 1938. *Am J Respir Crit Care Med*. 2006;173(5):475–482. doi:10.1164/rccm.200505-840oe.
6. Taylor C. Chronic pancreatitis and mutations of the cystic fibrosis gene. *Gut*. 1999;44(1):8–9. doi:10.1136/gut.44.1.8.
7. Rowntree R, Harris A. The phenotypic consequences of CFTR mutations. *Ann Hum Genet*. 2003;67(5):471–485. doi:10.1046/j.1469-1809.2003.00028.x.
8. Bosslet G. Parental procreative obligation and the categorization of disease: the case of cystic fibrosis. *J Med Ethics*. 2011;37(5):280–284. doi:10.1136/jme.2010.039230.
9. Gadsby D, Vergani P, Csanády L. The ABC protein turned chloride channel whose failure causes cystic fibrosis. *Nature*. 2006;440(7083):477–483. doi:10.1038/nature04712.
10. Effects of CF. Pancreas/gastrointestinal tract: pancreatic problems. Johns Hopkins Cystic Fibrosis Center. *Hopkinscforg*. 2017. http://www.hopkinscf.org/what-is-cf/effects-of-cf/pancreas-gastrointestinal-tract/pancreatic-problems. Accessed November 7, 2017.
11. van der Doef H, Kokke F, van der Ent C, Houwen R. Intestinal obstruction syndromes in cystic fibrosis: meconium ileus, distal intestinal obstruction syndrome, and constipation. *Curr Gastroenterol Rep*. 2011;13(3):265–270. doi:10.1007/s11894-011-0185-9.
12. Lusman S, Sullivan J. Nutrition and growth in cystic fibrosis. *Pediatr Clin North Am*. 2016;63:661–678. doi:10.1016/j/pcl.2016.04.005.
13. Gilljam M, Moltyaner Y, Downey G, et al. Airway inflammation and infection in congenital bilateral absence of the vas deferens. *Am J Respir Crit Care Med*. 2004;169(2):174–179. doi:10.1164/rccm.200304-558oc.
14. Fertility in Women with CF. Cff.org. https://www.cff.org/Life-With-CF/Transitions/Reproductive-Health-and-Fertility/CF-and-the-Female-Reproductive-System/Fertility-in-Women-With-CF/. Published 2018. Accessed Nov. 9, 2017.
15. Sanders DB, Fink AK. Background and epidemiology. *Pediatr Clin North Am*. 2016;63(4):567–584. doi:10.1016/j.pcl.2016.04.001.
16. Ferec C, Cutting G. Assessing the disease-liability of mutations in CFTR. *Cold Spring Harb Perspect Med*. 2012;2(12):a009480–a009480. doi:10.1101/cshperspect.a009480.
17. De Boeck K, Zolin A, Cuppens H, Olesen H, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. *J Cyst Fibros*. 2014;13(4):403–409. doi:10.1016/j.jcf.2013.12.003.
18. Okiyoneda T, Lukacs G. Fixing cystic fibrosis by correcting CFTR domain assembly. *J Cell Biol*. 2012;199(2):199–204. doi:10.1083/jcb.201208083.

19. Mainz J, Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. *Curr Allergy Asthma Rep*. 2012;12(2):163–174. doi:10.1007/s11882-012-0250-y.
20. Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic Fibrosis Center. *Hopkinscforg*. 2018. http://www.hopkinscf.org/what-is-cf/diagnosis/testing/sweat-test. Accessed October 10, 2017.
21. Price J. Newborn screening for cystic fibrosis: do we need a second IRT? *Arch Dis Child*. 2006;91(3):209–210. doi:10.1136/adc.2005.085084.
22. Taylor-Robinson D, Whitehead M, Diderichsen F, et al. Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. *Thorax*. 2012;67(10):860–866. doi:10.1136/thoraxjnl-2011-200953.
23. Harris J, De Groote M, Sagel S, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. *Proc Natl Acad Sci USA*. 2007;104(51):20529–20533. doi:10.1073/pnas.0709804104.
24. Mantero M, Gramegna A, Pizzamiglio G, D'Adda A, Tarsia P, Blasi F. Once daily aerosolized tobramycin in adult patients with cystic fibrosis in the management of Pseudomonas aeruginosa chronic infection. *Multidiscip Respir Med*. 2017;12(1):2. doi:10.1186/s40248-016-0083-y.
25. DailyMed. KALYDECO—ivacaftor tablet, film coated KALYDECO—ivacaftor granule. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25. Accessed November 11, 2017.
26. Molinski S, Ahmadi S, Ip W, et al. Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. *EMBO Mol Med*. 2017;9(9):1224–1243. doi:10.15252/emmm.201607137.
27. Stites S, Perry G, Peddicord T, Cox G, McMillan C, Becker B. Effect of high-frequency chest wall oscillation on the central and peripheral distribution of aerosolized diethylene triamine penta-acetic acid as compared to standard chest physiotherapy in cystic fibrosis. *Chest*. 2006;129(3):712–717. doi:10.1378/chest.129.3.712.
28. Lung Transplant Preparation. *University of California San Francisco*. 2017. https://www.ucsfhealth.org/conditions/lung_transplant/signs_and_symptoms.html. Accessed December 1, 2017.
29. DailyMed. ALBUTEROL SULFATE—albuterol sulfate solution. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab1cbed4-50c4-4769-9947-1927333f278c. Accessed November 22, 2017.
30. DailyMed. LEVALBUTEROL—levalbuterol hydrochloride solution. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6998949-e1cb-4c86-a480-c0dfd9cb75b5. Accessed November 16, 2017.
31. Reeves E, Molloy K, Pohl K, McElvaney N. Hypertonic saline in treatment of pulmonary disease in cystic fibrosis. *ScientificWorldsJournal*. 2012;2012:465230.
32. DailyMed. PULMOZYME—dornase alfa solution. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86. Accessed November 12, 2017.
33. DailyMed. BUDESONIDE INHALATION—budesonide suspension. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8ef9489-83a2-4817-b21c-ea3fecd8c8dd. Accessed November 9, 2017.
34. Iosifidis E, Antachopoulos C, Ioannidou M, et al. Colistin administration to pediatric and neonatal patients. *Eur J Pediatr*. 2010;169(7):867–874. doi:10.1007/s00431-009-1137-3.
35. DailyMed. CAYSTON—aztreonam. *Dailymednlmnihgov*. 2017. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67300ca3-8c53-4ce4-8e86-2c03be1f9b8a. Accessed October 17, 2017.
36. *Symdeko®*. Boston, MA: Vertex Pharmaceuticals Inc.; 2018:6. https://www.vrtx.com/pipeline-medicines/our-approved-medicines. Accessed April 18, 2018.
37. Sisson J, Wyatt T, Pavlik J, Sarna P, Murphy P. Vest chest physiotherapy airway clearance is associated with nitric oxide metabolism. *Pulm Med*. 2013;2013:291375. doi:10.1155/2013/291375.
38. Emmons E. Bronchiectasis: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. Available at: https://emedicine.medscape.com/article/296961-overview. Accessed March 30, 2018.
39. Barker AF. Clinical manifestations and diagnosis of bronchiectasis in adults. In: Mandel J, ed. *UpToDate*. Waltham, MA: Wolters Kluwer; 2017. https://www.uptodate.com Accessed March 10, 2017.
40. Hurst J, Elborn J, Soyza A. COPD–bronchiectasis overlap syndrome. *Eur Respir J*. 2015;45(2):310–313. doi:10.1183/09031936.00170014.
41. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. *Postgrad Med J*. 2010;86(1018):493–501. doi:10.1136/pgmj.2009.091041.
42. King P. The pathophysiology of bronchiectasis. *Int J Chron Obstruct Pulmon Dis*. 2009;4:411–419. doi:10.2147/copd.s6133.
43. Alpha-1 Antitrypsin Deficiency. National Heart, Lung, and Blood Institute (NHLBI). *Nhlbinihgov*. 2018. https://www.nhlbi.nih.gov/health-topics/alpha-1-antitrypsin-deficiency. Accessed April 1, 2018.
44. Shah A, Kaliner M, Shliozberg J. Hypogammaglobulinemia: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/136471-overview. Accessed April 13, 2018.
45. Hacken N, Wijkstra P, Kerstjens H. Treatment of bronchiectasis in adults. *BMJ*. 2007;335(7629):1089–1093. doi:10.1136/bmj.39384.657118.80
46. Troughton J, Warnock L, Faulkner J. The active cycle of breathing techniques. *Ouhnhsuk*. 2018. https://www.ouh.nhs.uk/patient-guide/leaflets/files/11659Pbreathing.pdf. Accessed April 18, 2018.
47. Saleh A, Hurst J. How to assess the severity of bronchiectasis. *Eur Respir J*. 2014;43(5):1217–1219. doi:10.1183/09031936.00226913.

CHAPTER

11

Burns and Inhalational Injuries

"Knowledge is being aware that fire can burn; wisdom is remembering the blister."

—Leo Nikolaevich Tolstoy

OUTLINE

OBJECTIVES

1. Recognize common characteristics, manifestations, and diagnostic features of cutaneous burns and inhalational injuries.
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of burn and inhalational injuries.
3. Relate how cutaneous burns can affect pulmonary ventilation.
4. Explain diagnostic testing and treatment for carbon monoxide poisoning.
5. Review recommended management of patients with inhalational and cutaneous burns.
6. Identify common complications associated with cutaneous burns and inhalational injuries.

KEY TERMS

Allografts
Burn shock
Carbonaceous particles
Carboxyhemoglobin (COHb)
Carboxymyoglobin (MbCO)
CO-oximetry
Dermis
Epidermis
Eschar
Escharectomy
Escharotomy
Fluid resuscitation
Full-thickness graft
Hyperbaric oxygen (HBO) therapy
Hypodermis
Inhalation injury
Meshing
Multiple organ dysfunction syndrome
Rule of Nines
Split-thickness graft
Total body surface area (TBSA)
Xenograft
Zone of coagulation
Zone of hyperemia
Zone of stasis

Case Study

A 6-foot 1-inch 42-year-old man is brought to the emergency department at 06:00 hours by ambulance after having been rescued from a house fire. The paramedic reports that the victim was conscious the entire time; however, the firefighters noted that the victim was in a semi-conscious state when they found him. The patient had ensured that his wife and three children were out of the house before he went back in to look for the family cat. At that time, he became trapped in a smoke-filled room on the second floor of the house. The patient said that he believes he lost consciousness briefly before he was rescued.

In the emergency department, the patient is fully awake and alert. Physical assessment reveals a blood pressure of 138/78 mm Hg, respiratory rate of 20 breaths/minute, body temperature of 37.1°C, oxygen saturation of 100% on room air, heart rate of 103 beats/minute, and a glucose level of 128 mg/dL. He has superficial burns on his face and on his left arm. He is the only one of his family that is in the hospital. He states that he is feeling fine and wishes to return to his family. The patient is discharged at 08:15 with instructions to return if he has any complications.

At 11:15, the patient's wife brings him back to the emergency department due to difficulty breathing and swallowing. The patient's lips and tongue are noticeably swollen. His respiratory rate is 46 breaths/minute and labored, blood pressure is 153/94 mm Hg, heart rate is 110 beats/minute, and stridor is audible. Laryngoscopy shows a swollen and erythematous upper airway with a Cormack and Lehane classification of grade IV. The patient is intubated using a bronchoscope and a size 7.5 mm ID endotracheal tube and placed on mechanical ventilation with pressure control continuous mandatory ventilation with 22 cm H_2O, inspiratory time of 1 second, respiratory rate of 12 breaths/minute, PEEP (positive end-expiratory pressure) of 5 cm H_2O, and FIO_2 of 1.0. The arterial blood gas values with these settings are pH 7.42, $PaCO_2$ 37 mm Hg, and PaO_2 380 mm Hg. The COHb level assessed by CO-oximetry is 23%. The patient is managed on the ventilator for 2 days. He is extubated at that time and discharged from the hospital 1 day later.

Introduction

Burn injury is a complex traumatic event with various local and systemic effects, affecting several organ systems beyond the skin. Burn victims are subject to potentially fatal pathophysiological mechanisms caused by heat, particulate matter, and carbon monoxide (CO). Heat will not only burn skin, but can also burn the airways. Particulate matter is the chief contributor to the pathophysiology of smoke inhalation injury, and CO causes tissue hypoxia.

Burn injuries are caused not only by heat, but also by freezing, electricity, chemicals, radiation, or friction. These injuries are highly variable in terms of tissue affected, the severity, and resultant complications. Skin, nerves, muscle, bone, and vascular tissue can all be damaged. Depending on the location affected and burn depth, a burn victim may experience a wide number of potentially fatal complications, including shock, infection, electrolyte imbalances, and respiratory failure.[1]

Respiratory injury from the inhalation of smoke or chemical products of combustion causes significant morbidity and mortality. Combined with cutaneous burns, inhalation injury increases **fluid resuscitation** requirements, incidence of pulmonary complications, and overall mortality of thermal injury. While many products and techniques have been developed to manage cutaneous injury, relatively few diagnosis-specific therapeutic options are available for patients with inhalation injury.[2] The treatment for inhalation injury is mostly supportive.

CO poisoning is common in modern society, resulting in significant morbidity and mortality in the United States annually.[3] Most cases of CO poisoning are from fire-related smoke inhalation. However, non-fire-related CO poisoning can be caused by poorly functioning heating systems, camping stoves, electrical generators, and motor vehicles.

All three types of injuries, cutaneous burns, inhalation injury, and smoke inhalation, can exist in a single patient, making treatment complex and the risk of mortality high.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Burns can be caused by freezing.
2. True or False: There are more treatment for cutaneous burns than there are for inhalation injury.

Definition/Diagnosis

The term *burn* refers to injuries resulting from the denaturing and destruction of tissue proteins and bone, having thermal, electrical, or chemical origin.

A major burn is defined as an injury involving 20% or more of the **total body surface area (TBSA)**.[4] The quality of life and the outcome for major burn patients have improved dramatically over the past 20 years.[5–7] This change first began with a realization that the natural history of burns can be influenced by prompt surgery; the early removal of **eschar** and rapid biologic closure of the resulting open wounds prevent the otherwise inevitable development of burn wound sepsis. To support a patient with a serious burn injury and associated respiratory failure through the physiologically taxing trial of staged wound closure is not a simple undertaking. Patients who experience a major burn injury have a better outcome when cared for at a specialty burn center staffed with experienced personnel.[8]

Inhalation injury is a generalized term describing damage to the lungs and upper airway by the inspiration of either superheated gases (temperatures greater than 150°C), steam, or noxious products of incomplete combustion. Inhalation injury also refers to the damage resulting from breathing irritant substances such as chlorine gas, hydrogen sulfide, smoke, or direct aspiration of petrochemicals. Although frequently paired with thermal injury, inhalation injury is more commonly the result of chemical interactions between foreign substances and the lung tissue rather than thermal injury. Despite advances in burn care as well as postinjury resuscitation, inhalation injury remains a critical determinant in burn outcome.[9]

Smoke inhalation is the most common form of inhalation injury. The components of smoke are determined by the burning material and the availability of oxygen where the fire has taken place. CO, a major component of smoke, is a colorless and odorless gas produced by an incomplete combustion of any carbon-containing substance. CO poisoning occurs after inhalation of CO, which binds to hemoglobin with much greater affinity than oxygen, forming **carboxyhemoglobin (COHb)** and resulting in impaired oxygen transport, leaving the body's organs and cells starved of oxygen. Other components of smoke depend on what is burning and include, for example, nitrogen dioxide, hydrogen cyanide, phosgene, formaldehyde, benzene, acid gases, and isocyanates.[10] These inhalants are classified as irritants, asphyxiants, or system toxins.

Diagnosis and initial treatment of a patient suffering from burns and smoke inhalation occur simultaneously. The essentials of the diagnosis begin with the immediate management of any life-threatening problems. This includes a rapid initial assessment of respiratory and cardiovascular status. See **Box 11-1**. The emergency department treatment focus is on airway management, respiratory care, and fluid resuscitation.[11] Part of these initial actions is to stop the burning process by removing jewelry, all clothing, and injurious material and decontaminate if needed.

BOX 11-1 Airway, Breathing, Circulation, Disability, Exposure (ABCDE) for Burns and Smoke Inhalation in Adults[12,13]

- Airway
  - Severe airway burns or smoke inhalation can cause airway edema within 12–24 hours
- Breathing
  - 100% supplemental oxygen for inhalation injuries, mechanical ventilation as needed
- Circulation
  - Fluid resuscitation with one or two large-bore peripheral lines in unburned areas of skin
  - Formulas for fluid resuscitation
    - Parkland formula 4 mL/kg crystalloid × TBSA% per 24 hours
    - Modified Brooke formula 2 mL/kg lactated ringers × TBSA%
    - Utilize acute trauma life support
- Disability
  - Assess mental status
  - Glasgow Coma Score
- Exposure
  - Expose the entire body to assess all areas of burn (remove all jewelry and clothing)
  - Avoid hypothermia (core temperature >34°C)
  - Decontaminate for chemical injuries

In addition to the ABCDEs, a secondary survey is necessary, which is a burn-specific survey and includes a full history. This survey includes the mechanism of injury (e.g., fire, smoke, steam, scald, electrical, or chemical), time of injury, length of time of exposure, associated symptoms, prehospital care received, height

KNOWLEDGE CHECK QUESTIONS

1. True or False: A major burn includes any burn over 10% TBSA.
2. True or False: Most inhalation injuries are due to heat.
3. True or False: Life-threatening injuries have priority over burn wounds.
4. True or False: CO has a greater affinity for hemoglobin than oxygen.

and weight, possibility of CO poisoning (enclosed or open space fire), presence of comorbid conditions, and substance abuse.[12] The AMPLE (**a**llergies, **m**edications, **p**ast medical history, **l**ast meal, **e**vents) trauma history should be obtained, if possible.[14] Examination of the cornea as well as the ear is important in cases of explosion trauma. A complete systematic head-to-toe examination needs to be performed during this phase.

Clinical Signs and Symptoms

The signs and symptoms of burns are easy to assess due to their visibility. However, the full extent of inhalational injury and CO poisoning is difficult to evaluate because patients will often have few external signs of injury. Therefore, a detailed history and physical exam is necessary.

Cutaneous Burns

An extensive cutaneous burn wound has a profound influence on pulmonary function, and accurate evaluation of the wound is important. The extent of the cutaneous burn needs to be assessed. The appearance of a burn depends on its degree of depth. The process of calculating burn depth and size is the first, crucial step in assessment. This task can prove to be difficult even for an experienced burn surgeon because the burn wound is a dynamic injury and will alter based on both extrinsic and intrinsic factors, such as thrombosis of dermal blood vessels, amount of resultant edema, release of inflammatory mediators, and initial treatment of the wound.[4,15–17]

Burns are classified as first, second, third, or fourth degree (**Figure 11-1**). In addition, they are classified by the depth of the injury, ranging from superficial to full thickness and finally to deep dermal[18] (**Table 11-1**). It can be difficult for even an experienced examiner to accurately determine the depth of a burn early on. As a rule, depth usually is underestimated on the initial examination.[16,18,19]

Burns also need to be evaluated for extent and circumferential components. It is critical to have an accurate estimate of TBSA involvement to determine the course and aggressiveness of the resuscitative efforts. Estimation of the involved body surface area in a burn wound is one of the more difficult, yet crucial,



FIGURE 11-1 Various degrees of burn severity. **(A)** First degree. **(B)** Second degree. **(C)** Third degree. **(D)** Fourth degree.
Robert L. Sheridan - Contributor/Mass Gen Hospital.

TABLE 11-1
Clinical Characteristics according to the Burn Depth[13,20]

Degree	Depth of Burn	Color and Appearance	Skin Texture	Capillary Refill	Sensation	Healing
1°	Superficial (epidermal)	Red, dry, blanches with pressure	Normal	Yes	Painful	3–6 days
2°	Partial thickness	Red, moist, weeping, blanches with pressure, blisters	Edematous	Yes	Painful to temperature and air	1–3 weeks No or minimal scaring
2°	Deep partial thickness	Variable color (patchy to cheesy white to red), wet or waxy dry, blisters, no blanching with pressure	Thick	Possibly	Painful, perceptive of pressure	>3 weeks Dense scar
3°	Full thickness	Waxy white to leathery gray to charred and black, dry and inelastic, no blanching with pressure	Leathery	No	No pain, deep pressure only	No spontaneous healing
4°	Full thickness involving subcutaneous tissue, tendon, or bone	Variable colors and appearance	Variable	No	None	No spontaneous healing

tasks to be performed during the assessment of the injury. Various methods to determine body surface area have been developed and introduced over the past 200 years of widely varying complexity. These range from paper templates used to cover the wound, mathematical formulas, estimation based on the proportion of a section of the body to the total surface area, computer models using digitized photographs, and small measuring devices intended to standardize the measuring area.[21]

Accurate measurement of the burned area, expressed as a percentage of body surface, is crucial in determining the need for hospital admission or referral to a burn center and in guiding initial fluid resuscitation and establishing a prognosis.[13] Burn size may be quickly estimated by using the Lund–Browder chart, a two-dimensional drawing of both anterior and posterior surfaces of a generalized body. The Lund–Browder chart accounts for variance in body proportions with growth (**Figure 11-2**). It has recently been noted that most Lund–Browder charts total up to 101% because demarcation of the body as described in the original text did not exactly coincide with the drawing, and this discrepancy has been carried on throughout the years.[22]

During the initial survey, the burn size is typically estimated using the Wallace **Rule of Nines**.[23] The Wallace Rule of Nines divides the body into sections representing 9% or multiples thereof to estimate body surface area (**Figure 11-3**). This technique is a rapid method of estimating burn surface area and is frequently used by first responders. If only a portion of an anatomic region is burned, further evaluation to determine the exact percentage burned is necessary.[23] The Rule of Nines tends to overestimate the extent of the burn, which has led to excessive fluid resuscitation.[5,24–26] The Rule of Nines also does not account for changes in body proportion with age and weight.[27] For example, an infant's head has significantly more surface area in proportion to the body than an adult's head, but they both account for the same area when using this technique. Using the size of the patient's palm, including the fingers, can act as an approximation as 1% TBSA and can be used as a guideline for estimating burn size.[23] Computerized methods have evolved and demonstrate high correlation and reproducibility that also facilitates the use of telemedicine.[23] See **Box 11-2**

Most methods used for estimating TBSA make the common assumption of normal body habitus. With morbidly obese patients (BMI >31), the affected body surface area is even less. Work has been done to incorporate various body types and shapes into different models using a Lund–Browder type of chart.[27–29]

The severity of the burn injury depends on several factors in addition to burn size and depth. Burns to certain body parts are considered major injuries. These include deep burns to the hands or feet (may produce permanent disability), partial- or full-thickness facial burns (associated with inhalation injury and compromised airway), burns of the eyes (associated with blindness), deep burns of the ears, perineum, and circumferential burns. Other factors considered in the severity of burns include inhalation injury, electrical injury, age of the patient, associated injuries, and major underlying medical problems.[13]



FIGURE 11-2 Lund–Browder chart for estimating body surface area involvement.

Some of the benefits of computerized TBSA programs are that the computed TBSA involvement is reproducible and can be obtained quickly even by clinicians who may have limited burn experience, and the injury maps can be sent along with the patient when he or she is transferred to a regional burn center. The initial injury thus is also better documented for evaluation by the burn surgeon. Serial measurements can also aid the burn surgeon in observing the progress in wound healing. A more direct need for having accurate burn maps is to determine the fluid requirements for the patient based on the severity of the injury. Inaccurate estimates can lead to improper fluid resuscitation.[30] Providing too little fluid during the initial resuscitation can lead to organ system failure. Too much fluid will contribute to systemic edema, which decreases peripheral circulation, leading to collateral tissue injury.[25,26]

Inhalation Injury

The likelihood of inhalation injury depends on the concentration of smoke inspired, the confines of the space where the fire is occurring as well as the duration of exposure. Burns on the face, soot marks, and singed eyebrows or facial hair are indicative of smoke



FIGURE 11-3 Wallace Rule of Nines for determining TBSA for burns.

BOX 11-2 Determining TBSA for Burn Injury

Lund–Browder Chart

- An age-specific chart that accounts for changes in body proportions. This is the preferred method used to determine the extent of a burn injury.

Wallace Rule of Nines

- A rough method of estimation that assumes adult body proportions. The head and neck are roughly 9%; the anterior and posterior chests are 9% each; the anterior and posterior abdomen (including buttocks) are 9% each; each upper extremity is 9%; each thigh is 9%; each leg and foot is 9%; and the genitals are 1%.

Palmar Surface of the Hand

- The palmar surface of a person's hand (without the fingers) is approximately 1% of the body surface over all age groups.

Computer Programs/Smartphone Applications

- These systems are typically based on either the Lund–Browder chart or the Rule of Nines and calculate involvement based on either photographs or drawings by the user.

inhalation. Large cutaneous burns indicate an inability to escape flame and a risk for smoke inhalation injury. However, inhalation injury can occur without evidence of burns.[31] See **Box 11-3**.

Upper airway edema following a burn-related injury can occur rapidly. Among patients who manifest signs of smoke inhalation, a sizable percentage develop complete airway obstruction and there is no means to

determine which patients will do so.[14] Of the signs and symptoms, the most worrisome for inhalation injury are voice changes, hoarseness, and stridor.[32] The larynx is one of the most affected organs in thermal inhalation injury, resulting in upper airway dysfunction later in the healing process.[33] Clinically assessed signs of thermal inhalation injury include hypoxemia, hypercapnia, and blistering or edema of the oropharynx.

BOX 11-3 Clinical Manifestations of Inhalation Injury[14,31]

- Decreased level of consciousness or confusion, agitation
- Deep facial or circumferential neck burns
- Carbonaceous sputum or burned matter in the mouth or nose
- Singed nasal or facial hair
- Persistent cough, stridor, or wheezing
- Hoarseness
- Dyspnea
- Tachypnea

Carbon Monoxide Poisoning

Symptoms of CO toxicity are usually present when COHb levels exceed 15%.[34] The clinical findings of CO poisoning are highly variable and largely nonspecific. Mild to moderately impaired individuals may present with headache, malaise, nausea, and dizziness. In the absence of involvement in a fire or trauma, these presenting signs may be misdiagnosed as an acute viral syndrome.[35] The standard method to assess the severity of exposure is to focus on neurological and cardiac symptoms indicating tissue hypoxia, such as loss of consciousness and chest pain.[36] The higher the COHb level, the more likely neurological and cardiac manifestations occur due to the decrease in tissue oxygenation (**Table 11-2**).

Altered vital signs in patients with CO poisoning may include tachycardia, hypertension or hypotension,

TABLE 11-2
Symptoms Associated with COHb in Healthy Adults and Susceptible Subpopulations

Healthy Adults		Susceptible Subpopulations	
COHb (%)	**Symptoms**	**COHb (%)**	**Symptoms**
≈1	Physiological background concentration	2	During physical exertion, reduced time to onset of angina and electrocardiogram signs of myocardial ischemia in subjects with coronary artery disease
5–6	Increase in cardiac arrhythmias in subjects with coronary artery disease	3–8	Background concentration in smokers
		7	Headache, nausea in children
10	No appreciable effect, except shortness of breath on vigorous exertion, possible tightness across the forehead, dilation of cutaneous blood vessels	13	Cognitive development deficits in children
		15	Myocardial infarction in subjects with coronary artery disease
20	Shortness of breath on moderate exertion, occasional headache with throbbing in temples	25	Syncopes in children
		25	Stillbirths
30	Headache, irritability, easily fatigued, disturbed judgment, possible dizziness, dimness of vision		
40–50	Headache, confusion, collapse, fainting on exertion		
60–70	Unconsciousness, intermittent convulsion, respiratory failure, death if exposure is long continued		
80	Rapidly fatal		

Reproduced with permission from Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 8. National Research Council (US) Committee on Acute Exposure Guideline Levels. Washington (DC): National Academies Press (US); 2010.

and hypothermia or hyperthermia. Mild tachypnea may be present; rarely patients with severe CO intoxication may have marked tachypnea. Noncardiogenic pulmonary edema may be present. The skin may exhibit pallor; the classic sign of cherry-red skin occurs rarely and is generally a postmortem finding. Other signs include bright red retinal veins, flam-shaped retinal hemorrhages, and papilledema.[31]

Cyanide toxicity presents in a very similar fashion, with obtundation in severe cases. The degree of cyanide toxicity depends directly on the concentration of HCN in the smoke. Diagnosis, however, is more difficult than CO toxicity because cyanide levels are not always readily available or reliable.[34]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The Wallace Rule of Nines accounts for changes in body proportion with age and weight.
2. True or False: Patients with large cutaneous burns are at a higher risk of inhalation injury.
3. True or False: Thermal inhalation injury most often affects the larynx.
4. True or False: Cherry-red skin is an early sign of CO poisoning.
5. True or False: Neurological and cardiac symptoms are manifestations of CO poisoning.

Etiology

Burns are typically thought of as a product of excessive heat on the skin. However, burns result from traumatic injuries to the skin or other tissues primarily caused by thermal or other acute exposures. Burns occur when some of the cells in the skin or other tissue are destroyed by heat, electrical discharge, friction, chemicals, or radiation.[20] Most burns are caused by contact with open flames. Fires may be due to automobile accidents, industrial accidents, structural fires, and explosions. However, there are several other causes. See **Box 11-4**.

Smoke is produced by combustion. Smoke is a colloid formed of airborne solids, liquid particles, and gases that are mixed with entrained air.[32] Up to 150 toxic compounds have been identified in smoke.[32] CO is released during combustion of any product. The other components of smoke are unique to the material that is involved, the availability of oxygen, and the nature of the combustion (**Table 11-3**).

The chemicals are irritants that disperse on the **carbonaceous particles** (soot). These particles can cause mechanical obstruction, increasing airway resistance, and increased work of breathing. The heat

BOX 11-4 Causes of Cutaneous Burns

- Chemical burns—strong acids, lye
- Contact burns—kitchen appliances, cigarettes
- Electrical burns—faulty electrical wiring, lightening
- Explosions
- Fire—house, industrial, office, cooking, forest fires
- Friction burns—traffic accidents with motorcycles or bicycles
- Radiation—radiation therapy for cancer treatment
- Scalds—hot liquids
- Sunburn—ultraviolet rays

Data from Rice, Jr P, Orgill D. Classification of burn injury. In: Jeschke M, Collins K, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed June 28, 2018.

from a fire can cause proximal burns of the nasal and oropharyngeal mucosa. The body effectively transfers the heat to the upper airway, so thermal burns below the vocal cords are rare.[32] However, smoke containing superheated steam can cause pulmonary damage, but usually this insult also causes glottic swelling and is rapidly fatal.[32]

KNOWLEDGE CHECK QUESTIONS

1. True or False: All combustible products produce oxygen radicals and CO.
2. True or False: Thermal airway burns below the vocal cords are common.
3. True or False: Smoke contains airborne solids, liquid particles, and gases.
4. True or False: Most burns are caused by contact with hot liquids.

Epidemiology

Unintentional and intentional burn injuries vary across age groups, gender, income, and global region. Adults are equally likely to sustain a burn in the home, outdoors, or at work. Men are most likely to sustain burns in outdoor or work locations, while burns to adult females occur mostly at home.[37] Older adults are likely to sustain a burn in the bathroom, followed by the kitchen. Pediatric burns are most likely to occur at home, when children are unsupervised.[37]

TABLE 11-3
Origin of Selected Toxic Smoke Compounds

Material	Source	Decomposition Products
All combustible products		CO, carbon dioxide, oxygen radicals
Cellulose	Wood, paper, cotton	Aldehydes, acrolein
Wool, silk	Clothing, fabric, blankets, furniture	Hydrogen cyanide, ammonia, hydrogen sulfide
Rubber	Tires	Sulfur dioxide, hydrogen sulfide, oxygen radicals
Polyvinyl chloride	Upholstery, wire/pipe coating, wall, floor, furniture coverings	Hydrogen chloride, phosgene
Polyurethane	Insulation, upholstery material	Hydrogen cyanide, isocyanates, ammonia, acrylonitrile
Polyester	Clothing, fabric	Hydrogen chloride
Polypropylene	Upholstery, carpeting	Acrolein, oxygen radicals
Polyacrylonitrile	Appliances, engineering, plastics	Hydrogen cyanide
Polyamide	Carpeting, clothing	Hydrogen cyanide, ammonia
Polyamine resins	Household and kitchen goods	Hydrogen cyanide, ammonia, formaldehyde
Acrylics	Aircraft windows, textiles, wall coverings	Acrolein, aldehydes
Fire retardants	Polymeric materials	Hydrogen cyanide, acetylene chloroethane, propene nitrite

Demling R. Smoke inhalation lung injury: an update. *Eplasty.* 2008;8(e27):254–282. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396464. Accessed June 27, 2018.

The World Health Organization estimates that 180,000 deaths are caused by burns each year, with most occurring in low- and middle-income countries.[38] In the United States, burn injuries receiving medical treatment in 2016 numbered 486,000, with 40,000 hospitalizations, including 30,000 at hospital burn centers.[39] Deaths from fire and smoke inhalation in the same year were 3,275. Both fire and inhalation deaths are combined because deaths from thermal burns in fires cannot always be distinguished from deaths from inhalation of toxins in smoke. The National Burn Repository of the American Burn Association reports up to 10.3% of the burn patients have concomitant inhalation injury.[39]

The American Burn Association compiled statistics for the years 2005 through 2014 from admissions to burn centers in the United States.[39] See **Box 11-5**.

Age is an important predictor of burn injury with older (>64 years) and younger (<10 years) victims being more likely to die due to fire.[32] These individuals also represent a disproportionate percentage of those injured by a fire. During 2010–2015, a total of 2,244 deaths resulted from unintentional CO poisoning, with the highest numbers of deaths each year occurring in the winter months. In 2015, a total of 393 deaths resulting from unintentional CO poisoning occurred, with 36% of the deaths occurring in December, January, or February.[40]

BOX 11-5 Selected Statistics: 2005–2014 Burn Admissions to Burn Centers

- Survival rate: 96.8%
- Gender: 68% male, 32% female
- Ethnicity: 59% Caucasian, 20% African American, 14% Hispanic, 7% other
- Admission cause: 41% fire/flame, 35% scald, 10% contact, 3% electrical, 3% chemical, 8% other
- Place of occurrence: 73% home, 8% workplace, 5% street/highway, 5% recreational/sport center, 9% other

Data from Burn Incidence Fact Sheet—American Burn Association. *Ameriburnorg.* 2018. https://ameriburn.org/who-we-are/media/burn-incidence-fact-sheet. Accessed June 30, 2018.

The case-fatality rate for non-fire CO poisoning ranges widely, but the analysis of aggregated national data from the United States supports an overall mortality of 1–3%.[35]

KNOWLEDGE CHECK QUESTIONS

1. True or False: About 10% of burn patients also have inhalation injury.
2. True or False: Death from CO poisoning is typically higher during the summer months.
3. True or False: Older individuals are most likely to sustain burn injuries in the bathroom.

Pathology/Pathophysiology

Understanding the pathophysiology of burn and inhalation injuries is important for effective management and appropriate respiratory care in the burn unit. The extent of any damage depends on the fire environment, meaning the ignition source, temperature, concentration, and solubility of the toxic gases. Successfully resuscitated burn patients manifest a sequence of predictable physiological changes. These changes can be anticipated, which aids in patient management.

Cutaneous Burns

The skin is the largest organ in the human body with a surface area of approximately 2 m^2 for an adult. The skin is composed of three layers: the **epidermis**, the dermis, and the hypodermis (subcutaneous tissue) (**Figure 11-4**). Each layer serves many key functions, including thermoregulation, neurosensory, immunologic, evaporative, metabolic (oxygen, nitrogen, and carbon dioxide diffusion), and protective. Equally as important, skin has a role in physical identity.[41] The thickness of the skin varies among different parts of the body, from 0.05 mm on the eyelids to over 1 mm on the soles of the feet.[42]

The epidermis, the outer layer, is the tough protective layer that contains the melanin-producing cells, melanocytes, the Langerhans cells (involved in the immune system in the skin), Merkel cells, and sensory nerves. The epidermis is made of five sublayers that work together to continually rebuild the surface of the skin. The **dermis** consists of two layers of connective tissue, which merge together with no clear demarcation. Sweat glands, hairs, sensory neurons, and blood vessels are in the dermis. The **hypodermis**, subcutaneous fascia, is the deepest layer of skin. It contains adipose lobules along with hair follicles, sensory neurons, and blood vessels[43] (**Table 11-4**).

Prolonged exposure to temperatures greater than 40°C leads to denaturation of proteins and loss of plasma membrane integrity. Burn injuries affect the skin in three histological zones extending away from the center of the injury in two directions, out and down.[41] These local pathophysiological changes occurring around the burn are called Jackson's burn zones.[1,4,44] At the center of the burn, the point of maximum damage, is the **zone of coagulation**. This damage is irreversible due to necrosis of the tissue when proteins denature and is the central focus of the injury (**Figure 11-5**). The most peripheral zone is the **zone of hyperemia**, characterized by vasodilation, inflammatory changes without structural damage.[1] Between these two zones is an intermediate region characterized by decreased tissue perfusion, the **zone of stasis**. This tissue is potentially salvageable. The focus of burn resuscitation



FIGURE 11-4 Basic anatomy of the human skin.

TABLE 11-4
Skin Layers, Cells, and Function[42,43]

Layer	Cells	Function
Epidermis—outermost layer protects the body from the environment		
Stratum basale or stratum germinativum	Basal cells	Produce new skin cells
	Melanocytes	Produce skin coloring
	Merkel cells	Sensory function for fine touch, most populous in fingertips
Stratum spinosum	Keratinocytes (squamous cells)	Produce keratin
	Langerhans cells	Take up antigens in skin and transport to lymph node
Stratum granulosum	Cells are fused together	
Stratum lucidum	Keratinocytes	Lose their nuclei
Stratum corneum	Dead keratinocytes, keratin and horny scales	Protection
Dermis—Thickest of the three layers; contains blood vessels, lymph vessels, hair follicles, sweat glands, sebaceous glands, nerve endings, collagen, and elastin		
Papillary layer	Collagen fibers thinly arranged	Thin extensive vascular system within this layer
Reticular layer	Thick collagen fibers, denser than papillary layer	Strengthens the skin providing structure, supports hair follicles, sweat glands, and sebaceous glands
Hypodermis—deepest layer of skin		
Subcutis	Fat cells	Insulates the body from cold temperatures and provides shock absorption



FIGURE 11-5 Jackson's burn zones. The center, zone of coagulation, is necrotic tissue, surrounded by the zone of stasis and of hyperemia.
Adapted from Hettiaratchy S, Dziewulski P. ABC of burns: pathophysiology and types of burns. *BMJ*. 2004;328:1427–1429.

is to increase tissue perfusion to this zone and prevent further damage. This tissue has the potential to heal or alternately to progress to a full-thickness lesion.[1] Clinically, this ischemic area can be salvaged only if revascularization is achieved within a few days. If not, additional insults, such as prolonged hypotension, infection, or edema, can convert this zone into an area of complete tissue loss.[45]

The thermal injury and the inflammatory mediators released are associated with increased capillary permeability and massive intravascular volume deficits, which peak within 24 hours following the burn. Major burns encompassing more than 20% of the TBSA result in a persistent pathophysiological stress response.[46] These responses severely alter homeostasis and are triggered by the release of inflammatory mediators and stress hormones. Circulating mediators deleteriously increase microvascular permeability and alter cellular membrane function, creating massive intravascular volume deficits, which peak within 24 hours following the

burn. Circulating mediators also favor renal conservation of water and salt, impair cardiac contractility, and cause vasoconstriction. This further aggravates ischemia due to combined hypovolemia and cardiac dysfunction. The result of this complex chain of events is decreased intravascular volume, increased systemic vascular resistance, decreased cardiac output, end-organ ischemia, and metabolic acidosis. Without early and full resuscitation therapy, these derangements can result in acute renal failure, organ dysfunction, cardiovascular collapse (**burn shock**), and death.[47] Burn shock is a unique combination of distributive and hypovolemic shock, recognized by intravascular volume depletion, low pulmonary artery occlusion pressure, increased systemic vascular resistance, and depressed cardiac output.[48] Subsequently, burn shock continues as a significant pathophysiological state, even if hypovolemia is corrected.[47] The increases in pulmonary and systemic vascular resistance and myocardial depression occur despite adequate preload and volume support. Such cardiovascular dysfunctions can further exacerbate the whole-body inflammatory response into a vicious cycle of accelerating organ dysfunction.[47]

Inhalation Injury

Inhalation injury complicates burns in approximately 10–20% of patients and significantly increases morbidity and mortality.[49] Smoke is composed of a gas phase and a particle phase. Particle size and tidal volume determine their distribution in the lung. The nasopharynx is responsible for clearing the inspiratory air of most particles with a diameter larger than 5 μm. During a fire, however, victims (consciously and unconsciously) breathe through the mouth due to irritation of the nasopharynx. This results in greater particle deposition in the airways, causing cellular injury.[50] Smoke inhalation results in three physiological types of injury: (a) thermal injury predominantly to the upper airway; (b) chemical injury to the upper and lower respiratory tract; and (c) systemic effects of the toxic gases such as CO and CN.[51] See **Box 11-6**.

Thermal injury to the upper airway is supraglottic, except for steam inhalation or blast injury, which can cause thermal injury to the lower airways. This damage is primarily due to the efficient heat exchange in the oro- and nasopharynx. The immediate injury results in erythema, ulcerations, and marked swelling of the tongue, epiglottis, and glottis.[51] In combined burn and inhalation injury, aggressive fluid administration required to treat burn shock promotes early edema formation.[52] This can progress rapidly, as edema continues to develop over the first 24–36 hours post injury.[32] Burns to the face and neck may cause anatomic distortion (swelling) or external compression of the upper airway, complicating airway management[52] (**Figure 11-6**).

BOX 11-6 Types and Locations of Inhalation Injury

- Types of Inhalation Injury
  - Thermal injury
  - Chemical irritation
  - Systemic toxicity
- Locations of Inhalation Injury
  - Upper airway
  - Tracheobronchial tree
  - Lung parenchyma
  - Systemic toxicity

Data from Rehberg S, Maybauer M, Enkhbaatar P, Maybauer D, Yamamoto Y, Traber D. Pathophysiology, management and treatment of smoke inhalation injury. *Expert Rev Respir Med.* 2009;3(3):283–297. doi:10.1586/ers.09.21.



FIGURE 11-6 A facial burn often associated with thermal injury to the upper airway. Notice the facial and tongue swelling.

Reproduced with permission from Cancio LC. Airway management and smoke inhalation injury in the burn patient. *Clin Plast Surg.* 2009; 36(4):555–567.

In addition to the acute inflammation, the damage of ciliary function impairs mucus clearance, increasing the risk of bacterial infection for several weeks. Increased mucus production can cause distal airway obstruction, atelectasis, and impaired gas exchange.[52]

Apart from inhalation of steam, injury to the tracheobronchial tree is usually caused by chemicals present in the smoke. These chemicals lead to inflammation and edema of the tracheobronchial tree. The materials that burned determine the composition of the smoke and the severity of the inflammatory reactions. The principle subglottic pathophysiological changes

occurring after inhalation injury include airway mucosal hyperemia, bronchospasm, and cast formation from fibrinous exudation into the airways, mucosal sloughing, inspissated mucus, and loss of surfactant and mucociliary escalator function.[53] These pathologies lead to small airway obstruction, including alveoli, and compromised ventilation, leading to ventilation/perfusion (V/Q) mismatch, causing intrapulmonary shunting and, ultimately, compromising oxygenation. Hypermetabolism and the systemic inflammatory response are much more intense when inhalation injury is accompanied by cutaneous burn.[53]

The damage of lung parenchyma following smoke inhalation injury is delayed. The time difference between the initial trauma and the parenchyma manifestation is correlated with the severity of the lung injury.[50] A faster time is associated with more severe injury. Parenchymal injury, diffuse alveolar damage, is characterized by atelectasis and alveolar collapse, resulting in increased transvascular fluid flux, a decrease in surfactant, and a loss of hypoxic vasoconstriction leading to impaired oxygenation.[54] These abnormalities cause reduced lung compliance, increased V/Q mismatch, and an increase in dead space ventilation. Respiratory failure may occur from 12 to 48 hours after smoke exposure.[2] Necrosis of the respiratory epithelium, impaired function of alveolar macrophages, polymorphonuclear leukocytes, and mucociliary transport leave patients predisposed to secondary bacterial invasion and superimposed bacterial pneumonia.[2]

Carbon Monoxide Poisoning

Direct systemic effect of inhalation injury is caused by breathing toxic chemicals formed by the combustion of various organic and inorganic materials. The two most relevant gases associated with increased morbidity and mortality are CO and hydrogen cyanide. CO is one of the most frequent immediate causes of death following inhalation injury.[54] CO poisoning causes tissue hypoxia in three ways. First, it binds with hemoglobin with about 250 times the affinity of oxygen, therefore preventing oxygen binding. Second, it leads to a shift in the oxygen dissociation curve to the left, impeding oxygen delivery. Third, it competitively inhibits binding of oxygen with cytochrome oxidase, a key mitochondrial enzyme, significantly impairing cellular utilization of oxygen.[32] In addition to tissue hypoxia, CO poisoning also causes direct cellular changes involving immunological or inflammatory damage by a variety of mechanisms.[3] These mechanisms include binding to intracellular proteins, peroxynitrite production from nitric oxide, lipid peroxidation by neutrophils, mitochondrial oxidative stress, apoptosis (programmed cell death), immune-mediated injury, and delayed inflammation.[3]

CO also binds to myoglobin, forming **carboxymyoglobin (MbCO)**, with heart muscle taking up about three times as much CO as skeletal muscle.[55] The formation of COHb results in an acute physiological anemia, much like an isovolemic hemodilution. A COHb concentration of 50% is physiologically similar to an isovolemic hemodilution to 50% of a baseline hemoglobin level.

Hydrogen cyanide (HCN) is the gaseous form of cyanide. It is a colorless gas that may be detected by the odor of bitter almonds. HCN poisoning is difficult to detect, as most inhalation injuries represent mixed intoxications.[50] HCN combines with the ferric ion in cytochrome a3 oxidase in mitochondria with high affinity, and so impairs cellular respiration by structurally changing the enzyme. Anaerobic metabolism ensues and leads to high lactate levels and decreased oxygen consumption. The presence of both HCN and CO has a synergistic effect of asphyxia.[32]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The deepest layer of skin is the hypodermis.
2. True or False: The zone of stasis has sustained the most damage from the burn injury.
3. True or False: Burns cause massive intravascular volume deficits, which require fluid resuscitation.
4. True or False: Thermal injuries to the lower airway can be caused by steam.
5. True or False: Lung parenchymal damage following smoke inhalation occurs immediately.
6. True or False: An elevated lactate level is indicative of hydrogen cyanide inhalation.
7. True or False: The skeletal muscles take up more CO than the heart muscle.

Risk Factors

Burn risk correlates with socioeconomic status, so those living in low- and middle-income countries are at higher risk for burns.[38] Those individuals who are in occupations that increase exposure to fire are at high risk for burns and inhalational injury. Individuals who live in overcrowded housing or housing without proper safety measures are at increased risk for burns. Other risk factors include alcohol abuse, smoking, small children (maltreatment), underlying medical conditions (epilepsy, peripheral neuropathy, physical and cognitive disabilities), lack of appropriate safety measures.[38] The risk of burns is highest in the 18- to 35-year-old age group. The male–female ratio is 2:1 for both injury and death. The incidence of scalds from hot liquids is higher in children 1–5 years of age and in the elderly.[56] Children

are at increased risk of burn morbidity and mortality.[57] The death rate in patients over the age of 65 is much higher than that in the overall burn population.[56]

Those who are at risk for burns are also at risk for inhalation injuries and CO poisoning, especially those who are victims of fires in an enclosed space, such as those trapped in burning buildings. In major fire disasters, such as the 9/11 disaster at the World Trade Center in New York, smoke inhalation injury was an important cause of morbidity and mortality.[51] Other risk factors include using indoor cooking fires, forest fires, and burning of crops. Children are less likely to experience smoke inhalation than adults.[58]

Unintended CO poisoning demonstrates a seasonal variation and is most common during the winter months in cold climates. Also, other risk factors include poorly functioning heating systems and improperly vented fuel-burning devices, such as camping stoves, gasoline-powered electrical generators, and motor vehicles operating in poorly ventilated areas such as garages.[35]

The key to risk reduction for burns and inhalation injuries is prevention. A reduction in the temperature setting on hot water heaters will help avoid scalds, mostly to children under the age of 5 years, and the elderly.[57] Using smoke and CO detectors represent effective prevention strategies. Fire sprinklers complement smoke detectors and can effectively extinguish a fire in an isolated area.[57] Fire safety prevention initiatives directed at the home are the key to reductions in the overall fire death toll. See **Box 11-7**.

BOX 11-7 Fire Safety Initiatives for the Home Environment

1. Widespread public fire safety education
2. Escape plans developed and practiced
3. Increased use of residential sprinkler systems
4. Increased production of fire-safe home products and construction material
5. Attention directed at fire safety needs of high-risk groups (e.g., young, old, poor, disabled)

Data from Hunt J, Arnoldo B, Purdue G. Prevention of burn injuries. In: Herndon D, ed. *Total Burn Care.* 4th ed. New York, NY: Saunders Elsevier; 2012.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The risk for burns is highest in the 18- to 35-year-old age group.
2. True or False: The highest risk for death from burns is in the 18- to 35-year-old age group.
3. True or False: Children are more likely to experience smoke inhalation than adults.

Complications

Deep and widespread burns and inhalation injury can lead to numerous complications (**Table 11-5**).

TABLE 11-5
Complications from Burns and Inhalation Injury[34,46,59–61]

System	Complication
Cardiac	Decreased preload due to volume loss, cardiac arrhythmias
Gastrointestinal	Feeding intolerance, mucosal ulceration, bleeding, abdominal compartment syndrome
Renal	Acute tubular necrosis, acute renal failure
Pulmonary	Airway obstruction, respiratory failure, pneumonia, acute respiratory distress syndrome
Endocrine	Hyperglycemia, insulin resistance, stress-induced diabetes
Systemic	Hypothermia, sepsis, multiorgan dysfunction syndrome, rhabdomyolysis, metabolic acidosis, wound infection
Neurological	Altered level of consciousness, anoxic brain injury
Muscles	Contractures, muscle wasting
Skin	Hypertrophic scars, keloid scars

Infection is a critical problem with burns, although modern therapy has reduced the incidence with the combination of early excision and grafting along with topical antibacterial agents.[34,46] The most common burn infections are caused by *Staphylococcus aureus, Pseudomonas aeruginosa*, and *Candida albicans*.[62] The most common complication following inhalation injury is respiratory tract infection. Pneumonia without the presence of inhalation injury increases the mortality of burn injury up to 40%.[63] It frequently is difficult to distinguish between pneumonia and tracheobronchitis (purulent infection of the denuded tracheobronchial tree), but the difference often has little practical clinical importance. Infection typically occurs toward the end of the first postinjury week; patients with serious inhalation injuries often are seen to deteriorate at this time. A patient with newly purulent sputum, fever, and perhaps diminished gas exchange should be treated with antibiotics, which should be adjusted as necessary after sputum culture information has been obtained. To repeat an important point: the physiology of inhalation

injury, which involves injury to endobronchial mucosa with hampered mucociliary clearance, makes good pulmonary hygiene a particularly important component of management.

Respiratory failure is common in individuals with inhalation injury. Respiratory failure among these patients is caused as often by sepsis as by inhalation injury (**Figure 11-7**). As in other forms of respiratory failure, the lung volume that can be recruited with mechanical ventilation is limited, and over-vigorous attempts to force high pressures into these lungs exacerbate the underlying injury.

The primary cause of death in burn patients who survive the initial burn shock resuscitation is from **multiple organ dysfunction syndrome**, which is a direct response to sepsis. In the case of burn injury, there are two potential causes of sepsis, infection or inflammation without infection. The difficulty is determining what is the cause, because the traditional indicators for infection, such as temperature and white blood cell count, are unreliable because of massive hypermetabolism and inflammation associated with recovery and healing.[59]

Full-thickness circumferential burns of an extremity or of the trunk pose special problems. These burns result in an eschar that is noncompliant, demonstrating mechanical properties like leather.[64] Swelling beneath the unyielding eschar can act as a tourniquet to blood and lymph flow. Pressure within the compartment increases and can result in necrosis of tissue within the compartment. Decompression is done by incising (**escharotomy**) the tightened inelastic skin to restore both arterial and venous flow. Permanent damage is avoided by performing the escharotomy before ischemia develops.[62] If left untreated, the result can be amputation, tissue loss, infection, or a painful muscle contracture. In the chest and abdomen, large areas of burn can prevent the natural expansion of skin during breathing (**Figure 11-8**). Without release, hemodynamic and respiratory compromise can result.[64]

Solid airway obstructive casts not only reduce normal air passage, but also become a perfect culture media for bacterial growth. Debris from sloughing of the dead cells as well as the hypersecretion of mucous glands contributes to small airway occlusion. Airway sloughing is typically treated with supportive measures or by evacuation with a bronchoscope[65] (**Figure 11-9**).



FIGURE 11-7 Contributing factors to respiratory failure in inhalation injury.

Reproduced with permission from Boots R, Dulhunty J, Paratz J, Lipman J. Respiratory complications in burns. *Clin Pulm Med.* 2009;16(3):132–138 (Figure 1). doi:10.1097/cpm.0b013e3181a39032.



FIGURE 11-8 In burn patients being mechanically ventilated, an escharotomy can improve chest wall compliance.



FIGURE 11-9 Cutaneous burn and smoke inhalation in a sheep after 48 hours. **(A)** Trachea. **(B)** Bronchi. **(C)** Smaller bronchi.

Reproduced from Enkhbaatar P, Cox R, Traber L, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. *Crit Care Med.* 2007;35:2805–2810. Reprinted with permission from Wolters Kluwer Health.

Acute respiratory distress syndrome (ARDS) may occur because of direct injury to the lung, which can be direct through smoke inhalation or pneumonia or indirect through mediators associated with sepsis. ARDS occurs because of damage to the vascular endothelium and alveolar epithelium. ARDS is an acute condition that takes place within a week of a known insult or that presents worsening of respiratory symptoms within this period, followed by bilateral radiographic opacities that are not fully explained by effusions, pulmonary collapse, or nodules.[66] The resulting increase in capillary permeability leads to leakage of fluid into the interstitium. Pulmonary edema is increased in areas of lung injury and occurs in uninjured lung tissue.[59] ARDS is common among burn patients, particularly among those requiring mechanical ventilation. The exact reasons why this occurs is not fully understood but are likely to be multifactorial. Inhalation lesions are associated with an increased risk of developing ARDS, which is associated with increased mortality rates in burn patients.[66]

KNOWLEDGE CHECK QUESTIONS

1. True or False: *P. aeruginosa* is a common cause of burn wound infections.
2. True or False: Pneumonia typically occurs within the end of the first postinjury week.
3. True or False: Full-thickness burns to the chest increases airway resistance, making it difficult to mechanically ventilate patients.
4. True or False: ARDS is a rare occurrence among mechanically ventilated burn patients.

Diagnostic Testing

Following the primary assessment of a patient suffering from burn or inhalation injury, the secondary assessment includes a complete physical examination with a careful neurological examination, as evidence of cerebral anoxic injury can be subtle. Patients with facial burns should have their corneas examined with fluorescent staining.[67] All extremities should be examined for pulses, especially with circumferential burns. This can be assisted by the use of a Doppler ultrasound flowmeter. Absent limb pulses may require decompression with an escharotomy.[67]

CO poisoning must be considered in every patient suspected of having inhalation injury based on being burned in a closed space along with physical evidence of inhalation injury.[34] Arterial blood gas analysis and COHb levels need to be determined. Standard pulse oximetry (Spo_2) screen for CO exposure is *not* reliable, as it does not differentiate COHb from oxyhemoglobin.[35] Confirmation of CO poisoning needs to rely on COHb levels of at least 3–4% in nonsmokers and at least 10% in smokers.[3,68] An absence of elevated CO level, however, does not exclude CO exposure due to the short half-life (250-minute breathing room air), especially if supplemental oxygen is being given.[69] If CO poisoning is confirmed, an electrocardiogram and cardiac biomarker evaluation is needed, especially in patients with ECG evidence of ischemia or a history of cardiac disease.[35]

Routine laboratory tests for burn patients include complete blood count, platelets, prothrombin time, activated partial thromboplastin time, thrombin time, blood urea nitrogen, creatinine, electrolytes, and blood glucose level. Ongoing cardiac monitoring is necessary for all patients with significant thermal burns. If inhalation injury is suspected, arterial blood gas analysis, COHb level, electrocardiogram, and chest radiograph are necessary. A cyanide level may be helpful, particularly in the setting of unexplained severe lactic acidosis.[14]

A blood type and cross-match are essential for any victim of significant trauma in anticipation of the need for transfusion. Other useful laboratory studies in assessing muscle, cardiac, or end-organ injury include urine myoglobin, serum creatine kinase, and serum lactate.[14] Additionally, urine drug test and alcohol tests are completed.

Fiberoptic bronchoscopy is indicated when there is suspicion of inhalation injury and in intubated patients, because this is both diagnostic and therapeutic in clearing the airways.[56] Bronchoscopy is considered the "gold standard" for early evaluation of upper airway injury and can be used to help predict acute lung injury. Fiberoptic bronchoscopy allows assessment of the larynx down to the fourth- to fifth-order bronchi and of the cough reflex, with the potential to remove airway debris.[69] It is an important tool in the initial evaluation of patients with suspected inhalational lung injury[70,71] (**Figure 11-10**).

The Abbreviated Injury Score (AIS) for inhalation injury classifies inhalation injury severity based on bronchoscopic findings (**Table 11-6**). This classification system determines the severity of the injury. The best tools for diagnosis of inhalation injury are clinical presentation and bronchoscopic findings. However, if performed too soon after the injury, it may not show mucosal injury.[72] Clinicians must be aware that acute lung injury due to systemic inflammation from cutaneous burns may take as much as 36–48 hours to become evident by bronchoscopy.

Chest radiography is considered an insensitive indicator of parenchymal injury after smoke inhalation.[72] However, a chest radiograph on arrival during initial assessment is a simple, easily achieved investigation that serves as a baseline for later comparison and may also reveal other useful information, such as coexistent pulmonary pathology.[74]



FIGURE 11-10 Bronchoscopic image of airway after sustaining inhalation injury. Note the carbonaceous buildup and inflammation of the airway wall.
Robert L. Sheridan-Contributor/Mass Gen Hospital.

TABLE 11-6
The AIS for Inhalation Injury Classification[73]

Grade	Bronchoscopic Findings	Injury Type
0	No carbonaceous deposits, erythema, edema, bronchorrhea, or obstruction	No injury
1	Minor or patchy areas of erythema, carbonaceous deposits, bronchorrhea, or bronchial obstruction present	Mild
2	Moderate erythema, carbonaceous deposits, bronchorrhea, or bronchial obstruction present	Moderate
3	Severe inflammation with friability, copious carbonaceous deposits, bronchorrhea, or obstruction present	Severe
4	Mucosal sloughing, necrosis, or endoluminal obstruction present	Massive

Reproduced from Endorf FW, Gamelli RL. Inhalation injury, pulmonary perturbations, and fluid resuscitation. *J Burn Care Res.* 2007 Jan-Feb; 28(1):80-3. https://academic.oup.com/jbcr/article-abstract/28/1/80/4636872?redirectedFrom=fulltext

KNOWLEDGE CHECK QUESTIONS

1. True or False: Circumferential burns can cause pulselessness in an extremity.
2. True or False: Routine pulse oximetry can identify CO poisoning.
3. True or False: Bronchoscopy is the gold standard for identifying inhalation injury.
4. True or False: Chest radiography is needed to identify lung parenchymal damage after smoke inhalation.

Treatment and Management

The function of the skin is to maintain normothermia, protect from infection, and maintain fluid balance within the body. Any injury that damages this organ has an impact on these three factors. Patients with large burns typically have a deep, painful wound that puts them at risk for sepsis and progressive multiorgan dysfunction from the break in skin integrity. Immediate clinical needs must be met, but an organized, overall plan of care must also be created. This organized plan of care can be described as four phases of care (**Table 11-7**).

The first phase, the initial evaluation and resuscitation, extends from day 1 (day of injury) through day 3. During this phase of care, the crucial events are to determine the size and extent of the injury, as well as provide replacement intravascular volume. Both assessments can have a profound effect on the remaining course of the injury. Providing adequate replacement fluid resuscitation to prevent and treat burn shock is the most important factor in treating patients with burn injury.[24,76,77] Untreated, burn shock is the major cause of morbidity and mortality in the burn patient.[78,79]

Management of Cutaneous Burns

Establishment of intravenous lines for fluid resuscitation are necessary for all patients with major burns, including those with inhalation injury or other associated injuries. A large-bore intravenous catheter should be inserted into a large peripheral vein, if possible. The loss of skin integrity provides a conduit for insensible fluid

TABLE 11-7
Four Phases of Burn Care[75]

Phase	Timing	Treatment Objectives
Initial evaluation and resuscitation	First 72 hours	To achieve accurate fluid resuscitation and perform a thorough evaluation
Initial wound excision and biologic closure	Days 1 through 7	To identify and remove all full-thickness wounds and obtain biological closure
Definitive wound closure	Day 7 through week 6	To replace temporary covers with definitive ones and close small, complex wounds
Rehabilitation, reconstruction, and reintegration	Entire hospitalization and post-discharge	Initially to maintain range of motion and reduce edema; subsequently to strengthen and prepare patients for return to community

loss through the patient. The amount of fluid needed to replace the volume lost is a function of burn size, time, and overall body surface area. One of the more common resuscitation formulas is the Parkland Formula, which calculates fluid requirement as

$$\text{Fluid required} = 4\ \text{mL} \times \%\text{TBSA} \times \text{Weight (kg)}$$

The first half of total fluid is given during the first 8 hours post burn because of the greater initial volume loss. The remainder is given over the next 16 hours, titrating to urine output.[80,81] Although fluid resuscitation is critically important in managing patients with significant burns, fluid status should be closely monitored to avoid overhydration and possible exacerbation of pulmonary edema.[14]

The response to fluid administration and physiological tolerance of a patient is the most important determinant.[52] Additional fluids are commonly needed with inhalation injury, electrical burns, associated trauma, and delayed resuscitation. The appropriate resuscitation regimen administers the minimal amount of fluid necessary for maintenance of vital organ perfusion; the subsequent response of the patient over time dictates if more or less fluid is needed. Fluid replacement is usually monitored by measuring urinary output. An acceptable hydration is indicated by a urine output of more than 30 mL/hour in an adult (0.5 mL/kg/hour).

Wound coverage for burns varies depending on the severity of the injury. First-degree burns require a dry, sterile dressing while more severe full-thickness second- and third-degree burns may require excision of the damaged tissue and coverage of the area by skin grafting. There are other kinds of dressings as well. Some dressings are impregnated with silver ions (Ag^{++}) because silver has antimicrobial properties; these are applied topically to prevent infection. Other dressing materials are combinations of biologically based and a nonbiologic substrate (Alloderm, Biobrane, and Integra). These products have cultured cells from either human or animal (bovine, porcine) origin usually on a silicone backing. These products are used to provide temporary coverage when there is insufficient donor skin available to cover the wound area as well as to prepare the wound bed for subsequent grafting. A common goal for using biologic dressings is to reduce scarring when compared with the nonbiologically based dressings.

Allografts are skin grafts where the skin being used comes from the patient being treated. The tissue forming the allograft originated from the patient himself or herself and will not pose any rejection of foreign tissue. Sometimes the area needing coverage is larger than the size of the graft; the surgeon will expand the coverage area of the graft by **meshing**. This term refers to passing the graft through a device that creates a matrix of small holes in the tissue, allowing it to be stretched. The holes in the meshed graft help with fluid drainage and decrease hematoma formation, allowing for a healthier graft.

Xenografts refer to skin that is from a donor (usually cadaver). This donated skin is usually stored frozen and thawed only when needed. Another source of xenograft skin is from animals, most typically porcine skin. Regardless of the source of the xenograft, these are temporary coverings that are used to protect the patient from infection and to prepare the wound bed for healing.

Grafts can be classified as either **split thickness** or **full thickness**. Split-thickness grafts have a layer of dermis, while full-thickness grafts contain all the components of the skin: epidermis, dermis, nerve endings, and even hair follicles.[15] Full-thickness grafts are attributed with less scar formation and are thus reserved when function or aesthetics (eyelids, face) are important.[15]

The second phase, initial wound excision and biologic closure, extends from day 1 through day 7. During this phase, the surgery is performed that changes the natural history of the injury. Typically, this period involves a series of staged operations to excise and debride the wound and place temporary covering over the denuded areas. The damaged or dead tissue needs to be removed (**escharectomy**). Otherwise, it poses an infection risk as well as having an impact on the patient's acid–base and electrolytes.

The third phase, definitive wound closure, lasts from day 7 through week 6. It involves replacement of temporary wound covers with a definitive cover, as well as closure and acute reconstruction of burns that have a small surface area but are highly complex, such as wounds on the face and hands.

The success of graft healing (graft take) depends on the nutritional status of the patient. If patients are not being given adequate nutrition to meet their caloric requirements, they will go into a catabolic state, which has a detrimental impact on graft and donor site healing. If a graft does not adhere to the wound and survive, it will need to be treated as a wound with removal of the dead tissue.

The final stage involves rehabilitation, reconstruction, and reintegration. Although this final stage really begins during the resuscitation period, it becomes very involved and time consuming toward the end of the acute hospital stay. Because this is an ongoing process, the psychological health of the burn patient is crucial for a successful rehabilitation. Issues that need to be addressed are impaired function, altered body image, and retraining/reconditioning. Still considered investigational, limb (arm, hand), and facial transplantation have been used in the most severe cases where the underlying tissue was destroyed beyond any functionality requiring surgical removal.[82] These procedures are being developed to restore function where a limb has been lost or extreme facial damage has occurred.

Management of Inhalation Injury

When a diagnosis of inhalation injury is suspected or confirmed, management is supportive only. See **Box 11-8**. The treatment of inhalation injury can be broken down into several main categories: ventilator management, pharmacological treatment to aid pulmonary function using aerosolized medications, early tracheostomy, and using evidence-based medicine to optimize patient outcomes.[83] There are no prophylactic or preemptive therapies for inhalation injury. There is no clear-cut value in using prophylactic antibiotics, and there is evidence to show that such use would promote the selection of antibiotic-resistant strains colonizing the airway.[84] Although many patients demonstrate reactive bronchospasm and benefit from early institution of nebulized beta$_2$ agonists, steroids are infrequently required to treat acute bronchospasm. The practice of nebulizing heparin alone or with *N*-acetylcysteine has been studied as a means to prevent or lessen the effects of small airway obstruction resulting from the sloughing of epithelial cells, excessive mucus production, and the formation of fibrin casts in a sheep model.[85,86] This practice has been undertaken by several burn centers, but the supporting evidence is anecdotal and small sample sizes prevent definitive conclusions.[83,85–87] It is important, however, to maintain high humidity within the ventilator circuit to prevent a humidity deficit of the airways that results in the desiccation of the secretions of the distal airways. Good pulmonary hygiene is crucial.[88]

Lung-protective strategies should be used in the ventilator management of these patients. The use of a low-tidal-volume (Vt) approach, like the ARDSnet protocol, is an acceptable method of managing these patients because it keeps ventilating pressures low, which would otherwise add to the already sustained lung injury.[89,90] Other practices to consider are permissive hypercapnia and prone positioning.[89–92]

In patients with inhalation injury, five predictable events occur that have important clinical implications and require intervention: acute upper airway obstruction, bronchospasm, small airway obstruction, infection, and respiratory failure.

Management of Acute Upper Airway Obstruction

During inhalation injury, airway obstruction caused by mucosal edema evolves over time (usually within the first 4–24 hours after injury) and ideally is anticipated and managed with intubation.[87] Early intubation for airway protection should be considered in the patient with suspected inhalation injury. Intubation attempts of these often-difficult airways can be approached in a studied manner if the impending obstruction is anticipated. After resuscitation has occurred, edema of the upper airway can change the anatomic structures from a relatively easy intubation to a difficult airway requiring a well-experienced anesthesiologist or even a surgical airway. Failure to recognize impending airway obstruction can result in serious morbidity and even mortality in burn patients. Clinicians should be alert in cases involving hot liquid aspiration, which can lead to sudden loss of airway patency and late sequelae of upper airway burns.[24,75,83,93,94] The critical importance of initial airway evaluation and proper control cannot be overemphasized, and this need continues throughout the period of intubation.

Oral endotracheal tubes are often used because they are easy to place and are subjectively more comfortable for the patient than nasal endotracheal tubes. Tubes should be secured in a manner that allows room for stabilization and easy adjustment as facial edema changes, but not for gross movement of the airway that might risk unintended extubation. Because the lips are not reliable landmarks, placement of the endotracheal tube must be monitored by notation of the centimeter mark at the incisor or gum. It is useful if this information is posted near the head of the bed for quick reference during routine and emergency airway care.

The security of the endotracheal tube should be verified regularly, because reintubation after accidental extubation can be difficult in burn patients, who commonly have significant facial and oropharyngeal edema. Clinicians who care for these patients should be equipped to deal with sudden airway emergencies and have the appropriate equipment on hand for managing a difficult, unstable airway. Maintenance of endotracheal tubes in burn patients is complicated by shifts in extravascular volume. The method used to secure the tube should facilitate simple loosening and tightening as needed

BOX 11-8 Management of Inhalation Injury

- Upper airway obstruction should be bypassed with endotracheal intubation or a tracheostomy; careful attention must be given to the endotracheal tube's position and patency.
- Bronchospasm should be treated with inhaled bronchodilators.
- Adequate humidification of the airway needs to be provided to lessen the chances of secretion desiccation.
- Pulmonary infection should be managed with a focus on organisms identified by sputum culture.
- Respiratory failure is managed with PEEP and low tidal volumes to avoid alveolar overdistention and subsequent ventilator-induced lung injury.

to provide for adjustments coinciding with changes in facial edema. A unique concern with airway securing techniques in burns is for a method that can function in a high relative humidity, heated environment. When facial burns are present, adhesive tape is seldom useful. Cloth ties can be effectively used to secure tubes.[95]

Another aspect of airway care should be maintaining adequate pressure in the cuff of the airway to prevent or at least minimize leakage and aspiration of trapped material from the oropharynx into the lungs. Elevating the head of the bed, if physiologically possible, at a 30-degree supine angle will also help minimize silent aspiration and potential ventilator-associated pneumonia (VAP).[88] By following these interventions, the VAP can be decreased, as this is a population where pulmonary involvements can double the morbidity of the underlying injury.[96,97]

The proper indication and optimum timing for tracheostomy in the burn patient remains the subject of debate. The consensus is that adult burn patients in whom protracted intubation is expected are candidates for tracheostomy, ideally after anterior neck burns have been addressed.

Management of Bronchospasm

Intense bronchospasm from aerosolized irritants is common during the first 24–48 hours after injury, especially in young children. This condition is well managed with inhaled $beta_2$ agonists in most patients, although some require low-dose epinephrine infusions or parenteral or inhaled steroids. One option is heliox if the oxygen requirement is minimal. The use of continuous nebulization of high-dose $beta_2$ agonists is another option. Recent evidence, however, has pointed to increased mortality when patients with ARDS are routinely treated with $beta_2$ agonists.[98,99]

Ventilator management strategy for patients with burns and/or inhalation injury is not significantly different from those for any other critically ill patient needing respiratory support. Some points of emphasis specific to patients with burn and inhalation injury should be emphasized, such as monitoring airway pressures, lung compliance and resistance, and good pulmonary hygiene techniques.

Thoracic escharotomies may be required to provide adequate chest excursion, allowing the patient to breathe more freely. Until this is done, airway pressures may need to be high to overcome the decreased compliance of the chest wall. Techniques used to minimize auto-PEEP, such as using short inspiratory times and high inspiratory flows, as well as attempting to match the auto-PEEP with applied PEEP, often may be necessary, but if air trapping is severe, some degree of carbon dioxide retention is acceptable. Plateau airway pressure (Pplat) and mean airway pressure should be monitored to assess the patient's gas exchange and transport status.[89,90]

Management of Small Airway Obstruction

During the first 24 hours after inhalation injury, airway obstruction is essentially limited to the bronchial airways. Major components of this obstructive material are mucus from extensive glandular secretion, inflammatory cells, fibrin, and exfoliated epithelial cells.[87] As necrotic endobronchial debris sloughs, pulmonary hygiene often becomes increasingly difficult. An aggressive program of pulmonary hygiene, including suctioning and bronchoscopy, is an important component of care. Along with aggressive airway clearance, it is important to provide adequate humidification of inspired gases. Therapeutic bronchoscopy can facilitate clearance of the airways and evaluation of the condition of the airway mucosa. Small endotracheal tubes can suddenly become occluded; staff members should be prepared to respond promptly. Pulmonary hygiene is an essential component of the management of patients with inhalation injury. It is crucial to provide 100% relative humidity to these patients and decrease the potential for creating a humidity deficit that might lead to thickened pulmonary secretions and increase the chances of occluding the endotracheal tube.

The use of mucolytic agents in treating small airway obstruction has been shown not to be as effective as was once believed. The main components of bronchial and small airway casts are fibrin and cellular debris. Use of mucolytic agents has not been shown to be effective in either clinical practice or animal models.[88]

Management of Pulmonary Infection

Pulmonary infection develops in 30–50% of patients with an inhalation injury. Pneumonia without the presence of inhalation injury increases the mortality of burn injury up to 40%.[63] It frequently is difficult to distinguish between pneumonia and tracheobronchitis (purulent infection of the denuded tracheobronchial tree), but the difference often has little practical clinical importance. Infection typically occurs toward the end of the first postinjury week; patients with serious inhalation injuries often are seen to deteriorate at this time. A patient with newly purulent sputum, fever, and perhaps diminished gas exchange should be treated with antibiotics, which should be adjusted as necessary after sputum culture information has been obtained. To repeat an important point: the physiology of inhalation injury, which involves injury to endobronchial mucosa with hampered mucociliary clearance, makes good pulmonary hygiene a particularly important component of management.

Management of Respiratory Failure

Respiratory failure is common in individuals with inhalation injury. Respiratory failure among these patients is caused as often by sepsis as by inhalation injury. As in

other forms of respiratory failure, the lung volume that can be recruited with mechanical ventilation is limited, and over-vigorous attempts to force high pressures into these lungs exacerbate the underlying injury. These patients do well with a volume-targeted, pressure-limited ventilation strategy. See **Box 11-9**. If this approach fails, innovative methods of support should be considered, such as extracorporeal membrane oxygenation or inhaled nitric oxide. Prone positioning also has been shown to improve oxygenation. With adequate personnel, the patient can be quickly and safely repositioned while special attention is given to maintenance of the airway and central lines.[92]

The use of a specific ventilator mode or ventilator often accompanies the discussion of inhalation injury. Some of these modes include high-frequency oscillatory ventilation (HFOV), volume diffusive respiration (VDR), and airway pressure release ventilation. Each of these ventilation techniques has the common goal of maintaining alveolar recruitment and gas exchange. Both HFOV and VDR require special-purpose ventilators. HFOV has recently been evaluated in several large randomized controlled studies, which have shown either no difference or a negative impact on outcome.[100,101]

VDR is pressure-controlled ventilation with superimposed subtidal oscillations that facilitates clearance of endobronchial debris. Although some data have been encouraging, burn patients with inhalation injury and respiratory failure can be very well managed with any other mode of ventilation with which the center is comfortable, paying particular attention to tidal volume, airway pressure, and aggressive pulmonary hygiene.[24,63,83,102]

Ventilator discontinuation and extubation of burn patients follow the general guidelines applicable to other patients. This patient group has some unique aspects that must be taken into consideration. See **Box 11-10**. Of great importance is the balance of the pain medication needs of patients with large wounds and donor sites with the need for an alert sensorium for extubation. There is evidence of benefit from combined

BOX 11-9 Therapeutic Responses to Progressive Respiratory Failure

- Address bronchospasm with nebulized beta$_2$-agonist agents.
- Address poor chest wall compliance that occurs secondary to overlying eschar with escharotomies.
- Ensure ventilator synchrony with adequate opiate and benzodiazepine infusions.
- Neuromuscular blockade occasionally may be required.
- Reset goal of ventilation to a physiological pH (7.2 or higher). Allow gradual onset of hypercapnia if the patient does not have a head injury.
- Reset goal of oxygenation to an arterial saturation of at least 88%, typically associated with an arterial oxygen content of 55 mm Hg or higher.
- Optimize inflating pressures.
- Utilize a lung-protective, low-tidal-volume approach to ventilation. Follow ARDSnet guidelines for adjusting tidal volumes based on the ideal body weight of the patient.
- Keep plateau pressure (Pplat) below 30 cm H_2O.
- Choose optimum PEEP.
- Choose optimum mean airway pressure. Lengthen inspiratory time to a target mean airway pressure of 20–25 cm H_2O, if auto-PEEP is not detectable.
- If these measures are inadequate, consider the use of adjuncts such as inhaled nitric oxide or extracorporeal support.

BOX 11-10 Important Considerations in Ventilator Discontinuation and Extubation of a Patient with a Burn Injury

- *Sensorium*: The patient must be awake and alert enough to protect the airway.
- *Airway patency*: Upper airway edema must be resolved to the extent that an air leak is audible around the endotracheal tube (with the cuff deflated if the tube is cuffed) at a moderate inflating pressure (20–30 cm H_2O).
- *Muscle strength*: Strength must be adequate for ventilation. An indirect measure of this is an unassisted tidal volume of 6–10 mL/kg and a maximum inspiratory pressure (Pi_{max}) less than −20 cm H_2O.
- *Compliance*: Combined chest wall and lung compliance must be high enough that work of spontaneous breathing is not excessive. Respiratory system compliance should be at least 50 mL/cm H_2O.
- *Gas exchange*: The Pao_2/FIO_2 should be greater than 200 mm Hg.
- *SBT*: The successful completion of an SBT.

spontaneous breathing trial (SBTs) along with routine periodic sedation discontinuation to facilitate mental status assessment.[103,104]

Management of Carbon Monoxide Poisoning

For unknown reasons, 5–25% of patients with serious CO exposure have been reported to develop delayed major neurological sequelae.[92,105] These patients can be managed with 100% isobaric oxygen or with **hyperbaric oxygen (HBO) therapy**. The half-life of COHb is about 5 hours breathing 21% oxygen at ambient pressure, about 74 minutes breathing 100% oxygen at ambient pressure (range 26–148 minutes), and less than 30 minutes breathing 100% oxygen at 3 atm. If serious exposure has occurred and is manifested by overt neurological impairment or a high COHb level, HBO is reasonable if it can be safely administered. There is some evidence that neurological impairment with CO poisoning can be delayed and the effects can be long term.[106,107] With inhalation injury, 100% oxygen should be administered until a safe COHb level is reached. MbCO has a slower dissociation than COHb, which can account for a rebound of COHb several hours after receiving normobaric oxygen.[55]

With inhalation injury the COHb level should be measured with **CO-oximetry**. In the presence of COHb, traditional pulse oximetry is unreliable and potentially misleading. Two-wavelength pulse oximetry does not measure COHb. The pulse oximeter displays high O_2 saturation (Spo_2) despite significant COHb, misleading the clinician into believing that COHb is not present. New-generation multiple-wavelength pulse oximeters allow noninvasive measurement of COHb. These portable, noninvasive devices can be part of emergency medical services crew equipment providing COHb measurements closer to the time of exposure. Because COHb does not affect gas exchange in the lungs, a patient with COHb who is breathing 100% oxygen may have a very high Pao_2 (more than 400 mm Hg) despite low hemoglobin oxygen saturation as measured by CO-oximetry. The high Pao_2 competes with CO for hemoglobin-binding sites, resulting in eventual displacement of CO from the hemoglobin. It is best to use COHb measurements taken close to the time of exposure. COHb measurements taken at the hospital can be less because treatment with supplemental oxygen may have already started prior to arrival.[55]

HBO has been proposed to improve the prognosis of those who suffer serious CO exposure, but its use remains controversial. On a busy burn service, the question of which patient to treat in the hyperbaric chamber commonly arises. Most patients who undergo hyperbaric oxygen therapy are treated in a monoplace hyperbaric chamber. Treatment regimens vary, but a typical CO poisoning protocol is 3 atm for the first treatment and then 2 or 3 atm for subsequent treatments, for 90 minutes, with two 10-minute air breaks to reduce the incidence of oxygen toxicity seizures. Providing HBO to a patient in a monoplace chamber severely limits access to the patient during treatment, so patients in unstable condition are poor candidates. Other relative contraindications are wheezing and air trapping, which increase the risk of pneumothorax, and high fever, which increases the risk of hyperoxia-induced seizures, which is also known as the Paul Bert effect.[108]

If a patient must be mechanically ventilated during HBO, adequate preparation measures before the chamber door is closed can prevent most complications. Prior to the patient's being placed into the chamber, the airway must be well positioned and adequately stabilized because patients who inadvertently awaken during the therapy may attempt self-extubation. For the same reason, patients must be well restrained before HBO regardless of their mental status. The endotracheal tube cuff must be converted from air filled and refilled with an appropriate volume of sterile water; this conversion prevents collapse of the cuff during the compression phase of the treatment. They must be evaluated for bronchospasm and aggressively treated with bronchodilators just before treatment. Suctioning of both the lower respiratory tract and the oral pharynx is helpful because this cannot be done while the patient is in the hyperbaric chamber. Prophylactic myringotomies are recommended for unconscious or intubated patients to prevent tympanic membrane rupture.

Providing mechanical breathing support at hyperbaric pressures can be a technically difficult task. Some considerations that need to be considered are patient and practitioner safety, the type of chamber being utilized (monoplace vs. multiplace), physiological monitoring needs, as well as sedation requirements. The design of monoplace chambers prevents immediate response in the event of a medical emergency. Multiplace chambers typically have a clinical attendant in the chamber to respond to a crisis.

Ventilators used with monoplace HBO chambers are usually modified versions of a pressure-limited, time-cycled device, although there is a limited choice for commercially available HBO-capable ventilators.[109,110] A base rate is maintained, but all spontaneous breathing efforts are unassisted. Patients who suddenly awaken during therapy and who cough or inspire vigorously can aspirate oral secretions, leading to an increase in airway pressure and a reduction in tidal volume. These same clinical signs occur with other clinical complications, such as a kinked endotracheal tube, main stem intubation, pneumothorax, or bronchospasm. Assessment and ascertaining the cause are difficult because the clinician is isolated from the patient. It may be best, if clinically appropriate, to adequately sedate the patient and avoid spontaneous breathing during the treatment.

Management of Hydrogen Cyanide Poisoning

Although CO poisoning is the more common condition to treat with inhalation injury, hydrogen cyanide (HCN) poisoning can be present and can result in similar problems with cellular respiration. HCN is produced by the combustion of nitrogen-containing compounds (such as those found in synthetic materials used in furniture) in a low-oxygen atmosphere. Like CO, HCN binds to the cytochrome oxidase system and inhibits cellular metabolism, resulting in tissue and systemic acidosis.[102] Cyanide antidotes are amyl nitrite and intravenous infusions of sodium nitrite and sodium thiosulfate. These treatments do have risks, and often care may be supportive.[102]

Burn Center Referral Criteria

Caring for a patient with a burn and inhalation injury can be challenging. Optimal treatment of severely burned patients requires significant healthcare resources and has led to the development of burn centers. A burn center is an ideal place for treating patients with any type of significant burn. The multidisciplinary team members in these centers are well trained and comfortable treating patients with massive cutaneous injuries and their systemic side effects. Knowing which individuals to treat and which to refer to a burn center is vital. See **Box 11-11**.[111]

Centralized care provided in designated burn units has promoted a tram approach to both scientific investigation and clinical care that has demonstrably improved the welfare of burn patients. Multidisciplinary efforts are imperative to continue improving and understanding the rehabilitation and emotional, psychological, and physiological recovery of burn patients.[112]

BOX 11-11 Burn Center Referral Criteria

Burn injuries that should be referred to a burn center include the following:

1. Partial thickness burns greater than 10% TBSA.
2. Burns that involve the face, hands, feet, genitalia, perineum, or major joints.
3. Third-degree burns in any age group.
4. Electrical burns, including lightning injury.
5. Chemical burns.
6. Inhalation injury.
7. Burn injury in patients with preexisting medical disorders that could complicate management, prolong recovery or affect mortality.
8. Any patient with burns and concomitant trauma (such as fractures) in which the burn injury poses the greatest risk of morbidity or mortality. In such cases, if the trauma poses the greater immediate risk, the patient may be initially stabilized in a trauma center before being transferred to a burn unit. Physician judgment will be necessary in such situations and should be in concert with the regional medical control plan and triage protocols.
9. Burned children in hospitals without qualified personnel or equipment for the care of children.
10. Burn injury in patients who will require special social, emotional, or rehabilitative intervention.

Reproduced with permission from Burn Center Referral Criteria—American Burn Association. *Ameriburnorg*. 2018. https://ameriburn.org/public-resources/burn-center-referral-criteria. Accessed July 5, 2018.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Additional fluids must be administered when a burn patient has an inhalation injury.
2. True or False: Meshing is used to increase the size of skin grafts.
3. True or False: Prophylactic intravenous antibiotics are indicated for all mechanically ventilated patients with inhalation injuries.
4. True or False: Relative humidity needs to be minimized to allow healing of the airways during mechanical ventilation.
5. True or False: The first treatment with hyperbaric oxygen therapy is achieved with 3 atm of pressure.

Prognosis

The treatment of patients with extensive burns remains a major challenge, even with advances in burn care over recent decades. Most patients do not suffer long-term functional impairment following smoke inhalation alone.[52] However, pulmonary-related complications following burns and inhalation injury are responsible for up to 77% of the deaths.[52] Three major risk factors for death from burns include age 60 or older, TBSA ≥40%, and the presence of inhalation injury.[113] The need for mechanical ventilation and severe inhalation injury on bronchoscopy predicts increased mortality in patients with inhalation injury due to burns.[52,114] Other factors contributing to a poor prognosis include ARDS and pneumonia, which have also been found to be independent predictive factors for mortality.[115] Clinical

observations suggest that a patient's previous medical history plays an important part in the prognosis, and this has been confirmed in some large studies, but not in others.[114] Age and full-thickness burns are factors associated with reductions in long-term survival.[114]

Support groups exist for burn survivors. These groups are an important measure in the phase of recovery and rehabilitation as much as surgical intervention. One of these groups, the Phoenix Society for Burn Survivors (http://www.phoenix-society.org), provides peer support for newly burned patients as well as survivors of burn injury. Peer support has been helpful in reintegrating burn survivors into society.

KNOWLEDGE CHECK QUESTIONS

1. True or False: More than 75% of deaths from cutaneous burns and inhalation injury are due to pulmonary-related complications.
2. True or False: Burn survivors require rehabilitation.

Chapter Summary

When a burn victim enters the emergency department, the focus of care is to stop the burning process, manage the airway, and provide respiratory care and fluid resuscitation. The primary survey includes simultaneous diagnosis and treatment of the patient. The secondary survey includes a complete burn-focused head-to-toe assessment of the patient and a gathering of pertinent patient information.

Cutaneous burns are classified by their depth, ranging from superficial to deep dermal burns, which correlate to the degree classification system. The percentage of TBSA that is burned is estimated for the calculation of initial fluid resuscitation and to decide on transfer to a burn center. A patient with any partial thickness burn that covers more than 10% TBSA, any third-degree burn, or burns involving the face, hands, feet, genitalia, perineum, or major joints should be transferred to a burn center.

A patient with a significant burn injury needs to be assessed for CO poisoning, especially if the patient was in an enclosed structure. CO poisoning is treated with 100% oxygen or hyperbaric oxygenation therapy or both. Facial burns are associated with inhalation injury and a compromised airway. Early intubation for airway protection should be considered in patients with suspected inhalation injury.

Respiratory complications are common in patients with inhalation injury and large cutaneous burns. These complications include pneumonia, respiratory failure, ARDS, and multiorgan dysfunction syndrome.

Key Points

1. An organized plan of care for patients with burn injury has four phases: initial evaluation and resuscitation, initial wound excision and biological closure, definitive wound closure, and rehabilitation.
2. Diagnosis and initial treatment for burn and inhalation injury patients occurs simultaneously using the ABCDE survey as a guide. The secondary survey is a more burn-specific, head-to-toe assessment and full history.
3. Burn wounds need to be evaluated for extent, depth, and circumferential components.
4. Estimates of TBSA percentage burned are important to determine the amount of fluid resuscitation required by the patient and whether the patient needs to be transferred to a burn center.
5. All clinicians who care for burn patients should be prepared to deal with airway emergencies.
6. Five predictable events occur in patients with inhalation injury: acute upper airway obstruction, bronchospasm, small airway obstruction, infection, and respiratory failure.
7. Lung-protective ventilation strategies should be used for patients with inhalation and burn injury.
8. COHb is treated with 100% oxygen or hyperbaric oxygen therapy or both.
9. Respiratory failure is a leading cause of morbidity and mortality in the burn unit. Approximately 20% of burn injury patients suffer inhalation injury. Pneumonia with the presence of inhalation injury increases the mortality of a burn injury up to 40%.

Chapter Questions

1. Cutaneous burns over _____ of total body surface area are considered major burns.
   a. 10%
   b. 15%
   c. 20%
   d. 25%
2. A third-degree cutaneous burn _____.
   a. is very painful
   b. heals spontaneously within 3–6 weeks
   c. is considered a full-thickness burn
   d. is mostly red and moist
3. The estimated burn size for a patient with circumferential burns to the right leg and right arm and an anterior chest burn is _____.
   a. 45%
   b. 36%
   c. 27%
   d. 18%

4. Symptoms from carbon monoxide poison typically manifest at a carboxyhemoglobin level of _____.
   a. 10%
   b. 15%
   c. 20%
   d. 25%
5. Hydrogen cyanide gas is produced by the burning of _____.
   a. household appliances
   b. tires
   c. polyvinyl chloride
   d. polyester
6. The hypodermal layer of skin _____ _____.
   a. contains an extensive vascular system
   b. provides the skin with structural support
   c. produces new skin cells and coloring
   d. insulates the body from cold temperatures
7. The maximal damage to the skin by a burn is contained within the _____.
   a. zone of stasis
   b. dermal layer
   c. zone of hyperemia
   d. zone of coagulation
8. Direct damage to the lower airways is due to _____.
   a. fire
   b. steam
   c. electricity
   d. chemicals
9. The presence of mucosal sloughing in the airways classifies the inhalation injury as _____.
   a. massive
   b. severe
   c. moderate
   d. mild
10. Initial hyperbaric oxygenation treatment for carbon monoxide poisoning is at _____.
    a. 2 atm
    b. 3 atm
    c. 4 atm
    d. 4.5 atm

References

1. Evers L, Bhavsar D, Mailänder P. The biology of burn injury. *Exp Dermatol*. 2010;19(9):777–783. doi:10.1111/j.1600-0625.2010.01105.x.
2. Dries D, Endorf F. Inhalation injury: epidemiology, pathology, treatment strategies. *Scand J Trauma Resusc Emerg Med*. 2013;21(1):31. doi:10.1186/1757-7241-21-31.
3. Hampson N, Piantadosi C, Thom S, Weaver L. Practice recommendations in the diagnosis, management, and prevention of carbon monoxide poisoning. *Am J Respir Crit Care Med*. 2012;186(11):1095–1101. doi:10.1164/rccm.201207-1284ci.
4. Hettiaratchy S, Papini R. Initial management of a major burn: I—overview. *BMJ*. 2004;328(7455):1555–1557. doi:10.1136/bmj.328.7455.1555.
5. Pauldine R, Gibson B, Gerold K, Milner S. Considerations in burn critical care. *Contemp Crit Care*. 2008;6:1–11.
6. Namias N. Advances in burn care. *Curr Opin Crit Care*. 2007;13(4):405–410. doi:10.1097/mcc.0b013e328263888f.
7. Meshulam-Derazon S, Nachumovsky S, Ad-El D, Sulkes J, Hauben D. Prediction of morbidity and mortality on admission to a burn unit. *Plast Reconstr Surg*. 2006;118(1):116–120. doi:10.1097/01.prs.0000221111.89812.ad.
8. Sheridan R, Barillo D, Herndon D, et al. Burn specialty teams. *J Burn Care Rehabil*. 2005;26(2):170–173. doi:10.1097/01.bcr.0000155544.38709.6e.
9. Ikonomidis C, Lang F, Radu A, Berger M. Standardizing the diagnosis of inhalation injury using a descriptive score based on mucosal injury criteria. *Burns*. 2012;38(4):513–519. doi:10.1016/j.burns.2011.11.009.
10. Hostler D. Treating smoke inhalation and airway burns. *JEMS*. 2014. https://www.jems.com/articles/print/volume-39/issue-10/features/treating-smoke-inhalation-and-airway-bur.html. Accessed June 26, 2018.
11. Taira B, Singer A, Thode H, Lee C. Burns in the emergency department: a national perspective. *J Emerg Med*. 2010;39(1):1–5. doi:10.1016/j.jemermed.2008.01.009.
12. Alharbi Z, Piatkowski A, Dembinski R, et al. Treatment of burns in the first 24 hours: simple and practical guide by answering 10 questions in a step-by-step form. *World J Emerg Surg*. 2012;7(1):13. doi:10.1186/1749-7922-7-13.
13. Drigalla D, Gemmill J. Burns and smoke inhalation. In: Stone C, Humphries R, eds. *Current Diagnosis & Treatment Emergency Medicine*. 7th ed. New York, NY: McGraw-Hill; 2011. https://accessemergencymedicine.mhmedical.com/Content.aspx?bookId=385&sectionId=40357261. Accessed June 16, 2017.
14. Rice P Jr, Orgill D. Emergency care of moderate and severe thermal burns in adults. In: Moreira M, Grayzel J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 28, 2018.
15. Kagan R, Peck M, Ahrenholz D, et al. Surgical management of the burn wound and use of skin substitutes. *J Burn Care Res*. 2013;34(2):e60–e79. doi:10.1097/bcr.0b013e31827039a6.
16. Hettiaratchy S, Papini R. Initial management of a major burn: II—assessment and resuscitation. *BMJ*. 2004;329(7457):101–103. doi:10.1136/bmj.329.7457.101.
17. Giretzlehner M, Dirnberger J, Owen R, Haller H, Lumenta D, Kamolz L. The determination of total burn surface area: how much difference? *Burns*. 2013;39(6):1107–1113. doi:10.1016/j.burns.2013.01.021.
18. Papini R. Management of burn injuries of various depths. *BMJ*. 2004;329(7458):158–160. doi:10.1136/bmj.329.7458.158.
19. Benson A, Dickson W, Boyce D. Burns. *Br Med J*. 2006;332:649–652.
20. Rice Jr P, Orgill D. Classification of burn injury. In: Jeschke M, Collins K, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed June 28, 2018.
21. Rickard R, Martin N, Lundy J. Imprecision in TBSA calculation. *Burns*. 2014;40(1):172–173. doi:10.1016/j.burns.2013.09.002.
22. Lundin K, Alsbjørn B. The 101 percent in Lund-Browder charts—a commentary. *Burns*. 2013;39(4):819–820. doi:10.1016/j.burns.2012.08.016.
23. Ahuja R, Gibran N, Greenhalgh D, et al. ISBI practice guidelines for burn care. *Burns*. 2016;42(5):951 -952. doi:10.1016/j.burns.2016.06.020.
24. Endorf F, Gamelli R. Inhalation injury, pulmonary perturbations, and fluid resuscitation. *J Burn Care Res*. 2006;27(suppl):S133. doi:10.1097/01253092-200603001-00169.
25. Cartotto R, Innes M, Musgrave M, Gomez M, Cooper A. How well does the parkland formula estimate actual fluid resuscitation volumes? *J Burn Care Rehabil*. 2002;23(4):258–265. doi:10.1097/00004630-200207000-00006.
26. Saffle J. The phenomenon of "Fluid Creep" in acute burn resuscitation. *J Burn Care Res*. 2007;28(3):382–395. doi:10.1097/bcr.0b013e318053d3a1.

27. Williams R, Wohlgemuth S. Does the "Rule of Nines" apply to morbidly obese burn victims? *J Burn Care Res*. 2013;34(4):447–452. doi:10.1097/bcr.0b013e31827217bd.
28. Williams J, King B, Aden J, et al. Comparison of traditional burn wound mapping with a computerized program. *J Burn Care Res*. 2013;34(1):e29–e35. doi:10.1097/bcr.0b013e3182676e07.
29. Yu C, Lin C, Yang Y. Human body surface area database and estimation formula. *Burns*. 2010;36(5):616–629. doi:10.1016/j.burns.2009.05.013.
30. Parvizi D, Kamolz L, Giretzlehner M, et al. The potential impact of wrong TBSA estimations on fluid resuscitation in patients suffering from burns: things to keep in mind. *Burns*. 2014;40(2):241–245. doi:10.1016/j.burns.2013.06.019.
31. Lafferty K. Smoke inhalation injury clinical presentation: history, physical examination. *Emedicinemedscapecom*. 2017. https://emedicine.medscape.com/article/771194-clinical. Accessed July 5, 2018.
32. Gill P, Martin R. Smoke inhalation injury. *BJA Educ*. 2015;15(3):143–148. doi:10.1093/bjaceaccp/mku017.
33. Valdez T, Desai U, Ruhl C, Nigri P. Early laryngeal inhalation injury and its correlation with late sequelae. *Laryngoscope*. 2006;116(2):283–287. doi:10.1097/01.mlg.0000197932.09386.0e.
34. Demling R. Smoke inhalation lung injury: an update. *Eplasty*. 2008;8(e27):254–282. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396464. Accessed June 27, 2018.
35. Clardy P, Manaker S, Perry H. Carbon monoxide poisoning. In: Traub S, Burns M, Grayzel J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 27, 2018.
36. Chiew A, Buckley N. Carbon monoxide poisoning in the 21st century. *Crit Care*. 2014;18(2):221. doi:10.1186/cc13846.
37. Peck M. Epidemiology of burn injuries globally. In: Jeschke M, Collins K, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed June 26, 2018.
38. Burns. *World Health Organization*. 2018. http://www.who.int/news-room/fact-sheets/detail/burns. Accessed June 30, 2018.
39. Burn Incidence Fact Sheet—American Burn Association. *Ameriburnorg*. 2018. https://ameriburn.org/who-we-are/media/burn-incidence-fact-sheet. Accessed June 30, 2018.
40. QuickStats: Number of deaths resulting from unintentional carbon monoxide poisoning,* by month and year—National Vital Statistics System, United States, 2010–2015. *MMWR Morb Mortal Wkly Rep*. 2017;66(8):234. doi:10.15585/mmwr.mm6608a9.
41. Niszczak J, Forbes L, Serghiou M. Burn rehabilitation. In: Maitin I, Cruz E, eds. *Current Diagnosis & Treatment: Physical Medicine & Rehabilitation*. New York, NY: McGraw-Hill; 2015.
42. Lewis G, Heimbach B, Gibran N. Evaluation of the burn wound: management decisions. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Elsevier Saunders; 2012:125–130.
43. Yousef H, Sharma S. Anatomy, skin (Integument), epidermis. In: *Statpearls [Internet]*. Treasure Island, FL: StatePearls Publishing; 2017. Available at: http://www.ncbi.nln.gov/books/NBK470464. Accessed June 30, 2018.
44. Garcia-Espinoza J, Aguilar-Aragon V, Ortiz-Villalobos E, Garcia-Manzano R, Antonio B. Burns: definition, classification, pathophysiology and initial approach. *Gen Med* (*Los Angeles*). 2017;5(5):298. doi:10.4172/2327-5146.1000298.
45. Hettiaratchy S, Dziewulski P. Pathophysiology and types of burns. *BMJ*. 2004;328(7453):1427–1429. doi:10.1136/bmj.328.7453.1427.
46. Porter C, Tompkins R, Finnerty C, Sidossis L, Suman O, Herndon D. The metabolic stress response to burn trauma: current understanding and therapies. *Lancet*. 2016;388(10052):1417–1426. doi:10.1016/s0140-6736(16)31469-6.
47. Kramer G. Pathophysiology of burn shock and burn edema. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Elsevier Saunders; 2012:103–113.
48. Weavind L. Burn shock, resuscitation of burn shock, burn shock resuscitation. *Cancer Therapy Advisor*. 2018. https://www.cancertherapyadvisor.com/critical-care-medicine/burn-shock-resuscitation-of-burn-shock-burn-shock-resuscitation/article/585933. Accessed June 28, 2018.
49. Walker P, Buehner M, Wood L, et al. Diagnosis and management of inhalation injury: an updated review. *Crit Care*. 2015;19(1):351. doi:10.1186/s13054-015-1077-4.
50. Rehberg S, Maybauer M, Enkhbaatar P, Maybauer D, Yamamoto Y, Traber D. Pathophysiology, management and treatment of smoke inhalation injury. *Expert Rev Respir Med*. 2009;3(3):283–297. doi:10.1586/ers.09.21.
51. Gupta K, Mehrotra M, Kumar P, Gogia A, Prasad A, Fisher J. Smoke inhalation injury: etiopathogenesis, diagnosis, and management. *Indian J Crit Care Med*. 2018;22(3):180–188. doi:10.4103/ijccm.ijccm_460_17.
52. Mlcak R. Inhalation injury from heat, smoke, or chemical irritants. In: Bulger E, Jeschke M, Mandel J, Collins K, Finlay G, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed June 28, 2018.
53. Foncerrada G, Culnan D, Capek K, et al. Inhalation injury in the burned patient. *Ann Plast Surg*. 2018;3(suppl 2):S106–S112. doi:10.1097/sap.0000000000001377.
54. Mlcak R, Suman O, Herndon D. Respiratory management of inhalation injury. *Burns*. 2007;33(1):2–13. doi:10.1016/j.burns.2006.07.007.
55. Stoller K. Hyperbaric oxygen and carbon monoxide poisoning: a critical review. *Neurol Res*. 2007;29(2):146–155. doi:10.1179/016164107x181770.
56. Werner, S. Thermal and chemical burns. In: Cline DM, Ma JO, Cydulka RK, Meckler GD, Handel DA, Thomas SH. eds. *Tintinalli's Emergency Medicine Manual* 7th ed. New York, NY: McGraw-Hill; 2011, 604-610.
57. Hunt J, Arnoldo B, Purdue G. Prevention of burn injuries. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Saunders Elsevier; 2012.
58. Fidkowski C, Fuzaylov G, Sheridan R, Coté C. Inhalation burn injury in children. *Pediatr Anesth*. 2009;19:147–154. doi:10.1111/j.1460-9592.2008.02884.x.
59. Chung K, Wold S. Critical care in the severely burned: organ support and management of complications. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Saunders Elsevier; 2012:377–395.
60. Latenser B. Critical care of the burn patient. In: Hall J, Schmidt G, Kress J, eds. *Principles of Critical Care*. 4th ed. New York, NY: McGraw-Hill; 2015.
61. Lo C, Chen S, Lee K, et al. Brain injury after acute carbon monoxide poisoning: early and late complications. *AJR Am J Roentgenol*. 2007;189(4):W205–W211. doi:10.2214/ajr.07.2425.
62. Demling R. Burns & other thermal injuries. In: Doherty G, ed. *Current Diagnosis & Treatment: Surgery*. 14th ed. New York, NY: McGraw-Hill; 2015, 227-240.
63. Freiburg C, Igneri P, Sartorelli K, Rogers F. Effects of differences in percent total body surface area estimation on fluid resuscitation of transferred burn patients. *J Burn Care Res*. 2006;27(suppl):S52. doi:10.1097/01253092-200603001-00007.
64. Orgill D, Piccolo N. Escharotomy and decompressive therapies in burns. *J Burn Care Res*. 2009;30(5):759–768. doi:10.1097/bcr.0b013e3181b47cd3.
65. Rezvani B, Mortman K. Extensive mucosal sloughing and tracheobronchial cast after inhalation injury. *J Bronchology Interv Pulmonol*. 2011;18(4):375–376. doi:10.1097/lbr.0b013e3182357fed.
66. Silva L, Garcia L, Oliveria B, et al. Acute respiratory distress syndrome in burn patients: Incidence and risk factor analysis. *Ann Burns Fire Disasters*. 2016;29(3):178–182.
67. Mlcak R, Buffalo M, Jimenez C. Pre-hospital management, transportation and emergency care. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Saunders Elsevier; 2012:93–102.

68. Nikkanen H, Skolnik A. Diagnosis and management of carbon monoxide poisoning in the emergency department. *Emerg Med Pract*. 2011;13(2):1–14.
69. Boots R, Dulhunty J, Paratz J, Lipman J. Respiratory complications in burns. *Clin Pulm Med*. 2009;16(3):132–138. doi:10.1097/cpm.0b013e3181a39032.
70. Bai C, Huang H, Yao X, et al. Application of flexible bronchoscopy in inhalation lung injury. *Diagn Pathol*. 2013;8(1):174. doi:10.1186/1746-1596-8-174.
71. Carr J, Crowley N. Prophylactic sequential bronchoscopy after inhalation injury: results from a three-year prospective randomized trial. *Eur J Trauma Emerg Surg*. 2013;39(2):177–183. doi:10.1007/s00068-013-0254-x.
72. Woodson L, Talon M, Traber D, Herndon D. Diagnosis and treatment of inhalation injury. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Saunders Elsevier; 2012:229–237.
73. Endorf F, Gamelli R, Patel P. Abbreviated Injury Score (AIS) for inhalation injury—MDCalc. *Mdcalccom*. 2018. https://www.mdcalc.com/abbreviated-injury-score-ais-inhalation-injury#evidence. Accessed June 29, 2018.
74. Garner J, Jenner J, Parkhouse D. Prediction of upper airway closure in inhalational injury. *Mil Med*. 2005;170(8):677–682. doi:10.7205/milmed.170.8.677.
75. Sheridan R. Airway management and respiratory care of the burn patient. *Int Anesthesiol Clin*. 2000;38(3):129–145. doi:10.1097/00004311-200007000-00009.
76. Holm C, Melcer B, Horbrand F, Worl H, von Donnersmarck G, Mhlbauer W. Intrathoracic blood volume as an end point in resuscitation of the severely burned: an observational study of 24 patients. *J Trauma*. 2000;48(4):728–734. doi:10.1097/00005373-200004000-00023.
77. Klein M, Hayden D, Elson C, et al. The association between fluid administration and outcome following major burn. *Ann Surg*. 2007;245(4):622–628. doi:10.1097/01.sla.0000252572.50684.49.
78. Pham T, Cancio L, Gibran N. American burn association practice guidelines burn shock resuscitation. *J Burn Care Res*. 2008;29(1):257–266. doi:10.1097/bcr.0b013e31815f3876.
79. Holm C, Mayr M, Hörbrand F, et al. Reproducibility of transpulmonary thermodilution measurements in patients with burn shock and hypothermia. *J Burn Care Res*. 2005;26(1):260–265.
80. Mitchell K, Khalil E, Brennan A, et al. New management strategy for fluid resuscitation. *J Burn Care Res*. 2013;34(1):196–202. doi:10.1097/bcr.0b013e3182700965.
81. Lindford A, Lim P, Klass B, Mackey S, Dheansa B, Gilbert P. Resuscitation tables: a useful tool in calculating pre-burns unit fluid requirements. *Emerg Med J*. 2009;26(4):245–249. doi:10.1136/emj.2008.058123.
82. Arno A, Barret J, Harrison R, Jeschke M. Face allotransplantation and burns. *J Burn Care Res*. 2012;33(5):561–576. doi:10.1097/bcr.0b013e318247eb06.
83. Palmieri T. Inhalation injury: research progress and needs. *J Burn Care Res*. 2007;28(4):549–554. doi:10.1097/bcr.0b013e318093def0.
84. Wahl W, Taddonio M, Arbabi S, Hemmila M. Duration of antibiotic therapy for ventilator-associated pneumonia in burn patients. *J Burn Care Res*. 2009;30(5):801–806. doi:10.1097/bcr.0b013e3181b47ef9.
85. Enkhbaatar P, Cox R, Traber L, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. *Crit Care Med*. 2007;35(12):2805–2810. doi:10.1097/01.ccm.0000291647.18329.83.
86. Holt J, Saffle J, Morris S, Cochran A. Use of inhaled heparin/N-acetylcysteine in inhalation injury: does it help? *J Burn Care Res*. 2008;29(1):192–195. doi:10.1097/bcr.0b013e31815f596b.
87. Cox R, Mlcak R, Chinkes D, et al. Upper airway mucus deposition in lung tissue of burn trauma victims. *Shock*. 2007;29:356–361. doi:10.1097/shk.0b013e31814541dd.
88. Blamoun J, Alfakir M, Rella M, et al. Efficacy of an expanded ventilator bundle for the reduction of ventilator-associated pneumonia in the medical intensive care unit. *Am J Infect Control*. 2009;37(2):172–175. doi:10.1016/j.ajic.2008.05.010.
89. Brower R, Matthay M, Morris A, Schoenfeld D, Thompson B, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med*. 2000;342(18):1301–1308. doi:10.1056/nejm200005043421801.
90. Serpa Neto A, Cardoso S, Manetta J, et al. Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome. *JAMA*. 2012;308(16):1651–1659. doi:10.1001/jama.2012.13730.
91. Galiatsou E, Kostanti E, Svarna E, et al. Prone position augments recruitment and prevents alveolar overinflation in acute lung injury. *Am J Respir Crit Care Med*. 2006;174(2):187–197. doi:10.1164/rccm.200506-899oc.
92. Guérin C. Prone positioning acute respiratory distress syndrome patients. *J Thorac Dis*. 2018;10(S16):S2092–S2094. doi:10.21037/jtd.2018.05.109.
93. Smith D. Acute inhalation injury. *Clin Pulm Med*. 1999;6(4):224–235. doi:10.1097/00045413-199907000-00003.
94. Liao W, Yeh F, Lin J, Huang C, Chang S, Lin S. Delayed tracheal stenosis in an inhalation burn patient. *J Trauma*. 2008;64(3):E37–E40. doi:10.1097/01.ta.0000233651.53591.51.
95. Lovett P, Flaxman A, Stürmann K, Bijur P. The insecure airway: a comparison of knots and commercial devices for securing endotracheal tubes. *BMC Emerg Med*. 2006;6(1):7. doi:10.1186/1471-227x-6-7.
96. Brown D, Archer S, Greenhalgh D, Washam M, James L, Warden G. Inhalation injury severity scoring system a quantitative method. *J Burn Care Rehabil*. 1996;17(6):552–557. doi:10.1097/00004630-199611000-00013.
97. Weireter L, Collins J, Britt R, Reed S, Novosel T, Britt L. Impact of a monitored program of care on incidence of ventilator-associated pneumonia: results of a longterm performance-improvement project. *J Am Coll Surg*. 2009;208(5):700–704. doi:10.1016/j.jamcollsurg.2009.01.041.
98. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung Injury. *Am J Respir Crit Care Med*. 2011;184(5):561–568. doi:10.1164/rccm.201012-2090oc.
99. Smith F, Perkins G, Gates S, et al. Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. *Lancet*. 2012;379(9812):229–235. doi:10.1016/s0140-6736(11)61623-1.
100. Young D, Lamb S, Shah S, et al. High-frequency oscillation for acute respiratory distress syndrome. *Survey Anesthesiol*. 2013;57(6):274–275. doi:10.1097/01.sa.0000435572.01496.5c.
101. Ferguson N, Cook D, Guyatt G, et al. High-frequency oscillation in early acute respiratory distress syndrome. *N Engl J Med*. 2013;368(9):795–805. doi:10.1056/nejmoa1215554.
102. Fraser J, Mullany D, Traber D. Inhalational lung injury in patients with severe thermal burns. *Contemp Crit Care*. 2007;4:1–12.
103. Jackson J, Girard T, Gordon S, et al. Long-term cognitive and psychological outcomes in the awakening and breathing controlled trial. *Am J Respir Crit Care Med*. 2010;182(2):183–191. doi:10.1164/rccm.200903-0442oc.
104. Mehta S. Daily sedation interruption in mechanically ventilated critically ill patients cared for with a sedation protocol. *JAMA*. 2012;308(19):1985. doi:10.1001/jama.2012.13872.
105. Edelman D, Khan N, Kempf K, White M. Pneumonia after inhalation injury. *J Burn Care Res*. 2007;28(2):241–246. doi:10.1097/bcr.0b013e318031d049.
106. Weaver L, Hopkins R, Chan K, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med*. 2002;347(14):1057–1067. doi:10.1056/nejmoa013121.
107. Weaver L, Valentine K, Hopkins R. Carbon monoxide poisoning. *Am J Respir Crit Care Med*. 2007;176(5):491–497. doi:10.1164/rccm.200701-026oc.

108. Patel D, Goel A, Agarwal S, Garg P, Lakhani K. Oxygen toxicity. *J Indian Academy Clin Med*. 2003;4:234–237.
109. Lefebvre J, Lyazidi A, Parceiro M, et al. Bench testing of a new hyperbaric chamber ventilator at different atmospheric pressures. *Intensive Care Med*. 2012;38(8):1400–1404. doi:10.1007/s00134-012-2590-4.
110. Weaver L. Hyperbaric oxygen in the critically ill. *Crit Care Med*. 2011;39(7):1784–1791. doi:10.1097/ccm.0b013e31821858d1.
111. Burn Center Referral Criteria—American Burn Association. *Ameriburnorg*. 2018. https://ameriburn.org/public-resources/burn-center-referral-criteria. Accessed July 5, 2018.
112. Al-Mousawi A, Suman O, Herndon D. Teamwork for total burn care: burn centers and multidisciplinary burn teams. In: Herndon D, ed. *Total Burn Care*. 4th ed. New York, NY: Saunders Elsevier; 2012:9–13.
113. Pavoni V, Gianesello L, Paparella L, Buoninsegni L, Barboni E. Outcome predictors and quality of life of severe burn patients admitted to intensive care unit. *Scand J Trauma Resusc Emerg Med*. 2010;18(1):24. doi:10.1186/1757-7241-18-24.
114. Pompermaier L. *Outcome of Burn Care: The Mortality Perspective*. 2017. https://liu.diva-portal.org/smash/get/diva2:1155796/FULLTEXT02.pdf
115. Monteiro D, Silva I, Egipto P, et al. Inhalation injury in a burn unit: a retrospective review of prognostic factors. *Ann Burns Fire Disasters*. 2017;30(2):121–125.

CHAPTER

12

Lung Carcinoma

"When you have exhausted all possibilities, remember this: You haven't."

—Thomas Edison

OUTLINE

OBJECTIVES

1. Recognize common characteristics, manifestations, and diagnostic features of lung cancer.
2. Review the incidence, prevalence, and risk factors, as well as prognostic determinants, of lung cancer.
3. Explain how lung cancer is staged.
4. Review recommended treatment and management of patients with various malignant and benign neoplastic disorders.

KEY TERMS

Adenocarcinoma
Adjuvant chemotherapy
Benign
Bronchogenic carcinoma
Bronchoalveolar carcinoma
Cachexia
Carcinoma
Driver mutations
Endobronchial ultrasound
Fine-needle aspiration
Horner syndrome
Keratin pearls
Large cell lung carcinoma (LCLC)
Malignant
Mediastinoscopy
Metastasize
Neoplasm
Neuroendocrine cells
Neuroendocrine (NE) markers
Neuroendocrine progenitors
Non-small cell lung carcinoma (NSCLC)
Pancoast syndrome
Positron emission tomography (PET)
Small cell lung carcinoma (SCLC)
Sputum cytologic studies
Squamous cell lung carcinoma (SQCLC)
Thoracoscopy
Transbronchial needle aspiration (TTNA)
Transthoracic needle aspiration
Video-assisted thoracoscopy (VAT)

Case Study

A 62-year-old man sees his family physician complaining of cough, shortness of breath, and weight loss. The patient is sent for a chest radiograph. The chest radiograph is reported, by the radiologist, to be abnormal, showing a "shadow" and a small left-side pleural effusion. The patient explains that the cough began about 5 weeks ago and is nonproductive. The patient attributed the cough to his "sinuses." He admitted to a 40+ pack-year history of cigarette smoking, which he discontinued about 10 years earlier. Over those past 5 weeks, the patient claims he has lost around 10 pounds. On physical examination, the patient appears thin for his height and has a palpable lymph node in the left supraclavicular fossa. Breath sounds over the left lower lobe are decreased. The patient's temperature is normal, heart rate is 106 beats/minute, respiratory rate is 18 breaths/minute, and blood pressure is 145/92 mm Hg. The oncologist finds a palpable liver, but his liver is enlarged. The patient receives a referral to an oncologist for follow-up of suspected lung cancer.

The oncologist performs a needle biopsy of the patient's left supraclavicular lymph node. Cytologic results of the needle aspirate reveal small cell lung carcinoma (SCLC). The patient's computed tomography (CT) scan showed a 4-cm mass in his left lung, a 1-cm mass in his right lung with mediastinal lymphadenopathy, enlargement of several superior mediastinal and supraclavicular lymph nodes, a pleural effusion, and metastasis to several spots within the liver. The pleural effusion is tapped, and the cytology report is positive for SCLC. Since the cancer spread to the pleural space and the liver, the patient has extensive-stage SCLC. The oncologist notes that the cancer is T2N3M1c lung cancer and recommends chemotherapy.

Introduction

Lung **neoplasms** are abnormal masses of tissue that proliferate abnormally due to rapid division into the tissue surrounding it. Neoplasms may either be **benign**, noncancerous, or **malignant**. Benign lung neoplasms tend not to grow in an unlimited, aggressive manner; do not invade surrounding tissues or structures; and do not **metastasize**. Malignant neoplasms tend to be aggressive and metastasize to other areas of the body. The term *lung* ***carcinoma***, or **bronchogenic carcinoma**, refers to malignancies that originate in the airways or pulmonary parenchyma.[1]

The World Health Organization (WHO) estimates that lung cancer is the cause of 1.37 million deaths globally per year.[2] Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer exceed those from any other malignancy worldwide.[2] This translates to 1.82 million new cases of lung cancer.[3] In the United States, lung cancer is also the leading cause of cancer mortality in men and women.[4]

Lung cancer is highly heterogeneous and can arise in many different sites in the bronchial tree. Due to its heterogeneous nature, lung cancer has highly variable signs and symptoms, which depend on its anatomic location. Most patients (70%) diagnosed with lung cancer present with advanced disease.[4]

The WHO divides lung cancer into two major classes based on their biology, therapy, and prognosis. These two categories are **non-small cell lung carcinoma (NSCLC)** and **small cell lung carcinoma (SCLC)**. NSCLC accounts for more than 80% of all lung cancer cases, and it includes two major types: nonsquamous, including **adenocarcinoma** (AdenoCA), **large cell lung carcinoma (LCLC)**, and other cell types, and **squamous cell lung carcinoma (SQCLC)**. AdenoCA is the most common type of lung cancer seen in the United States and is also the most frequently occurring histology in nonsmokers[5] (**Table 12-1**). In addition to

TABLE 12-1
Types of Lung Cancer

Lung Carcinoma Type	Percentage of all Lung Carcinoma	Anatomic Location
AdenoCA	40	Arise in peripheral bronchi
SQCLC	25–30	Arise in main bronchi and advance to the carina
LCLC	10	Tumors lack the classic glandular or squamous morphology
SCLC	10–15	Derived from the hormonal cells of the lung Cells disseminate into submucosal lymphatic vessels and regional lymph nodes almost without a bronchial invasion

Data from Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P. Lung cancer: biology and treatment options. *Biochim Biophys Acta.* 2015;1856(2):189–210. doi:10.1016/j.bbcan.2015.08.002.

the histologic classification, an additional biomarker profile is available for some of the lung cancers. Since these cancers originate in the lungs, they are also referred to as primary lung cancers.

Both absolute and relative frequencies of lung cancer have risen dramatically. Around 1953, lung cancer became the most common cause of cancer deaths in men. In 1985, it became the leading cause of cancer deaths in women, and now causes approximately twice as many deaths as breast cancer. Lung cancer deaths are declining in men, and the death rate in women has plateaued secondary to decreases in smoking. Now, however, almost one-half of all lung cancer deaths occur in women.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Bronchogenic carcinoma is a broad name for all malignancies originating in the airways or lung parenchyma.
2. True or False: Most patients present early on in their cancerous lung disease.
3. True or False: SQCLC is a type of SCLC.
4. True or False: AdenoCA is the most common type of lung cancer in the United States.

Non-Small Cell Lung Carcinoma

NSCLC accounts for approximately 80% of all lung cancers. These cancers are divided into three histologically different types: AdenoCA, SQCLC, and LCLC. Patients with NSCLC require a complete staging workup to evaluate the extent of the disease because stage plays a major role in determining the choice of treatment.[6]

Definition/Diagnosis

Methods used to obtain a definitive diagnosis of a suspected lung cancer is dependent on several factors, including the histology, size, and location of the primary tumor; the presence of metastasis; and the overall clinical status of the patient. This distinction allows for a more tailored selection of cytotoxic chemotherapy in advanced NSCLC. Optimal management of NSCLC now requires that tumors be screened for a range of predictive and prognostic biomarkers that help to predict sensitivity to targeted therapy and estimate prognosis, respectively.[7] Several mutations, called **driver mutations**, were identified in NSCLC research, and relevant targeted therapies are now available and new ones are on the horizon in the foreseeable future.[7]

Clinical Signs and Symptoms

While lung cancer is a common malignant disorder, its clinical presentation may be insidious with little advanced warning, often progressing asymptomatically until the disease is well advanced. Early symptom recognition of subtle manifestations or clues suggesting lung cancer involvement may potentially lead to early diagnosis. Early diagnosis is beneficial to outcome because it is estimated that 20% patients have localized resectable disease at initial diagnosis.[6] Unfortunately, 25% of patients have regional metastasis at initial diagnosis, with 55% patients having distant spread of disease.[6]

The most common presenting manifestations include cough (50–75%), hemoptysis (25–50%), dyspnea (25%), and chest pain (20%).[8] Less-common manifestations include the signs and symptoms or laboratory abnormalities of distant metastases. When any of these manifestations are present in a patient with suspected lung cancer, the patient needs to be promptly referred for additional testing (**Table 12-2**).

Musculoskeletal signs may include bone pain, muscle weakness, and spinal cord impingement. Systemic physical findings are usually associated with metastatic disease and are by nature nonspecific. Common manifestations may include unexplained weight loss, fatigue, **cachexia**, and low-grade fever. NSCLC may cause postobstructive pneumonia and pleural involvement. Pleural involvement can cause malignant pleural effusions. However, not all pleural effusions are malignant. They may be associated with lymphatic obstruction, postobstructive pneumonitis, or atelectasis.[1] Pleural effusions occur in 10–15% of patients with lung cancer.[1]

Etiology

Approximately 78–90% of all lung cancers are directly caused from tobacco smoking, which exhibits a clear dose response rate that accentuates its genetic predisposition.[6] Cigarette smoking is firmly established as a cause of lung cancer in industrialized North American and Europe.[9] One in nine smokers eventually develops lung cancer.[10] An increased intensity and duration of cigarette smoking strongly correlates with development of lung cancer. Environmental exposure (passive or "secondhand" exposure) is far less of a risk for lung cancer than active smoking. However, there is also a dose

TABLE 12-2
Signs and Symptoms of NSCLC

Central Tumors	Peripheral Tumors
Cough Hemoptysis Postobstructive pneumonia Shortness of breath Wheezing	Cough Pain Pleural effusion Shortness of breath

Data from Tan W. Non-small cell lung cancer: practice essentials, background, pathophysiology. *Emedicinemedscapecom.* 2018. https://emedicine.medscape.com/article/279960-overview. Accessed June 22, 2018.

response relationship between the intensity of exposure and the relative risk of developing lung cancer.

Other carcinogens positively associated with lung cancer include occupational and other environmental exposures to asbestos, radon products, polycyclic hydrocarbons, cadmium, chloromethyl ethers, halogen ether, chromium, nickel, and inorganic arsenic. See **Box 12-1**. The relative risk of asbestos exposure combined with tobacco use is multiplicative and estimated to be 100 times that of asbestos exposure alone. An undeniable relationship also has been identified between prolonged inhalation of atmospheric pollution and the development of lung cancer.[11]

Epidemiology

Primary lung cancer remains the most common malignancy after non-melanocytic skin cancer, and deaths from lung cancer exceed those from any other malignancy worldwide.[2] The major types of lung cancers include AdenoCA, SCLC, and LCLC, in addition to SCLC. NSCLC accounts for 85–90% of lung cancers.[2,6]

In 2012, a total of 1.8 million new cases of lung cancer and 1.6 million related deaths were reported. Men had the highest death rates in Central and Eastern Europe (47.6), Eastern Asia (44.8), and Micronesia (41.7) at that time. The highest mortality rate for women was reported in North America (23.5), Micronesia (20.8), and Northern Europe (19.1).[12] Lung cancer incidence in men in the United States has been decreasing since the early 1980s. However, in U.S. women, the rate has been decreasing only since the mid-2000s. From 2004 to 2013, the incidence of lung cancer decreased by 2% per year in men and by 1% per year in women.[13] The incidence and mortality rates for lung cancer tend to mirror each other because most patients diagnosed with lung cancer eventually die of it.[10]

A significantly higher proportion of lung cancer is diagnosed in patients aged 65 and over, and the median age at diagnosis is around 70 years. A subset of patients with NSCLC present at a younger age (<40 years), but the incidence in this population had decreased in the United States from 1978 to 2010.[2]

The term *never smokers* refers to individuals who smoked fewer than 100 cigarettes in their lifetime, including lifetime nonsmokers.[10] Available data show the overall global statistics estimate that 15% of lung cancer in men and up to 53% in women are not attributable to smoking, with never smokers accounting for 25% of all lung cancer cases worldwide.[10] Although all histologic types of lung cancer are associated with cigarette smoking, in smokers the association is stronger for SCLC and for SQCLC. In contrast, AdenoCA of the lung is more common in never smokers compared with smokers (**Figure 12-1**).

During the last 25 years, the distribution of NSCLC has changed. In the United States, SQCLC, which was formally the predominant histologic type, decreased, while AdenoCA increased in both genders. In Europe, similar trends have occurred in men, while in women, both SCLC and AdenoCA are still increasing.[2]

BOX 12-1 Etiology of NSCLC[6,10]

- Tobacco smoking
- Other types of smoking
  - Cigar
  - Pipe
  - Recreational drugs
- Genetic factors
- Environmental tobacco smoke
- Biomass and wood-smoke exposure
- Environmental air pollution
- Occupational carcinogens
  - Asbestos (asbestos mining, brake lining work, cement production, insulation work)
  - Radon (mining)
  - Beryllium (ceramic manufacture, electronic and aerospace equipment manufacture, mining)
  - Chloromethyl ethers (chemical manufacturing)
  - Chromium (chromate production, chromium electroplating, leather tanning, pigment production)
  - Nickel (nickel mining, refining, electroplating, production of stainless and heat-resistant steel, polycyclic aromatics, aluminum production, hydrocarbon compounds, Coke production, ferrochromium alloy production, nickel-containing ore smelting, roofing)
  - Silica (ceramics and glass industry, foundry industry, granite industry, metal ore smelting, mining and quarrying)

Pathophysiology

Lung cancer cells have defects in the regulatory circuits that govern normal cell proliferation and homeostasis.[4] Uninhibited and disorganized growth disrupts local and/or distant lung anatomy as well as normal physiologic processes. NSCLC consists of three distinct cell types: AdenoCA, SQCLC, and LCLC. Because they have overlapping clinical behaviors as well as similar responses to treatment and prognosis, these three lung cancer cell types are typically grouped together with some related though less-common variants. NSCLC represents most of all cases of lung cancer, with SCLC and tumors having more than one cell type in the same



FIGURE 12-1 Comparison of smokers to never smokers for AdenoCA and SQCLS. The ratio of never smokers to smokers for AdenoCA is 3.2:1, whereas the ratio of never smokers to smokers for SQCLS is 1:6.6.

Modified from Dela Cruz C, Tanoue L, Matthay R. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med.* 2011;32(4):605–644 (Figure 12, p. 52). doi:10.1016/j.ccm.2011.09.001.

neoplasm (classified as mixed NSCLC) comprising the remainder. While SQCLC and SCLC are the cell types most commonly associated with tobacco use, AdenoCA has replaced SQCLC as the most common presenting cell type of lung cancer.

Lung cancer typically begins with exposure to carcinogens. The most significant contributor is cigarette smoke. Tobacco smoke contains more than 300 harmful substances with at least 40 known potent carcinogens. Polyaromatic hydrocarbons and nicotine-derived nitrosamine ketone are known to cause DNA mutations.[6] Refer to Box 12-1 for other carcinogens.

Squamous Cell Lung Carcinoma

SQCLC currently accounts for approximately one-third of lung cancers. SQCLC usually originates from respiratory bronchial epithelium of the proximal airway, including the trachea, mainstem bronchi, and lobar and segmental bronchi. An abnormal change in the bronchial columnar epithelial cells occurs, allowing these cells to be replaced by squamous epithelial cells. These squamous cells become more and more atypical in appearance until there is development of a well-localized cancer. Eventually the cancer extends beyond the bronchial mucosa and becomes invasive. This is about the time that the cancer becomes symptomatic or radiologic changes are seen in a (routine) chest radiograph.[14] Sometimes malignant cells are present in a sputum specimen obtained for other reasons. Pathologic microscopic features demonstrate stratified layering of polygonal epithelial cells, prominent intercellular bridges between cells, and keratotic debris identified as **keratin pearls**.[6]

SQCLC are usually located in large or proximal airways, most commonly at the subsegmental, segmental, or lobar level. These airways can become obstructed when the cancer grows into the bronchial lumen, increasing the chance for postobstruction pneumonia. SQCLC more commonly causes a cavity to develop within the tumor mass. Metastasis of SQCLC typically involves direct extension to the pulmonary parenchyma or other neighboring structures or invasion of lymphatic vessels, with spread to local lymph nodes in the hilum or mediastinum. SQCLC tends to remain within the thorax and cause problems by intrathoracic complications rather than by distant metastasis.[14] Metastasis in advanced stages for the most part is local, involving regional lymph nodes and neighboring structures.

Adenocarcinoma

AdenoCA currently accounts for the highest incidence of all primary lung cancers (35–40%), especially in women.[6] It is the subtype observed most commonly in persons who are never smokers. AdenoCA originating in the lungs most likely arises from glandular goblet cells within the major bronchi. The majority of AdenoCA occurs in the lung periphery, and therefore, it is much more difficult to relate the origin to the bronchial wall. This tumor cell type typically presents radiographically as a solitary peripheral pulmonary nodule in an asymptomatic patient, though it may also present as a hilar or mediastinal mass. Malignant pleural effusion or chest wall involvement is less often seen with AdenoCA. **Bronchoalveolar carcinoma** represents a subset or variant of AdenoCA that usually presents as an interstitial lung disease on chest radiography. Pathologically, bronchoalveolar carcinoma typically displays a tuft-like proliferation along the alveolar lining.[6]

Large Cell Lung Carcinoma

LCLC accounts for a much smaller percentage of NSCLC, causing roughly 10% of all lung cancers. Histologically, LCLC has sheets of highly atypical cells with focal necrosis, with no evidence of keratinization, as is typical of SQCLC, or gland formation, as typical of AdenoCA. LCLC has a similar prognosis to AdenoCA and is combined with it in clinical trials.[6]

Risk Factors

There are two categories of risk factors for lung cancer: factors that are modifiable and those that are not (**Table 12-3**).[15]

Among lung cancer risk-reduction measures, smoking cessation is the most important preventive action affecting lung cancer incidence. Associated conditions

TABLE 12-3
Modifiable and Nonmodifiable Risk Factors for NSCLC

Modifiable Risk Factors	Nonmodifiable Risk Factors
Tobacco smoke • Cigarettes • Pipe smoking • Cigar smoking	Previous radiation therapy to the lungs
Secondhand smoke	Air pollution
Radon exposure	Family history
Asbestos exposure	
Radioactive ore exposure	
Inhaled chemicals • Arsenic • Beryllium • Cadmium • Silica • Vinyl chloride • Nickel compounds • Chromium compounds • Coal products • Mustard gas • Chloromethyl ethers	
Diesel exhaust exposure	

Data from Non-Small Cell Lung Cancer Risk Factors. *Cancerorg*. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/causes-risks-prevention/risk-factors.html. Accessed June 24, 2018.

such as chronic bronchitis and chronic obstructive pulmonary disease on the other hand, show more rapid improvement or stabilization following termination of smoking. Other risk factors include exposure to other respiratory toxins in the home or workplace environment, such as benzene-related products (polycyclic aromatic hydrocarbons), chromates and chromium, chloromethyl ethers, vinyl chloride, asbestos, arsenic, nickel, and mustard gas. Air pollution from combustion engines and indoor pollution from cooking fires increase risk, and radon and radon progeny and ionizing radioactive materials have been shown to cause lung cancer.

Complications

Distant metastases at the time of presentation of a patient with NSCLC are a frequent clinical problems. Approximately 30–40% of NSCLC patients present with metastatic disease at the time of diagnosis.[16] The most frequent sites that lung cancer spreads to include the bones, brain, liver, and adrenal glands.[6]

Most individuals with lung cancer develop some complications. These complications can all be explained by the growth of the cancerous mass, by the spread of the cancer cells throughout the body, by the body's immune response to the cancer, and by the inappropriate release of hormones by the cancer cells. See **Box 12-2**.

BOX 12-2 Complications from NSCLC

Regional lung cancer spread	Airway compression (dyspnea) Esophageal compression (dysphagia) Horner syndrome Pancoast syndrome Phrenic nerve palsy (elevated hemidiaphragm and worsening dyspnea) Recurrent laryngeal nerve palsy (hoarseness) Superior vena cava syndrome (superior vena cava obstruction)
Metastatic lung cancer spread	Brain metastases Bone pain Hepatomegaly Liver metastases Spinal cord compression

Data from Tan W. Non-small cell lung cancer: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/279960-overview. Accessed June 22, 2018.

Metastatic spread of NSCLC can lead to acute spinal cord compression, resulting in lower extremity weakness or paraplegia, sensory deficits, paresthesia, bowel and urinary incontinence or retention, reflex asymmetry, and vertebral pain. The severity of spinal cord compromise secondary to metastatic lung cancer may be limited to pain and minor sensory or motor disturbance or may result in pronounced neurologic abnormalities causing significant disability.

Pancoast syndrome is caused by a tumor in the superior pulmonary sulcus adjacent to the subclavian vessels. The actual pulmonary sulcus comprises the thoracic costovertebral gutter on either side of the vertebral column and is limited by the arch of the first rib superiorly and the diaphragmatic insertion inferiorly[17] (**Figure 12-2**). This type of tumor is most commonly caused by NSCLC, typically squamous cell. Pancoast syndrome manifests in shoulder pain, Horner syndrome, upper extremity complications, and supraclavicular lymph node enlargement.

Horner syndrome is a classic neurologic syndrome whose signs include miosis, ptosis, and anhidrosis. A Horner syndrome can be produced by a lesion anywhere along the sympathetic pathway that supplies the head, eye, and neck[18] (**Figure 12-3**).

Various therapeutic side effects and complications include those caused by individual chemotherapy agents. Common side effects with many chemotherapeutic agents include generalized weakness; pain; gastrointestinal symptoms, including nausea and/or vomiting; diarrhea as well as constipation; poor appetite and weight loss; urinary/kidney problems; low



FIGURE 12-2 The tumor in Pancoast syndrome in this chest radiograph is in the apex of the right lung.

Source: https://radiopaedia.org/articles/pancoast-tumour. Case courtesy of Dr Bruno Di Muzio, Radiopaedia.org, rID: 29403.



FIGURE 12-3 Right Horner syndrome in a 65-year-old man. Note the right-sided upper lid ptosis, right miosis, and "upside-down" ptosis of the right lower lid.

Reproduced with permission from Kanagalingam S, Miller N. Horner syndrome: clinical perspectives. *Eye Brain.* 2015;7:35–46 (Figure 1). doi:10.2147/eb.s63633.

white blood cells (neutropenia); mouth soreness; skin changes; neurologic changes, including headache; vision changes; sexual and fertility changes; and hair loss. Other less-frequent side effects include dyspnea, blood pressure variations, and dizziness. Radiation therapy can also cause a variety of complications and side effects, including radiation-induced cardiotoxicity, radiation-induced pulmonary fibrosis, pneumonitis, radiation recall (a phenomenon largely related to the skin that can occur at the site of previous radiation when certain chemotherapy drugs are given), as well as hair and weight loss.

Diagnostic Testing

In a patient with a long history of cigarette smoking or other risk factors for lung cancer, the presence of persistent respiratory symptoms will prompt a chest radiograph.[6] If the chest radiograph is suspicious, further testing is needed (**Figures 12-4** and **12-5**).



FIGURE 12-4 Anteroposterior chest radiograph of a patient with NSCLC located in the left lung.

Case courtesy of Dr Jeremy Jones, Radiopaedia.org, rID: 6230.



FIGURE 12-5 Chest radiograph of a patient with AdenoCA with a left pleural effusion.

Reproduced with permission from Isozaki H, Yasugi M, Takigawa N, et al. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene. *Jpn J Clin Oncol.* 2014;44(10):963–968 (Figure 1a). doi:10.1093/jjco/hyu110.

Standard laboratory testing includes complete blood count, electrolytes, calcium, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and creatinine. A detailed clinical exam together with laboratory testing can predict the likelihood of metastases in patients with lung cancer, especially those with NSCLC.[8] Abnormal findings in the routine laboratory tests prompt additional imaging that guides the clinicians in their diagnostic and staging workup. An abnormal liver function test could be due to liver metastasis and prompts the evaluation of the liver with direct imaging. An elevation of

calcium prompts additional imaging for bone metastasis. Elevation of the alkaline phosphatase could be due to either liver or bone metastases and prompts additional testing to isolate the source of the elevation.[8]

Imaging

The clinical staging of patients with suspected lung NSCLC begins with radiographic imaging.

CT with contrast is usually the initial imaging modality used to define the anatomic extent of lung cancer. It provides not only staging information but also information about anatomic relationships that are important for surgical or radiation therapy planning[19]. The findings of CT scans of the chest and the clinical presentation of the patient allow practitioners to make presumptive differentiation between NSCLC and SCLC. Massive lymphadenopathy and direct mediastinal invasion are commonly associated with SCLC.[6]

Magnetic resonance imaging (MRI) is most useful when evaluating a patient with possible spinal cord compression. Also, MRI has a greater sensitivity than CT scan for the detection of central nervous system metastasis.[6] The multiplanar capability of MRI enables a more accurate evaluation of hilar lymph nodes, aortopulmonary window lymph nodes, and subcarinal region lymph nodes than does CT imaging.[20] The clinical indications for MRI of the lung are related to three major objectives: the staging of lung tumors, the assessment of pulmonary vascular disease, and the investigation of any pulmonary abnormalities in patients who should not be exposed to radiation.[21]

Positron emission tomography (PET) scanning using fluoro-18-2-deoxyglucose (FDG) is an excellent modality for evaluating solitary pulmonary nodules and is approved by the U.S. Food and Drug Administration (FDA) for this indication.[20] This type of PET scan is used to differentiate benign from malignant pulmonary nodules. PET scans are also useful for detecting distant metastases when whole-body imaging is performed. PET imaging has higher sensitivity, specificity, and accuracy than does CT scanning in staging mediastinal tumors. Some hospitals and radiology centers have PET/CT scanners that can perform a PET and a CT simultaneously. This gives a more detailed appearance of the area on the CT scan. A PET/CT is useful for delineating the primary tumor volume of NSCLC if there is surrounding collapse or consolidation or possible invasion of the mediastinum; otherwise, CT alone with either soft tissue or lung windows is adequate.[22] PET/CT is less helpful when the histologic findings reveal bronchoalveolar AdenoCA[22] (**Figure 12-6**).



FIGURE 12-6 A combination of CT and PET may be useful for the radiotherapy planning of NSCLC if consolidation or collapse surrounds the primary tumor.

Biopsy

Patients with suspected lung cancer require tissue biopsy to confirm the diagnosis. Many patients will present with advanced disease, where mutation testing for targeted treatment is considered the standard of care.[23] Histologic confirmation can be achieved by **sputum cytologic studies**, bronchoscopy, **endobronchial ultrasound** with **transbronchial needle aspiration** (EBUS-TNA), CT-guided transthoracic needle biopsy of the mass, mediastinoscopy, thoracoscopy, and video-assisted thoracoscopy. The choice of methods depends on the location of the tumor.

Sputum cytology analysis represents the least invasive method of obtaining a diagnosis in an individual suspected of having lung cancer. Enough tissue must be obtained for histologic and molecular analyses.[24] Sputum cytology is principally useful in those individuals presenting with larger, centrally located tumors (SQCLC) and in those with hemoptysis. Sampling of sputum specimens is usually an appropriate first step in the individual presenting with a central lesion with or without radiographic evidence of metastatic disease, although positive sputum may also represent cells from a second primary site.

Bronchoscopy with its available technical procedures (including brush and forceps biopsy along with cytologic washings) is a valuable diagnostic procedure in the workup of a patient who is suspected of having lung cancer, especially with central lesions that are visually apparent.[6] Bronchoscopy is the technique of choice in patients with central tumors. Peripheral lesions not visible in the main or lobar airways have a lower sensitivity compared with that of central tumors. EBUS-TNA or endobronchial ultrasound guided **fine-needle aspiration** (EBUS-FNA) is used to obtain cytology or histology samples when there is a submucosal tumor spread or peribronchial tumor causing extrinsic compression.[24] Bronchoscopy with EBUS-directed biopsy has emerged as the most common modality used for diagnosis and staging of suspected NSCLC due to its high diagnostic accuracy for accessing central primary tumors and most mediastinal lymph nodes.[8] Furthermore, EBUS-directed biopsy in patients with mediastinal adenopathy on CT scan may be performed quickly and may reduce the time for establishing a treatment decision.[25]

Transthoracic needle aspiration (TTNA) is both a diagnostic and a therapeutic procedure in patients

presenting in respiratory distress. Thoracentesis has a sensitivity of only 80% with a specificity greater than 90%.[6] When a patient has suspected lung cancer with an accessible pleural effusion and the pleural fluid is negative after two times, a thoracoscopy is needed as the next step to aid in diagnosis.

Mediastinoscopy and **thoracoscopy** are important surgical diagnostic procedures for evaluating lymph nodes of the mediastinum, which are common sites of early metastases in NSCLC. Tissue obtained via mediastinoscopy from the superior and inferior mediastinal, aortic, and hilar lymph nodes that are larger than 1 cm in their short axis have an 80% probability of being malignant. Mediastinoscopy normally allows for the direct visualization of the superior mediastinum, including subcarinal, aortopulmonary window, and periaortic lymphadenopathy, better than if assessed by an anterior mediastinotomy (also known as the Chamberlain procedure). Mediastinoscopy as both a diagnostic and a staging procedure provides the capability of detecting advanced lung cancer and consequently excluding patients from futile attempts at thoracotomy and lung resections.

Video-assisted thoracoscopy (VAT) is used as a minimally invasive surgical procedure that permits evaluation of the pleural space and ipsilateral lymph nodes. VAT can directly visualize tumors that are radiographically noted as late stage. VAT also provides an alternative approach to anterior and extended cervical mediastinoscopy for the evaluation of certain lymph node stations[26] (**Figure 12-7**).



FIGURE 12-7 The incisions for VAT versus the incision for an open thoracotomy.

Reproduced from Cao C, D'Amico T, Demmy T, et al. Less is more: a shift in the surgical approach to non-small-cell lung cancer. *Lancet Respir Med.* 2016;4(3):e11–e12. doi:10.1016/s2213-2600(16)00024-2.

Histopathology

Pathologic diagnosis of all tissue sample types need to be made using the most up-to-date classification system. Distinguishing between NSCLC and SCLC and among the different histologic subtypes of NSCLC is increasingly important to guide subsequent testing for specific mutations and to guide treatment selection, including the identification of patients who are more likely to respond to newer targeted therapies (**Figure 12-8**).

Select patterns of immunohistochemical staining are typically used to confirm the tissue of origin in NSCLC. Biomarkers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign conditions. Tumor-associated biomarkers are biologic molecules that can be detected and serve as indicators of pathogenic processes or pharmacologic response to treatment.[27] Different biomarkers can be used to distinguish normal and pathogenic processes. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Numerous biomarkers have emerged as predictive and prognostic markers for NSCLC. A predictive biomarker is indicative of therapeutic efficacy, because there is an interaction between the biomarker and the therapy on patient outcome. A prognostic biomarker is indicative of patient survival independent of the treatment received, because the biomarker is an indicator of the innate tumor aggressiveness.[5]

Tumor biomarkers are divided into several types: genetic (mutations, changes in number of copies, matrix RNA expression), proteomic (changes in the level and profile of protein expression), metabolic (changes in the level and spectrum of low-molecular-weight metabolites), DNAs and RNAs circulating in blood plasma, exosomal microRNAs (miRNAs), synthesis profile and level of miRNAs, protein biomarkers, circulating tumor cells, and immune, stromal, and endothelial cells.[27] Overall, proteins are the most suitable biomarkers for lung cancer diagnosis because of their involvement in cellular processes[27] (**Table 12-4**).

Staging

The extent or stage of cancer at the time of diagnosis is a key factor that defines prognosis and is a critical element in determining appropriate treatment based on the experience and outcomes of groups of previous patients with similar state.[28] Utilizing a standardized staging system permits comparison of information across treatment centers and within and between cancer-specific registries, and to serve as a basis for cancer research.

Cancer treatment requires assessment of the extent and behavior of the tumor and patient-related factors. Several cancer staging systems are used worldwide. The most clinically useful staging system is the tumor, node, and metastasis (TNM) staging system developed by the American Joint Committee on Cancer (AJCC) in



FIGURE 12-8 Differentiation of cells into the major types of lung cancers. CA, cell carcinoma; EC, epithelial cell; L, lymphocyte; M, macrophage; NC, neuroendocrine; SC, secretory cell; SM, smooth muscle.

Zamay T, Zamay G, Kolovskaya O, et al. Current and prospective protein biomarkers of lung cancer. *Cancers (Basel)*. 2017;9(12):155 (Figure 2). doi:10.3390/cancers9110155.

TABLE 12-4
Protein Biomarkers of Lung Cancer

Lung Cancer Type	Protein Biomarkers of Lung Cancer
NSCLC, SCLC	AGER, C10orfl16, ADD2, PRX, LAMB3, SYNM, SPTA1, ANK1, HBE1, HBG1, CA1, TNXB, MMRN2, HBA1, CAV1, HBB, COL6A6, Clorfl98, CLIC2, SDPR, EHD2, APOA2, NDUFB7, PRKCDBP, LAMA3, LBN
	ACT, 3 IGFBP3, L-PGDS
	SAA
	SAA, HAP, HGF
	TTR
	SAA, AAG1.2, CLU, SSA, AAG1, SAA, TTR
	APOA4, FIBA, LBN, SAA, CP, HP, TTR, KRT2A, GLT1B, CK1, AKT, MBL2, AAG1-2, FGA
	GSN, HP, FCN3, CNDP1
Lung AdenoCA	CALCA, CPS1, CHGB, IVL, AGR2, NASP, PFKP, THBS2, TXNDC17, PCSK1, CRABP2, ACBD3, DSG2, LRBA, STRAP, VGF, NOP2, LCN2, CKMT1B, AKR1B10, PCNA, CPD, PSME3, VIL1
SQCLC	SERPINB5, RPL5, RKP1, RPL10, AKR1B10, AKR1C1, PCNA, RPS2, AKR1C3, THBS2, ACBD3, VSNL1, AHCY, IMMP10, PAK2, IVL, IARS, PSMD2, GBP5, MCM6, NDRG1, NOP58, S100A2, NRGI-2, CNDP1
	UCRP, CER, UPA, MT1-MMP, SFN, TF, ALB, S100A9, STMN, ENO, PLAU, IGFBP7, MMP14, THBS1, TTR

Data from Zamay T, Zamay G, Kolovskaya O, et al. Current and prospective protein biomarkers of lung cancer. *Cancers (Basel)*. 2017;9(12):155 (Table 1). doi:10.3390/cancers9110155.

collaboration with the Union for International Cancer Control, otherwise known as the AJCC TNM system.

The AJCC TNM stage for each cancer type is built by defining the anatomic size of the original tumor (T), whether the cancer is present in the lymph nodes (N), and whether the cancer has spread to other parts of the body or metastases (M), supplemented in some cases with nonanatomic factors.[28] A number (0–4) or the

letter X is assigned to each factor. A higher number indicates increasing severity. The letter X means the information could not be assessed. For example, a T1 score indicates a smaller tumor than a T2 score (Table 12-5).

The analysis of the "T" component is complex. It has many descriptors, including tumor size, endobronchial location, atelectasis/pneumonitis, and the invasion of the many anatomic structures around the lung.[29]

TABLE 12-5
Categories, Subcategories, and Descriptors of the Eighth Edition of the TNM Classification of Lung Cancer[29]

Category	Subcategory	Descriptors
T: Primary tumor		
TX		Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy
T0		No evidence of primary tumor
Tis		Carcinoma in situ: • Tis (AIS): AdenoCA • Tis (SCIS): squamous cell carcinoma
T1		Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus); the uncommon superficial spreading tumor of any size with its invasive component limited to the bronchial wall, which may extend proximal to the main bronchus, is also classified as T1a
	T1mi	Minimally invasive AdenoCA
	T1a	Tumor 1 cm or less in greatest dimension
	T1b	Tumor more than 1 cm but not more than 2 cm in greatest dimension
	T1c	Tumor more than 2 cm but not more than 3 cm in greatest dimension
T2		Tumor more than 3 cm but not more than 5 cm; or tumor with *any* of the following features (T2 tumors with these features are classified as T2a if 4 cm or less or if size cannot be determined and T2b if greater than 4 cm but not larger than 5 cm): • Involves main bronchus regardless of distance to the carina, but without involving the carina • Invades visceral pleura • Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, either involving part of the lung or the entire lung
	T2a	Tumor more than 3 cm but not more than 4 cm in greatest dimension
	T2b	Tumor more than 4 cm but not more than 5 cm in greatest dimension
T3		Tumor more than 5 cm but not more than 7 cm in greatest dimension or one that directly invades any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or associated separate tumor nodule(s) in the same lobe as the primary
T4		Tumors more than 7 cm or one that invades any of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina; separate tumor nodule(s) in a different ipsilateral lobe to that of the primary
N: Regional lymph nodes		
NX		Regional lymph nodes cannot be assessed
N0		No regional lymph node metastasis
N1		Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension
N2		Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)
N3		Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral, or contralateral scalene, or supraclavicular lymph node(s)

(*Continues*)

TABLE 12-5
Categories, Subcategories, and Descriptors of the Eighth Edition of the TNM Classification of Lung Cancer (*Continued*)

Category	Subcategory	Descriptors
M: Distant metastasis		
M0		No distant metastasis
M1		Distant metastasis
M1a		Separate tumor nodule(s) in a contralateral lobe; tumor with pleural nodules or malignant pleural or pericardial effusion; most pleural (pericardial) effusions with lung cancer are due to tumor; in a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and is not an exudate; where these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor
M1b		Single extrathoracic metastasis in a single organ and involvement of a single distant (nonregional) node
M1c		Multiple extrathoracic metastases in one or several organs

Reproduced with permission from Rami-Porta R, Asamura H, Travis W, Rusch V. Lung cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin.* 2017;67(2):138–155 (Table 3). doi:10.3322/caac.21390.



FIGURE 12-9 The IASLC lymph node map, including the groupings for node stations for prognostic analyses.

Reproduced with permission from Rice D. The staging of lung cancer. In: Weissferdt A, Moran C, eds. *Diagnostic Pathology of Pleuropulmonary Neoplasia.* 1st ed. New York, NY: Springer Science+Business Media; 2013:39–51. https://www.springer.com/cda/content/document/cda_downloaddocument/9781441907868-c1.pdf?SGWID=0-0-45-1355809-p174546164. Accessed June 24, 2018.

Analyses of the "N" descriptors at clinical and pathologic staging show that they clearly separate tumors of significantly different prognosis. The nodal zones group neighboring nodal stations (**Figure 12-9**). The nodal stations contain lymph nodes that are located within clearly defined anatomic landmarks in the lung, the hilum, the mediastinum, and the supraclavicular area. The more nodal stations are involved, the worse the prognosis.[29]

Once the T, N, and M scores are assigned, an overall stage is designated. **Box 12-3** shows the stage groupings.

BOX 12-3 Pathologic Stages of NSCLC

Stage I: The cancer is located only in the lungs and has not spread to any lymph nodes.
Stage II: The cancer is in the lung and nearby lymph nodes.
Stage III: The cancer is found in the lung and in the lymph nodes in the middle of the chest, also described as locally advanced disease. Stage III has two subtypes:

- If the cancer has spread only to lymph nodes on the same side of the chest where the cancer started, it is called stage IIIA.
- If the cancer has spread to the lymph nodes on the opposite side of the chest, or above the collar bone, it is called stage IIIB.

Stage IV: This is the most advanced stage of lung cancer and is also described as advanced disease. This is when the cancer has spread to both lungs, to fluid in the area around the lungs, or to another part of the body, such as the liver or other organs.

Data from Lung Cancer 101 | Lungcancer.org. *Lungcancerorg*. 2018. https://www.lungcancer.org/find_information/publications/163-lung_cancer_101/268-types_and_staging. Accessed June 25, 2018.

Treatment and Management

Treatment and management options for NSCLC include surgery, chemotherapy, and radiation. Complete surgical resection is the preferred approach for patients who are surgical candidates. Radiation is the alternative if the patient is not a surgical candidate or if the patient refuses surgery. **Adjuvant chemotherapy** (chemotherapy after surgery) is indicated for those with pathologic Stage II disease and for those patients with Stage IB disease, especially those with high-risk features. Adjuvant chemotherapy is not indicated for patients with resected Stage IA tumors.[31] The benefit of adding adjuvant chemotherapy increases as the disease stage increases.[32] Postoperative radiation therapy (RT) is indicated only for patients with positive surgical margins; it is not indicated for other patients with Stage I or II disease. For those with pathologic Stage III disease after resection, adjuvant chemotherapy is indicated, and sequential postoperative RT is generally recommended for those with mediastinal lymph node involvement.[31]

A subset of treatment for NSCLC is listed in **Box 12-4**. A review of all treatment regimens for NSCLC is quite extensive and beyond the scope of this textbook.

Fatigue, cough, and breathlessness are distressing symptoms for patients with any type of lung cancer. Breathlessness represents one of the most common and distressing symptoms in lung cancer,[33] occurring in up to 90% patients.[34] Cough presents a significant burden for people with lung cancer and is present in 40–70% of patients with lung cancer at initial presentation and as the disease progresses.[35] Cough typically exacerbates breathlessness and has a profound effect on the quality of life. Breathlessness and cough can be treated with a combination of pharmacologic and nonpharmacologic interventions.[33] In lung cancer patients receiving palliative care, these pharmacologic agents may include opioids, including morphine, given by mouth, by nebulizer, or injected; codeine for cough suppression; antitussive drugs; bronchodilators; benzodiazepines; and supplemental oxygen.[33,36] Only low-quality evidence

BOX 12-4 Sample Treatments for NSCLC

- Surgery (Stages I and II)
  - Lobectomy
  - Pneumonectomy
  - Wedge resection/segmentectomy
  - Video-assisted thoracoscopic surgery
  - Mediastinal lymphadenectomy
- RT (Stages I and II when surgical resection is not possible)
- Systemic chemotherapy (adjuvant for Stages II and IIIA)
  - Cisplatin
  - Paclitaxel
  - Cisplatin-gemcitabine
  - Ramucirumab and Docetaxel (second line)
- Molecular-targeted therapy
  - Erlotinib
  - Afatinib
  - Gefitinib
  - Osimertinib
  - Cetuximab
  - Necitumumab
  - Crizotinib
  - Ceritinib
  - Alectinib
  - Brigatinib
  - Bevacizumab
  - Ramucirumab

Data from Tan W. Non-small cell lung cancer: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/279960-overview. Accessed June 22, 2018.

TABLE 12-6
Five-Year Survival Rate for NSCLC by Stages

Stage of NSCLC	Five-Year Survival Rate (%)
IA1	92
IA2	83
IA3	77
IB	68
IIA	60
IIB	53
IIIA	36
IIIB	26
IIIC	13
IVA	10
IVB	<1

Data from Non-Small Cell Lung Cancer Survival Rates, by Stage. *Cancerorg*. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed June 25, 2018.

shows benefit for the use of oral or parenteral opioids to palliate breathlessness, with no evidence of the use of nebulized opioids.[37] Breathlessness self-management techniques can include breathing retraining, relaxation techniques, and psychosocial support.[33] Cancer-related fatigue may be reduced using exercise and acupressure.[34]

Prognosis

The United States has the highest 5-year patient survival rates. From 2008 to 2014, the 5-year survival rate was 18.6%, up from 12.5% in 1975.[6] The most important prognostic factor in patients with NSCLC is the stage of the disease at presentation. The 5-year survival rate for those with localized disease is 55.6%, for regional disease 28.9%, and for those with distant metastasis 4.5%.[38] The 5-year survival rates for different stages of NSCLC are listed in **Table 12-6**.[39]

The prognostic factors for NSCLC include the stage at presentation, performance score, and weight loss.[6] Patients with in situ tumors and Stage I NSCLC have a far better prognosis than more advanced disease. Nonresectable NSCLC has a poor prognosis with a mean survival rate of 8–14 months.[6]

Small Cell Lung Carcinoma

SCLC is distinguished from NSCLC by its ability to rapidly double and cause widespread metastases early on in its development, making it an aggressive lung cancer. SCLC accounts for 10–15% of lung cancers in the United States and occurs almost exclusively in smokers, when compared with NSCLC.

Definition/Diagnosis

There is no screening test available to detect early-stage SCLC. This disease is typically diagnosed when a patient presents with symptoms indicative of advanced-stage disease. Only about one-third of these patients present with limited disease confined to the chest.[40] Although SCLC is initially highly responsive to chemotherapy and radiotherapy, most patients relapse with highly resistant disease within a few months to a year from the initial therapy.

Clinical Signs and Symptoms

Most patients with SCLC are symptomatic at the time of presentation. Most of the presenting signs and symptoms of the disease occur in the advanced stage. See **Box 12-5**. Usually these symptoms are present only within the past 8–12 weeks prior to patient presentation.

BOX 12-5 Signs and Symptoms of SCLC

- Bone pain
- Cough
- Fatigue
- Neurologic dysfunction
- Shortness of breath
- Weight loss

Data from Tan W. Small cell lung cancer: practice essentials, pathophysiology, etiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/280104-overview. Accessed June 25, 2018.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Biomarkers help to predict targeted therapy and estimate prognosis for NSCLC.
2. True or False: Hemoptysis is the most common sign of NSCLC.
3. True or False: Worldwide deaths from lung cancer is second to non-melanocytic skin cancer.
4. True or False: Most of all cases of lung cancer in the United States are SCLC.
5. True or False: Pancoast syndrome is due to a tumor in the superior pulmonary sulcus.
6. True or False: SCLC manifests mostly as a centrally located tumor.

Physical findings of patients presenting with SCLC depend on the extent of local and distant spread and the organ system involved.[41] Obstruction of a bronchus can cause atelectasis and postobstructive pneumonia. Malignant pleural effusions also occur, as can pericardial effusion and pericardial tamponade. Neurologic dysfunction is a manifestation of metastases to the central nervous system. Lymph node involvement is common.

Etiology

The single most important cause of SCLC is tobacco use. At least 95% of patients with SCLC have a positive smoking history.[42] Other environmental and occupational carcinogens have been related to SCLC, including exposure to chloromethyl ether, used in the chemical manufacturer industry, and high radon levels, to which uranium miners are exposed.[43]

Epidemiology

In the United States, lung cancer is the second most common malignancy in both genders, exceeded only by prostate cancer in men and breast cancer in women.[41] However, twice as many women in the United States die of lung cancer each year than from breast cancer.[41] According the American Cancer Society, the estimate for new cases of lung cancer in 2018 is 234,030 and the estimate for deaths from lung cancer is 154,050.[13] SCLC represents approximately 10–15% of the 234,030 cases estimated for 2018. This new case rate for SCLC declined from 17% in 1986 to 13% in 2002.[44] No data are available specifically for SCLC worldwide.

A decrease in the percentage of smokers and number of cigarettes smoked per person in the United States might explain the recent reduction in the SCLC incidence rates. Despite the decreased incidence rate over the last three decades, the survival rate remains relatively stable. Between 1983 and 2012, the 5-year survival rate increased from 4.9% to 5.9% to 6.4% each decade.[45]

Pathophysiology

The distinction between SCLC and NSCLC is critical, both clinically and in terms of tumor genetics and biology.[46] The WHO and the International Association for the Study of Lung Cancer (IASLC) developed standardized morphologic classifications of lung cancer and SCLC subtypes. Although the subtypes of SCLC are not clinically useful in determining therapy, the recognition that mixed tumors contain two or more elements of SCLC, AdenoCA, or SQCLC has promoted the concept that the major forms of lung cancer are closely related, perhaps arising from a common stem cell[46] (Figure 12-9).

SCLC is a poorly differentiated neuroendocrine tumor that arises in the peribronchial locations in the epithelium and infiltrates the bronchial submucosa. Distant metastasis occurs early during this disease. The most common areas of metastasis include mediastinal lymph nodes, liver, bones, adrenal glands, and brain. It is this propensity for early metastatic involvement that gives SCLC the worst prognosis among the major categories of lung cancer.[14]

SCLC is characterized by expression of **neuroendocrine (NE) markers** released from either **neuroendocrine cells** or their progenitors (**neuroendocrine progenitors**). Neuroendocrine cells receive information from neurotransmitters, causing them to release hormones into the blood.[47] Recent research has determined that SCLC tumors and cell lines can exhibit distinct inter-tumor heterogeneity with respect to the expression of NE features. Loss of NE expression results in major alterations in morphology, growth characteristics, and molecular properties, which can have major clinical implications due to very different responses to targeted therapies.[48]

Risk Factors

Smoking is a strong relative risk factor for all forms of lung cancer. SCLC and SQCLC are the two predominant lung cancers closely associated with smoking. The greater the amount smoked, the greater the risk for SCLC and SQCLC. Smoking cessation reduced the relative risk in the short term and long term, but risks among heavy former smokers never fully return to baseline risks of nonsmokers.[42] Other risk factors include cigar smoking; secondhand smoke; exposure to radon, asbestos, and radioactive uranium; and inhaled chemicals and diesel exhaust (Table 12-3).

Complications

The complications from SCLC stem from the metastasis of the cancer. See **Box 12-6**.

Tumor lysis syndrome can occur rapidly in patients with SCLC once chemotherapy begins, especially in cases of extensive disease. Tumor lysis causes hyperuricemia, hyperphosphatemia, hypocalcemia, and hyperkalemia. Another abnormality includes hyponatremia. Hyponatremia is caused by inappropriate secretion of antidiuretic hormone, which results in the inability of the kidneys to excrete free water.[41]

Diagnostic Testing

The initial workup for SCLC includes a thorough history and physical examination, which provide the clues to the organ systems involved. See complications of SCLC in Box 12-6.

Chest radiography is a means by which lung cancer is often incidentally first discovered. It allows for a coarse assessment of the primary tumor size and may reveal mediastinal lymphadenopathy. Indirect, nonspecific findings associated with a primary mass include pleural effusion, atelectasis, obstructive pneumonitis, and mediastinal widening. Chest radiographs of patients

BOX 12-6 Complications of SCLC

Regional lung cancer spread	Left vocal cord paralysis (tumor invasion) Hemidiaphragm elevation (phrenic nerve compression) Dysphagia (esophageal compression) Chest pain (pleural or chest wall involvement) Superior vena cava syndrome Pericardial effusion and tamponade Cervical or supraclavicular lymph node enlargement
Metastatic lung cancer spread	Brain metastases (neurologic problems) Leptomeningeal carcinomatosis (carcinoma spread to the meninges) Adrenal metastases (adrenal insufficiency) Liver metastases (hepatomegaly, jaundice, tenderness) Bone metastases (bone pain, spinal cord compression) Anorexia/cachexia Fatigue

Data from National Comprehensive Cancer Network. *Small Cell Lung Cancer.* Fort Washington, PA: National Comprehensive Cancer Network; 2018. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed June 25, 2018.



FIGURE 12-10 Left hilar mass in a patient with SCLC.
https://radiopaedia.org/articles/small-cell-lung-cancer-1. Case 8.
Case courtesy of Dr Henry Knipe, Radiopaedia.org, rID: 300.

BOX 12-7 Diagnostic Testing for SCLC

- Complete history and physical examination
- Complete blood count (CBC) with differential
- Serum electrolytes levels, including calcium
- Liver function tests (LFTs)
- Renal function tests (RFTs)
- Serum lactate dehydrogenase (LDH) level
- Serum alkaline phosphatase (ALP) level
- Chest radiography
- CT scanning of the chest and abdomen with intravenous contrast (including liver and adrenal glands)
- CT scanning/MRI of the brain with IV contrast
- Bone scanning
- Bone marrow aspiration and biopsy if abnormalities are present in the CBC or peripheral smear
- Pleural effusion thoracentesis and cytology testing

Data from Tan W. Small cell lung cancer: practice essentials, pathophysiology, etiology. *Emedicinemedscapecom.* 2018. https://emedicine.medscape.com/article/280104-overview. Accessed June 25, 2018.

with SCLC may demonstrate unilateral hilar enlargement, increased hilar opacity, a perihilar mass, mediastinal mass, or a combination of these. It is uncommon for SCLC to appear as a solitary pulmonary nodule (**Figure 12-10**). Small cell tumors are located centrally in 90% of the cases of SCLC.[49] These tumors arise from the mainstem of lobar bronchi and appear as hilar or perihilar masses. They frequently have mediastinal lymph node involvement at presentation. On chest radiography this appears as a mediastinal widening due to the lymph node enlargement. This is usually the most striking feature on the chest radiograph.[49]

In addition to the chest radiograph, numerous other diagnostic tests are used to complete a staging workup on patients with SCLC. The prognosis and management of SCLC depends on this staging workup. See **Box 12-7**.

CT scanning of the sites of possible metastasis needs to be performed to evaluate the disease for staging. This should involve CT scanning of the thorax (lungs and mediastinum) (**Figure 12-11**) and the abdomen, including the liver, adrenals, and other organs. Intravenous contrast agents can be used whenever possible. In the United States, CT scans of the chest and upper abdomen, including the liver and adrenal glands, are standard.[41] If metastasis to the brain is suspected, MRI of the brain is in order, because MRI is more sensitive than CT scanning with contrast for detection of brain metastasis.[41]

Further investigations uncover the extent of the disease and assesses organ function prior to therapy. In general, depending on the tumor localization, biopsies from the primary tumor can be obtained via bronchoscopy, mediastinoscopy, EBUS, TNA, or thoracoscopy. When a metastatic lesion is easily and safely accessible,



FIGURE 12-11 A 61-year-old female with SCLC (Type IIIc). **(A–C)** Axial CT mediastinal images show extensive bilateral mediastinal conglomerate mass, which are reliably distinguished from enlarged lymph nodes. This single mass is encasing and compressing the trachea to mainstem bronchi and invading the superior vena cava (B: white arrowhead) and the right main pulmonary artery.

a biopsy specimen may be taken to provide pathologic staging.[41] A pleural effusion needs to be tested for malignant cells, and liver or adrenal lesions may be sampled via FNA.

Staging

The National Comprehensive Cancer Network Expert Panel Clinical Practice Guideline recommends a combined approach for staging SCLC using both the AJCC TNM staging system and the older Veterans Administration (VA) scheme for SCLC. Once a patient receives an initial assessment of the extent of the cancer using the VA scheme, either limited-stage SCLC or extensive-stage SCLC, a decision can be made to continue further staging. See **Box 12-8**. Further staging is optional if the patient has extensive-stage SCLC, except for brain imaging.[40] If limited-stage SCLC is suspected, a PET/CT scan (skull to mid-thigh) is done to assess for distant metastases. PET scans increase staging accuracy in patients with SCLC, because SCLC is a highly metabolic disease.[40]

Since LS-SCLC is a curable disease, the most important issue in staging is to determine whether there are any distant metastases.[50] Treatment for LS-SCLC is based on a combination of the two-stage scheme and the TNM staging system (Table 12-4). However, TNM staging does not alter clinical management frequently due to the predominance of advanced stage at presentation, and it is less powerful in prognostication for SCLC than for NSCLC.[44] TNM is most useful in the identification of patients for whom resection may be beneficial (e.g., for patients that are thoroughly evaluated and have clinical stage I [T1-2N0] disease). In these cases, resection followed by adjuvant chemotherapy is recommended; however, this applies to fewer than 5% of patients.[44]

Treatment and Management

Once SCLC has been appropriately staged, primary and adjuvant therapeutic planning can commence. The treatment options for SCLC do not change as dramatically as they do with NSCLC. The standard treatment in patients with LS-SCLC includes chemoradiation, combination chemotherapy, and/or surgical resection.

BOX 12-8 The VA Two-Stage Classification Scheme[40,50,51]

Limited-Stage SCLC (LS-SCLC)

- Cancer usually is only in one lung and possibly in lymph nodes on the same side of the chest.
- Primary tumor and regional nodes can be adequately encompassed within one radiation field.

Extensive-Stage SCLC (ES-SCLC)

- Cancer has spread to the opposite lung, to the lymph nodes on the other side of the chest, or to distant organs.
- Includes malignant pleural or pericardial effusion or hematogenous metastases.

BOX 12-9 Sample of Treatments Used for SCLC[41,52]

- Chemotherapy
  - Cisplatin + etoposide (LS-SCLC and ES-SCLC)
  - Carboplatin + etoposide (LS-SCLC)
  - Cisplatin + irinotecan + (ES-SCLC)
  - Carboplatin + irinotecan (ES-SCLC Stage IV)
  - Cyclophosphamide + doxorubicin + vincristine (ES-SCLC Stage IV)
- Thoracic RT (combined with chemotherapy)
- Prophylactic cranial irradiation (LS-SCLC)
- Surgery (LS-SCLC only, Stage 1 [T1 to 2, N0])

TABLE 12-7
Five-Year Survival Rate for SCLC by Stages[53]

Stage of SCLC	Five-Year Survival Rate (%)
I	31
II	19
III	8
IV	2

Data from Baldini E, Kalemkerian G. Limited-stage small cell lung cancer: initial management. In: Lilenbaum R, Schild S, Vora S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 25, 2018.

ES-SCLC is treated with a combination of chemotherapy and radiation (National Comprehensive Cancer Network).

For approximately 30% of patients with LS-SCLC at the time of diagnosis, management typically involves combination platinum-based chemotherapy and thoracic RT. Patients who achieve a complete or partial response are usually offered prophylactic cranial irradiation.[41] Some of the therapies for SCLC are listed in **Box 12-9**.

Prognosis

Approximately 60–70% of patients with SCLC have clinically disseminated or extensive disease at presentation.[41] ES-SCLC is incurable. Patients with advanced disease have on average disease-free survival of 5.5 months and median survival of less than 10 months.[43] Patients with LS-SCLC treated with combination chemotherapy plus thoracic RT have a complete response rate of 80%[41] (**Table 12-7**).

Indicators of poor prognosis include a relapse of the disease, weight loss of more than 10% of baseline body weight, poor performance stats, and hyponatremia.[41]

KNOWLEDGE CHECK QUESTIONS

1. True or False: SCLC proliferates more rapidly than NSCLC.
2. True or False: SCLC can be detected by cancer screening tests.
3. True or False: Neuroendocrine markers are often present with SCLC.
4. True or False: The treatment protocols for the different stages of SCLC vary as much as those treatment protocols for NSCLC.
5. True or False: The prognosis for SCLC is the same as for NSCLC.

Chapter Summary

Lung cancer is the most common cause of cancer mortality worldwide for both men and women. The first step in the management of lung cancer is to confirm the diagnosis of a malignancy and to assess which type of cancer the patient has, the disease stage, and the overall status of the patient. With NSCLC, the initial management is to determine the stage of the disease, because it is a slower progressing type of cancer. In those patients with an early stage of NSCLC, surgical resection is the treatment of choice and offers the best opportunity for a cure. Those patients who have more extensive intrathoracic disease, surgical resection and adjuvant chemotherapy are preferred. Patients with advanced-stage NSCLC are managed palliatively. With SCLC, systemic chemotherapy is the most important treatment because this type of cancer metastasizes rapidly. For patients with limited-stage SCLC, management includes both chemotherapy and thoracic RT. Preventive brain irradiation is used most often because brain metastasis is common, and preventive irradiation of the brain will reduce its incidence.

The survival of lung cancer is inversely proportional to the stage of the cancer. The key to survival is early detection and diagnosis. Chest radiography is important in the identification of lung cancer but is not helpful in the staging of the disease. To assess for the extent of the lung cancer, imaging with CT or MRI with contrast is the least expensive, but PET is the most sensitive for the detection of both primary tumor and metastasis. Biopsies of the primary tumor and regional metastasis can be achieved with endobronchial ultrasound and TNA. Other more invasive methods, used for more extensive disease or those that cannot be viewed endobronchially, include transthoracic needle aspiration under imaging guidance, mediastinoscopy, and thoracoscopy.

Key Points

1. Lung neoplasms can be either benign or malignant. Benign neoplasms tend not to spread, but malignant neoplasms are typically aggressive and metastasize to other parts of the body.
2. The WHO classifies two major types of lung cancers based on biology, therapy, and prognosis. These two categories are NSCLC and SCLC.
3. NSCLC accounts for 80% of all lung cancers and consists of three main categories of cancers. These categories include AdenoCA, SQCLC, and LCLC. Some genetic mutations that cause cancer have been identified and are the basis for certain therapies.
4. The signs and symptoms of all lung cancers are similar, with the most common being cough, shortness of breath, fatigue, hemoptysis, cachexia, and chest pain.
5. The single major etiology for lung cancer is cigarette smoking, with the association being highest with SCLC and SQCLC. Never smokers can develop lung cancer as well. AdenoCA of the lung is more common with never smokers compared with smokers.
6. Smoking and exposure to carcinogens are the two modifiable risk factors for both NSCLC and SCLC. Nonmodifiable risk factors for these cancers include previous radiation to the lungs, air pollution, and family history.
7. Most patients presenting with symptoms of lung cancer for the first time have advanced disease. SCLC is the more aggressive type of cancer, due to these cancer cells' ability to rapidly divide.
8. Complications from lung cancer are due to metastasis to other organs and to cancer treatment.
9. Tumor biopsy and imaging are used to stage lung cancer. Staging plays a major role in determining treatment. These treatments include surgical resection, chemotherapy, and RT.
10. The stage of cancer at the time of diagnosis is a key factor in the prognosis. The more lymph node stations involved, the worse the patient's prognosis.

Chapter Questions

1. Benign neoplasms _____ _____.
   a. are just as aggressive as malignant neoplasm
   b. typically originate in the lung periphery
   c. are usually non-metastasizing
   d. are staged like malignant neoplasms
2. Lung cancers that originate in the peripheral bronchi tend to be _____.
   a. adenocarcinomas (AdenoCA)
   b. squamous cell carcinomas
   c. large cell carcinomas
   d. small cell carcinomas
3. The most common presenting physical manifestation of lung cancer is _____.
   a. dyspnea
   b. cough
   c. hemoptysis
   d. chest pain
4. Never smokers most commonly develop _____.
   a. small cell lung carcinoma (SCLC)
   b. large cell lung carcinoma (LCLC)
   c. squamous cell lung carcinoma (SQCLC)
   d. AdenoCA
5. Cigarette smoking most commonly causes _____.
   a. SCLC and SQCLC
   b. AdenoCA and LCLC
   c. SQCLC and adenocarcinoma
   d. LCLC and SCLC
6. Keratin pearls can be found in biopsies of _____.
   a. AdenoCA
   b. small cell lung carcinoma
   c. SQCLC
   d. LCLC
7. _____ tends to remain within the thorax and cause intrathoracic complications without metastasis to other parts of the body.
   a. SQCLC
   b. AdenoCA
   c. LCLC
   d. SCLC
8. _____ is the most commonly used modality to locate centrally located tumors and mediastinal lymph nodes for≈biopsy.
   a. Video-assisted thoracoscopy
   b. Bronchoscopy with endobronchial ultrasound
   c. Mediastinoscopy
   d. Computed tomography
9. _____ biomarkers are most suitable for identifying lung cancer.
   a. Genomic
   b. Transcriptomic
   c. Anatomic
   d. Protein
10. _____ is characterized by neuroendocrine markers.
    a. AdenoCA
    b. SCLC
    c. SQCLC
    d. LCLC
11. Prophylactic cranial irradiation is a common practice when treating _____.
    a. AdenoCA
    b. LCLC
    c. SCLC
    d. SQCLC

12. _____ almost exclusively occurs in cigarette smokers.
- **a.** SCLC
- **b.** LCLC
- **c.** AdenoCA
- **d.** SQCLC

13. The pathologic stage for a non-small cell lung carcinoma (NSCLC) that has spread to both lungs and caused a malignant pleural effusion and liver metastasis is _____.
- **a.** Stage I
- **b.** Stage II
- **c.** Stage III
- **d.** Stage IV

14. The most appropriate treatment for NSCLC with staging T1N0M0 is _____.
- **a.** chemotherapy
- **b.** surgical resection
- **c.** chemotherapy and radiation therapy
- **d.** surgical resection followed by radiation therapy

15. A positive smoking history puts a patient at greatest risk for _____.
- **a.** SQCLC
- **b.** LCLC
- **c.** SCLC
- **d.** AdenoCA

References

1. Midhun D. Overview of the initial evaluation, treatment and prognosis of lung cancer. In: Lilenbaum R, Schild S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodat.com. Accessed June 21, 2018.
2. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27(suppl_5):v1–v27. doi:10.1093/annonc/mdw326.
3. *Global Cancer Facts & Figures*. 3rd ed. Atlanta, GA: American Cancer Society; 2015. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-3rd-edition.pdf. Accessed June 26, 2018.
4. Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P. Lung cancer: biology and treatment options. *Biochim Biophys Acta*. 2015;1856(2):189–210. doi:10.1016/j.bbcan.2015.08.002.
5. Ettinger D, Wood D, Aisner D, et al. Non-small cell lung cancer, version 5.2017 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2017;15(4):504–535. doi:10.6004/jnccn.2017.0050.
6. Tan W. Non-small cell lung cancer: practice essentials, background, pathophysiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/279960-overview. Accessed June 22, 2018.
7. Chan B, Hughes B. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. *Transl Lung Cancer Res*. 2014;4(1):36–54. doi:10.3978/j.issn.2218-6751.2014.05.01.
8. Thomas K, Gould M. Overview of the initial evaluation, diagnosis, and staging of patients with suspected lung cancer. In: Midhun D, Finlay G, Lee S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 22, 2018.
9. Mannino D. Cigarette smoking and other possible risk factors for lung cancer. In: Stoller J, Midhun D, Vora S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 22, 2018.
10. Dela Cruz C, Tanoue L, Matthay R. Lung cancer: epidemiology, etiology, and prevention. *Clin Chest Med*. 2011;32(4):605–644. doi:10.1016/j.ccm.2011.09.001.
11. Kurt O, Zhang J, Pinkerton K. Pulmonary health effects of air pollution. *Curr Opin Pulm Med*. 2016;22(2):138–143. doi:10.1097/mcp.0000000000000248.
12. Wong M, Lao X, Ho K, Goggins W, Tse S. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. *Sci Rep*. 2017;7(1):14300. doi:10.1038/s41598-017-14513-7.
13. American Cancer Society. Cancer Facts & Figures 2018. *Cancerorg*. 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed June 23, 2018.
14. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. 6th ed. Philadelphia, PA: Elsevier/Saunders; 2014.
15. Non-Small Cell Lung Cancer Risk Factors. *Cancerorg*. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/causes-risks-prevention/risk-factors.html. Accessed June 24, 2018.
16. Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. *Mol Clin Oncol*. 2014;3(1):217–221. doi:10.3892/mco.2014.410.
17. Arcasoy S, Jett J, Friedberg J. Superior pulmonary sulcus (Pancoast) tumors. In: Lilenbaum R, Friedberg J, Vora S, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 23, 2018.
18. Kedar S, Blousse V, Newman N. Horner syndrome. In: Brazis P, Wilterdink J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 23, 2018.
19. Rice D. The staging of lung cancer. In: Weissferdt A, Moran C, eds. *Diagnostic Pathology of Pleuropulmonary Neoplasia*. 1st ed. New York, NY: Springer Science+Business Media; 2013:39–51.
20. Sharma S. Imaging in non-small cell lung cancer: overview, radiography, computed tomography. *Emedicinemedscapecom*. 2015. https://emedicine.medscape.com/article/358433-overview. Accessed June 23, 2018.
21. Hochhegger B, Marchiori E, Irion K, Souza, A Jr, Volkart J, Rubin A. Magnetic resonance of the lung: a step forward in the study of lung disease. *J Bras Pneumol*. 2012;38(1):105–115.
22. Pawaroo D, Cummings N, Musonda P, Rintoul R, Rassl D, Beadsmoore C. Non–small cell lung carcinoma: accuracy of PET/CT in determining the size of T1 and T2 primary tumors. *Am J Roentgenol*. 2011;196(5):1176–1181. doi:10.2214/ajr.10.4980.
23. Dietel M, Bubendorf L, Dingemans A, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. *Thorax*. 2015;71(2):177–184. doi:10.1136/thoraxjnl-2014-206677.
24. Munoz M, Lechtzin N, Li Q, et al. Bronchoscopy with endobronchial ultrasound guided transbronchial needle aspiration vs. transthoracic needle aspiration in lung cancer diagnosis and staging. *J Thorac Dis*. 2017;9(7):2178–2185. doi:10.21037/jtd.2017.07.26.
25. Navani N, Nankivell M, Lawrence D, et al. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. *Lancet Respir Med*. 2015;3(4):282–289. doi:10.1016/s2213-2600(15)00029-6.
26. Chen T. The diagnosis and staging of lung cancer. In: Langhorne C, Sandt L, eds. *Lung Cancer Choices*. 3rd ed. Oregon City, OR: Caring Ambassadors Program, Inc; 2016. http://lungcancercap.org/wp-content/uploads/2017/09/1_Diagnosis_and_Staging_of_Lung_Cancer_3rdEdition.pdf. Accessed June 27, 2018.
27. Zamay T, Zamay G, Kolovskaya O, et al. Current and prospective protein biomarkers of lung cancer. *Cancers (Basel)*. 2017;9(12):155. doi:10.3390/cancers9110155.
28. Gress D, Edge S, Greene F, et al. Principles of cancer staging. *AJCC Cancer Staging Man*. 2016:3–30. doi:10.1007/978-3-319-40618-3_1.

29. Rami-Porta R, Asamura H, Travis W, Rusch V. Lung cancer–major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(2):138–155. doi:10.3322/caac.21390.
30. Lung Cancer 101 | Lungcancer.org. *Lungcancerorg*. 2018. https://www.lungcancer.org/find_information/publications/163-lung_cancer_101/268-types_and_staging. Accessed June 25, 2018.
31. West H, Vallieres E, Schild S. Management of stage I and stage II non-small cell lung cancer. In: Friedberg J, Lilenbaum R, Vora S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 23, 2018.
32. Stevenson M. Non-small cell lung cancer treatment protocols: treatment recommendations, early or localized disease, chemoradiation therapy, locally advanced disease, first-line chemotherapy, metastatic or recurrent disease. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/2007153-overview. Accessed June 23, 2018.
33. Yorke J, Brettle A, Molassiotis A. Nonpharmacological interventions for managing respiratory symptoms in lung cancer. *Chron Respir Dis*. 2012;9(2):117–129. doi:10.1177/1479972312441632.
34. Yorke J, Lloyd-Williams M, Smith J, et al. Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. *Support Care Cancer*. 2015;23(11):3373–3384. doi:10.1007/s00520-015-2810-x.
35. Schulte T, Schniewind B, Dohrmann P, Küchler T, Kurdow R. The extent of lung parenchyma resection significantly impacts long-term quality of life in patients with non-small cell lung cancer. *Chest*. 2009;135(2):322–329. doi:10.1378/chest.08-1114.
36. Xue D, Abernethy A. Management of dyspnea in advanced lung cancer: recent data and emerging concepts. *Curr Opin Support Palliat Care*. 2010;4(2):85–91. doi:10.1097/spc.0b013e328339920d.
37. Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. *Cochrane Database Syst Rev*. 2016;3:CD011008. doi:10.1002/14651858.cd011008.pub2.
38. Lung and Bronchus Cancer—Cancer Stat Facts. *Seercancergov*. 2018. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed June 25, 2018.
39. Non-Small Cell Lung Cancer Survival Rates, by Stage. *Cancerorg*. 2018. https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed June 25, 2018.
40. National Comprehensive Cancer Network. *Small Cell Lung Cancer*. Fort Washington, PA: National Comprehensive Cancer Network; 2018. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed June 25, 2018.
41. Tan W. Small cell lung cancer: practice essentials, pathophysiology, etiology. *Emedicinemedscapecom*. 2018. https://emedicine.medscape.com/article/280104-overview. Accessed June 25, 2018.
42. Pesch B, Kendzia B, Gustavsson P, et al. Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies. *Int J Cancer*. 2011;131(5):1210–1219. doi:10.1002/ijc.27339.
43. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? a review. *Transl Lung Cancer Res*. 2016;5(1):26–38. doi:10.3978/j.issn.2218-6751.2016.01.13.
44. Glisson B, Byers L. Pathobiology and staging of small cell carcinoma of the lung. In: Lilenbaum R, Nicholson A, Vora S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 23, 2018.
45. Wang S, Tang J, Sun T, et al. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. *Sci Rep*. 2017;7(1):1339. doi:10.1038/s41598-017-01571-0.
46. Miller K, Siegel R, Lin C, et al. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin*. 2016;66(4):271–289. doi:10.3322/caac.21349.
47. Karachaliou N, Pilotto S, Lazzari C, Bria E, de Marinis F, Rosell R. Cellular and molecular biology of small cell lung cancer: an overview. *Transl Lung Cancer Res*. 2016;5(1):2–15.
48. Zhang W, Girard L, Zhang Y, et al. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. *Transl Lung Cancer Res*. 2018;7(1):32–49. doi:10.21037/tlcr.2018.02.02.
49. Danaher L, Luikjx T. Small cell lung cancer | Radiology Reference Article | Radiopaedia.org. *Radiopaediaorg*. 2018. https://radiopaedia.org/articles/small-cell-lung-cancer-1. Accessed June 26, 2018.
50. Kalemkerian G. Staging and imaging of small cell lung cancer. *Cancer Imaging*. 2011;11(1):253–258. doi:10.1102/1470-7330.2011.0036.
51. Ahmad I, Chufal K, Gupta S, Bhatt C. Defining limited stage small cell lung cancer: a radiation oncologist's perspective. *BMJ Case Rep*. 2018:bcr-2017-223708. doi:10.1136/bcr-2017-223708.
52. Baldini E, Kalemkerian G. Limited-stage small cell lung cancer: initial management. In: Lilenbaum R, Schild S, Vora S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 25, 2018.
53. Small Cell Lung Cancer Survival Rates, by Stage. *Cancerorg*. 2018. https://www.cancer.org/cancer/small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html. Accessed June 26, 2018.

CHAPTER

13

Pneumonia

"Pneumonia may well be called the friend of the aged. Taken off by it in an acute, short, not often painful illness, the old man escapes those 'cold gradations of decay' so distressing to himself and to his friends."

—Osler W. *The principles and practice of medicine.* 7th ed, 1909. New York, NY: D. Appleton.

OUTLINE

OBJECTIVES

1. Recognize common characteristics, manifestations, and anatomic features of pneumonia.
2. Identify common complications associated with the different types of pneumonias.
3. Discuss the mechanisms that permit the infectious organisms to enter the lower respiratory tract.
4. Compare the characteristics of the pneumonias classified by the origin of development.
5. Differentiate the risk factors associated with the development of antimicrobial resistance.

KEY TERMS

Aerobic
Anaerobic
Atypical pneumonia
Bacteremia
Bacteremic septicemia
Bronchoalveolar lavage (BAL)
Bronchopneumonia
Community-acquired pneumonia (CAP)
Consolidation
C-reactive protein (CRP)
CURB-65
Disseminated intravascular coagulation (DIC)
Empirical antimicrobial treatment
Endemic
Facultative anaerobes
Fungi
Gram negative
Gram-negative pneumonia
Gram positive
Gram staining
Granulomas
Hemoptysis
Hospital-acquired pneumonia (HAP)
Immunosenescence
Interstitial pneumonia
Left shift
Lobar pneumonia
Microaspiration
Microbiome
Microbiota
Multidrug-resistant organism (MDRO)
Necrosis
Nosocomial
Opportunistic
Pathogens
Pneumatocele
Pneumonia
Pneumonia severity index (PSI)
Polymicrobial infection
Procalcitonin (PCT or ProCT)
Round pneumonia
Ventilator-associated pneumonia (VAP)
Virulence
Virus

Case Study

A 68-year-old semi-retired male self-employed as a custodian presents to the emergency room with complaints of persistent fever and a cough productive of a copious amount of sputum with a putrid odor. He described a history of fever, generalized weakness, and malaise as well as a 5-pound weight loss associated with some shortness of breath. He is unable to give a precise date of onset of his symptoms but suspects that they have persisted for at least 1 month. He lives alone and is a long-time cigarette smoker (at least 60+ pack-year) with a history of chronic alcohol abuse, including beer and wine consumption when he is able to afford them. He also reports "sparsely" using intravenous drugs. Over the past year he has been admitted twice to the local emergency room following head trauma sustained in a fall and after being found unconscious due to alcohol intoxication.

On physical examination, his temperature was 102°F, pulse was 110, and the respiratory rate was 20 and somewhat labored. His weight is 117 pounds, height 5 feet 3 inches, and blood pressure 110/65 mm Hg. On physical examination, the patient appeared severely malnourished. Examination of the head and scalp revealed two healed scars. Evaluation of his oral cavity revealed very poor dentition with gingival disease, and a foul-smelling odor to his breath was detected. Auscultation of the heart revealed a mild tachycardia of 110 beats/minute. Lung auscultation revealed diminished breath sounds over the posterior region of his upper right lobe and superior segment of the right lower lobe. E to A changes (egophony) suggestive of **consolidation** were also present over the upper areas of the right lung. An examination of the abdomen was noncontributory as was examination of the lower extremities. A sputum Gram stain revealed several mixed flora and white blood cells (WBC), whereas sputum culture grew a mixed microbial population of aerobes and anaerobes. A posterioranterior and lateral chest x-ray taken in the emergency room displayed a large area of patchy opacification involving the posterior portion of the right upper and superior segment portion of the right lower lobe. The cardiac size on chest x-ray is normal.

Introduction

Pneumonia is an acute infection of the lung parenchyma by one or coinfecting **pathogens**.[1] The absence or dysfunction of the normal protective defense mechanisms within the respiratory tract is the typical prerequisite for the development of pneumonia. Organisms can invade and colonize the respiratory tract when defenses are compromised. Less commonly, pneumonia can develop from the spread infection to the lung parenchyma from a different site. Mortality from influenza and pneumonia together was the eighth cause of mortality in the United States in 2014.[2] In 2015, pneumonia alone was the cause of death for 51,811 individuals in the United States.[3] In fact, in the 21st century, community-acquired pneumonia (CAP) continues to be a leading cause of death in both developed and developing worlds.[4]

Although it was Hippocrates who first described pneumonia, it was Laennec who first described its clinical and pathologic features in the 19th century.[1] Since those early times, numerous terms have been used to describe pneumonia. Currently, the ICD-10 classification of diseases has removed some of the historical descriptive terms, and "pneumonia" is listed as the primary term in seven codes (J12–J18).[5] Pneumonia is classified in several different ways. These classifications include the causative organism, the place in which the pneumonia was acquired, and the location in the lungs. The availability and development of effective antibiotics and valuable supportive measures such as the availability of mechanical ventilation have modified the natural history of pneumonia and reduced the case-fatality rate. Unfortunately, the emergence of drug-resistant pathogenic organisms is responsible for the increased mortality from pneumonia.[6]

The basis for this chapter is the causative organisms that include the commonly encountered bacteria, viruses, and fungi. The remainder of the chapter addresses pneumonia by location in the lung and the place the pneumonia was acquired.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Pneumonia can be caused only by one pathogen.
2. True or False: There are numerous ways to classify pneumonia.

Pneumonia Classification by Causative Microorganism

A key factor for managing and effectively guiding appropriate antimicrobial therapy is an understanding of the role of the different causative microorganisms in the etiology of pneumonia, because it has been shown

that the adequacy of initial antimicrobial therapy is a key factor for prognosis in pneumonia.[2] Numerous microorganisms can cause pneumonia, including bacteria, viruses, atypical bacteria, fungi, and parasites. However, bacterial pneumonias are the most common type of pneumonia in adults in the United States.[7]

Bacterial Pneumonia

In the second half of the 20th century, bacterial pneumonia decreased in prominence as a major public health issue because of the discovery and development of antibiotics and vaccines that improved its treatment and prevention.[8] However, pneumonia (lower respiratory tract infections) remains a substantial source of global mortality and morbidity.[9,10]

Traditionally, bacterial pneumonia is divided into two main groups: "typical" and "atypical" causes. In the individual patient, there are no findings from history, physical examination, or routine laboratory studies that allow the clinician to distinguish pneumonia caused by either type of organism.[11]

Definition/Diagnosis

Bacteria are microscopic unicellular organisms that inhabit virtually all environments, including soil, water, organic matter, and the bodies of multicellular animals. There are more bacteria occurring as individual microorganisms than any other type of organism. Bacterial counts in different soils range from 4×10^6 to 2×10^9 in dry soil.[12] The bacteria that cause disease, such as pneumonia, are pathogens. Pathogenic bacteria have certain characteristics that give them the ability to cause disease. Nonpathogenic bacteria lack those characteristics and exist within the human body primarily in the gastrointestinal (GI) tract, but also in the lungs. In fact, the human body is an ecosystem of nonpathogenic bacteria known as the human **microbiota** or **microbiome**.[13]

Bacterial pathogens are distinguished from other disease-producing organisms in part by their morphological and genetic features, including their lack of a membrane-bound nucleus and membrane-bound organelles. Morphological diversity exists among bacteria. Bacteria have distinct cell body shapes, ranging from spheres (cocci) to rods (bacilli) of various curvatures and helicities and to more exotic shapes, such as stars. Bacteria can also produce a variety of appendages, such as pili or flagella, which show diversity in overall shape, length, and width as well as placement with respect to the cell body. Finally, bacteria can change morphology during their life cycle or in response to environmental conditions and cell shape may be related to **virulence**.[14]

Bacteria are characteristically grouped in several ways with most assuming one of three typical forms, including rod-shaped (bacillus; e.g., *Klebsiella* species), round (coccus; e.g., *Streptococcus*), and spiral (spirillum). Bacteria may be characterized by their displayed patterns of growth, such as the chains formed by streptococci, or by their ability to be inherently motile, such as with the bacillus and spirillum forms. Other bacteria have rigid rod-like protuberances called pili that function as tethers. See **Figure 13-1**.

Aerobic forms of bacteria can function metabolically only in the presence of atmospheric oxygen, whereas



FIGURE 13-1 Basic morphological differences between bacteria.

anaerobic bacteria cannot grow in the presence of oxygen. **Facultative anaerobes** bacteria can grow with or without free oxygen, while obligate anaerobes are poisoned by oxygen. Many bacterial cells are also commonly grouped into categories based on cell wall structure characteristics, which surround the cytoplasm and plasma membrane of most bacterial cells. The terms **gram positive** and **gram negative** reflect the laboratory **Gram staining** technique used to distinguish distinct differences in cell wall structure of various bacteria. Gram-positive cells retain crystal violet in an ethanol solution and subsequently appear purplish-blue when viewed under light microscopy. Gram-negative bacteria (GNB), on the other hand, do not retain crystal violet but do retain a counterstain, safranin, causing the bacterium to appear pinkish-red under the microscope. These differences in staining coloration result from differences in the structures of the outer surfaces of bacteria. While gram-positive as well as gram-negative cells have a peptide-glycan layer as part of their cell wall structure, gram-negative cells have an intact outer membrane that provides a barrier to the uptake of the stain. See **Figure 13-2**.

Clinical Signs and Symptoms

The clinical presentation of bacterial pneumonia is variable, but many features are particularly prominent and noteworthy. Normally, the sudden onset of symptoms and rapid illness progression are distinguishing features associated with bacterial pneumonias compared to pneumonia caused by vial or atypical infectious origin. Chest pain, fever, rigors of shaking chills, shortness of breath, hemoptysis, decreased exercise tolerance, malaise, and abdominal pain associated with pleuritis are also highly suggestive of a bacterial pulmonary process. While the presence of a productive cough is the most consistent presenting symptom in bacterial pneumonia, it is not diagnostic of a causative organism.[15] The character of the sputum, however, may be somewhat suggestive of a likely pathogen. Bacterial pneumonia associated with *Pseudomonas*, Haemophilus, and pneumococcal species often produce green sputum, whereas *Klebsiella* species is classically associated with a cough productive of red currant-jelly sputum. Anaerobic infections, on the other hand, typically produce foul-smelling and/or bad-tasting



FIGURE 13-2 Gram staining is a method of differentiating bacterial species into two large groups. GNB have an intact outer membrane.

sputum. *Staphylococcus pneumoniae* is associated with rust-colored sputum.[15]

Physical examination findings often vary in bacterial pneumonia depending on the type of bacterial organism involved, the severity of the infection, the presence of host comorbidities, and whether additional complications develop. See **Box 13-1**.

Physical exam findings that are particularly associated with a specific etiology that warrant specific consideration include bradycardia, GI symptoms, and altered mental status, which may indicate a Legionella etiology. Periodontal disease frequently accompanies an anaerobic and/or **polymicrobial infection**. While physical signs and symptoms may suggest the possibility of a specific bacterial pneumonia etiology, a notable exception occurs in elderly patients with cough because these patients are more often characterized by an absence of distinctive signs and symptoms.

BOX 13-1 Common Clinical Signs of Bacterial Pneumonia[15]

- Abnormal voice sounds over areas of consolidation
  - Egophony
  - Whispering pectoriloquy
- Adventitious breath sounds
  - Audible crackles
  - Crackles
  - Rhonchi
  - Wheezes
  - Bronchial breath sounds
  - Pleural friction rub
- Cardiac
  - Tachycardia
  - Bradycardia
- Fever (typically >38°C) or hypothermia (<35°C)
- Observation and inspection
  - Central cyanosis
  - Altered mental status
- Palpation and percussion
  - Percussion note—dull over areas of consolidation
  - Tracheal deviation toward atelectasis
  - Lymphadenopathy
- Respirations
  - Tachypnea
  - Accessory muscle use
  - Labored breathing
  - Productive cough

Etiology

Dozens of types of bacteria can cause pneumonia. However, only a few are commonly responsible for most of pneumonia cases. The bacteria that cause **community-acquired pneumonia (CAP)** are different from the bacteria that cause hospitalized patients to develop **hospital-acquired pneumonia (HAP)**. **Table 13-1** shows the features of the gram-positive organisms that cause typical bacterial pneumonia.

Gram-negative pneumonias predominately occur in individuals who are debilitated or immunocompromised, or have been recently hospitalized.[15] GNB are less likely to cause pneumonia outside the hospital environment. However, when a GNB causes pneumonia in the community, it commonly results in the need for hospitalization and intensive care.[16] Predisposing risk factors appear to vary with the population at risk outside the hospital environment. These predisposing factors are chronic respiratory illnesses, such as chronic obstructive pulmonary disease (COPD) and bronchiectasis, diabetes, alcoholism, and human immunodeficiency virus (HIV).[16] Patients who are intubated for prolonged periods or have a tracheostomy are at risk of developing a GNB pneumonia. Recent information from the U.S. National Healthcare Safety Network (NHSN) indicate that GNB are responsible for more than 30% of hospital-acquired infections, and these bacteria predominate in cases of **ventilator-associated pneumonia (VAP,** 47%) and urinary tract infections (47%).[17] **Table 13-2** shows the features of the gram-negative organisms that cause typical bacterial pneumonia.

Atypical pneumonias, a group of diseases relatively unfamiliar to most clinicians, are caused by bacteria not normally associated with pneumonia and usually occur in patients with comorbidities. They can present as extrapulmonary infections, and prognosis can differ from that of typical pneumonias. Many clinicians are unfamiliar with the diagnosis of these diseases, and they are often incorrectly treated.[21] These pathogens are not detectable on typical Gram staining, cannot be successfully cultured using standard bacterial media, and do not respond to the usual antibiotic treatment. In contrast to other typical forms of pneumonia, atypical microbes such as *Mycoplasma* and *Chlamydophila* are generally mild. Because atypical pathogens, in general, are associated with a milder form of pneumonia, they are commonly called "walking pneumonia."[15] Legionella pneumonia represents an exception to the bacteria considered as atypical because it can manifest as very severe infection. Atypical bacterial pneumonias are usually community-acquired infections. The key to making the clinical diagnosis of atypical pneumonia depends on

TABLE 13-1
Common Gram-Positive Bacteria That Cause Typical Pneumonia[15]

Organism	Mode of Transmission	Organism Features	Pneumonia Features
Actinomyces israelii	• Aspiration	• Beaded, filamentous anaerobe (rod) • Nonspore forming • Normal flora in GI tract • Colonizes oral cavity in patients with periodontal disease	• Forms lung abscesses and cavitation • May erode into pleura and spread • Can cause chronic granulomatous infiltrates • Higher incidence with COPD, bronchiectasis, alcohol abuse • Cause of chronic pneumonia
Enterococcus faecalis, E. faecium	• Poor hand hygiene	• Facultative anaerobe • Survives temperatures of 60°C for short periods of time • Grow in chains • *E. faecium* is responsible for most vancomycin-resistant enterococci (VRE) infections	• Superinfections in patients receiving broad-spectrum antibiotics, including cephalosporin-aminoglycoside therapy and third-generation cephalosporin • Common in lung transplant patients
Nocardia asteroides	• Inhalation • Immunocompromised hosts	• Partially acid-fast bacillus • Beaded, branching, thin filaments	• Opportunistic • Causes lung abscesses and cavitations • Can involve pelura and chest wall • Cause of chronic pneumonia
S. aureus	• Inhalation of droplets • Post influenza • Intravenous drug abusers	• Facultative anaerobe • Cluster-like staining pattern • Resistant strain is methicillin-resistant *S. aureus* (MRSA) • Many strains contain toxins	• HAP • VAP • Pleural effusions are common • Multiple bilateral nodular infiltrates with central cavitation, lung abscesses • Common cause of pneumonia in cystic fibrosis patients
Streptococcus pneumoniae	• Inhalation of droplets	• Diplococci or short chains • Facultative anaerobe	• CAP • Rusty sputum • Shaking chills • Most common in children <2, adults >65 • Most common cause of pneumonia

recognizing the systemic infections causing a characteristic variety of extrapulmonary features accompanying each pathogen.[22]

The most commonly occurring organisms responsible for causing atypical pneumonia are *Chlamydophila pneumoniae, Chlamydia psittaci, Legionella pneumophila,* and *Mycoplasma pneumoniae*. See **Table 13-3**.

Epidemiology

In the United States, acute lower respiratory tract infections including various classifications of pneumonia cause more disease and death than any other infection.[15] The prevalence of various pathogens and epidemiology of pneumonia probably varies widely between countries and regions especially because a true incidence is not feasible because of non-mandatory reporting. This makes precise discussion of United States and international disease burden difficult to determine. Experts, however, estimate that more than 3 million cases of pneumonia caused by bacteria along with virus and lesser occurrences by fungi and parasites occur annually in the United States.[15] Pneumonia does appear to be more prevalent during the winter months and in colder climates, which is most likely from viral upper and lower respiratory infections that increase during those circumstances, resulting in impaired host defenses to bacterial superinfection. In 2013, the age-adjusted rates for pneumonia were highest among American Indians or Alaska Natives and lowest among Hispanics. Compared to whites, the rates were 8% higher among blacks, 21% higher among American Indians or Alaska Natives, 6% lower among Asians or Pacific Islanders, and 18% lower among Hispanics.[25]

It is estimated that the three major atypical pathogens (*M. pneumoniae, Chlamydia pneumoniae,* and *L. pneumophila*) are responsible for up to 40% of CAP.[26] The precise incidence of atypical pneumonia is not known at least in part because the disorder is not always obvious or specifically identified in clinical practice due to lack of readily available and reliable standardized tests to confirm the diagnosis. Atypical pathogens have also been found to commonly occur as

TABLE 13-2
Common GNB That Cause Typical Pneumonia[15,16,18–20]

Organism	Mode of Transmission	Organism Features	Pneumonia Features
Acinetobacter baumannii	• Inhalation • Aspiration • Person-to-person contact • Contact with contaminated surfaces	• Short, rod shaped coccobacillus • Opportunistic • Can colonize without causing infection or symptoms	• Common pathogen of HAP and VAP • Susceptible individuals include those with chronic lung disease, diabetes, alcoholism, and tobacco use • Multidrug resistant • Multilobar infiltrates with occasional evidence of necrosis or pleural effusion
Escherichia coli	• Microaspiration of upper airway secretions • Hematogenous dissemination from urinary tract infection or GI infection	• Facultative anerobe • Motile baccilli	• Susceptible individuals have COPD, diabetes, alcoholism • Bronchopneumonia of lower lobes • Empyema
Enterobacter species	• Poor hand hygiene	• Motile bacilli • Some are encapsulated • Opportunistic	• Susceptible individuals are those being mechanically ventilated, having prior antibiotic exposure, COPD, and the elderly
Haemophilus influenzae	• Inhalation	• Small pleomorphic encapsulated bacillus (Type B) • Varying levels of pathogenicity depending on subtype	• Encapsulated Type B is most virulent • Most common in patients with COPD, post influenza, sickle cell anemia, alcoholism, and the elderly • Pleural effusions are common • Bacteremia
Klebsiella pneumoniae	• Aspiration • Person-to-person contact	• Facultative anaerobe • Large encapsulated bacillus	• Aggressive, necrotizing, lobar pneumonia • Susceptible individuals include those with COPD, alcoholism, diabetes • Currant-jelly sputum
Moraxella catarrhalis	• Person to person • Inhalation	• Aerobic • Diplococcus • Produces endotoxin	• Susceptible individuals have COPD • Causes exacerbations of COPD
Pseudomonas aeruginosa	• Aspiration • Inhalation • Direct contact with contaminated medical equipment	• Aerobic, motile bacillus • Distinct (grapelike) odor • Creates protective biofilm	• Responsible for HAP and VAP • Susceptible individuals include those with pre-existing lung disease (cystic fibrosis), HIV, neutropenia, endotracheal intubation, and prior antibiotic use • Predominant in lower lobes of the lung, causing patchy bronchopneumonia or extensive consolidation either unilaterally or bilaterally • Green-colored sputum • Abcess formation

co-pathogens in CAP caused by mixed-infection with *S. pneumoniae* often isolated as the primary pathogen. Unlike most primary solo atypical infections, pneumonia of mixed etiology is associated with significantly high mortality (up to 25%).[26]

Advanced age increases the incidence of and the mortality from pneumonia. Comorbidity and a diminished immune response and defense against aspiration increase the risk of bacterial pneumonia.[15] For individuals aged 65 years and older, pneumonia and influenza were the seventh leading cause of death in 2013.[25] About 85% of all pneumonia and influenza deaths occur in this age group. Only about three percent of pneumonia and influenza dealths occurred in those under age 45.[25]

Pathology/Pathophysiology

Most bacteria that enter the respiratory tract do not normally cause pneumonia due to multple defense mechanisms, including sneezing, coughing, mucociliary escalator, alveolar macrophages, immunoglobulin G (IgG), and immunoglobulin M (IgM). Pathogenic bacteria that reach the alveolar level and interstital tissue initiate intense reactions leading to an outpour of

TABLE 13-3
Most Common Bacteria Causing Atypical Pneumonia[21–24]

Organism	Mode of Transmission	Organism Features	Pneumonia Features
C. pneumoniae	• Inhalation of aerosols • Direct contact	• Obligate intracellular gram negative • Can survive in hostile environments • Undergoes several life cycle transformations	• Two stages of symptoms, initial upper respiratory tract symptoms followed by pneumonia symptoms • Rhonchi and crackles are often present • Can cause systemic disease by hematogenous spread • May cause asthma exacerbations
C. psittaci	• Exposure to an infected bird • Direct contact or aerosolization	• Obligate intracellular, gram negative • Coccoid and non-motile • Undergoes several life cycle transformations • Most often infects birds (avian chlamydiosis)	• Causes high fever (103–105°F) without elevated pulse • Chest pain is common, not pleuritic pain • Few auscultatory findings • Susceptible individuals are those that handle birds
L. pneumophila	• Inhalation of contaminated aerosols	• Aerobic, nonencapsulated, nonspore forming, flagellated bacteria • Gram-negative bacilli • Facultative intracellular bacterium • Can form biofilms • Can live in both extracellular and intracellular environments	• High-grade fever (≥103°F), hyponatremia, and altered mental status are common • Can cause systemic disease by hematogenous spread • Susceptible individuals include elderly, those with chronic illnesses, solid organ transplant (SOT) recipients, smokers, and those that are immunocompromised
M. pneumoniae	• Inhalation of droplets	• Free-living organism • Short bacillus, commonly • Not visible on Gram stain due to lack of cell wall • Grows in aerobic and anaerobic conditions	• Most frequently during fall and winter, but may develop year round • Most common of the atypical pneumonia • Usually community acquired • Susceptible individuals are school-aged children, military recruits, and college students • Often exhibits extrapulmonary symptoms such as anemia, rashes, and neurologic syndromes such as meningitis, myelitis, and encephalitis • May cause asthma exacerbations

inflammatory exudative fluid and migrating cells. Neutrophils migrate out of capillaries and into the alveolar spaces, forming a pool of neutrophils that is ready to respond when needed. These neutrophils phagocytize microbes and kill them with reactive oxygen species, antimicrobial proteins, and degradative enzymes. Resident alveolar macrophages are assisted by local proteins (surfactant proteins A and D) that have intrinsic properties that make foreign invaders more susceptible to phagocytosis. Engulfed bacteria are eliminated by either the mucociliary escalator or the lymphatics. When the capacity of the alveolar macrophages to ingest or kill the bacteria is exceeded, clinical pneumonia manifests. It is the host's inflammatory response, rather than the proliferation of microorganisms that triggers the clinical syndrome of pneumonia.[27] Pneumonia occurs when bacteria are exceedingly virulent, when the host is exposed to a large dose of bacteria, or when the host defense mechanism is impaired or overwhelmed.

When bacteria enter the lower respiratory tract, they adhere to the walls of the bronchi and bronchioles, triggering the release of chemical mediators that cause inflammation. See **Figure 13-3**.

As a significant portion of the lung alveoli, interstitial and alveolar spaces become filled with inflammatory cells and necrotic exudate. This alveolar exudate tends to solidify, a process known as consolidation, and expectoration of the infected mucus becomes difficult. Spread of the inflammation may occur, resulting in affected pleura and resultant effusion and/or empyema. Bacterial organisms may also enter the bloodstream from a remote site, causing **bacteremic septicemia**, which can seed the lung as well as cause nonpulmonary infection from hematologic spread. Simultaneous infectious involvement of the airways and the lung parenchyma is known as **bronchopneumonia**. Red blood cells may cross the alveolar–capillary membrane, causing **hemoptysis**. See **Figure 13-4**.

As this pathophysiologic process is eventually stabilized with the appropriate antimicrobial treatment, the resolution of inflammation and infection should enable the healing process to proceed. **Necrosis** during active inflammation and infection can cause significant



FIGURE 13-3 Bacteria that overwhelm the natural defenses of the respiratory tract trigger inflammation and fluid buildup in the alveoli, causing the clinical presentation of pneumonia.



FIGURE 13-4 Pathophysiology of bacterial pneumonia.

destructive changes. Normal lung function may not be fully restored if there is scaring and lung tissue remodeling causing alterations in ventilatory functions and blood flow to the lungs.

Risk Factors

Those individuals who are at risk for developing bacterial pneumonia are summarized in **Box 13-2**.

While infection due to atypical pneumonia such as *M. pneumoniae* typically affects younger people under the age of 40 years, it is less likely to occur in children younger than 5 years.[29] Factors suspected of increasing the risk of atypical pneumonia in the very young include close contact with other children at home or in day care and exposure to passive smoking.

Complications

Potential complications of bacterial pneumonia usually depend on the type and virulence of the offending pathogen. In 2009, bacterial pneumonia complicated between 25% and 50% of severe influenza infections in both children and adults. *S. aureus* and *S. pneumoniae* were the most common complicating organisms, although *Streptococcus pyogenes, H. influenzae*, and gram-negative rods were also found in biologic specimens of critically ill patients.[30] Regardless of the organism, bacterial superinfection was associated with higher morbidity and mortality during the 2009 influenza pandemic.[30]

Bacteremia (bacteria in the blood) is the most common complication of pneumococcus infection.[31] However, gram-negative organisms such as *H. influenzae* can cause bacteremia.[17] Bacteremia can lead to septic shock. Many of the more virulent microorganisms cause necrosis with resultant tissue destruction, sloughing, and hemoptysis or fibrosis/organization of lung parenchyma, eventually leading to parenchymal scarring. Other potential harmful effects may include lung abscess and/or cavitation formation. Lung abscesses adjacent to the thoracic wall can erode into the pleural space, causing either pleural effusion or frank empyema. The patients with empyema are more likely to be younger and to be illicit drug users.[32] Other possible complications include bronchiectasis, pleural effusions, pleurisy, renal failure, respiratory failure, and acute respiratory distress syndrome (ARDS). See **Box 13-3**.

Atypical pneumonia (especially *M. pneumoniae*) may result in a variety of extrapulmonary complications.[34] Cutaneous manifestations associated with atypical infections may include erythema multiforme, erythema nodosum, maculopapular or vesicular rash, urticaria, and Stevens–Johnson syndrome with severe cases.[34] Neurologic complications like aseptic meningitis,

BOX 13-2 Predisposing Host Factors for Bacterial Pneumonia[11,28]

- Adults >65 years old (due to impaired host defenses and increased comorbidities)
- Chronic lung diseases
  - Bronchial obstruction due to stenosis, tumor, or foreign body
  - Bronchiectasis
  - Chronic obstructive pulmonary disease
  - Cystic fibrosis
  - Immotile cilia syndrome
  - Kartagener syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)
  - Lung cancer
  - Previous episodes of pneumonia
  - Young syndrome (azoospermia, sinusitis, pneumonia)
- Increased risk of microaspiration of stomach contents or upper airway secretions
  - Decreased level of consciousness
  - Dysphagia
  - Wearing dentures while sleeping
- Immunocompromising conditions
  - Diabetes mellitus
  - HIV infection
  - Hyperimmunoglobulin E syndrome
  - Immunosuppressive medication
  - Solid organ or hematopoietic stem cell transplantation (HSCT)
- Metabolic disorders
  - Acidosis
  - Hypoxemia
  - Malnutrition
  - Uremia
- Lifestyle factors and environment exposures
  - Alcohol consumption
  - Homelessness
  - Overcrowding in jails and shelters
  - Smoking tobacco
  - Toxic inhalations
- Instrumentation of the respiratory tract (intubation or bronchoscopy)
- Viral respiratory tract infection, especially influenza

BOX 13-3 Serious Complications from Bacterial Pneumonia[33]

- ARDS
- Bacteremia
- Bronchiectasis
- Coagulopathy
- Exacerbation of comorbid illnesses
- Lung abscess
- Metastatic infection (brain abscess, endocarditis)
- Multiorgan failure
- Pleural effusion
- Pleurisy
- Respiratory failures
- Scarring of lung tissue
- Septic shock

encephalitis, cranial nerve palsies, cerebellar syndrome, and Guillain–Barré syndrome may rarely develop following the overt onset of infection with *M. pneumoniae* pneumonia.[34]

Diagnostic Testing

The etiology of pneumonia usually cannot be determined solely based on clinical presentation; instead, clinicians must rely on diagnostic testing for support. Chest radiography is considered the criterion for identifying suspected pneumonia but is not reliable in differentiating pneumonia into typical or atypical forms or for establishing an etiologic diagnosis. Occasionally, radiographic results are suggestive of the etiology. For example, **pneumatoceles** suggest infection with *S. aureus*.[27] The presence of an infiltrate on plain chest radiograph is considered the gold standard for diagnosing pneumonia when clinical features are supportive.[34] The inability to rely on radiographic findings to identify the causative organism necessitates the collaboration of radiographic findings along with clinical and laboratory data to narrow the diagnostic possibilities. The chest radiograph can identify the presence of complications such as pleural effusion, empyema, and lung abscess. See **Figures 13-5** and **13-6**.

Diagnostic testing in patients with suspected pneumonia is driven mostly by the possibility that the results would significantly alter empiric therapy and management decisions.[15] Standard laboratory testing may not be useful for diagnostic purposes in pneumonia but is useful for classifying illness severity and site-of-care/admission decisions. Serum chemistry panel should include sodium, potassium, bicarbonate, blood urea nitrogen (BUN), creatinine, and glucose. Complete blood count (CBC) with differential with acute bacterial infection typically reveals an elevated WBC count (leukocytosis usually >15,000/mL).

Hyponatremia (sodium level <130 mEq/L) and microhematuria may be associated with *Legionella* pneumonia.[15] Coagulation studies may reveal an elevated international normalized ratio (INR) in more severe illness, suggesting the development of **disseminated intravascular coagulation (DIC)**. CBC count with differential typically shows leukocytosis with a left shift. However, its absence, particularly in patients who are elderly, should not cause the clinician to discount the possibility of a bacterial infection. Leukopenia (usually defined as a WBC count <5,000 cells/μL) may be an ominous clinical sign of impending sepsis.[15]



FIGURE 13-5 Anteroposterior (AP) chest radiograph of a patient with pneumonia and a left-sided pleural effusion.



FIGURE 13-6 AP chest radiograph of a patient with pneumonia, including a pneumatocele and pneumothorax. Chest radiographs can identify the presence of pneumonia, but usually not its etiology.

The 2007 Infectious Diseases Society of America (IDSA)/American Thoracic Society (ATS) consensus guidelines recommend diagnostic testing for a specific organism when, based on clinical or epidemiologic data, pathogens that would not respond to usual empiric antibiotic regimens are suspected.[27] The guidelines support optional diagnostic tests for outpatients with CAP, except for those patients who are suspected of being exposed to certain pathogens, such as *Legionella* species. Blood cultures and sputum Gram stain and culture are encouraged for pneumonia patients requiring intensive care unit (ICU) admission. Blood cultures require 24 hours (minimum) to incubate. Because blood cultures have a high specificity, positive findings correlate well with the causative agent. Pleural fluid may show organisms on Gram staining and following culture. Sputum specimens obtained need to be of good quality, be contaminant sparse, and contain <10 squamous epithelial cells per low-power field. The WBC count present on sputum microscopic examination should be more than 25 per low-power microscopic field.[15] Unless aspiration of mixed flora observed with anaerobic infections is suspected, a single predominant microbe should be noted at Gram staining. However, often, patients cannot produce an adequate specimen. Cultures of the sputum have similar limitations, and therefore, only specimens that have been examined microscopically and have satisfied the previously mentioned criteria must be submitted for culturing.

In patients with underlying acute lung disorders, such as COPD or asthma exacerbation, **C-reactive protein (CRP)** and **procalcitonin (PCT or ProCT)** values may be helpful in distinguishing infectious from noninfectious pneumonia underlying disease exacerbations.

Lung tissue can be visually evaluated, and bronchial washing specimens can be obtained with the aid of a fiberoptic bronchoscope. Protected brushings and **bronchoalveolar lavage (BAL)** can be performed for fluid analysis and cultures. A diagnostic thoracentesis is almost always an essential procedure in patients with a pleural effusion. Obtaining fluid from the pleural space for laboratory analysis allows for the differentiation between benign and complicated effusions, allowing helpful guidance in further therapeutic intervention. Fluid obtained from pleural effusions and frank empyema should also be sent for Gram staining and culture.

The 2013 recommendations by the IDSA and the American Society for Microbiology (ASM)[35] for laboratory tests to identify the etiology of pneumonia appear in **Table 13-4**.

Diagnostic testing helps to classify the severity-of-illness and site-of-care decisions (outpatient vs. inpatient vs. ICU). The most obvious indication for extensive diagnostic testing is in the critically ill patient.[27] Assessing the severity of the pneumonia is essential to determine whether the patient, with a CAP, can be safely treated without being admitted to the hospital. Severity of illness is the most critical factor in making this determination, but other factors need to be considered. These factors include the ability to maintain oral intake, likelihood of medication adherence, history of active substance abuse, mental illness, cognitive or functional impairment, and living or social circumstances (e.g., homelessness, residence far enough from a healthcare facility that precludes timely return to care in the event of clinical worsening).[36]

There is evidence from well-conducted, randomized controlled trials that severity-of-illness scores (CURB-65) or prognostic models (PSI) can be used to identify patients with CAP who may be candidates for outpatient treatment.[27] The **Pneumonia Severity Index (PSI)** prediction rule assigns points based on age, comorbidities, abnormal physical findings, and abnormal laboratory findings at the patient's presentation.[37] It estimates mortality for adult patients with CAP. See **Box 13-4**. Based on associated mortality rates, risk Class I and II patients should be treated as outpatients, risk Class III patients should be treated in an observation unit or with a short hospitalization, and risk Class IV and V patients should be treated as inpatients.[37] A calculator for the PSI is located at https://www.mdcalc.com/psi-port-score-pneumonia-severity-index-cap.

An alternative method of the severity of CAP on presentation is to evaluate the confusion, urea, respiratory rate, blood pressure, and age ≥65 years (CURB-65). The **CURB-65** is a one-step strategy for stratifying patients with CAP into risk groups according to the risk of mortality.[39] The CURB-65 can be used in the emergency department (ED) setting to risk stratify a patient's CAP. See **Box 13-5**. A calculator for the CURB-65 is located at https://www.mdcalc.com/curb-65-score-pneumonia-severity.

Treatment and Management of Bacterial Pneumonia

Antimicrobial treatment for bacterial pneumonia differs depending on the causative agent. **Empirical antimicrobial treatment** may be initiated to avoid pneumonia progression. However, optimal treatment needs modification when the results of reliable culture data become available. In cases of serious bacterial pneumonia requiring hospitalization and the ICU, other supportive measures are frequently necessary to obtain successful outcomes. Individuals with acute inflammation and infection often develop bronchospasm that usually benefit from the use of inhaled bronchodilators. Patients with mild shortness of breath often obtain symptomatic relief with supplemental oxygen. Those patients who develop respiratory failure may require ventilatory support. Patients need appropriate positioning to minimize aspiration risk. Aerosolized bronchodilators and mucolytic agents along with airway

TABLE 13-4
Laboratory Tests for the Diagnosis of Bacterial Pneumonia[35]

Suspect Organism	Specimen Type	Diagnostic Test
CAP		
C. pneumoniae	• Nasopharyngeal swab • Sputum • Bronchoscopic specimens	• Nucleic acid amplification test (NAAT)
	• Serum	• IgM antibody titer • IgG on paired serum 2-3 weeks apart
Enterobacteriaceae *H. influenzae* *P. aeruginosa* *S. aureus*	• Sputum • Bronchoscopic specimens	• Gram stain • Culture
Legionella species	• Urine	• Urinary antigen test
	• Sputum from induction • Bronchoscopic specimens	• Culture on buffered charcoal yeast extract agar (BCYE) media • NAAT
Anaerobic bacteria (aspiration)	• Bronchoscopic specimens	• Gram stain
	• Pleural fluid	• Cultures
M. pneumoniae	• Nasopharyngeal swab • Sputum • Bronchoalveolar lavage (BAL)	• NAAT
	• Serum	• IgM antibody titer • IgG on paired serum 2-3 weeks apart
S. pneumoniae	• Sputum • Bronchoscopic specimens • Urine	• Gram stain • Culture • Urinary antigen test
HCAP, HAP, VAP		
Acinetobacter species Enterobacter species *E. coli* *H. influenzae* *K. pneumoniae* *P. aeruginosa* *S. aureus* and MRSA	• Sputum	• Gram stain
	• BAL • Bronchoscopic specimens • Lung tissue	• Culture
	• Blood	• Blood culture
Anaerobic bacteria (aspiration)	• Bronchoscopic specimens	• Gram stain
	• Lung tissue	• Culture
Legionella species	• Sputum from induction or tracheobronchial suction • BAL • Bronchoscopic specimens • Lung tissue	• Culture on BCYE media • NAAT
	• Urine	• Urine antigen test
S. pneumoniae	• Urine	• Urine antigen test
	• Sputum	• Gram stain • Culture

Data from Baron E, Miller J, Weinstein M, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) (a). *Clin Infect Dis*. 2013;57(4):e22–e121 (Tables VI 2 and VI 3). doi:10.1093/cid/cit278.

BOX 13-4 The Pneumonia Severity Index[37,38]

Step 1:

- If the patient is >50 years of age, assign to risk Class II–V and proceed to Step 2.
- If the patient is <50 years of age, but has a history of neoplastic disease, congestive heart failure, cerebrovascular disease, renal disease, or liver disease, assign to risk Class II–V and proceed to Step 2.

If the patient has an altered mental status, pulse ≥125 per minute, respiratory rate ≥30 per minute, systolic blood pressure ≤90 mm Hg, or temperature <35°C or ≥40°C, assign to risk Class II–V and proceed to Step 2.
If none of the above apply, assign to risk Class I = low risk.

Step 2:
Assign points based on age, gender, nursing home residence, comorbid illness, physical examination findings, and laboratory and radiographic findings.
Point distribution:

Characteristic	Points Assigned
• Demographic factors	
Age for a man	Age (in years)
Age for a woman	Age (in years)–10
Nursing home resident	+10
• Coexisting illnesses	
Neoplastic disease	+30
Chronic liver disease	+20
Heart failure	+10
Cerebrovascular disease	+10
Chronic renal disease	+10
• Physical examination findings	
Altered mental status	+20
Respiratory rate ≥30 per minute	+20
Systolic blood pressure <90 mm Hg	+20
Temperature <35°C or ≥40°C	+15
Pulse ≥125 beats/minute	+10
• Laboratory and radiologic findings	
Arterial pH <7.35	+30
BUN ≥30 mg/dL (11 mmol/L)	+20
Sodium <130 mmol/L	+20
Glucose ≥250 mg/dL (14 mmol/L)	+10
Hematocrit <30%	+10
Partial pressure of arterial oxygen <60 mm Hg or <90% on pulse oximetry	+10
Pleural effusion on chest radiograph	+10
Total score	

Score	Risk	Disposition
≤70	Low risk	Outpatient care
71–90	Low risk	Outpatient vs. observation admission
91–130	Moderate risk	Inpatient admission
>130	High risk	Inpatient admission

BOX 13-5 The CURB-65 Score for Pneumonia Severity[39,40]

For each of the following, a Yes reply earns +1 and a No earns 0.		
Criteria	No	Yes
Confusion	0	+1
BUN >19 mg/dL (>7 mmol/L)	0	+1
Respiratory rate ≥30 per minute	0	+1
Systolic BP <90 mm Hg or diastolic BP ≤ 60 mm Hg	0	+1
Age ≥65 years	0	+1
Total points		

The CURB-65 score ranges from 0 to 5.		
Score	Risk	Disposition
0 or 1	1.5% mortality	Outpatient care
2	9.2% mortality	Inpatient vs. observation admission
≥3	22% mortality	Inpatient admission, consider ICU for 4 or 5

clearance therapy can enhance elimination of purulent sputum.

Many individuals with pneumonia who have volume depletion may benefit from judicious and proper rehydration or the administration of an intravenous crystalloid.[15] While often beneficial in otherwise healthy adults, care must be exercised to avoid aggressive fluid administration in elderly patients with underlying cardiac disease to avoid volume overload. Early mobilization may also benefit respiratory-stabilized ICU patients on mechanical ventilation from the detrimental effects of bed rest, including insulin resistance, thromboembolic disease, disuse atrophy of muscles, and joint contractures. Other initial treatments may include correction of abnormal electrolyte levels and chest physiotherapy to assist secretion drainage when present.

Empiric antibiotic therapy for the hospitalized patient needs to begin early with a broad-spectrum antibiotic to cover the likely causative organism. The antibiotic may be later tailored based on the culture and sensitivity identification. The goals of pharmacotherapy for bacterial pneumonia are to eradicate the infection, reduce morbidity, and prevent complications. Antimicrobial treatment, therefore, should depend largely on the empiric use of antibiotic regimens directed against potential pathogens as determined by the setting in which the infection took place and the potential for exposure to **multidrug-resistant organisms (MDROs)** and other more virulent pathogens (i.e., CAP, HAP, VAP). Directed use of antibiotic agents in bacterial pneumonia needs to be based on laboratory data as well as clinical response. Because the most prevalent causative bacterial organism is *S. pneumoniae*, regardless of the host or the clinical setting, empiric therapy must be selected with this consideration in mind. Specific antimicrobials used for the treatment of bacterial pneumonia can be found in the current IDSA/ATS guidelines for the management of CAP in adults.[27] These guidelines provide evidence-based support of improved health outcomes, decreased length of hospital stay, and overall decreased mortality in patients hospitalized with CAP.

Prognosis

The prognosis of patients with bacterial pneumonia is dependent upon several factors, including the severity and virulence of the infecting organism and the overall risk status of the individual affected. Prognosis generally is good in the otherwise healthy patient with uncomplicated pneumonia. With appropriate treatment, most patients improve markedly within 2 weeks. However, it is important to keep in mind that untreated pneumonia is not a self-limiting disease because it is capable of considerable morbidity and mortality.

The mortality associated with CAP greatly depends on the clinical setting where it is treated. This mortality is only less than 3% in the outpatient setting, around 5–10% in inpatients not requiring ICU care, as high as 25% in intubated patients, and nearly 50% in ICU patients requiring vasopressors.[41] Therefore, the in-hospital case-fatality rate for patients with severe disease remains unacceptably high.[41] The elderly, who typically have a higher incidence of comorbidities and are often residents of nursing homes, are at higher risk of mortality from pneumonia than younger people. Pneumonia poses a special hazard for women who are pregnant and those individuals with impaired immune systems (particularly AIDS patients). Patients with serious medical conditions, such as diabetes, cirrhosis, sickle cell disease, and cancer, and those who have had their spleens removed are at higher risk of acquiring and dying from pneumonia.

Specific organisms vary in their effects. Mild pneumonia is usually associated with the atypical bacterial organisms such as *Mycoplasma* and *Chlamydia*. Severe pneumonia is most often associated with a wide range of organisms, with some bacterial pathogens being very virulent (potent) but particularly curable, while others such as those with multidrug resistance are difficult to treat. *Streptococcal pneumoniae* is an

example of a gram-positive pathogen that can produce severe pneumonia with mortality rates of 10%, yet it is very responsive to many antibiotics.[42] CAP due to gram-negative bacilli is uncommon but associated with a poor outcome.[43]

The prognosis with an atypical pneumonia is characteristically good with complete recovery in most cases, although the return to normal usual health may be gradual after a temporarily extended period of weakness and fatigue. Individuals who develop community-acquired atypical pneumonia can be reliably predicted based on the initial severity of illness. In non-severe disease forms of atypical pneumonia, mortality rates in persons adequately managed as outpatients are under 1%. Those affected by atypical pneumonia developing more serious disease (especially those not responding to initial therapy) may have significant mortality rates up to 50%.[27]

Viral Pneumonia

Viral pneumonia occurs most frequently in the extreme ages of life, in young children and elderly adults. Children do not have previous immunity, and their smaller immature airways facilitate infection, while in the case of the elderly, **immunosenescence** and the presence of chronic medical conditions increase their vulnerability.[44]

Definition/Diagnosis

A **virus** is a group of infectious organisms distinguished by its submicroscopic size and lack of ability to replicate outside of and without assistance of a living host cell. These minute infective microorganisms lack independent metabolic activity and thus can replicate only within a cell of a living animal or plant host. A virus consists of a core of DNA or RNA, which is surrounded by a coat of antigenic protein that is sometimes surrounded by an envelope of lipoprotein. The virus provides the genetic code for replication, while the host cell provides the necessary energy and raw materials. As a complete virus particle (viron) encounters a host cell, only the viral nucleic acids, and in some viruses, a few enzymes, are injected into the host cell. Replication of a virus subsequently occurs as biochemical mechanisms of a host cell are utilized to synthesize and assemble their separate components.

Viruses that cause pneumonia account for almost 50% of the total cases of pneumonia.[45] Several rapid tests have been recently developed to determine various viral etiologies that have become increasingly more useful in the ED.[46] Viral pneumonia severity varies from a mild illness to severe life-threatening hypoxemia.

Clinical Signs and Symptoms

The early symptoms associated with viral pneumonia typically mimic those of bacterial pneumonia. However, the course of the viral pneumonia is more insidious. Most cases of viral pneumonia are overall milder than bacterial pneumonia, which tends to occur abruptly and cause higher levels of fever than viral pneumonia. Bacterial pneumonia also typically exhibits a higher probability of presenting with chest pain and rigors compared to viral pneumonia, while chest x-ray findings in contrast to viral chest x-ray manifestations usually display substantially larger patchy infiltrates with consolidation.[47]

The clinical presentation associated with viral pneumonia often varies primarily because they are caused by many diverse pathogens. Several viral pneumonias typically occur during specific times of the year, among clustered populations, or in specific groups of individuals with underlying cardiopulmonary or immunocompromising disease. Common constitutional symptoms associated with virtually all viral pneumonias include fever, chills, nonproductive cough, rhinitis, muscle soreness, headaches, and increased fatigue. Other manifestations may include slight sputum production, shortness of breath, throat soreness, and sweating. Clinical signs and symptoms of viral along with bacterial pneumonia are highly variable and often have common characteristics such that they cannot be relied on to reliably differentiate.[45,48] See **Box 13-6**.

BOX 13-6 Clinical Signs of Viral Pneumonia Are Nonspecific[45]

- Inspection/observation
  - Sternal or intercostal retractions
  - Cyanosis
  - Rash
  - Cough (with or without sputum production)
  - Acute respiratory distress
- Vital signs
  - Fever and/or chills
  - Tachypnea
  - Tachycardia or bradycardia
- Auscultation
  - Crackles
  - Decreased breath sounds
  - Rhonchi
  - Wheezing
  - Pleural friction rub
- Percussion—dull
- Symptoms
  - Pleural pain
  - Shortness of breath

Etiology

Respiratory viruses that are the etiological agents causing pneumonia include influenza viruses (A and B), respiratory syncytial virus (RSV), adenovirus, parainfluenza viruses (PIV) -1, -2, and -3, rhinovirus, and coronaviruses.[2] Although immunocompromised patients are at higher risk for viral pneumonia from cytomegalovirus (CMV), varicella-zoster virus (VZV), herpes simplex virus (HSV), measles, adenoviruses, and seasonal viruses (influenza, RSV, PIV) remain a major cause of pneumonia. See **Table 13-5**. HSCT and SOT recipients are particularly at risk for acquiring lower respiratory

TABLE 13-5
Most Common Viruses Causing Pneumonia[44,45,49–51]

Virus	Mode of Transmission	Organism Features	Pneumonia Features
Adenovirus	• Inhalation of virus-laden aerosols • Direct contact • Contact with contaminated objects	• Double-stranded enveloped DNA virus • Linear and non-segmented • 52 serotypes • Serotypes 3, 7, and 14 are most virulent	• Contagious any time of year • Fever, cough, dyspnea • Bilateral interstitial markings • Can cause fatal necrotizing pneumonia • Susceptible individuals include children, immunocompromised adults, and adults in military centers
Coronavirus	• Inhalation of virus-laden aerosols • Direct contact • Contact with contaminated objects	• Single-stranded RNA virus • Covered with crownlike projections • 6 human coronaviruses	• Causes SARS, a life-threatening pneumonia • Fever, cough, dyspnea, progressive hypoxemia, and respiratory failure • Early interstitial infiltrates, leading to widespread opacification • Susceptible individuals include travelers to areas with SARS outbreaks, adults >60 years, individuals with diabetes or hepatitis B
Influenza	• Inhalation of virus-laden aerosols • Direct contact • Contact with contaminated objects	• Single-stranded RNA virus • Serotypes A, B, and C • Serotype A is the most virulent pathogen • Incudes H1N1 and H5N1	• Fever, cough, dyspnea • Patchy lower lobe infiltrates or interstitial infiltrates • Increased lactic dehydrogenase levels • ARDS • Susceptible individuals include children with cystic fibrosis or transplants, adults with cardiovascular or respiratory diseases, diabetes mellitus, renal disease, hemoglobinopathies or immunosuppression, residents of nursing homes, adults older than 65 years, and pregnant women.
Parainfluenza	• Inhalation of virus-laden aerosols • Contact with contaminated objects • Direct contact	• Single-stranded RNA virus • Closely related to rubella, mumps, and RSV viruses • 5 distinct antigenic subtypes (1, 2, 3, 4A, 4B) • Human PIV-3 causes pneumonia and is most virulent • Human PIV-1 and -2 cause croup	• Low-grade fever, coryza, barking cough • Susceptible individuals include children, lung transplant recipients, and the immunocompromised
RSV	• Inhalation of virus-laden aerosols • Contact with contaminated objects • Direct contact	• Single-stranded RNA virus • Linear and medium sized • Subtypes A and B • Subtype A is more virulent	• Highly contagious • Causes bronchiolitis in infants and children • Nasal congestion, dyspnea, wheezing, cough • Bilateral pulmonary infiltrates • Susceptible individuals include infants, children, elderly, those with cardiopulmonary disease, and who are immunocompromised
Rhinovirus	• Inhalation of virus-laden aerosols • Contact with contaminated objects • Direct contact	Single-stranded RNA virus • Serotypes A, B, and C	• Nasal symptoms, cough, scratchy throat • Susceptible individuals include infants, children, elderly, those with cardiopulmonary disease, and who are immunocompromised • Causes exacerbations of chronic pulmonary diseases, including asthma, COPD, and cystic fibrosis

tract infection due to CMV and RSV.[45] Other viruses less frequently causing pneumonia may include varicella virus (chickenpox), *Paramyxovirus* species (Measles), and human metapneumovirus. Viruses capable of producing *severe* pneumonia syndromes include a coronavirus producing severe acute respiratory syndrome (SARS), avian H5N1 influenza A viruses, and Hantavirus. Influenza A H1N1 (swine flu) is a recent pandemic form of viral pneumonia infection.

Epidemiology

Globally, it is estimated that 100 million adult cases and 100 million childhood cases of viral pneumonia occur annually.[52] This represents an increase most likely due to the improvement in molecular diagnostic techniques.[2,49] Viruses play a large role in CAP, as either the sole pathogen (up to 50%) or as part of mixed bacteria–virus infections (up to 27%).[47,53–55]

Viral pneumonia occurs most frequently in the extreme ages of life. Young children do not have previous immunity and their smaller immature airways facilitate infection, while in the case of elderly adults, immunosenescence and the presence of chronic medical conditions increase their vulnerability.[44] Infections caused by respiratory viruses typically follow seasonal patterns of activity and consequently are most likely to cause pneumonia during those periods.

Viruses are more commonly detected than bacteria in both adults and children hospitalized with CAP,[56] with more than 50% of the cases attributed to influenza virus types A and B.[45] RSV is the most common etiology of viral pneumonia in infants and children,[57] is the second most commonly identified cause of pneumonia in the elderly,[58] and causes severe RSV infection in adults who are severely immunodeficient.[2]

Pathology/Pathophysiology

Although a comprehensive understanding of the pathophysiology of viral pneumonia presently does not currently exist, many feel that it is likely that following initial infectivity, most respiratory viruses tend to multiply in the upper airway epithelium where they secondarily infect the lung via airway secretions or hematogenous spread.[45] Extensive lung consolidation with varying degrees of hemorrhage usually results from severe viral pneumonias. The damage process to tissues is ultimately dependent on the virus involved, with some patients revealing bloody effusions and alveolar damage. Some viruses are primarily cytopathic and directly affect bronchial pneumocytes. Another viral mechanism may include an over-exuberant inflammatory response as the mainstay of the pathogenic process.[45] Viral damage affecting the respiratory tract stimulates the host to release several humoral factors, including histamine, leukotriene C4, and virus-specific immunoglobulin E in RSV infection. RSV infections can also disrupt bacterial colonization patterns, increase bacterial adherence to respiratory epithelium, reduce mucociliary clearance, and alter bacterial phagocytosis by host cells. Rhinovirus, on the other hand, primarily affects the release of bradykinin, interleukin 1, interleukin 6, and interleukin 8.[45]

A mixed viral-bacterial coinfection interaction in the pathogenesis of pneumonia has stimulated increased interest from supportive evidence obtained from cell culture, ecological, postmortem, and clinical studies. Up to 75% of those infected with influenza go on to acquire pneumonia and are confirmed to have a bacterial coinfection.[59] *S. pneumoniae, H. influenzae,* and *S. aureus* are the most commonly reported bacteria associated with co/secondary infections during influenza pandemics since the late 19th century.[59] Although influenza virus is considered the major pathogen in this coinfective context, other respiratory viruses, including RSV, PIV, adenovirus, and rhinoviruses, are also likely to predispose individuals to secondary bacterial infection.[60]

Viruses are frequently identified in the respiratory tract of patients with pneumonia requiring ICU admission, with a strong predominance of influenza and rhinovirus.[60] Secondary bacterial pneumonia is a major cause of influenza-related deaths.[61] Viral-bacterial coinfection during severe CAP in adults is associated with an impaired presentation[60] and a complicated course,[47,60] and has longer hospitalizations than that with a bacterial etiology alone.[62] The interaction of viral–bacterial infections in part can be explained by the viral alteration of respiratory epithelium predisposing the normal anatomic defense to bacterial infection. Evidence suggests that additional and much more complex interactions occur between viruses and bacteria, causing not only a disruption of the normal pulmonary physiology, but also a reduction in host immune defense, alterations in receptors to which bacteria adhere, and increased inflammatory response.[59,60]

Risk Factors

Men who are virally infected develop pneumonia at a slightly higher rate than women.[45] Those pathogens considered seasonal viruses (including influenza, RSV, PIV) remain major causes of pneumonia. Pregnant women appear to be at increased risk for developing influenza pneumonia, VZV, and measles virus pneumonia. Pregnant women with viral pneumonia are at higher risk for severe disease than their nonpregnant counterparts. Pregnant women also displayed a disproportionate risk of severe disease associated with the 2009 H1N1 (swine flu) infection strain, and therefore, treatment should be initiated as soon as H1N1 infection is suspected.[63] Patients who are immunocompromised are at higher risk for viral pneumonia from CMV, VZV, HSV, measles, as well as adenoviruses. HSCT and SOT

BOX 13-7 Risk Factors for the Development of Viral Pneumonia Requiring Hospitalization[45]

Chronic pulmonary disease
Elderly
Immunocompromised
Men > women
Pregnancy
Very young

BOX 13-8 Diagnostic Tests Used for Viral Pneumonia[45,68,69]

- Viral cultures
  - Hemagglutination assay (HA)—IV, PIV
  - Shell viral culture (SV)—IV, AV, RSV, PIV
  - Cytopathogenic effects (CE)—AV, RSV
- Rapid antigen detection
  - Immunofluorescence foci assay (IF)—IV, AV, RSV, PIV, CoV
  - Enzyme-linked immunosorbent assay (ELISA)—IV, AV, RSV, PIV, SARS-CoV, RV
- Gene amplification
  - Reverse transcriptase polymerase chain reaction (RT-PCR)—IV, AV, RSV, PIV, SARS-CoV

recipients are particularly at risk for acquiring lower respiratory tract infection due to CMV and RSV.[64,65] Elderly individuals (>75 years old) are at high risk for developing viral pneumonia due to impaired immunity.[66] See **Box 13-7**.

Diagnostic Testing

Viral cause of pneumonia is often suggested by interstitial infiltrates on chest radiographs, while alveolar infiltrates are more likely to indicate a bacterial cause.[67] Bacterial and viral lung infections that are present radiographically alone or in combination, however, can produce a diversity of chest radiographic alterations that are helpful only in specific cases to confirm an infective cause of pneumonia.

Arterial blood gas analysis findings in viral pneumonia are variable depending on etiology. In uncomplicated viral pneumonia, mild respiratory alkalosis with mild hypocapnia and increased pH secondary to tachypnea would be expected with no other significant gas exchange abnormality.

Sinus tachycardia is a common ECG manifestation associated with pleuritic chest pain. In pleuritis secondary to acute coronary syndrome, ECG findings may show ST segment elevation with myocardial infarction, ST segment elevation of >1 mm in two or more anatomically contiguous leads, new left bundle branch block, as well as ST segment depression and/or T wave inversion.

The CBC in viral pneumonia may be normal or may demonstrate leukocytosis with lymphocytic predominance. This finding is in contrast with the CBC associated with bacterial pneumonia, which typically reveals elevation in the WBC count with a **left shift** (polymorphonuclear cell predominance or band forms). Sputum Gram stains are unfortunately often contaminated with oral pathogens and are difficult to obtain. They are usually not recommended with viral infections. Nasopharyngeal cultures, on the other hand, taken from swabs and washings may be helpful because viral cultures remain the standard criterion for most viral pathogens. The major drawback of culture is that they take a long time to complete.[45] Viral-antigen detection represents an alternative, although results are generally less sensitive and less specific than those of conventional cell cultures.

Several of these rapid detection tests to determine viral etiologies are available for their use in the ED to allow bedside diagnosis of the etiology of viral pneumonia. Precise etiologic diagnosis for viral pneumonia may be achieved with virologic tests. Rapid antigen detection kits can provide results within hours, making them useful in the ED.[45] See **Box 13-8**.

Treatment and Management of Viral Pneumonia

The treatment of viral pneumonia is determined by the severity of illness and specific infectious viral agents. Supportive measures used depend on the patient signs and symptoms. These measures may include oxygen administration as necessary, hydration, as well as ventilatory support. The goals of pharmacotherapy are to reduce morbidity and to prevent complications. Antiviral therapy may be necessary in severe cases and with immunocompromised patients. Current evidence supports that antibiotic treatment for viral infections with secondary concurrent bacterial infection should be instituted.

Antibiotics are ineffective against viral pathogens. There are antiviral medications for specific viruses. See **Table 13-6**. CMV pneumonia commonly occurs in people with immune dysfunction and can be treated with ganciclovir or foscarnet.

Prognosis

The prognosis of an individual who develops viral pneumonia is at least partly dependent upon the virulence of the organism as well as the age and comorbidities of the patient. Therefore, the prognosis can vary from a mild

TABLE 13-6
Medications Used to Treat or Prevent the Common Causes of Viral Pneumonia[45]

Medication	Virus Targeted
Antiviral Agents (Treatment)	
Cidofovir	Adenovirus, including serotype 14
Ribavirin	RSV
Peramivir	Influenza
Oseltamivir	Influenza A or B
Zanamivir	Influenza A or B
Monoclonal Antibodies (Prevention)	
Palivizumab	RSV

and self-limited illness to a life-threatening disease. The prognosis is normally considered good in most individuals without associated risk factors and generally considered in good health. Most individuals with viral pneumonia develop a mild and self-limited illness. Mortality is significantly increased, however, in affected individuals who are very young or those older than 65 years and have neoplastic disease, comorbid cardiopulmonary disorders, cerebrovascular disease, liver or renal disease, an altered mental state, or abnormal clinical signs, including fever (of 104°F or <95°F, pulse >125 beats/minute, respiratory rate >30 breaths/minute, or systolic blood pressure <90 mm Hg). Mortality is also substantially increased in immunocompromised patients.

Viral pneumonia due to adenovirus serotypes 2, 3, 7, and 21 may cause serious chronic pulmonary morbidity following acute respiratory illness. Viral pneumonia is especially prone to respiratory failure, severe hypoxemia, and various pulmonary maladies in those patients who are immunocompromised. It can also infrequently result in residual disability from interstitial fibrosis in previously healthy patients.

Fungal Pneumonia

The term "fungus" is used to encompass a very broad range of organisms, and the number capable of causing respiratory infection is extensive, varying from yeasts to complex, highly resistant molds. **Fungi** are commonly found in our environment in soil and decaying vegetation. Exposure of the respiratory system to these organisms is common, and accordingly, many fungal infections present with pulmonary involvement. A few fungi are highly virulent and can cause disease even in hosts with intact immunity. However, the virulence of most fungal organisms is low, and exposure frequently results in transient colonization, which is cleared by the intact immune system. Highly immunosuppressed hosts states, such as with organ transplantation and cancer chemotherapy, have resulted in an increasing incidence of invasive fungal infections over the last several decades.[70] In fact, many fungal organisms previously not thought to be pathogenic have been found to cause disease, most commonly as **opportunistic** infections in immunosuppressed populations.[71]

Definition/Diagnosis

Fungal infections can cause a spectrum of disorders in humans that range from superficial skin and mucous membrane infections to systemic and potentially life-threatening involvement of the internal organ systems. Fungal pulmonary involvement presents characteristics that complicate the patient's management. Presence of fungi may represent a true infection, although frequently it only implies colonization of the respiratory tract, leading to a very different management and prognosis.[72] Exposure to fungi may cause a hypersensitivity response to fungal antigens, mycotoxicosis from ingestion of fungal toxins, and fungal pneumonia. Fungal pneumonia refers to an acute infectious mycosis involving the lung parenchyma caused by a single or a combination of **endemic** or opportunistic fungi.[73]

There are millions of different fungal species on Earth, but only about 300 of those are known to cause illness. Fungal diseases are often caused by fungi that are common to the environment.[74] The common fungi that cause illness are endemic fungal pathogens and include *Histoplasma capsulatum, Paracoccidioides brasiliensis, Blastomyces dermatitidis,* and *Coccidioides immitis*. These endemic fungal pathogens can cause infection in healthy as well as immunocompromised individuals in the Americas and around the world.[73] Opportunistic fungal pathogens normally do not cause infections in otherwise healthy individuals. These fungi do take advantage of patients with hematologic malignancies as well as those with congenital or acquired immune system defense defects. These fungal pathogens include *Aspergillus* species, *Mucor* species, *Cryptococcus neoformans*, and *Candida* species.

Clinical Signs and Symptoms

Clinical manifestations of primary fungal pneumonia in persons infected may be asymptomatic but can also cause flu-like illness consisting of fever, cough (which is usually not productive), shortness of breath, and chest as well as muscle discomfort, which may be dull or pleuritic in nature. The clinical signs and symptoms of fungal pneumonia are not specific and therefore can be confused with those of bacterial or viral pneumonia. Physical findings in patients with fungal pneumonia are like other more common pneumonia pathogens and include fever, tachycardia, respiratory distress, pleural

BOX 13-9 Factors Suggesting Possible Fungal Lung Infection

- Patient has traditional immune suppression (significant neutropenia, hematologic malignancy, transplant, or chemotherapy)
- Patient has emerging immunocompromising conditions (corticosteroid use, novel biologic immune suppression, cirrhosis, renal insufficiency, COPD, diabetes)
- Exposure or recent travel to endemic geographic regions
- Nonrevolving lung infiltrates and fever despite antibacterial antibiotics
- May or may not have associated adenopathy
- May have associated skin, bone, central nervous system finding

Data from Limper A. The changing spectrum of fungal infections in pulmonary and critical care practice: clinical approach to diagnosis. *Proc Am Thorac Soc*. 2010;7(3):163–168 (Table 1). doi:10.1513/pats.200906-049al.

rub, and signs of pulmonary consolidation.[73] In addition to physical findings consistent with pulmonary involvement, other potential extrapulmonary findings that may accompany fungal pneumonia include meningitis (including neck stiffness, headaches, and mental status change), skin lesions, and rheumatologic and allergic findings. See **Box 13-9**.

Etiology

Fungal pneumonia is a mycosis infectious process of the lung caused by one or more endemic or opportunistic fungi. Fungal lung infection occurs because of several potential mechanisms, including the inhalation of spores, following inhalation of conidia, by the reactivation of a latent infection, as well as via hematogenous dissemination (occurring predominately in an immunocompromised host). Endemic fungal pathogens cause lung infection in typically healthy hosts (as well as in immunocompromised persons) in defined geographic locations around the world. In the United States, these organisms include *H. capsulatum*, *C. immitis*, and *B. dermatitidis*.[75] Opportunistic fungal organisms, on the other hand, tend to cause pneumonia in individuals with acquired or congenital defects in their host defenses. These organisms may include *Candida* species, *Aspergillus* species, *Mucor* species, *C. neoformans*, and *Pneumocystis jirovecii*.[76]

Epidemiology

Endemic fungal pathogens affect men substantially more often than women, which may be in part due to estrogen-mediated inhibition of mycelium-to-yeast transformation resulting in male predominance. Estrogen also seems to have a protective effect against cryptococcal infection because studies have found a male-to-female ratio of approximately 3:1 in cryptococcosis.[73] Work-related exposure may also contribute to the skewed distribution. Endemic fungi causing infection in the United States are predominately found in the Mississippi River Valley and the Ohio River Valley (e.g., *H. capsulatum, B. dermatitidis*), the southwestern United States.[73] International presence of fungal infection has caused several pneumonia outbreaks in Argentina and other areas of Central and South America. In the Dominican Republic, there was an outbreak of histoplasmosis among tunnel workers in September 2015 and an outbreak of invasive disease by *Trichosporon asahii* in Kingston, Jamaica, in 2010.[77] Endemic fungal pneumonias are generally self-limited in presumably healthy hosts.

Invasive aspergillosis represents the leading cause of pulmonary lung infection and death among patients who are neutropenic, with a 50–85% mortality rate.[78] The second most common cause of fungal pneumonia is mucormycosis. Mucormycosis accounts for approximately 10% of all invasive pulmonary infections in immunosuppressed patients resulting in significant morbidity and mortality.[73]

Pathology/Pathophysiology

Most pulmonary fungal infections occur after inhalation of fungi due to the disturbance of their natural habitat. Fungi typically enter the lung with inhalation of their spores, though they can reach the lung through the bloodstream if other parts of the body are infected. Also, fungal pneumonia can be caused by reactivation of a latent infection. Once in the lungs, the fungi are engulfed by the alveolar macrophages and other cells involved in the primary immune response. Macrophages are usually able to neutralize and destroy pathogens; however, many fungi have developed ways to disable the macrophages and some have developed the ability to grow and multiply inside macrophages. Fungi also travel into the spaces between the cells and between adjacent alveoli through the pores of Kohn. This invasion triggers the immune system to respond by sending neutrophils responsible for attacking microorganisms to the lungs. The neutrophils not only engulf and kill the fungi but also release cytokines that result in a general activation of the immune system. This results in fever, chills, and fatigue common with bacterial pneumonia. Fluids are leaked from neighboring blood vessels that fill the alveoli, leading to impaired oxygen transport.[73]

In healthy individuals, the infection is contained. However, the site of the initial infection can remain as **granulomas**, which can later degenerate to scars

and can calcify. The disposition of the fungal pathogen following its initial infection is dependent upon the host's overall immune response and the type of involved fungus. When cellular immunity is impaired, as with immunocompromised individuals, infection with fungi cannot be controlled and the infection can spread throughout the body through the bloodstream. The presence of chronic pulmonary disease impairs the clearance of the infection.

Risk Factors

In general, outdoor workers such as farmers that become significantly exposed to bird, bat, or rodent droppings or other animal excreta in endemic areas where fungi are known to be present may acquire any of the endemic fungal pneumonias. It is also known that laboratory personnel working with *C. immitis* in a presumed protected environment may become infected because of its intense virulence. **Box 13-10** shows risk factors for opportunistic fungal pathogens.

Risk factors associated with *non-albicans Candida* infection include systemic antifungal therapy, central venous catheter placement, and prior GI surgery. Much of invasive candidiasis results from endogenous floral strains, although **nosocomial** *Candida* infection may be transmitted from healthcare workers' hands or contaminated fluids.[80] Increasing evidence currently exists that individuals with COPD are at increased risk for invasive aspergillosis, and COPD patients who receive high-dose or long-term corticosteroid therapy are at higher risk.

BOX 13-10 Risk Factors for Fungal Pneumonia Caused by Opportunistic Fungi[73,79]

- Acute leukemia or lymphoma during myeloablative chemotherapy
- Bone marrow or peripheral blood stem cell transplantation
- Solid organ transplantation on immunosuppressive treatment
- Prolonged corticosteroid therapy
- Acquired immunodeficiency syndrome
- Prolonged neutropenia from various causes
- Congenital immune deficiency syndromes
- Post-splenectomy state
- Genetic predisposition
- Severe burns
- Malnutrition
- Prolonged stays in intensive care

Complications with Fungal Pneumonia

Complications associated with fungal pneumonia infections include (1) disease dissemination to other extrapulmonary sites such as the brain, meninges, skin, liver, spleen, kidneys, adrenals, heart, and eyes; (2) fungal sepsis syndrome; and (3) blood vessel involvement, which can lead to pulmonary hemoptysis, lung parenchymal infarction, myocardial infarction, cerebral emboli, cerebral infarction, or blindness.[73] Other potential complications that may occur because of fungal pneumonia include bronchopleural or tracheoesophageal fistulas, chronic pulmonary disorders, mediastinal fibrosis, or broncholithiasis (primarily with histoplasmosis). Pericarditis as well as other rheumatologic-like symptoms may also be sometimes seen.

Diagnostic Testing

Radiographic findings in primary fungal pneumonias are generally nonspecific and mimic those seen in bacterial or viral lung infections. Patchy infiltrates, nodules, and radiographic evidence of consolidation, cavitation, as well as pleural effusion may be identified. In contrast to bacterial or viral pneumonias, mediastinal adenopathy may be present in patients with endemic fungal pneumonias occurring either unilaterally or bilaterally. Miliary infiltration of fungal infections frequently occurs in individuals with disseminated disease.[73]

Standard laboratory testing like other infectious processes are usually nondiagnostic. On CBC with differential, elevation of the total WBC count may be present in normal hosts with endemic mycosis, while eosinophilia may be seen particularly in persons with coccidioidomycosis. The presence of neutropenia or leukopenia on CBC should raise the possibility of an opportunistic infection with *Candida* or *Aspergillus* organisms under appropriate conditions.

The laboratory tools used in the diagnosis of pulmonary fungal infection appears in **Table 13-7**.

Treatment and Management

Spontaneous recovery often occurs without treatment in individuals with endemic mycosis, especially in those patients who are mildly affected and immunocompetent without evidence of dissemination.[73] In fungal cases involving an immunocompromised host, aspergillosis, mucormycosis, and candidiasis infection recovery is primarily based upon the reversal of factors suspected of negatively affecting the patient's immune status. See **Box 13-11**.

Aggressive treatment is mandatory with an invasive symptomatic opportunistic fungal pneumonia in the immunocompromised patient, including antifungal agents that typically require prolonged treatment and are often associated with significant toxicity. The specific type of antifungal agent to be used needs to be

TABLE 13-7
Diagnostic Techniques to Identify Fungal Pneumonia[70]

Technique	Characteristics
Microbiologic Diagnostics	
Direct microscopy	Respiratory secretions, BAL, and tissue sampling, identification via macroscopic and microscopic morphologic characteristics
Culture	A key method for diagnosis, more sensitive than direct microscopy, performed on all acceptable clinical specimens, if suspected
Susceptibility testing	Identify antifungal medication susceptibility
Histopathologic Diagnostics	
Microscopy	Visualization of fungal elements within tissue samples, can be difficult with small sample size
Immunohistochemistry	Using antibodies directed at fungal cell antigens to identify organism visualized in tissue samples
Immunologic and Biochemical Diagnostics	
Complement fixing antibodies titer	High titers typically mean severe or disseminated disease; decreased titer means recovery from infection
Direct fungal antigen detection	Body fluids or blood, used for histoplasmosis, cryptococcosis, invasive aspergillosis, and other invasive fungal diseases
Serologic tests for endemic fungi	High degree of test cross reactivity between different pathogens; performance of tests depends on the extent and site of infection
Cryptococcal antigen test	Serum and cerebrospinal fluid
Aspergillus galactomannan antigen test	Serum and other body fluids
(1→3)-β-D-Glucan test	Serum is needed for testing, detects cell wall components of *Aspergillus* and *Candida, Pneumocystis, Fusarium*, and *Trichosporon*
Molecular Diagnostics	
PCR–based assays	Can detect *Candida, Aspergillus*, and *P. jirovecii*

BOX 13-11 Promoting Recovery from an Opportunistic Fungal Infection[73]

- Reverse neutropenia in patients receiving chemotherapy and bone marrow transplants with various growth factors
- Withdraw or taper immunosuppressive agents and steroids, if possible
- Remove contaminated or colonized catheters from patients with candidiasis

tailored to the fungal pathogen isolated or clinically suspected. Many classes of antifungal agents are currently available, including the classic antibiotics; first-, second-, and third-generation triazoles; and echinocandins. Unfortunately, the use of these agents in those invasive infections that are most serious and more often deadly may not begin working rapidly enough in the patient who is immunocompromised. While amphotericin B remains the mainstay of initial therapy in many patients who are acutely ill, newer formulations, including liposomal preparations of amphotericin B, offer equal efficacy with less toxicity. Voriconazole is currently considered the new standard of care for individuals who develop pulmonary aspergillosis based on its proven superiority over amphotericin B as the principal therapy.[73]

Empirically initiated treatment with conventional amphotericin B or liposomal amphotericin B is sometimes begun for presumed fungal infections in individuals who are febrile and neutropenic and whose fever continues after receiving broad-spectrum antibiotics for a few days. An alternative of combination agents that may be potentially used in this setting are itraconazole and echinocandin. All these choices

are continued until the neutropenia is corrected and the patient no longer demonstrates evidence of fungal infection or radiographic infiltrate. Prophylactic therapy (suppressive therapy) with amphotericin B may be used to prevent recurrence or relapse of coccidioidomycosis, cryptococcosis, or histoplasmosis fungal infections in those individuals infected with the HIV who have previously received presumed adequate treatment for the infection.

Surgery may be considered in patients with recognized invasive aspergillosis who have previously received treatment with antifungal agents yet continue to demonstrate residual lesions. Surgery may also be carried out to prevent disease relapse when additional immunosuppression is necessary. Consideration for surgery intervention may also be necessary to prevent or treat massive bleeding, especially when fungal involvement is contiguous with a large blood vessel.

Rapidly progressive respiratory failure can occur in patients who are neutropenic and require management with mechanical ventilatory support. In persons severely neutropenic who develop abrupt progression of fungal pneumonia and dissemination of fungal infection, it is vital that rapid identification of the disorder along with early empiric antifungal therapy, and specific corrective measures (if possible) to reverse the presence of neutropenia or other causes of immunosuppression, is instituted. These measures may include the rapid reduction and/or withdrawal of immunosuppressive agents, if possible. Correction of neutropenia may necessitate the administration of growth factors (such as filgrastim [Neupogen]) or leukocyte transfusions. Other measures that should be addressed include the correction hyperglycemia as well as acidosis.

Continued maintenance therapy may be necessary to suppress fungal disease reactivation or recurrent disease in immunocompromised patients, including those fungi-infected individuals with HIV. If suppressive or preventative treatment is continued, it necessary to monitor for possible recurrence. Individuals who have ongoing immune deficiencies will probably require extended or lifelong maintenance therapy with antifungal agents to prevent recurrences.

Prognosis

The overall prognosis associated with fungal infection causing pneumonia is ultimately linked to the underlying health of the individual exposed to the fungal organisms, the severity or virulence of the infection, the outcome of the underlying disease that may be present, and whether the reversal of factors affecting the patient's immune status is possible. While endemic fungal infections may be asymptomatic and cause little, if any, residual complications, the most virulent forms of systemic disease have an 80% mortality rate if the disease goes untreated.[73]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The most common types of pneumonias in the United States are caused by bacteria.
2. True or False: Debilitated or immunocompromised individuals most often develop gram-positive pneumonias.
3. True or False: Atypical pneumonias cause extrapulmonary issues.
4. True or False: Atypical bacterial pneumonias occur only in hospitalized patients.
5. True or False: The onset of viral pneumonia is more abrupt than the onset of bacterial pneumonia.
6. True or False: Viral pneumonia occurs most frequently in young children and elderly adults.
7. True or False: ICU admission for viral pneumonia is most often caused by influenza and rhinovirus.
8. True or False: Antibiotics also work for the treatment of viral pneumonia.
9. True or False: Immunosuppressed individuals are at risk for the development of fungal pneumonia.
10. True or False: Individuals with mild cases of fungal pneumonia can spontaneously recover.

Pneumonia Classification by Anatomic Location

Pneumonia caused by infection of the lungs can be broadly classified by the chest radiographic anatomic distribution pattern into lobar pneumonia, bronchopneumonia, and pneumonia producing an interstitial pattern. **Lobar pneumonia** involving a distinct area of lung often as a single lobe is primarily associated with CAP. Bronchopneumonia in contrast to lobar pneumonia is a multifocal process typically enveloping bronchi and involving multiple regions of one or both lungs typically seen with hospital-acquired infection. Pathologically, lobar pneumonia and bronchopneumonia are characterized by alveolar space flooding associated with acute inflammatory cells, fibrin, and edema. **Interstitial pneumonia** represents a third radiographic



FIGURE 13-7 Radiologic patterns of pneumonia.
Source: Infection and Inflammatory Disorders. Radiology Key. 2016. https://radiologykey.com/infection-and-inflammatory-disorders/. Accessed June 4, 2018.

infectious pneumonic pattern involving the lung that is commonly associated with viral infections involving the lung. *M. pneumoniae* is the most frequent bacterial-like cause of interstitial pneumonia. The distributive pattern affecting primarily alveolar walls rather than the alveolar spaces can be caused by viruses or organisms such as *M. pneumoniae*. Interstitial pneumonia in contrast to both lobar pneumonia and bronchopneumonia causes thickening of the alveolar walls while demonstrating less inflammatory cells. See **Figure 13-7**.

Lobar Pneumonia

Lobar pneumonia (also called alveolar pneumonia) commonly presents in one or more of the five major lobes of the lungs. Clinical manifestations of lobar types of pneumonia are characterized by cough producing rusty sputum, fever, chills, rapid and shallow breathing, cyanosis, nausea, vomiting, and sometimes pleurisy. While *S. pneumoniae* is the most common cause of lobar pneumonia, accounting for around 40% of cases, other organisms causing lobar pneumonia include *K. pneumoniae*, *H. influenzae*, anaerobes from aspiration pneumonia, and *L. pneumophila*.[81] The lobar pneumonia chest x-ray findings typically consist of focal or nonsegmental pneumonia, which presents as homogeneous consolidation from the production of edema involving one or more lobes.[82] See **Figure 13-8**.

Lung consolidation initially begins in the lung periphery and later spreads between acini through the pores of Kohn and canals of Lambert.[81] Anatomically larger bronchi within areas of consolidation may remain patent, with air creating the characteristic air bronchogram. This is frequently seen with *S. pneumoniae* infections causing homogenous parenchymal lobar opacities with air bronchograms. *S. pneumoniae* can display itself as a rounded opacity mimicking a pulmonary mass,



FIGURE 13-8 Right upper lobe consolidation in an adult with *S. pneumoniae*.

called **round pneumonia**.[82] When acute pneumonia is lobar in distribution associated with consolidation and air bronchograms, a higher incidence of bacteremia is typically observed.

Bronchopneumonia

Bronchopneumonia (also known as multifocal or lobular pneumonia) is caused by aspiration of secretions from a colonized trachea. This pneumonia is typically multifocal and centered in distal airways.[81] See **Figure 13-9**. This pattern is characterized by the predominance of parabronchial nodules, including centrilobular nodules with or without peribronchial consolidations.[82] The degree of severity and location of involvement are dependent upon the etiology of the obstruction, individual health status, and virulence of the causative organism. Bronchopneumonia may be caused by a variety of bacterial and nonbacterial organisms.



FIGURE 13-9 A chest radiograph of bronchopneumonia from aspiration showing nodular opacities, which represent multiple secondary lobules filled with inflammatory exudate.

Source: Infection and Inflammatory Disorders. Radiology Key. 2016 (Figure 3-7a). https://radiologykey.com/infection-and-inflammatory-disorders/. Accessed June 4, 2018.

With increasing illness severity, consolidation eventually occurs involving the terminal bronchioles and alveoli, which usually lead to the development of a lobular or lobar pattern of involvement.

Bronchopneumonia may be identified radiographically by its patchy, less distinctive appearance with peribranchial thickening and poorly defined air-space opacities. In contrast to lobar pneumonia, air bronchograms are usually not present. Because bronchopneumonia is characteristically caused by particularly destructive organisms, abscesses, pneumatoceles, and pulmonary gangrene may be seen, although organisms are not normally life threatening in persons with normal defense mechanisms. Bronchopneumonia is associated with HAP due to organisms such as *S. aureus* and GNB.[81] However, most pathogens can take this pattern of pneumonia.[82] The signs and symptoms of bronchopneumonia are like those of lobar pneumonia, including chills, fever, rapid pulse and respiratory rates, bronchial breathing, cough with purulent bloody sputum, chest pain, and occasional abdominal distension.

Interstitial Pneumonia

Interstitial pneumonia is most commonly caused by mycoplasma, viruses, and (in immunocompromised patients) pneumocystis.[82] This pattern appears as predominantly ground-glass opacities. Pathologically, these ground-glass opacities may correspond to incomplete alveolar filling by inflammatory cells or exudate; pulmonary edema secondary to infection, leaving air in the alveoli; or interstitial infiltrates of inflammatory cells.[82] See **Figure 13-10**. Development of interstitial pneumonia proceeds as either (1) an insidious infectious course resulting in lymphatic infiltration of alveolar septa without parenchymal abnormality or (2) acute or rapidly progressive disease resulting in diffuse alveolar damage affecting the interstitial and air spaces. Radiographically, the disease process displays a reticular or reticulonodular pattern.

Although most interstitial pneumonias are infectious in etiology, including viral, bacterial, fungal, and protozoal, they may be caused by acute processes such as chemical injury, acute pancreatitis, or a state of shock as in ARDS. Chest radiographic findings in noninfectious interstitial lung disorders are more likely to display indistinct patchy shadows though later stages of the process may reveal bronchiectasis, bronchi dilation, and contraction of the lungs.



FIGURE 13-10 Interstitial pneumonia pattern of ground glass in a patient with *P. jirovecii* pneumonia.

Reproduced with permission from Nambu A. Imaging of community-acquired pneumonia: roles of imaging examinations, imaging diagnosis of specific pathogens and discrimination from noninfectious diseases. *World J Radiol.* 2014;6(10):779 (Figure 14A). doi:10.4329/wjr.v6.i10.779.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Interstitial pneumonia is commonly associated with viral infections involving the lungs.
2. True or False: Lung consolidation seen on chest radiography begins in the alveoli and spreads to the lung periphery.
3. True or False: Lobular pneumonia is another name for lobar pneumonia.
4. True or False: Pneumocystis pneumonia is typically an interstitial pneumonia.

Pneumonia Classification by Origin of Development

Clinically, it is prudent to classify pneumonia according to its site of origin because it helps the medical team to provide empirical antimicrobial therapy.[57] Accordingly, pneumonia may be classified as CAP, HAP, and VAP. Another category that is sometimes seen in the literature is healthcare-associated pneumonia (HCAP). This type of pneumonia is acquired in healthcare facilities, such as nursing homes, hemodialysis centers, and outpatient clinics, or during a hospitalization within the past 3 months. The 2016 IDSA/ATS guidelines did not include HCAP.[83]

Community-Acquired Pneumonia

Constant exposure to the environment and frequent aspiration of nasopharyngeal flora expose the lungs to microorganisms that are virulent. Colonization of the upper respiratory tract by pathogenic organisms, followed by **microaspiration**, is considered the primary pathogenesis of pneumonia.[84] Key early decisions in CAP management are based on severity scores and presumed pathogens guided according to the clinical presentation, age, presence of comorbidities, and other significant antecedents and site of care.[27]

Definition/Diagnosis

CAP is an infectious pneumonia with symptoms onset in the community. Diagnosis can be made within 48 hours of hospital admission to meet criteria for CAP.[85] CAP presents as an acute infectious process involving the lower respiratory tract typically associated with characteristic manifestations, including the presence of a new chest radiograph infiltrate. CAP is a common and potentially serious illness and is associated with considerable morbidity and mortality, particularly in older adult patients and those with significant comorbidities.[34]

Clinical Signs and Symptoms

No clinical symptom or physical finding is sufficiently sensitive or specific to either confirm or exclude the diagnosis of CAP. Manifestations typically associated with CAP unfortunately are difficult to distinguish from other causes of respiratory illness. The patient's medical history, therefore, becomes significantly important in identifying the presence of key risk factors. See **Box 13-12**.

The PSI or the CURB-65, discussed earlier in this chapter, are used to stratify patients who can be treated at home or in the hospital. See Boxes 13-4 and 13-5.

Criteria for the admission of a patient to intensive care were established by the IDSA/ATS guidelines, using parts of the CURB-65 and ATS criteria. The threshold for ICU admission is the presence of at least three minor criteria or one of the major criteria.[27] See **Box 13-13**.

BOX 13-12 Key Elements in Diagnosis of CAP[48,86]

- Symptoms
  - Cough, dry (initially) or productive
  - Shortness of breath
  - Chest discomfort with deep breathing
  - Abdominal pain (with lower lobe involvement)
  - Chills
  - Night sweats
  - Reduced appetite
- Signs
  - Tachypnea
  - Tachycardia
  - Auscultation
    - Crackles
    - Decreased breath sounds
  - Fever
- Patient history
  - >65 years of age
  - Recent respiratory infection or antibiotic use
  - History of tobacco smoking
  - Comorbid medical disorders

BOX 13-13 Criteria for Severe CAP[27]

Minor criteria*

- Respiratory rate ≥30 breaths/minute
- Arterial oxygen pressure/fraction of inspired oxygen (PaO_2/FIO_2) ratio† ≤250
- Multilobar infiltrates
- Confusion/disorientation
- Uremia (BUN level ≥20 mg/dL)
- Leukopenia‡ (WBC count <4,000 cells/mm^3)
- Thrombocytopenia (platelet count <100,000 cells/mm^3)
- Hypothermia (core temperature <36°C)
- Hypotension requiring aggressive fluid resuscitation

Major criteria

- Invasive mechanical ventilation
- Septic shock with the need for vasopressors

*Other criteria to consider include hypoglycemia (in nondiabetic patients), acute alcoholism/alcoholic withdrawal, hyponatremia, unexplained metabolic acidosis, or elevated lactate level, cirrhosis, and asplenia.

†A need for noninvasive ventilation can substitute for a respiratory rate >30 breaths/minute or a PaO_2/FIO_2 ratio <250.

‡As a result of infection alone.

Etiology

Most often it is the virulent pathogens that can overwhelm the body's defensive mechanisms in the respiratory tract. These pathogens are either inhaled or aspirated and are more likely to occur in patients with reduced host defenses. The pathogens responsible for CAP are varied and wide ranging in their capacity to cause severe disease and extrapulmonary features.[85] CAP may be caused by one or more of over 100 potential pathogens that manifest in different degrees of severity. Severe CAP is the type of pneumonia that requires supportive therapy with a critical care environment and the type of CAP that causes patients to present with multiple organ failure. See **Table 13-8**.

Epidemiology

The estimated U.S. burden of CAP is substantial, with more than 1.5 million unique adults being hospitalized annually, 100,000 deaths occurring during hospitalization, and approximately one of three patients hospitalized with CAP dying within 1 year.[87] Almost 1 million cases are among elderly persons annually.[88] Most cases of CAP are treated on an outpatient basis[89] with *S. pneumoniae, H. influenzae,* and *M. catarrhalis* accounting for 85% of the total U.S. incidence of CAP.[90] *S. pneumoniae* is the most commonly identified bacterial cause of CAP worldwide.[11] The overall rate of CAP in adults is approximately 5.16 to 7.06 cases per 1,000 persons per year; the rate of CAP increases with increasing age.[91]

Pathology/Pathophysiology

A lung infection normally occurs when at least one component of the defense mechanism is not functioning properly, or the virulence or quantity of the infecting pathogen is substantial. When such a circumstance exists, microorganism colonization of the upper respiratory tract is generally followed by microbe invasion

TABLE 13-8
Common Pathogens Implicated in Severe CAP

Pathogen	Risk Factors	Other Features
S. pneumoniae	Alcohol abuse, HIV, intravenous drug abuse, hyposplenism	Pleural effusion, empyema
S. aureus	Structural lung disease, intravenous drug abuse, influenza	Pneumothoraces, lung cavitation
Community-acquired MRSA (CA-MRSA)	Influenza	Necrotizing pneumonia, lung cavitation, neutropenia, skin pustules
Legionella species	Smoking, foreign travel	Neurologic symptoms, increased creatinine kinase, diarrhea, transaminitis, relative bradycardia
Gram-negative bacilli • *K. pneumoniae* • *A. baumannii* • *P. aeruginosa*	Structural lung disease, recent antibiotics, immunosuppression • Alcohol abuse, aspiration • Alcohol abuse, aspiration • Smoking, aspiration, HIV, structural lung disease	Leucopenia, cavitation, empyema
H. influenzae	Aspiration, COPD, smoking, HIV, intravenous drug abuse	
M. catarrhalis	COPD, smoking	
Respiratory viruses	Viral pandemics	Interstitial infiltrates or normal chest radiography
M. pneumoniae	Cyclical pandemics	Headache, erythema multiforme, positive cold agglutinin titers
Chlamydophila • *C. pneumoniae* • *Chlamydophila psittaci*	 • COPD, smoking • Exposure to birds	Interstitial infiltrates Horder spots (facial rash), transaminitis (increase liver enzymes)
Anaerobes	Alcohol abuse, aspiration, intravenous drug abuse	Lung cavitation

Data from Morgan A, Glossop A. Severe community-acquired pneumonia. *BJA Educ*. 2016;16(5):167–172 (Table 1). doi:10.1093/bjaed/mkv052.

of the lower respiratory tract. Several mechanisms of pathogen transmission may result in the pathogenesis of pneumonia in immunocompetent adults. See **Table 13-9**

An inflammatory response is evoked when numerous or more virulent microorganisms invade the lungs and reach the alveoli. This infectious process results in the breakdown of local defense mechanisms and the production of intra-alveolar exudate. While inflammation generated by these processes is necessary for innate immunity and host defenses for the disposal of microorganisms, it can also harm host cells. There is a balance between pathogen-related factors (e.g., virulence and inoculum size) and host-related factors (e.g., age, gender, and comorbidities) in the development and severity of pneumonia.[92]

TABLE 13-9
Mechanisms of Pathogenic Transmission[57]

Mechanism	Examples
Aerosol inhalation	*M. pneumoniae, C. psittaci, C. pneumoniae, L. pneumophila*
Oropharyngeal secretions microaspiration	*S. pneumoniae, H. influenzae,* anaerobes, gram-negative bacilli
Hematogenous spread	*S. aureus*
Reactivation of latent microorganisms	*Mycobacterium tuberculosis, P. jirovecii*

Risk Factors

Several risk factors may predispose an individual to CAP. See **Box 13-14**.

Complications

Complications associated with CAP are dependent on the infecting pathogen and the affected individual's health. Table 13-8 shows the organisms and some of their associated complications. These complications include pleural effusion, empyema, pneumothorax, lung cavitation, skin pustules, and lung tissue necrosis. A small proportion of patients with CAP develop progressive pneumonia and ARDS. Although risk factors such

BOX 13-14 Predisposing Host Conditions[11]

- Older age (marked increase in CAP among adults >65 years)
- Chronic lung diseases or other disorders that impair airway clearance
  - Chronic obstructive pulmonary disease
  - Cystic fibrosis
  - Bronchiectasis
  - Pulmonary edema
  - Bronchial obstruction due to stenosis, tumor, or foreign body
  - Lung cancer
  - Previous episode of pneumonia
  - Immotile cilia syndrome
  - Kartagener syndrome (ciliary dysfunction, situs inversus, sinusitis, bronchiectasis)
  - Young syndrome (azoospermia, sinusitis, pneumonia)
- Conditions that increase the risk of microaspiration of stomach contents and/or microaspiration of upper airway secretions
  - Any alteration in the level of consciousness
  - Dysphagia due to esophageal lesions and motility problems
  - Wearing dentures while sleeping
- Immunocompromising conditions
  - Diabetes mellitus
  - HIV infection
  - SOT or HSCT
  - Immunosuppressive medication use
  - Hyperimmunoglobulin E syndrome
- Metabolic disorders
  - Malnutrition
  - Uremia
  - Hypoxemia
  - Acidosis
- Lifestyle factors and environmental exposures
  - Smoking tobacco
  - Alcohol consumption
  - Toxic inhalations
  - Overcrowding in jails and shelters
  - Homelessness
- Instrumentation of the respiratory tract (e.g., intubation, bronchoscopy)
- Viral respiratory tract infection, especially influenza

as being an infant, being elderly, comorbidity with other diseases, and immunodeficient states are associated with the development of ARDS in various respiratory infections, including influenza virus infection, previously healthy patients can also develop ARDS.[61]

Diagnostic Testing

The most specific and sensitive test that may consider the gold standard for documenting the presence of pneumonia is the standard AP and lateral view chest radiographs. Unfortunately, the chest radiography is neither 100% sensitive nor specific for this pneumonia.[82] When compared with computed tomography (CT) imaging (not recommended as an initial diagnostic tool), many of the cases of pneumonia are missed by the standard chest radiograph.[93] High-resolution CT imaging may be particularly helpful in better defining complex lung patterns, including various nodular patterns, linear patterns, reticular patterns, ground-glass opacities, as well as consolidation. However, CT imaging is not utilized routinely as a diagnostic test for pneumonia.[27] For patients who are hospitalized for suspected pneumonia but who have negative chest radiography finding, it may be reasonable to treat their condition presumptively (empirically) with antibiotics and repeat the imaging in 24–48 hours.[27] Lung ultrasonography may be helpful in recognizing clinically suspected adult CAP.[94]

Oximetry or arterial blood gas analysis is useful in defining severity of illness and potential need for oxygen therapy. Usually pulse oximetry is adequate to make this determination unless hypercarbia is suspected. If pending ventilatory failure is suspected, arterial blood gas measurements are required.

Standard laboratory chemistries, such as CBC, electrolytes, BUN, and liver function tests, are nondiagnostic for CAP but may be helpful in defining the severity of the overall illness and systemic complications. Elevation of the WBC and BUN level is generally indicative of more severe illness. The serum albumin level obtained within 24 hours of patients admitted to the hospital has been shown to be a good prognostic marker in CAP.

Patients with CAP should be investigated for specific pathogens that would significantly alter standard (empirical) management decisions, when the presence of such pathogens is suspected based on clinical and epidemiologic clues.[27] The main downside of extensive diagnostic testing of all patients with CAP is cost, which is driven by the poor quality of most sputum microbiologic samples, and the low yield of positive culture results in many groups of patients with CAP.[27] Urinary antigen tests are used for the detection of *S. pneumoniae* and *L. pneumophila* serogroup 1. This type of testing has a higher diagnostic yield in patients with more severe illness.[27]

Bronchoscopic samples of lower respiratory secretions may be indicated in those selected cases of CAP who present with complications, persistent hypoxia, no response to therapy, or pulmonary abscess for culturing the selected areas of involvement or endotracheal aspirate for drug-resistant and unusual pathogens. This can be usually accomplished by selective BAL analysis or protected brush biopsy. Thoracentesis with pleural fluid analysis, including Gram staining and pleural fluid culture, is indicated in patients with a pleural effusion.

Treatment and Management

Preventative measures are always warranted but unfortunately are not always followed by those particularly at risk for developing pneumonia. It is without question that smoking cessation advice needs to be offered and its importance emphasized as a major avoidance of all current smokers with CAP. Modifications to the presence of specific risk factors, such as occupational or environmental exposures or social behavior (as in limiting direct exposure to bat or bird droppings or the excessive abuse of alcohol) known to be associated with certain CAP pathogens, should also be stressed.

Influenza vaccine is strongly recommended and should be provided for susceptible individuals >50 years of age along with others particularly at risk for influenza complications. The vaccine is encouraged among individuals who are close household contacts of high-risk people as well as healthcare workers if not contraindicated. See **Box 13-15**.

The site where care is administered in the treatment of CAP whether performed as outpatient, hospitalized, or directly admitted to the ICU can be determined

BOX 13-15 Recommendation from the Centers for Disease Control (CDC) for Administration of the Pneumococcal Vaccine[95]

The CDC recommends the pneumococcal polysaccharide vaccination for

- Individuals aged 65 years or greater
- Individuals age 2–64 years old with certain medical conditions
- Adults 19–64 years old who smoke cigarettes

The CDC recommends the pneumococcal conjugate vaccination for

- All babies and children younger than 2 years
- All adults 65 years or older
- People 2–64 years old with certain medical conditions

either by PSI or CURB-64 indexes (Boxes 13-4 and 13-5). Then the interventions necessary, the optimal route of antimicrobial therapy, and the intensity of clinical observation required to affect a positive outcome can be determined.

Antibiotic therapy is typically begun on an empiric basis, because the causative organism is not identified in an appreciable proportion of patients. Current empiric treatment recommendations for CAP are listed in **Table 13-10**.

As with any suspected pneumonic process, patients should be carefully assessed as to their hydration, adequacy of gas exchange, nutritional status, and hemodynamic stability. Supplemental oxygen and ventilatory support should be initiated immediately if necessary. Individuals with CAP who develop respiratory failure and hypoxemia unresponsive to conventional oxygen treatment at maximal concentrations may be managed with ventilatory support from noninvasive positive pressure ventilation. Patients with pneumonia who fail to respond to conventional and noninvasive therapies, especially those complicated by ARDS, require appropriate invasive mechanical ventilation and recruitment maneuvers.

Prognosis

Negative prognostic factors in CAP include preexisting lung disease, underlying cardiac disease, poor splenic function, advanced age, multilobar involvement, and delayed initiation of appropriate antimicrobial therapy.[41,88] The general well-being of patients with mild to moderate-severe CAP requiring hospitalization returned to prepneumonia status within 6 months of

TABLE 13-10
Empiric Antibiotic Recommendations for CAP

Patient Type	Likely Etiology (in Decreasing Order of Occurrence)	Treatment
Outpatient	*S. pneumoniae* *M. pneumoniae* *H. influenzae* Respiratory viruses*	1. Previously healthy and no use of antimicrobials within the previous 3 months: a macrolide (azithromycin, clarithromycin, or erythromycin) or doxycycline (not strongly recommended) 2. Presence of comorbidities (chronic heart, lung, liver or renal disease; diabetes mellitus; alcohol abuse; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs; or use of antimicrobials within the previous 3 months, in which case an alternative from a different class should be selected): A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin) or β-lactam plus a macrolide 3. In regions with a high rate (>25%) of infection with high-level (MIC ≥16 μg/mL) macrolide-resistant *S. pneumoniae*, consider use of alternative agents listed above in (2) for patients without comorbidities.
Inpatient (non-ICU)	*S. pneumoniae* *M. pneumoniae* *C. pneumoniae* *H. influenzae* *Legionella* species Aspiration Respiratory viruses*	A respiratory fluoroquinolone or a β-lactam plus a macrolide
Inpatient (ICU)	*S. pneumoniae* *S. aureus* *Legionella* species Gram-negative bacilli *H. influenzae*	A β-lactam (cefotaxime, ceftriaxone, or ampicillin–sulbactam) plus either azithromycin or a respiratory fluoroquinolone (for penicillin-allergic patients, a respiratory fluoroquinolone and aztreonam are recommended)
Special concern	*P. aeruginosa*	An antipneumococcal, antipseudomonal β-lactam (piperacillin–tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin OR any of the above β-lactam plus an aminoglycoside and azithromycin OR any of the above β-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone (for penicillin-allergic patients, substitute aztreonam of the above β-lactam)
Special concern	CA-MRSA	If CA-MRSA is a consideration, add vancomycin or linezolid

Modified from Mandell L, Wunderink R, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(suppl_2):S27–S72 (Tables 6 and 7, pp. S44 and S45). doi:10.1086/511159.

discharge. Persistent respiratory symptoms beyond 28 days are more likely to reflect age or comorbidity than the effect of pneumonia.[88]

Ventilator-Associated Pneumonia and Hospital-Acquired Pneumonia

In the United States, pneumonia is a common reason for hospital admission and a leading cause of death.[96] Patients who have frequent contact with the healthcare system have pneumonia outcomes that are worse than patients without such exposures, a finding thought to be associated with their increased risk for harboring resistant organisms.[97]

Definition/Diagnosis

The IDSA and the ATS define HAP (nosocomial) as an episode of pneumonia not incubating at the time of hospital admission and occurring 48 hours or more after admission and not associated with mechanical ventilation within the hospital.[83] Any pneumonia that arises more than 48–73 hours following endotracheal intubation is defined as VAP.[83] Patients with severe nosocomial pneumonia who require mechanical ventilation during their treatment after the onset of infection do not meet the definition of VAP. In contrast, ventilator-associated tracheobronchitis (VAT) is characterized by signs of respiratory infection without new radiographic infiltrates, in a patient who has been ventilated for at least 48 hours.[98]

The IDSA/ATS recognizes that there is no gold standard for the diagnosis of HAP or VAP. Much of the literature on this subject is complicated by inconsistent usage of the term *HAP*, with some using the term to denote any pneumonia developing in the hospital, and others excluding VAP from the HAP designation. However, HAP and VAP belong to two mutually exclusive groups.[83]

Clinical Signs and Symptoms

Clinical features in non-intubated individuals who develop HAP are like those features present with CAP. These clinical manifestations include cough, shortness of breath, recent appearance of purulent sputum, fever, development of a leukocytosis, and the appearance of a new or progressive infiltrate on chest x-ray. While clinical manifestations of HAP are often very similar to those observed with CAP, manifestations can be misleading or overshadowed in those patients confounded by other disease processes commonly present in hospitalized patients. Physical findings suggestive of superimposed pneumonia in these cases usually include fever or hypothermia, leukocytosis or leukopenia, the onset of purulent respiratory secretions, and a reduction in oxygenation consistent with deterioration in gas exchange.

The diagnosis of VAP is based on a combination of clinical, radiologic, and microbiologic criteria. There are a wide range of clinical conditions that mimic VAP in ventilated patients, including ARDS, pulmonary edema, pulmonary contusion, tracheobronchitis, and thromboembolic disease. Some of the clinical features used to define a VAP are subjective, such as changes in tracheal secretions, and are subject to inter- and intra-observer variation.[99]

The clinical presentation of HAP in the elderly presents added diagnostic challenges because it notably develops insidiously often in the absence of cough, fever, and increased sputum. Elderly patients with HAP present with atypical symptoms such as mental change or failure to thrive. In these patients, it is important to maintain a high index of suspicion and obtain radiographic studies when considered a possibility. Apart from clinical criteria used to identify the presence of HAP or VAP, microbiologic assessment is important to help guide therapy. If VAP is suspected, an endotracheal sputum sample is recommended for microbiologic studies.[83] If HAP is suspected, respiratory samples are also obtained for microbiologic studies.[83] Sampling, in this case, is typically from spontaneous expectoration, sputum induction, or nasotracheal suctioning in a cooperative patient.

Etiology

The development of HAP represents an imbalance between normal host defenses and the ability of microorganisms to colonize and then invade the lower respiratory tract.[22] It is GNB that are implicated in 50–80% of HAP cases in the ICUs.[2] **Table 13-11** shows the most common causative pathogens of HAP and VAP.

TABLE 13-11
Most Common Organisms Associated with HAP and VAP[22,100]

Common Organisms Associated with VAP*	Common Organisms Associated with HAP*
Acinetobacter species (gram negative) *Enterobacter* species (gram negative) *Klebsiella* species (gram negative) *P. aeruginosa* (gram negative) *Serratia* species(gram negative) *S. aureus* (including MRSA) (gram positive) *Stenotrophomonas maltophilia* (gram negative)	*Acinetobacter* species (gram negative) *Enterobacter* species (gram negative) *E. coli* (gram negative) *Klebsiella* species (gram negative) *P. aeruginosa* (gram negative) *Serratia* species (gram negative) *S. aureus* (including MRSA) (gram positive)

*Alphabetical.

The causative pathogens for HAP and VAP generally have similar statistics worldwide.[100]

S. aureus is the most common cause of both HAP and VAP.[100] Less common pathogens implicated in HAP include *Legionella* species, Influenza A virus, RSV, human PIV-3, and human metapneumovirus.[22] These usually occur in clusters or outbreaks. The viruses are typically spread from person to person.

Epidemiology

According to the NHSN, there was a steady decline in reported VAP rates in the United States between the years 2006 and 2012; in medical ICUs, the reported incidence of VAP per 1,000 ventilator days decreased from 3.1 to 0.9 and, in surgical ICUs, the reported incidence decreased from 5.2 to 2.0.[101] VAP is associated with increased ICU stay, patient ventilator days, and mortality, as well as significant costs.[99] Both HAP and VAP constitute the most common cause of death among all hospital-acquired infections, with mortality of up to 30% in the United States and worldwide.[22] There is no racial or gender predilection for HAP and VAP. However, they are more common in the elderly, but any patient may be affected.[22]

Pathology/Pathophysiology

The pathogenesis of HAP is multifactorial and is predominately initiated by the introduction or invasion of bacteria or other pathogens into the lower respiratory tract by aspiration of oropharyngeal organisms, inhalation of aerosols containing bacteria, or, less frequently, hematogenous spread from a distant body site or infected intravenous catheter. Microaspiration of oropharyngeal pathogens or a leakage of secretions containing bacteria around an endotracheal tube cuff into alveoli is considered the most frequent method of pathogen transmission in HAP or VAP. Other less common pathways include direct inoculation (such as during thoracentesis), and translocation from the GI tract.

The concomitant illnesses of hospitalized patients are a risk for nosocomial infections. In hospitalized patients, alterations in immune function make them more susceptible to invasive infections that would not occur in healthy individuals. Many hospitalized patients are in poor nutritional status, increasing their risk of infection. Severe illness and hemodynamic compromise are associated with increased rates of HAP. In hospitalized patients, the combination of altered immune function, impaired mucociliary clearance of the respiratory tract, and oropharynx colonization by enteric gram-negative pathogens make aspiration an important contributor to pneumonia. Moreover, supine positioning contributes greatly to the aspiration risk. Hospitalized patients often become colonized with microorganisms acquired from the hospital environment, and as many as 75% of severely ill patients become colonized within 48 hours.[101] The inability of the pulmonary clearance mechanisms and immune system to contain the organism allows for an ensuing invasion of the pulmonary parenchyma.

Risk Factors

Individuals admitted to a hospital commonly have host risk factors, such as extremes of age or serious underlying conditions that reduce the individual's natural immune defenses and predispose them to additional infection. This is particularly true of hospitalized patients with preexisting lung disease. The risk of developing HAP is substantially greater for patients who undergo thoracic or abdominal procedures than for those undergoing procedures involving other body sites. **Box 13-16** shows the risk factors for HAP and VAP.

BOX 13-16 Risk Factors for HAP and VAP[102]

- Increasing age (>55 years)
- Chronic lung disease
- Depressed consciousness
- Aspiration
- Chest or upper abdominal surgery
- The presence of an intracranial pressure monitor
- Agents that increase gastric pH (H_2 blockers, antacids, proton pump inhibitors [PPIs])
- Previous antibiotic exposure, especially broad spectrum
- Reintubation or prolonged intubation
- Mechanical ventilation for ARDS
- Frequent ventilator circuit changes
- Benzodiazepines, opioids, and paralytic medication use
- Multiple trauma
- Paralysis
- Number of central venous catheter placements and surgeries
- Use of muscle relaxants or glucocorticoids
- Malnutrition, chronic renal failure, anemia, Charlson Comorbidity Index,* previous hospitalization
- Endotracheal tube cuff pressure <20 cm H_2O

*Predicts 10-year survival in patients with multiple comorbidities. The higher the Charlson Comorbidity Index, the lower the estimated 10-year survival. https://www.mdcalc.com/charlson-comorbidity-index-cci#creator-insights

Patients in the hospital are at higher risk for developing a multidrug-resistant pneumonia. Prior exposure to intravenous antibiotics has been consistently identified as a predisposing factor to multidrug-resistant pathogens in VAP and HAP.[83]

Complications

The rise in complication rates of infections associated with HAP and VAP may at least in part be inversely attributed to continuing advances in medical technology. These advances include progress in the treatment of critically ill patients; prolonged survival of the critically ill; extended periods of hospitalization; use of cytotoxic and immunosuppressive medications; extensive, extended, and sometimes unwarranted use of broad-spectrum antibiotics; and an increasing variety of diagnostic and therapeutic devices. Although patients who receive mechanically assisted ventilation have higher mortality rates than hospitalized patients not receiving ventilatory support, other factors including the patient's underlying comorbidities and presence of organ failure are major predictors of death in patients who develop nosocomial pneumonia.

Complications such as bacteremia may arise from catheter-related infections, which may be prevented using sterile technique during placement, using an antibiotic disc at the insertion site, and replacing the catheter dressing weekly. Adverse effects resulting from pneumonia can include respiratory failure by triggering ARDS, which results from a combination of infection and the body's innate inflammatory response. Sepsis and septic shock are also potential complications of pneumonia resulting from predominately bacterial microorganisms (notably *S. aureus*) entering the bloodstream and causing the immune system to respond by secreting cytokines that can affect multiorgan systems and result in high mortality. Other complications include empyema, pleural effusions, abscess formation, and bronchopleural fistulas.[103]

Diagnostic Testing

The clinical diagnosis of HAP and VAP is difficult in part because the clinical findings are nonspecific. The 2016 IDSA/ATS guidelines for the management of HAP and VAP continue to recommend a clinical diagnosis based upon a new lung infiltrate plus clinical evidence that the infiltrate is of infectious origin, which includes the new onset of fever, purulent sputum, leukocytosis, and decline in oxygenation.[83] The standard AP and lateral chest radiographs are ordered with any suspicion of a HAP despite their apparent limitations in differentiating between opacity and fluid. Chest radiographic findings present in HAP are often like those seen in CAP but may be greatly confounded by other disease processes common in hospitalized patients, particularly those in intensive care. Radiographically, pneumonias can be difficult to differentiate from other causes of air-space shadowing, including atelectasis and early ARDS. Usually pneumonia initially appears as patchy consolidation or ill-defined nodules.[103] Serial chest radiograph is most useful in ruling out progression of the pneumonia and serves as an indicator of the efficacy of appropriate antimicrobial therapy. It is important to note that radiographic improvement lags far behind microbiologic cure, often by several months.[22]

The diagnosis of VAP in patients who have sustained trauma to the chest may also be particularly difficult because the trauma process itself can create a proinflammatory state that mimics infection, causing difficulty in correctly interpreting the chest x-ray with pneumonic infiltrate. CT scan imaging may be necessary to appropriately identify opacity and help to determine whether a procedure is indicated.

No definitive standard diagnostic laboratory test is available for the diagnosis of pneumonia. The WBC count may be normal or elevated with HAP or VAP. Neither leukocytosis nor a normal WBC count favors the diagnosis of HAP or VAP or diseases that mimic these nosocomial pneumonias.[22]

A respiratory sample for microbiologic studies is recommended to help diagnose VAP and HAP.[83] The IDSA/ATS guidelines recommend noninvasive sampling rather than invasive sampling (bronchoscopy, BAL) of respiratory secretions is recommended whenever possible.[83] If culture identification of the infecting organism or organisms is successful, most microbiology laboratories report the susceptibility of the organism as susceptible (S), intermediate (I), or resistant (R). Positive cultures need to be clinically correlated because they may merely be evidence of colonization of the trachea and potentially mislead directed therapy. When microbiologic study results are obtained, empiric, antibiotic therapy needs to be adjusted to the organisms found.[83] Any pleural fluid removed by diagnostic thoracentesis needs to be tested to determine whether the pleural space needs to undergo placement of chest tube drainage. Analysis findings that are usually predictive of the need for closed tube drainage include a pH < 7.20, a glucose level <40 mg/dL, and an lactate dehydrogenase (LDH) level $>1{,}000$ U/L.

Blood cultures, unfortunately, are poorly sensitive and therefore are often negative in many cases. There is limited support for utilizing blood cultures for patients with VAP. However, approximately 15% of patients with VAP are bacteremic, and in these patients, the definitive identification of a pathogen, often multidrug resistant, may alter management.[83]

ABG studies are useful in assessing the degree of severity of lung dysfunction but not in determining the specific etiology. In general, bacterial nosocomial pneumonia/VAP have low A-a gradients (<35).[22]

Treatment and Management

Prevention is always preferred over treatment of a hospital-acquired infection, especially in an individual who is already medically compromised from an existing disease disorder leading to hospital admission. Reducing the potential for the transmission of relatively antimicrobial-resistant pathogens between patients and their caregivers clearly is a key priority. Fundamental measures utilized to accomplish this include hand washing before and after patient contact by all caregivers, avoiding the sharing of bedside or respiratory therapy equipment between patients, and isolating patients known to be infected or colonized with multiple resistant bacterial pathogens. Several other modifiable factors may be initiated to avert added risk of acquiring a nosocomial infection (including VAP) that often poses serious and life-threatening threats. These include preventative steps such as semi-recumbent head positioning at 30–45 degrees to help prevent aspiration (particularly for patients being enterally fed), proper handwashing prior to and following patient contact, and minimizing invasive oropharyngeal devices such as endotracheal tubes and nasogastric tubes. Studies also suggest some value in the use of agents to produce selective decontamination of the digestive tract or decontamination of the oropharyngeal tract. In patients with suspected HAP, culture specimens should be obtained immediately followed by the empiric initiation of appropriate broad-spectrum antibiotics without delay. Although identifying specific preventative measures is important and considered necessary to reduce the risk and incidence of HAP and VAP, no current program eliminates these infections.

In those patients who are already critically ill and require ventilatory assistance in the ICU, there are measures to prevent the occurrence of VAP. See **Box 13-17**.

BOX 13-17 VAP Prevention[99]

- Avoid endotracheal intubation by using noninvasive positive pressure ventilation (NIPPV) assistance when feasible.
- When mechanical ventilation is necessary, endotracheal tube cuff pressure should be sufficient to prevent potential regurgitation of gastric contents.
- Use of a silver-coated endotracheal tube may help in preventing VAP through its antimicrobial properties to reduce biofilm formation and bacterial adherence to the endotracheal tube.
- Use subglottic secretion drainage systems.
- Use a tapered tracheostomy tube cuff to avoid cuff folds that promote secretion drainage into the lungs.
- Minimize the duration of mechanical ventilation and determine the appropriate timing for tracheostomy placement when long-term mechanical ventilation is necessary.
- Provide timely nutritional support that includes appropriate blood glucose control in patients with diabetes and preferably an enteral feeding route with feeding tubes placed in the mid-duodenum and beyond to reduce the risk of aspiration.
- Use strict hand hygiene, closed circuit suction systems, and heat moisture exchangers and limit tubing changes to promote the reduction of biofilm formation.

Antibiotics remain the cornerstone of treatment in HAP and VAP. Decisions regarding the appropriate choice of antibiotic use may be optimally guided by culture results from respiratory secretions. However, these require a variable waiting period for confirmatory culture identification. Although clinicians need to obtain a suitable valid specimen for antimicrobial culture, an empiric antibiotic regimen needs to begin as soon as possible without waiting for the culture results.[83] The IDSA/ATS HAP/VAP guidelines recommend that all hospitals regularly generate and disseminate a local antibiogram (a periodic summary of antimicrobial susceptibilities of local bacterial isolates submitted to the hospital's clinical microbiology laboratory,[104] specific to their intensive care population, if possible).[83] See **Box 13-18**.

There is a 10–20% threshold for deciding to target MRSA in the empiric treatment of VAP and HAP. See **Table 13-12**. There is a 10% threshold for deciding to prescribe one antipseudomonal agent or two. The goal is to try to assure that ≥95% of patients receive empiric therapy active against their likely pathogens. Individual ICUs may elect to modify the thresholds. If a patient has structural lung disease increasing the risk of gram-negative infection (e.g., bronchiectasis or cystic fibrosis), two antipseudomonal agents are recommended.[83]

Patients with VAP due to gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins are suggested to receive both inhaled and systemic antibiotics, rather than systemic antibiotics alone.[83]

A 7-day course of antimicrobial therapy is recommended for both HAP and VAP. For patients with both HAP and VAP, antibiotic therapy should be de-escalated from an empiric broad-spectrum antibiotic regimen to a narrower antibiotic regimen by switching the antimicrobial agent or reducing a combination therapy to a monotherapy.[83] The 7-day course reduces

BOX 13-18 Recommended Empiric Treatment of Hospital-Acquired and Ventilator-Associated Pneumonia[83]

Empiric Treatment for Clinically Suspected HAP (non-VAP)

- Antibiotic with activity against *S. aureus*
  - If MRSA is suspected—vancomycin or linezolid
  - No risk factors for MRSA—piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem
  - Proven methicillin-sensitive *S. aureus* (MSSA)—oxacillin, nafcillin, or cefazolin
- Antibiotic with activity against *P. aeruginosa* and other gram-negative bacilli

Empiric Treatment for Clinically Suspected VAP

- Antibiotics with activity against *S. aureus*, *P. aeruginosa*, and other gram-negative bacilli
  - Risk factor for antibiotic resistance (MRSA)—vancomycin or linezolid and two antipseudomonal antibiotics from different classes
  - No risk for antibiotic-resistant MSSA is suspected—piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem and one antipseudomonal antibiotic

TABLE 13-12
Risk Factors for Multidrug-Resistant Pathogens[83]

Risk Factors for Multidrug-Resistant VAP • Prior intravenous antibiotic use within 90 days • Septic shock at the time VAP is suspected • ARDS preceding VAP • Five or more days of hospitalization prior to the occurrence of VAP • Acute renal replacement therapy prior to VAP onset
Risk Factors for Multidrug-Resistant HAP • Prior intravenous antibiotic use within 90 days
Risk Factors for Methicillin-Resistant VAP/HAP • Prior intravenous antibiotic use within 90 days
Risk Factors for Multidrug-Resistant *Pseudomonas* VAP/HAP • Prior intravenous antibiotic use within 90 days

Adapted from Kalil A, Metersky M, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61–e111 (Table 2). doi:10.1093/cid/ciw353.

antibiotic exposure, antibiotic-related side effects, and the potential for antibiotic resistance. Testing for PCT levels and clinical criteria are suggested as a guide for the discontinuation of antibiotic therapy. Clinical criteria include fever, cough, abnormal findings on examination, and infiltrates on chest radiography. Serum PCT levels decrease with successful treatment of bacterial infection.

BOX 13-19 Risk Factors for Increased Mortality Due to Hospital-Acquired and Ventilator-Associated Pneumonia[106]

- Serious illness at the time of VAP/HAP diagnosis (shock, coma, respiratory failure, ARDS)
- Bacteremia
- Severe underlying comorbid disease
- Infection with multidrug-resistant organism
- Multilobar, cavitating, or rapidly progressive infiltrates on lung imaging
- Delay in the institution of effective antimicrobial therapy

Prognosis

Despite high absolute mortality rates in hospital-acquired (or nosocomial) pneumonia (HAP) patients, the mortality attributable to the infection is difficult to gauge. Many studies have found that HAP is associated with significant excess risk of death. However, many of these critically ill patients die from their underlying disease and not from pneumonia. While all-cause mortality associated with VAP has ranged from 20% to 50% in different studies,[83] a meta-analysis of randomized trials of VAP prevention estimated the attributable mortality at 13%.[105] Several variables are associated with increased mortality from HAP and VAP. See **Box 13-19**.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The development of pneumonia represents an imbalance between the pathogen and the host defense mechanisms.
2. True or False: CAP causes patients to have persistent respiratory symptoms beyond 28 days.
3. True or False: Clinical manifestations of CAP and HAP are similar.
4. True or False: Elderly patients with HAP many times present with atypical symptoms.
5. True or False: The most common cause of HAP and VAP is *S. pneumoniae*.
6. True or False: HAP risk is greatest for patients who had thoracic or abdominal surgery.
7. True or False: The proinflammatory state caused by trauma mimics infection sometimes causing difficulty with VAP diagnosis.
8. True or False: A 14-day antibiotic course is standard treatment for both HAP and VAP.

Key Points

1. The 21st century has seen the continuation of pneumonia as a leading cause of death in both developed and developing worlds, with an increasing prevalence of antimicrobial resistance and subsequent treatment failure in key respiratory pathogens.
2. Pneumonia is classified in several different ways, including by the causative organism, the place in which the pneumonia was acquired, and the location in the lungs.
3. No definitive standard diagnostic laboratory test is available for the diagnosis of pneumonia.
4. Bacterial pneumonias are the most common type of pneumonia in adults in the United States. Gram-negative pneumonias predominately occur in individuals who are debilitated or immunocompromised, or have been recently hospitalized.
5. The majority of patients with CAP are treated as outpatients.
6. The most commonly occurring organisms responsible for causing atypical pneumonia are *C. pneumoniae, Chlamydia psittaci, L. pneumophila*, and *M. pneumonia*.
7. Empiric antibiotic treatment selection for CAP, HAP, and VAP is usually chosen and begin prior to specific pathogen identification based on known pathogens associated with the condition and their antibiotic susceptibility patterns in the community.
8. Prevention is always preferred over treatment of a hospital-acquired infection, especially in an individual who is already medically compromised from an existing disease disorder leading to hospital admission.
9. Hospitalized patients are at higher risk for developing a multidrug-resistant pneumonia.
10. The adequacy of initial antimicrobial therapy is a key factor for prognosis in pneumonia.

Chapter Questions

1. _____ is transmitted by poor hand hygiene.
   a. *Actinomyces israelii*
   b. *Nocardia asteroides*
   c. *Enterococcus faecalis*
   d. *Streptococcus pneumoniae*
2. Rust-colored sputum and shaking chills are indicative of pneumonia caused by _____.
   a. *Escherichia coli*
   b. *Acinetobacter baumannii*
   c. *Staphylococcus aureus*
   d. *S. pneumoniae*
3. _____ creates a biofilm protecting it from the host's immune system defenses.
   a. *Pseudomonas aeruginosa*
   b. *Moraxella catarrhalis*
   c. *Haemophilus influenzae*
   d. *A. baumannii*
4. One of the bacteria that cause atypical pneumonia is _____.
   a. *N. asteroides*
   b. *S. pneumoniae*
   c. *Klebsiella pneumoniae*
   d. *Mycoplasma pneumoniae*
5. Bacterial pneumonia from _____ is caused by exposure to an infected bird.
   a. *M. catarrhalis*
   b. *Chlamydophila pneumoniae*
   c. *Chlamydia psittaci*
   d. *A. baumannii*
6. Green-colored sputum is indicative of pneumonia caused by _____.
   a. *K. pneumoniae*
   b. *P. aeruginosa*
   c. *H. influenzae*
   d. *E. coli*

7. Simultaneous infectious involvement of the airways and lung parenchyma is _____.
   a. bronchopneumonia
   b. lobar pneumonia
   c. *Klebsiella* pneumonia
   d. *A.* pneumonia
8. _____ typically causes pneumonia in people between the ages of 5 and 40 years.
   a. *M. catarrhalis*
   b. *K. pneumoniae*
   c. *M. pneumoniae*
   d. *Legionella pneumophila*
9. A patient arrives in the emergency department with all the typical signs and symptoms of acute pneumonia and receives a pneumonia severity index (PSI) of 170 points. This patient needs to be treated _____.
   a. in the emergency department and released
   b. as an outpatient
   c. in the hospital as an inpatient
   d. in the intensive care unit
10. Individuals with pneumonia due to _____ are highly contagious.
    a. *M. catarrhalis*
    b. influenza
    c. *Enterobacter pneumoniae*
    d. *L. pneumophila*
11. Patients who are suspected of having fungal pneumonia can be treated empirically with _____ before diagnostic test results are received.
    a. levofloxacin
    b. amoxicillin
    c. amphotericin B
    d. vancomycin
12. The Center for Disease Control (CDC) recommends the pneumococcal polysaccharide vaccination for _____.
    a. all individuals no matter what age
    b. adults between the ages of 19 and 64 years
    c. all babies and children younger than 2 years
    d. all individuals aged 65 years and older
13. The most common cause of hospital-acquired pneumonia are _____.
    a. gram-negative bacteria
    b. gram-positive bacteria
    c. viruses
    d. fungi
14. Pleural fluid analysis results that indicate the possible need for closed chest tube drainage include _____.
    a. pH >7.20
    b. glucose level <40 mg/dL
    c. LDH <400 U/L
    d. pH >7.40
15. Empiric treatment for clinically suspected methicillin-resistant *Staphylococcus aureus* (MRSA) ventilator-associated pneumonia includes _____.
    a. vancomycin
    b. levofloxacin
    c. oxacillin
    d. cefazolin

References

1. Mackenzie G. The definition and classification of pneumonia. *Pneumonia*. 2016;8(1):14. doi:10.1186/s41479-016-0012-z.
2. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial etiology of pneumonia: epidemiology, diagnosis and resistance patterns. *Int J Mol Sci*. 2016;17(12):2120. doi:10.3390/ijms17122120.
3. Murphy S, Xu J, Kochanek K, Curtin S, Arias E. *Deaths: Final Data For 2015*. Hyattsville, MD: National Center for Health Statistics; 2017. https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf. Accessed June 7, 2018.
4. Shaddock E. How and when to use common biomarkers in community-acquired pneumonia. *Pneumonia*. 2016;8(1):17. doi:10.1186/s41479-016-0017-7.
5. Codes I. 2018 ICD-10-CM Codes J00-J99: Diseases of the respiratory system. 2018. https://www.icd10data.com/ICD10CM/Codes/J00-J99. Accessed June 7, 2018.
6. Ventola C. The antibiotic resistance crisis: part 1: causes and threats. *Pharmacy and Therapeutics*. 2015;40(5):227–283. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378521. Accessed May 10, 2018.
7. Pneumonia—Causes | National Heart, Lung, and Blood Institute (NHLBI). 2018. https://www.nhlbi.nih.gov/node/3499. Accessed May 23, 2018.
8. Dickson R, Erb-Downward J, Huffnagle G. The role of the bacterial microbiome in lung disease. *Expert Rev Respir Med*. 2013;7(3):245–257. doi:10.1586/ers.13.24.
9. Mizgerd J. Lung infection—a public health priority. *PLoS Med*. 2006;3(2):e76. doi:10.1371/journal.pmed.0030076.
10. Troeger C, Forouzanfar M, Rao P, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Infect Dis*. 2017;17(11):1133–1161. doi:10.1016/s1473-3099(17)30396-1.
11. Marrie T, File T Jr. Epidemiology, pathogenesis, and microbiology of community acquired pneumonia in adults. In: Bartlett J, Ramirez J, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018.
12. Vieira F, Nahas E. Comparison of microbial numbers in soils by using various culture media and temperatures. *Microbiol Res*. 2005;160(2):197–202. doi:10.1016/j.micres.2005.01.004.
13. Dickson R, Huffnagle G. The lung microbiome: new principles for respiratory bacteriology in health and disease. *PLoS Pathog*. 2015;11(7):e1004923. doi:10.1371/journal.ppat.1004923.
14. Yang D, Blair K, Salama N. Staying in shape: the impact of cell shape on bacterial survival in diverse environments. *Microbiol Mol Biol Rev*. 2016;80(1):187–203. doi:10.1128/mmbr.00031-15.
15. Gamache J, Harrington A, Kamangar N. Bacterial pneumonia clinical presentation: history, physical examination, risk stratification. Medscape. 2018. https://emedicine.medscape.com/article/300157-clinical. Accessed June 8, 2018.
16. Grosso A, Luna C, Famiglietti A. Community-acquired pneumonia due to gram-negative bacteria. *Community Acquir Infect*. 2015;2(4):117–122. doi:10.4103/2225-6482.172651.
17. Peleg A, Hooper D. Hospital-acquired infections due to gram-negative bacteria. *N Engl J Med*. 2010;362(19):1804–1813. doi:10.1056/nejmra0904124.
18. Murphy T, Parameswaran G. *Moraxella catarrhalis*, a human respiratory tract pathogen. *Clin Infect Dis*. 2009;49(1):124–131. doi:10.1086/599375.

19. Cukic V, Hadzic A. The most common detected bacteria in sputum of patients with community acquired pneumonia (CAP) treated in hospital. *Med Arch*. 2016;70(5):354–358. doi:10.5455/medarh.2016.70.354-358.
20. Villegas M, Quinn J. *Enterobacter* Species—Infectious Disease and Antimicrobial Agents. 2018. http://www.antimicrobe.org/b97.asp. Accessed May 29, 2018.
21. Berebichez-Fridman R, Blachman-Braun R, Azrad-Daniel S, Vázquez-Campuzano R, Vázquez-López R. Atypical pneumonias caused by *Legionella pneumophila*, *Chlamydophila pneumoniae* and *Mycoplasma pneumonia*. *Rev Med Hosp Gen Mex*. 2015;78(4):188–195. doi:10.1016/j.hgmx.2015.06.005.
22. Cunha B. Atypical pneumonias: current clinical concepts focusing on Legionnaires' disease. *Curr Opin Pulm Med*. 2008;14(3):183–194. doi:10.1097/mcp.0b013e3282f79678.
23. Baum S. *Mycoplasma pneumoniae* infection in adults. In: Bartlett J, File T Jr, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www/uptodate.com/. Accessed May 29, 2018.
24. Oba Y. Chlamydial Pneumonias: Overview, Pathophysiology, Epidemiology. 2018. https://emedicine.medscape.com/article/297351-overview. Accessed May 29, 2018.
25. American Lung Association Epidemiology and Statistics Unit, Research and Health Division. *Trends in Pneumonia and Influenza Morbidity and Mortality*. Chicago, IL: American Lung Association; 2015. http://www.lung.org/assets/documents/research/pi-trend-report.pdf. Accessed May 29, 2018.
26. Gleason P. The emerging role of atypical pathogens in community-acquired pneumonia. *Pharmacotherapy*. 2002;22(1 Part 2):2S–11S. doi:10.1592/phco.22.2.2s.33130.
27. Mandell L, Wunderink R, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis*. 2007;44(suppl_2):S27–S72. doi:10.1086/511159.
28. Lee K, Gordon A, Foxman B. The role of respiratory viruses in the etiology of bacterial pneumonia. *Evol Med Public Health*. 2016;2016(1):95–109. doi:10.1093/emph/eow007.
29. Bono M. Mycoplasmal Pneumonia: Background, Pathophysiology, Etiology. Medscape. 2018. https://emedicine.medscape.com/article/1941994-overview. Accessed May 30, 2018.
30. Rynda-Apple A, Robinson K, Alcorn J. Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. *Infect Immun*. 2015;83(10):3764–3770. doi:10.1128/iai.00298-15.
31. Pneumococcal Disease | Symptoms and Complications | CDC. 2018. https://www.cdc.gov/pneumococcal/about/symptoms-complications.html. Accessed May 30, 2018.
32. Narita M. Classification of extrapulmonary manifestations due to *Mycoplasma pneumoniae* infection on the basis of possible pathogenesis. *Front Microbiol*. 2016;7:23. doi:10.3389/fmicb.2016.00023.
33. Ost D, Fein A, Feinsilver S. Nonresolving pneumonia. In: Bartlett J, Ramirez J, eds. *Uptodate*. Waltham, MA: UpToDate; 2018.
34. File T Jr. Treatment of community-acquired pneumonia in adults in the outpatient setting. In: Bartlett J, Ramirez J, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018.
35. Baron E, Miller J, Weinstein M, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) (a). *Clin Infect Dis*. 2013;57(4):e22–e121. doi:10.1093/cid/cit278.
36. Yealy D, Fine M. Community-acquired pneumonia in adults: assessing severity and determining the appropriate site of care. In: Bartlett J, Ramirez J, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed June 8, 2018.
37. Fine M, Auble T, Yealy D, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med*. 1997;336(4):243–250. doi:10.1056/nejm199701233360402.
38. Fine M. PSI/PORT Score: Pneumonia Severity Index for CAP—MDCalc. 2018. https://www.mdcalc.com/psi-port-score-pneumonia-severity-index-cap. Accessed June 8, 2018.
39. Lim W, van der Eerden M, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax*. 2003;58(5):377–382. doi:10.1136/thorax.58.5.377.
40. Macfarlane J. CURB-65 Score for Pneumonia Severity—MDCalc. 2018. https://www.mdcalc.com/curb-65-score-pneumonia-severity#creator-insights. Accessed May 30, 2018.
41. Restrepo M, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. *Curr Opin Infect Dis*. 2013;26(2):151–158. doi:10.1097/qco.0b013e32835ebc6d.
42. Gierke R, McGee L, Beall B, Pilishivili T. Pneumococcal. In: Roush S, Baldy L, eds. *Manual for the Surveillance of Vaccine-Preventable Diseases*. Atlanta, GA: Centers for Disease Control and Prevention; 2015. https://www.cdc.gov/vaccines/pubs/surv-manual. Accessed May 31, 2018.
43. Falguera M, Carratalà J, Ruiz-Gonzalez A, et al. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. *Respirology*. 2009;14(1):105–111. doi:10.1111/j.1440-1843.2008.01371.x.
44. Oyarzun R. Respiratory viruses and severe community-acquired pneumonia. *Community Acquir Infect*. 2017;4(2):32–37. doi:10.4103/cai.cai_9_17.
45. Mosenifar Z. Viral Pneumonia: Practice Essentials, Background, Pathophysiology. Medscape. 2017. https://emedicine.medscape.com/article/300455-overview. Accessed May 31, 2018.
46. Rapid Influenza Diagnostic Tests | Seasonal Influenza (Flu) | CDC. 2017. https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm. Accessed June 2, 2018.
47. Jennings L, Anderson T, Beynon K, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. *Thorax*. 2008;63(1):42–48. doi:10.1136/thx.2006.075077.
48. Huijskens E, Koopmans M, Palmen F, van Erkel A, Mulder P, Rossen J. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. *J Med Microbiol*. 2013;63(Pt_3):441–452. doi:10.1099/jmm.0.067108-0.
49. Cesario T. Viruses associated with pneumonia in adults. *Clin Infect Dis*. 2012;55(1):107–113. doi:10.1093/cid/cis297.
50. Almond M, McAuley D, Wise M, Griffiths M. Influenza-related pneumonia. *Clin Med*. 2012;12(1):67–70.
51. Jacobs S, Lamson D, St. George K, Walsh T. Human rhinoviruses. *Clin Microbiol Rev*. 2013;26(1):135–162. doi:10.1128/cmr.00077-12.
52. Ruuskanen O, Lahti E, Jennings L, Murdoch D. Viral pneumonia. *Lancet*. 2011;377(9773):1264–1275. doi:10.1016/s0140-6736(10)61459-6.
53. Marcos M, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. *Antivir Ther (Lond)*. 2006;11:351–359.
54. Templeton K, Scheltinga S, van den Eeden W, Graffelman W, van den Broek P, Claas E. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. *Clin Infect Dis*. 2005;41(3):345–351. doi:10.1086/431588.
55. Johnstone J. Viral infection in adults hospitalized with community-acquired pneumonia. *Chest*. 2008;134(6):1141–1148. doi:10.1378/chest.08-0888.
56. Jain S. Epidemiology of viral pneumonia. *Clin Chest Med*. 2017;38(1):1–9. doi:10.1016/j.ccm.2016.11.012.
57. Singh Y. Pathophysiology of community acquired pneumonia. *J Assoc Physicians India*. 2012;60(suppl.):7–9. http://www.japi.org/january_special_2012/contents.html. Accessed June 4, 2018.
58. Falsey A, Walsh E. Viral pneumonia in older adults. *Clin Infect Dis*. 2006;42(4):518–524. doi:10.1086/499955.
59. Morris D, Cleary D, Clarke S. Secondary bacterial infections associated with influenza pandemics. *Front Microbiol*. 2017;8:1041. doi:10.3389/fmicb.2017.01041.
60. Voiriot G, Visseaux B, Cohen J, et al. Viral-bacterial coinfection affects the presentation and alters the prognosis of severe community-acquired pneumonia. *Crit Care*. 2016;20(1):375. doi:10.1186/s13054-016-1517-9.
61. Lee K. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. *Int J Mol Sci*. 2017;18(2):388. doi:10.3390/ijms18020388.
62. Johansson N, Kalin M, Hedlund J. Clinical impact of combined viral and bacterial infection in patients with community-acquired

pneumonia. *Scand J Infect Dis*. 2011;43(8):609–615. doi:10.3109/00365548.2011.570785.
63. Maraví-Poma E, Martin-Loeches I, Regidor E, et al. Severe 2009 A/H1N1v influenza in pregnant women in Spain*. *Crit Care Med*. 2011;39(5):945–951. doi:10.1097/ccm.0b013e318208ee12.
64. Anderson D, Jordan M. Viral pneumonia in recipients of solid organ transplants. *Semin Respir Infect*. 1990;5(1):38–49.
65. Harrington R, Hooton T, Hackman R, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. *J Infect Dis*. 1992;165(6):987–993. doi:10.1093/infdis/165.6.987.
66. Yin L, Zheng D, Limmon G, et al. Aging exacerbates damage and delays repair of alveolar epithelia following influenza viral pneumonia. *Respir Res*. 2014;15(1):116. doi:10.1186/s12931-014-0116-z.
67. Virkki R. Differentiation of bacterial and viral pneumonia in children. *Thorax*. 2002;57(5):438–441. doi:10.1136/thorax.57.5.438.
68. Zhai J, Briese T, Dai E, et al. Real-time polymerase chain reaction for detecting SARS coronavirus, Beijing, 2003. *Emerging Infect Dis*. 2004;10(2):311–316. doi:10.3201/eid1002.030799.
69. Do D, Laus S, Leber A, et al. A one-step, real-time PCR assay for rapid detection of rhinovirus. *J Mol Diagn*. 2010;12(1):102–108. doi:10.2353/jmoldx.2010.090071.
70. Lease E, Alexander B. Fungal diagnostics in pneumonia. *Semin Respir Crit Care Med*. 2011;32(6):663–672. doi:10.1055/s-0031-1295714.
71. Limper A. The changing spectrum of fungal infections in pulmonary and critical care practice: clinical approach to diagnosis. *Proc Am Thorac Soc*. 2010;7(3):163–168. doi:10.1513/pats.200906-049al.
72. Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. *Rev Esp Quimioter*. 2018;26(2):173–188.
73. Mandanas R. Fungal Pneumonia: Overview of Fungal Pneumonia, Risk Factors, Epidemiology of Fungal Pneumonia. 2017. https://emedicine.medscape.com/article/300341-overview. Accessed June 1, 2018.
74. Types of Fungal Diseases | Fungal Diseases | CDC. 2018. https://www.cdc.gov/fungal/diseases/index.html. Accessed June 3, 2018.
75. Baddley J, Winthrop K, Patkar N, et al. Geographic distribution of endemic fungal infections among older persons, United States. *Emerging Infect Dis*. 2011;17(9):1664–1669. doi:10.3201/eid1709.101987.
76. Bajwa S, Kulshrestha A. Fungal infections in intensive care unit: challenges in diagnosis and management. *Ann Med Health Sci Res*. 2013;3(2):238–244. doi:10.4103/2141-9248.113669.
77. Outbreaks and Investigations| Fungal Diseases | CDC. 2017. https://www.cdc.gov/fungal/outbreaks/index.html. Accessed June 8, 2018.
78. Smith J, Kauffman C. Pulmonary fungal infections. *Respirology*. 2012;17(6):913–926. doi:10.1111/j.1440-1843.2012.02150.x.
79. Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. *Indian J Med Res*. 2014;139(2):195–204.
80. Alangaden G. Nosocomial fungal infections: epidemiology, infection control, and prevention. *Infect Dis Clin North Am*. 2011;25(1):201–225. doi:10.1016/j.idc.2010.11.003.
81. Reynolds J, McDonald G, Alton H, Gordon S. Pneumonia in the immunocompetent patient. *Br J Radiol*. 2010;83(996):998–1009. doi:10.1259/bjr/31200593.
82. Nambu A, Ozawa K, Kobayashi N, Tago M. Imaging of community-acquired pneumonia: roles of imaging examinations, imaging diagnosis of specific pathogens and discrimination from noninfectious diseases. *World J Radiol*. 2014;6(10):779–793. doi:10.4329/wjr.v6.i10.779.
83. Kalil A, Metersky M, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63(5):e61–e111. doi:10.1093/cid/ciw353.
84. Wiemken T, Jala V, Kelley R, et al. The upper respiratory tract microbiome of hospitalised patients with community-acquired pneumonia of unknown aetiology: a pilot study. *Pneumonia*. 2015;6(1):83–89. doi:10.15172/pneu.2015.6/682.
85. Morgan A, Glossop A. Severe community-acquired pneumonia. *BJA Educ*. 2016;16(5):167–172. doi:10.1093/bjaed/mkv052.
86. Kelsberg G, Safranek S. How accurate is the clinical diagnosis of pneumonia? *J Fam Pract*. 2003;52(1):63–64.
87. Ramirez J, Wiemken T, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology and mortality. *Open Forum Infect Dis*. 2017;4(suppl_1):S571. doi:10.1093/ofid/ofx163.1493.
88. Baer S. Community-Acquired Pneumonia (CAP): Practice essentials, overview, etiology of community-acquired pneumonia. 2017. https://emedicine.medscape.com/article/234240-overview. Accessed June 5, 2018.
89. Urgent Care Evaluation of Pneumonia | Journal of Urgent Care Medicine. *Journal of Urgent Care Medicine*. https://www.jucm.com/urgent-care-evaluation-pneumonia. Accessed June 5, 2018.
90. Woolfrey K. Pneumonia in adults: the practical emergency department perspective. *Emerg Med Clin North Am*. 2012;30(2):249–270. doi:10.1016/j.emc.2011.12.002.
91. Ramirez J. Pneumonia pathogenesis and the lung microbiome: back to the drawing board. *J Respir Infect*. 2017;1(4):Article 2. doi:10.18297/jri/vol1/iss4/2.
92. Cillóniz C, Cardozo C, García-Vidal C. Epidemiology, pathophysiology, and microbiology of community-acquired pneumonia. *Ann Res Hosp*. 2018;2:1. doi:10.21037/arh.2017.12.03.
93. Upchurch C, Grijalva C, Wunderink R, et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs. *Chest*. 2018;153(3):601–610. doi:10.1016/j.chest.2017.07.035.
94. Ye X, Xiao H, Chen B, Zhang S. Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. *PLoS ONE*. 2015;10(6):e0130066. doi:10.1371/journal.pone.0130066.
95. Pneumococcal Vaccination | CDC. 2017. https://www.cdc.gov/vaccines/vpd/pneumo/index.html. Accessed June 5, 2018.
96. FastStats. Pneumonia. 2017. https://www.cdc.gov/nchs/fastats/pneumonia.htm. Accessed June 8, 2018.
97. Rothberg M, Zilberberg M, Pekow P, et al. Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia. *J Antimicrob Chemother*. 2015;70(5):1573–1579. doi:10.1093/jac/dku533.
98. Torres A, Niederman M, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. *Eur Respir J*. 2017;50(3):1700582. doi:10.1183/13993003.00582-2017.
99. Gunasekera P, Gratrix A. Ventilator-associated pneumonia. *BJA Educ*. 2016;16(6):198–202. doi:10.1093/bjaed/mkv046.
100. Jones R. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. *Clin Infect Dis*. 2010;51(S1):S81–S87. doi:10.1086/653053.
101. File T. Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults. In: Bartlett J, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www.uptodate.com. Accessed June 5, 2018.
102. Klompas M. Risk factors and prevention of hospital-acquired and ventilator-associated pneumonia in adults. In: File T, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www.uptodate.com. Accessed June 8, 2018.
103. Khan A, Hamdan A, AL-Ghanem S, Alaa G. Reading chest radiographs in the critically ill (Part II): radiography of lung pathologies common in the ICU patient. *Ann Thorac Med*. 2009;4(3):149–157. doi:10.4103/1817-1737.53349.
104. Joshi S. Hospital antibiogram: a necessity. *Indian J Med Microbiol*. 2010;28(4):277–280. doi:10.4103/0255-0857.71802.
105. Kollef M, Shorr A, Tabak Y, Gupta V, Liu L, Johannes R. Epidemiology and outcomes of health-care–associated pneumonia. *Chest*. 2005;128(6):3854–3862. doi:10.1378/chest.128.6.3854.
106. File T. Treatment of hospital-acquired and ventilator-associated pneumonia in adults. In: Bartlett I, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. https://www.uptodate.com. Accessed June 7, 2018.

CHAPTER

14

Cardiac Arrhythmias

"Life is about timing."

—Carl Lewis

OUTLINE

Introduction
Cardiac Arrest Arrhythmias
  Ventricular Fibrillation
  Ventricular Tachycardia
  Pulseless Electrical Activity
  Asystole
Non-arrest Arrhythmias
  Supraventricular Tachycardia
  Atrial Fibrillation
  Atrial Flutter
  First-Degree AVB
  Second-Degree AVB
  Third-Degree AVB

OBJECTIVES

1. State the working clinical definition of arrhythmia.
2. Outline the incidence, prevalence, and risk factors of cardiac arrhythmias.
3. Define and discuss secondary problems associated with cardiac arrhythmias.
4. Predict the clinical manifestations associated with cardiac arrhythmias.
5. Explain diagnostic testing used in identifying the causes of a cardiac arrhythmia.
6. Summarize the recommended management of patients with cardiac arrhythmias.
7. Identify common complications associated with cardiac arrhythmias.
8. Define the prognosis of cardiac arrhythmias.

KEY TERMS

Antidromic
Arrhythmia
Asystole
Atrial fibrillation (AF)
Atrial flutter
Atrioventricular nodal re-entrant tachycardia (AVNRT)
Atrioventricular (AV) node
Atrioventricular re-entrant tachycardia (AVRT)
Bradycardia
Bundle of His
Complete heart block
Electrophysiologic studies (EPS)
Fibrillation
First-degree AV block (1° AVB)
Heart block
Implantable cardioverter defibrillator
Mobitz I
Mobitz II
Normal sinus rhythm (NSR)
Orthodromic
Ostium
Polymorphic ventricular tachycardia
Pulseless electrical activity (PEA)
Purkinje fibers
Radio frequency catheter ablation (RFCA)
Second-degree AVB (2° AVB)
Sinoatrial (SA) node
Sinus bradycardia (SB)
Sinus tachycardia (ST)
Supraventricular tachycardias (SVTs)
Synchronized direct-current (DC) cardioversion
Tachycardia
Third-degree AVB (3° AVB)
Torsades de pointes
Type I AVB
Type II AVB
Ventricular fibrillation (VF)
Ventricular tachycardia (VTach)
Wenckebach
Wolff–Parkinson–White (WPW)

Case Study

A 65-year-old female patient arrived at the cardiac catheterization laboratory for diagnostic left and right heart catheterizations. The patient's left coronary artery angiogram revealed no blockages. During cannulation of the right coronary artery (RCA) **ostium** (opening), a drop in the aortic (AO) pressure occurred. The physician removed the catheter, and the AO pressure returned to baseline. A second attempt was successful, and contrast medium injection revealed a severe blockage in the ostium of the RCA.

As the physician was looking at the angiogram, the recording registered cardiovascular invasive specialist (RCIS) said, "The patient is in **ventricular fibrillation**." See **Figure 14-1**.

The physician immediately removed the catheter from the ostium of the RCA and asked the patient to cough. The "scrubbed in" RCIS assisting the doctor pulled the sterile drape from the patient's chest and the circulator RCIS obtained the defibrillator. The patient received 200 joules of electricity. After the defibrillation shock, the patient's cardiac rhythm converted from **ventricular fibrillation (VF)** to **sinus bradycardia (SB)**. See **Figure 14-2**.

At that time, the patient was hypotensive with a heart rate of 38 beats/minute. The physician immediately requested the nurse to give a 500-mL bolus of normal saline and 0.5 mg of atropine. Following administration of the atropine, the heart rate increased to 82 beats/minute with a **normal sinus rhythm (NSR)**. See **Figure 14-3**. The patient's blood pressure normalized.



FIGURE 14-1 Ventricular fibrillation.



FIGURE 14-2 Sinus bradycardia.



FIGURE 14-3 Normal sinus rhythm.

Introduction

For the heart muscle to contract, it must first have electrical stimulation. The electrical flow in the heart can travel from cell to cell, which is slow and unorganized, or it can travel through the heart's electrical conduction system, which is fast and organized.[1] The primary pacemaker of the heart (sets the heart rate) is the **sinoatrial (SA) node** and has a fixed rate between 60 and 100 beats/minute.[1] The normal rhythm of the heart is known as NSR. See Figure 14-3. The criteria for NSR is in **Box 14-1**.

If a rhythm does not match the criteria for NSR, it is an **arrhythmia**. There are many causes of cardiac arrhythmias, including myocardial infarction (MI), ischemic heart disease, heart failure, electrolyte imbalance, electrical conduction problems, aging, or healing from heart surgery.[2] Some arrhythmias are benign and easy to treat. However, some arrhythmias can be life threatening if not recognized and properly treated, while others are not life threatening, but may need immediate treatment.[3] The arrhythmias discussed in this chapter, see **Table 14-1**, are categorized into two groups: arrest and non-arrest arrhythmias. These arrhythmias are considered the core advanced cardiac life support (ACLS) arrhythmias.

BOX 14-1 Criteria for NSR

- Heart rate: 60–100 beats/minute
- P wave for each QRS complex
- PR interval: 0.12–0.20 seconds
- QRS complex: <0.11 seconds
- Normal QT interval
- No ST segment elevations or depressions

TABLE 14-1
Core ACLS Arrhythmias

Arrest arrhythmias	Non-arrest arrhythmias
1. VF 2. VTach 3. PEA 4. Asystole	1. ST 2. AF 3. Paroxysmal SVTs • AVNRT • AVRT 4. First-degree heart block 5. Second-degree heart block Type I (Mobitz I or Wenckebach) 6. Second-degree heart block Type II (Mobitz II) 7. Third-degree heart block

Modified from *ACLS Provider Manual Supplementary Material*. 1st ed. American Heart Association; 2012.

Cardiac cells are capable of creating and conducting electrical impulses that cause the contraction and relaxation of the myocardial cells. It is the movement of electrolytes, the electrically charged particles, that controls the generation and propagation of electrical stimulation in the body.[1] The primary positively charged electrolytes (cations) in the heart are sodium (Na^+), calcium (Ca^{++}), and potassium (K^+). The negatively charged electrolyte is chloride (Cl^-) (anion).[1] These electrolytes are both inside and outside of the myocardial cells but in varying concentrations. There are more potassium cations on the inside of the myocardial contractile cell than on the outside, and there are more sodium and calcium cations on the outside of the myocardial contractile cell than on the inside.[1] As a result, the inside of the cell is negative as compared to the outside of the cell. This is the resting membrane electrical potential.[1] At this time, the electrolytes or ions are aligned, and the resting cell is polarized with no electrical activity occurring. The voltage on the inside of the cell is negative when compared to the outside of the cell; the difference is normally –90 mV. During cell depolarization, the voltage in the interior of the cell will increase from –90 to +30 mV. During the repolarization phase, the voltage will return to approximately −90 mV.[1] The cell will then rest for a brief period. These electrical changes can be graphed to create a schematic representation of cardiac action potential.

There are two types of cardiac cells: (1) pacemaker cells and (2) contractile cells.[1] The pacemaker cells are specialized cells located in the SA node, **atrioventricular (AV) node**, and the **Purkinje fibers**. **Figure 14-4** shows the conduction system of the heart. Four structures comprise the conduction system of the heart's SA node, AV node, AV bundle, and Purkinje fibers. See the five phases of the cardiac action potential in **Figure 14-5**.

The voltage in Phase 4 is −90 mV, the resting phase when the cells are considered polarized. During this phase in the contractile cells, the sodium/potassium



FIGURE 14-4 The electrical conduction system of the heart.



FIGURE 14-5 Action potential waveform of a myocardial cell. See text for the explanation.

pump will pump sodium and potassium in and out to maintain the voltage at −90 mV.[1] In the pacemaker cells, there are slow calcium channels that allow the calcium to flow into the cell. Because calcium is a double positive (Ca^{++}), the voltage increases. Once the voltage inside the cell reaches approximately −70 mV, the cell will depolarize on its own (this is known as automaticity).[4] An electrical impulse propagates from the SA node to the AV node. Within the AV node, there is an approximate 0.1-second delay. The electrical impulse then goes through the **bundle of His**, to the bundle branches, and finally to the Purkinje cells.[4]

The sharp upstroke in the action potential waveform is Phase 0, or the depolarization phase. The stimulation of a contractile cell from an adjoining cell above it will open the fast sodium channels. These fast sodium channels are in myocardial cells *other than* the SA and AV nodes. Sodium will follow the concentration gradient and will rush in the cell. This causes the voltage to rise from −90 to +30 mV. This process is rapid depolarization.[1]

Once the voltage reaches about +30 mV, the chloride channels open and the fast sodium channels close. This is Phase 1. At this time the cells will start to repolarize, but will be interrupted by Phase 2.[1]

Soon after the chloride channels open and the influx of sodium slows down, the slow calcium channels open. This occurrence slows down repolarization and is Phase 2 or the plateau phase. During Phase 2, calcium enters the cells and causes the muscles to contract.[1]

The slow calcium channels then close, stopping the influx of calcium. This is Phase 3, or rapid repolarization. During this time, potassium is pumped out of the cell, returning the voltage to −90 mV.[1]

Anything that can cause an electrolyte imbalance or electrical conduction problem usually leads to an arrhythmia.

Cardiac Arrest Arrhythmias

The cardiac arrest arrhythmias are those types of myocardial electrical activity that put the patient at substantial risk for sudden cardiac arrest and sudden cardiac death (SCD). During these cardiac arrest arrhythmias, the spontaneous cardiac output ceases or is minimal. Without intervention, with basic life support or ACLS, these individuals will die.

Ventricular Fibrillation

VF occurs as a result of numerous localized areas of micro-reentry with disorganized electrical activity. During this arrhythmia the ventricles quiver uselessly, reducing cardiac output to zero.

Definition

VF is a life-threatening cardiac arrhythmia (Figure 14-1) that, if not, treated immediately will result in death.[5] Under normal conditions, the ventricles receive one electrical impulse, which causes an organized ventricular contraction. However, in VF the ventricles receive numerous electrical stimulations, which cause the ventricles to quiver. This is cardiac chaos. Consequently, cardiac output will drop to zero, resulting in the loss of consciousness and death within minutes.[5]

Etiology

Predisposition to VF is increased in the presence of coronary artery disease (CAD) and is often its first expression. Autopsies show that the most common pathologic finding in VF death was CAD and that 40–86% had a 75% or more blockage in a coronary artery.[5] Approximately 50% of deaths from CAD can be attributed to VF, and often occurs within the first hour after the onset of an acute myocardial infarction (AMI) or acute coronary syndrome.[5] When treating an AMI, the reperfusion of ischemic myocardium may trigger a reperfusion arrhythmia like VF. This is true when using fibrinolysis or angioplasty to treat CAD. Coronary artery spasm can cause VF due to the ischemia and reperfusion insults.[5] Spasms can be a result of autonomic nervous system factors, especially alpha-adrenergic activity, vagal activity, and vessel susceptibility. Humoral factors, particularly those associated with platelet activation and aggregation, can cause VF.[5] Etiologies of VF are listed in **Box 14-2**.

Most often rapid **ventricular tachycardia (VTach)** precedes VF, especially in the presence of chronic ischemic heart disease or monomorphic VTach (electrical impulse originates from one particular place in the ventricles, and the QRS complexes look the same). Other factors associated with increased risk of VF include frequent premature ventricular contractions (PVCs), particularly complex forms (such as multifocal PVCs), and ones with short coupling intervals (R-on-T

BOX 14-2 Causes of VF

- AF
- Congenital heart disease
- CAD
- Hypertension
- Hyperlipidemia
- Hypoxia
- Ischemia
- Left ventricular hypertrophy
- Nonischemic cardiomyopathies
- Obesity
- Smoking

Modified from Goyal S. Ventricular fibrillation: background, pathophysiology, etiology. E-Medicine Medscape.com. 2014. http://emedicine.medscape.com/article/158712-overview. Accessed September 3, 2015.

BOX 14-3 ECG Findings That Increase the Risk for VF

- Digitalis toxicity
- MI
- Prolonged or short QT interval
- Short PR interval
- WPW pattern

Modified from Goyal S. Ventricular fibrillation: background, pathophysiology, etiology. E-Medicine Medscape.com. 2014. http://emedicine.medscape.com/article/158712-overview. Accessed September 3, 2015.

BOX 14-4 Risk Factors for VF

- Cardiomyopathy
- Congenital heart defect (CHD)
- Electrolyte abnormalities
- Hear muscle injury (electrocution)
- Illicit drug use (cocaine or methamphetamine)
- Previous episode of VF
- Previous heart attack

Data from Mayo Clinic Staff. Ventricular Fibrillation Risk Factors—Mayo Clinic. Mayo Clinic Org. 2014. http://www.mayoclinic.org/diseases-conditions/ventricular-fibrillation/basics/risk-factors/con-20034473. Accessed September 4, 2015.

phenomenon).[5] Other causes of VF are idiopathic, previous episodes (out-of-hospital resuscitation), and dilated and hypertrophic cardiomyopathies.[5]

The number of cases of VF is hard to assess because most episodes are unwitnessed. Each year there are approximately 300,000 cases of SCD, and up to one-third are attributed to VF.[5] The incidence of VF in the adult population is 0.08–0.16% per year.[5] There are more deaths from VF than from lung cancer, breast cancer, or acquired immunodeficiency syndrome. The incidence in the pediatric and adolescent age groups is 1.3–8.5 cases per 100,000 persons annually and accounts for approximately 5% of all deaths in this group.[5]

There has been a decline in incidences of out-of-hospital cardiac arrests in the United States; however, the proportion of sudden deaths from VF in patients with CAD has not changed.[5] There is a 3:1 ratio in the incidence of VF in men than in women. Occurrences of VF are directly proportional to the prevalence of CAD. This number peaks in people 45–75 years old.[5]

Pathophysiology

There are many clinical situations where VF occurs; however, it is most often associated with CAD and can be a result of an AMI, ischemia, or myocardial scarring from an old infarct.[5] In some cases, VTach will degenerate into VF. The heart depolarizes and repolarizes in a synchronized manner. However, at times some of the myocardial cells initiate an ectopic beat resulting in a PVC. The occurrence of PVCs can lead to a re-entry arrhythmia. If a PVC occurs during a T wave (known as R on T), VF can occur. The R-on-T PVC propagates an erratic electrical signal through the refractory myocardial cells, establishing re-entry patterns. This re-entry results in chaotic ventricular depolarization, and consequently, normal myocardial contraction becomes disrupted.[5] This disruption causes cardiac output to drop quickly.[5]

Clinical Manifestations

In many cases, there are no symptoms, and when there are, they may be related to VTach, which precedes VF. Symptoms from VTach include chest pain, rapid heartbeat, dizziness, nausea, cyanosis, and shortness of breath.[6] Also, the blood pressure, pulse, and heart sounds may be absent.[7]

Diagnostic Testing

Using a 12-lead electrocardiography (ECG) is the only way to confirm VF.[5] On the ECG, VF manifests as a chaotically irregular pattern. This pattern is coarse initially but becomes finer as ventricular disorganization increases. As the ECG waveform flattens, the likelihood of successful defibrillation decreases.[5] ECG can also identify other conditions that may increase the risk for VF.[5] See **Box 14-3**. After an episode of VF, further diagnostic testing is needed to help determine the cause and risks for another episode. See **Box 14-4**.[8]

Using two-dimensional (2D) echocardiography with Doppler in patients who have had an MI is vital. It will evaluate the wall motion of the left ventricle (LV) and help to predict the outcomes and risks for major cardiac events, including sudden death. A decrease in the ejection fraction (EF) and worsening wall-motion abnormalities with exercise may confer increased risk for the development of VF.[5]

Using nuclear imaging for obtaining resting images of the heart is helpful in assessing myocardial damage after an MI, and is helpful in the presence of low functional capacity.[5] A large myocardial defect, shown on resting images, increases the risk for future cardiac events. The resting EF has been demonstrated, by the Multicenter Post-Infarction Research Group, to be the most important noninvasive predictor of SCDs, most commonly from VF, and other cardiac events in patients with MIs.[5] Patients with a previous MI and a low EF (<30%) may need an **implantable cardioverter defibrillator** (ICD). Nuclear stress tests are very sensitive for detecting the presence, extent, and location of myocardial ischemia, which can lead to an MI.[5]

Electrophysiologic studies (EPS) may be used to distinguish whether the VTach/VF is inducible or not. There is a higher risk for SCD if the VTach/VF is inducible, especially if antiarrhythmic medications are in use. Significantly lower ventricular function has also been observed in patients with inducible sustained VTach or VF. The cardiac EF can also be obtained during EPS.[5]

Cardiac catheterization and coronary angiography help to determine the presence of CAD and/or a low EF. Both of these are predictors of VF. If CAD is present, revascularization may help to prevent VF.[5]

Blood tests, such as serum electrolytes and cardiac enzymes, can determine the presence of abnormalities that can cause VF.[5] See **Table 14-2**.

Treatment and Management

VF requires immediate treatment with defibrillation to be successful. Defibrillation delivers an electric shock to the heart, and will uniformly and simultaneously depolarize the excitable myocardium. This electrical shock interrupts the re-entry signals, allowing the primary pacemaker to resume control.[5] If a defibrillator is not available, cardiopulmonary resuscitation (CPR) must begin immediately and must be continued until a defibrillator is available. If three defibrillation attempts do not resolve the VF, vasopressin, epinephrine, or amiodarone is necessary.

Automatic external defibrillators are portable devices that check the heart rhythm and can administer the electric shock and restore a normal heart rhythm. This enables a layperson to defibrillate someone with VF in a public place.[5]

Once a person has been successfully resuscitated, the next step is to prevent reoccurrence. If EPS identifies the area of the myocardium causing the VF, **radio frequency catheter ablation (RFCA)** can burn the particular area to eliminate reoccurrence. RFCA is an ablation catheter that is heated up using radio frequency; this will burn the myocardium that is causing the VF. After the ablation, scar tissue forms. This scar tissue becomes an electrically neutral area of myocardium thereby eliminating VF from being generated by these cells.[5]

An ICD is an implantable device that performs the same function as an external defibrillator but from the inside of the heart. An ICD detects VF and delivers an appropriate electrical shock to stop the VF. An ICD also has a pacemaker function associated with it. The pacemaker portion can treat **bradycardia** arrhythmias, which can cause or complicate VTach/VF.[5] Patients who

TABLE 14-2
Blood Tests for VF Etiology

Blood Test	Reason
Serum electrolyte levels	Electrolyte imbalances can change the action potential, especially potassium.
Cardiac enzymes or biomarkers	Cardiac enzymes, especially troponin I, troponin T, and CK-MB, become elevated after a MI.
Complete blood count (CBC)	Detects anemia, which can contribute to myocyte hypoxia.
Arterial blood gas (ABG)	Assesses the degree of blood acidosis and hypoxemia.
Quantitative drug levels	Identifies medications that have arrhythmia side effects, certain antibiotics, antidepressants, and antiarrhythmics.
Toxicologic screens and levels as clinically indicated	Identifies illicit drugs that are known to cause cardiac arrhythmias.
Thyroid-stimulating hormone level	Hyperthyroidism can lead to tachycardia and tachyarrhythmias; over time, it can also lead to heart failure.
B-type natriuretic peptide (BNP)	Identifies heart failure as a cause of VF.

Goyal S. Ventricular fibrillation: background, pathophysiology, etiology. E-Medicine Medscape.com. 2014. http://emedicine.medscape.com/article/158712-overview. Accessed March 24, 2018.

refuse ICD or who are not candidates for ICD use can take amiodarone on a long-term basis.

Risk Factors

The risk factors for VF are summed up in Box 14-4.

Complications

The complications of VF are listed in **Box 14-5**.

BOX 14-5 Complications from VF

- Aspiration pneumonia
- Central nervous system ischemic injury
- Death
- Defibrillation injury to self or others
- Injuries from CPR and resuscitation
- Myocardial injury
- Post-defibrillation arrhythmias
- Skin burns

Reproduced with permission from Ventricular Fibrillation. Information about VF | Patient. Patient. 2014. Available at: http://patient.info/doctor/ventricular-fibrillation. Accessed September 4, 2015.

Prognosis

Prognosis for survivors of VF will depend on the time between onset and medical intervention. There is a poor prognosis for those not treated within 4–6 minutes of onset.[9] If defibrillation is immediate, the survival rates are 75% and cardiac functionality is intact. Delayed treatment can lead to long-term disabilities. Death and disability from VF are directly proportional to the amount of damage to the central nervous system. There is a higher rate of VF recurrence if the VF occurs more than 48 hours following an acute MI.[9]

Ventricular Tachycardia

VTach is an arrhythmia that causes the heart to beat very rapidly. This reduces the ability of the ventricles to fill with blood, which happens during diastole. The extremely rapid ventricular rate seriously reduces cardiac output, causes the person to faint, and can lead to SCD.

Definition

VTach is an arrhythmia that originates from an ectopic pacemaker below the bundle of His. The heart rate is usually between 100 and 200 beats/minute and has a series of three or more premature ventricular beats. **Figures 14-6** and **14-7** show two different VTach ECGs. When the morphology of the QRS complexes is the same, it is monomorphic VTach, and when the morphologies of the QRS complexes are different, then it is polymorphic VTach.[10]



FIGURE 14-6 Ventricular tachycardia.



FIGURE 14-7 Ventricular flutter. Ventricular flutter is very fast ventricular tachycardia. When a QRS complex, a T wave, or an ST segment is no longer visible, it is ventricular flutter. The heartbeats occur so quickly that they fuse into an almost straight sinusoidal pattern with no discernible components.



FIGURE 14-8 Torsade de pointe occurs with an underlying prolonged QRT interval. It has an undulating sinusoidal appearance in which the axis of the QRS complexes changes from positive to negative and back in a haphazard fashion. It can convert into either NSR or VF.

Etiology

The most common cause of VTach is ischemic heart disease from CAD. Other triggers include electrolyte imbalances (i.e., hypokalemia, hyperkalemia, and hypomagnesemia), AF, sleep apnea, and a prolonged QT interval (long QT syndrome).[10] Long QT syndrome is either acquired by the use of potassium channel–blocking medications (i.e., Class Ia and Class III antiarrhythmic agents) or is hereditary. In people younger than 35 years, VTach may be attributable to hypertrophic cardiomyopathy, right ventricular cardiomyopathy, myocarditis, long QT syndrome, or congenital coronary artery abnormalities.[10]

Epidemiology

In developed countries, CAD is common, and, therefore, so is VTach. However, in developing countries where CAD is less common, VTach is also less common.[10] It is difficult to quantify VTach because of the overlap with VF. Most SCDs are due to VTach or VF and result in approximately 300,000 deaths per year in the United States. This accounts for about half of the estimated cardiac mortality and is a product of a hemodynamic collapse.[10] After successful resuscitation, problems that may appear include acute renal insufficiency, aspiration pneumonitis, ischemic encephalopathy, transient ventricular dysfunction, and trauma related to resuscitative efforts.[10] It is rare to see VTach in young children; however, the incidences do increase with age. Males are more susceptible than women due to more men having ischemic heart disease than women.[10]

Pathophysiology

The cause of VTach is electrical re-entry or abnormal automaticity. Any scarring of the myocardium may increase the likelihood of re-entrant electrical circuits. Scarring from a previous MI will cause the electrical signal to slow down and is the most common cause of sustained monomorphic VTach.[10] In a healthy heart, VTach results from mechanisms such as triggered activity or enhanced automaticity. One example of triggered activity (early afterdepolarizations) and re-entry is **torsades de pointes**, which can be acquired due to drugs. See **Figure 14-8**.

As the heart rate in VTach increases, the cardiac output decreases due to the reduced filling time. Other factors (i.e., mitral insufficiency and LV dysfunction) may also contribute to decreased cardiac output and subsequent hemodynamic collapse.[10] As the cardiac output drops, so will myocardial perfusion, which can lead to VF and death.

Monomorphic and polymorphic VTach in combination with structural heart disease (i.e., ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy) causes increased mortality due to the degeneration of VTach into VF and SCD.[10] Even when VTach does not lead to VF, morbidity and mortality can increase due to congestive heart failure (CHF) and hemodynamic compromise. In some cases, the VTach is hemodynamically tolerated but may cause a dilated cardiomyopathy. The dilated cardiomyopathy may develop over a period of weeks to years and may resolve with successful suppression of the VTach.[10]

Clinical Manifestations

Symptoms typically seen with VTach include palpitation, lightheadedness, and syncope; the latter two are a result of reduced blood to the brain. If the VTach occurs with structural heart disease, then syncope is more common. Chest pain may also be present due to ischemia or from the rhythm itself. Other symptoms include a sensation of neck fullness (may be from an increase in central venous pressure) or dyspnea (may be related to increased pulmonary venous pressures).[10] The symptoms of VTach vary depending on the rate of the **tachycardia**, its duration, and the underlying condition of the heart.[11]

The degree of hemodynamic instability will determine signs and symptoms. These signs and symptoms include hypotension, tachypnea, diminished level of consciousness, pallor, and diaphoresis. Also, VTach and AV dyssynchrony can cause elevated jugular venous pressure and jugular vein distension. AV dyssynchrony occurs as a result of the atria trying to contract against closed valves.[10]

Diagnostic Testing

An ECG is a standard for the diagnosis of VTach. If the VTach is unstable, the diagnosis comes from the physical findings and ECG rhythm strip only. After the VTach resolves, diagnostic tests are done to determine its cause.[10]

Laboratory studies check the blood levels of potassium, magnesium, calcium, and phosphate. If indicated by the physical exam, levels of therapeutic and/or illicit drugs are obtained. These drugs include digoxin, tricyclic antidepressants, methamphetamine, and cocaine. Cardiac markers can identify infarction or myocarditis.[10] Echocardiography can detect dilated, hypertrophic, or right ventricular cardiomyopathy, MI, and inherited disorders associated with SCD.[10] As with VF, an EPS can be done to find the cause of the VTach.

If diagnostic tests do not identify the cause of the VTach, continuous cardiac monitoring may be indicated using two devices that can either be worn or implanted. The Holter monitor is an external device that uses ECG leads and is typically worn by the patient for 24–48 hours. During that time, the Holter will digitally record and store every heartbeat. The user keeps a diary of activity to be compared with the ECG results when completed. Identification of the causative abnormalities leads to the development of a treatment plan. One disadvantage of the Holter monitor is that it has little diagnostic value.[10] A device that has a higher yield is the implantable loop recorder.[10] The loop recorder is implanted under the skin on the left side of the chest and continuously monitors the heart rhythm. If it detects an arrhythmia, the information remains in the device.[12] This information can either be transmitted wirelessly to the physician or retrieved during a practitioner office visit. The implantable loop recorder is designed to last up to 4 years.[10]

Treatment and Management

An unstable patient (e.g., low blood pressure, low oxygen saturations, and unconscious) with monomorphic VTach requires **synchronized direct-current (DC) cardioversion** immediately. Unlike defibrillation, cardioversion delivers the electrical shock on the "R" wave of the ECG. The starting electrical dose in a cardioversion is 100 joules. In contrast with monomorphic VTach, polymorphic VTach does not usually have a detectable R wave due to the changing morphology of the QRS complexes. Therefore, an unstable patient with polymorphic VTach requires immediate defibrillation.[10,11]

Stable VTach does not cause a loss of organ perfusion or hemodynamic compromise. Treatment, therefore, depends on whether the VTach is monomorphic or polymorphic and whether left ventricular function is normal or impaired. Medications are the first line of therapy in stable monomorphic VTach with normal left ventricular function. Appropriate drugs for pharmacologic conversion include procainamide, sotalol, or lidocaine.[10,11] Preferred treatment for monomorphic VTach with left ventricular dysfunction is amiodarone or lidocaine as opposed to procainamide for pharmacologic conversion. Procainamide is contraindicated due to its potential for exacerbating heart failure. If medications do not convert the VTach to NSR, cardioversion is necessary.[10]

Usually stable polymorphic VTach will terminate on its own; however, recurrence is likely. Following the return to NSR, an ECG needs to be obtained to determine if long QT syndrome is present. If the QT interval is normal, treatment is the same as for stable monomorphic VTach. Stable polymorphic VTach with long QT syndrome requires treatment with magnesium sulfate, isoproterenol, pacing, or a combination of them. Other medications for long QT syndrome include phenytoin and lidocaine. These medications may shorten the QT interval. Procainamide and amiodarone are contraindicated due to their QT-prolonging effects.[10] See **Table 14-3**.

If there is an electrolyte imbalance, cardioversion may not be successful until the imbalance is corrected. The use of antidigitalis antibody may be necessary if severe digitalis toxicity is present.[10]

TABLE 14-3
Immediate Treatment for Varying Types of VTach[10]

Type of VTach	Immediate Treatment
Unstable monomorphic VTach	Cardioversion
Stable monomorphic VTach with normal left ventricular function	First line: procainamide, sotalol, lidocaine Second line: cardioversion
Stable monomorphic VTach with left ventricular dysfunction	First line: amiodarone, lidocaine Second line: cardioversion
Unstable polymorphic VTach	Defibrillation
Stable polymorphic VTach without long QT syndrome	Self-terminating Prevention of recurrence: same treatment as stable monomorphic VTach
Stable polymorphic VTach with long QT syndrome	First line: magnesium sulfate, isoproterenol, cardiac pacing, or combination Second line: phenytoin, lidocaine

Data from Compton S. Ventricular Tachycardia: Practice Essentials, Background, Pathophysiology. EMedicineMedscape.com. 2014. http://emedicine.medscape.com/article/159075-overview.

After the restoration of NSR, it is possible to identify underlying structural heart disease. These structural defects may include displacement of the point of maximal impulse, murmurs related to valvular heart disease, hypertrophic cardiomyopathy, an S3 gallop, or pulmonary crackles if uncompensated heart failure is present. Changes in mental status are also possible, including anxiety, agitation, lethargy, or coma.[10] Upon the return of NSR, the cause of the VTach needs to be determined and treated. The underlying cause determines this treatment and may include antiarrhythmic medications, ICD, RFCA, or a combination.[11] While the use of antiarrhythmic drugs has been the first line of therapy in stable VTach, there may be many side effects or frequent recurrences of VTach with drug therapy. This has led to the use of devices and procedures designed to abort VTach or to ablate the foci in the heart.[10]

Idiopathic VTach from a focal source that is resistant to drug therapy is treated with RFCA.[12] RFCA is also used if drug therapy is not well tolerated or long-term drug therapy is undesirable. This is done to treat symptoms, not to reduce the risk of SCD. In the presence of cardiomyopathy, RFCA may be used to minimize the recurrence of the arrhythmia, therefore lessening the number of ICD electrical shocks.[10] **Polymorphic ventricular tachycardia** may have multiple re-entrant bypass circuits. At that point, RFCA becomes an adjunct to ICD therapy. VTach is caused by an automatic focus; that focus is targeted for ablation.[10]

An ICD can be implanted to terminate VTach before it causes hemodynamic collapse or left ventricular failure. An ICD is recommended in conjunction with medical therapy for unstable VTach (before MI), stable sustained VTach, and cardiomyopathy with unexplained syncope. An ICD is contraindicated for VTach occurring during an acute ST segment elevation MI (STEMI); for reversible, drug-induced VTach; and for poor survival because of comorbid conditions.[10]

Risk Factors

A summary of the risk factors for VTach is provided in **Box 14-6**.

Complications

The type and severity of the VTach dictate the severity of the complications. These complications may include blood clots, heart failure, frequent fainting spells, VF, or sudden death.[13]

Prognosis

The prognosis of VTach varies with the particular cardiac process involved but is predicted best by left ventricular function. VTach may result in heart failure, and its morbidity and mortality is a result of hemodynamic compromise. Ischemic cardiomyopathy and nonsustained VTach have a sudden-death mortality of almost 30% in 2 years. While the prognosis for idiopathic VTach is excellent, the risk of injury from fainting is high. Proper treatment with medications and ICD implantation can improve the prognosis. The prognosis for those with VTach in the presence of long QT syndrome, right ventricular dysplasia, or hypertrophic cardiomyopathy is not as good due to the risk of SCD.[10]

BOX 14-6 Risk Factors for VTach

- Cardiomyopathy
- Cocaine use
- Congenital heart disease
- Heart failure
- Ischemia
- Medication: quinidine, phenothiazines, and tricyclic antidepressants
- MI
- Pericardial inflammation
- Primary and metastatic malignancies involving the heart muscle
- QT prolongation and Marfan syndrome in neonates
- Surgical repair of CHDs
- Trauma

Data from Compton S. Ventricular Tachycardia: Practice Essentials, Background, Pathophysiology. EMedicineMedscape.com. 2014. http://emedicine.medscape.com/article/159075-overview.

Pulseless Electrical Activity

Pulseless electrical activity (PEA) is a cardiac arrhythmia that reflects a serious underlying medical event. It is a clinical condition that is characterized by a lack of a palpable pulse in the presence of organized electrical activity.

Definition

PEA is the absence of a detectable pulse or blood pressure due to weak cardiac contractions in the presence of an electrical signal (**Figure 14-9**). Consequently, little or no cardiac output exists, and if not treated immediately, it will result in death.[14]

Etiology

Some of the causes of PEA include severe prolonged hypoxia, acidosis, extreme hypovolemia, blood flow–restricting pulmonary embolus, or tension



FIGURE 14-9 PEA: There is electrical activity on the ECG. However, no pulse or blood pressure is detectable.

TABLE 14-4
Frequent Causes of PEA (H's and T's)

H's	T's
Hypovolemia	Toxins
Hypoxia	Tamponade
Hydrogen ion (acidosis)	Tension pneumothorax
Hyperkalemia	Thrombosis (coronary)
Hypothermia	

Reproduced with permission from Swiss Medical Publishers Ltd. Beun L, Yersin B, Osterwalder J, & Carron PN. (2015). Pulseless electrical activity cardiac arrest: time to amend the mnemonic "4H&4T"? *Swiss Med Wkly*, 145, w14178. http://www.smw.ch



FIGURE 14-10 New classification of PEA based on its initial ECG manifestation. PTX, pneumothorax; US, ultrasound; RV, right ventricular.

Reproduced with permission from Littmann L, Bustin D, Haley M. A Simplified and structured teaching tool for the evaluation and management of pulseless electrical activity. *Med Princ Pract.* 2014;23(1):1–6. doi:10.1159/000354195.

pneumothorax. As a consequence, the cardiac muscle is not able to produce a sufficient contraction following the depolarization of the muscle.[14] See **Table 14-4**.

Approximately 40–50% of PEA occurs due to hypoxia secondary to respiratory failure. Also, sudden changes in preload, afterload, or contractility often result in PEA.[14]

Epidemiology

The frequency of PEA will differ depending on the demographics. Approximately 20% of cardiac arrests that occur outside the hospital are caused by PEA. In hospitals, PEA accounts for about 68% of monitored deaths and 10% of all deaths.[14] These numbers are attributed to the greater chance of pulmonary emboli when in a hospital. PEA is more likely to develop in females than in males, and the average age is 70 years.[14]

Pathophysiology

Contractility of the heart is dependent on the stretching of the sarcomeres. Forceful cardiac contractions occur only when there is sufficient preload to stretch the sarcomeres. If the preload is too low, the contraction will not generate enough pressure to overcome afterload. Other causes of decreased contractility are hypocalcemia (myocardium needs calcium to contract) and the availability of epinephrine and norepinephrine.

Reduced preload can occur due to low blood volume (hypovolemia) or decreased blood return to the heart due to pulmonary thrombosis.[15] If the afterload is too high, even a strong contraction will not be able to produce cardiac output. However, elevated afterload is rarely responsible for PEA alone.[14]

Clinical Manifestations

The clinical manifestation of PEA includes collapse, unresponsiveness, agonal gasp, apnea, no pulse detected by palpitation, and no heart sounds on auscultation. The rhythm seen on the ECG may help to determine the underlying cause of the PEA.[3]

Diagnostic Testing

Identification of PEA utilizes ECG, pulse, and blood pressure. Because PEA requires immediate CPR, identification of the etiology of the PEA can be difficult in cases other than trauma.[15] A simplified evaluation of PEA was developed to simplify the diagnostic aspects of PEA.[15] See **Figure 14-10**. Here PEA is divided into two broad

classifications: narrow and wide QRS complexes. The general assumption is that narrow-complex PEA is due to a mechanical problem frequently caused by right ventricular inflow or outflow obstruction, whereas wide-complex PEA is typically due to a metabolic problem or ischemia and left ventricular failure.[15]

Treatment and Management

When PEA is detected, it is important to start CPR immediately. If the patient does not already have an intravenous (IV) or intraosseous (IO) line, then one needs to be started. Because hypoxia is a common cause of PEA, 100% supplemental oxygen is necessary, and the patient requires intubation.[14] According to the American Heart Association ACLS 2015 guidelines,[16] epinephrine is the only medication given during resuscitation for PEA. Epinephrine should be administered in 1 mg doses IV/IO every 3–5 minutes; higher doses of epinephrine have been shown not to help.[16] Using sodium bicarbonate is recommended only when systemic acidosis, hyperkalemia, or a tricyclic antidepressant overdose is present; dosage is 1 mEq/kg. Use sodium bicarbonate with caution as it may worsen intracellular and intracerebral acidosis and does not appear to alter the mortality rate.[14] In certain cases of PEA, when there is a profound low-output state, a circulatory assist device (intra-AO balloon pump, extracorporeal membrane oxygenation, cardiopulmonary bypass, or ventricular assist device) may be beneficial.[14]

The simplified classification of PEA, seen in Figure 14-10, is used to guide initial treatment, as shown in **Figures 14-11** and **14-12**. For patients with narrow-complex PEA from a suspected mechanical etiology, an aggressive intravenous fluid administration needs initiation because these issues are potentially fluid responsive. After that, the treatment depends on the patient's clinical manifestations, pericardiocentesis for cardiac tamponade, needle decompression for tension pneumothorax, ventilator settings changes for mechanical hyperinflation, and thrombolysis for pulmonary embolism.[15]

Wide-complex PEA is most often caused by severe hyperkalemia or sodium-channel blocker toxicity and treatment includes intravenous calcium chloride for the hyperkalemia or intravenous sodium bicarbonate boluses for the sodium-channel blocker toxicity.[15]

Risk Factors

Risk factors for PEA include causes for the development of anything that could lead to one of the etiologies seen in Table 14-4.

Prognosis

The sooner the cause of the PEA is found and reversed, the better the prognosis. The prognosis is worse if the ECG is abnormal. The prognosis is even worse once the QRS complex is greater than 0.20 second. The prognosis of out-of-hospital PEA is better than when it occurs in the hospital. This is because out-of-hospital cases are more likely to have reversible etiologies (i.e., hypothermia). When PEA is the first rhythm following cardiac arrest, the prognosis is poor. According to a study in 2006 by Nadkarni et al., when PEA was present, only 11.2% of patients survived to hospital discharge.[17] Another study in 2010 by Meaney et al. showed that fewer patients survived to discharge when PEA was present versus when VF or VTach was present.[18]

Asystole

Asystole or "flat line" occurs when the heart is not functioning. It is a complete and sustained absence of electrical activity typically due to the deterioration of VF, VTach, and PEA.

Definition

Asystole results from no electrical or mechanical activity in the heart (**Figure 14-13**). This is also known as cardiac standstill, and there is no cardiac output. Some causes of asystole are chronic hypertension, renal failure, CAD, CHF, or cardiac dysrhythmias.[19]

Etiology

The most common causes of asystole include drug overdoses, electrical shocks, hyperkalemia, hypokalemia, hypothermia, and hypoxemia.



FIGURE 14-11 Treatment recommendations for narrow-complex PEA.

Reproduced with permission from Littmann L, Bustin D, Haley M. A simplified and structured teaching tool for the evaluation and management of pulseless electrical activity. *Med Princ Pract.* 2014;23(1):1–6. doi:10.1159/000354195.



FIGURE 14-12 Treatment recommendations for wide-complex PEA.

Reproduced with permission from Littmann L, Bustin D, Haley M. A simplified and structured teaching tool for the evaluation and management of pulseless electrical activity. *Med Princ Pract.* 2014;23(1):1–6. doi:10.1159/000354195.



FIGURE 14-13 Asystole on an ECG.

Asystole can be primary or secondary depending on the cause. Primary asystole occurs when the metabolic functions of the cells are not working properly and cannot generate an electrical impulse. This is seen in ischemic events, and the pacemaker cells cannot transport the ions to create an action potential (i.e., pacemaker cells lose their automaticity). If a patient is dependent on an implanted pacemaker to live, and if there is a failure of the pacemaker, this will cause primary asystole. The majority of the time the RCA feeds the SA and AV nodes. If there is a blockage of the RCA, this can result in damage or death of the SA and/or AV nodes. There may also be damage to the bundle branches that travel through the intraventricular septum (IVS), which will cause intranodal **heart blocks**, including a complete heart block. Asystole may also occur from congenital heart block, local tumor, cardiac trauma, or DC (i.e., indirect lighting strike). A shock from alternating current will also cause VF.[19]

Secondary asystole may be due to suffocation, near drowning, stroke, massive pulmonary embolus, hyperkalemia, hypothermia, post-defibrillation, and sedative-hypnotic or narcotic overdoses leading to respiratory failure. An MI that is complicated by VF or VTach and deteriorates to asystole is also considered secondary asystole. Asystole secondary to hypothermia is tolerated better than the other causes.[19]

Epidemiology

The epidemiology of asystole varies and is not always accurate. This is because the population being studied and/or the reporting method of the initial rhythm was not accurate. A study out of Gothenburg, Sweden, showed that 35% of the patients had out-of-hospital cardiac arrest, an initial rhythm of asystole.[20]

Race does not play a direct role in the occurrence of asystole, but will affect the underlying conditions that may lead to asystole. Children will have a higher prevalence of asystole as the presenting cardiac rhythm than in adults. The prevalence in adults is 25–56%, and in children, it is 90–95%. Asystole in children is most likely found in cardiopulmonary arrests. This is usually secondary to respiratory arrest due to sudden infant death syndrome, infection, choking, drowning, or poisoning. Also, babies are more likely to suffer a cardiac arrest than older children or adolescents. The frequency of asystole is higher in women than in men.[19]

Pathophysiology

Primary asystole occurs when the pacemaker cells of the heart fail to generate a ventricular depolarization. This can happen as a result of CAD, which leads to ischemia. Consequently, the pacemaker cells will not be able to function properly, and they will lose their automaticity. Also, the SA node and/or AV node may degenerate, which leads to conduction disorders and arrhythmias. Bradyarrhythmia followed by primary asystole is usually due to sinus node block, sinus arrest, complete heart block, or all of these. Reflex bradycardia or asystole can result from ocular surgery, retrobulbar block, eye trauma, direct pressure on the globe, maxillofacial surgery, hypersensitive carotid sinus syndrome, or glossopharyngeal neuralgia.[19]

Secondary asystole occurs when the heart's electrical conduction system is unable to generate an electrical depolarization. This is a consequence of severe tissue hypoxia with metabolic acidosis. If not treated quickly, VF will lead to asystole and is common following unsuccessful attempts at defibrillation.[19]

Clinical Manifestation

If bradycardia precedes asystole, the patient may have lightheadedness or syncope. Asystole causes the patient to be unresponsive and pulseless. However, proper diagnosis of asystole requires recognition of a full cardiac arrest and a confirmed flat-line rhythm in two different leads (i.e., Lead II and Lead AVL).[19,21] Asystole is the most common dysrhythmia seen in patients sustaining cardiac arrest of longer than 10 minutes.[21]

Diagnostic Testing

Before initiating resuscitation efforts, the ECG leads need proper placement. During the resuscitation efforts, continuous cardiac monitoring via ECG and serial pulse checks is essential. Using pulse oximetry to monitor the effectiveness of the chest compressions during CPR can be helpful; however, if the forward blood flow

is not strong enough, the sensors will not be able to detect it. Obtaining a potassium level and an ABG can be helpful if they are drawn quickly; in some laboratories, an ABG result will also provide potassium levels. An ABG can be used to analyze ventilation, acid–base status, and hemoglobin level. Use these results with caution in a full arrest situation, as a blood gas level does not accurately reflect the overall pH status of the tissues. An echocardiogram can be used to verify cardiac standstill. Using two perpendicular leads will help to differentiate asystole from fine VF.[19]

Treatment and Management

Whether asystole occurs in or out of the hospital during resuscitation, there should be continuous cardiac monitoring, endotracheal intubation, and either an IV or an IO access for administering fluids and medication. In the emergency department, treatment will include providing oxygenation and ventilation through the endotracheal intubation, circulation through CPR, and administration of pharmacologic agents. In primary asystole that has just occurred, transcutaneous pacing (TCP) may help. If asystole is present, defibrillation is contraindicated. Using defibrillation on an asystole is detrimental and usually eliminates any chance of recovering a rhythm. The outcomes of defibrillation use are worse than the usual treatment.[19]

Following the return of a rhythm, finding and treating the underlying cause is necessary. Induced hypothermia to body temperatures between 32°C and 34°C in patients who are electrically and hemodynamically stable, but comatose, has been shown to be beneficial. The cooling of the patient occurs in the intensive care unit. A study by Testori et al. shows improved neurologic outcomes when using induced hypothermia treatment for patients following cardiac arrest with non-shockable rhythms.[19]

The most widely used drug for adults in asystole is epinephrine. Epinephrine is considered the single most useful drug in cardiac arrest and is used to increase coronary and cerebral blood flow during CPR.[13] See **Box 14-7**. TCP has not been shown to increase the outcomes. However, TCP may be lifesaving when no metabolic deficit exists.[19]

BOX 14-7 Treatment of Asystole

- Perform CPR
- Identify and treat potentially correctable causes
- Give epinephrine 1.0 mg intravenous (may repeat every 3–5 minutes if asystole persists)
- Consider termination of resuscitative measures

Data from Pozner CN, Link MS. Supportive data for advanced cardiac life support in adults with sudden cardiac arrest. In: Walls RM, Page RL, Downey BC, eds. UpToDate. Waltham, MA: UpToDate; 2018.

Risk Factors

The risk factors for asystole depend on its etiology.

Complications

Despite administrating the full allowable dosage of atropine in conjunction with epinephrine, few patients survive to leave the hospital neurologically intact. Complications from asystole include not only the direct consequences of permanent neurologic impairment and death, but also the secondary complications from CPR, such as liver laceration, fractured ribs, pneumothorax, hemothorax, air embolus, aspiration, and gastric or esophageal rupture.[19]

The prognosis in asystole will depend on its etiology, timing of the interventions, and success or failure of ACLS. In secondary asystole, if the cause is identified and treated quickly (i.e., cardiac arrest due to choking on food), and an airway established, resuscitation will likely be successful. If primary asystole arises from pacemaker failure and resolves quickly, resuscitation will probably be successful. Regardless of the cause, the prognosis of asystole is poor.[19] In a study by Engdahl et al., 10% of the 1,635 patients were studied; however, only 2% of them survived to hospital discharge.[22]

The prognosis for the patient improves with shorter times between asystole onset and resolution. Prevention of primary asystole includes the implantation of a permanent pacemaker. This is particularly the case in the presence of a high-grade second- or third-degree heart block or sinus arrest. Preventing and treating the underlying cause of secondary asystole helps to prevent reoccurrence.[19]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Unorganized atrial contractions cause VF.
2. True or False: In the presence of chronic ischemic heart disease, VTach does not precede VF.
3. True or False: The most common cause of VTach is ischemia from CAD.
4. True or False: Torsades de pointes is a type of VTach.
5. True or False: Unstable monomorphic VTach requires immediate treatment with procainamide.
6. True or False: PEA needs immediate CPR.

Non-arrest Arrhythmias

Non-arrest arrhythmias may be benign or serious depending on their hemodynamic consequences and the chances of evolving into a cardiac arrest arrhythmia. Some of these arrhythmias can predispose a person to stroke and are, therefore, important to identify.

Supraventricular Tachycardia

Supraventricular tachycardias (SVTs) are also called paroxysmal SVTs and are defined as an abnormally rapid heartbeat. The origin of the SVTs is in areas of the heart above the ventricles, in either the atria or the AV node.

Definition

SVTs are a group of arrhythmias that result from either an ectopic focus above the bundle of His or a re-entry circuit.[21] The heart rate with these types of arrhythmias is greater than 100 beats/minute.[1] SVTs include those with constant P–P intervals or regular rhythms and those with an irregular rhythm with either three or more P wave shapes or no distinct P waves. The SVTs with normal rhythms include **sinus tachycardia (ST)**, re-entrant SVTs, focal atrial tachycardia, and atrial flutter. The SVTs with irregular rhythms include multifocal atrial tachycardia and AF. See **Table 14-5**.

Etiology

The causes of SVT include abnormal electrical pathways and ectopic beats. The triggers for these include beta-agonist medications, ingesting large amounts of caffeine or alcohol, stress, tiredness, and cigarette smoking. Each type of SVT has its etiologies.

TABLE 14-5
Types of Common SVTs

Regular Rhythm (Constant P–P Intervals)	Irregular Rhythm
ST	Multifocal atrial tachycardia (≥3 P wave shapes)
Re-entrant SVTs AVNRT AVRT	AF (no distinct P waves)
Focal atrial tachycardia	
Atrial flutter	

Epidemiology

The prevalence of SVT covers a wide demographic range and can affect the younger population as much as the older population. In the United States, the incidence of SVT is about one to three cases per 1,000 persons with a prevalence of 0.2%.[23] **Atrioventricular nodal re-entrant tachycardia (AVNRT)** is more common in patients who are middle aged or older, and **atrioventricular re-entrant tachycardia (AVRT)** is more common in younger people.[23]

The prevalence of AVRT is higher in the younger population (<20 years old) and is the most common type of SVT in the pediatric population. In the more elderly population, AVNRT is more prevalent. The relative frequency of tachycardia mediated by an accessory pathway decreases with age.[23] The risk of developing paroxysmal SVT is higher in women than in men.[23] Atrial flutter is usually not typically seen in the younger population but becomes more prevalent in the older population. Most atrial flutter cases occur among populations 65 years old and older.[23]

The pathophysiology, clinical manifestations, diagnostic testing, treatment and management, risk factors, complications, and prognosis appear under each type of SVT.

Sinus Tachycardia

ST originates in the SA node, and the rate is above 100 beats/minute in adults (typically 100–180 beats/minute) with regular P waves and QRS complexes.[11] In infants, the rate must be greater than 200 beats/minute before it is considered ST, and greater than 140 beats/minute for a child.[6] **Figure 14-14** shows the ECG of a patient with ST.

ST is the most frequently encountered arrhythmia in clinical practice. The causes of ST are listed in Table 14-10.[15] This rhythm most often results from increased sympathetic or decreased vagal tone and is a normal response to exercise.[11] ST due to pathology is caused by fever, hypoxemia, hyperthyroidism, hypovolemia, and anemia (Figure 14-14). In disease states, ST is most often a sign of the severity of the primary



FIGURE 14-14 Sinus tachycardia.

pathophysiologic process and treatment should be directed at the underlying cause.[11] See **Box 14-8**. When the resting heart rate is greater than 100, even in the supine position, with no root cause, it is inappropriate sinus tachycardia (IST). This type of ST accounts for approximately 5% of the cases. In IST, symptoms can become apparent even with minimal exertion.[24]

The pathology of IST is still under investigation, and it is not completely understood. However, some studies have shown that there may be multiple pathologies. One pathology is the balance between the PNS and the SNS, with the SNS being in control and enhancing the intrinsic sinus node automaticity.[25] Other pathologies causing ST include hypersensitive beta1-receptors in the cardiac cells and a dysfunctional autonomic nervous system.[25]

Because tachycardia in healthy individuals is usually a benign dysrhythmia, it does not require treatment. Most of the time, ST is asymptomatic; however, palpitations are the most common complaint. Additional symptoms may include dizziness, lightheadedness, syncope, chest pain, anxiety, fatigue, and exercise intolerance. It is hard to diagnose IST; it is usually diagnosed after the etiologies for secondary ST are ruled out.[24]

The primary issues to be concerned with when addressing any tachycardia are twofold. First, how does the tachycardia affect the heart's demand for oxygen? A heart with a significant underlying cardiovascular disease does not tolerate the increase in oxygen demand that tachycardia causes.[26] See **Table 14-6**. This may lead to ischemia, infarction, and potentially lethal dysrhythmias. The second, more common, issue is the decrease in cardiac output stemming from the reduction in the time for diastole. Incomplete cardiac filling can lead to syncope and shock.[26]

Obtaining a 12-lead ECG is the best way to determine ST. See **Table 14-7**. However, in IST the standard diagnostic tools include the 12-lead ECG, and also echocardiography, 24-hour Holter monitoring, and a treadmill exercise test. An echocardiogram facilitates the evaluation for structural heart disease. The EPS may be able to identify the etiology of the tachycardia if it is unclear. Electrophysiology testing provides diagnostic clues for IST and is useful to evaluate and appropriately diagnose IST. IST can often be induced via EPS and therefore makes it useful in its diagnosis.[25]

The treatment for secondary ST depends on its cause. Treatment includes smoking cessation, reduction in or elimination of alcohol consumption, infection treatment, anxiety reduction, and certain medications.[6]

Managing IST remains a challenge. At times, symptoms persist despite the lowering of the heart rate. Treatment is predominantly symptom driven. See **Box 14-9**. Medications and/or RFCA may slow the heart rate. Also, treatment of any associated behavioral and psychologic disorders, physical conditioning, and lifestyle modification is also necessary.[25] The medications used to treat IST include beta-blockers and calcium channel blockers, and are not always found to be effective on IST. The use of RFCA remains controversial. There are only a few small studies supporting the use of RFCA in patients with medically refractory IST.[25]

BOX 14-8 Causes of ST

- Alcohol ingestion
- Anemia
- Anxiety
- Caffeine ingestion
- CHF
- Drug (cocaine, amphetamines, epinephrine)
- Fever
- Hypoglycemia
- Hypothyroidism
- Hypoxemia
- Hypovolemia
- Infection
- MI
- Persistent pain
- Pneumothorax
- Pulmonary embolism
- Shock
- Tobacco use

Reproduced with permission from Homoud MK. Sinus tachycardia: evaluation and management. In: Piccini J, Downey BC, eds. *UpToDate*. Waltham, MA: UpToDate; 2018.

TABLE 14-6
Underlying Diseases That Increase the Hazards from ST

Underlying Disease	Hazard from ST
1. Mitral stenosis	Pulmonary edema
2. Hypertrophic cardiomyopathy	Left ventricular outflow obstruction
3. Myocardial ischemia	Decreased myocardial perfusion Increase ischemia

Modified from Lilly L, ed. *Pathophysiology of Heart Disease*. 6th ed. Philadelphia: Lippincott Wiliams & Wilkins; 2016

TABLE 14-7
Diagnostic Criteria for ST

Criteria	Findings
Origin of arrhythmia	SA node
Heart rate	>100 beats/minute
Rhythm	Regular
P waves	Normal, rounded, and upright
PR interval	Shortened to normal
P-to-P and R-to-R intervals	Equal and regular
QRS complexes	Normal, wide if conduction delays exist

Modified from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management*. St. Louis, MO: Elsevier; 2011.

The risk factors for ST are related to its etiology. As heart rate increases, cardiac output initially increases; however, as the rate continues to climb, cardiac output will eventually decrease. This can result in myocardial ischemia due to an increase in oxygen demand and reduction in oxygen supply. Other complications include dizziness and syncope.[1]

Its etiology determines the prognosis for secondary ST. The prognosis of IST is unclear. There is a low risk of developing a tachycardia-induced cardiomyopathy or hypertension. Current studies have not shown an increase in mortality associated with IST.[25]

Atrioventricular Nodal Re-entry Tachycardia

AVNRT is a re-entry arrhythmia caused by an alternate pathway in the AV node and is considered a paroxysmal (abrupt onset and termination) SVT (PSVT).[1] See Figure 14-13. In the normal heart, the AV node is a lobulated structure that consists of a compact portion and several atrial extensions. The latter constitute two (or more) potential pathways for conduction through the AV node. See **Figure 14-15**. In some people, these extensions have different conduction times, providing both slow- and fast-conducting pathways.[11] The fast conduction pathway has a fast conduction velocity but has a slow refractory time. The other pathway has a slow conduction velocity, but a quick refractory time.[1] See **Figure 14-16**.

In the absence of a premature atrial contraction (PAC), the two separate channels do not cause a problem. When the signal reaches the beginning of the two channels, it will split and travel down both. The signal in the fast path will reach the AV node first and travel down to the ventricle and initiate a ventricular contraction. At the same time, part of the signal from the fast pathway will move in a retrograde fashion back up the slow pathway. When the two signals meet, they are canceled out.[1] The problem arises when a PAC occurs. Because the fast channel has not had time to repolarize, the signal cannot travel down the fast pathway. However, because the slow pathway has a short refractory time, the signal can go down the slow pathway.[11] Upon reaching the AV node, the signal will travel down to the ventricles and initiate a contraction. Also, part of the signal will travel up the fast pathway. By this time, the fast channel has recovered, and the signal can travel retrograde back to the RA. When the signal reaches the proximal portion, the slow pathway has recovered, and the signal goes back down the slow pathway and will initiate another ventricle contraction. This will continue and will result in the ventricles becoming tachycardic.[1,11] This is the most common form of PSVT in adults.[11] However, in about 5–10% of the population, the signal will enter the fast track and travel retrograde up the slow track and initiate AVNRT; this is known as atypical AVNRT.[1] In both typical and atypical AVNRT, there will be atrial activation. In typical AVNRT, the P wave is buried in the QRS complex, and with atypical AVNRT, the P wave will follow the ST segment.[1] Diet may play a role in the initiation of an episode of AVNRT. Triggers for AVNRT to be avoided include caffeine, theophylline, theobromine in selected foods (coffee, tea, or chocolate), and alcohol.[27]

Women are more likely to have AVNRT than men. Worldwide AVNRT accounts for 60% of all PSVT. The prevalence of SVT in the general population is approximately two cases per 1,000 persons. SVT may occur at any age, but most often presents in the seventh or eighth decade of life.[27]

BOX 14-9 Treatment of IST

- Search for underlying cause (e.g., pulmonary embolism, drug effects, fever) and institute appropriate treatment
- Beta-blockers: propranolol 1–3 mg IV, atenolol 5 mg IV (may be repeated up to a total of 15 mg), long-acting metoprolol 25–50 mg daily
- Ivabradine: for patients with persistently symptomatic IST, 5–7.5 mg twice daily

Reproduced with permission from Homoud MK. Sinus tachycardia: Evaluation and management. Post TW, ed. *UpToDate*. Waltham, MA: UpToDate; 2018.



FIGURE 14-15 Atrioventricular nodal re-entry tachycardia.



FIGURE 14-16 Dual pathways entering AV node can create arrhythmias.

Episodes of AVRNT can last from seconds to minutes to days. In the absence of structural heart disease, it is usually well tolerated. During AVNRT, the SA node is depressed, and when the arrhythmia breaks, there may be transient asystole and may result in syncope. Syncope may also occur if there is a rapid ventricular rate or prolonged tachycardia due to poor ventricular filling, decreased cardiac output, hypotension, and reduced cerebral perfusion.[27]

The heart rate is usually rapid, ranging from 150 to 250 beats/minute. Hypotension may occur initially or with rapid ventricular rates and prolonged episodes. Sometimes, initial hypotension evokes a sympathetic response that increases blood pressure and may terminate the tachycardia by an increase in vagal tone. See **Box 14-10**.

Upon evaluation of an ECG, the rhythm is regular and has QRS complexes that originate from above the ventricular (supraventricular). The heart rate will be 150–250 beats/minute, and the QRS complex is usually narrow, unless a conduction abnormality is present. An echocardiogram can be used to evaluate for the presence of structural heart disease. In an electrophysiology study (EPS), the typical findings are dual-node physiology and/or atrial-to-ventricular conduction intervals or gaps.[28]

The initial treatment for AVNRT may be rest, reassurance, sedation, and/or vagal maneuvers. These things have been shown to terminate an attack of AVNRT. However, the presence of underlying heart disease and the history of previous episodes need to be considered and will help to manage an attack successfully. If the ECG shows a wide-complex tachycardia, before starting therapy, review any prior cardiac history, LV function, and previous ECGs. This will help to determine the origin of the arrhythmia (i.e., supraventricular vs. ventricular).[27]

For immediate treatment, vagal maneuvers (i.e., carotid sinus massage, ice water on the face, or Valsalva maneuver) may be successful and should be

BOX 14-10 Symptoms of AVNRT

- Angina or MI in patients with CAD
- Anxiety
- Dyspnea
- Palpitations
- Nervousness
- Light headedness
- Neck pounding
- Neck and chest discomfort
- Polyuria
- Worsened heart failure in patients with poor LV function.

Reproduced with permission from Homoud MK. Sinus tachycardia: Evaluation and management. Post TW, ed. *UpToDate*. Waltham, MA: UpToDate; 2018.

attempted before medication use. In the presence of hypotension, vagal maneuvers are usually not successful.[27] DC cardioversion is employed only in rare conditions, such as hemodynamic compromise, or if medication is not effective and symptoms are present.[27] See **Table 14-8**.

Medication can be used to terminate an attack. Adenosine is the first drug used and is administered through a large IV. Close observation is necessary after adenosine administration to assess for AF or asystole for short periods. Adenosine may not work in the presence of theophylline, and it may increase the effects of dipyridamole (Persantine).[27] Other medications include nondihydropyridine calcium channel blockers (i.e., diltiazem, verapamil), beta-blockers, and digitalis. Calcium channel blockers are contraindicated if the origin of the tachycardia is the ventricles because it may cause hemodynamic compromise and death.[27]

If the reoccurrence of AVNRT is frequent or has severe symptoms and medication cannot be used (patient refuses, do not work, or is not tolerated well), then radio frequency ablation (RFA) of the re-entrant circuit should be considered. The cure rate for RFA is 95% and has a low risk of causing an AV block (AVB, <1%). This is an invasive procedure that requires an ablation catheter placed at the location of the slow pathway and burned. This creates a scar that will prevent the transmission of the problem electrical signal.[27]

Complications of AVNRT include hemodynamic compromise, CHF, syncope, tachycardia-induced angina, cardiomyopathy, myocardial ischemia, and MI. As long as no structural heart disease is present, the prognosis of AVNRT is good. In most cases, AVNRT responds to vagal maneuvers, adenosine, or RFA.[27,29]

TABLE 14-8
Treatment for AVNRT

Immediate treatment	Vagal maneuvers • Carotid sinus massage • Ice water on the face • Valsalva maneuver Cardioversion Adenosine intravenous
Pharmacologic treatment	Nondihydropyridine calcium channel blockers Beta-blockers Digitalis
Treatment for recurrent, nonresponse to pharmacologic therapy	RFA of re-entrant circuit Cryoablation of re-entrant circuit

Olshansky B. Atrioventricular Nodal Reentry Tachycardia: Background, Etiology, Epidemiology. Emedicinemedscapecom. 2017; Helton M. Diagnosis and management of common types of supraventricular tachycardia. *Am Fam Physician*. 2015;92(9):793–800.

Atrioventricular Re-entry Tachycardia

AVRT occurs because of an accessory pathway that develops in the left or right AV septum or the lateral walls of the right or left atrium. This channel allows the signal to bypass the delay in the AV node, which results in the ventricles depolarizing early and is call pre-excitation. The AVRT accessory pathways have individual rates of conduction and refractory periods.[1,11]

In AVRT, the signal from the SA node reaches the AV node and the accessory pathway approximately at the same time. The signal through the AV node is delayed due to the normal physiologic block in the AV node. However, the signal that travels through the accessory will not be delayed, and the ventricles will start to depolarize; this is evident by the upward deflection of the PR interval on ECG; this is called a delta wave.[1] The signal that travels through the accessory pathway will travel by cell-to-cell transmission, which is slower than the regular channel. After the delay in the AV the signal travels rapidly through the electrical conduction system and will meet the other signal, and they will cancel each other out.[1]

Under normal conditions, this accessory pathway does not cause a problem. However, if there is a PAC or PVC, then a re-entry tachycardia can develop. There are two types of AVRT: **orthodromic** and **antidromic**.[1] Orthodromic is caused when the electrical impulse travels from the AV node and returns in a retrograde fashion through the accessory pathway into the atria (Figure 14-16).[1,11] PACs usually cause orthodromic AVRT; however, a PVC can also cause it. When a PVC occurs, it can cause a transient block in the HIS-AV node area, which would prevent the electrical impulse from spreading back into the atria. However, the PVC will result in ventricular depolarization, which will then continue through the accessory pathway and cause atrial depolarization. The electrical impulse from the atria depolarization will then travel back to the AV node, and after the natural delay in the AV node, the ventricles will depolarize again. The electrical impulse will then travel through the accessory pathway and cause a re-entry circuit. In this type of AVRT, the signal passes through the normal electrical pathways so the QRS complexes are narrow, and the rate will be 140–250 beats/minute. In orthodromic AVRT the AV node is in control and is tolerated better and easier to treat.[1]

In antidromic AVRT, the signal caused by the ectopic beat will travel through the accessory pathway and back to the AV node in a retrograde fashion (**Figure 14-17**). The signal then travels through the AV node, and atrial depolarization will occur. The signal will then go back through the accessory pathway, setting up a re-entry circuit. In antidromic AVRT, the AV node does not control the electrical impulse. Therefore, the QRS complex will widen; this type is the most dangerous. The heart rate will be between 140 and 250 beats/minute; however, because



FIGURE 14-17 Orthodromic AVRT. In this form of AVRT, the impulse proceeds down the ventricles via the AV node and the normal electrical conduction system. The net result is that the tachycardia is "controlled" by the AV node and the QRS complexes are narrow.

the AV node is not in control, the heart can reach up to 360 beats/minute or more.[1] Antidromic AVRT does not respond to medications that affect the AV node.[1] The most common type of AVRT is **Wolff–Parkinson–White (WPW)**. The accessory pathway causing WPW is the Bundle of Kent and can be within the right or left AV septum or the lateral wall of the right or left atrium.[11] The most likely cause of WPW is hereditary as a familial trait, with or without associated CHDs.[11] Approximately 3.4% of those with WPW syndrome have first-degree relatives with pre-excitation.[30] See **Figure 14-18**.

The prevalence of ventricular pre-excitation is about 1–3 per 1,000 people in the general population.[30] This is true not only in the United States but also globally. About 80% of patients with WPW syndrome will develop a re-entry tachycardia, 15–30% will develop AF, and 5% will have A-flutter. Age is not a factor for developing WPW syndrome, and it is most present during infancy. However, a secondary rise in its presentation occurs in school-aged children and adolescents. Males and females are equally affected by WPW syndrome.[30]

The symptoms for WPW can be anything from mild chest discomfort or palpitations with or without syncope to severe cardiopulmonary compromise or cardiac arrest. An infant may frequently be irritable, not tolerate feedings, or demonstrate evidence of CHF. A verbal child will express they have feelings of chest pain, palpitations, or breathing difficulty. Adults will describe the sudden onset of a pounding heartbeat and a change in their tolerance for activity.[30]

An ECG and a history and physical exam are the methods of diagnosis for WPW. The ECG shows evidence of pre-excitation in symptomatic tachycardia displaying SVT or wide-complex tachycardia. The ECG shows a shortened PR interval, a slurring, and slow rise of the initial upstroke of the QRS complex (the characteristic delta wave). See **Figure 14-19**. An electrophysiologist consultation is necessary to check for very short refractory periods and possible ablation of the area causing the problem.[30]

Blood tests to rule out noncardiac conditions that may cause tachycardia include a CBC, BUN, creatinine, liver function test, and thyroid panel. Blood levels of intravenous lidocaine and procainamide are measured. If the patient is taking digoxin due to its slowing effect on the AV node conduction and its increase in the refractory period, blood levels of the drug are necessary. An echocardiogram can check for cardiac function and dimensions, cardiomyopathy, CHD, hypertrophic cardiomyopathy, or Ebstein anomaly.[30]

Verapamil and metoprolol do not affect conduction in the AV bypass tract. Verapamil is not recommended as a sole agent in patients with WPW syndrome. Digitalis will cause the refractory period in the myocardium and the bypass tract to be shorter. Consequently, it may accelerate the ventricular response in the setting of AF in a patient with WPW syndrome and needs



FIGURE 14-18 Antidromic AVRT. The original impulse travels down the accessory pathway, and a re-entry circuit is formed when the ventricular depolarization wave, being spread by direct cell-to-cell contact, reaches the AV node. It then moves retrograde up through the AV node to re-stimulate the atria. The circuit is completed when the retrograde-conducted atrial impulse reaches the accessory pathway once again restarting the circuit. The resulting complexes are wide and bizarre due to the slow ventricular conduction. Also note the absence of AV nodal control over the rate.



FIGURE 14-19 Impulse propagation through an accessory pathway and formation of the delta wave.

avoiding. The medications that work on the accessory pathway are Class IA drugs and Class IC drugs. These medicines will slow conduction velocity in the accessory pathway and prolong the accessory pathway refractory period in the bypass tract.[30] See **Table 14-9**.

An EP study can be done to locate the accessory pathway. Once this channel is found, it can be eliminated through the use of RFA. Once WPW is identified and appropriately treated, the prognosis is excellent. In asymptomatic AVRT, the prognosis is good.

The prognosis worsens if there is a family history of SCD, significant symptoms of tachyarrhythmia, or cardiac arrest. However, with early detection and treatment, the prognosis will improve. The risk of SCD increases in the presence of WPW, multiple bypass tracts, short accessory pathway refractory periods, AF, A-flutter, or a family history.[30]

Atrial Fibrillation

Atrial fibrillation (AF) is the result of disorganized electrical activity in the atria.[6] This chaotic activity results in rapid depolarization of the atria, causing the loss of coordinated atrial contractions.[6,15] As a result, the heartbeat will be irregular, hemodynamics becomes compromised, and there is an increased risk of blood clots.[6] While the rate of atrial electrical discharges typically ranges from 400 to 700 per minute, decreased conduction by the AV node results in an average ventricular response of 160–180 beats/minute.[11,21] See **Figure 14-20**. There are no regular P waves in AF. Instead, the chaotic rapid firing of the multiple ectopic atrial sites results in the characteristic AF "f" wave. AF is attributed to one or more rapidly firing ectopic foci and chaotic re-entry within the atria. Because no site paces the ventricles, the intervals are completely random.[6,21]

The most common conditions associated with AF are ischemic heart disease, hypertension, thyrotoxicosis, and rheumatic heart disease in developing countries.[21] The common causes of AF are listed in **Box 14-11**.

AF has several different classifications based on its onset, persistence, and ability to be converted to a NSR.[31] See **Table 14-10**.

The number of AF cases in the United States is roughly between 2.7 and 6.1 million. Age is a risk factor for AF. Approximately 2% of the population under 65 years old have AF, but 9% of the population over 65 years old have it.[32] Based on the growing number

TABLE 14-9
Treatment for WPW Syndrome

Pharmacologic therapy	Agents acting on the AV node • Calcium channel blockers (e.g., verapamil, diltiazem) • Beta-blockers (e.g., metoprolol, atenolol) Agents acting on the accessory pathway • Class Ia (e.g., quinidine) • Class Ic (e.g., flecainide, propafenone)
Nonpharmacologic therapy (first-line treatment for symptomatic WPW)	EPSs with RFA

Data from Ellis C. Wolff-Parkinson-White Syndrome: Practice Essentials, Background, Pathophysiology. Emedicinemedscapecom. 2017.

BOX 14-11 Most Common Causes of AF

- Acute alcohol intoxication (holiday heart)
- Atrial septal and other CHDs
- CAD
- Chronic obstructive pulmonary disease
- Hypertension
- Hyperthyroidism
- Cardiomyopathy
- Mitral or tricuspid valvular disorders
- Myocarditis
- Pericarditis
- Pulmonary embolism

Data from Mitchell LB. Atrial Fibrillation. Merck Manuals Professional Edition. 2018. https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmiasand-conduction-disorders/atrial-fibrillation-af.



FIGURE 14-20 Atrial fibrillation.

TABLE 14-10
Classification of AF

Name	Onset	Persistence	Conversion to NSR
Acute AF	New onset	<48 hours	Spontaneous
Paroxysmal AF	Recurrent	<1 week	Spontaneous or with intervention; episodes may reoccur
Persistent AF	Continuous	>1 week	Spontaneous or with treatment
Longstanding persistent AF	Continuous	>1 year	Possible to restore with treatment; the longer AF persists, the more difficult the conversion
Permanent AF	Continuous	Longstanding	Cannot be converted due to atrial remodeling

Data from Mitchell LB. *Atrial Fibrillation. Merck Manuals Professional Edition.* 2018. https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmias-and-conduction-disorders/atrial-fibrillation-af.

of baby boomers, the number of people in the United States with AF is expected to grow. Americans of European descent are more likely to develop AF than African Americans. The incidence of AF in women is increasing due to women's longevity.[32] The hospitalization rate for AF is approximately 750,000 per year with about 130,000 deaths per year due to AF.[32]

The initiation and perpetuation of tachyarrhythmias require both triggers for its onset and a substrate for its maintenance. The mechanism of AF likely involves multiple wandering re-entrant circuits within the atria. A re-entrant circuit occurs when an electrical impulse repeatedly circulates a re-entry path, recurrently depolarizing a region of cardiac tissue. Re-entry requires a susceptible substrate and a trigger. The trigger for AF is thought to be rapidly firing foci that come from the sleeves of atrial muscle that extend into the pulmonary veins.[11] Also, this area may fire repetitively through some re-entrant circuits which may contribute to the persistence of AF.[11,19]

The cardiac diseases predisposing atria to fibrillation cause fibrotic, degenerative, and inflammatory changes in atria. These changes occur either by involving atria directly in the disease process, such as in cardiomyopathy, ischemic heart disease, pericarditis, rheumatic heart disease, and sick sinus syndrome, or indirectly secondary to hemodynamic changes in ventricles, such as cor pulmonale and hypertensive heart disease.

The signs and symptoms of AF are variable. The loss of atrial contraction (atrial kick) can result in the incomplete filling of the ventricles before systole, causing a reduction in cardiac output by as much as 25%.[26] In patients with compromised cardiac output, the loss of effective atrial contractions may precipitate CHF. Angina, respiratory distress, and hypotension are also common presentations with acute AF, particularly with rapid ventricular response.[21]

In many cases, AF is asymptomatic. However, the most typical clinical findings include palpitations, vague chest discomfort, weakness, light headedness, dyspnea (symptoms of heart failure), and tachyarrhythmia.[31] There may be a pulse deficit due to a difference between the apical ventricular rate and the radial pulse caused by low EF.[31]

TABLE 14-11
Diagnostic Criteria for AF

Criteria	Findings
Origin of arrhythmia	Ectopic atrial sites usually within the atrial muscle sleeve of the pulmonary vein
Heart rate	Atrial 350–600 beats/minute Ventricular >100 beats/minute (uncontrolled) Ventricular <100 beats/minute (controlled)
Rhythm	Irregularly irregular
P waves	Absent "f" waves present
PR interval	Absent
P-to-P and R-to-R intervals	P–P absent R–R unequal
QRS complexes	Normal; wide if conduction delay exists

Data from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.

The diagnosis of AF requires an ECG. The diagnostic criteria for AF are listed in **Table 14-11**. In an ECG, there is an absence of P waves that typically occur between the T waves and the QRS complexes. Instead, there will be a quivering line representing the fibrillating of the atria. The rhythm of the atria will be irregular in timing and morphology. The atrial rate is usually above 350 beats/minute. Not all of the signals that reach the AV node transmit through to the ventricle. Consequently, the ventricle rhythm will be irregular, and the rate will fluctuate.[31]

Echocardiography is also able to diagnose AF and can evaluate and identify structural abnormalities of the heart. These abnormalities include left atrial

enlargement, left ventricular wall-motion abnormalities, valvular disorders, or cardiomyopathy.

Treatment plans for AF focus on three aspects of the arrhythmia: ventricular rate control (only if hemodynamically stable), prevention of thromboembolism, and restoration of sinus rhythm. These plans are designed to address ventricle rate control and prevention of blood clot formation.[11] Some of the treatment possibilities[11,21,33] are listed in **Table 14-12**.

Converting AF to NSR prevents the need for long-term rate control and anticoagulants. Hemodynamics and exercise are improved when AF converts to NSR. With the return of NSR, cardiac output increases, diminishing the risk of CHF development and improving the patient's quality of life.[34]

The conversion of AF to NSR occurs with pharmacologic, electrical cardioversion, ablation via RFA, or cryogenically. The RFA will burn the atrial tissue around the pulmonary vein; the cryoablation freezes that same tissue.[35,36] With either device, the goal is to create a scar, because scar tissue is not able to conduct electricity, eliminating the ectopic signals causing the AF.[33]

TABLE 14-12
Treatment for AF[11,21,33]

Treatment Focus	Specific Treatments
Ventricular rate control	• Metoprolol • Diltiazem • Verapamil • Digoxin (less effective)
Emboli prevention	• Warfarin (for high-risk patients) • Unfractionated heparin • Dabigatran • Rivaroxaban • Apixaban • Edoxaban • Left atrial appendage (LAA) ligation or occlusion
Restoration of NSR	Pharmacologic cardioversion: • Class IC—flecainide, propafenone • Class IA—quinidine, procainamide, disopyramide • Class III—amiodarone, dronedarone, sotalol, dofetilide, ibutilide Synchronized cardioversion: • Anticoagulation for at least 3 weeks prior to cardioversion RFA • Burn atrial tissue surrounding pulmonary veins Cryoballoon ablation (CBA) • Cryogenically freeze atrial tissue surrounding pulmonary veins MAZE surgical procedure • Surgical ablation using cut-and-sew technique

Surgical ablation using the MAZE III procedure incorporates the creation of four lesion sets, including the encirclement of the pulmonary veins, a lesion joining the circumferential pulmonary vein lesion to the mitral annulus with amputation of the LAA, a circumferential lesion in the coronary sinus, and the ablation of the right atria.[33] This is a complicated procedure that carries all the possible risks of surgery, including mortality.

Pharmacologic cardioversion has the advantage of not requiring sedation or anesthesia, but the major disadvantage of VTach or other serious arrhythmia development. Electrical cardioversion is performed electively or emergently to restore sinus rhythm in patients with new-onset AF. The need for cardioversion may be acute when AF is responsible for hypotension, heart failure, or angina.

One of the most important considerations in the acute management of AF is the need for anticoagulation. Both pharmacologic and electric cardioversion increase the risk of thromboembolic development. The longer the AF persists, the greater the risk of thromboembolic events. Transesophageal echocardiography (TEE) can evaluate for the presence of blood clots in the LAA caused by blood stasis within the left atria.[11]

Because AF contributes to pathologic atrial and ventricular remodeling, restoration of sinus rhythm can slow or, in some cases, reverse atrial dilatation and left ventricular dysfunction.[34] Therefore, the primary focus is initially on restoration and maintenance of sinus rhythm in patients with new-onset AF and on opting for a rate-control strategy only if rhythm control fails.[34] Because AF is associated with other cardiovascular risk factors, managing these helps to reduce the chances of AF returning. Optimal long-term strategies for AF feature a patient-by-patient approach. Typically, younger patients with more severe symptoms and fewer comorbidities will benefit from rhythm control. Trying to manage the rhythm in older patients with structural heart disease is more difficult as they are less likely to remain in sinus rhythm. Also, there is an increased chance of severe side effects from antiarrhythmic drugs. For this population, the focus is on long-term rate control.[34]

The risk factors for AF include advancing age, cardiomyopathy, chronic kidney disease, diabetes, European ancestry, heart failure, hypertension, hyperthyroidism, heavy alcohol use, and obesity.[32]

Complications from AF are a direct result of thrombus formation. The annual risk of embolic cerebrovascular events for the patient with AF is about 7%. Patients with rheumatic valvular disorder, hyperthyroidism, hypertension, diabetes, left ventricular systolic dysfunction, or previous thromboembolic events have an even higher risk of stroke.[34]

AF is associated with increased morbidity and mortality, in part due to the potential for thromboembolic disease, particularly stroke, and part due to



FIGURE 14-21 Atrial flutter with 3:1, 4:1, and 5:1 conduction rates. Each upward deflection in the flutter is an F wave. The pattern of atrial F waves is "saw-tooth."

its associated risk factors. Studies have shown that individuals in sinus rhythm live longer than people with AF. Disruption of normal atrial electromechanical function in AF leads to blood stasis. This, in turn, can result in the development of thrombus, most commonly in the LAA. Dislodgement or fragmentation of a clot can then lead to embolic phenomena, including stroke.[34]

Atrial Flutter

Atrial flutter (A-flutter) is a cardiac arrhythmia arising in an ectopic pacemaker or the site of rapid re-entry circuit in the atria, characterized by rapid, regular atrial activity at a rate of 250–350 beats/minute.[1] The atrial contraction rate is greater than the ventricular rate, as evidenced by the existence of multiple P waves for every QRS complex. These fast impulses reach the AV node during its refractory period and do not conduct to the ventricles, resulting in a slower ventricular rate, often an even fraction of the atrial rate.[11] The ventricular response depends on the degree of the block at the AV node. The block may be constant or variable and acts as a protective mechanism to prevent excessive ventricular rates.[11] The AV conduction ratio in most instances of atrial flutter is 2:1. A 2:1 AV conduction rate indicates that a QRS complex follows every other F wave. See **Figure 14-21**. The AVB may be greater (e.g., 3:1, 4:1) or even variable due to the disease of the AV node, vagal tone, and certain drugs (e.g., digitalis, beta-blockers, or calcium channel blockers).[26]

There are two types of A-flutter. The most common A-flutter involves a single re-entrant circuit along the tricuspid valve annulus.[11,37] See **Figure 14-22**. This signal travels in a counterclockwise around the annulus of the tricuspid valve and is self-perpetuating.[37] The other type of A-flutter is atypical. This type follows a different circuit, and it may involve the right or left atrium. Either way, the electrophysiologic mechanism responsible for atrial flutter is either enhanced automaticity or re-entry.[26]

Atrial flutter occurs in patients with preexisting cardiovascular diseases, such as coronary or hypertensive heart disease.[11,26] Open-heart surgeries may also cause



FIGURE 14-22 The tricuspid valve annulus is the location of a single re-entrant circuit that causes atrial flutter.

atrial flutter due to atrial incision and scaring. Other etiologies include ischemic heart disease, acute MI, hypoxia, hypokalemia, pulmonary embolism, thyrotoxicosis, myocarditis, congestive cardiomyopathy, valvular disease, and drug toxicity (digoxin).[21]

Atrial flutter is less common than AF. Only 10% of the patients admitted to the hospital for an SVT between 1985 and 1990 had A-flutter; 77% had AF. There are approximately 200,000 new cases per year, chances of developing A-flutter increase with age, and men are two and half times more likely to have A-flutter than women.[37] The prevalence of AF increases with age from two to three cases per 1,000 population in 25- to 35-year-olds to 50–90 cases per 1,000 population in 65- to 90-year-olds.[37]

The clinical manifestations of atrial flutter are dependent on its etiology, the patient's existing medical condition, and the ventricular response.[21] If the rate is <100 beats/minute, the patient may be asymptomatic. Conversely, faster rates often cause palpitations, dyspnea, or weakness. See **Box 14-12**.

The use of an ECG is essential in making the diagnosis. See **Table 14-13**. In atrial flutter, there is no isoelectric line between each P wave, and therefore, these waves are called flutter (F) waves. Flutter waves are often visualized best in leads II, III, aVF, or V_1. If there

is a 2:1 conduction ratio, the ST segment time can be affected, and the ECG can resemble ischemic injury. If there was a 1:1 to ratio, hemodynamic collapse might occur. A patient WPW syndrome (a type of AVRT) is at greater risk of developing a 1:1 conduction ratio.[37]

The onset and end of the atrial flutter F waves cannot be determined with certainty but consists of an abnormal atrial depolarization wave that corresponds to an ectopic P wave followed by an atrial T wave or atrial repolarization. The atrial F waves consist of negative (inverted) V-shaped atrial wave immediately followed by an upright, peaked atrial T wave in Lead II.[26] See **Figure 14-23**.

An echocardiogram can evaluate the right and left atrial size, and the size and function of the right and LVs. This helps determine the presence of valvular heart disease, left ventricular hypertrophy, or pericardial disease. To assess for the presence of a thrombus in the atria, the TEE is the preferred technique.[37]

Atrial flutter by itself is not life threatening. However, if not treated properly, the side effects can be life threatening. In patients with limited cardiac reserve, atrial flutter with a rapid ventricular rate may result in a profound reduction in cardiac output and hypotension. This could lead to atrial thrombus formation and the increased likelihood of MI, stroke, or other vital organ problems. An uncontrolled ventricular rate can result in hemodynamic collapse and cardiomyopathy.[11] Atrial flutter can degenerate to AF or spontaneously convert to NSR.[21]

The treatment for A-flutter is very similar to that for AF. As with AF, atrial flutter also predisposes to atrial thrombus formation, and anticoagulation therapy is often appropriate.[11] Therefore, the goal for atrial flutter treatment is to prevent thrombosis, rate control, and conversion to NSR. **Table 14-14** reviews the treatments for atrial flutter.

The risk factors for the development of atrial flutter include the presence of cardiac diseases, such as congenital abnormalities, heart failure, valvular disease, hypertension, and previous MI. Other factors that put a patient at risk for atrial flutter include recent surgery, thyroid dysfunction, chronic alcoholism, diabetes, and chronic lung disease.

The prognosis for atrial flutter is different for each patient and is influenced by the patient's underlying

BOX 14-12 Symptoms of Atrial Flutter

- Angina
- Fatigue or reduced exercise tolerance
- Light headedness
- Mild dyspnea
- Palpitations
- Profound dyspnea
- Symptoms of underlying cardiovascular disease
- Syncope
- Thromboembolic events

Data from Mitchell LB. Atrial Fibrillation. Merck Manuals Professional Edition. 2018. https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmiasand-conduction-disorders/atrial-fibrillation-af.

TABLE 14-13
Diagnostic Criteria for Atrial Flutter

Criteria	Findings
Origin of arrhythmia	Single re-entrant circuit along the tricuspid valve annulus
Heart rate	Atrial rate: 250–350 beats/minute Ventricular rate: 125–176 beats/minute
Regularity	Usually regular, but can vary
P waves	Saw-toothed appearance, F waves
PR interval	Variable
P to QRS ratio	Most commonly 2:1 ratio
QRS width	Normal

Data from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.



FIGURE 14-23 Atrial flutter (with atrial F waves).

TABLE 14-14
Treatments for Atrial Flutter

Unstable Hemodynamics or Chronic Atrial Flutter	Stable Hemodynamics	After Rate Control Is Achieved	Antithrombic Therapy
• Electrical cardioversion • Burst pacing with a pacemaker • RFCA (chronic A-flutter)	• Diltiazem • Verapamil • Digoxin (if already receiving, could be the cause) • Beta-blockers: esmolol Unclear diagnosis • Vagal maneuvers • Adenosine Impaired EF • Amiodarone	• Procainamide • Quinidine	• Patients with mechanical heart valves—warfarin • Patients with nonvalvular AF and a history of previous stroke/transient ischemic attack—warfarin, dabigatran, rivaroxaban, apixaban • Patients with nonvalvular AF—assess stroke risk and treat accordingly

Data from Borke J. Emergent Management of Atrial Flutter: Overview, Emergency Department Care, Cardioversion for Unstable Patients. Emedicinemedscapecom. 2017. https://emedicine.medscape.com/article/757549-overview. Accessed March 24, 2018.



FIGURE 14-24 First-degree AVB.

medical condition. The morbidity and mortality for atrial flutter result from complications of rate (e.g., syncope and CHF). In patients with atrial flutter, the risk of embolic occurrences approaches that seen in AF.[37] The ventricle rate in A-flutter will be higher than in AF and harder to control. If WPW is present, life-threatening ventricular responses may develop. In these cases, RFCA of the accessory bypass tract is appropriate. Following an ablation, these patients have a good prognosis.[37]

First-Degree AVB

First-degree AVB (1° AVB) is a prolongation of the normal delay of the electrical signal in the AV node, causing the length of the PR interval to be greater than 0.20 seconds (>5 small boxes on the ECG). See **Figure 14-24**. Even though there is a delay, the electrical signal is relayed to the ventricles and results in the depolarization and contraction of the ventricles. There is one QRS complex for every PR interval.[1]

Reversible causes of 1° AVB include heightened vagal tone, transient AV nodal ischemia, and drugs that depress conduction through the AV node, including beta-blockers, certain calcium channel blockers, digitalis, and other antiarrhythmic medications.[11,26] Structural causes of 1° AVB include MI and chronic degenerative diseases of the conducting system, which commonly occur with aging.[11,26]

The prevalence of 1° AVB among young adults ranges from 0.65% to 1.6%, and is 8.7% in studied trained athletes. Approximately 5% of men over the age of 60 years have 1° AVB, which increases with advancing age. The overall prevalence is 1.13 cases per 1,000 people. African Americans are more likely to have 1° AVB than Caucasians.[38]

The AV node is the only normal electrical connection between the atria and the ventricles.[38] The AV node is oval or elliptical in shape, measures 7–8 mm long, and is in the wall of the interatrial septum next to the opening of the coronary sinus and the septal leaflet of the tricuspid valve.[1,38] The blood supply for the AV node is provided by the AV nodal artery. In the majority of people the AV nodal artery branches off the RCA; however, it can branch off the circumflex artery.[38]

The PR interval represents the time needed for an electrical impulse from the SA node to conduct through the atria, the AV node, the bundle of His, the bundle branches, and the Purkinje fibers. The most common place for a delay in the electrical signal is in the AV node. However, a delay can occur within the right atrium, the AV node, the His-Purkinje system, or a combination of these.[38] If the QRS complex appears normal on the ECG, the conduction delay is almost

TABLE 14-15
Diagnostic Criteria for First-Degree AVB

Criteria	Findings
Origin of arrhythmia	AV node
Heart rate	Underlying rhythm
Regularity	Regular
P waves	Upright (Lead II)
PR interval	>0.20 seconds
Conduction ratio	1:1
QRS width	Normal unless conduction delay is present

Data from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.

always at the level of the AV node. However, if the QRS seems to have a bundle branch morphology, then the level of the conduction delay is often localized to the His-Purkinje system.[38]

There are no symptoms associated with 1° AVB.[26] The one exception is in the presence of LV systolic dysfunction, which may cause reduced exercise tolerance. A physical examination is unremarkable with nothing specifically associated with 1° AVB. Most often this block is discovered during an ECG performed for another reason. See **Table 14-15**. The first heart sound (S_1) may be decreased, with a short, soft, blowing, diastolic murmur heard at the apex. The diastolic murmur may arise from blood flow through the mitral valves leaflets that are stiffer than normal.[38]

If a metabolic dysfunction or drug toxicity is suspected, a blood test for electrolyte imbalance is performed. If symptoms are present, a His bundle ECG is necessary and is used to locate the site of the block. If AV nodal medications are administered, a follow-up ECG is indicated.[38]

If there is LV systolic dysfunction, a Doppler ultrasound is performed to see if the cardiac output will improve during dual-chamber pacing using a short AV nodal delay. This helps to determine if a permanent pacemaker is needed for hemodynamic support. Biventricular pacemakers are used when 1° AVB occurs with cardiomyopathy, CHF, or intraventricular conduction delay (IVCD).[38]

For asymptomatic 1° AVB, no treatment is needed; however, if the PR interval is greater than 0.30 seconds, some studies suggest putting a dual-chamber pacemaker.[39] If 1° AVB occurs with any other condition (i.e., MI, digitalis intoxication, electrolyte imbalance), these should be treated appropriately. Significant electrolyte abnormalities should be corrected. If there are symptoms, a review of the patient's current medications is done to assess for a cause of the block. Also, an electrophysiology (EP) consult may be indicated, especially in the presence of syncope and heart failure. Hospitalization is not required. A 1° AVB can progress to a higher-grade AVB. As such, long-term monitoring is done using serial ECGs.[38]

If a 1° AVB advances to higher-grade AVB, it is usually to Mobitz I second-degree heart block (the "Second-Degree AVB" section). However, in the presence of acute MI, myocarditis, or acute drug overdoses, it could progress to a higher-grade block. Certain medications slow conduction through the AV node, which increases the risk of progression to higher-grade heart blocks. Other potential complications include the reduction in left ventricular stroke volume and cardiac output and pacemaker syndrome.[38]

The prognosis for isolated 1° AVB usually is good, because it rarely progresses to a high-degree block and is considered a benign condition.[38] However, information from the Framingham Heart Study have shown that 1° AVB is associated with increased risk of all-cause mortality in the general population. A study by Cheng et al. found that 1° AVB is associated with increased risk of AF, pacemaker implantation, and all-cause mortality. When compared with normal PR intervals, those with 1° AVB had a 2-fold adjusted risk of AF, a 3-fold adjusted risk of pacemaker implantation, and a 1.4-fold adjusted risk of all-cause mortality.[40]

Second-Degree AVBs

Second-degree AVBs (2° AVB) are arrhythmias characterized by a delay or interruption of atrial impulse conduction to the ventricles through the AV node.[41] The ECG shows that some P waves are not conducted through to the ventricles, which results in a dropped QRS complex. The AVB can be permanent or transient, depending on the etiology.

Cardioactive medications are considered an important cause of 2° AVBs. These drugs may directly exert an adverse effect on the AV node, indirectly through the autonomic nervous system, or both.[41] Cardioactive medications that have been shown to cause 2° AVBs are digoxin, beta-blockers, calcium channel blockers, and certain antiarrhythmic. The Class I antiarrhythmics (sodium-channel blockers) may cause a distal block in the His-Purkinje system. Also, there are reports of 2° AVBs following adenosine infusion for nuclear stress testing.[41] See **Box 14-13** for other causes of 2° AVB.

Highly trained athletes in the United States have a higher risk of developing a 2° AVB than a young adult. For young adults, the prevalence has been reported to be 0.003%. In the presence of structural heart disease, nearly 3% will develop some form of a 2° AVB. There is no statistical difference between the prevalence for males and females.[41] The two distinct types of 2° AVB are **Type I AVB** (**Mobitz I** or **Wenckebach**) and **Type II AVB** (**Mobitz II**).

BOX 14-13 Etiologies for 2° AVB

- Acute ethanol poisoning
- Acute MI
- Cardiac tumors
- Collagen vascular diseases—rheumatoid arthritis
- Corrective congenital heart surgery
- Ethanol septal reduction
- Following some RFCA procedures
- Infiltrative diseases—amyloidosis, hemochromatosis, sarcoidosis
- Infiltrative malignancies—Hodgkin lymphoma
- Inflammatory diseases—endocarditis, myocarditis, rheumatic fever
- Metabolic and endocrine disorders—hyperkalemia
- Muscular dystrophies
- Myocardial bridging
- Obstructive sleep apnea
- Progressive (age-related) idiopathic fibrosis of the cardiac skeleton
- Transcatheter closure of atrial and ventricular septal defects
- Trauma following transcatheter valve replacement
- Valvular heart disease complications

Modified from Sovari A. Second-Degree Atrioventricular Block: Practice Essentials, Background, Pathophysiology. Emedicinemedscapecom. 2017.

TABLE 14-16
Signs and Symptoms of 2° AVBs

Mobitz I 2° AVB	Mobitz II 2° AVB
Majority asymptomatic (no heart disease)	Majority of regularly irregular heartbeats
Recurrent syncope (heart disease)	Light headedness
Presyncope (heart disease)	Dizziness
Bradycardia (heart disease)	Syncope
	Asymptomatic
	Chest pain (related to myocarditis or ischemia)
	Bradycardia

Modified from Sovari A. Second-Degree Atrioventricular Block: Practice Essentials, Background, Pathophysiology. Emedicinemedscapecom. 2017.

Second-degree AVBs may be asymptomatic or symptomatic, or may progress to complete heart block, which has an increased risk of mortality.[41] See **Table 14-16**. Patients who are symptomatic with either type of 2° AVB may have signs of hypoperfusion, including hypotension.[41]

An EP study can be done to determine the exact location of the block and whether a permanent pacemaker is needed. An EP study is indicated if one of the following is present: Mobitz I associated with a wide QRS complex in the absence of symptoms, 2:1 2° AVB with a wide QRS complex in the absence of symptoms, or Mobitz I second-degree block with a history of unexplained syncope.[41]

A Mobitz I block caused by the AV node has a favorable prognosis, with little risk of developing a third-degree heart block. Also, if Mobitz I is in the AV node then morbidity or death rates are not increased; however, if the cause is a result of an MI, mortality is increased. Mobitz I from an intranodal block may progress to a third-degree heart block, and if it does, the prognosis is worse. Mobitz II blocks have an increased risk of progressing to a third-degree heart block and an increased risk of mortality. Also, they are associated with MI and all its attendant risks.[41]

Second-Degree Heart Block Type I (Mobitz I or Wenckebach)

Second-degree AVB Type I (Mobitz I or Wenckebach) is a dysrhythmia in which there is a progressive delay following each P wave in the conduction of electrical impulses through the AV node until conduction does not occur. This dysrhythmia is characterized by progressive lengthening of the PR intervals until a QRS complex fails to appear after a P wave (dropped beat). The sequence of increasing PR intervals and an absent QRS complex is repetitive.[26] Following the dropped QRS complex the PR interval will return to normal, and the cycle repeats.[15] The QRS complexes are usually typical in width.[1] See **Figure 14-25**.

Mobitz I is the most common type of 2° AVB and is diagnosed with an ECG. See **Table 14-17**. On an ECG, there will be a gradual prolongation of the PR interval until one of the impulses from the SA node is blocked. Following the non-conducted impulse, there will be a pause, and on the next conducted beat, the PR interval will return to normal. The number of P waves before the dropped beat will vary. In some cases, there may be six P waves before a dropped beat and can cause a misdiagnosis of Mobitz II. The main diagnostic characteristic is the return of the PR interval to normal following the dropped beat.[41]



FIGURE 14-25 Second-degree AVB Type I (Mobitz I).

TABLE 14-17
Diagnostic Criteria for 2° AVB Type I (Mobitz I or Wenckebach)

Criteria	Findings
Origin of arrhythmia	AV node
Heart rate	Underlying rhythm
Regularity	Patterned irregularity
P waves	Upright (Lead II)
PR interval	Progressively longer until a dropped, QRS complex occurs
Conduction ratio	Variable (commonly 5:4, 4:3, or 3:2)
QRS width	Average duration and shape

Data from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.

No treatment is needed in Mobitz I if there are no symptoms. If symptoms are present, they need to be identified and treated. If symptoms are due to bradycardia, atropine and TCP are indicated. Use atropine with caution when cardiac ischemia is present. Atropine helps improve conduction through the AV node by reducing vagal tone. If the block is outside the AV node, atropine may not be effective.[41]

If the cause is from ischemia, then the primary goal should be to restore perfusion. This occurs with medications or a percutaneous coronary intervention. If a cardioactive drug is a cause, then blood tests should be done to determine which medication is the cause and treat appropriately. Regardless of symptoms, a cardiology consult is recommended. The use of drugs that act on the AV node is not indicated.[41]

Second-Degree AVB Type II (Mobitz II)

Second-degree AVB Type II (Mobitz II) is a dysrhythmia in which a complete block of conduction of the electrical impulses occurs in one bundle branch and an intermittent block in the other. This produces an AVB characterized by regularly or irregularly absent QRS complexes, commonly creating an AV conduction ratio of 4:3 or 3:2, and a bundle branch block.[26]

Mobitz II can be diagnosed using an ECG. On an ECG, the PR interval will be the same length for each conducted beat, both before and after the non-conducted beat. Mobitz II AVBs occur infranodally. This usually occurs at the bundle branches and, less commonly, at the bundle of His.[26] ECG characteristics include normal P waves with more P waves than QRS complexes, a PR interval that may be prolonged from normal but remains constant, and an irregular ventricular rate associated with a regular atrial rate. Mobitz II AVBs usually occur in association with bundle branch blocks; therefore, QRS complexes are usually wide.[21,41] See **Figure 14-26**.

In contrast to Mobitz I, Mobitz II is a more dangerous condition. It is characterized by the sudden intermittent loss of AV conduction, without preceding gradual lengthening of the PR interval. The block may persist for two or more beats (i.e., two sequential P waves not followed by QRS complexes), in which case it is a high-grade AVB.[11]

Mobitz II AVBs are more likely than Mobitz I AVBs to progress to a complete heart block. The use of AV nodal pharmacologic agents needs to be avoided. If the cause of the Mobitz II AVB is ischemia, perfusion needs restoration. Due to the risk of developing a third-degree heart block, permanent pacing is now used instead of atropine for symptomatic Mobitz II. Atropine is not useful in Mobitz II. It is recommended to use TCP pads for asymptomatic Mobitz II. When using a temporary pacemaker, it should be tested to ensure it will initiate a heartbeat (capture). If capture does not occur, insertion of a temporary pacemaker needs consideration. A cardiologist needs consultation as quickly as possible. Mobitz II caused by drug toxicity, Lyme disease, or hypoxia in sleep apnea will usually resolve with treatment.[41]

Third-Degree AVB

Third-degree AVB (**3° AVB** or **complete heart block** or **3° HB**) is a result of a total failure of conduction between the atria and the ventricles.[11] Third-degree AVB



FIGURE 14-26 Second-degree AVB Type II (Mobitz II).



FIGURE 14-27 Third-degree AVB.

has no electrical conduction through the AV node, leading to the full dissociation of atrial and ventricular activity.[42] The term *AV dissociation* is a general description that refers to any situation in which the atria and ventricles beat independently, without any direct relationship between P waves and QRS complexes.[11] Because no atrial impulses reach the ventricles, the ventricular response is controlled by an ectopic ventricular focus. ECG findings include a ventricular response that is slower than the atrial rate and usually regular, and an atrial rate that is typically normal with normal P waves; because the atria and ventricles are depolarized at different speeds from different foci, the PR interval is variable.[21] See **Figure 14-27**.

A 3° AVB can be either congenital or acquired. If congenital, the block is usually at the level of the AV node with no symptoms at rest. However, symptoms develop later on due to the inability to adjust for exertion. Acquired 3° AVB causes include medications, ischemia, and infections.[42]

An isolated single-agent drug overdose can cause 3° AVB. However, in most cases, it is due to a combination of AV nodal, beta-adrenergic, and calcium channel–blocking agents.[42] A 3° HB can develop from an anterior wall MI, which can result in an infranodal 3° HB; this is an unfavorable finding. An inferior wall MI can also cause a 3° HB and is much less dangerous, and will usually resolve within hours to a few days.[42] Other treatments can lead to a 3° HB, such as AO valve surgery, alcohol septal ablation, percutaneous coronary intervention to the left anterior descending artery, or ablation of the slow or fast pathway of the AV node.[42] See **Table 14-18**.

In the United States, the prevalence of 3° AVB is 0.02% and worldwide it is 0.04%. Advancing age increases the risk for 3° AVB. These increases are similar to that of ischemic heart disease. An early peak in the incidence of 3° AVB occurs in infancy and early childhood from congenital 3° AVB.[42]

A 3° AVB has more P waves than QRS complexes with no relationship between them. Approximately 20% of 3°AVB occurs at the level of the AV node, another 20% at the bundle of His, and around 60% at the bundle branch. The width of the QRS complex depends on the site of the block and the site that initiates the heartbeat. If the initiating focus is above the bundle of His, the QRS complex will be narrow. If it is below the bundle of His, the QRS complex will be wide.[42]

If the heartbeat originates from the AV nodal area (junctional pacemaker), the heart rate is approximately 45–60 beats/minute, the hemodynamics are stable, and the heart rate increases in response to exercise and atropine. If the heartbeat originates from the junctional pacemaker, atropine may improve conduction through the AV node by reducing vagal tone via receptor blockade.[42]

If the pacemaker is below the AV node (His bundle) the heart rate is <45 beats/minute, the hemodynamics are not stable, and the heart will not increase with exercise or atropine. Using atropine when the block is below the AVN may lead to an increased atrial rate. This increase in atrial rate may lead to a greater degree of block

and a slower ventricular rate. Atropine is unlikely to be successfully used with wide-complex bradyarrhythmias, where the level of the block is below the level of the AV node.[42]

The signs and symptoms of 3° AVB are the same as those in symptomatic SB, except that 3° AVB can be more ominous, especially when associated with broad and bizarre QRS complexes. If an AV junctional or ventricular escape rhythm does not take over following a sudden onset of 3° AVB, asystole will occur. This results in faintness, followed within seconds by a loss of consciousness and death if an escape pacemaker does not respond.[26] If the block is above the bundle of His, symptoms are minimal and are related to hypoperfusion. These symptoms include fatigue, dizziness, impaired exercise tolerance, and chest pain.[42] If the block is below the bundle of His, which is more common, the symptoms are more profound, and include syncope, confusion, dyspnea, severe chest pain, and sudden death.[42]

Some of the symptoms may be related to the cause of the 3° HB, and not the block itself. Some AMI symptoms include chest pain, dyspnea, nausea or vomiting, and diaphoresis. CHF usually causes a decrease in cardiac output, and the associated symptoms include tachypnea, respiratory distress, crackles, jugular venous distension, altered mental status, hypotension, lethargy, anxiety, diaphoresis, and a pale or pasty complexion.[42]

Blood work cannot detect 3° AVB, but can detect other etiologies (i.e., digoxin toxicity, AMI, and electrolyte imbalance). A chest x-ray can show evidence of cardiomyopathy or valvular disease. An echocardiogram to determine LV function can help identify if a pacemaker or defibrillator needs implantation.[42]

The best diagnostic tool to diagnose 3° AVB is an ECG. The ECG demonstrates that no P waves are causing QRS complexes. The P–P and R–R intervals are regular, and the atrial rate is faster than the ventricular rate. See **Table 14-19**. Analyzing the morphology of the QRS complex is helpful to determine whether the block is within the AV node (narrow QRS complexes), the bundle of His (wide QRS complexes), or bundle branches (wide QRS complexes). If the patient has a history of CAD or if the ECG shows signs of ischemia or MI, cardiac enzyme levels need checking, a stress test performed, and a cardiac catheterization considered. Diagnostic EP studies assess AV conduction and discern the level of block (AV nodal or infranodal) when necessary.[42]

A new-onset 3° AVB is considered a medical emergency, and treatment depends on the level of the block. One mistake commonly made is to treat the arrhythmia by evaluation of the heart rate and blood pressure rather than the symptoms and level of the block.[42]

If the cause of the 3° HB is from an inferior wall MI, and there are no symptoms, there is very little immediate risk, even with a heart rate of 35 beats/minute. However, if the cause is an acute anterior wall MI, there

TABLE 14-18
Etiologies for Third-Degree AV Block

General Etiology	Specific Causes
Degenerative diseases	Lenegre disease Lev disease Noncompaction cardiomyopathy Nail-patella syndrome Mitochondrial myopathy
Drugs	Class Ia antiarrhythmic agents • Quinidine • Procainamide • Disopyramide Class Ic antiarrhythmia agents • Flecainide • Encainide • Propafenone Class II antiarrhythmia agents • Beta-blockers Class III antiarrhythmia agents • Amiodarone • Sotalol • Dofetilide • Ibutilide Class IV antiarrhythmia agents • Calcium channel blockers Digoxin or other cardiac glycosides
Iatrogenic	AO valve surgery Septal alcohol ablation Percutaneous coronary intervention of left anterior descending artery
Infectious diseases	Rheumatic fever *Aspergillus* myocarditis Varicella-zoster virus infection Valve ring abscess Lyme borreliosis *Trypanosoma cruzi* infection
Infiltrative processes	Amyloidosis Sarcoidosis Tumors Hodgkin disease Multiple myeloma
Metabolic disorders	Hypoxia Hyperkalemia Hypothyroidism
Neuromuscular disorders	Becker muscular dystrophy Myotonic muscular dystrophy
Phase 4 block	Also known as bradycardia-related block
Rheumatic diseases	Ankylosing spondylitis Reiter syndrome Relapsing polychondritis Rheumatoid arthritis Scleroderma
Toxins	"Mad" honey (grayanotoxin) Cardiac glycosides

Data from Budzikowski A. Third-Degree Atrioventricular Block: Background, Pathophysiology, Etiology. Emedicinemedscapecom. 2015.

TABLE 14-19
Diagnostic Criteria for Third-Degree AV Block (Complete AVB)

Criteria	Findings
Origin of arrhythmia	Complete failure of conduction between the atria and ventricles
Heart rate	Underlying rhythm
Regularity	Regular
P waves	Upright (Lead II), f or F waves
PR interval	Variable
Conduction ratio	Atrial rate and the ventricular rate are independent of each other; therefore, there is no conduction ratio
QRS width	Usually >0.12 seconds

Data from Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.

is an immediate danger of asystole, and preparation for pacing the heart is needed.[42]

The medications taken by the patient need reviewing as they may be the cause of the block. If the cause of the 3° AVB is calcium channel blocker toxicity, a temporary pacemaker may be necessary. Also, the administration of IV fluids, calcium, glucagons, vasopressors, and high-dose insulin (hyperinsulinemic euglycemia [HIE] therapy) may also be necessary. Overdoses of beta-blockers are managed similarly to overdoses of calcium channel blockers, although HIE therapy for beta-blocker overdoses is less established.[42]

If the 3° AVB is symptomatic or associated with repeated pauses, inadequate escape rhythm, or block below the AV node, TCP is the best initial treatment. If TCP is not successful, a transvenous pacemaker is necessary.[42] Implantation of a permanent pacemaker or defibrillator is a possibility, and the guidelines for device-based therapy of cardiac rhythm abnormalities is useful in making that determination.[43]

In a 3° AVB with hemodynamic instability, atropine is used cautiously. In these cases, atropine reduces the vagal tone via receptor blockade, and the heart rate increases in 2–4 minutes. If the block is in the bundle of His, atropine may lead to an increase in atrial rate, and may cause a greater degree of block without increasing the heart rate. Atropine is usually unsuccessful when the level of the block is below the AV node. If an AMI is the cause of the 3° HB, atropine could lead to more serious problems.[42]

The main risk factors for a complete heart block are preexisting heart disease and advancing age. Other risk factors include heart failure, coronary heart disease, cardiomyopathy, sarcoidosis, degenerative muscle disorders, Lev and Lenegre disease, exposure to toxic substances, and certain medications (digitalis).[44] Complications of 3° AVB include reduced cardiac output, circulatory impairment, heart failure, SCD, excessive urea in the blood (uremia), and low blood hemoglobin (anemia). If a pacemaker is inserted, the complications from this include infection, medication reaction, malposition of the pacemaker leads, and failure of the pacemaker. When 3° AVB is treated with a pacemaker, prognosis is good. There is usually an improvement of symptoms within a month of implantation.[42]

KNOWLEDGE CHECK QUESTIONS

1. True or False: A re-entry tachycardia usually has a heart rate of >100 beats/minute.
2. True or False: Decreased sympathetic tone and increased vagal tone lead to ST.
3. True or False: The fast-conducting pathway in AVNRT has a rapid conduction rate but a slow refractory time.
4. True or False: All accessory pathways in AVRT have the same rates of conduction and refractory periods.
5. True or False: AF has an atrial depolarization rate of 160–180 beats/minute.
6. True or False: The most common conduction ratio in atrial flutter is 2:1.
7. True or False: Mobitz I or Wenckebach has a progressive delay after each P wave until there is a dropped beat.
8. True or False: Mobitz II blocks are more likely to progress to a complete heart block.

Chapter Summary

The heart has electrical and mechanical activity. Before the mechanical action can happen, there must be electrical activity. This electrical activity is known as an action potential and is caused by potassium, sodium, calcium, and chloride. The action potential has five phases. Phase 1 is depolarization, Phase 4 is resting, and the other three phases are repolarization. The two types of cardiac cells are the pacemaker cells and the contractile cells. The native primary pacemaker of the heart is the SA node, and it will pace the heart at 60–100 beats/minute.

When the heart depolarizes and repolarizes, the heart is in NSR; when it does not, there will be an arrhythmia. Some of the arrhythmias can be life threatening and require immediate treatment.

The life-threatening arrhythmias are VF, VTach, PEA, and asystole. Others arrhythmias are not immediately life threatening but need to be treated to prevent them from causing a problem or becoming life threatening. These arrhythmias are ST, AF, AV nodal re-entry tachycardia, AV re-entry tachycardia, first-degree heart block, second-degree heart block Type I, second-degree heart block Type II, and third-degree heart block.

Etiologies/risk factors for arrhythmias are age, CAD, inflammation, infections, heart surgery, valve problems, valve replacement, smoking, hypoxia, hyperlipidemia, cardiomyopathies, hypertension, obesity, medication, illicit drug use, and/or MI. The prevalence and incidence of these arrhythmias range from 100,000 per year for VF to 2.7–6.1 million for AF.

The symptoms for these arrhythmias can be asymptomatic, light headedness, syncope, palpitations, chest pain, dyspnea, and/or tachyarrhythmia. These arrhythmias and their etiologies are diagnosed with a 12-lead ECG, echocardiogram, blood tests, EPSs, stress tests, nuclear studies, ambulatory cardiac monitoring, and/or heart catheterizations. The treatment of these arrhythmias can be medications, pacemaker or defibrillator implantation, RFA, monitoring, and/or coronary angioplasty. The complications from these arrhythmias can be death, developing a more serious arrhythmia, MI, blood clots, stroke, hemodynamic compromise, and/or CHF.

Key Points

1. The heart has to have an action potential to have a contraction.
2. Ions are responsible for the action potential.
3. Anything that can cause an electrolyte imbalance or electrical conduction problem may lead to an arrhythmia.
4. Some arrhythmias can be life threatening if not treated immediately.
5. Some arrhythmias may become life threatening if not treated appropriately and promptly.
6. The prevalence of some arrhythmias is 2.7–6.1 million per year.
7. Causes of arrhythmias can range from age to MIs.
8. Noninvasive and invasive tests are used to diagnose arrhythmias.
9. Treatment can be from monitoring the patient to coronary angioplasty.
10. Symptoms can be from none to chest pain to death.
11. Complications can range from death to blood clots.
12. Prognosis will depend on each of the risk factors of the individuals.

Chapter Questions

1. The electrolytes used by the heart muscle include _____.
   a. sodium
   b. chloride
   c. calcium
   d. all of the above
2. The resting voltage of a contractile myocardial cell is _____.
   a. −90 mV
   b. −70 mV
   c. +30 mV
   d. −25 mV
3. The primary pacemaker of the heart is the _____.
   a. bundle branch
   b. bundle of Kent
   c. SA node
   d. Atrioventricular (AV) node
4. How many phases are there to the action potential?
   a. 2
   b. 3
   c. 4
   d. 5
5. Pacemaker cells have automaticity. In which phase does the calcium slowly move into the cells?
   a. 5
   b. 4
   c. 2
   d. 0
6. Of the problems listed below, which one is a cause for ventricular fibrillation (VF)?
   a. Hypertension
   b. Low cholesterol
   c. Hypotension
   d. Sinus tachycardia (ST)
7. Which of the following has an increased risk for VF?
   a. Short QRS duration
   b. Myocardial infarction
   c. Wide R-to-R interval
   d. Prolonged PR interval
8. Which risk factors listed below will cause ventricular tachycardia (VTach)?
   a. Cardiomyopathy
   b. Heart failure
   c. Cocaine use
   d. All of the above
9. Which of the arrhythmias listed below is considered a supraventricular tachycardia?
   a. Normal sinus rhythm
   b. VTach
   c. Atrial fibrillation (AF)
   d. Junctional escape

10. Which of the conditions listed below is a cause of ST?
- **a.** Hypervolemia
- **b.** Hyperthyroidism
- **c.** Hyperglycemia
- **d.** Tobacco use

11. What is the major concern in patients with AF?
- **a.** Thrombus formation
- **b.** Reduced cardiac output
- **c.** Decreased preload
- **d.** Decreased afterload

12. The classifications of AF include which of the following?
- **a.** Acute AF
- **b.** Paroxysmal AF
- **c.** Persistent AF
- **d.** All of the above

13. AV re-entry tachycardia (AVRT) is a result of an accessory pathway, which develops in what part of the cardiac anatomy?
- **a.** Intraventricular septum
- **b.** Intra-atrial septum
- **c.** Atrioventricular septum
- **d.** AV node and ventricles

14. How many accessory pathways are there that lead from the right atrium to the AV node in AV nodal re-entry tachycardia?
- **a.** 3
- **b.** 2
- **c.** 5
- **d.** 4

15. The most common site for a first-degree heart block is in which part of the heart?
- **a.** Bundle branches
- **b.** Bundle of His
- **c.** Purkinje fibers
- **d.** AV node

16. What is the contributing factor that will initiate AVRT?
- **a.** Premature ventricular contraction
- **b.** Premature atrial contraction
- **c.** ST
- **d.** VF

17. What device can be implanted to treat VF?
- **a.** Implantable cardioverter defibrillator
- **b.** Dual-chamber pacemaker
- **c.** Biventricular pacemaker
- **d.** None of the above

18. Which patient population has a higher risk of developing second-degree AV blocks?
- **a.** Young adults
- **b.** Women
- **c.** Highly trained athletes
- **d.** Children

19. Treatment for AF includes which of the following?
- **a.** Biventricular pacemaker
- **b.** Pulmonary vein isolation
- **c.** Defibrillation
- **d.** Implantable cardioverter defibrillator

20. The first-line diagnostic tool used to identify a third-degree AV block is _____.
- **a.** blood work
- **b.** heart catheterization
- **c.** electrocardiography
- **d.** electrophysiology studies

References

1. Garcia T, Miller G. *Arrhythmia Recognition*. Sudbury, MA: Jones and Bartlett Publishers; 2004.
2. Abnormal Heart Rhythms (Arrhythmias). WebMD. 2016. http://www.webmd.com/heart-disease/guide/heart-disease-abnormal-heart-rhythm. Accessed September 3, 2015.
3. *ACLS Provider Manual Supplementary Material*. 1st ed. Dallas, TX: American Heart Association; 2012.
4. Klabunde R. CV physiology: sinoatrial node action potentials. 2015. http://cvphysiology.com/Arrhythmias/A004.htm. Accessed September 3, 2015.
5. Goyal S. Ventricular fibrillation: background, pathophysiology, etiology. 2014. http://emedicine.medscape.com/article/158712-overview. Accessed March 24, 2018.
6. Mayo Clinic Staff. Ventricular Fibrillation Symptoms—Mayo Clinic. 2017. http://www.mayoclinic.org/diseases-conditions/ventricular-fibrillation/basics/symptoms/con-20034473. Accessed March 24, 2018.
7. Conover MD. *Understanding Electrocardiography*. St Louis, MO: Mosby; 2002.
8. Ventricular Fibrillation. Information about VF | Patient. 2014. http://patient.info/doctor/ventricular-fibrillation. Accessed March 24, 2018.
9. Compton S. Ventricular Tachycardia: Practice Essentials, Background, Pathophysiology. 2017. http://emedicine.medscape.com/article/159075-overview. Accessed March 24, 2018.
10. Prust M, Stevenson W, Lilly L. Clinical aspects of cardiac arrhythmias. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2016: 287–309.
11. Akdeniz C, Ozyilmaz I, Saygi M, Ergul Y, Tuzcu V. Idiopathic ventricular arrhythmias detected by an implantable loop recorder in a child with exercise-induced syncope. *Tex Heart Inst J*. 2013;40(3):347–349.
12. Baher A, Valderrabano M. Management of ventricular tachycardia in heart failure. *Methodist DeBakey Cardiovasc J*. 2013;9(1):20–25. doi:10.14797/mdcj-9-1-20.
13. Shah S. Pulseless Electrical Activity: Background, Etiology, Epidemiology. 2017. http://emedicine.medscape.com/article/161080-overview. Accessed March 25, 2018.
14. Littmann L, Bustin D, Haley M. A simplified and structured teaching tool for the evaluation and management of pulseless electrical activity. *Med Princ Pract*. 2014;23(1):1–6. doi:10.1159/000354195.
15. *Advanced Cardiovascular Life Support*. Dallas, TX: American Heart Association; 2015.
16. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults. *JAMA*. 2006;295(1):50. doi:10.1001/jama.295.1.50.

17. Meaney P, Nadkarni V, Kern K, Indik J, Halperin H, Berg R. Rhythms and outcomes of adult in-hospital cardiac arrest. *Crit Care Med*. 2010;38(1):101–108. doi:10.1097/ccm.0b013e3181b43282.
18. Shah SN. Asystole. 2015. http://emedicine.medscape.com/article/757257-overview. Accessed March 25, 2018.
19. Engdahl J, Bång A, Lindqvist J, Herlitz J. Can we define patients with no and those with some chance of survival when found in asystole out of hospital? *Am J Cardiol*. 2000;86(6):610–614. doi:10.1016/s0002-9149(00)01037-7.
20. Lauro J. Dysrhythmias. In: Aghababian R, ed. *Essentials of Emergency Medicine*. 2nd ed. Sudbury, MA: Jones & Bartlett Learning; 2011:138–153.
21. Testori C, Sterz F, Behringer W, et al. Mild therapeutic hypothermia is associated with favorable outcome in patients after cardiac arrest with non-shockable rhythms. *Resuscitation*. 2011;82(9):1162–1167. doi:10.1016/j.resuscitation.2011.05.022.
22. Orejarena LA, Vidaillet H Jr, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. *J Am Coll Cardiol*. 1998;31(1):150–157.
23. Olshansky B, Chung Mk, Pogwizd SM, Goldschlager N. *Arrhythmia Essentials*. Sunbury, MA: Jones & Bartlett Learning; 2012.
24. Hottigoudar R, Gopinathannair R. 'Inappropriate' sinus tachycardia: does the 100 beats per min cut-off matter? *Future Cardiol*. 2013;9(2):273–288. doi:10.2217/fca.13.5.
25. Wesley K. *Huszar's Basic Dysrhythmias and Acute Coronary Syndromes: Interpretation and Management.* St. Louis, MO: Elsevier; 2011.
26. Mitchell LB. Atrial Fibrillation. *Merck Manuals Professional Edition*. 2018. https://www.merckmanuals.com/professional/cardiovascular-disorders/arrhythmias-and-conduction-disorders/atrial-fibrillation-af. Accessed March 24, 2018.
27. Helton M. Diagnosis and management of common types of supraventricular tachycardia. *Am Fam Physician*. 2015;92(9):793–800.
28. Gugneja M. Paroxysmal Supraventricular Tachycardia. 2017. http://emedicine.medscape.com/article/156670-overview#a6. Accessed March 25, 2018.
29. Ellis C. Wolff-Parkinson-White Syndrome: Practice Essentials, Background, Pathophysiology. 2017. http://emedicine.medscape.com/article/159222-overview#a1. Accessed March 24, 2018.
30. Alaeddini J. First-Degree Atrioventricular Block: Background, Pathophysiology, Etiology. 2015. http://emedicine.medscape.com/article/161829-overview. Accessed March 24, 2018.
31. Center for Disease Control and Prevention. Atrial Fibrillation Fact Sheet| Data & Statistics| DHDSP| CDC. 2017. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm. Accessed March 25, 2018.
32. Miyazaki S, Shah A, Scherr D, Haïssaguerre M. Atrial fibrillation: pathophysiology and current therapy. *Ann Med*. 2011;43(6):425–436. doi:10.3109/07853890.2011.554426.
33. Rosenthal L. Atrial Fibrillation. 2017. http://emedicine.medscape.com/article/151066-overview#a3. Accessed March 25, 2018.
34. Aryana A, Singh S, Kowalski M, et al. Acute and long-term outcomes of catheter ablation of atrial fibrillation using the second-generation cryoballoon versus open-irrigated radiofrequency: a multicenter experience. *J Cardiovasc Electrophysiol*. 2015;26(8):832–839. doi:10.1111/jce.12695.
35. Wasserlauf J, Pelchovitz D, Rhyner J, et al. Cryoballoon versus radiofrequency catheter ablation for paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol*. 2015;38(4):483–489. doi:10.1111/pace.12582.
36. Rosenthal L. Atrial Flutter: Practice Essentials, Background, Pathophysiology. 2017. http://emedicine.medscape.com/article/151210-overview. Accessed March 25, 2018.
37. Olshansky B. Atrioventricular Nodal Reentry Tachycardia: Background, Etiology, Epidemiology. 2017. http://emedicine.medscape.com/article/160215-overview#a6. Accessed March 24, 2018.
38. Barold S, Ilercil A, Leonelli F, Herweg B. First-degree atrioventricular block. Clinical manifestations, indications for pacing, pacemaker management & consequences during cardiac resynchronization. *J Interv Card Electrophysiol*. 2006;2(17):139–152.
39. Cheng S. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. *JAMA*. 2009;301(24):2571. doi:10.1001/jama.2009.888.
40. Sovari A. Second-Degree Atrioventricular Block: Practice Essentials, Background, Pathophysiology. 2017. http://emedicine.medscape.com/article/161919-overview#a5. Accessed March 24, 2018.
41. Budzikowski A. Third-Degree Atrioventricular Block: Background, Pathophysiology, Etiology. 2015. http://emedicine.medscape.com/article/162007-overview. Accessed March 24, 2018.
42. Tracy C, Epstein A, Darbar D, et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Heart Rhythm*. 2012;9(10):1737–1753. doi:10.1016/j.hrthm.2012.08.021.
43. Heart Block—Who Is at Risk for Heart Block? | National Heart, Lung, and Blood Institute (NHLBI). 2018. https://www.nhlbi.nih.gov/node/4310. Accessed March 24, 2018.
44. Mayo Clinic Staff. Tachycardia. 2018. https://www.mayoclinic.org/diseases-conditions/tachycardia/symptoms-causes/syc-20355127. Accessed March 24, 2018.

CHAPTER

15

Heart Failure

"A rude unhinging of the machinery of life."

—Thomas Edison, The Gross Clinic, 1875

OUTLINE

OBJECTIVES

1. State the working definition of heart failure (HF).
2. Outline the incidence, prevalence, and risk factors for HF.
3. Discuss the etiologies of HF.
4. Compare and contrast left-side and right-side HF.
5. Define and discuss secondary problems associate with HF.
6. Predict the clinical manifestations of a patient with HF.
7. Explain diagnostic testing used to identify HF.
8. Summarize the recommended management strategies for patients with HF.
9. Identify common complications associated with HF.
10. Discuss the prognosis of the different types of HF.

KEY TERMS

Acute pericarditis
Afterload
AHA/ACC classification system
Alcohol septal ablation (ASA)
Alcoholic dilated cardiomyopathy (ACM)
Aortic insufficiency (AI)
Aortic stenosis (AS)
Atrial septal defects (ASD)
Cardiac tamponade
Concentric hypertrophy
Constrictive pericarditis
Contractility
Dilated cardiomyopathy (DCM)
Eccentric hypertrophy
Heart failure (HF)
Holosystolic murmur
Hypertrophic cardiomyopathy
Hypertrophic obstructive cardiomyopathy (HOCM)
Idiopathic dilated cardiomyopathy (IDCM)
Ischemic dilated cardiomyopathy (ICM)
Ischemic heart disease
Kussmaul sign
Left heart failure
Left-sided heart failure
Left ventricular ejection fraction (LVEF)
Left ventricular hypertrophy (LVH)
Left ventricular outflow tract (LVOT)

Mitral regurgitation (insufficiency) (MR)
Mitral stenosis (MS)
Nonrestrictive VSDs
New York Heart Association (NYHA) functional classification
Ostium primum defect
Ostium secundum defect
Pericardial effusion
Pericarditis
Preload
Pulmonary stenosis (PS)
Pulmonic regurgitation (insufficiency) (PI)
Renin-angiotensin-aldosterone system (RAAS)
Restrictive cardiomyopathy (RCM)
Restrictive VSDs
Right heart failure
Septal myomectomy
Sinus venosus defect
Subacute pericarditis
Tricuspid regurgitation (TR)
Tricuspid stenosis (TS)
Ventricular septal defect (VSD)

Case Study

A 45-year-old-male office worker presents to the emergency department complaining of shortness of breath. Physical examination reveals the patient is slightly short of breath. The patient's vital signs are blood pressure (BP) 110/65, respirations 23 breaths/minute, heart rate 106 beats/minute, temperature 98.4°F. The patient's height is 73 inches, weight 295 pounds, and body mass index 39. Auscultation reveals S_3 heart murmurs, fine crackles over the posterior lung bases, and no carotid bruit. The electrocardiogram (ECG) shows a left bundle branch block (LBBB) and left atrial enlargement (LAE; **Figure 15-1**).

The patient's history reveals that he is a nonsmoker, does not use illicit drugs, but has been drinking about a 12 pack of beer a day for the last 8–10 years. The patient admitted to no exercise with a favorite pass time of television sports.

His shortness of breath began a few months ago. At that time, he noticed that walking around at work caused him shortness of breath. Also, he noticed a bit of weight gain. His shoes became tight, and he had to sleep with three pillows to avoid shortness of breath (three-pillow orthopnea).



FIGURE 15-1 An ECG showing LAE and LBBB.

Heart Failure

Heart failure (HF) is present when a weakened heart muscle is unable to pump enough oxygenated blood to meet the metabolic demands of the body. As a result, the body does not receive a sufficient amount of oxygenated blood.[1] HF is a clinical syndrome rather than a specific disease entity. HF can affect either the left or the right ventricle (RV) or both. Left ventricular (LV) failure, or left HF, is the most common type of HF. The most common cause of right-side HF is left-side HF.[2]

According to statistics from 2007 to 2010, approximately 5.1 million people in the United States have HF. In 2009, 1 in 9 deaths was from HF. HF costs $32 billion a year in the United States.[3] Numerous conditions or disease processes can cause HF.[4] These cardiac diseases may include cardiomyopathy, valvular heart disease, congenital malformations, **ischemic heart disease**,

myocardial infarction (MI), and hypertension.[5] This chapter reviews HF in general, and cardiomyopathy, valvular heart disease, congenital heart disease, pericardial disease, and hypertension as causes of HF. Chapter 16 addresses ischemic heart disease and MI.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Hypertension does not lead to HF.
2. True or False: HF may be isolated to one side of the heart.

Definition and Diagnosis

HF is a syndrome characterized by an inability of the heart to pump enough blood to meet the metabolic needs of the body.[1] **Figure 15-2** shows that the heart has four chambers: two atria and two ventricles. The LV pumps blood into the peripheral circulatory system, and the RV pumps blood into the pulmonary system. Veins bring blood back to the heart and arteries take blood away from the heart. This is a closed system, meaning the blood circulates inside this closed system repeatedly, picking up oxygen in the lungs and bringing it to the organs and peripheral tissues.

HF results from the heart's inability to fill with blood (diastolic dysfunction) or the inability of the heart to pump blood to the body (systolic dysfunction). This problem can affect the left side of the heart (**left heart failure**), the right side of the heart (**right heart failure**), or both sides of the heart.[1] **Figure 15-3** breaks down the heart into a series of interconnected pumps and tubing. This figure shows the four chambers of the heart in sequence. The two smaller pumps represent the atria, and the larger pumps represent the ventricles. The ventricles differ in size and in the pressure they can generate to pump the blood forward.

HF is a progressive disorder that results from a weakened heart muscle. This weakening is a consequence of an underlying cardiac issue.[6] Identification of the underlying cardiac problem and its cause is crucial for proper treatment. Causes of these cardiac problems involve circulation, the pulmonary and neuroendocrine systems, and other organs.[6] HF can occur acutely, as with endocarditis or MI. HF can also be a result of insults the heart has received over the course of an individual's life.[6]

The main terminology used to identify left HF relies on the measurement of **left ventricular ejection fraction (LVEF)**. The ejection fraction (EF) is the percentage of blood pumped out with each LV contraction. It is equal to the volume in the LV at the end of diastole minus the volume in the LV at the end of systole divided by the volume in the LV at the end of diastole. The EF categorizes two types of HF. One type has a reduced EF, HF-REF. The second type has preserved EF (PEF), which is more difficult to diagnose than HF-REF.[6] **Table 15-1** describes the conditions needed to diagnose HF-REF and HF-PEF.

The diagnostic tests to identify HF include chest x-ray (CXR), blood work, heart catheterization, echocardiogram, electrocardiogram (ECG), treadmill exercise stress test, and a tracer study.

Two methods are used to classify HF. The term HF describes the symptomatic syndrome, graded according to the **New York Heart Association (NYHA) functional classification**. The **AHA/ACC classification system** utilizes the progressiveness of HF and its risk factors. The AHA/ACCF scale allows an individual to move in both directions as their symptoms improve.[7] Both classification methods appear side by side for comparison in **Box 15-1**.



FIGURE 15-2 The heart as a pump.



FIGURE 15-3 Simplified pump function of the normal heart. LA, left atrium; RA, right atrium. (Blue represents deoxygenated blood; red represents oxygenated blood.)

TABLE 15-1
Diagnostic Criteria for Heart Failure

Type of HF		HFrEF	HFmrEF	
CRITERIA	1	Symptoms ± Signs[a]	Symptoms ± Signs[a]	Symptoms ± Signs[a]
	2	LVEF <40%	LVEF 40 - 49%	LVEF ≥50%
	3	-	1. Elevated levels of natriuretic peptides[b]; 2. At least one additional criterion: a. relevant structural heart disease (LVH and/or LAE), b. diastolic dysfunction (for details see Section 4.3.2).	1. Elevated levels of natriuretic peptides[b]; 2. At least one additional criterion: relevant structural heart disease (LVH and/or LAE), diastolic dysfunction (for details see Section 4.3.2).

BNP = B-type natriuretic peptide; HF = heart failure; HFmrEF = heart failure with mid-range ejection fraction; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; LAE = left atrial enlargement; LVEF = left ventricular ejection fraction; LVH = left ventricular hypertrophy; NT-proBNP = N-terminal pro-B type natriuretic peptide.

[a]Signs may not be present in the early stages of HF (especially in HFpEF) and in patients treated with diuretics.

[b]BNP > 35 pg/ml and/or NT-proBNP > 125 pg/mL.

Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, *Eur Heart J.* 2016:37(27): 2129–2200. doi:10.1093/eurheartj/ehw128

BOX 15-1 Comparison of HF Classifications[7]

American Heart Association/American College of Cardiology (AHA/ACC)

Stage A—High risk for HF but without structural heart disease or symptoms of HF
Stage B—Structural heart disease but without symptoms or signs of HF
Stage C—Structural heart disease with prior or current symptoms of HF
Stage D—Refractory HF requiring special interventions

NYHA Functional Class System

Class I—No limitations of physical activity
Class II—Slight limitations of physical activity and comfortable at rest
Class III—Marked limitations of physical activity and comfortable at rest
Class IIIa—No dyspnea at rest
Class IIIb—Recent dyspnea at rest
Class IV—Inability to carry on any physical activity without discomfort and symptoms present even at rest

KNOWLEDGE CHECK QUESTIONS

1. True or False: HF occurs only when the EF is reduced.
2. True or False: The AHA/ACC use risk factors to classify HF.

Etiology

In HF, the myocardium weakens and the muscle is no longer capable of pumping blood out to the body and the lungs. This diminished capacity of the heart to eject blood causes a backup of blood. Left HF causes a backup of blood in the lungs, leading to pulmonary edema. Right HF causes a backup of blood in the periphery or venous system, leading to edema in the extremities. In some cases, the blood can back up into both the lungs and the periphery.[5] The weakening of the heart muscle is a consequence of other diseases or conditions.[1] HF is the most severe consequence of all cardiac diseases. The causes of HF are reviewed in **Box 15-2**.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Left HF causes pulmonary edema.
2. True or False: Right HF causes peripheral edema.

BOX 15-2 Causes of HF

- Cardiomyopathy
  - Dilated cardiomyopathy (DCM)
  - Hypertrophic cardiomyopathy (HCM)
  - Restrictive cardiomyopathy (RCM)
- Valvular heart disease
  - Aortic valve regurgitation and stenosis
  - Mitral valve regurgitation and stenosis
  - Pulmonic valve regurgitation and stenosis
  - Tricuspid valve regurgitation and stenosis
- Congenital heart disease
  - Ventricular septal defects (VSDs)
  - ASDs
- Pericardial disease
  - Constrictive pericarditis
  - Cardiac tamponade
- Hypertension
- Left ventricular hypertrophy (LVH)
- Ischemia

Epidemiology of HF

HF has become a major public health problem in the United States and worldwide. In 1997, HF was an emerging epidemic.[8] Currently, more than 5.8 million people in America and more than 23 million worldwide are diagnosed with HF. There are more than 550,000 new cases each year.[8] In 2009, 1 in 9 deaths included HF as a contributing cause. Within 5 years of diagnosis with HF, approximately 50% die.[9] The AHA projected that by the year 2030, the prevalence of HF is expected to increase 25% from the 2013 estimates.[9] The total direct medical cost for HF in 2012 was $20.9 billion. This is expected to increase to $53.1 billion by 2030.[9] The total indirect cost in 2012 was $9.8 billion and is expected to be $16.6 billion by 2030.[10] HF among the different racial and ethnic groups is expected to increase substantially by 2030. The largest increase is projected to be in the black population (29%) followed by the white non-Hispanic population. The lowest increases are expected in the white Hispanic population. The rate of HF among men and women is expected to grow similarly; however, men have a higher prevalence than women.[10]

KNOWLEDGE CHECK QUESTIONS

1. True or False: By the year 2030, the total direct medical cost for HF is expected to be less than $10 billion.
2. True or False: Men have a higher prevalence for HF than women.

Pathophysiology of HF

Numerous diseases/conditions can cause HF. The pathophysiology, clinical manifestations, diagnostic testing, complications, risk factors, and prognosis for each cause of HF are unique. Whatever the etiology, the consequence is either left-sided HF, or right-sided HF, or both.

The three determinants of ventricular function include **preload**, **afterload**, and **contractility** (**Box 15-3**). Preload is the amount of ventricular stretch at the end of diastole, just before the initiation of contraction. The measurement of preload is left ventricular end-diastolic pressure (LVEDP). Afterload is the amount of resistance

BOX 15-3 Determinants of Ventricular Function or Stroke Volume

- Preload
- Afterload
- Contractility



FIGURE 15-4 Normal diastole and systole.
© udaix/Shutterstock.

the heart needs to overcome to open the aortic valve and pump out blood volume into the systemic circulation. It is the forces that oppose ejection of blood out of the ventricle and is the systemic vascular resistance (SVR). Contractility refers to the internal strength of the ventricle to squeeze the blood out of its chamber.

Left-sided heart failure is a result of impaired LV function. **Figure 15-4** shows normal diastole and systole. Impaired cardiac muscle contractility will cause systolic dysfunction and impaired diastolic filling results in diastolic dysfunction.[10] In either case, the blood volume that remains in the LV after contraction ends increases, resulting in an increase in the LVEDP or preload. However, in hypertrophic obstructive cardiomyopathy, RCM, or mitral stenosis (MS), the LV pressure decreases, reducing preload.[11]

A systolic problem results from LV myocardium weakness or overstretch. This causes a contractile impairment. In either case, the blood volume in the LV increases, ultimately causing the LV to dilate. The blood backs up into the LA, pulmonary veins, and lungs, eventually causing pulmonary edema. **Figure 15-5** shows pulmonary edema caused by left-sided HF. Typically, this occurs in males between 50 and 70 years who have had a MI.[12]

A diastolic problem results from the muscle of the LV becoming stiff and noncompliant, restricting ventricular filling. In restricted ventricular filling, the myocardium cannot relax to accept the optimal amount of blood. The results lead to a backup of blood in the lungs and pulmonary edema. Women, overweight individuals, and elderly, with high BP and diabetes, most often have diastolic HF. MS is another cause of restricted filling and diastolic HF.[12]

Right-sided HF in most cases results from left-sided HF. When the right side fails, blood backs up into the systemic venous system, causing venous congestion.[12] Consequently, the patient has swollen legs, liver enlargement, and jugular vein distention (JVD).[12] Pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD) are other common causes of right-sided HF.[12] **Figure 15-6** shows systemic edema caused by right HF. **Table 15-2** demonstrates the pathophysiology of HF with clinical examples.

Although pump failure is a key component of HF, the progression of the disease and exacerbations of acute HF are manifestations of maladaptive neurohormonal responses that occur during HF. These neurohormonal responses include activation of the sympathetic nervous system, the **renin–angiotensin–aldosterone system (RAAS)**, and antidiuretic hormone. One of the first responses to decreasing cardiac output is the activation of the sympathetic nervous system to release norepinephrine, in an attempt to improve cardiac output. Norepinephrine is also a potent vasoconstrictor that keeps



FIGURE 15-5 Pulmonary edema caused by left-sided HF, resulting in fluid buildup in the alveolar spaces.



FIGURE 15-6 Systemic edema due to right HF.

organ perfusion stable. Activation of the RAAS also promotes vasoconstriction, and increasing levels of antidiuretic hormone promote water reabsorption. Also, the atrial natriuretic peptide (NP) is increased. These neurohormonal responses are beneficial in the short term but are deleterious in the long term. These effects can aggravate HF by increasing ventricular afterload, which depresses stroke volume and increases

TABLE 15-2
Pathophysiology of HF with Clinical Examples

Pathophysiology	Explanation	Clinical Examples
Contractility impairment	The myocardium is unable to increase the strength of contraction independent of the preload and afterload.	• DCM • Ischemia • Myocarditis
Restricted filling	There is decrease in the compliance of the ventricle, causing an inability to fill.	• RCM • HCM • MS • Tricuspid stenosis (TS) • Constrictive pericarditis • Cardiac tamponade
Pressure overload	A sustained increase in afterload ≥160 mm Hg causes a decrease in cardiac output.	• Aortic stenosis (AS) • Pulmonary stenosis (PS) • Systemic hypertension • Pulmonary embolism • PH
Volume overload	Progressive regurgitation of blood back into the atria or ventricle (or between atria or ventricles) causes decreased cardiac output.	• Mitral regurgitation (MR) • Aortic regurgitation • Pulmonary regurgitation • Tricuspid regurgitation (TR) • Septal defects
Arrhythmia	Rates too fast or too slow decrease cardiac output.	• Tachycardia • Bradycardia

preload to the point of pulmonary and/or systemic congestion and edema.[13]

HF is typically a chronic disease with several natural compensatory mechanisms. Acute HF is life threatening. It may develop in a previously asymptomatic patient with acute coronary syndrome or acute valvular regurgitation. Additionally, it can complicate chronic HF. In either case, it requires hospitalization and prompt interventions.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Afterload is the amount of ventricular stretch at the end of diastole.
2. True or False: Preload is measured using LVEDP.
3. True or False: A sustained increase in afterload of more than 160 mm Hg causes a decrease in cardiac output.

TABLE 15-3
Signs and Symptoms Typical of Heart Failure

Symptoms	Signs
Typical	**More Specific**
Breathlessness Orthopnoea Paroxysmal nocturnal dyspnea Reduced exercise tolerance Fatigue, tiredness, increased time to recover after exercise Ankle swelling	Elevated jugular venous pressure Hepatojugular reflux Third heart sound (gallop rhythm) Laterally displaced apical impulse
Less Typical	**Less Specific**
Nocturnal cough Wheezing Bloated feeling Loss of appetite Confusion (especially in the elderly) Depression Palpitations Dizziness Syncope Bendopnea	Weight gain (>2 kg/week) Weight loss (in advanced HF) Tissue wasting (cachexia) Cardiac murmur Peripheral oedema (ankle, sacral, scrotal) Pulmonary crepitations Reduced air entry and dullness to percussion at lung bases (pleural effusion) Tachycardia Irregular pulse Tachypnoea Cheyne Stokes respiration Hepatomegaly Ascites Cold extremities Oliguria Narrow pulse pressure

HF = heart failure.

Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur Heart J.* 2016:37(27): 2129–2200. doi:10.1093/eurheartj/ehw128

Clinical Manifestations

Regardless of the cause of HF, some of the clinical manifestations are the same. See **Table 15-3**. Each disease/conditions that can cause HF have additional manifestations that are unique. The heart's ability to compensate for changing conditions hides clinical symptoms at first. When they do occur, the majority of the signs and symptoms of HF are secondary compensatory mechanisms responding to a fall in cardiac output.

The progression of HF causes fluid buildup in the pulmonary and systemic venous system. The dominant symptoms in HF are shortness of breath (dyspnea) and fatigue. Other complaints may include swelling of the extremities, weight gain, frequent urination, and a paroxysmal nocturnal cough.[1]

The physical findings of HF depend on the severity and chronicity of the condition. The lack of appetite and the increased metabolic demands of breathing can lead to the patient appearing frail or cachectic. Fluid retention leading to peripheral edema may be present in the legs or back and is most often due to right HF. Elevated filling pressures and TR may cause an enlarged liver. Right HF causes JVD via the hepatojugular reflux.



FIGURE 15-7 Clinical manifestations of both right and left HF. GI, gastrointestinal.

Auscultation of the lungs can reveal crackles heard over the bases or dependent regions of the lungs. This is indicative of pulmonary edema. The presence of pulmonary edema is a sign of acute left HF caused by elevated capillary hydrostatic pressure pushing fluid into the interstitial spaces and alveoli. Compression of the conducting airways by pulmonary congestion may produce coarse rhonchi and wheezing. Cardiac auscultation can reveal an early diastolic sound (S_3) indicative of systolic HF. A late diastolic sound (S_4) results from a diastolic dysfunction.

A thorough history and physical examination assist in the identification of HF, but most of the symptoms are nonspecific and frequently present in a host of other conditions. The most notable of those is COPD, which is a frequent confounder in the diagnosis of HF.[13] **Figure 15-7** shows the manifestations of left and right HF.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The presence of the third heart sound (S_3) is normal.
2. True or False: A diastolic dysfunction causes the fourth heart sound (S_4).
3. True or False: Left HF causes liver congestion.

Diagnostic Testing

Diagnostic testing for HF includes the measurement and monitoring of cardiac function. These tests include CXR, electrocardiography, routine laboratory evaluation, and NP assays.



FIGURE 15-8 Anteroposterior CXR of a patient with HF.

Chest Radiography

A CXR is routine in the evaluation of the patient with shortness of breath. The CXR is useful in the identification of pulmonary venous congestion, interstitial edema, alveolar edema (pulmonary edema), cardiomegaly, and pleural effusions. The presence of these increases the likelihood of HF, but it does not rule out other possibilities. Kerley B lines on a CXR indicate pulmonary venous congestion or interstitial edema due to interlobular edema. Pulmonary edema shows up as opacification of the air spaces. See **Figure 15-8**.

Electrocardiography

All suspected HF patients have an ECG done. Although the ECG is not a good predictor of HF, it is useful in determining the etiology of the HF together with other diagnostic tests. See **Table 15-4** for the common abnormalities found on the ECG with HF.[13]

Echocardiography

The echocardiogram provides immediate information on chamber volumes, ventricular systolic and diastolic function, ventricular wall thickness, and valve function.[5] Together with the ECG, it is the most useful test for patients with suspected HF. The echocardiogram is critical to the determination of appropriate therapy.

Laboratory Tests

Patients suspected of HF have blood tests that include serum electrolytes, renal function, complete blood count, and cardiac markers. **Table 15-5** summarizes the common lab tests and causes of abnormalities and their clinical implications.

Many times the signs and symptoms of patients with suspected HF are nonspecific, and the echocardiogram shows no important cardiac abnormalities. In this case, cardiac markers are vital to the diagnosis. There is a family of hormones secreted in increased amounts when the heart is diseased or the load on any chamber in increased. The NPs increase in response to LV stretch due to high filling pressures.[13] The two markers are B-type natriuretic peptide and N-terminal proB-type NP (NT-BNP). See **Figure 15-9**.

The use of NP tests in conjunction with a standard clinical evaluation can help to identify a majority of patients with HF. BNP is most useful in distinguishing acute HF from other causes of dyspnea.[13]

When HF is suspected, NP tests, or echocardiogram, or both are necessary depending on test results. **Figure 15-10** is an example of an algorithm for the diagnosis of HF using both echocardiogram and NP tests.

TABLE 15-4
Most Common Abnormalities on the ECG in HF

Abnormality	Causes	Clinical Implications
Sinus tachycardia	Decompensated HF, anemia, hyperthyroidism	Clinical assessment Laboratory investigation
Sinus bradycardia	Beta-blockade, digoxin, ivabradine, verapamil, diltiazem Antiarrhythmics Sick sinus syndrome	Review drug therapy Laboratory investigation
Atrial tachycardia/ flutter/fibrillation	Hyperthyroidism, infection, mitral valve disease Decompensated HF, infarction	Slow AV conduction, anticoagulation, pharmacologic cardioversion, electrical cardioversion, catheter ablation
Ventricular arrhythmias	Ischemia, infarction, cardiomyopathy, myocarditis, hypokalemia, hypomagnesemia Digitalis overdose	Laboratory investigation Exercise test, perfusion studies, coronary angiography, electrophysiology testing, internal cardiac defibrillator
Myocardial ischemia/ infarction	Coronary artery disease (CAD)	Echocardiogram, troponins, perfusion study, coronary angiography, revascularization
Q waves	Infarction, HCM, LBBB, pre-excitation	Echocardiogram, perfusion studies, coronary angiography
LVH	Hypertension, aortic valve disease, HCM	Echocardiogram, cardiac magnetic resonance (CMR)
AV block	Infarction, drug toxicity, myocarditis, sarcoidosis, genetic cardiomyopathy, Lyme disease	Review drug therapy, evaluate for systemic disease, family history/genetic testing indicated, pacemaker or Implantable cardioverter defibrillator (ICD) indicated
Low QRS voltage	Obesity, emphysema, pericardial effusion, amyloidosis	Echocardiogram/CMR, CXR; for amyloidosis, consider further imaging and endomyocardial biopsy
QRS duration ≥ 120 ms and LBBB morphology	Electrical and mechanical dyssynchrony	Echocardiogram Pacemaker Pacemaker/defibrillator

Reproduced from ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J.* 2012;33:1787–1847. doi:10.1093/eurheart/ehs104.

TABLE 15-5
Common Laboratory Test Abnormalities in HF

Abnormality	Causes	Clinical Implications
Renal impairment (creatinine > 150 µmol/L 1.7 mg/dL, eGFR < 60 mL/min/1.73 m^2)	Renal disease Renal congestion Angiotensin-converting enzyme (ACE) inhibitor/angiotensin-receptor blocker (ARB), Mineralocorticoid receptor antagonist (MRA) Dehydration NSAIDs and other nephrotoxic drugs	Calculate eGRF Consider reducing ACE inhibitor/ARB or MRA dosage (or postpone dose up-titration) Check potassium and BUN Consider reducing diuretic dose if dehydrated, but if there is renal congestion, more diuresis may help Review drug therapy
Anemia (<13 g/dL in men, <12 g/dL in women)	Chronic HF, hemodilution, iron loss or poor utilization, renal failure, chronic disease, malignancy	Diagnostic workup Consider treatment
Hyponatremia (<135 mmol/L)	Chronic HF, hemodilution, AVP release, diuretics (especially thiazides) and other drugs	Consider water restriction, adjusting diuretic dosage Ultrafiltration, vasopressin antagonist Review drug therapy
Hypernatremia (>150 mmol/L)	Water loss, inadequate water intake	Assess water intake Diagnostic workup
Hypokalemia (<3.4 mmol/L)	Diuretics, secondary hyperaldosteronism	Risk of arrhythmia Consider ACE inhibitor/ARB, MRA, potassium supplements
Hyperkalemia (>5.5 mmol/L)	Renal failure, potassium supplement, RAAS blockers	Stop potassium supplements/potassium-sparing diuretic Reduce dose of/stop ACE inhibitor/ARB, MRA Assess renal function and urine pH Risk of bradycardia and serious arrhythmias
Hyperglycemia (>117 mg/dL)	Diabetes, insulin resistance	Evaluate hydration, treat glucose intolerance
Hyperuricemia (>8.4 mg/dL)	Diuretic treatment, gout, malignancy	Allopurinol Reduce diuretic dose
Albumin high (>45 g/L)	Dehydration	Rehydrate
Albumin low (<30 g/L)	Poor nutrition, renal loss	Diagnostic workup
Transaminase increase	Liver dysfunction Liver congestion Drug toxicity	Diagnostic workup Liver congestion Review drug therapy
Elevated troponins	Myocyte necrosis Prolonged ischemia, severe HF, myocarditis, sepsis, renal failure	Evaluate pattern of increase (mild increases common in severe HF) Perfusion studies Coronary angiography Evaluation of revascularization
Elevated creatine kinase	Inherited and acquired myopathies	Consider genetic cardiomyopathy, muscular dystrophies Statin use
Abnormal thyroid tests	Hyper-/hypothyroidism Amiodarone	Treat thyroid abnormality Reconsider amiodarone use
Urine analysis	Proteinuria, glycosuria, bacteria	Diagnostic workup Rule out infection, diabetes
International normalized ratio > 3.5	Anticoagulant overdose Liver congestion/disease Drug interactions	Review anticoagulant dose Assess liver function Review drug therapy
CRP > 10 mg/L, neutrophilic leukocytosis	Infection, inflammation	Diagnostic workup

Reproduced from ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J.* 2012;33:1787–1847. doi:10.1093/eurheart/ehs104.



FIGURE 15-9 Flowchart for the diagnosis of acute HF with NP in patients with suggestive symptoms.
Kirk J, Diercks D, Dhingr K. Acute heart failure. In: Aghababian R, ed. *Essentials of Emergency Medicine.* 2nd ed. Sudbury, CA: Jones & Bartlett Learning; 2011:122–129.



FIGURE 15-10 An example of a diagnostic flowchart for patients with suspected non-acute heart failure.
Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, *Eur Heart J.* 2016;37(27):2129–2200. doi:10.1093/eurheartj/ehw128.

KNOWLEDGE CHECK QUESTIONS

1. True or False: HF can cause a pleural effusion that is seen on CXR.
2. True or False: Ventricular function, ventricular wall thickness, and valve function can be determined using echocardiography.
3. True or False: Echocardiography is most useful in distinguishing acute HF from other causes of dyspnea.

Treatment and Management

The overall goals of treatment in patients with HF are to relieve the signs and symptoms, prevent hospital admission, and improve survival.[5] **Box 15-4** shows the goals for treatment in acute HF.

Regardless of the cause of HF, some of the treatments are similar. Other treatment strategies for HF are unique to the specific etiology. The treatment of all forms of HF requires lifestyle changes. The general pharmacologic treatments indicated for HF appear in **Table 15-6**.

BOX 15-4 Goals of Treatment in Acute HF

Immediate (ED/ICU/CCU)

Improve haemodynamics and organ perfusion.
Restore oxygenation.
Alleviate symptoms.
Limit cardiac and renal damage.
Prevent thrombo-embolism.
Minimize ICU length of stay.

Intermediate (in hospital)

Identify aetiology and relevant co-morbidities.
Titrate therapy to control symptoms and congestion and optimize blood pressure.
Initiate and up-titrate disease-modifying pharmacological therapy.
Consider device therapy in appropriate patients.

Pre-discharge and long-term management

Develop a careplan that provides:

- A schedule for up-titration and monitoring of pharmacological therapy.
- Need and timing for review for device therapy.
- Who will see the patient for follow-up and when.

Enrol in disease management programme, educate, and initiate appropriate lifestyle adjustments.
Prevent early readmission.
Improve symptoms, quality of life, and survival.

CCU, coronary care unit; ED, emergency department; ICU, intensive care unit. Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal 2016; 37 (27): 2129–2200, doi:10.1093/eurheartj/ehw128

TABLE 15-6
Medications Used for HF

Medication	Reason
ACE inhibitors	To reduce the risk of HF hospitalization and the risk of premature death. Use with beta-blocker for all patients with an EF ≤ 40%.
Beta-blockers	Use with ACE inhibitor Use with ARB if ACE inhibitor is not tolerated, for all patients with EF ≤ 40%, to reduce the risk of HF hospitalization and the risk of premature death.
MRA	Use for patients with persisting symptoms and an EF ≤ 35%, despite treatment with an ACE inhibitor (or an ARB) and a beta-blocker, to reduce the risk of HF hospitalization and the risk of premature death.
Diuretics	Use as first-line, short-term therapy in the emergency management of patients with acute HF to remove excess fluid in patients with signs of congestion from volume overload.
Supplemental oxygen	Use for a patient with documented or suspected hypoxemia.

Other pharmacologic agents or surgical intervention may be appropriate depending on the etiology of the HF.

KNOWLEDGE CHECK QUESTIONS

1. True or False: All HF patients with EFs less than 40% should initially be treated with an ACE inhibitor and a beta-blocker.
2. True or False: HF patients with pulmonary edema are treated with diuretics.

Risk Factors

Early identification of risk factors for the development of HF is important for preventive interventions. Preventive measures need to be in place before the appearance of ventricular dysfunction to reduce the risk of HF. The AHA/ACC system uses risk factors to classify HF, shown in **Figure 15-11**. The important risk factors for the development of HF include hypertension, atherosclerotic disease, diabetes mellitus, obesity, metabolic syndrome, patients who use cardiotoxic drugs, and those with a family history of cardiomyopathy. Metabolic syndrome is the name for a group of risk factors that include obesity, high triglyceride level, low high-density lipid level, hypertension, and high fasting blood sugar level. Cardiotoxic drugs are substances that may trigger the development of cardiac injury even when properly used.

These drugs include amphetamine, anabolic-androgenic steroids, catecholamines, cocaine, ephedrine, pentamidine, and tricyclic antidepressants.



FIGURE 15-11 AHA and ACC HF classification.

Reproduced with permission from Georgiopoulou V, Kalogeropoulou A, Butler J. Heart failure in hypertension: prevention and treatment. *Drugs*. 2012;72(10):1373–1398.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Patients with diabetes mellitus have a high risk for the development of HF.
2. True or False: A patient with a known structural heart disease and symptoms is classified as Stage B according to the AHA/ACC.

Complications

The complications from HF depend on the cause of the HF and its severity. Renal damage or failure can occur from kidney hypoperfusion during times of low cardiac output. Erythropoietin (which stimulates RBC production) secreted by the kidneys is reduced by kidney damage, causing anemia. Right HF causes fluid buildup in the liver, causing cardiac cirrhosis or congestive hepatopathy. The heart valves can be affected by HF due to the increased cardiac workload. The most common valve problem caused by HF is MR. Arrhythmias, such as atrial fibrillation (AF) or ventricular fibrillation, can occur due to damage to the heart's electrical system. Unintentional weight loss, cardiac cachexia, is yet another complication from HF.[7]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Hyperperfusion of the kidneys occurs during HF and causes renal failure.
2. True or False: Congestive hepatopathy is caused by left HF.

Prognosis

Numerous variables provide prognostic information about HF. The most common of these variables include age, etiology, NYHA classification, EF, and the presence of key comorbidities, such as diabetes, renal dysfunction, and anemia. These variables do change with time and require frequent assessment. This assessment is particularly important to the patient's prognosis and the course of treatment, for example, the need for device implantation; surgery, including transplantation; and planning end-of-life care.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The presence of comorbidities is a major factor in a patient's prognosis for HF.
2. True or False: The prognosis for HF can change with treatment.

The Cardiomyopathies

The cardiomyopathies are a group of heart disorders that cause changes in the structure and function of the myocardium that is either idiopathic in nature (primary) or caused by another disorder of the heart or other organs (secondary).[14] The World Health Organization has identified three types of cardiomyopathies: dilate cardiomyopathy, HCM, and RCM. Anatomic appearance and abnormal physiology of the LV is the basis for this classification. These disorders often result in the symptoms of HF reviewed previously.

Dilated Cardiomyopathy

Dilated cardiomyopathy (DCM), once known as congestive cardiomyopathy, is the most common type of cardiomyopathy.[15] Myocyte damage and cardiac enlargement

in DCM result from a wide spectrum of genetic, inflammatory, toxic, and metabolic causes.[14] See **Box 15-5**.

Although the etiology of each type is different, they cause the same structural abnormality. The hallmark of DCM is ventricular dilatation with decreased contractile function. This results in excessive blood accumulating in the affected ventricle, causing volume overload.

At first, the extra blood increases the stretch of the myocardium, causing LVEF and cardiac output to increase as a compensatory mechanism. However, as the volume within the LV increases, its walls become stretched and thin (**Figure 15-12**). Ultimately both the EF and the cardiac output decrease. This can cause cardiogenic pulmonary edema. Without prompt treatment, congestive heart failure (CHF) and possible death occur.[14,15]

Acute viral myocarditis afflicts young, previously healthy people, with some of these individuals progressing to DCM. Alcoholic DCM develops in a small number of people who consume alcoholic beverages excessively and chronically. Postpartum DCM causes the presentation of HF symptoms between the last month of pregnancy and up to 6 months postpartum. Risk factors for postpartum DCM include being African American, older maternal age, and having multiple pregnancies. Genetic DCM is responsible for approximately 20–30% of idiopathic DCM (IDCM).[14]

In the early stages of DCM, the heart is usually able to compensate for the increased volume and the patient is asymptomatic. However, as heart function declines, signs and symptoms appear.[15] The clinical manifestations of DCM are those of CHF. See Table 15-3. Common signs and symptoms include fatigue, shortness of breath on exertion, decreased tissue perfusion, and swelling of the lower extremities. Other signs and symptoms include weight gain, orthopnea, fainting, palpitations, dizziness or light headedness, chest pain or pressure, loss of appetite, decreased concentration, cough, paroxysmal nocturnal dyspnea, ascites, and arrhythmias (tachycardia, fibrillation).[15,16] Another consequence of reduced cardiac output is blood pooling in both the ventricles and the atria, leading to clot formation. The presence of clots increases the risk of acute MI, leg ischemia, stroke, or pulmonary embolus.[15] With a persistent reduction in cardiac output, the decline in renal blood flow prompts the kidneys to secrete increased amounts of renin. This activation of the RAAS increases peripheral vascular resistance and intravascular volume. These effects are also initially helpful in buffering the fall in cardiac output. However, the compensatory effects of the RAAS prove detrimental and contribute to pathologic myocardial remodeling and fibrosis.[14]

The diagnosis of DCM begins with the patient's history and a physical examination. This helps to eliminate other causes of ventricular failure.[17] If the diagnosis is inconclusive after the history and physical exam, the tests seen in **Table 15-7** are used to make the diagnosis of DCM.

When the medications described earlier in the HF section of this chapter are unable to control the patient's symptoms, an implantable medical device may be necessary. All of these devices are designed to pace the heart but have additional functions as well.[14] **Table 15-8** shows common medical devices used to treat electrical conduction abnormalities associated with DCM and other forms of HF. See **Figure 15-13**. If medical and device therapy is insufficient to manage end-stage HF, heart transplantation may be indicated.[14]

The presence of AF, a previous thromboembolic event, or an intracardiac thrombus, is an indication for the use of anticoagulation therapy.

BOX 15-5 Examples of Dilated Cardiomyopathies

- Idiopathic
- Ischemic heart disease
- Genetic
- Inflammatory
  - Infectious (especially viral)
  - Noninfectious
    - Connective tissue diseases
    - Peripartum cardiomyopathy
    - Sarcoidosis
- Toxic
  - Chronic alcohol ingestion
  - Chemotherapeutic agents
- Metabolic
  - Hypothyroidism
  - Chronic hypocalcemia or hypophosphatemia
- Neuromuscular
  - Muscular or myotonic dystrophy

Reproduced from Lee C, Dec G, Lilly L. The Cardiomyopathies. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.



FIGURE 15-12 Dilated cardiomyopathy.

TABLE 15-7
Diagnostic Tests for DCM

Diagnostic Test	Identifiers
Blood tests	• Elevated troponin • Elevated BNP
Cardiac magnetic resonance imaging (CMRI)	• Identifies myocardial structure and function • May show abnormal myocardial tissue texture or scarring
CXR	• Cardiomegaly • Pleural effusion from elevated pulmonary venous pressure (most common on the right side)
Coronary angiography	• Used if other diagnostic tests are inconclusive • For patients with high risk for CAD, chest pain, elderly, and those with several cardiovascular risk factors
ECG	• Reveals arrhythmias: nonspecific ST-segment depression, inverted T waves, and LBBB • Reveals signs of previous MI: pathologic Q waves in precordial leads
Echocardiogram	• Reveals dilated and hypokinetic heart chambers • Rules out valvular disorders • Shows wall motion abnormalities • Shows stationary thrombus against chamber wall (mural thrombus)
Positron-emission tomography	• Diagnoses cardiac sarcoidosis • Diagnoses RCM

TABLE 15-8
Medical Devices for DCM and Their Function

Device Name	Device Function
ICD	The ICD can sense life-threatening arrhythmias (V-fib or V-tach) and automatically deliver the appropriate electrical shock to correct them. ICD reduces arrhythmic deaths in patients with DCM.
Cardiac resynchronization therapy (CRT)	The CRT is a pacemaker that paces both the RV and the LV, and may also include an ICD.
Right ventricular assist device (RVAD)	The RVAD is a surgically implanted medical device that helps the RV pump blood to the lungs.
Left ventricular assist device (LVAD)	The LVAD is a surgically implanted medical device that helps the LV pump blood to the body.

Risk factors for DCM include family history of cardiomyopathy, HF, or sudden cardiac arrest (SCA), coronary heart disease (CHD), MI, viral infection, diabetes, severe obesity, RCM, long-term alcoholism, or long-term high BP.[18]



FIGURE 15-13 A cardiologist implants a heart defibrillator in a patient. The ICD also includes a pacemaker.

Complications from all forms of DCM include HF, heart valve regurgitation, enlargement of the left or RV, pulmonary or systemic edema, cardiac arrhythmias, SCA, and system or pulmonary emboli.[19]

If left untreated, DCM leads to HF. Identification of the cause (viral, bacterial, CAD, ischemic, or alcohol) and its correction (antivirals, antibiotics, angioplasty, or abstinence from alcohol) may lead to some improvement. The etiology of the DCM is the number one factor in its prognosis. Other factors affecting the prognosis include increased age, male gender, and severe CHF. If CHF develops, approximately 50% of the patients die within 5 years. There is a 50% mortality rate each year after a diagnosis of severe HF. If the HF is mild and optimal medical therapy is given, the prognosis improves.[20]

Ischemic Dilated Cardiomyopathy

The cause of **ischemic dilated cardiomyopathy (ICM)** is CAD. This is the only DCM that is caused by ischemia. All other types of DCM are considered non-ischemic. CAD is the narrowing of the lumen of the coronary arteries caused by plaque buildup. One of the consequences of CAD is a MI. This causes the myocardium to become weak and unable to pump efficiently. The inefficient pump leads to a decrease in the EF, causing volume overload. This results in DCM.[14] The treatment for ICM is repair of the coronary artery by angioplasty and stenting. See Chapter 16.

Alcoholic Dilated Cardiomyopathy

Alcoholic dilated cardiomyopathy (ACM) is caused by dilation of the LV due to alcohol abuse.[14] Although there is extensive research on ACM, the exact pathogenesis of ACM is not fully understood.[21] In long-term alcohol consumption, there are changes at the cellular level, including intracellular organelle dysfunction, contractile proteins dysfunction, and calcium homeostasis.[21] These changes cause myocyte dysfunction. The incidence of ACM is lower in women as compared to men, and occurs most often in alcoholics in their late 40s. It is not

clear how much alcohol consumption is necessary, but individuals who drink more than eight drinks per day for at least 5 years are at risk. The best treatment is to abstain from alcohol consumption.[21]

Case Study

The case study patient has revealed the symptoms of HF: shortness of breath, orthopnea, and swollen lower extremities. He has fine crackles in the posterior lung bases consistent with pulmonary edema from left-sided HF and has peripheral edema consistent with right-sided HF. The S_3 murmur is consistent with left-sided HF. His ECG shows a LBBB and LA enlargement. All findings point to HF, the etiology of which is not smoking. However, his excessive alcohol intake makes him a candidate for the diagnosis of alcoholic cardiomyopathy. Further tests are needed to make that diagnosis, including Doppler echocardiogram and blood tests.

Idiopathic Dilated Cardiomyopathy

A diagnosis of **idiopathic dilated cardiomyopathy (IDCM)** occurs when the cause of cardiomyopathy is unknown. IDCM accounts for approximately 50% of all cases of cardiomyopathy.[22] The possible triggers for IDCM appear in **Table 15-9**.

When a virus causes IDCM, it can be from virus-positive or virus-negative infection. For a virus-positive infection, using high doses of intravenous immunoglobulin (2 g/kg) has demonstrated favorable effects on both cardiac function and virus elimination. This treatment has been shown to eliminate the B19V; this is a parvovirus and is the most frequently found virus in cardiac biopsies.[22] Using an immunosuppressive therapy in a virus-negative infection has shown beneficial effects on myocardial function.[22]

TABLE 15-9
Possible Triggers of IDCM

Classification of IDCM	Causative Agents/Factors
Toxic cardiomyopathy	Cocaine, lithium, cobalt, lead, arsenic, radiation, catecholamines, phenothiazines, and chemotherapy
Metabolic cardiomyopathy	Diabetes mellitus, hyperthyroidism, hypothyroidism, hyperparathyroidism, pheochromocytoma
Tachycardia-induced cardiomyopathy	Sustained rapid ventricular rates from supraventricular tachyarrhythmia, ventricular tachycardia, frequent premature ventricular complexes
Inherited	Autosomal dominant transmission of mutated genes encoding cytoskeletal and sarcomeric proteins
Virus infection	Adenovirus, enteroviruses, parvovirus B19 (B19V), human herpes virus-6
Other	Amyloidosis, Gaucher disease, Hurler disease, Hunter disease

Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is hypertrophy of mainly the LV myocardium by more than 1.5 cm.[23] See Figure 15-6. HCM is genetic. Its cause is the inheritance of mutated genes. The proteins encoded by the responsible genes are all part of the sarcomere complex and impair the contractile function of the ventricles.

HCM is common with an incidence of about 1 in 500 people. It can occur at any age, and affects men more than women and African Americans more than Caucasians.[23] This cardiomyopathy is the cause of sudden death in young athletes during vigorous physical exertion (**Figure 15-14**).

In HCM, the cells of the heart muscle become enlarged, causing ventricular hypertrophy (ventricle wall thickening). The hypertrophy reduces the compliance and relaxation ability of the ventricles, impairing their ability to fill. This thickening can be either obstructive or nonobstructive. Nonobstructive HCM is less common than its obstructive counterpart. The nonobstructive type is due to symmetrical hypertrophy of the ventricular walls. This hypertrophy can also occur only in the apex or mid-region of the LV.

Hypertrophic Obstructive Cardiomyopathy

If there is an asymmetric hypertrophy of the upper interventricular septum, a transient obstruction of the LV outflow tract (LVOT) may occur during systole. This is called **hypertrophic obstructive cardiomyopathy (HOCM)**.[24] With time, the LVH and small LV chamber size regress and lead to DCM, which can lead to left-sided HF.[23]



FIGURE 15-14 Hypertrophic cardiomyopathy.



FIGURE 15-15 Common septal morphologies in HOCM.

Redrawn from Bos J, Towbin J, Ackerman M. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. *J Am Coll Cardiol.* 2009;54(3):204.

In HOCM, usually only the septal wall has asymmetrical hypertrophy, as shown in **Figure 15-15**, and it obstructs the **left ventricular outflow tract (LVOT)**. Hypertrophy of the apical wall alone is rare and called Yamaguchi disease.[25] The LVOT reduces the amount of blood leaving the LV and increases the workload of the LV.[23,25] MR occurs in HOCM when the leaflets of the mitral valve are pulled anteriorly during systolic ejection, systolic anterior motion (SAM) of the mitral valve.[23,25] The pressure gradient falls below the valve (subvalvular) and changes (dynamic) as the flow increases through the narrowed LVOT. As the LVOT obstruction increases, the velocity of the blood passing through it increases (the Venturi effect). The increased velocity of the blood decreases the fluid pressure and causes an increase in the SAM of the mitral valve. This worsens the MR.[23] The gradient increases if the preload of the LV is low, or there is an increase in contractility. Obstruction can exist at rest or can be brought on by provocative maneuvers (i.e., Valsalva, exercise, sudden upright position, amyl nitrite).[23] In hypertrophic nonobstructive cardiomyopathy, the hypertrophied muscle is not large enough to cause any obstructions.[26]

Symptoms are not always present. The symptoms of HOCM correlate with the severity of the MR and LV diastolic dysfunction, not the magnitude of the LVOT obstruction.[23] **Box 15-6** includes the signs and symptoms of HOCM. As the disease progresses, the LV dilates, and it may progress to DCM and HF. HOCM is sometimes the cause of sudden cardiac death (SCD) at an early age because the heart is unable to increase cardiac output during strenuous exertion.[23] This leads to syncope or sudden death.

BOX 15-6 Signs and Symptoms of HOCM

AF	Palpitations
Chest discomfort	Paroxysmal nocturnal dyspnea
Chest pain	Pre-syncope or syncope
Dyspnea (most common)	Stroke
Fatigue	SCD
Leg edema	Ventricular tachycardia
Orthopnea	Ventricular fibrillation

The carotid pulse in HOCM has a brisk upstroke during early systole and decreases due to the obstruction.[23] Lack of HF reveals clear lungs on auscultation and normal jugular venous pressure. Cardiac assessment reveals a forceful, sustained, and laterally placed point of maximal impulse. An atrial gallop, S_4 heart sound, is present. Auscultation along the upper left sternal border reveals a harsh, crescendo-decrescendo systolic murmur. A Valsalva maneuver reduces venous return, resulting in decreased preload. This increases the systolic murmur heard in HOCM.[23]

Following a history and physical exam, the tests listed in **Table 15-10** confirm the HOCM diagnosis.

The lifestyle modifications used in the treatment of HCM include the avoidance of the triggers that cause symptoms such as strenuous activity, Valsalva

TABLE 15-10
Diagnostic Tests for HOCM

Test	Uses
Blood work	Increased BNP indicates HF
CXR	Identify LVH
ECG	LVH • R wave > 12 mm in Lead I • R wave > 11 mm in Lead aVL • R wave > 20 mm in Lead aVF • Height of S wave in V1 or V2 + Height of R wave V2 or V6 >35 mm LAE • M-shaped P waves in Lead II • Biphasic P waves in Lead V1
Echocardiogram	Identifies the location of hypertrophy (**Figure 15-16**) Measures wall thickness Identifies the degree of LVOT Identifies the presence of SAM
Transesophageal echocardiogram (TEE)	Used if echocardiogram is inconclusive
CMRI	Determines location, pattern, and extent of myocardial fibrosis
Cardiac catheterization	Reserved for uncertain diagnosis using other tests Identifies and verifies dynamic pressure gradient across the LVOT
Genetic testing	Establishes or excludes HOCM Identifies specific mutation

maneuvers, and competitive athletics. To avoid underfilling of the LV and reduce LVOT obstruction, patients need to be kept well hydrated.[23]

The medications used in the treatment of both HOCM and HCM without outflow obstruction appear in **Table 15-11**.

Several medications worsen the LVOT obstruction. They include those drugs that decrease afterload, including ACE inhibitors, ARB, and nitrates. Drugs that have positive inotropic effects increase the force of myocardial contraction and the LVOT gradient. These drugs include digoxin, dopamine, dobutamine, and norepinephrine.[23]

The indication for surgical intervention occurs when the symptoms do not respond to pharmacologic treatment, and there is a resting pressure gradient ≥ 50 mm Hg between the LV apex and the LVOT. This surgical intervention is a **septal myomectomy** that cuts away the septal wall to open the LVOT.[23]

A less-invasive and alternative intervention is percutaneous **alcohol septal ablation (ASA)**. This procedure involves injecting a small amount (1–3 mL) of desiccated ethanol into the artery feeding the hypertrophied septum. The alcohol causes a MI localized to the septal wall, which results in localized muscle death. As the muscle becomes necrotic, it shrinks (this may take weeks) and the LVOT gradient decreases.[23]

Risk factors that may worsen HCM include strenuous exercise that increases afterload (i.e., heavy weight lifting/training), a family history of HCM, increased ventricular wall thickness, along with the presence of certain genetic mutations in certain individuals.[23] Complications from HCM are arrhythmias, obstructed blood flow, DCM, mitral valve problems (MR), HF, and SCD.[27]



FIGURE 15-16 ECG of HOCM with LVH.

Mortality is affected by the age at which the symptoms appear and is higher in children than in adults (1–3%). Mortality is higher when there are frequent non-sustained ventricular tachycardia, syncope, or resuscitation following SCA. HF does not always occur. The prognosis is worse for young people who have a family history of sudden death and people older than 45 years with chest pain or exertional dyspnea.[28]

Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is the least common cardiomyopathy in the United States. RCM is due to abnormally rigid (but not necessarily thickened) ventricles with impaired diastolic filling but usually normal, or near-normal, systolic function.[29] This condition results from either fibrosis or scarring of the endo-myocardium or infiltration of the myocardium by an abnormal substance.[14] Causes of RCM appear in **Figure 15-17**. Genetic diseases can also cause RCM, notably Fabry disease, Gaucher disease, or hemochromatosis.[30]

RCM causes endocardial thickening or myocardial infiltration in one, typically the left, or both ventricles. This thickening may result in mitral valve regurgitation or tricuspid valve (TV) regurgitation. If the sinoatrial (SA) node or atrioventricular (AV) node is affected, various grades of AV blocks may occur.[29] The main hemodynamic consequence of RCM is a result of the noncompliant ventricles. The ventricles become rigid, impairing diastolic filling. This causes high filling pressure that leads to pulmonary and systemic hypertension.[30] If the myocardium cannot compensate through hypertrophy, systolic dysfunction occurs.[30]

Symptoms result from the inability of the myocardium to relax and distend. They include exertional dyspnea, orthopnea, and fatigue. If the RV is affected, peripheral edema will occur.[30] Atrial and ventricular arrhythmias and AV blocks may occur. Angina and syncope are uncommon. Signs and symptoms closely mimic those of constrictive pericarditis (see the "Constrictive Pericarditis" section below).[30]

Palpitation and auscultation reveals a low-volume and rapid carotid pulse, pulmonary crackles, and pronounced neck vein distention. S_3 and S_4 heart sounds are present.[30] The fibrous changes to the heart may affect the chordae tendineae or the shape of the ventricle, and this causes mitral or TR.[30]

TABLE 15-11
Medications for HCM

Medications	Use in HCM
Beta-blockers	• Reduces myocardial oxygen demand by slowing the heart rate and contraction force • Decreases contraction force—reduced LVOT gradient during exercise
Calcium-channel blockers	• Second-line therapy for those in whom beta-blockers failed • A negative chronotropic effect, which leads to increased diastolic relaxation time (thus increasing preload)
Type IA antiarrhythmic drug	• AF in HCM • Negative inotropic effects improve diastolic function



FIGURE 15-17 Causes of restrictive cardiomyopathy.
Modified from Lee C, Dec G, Lilly L. The Cardiomyopathies. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:257.

TABLE 15-12
Summary of the Cardiomyopathies

	DCM	HCM	RCM
Ventricular morphology	Dilated LV usually without hypertrophy	Marked hypertrophy, often asymmetric	Fibrotic or infiltrated myocardium
Etiologies	Genetic, infectious, alcoholic, peripartum	Genetic	Amyloidosis, hemochromatosis, scleroderma, radiation therapy
Symptoms	Fatigue, weakness, dyspnea, orthopnea, paroxysmal nocturnal dyspnea	Dyspnea, angina, syncope	Dyspnea, fatigue
Physical exam	Pulmonary crackles, S_3; if RV failure present: JVD, hepatomegaly, peripheral edema	S_4, if outflow obstruction present: systolic murmur loudest at left sternal border, accompanied by MR	Predominantly signs of RV failure: JVD hepatomegaly, peripheral edema
Pathophysiology	Impaired systolic contraction	Impaired diastolic relaxation; LV systolic function vigorous, often with dynamic obstruction	"Stiff" LV with impaired diastolic relaxation but usually normal systolic function
Cardiac size on CXR	Enlarged	Normal or enlarged	Usually normal
Echocardiogram	Dilated, poorly contractile LV	LVH, often more pronounced at septum, systolic anterior movement of MV with MR	Usually normal systolic contraction, speckled appearance in infiltrative disorders
Medications to control symptoms	Diuretic ACE inhibitor Angiotensin II receptor blocker Beta-blocker Amiodarone	Beta-blocker Calcium-channel blocker Type IA antiarrhythmic agent	Diuretic Oral anticoagulant
Devices/surgery	ICD CRT RVAD LVAD	ICD Septal myomectomy Percutaneous septal ablation	Septal myomectomy ICD

Reproduced with permission from Lilly LS & Harvard Medical School. (2016). Pathophysiology of heart disease: A collaborative project of medical students and faculty.

The tests used to diagnose RCM include ECG, CXR, and echocardiogram. An ECG may show low voltage with ST-segment and T-wave abnormalities, pathologic Q waves (not from a previous MI), and HOCM. In many cases, a CXR shows a normal-sized heart; however, it may reveal a small heart, or in the late stages, it may be enlarged. Appropriate tests should be done to check for amyloidosis, iron, or hemochromatosis, which are common causes of RCM.[30]

The medications used in RCM are to treat the symptoms, not the disease. Diuretics can be given to reduce pulmonary congestion. Caution is needed not to compromise preload. If preload becomes too low, the noncompliant ventricles cannot maintain cardiac output.[30] In cases with elevated heart rates, beta-blockers or rate-limiting calcium-channel blockers may be used cautiously in low doses. Medications that lower afterload may cause hypotension and are not helpful.[30] Oral anticoagulants are used to control intraventricular thrombus formation in some individuals.[14]

Performing septal myomectomy/ablation may improve some symptoms. Pacemakers may be helpful in older patients, and ICDs may help younger patients at higher risk of SCD. Transplantation is not recommended because the disorder may recur in the transplanted heart.[30]

Risk factors for RCM include a family history of cardiomyopathy and of other types of heart disease, CHD, obesity, diabetes, high BP, and alcoholism.[31] Complications from RCM are HF, mitral valve regurgitation, arrhythmias, pulmonary edema, and heart attacks.[31] Because most of the treatments available are for treating the symptoms, the prognosis of RCM is poor.[30]

Summary of the Cardiomyopathies

A summary of all the cardiomyopathies is in **Table 15-12**.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The anatomic appearance and abnormal physiology of the RV is the basis for cardiomyopathy classification.
2. True or False: The hallmark of DCM is ventricular dilation.
3. True or False: The etiology of HCM is genetic.
4. True or False: Ischemia can cause HCM.

Valvular Heart Diseases

The four valves in the heart are the mitral, tricuspid, pulmonary, and aortic. The mitral valve sits between the LA and the LV, the TV is located between the RA and the RV, the aortic valve is located between the LV and the aorta, and the pulmonary valve is located between the RV and the pulmonary artery (PA). **Figure 15-18** shows the circulation of blood through the chambers and valves of the heart. These valves prevent blood from flowing backward and causing systemic venous congestion or pulmonary congestion. Also, they help direct the blood forward. A stenotic valve does not open all the way and will restrict forward blood flow. If the valve is incompetent, this will allow the blood to flow backward, and this is regurgitation.[4]

Aortic Insufficiency (Aortic Regurgitation)

Aortic insufficiency (AI) is the inability of the aortic valve to close properly, allowing the blood to regurgitate back into the LV during diastole. This regurgitation increases the preload and leads to volume overload.[29] The results are LV dilatation and HF. Causes of AI include rheumatic fever, infective endocarditis, collagen vascular diseases, degenerative aortic valve disease, trauma, postsurgical (including post-transcatheter) aortic valve



FIGURE 15-18 Circulation of blood through the heart.

TABLE 15-13
Scale Used to Quantify Valvular Insufficiency

Scale	Explanation
Mild (1+)	A small amount of blood/contrast enters the LV during diastole and clears with each systole.
Moderate (2+)	Blood/contrast enters the LV with each diastole, but the LV chamber is less dense than the aorta.
Moderately severe (3+)	The LV chamber is equal in density to the ascending aorta.
Severe (4+)	Complete, dense opacification of the LV chamber occurs on the first beat, and the LV is more densely opacified than the ascending aorta.

replacement, or dilatation of the aorta.[29] An angiogram of the ascending aorta quantifies the regurgitant flow. An echocardiogram quantifies the regurgitant flow using the scale shown in **Table 15-13**.

AI causes the aortic diastolic pressure to decrease and the systolic pressure to increase. This widens the pulse pressure, the difference between aortic systolic and diastolic pressure.[29] The severity of the AI is quantified by determining the diastolic pressure gradient between the aorta and the LV and measuring the diastolic valve area.[29] The effect AI has on an individual depends on whether it is acute or chronic.

In acute AI, there is a high mortality rate because the LV does not have time to adapt to the volume overload. If not treated promptly it will quickly progress from pulmonary edema to refractory HF and cardiogenic shock.[29] In chronic AI, the LV has time to adapt and will dilate to handle the volume overload. Consequently, this will cause a dilated LV with contractility.[29]

The symptoms of acute AI are the same symptoms listed in the DCM section. These symptoms include tachycardia, cool extremities, lung crackles, low BP, and cardiogenic shock. Because acute AI has a rapid onset, the heart is unable to compensate and will result in an emergency. Upon auscultation, the first heart sound (S_1) is usually absent or diminished due to equal diastolic pressure in the LV and AO. There is usually a third heart sound (S_3 or ventricle gallop). There will be a mid-to-late diastolic rumble heard at the apex (Austin Flint murmur).[32]

Symptoms of chronic AI may not become apparent for a long time. By the time symptoms do become apparent, the heart is usually severely affected.[32] The symptoms can be inconspicuous and are the same as DCM. An abnormal aortic valve is more susceptible to endocarditis. The presence of endocarditis causes additional signs and symptoms, such as fever, anemia, weight loss, and embolic phenomena.[32] As the disease progresses, the PMI becomes enlarged, sustained, increased in amplitude, and displaced downward and laterally.[32] The cardiac sounds include a loud sharp or slapping second heart sound (S_2), caused by increased elastic aortic recoil, and a high-pitched decrescendo diastolic murmur is heard at the third or fourth left parasternal intercostal space.[32]

If infectious endocarditis causes the AI blood tests, identify the causative organism. Also, renal and liver function tests are necessary to check for medication clearance.[33] When AI is a result of infectious endocarditis, early surgical intervention is appropriate. With aortic dissection, emergent intervention is warranted.[33]

Suspected AI requires an echocardiogram to confirm it and establish a baseline of the regurgitant flow.[33] If previous echocardiograms have documented AI, then regular echocardiograms quantify any changes in the regurgitant flow. Using echocardiogram will help to determine the information listed in **Box 15-7**.

A CXR may show structural abnormalities like aortic dilation, prosthetic valve dislodgement, aortic valvular calcification, or cardiomegaly.[33] Radionuclide imaging determines the regurgitant fraction and the LV/RV stroke volume ratio.[33]

Cardiac catheterization is optional in AI. But it can provide valuable clinical information when surgery is being contemplated. The catheterization will allow for coronary artery anatomy evaluation and the regurgitant flow through the aortic valve.[33] An aortic angiography quantifies the regurgitant flow using the scale in Table 15-13.[33]

BOX 15-7 Information Obtained from an Echocardiogram for AI

1. Proper time to replace the valve
2. Structure and morphology of the leaflets (bi-leaflet vs. tri-leaflet, flail, thickening)
3. Presence of vegetation or nodules
4. Severity of AI
5. Regurgitant volume
6. Orifice area
7. Premature closure of the mitral valve
8. Opening of the aortic valve
9. Aortic dilation
10. Aneurysm
11. Dissection
12. LV structure and function
13. LVH and dilation
14. EF
15. End-systolic dimension

Cardiac CT scanning and magnetic resonance imaging (MRI) are not widely recognized as a diagnostic tool for AI. However, there is growing support in the literature for the potential clinical use of these imaging techniques. Electrocardiographic findings are nonspecific but may include LVH (see the "Hypertrophic Cardiomyopathy" section), left-axis deviation, LAE, LV volume overload pattern, and LV conduction defects.[33]

When the AI is from aortic root dilatation, an ARB medication may be used. This class of medication slows the progression, especially if it is accompanied (concomitant) by hypertension.[33]

Surgery is appropriate when the AI is severe and symptoms or evidence of LV dysfunction is present. Identification of LV dysfunction includes EF $<$ 50%, LV end-systolic dimension $>$ 50–55 mm, or LV end-diastolic dimension $>$ 65–75 mm. When the ascending aorta is dilated $>$ 55 mm, surgery is considered sooner.[33]

Currently, only surgical options for aortic valve replacement exist. AI replacement involves open-heart surgery similar to coronary artery bypass surgery. If surgery is not an option, the patient needs the same treatment as HF from DCM. AI is a contraindication for the use of an intra-aortic balloon pump because the pump worsens the AI.[33]

Risk factors for AI include congenital heart defects (having one or two leaflets instead of three), old age, being male, Marfan syndrome (an inherited disorder that affects connective tissue), high BP, and autoimmune diseases.[34] The complications from AI are abnormal heart rhythms, HF, and infection in the heart.[35] Early valve replacement produces the best long-term results. Replacing the valve when AI is mild or moderate will result in a 10-year survival rate of 80–95%. If AI is severe and HF is not present, long-term prognosis is good. However, if the AI is severe, and HF symptoms are present, the long-term prognosis is poor.[36] A summary of AI can be found in **Table 15-14**.

TABLE 15-14
Summary of AI

Description	The inability of the aortic valve to close properly, allowing blood to regurgitate back into the LV during diastole
Etiology	Rheumatic fever Infective endocarditis Collagen vascular diseases Degenerative aortic valve disease Trauma Postsurgery (including post-transcatheter aortic valve replacement) Dilatation of the aorta
Clinical manifestations	Same as DCM Tachycardia Cool extremities Pulmonary crackles Hypotension Cardiogenic shock
Diagnostic tests	CXR Cardiac catheterization Aortic angiography ECG
Medical treatment	AI from aortic root dilatation using ARB medication
Surgical treatment	Aortic valve replacement via open-heart surgery

Data from Novara GM. Aortic Valve Disease.: Cleveland Clinic Center for Continuing Education. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/aortic-valve-disease/

Aortic Stenosis

In **aortic stenosis (AS)**, the opening between the LV and the AO becomes stenotic. Left ventricular emptying becomes impaired because of the increased outflow resistance.[37] AS leads to an increase in LV systolic pressure and causes a mean pressure gradient of at least 10 mm Hg. AS is the most common of the valvular heart diseases. Calcified AS and congenital bicuspid AS account for the majority of AS cases.[37] Approximately 25% of the population over 65 years old with a normal valve at birth will develop mild thickening, or calcification, or both without restricted leaflet movement (i.e., aortic sclerosis). AS can lead to AI (see the "Aortic Insufficiency (Aortic Regurgitation)" section).[37]

In AS, the LV must generate a higher pressure to eject the blood through a narrowed opening, which causes a pressure overload problem.[31] If the mitral valve is intact, the lungs will not be affected. However, if there is MR, there will be an increase in pulmonary pressures.[37] As the LV works harder to eject the blood, the cells of the LV increase in size (LVH). The LVH is a compensatory mechanism and increases the systolic pressure to maintain the stroke volume and cardiac output. Years may pass without any symptoms. The LVH will eventually lead to diastolic dysfunction and LV dilatation.[37] As the LV becomes larger, it requires more oxygen. Eventually the cardiac output will not be able to meet the needs of the heart, and myocardial ischemia will occur (see Ischemic Heart Disease in Chapter 22).[37]

Symptoms of AS include angina, syncope, or HF.[37] Cardiac auscultation reveals a harsh systolic murmur, which will be loudest at the base of the heart and radiate to the carotids. Obesity, low cardiac output, and chronic lung disease mask the sound of this murmur.[38] Other findings from an examination are a single (pulmonic) component of the second heart sound, left ventricular apical impulse with an S_4 heart sound, and a low-volume carotid pulse in younger patients; changes in arterial compliance often mask these findings in older adults.[38]

An echocardiogram is the gold standard for the diagnosis of AS. An echocardiogram will identify a stenotic aortic valve and its possible causes. It will also quantify

TABLE 15-15
AS Classifications[37]

Scale	Valve Area (cm^2)	Mean Pressure Gradient (mm Hg)
Mild	1.5–2.0	<20
Moderate	1.0–1.5	20–39
Severe	0.6–1.0	60–59
Very severe	<0.6	>60

Data from Novara GM. Aortic Valve Disease. Cleveland Clinic Center for Continuing Education. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/aortic-valve-disease/

LVH and the degree of systolic dysfunction, and detect coexisting valvular heart disorders (AI, mitral valve) and complications (e.g., endocarditis).[39] Adding Doppler to the echocardiogram helps to quantify the jet velocity, systolic pressure gradient, and valve area.[37] The severity of the stenosis appears in **Table 15-15**.

If the echocardiogram reveals that the valve is critical and needs replacement, the patient has a heart catheterization. During the catheterization, the coronary arteries are assessed and right heart pressures evaluated. Additionally, the cardiac output and valve area are calculated. The finding from the heart catheterization should match the echocardiogram findings.[39]

An ECG will show the same changes seen in HCM (see the "Hypertrophic Cardiomyopathy" section). A CXR may show calcification of the aortic cusps and evidence of HF. Heart size may be normal or only mildly enlarged.[39]

AS that is asymptomatic requires regular examinations. In mild AS, an echocardiogram is done every 3 years. For moderate AS, an echocardiogram is done every 1–2 years, and for severe AS, an echocardiogram should be done every 6–12 months. For moderate-to-severe AS, strenuous activity needs to be avoided.[37]

When AS becomes moderate to severe and symptoms are present, the valve will need replacement. Aortic valve replacement done by open-heart surgery is a surgical aortic valve replacement (SAVR). Two types of valves are used for replacements: mechanical and bioprosthetic.[37] See Figure 15-17. Younger patients receive mechanical valves because they last longer than a bioprosthetic. The disadvantage is that mechanical valves require long-term oral anticoagulation (i.e., warfarin) to prevent clots. Bioprosthetic valves do not require the use of long-term oral anticoagulation, but their durability is only 15–20 years. Older patients receive bioprosthetic valves.[37]

In some cases, the patient is not a candidate for SAVR. These patients are candidates for transcatheter aortic valve replacement (TAVR). This procedure is performed in a hybrid operating room/catheterization



FIGURE 15-19 SAVR with a mechanical valve.
© miralex/iStock/Getty Images.



FIGURE 15-20 Preparation of a transcatheter aortic valve in cold saline.
© ChaNaWiT/Shutterstock.

lab while the patient is awake.[40] In this procedure, a bioprosthetic valve is supported by a stent and is mounted on a balloon catheter.[40] See **Figure 15-19**. This catheter is advanced to the heart and is placed inside of the stenotic valve. After confirmation of placement, the balloon is inflated and the new valve deployed over the stenotic valve. The catheter can be inserted into the femoral artery (transfemoral approach) or the apex of the heart (transapical approach) (**Figure 15-20**).[40]

Risk factors for AS are deformed aortic valve, family history of congenital problems, age, rheumatic fever, chronic kidney disease, high BP, high cholesterol, Type 2 diabetes, and smoking.[41] If AS is left untreated, the LV will hypertrophy and cause chest pain (angina), fainting (syncope), HF, arrhythmias, and cardiac arrest.[41]

Once symptoms manifest, the survival rate is only 2–3 years. The valve needs replacement quickly. This will help to improve symptoms and survival rates. Surgery risks will increase if the patient has coronary artery bypass grafting and if there is a reduction in LV systolic function. Once the AS becomes severe, there is a 50% mortality rate from sudden death (**Table 15-16**).[39]

TABLE 15-16
Summary of AS

Description	Opening between the LV and the AO is stenotic, mainly from calcification
Etiology	Rheumatic fever
Clinical manifestations	Angina Syncope Heart failure
Diagnostic tests	CXR Cardiac catheterization Doppler echocardiogram ECG
Medical treatment	Supportive
Surgical treatment	SAVR TAVR

Mitral Regurgitation (Insufficiency)

Mitral regurgitation (insufficiency) (MR) is the result of backward movement of blood between the LV and the LA during LV systole.[42] The mitral valve handles the highest pressures in the heart. It has only an anterior and a posterior leaflet; the other three valves have three leaflets.[42] The leaflets of the mitral valve attach to the chordae tendineae, which attach to the papillary muscles. This configuration prevents the mitral valve leaflets from flipping into the LA during LV systole. The papillary muscles are along the inferior and anterior walls of the LV, and one end of the chordae tendineae is attached to them while the other end attaches to the free edges of the mitral valve leaflets. See **Figure 15-21**.

During LV systole, the papillary muscles will contract pulling the chordae tendineae tight and preventing the leaflets from prolapsing into the LA.[42] A normally functioning valve allows blood to flow unimpeded from the LA to the LV during diastole and prevents regurgitation during systole. The causes of MR can be from a problem with the valve itself (primary) or the LV (secondary).[42]

The primary causes of MR are rheumatic fever, infectious endocarditis, or myxomatous degeneration.[42] Rheumatic fever is an infection triggered by Group A streptococcus and, if not treated with antibiotics, will cause scarring on the heart valves, which can lead to regurgitation or stenosis.[43] The endocardium lines the inner walls of the LV and heart valves, and infectious endocarditis is a result of bacteria or other microbes. If the infection remains untreated, the bacteria can destroy the leaflets, which can lead to MR and HF.[44] Myxomatous degeneration causes the fibrous collagen layer of the valve to thin and a layer of mucoid (myxomatous) material will accumulate. Because of this, the chordae tendineae will become longer and thinner, which results in the leaflets becoming enlarged and rubbery.[45]



FIGURE 15-21 In mitral valve regurgitation, as the LV pumps blood into the aorta, some blood leaks back into the LA, increasing blood volume and pressure there. The increased BP in the LA increases BP in the veins leading from the lungs to the heart (pulmonary veins) and causes the LA to enlarge to accommodate the extra blood leaking back from the ventricle.

Secondary causes of MR can be from CAD or LV dilatation.[42] If the LV becomes dilated as described in the "Dilated Cardiomyopathy" section, the valve annulus will also dilate, resulting in MR. A MI that affects the anterolateral and posteroinferior LV walls can cause the papillary muscle to die. Without the papillary muscle to pull the chordae tendineae tight, the mitral valve leaflets will prolapse, and blood will regurgitate into the LV.[46] **Table 15-17** lists the causes of mitral valve regurgitation.

In significant MR, the LA is receiving blood from the lungs and the LV, and this will cause the LA to dilate from volume overload. If the MR is acute, the pressure in the LA and pulmonary veins (PV) will increase quickly, leading to pulmonary congestion and pulmonary edema; this can result in an emergency.[39] If the MR is chronic, the LA can dilate, which is a compensatory mechanism and will keep the LA and PV pressure lower until late in the course of the disease.[42] With the progression of the regurgitation, the LV will dilate and will lead to an increase in afterload, contractile dysfunction, and HF.[42] As the LA enlarges to compensate, it may cause AF, which can lead to blood clots. If MR is allowed to continue, it will lead to PH and right-side HF.[42]

The signs and symptoms of acute MR are similar to those for HF (Table 15-3). In chronic MR, the heart has time to compensate. There are no signs or symptoms at onset.[39,47] Once the LV and LA have reached their limits, the PA and venous pressure increases. At that time, the symptoms will be dyspnea, fatigue, orthopnea, palpitations, and AF.[47] Upon palpation, a brisk apical impulse may be detected, and if the LV is hypertrophied and dilated, then the LV impulse will be sustained, enlarged, and displaced downward and to the left.[47] As the

TABLE 15-17
Common Etiologies of MR and Their Structural Abnormalities

Primary Etiology	Anatomy Affected
Myxomatous degeneration	Mitral valve leaflets
Rheumatic fever	Mitral valve leaflets, chordae tendineae
Endocarditis	Mitral valve leaflets, chordae tendineae
HCM	Mitral valve leaflets
Annular calcification	Mitral annulus
DCM	Ventricular cavity dilation
MI anterolateral/posteroinferior	Papillary muscles

LA becomes enlarged, a diffuse precordial lift occurs, causing anterior cardiac displacement. On auscultation, the S_1 sound may be soft, but could occasionally be loud.[47] The S_3 heart sound is heard at the apex, reflecting LV dilation. The S_3 sound indicates the MR is severe and is progressing to HF.[47] In MR a holosystolic, or pansystolic, murmur will be heard at the apex of the heart when the patient is laying on their left side. In mild MR, the systolic murmur may be abbreviated or occur late in systole.[47]

As the disease progresses, an ECG will show LAE (see the "Hypertrophic Cardiomyopathy" section) and AF. If PH is present, then the ECG will also reveal right ventricular hypertrophy (RVH). The tall R wave in Leads V_1 or V_2 is an indication of RVH.[48] A CXR may demonstrate LAE and/or cardiomegaly.[42] See **Figure 15-22**. The major pathophysiologic differences between acute and chronic MR depend greatly on the size of the LA and its compliance. In chronic MR, the LV gradually compensates for the volume overload through hypertrophy.

If MR is suspected, an echocardiogram will be done to confirm its presence, assess etiology, and determine its severity.[42] See Table 15-13. If the echocardiogram is inconclusive, a presurgical TEE is indicated to assess the feasibility of repair.[42]

CMRI is used in patients with chronic primary MR. This test will evaluate the LV and RV volumes, function, or MR severity. If this test is inconclusive, then a TEE will be performed.[42]

Having the patient perform an exercise treadmill testing can help to establish symptom status and exercise tolerance. Hemodynamic measurements are obtained during a treadmill test by using Doppler echocardiogram.[42]



FIGURE 15-22 CXR of a 56-year-old woman with huge cardiomegaly and no pulmonary infiltration.

Cardiac catheterization can be performed to obtain hemodynamics, regurgitant fraction, and coronary angiograms and assess myocardial function; noninvasive imaging may be an option. These tests will help to decide the best way to manage the MR.[42]

When MR is acute, using intravenous nitroprusside and nitroglycerin will help to reduce the regurgitant fraction and pulmonary pressures. An intra-aortic balloon pump also helps stabilize these patients. Both of these treatments will help only for a short time, and mitral valve repair or replacement is required.[42]

No medications are used if the MR is chronic and asymptomatic, and there is normal LV function. The primary goal in these cases is to time the repair or replacement of the valve appropriately. Waiting too long will lead to the development of irreversible LV dysfunction.[42]

In chronic primary MR that is symptomatic and the LV has become dysfunctional, intervention is needed. An indication of LV dysfunction is the EF being less than 60%, or LV end-systolic diameter greater than 40 mm.[33] The risk of surgery will increase once the EF falls below 30%.[33]

A device that is currently being tested in the United States is the mitral clip. This device uses a clip to pull the mitral leaflets together, thus reducing the regurgitation. The clip is mounted on a catheter that is introduced through the venous system and is advanced to the LA via an atrial septal wall puncture.[42]

TABLE 15-18
Summary of MR

Description	The backward movement of blood between the LV and the LA during LV systole
Etiology	Myxomatous degeneration Rheumatic fever Endocarditis HCM Annular calcification DCM MI anterolateral/posteroinferior
Clinical manifestations	Acute: pulmonary edema Chronic: similar to left-sided HF
Diagnostic tests	Echocardiogram CMRI TEE Exercise testing Cardiac catheterization
Medical treatment	Acute MR—intravenous nitroprusside, nitroglycerin
Surgical treatment	Acute MR before surgery—intra-aortic balloon pump Mitral valve repair Mitral valve replacement

Risk factors for MR are mitral valve prolapse, mitral valve stenosis, family history of valve disease, heart attack, heart disease, DCM, certain medications (diet pills), endocarditis, rheumatic fever, congenital heart disease, MI, and age.[49] Mild MR may not cause any problems; however, severe MR will cause HF, right-sided HF, A-fib, and PH.[49] Prognosis will be affected by duration, severity, and cause of MR (**Table 15-18**).[33]

Mitral Stenosis

Mitral stenosis (MS) is a result of the opening between the LA and the LV becoming thick and immobile or stenotic. Consequently, less blood will flow into the LV from the LA.[42] Causes of MR are rheumatic heart disease (most common), severe calcification of the mitral annulus, infectious endocarditis, systemic lupus erythematosus, rheumatoid arthritis, and carcinoid heart disease.[42] Although rheumatic heart disease has declined greatly in the past 40 years, it is still prevalent in developing countries. Approximately 15.6 million people suffer from rheumatic heart disease worldwide, and there are approximately 282,000 new cases each year and 233,000 related deaths.[42]

Typically, it is more than 20 years after an episode of rheumatic fever that symptoms from MS appear. Rheumatic fever can cause inflammation of the heart,



FIGURE 15-23 Rheumatic mitral valve specimen.

which leads to the leaflets and chordae tendineae becoming thickened, scarred, and calcified (Figure 15-21).[42] The scarring and calcification creates an obstruction to blood flow. The LA will become hypertrophied to create more pressure to move the blood through the stenotic opening. This will increase the pressure in the LA and PV, and there will be a pressure gradient across the mitral valve during diastole.[42] Consequently, the pressure increase will lead to LAE, which may cause atrial fib and arterial thromboembolism. As the pressure in the PV increases, it will induce pulmonary congestion and pulmonary edema. If MS goes untreated, PH and right-sided HF will develop (**Figure 15-23**).[42]

The signs and symptoms of MS include exertional dyspnea, fatigue, atrial arrhythmias, embolic events, angina-like chest pain, and hemoptysis.[42] There may be no symptoms or symptoms appear acutely during exercise, emotional stress, pregnancy, infection, or with uncontrolled AF.[42] Upon auscultation there will be an opening snap, a mid-diastolic rumble, and an accentuated S_1 heart sound. In heavily calcified valves, the first heart sound may be diminished. During atrial contraction, there may be a presystolic accentuation of the murmur.[42] If the valve narrowing is caused by a noncancerous tumor (left atrial myxoma), there will be a "tumor plop" versus an opening snap murmur in early diastole.[42]

An ECG may reveal LAE (see the "Hypertrophic Cardiomyopathy" section). As the disease advances, AF and/or RVH can develop (see the "Mitral Regurgitation (Insufficiency)" section). The RVH is a result of the increase in pulmonary pressure.[42]

A CXR will reveal LAE, cardiomegaly (this is not always present), enlargement of the main pulmonary arteries, and pulmonary congestion.[42] An echocardiogram is done to assess MS. The information obtained from this echocardiogram appears in **Box 15-8**.

The valve morphology will determine whether the valve can be repaired surgically by making an incision

BOX 15-8 Information Obtained from an Echocardiogram for MS

1. Confirm the diagnosis
2. Quantify hemodynamic severity (mean pressure gradient)
3. Mitral valve area (MVA)
4. PA pressure
5. Assess valvular lesions and valve morphology
6. Detection of other valve diseases
7. Visualization of left atrial thrombus
8. Identify if a left atrial myxoma is present



FIGURE 15-24 Commissurotomy in rheumatic mitral valve stenosis.

in the valve leaflets called a mitral commissurotomy.[42] See **Figure 15-24**. The findings from an echocardiogram include valve thickening, restricted valve opening, anterior leaflet doming, and fusion of the leaflets where they join (commissures).[42] Doppler can be used to quantify the pressure gradient and MVA. There is, at least, a 5-mm Hg pressure gradient across the mitral valve between the LV and the LA in MS and is severe if the gradient is greater than 10 mm Hg. Once the MVA falls below 1.0 cm^2, it is considered critical.[42]

Medications for MS are designed to ease the symptoms. Using beta-blockers, calcium-channel blockers, digoxin, and ivabradine (works on the electrical activity of the SA node) to control the heart in MS has been proven beneficial. When A-fib is present, an oral anticoagulation may be used to prevent thromboembolism.[42]

Two invasive procedures are used to repair the mitral valve in MS. The first is percutaneous mitral balloon commissurotomy (valvuloplasty) (PMBC) and is a catheter-based technique.[19] In this procedure, a balloon



FIGURE 15-25 Percutaneous transluminal mitral commissurotomy balloon inflation in a 5-year-old with severe MS.
Reproduced with permission from Ullah M, Sutan M, Akbar H, Sadiq N. Percutaneous transluminal mitral commissurotomy for rheumatic mitral stenosis in a 5-year-old child. *Pediat Cardiol.* 2012;33:815.

is inflated across the stenotic valve to split the fused commissures and increase the valve area; before 1984, this was done surgically. See **Figure 15-25**. Normally, improvements in the hemodynamics are is seen immediately as well as clinical improvements.[42]

This procedure is usually the first option for treating MS, and should be considered when the symptoms have become severe, and the valve morphology is favorable. This procedure is considered palliative, and in the majority of cases, further treatment will be needed.[42]

The other type of invasive procedure is mitral valve replacement. As with SAVR, two types of valves are used (mechanical and bioprosthetic). The selection of the valve will be the same as in AS (see "Aortic Stenosis" section). Mitral valve replacement is indicated when the MS is severe and symptoms are severe, and the NYHA HF class is III/IV, is not high risk for surgery, is not a candidate for PMBC, or had a failed PMBC.[42]

Risk factors for MS are rheumatic fever and untreated strep infections.[42] Mitral valve stenosis can cause a strain on the heart and decrease blood flow. When MS goes untreated, complications such as PH, right HF, heart enlargement, A-fib, blood clots, and pulmonary edema may occur.[50] Severe disabilities will occur approximately 7–9 years following the manifestation of symptoms. The outcome is affected by pre-procedural age, functional status, PH, and the degree of MR (if present). The time between valve repair and restenosis varies, and once function declines, valve replacement may become necessary (**Table 15-19**).[51]

TABLE 15-19
Summary for MS

Description	The opening between the LA and the LV is thick and immobile or stenotic.
Etiology	Rheumatic heart disease (most common) Severe calcification of the mitral annulus Infectious endocarditis Systemic lupus erythematosus Rheumatoid arthritis Carcinoid heart disease
Clinical manifestations	Exertional dyspnea Fatigue Atrial arrhythmias Embolic events Angina Hemoptysis Accentuated S_1 heart sound (in early MS)
Diagnostic tests	ECG CXR Echocardiogram
Medical treatment	Beta-blocker Calcium-channel blocker Digoxin Ivabradine Oral anticoagulant to prevent thromboembolism with AF
Surgical treatment	PMBC Mitral valve replacement

Pulmonic Regurgitation

Pulmonic regurgitation (insufficiency) (PI) occurs as a result of an incompetent leaky pulmonic valve.[52] PI is most often a result of severe PH. The three pathologic processes that cause PI are dilatation of the pulmonic valve ring, alteration of the pulmonic valve leaflet, or congenital absence or malformation of the valve.[52] In the majority of cases, PI is seldom clinically significant; however, symptoms of right-sided HF can occur, and the RV can become dilated when the severity and duration of the regurgitation is chronic.[52] Dyspnea on exertion is the most common complaint. However, other symptoms include fatigue, light headedness, peripheral edema, chest pain, palpitations, and syncope. These symptoms usually occur in right-sided HF.[52]

In severe and long-term PI, there will be RV enlargement, decompensation, and, eventually, right-sided HF.[53] Symptoms include dyspnea on exertion, fatigue, lightheadedness, peripheral edema, chest pain, palpitations, and frank syncope. Many of these symptoms are attributed to poor physical fitness or anxiety, which will cause a delay in seeing a physician.[53] Once it advances to right-sided HF, there may be abdominal distension secondary to ascites, increased jugular venous pressure, enlarged and pulsatile liver, and right upper quadrant pain secondary to hepatic distension.[53,54] Upon auscultation, a decrescendo murmur will be heard in early diastole, and an S_3 or S_4 sound will be heard at the left mid-to-lower sternal border.[54] In the presence of PH, there will be a Graham Steell murmur. This is a high-pitched, early diastolic decrescendo murmur noted over the left upper to left mid-sternal area.[54]

A CXR will show little change unless TR also occurs. If there is TR, then cardiomegaly and enlargement of the right heart are observed.[36]

Cardiac catheterization is usually not necessary for diagnosing PI, but it can help in determining the cause and diagnosis of CAD that are risk factors in patients. All of this information will influence the treatment and/or repair decisions.[36] Performing a PA angiography may reveal evidence of pulmonary emboli as a cause of PH, and the degree of regurgitant flow; this is measured using the same scale as discussed in the "Aortic Insufficiency (Aortic Regurgitation)" section.[36]

An echocardiogram can reveal RVH and dilatation. RV volume overload can cause abnormal septal wall motion during diastole, and RV pressure overload can cause abnormal septal wall motion during systole.[47] An echocardiogram can reveal a lack of a pulmonic valve or valve deformities; however, the pulmonic valve apparatus typically appears unremarkable. In some cases, pulmonic ring dilatation with poor valve leaflets can be seen.[36]

A Doppler echocardiogram shows the regurgitant flow and regurgitant jets, measures the flow velocities of the regurgitant jets, and accurately estimates pulmonary pressures.[36] If the regurgitation occurs throughout diastole, this suggests the presence of PH; however, if the regurgitation diminishes in early diastole, then pulmonary arterial pressures may be normal.[36]

CMRI has excellent temporal and spatial resolution, and can provide an accurate estimation of the severity of regurgitation, mechanism of regurgitation, and RV size and function.[36] An ECG may demonstrate findings of RV dilatation, incomplete right bundle branch block, right-axis deviation, and RVH (see the "Mitral Regurgitation (Insufficiency)" section).[36]

If the pressure in the RV becomes too high, it may cause right-sided HF, and the pulmonary valve will need replacement. When it becomes impossible to treat the symptoms with medications, the valve will need to be repaired or replaced. When replacing the valve, a bioprosthetic one is preferred. Recent studies have shown a percutaneous bioprosthetic valve is a reasonable option. A study of percutaneous bioprosthetic valve replacement, the Melody Valve Trial, reported that freedom from valve dysfunction or reintervention following percutaneous bioprosthetic valve placement was 93.5% in 1 year.[52]

The risk factors for PI are PH, surgical repair of Tetralogy of Fallot, PS, pulmonary atresia, endocarditis, left-sided heart disease, or previous Ross procedure (with prosthetic pulmonary valve, homograph valve

TABLE 15-20
Summary for Pulmonary Regurgitation

Description	A result of an incompetent leaky pulmonic valve
Etiology	Severe PH
Clinical manifestations	Symptoms of right-sided HF Dyspnea on exertion Fatigue Light headedness Peripheral edema Angina Palpitations Syncope S_3 or S_4 sound heard at the left mid-to-lower sternal border
Diagnostic tests	Doppler echocardiogram CMRI ECG
Medical treatment	Supportive
Surgical treatment	Pulmonary valve repair Pulmonary valve replacement Percutaneous bioprosthetic valve replacement

replacement).[55] Complications from PI are abnormal heart rhythms, HF, and infection in the heart.[35]

The key to an improved prognosis with PI is early detection and treatment. The RV can compensate for many years if the PI is mild or moderate. However, if the PI becomes severe and the RV volume increases, the RV will start to dilate, which will lead to right-sided HF. The conditions that affect the prognosis of PI where PH has developed are the severity and duration of PH at the time of diagnosis and the RV response to the state of volume overload (**Table 15-20**).[56]

Pulmonary Stenosis

Pulmonary stenosis (PS) is due to stenosis of the opening between the RV and the PA[57] Most often it is congenital and affects children. The stenosis can be at the valve or in the outflow track immediately below the valve (infundibular). It commonly is a component of Tetralogy of Fallot.[57]

There will be a systolic pressure gradient between the RV and the PA. This gradient is necessary to maintain the cardiac output, and will cause RVH.[58] When the RV is not able to maintain the cardiac output, right-sided HF will occur. Right-sided HF occurs in neonates with critical PS and if there is a severe obstruction.[58]

Symptoms from PS may not appear until adulthood even if it is congenital. When symptoms do appear, they resemble those of AS. However, the effects will be right HF instead of left HF and systemic venous congestion instead of pulmonary congestion. Signs and symptoms

TABLE 15-21
Summary of PS

Description	Stenosis of the opening between the RV and the PA
Etiology	Congenital Tetralogy of Fallot
Clinical manifestations	Not apparent Widened splitting of S_2 heart sound Systolic heart murmur Resemble AS, except with right HF
Diagnostic tests	Doppler echocardiogram ECG
Medical treatment	Supportive
Surgical treatment	Balloon valvuloplasty Pulmonary valve replacement

of RVH and RV failure are a prominent jugular venous, a wave, an RV precordial lift or heave, systemic venous congestion, and a left parasternal systolic thrill at the second intercostal space.[57]

Upon auscultation, the S_1 sound is normal, and the normal splitting of S_2 is widened because of prolonged pulmonic ejection. In RV failure and hypertrophy, the S_3 and S_4 heart sounds are rarely audible.[57] The murmur is systolic and occurs at the left parasternal second intercostal for valvular and the fourth intercostal space for infundibular stenosis. The murmur will be a harsh crescendo-decrescendo ejection murmur.[57]

A Doppler echocardiogram will confirm PS. The classifications of the severity of the stenosis are mild: peak systolic gradient less than 36 mm Hg, moderate: peak systolic gradient 36–64 mm Hg, and severe: peak systolic gradient greater than 64 mm Hg.[57]

The ECG may be normal and may show RVH (see the "Hypertrophic Cardiomyopathy" section) or right bundle branch block. If valvular and infundibular stenosis is present, then a heart catheterization is indicated.[57]

Treatment will include balloon valvuloplasty if peak systolic gradient is greater than 40–50 mm Hg, or valve replacement. If the valve is replaced, a bioprosthetic valve (Melody valve by Medtronic) is used because of the high rates of thrombosis of right-sided mechanical heart valves.[57]

Risk factors for PS are carcinoid syndrome, rheumatic fever, and Noonan syndrome.[59] Complications are bacterial infection, endocarditis, RVH, HF, and arrhythmias.[60] Even without treatment, the prognosis is good; however, appropriate treatment will improve the prognosis (**Table 15-21**).[57]

Tricuspid Regurgitation

Tricuspid regurgitation (TR) results from the leaflets of the TV not closing properly, allowing blood



FIGURE 15-26 A malfunctioning TV that allows blood to backflow into the RA during systole causes TR.
Courtesy of U.S. National Library of Medicine.

to flow from the RV to the RA during systole. See **Figure 15-26**.

The most common cause of TR is RV dilation.[61] Moderate or severe TR is most frequently functional in nature and caused by TV leaflet pathology. Also, moderate TR will increase the volume in the RV and cause RV dilatation. As the RV dilates, the TV annulus will stretch, which will exacerbate TR.[62] The causes of TR appear in **Table 15-22**.

There can be a prolonged latent period for TR, even if it is severe. As the RA dilates, atrial arrhythmias will become common. There is a significant reduction in exercise capacity with severe TR, which is caused by impaired cardiac output response.[62]

Normally TR will not have symptoms; however, some patients experience neck pulsations due to elevated jugular pressures. If TR becomes severe, then the symptoms are fatigue, abdominal bloating, and anorexia; in some cases, symptoms of AF or atrial flutter can be seen.[61]

Signs of moderate-to-severe TR include JVD, possible liver enlargement, and peripheral edema. In most cases, the murmur from TR is not heard; however, if it is present, then it is best heard at left middle or lower sternal border when the patient is sitting upright or standing.[61] The murmur is heard through systole (holosystolic) and will be high pitched if it is trivial and from PH; if from other causes, then it will be medium pitched.[34] The sound of the murmur will increase with inspiration (Carvallo sign).[61]

An echocardiogram is the best way to confirm TR. Echocardiograms identify most cases of mild TR when used to diagnose other problems. Conditions that need to be present to confirm severe TR appear in **Box 15-9**.

TABLE 15-22
Causes of TR

Type	Cause
Congenital	• Ebstein anomaly • TV dysplasia • TV hypoplasia • TV cleft • Double-orifice TV • Unguarded TV orifice

Acquired	• Endocarditis
	• Trauma
	• Carcinoid heart disease
	• Rheumatic heart disease
	• TV prolapse
	• Iatrogenic
	  • Radiation
	  • Drugs
	  • Biopsy

Functional (normal leaflets)	• Annular dilatation • RV dysplasia • Endomyocardial fibrosis • Primary PH • Secondary PH • ASD • Anomalous pulmonary venous drainage

Data from Bruce C, Connolly H. Right-sided valve disease deserves a little more respect. *Circulation.* 2009;119(20):2726–2734. doi:10.1161/circulationaha.108.776021.

An ECG in TR is usually normal. However, if the TR is severe, there may be right atrial enlargement (tall peaked P waves in Lead II), RVH (see the "Hypertrophic Cardiomyopathy" section), or AF. Early on in TR, the CXR is normal. As TR advances the CXR may show

BOX 15-9 Conditions Indicating Severe TR

1. Failure of the leaflets to join (coaptation)
2. Flail leaflet (chordae tendineae not holding leaflet in place)
3. Large regurgitant jet on color Doppler
4. Large flow convergence zone proximal to the valve
5. Systolic flow reversal in the hepatic veins

RVH, RV dysfunction, HF, enlarged superior vena cava, and an enlarged right atrial or RV silhouette.[61]

If surgery is planned, a cardiac catheterization is performed. This will allow for accurate pressure measurements and evaluation of the coronary anatomy. On the right atrial pressure waveform, a large V wave is seen.[61]

Very mild TR is not usually medically treated unless endocarditis causes it. However, severe TR necessitates repair as soon as symptoms are present or when it is moderate with progressive RV enlargement or dysfunction.[61] As the TR becomes severe, it will cause RV volume overload. Eventually, the RV will not be able to function properly. When this occurs, the problem is irreversible. The prognosis at this point is poor.[61] TR has a negative impact on long-term survival.[62]

Repair options include annuloplasty (the valve annulus is sutured to a prosthetic ring), valve repair, and valve replacement. If annuloplasty is not feasible or the valve is abnormal, then valve repair or replacement is necessary. The indication for valve replacement includes damage by the chemical released from a carcinoid tumor (carcinoid syndrome) or Ebstein anomaly (the inferiorly displaced valve located in the RV). The pressures on the right side of the heart are low and reduce the chances of thrombus by using a bioprosthetic.[61]

The main complication with TR is endocarditis. Good dental care reduces the risk of this complication. Before any invasive medical procedure, including dental work, anyone with TR needs to take antibiotics to prevent infection (**Table 15-23**).[63]

Tricuspid Stenosis

Tricuspid stenosis (TS) obstructs blood flow from the RA to the RV during diastole.[64] Rheumatic heart disease accounts for approximately 90% of TS cases. TS is rare in developed countries.[62] Mitral valve disease invariably accompanies rheumatic TS, and it is difficult to separate symptoms specific to TS. The causes of TS appear in **Box 15-10**.

The signs and symptoms of severe TS appear in **Box 15-11**.

TABLE 15-23
Summary of TR

Description	TV leaflets do not close properly, allowing blood to flow from the RV to the RA during systole.
Etiology	Congenital Acquired Functional
Clinical manifestations	Prolonged latent period (mild) JVD (moderate to severe) Liver enlargement (moderate to severe) Peripheral edema (moderate to severe) Carvallo sign
Diagnostic tests	Doppler echocardiogram ECG Cardiac catheterization
Medical treatment	
Surgical treatment	Annuloplasty repair Surgical valve repair Surgical bioprosthetic valve replacement

BOX 15-10 Causes of TS

- Rheumatic heart disease
- Congenital TS
- RA tumors
- Carcinoid heart disease
- Endomyocardial fibrosis
- Valvular vegetation
- Extracardiac tumors

Data from Bruce C, Connolly H. Right-sided valve disease deserves a little more respect. *Circulation*. 2009;119(20):2726–2734. doi:10.1161/circulationaha.108.776021.

BOX 15-11 Signs and Symptoms of Severe TS

- Fluttering discomfort in the neck
- Fatigue
- Cold skin (due to low cardiac output)
- Right upper quadrant abdominal discomfort (due to an enlarged liver)
- JVD increasing with inspiration (Kussmaul sign)
- Face dusky in color
- Scalp veins may dilate when the patient is lying down (recumbent)
- Hepatic congestion
- Peripheral edema

Upon physical examination and auscultation, TS is often inaudible but may produce a soft opening snap. Upon inspiration, the murmur becomes louder and longer and will be softer and shorter with the Valsalva maneuver.[64] Findings of TS often coexist with those of MS and are less prominent. The murmurs are clinically distinguishable.[64]

A suspected TS from an examination requires an echocardiogram to confirm its presence. An echocardiogram shows a diastolic pressure gradient across the TV (>5 mm Hg if severe), thickened leaflets with reduced movement, and RA enlargement.[64] An ECG may show RA enlargement with tall peaked P waves in inferior leads and V_1. The superior vena cava and RA will appear enlarged on a CXR. Blood work will reveal elevated liver enzymes due to hepatic congestion.[64]

A cardiac catheterization is usually not performed; however, if performed, it will show elevated RA pressure with a slow fall in early diastole and a diastolic pressure gradient across the TV.[64]

Because there is not much evidence to show that valve replacement is beneficial, the valve is rarely replaced; medical treatment will include a low-salt diet, diuretics, and aldosterone antagonists. If the symptoms worsen, then the valve needs replacement.[64]

Risk factors for TS include Group A streptococcal pharyngitis, metastatic carcinoid tumors, artificial TV, intravenous drug use, pacemaker/defibrillator leads crossing TV orifice, and genetic predisposition and environmental factors.[65] Complications from TS are right atrial enlargement, right-sided HF, stroke, arrhythmias, or blood clots.[66] The prognosis of TS is usually good, but it is dependent on the progression of the underlying causes, other related heart abnormalities, and associated arrhythmias (**Table 15-24**).[67]

TABLE 15-24
Summary of TS

Description	Obstruction of blood flow from the RA to the RV during diastole due to stenosis
Etiology	Rheumatic heart disease (90% of cases)
Clinical manifestations	JVD Abdominal distension Hepatomegaly
Diagnostic tests	Echocardiogram ECG CXR Liver enzymes
Medical treatment	Low-sodium diet Diuretic Aldosterone antagonist
Surgical treatment	Surgical valve replacement

KNOWLEDGE CHECK QUESTIONS

1. True or False: AI leads to LV volume overload.
2. True or False: The most common valvular heart disease is MS.
3. True or False: DCM can cause MR.
4. True or False: The S_1 heat sound is accentuated with MS.
5. True or False: Chronic severe pulmonary insufficiency causes left-sided HF.
6. True or False: PS is a component of Tetralogy of Fallot.

Congenital Heart Disease

A congenital heart disease is due to a structural and functional problem within the heart that has been present since birth. VSDs and ASDs are the most common types of congenital heart defects that can go undetected for years if small enough.

Ventricular Septal Defects

A **ventricular septal defect (VSD)** is the abnormal opening in the intraventricular septal wall[6] (Figure 15-25). The incidence of VSDs is 1.5–3.5 per 1,000 live births.[68] The size, and not the location, of the VSD dictates some hemodynamic changes and symptoms. A VSD allows communication between systemic and pulmonary circulations. The blood flow through the VSD typically moves from the LV (high pressure) to the RV (low pressure), causing a left-to-right shunt (**Figure 15-27**).



FIGURE 15-27 Ventricle septal defect.

The smaller the VSD, the more resistance flows through it, resulting in less shunted blood. Small VSDs are **restrictive VSDs** because the defect itself offers more resistance to flow than the pulmonary or systemic vasculature.[68] Large VSDs allow significant shunting to occur. A fetus with a large VSD has little shunting because both pulmonary and SVR are equivalent. After birth, however, the normal fall in pulmonary vascular resistance (PVR) causes increasing left-to-right shunting through a large VSD. Because no physical resistance to blood flow exists with a large VSD, they are **nonrestrictive VSDs**.[68]

A small VSD may not produce symptoms and may have an excellent long-term prognosis, even without treatment. A large VSD requires a trial of a medical therapy to manage symptomatic CHF.[32] Many VSDs may become smaller over time. However, uncontrolled CHF accompanied by a failure to thrive and recurrent respiratory infections are indications of surgical repair. Neither the age nor the size of the patient is prohibitive when considering surgery.[68]

The pathophysiologic effects of a VSD result from a large left-to-right shunt. The hemodynamic consequences of a left-to-right shunt are volume overload of the RV, pulmonary circulation, LA, and LV. Initially, the increased blood return to the LV augments stroke volume (via the Frank–Starling mechanism), but over time, the increased volume load can result in chamber dilatation, systolic dysfunction, and symptoms of HF.[68] The volume overload in the RV increases pressure and may lead to pulmonary vascular disease.[69] The presence of pulmonary vascular disease may change the shunt to a right-to-left shunt (Eisenmenger syndrome).[69] A right-to-left shunt will send deoxygenated blood directly to the systemic arterial circulation, causing systemic hypoxemia and cyanosis.[68]

The size of the VSD and left-to-right shunt influences the patient signs and symptoms.[70] The large VSDs are typically found early and repaired. If an adult has a VSD, it is usually small in size.[70] Small VSDs are typically asymptomatic or mild, with no murmur heard during auscultation.

Newborns with moderate VSD may sweat excessively during feedings due to increased sympathetic tone. The increased cardiac output needed for feeding fatigues the infant, resulting in failure to thrive and frequent respiratory infections. Symptoms become more apparent as the PVR decreases.[70] The symptoms of a large VSD will be similar to those of a moderate VSD, but with increased severity. A delayed decrease in PVR will delay the symptoms.

Cardiac auscultation detects a VSD over the lower left sternal border. The sound heard is related to the oxygenated blood "swishing" through the hole or VSD into the RV (**holosystolic murmur**).[71] The smaller the defect, the louder the holosystolic murmur. This occurs because smaller holes create more turbulent flow. When suspected, a VSD is confirmed by Doppler echocardiogram. The echocardiogram quantifies the amount of blood shunted and the pulmonary pressure. A CXR may show an enlarged heart, pulmonary congestion, or alveolar edema.[71] An ECG may show LVH or RVH (see "Hypertrophic Cardiomyopathy" section). With RVH, there is a concern with PH and immediate intervention is necessary. A right and left heart catheterization may be necessary to obtain right heart, left heart, and pulmonary pressures.[71]

By age 2, at least 50% of small and moderate-sized VSDs undergo sufficient partial or complete spontaneous closure to make intervention unnecessary.[68] Even after this type of closure, long-term follow-up is required.[72]

An untreated VSD can lead to pulmonary vascular disease and HF. If HF develops, it is treated with the same drugs used for DCM. Ultimately, a large VSD will need to be repaired surgically. Two types of surgeries are available to correct a VSD: the intracardiac technique and the transcatheter technique.[72] The surgical procedure is open-heart surgery, using the heart–lung bypass machine. The surgery to repair a VSD usually involves placing a patch to close the hole.[73] The patch is a strong woven fabric made of Gore-Tex or Dacron. During the healing process, the heart's cells will grow over the patch, making it part of the body.[73]

The transcatheter approach, currently in clinical trials, involves surgical instruments passed through catheters inserted into the body. To close the hole, a disk is deployed through the catheter.[72]

Risk factors for VSD include Asian heritage (Asians are more likely to be born with VSD), family history of congenital heart disease, and other genetic disorders, such as Down syndrome.[74]

Complications from VSD include aortic regurgitation, Eisenmenger syndrome, RV outflow tract obstruction, discrete fibrous sub-AS (a fibrous lesion obstructing the LVOT), and infective endocarditis.[75]

Children with small VSDs, who are asymptomatic, have a good prognosis. However, the outcome of medical therapy for children with moderate or large VSDs varies. Many infants show improvement between the ages of 6 and 24 months. Surgical intervention carries less than a 2% mortality rate for isolated VSDs (**Table 15-25**).[68]

Atrial Septal Defect

Atrial septal defects (ASD) are persistent openings in the heart between the left and the right atria, as seen in **Figure 15-28**. The opening can occur anywhere along the atrial septum, but most commonly occurs in the area of the foramen ovale. This is an **ostium secundum defect**. Its development is due to inadequate formation of the septum secundum, excessive resorption of the septum primum, or a combination.

TABLE 15-25
Summary of VSDs

Description	Abnormal opening in the intraventricular septal wall
Etiology	Congenital defect
Clinical manifestations	Small VSD—holosystolic murmur Large VSD—signs and symptoms of CHF and pulmonary vascular disease
Diagnostic tests	Doppler echocardiogram Right and left heart catheterization
Medical treatment	Same drugs used for DCM
Surgical treatment	Open-heart surgical repair with a Gore-Tex or Dacron patch



FIGURE 15-28 ASD locations.

Less common ASDs include the **ostium primum defect** located in the lower right portion of the interatrial septum (a defect of the endocardial cushion tissue) and the **sinus venosus defect** located in the high RA (is an error in the incorporation of the sinus venosus chamber into the RA).[69]

The pathophysiology in all three ASDs is the same. The flow through the defect will occur during both systole and diastole, and is mostly a left-to-right shunt. The majority of the shunted blood occurs during diastole. It is at this time that the blood can flow through the AV valve to the ventricles, or through the defect.[69] The direction of flow across the ASD during diastole is determined by the compliance and the capacity of the two ventricles. The LV has thicker walls than the RV and, therefore, is less complaint, which will favor a left-to-right shunt.[69] If the RV develops an increase in afterload due to increasing PVR, it will become hypertrophied and less compliant. Consequently, there will be a decrease in the left-to-right shunt. The more hypertrophied the RV becomes, the less the left-to-right shunt will be. A continued RV compliance reduction will shift the shunt to a right-to-left shunt (Eisenmenger syndrome).[69]

The size of the ASD will determine the volume of blood shunted. In a large ASD, there is little or no resistance to flow. Blood flow across the defect in diastole is determined entirely by the relative properties of the ventricles. A small ASD is considered a restrictive defect. Blood flow is limited by the resistance of the ASD itself, no matter how large the difference in ventricular compliance.[69]

Children with an ASD are not always symptomatic because the myocardium is compliant and of normal size. As people with an ASD age, the myocardium hypertrophies and becomes less compliant. Symptoms usually appear between the ages of 40 and 50.[69]

Because the shunt is between the left and the right atria, the LV receives less blood. This reduces preload, leading to a reduction in contractility and systemic cardiac output. There is an increase in pulmonary cardiac output, causing pulmonary volume overload. Less oxygenated blood going into the systemic circulation causes shortness of breath on exertion, the most common symptom.[69]

The increased volume in the RA and RV causes the myocardium to stretch, resulting in atrial arrhythmias, usually the first sign of an ASD. A young adult presenting with atrial arrhythmia needs evaluation for dilatation of the RA and RV and evidence of an atrial-level shunt.[69]

If dilation of the RA and RV exist, a CXR will show cardiomegaly with a prominent PA and pulmonary vascular markings in the lung fields.[76] An ECG will vary depending on the location of the septal defect. A secundum ASD may show normal sinus rhythm, right-axis deviation, an interventricular conduction delay, or right bundle branch block.[76] An ostium primum ASD will show left-axis deviation, an interventricular conduction delay, or right bundle branch block.[76]

An echocardiogram will confirm the diagnosis of ASD. Doppler studies can demonstrate flow across the atrial septum. They typically show a biphasic pattern with a small right-to-left shunt at the beginning of systole. Using a contrast agent during the echocardiography provides confirmation of the shunt direction (right to left or left to right).[76] If an echocardiogram is inconclusive, a TEE can provide confirmation.[76]

MRIs can identify the size and position of an ASD. The MRI, however, does not detect small ASDs. Advantages of MRI use are visualization and quantification of the RV size, volume, and function and evaluation of the systemic and pulmonary venous return.[76]

Asymptomatic ASDs do not require medical therapies. Symptomatic ASDs require medical treatment

that include anticoagulant agents, antiarrhythmic agents, and diuretic agents (for CHF symptoms). ASD repair either surgically or percutaneously is the most effective treatment.[67] The surgical procedure is considered open-heart surgery and uses autologous pericardium, synthetic patches made of polyester polymer (Dacron), or polytetrafluoroethylene (PTFE) to close the ASD.[67]

An ostium primum ASD is the most complicated and difficult to repair. Placing the patch is difficult and must be attached to the septum at the juncture of the mitral and TVs. The mitral valve may also need to be repaired, including closure of the cleft mitral leaflet and, possibly, annuloplasty.[67]

A sinus venosus ASD may cause one or more of the PV to drain into the RA (anomalous pulmonary venous return). During the repair of the sinus venosus ASD, the patch must be placed so as to close the ASD and ensure the anomalous pulmonary venous drainage is diverted into the LA. If not done correctly, the pulmonary venous return will be compromised and may lead to pulmonary venous hypertension.[67]

Transcatheter ASD closure is associated with fewer complications, shortened hospitalization, and reduced need for blood products. Catheters with the ASD patch are placed through a femoral vein and deployed like an umbrella to seal the septal defect. The transcatheter devices work best for centrally located ostium secundum ASDs and for a patent foramen ovale. Prior to the procedure, a TEE determines the static diameter of the ASD. During the procedure, the diameter is measured using a sizing balloon; a balloon is inflated until no flow is visible through the defect using TEE.[67]

As with VSDs, ASDs are birth defects. They can occur alone or with other genetic problems, such as Down syndrome.[77] The risk of congenital ASDs is increased by the presence of certain conditions before or during pregnancy. These conditions include rubella, drug, tobacco or alcohol use, diabetes, lupus, obesity, and phenylketonuria (PKU).[77]

If an ASD is not repaired, the extra blood being shunted through the hole can lead to complications such as right HF, arrhythmias, stroke, and PH.[78] The mortality rate for ASD is less than 1%. The morbidity for ASD is low if it is repaired before age 45, if HF has not developed, and the pulmonary pressure is less than 60 mm Hg. When a sinus venosus ASD is surgically repaired, the mortality and morbidity are low, and clinical improvement occurs regardless of the patient's age at surgery. Whether the ASD is repaired surgically or percutaneously, the long-term results are similar. More arrhythmias are seen following surgical repair than percutaneous repair. However, there are more embolic events with the percutaneous repairs (**Table 15-26**).[67]

TABLE 15-26
Summary of ASDs

Description	Persistent opening in the heart between the left and the RA
Etiology	Congenital Maternal exposure to rubella, smoke, drugs, alcohol Maternal diabetes, lupus, obesity, or PKU
Clinical manifestations	Small ASD—asymptomatic Large ASD—CHF symptoms, myocardial hypertrophy
Diagnostic tests	CXR ECG Doppler echocardiogram TEE MRI
Medical treatment	Anticoagulant agents Antiarrhythmic agents Diuretic agents
Surgical treatment	Open-heart surgical repair with polyester polymer (Dacron) patch or PTFE patch Transcatheter closure with patch

KNOWLEDGE CHECK QUESTIONS

1. True or False: The location of the VSD determines the hemodynamic changes.
2. True or False: A holosystolic murmur is caused by a VSD.
3. True or False: There are three types of ASDs.
4. True or False: Small ASDs are usually asymptomatic.

Pericardial Diseases

The pericardium is a double-layer fibroelastic sac that contains the heart and the roots of the great vessels. This sac contains a thin layer of pericardial fluid, which provides lubrication for movement of the heart and protection against infection. Pericardial diseases may occur as a component of other systemic disorders or as an isolated disease.

Pericarditis

Pericarditis is caused by inflammation of the pericardium, often with fluid accumulation (pericardial effusion). **Acute pericarditis** is a rapidly developing inflammation of the pericardium. The pericardium is a two-layered sac that surrounds the heart. The visceral

BOX 15-12 Causes of Acute Pericarditis

- Idiopathic
- Noninfectious
  - Drug induced
    - Hydralazine
    - Procainamide
  - Connective tissue diseases
    - Rheumatoid arthritis
    - Systemic lupus erythematosus
    - Systemic sclerosis
  - Cancer
    - Breast cancer
    - Leukemia
    - Lung cancer
  - Post-MI
  - Radiation therapy
- Infectious
  - Bacteria
    - Pneumococci
    - Staphylococci
    - Tuberculosis
  - Viral
    - Coxsackie B
    - Echovirus
    - Influenza
  - Fungal
    - Blastomycosis
    - Candidiasis
    - Coccidioidomycosis
    - Histoplasmosis

pericardium contains a single layer of mesothelial cells, which adhere to the outer wall of the heart. The visceral pericardium reflects back on itself over the origin of the great vessels and joins with a tough, fibrous outer layer, the parietal pericardium. The sac created by these two layers normally contains a thin film of pericardial fluid that decreases the friction between the layers during movement.[79]

There are three main causes of acute pericarditis: idiopathic, infectious and noninfectious. See **Box 15-12**.

The most frequent symptoms of acute pericarditis are chest pain and fever. The chest pain resembles an acute MI or pulmonary infarction. Auscultation reveals a pericardial friction rub created by the movement of the inflamed pericardial layers against each other. The rub becomes louder when the patient leans forward and exhales.

TABLE 15-27
ECG Stages in Acute Pericarditis

Stages	Description
I	• ST segments show upward concave elevation • The PR segments may be depressed
II	• ST segments return to baseline • T waves flatten
III	• T waves are inverted throughout the ECG • T-wave inversion occurs after the ST segments return to baseline (different pattern than acute ischemia or MI)
IV	• T-wave changes resolve

Diagnostic studies to identify acute pericarditis include the ECG, echocardiography, and blood studies. Serial ECGs may be necessary to observe any abnormalities. ECG changes in pericarditis can occur in four stages although not all stages are present in all cases[79] (**Table 15-27**). Stage I ECG is shown in Figure 15-27.

Lab tests usually show an elevated white blood cell count and elevated erythrocyte sedimentation rate. Additional tests, blood work for serum cardiac marker (troponin), and a lung scan may be required if the ECG is atypical for pericarditis.[79] Troponin is often elevated in acute pericarditis due to epicardial inflammation, and therefore, it cannot be used to distinguish between pericarditis, acute infarction, and pulmonary embolism.[79] An echocardiogram can identify the presence and hemodynamic consequences of pericardial effusion (**Figure 15-29**).

Idiopathic or viral pericarditis is a self-limiting disease that usually runs its course in 1–3 weeks. Management involves rest, analgesics, and anti-inflammatory drugs. If a large pericardial effusion is present, it may require removal (pericardiocentesis).[80] **Subacute pericarditis** is a prolongation of acute pericarditis and has the same causes.[79]

Constrictive pericarditis results from a rigid pericardium that does not allow the heart to stretch and fill appropriately during diastole. Its etiology includes any disorder that causes acute pericarditis. Constrictive pericarditis occurs when the visceral and parietal layers adhere to each other or to the myocardium due to marked inflammatory, fibrotic (may contain calcium) thickening of the pericardium. The stiff, thickened pericardium inhibits the normal filling of the cardiac chambers.[80] The RV will quickly reach its limit, and venous return to the right heart ceases. This causes the systemic venous pressure to rise and signs of right HF to ensue.[80] Impairment of LV filling decreases cardiac output.

Clinically, constrictive pericarditis causes jugular veins to become more distended during inspiration



FIGURE 15-29 Twelve-lead ECG of acute pericarditis showing a Stage I ECG. The ST segments in all but Leads aVR and V_1 show upward concave elevation. The T waves are depressed in Leads aVR and V_1.

(**Kussmaul sign**) due to the inability of the right heart to accommodate the increased venous return created from the negative intrathoracic pressure generated by inspiration.[80]

Diagnostic testing includes ECG, lateral CXR, Doppler echocardiogram, cardiac catheterization, CT, or MRI. The ECG and echocardiography have nonspecific findings. A lateral CXR may show pericardial calcification. The Doppler echocardiography can distinguish constrictive pericarditis from RCM. Right and left cardiac catheterizations can quantify the hemodynamic changes. A CT or MRI can identify pericardial thickening greater than 5 mm.[80]

Treatment for severe constrictive pericarditis is a pericardial resection. Newly diagnosed patients who are hemodynamically stable and without evidence of chronic constriction may be given a 2- to 3-month trial of anti-inflammatory drugs, rather than pericardial resection.[79]

Pericardial Effusion

A **pericardial effusion** is an accumulation of fluid in the pericardium. Normally the pericardial sac contains between 15 and 50 mL of pericardial fluid. A larger volume of fluid may accumulate in association with acute pericarditis.[80]

Because the pericardium is a relatively stiff structure, the relationship between its internal volume and pressure is not linear.[80] A small increase in volume in the pericardium will result in a small rise in pressure. However, when the intrapericardial volume expands beyond a critical level, a dramatic increase in pressure is caused by the nondistensible sac.[80]

Three factors determine whether a pericardial effusion remains clinically silent or whether symptoms of cardiac compression are created: (1) the volume of fluid, (2) the rate at which the fluid accumulates, and (3) the compliance characteristics of the pericardium.[80]

A pericardial effusion can be seen on a CXR, if there is more than approximately 250 mL in the pericardium, as an enlarged cardiac silhouette. See **Figure 15-30**. The ECG in **Figure 15-31** shows the decreased waveform voltage (small QRS complexes, P waves, and T waves). If a large effusion exists, then the QRS complexes on the ECG will alternate between large and small, known as electrical alternans. Electrical alternans occurs with variation in the cardiac position (swinging heart). An echocardiography is used to estimate the volume of pericardial fluid, identifies cardiac tamponade, acute myocarditis, and/or HF.[79]

Treatment for pericardial effusion includes finding and treating the cause. In effusions where the etiology is unknown, and there are no symptoms, only observation is required.[79] Symptomatic and persistent pericardial effusions may require a window to be placed in the pericardium so the fluid can drain continuously. This can be done either surgically or percutaneously using a balloon pericardiotomy. A balloon pericardiotomy requires insertion of a catheter with a camera between the ribs. A puncture in the pericardial sac allows for the inflation of the balloon to create the window.[79]

Cardiac Tamponade

Cardiac tamponade is a life-threatening condition caused by the accumulation of pericardial fluid under high pressure, compressing the heart and severely limiting the filling of its chambers. There is a reduction in both stroke volume and cardiac output that may lead to hypotensive shock and death.[80]



FIGURE 15-30 An anteroposterior view of a 40-year-old man with a hemopericardium (blood in the pericardium) and pleural effusion after pericardial tapping of 550 mL. The radiograph demonstrates the air-fluid level between the heart and the pericardium.

Cardiac tamponade may develop from acute pericarditis, neoplasm, post-viral infection, acute hemorrhage into the pericardium from blunt or penetrating chest trauma, rupture of the LV wall post-MI, and as a complication of a dissecting aortic aneurysm.

Cardiac tamponade is suspected in any patient with known pericarditis, pericardial effusion, or chest trauma who develop signs of cardiogenic shock. These signs include a low cardiac output, low systemic arterial pressure, tachycardia, and dyspnea. Pulsus paradoxus characterized by greater than 10 mm Hg inspiratory fall in systolic BP is a useful sign of tamponade.[81] This sign is also present in severe asthma exacerbations and pulmonary embolism. A CXR showing cardiomegaly is common[81] (**Figure 15-32**). The clinical manifestations of cardiac tamponade appear in **Box 15-13**.

Cardiac tamponade is suggested by low voltage and electrical alternans on the ECG. However, these findings lack sensitivity and specificity. Echocardiography is the most useful noninvasive technique to evaluate whether pericardial effusion has led to cardiac tamponade physiology.[80,81] When tamponade is suspected, echocardiography is done unless even a brief delay might be life threatening. Then pericardiocentesis is done immediately for diagnosis and treatment. On an echocardiogram, respiratory variation of transvalvular and venous flows and compression or collapse of right cardiac chambers in the presence of a pericardial effusion support the diagnosis.[79] The definitive diagnostic procedure for cardiac tamponade is cardiac



FIGURE 15-31 Twelve lead ECG of pericardial effusion.
Garcia GB, Holtz EH. *12-Lead ECG: The Art of Interpretation.* Burlington, MA: Jones & Bartlett Learning; 2013.



FIGURE 15-32 A 21-year-old man with an enlarged cardiac silhouette due to cardiac tamponade manifested by a systemic inflammatory disease.

Reproduced with permission from Carrilho-Ferreira P, Silva D, de Jesus Silva M, André R, Varela M, Diogo A. Adult-onset Still's disease and cardiac tamponade: a rare association. *Texas Heart Inst J.* 2015;42(3):277–280. doi:10.14503/thij-14-4101.

BOX 15-13 Clinical Manifestations of Cardiac Tamponade

- Dyspnea
- Hypoxemia
- Hypotension with pulsus paradoxus (fall of >10 mm Hg in systolic BP during inspiration)
- JVD
- Muffled heart sounds
- Sinus tachycardia

catheterization with measurement of intracardiac and intrapericardial pressures, usually combined with therapeutic pericardiocentesis.[80]

To perform a pericardiocentesis, the patient needs to be in the supine position with the head elevated 30° from supine. Echocardiography is used to perform a detailed evaluation before pericardiocentesis to determine the ideal entry site to obtain the maximal amount of fluid.[82] After using lidocaine to numb the area, a needle is inserted into the pericardium. Once in place, the fluid is aspirated into a syringe. ECG monitoring is essential for detecting arrhythmias produced when the myocardium is touched or punctured. The fluid is removed until the intrapericardial pressure falls below the right atrial pressure. If the effusion is large, a catheter will be inserted and attached to a plastic bag so the fluid can continue draining.[79]

If cardiac tamponade recurs after pericardiocentesis, the procedure can be repeated. In some cases, removal of part or all of the pericardium is required to prevent re-accumulation of the effusion.[80]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Chest pain and fever occur commonly with acute pericarditis.
2. True or False: Troponin levels are normal with acute pericarditis.
3. True or False: Severe constrictive pericarditis can be controlled with medications.
4. True or False: Cardiac tamponade is a life-threatening condition requiring immediate attention.

Left Ventricular Hypertrophy

Left ventricular hypertrophy (LVH) results from the thickening of the LV walls due to chronic overload (**Figure 15-33**). The two most important factors contributing to the development of LVH are chronic pressure overload and chronic volume overload.[38] Chronic pressure overload can be due to hypertension or AS.[38] Hypertension and AS increase ventricular afterload and cause LVH as a compensatory mechanism. This results from the thickening of myocytes, causing increased ventricular wall thickness, or **concentric hypertrophy**.

Volume overloading is an even more potent stimulus to the development of atrial dilation and LVH. MR or aortic regurgitation cause chronic volume overload. This leads to the elongation of the myocytes, enlarging the ventricle chamber and thickening the ventricle walls, or **eccentric hypertrophy**.[83]

The chronic volume or pressure overload causes the myocytes to remodel by either elongating or thickening. At first, this helps to reduce the stress on the ventricular wall and maintain the contractile force. Eventually, ventricular function declines, leading to chamber dilation out of proportion to wall thickness. As LVH continues and complications develop, symptoms appear. These symptoms include shortness of breath, exertional chest pain, palpitations, dizziness, and fainting.[83]

Patients with LVH due to continuous pressure or volume overload may remain in a compensatory phase with no symptoms and normal or near-normal exercise reserve for years. Others have a transition to HF that may be due to diastolic dysfunction, or systolic dysfunction, or both.[38]

The ECG remains a clinical tool, quickly and easily available to most practitioners, at a relatively small cost.[84] ECG criteria have a high specificity (ability to



FIGURE 15-33 LVH is a thickening of the myocardium of the LV.

TABLE 15-28
Causes of LVH and Its Treatment

Cause	Nonpharmacologic Treatment	Pharmacologic Treatment
Aortic regurgitation	Surgical correction	Calcium-channel blockers ACE inhibitors
AS	SAVR TAVR	Supportive therapy
Congenital heart disease	Surgical correction	Supportive therapy
Hypertension	Weight reduction Exercise Sodium restriction Alcohol reduction Smoking cessation	Diuretics Beta-blockers Alpha$_2$ adrenergic agonists Alpha$_1$ antagonists Calcium-channel blockers Angiotensin II receptor blockers Direct renin inhibitor
HCM	Genetic counseling Myomectomy Percutaneous septal ablation	Beta-blockers Calcium-channel blockers Type IA antiarrhythmic agents
MR	Acute MR before surgery intra-aortic balloon pump Mitral valve repair Mitral valve replacement	Acute MR—intravenous nitroprusside, nitroglycerin
Obesity	Weight reduction	Supportive therapy

rule in LVH) but low sensitivity (unable to always rule out LVH).[85] TEE has poor reproducibility and is costly. CMRI is currently the gold standard for assessing LV mass. It is highly specific and highly sensitive, and has excellent reproducibility.[85] However, it is costly and not readily available. So, the 12-lead ECG remains the simple and cost-effective screening test for LVH.

The treatment, risk factors, and prognosis for LVH depend on its cause. See **Table 15-28** for causes of LVH and a summary of its treatments.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Hypertension causes chronic pressure overload in the LV.
2. True or False: Aortic regurgitation causes chronic volume overload in the LV.

Chapter Summary

HF is the heart's inability to supply the blood needed by the body to survive. It can be caused due to a filling problem, or pumping problem, or both, and becomes progressively worse unless treated. HF is not a disease itself, but a complication of other diseases. As a result, HF and its underlying cause must be treated. Two scales quantify HF (NYHA functional class and the American Heart Association and American College of Cardiology Foundation [AHA/ACCF]). HF can result from one or more of the following:

1. CHD
2. MI
3. Hypertension
4. Heart valve failure
5. Heart damage (due to alcohol, drug abuse, or chemotherapy)
6. Cardiomyopathy (dilated, hypertrophic, or restrictive)
7. Congenital heart disease
8. Pulmonary emboli
9. Myocarditis (bacterial or viral)
10. HIV
11. VSD
12. ASD
13. Diabetes
14. Pericardial disease

Currently, more than 5.8 million people in America and more than 23 million worldwide are diagnosed with HF. Each year more than 550,000 new cases are diagnosed, and in 2009, 1 in 9 deaths included HF as the contributing cause. By the year 2030, the prevalence of HF will increase 25% from the 2013 estimates. The total medical cost for HF in 2012 was $20.9 billion, and is expected to increase to $53.1 billion by 2030; this is a 2.5-fold increase. HF among the different racial and ethnic groups is expected to increase substantially. The African American population will have the largest increase followed by white non-Hispanic; white Hispanics will have the lowest increase.

HF can be either left or right sided. It can be acute or chronic. It can occur during diastole or systole. Left-sided HF or pulmonary disease causes right-sided HF. The problem can be a forward, backward, or congestive failure. The diseases that can cause HF are the cardiomyopathies (dilated, hypertrophic, obstructive, or restrictive), ventricle hypertrophy, heart valve problems, defects in the ventricle or atrial septal wall, or pericarditis. The causes of the diseases can be congenital, CAD, infections, trauma, cancer, or gene mutations. The tests that can be performed to diagnose HF are CXR, blood test, echocardiogram, Doppler echocardiogram, ECG, heart catheterization, treadmill exercise stress test, and/or tracer study. The treatment for HF includes medication, valve repair or replacement, surgery to repair a defect in the septal wall, putting a pericardial window, removing the pericardium, or heart transplant. Risk factors can be family history, gender, age, diet, smoking, or alcohol. Complications can be death, stroke, heart attack, valve problem, or infections. Prognosis can be good with early intervention to poor.

Key Points

1. HF occurs when cardiac output cannot meet the body's metabolic demands.
2. There are two types of chronic HF: (1) HF with REF due to impaired LV systolic function and (2) HF with PEF due to diastolic dysfunction.
3. HF can occur on the right side, or the left side, or both sides.
4. Symptoms of HF may be brought on by increased metabolic demand, increase circulating volume, increased afterload, or decreased contractility.
5. HF treatment requires the identification, elimination, or treatment of the underlying condition causing the HF.
6. Medications for HF with REF include ACE inhibitors, beta-blockers, and, if necessary, diuretics, and inotropic drugs or ARB for those who do not tolerate ACE inhibitors. Medications for HF with PEF include diuretics and vasodilators.
7. The cardiomyopathies are heart muscle diseases that are classified by their pathophysiology as dilated, hypertrophic, or RCMs.
8. LV dilation with impaired systolic function is the hallmark of dilated cardiomyopathies. Thickening of the LV with impaired diastolic relaxation is the pathology behind hypertrophic cardiomyopathies. Ventricular arrhythmias associated with HCM cause sudden death. The rarest of the cardiomyopathies is RCM, characterized by an impairment of diastolic ventricular relaxation. All cardiomyopathies cause HF symptoms.
9. Rheumatic fever and congenital issues are the causes of a number of valvular heart diseases. Treatment of these valve diseases depends on the severity of the valve lesions and symptoms. Treatment ranges from no treatment to open-heart surgery for valve replacement.

10. Ventricular and ASDs are congenital heart defects that are present at birth. Mild defects may remain asymptomatic until adulthood. The larger the defect, the more likely it will be detected in infancy. Septal defects allow blood to be shunted between atria or ventricles, bypassing the blood's normal course. Symptomatic septal defects are treated with surgical or percutaneous repair.
11. Acute pericarditis usually has an idiopathic or viral etiology. Common findings include chest pain and fever. Complications of acute pericarditis include pericardial effusions, constrictive pericarditis, and cardiac tamponade. Excessive fluid in the pericardial sac is drained by pericardiocentesis.
12. LVH is a consequence of LV compensation for chronic pressure or chronic volume overload due to a variety of etiologies. ECG remains the quickest, easiest, and least expensive method of detection for LVH. Treatment depends on the etiology.

Chapter Questions

1. Heart failure (HF) occurs when _____.
   a. the heart is unable to meet the body's metabolic needs
   b. the heart stops working
   c. the heart has a congenital problem
   d. the left ventricle (LV) becomes hypertrophied
2. In 2009, what was the mortality rate for HF?
   a. 1 in 15
   b. 1 in 20
   c. 1 in 9
   d. 1 in 5
3. HF can affect _____.
   a. only the left side of the heart
   b. only the right side of the heart
   c. both sides of the heart
   d. the cardiac valves only
4. Tests used to diagnose HF include which of the following?
   a. Heart catheterization
   b. Electrocardiogram
   c. Blood test
   d. All of the above
5. Besides the initial cause of the HF, what else must be treated?
   a. Peripheral vascular problem
   b. Neuroendocrine system
   c. Muscular system
   d. Central nervous system
6. When the right heart is affected, which other system become congested?
   a. Pulmonary system
   b. Arterial system
   c. Venous system
   d. All of the above
7. The total direct medical cost for HF in 2012 was _____.
   a. $8 billion
   b. $20.9 million
   c. $579 million
   d. $20.9 billion
8. Left HF is when the systolic and/or the diastolic function is compromised, resulting in _____.
   a. increased LV end-systolic pressure
   b. increased LV end-diastolic pressure
   c. decreased LV end-systolic pressure
   d. decreased LV end-systolic pressure
9. What is the most common cause of right-sided HF?
   a. Cardiac arrhythmias
   b. Renal failure
   c. Left-sided HF
   d. Venous insufficiency
10. Right-sided HF will cause which of the following?
    a. Chest pain
    b. Liver enlargement
    c. Stroke
    d. Pulmonary edema
11. What medication below can be a treatment for HF?
    a. ACE inhibitors
    b. Vasodilators
    c. Beta-blockers
    d. All of the above
12. Of the etiologies listed below, which one does **NOT** cause idiopathic dilated cardiomyopathy?
    a. Toxins
    b. Alcohol
    c. Virus
    d. Inherited
13. What are the estimated drinks per day needed to develop alcoholic DCM?
    a. 2
    b. 4
    c. 10
    d. 8
14. What is the usual cause of hypertrophic cardiomyopathy (HCM)?
    a. Hypertension
    b. Aortic stenosis
    c. Inherited
    d. None of the above
15. The obstruction in HCM occurs in which area?
    a. Supravalvular
    b. Subvalvular
    c. At the valve
    d. Within the ventricle

16. Symptoms that are seen in acute aortic insufficiency are the same as _____.
    a. HCM
    b. restrictive cardiomyopathy (RCM)
    c. constrictive pericarditis
    d. DCM
17. The heart sound heard with aortic stenosis is a _____.
    a. loud systolic murmur
    b. diastolic murmur
    c. loud S_2 sound
    d. low S_1 sound
18. Mitral regurgitation is caused by which of the following?
    a. Syphilis
    b. Infectious endocarditis
    c. Renal failure
    d. Hypertension
19. Which arrhythmia is common with mitral stenosis?
    a. Sinus tachycardia
    b. Sinus bradycardia
    c. Atrial fibrillation
    d. Atrial tachycardia
20. Acute pericarditis can lead to _____.
    a. cardiac tamponade
    b. HCM
    c. RCM
    d. DCM

References

1. What Is Heart Failure? National Lung, Heart, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/hf. Accessed July 10, 2015.
2. Right-Sided Heart Failure. eMedicineHealth. http://www.emedicinehealth.com/right-sided_heart_failure-health/article_em.htm. Accessed July 10, 2015.
3. Heart Failure Fact Sheet. Centers for Disease Control and Prevention. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_failure.htm. Accessed July 10, 2015.
4. What Causes Heart Failure? National Lung, Heart, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/hf/causes. Accessed July 10, 2015.
5. Heart Failure. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/heart-failure/basics/causes/con-20029801. Accessed July 13, 2015.
6. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*. 2012;33:1787–1847. doi:10.1093/eurheart/ehs104.
7. Stages of Heart Failure. Heartfailure.org. http://www.heartfailure.org/heart-failure/the-stages-of-heart-failure. Accessed July 14, 2015.
8. Roger V. Heart failure compendium: epidemiology of heart failure. *Circ Res*. 2013;113:646–659. doi:10.1161/CIRCRESAHA.113.300268.
9. Go A, Mozaffarian D, Roger V, et al. AHA statistical update: heart disease and stroke statistics—2013 update. *Circulation*. 2013;127:e6–e245. doi:10.1161/CIR.0b013e31828124ad.
10. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States a policy statement from the American Heart Association. *Circ Heart Fail*. 2013;6(3):606–619.
11. Beyond the Basics: Right vs. Left Heart Failure. EMS World. http://www.emsworld.com/article/10323146/beyond-the-basics-right-vs-left-heart-failure. Accessed July 14, 2015.
12. Heart Failure. University of Maryland Medical Center. http://umm.edu/health/medical/reports/articles/heart-failure. Accessed July 14, 2015.
13. Kirk J, Diercks D, Dhingr K. Acute heart failure. In: Aghababian R, ed. *Essentials of Emergency Medicine*. 2nd ed. Sudbury, CA: Jones & Bartlett Learning; 2011:122–129.
14. Lee C, Dec G, Lilly L. The cardiomyopathies. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:244–260.
15. Heart Disease and Dilated Cardiomyopathy. WebMD. http://www.webmd.com/heart-disease/guide/dilated-cardiomyopathy. Accessed July 23, 2015.
16. Alcoholic Cardiomyopathy. Health Central. http://www.healthcentral.com/encyclopedia/adam/alcoholic-cardiomyopathy-4006997/symptoms. Accessed July 23, 2015.
17. Arnold JMO. Dilated Cardiomyopathy. Merck Manuals Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/dilated-cardiomyopathy. Accessed August 3, 2015.
18. Who Is at Risk for Cardiomyopathy? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/cm/atrisk. Accessed August 8, 2015.
19. Mayo Clinic Staff. Dilated Cardiomyopathy. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/dilated-cardiomyopathy/symptoms-causes/syc-20353149. Accessed August 9, 2015.
20. Goswami VJ. Dilated Cardiomyopathy. Medscape. http://emedicine.medscape.com/article/152696-overview#a7. Accessed August 10, 2015.
21. Piano MR. Alcoholic cardiomyopathy incidence, clinical characteristics, and pathophysiology. *Chest*. 2002;121:1638–1650. doi:10.1378/chest.121.5.1638.
22. Hazebroek M, Dennert R, Heymans S. Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. *Neth Heart J*. 2012;20(7–8):332–335. doi:10.1007/s12471-012-0285-7.
23. Pantazis A, Vischer AS, Perez-Tome MC, Castelletti S. Diagnosis and management of hypertrophic cardiomyopathy. *Echo Research and Practice*. 2015;2(1):R45-R53. doi:10.1530/ERP-15-0007.
24. Hypertrophic Cardiomyopathy. American Heart Association. http://www.heart.org/HEARTORG/Conditions/More/Cardiomyopathy/Hypertrophic-Cardiomyopathy_UCM_444317_Article.jsp. Accessed July 20, 2015.
25. Hypertrophic Cardiomyopathy. Cleveland Clinic. http://my.clevelandclinic.org/services/heart/disorders/hcm. Accessed July 21, 2015.
26. Hypertrophic Cardiomyopathy—Adult. Mount Sinai Hospital. https://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/hypertrophic-cardiomyopathy-adult. Accessed July 21, 2015.
27. Mayo Clinic Staff. Hypertrophic Cardiomyopathy. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/hypertrophic-cardiomyopathy/symptoms-causes/dxc-20122103. Accessed August 9, 2015.
28. Arnold MO. Hypertrophic Cardiomyopathy. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/hypertrophic-cardiomyopathy. Accessed August 10, 2015.
29. Wang SS, Lange RA. Aortic Regurgitation. Medscape. http://emedicine.medscape.com/article/150490-overview. Accessed July 15, 2015.
30. Arnold JM. Restrictive Cardiomyopathy. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/cardiomyopathies/restrictive-cardiomyopathy. Accessed July 21, 2015.

31. Moore K. Restrictive Cardiomyopathy. Healthline. http://www.healthline.com/health/restrictive-cardiomyopathy#Overview1. Accessed August 9, 2015.
32. Wang SS. Aortic Regurgitation Workup. Medscape. http://emedicine.medscape.com/article/150490-workup#showall. Accessed August 3, 2015.
33. Armstrong GP. Aortic Regurgitation. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/aortic-regurgitation. Accessed August 7, 2015.
34. Aortic Valve Insufficiency: Causes, Symptoms & Diagnosis. Healthline. https://www.healthline.com/health/aortic-insufficiency. 2018. Accessed September 24, 2018.
35. Chen M. Aortic Insufficiency. MedlinePlus. http://www.nlm.nih.gov/medlineplus/ency/article/000179.htm. Accessed August 9, 2015.
36. Ren X. Pulmonic Regurgitation Workup. Medscape. http://emedicine.medscape.com/article/157639-workup#showall. Accessed August 4, 2015.
37. Aortic Regurgitation - Doctors Lounge (TM). 2017. https://www.doctorslounge.com/cardiology/diseases/aortic_incompetence.htm
38. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation*. 2000;102(4):470–479. doi:10.1161/01.CIR.102.4.470.
39. Armstrong GP. Aortic Stenosis. Merck Manuals Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/aortic-stenosis. Accessed August 10, 2015.
40. Heart Valve Disease—Percutaneous Interventions. Cleveland Clinic. http://my.clevelandclinic.org/services/heart/disorders/valvetreatment/percutaneousValve. Accessed August 8, 2015.
41. Mayo Clinic Staff. Aortic Valve Stenosis. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/aortic-stenosis/basics/risk-factors/con-20026329. Accessed August 9, 2015.
42. Problem: Heart Valve Stenosis. 2018 http://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-problems-and-causes/problem-heart-valve-stenosis. Accessed July 15, 2015.
43. Understanding Rheumatic Fever—the Basics. WebMD. http://www.webmd.com/a-to-z-guides/understanding-rheumatic-fever-basics. Accessed July 20, 2015.
44. Endocarditis, Infective. WebMD. http://www.webmd.com/heart-disease/endocarditis-infective. Accessed July 20, 2015.
45. Armstrong GP. Mitral Valve Prolapse (MVP). Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/mitral-valve-prolapse-mvp. Accessed July 20, 2015.
46. Burton LV, Beier K. Papillary Muscle Rupture. [Updated 2018 May 11]. Treasure Island, FL: StatPearls Publishing; 2018 https://www.ncbi.nlm.nih.gov/books/NBK499976/. Accessed September 24, 2018
47. Armstrong GP. Mitral Regurgitation. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/mitral-regurgitation. Accessed July 27, 2015.
48. Garcia GB, Holtz EH. *12-Lead ECG: The Art of Interpretation*. Burlington, MA: Jones & Bartlett Learning; 2013.
49. Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell H. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. *Circulation*. 2001;103(19):2346–2351. doi:10.1161/01.cir.103.19.2346.
50. Mayo Clinic Staff. Mitral Valve Stenosis. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/index?letter=M. Accessed August 9, 2015.
51. Armstrong GP. Mitral Stenosis. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/mitral-stenosis. Accessed August 10, 2015.
52. Ren X, Lange RA. Pulmonic Regurgitation: Background. Medscape. http://emedicine.medscape.com/article/157639-overview. Accessed July 15, 2015.
53. Ren X, Lange RA. Pulmonic Regurgitation: Clinical Presentation History. Medscape. http://emedicine.medscape.com/article/157639-clinical#b1. Accessed July 27, 2015.
54. Ren X, Lange RA. Pulmonic Regurgitation: Clinical Presentation Physical. Medscape. http://emedicine.medscape.com/article/157639-clinical#b4. Accessed July 27, 2015.
55. Pulmonary Regurgitation. Epocrates. https://online.epocrates.com/u/2932474/Pulmonary+regurgitation. Accessed August 8, 2015.
56. Ren X, Lange RA. Pulmonic Regurgitation: Follow-Up. Medscape. http://emedicine.medscape.com/article/157639-followup#e7. Accessed August 10, 2015.
57. Armstrong GP. Pulmonic Stenosis. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/pulmonic-stenosis. Accessed August 15, 2015.
58. Rao PS. Valvar Pulmonary Stenosis. Medscape. http://emedicine.medscape.com/article/891729-overview#a5. Accessed August 15, 2015.
59. Mayo Clinic Staff. Pulmonary Valve Stenosis: Risk Factors. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/pulmonary-valve-stenosis/basics/risk-factors/con-20013659. Accessed August 15, 2015.
60. Mayo Clinic Staff. Pulmonary Valve Stenosis: Complications. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/pulmonary-valve-stenosis/basics/complications/con-20013659. Accessed August 15, 2015.
61. Armstrong GP. Tricuspid Regurgitation. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/tricuspid-regurgitation. Accessed July 22, 2015.
62. Bruce C, Connolly H. Right-sided valve disease deserves a little more respect. *Circulation*. 2009;119(20):2726–2734. doi:10.1161/circulationaha.108.776021.
63. Nall R. Tricuspid Regurgitation (Tricuspid Valve Insufficiency). HealthLine. http://www.healthline.com/health/tricuspid-regurgitation#Overview1. Accessed August 10, 2015.
64. Armstrong GP. Tricuspid Stenosis. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/valvular-disorders/tricuspid-stenosis. Accessed July 22, 2015.
65. Mancini M. Tricuspid Regurgitation Clinical Presentation. Medscape. http://emedicine.medscape.com/article/158484-clinical#b1. Accessed August 9, 2015.
66. HVD-Tricuspid Valve Disease. The International Heart Institute Foundation. http://www.ihimontanafoundation.org/Heart_Information/Heart_Conditions/HVDTricuspid_Valve_Disease. Accessed August 10, 2015.
67. Adler DH. Atrial Septal Defect Treatment and Management. Medscape. http://emedicine.medscape.com/article/162914-treatment#d14. Accessed August 10, 2015.
68. Berg DD, Brown DW. Congenital heart disease. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:361–385.
69. Sommer R, Hijazi Z, Rhodes J. Pathophysiology of congenital heart disease in the adult: part I: shunt lesions. *Circulation*. 2008;117(8):1090–1099. doi:10.1161/circulationaha.107.714402.
70. Ramaswamy P. Ventricular Septal Defects Clinical Presentation. Medscape. http://emedicine.medscape.com/article/892980-clinical. Accessed August 3, 2015.
71. Merlin M. Ventricular Septal Defect. Emedicinehealth. http://www.emedicinehealth.com/ventricular_septal_defect/page5_em.htm. Accessed August 6, 2015.

72. Mersch J. Ventricular Septal Defect. MedicineNet. http://www.medicinenet.com/ventricular_septal_defect/page3.htm#how_is_a_small_vsd_treated. Accessed August 8, 2015.
73. Pediatric Cardiothoracic Surgery–Ventricular Septal Defect. 2018. https://pediatricct.surgery.ucsf.edu/conditions--procedures/ventricular-septal-defect.aspx. Accessed September 24, 2018.
74. Krause L. What Is Ventral Septal Defect (VSD)? Healthline. http://www.healthline.com/health/ventricular-septal-defect#Overview1. Accessed August 9, 2015.
75. Ramaswamy P. Discrete Fibrous Subaortic Stenosis. Medscape. http://emedicine.medscape.com/article/892980-clinical#showall. Accessed August 10, 2015.
76. Adler DH. Atrial Septal Defect Workup. Medscape. http://emedicine.medscape.com/article/162914-workup#showall. Accessed August 7, 2015.
77. Mayo Clinic Staff. Atrial Septal Defect (ASD). Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/atrial-septal-defect/basics/risk-factors/con-20027034. Accessed August 9, 2015.
78. Types of Holes in the Heart: Atrial Septal Defect. The University of California, San Francisco: Department of Surgery. http://www.surgery.ucsf.edu/conditions--procedures/ventricular-septal-defect.aspx. Accessed August 10, 2015.
79. Hoit BD. Pericarditis. Merck Manual Professional Edition. http://www.merckmanuals.com/professional/cardiovascular-disorders/pericarditis/pericarditis#v939902. Accessed July 21, 2015.
80. Ren Y, Lilly LS. Diseases of the pericardium. In: Lilly L, ed. *Pathophysiology of Heart Disease*. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:324–338.
81. Chandraratna P, Mohar D, Sidarous P. Role of echocardiography in the treatment of cardiac tamponade. *Echocardiography*. 2014;31(7):899–910. doi:10.1111/echo.12605.
82. Degirmencioglu A, Karakus G, Güvenc T, Pinhan O, Sipahi I, Akyol A. Echocardiography-guided or "sided" pericardiocentesis. *Echocardiography*. 2013;30(9):997–1000. doi:10.1111/echo.12214.
83. Drazner MH. Contemporary reviews in cardiovascular medicine: the progression of hypertensive heart disease. *Circulation*. 2011;123:327–334. doi:10.1161/circulationaha.108.845792.
84. Estes E, Jackson K. The electrocardiogram in left ventricular hypertrophy: past and future. *J Electrocardiol*. 2009;42(6):589–592. doi:10.1016/j.jelectrocard.2009.06.016.
85. Klodas E. High Blood Pressure and Hypertensive Heart Disease. WebMD. http://www.webmd.com/hypertension-high-blood-pressure/guide/hypertensive-heart-disease?page=2#2. Accessed August 7, 2015.

CHAPTER

16

Ischemic Heart Disease

"When the heart speaks, the mind finds it indecent to object."

—Milan Kundera, 1984

OUTLINE

OBJECTIVES

1. State the working definition of ischemic heart disease (IHD).
2. Outline the incidence, prevalence, and risk factors for IHD.
3. Define and discuss secondary problems associated with IHD.
4. Predict the clinical manifestations of a patient with IHD.
5. Explain diagnostic testing used in identifying IHD.
6. Summarize the recommended management of patients with IHD.
7. Identify common complications associated with IHD.
8. Discuss the prognosis of IHD.

KEY TERMS

Aerobic metabolism
Anaerobic metabolism
Angina pectoris
Atherosclerosis
Bare-metal stent (BMS)
Bruce protocol
Carotid bruit
Coronary artery bypass grafting (CABG)
Coronary artery disease (CAD)
Coronary heart disease
Drug-eluting stent (DES)
Dual antiplatelet therapy (DAPT)
Fatty streak
Fractional flow reserve (FFR)
Heart disease
Heart failure
High-density lipoprotein (HDL)
Hyperacute phase
Hyperemia
Indeflator
Intima

Ischemia
Ischemic heart disease (IHD)
Intravascular ultrasound (IVUS)
Left heart catheterization
Low-density lipoprotein (LDL)
Optical coherence tomography (OCT)
Pathologic Q wave
Percutaneous coronary angioplasty
Prinzmetal angina
Restenosis
Resting scan
Rotational atherectomy
Silent heart attack
Spontaneous coronary artery dissection (SCAD)
Stable angina
Stent
Stress scan
Translesional pressure
Unstable angina
Variant angina

Case Study

A 58-year-old female attorney has her first appointment with a new family physician. She has been experiencing some unusual symptoms lately. Her symptoms are discomfort in both arms, breaking out in a cold sweat, pain in her jaw, nausea, and shortness of breath without chest discomfort. Originally, these symptoms appeared only when she was having an extremely stressful day at work; however, lately the symptoms have been appearing even when she is resting. Before going to see her family physician, she tried using antacids to help with nausea and acetaminophen to help with the pain, but this did not help. When she told her current family physician about them, he just told her it was anxiety and stress and gave her an anti-anxiety medication. The medication did not seem to help, so she decided to see a new physician and hopes the new physician can diagnose her problem.

In addition to her job, she has a husband that travels a lot for his job, and she cares for two young children at home. She does not smoke, but she is around secondhand smoke all day. She denies illicit drug use or alcohol abuse. She admits to not exercising on a regular basis, citing her work and home schedule is too busy to find the time. Her mother and father are still alive, and both receive treatment for **heart disease**.

On physical examination, the patient was not experiencing any pain, discomfort, nausea, or shortness of breath. The exam reveals hypertension with a blood pressure of 154/102 mm Hg. The patient's temperature is 97.9°F, respiratory rate is 16 breaths/minute, and pulse is 102 beats/minute. She is 65 inches tall, weighs 162 pounds, and has a body mass index (BMI) of 27. She has no heart murmurs, no **carotid bruit** (a sound caused by turbulent blood flow in the carotid artery resulting from stenosis of the artery). The patient's lungs are clear to auscultation. An electrocardiogram (ECG) performed in the office revealed sinus tachycardia with ST-segment changes in leads V_1 through V_4, indicating anteroseptal **ischemia**.

Introduction

Ischemic heart disease (IHD) is **coronary heart disease (CHD)** or **coronary artery disease (CAD)**.[1] IHD can lead to a heart attack and ischemic cardiomyopathy.[1,2] Statistics from the Centers for Disease Control and Prevention (CDC) shows that IHD is the number one killer of men and women in the United States, and approximately 611,000 died in 2009 from heart disease.[3] While genetics has a large influence on CAD, there are other risk factors that are independent of genetics. **Table 16-1** lists the uncontrollable and controllable risk factors for IHD.

The American Heart Association (AHA) reports that the annual cost of treating IHD is over $108 billion.[3] As the population in America ages, the cost of heart disease increase. One study puts the cost at $818 billion by the year 2030.[5] In an effort to reduce risk and cost, the AHA and the American College of Cardiology Foundation (ACCF) released their updated 2011 guideline for prevention and risk reduction therapy for CHD.[6] This guideline lists several strategies and goals that need to be implemented (**Table 16-2**).

TABLE 16-1
Uncontrollable and Controllable IHD Risk Factors

Uncontrollable IHD Risk Factors	Controllable IHD Risk Factors
Age	Hypertension
Gender	Hyperlipidemia
Family history	Diabetes and prediabetes
History of preeclampsia during pregnancy	Tobacco smoking
	Overweight or obese
	Physically inactivity
	Unhealthy diet[4]

TABLE 16-2
AHA/ACCF Goals for Prevention and Risk Reduction for CHD

Risks	Goals/Strategies
Smoking	Complete cessation
Hypertension	Below 140/90 mm Hg; if diabetic, kidney failure, or CAD then below 130/80 mm Hg
Hyperlipidemia	LDL-C below 100 mg/dL
Physical inactivity	A least 30 minutes of physical activity every day (5 days minimum)
Obesity	BMI: 18.5–24.9 kg/m
Diabetes	Control blood sugar and A_{1c}
Blood clots	75–162 mg aspirin daily (unless contraindicated)

KNOWLEDGE CHECK QUESTIONS

1. True or false: A history of preeclampsia during pregnancy is a controllable risk factor for IHD.
2. True or false: Another name for IHD is CAD.

Definition and Diagnosis

Diet and exercise can prevent, delay, or reverse CHD. The cause of CHD is plaque buildup in the coronary arteries, known as **atherosclerosis** (**Figure 16-1**).[7] As the plaque builds in the coronary arteries, the lumen of the vessels become narrowed, reducing the amount of blood the heart receives. When this happens, the heart does not receive the oxygen supply it needs to function properly; this is ischemia.[8] Ischemia can manifest itself in different ways. The most obvious one is severe chest pain; however, shortness of breath and sweating (diaphoretic) are common. Other signs, which may not always be visible, are chest pressure or discomfort, indigestion, weakness, nausea, dizziness, and rapid heartbeat. These symptoms may appear only while the person is under exertion, known as **stable angina**, or they can appear at rest, known as **unstable angina**.[9] Both men and women may experience these symptoms. Also, women may experience neck, jaw, shoulder, upper back or abdominal discomfort, right arm pain, unusual fatigue, or no pain at all (known as a **silent heart attack**).[10]



FIGURE 16-1 Normal artery and artery with atherosclerosis.

KNOWLEDGE CHECK QUESTIONS

1. True or false: The buildup of plaque in the coronary arteries is called atherosclerosis.
2. True or false: Chest pain that subsides with rest following exertion is unstable angina.

Etiology

The main cause of IHD is atherosclerosis.[11] The atherosclerosis process starts when the **intima** layer (inner layer) of the artery becomes damaged. **Figure 16-2** shows the proper anatomy of an artery. Damage to the intima layer occurs from high blood pressure, smoking, high levels of certain fats and cholesterol, and diabetes.[12] Other causes of IHD are coronary artery spasms and dissections.[13]

KNOWLEDGE CHECK QUESTIONS

1. True or false: Damage to the intima layer of the artery begins the atherosclerosis process.
2. True or false: Smoking does not damage the intima layer of the coronary arteries.



FIGURE 16-2 Anatomy of an artery.

Epidemiology

The diseases/conditions that included in the term *cardiovascular disease* (CVD) are IHD, stroke, arrhythmias, heart valve disorders, and peripheral vascular disease (PVD).[14] Of the 611,000 people that died in 2010 of CVD, approximately 370,000 died from IHD.[3] The breakdown of the demographics for 2010 appears in **Table 16-3**.

Every year approximately 735,000 people have a heart attack. The majority, 525,000, represent people who are having their first heart attack. The remaining 210,000 represents people who have had previous heart attacks.[15]

The prevalence of CVD in the United States shows that over 82 million people have one form of CVD, approximately 16 million with IHD. Almost 8 million people have heart attacks each year, 9 million with angina pectoris.[16] The death rate from CVD is higher than that from any other disease in the world. According to the World Health Organization, of the 17.5 million deaths in 2012, 6.7 million died from IHD. Heart disease represented 31% of all global deaths.[17]

The total cost for CVD in 2012 was over $300 billion. The direct costs (hospital, home health, and prescriptions) for CVD in 2012 were over $195 billion, and the indirect costs (lost productivity/mortality) were over $124 billion.[18] The AHA 2030 projection for CVD in the United States is over 43%.[18]

TABLE 16-3
2010 CVD Mortality Demographics

Group	Rate
Males	210,000
Females	176,000
White, non-Hispanic	315,000
Black, non-Hispanic	39,000
Hispanic	20,000
Asian/Pacific Islander	7,600
American Indian/Alaska Native	1,700

Heart Disease Fact Sheet: Centers for Disease Control and Prevention. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_disease.htm. Published February 19, 2015. Accessed June 26, 2015.

KNOWLEDGE CHECK QUESTIONS

1. True or false: CVD is the number one killer in the world.
2. True or false: CVD does not include PVD.

Pathology/Pathophysiology

CAD is the result of plaque building up in the coronary arteries, a process known as atherosclerosis. When this occurs, the blood supply to the heart is diminished, and the heart muscle becomes ischemic, which may cause a heart attack.[11] The atherosclerotic process does not happen all at once but is a chronic condition.[19] Damage to the intimal layer of the coronary artery is the first step in the process.[12] **Figure 16-3** demonstrates the development of atherosclerosis. The human body needs cholesterol to function, and there are two types of cholesterol. One is the **low-density lipoprotein (LDL)**, which is the bad cholesterol, and the other is the **high-density lipoprotein** (HDL), which is the good cholesterol.[11] Damage to the intima causes LDL to migrate from the blood into the subendothelial space between the intima and media. Upon reaching the subendothelial space, the LDL oxidizes. As a result, the modified LDLs become potent chemotactic molecules that promote monocyte adhesion and migration to the subendothelial space.[19] Monocytes become macrophages in the subendothelial space and phagocytize (ingest) the modified LDL, and become foam cells. These cells have



FIGURE 16-3 The development of atherosclerosis.

proinflammatory functions and release cytokines, such as interleukins and tumor necrosis factor. This process forms a **fatty streak** in the subendothelial space.[19]

After the formation of the fatty streak, lymphocytes and mast cells accumulate in the subendothelial space. The migration of these cells results in cellular and humoral immune responses, which causes a chronic inflammatory state in the artery producing several proinflammatory molecules.[19] The next step in the atherosclerotic process is the migration of smooth muscle cells (SMC) from the medial layer of the artery into the intima. This transforms the fatty streak to a more complex lesion.[19] The migration of the SMCs into the subendothelial space produces extracellular matrix molecules. These extracellular matrix molecules create the fibrous cap that covers the fatty streak.[19] After the fibrous cap is formed, the foam cells inside start to die, resulting in the release of lipids. These lipids accumulate in the extracellular space, forming a lipid-rich pool known as the necrotic core.[19]

At this point in the atherosclerotic process, the plaque becomes either stable or unstable (unstable plaque is also called vulnerable plaque).[19] The key ingredient that determines this is the thickness of the fibrous cap. The cap on a stable plaque is intact, thick, and composed of SMCs in a matrix rich in Type I and III collagen. As this kind of plaque grows and protrudes into the lumen of the artery, it reduces the quantity of blood reaching the heart muscle. This lesion will usually produce angina only upon exertion, which is called stable angina.[19] The cap on the unstable plaque is thin and consists mainly of Type I collagen, and has few or no SMCs. However, there are abundant macrophage, proinflammatory, and prothrombotic molecules.[19] Unstable plaques are more vulnerable to erosion or rupture. If the plaque ruptures, the core is exposed to

circulating coagulation proteins, which can cause a clot to form (thrombosis). When the clot forms, it results in the coronary artery occlusion, which leads to acute coronary syndrome (ACS), also known as an acute myocardial infarction (AMI).[19]

Prinzmetal angina or **variant angina** is another type of CAD that is caused by coronary spasms.[20] This rare condition accounts for only 2 out of every 100 angina cases. The stimuli for this type of angina are thought to be exertion or stress. It occurs while the person is at rest, and between the hours of midnight and morning.[20] Some of the factors that can cause coronary spasms are cold weather, cocaine, stress, medications, or smoking.[20]

Spontaneous coronary artery dissection (SCAD) is a rare type of CAD that causes myocardial infarction (MI) or sudden death. The mean age for SCAD is 42 years. Most cases are women (70% of all reported cases), and 30% of those women are in their third trimester of pregnancy or early postpartum period.[21] The left anterior artery is the most common coronary artery affected by SCAD. The causes of SCAD are not clear. Conditions commonly associated with SCAD are CAD and the peripartum period. Some other risk factors include hypertension, connective tissue disorders (Marfan syndrome, Ehlers–Danlos syndrome), or vasculitis.[21]

KNOWLEDGE CHECK QUESTIONS

1. True or false: The thickness of the fibrous cap on a lesion determines its vulnerability to rupture.
2. True or false: The right anterior artery is most commonly affected by SCAD.

Clinical Manifestations

Symptoms of IHD appear because the heart muscle is not receiving enough oxygenated blood. In 90% of the cases, it is a result of plaque buildup in the coronary arteries.[22] However, not all patients can feel angina; asymptomatic ischemia is called silent ischemia.[22]

Angina pectoris (chest pain) is most often the first sign a person has when something is wrong. As the artery starts to narrow, the heart muscle does not receive the proper amount of oxygen; however, it is usually not diminished enough to cause the death of the cardiac muscle (infarct).[22] Angina pectoris is a symptom that lasts up to 15 minutes. The pain is located under the sternum or in the precordial chest and is a discomfort that feels like constricting, squeezing, choking, or knifelike. The combination of increased myocardial demand and decreased myocardial perfusion is responsible for angina. The decline in perfusion is due to artery narrowing because of plaque, disrupted plaque, vasospasm, thrombosis, platelet aggregation, and embolization. There are three variants of angina: stable angina, Prinzmetal angina, and unstable angina. The last one is the most dangerous and can lead to an AMI.[22]

Stable or typical angina is the most common form and results from the reduction of coronary perfusion to a critical level by plaque buildup. Because of the plaque buildup, the heart is vulnerable to further ischemia whenever there is an increase in the demand. Demand increases with physical activity or emotional excitement.[22] This type of angina is relieved either by rest (reducing the demand) or by medications to dilate the coronary arteries (increase supply).[22]

Coronary spasms cause Prinzmetal or variant angina, as described in the "Pathology/Pathophysiology" section. Usually, there is an elevated ST segment on the ECG, indicative of ischemia. There may be plaque buildup with Prinzmetal angina, but attacks are unrelated to physical activity, heart rate, or blood pressure. Prinzmetal angina responds to vasodilators, such as nitroglycerin and calcium channel blockers.[22]

Unstable or crescendo angina is the same type of pain that occurs with stable angina, but with increasing frequency. This pain is present with little or no exertion, and may come on at rest and have a longer duration. The same factors that create stable angina cause unstable angina. However, unstable angina is usually an indication of an AMI.[22]

All three of these can lead to ACS. In ACS, there may be a rupture of the plaque (total occlusion), which results in an AMI. This type of AMI is ST elevation myocardial infarct (STEMI) and is transmural (**Figure 16-4**). Transmural MIs cause cellular death that involves the full or nearly full thickness of the ventricular wall in the area supplied by the occluded artery. In contrast, if there is a reduction in the blood flow, unstable angina occurs. This does not result in heart damage but is a warning sign. The subendocardial (nontransmural) infarct affects part of the ventricular wall in the areas supplied by the occluded artery and causes a non-STEMI.[22]

KNOWLEDGE CHECK QUESTIONS

1. True or false: Ischemia results in a depressed ST segment on an ECG.
2. True or false: Transmural MIs cause full-thickness cell death of the ventricular wall supplied by the occluded coronary artery.

Noninvasive Diagnostic Testing

Several noninvasive tests can be performed to diagnose IHD. Some are more definitive than others. Usually, more than one test is needed. Listed below are the noninvasive tests that can be ordered by a physician.



FIGURE 16-4 Twelve-lead ECG showing an STEMI.



FIGURE 16-5 Hyperacute phase of AMI.

Twelve Lead Electrocardiogram

One test that can be performed to detect heart muscle ischemia, injury, or an AMI is a 12-lead ECG.[23] An ECG shows the electrical activity of the heart and produces a series of waves and complexes that look like spikes and dips. Approximately half of people who suffer from angina or silent ischemia have normal ECG readings.[11] As the blood flow to the heart muscle diminishes, the muscle becomes ischemic and switches from using oxygen to produce energy, called **aerobic metabolism**, to producing energy without oxygen, called **anaerobic metabolism**.[23] This results in the muscle becoming acidotic. This acidosis can, if not reversed, cause cell injury and eventually death.[23] Consequently, changes in the ECG occur.

The early stage of an AMI may not be visible on an ECG. If visible, it shows as broadened, asymmetric, and peaked T waves.[23] This is called the **hyperacute phase**, see **Figure 16-5**. Ischemia occurs next and results in electrical changes in the ischemic areas. Because of the electrical changes, there are ST

depressions and the T wave becomes inverted.[23] If normal blood flow does not return, the heart muscle starts to suffer injury. The damage prevents the cells from repolarizing correctly. These cells remain more positively charged than normal. The abnormal repolarization usually causes ST elevations greater than 2 mm with a flipped T wave.[23] This process is reversible with improved blood flow.

If blood flow to the area does not improve, the muscle infarcts, or dies, an irreversible process. When heart muscle dies, there is no electrical activity. As a result, the ECG looks through the dead tissue to the tissue behind it. This results in the development of a permanent Q wave or a deeper-than-normal Q wave. This Q wave is called a **pathologic Q wave**, see **Figure 16-6**.[23] The tissue surrounding the infarcted area still suffers from ischemia or injury. This keeps the ST segment elevated, and the T waves flipped.[23]

Analyzing ECG waves and complexes can detect other cardiac abnormalities. These abnormalities include enlarged heart chambers or inflammation of the pericardium. Review of an ECG can also check the medication effectiveness, monitor the location of implanted mechanical devices (i.e., pacemakers), and check device function.[24]

Exercise Stress Testing

Patients who have some angina and a normal ECG at rest could still have IHD. Others with obvious symptoms and suspicious ECG may not have IHD. In either case, these patients require an exercise stress test to diagnose the presence of IHD.[25] An exercise stress test uses a treadmill or stationary bicycle to put stress the heart. The most common type of an exercise stress test has a patient walk on a treadmill using the **Bruce protocol**.[25] In the Bruce protocol, the treadmill starts with a warm-up phase; this is a slow speed. Every 3 minutes the treadmill speed and its incline increase. Each 3-minute interval is a stage (**Figure 16-7**).[25]

The test is over when the heart rate reaches 85% of its maximum heart rate that is determined by the patient's age. Testing ends early when any of the following occur: ST-segment depressions, chest pain, certain heart arrhythmias (ventricular tachycardia or ventricular fibrillation), fatigue, or the patient wants to stop.[11] During stress testing, certain vital patient assessments are made. These particular assessments appear in **Table 16-4**.

Exercise stress tests are not 100% accurate and are incorrect approximately 10% of the time. A false-positive test indicates there is heart disease when there is no heart disease.[11] A false-negative test indicates there is no disease when there is heart disease. When the heart has to work harder, it requires more oxygenated blood. The coronary arteries dilate. If IHD exists in the coronary arteries, they are not able to dilate as much, resulting in diminished blood flow and oxygen delivery to the heart, causing ischemia.[25]



FIGURE 16-6 Pathologic Q waves.

FIGURE 16-7 Treadmill stress test.

TABLE 16-4
Exercise Stress Test Patient Assessments

Assessment	Explanation
Exercise capacity	Maximum amount of physical exertion a patient can sustain
ECG	Monitor for ST-segment depressions or arrhythmias
Heart rate	Heart rates increase due to decreased vagal tone and increased sympathetic outflow Monitor heart rate recovery following exercise
Blood pressure	Systolic blood pressure usually rises with increasing work rates Monitor for changes
Oxygen saturation	Assessing for abnormal exercise-induced hypoxemia
Chest discomfort	Can be used as a criterion for diagnosis and prognosis

Pharmacologic (Chemical) Stress Test

Exercise stress tests, using a treadmill, are the diagnostic test of choice for IHD. However, there are times when a patient is unable to walk on a treadmill.[26] Physical limitations, such as back problems, joint disease, marked fatigue, unsteady gait, prior stroke, dizziness, or shortness of breath, prevent the use of an exercise stress test.[26] The primary medications for chemical stress testing include adenosine, dipyridamole, dobutamine, and regadenoson. These medications should mimic the effects of exercise on the heart and coronary arteries, and may reveal any underlying CAD.

Adenosine dilates the coronary arteries and mimics what occurs during exercise. This drug dilates normal arteries more than stenotic arteries. The administration of adenosine is via an intravenous (IV) pump. This medication has a half-life of approximately 6 seconds. Adenosine increases the blood velocity and flow rate in normal vessels. However, the diseased artery is limited as to how much they can dilate, and this shows up as ischemia.[26,27] Dipyridamole, brand name Persantine, has the same effect on the coronary arteries as adenosine. This medication is given over a 4-minute period through an IV as an IV push.[26,27] Dobutamine is a positive cardiac inotrope and chronotrope, and it causes the heart rate to increase. The administration is through an IV with a pump. The amount administered is increased every 3 minutes until the heart rate reaches 85% of its maximum.[26,27] Regadenoson is an adenosine analog and has the same effect on the coronary arteries as adenosine, but has a longer half-life. Administration is through the IV as an IV push.[26,27]

Echocardiogram

An echocardiogram uses high-frequency sound waves, called ultrasound, to look at the heart.[28] The sound waves originate in a probe placed on the chest wall over the heart. When the sound waves reach the heart, they bounce back or echo to the probe. The probe sends these echoes to a computer, which converts the echoes into real-time moving images of the heart.[28] An echocardiogram can evaluate the heart's wall size, wall function, valve function, blood flow, chamber size, and pumping function (**Figure 16-8**).[28]

A physician may also order a stress echocardiogram. This is used to look at the wall motion of the heart.[29] When the heart muscle is ischemic, it cannot pump as well. In a stress echocardiogram, the patient has an echocardiogram or resting scan first.[29] Then a chemical or treadmill stress test is performed. Following the stress test, the patient is re-scanned. The pre- and post-stress test scans undergo comparison. If the wall motion of the heart and ejection fraction (fraction of blood pumped from the heart with each beat) are less on the second exam, there is a possibility that the patient has CAD.[29]

Radiological Imaging

Radiological imaging, also known as nuclear imaging, uses a radioactive isotope to evaluate blood flow in the heart.[29] When the work of the heart increases, it requires more blood. The coronary arteries dilate



FIGURE 16-8 Echocardiogram with and without Doppler.

to increase the blood flow. Coronary arteries that have plaque in them are not able to dilate as much as normal arteries. This results in reduced blood flow to the heart.[25] When the less-expensive diagnostic approaches are unreliable, radiological imaging is used.[11] The radioactive isotopes used in radiological imaging are thallium, Cardiolite, or Myoview.[29] An IV is used to inject the isotopes, and as they circulate in the body, they are taken up by the viable heart tissue. Because more blood circulates to the areas of the heart without diseased arteries, more isotopes appear in these areas during the scan.[27]

Radiological imaging is a three-step process. In the first step, the isotope is injected, and pictures are taken using a scanning camera; this is a **resting scan**. The camera rotates around the patient's chest, stopping at specific intervals to take pictures. The camera is designed to detect the gamma radiation emitted by the isotope.[29] After the scan, the pictures are sent to a computer for the physician to view and interpret. These images demonstrate coronary artery perfusion at rest. Next, the patient receives a stress test. The stress test is administered chemically or performed with a treadmill. One minute before the end of the stress test, the isotope is injected, again through the IV. The isotope needs to circulate for 1 minute before the stress test ends; therefore, it is important that patients inform the physician when they can endure only another minute.[29] The third step is a repeat scan called the **stress scan**. A scan comparison looks for any differences. If an area of the heart does not have any color present, there is no blood flow to the muscle in this field. Reversible ischemia shows when the resting scan has more color than the stress scan. If the resting scan and stress scan do not have any color, this indicates irreversible ischemia (**Figure 16-9**).[30]

Computed Tomography

Another type of testing for IHD is computed tomography (CT) scanning. These are used to evaluate IHD.[11] Two types of CT scans can be used to assess for IHD: calcium-scoring CT scan and the coronary CT angiography (CCTA).

The calcium-scoring CT scan looks at the coronary arteries and detects any calcium. The presence of calcium correlates well with the presence of IHD. The calcium score indicates IHD. If the score is low, it is unlikely the patient has IHD. A high score does not mean the patient has IHD, but it is an indication for additional testing.[11] This type of diagnostic test is used primarily for risk stratification of asymptomatic patients.

CCTA scans are also used to visualize the coronary arteries for patients with acute or chronic chest pain. However, CCTA scans are not as accurate as the invasive coronary angiograms and are only for diagnosing, not treatment, discussed in the invasive section of this chapter. Other types of newer CT techniques include electron beam CT and multidetector CT.[11]



FIGURE 16-9 Coronary angiograms and nuclear scan images.

Reproduced with permission from Pijls N. (2004). Non-invasive testing is not specific enough: why and how to obtain objective signs of ischemia in the cath lab. *Cath Lab Digest, 12*(10), 12–20. https://www.cathlabdigest.com/articles/Non-invasive-Testing-Not-Specific-Enough-Why-and-How-Obtain-Objective-Signs-Ischemia-Cath-L.

KNOWLEDGE CHECK QUESTIONS

1. True or false: Electrical changes due to ischemia can invert the T wave on an ECG.
2. True or false: The ventricular wall movement is assessed using nuclear imaging.

Diagnostic Testing—Invasive

Based on the information collected in the noninvasive testing, an individual may need to have a more invasive test called a **left heart catheterization**. This type of catheterization shows coronary angiograms. This test is invasive and, therefore, has more risks of complications.

Coronary Angiograms

Although invasive, the cardiac catheterization is the gold standard for diagnosing and treating coronary vessel occlusions. Indications for a coronary angiogram include a positive result from one or more of the noninvasive tests, inconclusive noninvasive tests, or during an AMI.[11] With this procedure, the physician can directly visualize the coronary arteries and assess the pumping function of the left ventricle.[11]

For this procedure, the physician accesses the artery in the groin via the femoral artery or in the wrist via the radial artery. Usually, the right leg or right wrist is used. Figure 16-8 shows the sites for catheter entry. Once the artery is accessed, the physician uses a small wire and a small hollow tube called a catheter to advance through the artery to the opening of the coronary artery, the coronary artery ostium. This is called cannulating the coronary artery ostium. The next step is to inject the contrast medium (dye) into the coronary artery. This injection is the coronary angiogram (**Figure 16-10**).[11]

Coronary angiogram observation occurs under X-ray; the physician watches the contrast as it flows through the coronary arteries. Narrowing of an artery on X-ray represents stenosis and is a lesion. The basis for treatment is the severity of the lesion, the number of arteries with lesions, and location of lesions.[11] Treatments can range from medications to percutaneous coronary intervention (PCI) to open-heart surgery. **Figure 16-11** shows a coronary angiogram before and after a PCI.



FIGURE 16-10 Sites used for arterial entry to perform a cardiac catheterization.



FIGURE 16-11 Coronary angiograms before and after PCI of a coronary lesion.

Coronary angiograms will not always be definitive. There are times when angiograms do not provide the information needed to make a decision about the proper treatment of a lesion. When this occurs, other tools are available during a heart catheterization that assists the physician in making a decision. Three tools help in the decision-making process in the catheterization lab.[31] They are the fractional flow reserve (FFR) wire, Intra-Vascular UltraSound (IVUS), and optical coherence tomography (OCT).

Fractional Flow Reserve

Fractional flow reserve (FFR) calculates blood flow across a stenosis. The basis for this test rests on the three principles of coronary pressure and flow. The first principle is that aortic pressure is transmitted through normal coronary arteries without any loss; even to the distal regions of the vessels.[31] The second principle is narrowing of the artery lumen results in resistance to blood flow. This resistance causes a drop in pressure in the artery distal to the lesion. This drop is used to calculate the resistance. The velocity of the blood flow through the lumen of an artery increases as the lumen size decreases. As a result, the pressure across the lesion decreases.[31] The third principle involves the morphology of the stenosis. A standard coronary angiogram cannot quantify the resistance created by the lesion morphology.[31] The FFR wire measures the pressure across the lesion or **translesional pressure** using a 0.014-inch pressure sensor guide wire. Measuring the pressure before and after the lesion quantifies the effect of the stenosis on blood flow.[31] Adenosine (IV or intracardiac [IC]) is administered to increase the blood in the artery, called **hyperemia**.[31] The FFR wire uses a ratio of the pressure distal to the lesion compared to the pressure in the aorta; normally, this is a 1:1 ratio. **Figure 16-12** shows a schematic of this principle. If the ratio is below 1, this represents the percentage reduction of normal flow (i.e., if the ratio is 0.80, the artery transmits 80% of the expected normal flow).[31] The FFR versus angiography in multivessel evaluation (FAME) trial demonstrated that a lesion with a ratio below 0.80 needs repair. With a lesion having a ratio greater than 0.80, medical treatment is the best option.[32] The FAME study also demonstrated that use of FFR to guide treatment reduced cost and was superior to coronary angiogram guided treatment.[32]



FIGURE 16-12 The flow of blood increases distal to the lesion in the vessel, decreasing the pressure across the lesion.

IntraVascular UltraSound/Optical Coherence Tomography

While FFR is perfect for physiologic lesion assessment, it cannot give vessel size, stent expansion, stent apposition, lesion length, or plaque morphology. To assess these characteristics, **intravascular ultrasound (IVUS)** or **optical coherence tomography (OCT)** is the proper tool.[31] An IVUS or OCT catheter can provide images from within the coronary artery. With IVUS or OCT, the physician can accurately quantify the dimensions of the vessel, the length of the lesion, the composition of coronary arteries, and plaque morphology. The images returned from the IVUS or OCT catheter can give precise details with good resolution.[31] The standard coronary angiogram cannot provide all this information that is helpful in the selection of the correct stent size. After stent implantation, information from the IVUS or OCT is used for the assessment of the stent's appropriate placement, proper size, full expansion, and the complete apposition of the struts to the vessel wall.[31]

IVUS catheters have an ultrasound probe on the tip. This probe uses the same technology as the ultrasound probe described in the "Echocardiogram" section. The IVUS catheter fits over an angioplasty guide wire that is already in the artery distal to the lesion. The IVUS probe is advanced distal to the lesion. A recording of the images occurs as the probe is pulled back through the lesion.[31] The physician can view the pictures on the IVUS computer (**Figure 16-13**). The recorded images allow the physician to measure the minimal lumen diameter, reference vessel diameter, and vessel area.[31] The selection of the stent size is based on the reference vessel size. Using IVUS after a stent is in place has resulted in superior stent outcomes, reduced abrupt closure, and lower restenosis; all of these are a major advance in interventional cardiology.[31]



FIGURE 16-13 IVUS image.
Cath Lab Digest. 2013;21(4):28–30.

The OCT catheter contains a single optical fiber that emits infrared light with a wavelength between 1,250 and 1,350 nm.[33] Resolution is better with OCT than with IVUS; however, tissue penetration is better with



FIGURE 16-14 OCT image.

IVUS than with OCT.[33] **Figure 16-14** shows an image from an OCT catheter. Red blood cells can interfere with the light from the OCT catheter. Therefore, the vessel fills with contrast when obtaining images. The tip of the OCT catheter is in a place distal to the lesion and scans the lesion as the physician pulls it back.[33] The catheter measures the echo time delay and the signal intensity after it is reflected from the coronary wall structures.[33] Physicians can obtain the same information from an OCT catheter as an IVUS catheter. See the "IVUS" section for this information.

KNOWLEDGE CHECK QUESTIONS

1. True or false: Access for a left heart catheterization is through the femoral vein.
2. True or false: The most appropriate treatment for a FFR of 50% is angioplasty.

Treatment and Management

The best treatment for a patient with IHD is a decision made by the physician and the patient. The physician takes into consideration the patient history, current medical condition, and the results from the heart catheterization. Some of these factors are diabetes, **heart failure**, the number of arteries affected, location and severity of the lesion(s), and other comorbidities.[34] Studies have shown that if a patient is diabetic and has lesions in three or more vessels, **coronary artery bypass grafting (CABG)** is the best option. Also, if the lesion is in the left main coronary artery, then CABG is the best choice.[34] The treatment options for IHD include medical management, invasive management, or surgery.

Pharmacologic Management

If the physician determines the patient has mild IHD, medical management is best. Medical management includes certain medications and lifestyle changes. These lifestyle changes help to prevent the progression of the disease (see the section on "Prevention").[34] When lifestyle changes are not enough, the physician prescribes certain medication to help (**Table 16-5**). These medications help to reduce the risk of heart attack, stroke, and heart failure, which helps lessen the likelihood of death. The medications prescribed are antianginal medications, anticoagulation medications, antihypertensives, and cholesterol-lowering medications.

Antianginal medications help with angina (chest pain). One way to reduce angina is to reduce the myocardial oxygen demand by using drugs that block the beta-1 receptors in the heart. These beta blockers slow the heart rate. Another method to reduce angina is to reduce the resistance the heart has to work against to open the heart valves. This is afterload, and the medications that reduce afterload are calcium channel blockers. A third way of alleviating angina is to use nitrates. Nitrates dilate the coronary arteries and thus increase the amount of blood flow to the heart.[34]

Anticoagulant medications help thin the blood and reduce the risk of clot formation (thrombus). Aspirin is an anticoagulant that is available without a prescription and is available in low dose (50 mg) for this purpose. Physicians use aspirin for patients with stable CAD. For unstable CAD, platelet $P2Y_{12}$ inhibitor is used (clopidogrel, brand name Plavix).[34]

Antihypertension medications help reduce high blood pressure. Some people have high blood pressure due to water retention. This may be due to intake of too much sodium. For these individuals, a diuretic helps remove the excess sodium and water from their body, thereby reducing the blood pressure.[35] Angiotensin II is a potent vasoconstrictor. Angiotensin-converting enzyme (ACE) inhibitors prevent an enzyme in the kidney from converting angiotensin I to angiotensin II.[35] All muscles need calcium to contract. Calcium channel blockers prevent calcium from entering the muscles in the heart and blood vessels. This leads to a drop in the heart rate and vasodilatation, thus lowering the blood pressure.[35]

The largest class of cholesterol-lowering medications is the statins. Statins work in the liver by preventing the formation of cholesterol, which lowers the cholesterol in the body. They work mainly on the bad cholesterol (LDL), but may also raise the good cholesterol (HDL) and lower triglycerides. People taking these medicines may have muscle pain and need to have their liver functions regularly tested.[36]

Angioplasty

If determined during a heart catheterization that the patient has severe IHD or is having an AMI, **percutaneous coronary angioplasty** (PCI) of the artery or arteries is necessary. Initiation of a PCI occurs following the coronary angiogram. There are certain situations where the physician may wait to perform

TABLE 16-5
Medical Treatment for IHD

Medication Class	Medication Type	Examples of Medication	Mechanism of Action
Antianginal drugs	Beta blockers	Carvedilol (Coreg) Atenolol (Tenormin)	Decreases heart rate and heart's demand for oxygen.
	Calcium channel blockers	Verapamil (Calan) Amlodipine (Norvasc)	Decreases afterload and prevents coronary artery spasm.
	Nitrates	Nitroglycerin	Dilates coronary arteries.
Anticoagulant drugs	PGHS-1 inhibitor	Aspirin	Prevents thrombosis.
	$P2Y_{12}$ inhibitor	Clopidogrel (Plavix)	Interferes with platelet aggregation.
Antihypertensive drugs	Diuretics	Furosemide (Lasix) Spironolactone (Aldactone)	Reduces the amount of water in the body.
	ACE inhibitors	Benazepril (Lotensin) Lisinopril (Prinivil)	Relaxes blood vessels and reduces the workload on the heart.
	Calcium channel blockers	Verapamil (Calan) Amlodipine (Norvasc)	Decreases heart rate and causes vasodilation.
Cholesterol-lowering drugs	Statins	Simvastatin (Zocor) Atorvastatin (Lipitor)	Prevents the formation of cholesterol in the liver.

the PCI or stage the PCI. The basis for this decision is the patient's condition. The contrast used in a heart catheterization can harm the kidneys by causing contrast-induced nephropathy (CIN). This compromises kidney function, causing elevated blood urea nitrogen (BUN) and creatinine levels. Accordingly, the PCI can be delayed for a few days, allowing time for the kidneys to recuperate. The contrast needs to be flushed out with IV fluids following heart catheterization. Giving fluids to patients with renal dysfunction before a heart catheterization will help to reduce the chance of CIN.[37] If there are multiple lesions, the procedure is staged, and this helps to reduce the likelihood of CIN.

In some patients, the treated artery closes back down. This is **restenosis** and has been a major problem with PCIs since its inception. After an artery undergoes repair, the vessel grows new tissue in the repaired area. This new tissue consists of healthy cells from the lining of the arterial wall (endothelium) and is desirable. This new tissue allows the blood to flow smoothly and reduces the risk of thrombus development. In some cases, scar tissue may form underneath the new healthy lining. If the scar tissue becomes too thick, it obstructs the blood flow and causes restenosis.[38]

All invasive procedures require the use of anticoagulants to prevent the formation of clots on the equipment while in the body. In the early days of angioplasty, the anticoagulant used was unfractionated heparin (heparin). Heparin is an antithrombin agent that inactivates thrombin.[39] Heparin and drugs derived from heparin are considered indirect thrombin inhibitors. One complication of using heparin over long periods is the development of heparin-induced thrombocytopenia with or without thrombosis syndrome (HIT[TS]). This syndrome causes thrombi to form even when receiving heparin; it rarely occurs during PCIs.[39] Today, direct thrombin inhibitors are used during PCIs. The most commonly used is bivalirudin.[39] This drug does not carry the threat of HIT(TS) but does not have a reversal agent like heparin. The half-life of bivalirudin is 25 minutes.[39]

There are several types of angioplasty. Each one follows the same catheter introduction as described for the coronary angiogram.

Plain Old Balloon Angioplasty

This procedure is useful on the soft plaque. The plaque morphology is determined by using IVUS or OCT, as described earlier. During this procedure, a small (0.014 inches in diameter) coronary guide wire is advanced into the coronary artery with the lesion. The guide wire continues to be advanced until it is at a distal point in that coronary artery. The physician uses a coronary balloon catheter that matches the size of the reference diameter and the length of the lesion (**Figure 16-15**). The balloon catheter loads onto the coronary guide wire and advances to the lesion. The balloon has two radiopaque markers. One is on the proximal end, and the other is on the distal end of the balloon. The physician uses these markers to place the balloon to cover the lesion before inflating. If the balloon inflation occurs in the wrong place, it causes damage to healthy tissue.



FIGURE 16-15 Balloon angioplasty.

The balloon must cross the lesion before inflation. If the balloon is unable to cross the lesion, a smaller balloon is tried. The appropriate balloon is the one that crosses the lesion. When smaller balloons are used, several balloons are needed to repair the artery.[40]

Once the balloon is in place, it is inflated using a device called an **indeflator**. The indeflator pushes a contrast/saline mixture into the balloon, causing the balloon to inflate. The balloon puts pressure on the plaque in the lesion, compressing and fracturing the inside vessel walls. The pressure exerted on the vessel wall is measured in atmospheres (1 atm equals 15 psi). The amount of pressure required depends on the lesion and the physician.[40] Balloon angioplasty carries a 40% chance of restenosis.[38]

Rotational Atherectomy

Rotational atherectomy uses a catheter with an oval-shaped burr resembling a football. Attached to the front portion are crushed diamonds (**Figure 16-16**). The burr rotates at high speeds (150,000 rpm) to grind hard plaque away. The plaque morphology is determined using the IVUS or OCT. Rotational atherectomy requires a 0.009-inch diameter coronary guide wire advanced down the coronary artery with the lesion. The guide wire advances to a distal point in the coronary artery. The burr catheter attaches to a console, which displays the



FIGURE 16-16 Rotablator burr.

speed of the burr and allows manipulation of the catheter. The drive unit attaches to a flush solution through an irrigation port. The flush mixture usually contains 1,000 units heparin, 2 mg nitroglycerin, and 5 mg verapamil in 500 mL of normal saline.[40] Using a pressure bag on the saline mixture provides a continuous flow to the catheter. The mixture lubricates the catheter, reduces the chance of spasms, and reduces clot formation. The rotational atherectomy device is pneumatic and uses pressurized nitrogen gas.[40] The burr sizes range from 1.25 to 2.38 mm. The larger the burr, the larger the guide catheter has to be. Rotational atherectomy removes calcified plaque by grinding it away. After grinding the plaque away, a stent is placed. The largest burr used should be smaller than the reference lumen diameter. Several burr sizes are often required to grind away the plaque. This is done in increments of 0.5 mm to reduce the risks of complications.[40] The manufacturer recommends a temporary pacemaker for the patient before using the rotational atherectomy device.[40]

Stents

In most cases after a plain old balloon angioplasty (POBA) or rotational atherectomy, the artery is stented (**Figure 16-17**). A **stent** is a wire mesh tube that acts as scaffolding for the artery to help keep it open. Stents are pre-mounted on a balloon catheter.[34] The stent catheter has the same characteristics as the balloon catheter, and inflation is the same. Stent selection requires matching the size of the reference vessel and length of the lesion. After the balloon deflation of the stent catheter, the catheter is removed, leaving the stent behind.[41] Stents



FIGURE 16-17 A stent catheter placed in the coronary artery with the lesion. The balloon is inflated and then deflated, leaving the stent in the artery.

increase the structural integrity of the coronary arteries and become incorporated into the coronary arteries through endothelialization.

Bare-Metal Stent

As the name implies, these stents consist of metal without any coating. These were the first stents made. The invention of stent reduced the restenosis rate to 25%. Using a **bare-metal stent (BMS)** increases the risk of clot formation on the stent. To prevent this, the patient has to take **dual antiplatelet therapy (DAPT)**. DAPT consists of taking two blood thinners for 1 month. These are aspirin and a platelet $P2Y_{12}$ inhibitor (such as clopidogrel).[34] After 1 month, the endothelial cells cover the stent, reducing the risk for clots.[34] If the patient goes 12 months without an event, it is rare for restenosis to develop.[34]

Drug-Eluting Stents

Drug-eluting stent (DES) material is the same as the BMS. However, they have a drug on them to reduce the restenosis rate. The restenosis rate associated with the use of DESs is 5%.[42] DESs have three basic parts: a stent platform, a polymer, and an anti-restenotic drug.[43] The polymer must be non-thrombotic, non-inflammatory, and nontoxic to cells, and should encourage arterial healing by re-endothelialization.[43] Different types of medicines are used with the stents. Paclitaxel is a cancer drug made from the Pacific Yew trees. This medication prevents restenosis by stopping the cells from dividing. The other type of drug prevents restenosis by slowing the cell division. These drugs all have names ending in "olimus."[43] As with BMS stents, there is a risk of stent thrombosis, and because of this, DAPT is required. Because the drugs do not differentiate between healthy tissue and scar tissue, it takes a long time for the healthy endothelial cells to cover the DES. For this reason, the patient uses DAPT longer. According to the 2011 ACCF/AHA/SCAI Guideline for PCI, after a DES has been implanted, DAPT must continue for 12 months.[44]

Coronary Artery Bypass Grafting

Some patients with IHD need to have surgical management with CABG. Patients considered for CABG have one or more of the following: diabetes, severe lesions, lesion in the left main coronary artery, or disease involving two or three coronary arteries.[34] A CABG entails the creation of a bypass (detour) around the blockage. To create the bypass, either the saphenous vein from a leg (SVG) or the left internal mammary artery (LIMA) from the patient's chest becomes the bypass graft.[34] The LIMA grafts have been proven to last the longest. The radial artery in the arm may also serve as a graft. The number of bypasses varies depending on the number of blockages.[34] CABG operations require general anesthesia and a heart–lung machine to maintain circulation. The typical hospital stay post CABG is 4–7 days. Full recovery from the surgery can take up to 3 months.[34]

Recently, a new method of performing CABG has been developed. It is the minimally invasive direct coronary artery bypass (MIDCAB). This technique does not require stoppage of the heart. Therefore, the heart–lung machine is not used. The MIDCAB is less invasive than the CABG and does not require the surgeon to cut through the breastbone (sternum).[34] MIDCAB requires only a small incision between the ribs to operate on the blocked artery. The entire procedure occurs while the heart is beating, and requires only a 3-day hospital stay.[34] This approach is less invasive and has a lower length of stay. If the patient has more than two blocked arteries, this technique is not utilized.

Cardiac Rehabilitation

After a PCI or CABG, the patient is referred to cardiac rehabilitation.[45] Cardiac rehab is a supervised program that helps improve the lives of people diagnosed with heart problems. Almost every person with IHD can benefit from cardiac rehab. The cardiac rehab team may include doctors, nurses, exercise specialists, physical and occupational therapists, dietitians or nutritionists, and psychologists or other mental health specialists.[45]

Cardiac rehab teaches the patient the proper way to exercise. Through education, counseling, and training, the patient can understand the heart condition, cope with stress, and deal with fears about the future. The cardiac rehab team works together to develop

a program designed to meet the individual patient's needs. The program shows the patient how to exercise safely and strengthen their muscles, and improve their stamina.[45]

KNOWLEDGE CHECK QUESTIONS

1. True or false: The best treatment option for a patient with diabetes and lesions in three or more vessels is CABG.
2. True or false: An inflated angioplasty balloon contains air.
3. True or false: The bypass vessel used in a CABG is either the saphenous vein from a leg or the left internal mammary artery from the patient's chest.
4. True or false: The MIDCAB procedure for performing a CABG requires a heart–lung machine to maintain circulation.
5. True or false: Cardiac rehabilitation is a management strategy used only for post-CABG patients.
6. True or false: Patients who have completed a cardiac rehabilitation program will have improved stamina.

Risk Factors

The risk factors for IHD include those that are controllable and those that are uncontrollable.

Table 16-6 lists controllable risk factors with strategies to control them.

TABLE 16-6
Controllable Risk Factors and Strategies

Risk Factor	Control Strategies
Hypertension	Reduce stress Reduce sodium intake Weight loss Smoking cessation Exercise Diet Medications
Hyperlipidemia	Diet Exercise Medications
Diabetes/prediabetes	Diet Exercise Weight loss Decrease sugar intake Medications
Smoking	Smoking cessation program Medications Reduce stress Behavior modification
Overweight/obese	Diet Exercise Stress reduction Reduce sugar intake Weight loss program
Sedentary lifestyle	Exercise program
Unhealthy diet	Dietician consultation Healthy diet

KNOWLEDGE CHECK QUESTIONS

1. True or false: A sedentary lifestyle increases the risk for the development of IHD.
2. True or false: Diabetes is an uncontrollable risk factor for IHD.

Prevention

The best treatment for IHD is prevention. The first step in prevention is for the patient to identify the risk factors and take appropriate action to eliminate the controllable factors, and minimize the effects of the uncontrollable risk factors (see risk factors in the "Introduction" section).[46] The more risk factors a patient has, the higher the risk for IHD.[46]

The effects of the controllable risk factors for IHD are reduced by adopting a healthy diet consisting of vegetables, fruits, whole grains, fat-free or low-fat dairy products, and protein foods.[46] Protein food includes lean meats, poultry without skin, seafood, processed soy products, nuts, seeds, beans, and peas.[46] Avoid or reduce sodium (salt), added sugars, solid fats (saturated fat and trans fatty acids), and refined grains. Eating whole grains increases nutrient and fiber intake.[46]

Adopting a healthy diet also helps to reduce obesity and hypertension. However, sometimes diet is not enough to control IHD and medication is necessary. Exercise in conjunction with a healthy diet helps to reduce weight and blood pressure and control diabetes.[46]

Smoking cessation reduces the risk of IHD. Smoking damages and constricts blood vessels, increasing the risk of IHD. Also, secondhand smoke needs to be avoided.[47] There are numerous smoking cessation programs and medications to aid in the smoking cessation process.

A reduction in stress can reduce the risk of IHD. Research shows that stress from anger or an emotional event can induce a heart attack.[45] Stress causes a person to overeat and increases alcohol consumption and tobacco use. Eating right, getting exercise and relaxation therapy, or taking stress management classes helps reduce stress.[45]

KNOWLEDGE CHECK QUESTIONS

1. True or false: Diet and exercise can reduce the risk of IHD.
2. True or false: Stress, alone, cannot cause a heart attack.

Complications

Diagnostic testing for IHD has a risk of complications. Exercise and chemical stress testing have very few complications. There is a 1-in-5,000 chance of a person having a heart attack or dying during the exercise test.[48] Patients commonly develop arrhythmias, which normally subside with rest. If arrhythmias persist, the patient is monitored and receives prescribed medication. Hypotension may occur during testing, causing the patient to feel lightheaded or dizzy. This usually goes away when the patient stops exercising.[48]

The chemical stress test may lead to jitteriness, wheezing, shortness of breath, and other asthma-like symptoms. These symptoms may last several hours, can be severe, and require treatment.[48] The use of radioactive contrast may cause an allergic reaction requiring medical treatment.[49]

Diagnostic cardiac catheterization is an invasive procedure and as a result carries an increased risk of complications. The possible complications appear in Table 16-7.

The PCI carries all the same complications discussed in the "Diagnostic Cardiac Catheterization" section. Also, PCI complications are listed in Table 16-8.

Individuals who are over the age of 65, have chronic kidney disease, have extensive heart disease with significant coronary artery blockages, or are in shock have a higher risk of complications from PCI.

The more invasive the procedure, the more complications there can be. Following CABG surgery, there is usually some inflammation involving the lung and pericardium; this is from the incision in the pericardium. It is usually mild, but may require some treatment. The presence of comorbidities, such as diabetes kidney disease, lung disease, or peripheral arterial disease, increases the risk for complications following CABG surgery.[51] Complications involving memory loss and problems with concentration may occur with older patients. The risk for complications increases when the CABG is an emergency (such as with an active MI). Other complications involve reactions to anesthesia, wound infection, bleeding, fever, pain stroke, heart attack, and death.

TABLE 16-7
Complications from Diagnostic Catheterization

Injury	Explanation
Vessel injury	Injury to the catheterized artery or vein (both arm and leg) occurs in 0.5–1.5% of patients.
Site bruising	Bruising with skin discoloration at the site occurs in 1–5% of patients.
Reaction to contrast medium	Contrast may cause transient nausea and vomiting in 3–15% of patients, itching or hives in 1–3%, and a life-threatening allergic reaction in approximately 0.2%. Many physicians will give Benadryl as a precaution.
CIN	The kidney function is compromised by excessive amounts of contrast, causing elevated BUN and creatinine levels. Extra IV fluids will flush out the contrast.
Infection	Rarely occurs.
Heart attack, stroke	Within 24 hours of catheterization, this occurs in only 0.2–0.3% of patients.
Death	Perforation of the heart or surrounding vessels, cardiac arrhythmia, or anaphylactic shock due to contrast medium can cause death.[50]

TABLE 16-8
PCI Complications

Complication	Cause
Discomfort and bleeding at the catheter insertion site	Insertion of catheter
Blood vessel damage	Catheter
Cardiac arrhythmia (irregular heartbeat)	Irritation by catheter
The need for emergency CABG (<3% of people)	Occlusion of blood vessel
Kidney damage	Contrast used in procedure
Heart attack (3–5% of people)	Blockage of coronary artery
Stroke (<1% of people)	Blood clot
Temporary chest pain	Balloon inflation
Death	Heart attack, Stroke

KNOWLEDGE CHECK QUESTIONS

1. True or false: Temporary chest pain during an angioplasty is due to the inflation of the balloon in a coronary artery temporarily blocking coronary circulation.
2. True or false: More than 15% of patients having PCI require emergency coronary artery bypass graft surgery.

KNOWLEDGE CHECK QUESTIONS

1. True or false: The Framingham Heart Study shows a substantial risk reduction for individuals who are 50 years old with no CVD and major risk factors.
2. True or false: Mild atherosclerosis has a very low rate of progression.

Prognosis

CAD is believed to begin at an early age as a fatty streak (see discussion in the "Pathology/Pathophysiology" section), and it progresses over time in response to a person's risk factors (see the "Risk Factors" section).[52] Studies show that in some individuals with IHD, the progression is slow, if at all.[52] Several studies have shown that if a middle-aged adult lacks risk factors and/or there is an absence of subclinical IHD, the prognosis for developing cardiovascular problems is low.[52] Furthermore, the Framingham Heart Study has shown that there is a substantial risk reduction in developing IHD in individuals who are 50 years old and are free of CVD and major risk factors. Also, these individuals have a longer median survival time than participants who had two or more major risk factors.[52]

To determine the progression of IHD, a study was conducted in North Carolina between January 1, 1990, and March 31, 2011, and included 4,068 patients. The coronary angiograms demonstrated that 167 patients (5.8%) had no CAD (normal group), and 251 patients (6.4%) had mild atherosclerotic disease (stenosis $< 30\%$) (mild-atherosclerosis group).[52] The demographics of the patients in the normal-angiogram group were younger, more often female, and less likely to use tobacco than the patients in the other group. The rates of diabetes and hypertension were the same between both groups.[52] The coronary angiograms at the end of the follow-up period (approximately 75 months) reveal that in the normal group, 26% had evidence of CAD and 4.8% had evidence of obstructive CAD.[7] However, the coronary angiograms in the mild-atherosclerosis group showed a 78% progression of CAD and 31% developed obstructive CAD.[52] The revascularization rates were higher in the mild-atherosclerosis group as compared to the normal-angiogram group (24% vs. 3.5%), and MIs were higher in the mild-atherosclerosis group as compared to the normal-angiogram group (12% vs. 4.8%).[52] The progression of CAD increased 10-fold and the rate of revascularization by eightfold in individuals who had mild atherosclerosis on the initial angiogram.[52]

Chapter Summary

Heart disease is the number one killer in America and the world. In 2009, over 600,000 people died from CVD and about 370,000 from IHD. The AHA projects that by the year 2030, 43% of the population will have some form of CVD. The cost in America from CVD in 2012 was $320 billion and is projected to be $818 billion by the year 2030.

There are several risk factors for IHD. Some of them are uncontrollable (e.g., genetics) and some controllable (e.g., smoking). The AHA/ACCF have issued guidelines that encourage people to lose weight, lower their cholesterol, stop smoking, and get more exercise.

Atherosclerosis is the process of plaque building up in the coronary arteries and is responsible for IHD. The atherosclerotic process begins with damage to the intima layer of the coronary artery, which results in the development of fatty streak. Inflammation follows SMC migration, resulting in the formulation of a complex lesion. This lesion can be an unstable plaque, with a thin cap and a large lipid core, or a stable plaque, with a thick fibrous cap and a small lipid core. Another type of IHD is Prinzmetal angina, caused by spasm or SCAD. These spasms can lead to coronary artery dissecting for no apparent reason. When the artery becomes totally occluded or small enough, a person starts to have symptoms. The most obvious symptom is crushing chest pain. Other symptoms include chest pressure or jaw pain. The symptoms may appear only on exertion, but can be present at rest. Through diet and exercise, IHD can be slowed, stopped, or reversed.

Most people have symptoms before they have an MI (chest pain or indigestion). However, there are times when no symptoms present. This is a silent heart attack. People may not know they have had a heart attack until symptoms from other problems arise (i.e., shortness of breath from ischemic cardiomyopathy). Angina is located in the center of the left side of the chest. Some people have angina on exertion (stable angina), and other experience angina at rest (unstable angina).

Several tests can diagnose IHD. The noninvasive tests are 12-lead ECG, echocardiogram, exercise stress test (with or with a nuclear scan), chemical stress test with a nuclear scan, CT angiograms, or an MRA. The invasive test is a heart catheterization. In this test, catheters are inserted into the body and are used to take pictures of the coronary arteries. If these are not conclusive, then there is the FFR, IVUS, or OCT as an additional tool to help make a diagnosis.

There are several ways to treat IHD. Preventing the disease from starting or progressing and medical management are the only ones that are noninvasive. There are several ways to repair an artery during a heart catheterization. These procedures are invasive and range from just using a balloon (POBA) to using a diamond tip burr to a stent. The most invasive treatment is open-heart surgery.

Complications vary depending on the procedure. They can range from feeling dizzy during a stress test to having bruises from the heart catheterization to death. The prognosis of IHD varies for each person. The more risk factors an individual has, the greater the chance of developing IHD. If a person has very few risk factors and does not have IHD by age 50, the chances of not getting IHD is good.

Key Points

1. Heart disease is the number one killer in America and the world.
2. More than 43% of the people in America will have one or more forms of heart disease by 2030.
3. The projected cost for heart disease is $818 billion by the year 2030.
4. There are many risk factors for CVD. Some are controllable, and others are not. As the number of risk factors increases, so does the risk for CVD.
5. CHD starts when the intima of the coronary artery becomes damaged and results in plaque building up in the coronary artery.
6. As the plaque grows, the artery becomes narrow, and the heart muscle becomes ischemic and can lead to MI if left untreated.
7. The most recognized sign of a heart attack is chest pain. However, women do not usually have this chest pain.
8. Noninvasive and invasive tests are used to diagnose IHD.
9. The best way to treat IHD is to prevent it from happening.
10. The severity of the disease determines the treatment.
11. Treatment ranges from medications to open-heart surgery.
12. Prognosis depends on the patient's risk factors.

Chapter Questions

1. The leading cause of death in America is _____.
   - **a.** cancer
   - **b.** chronic obstructive pulmonary disease
   - **c.** heart disease
   - **d.** chronic kidney disease
2. Which of the risk factors below are uncontrollable?
   - **a.** Smoking
   - **b.** Gender
   - **c.** Diet
   - **d.** Cholesterol
3. What is the most common symptom of an AMI in a woman?
   - **a.** Chest pain
   - **b.** Back pain
   - **c.** Indigestion
   - **d.** Jaw pain
4. The best way to diagnosis IHD is _____.
   - **a.** left heart catheterization
   - **b.** chemical stress test
   - **c.** stress echocardiogram
   - **d.** nuclear scan
5. The best way to treat IHD is _____.
   - **a.** CABG
   - **b.** prevention
   - **c.** PCI
   - **d.** stents
6. What ECG change is indicative of an AMI?
   - **a.** Tall peaked P waves
   - **b.** ST depression of less than 0.5 mm
   - **c.** ST elevation greater than 2 mm
   - **d.** PR depressions
7. What group of the population has a higher risk of complications?
   - **a.** Over 65 years old
   - **b.** Single-vessel disease
   - **c.** High cholesterol
   - **d.** Slightly obese
8. What is one of the goals of the AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline from the American Heart Association and the American College of Cardiology Foundation?
   - **a.** At least 30 minutes of everyday physical activity
   - **b.** Blood pressure below 110/65
   - **c.** Reduction in smoking
   - **d.** Reduction in sugar intake
9. Symptoms of ischemia include which of the following?
   - **a.** Severe chest pain
   - **b.** Shortness of breath
   - **c.** Indigestion
   - **d.** All of the above

10. Which of the factors listed below can damage the intima layer of the artery?
- **a.** Hypotension
- **b.** Low sugar
- **c.** Smoking
- **d.** Exercise

11. The total cost for CVD in 2012 was _____.
- **a.** $300 billion
- **b.** $195 billion
- **c.** $124 billion
- **d.** $500 billion

12. The fat that causes CAD is _____.
- **a.** high-density lipoproteins (HDL)
- **b.** triglycerides
- **c.** vegetable fats
- **d.** low-density lipoprotein (LDL)

13. Angina that is relieved with rest is called _____.
- **a.** unstable angina
- **b.** variant angina
- **c.** stable angina
- **d.** ischemia

14. An exercise stress test is stopped prematurely when which of the following conditions occur?
- **a.** The heart rate reaches 25% of its maximum heart rate.
- **b.** ST depressions occur on ECG.
- **c.** Systolic blood pressure increases by 15 mm Hg.
- **d.** Sinus tachycardia

15. A chemical stress test uses which medication?
- **a.** Nitroglycerin
- **b.** Adenosine
- **c.** Atropine
- **d.** Heparin

16. An echocardiogram uses _____ to view the heart.
- **a.** x-rays
- **b.** infrared light
- **c.** ultrasound waves
- **d.** ultraviolet light

17. A nuclear stress test uses an isotope is used that emits _____.
- **a.** x-rays
- **b.** beta radiation
- **c.** alpha radiation
- **d.** gamma radiation

18. A heart catheterization uses _____ to see inside the body.
- **a.** x-rays
- **b.** beta radiation
- **c.** alpha radiation
- **d.** gamma radiation

19. Which of the following requires long-term DAPT?
- **a.** Bare-metal stent
- **b.** Drug-eluting stent
- **c.** Rotational atherectomy
- **d.** Balloon angioplasty

20. What diagnostic tool emits infrared light?
- **a.** Optical coherence tomography
- **b.** Intravascular ultrasound
- **c.** Echocardiogram
- **d.** C-arm

References

1. Silent Ischemia and Ischemic Heart Disease. The American Heart Association. http://www.heart.org/HEARTORG/Conditions/HeartAttack/PreventionTreatmentofHeartAttack/Silent-Ischemia-and-Ischemic-Heart-Disease_UCM_434092_Article.jsp. Accessed June 28, 2015.
2. Dilated Cardiomyopathy (DCM). The American Heart Association. http://www.heart.org/HEARTORG/Conditions/More/Cardiomyopathy/Dilated-Cardiomyopathy_UCM_444187_Article.jsp. Accessed June 28, 2015.
3. Heart Disease Fact Sheet. Centers for Disease Control and Prevention. http://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_disease.htm. Accessed June 26, 2015.
4. What Are the Risk Factors for Heart Disease? Centers for Disease Control and Prevention. http://www.nhlbi.nih.gov/health/educational/hearttruth/lower-risk/risk-factors.htm. Accessed June 26, 2015.
5. Heidenreich P, Trogdon J, Khavjou O, et al. Forecasting the future of cardiovascular disease in the United States. *Circulation*. 2011;123:933–944. doi:10.1161/CIR.0b013e31820a55f5.
6. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update a guideline from the American Heart Association and American College of Cardiology Foundation. *Circulation*. 2011;124:2458–2473. doi:10.1161/CIR.0b013e318235eb4d.
7. Atherosclerosis. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis. Accessed June 25, 2015.
8. Ischemia. The Free Dictionary by Farlex. http://medical-dictionary.thefreedictionary.com/Ischemia. Accessed June 26, 2015.
9. Coronary Artery Disease (CAD) Symptoms. Healthline. http://www.healthline.com/health/coronary-artery-disease/symptoms#Angina2. Accessed June 28, 2015.
10. Heart Disease in Women: Understand Symptoms and Risk Factors. Mayo Clinic. http://www.mayoclinic.org/diseases-conditions/heart-disease/in-depth/heart-disease/art-20046167. Accessed June 28, 2015.
11. Coronary Artery Disease. University of Maryland Medical Center. https://www.umms.org/ummc/patients-visitors/health-library/in-depth-patient-education-reports# . Accessed June 28, 2015.
12. What Causes Atherosclerosis? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis/causes. Accessed June 28, 2015.
13. Coronary Artery Disease (CAD) Causes. Healthline. http://www.healthline.com/health/coronary-artery-disease/causes#Overview1. Accessed June 29, 2015.
14. What is Cardiovascular Disease? The American Heart Association. http://www.heart.org/HEARTORG/Caregiver/Resources/WhatisCardiovascularDisease/What-is-Cardiovascular-Disease_UCM_301852_Article.jsp#. Accessed June 29, 2015.
15. Heart Disease Facts. Centers for Disease Control and Prevention. http://www.cdc.gov/HeartDisease/facts.htm. Accessed June 29, 2015.
16. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf. Accessed June 29, 2015.
17. Cardiovascular diseases (CVDs). World Health Organization. http://www.who.int/mediacentre/factsheets/fs317/en. Accessed June 29, 2015.

18. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update a report from the American Heart Association. *Circulation*. 2015;131:e29–e322. doi:10.1161/CIR.0000000000000152.
19. Sayols-Baixeras S, Lluís-Ganella C, Lucas G, Elosua R. Pathogenesis of coronary artery disease: focus on genetic risk factors and identification of genetic variants. *Appl Clin Genet*. 2014;7:15–32. doi:10.2147/TACG.S35301.
20. Prinzmetal's Angina, Variant Angina and Angina Inversa. American Heart Association. http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Prinzmetals-Angina-Variant-Angina-and-Angina-Iversa_UCM_435674_Article.jsp. Accessed June 30, 2015.
21. Chaker O, Zied B, Faten J, Nadia H, Faouzi A, Salem K. Management of spontaneous coronary artery dissection causing an acute myocardial infarction in a young female. *Cath Lab Digest*. 2013; 21(9). http://www.cathlabdigest.com/articles/Management-Spontaneous-Coronary-Artery-Dissection-Causing-Acute-Myocardial-Infarction-Young. Accessed July 1, 2015.
22. Coronary artery disease—Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/symptoms-causes/syc-20350613. Accessed September 25, 2018.
23. Garcia GB, Holtz EH. *12-Lead ECG: The Art of Interpretation*. Burlington, MA: Jones and Bartlett Learning; 2013.
24. Electrocardiogram. WebMD. http://www.webmd.com/heart-disease/electrocardiogram. Accessed July 1, 2015.
25. Treadmill Stress Test. HeartSite. http://www.heartsite.com/html/regular_stress.html. Accessed July 1, 2015.
26. Chemical Stress Test. HeartSite. http://www.heartsite.com/html/chemical_stress.html. Accessed July 1, 2015.
27. Medication Summary. Webscape. http://emedicine.medscape.com/article/1827166-medication. Accessed July 1, 2015.
28. Echocardiogram. HeartSite. http://www.heartsite.com/html/echocardiogram.html. Accessed July 1, 2015.
29. Echo Stress Test. HeartSite. http://www.heartsite.com/html/echo_stress.html. Accessed July 1, 2015.
30. Isotope Stress Test. HeartSite. http://www.heartsite.com/html/isotope_stress.html. Accessed July 1, 2015.
31. Kern M. FFR, IVUS, apples, oranges, and overcoming conventional wisdom: a review of basic concepts to guide everyday usage. *Cath Lab Digest*. 2010; 18(4). http://www.cathlabdigest.com/articles/FFR-IVUS-Apples-Oranges-and-Overcoming-Conventional-Wisdom-A-review-basic-concepts-guide-ev. Accessed July 2, 2015.
32. Tonino P, Bruyne B, Pijls N, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. *N Engl J Med*. 2009;360:213–224. doi:10.1056/NEJMoa0807611.
33. Tamburino C, La Manna A, Geraci S. Optical coherence tomography for coronary imaging. *J Cardiol Pract*. 2010;9. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-9. Accessed July 2, 2015.
34. Michaels AD, Chatterjee K. Angioplasty versus bypass surgery for coronary artery disease. *Circulation*. 2002;106:e187–e190. doi:10.1161/01.CIR.0000044747.37349.64.
35. Drugs for Hypertension or High Blood Pressure: How They Work and Why You Might Need Them. The Healthsite. http://www.thehealthsite.com/diseases-conditions/drugs-for-hypertension-or-high-blood-pressure-how-they-work-and-why-you-might-need-them. Accessed July 6, 2015.
36. Drug Therapy for Cholesterol. American Heart Association. http://www.heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Drug-Therapy-for-Cholesterol_UCM_305632_Article.jsp. Accessed July 6, 2015.
37. Nough H, Eghbal F, Soltani M, et al. Incidence and main determinants of contrast-induced nephropathy following coronary angiography or subsequent balloon angioplasty. *Cardiorenal Med*. 2013;3(2):128–135. doi:10.1159/000351981. Accessed July 6, 2015.
38. Dangas G, Kuepper F. Restenosis: repeat narrowing of a coronary artery prevention and treatment. *Circulation*. 2002;105:2586–2587. doi:10.1161/01.CIR.0000019122.00032.DF. Accessed July 6, 2015.
39. Rao S, Ohman EM. Anticoagulant therapy for percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2010;3:80–88. doi:10.1161/CIRCINTERVENTIONS.109.884478. Accessed July 6, 2015.
40. Watson S, Kelly L, Gorski K. "Rotational Atherectomy," excerpted from invasive cardiology: a manual for cath lab personnel. *Cath Lab Digest*. 2002;10(3). http://www.cathlabdigest.com/articles/Rotational-Atherectomy-Excerpted-Invasive-Cardiology-A-Manual-Cath-Lab-Personnel. Accessed July 6, 2015.
41. Drug-Eluting Stents—Part I. Angioplasty.org. http://www.ptca.org/des.html. Accessed July 6, 2015.
42. Teirstein PS. Drug-eluting stent restenosis. *Circulation*. 2010;122:5–7. doi:10.1161/CIRCULATIONAHA.110.962423.
43. Khan W, Farah S, Domd A. Drug-eluting stents developments and current status. *J Control Release*. 2012;161(2):703–712. doi:10.1016/j.jconrel.2012.02.010. Accessed July 6, 2015.
44. Levine G, Bates E, Blankenship J, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. *Circulation*. 2011;124:e574–e651. doi:10.1161/CIR.0b013e31823ba622. Accessed July 6, 2015.
45. How Is Coronary Heart Disease Treated? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/cad/treatment. Accessed July 6, 2015.
46. How Can Coronary Heart Disease Be Prevented or Delayed? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/cad/prevention. Accessed July 4, 2015.
47. How Does Smoking Affect the Heart and Blood Vessels? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/smo. Accessed July 5, 2015.
48. What Are the Risks of Stress Testing? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/stress/risks. Accessed July 6, 2015.
49. Nuclear Stress Test. Mayo Clinic. http://www.mayoclinic.org/tests-procedures/nuclear-stress-test/basics/risks/prc-20012978. Accessed July 6, 2015.
50. Lange R, Hillis LD. Diagnostic cardiac catheterization. *Circulation*. 2003;107:e111–e113. doi:10.1161/01.CIR.0000070982.94049.A2. Accessed July 6, 2015.
51. What Are the Risks of Coronary Artery Bypass Grafting? National Heart, Blood and Lung Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/cabg/risks. Accessed July 6, 2015.
52. Golla Rao MS, Paul T, Rao S, Wiesen C, Yeung M, Stouffer GA. Risk of developing coronary artery disease following a normal coronary angiogram in middle-aged adults. *J Invasive Cardiol*. 2014;26(12):624–628. http://www.invasivecardiology.com/articles/risk-developing-coronary-artery-disease-following-normal-coronary-angiogram-middle-aged. Accessed July 8, 2015.

CHAPTER

17

Pulmonary Vascular Diseases

"The art of medicine consists of amusing the patient while nature cures the disease."

—François-Marie Arouet Voltaire

OUTLINE

OBJECTIVES

1. State the working definitions for each type of pulmonary vascular disease.
2. Outline the incidence, prevalence, and risk factors for each type of pulmonary vascular disease.
3. Define and discuss the clinical manifestations associated with each type of pulmonary vascular disease.
4. Explain diagnostic testing used in diagnosing each type of pulmonary vascular disease.
5. Summarize the recommended management of patients with each type of pulmonary vascular disease.
6. Identify common complications associated with each type of pulmonary vascular disease.
7. Define the prognosis of each type of pulmonary vascular disease.

KEY TERMS

Cardiopulmonary exercise testing (CPET)
Computed tomographic pulmonary angiography (CTPA)
D-dimer
Deep vein thrombosis (DVT)
Embolus
Endothelin receptor antagonists (ERAs)
Endothelium-derived relaxing factors (EDRFs)
Fibrinolysis
Graduated compression stockings (GCS)
Guanylate cyclase stimulators
Hampton hump
Massive pulmonary embolism
Nitric oxide (NO)
Phosphodiesterase Type 5 inhibitors (PDE-5i)
Plexiform lesions (PL)
Pneumatic compression devices (PCD)
Postthrombotic syndrome
Prostacyclin analogues
Prostacyclin receptor agonists
Pulmonary arterial hypertension (PAH)
Pulmonary embolism (PE) or pulmonary thromboembolism
Pulmonary hypertension (PH)
Pulmonary vascular resistance (PVR)
Saddle pulmonary embolism
Six-minute walking test (6MWT)
Thrombus
Venous thromboembolism (VTE)
Ventilation–perfusion (V/Q) scanning
Virchow triad

Case Study

A 53-year-old man presents to his family physician complaining of new-onset shortness of breath on exertion over the preceding 2 months. The man denies any significant personal past medical history other than high blood pressure (BP) and childhood asthma. He is a nonsmoker with a family history of heart disease. He exercised regularly on a home treadmill at a moderate incline usually for 30 minutes without difficulty; however, now he can walk for only 15 minutes despite less of an incline. He denies exertional chest pain.

Physical examination reveals an oral temperature of 98.4°F, pulse of 86 beats/minute, and a respiratory rate of 14. He is 205 pounds, 5 feet 11 inches tall, with a body mass index of 28.5 kg/m^2 and BP of 172/95 mm Hg. There is no cervical or supraclavicular adenopathy. Examination of the chest, abdomen, and extremities is normal. The blood work studies show a normal chemistry panel, normal complete blood count, and normal thyroid function studies. A chest x-ray (CXR) shows no obvious pulmonary parenchymal abnormalities. Due to the patient's history of childhood asthma, empiric treatment for asthma begins with an inhaled corticosteroid and long-acting beta-agonist. After 5 months, both medications fail to improve the patient's shortness of breath symptoms.

Worsening shortness of breath and moderate exertional limitations, despite compliance with the inhaled asthma medications, leads to a reevaluation approximately 5 months later. The patient reports noticing the development of some chest tightness and discomfort on minimal exertion that caused him to stop regularly exercising. He denies having symptoms of orthopnea or paroxysmal nocturnal dyspnea though he did experience some shortness of breath while at rest. Due to the patient's age, weight, history of hypertension, exertional chest discomfort, and progressive breathlessness, he is given a referral to a cardiologist for further evaluation and possible treatment of suspected coronary artery disease.

The cardiologist physical examination reveals a BP of 165/95 mm Hg. Lung auscultation reveals normal breath sounds without wheezing, crackles, or rhonchi. Cardiac examination reveals a normal rhythm with an accentuated second heart sound (P2) and a high-pitched holosystolic murmur best heard at the left sternal border. The remainder of the patient's cardiovascular examination is normal. An electrocardiogram (ECG) showed a normal sinus rhythm with an incomplete right bundle branch block pattern. An echocardiogram showed normal left ventricular (LV) ejection fraction. The right ventricular (RV) chamber is mildly enlarged with no valvular abnormalities identified. The estimated mean pulmonary artery pressure (PAP) on echocardiogram studies is 42 mm Hg (normal mean values ranging from 9 to 18 mm Hg). A nuclear myocardial perfusion test shows a mild reversible inferior wall perfusion defect suggestive of ischemic changes. A subsequent coronary angiogram demonstrates mild luminal irregularities with no significant stenosis. Hemodynamic studies, using a Swan-Ganz pulmonary artery catheter, appear in **Table 17-1**.

TABLE 17-1
Hemodynamic Studies for the 53-Year-Old Man

Name	Measurement	Normal Value
Right atrial pressure, mm Hg	7	25
RV pressure, mm Hg	89/7	20–30/0–5
PAP, mm Hg	89/33	20–30/8–12
Mean PAP, mm Hg	55	25
Pulmonary capillary wedge pressure (PCWP), mm Hg	21	4–12
Cardiac output (CO), L/minute	5.45	4–8
Cardiac index (CI), L/minute/m^2	2.6	2.5–4

Introduction

The primary function of the pulmonary circulation is to carry mixed venous blood to the alveoli, where gas exchange occurs, then back to the left side of the heart for delivery of oxygenated blood to the rest of the tissues in the body. Circulatory disorders commonly affect the lung, with the most important and common of these being pulmonary embolic disease causing occlusion or blockage of the pulmonary artery (PA) or more of its vascular branches by a substance or material carried within the bloodstream. Other pulmonary vascular diseases include pulmonary arterial hypertension (PAH), pulmonary vasculitis, and diffuse alveolar hemorrhage syndrome.

The lungs have a unique dual vascular circulation different from other organs. The normal pulmonary



FIGURE 17-1 Schematic drawing of pulmonary circulation. IVC, inferior vena cava; SVC, superior vena cava.

circulation can accommodate the entire CO at perfusion pressures that are one-fifth of those in the systemic circulation, even when CO increases significantly during exercise. See **Figure 17-1**. The pulmonary circulatory bed is thin walled, has a larger internal diameter, is less affected by neural regulation of vasomotor tone, and contains far less vascular smooth muscle than its corresponding systemic and bronchial circulations. Maintenance of homeostasis in the pulmonary vasculature occurs by the actions of vasoactive compounds known as **endothelium-derived relaxing factors (EDRFs)**. The EDRF are endogenous substances that include acetylcholine, bradykinin, histamine, thrombin, serotonin, adenosine triphosphate (ATP), and some prostaglandins, including **nitric oxide** (NO).[1] NO is the predominant EDRF and is critical for normal development of the pulmonary vasculature. NO continues to mediate normal vasoregulation in adulthood. Loss of NO bioavailability is one component of the endothelial dysfunction and vascular pathology found in pulmonary hypertension (PH).[2] Several unique characteristics assist the pulmonary vasculature in the accommodation of a significant amount of blood volume. The pulmonary vessels can dilate, and the unused vasculature (e.g., arterioles and capillaries) can be recruited to accommodate blood volume beyond the normal right ventricular CO. While the pulmonary capillaries cannot constrict, their diameter can decrease in response to increases in intra-alveolar or intrapleural pressure. The pulmonary capillaries also dilate when there is perivascular inflammation or movement of intravascular fluid into the tissue interstitium.

The pulmonary circulation minimizes increases in perfusion pressure and maximizes gas exchange as it carries blood over the pulmonary capillary–alveolar membrane. Approximately 280 billion pulmonary capillaries supply an estimated 300 million alveoli over a 70 m^2 surface area. The newly oxygenated blood ultimately returns to the left atrium via pulmonary venules and veins. This low-pressure, low-resistance vascular system is very compliant, allowing increased blood flow to occur with exercise without a related increase in pressure, being controlled by the autonomic nervous system.[1] These vessels are also under the influence of alveolar oxygen tension, changes in acid–base balance, and various vasoactive substances. Regional pulmonary circulation blood flow variations are also affected by gravitation and ventilatory alteration.[1]

The bronchial circulation is, in contrast to the pulmonary circulation, a low-compliance, high-resistance vascular system originating from branches of the thoracic aorta. See **Figure 17-2**. It supplies a small quantity of LV oxygenated blood to the walls of the tracheobronchial tree, including the terminal bronchioles. The bronchial vascular system also delivers arterial blood to pulmonary arteries and veins, hilar lymph nodes, visceral pleura, vagus nerve, and esophagus. This second vascular system that supplies the lung tissue delivers a blood flow of approximately 70 mL/minute/m^2 at a blood flow pressure equal to that of the aorta. The bronchial circulation venous drainage follows arterial delivery, then contributes to a normal anatomic right-to-left shunt by draining deoxygenated blood into pulmonary veins, which carry oxygenated blood following alveolar gas exchange.[1]

Pulmonary circulation disorders originate from a range of individual and interrelated abnormalities in the lungs, its vasculature, or the heart. These disorders may result from direct injury, a disease process, or indirectly from hypoxemia or acid–base imbalance (acidemia). These pulmonary circulation disorders, also, adversely affect the myocardium and heart chambers, resulting in either right heart failure, or left heart failure (LHF), or both. Disorders affecting the bronchial circulation include chronic inflammatory or necrotizing diseases, such as tuberculosis or bronchiectasis. These diseases



FIGURE 17-2 The circulation of the lung. Vascular connections are present between the bronchial artery and the PA and between the pulmonary vein and the bronchial vein. Also, there are direct arteriovenous shunts. The bronchial veins anastomose with mediastinal veins and the mediastinal veins connect with the veins of the esophagus.

Reproduced with permission from de Leval M. The Fontan circulation: a challenge to William Harvey? *Nat Clin Pract Cardiovasc Med.* 2005;2(4):202–208 (Figure 4). doi:10.1038/ncpcardio0157.

cause intense neovascularization, which may collateralize with intercostals arteries. Life-threatening hemoptysis primarily originates from the high-pressure bronchial circulation.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The normal pulmonary circulation can accommodate all of the CO at perfusion pressures significantly less than the systemic circulation.
2. True or False: The pulmonary circulation is a high-pressure, high-resistance vascular system.
3. True or False: The bronchial circulation is a high-resistance vascular system.

Pulmonary Embolism

Pulmonary embolism (PE) or **pulmonary thromboembolism** is an occlusion of one or more branches of the PA by a substance, mostly blood clots, carried in the bloodstream. PE primarily originates from a blood clotting condition, **venous thromboembolism (VTE)**, that has two major manifestations: **deep vein thrombosis (DVT)** and PE. About 90% of pulmonary emboli come from the legs, with most involving the proximal (popliteal) or more central leg veins.[3] A blood clot attached to its site of origin in a blood vessel or a heart chamber is a **thrombus**. Once the clot detaches from its site of origin (embolization) and travels, it is an **embolus**. PE occurs when the embolus travels to the lungs and blocks the arterial blood supply in a single area or multiple areas of the lungs. While typically caused by blood clot embolization, several other substances such as fat globules, amniotic fluid, tissue or tumor fragments, or foreign bodies can also result in PA occlusion. PE, however, is reserved to indicate VTE unless specifically identified.

Definition/Diagnosis

PE is one of the most important disorders that affect the pulmonary vasculature. Not only is it found in more than 60% of autopsies, but it is widely "overdiagnosed" when not present and "underdiagnosed" when present.[4] The incidence of unrecognized or "silent pulmonary embolism" is higher with proximal DVT than with distal DVT.[5] Even when signs and symptoms are recognized, and the potential diagnosis is considered,

appropriate diagnostic and therapeutic management is unfortunately not initiated. Approximately one-third of untreated patients that somehow survive their initial PE subsequently die of a future embolic episode.[6]

VTE mimics other illnesses, and PE is known as "the Great Masquerader," making diagnosis difficult. PE is especially difficult to detect when it occurs concomitantly with overt heart failure or pneumonia.[7]

The 2014 European Society of Cardiology Guidelines on the diagnosis and management of acute PE states that the clinical diagnosis of PE, "confirmed PE," rests on the probability of PE high enough to indicate the need for PE-specific treatment, and "exclude PE" is the probability of PE low enough to justify withholding PE-specific treatment with an acceptably low risk.[8] Diagnosis of PE is made based on the assessment of clinical probability using validated clinical prediction rules.[8]

Clinical Signs and Symptoms

PE may escape prompt diagnosis because the clinical signs and symptoms are nonspecific.[8] Not all thrombosis is symptomatic and much is of uncertain clinical importance. Tibia fractures have a VTE rate of 45%, but only one-third are symptomatic. Up to 80% of hemiplegic patients have venous thrombosis in the affected limbs without embolic events. Similarly, more than 45% of trauma patients have been found to have DVT, with 12% being proximal. Consideration of both symptoms and epidemiologic risk is required to establish the need for treatment.[9]

The most frequent signs of acute PE are tachypnea, tachycardia, and leg swelling suggestive of DVT. The most frequent symptoms of PE include dyspnea, pleuritic chest pain, cough, palpitations, anxiety, and hemoptysis. See **Table 17-2**. These signs and symptoms are nonspecific for PE and may also be present in many other acute cardiopulmonary conditions.[10] See **Box 17-1** for differential diagnosis of PE. The differential diagnosis is critical because not all leg pain is due to DVT and not all dyspnea is due to PE. Finally, PE may be completely asymptomatic and be discovered incidentally during diagnostic workup for another disease or at autopsy.[8]

TABLE 17-2
Common Signs and Symptoms of PE

Signs	Symptoms
Leg swelling suggestive of DVT Tachycardia Tachypnea	Anxiety Cough Dyspnea Hemoptysis Palpitations Pleuritic chest pain

BOX 17-1 Differential Diagnosis of PE

- Acute coronary syndrome
- Anxiety
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Congestive heart failure
- Costochondritis
- Musculoskeletal discomfort
- Pericarditis
- Pleurisy
- Pneumonia
- Pneumothorax
- Rib fracture

TABLE 17-3
Simplified Well's Prediction Rule for Diagnosing PE

Parameter	Score
Clinical signs of DVT	+1
Alternative diagnosis is less likely than PE	+1
Previous PE or DVT	+1
Heart rate >100 beats/minute	+1
Recent surgery or immobilization (within the last 20 days)	+1
Hemoptysis	+1
Cancer treated within the last 6 months	+1
Clinical Probability of PE	**Score**
PE unlikely	0–1
PE likely	≥2

After the history and physical exam have raised the question of PE as a possibility, the relative risk is important to consider. Investigations and decisions are made on the determination of the risk for PE. **Table 17-3** shows the Well's clinical criteria for categorizing patients' probability of PE. Using the simplified two-level prediction rule reduces the proportion of underdiagnosed patients with PE to around 12%.[8]

Patients with massive PE present with systemic arterial hypotension and usually have anatomically widespread thromboembolism. Patients with moderate to large PE have RV hypokinesis on echocardiography but normal systemic arterial pressure. Those with small to moderate PE have both normal right heart function and normal systemic arterial pressure.[7]

Pleuritic chest pain is common with small, peripheral emboli. These small pulmonary emboli lodge, peripherally, near the innervation of pleural nerves and often cause pulmonary infarction.[7,8] In central PE, chest pain may have a typical angina character, possibly reflecting RV ischemia and requiring differential diagnosis with acute coronary syndrome or aortic dissection. Arterial hypotension and shock are rare but important clinical presentations because they indicate central PE and a severely reduced hemodynamic reserve.[8]

Etiology

PE and DVT are thought to represent a continuous spectrum of a single disease entity. PE is usually a consequence of DVT. See **Figure 17-3**. About 40% of patients with proximal DVT are found to have an associated PE via lung scan, and about 70% of patients presenting with PE are found to have DVT in the legs.[5] Other sites of thrombosis formation and subsequent source of PE can potentially involve any systemic vein or right heart chamber, though are far less common than the more proximal deep veins. Thrombi may infrequently arise from superficial veins as well as prostatic, uterine, renal, and other venous origins. Upper extremity DVT (UEDVT) are rare and occur as the result of primary UEDVT in young or otherwise healthy athletes or as secondary UEDVT in patients with cancer or individuals who have complications associated with intravascular devices.

Three primary influences predispose a patient to thrombus formation. These three influences are endothelial injury, stasis or turbulence of blood flow, and blood hypercoagulability. Thrombosis usually originates



FIGURE 17-3 Most likely places for thrombus formation. **(A)** Hip: external iliac vein, uterine vein, pelvic venous plexus, gonadal veins, lateral circumflex femoral vein; **(B)** Thigh: femoral vein, deep femoral vein, great saphenous vein; **(C)** Leg (calf): popliteal vein, small saphenous vein, posterior tibial veins, soleal plexus of veins.

when platelets gather on valves in the veins of the lower extremities. Further growth occurs by the gradual accumulation of platelets and fibrin and progression to red fibrin thrombus, which may either break off and embolize or result in total occlusion of the vein. Once embolized, the thrombus travels to the lungs. The large thrombi can lodge at the bifurcation of the main PA (**saddle pulmonary embolism**) or the lobar branches and cause hemodynamic compromise. Smaller thrombi typically travel more distally, occluding smaller vessels in the lung periphery.[11] The underlying causes for PE are multifactorial and are not clear in many cases. See **Box 17-2**.

Epidemiology

In the United States, the estimated incidence of PE is 1 case per 1,000 persons per year.[12] The incidence of VTE in the United States is also 1 person per 1,000 population, with an annual incidence of 250,000.[13] PE is present in 60–80% of patients with DVT, even though more than half of these patients are asymptomatic.[11] The incidence of DVT and PE worldwide is high in all racial groups, yet varies substantially from country to country.[11] Pulmonary thromboembolism is a worldwide problem, particularly in people with known common risk factors. Observed variance in frequency of occurrence from region to region may be due to diagnostic methodology differences rather than differences in actual disease frequency. Whether true differences are eventually proven to exist and whether they are due to either genetic variation or nonhereditary differences in diet and activity requires further investigation.

BOX 17-2 Underlying Causes for PE

- AIDS (lupus anticoagulant)
- Behcet disease
- Congestive heart failure
- Hereditary factors
- Hypercoagulable states
- Immobilization
- Malignancy
- Myocardial infarction
- Oral contraceptives and estrogen replacement
- Polycythemia
- Pregnancy
- Surgery
- Systemic lupus erythematosus
- Trauma
- Ulcerative colitis
- Venous stasis

The incidence of DVT is three times higher than that of PE during pregnancy. PE is less common during pregnancy than in the postpartum period (10.6 vs. 159.7 incidents, respectively, per 100,000 women).[13] There is conflicting data on whether men or women are at higher risk for PE. An analysis of national mortality data shows that death rates for PE are 20–30% higher among men than among women.[12] In the pediatric population, both DVT and PE are rare. However, among pediatric patients in whom DVT or PE do occur, these conditions are associated with significant morbidity and mortality.[11] Mortality rates for PE in the black population is 50% higher than in the white population. Mortality rates for whites are 50% higher than those for people of other races, such as Asian or Native American.[12]

PE is the third most common cause of death from cardiovascular disease, following heart attacks and strokes, in the United States, with at least 650,000 cases occurring annually.[11,14] PE represents a major cause of unexpected death in most age groups. The highest incidence of recognized PE occurs in hospitalized patients. Without proper anticoagulant prophylaxis, acute DVT occurs in 10–13% of general medical patients placed on bed rest for a week.[11] While it is easy to see why hospitalized patients represent a particularly high-risk, pulmonary thromboembolism, unfortunately, does not often manifest until after discharge.

Pathology/Pathophysiology

PE is not a distinct disorder but a serious and often fatal complication of underlying venous thrombosis. Under normal stable conditions, microthrombi (an aggregate of red cells, platelets, and fibrin) form in the venous circulatory system, which are promptly lysed by the body's intrinsic fibrinolytic system providing local hemostasis in response to injury without permitting uncontrolled propagation of clot. One or more features that compose **Virchow triad** (**Figure 17-4**) occur in all known risk factors, causing microthrombi to grow and propagate. PE occurs when a formed blood clot breaks loose and travels (embolizes) to occlude pulmonary blood vessels.



FIGURE 17-4 Virchow triad consists of blood vessel endothelial wall damage, abnormal blood flow in the form of stasis, and a state of increased coagulability.

After the thrombus becomes detached from its formation site, it travels to the right heart, then on to the PA system. In the lungs, the thrombus usually lodges in the more dependent areas (lower bases). When the thrombus lodges within a pulmonary vessel, a variety of consequences ensue. These consequences include mechanical obstruction of one or more vessels and chemical mediator release from the thrombus and the ischemic tissue.[4]

Pathophysiologically, occlusion of blood supply to an involved artery results in nonperfusion of involved areas of the lung that continue to be ventilated, increasing the overall dead-space ventilation. Alveolar dead space increases because the inhaled gas does not diffuse through the alveolar capillary membrane because there is no perfusion. Therefore, the physiologic dead space increases because ventilation to gas exchange areas exceeds blood flow through the pulmonary capillaries.[7] Assuming minute ventilation remains constant, the increased dead space automatically decreases alveolar ventilation and hence CO_2 excretion. However, despite the potential for CO_2 retention due to PE, patients increase their minute ventilation after an embolism occurs and more than compensate for the increase in dead space.[4] The most common gas exchange abnormalities due to PE are hypoxemia and an increase in the alveolar–arterial O_2 gradient. See **Table 17-4**.

An occlusion of 30–50% of the total cross-sectional area of the pulmonary arterial bed can increase PAP.[8] Pulmonary vasoconstriction occurs due to the release of chemical mediators when approximately 50–75% of the pulmonary vascular bed is occluded. The pulmonary vasoconstriction causes pulmonary vascular resistance (PVR) to increase. Both the anatomical obstruction and the vasoconstriction contribute to the increase in PVR.[4] The PAP and PVR may rise so high that the RV is unable to accommodate the acute increase in afterload. Thus, the forward output of the RV diminishes, BP falls, CO decreases, and the patient develops hemodynamic instability. Clinically, this may be evident as syncope or cardiogenic shock. See **Figure 17-5**.

The hemodynamic consequences of acute PE depend mostly on the presence of preexisting emboli and whether underlying pulmonary vascular disease or cardiac disease is present. Even if there are no risk factors and the emboli is small and distal, it may create areas of alveolar hemorrhage, causing hemoptysis, pleuritis, and pleural effusion. The clinical presentation is "pulmonary infarction." Its effect on gas exchange is normally mild, except in a patient with preexisting cardiopulmonary disease.[8]

Respiratory failure in PE is a consequence of hemodynamic disturbances. Vascular compromise to one or more regions of the lungs causes a reduction in the synthesis of pulmonary surfactant. Reduction in pulmonary surfactant leads to atelectasis, ventilation–perfusion mismatch, and shunt, causing worsening hypoxemia. Chemical mediator release and hyperventilation cause bronchoconstriction of the small airways.

In massive, acute PE, low CO due to right heart failure results in a reduction of mixed venous oxygen

TABLE 17-4
PE Pathophysiologic Abnormalities and Their Causes

Pathophysiologic Abnormality	Cause of Abnormality
Hypoxemia	Increased alveolar dead space Increase in alveolar-to-arterial O_2 gradient
Alveolar hyperventilation	Reflex stimulation of irritant receptors Compensation for hypoxemia
PH	Occlusion of 30–50% of total cross-sectional area of pulmonary arterial capillaries
PVR increase	Occlusion of 50–75% of pulmonary vascular bed
Airway resistance increase	Chemical mediator release causing bronchoconstriction
Pulmonary compliance decrease	Decrease in surfactant synthesis in affected alveoli



FIGURE 17-5 The pathophysiology of submassive PE.

Reproduced with permission from Piazza G, Goldhaber S. Management of submassive pulmonary embolism. *Circulation.* 2010;122(11):1124–1129 (Figure 1, p. 1126). http://dx.doi.org/10.1161/circulationaha.110.961136.

content. Other significant pathophysiologic effects that may subsequently occur include an increase in PVR, PH, systemic hypotension, and circulatory failure leading to death. See **Figure 17-6**.

Risk Factors

Several risk factors, including hereditary as well as acquired circumstances, are identified as associated with the likely development of DVT and subsequent PE. Virchow triad involving components of prolonged stasis, vessel injury, and hypercoagulability, first described in the mid-1800s, supports the effects and influences of genetic and environmental thromboembolic risk factors. See **Figure 17-7**. Several leading acquired risk factors include acute medical illness, total hip and knee replacement, underlying malignancy and surgery for cancer, pregnancy and the postpartum period, along with prolonged immobilization. See **Box 17-3**.

Clinical risk factors account for approximately 75% of VTE cases in the community, while about 25% remain idiopathic. Appropriate prophylaxis therapy is necessary for all patients at risk and where possible exposure to risk factors needs avoidance.[15]



FIGURE 17-6 Key factors contributing to hemodynamic collapse in acute PE.

Reproduced with permission from 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J.* 2014;35(43):3033–3073 (Figure 1, p. 7). doi:10.1093/eurheartj/ehu283.

Complications

PE, in and of itself, is a complication of VTE. The second complication of VTE is **postthrombotic syndrome** or chronic venous insufficiency. Postthrombotic syndrome is a delayed complication that causes the venous valves of the leg to become incompetent and exude interstitial fluid. This syndrome includes chronic leg pain, swelling, heaviness, and other signs, including venous ulcers in the thrombosis-affected limb, and is responsible for greater morbidity. More than half of individuals surviving an episode of VTE develop postthrombotic syndrome, resulting in lifelong pain and disability.[7]

Findings associated with increased in-hospital mortality as the result of PE occur in those patients who present with clinical or echocardiographic evidence of instability due to acute right heart failure, usually associated with **massive pulmonary embolism**. The term *massive pulmonary embolism* refers to a PE that is accompanied by hypotension or shock, severe hypoxemic respiratory failure, acute right-sided heart dysfunction, or anatomically as the obstruction of the pulmonary vasculature that exceeds 50%. The primary physiologic consequence of massive PE is RV failure. RV failure ultimately progresses to decreased LV preload with diminished CO, hypotension, and end-organ hypoperfusion.[16]



FIGURE 17-7 Risk factors for VTE and PE.

BOX 17-3 Additional Factors Found to Influence the Risk of Acquired PE

- Acute medical illness
- Advanced age (>40 years)
- Anticoagulant deficiencies (antithrombin, protein C, protein S, plasminogen, heparin cofactor II) and combination anticoagulation deficiencies
- Antiphospholipid antibody syndrome
- Behcet disease (systemic vasculitis)
- Blood type A
- Burns
- Central venous catheterization
- Chemotherapy
- Congestive heart failure
- COPD
- Diabetes
- Dysfibrinogenemia and high fibrinogen
- Factor V Leiden mutation from activated protein C resistance
- Family history
- Fractures and presence of orthopedic casts
- Hemolytic anemias
- High-dose hormone replacement and tamoxifen
- Hospitalized patients with chronic liver disease
- Increased travel time
- Intravenous drug abuse
- Lupus anticoagulant (SLE, AIDS)
- Major surgery
- Microalbuminuria (>30 mg/24 hours)
- Myocardial infarction
- Obesity
- Oral contraceptive use
- Phenothiazines
- Polycythemia, thrombocytosis, sickle cell disease, and multiple myeloma
- Pregnancy
- Previous history of DVT or PE
- Prothrombin gene mutation (prothrombin G20210A mutation)
- Sedentary lifestyle, reduced mobility
- Spinal cord injury
- Venography

A major complication of PE is due to the therapy that treats the embolism. Anticoagulation therapy and thrombolytic therapy both increase the risk of bleeding, including intracranial hemorrhage.

Diagnostic Testing

Diagnosis of PE begins with an assessment of clinical pretest probability (CPTP) based on the combination of individual symptoms, signs, and common tests evaluated using prediction rules (Table 17-3) or clinical judgment. The primary goal of diagnostic testing for PE is to identify patients who would benefit from treatment.[3] Every patient for whom PE is initially considered does not need testing for PE, a convincing alternative diagnosis may subsequently be found.[3] Diagnostic management algorithms are used to exclude PE without the need for imaging tests in a proportion of patients. These algorithms begin with the CPTP, followed by a D-dimer blood test or a computed tomography pulmonary angiography (CTPA).[10] See **Figure 17-8**.



FIGURE 17-8 Diagnostic testing algorithm for PE.

D-Dimer

D-dimer is a degradation product of cross-linked fibrin, and therefore, levels are increased in the setting of thrombosis of any type. Plasma levels of D-dimer increase not only in the setting of venous thrombosis but also in many other conditions, including myocardial infarction, pneumonia, sepsis, trauma, surgery, cancer, and inflammation. Thus, D-dimer testing for VTE or PE is very sensitive, but the test is nonspecific.[4] The test is inappropriate to "screen out" PE in patients who

have not been evaluated clinically because the high frequency of false positive results will increase, rather than decrease, the need for additional testing.[3] A negative D-dimer in a low clinical probability patient does reduce the risk of PE to approximately 1% (when followed for 3 months), allowing such patients to be discharged without further investigation.

Computed Tomographic Pulmonary Angiography

Since the introduction of multidetector computed tomographic (MDCT) angiography with high spatial and temporal resolution and quality of arterial opacification, computed tomographic (CT) angiography has become the method of choice for imaging the pulmonary vasculature in patients with suspected PE.[8] The **computed tomographic pulmonary angiography (CTPA)** outlines the thrombi in the pulmonary arteries with intravenous contrast medium (**Figure 17-9**). The newest generation of CT scanners can image small peripheral emboli. Six-order branches can be seen with resolution superior to that of conventional invasive contrast pulmonary angiography.[7]

CT venography is a simple method for diagnosing DVT in patients with suspected PE, as it can be combined with CTPA in a single procedure, using only one intravenous injection of contrast medium. However, because CT adds a significant amount of irradiation, ultrasonography is appropriate instead of CT venography, if indicated.[8]

CTPA can lead to contrast-induced nephropathy and substantial radiation exposure. Allergic reactions to contrast medium are also possible.

Pulmonary Angiography Imaging

Pulmonary angiography has for decades remained the 'gold standard' for the diagnosis or exclusion of PE but is rarely performed now as less-invasive CTPA offers similar diagnostic accuracy.[8] When performed carefully and completely, a positive pulmonary angiogram provides virtually a 100% certainty of pulmonary arterial blood flow obstruction. A negative pulmonary angiogram similarly provides greater than 90% certainty that PE does not exist. Pulmonary angiography is more often used to guide percutaneous catheter-directed treatment of acute PE. Digital subtraction angiography requires less contrast medium than conventional cineangiography and has excellent imaging quality for peripheral pulmonary vessels in patients who can hold their breath; it is less useful for imaging of the main pulmonary arteries, due to cardiac motion artifacts.[8]

Pulmonary angiography is useful as a second-line imaging technique if previous studies have been nondiagnostic and clinical suspicion remains high. It is useful if a patient is unable to tolerate a CT scan. Pulmonary angiography carries a low morbidity/mortality rate, related more to the severity of the clinical presentation than the test itself. Its limitations include moderate to poor interobserver reliability, a risk of renal injury from contrast load, and missing subsegmental emboli. Despite it being a highly accurate investigation, it is rarely performed.[9]



FIGURE 17-9 CTPA showing normal pulmonary vessels.

Ventilation–Perfusion Scan Imaging

Ventilation–perfusion (V/Q) scanning is an established diagnostic test for suspected PE. The V/Q scan, also known as V/Q scintigraphy, does not cause allergic reactions, as does diagnostic tests that require intravenous contrast.[8] This imaging test is a second-line diagnostic test for patients who cannot tolerate intravenous contrast.[7] The perfusion scan utilizes the intravenous injection of radiolabeled macroaggregated albumin particles into a peripheral vein. In areas of normal blood flow in the lungs, the albumin particles lodge in a fraction of the perfused small vessels. When a clot obstructs blood flow within the pulmonary arterial system, the perfusion scan shows decreased blood flow. See **Figure 17-10**. The perfusion scan is combined with a ventilation study that utilizes a radiolabeled inhaled gas such as xenon-133- or Tc-99m-labeled aerosols, or Tc-99-labeled carbon microparticles. The V/Q scan exploits the unique pulmonary arterial segmental anatomy. Each bronchopulmonary segment receives blood from a single end artery. Occlusive thrombi affecting individual pulmonary arteries, therefore, produce characteristic lobar, segmental, or subsegmental peripheral wedge-shaped defects with the base projecting to the lung periphery.[17] The combination of ventilation and perfusion studies increases the specificity of the test. With acute PE, ventilation is expected to be normal in hypoperfusion segments.[8] Therefore, the diagnosis of PE depends on identifying the V/Q mismatch.

A normal V/Q study excludes PE with the same degree of certainty as a negative pulmonary angiogram. A "high-probability" V/Q study establishes the diagnosis. A nondiagnostic V/Q study, on the other hand, is not



FIGURE 17-10 Perfusion scan of lungs with PE. The embolism shows in the left upper lobe.

an acceptable end point in the workup for pulmonary thromboembolism and must be further followed up with another definitive test when the diagnosis remains unclear.[5] For patients with contraindications to CTPA, including contrast allergy, renal disease, and pregnancy, V/Q scanning may be the preferred imaging modality for the evaluation of possible PE.[18]

Magnetic Resonance Pulmonary Angiography

Magnetic resonance pulmonary angiography (MRPA) may provide an important safer alternative to CTPA because it is free of long-term cancer risks from ionizing radiation and has an overall decreased risk of complication from contrast material adverse reaction.[19] The conclusion of a large-scale clinical trial studying the use of MRPA to diagnose PE is that it should be considered only by centers that routinely perform it well and only for patients for whom standard tests are contraindicated.[20]

Venous Doppler

Doppler ultrasonography is the most widely used modality for evaluating patients with suspected DVT and PE, because of its accuracy in detecting proximal thrombi, noninvasiveness, and wide availability. When used in combination with a CPTP, ultrasound examination is accurate in predicting the need for anticoagulation. A normal ultrasound study in a high-probability patient requires additional investigations before the possibility of DVT and PE can be ruled out. There are certain limitations on the use of Doppler ultrasonography. These limitations include operator accuracy, inability to differentiate between old and new thrombus, and specific site limitations, such as the detection of a DVT in the pelvic veins or small vessels of the calf. Another obstacle limiting the use of Doppler ultrasonography is the presence of significant obesity or edema. A positive Doppler allows diagnosis of thromboembolism, while a negative study mandates further investigation.[9]

Radiologic Imaging

Initial CXR findings of patients with PE are most often normal. Later, an initially normal CXR may deteriorate to atelectasis, or develop a pleural effusion or elevation of the hemidiaphragm. Also, some cases may demonstrate focal infiltrates that simulate infection (especially in the face of low-grade fever).

The CXR is important for ruling out other diagnoses because most CXR findings are nonspecific or rare. The rare CXR findings that occur with PE include the Westermark sign, Hampton hump, and Fleischner sign. The Westermark sign is an area of decreased pulmonary vascularity (oligemia) that causes a unilateral hyperlucency corresponding to the embolized arterial branch. **Hampton hump** is a wedge-shaped or rounded pleural-based infiltrate with the apex pointed toward the hilum and is frequently located adjacent to the diaphragm. Hampton hump is typically a late CXR finding associated with pulmonary infarction distal to the thrombus. Fleischner sign refers to a localized widening of an artery due to impaction of an embolus.

Electrocardiogram

The ECG is abnormal in approximately 85% of individuals with PE. PE frequently causes sinus tachycardia and T-wave inversion in Leads V_1 to V_4. An S1-Q3-T3 electrocardiographic pattern is another common finding. This pattern includes an S wave in Lead I, a Q wave in Lead III, and an inverted T wave in Lead III. This finding is relatively specific, but insensitive.[7] While ECG abnormalities may be suggestive of PE, the absence of such abnormalities has no significant predictive value.

Echocardiography

Echocardiography can detect RV pressure overload and dysfunction caused by an acute PE. However, a negative result cannot exclude PE and signs of RV overload, or dysfunction may also be found in the absence of acute PE and due to concomitant cardiac or respiratory disease.[8] The echocardiography is helpful when estimating the extent of PE in clinically severe cases.

Suspected high-risk PE is an immediately life-threatening situation, and patients presenting with shock or hypotension have a distinct clinical problem. In this situation, the probability of PE is high, and the differential diagnosis includes cardiac tamponade, acute coronary syndrome, acute valvular dysfunction, and aortic dissection. These patients may be so critical that only bedside diagnostic tests are possible. The most useful initial test, in this situation, is bedside transthoracic echocardiography (TTE). If PE is the cause of the patient's hemodynamic decompensation, the TTE will demonstrate acute PH and RV dysfunction. A transesophageal echocardiogram may allow the direct visualization of thrombi in the PA, and its main branches and a bedside venous Doppler can detect a DVT.[8]

Arterial Blood Gas Findings

Patients with acute PE usually present with tachypnea and hyperventilation, causing arterial blood gases (ABGs) to commonly exhibit a low $Paco_2$, with an elevated pH consistent with an acute respiratory alkalemia. The size of the vascular impairment determines the extent of the patient's hypoxemia. In patients with suspected PE, a normal Pao_2 does not rule out PE. ABG findings are not diagnostic of PE. However, profound hypoxemia without clear explanation is suspicious for possible PE.

Cardiac Biomarkers

Elevated plasma troponin I or troponin T levels can occur in patients with PE secondary to RV dilation and collateral myocardial injury. Elevated troponin levels have a high risk of short-term mortality.[10] PE needs to be considered in individuals presenting with chest pain or dyspnea and elevated plasma troponin levels.

High concentrations of brain-type natriuretic peptides (BNPs) or the N-terminal of the prohormone of BNP (NT-proBNP) may be elevated during a PE that is associated with RV overload. Elevated levels of BNPs are strongly associated with mortality in acute PE. Normal BNP levels are associated with a low mortality rate in PE.[10]

Treatment and Management

The degree of hemodynamic compromise is the single most important predictor of in-hospital death in patients with massive PE. The PE-related mortality risk of these patients is >15%.[8] Hemodynamic instability is a systolic BP <100 mm Hg with a heart rate >100 beats/minute.[21] Patients with low-risk PE may be candidates for early discharge or outpatient treatment. These patients are identified using the Hestia Decision Rule or the Simplified Pulmonary Embolism Severity Index (sPESI).[22] The Hestia Decision Rule consists of 11 bedside criteria that all need to be negative for a patient to be considered for early discharge or outpatient treatment. The sPESI includes six criteria that must all be negative for the patient to be considered for early discharge or outpatient treatment. **Table 17-5** shows both

TABLE 17-5
The sPESI and the Hestia Criteria

sPESI Criteria	No	Yes	Hestia Criteria	No	Yes
Is the patient age >80 years?			Is the patient hemodynamically unstable?*		
Does the patient have cardiopulmonary comorbidity?			Is thrombolysis or embolectomy necessary?		
Does the patient have a history of cancer?			Does the patient have a high risk for bleeding?†		
Is the Sao_2 <90%?			Has supplemental oxygen been necessary to maintain an Sao_2 >90% for more than 24 hours?		
Is the systolic BP <100 mm Hg?			Was PE diagnosed during anticoagulant treatment?		
Is the heart rate ≥110 beats/minute?			Has intravenous pain medication been needed for more than 24 hours?		
			Is there a medical or social reason for treatment in hospital for more than 24 hours?		
			Is the patient's creatinine clearance <30 mL/minute?‡		
			Does the patient have a severe liver impairment?§		
			Is the patient pregnant?		
			Does the patient have a documented history of heparin-induced thrombocytopenia?		
If the answer to any of the questions is yes, the patient is regarded as high risk.			If the answer to any of the questions is yes, the patient cannot be treated at home.		

*Systolic BP <100 mm Hg with heart rate >100 beats/minute (physician discretion may be used), a condition requiring admission to an intensive care unit.

†Gastrointestinal bleeding in the preceding 14 days, stroke less than 2 weeks ago, operation within past 2 weeks, bleeding disorder or thrombocytopenia (platelet count $<75 \times 10^9$/L), uncontrolled hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg).

‡Creatinine clearance calculated per the Cockcroft-Gault formula.

§Left to the discretion of the physician.

decision rules side-by-side. Both decision criteria can identify low-risk PE patients and serve as risk stratification methods.[23]

Acute RV failure with resulting low systemic output is the leading cause of death in patients with high-risk PE. Therefore, supportive treatment is important in patients with PE and RV failure. A fluid challenge, with 500 mL fluid, may increase CI in patients with PE, low CI, and normal BP.[8] Hypotension due to PE is initially managed with an intravenous normal saline bolus of 500–1000 mL. This intravenous normal saline bolus therapy is successful in patients with a lower RV end-diastolic volume. Care need to be taken not to cause wall stress by using an excess of fluid in the presence of RV dysfunction because this exacerbates RV ischemia and leads to a further interventricular septal shift toward the LV.[23] The left septal shift reduces LV compliance and filling, leading to decreased CO. Norepinephrine can increase CO and systemic vascular resistance, making it beneficial for patients with PE and shock.[8,23] However, the first-line inotropes for the treatment of PE-related shock are dobutamine and dopamine. If these agents fail, epinephrine, milrinone, and phenylephrine can also be added. Hypoxemia and hypocapnia are frequent in patients with PE, but they are of moderate severity in most cases.[8] Oxygen usually reverses the hypoxemia. If mechanical ventilation is required, care needs to be taken to limit its adverse hemodynamic effects. Patients with RV failure from massive PE are at great risk for reduced venous return with the positive intrathoracic pressure induced by mechanical ventilation. Therefore, PEEP is to be applied cautiously, tidal volume set at approximately 6 mL/kg lean body weight, and plateau pressure kept <30 cm H_2O.[8]

Pharmacologic Treatment

Anticoagulation is the foundation for successful treatment of PE and DVT. Immediate anticoagulation with a parenteral drug, unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), or fondaparinux,[7,8,10] is delivered over the first 5–10 days. Parenteral heparin administration overlaps the initiation of a vitamin K antagonist or is followed by the initiation of the newer oral anticoagulants: dabigatran or edoxaban. Oral treatment with rivaroxaban or apixaban can begin directly or after a 1- to 2-day administration of UFH, LMWH, or fondaparinux. See **Figure 17-11**.

Thrombolytic agents, **fibrinolysis**, activate plasminogen and convert it to plasmin that degrades fibrin. Systemic administration of thrombolytic agents is appropriate for hemodynamically unstable patients with massive PE or patients with submassive PE who develop acute right heart strain that exhibits exhausted



FIGURE 17-11 Suggested management algorithm for the management of PE.

cardiopulmonary reserves.[23] Patients with imminent or actual cardiac arrest should receive a bolus infusion of thrombolytic therapy. Fibrinolysis is not recommended in patients with acute PE who do not have hypotension.[23]

Successful fibrinolysis can rapidly reverse right heart failure and may result in a lower rate of death and recurrent PE. This is possible by dissolving the anatomic obstruction, preventing continued release of neurohumoral factors that exacerbate PH, and by breaking up the DVT, decreasing the likelihood of recurrent PE.[7] See Figure 17-11.

Nonpharmacologic Prevention

Reduction of the risk factors is crucial in the prevention of DVT or PE. The risk of VTE is substantial in hospitalized patients but can be reduced when patients receive suitable prophylaxis based on appropriate situations. The burden of pulmonary thromboembolism is measured in terms of the risk of fatal PE, the morbidity and costs associated with the onset of symptomatic disease, the risk of long-term post-embolism complications, and risks of recurrence in those untreated. Nonpharmacologic mechanical prophylaxis modalities have proven effective in certain clinical settings. **Graduated compression stockings (GCS)** may be adequate when tailored to provide an effective gradient of pressures in young and healthy individuals with less severe medical problems who are likely to have limited immobilization. The use of mechanical intermittent **pneumatic compression devices (PCD)** or of a prophylactic low-dose anticoagulant, such as subcutaneous heparin or a coumarin compound, should provide adequate protection for those at low or moderate risk.

Nonpharmacologic Treatment

IVC filters are placed, angiographically, in the infrarenal portion as a means of trapping thromboemboli from a lower extremity and thus reducing the incidence of recurrent PE. Venous filters are indicated in patients with acute PE who have absolute contraindications to anticoagulant medications, and in patients with objectively confirmed recurrent PE despite adequate anticoagulation treatment.[7,8] IVC filters are useful for the prevention of recurrent PE in patients with right heart failure who are not candidates for fibrinolysis. IVC filters are useful for the prophylaxis of extremely high-risk patients.[7] Complications of the IVC filter include the passage of small- to medium-size clots through the filter, large thrombi embolization through collateral veins, and cava thrombosis with bilateral leg swelling.[7] Nonpermanent IVC filters are retrievable devices that are removed within a few days or when it is safe to use anticoagulants, up to several months after insertion.[7,8] See Figure 17-11.

Surgical Treatment

Current treatment of individuals with massive PE involves intravenous anticoagulant heparinization along with systemic fibrinolysis to rapidly reverse RV failure and cardiogenic shock. Either catheter embolectomy or surgical embolectomy is reasonable for patients with massive PE who have contraindications to fibrinolysis or who remain unstable after receiving fibrinolysis.[24] The role of surgery in the treatment of PE is limited and has been all but replaced by fibrinolytic therapy and catheter embolectomy because they are less invasive and have fewer complications. If either surgical or catheter embolectomy is not available locally, the patient requires transfer to an institution with experience in one of these procedures. Catheter embolectomy and surgical thrombectomy are inappropriate for patients with low-risk PE or submassive acute PE with minor RV dysfunction, minor myocardial necrosis, and no clinical worsening.[24] See Figure 17-11.

Prognosis

The prognosis of patients with PE is dependent upon two factors: appropriate diagnosis and treatment of the PE and the patient's underlying disease state. Approximately 10% of patients who develop PE die within the first hour and 30% die subsequently from a recurrent embolism.[11,25] Mortality for acute PE is broken down into two categories: massive PE and non-massive PE.[11]

Anticoagulation therapy reduces mortality to below 5%. Thirty-six percent of lung scan defects resolve at 5 days of anticoagulant therapy, 52% resolve within 2 weeks, and 73% resolve by 3 months. Most patients treated with anticoagulant therapy do not develop long-term sequelae upon follow-up evaluation. The mortality in patients with undiagnosed PE is 30%.[11,25]

During the first 3 months after the diagnosis of PE, death and morbidity are most commonly due to shock and recurrent PE. This highest risk of death is within the first 2 hours of presentation. The risk of recurrence (DVT and PE) is greatest in the first 2 weeks and declines after that. The cumulative proportion of patients with early recurrence while taking anticoagulant therapy is 2% at 2 weeks and 6% at 3 months. The major predictors of increased risk of recurrence during this period include cancer and failure to rapidly achieve therapeutic levels of anticoagulation.[25]

At 3 months or later following the diagnosis of PE, recurrent events have a 9–32% occurrence rate.[25] These late mortality rates are mostly due to predisposing comorbidities and less commonly due to recurrent thromboembolism. Patients diagnosed with PE who have poor prognostic factors include those with shock and RV dysfunction, RV thrombus, DVT, and hyponatremia.[25]

KNOWLEDGE CHECK QUESTIONS

1. True or False: About 50% of pulmonary emboli are due to DVT.
2. True or False: The clinical signs and symptoms of PE are mostly nonspecific.
3. True or False: PE is the third most common cause of death from cardiovascular disease.
4. True or False: PAP increases when there is an occlusion of more than 30–50% of the total cross-sectional area of the PA bed.
5. True or False: The diagnostic technique of choice for imaging the pulmonary vasculature, to diagnose PE, is a ventilation/perfusion scan.
6. True or False: Anticoagulation is the first-line treatment for patients with pulmonary emboli.

Pulmonary Artery Hypertension

The pulmonary circulation is a low-pressure, low-resistance, high-capacitance circuit that can accommodate large increases in blood flow during exercise without significant increases in pressure. The high capacitance of the pulmonary circulation is a result of recruitment of under-perfused microvessels and the distension of open vessels in response to increases in blood flow. The tone of the smooth muscles in the pulmonary arterioles is lower, and the smooth coat of pulmonary resistance vessels is thinner than that of most systemic vascular beds.[26] PH is a pathophysiologic disorder of the pulmonary circulation that involves multiple clinical conditions and can complicate many cardiovascular and respiratory diseases.[27]

Definition/Diagnosis

Pulmonary hypertension (PH) is an increase in mean PAP (PAPm) ≥25 mm Hg at rest as assessed by right heart catheterization (RHC).[28] **Pulmonary arterial hypertension (PAH)**, which is sometimes erroneously confused as synonymous with PH, is a subset of PH requiring the presence of elevated PAPm, a pulmonary artery wedge pressure (PAWP) ≤15 mm Hg, and a **pulmonary vascular resistance (PVR)** >3 Wood units (WU) (or 240 dyne/second/cm^5). The different hemodynamic definitions of PH arise from various combinations of PAP, PAWP, CO, diastolic pressure gradient (DPG), and PVR assessed in stable clinical conditions. **Table 17-6** shows the different hemodynamic definitions of PH and their clinical classifications. See **Table 17-7** for the clinical classifications.

The current classification groupings of PH used by the World Health Organization (WHO) is the result of the Fifth World Symposium on Pulmonary Hypertension in 2013. The current guidelines represent the present understanding of pathophysiology and clinical-based differences or similarities within the five PH diagnostic categories. The five groups

TABLE 17-6
Hemodynamic Definitions of PH

Definition	Characteristics Based on At-Rest Measurements	Clinical Classification
PH	PAPm ≥25 mm Hg	All
Precapillary PH	PAPm ≥25 mm Hg PAWP ≤15 mm Hg	PAH (Group 1) PH due to lung diseases (Group 3) CTEPH (Group 4) PH with unclear and/or multifactorial mechanisms (Group 5)
Postcapillary PH	PAPm ≥25 mm Hg PAWP >15 mm Hg	PH due to left heart disease (Group 2) PH with unclear and/or multifactorial mechanisms (Group 5)
Isolated postcapillary PH (Ipc-PH)	DPG <7 mm Hg and/or PVR ≤3 WU	PH due to left heart disease (Group 2) PH with unclear and/or multifactorial mechanisms (Group 5)
Combined postcapillary and precapillary PH (Cpc-PH)	DPG ≥7 mm Hg and/or PVR >3 WU	PH due to left heart disease (Group 2) PH with unclear and/or multifactorial mechanisms (Group 5)

TABLE 17-7
Classification of PH

Group Name	Subgroup	Etiology
1. PAH	1.1	Idiopathic PAH (IPAH)
	1.2 1.2.1 1.2.2 1.2.3	Heritable PAH (HPAH) Bone morphogenetic protein receptor Type 2 (BMPR2) Other mutations Unknown
	1.3	Drug and toxin induced
	1.4 1.4.1 1.4.2 1.4.3 1.4.4 1.4.5	Associated with: Connective tissue disease Human immunodeficiency virus (HIV) infection Portal hypertension Congenital heart diseases Schistosomiasis
1'. Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis	1'.1	Idiopathic
	1'.2	Heritable
	1'.3	Drug, toxin, and radiation induced
	1'.4 1'.4.1 1'.4.2	Associated with: Connective tissue disease HIV infection
1". Persistent pulmonary hypertension of the newborn (PPHN)		
2. PH due to left heart disease	2.1	LV systolic dysfunction
	2.2	LV diastolic dysfunction
	2.3	Valvular disease
	2.4	Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
	2.5	Congenital/acquired pulmonary veins stenosis
3. PH due to lung diseases and/or hypoxia	3.1	COPD
	3.2	Interstitial lung disease
	3.3	Other pulmonary diseases with mixed restrictive and obstructive pattern
	3.4	Sleep-disordered breathing
	3.5	Alveolar hypoventilation disorders
	3.6	Chronic exposure to high altitude
	3.7	Developmental lung diseases
4. CTEPH and other PA obstructions	4.1	CTEPH
	4.2 4.2.1 4.2.2 4.2.3 4.2.4 4.2.5	Other PA obstructions Angiosarcoma Other intravascular tumors Arteritis Congenital pulmonary arteries stenosis Parasites (hydatidosis)

(*Continues*)

TABLE 17-7
Classification of PH (*Continued*)

Group Name	Subgroup	Etiology
5. PH with unclear and/or multifactorial mechanisms	5.1	Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
	5.2	Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
	5.3	Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
	5.4	Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH

specified by the World Symposium on PH are PAH (Group 1); PH due to left heart disease (Group 2); PH due to chronic lung disease and/or hypoxia (Group 3); chronic thromboembolic PH (CTEPH; Group 4); and PH due to unclear multifactorial mechanisms (Group 5).[29] See Table 17-7. Each of the five categories or classification groupings of PH has a distinct mechanism responsible for the elevated PAP, a different natural history, and a different approach to treatment. Diagnosis, understanding, and the correct clinical application of the specific classifications of PH compels a sequence of investigative stages intended to establish a specific diagnosis, clarify clinical category and type of PH, and assess functional and hemodynamic impairment.

A systematic approach typically begins with a clinical suspicion of PH followed by the employment of methods to detect PH, which ordinarily leads to the identification of an appropriate clinical classification. Proceeding with appropriate testing can potentially establish the specific type, functional capacity (FC), and hemodynamic status of persons with PH.

Clinical Signs and Symptoms

The overall group of symptoms in patients with PH depends on the underlying disease; there are certain characteristic complaints attributed to PH. These characteristic complaints, however, are nonspecific and can lead to a delay in diagnosis. Initially, patients present with exertional dyspnea, lethargy, and fatigue. Because PH is progressive, the presentation evolves over time. Patients may eventually develop the signs and symptoms of severe PH with overt RV failure (e.g., exertional chest pain or syncope and congestion, including peripheral edema, ascites, and pleural effusion).[30] Exertional chest pain may be difficult to distinguish from classical angina pectoris. In most circumstances, the chest pain is presumed to be related to the increased workload of the RV and RV ischemia, although in some cases an enlarged PA can compress the left main coronary artery and produce true LV ischemia. When PH is severe, and the RV is failing, patients are unable to increase CO with exertion and may experience exertional light headedness or frank syncope. These are very poor prognostic signs.[4]

Uncommon symptoms include cough, hemoptysis, hoarseness, and wheezing. The hemoptysis is related to rupture of hypertrophied bronchial arteries.[27] The hoarseness is due to Ortner syndrome, a compression of the left recurrent laryngeal nerve by a dilated main PA.[30] Large airway compression can cause wheezing.[27] Significant dilation of the PA may result in its rupture or dissection, leading to signs and symptoms of cardiac tamponade.[27]

Physical examination of the patient may reveal signs more related to the cardiac consequences of PH than to the actual disease of pulmonary vessels. PH does not cause any changes that can be noted on examination of the lungs, although patients with underlying lung disease often have findings related to their primary disease.[4] There may be a left parasternal heave, due to RV enlargement. Patients frequently exhibit an accentuation of the pulmonic component of the second heart sound (P_2) because of earlier and more forceful valve closure attributable to high pressure in the PA.[4] Elevated jugular venous pressure, hepatomegaly, ascites, peripheral edema, and cool extremities characterize patients with advanced disease.[27]

Clinical examination may suggest an underlying cause of PH, such as COPD, interstitial lung disease, connective tissue disease, liver disease, and heart failure.

Etiology

Several factors, occurring either individually or in combination, can affect the pulmonary circulation, resulting in an abnormal rise in PAP. The most common mechanism contributing to increased PAP (Table 17-6) is precapillary



FIGURE 17-12 Pulmonary circulation showing areas affected by PH. See text for description.

PH. Precapillary PH develops through processes involving arterial destruction, obstruction, and constriction. Etiologies for this type of PH include PA hypertension, lung diseases, chronic thromboembolic disease, and multifactorial mechanisms.

Postcapillary PH results in an increased pressure in the pulmonary vascular circuit distal to the capillaries and causes PAP elevation from left heart disease and multifactorial mechanisms. See **Figure 17-12**.

Epidemiology

The true prevalence of PH in the general population is unknown, likely because of the broad classification and multiple etiologies. PH affects all age groups and racial populations as well as both genders.[31] The age-standardized death rate in the United States ranges between 4.5 and 12.3 per 100,000 population.[27] The mortality rates associated with PH for women are higher than those for men. One reason may be that women have a higher rate of connective tissue disease than men.[32]

The epidemiology of PH varies among the different etiologies of the five groups and even within each group. The group best studied is Group 1 PAH; idiopathic and heritable PAH is rare in the general population and estimated to be 5–15 cases per 1 million adults.[33,34] PAH may occur in different settings depending on associated clinical conditions.[29] The mean age at the time of diagnosis of PAH has increased from 36 years, in 1981, to between 50 and 65 years.[27]

In Group 2, PH due to left heart disease (PH-LHD), the prevalence of PH increases with the severity of the defect and the symptoms. PH occurs in virtually all patient with severe symptomatic mitral valve disease and in up to 65% of those with symptomatic aortic stenosis.[35]

The incidence of PH in Group 3 depends on the type and severity of the lung disease. Mild PH is common in both severe interstitial lung disease and severe COPD.[36] Several studies suggest that 90% of those with severe COPD have mild-to-moderate PH and 3–5% have severe PH.[37] The prevalence of PH due to interstitial lung disease is estimated to be between 8% and 32%, and the estimated prevalence of PH due to obstructive sleep apnea is 15–20%.[31]

The incidence of PH in Group 4, CTEPH, is unknown but estimated to be between 1% and 5% among survivors of acute PE.[38]

Within Group 5 (PH with unclear and/or multifactorial mechanisms), PH due to sickle cell has an incidence between 6% and 10%.[39] PH is common in advanced sarcoidosis. Among sarcoidosis patients awaiting lung transplant, over 70% have significant PH.[40]

Pathology/Pathophysiology

A normal PAPm at rest is ≤20 mm Hg; the definition of PH includes a PAPm of ≥25 mm Hg at rest. The hemodynamic variables that contribute to PAP can be explained using a variation of Ohm's law, which is a fundamental law of physics. It states that the electric current flowing through a fixed linear resistance is directly proportional to the voltage applied across it and inversely proportional to the resistance.[41] Hemodynamics are the physical factors that govern blood flow. In relating Ohm's law to fluid flow, the voltage difference is the pressure difference (ΔP; sometimes called driving pressure, perfusion pressure, or pressure gradient), the resistance is the resistance to flow (R) caused by the blood vessels and their interactions with the moving blood, and the current is the blood flow (F). See **Box 17-4**.

From the equation in Box 17-4, it is apparent that the PAPm is determined by the right-sided CO, PVR, and

BOX 17-4 Hemodynamic Variables of PH

$$\Delta P = F \times R$$

$$\Delta P = \text{PAPm} - \text{PVPm}$$

$$F = Q$$

$$R = \text{PVR}$$

Therefore,

$$\text{PAPm} - \text{PVPm} = Q \times \text{PVR}$$

Then:

$$\text{PAPm} = (Q \times \text{PVR}) \div \text{PVPm}$$

Key: ΔP = pressure gradient; F = blood flow; R = resistance; PAPm = mean pulmonary arterial pressure; PVPm = mean pulmonary venous pressure; Q = right-sided CO; and PVR = pulmonary vascular resistance.

TABLE 17-8
Pulmonary Vascular Hemodynamic Abnormalities, Their Mechanisms, and Causative Medical Conditions

Hemodynamic Variable	Mechanism	Medical Conditions
Increased PVR	Occlusive vasculopathy of small pulmonary arteries and arterioles	• IPAH • Connective tissue disease • HIV infection • Congenital heart disease
	Decreased area of pulmonary vascular bed	• Pulmonary emboli • Interstitial lung disease
	Hypoxic vasoconstriction	• Hypoventilation syndromes • Parenchymal lung disease
Increased pulmonary vascular blood flow	Left-to-right shunt	• Atrial septal defects • Ventricular septal defects • Patent ductus arteriosus • Liver cirrhosis
Increased pulmonary venous pressure	Decreased forward blood movement	• Mitral valve disease • LV systolic or diastolic dysfunction • Constrictive pericarditis • Restrictive cardiomyopathy • Pulmonary venous obstruction

mean pulmonary venous pressure.[42] Increases in blood flow alone do not usually cause significant PH because the pulmonary vascular bed vasodilates and increases the number of vessels in response to increased flow. Increases in pulmonary venous pressure alone do not usually cause significant PH. However, a chronically increased flow and increased pulmonary venous pressure can increase PVR.[42] Various medical conditions cause changes in PVR, blood flow, and pulmonary venous pressure. See **Table 17-8**.

Regardless of the cause of the PH, a predictable sequence of events occurs. The RV hypertrophies and then dilates, causing the CO to fall. By the time the CO falls, the patient may have severe symptoms, including symptoms at rest.[42]

The five PH classifications have different pathophysiologic mechanisms, although each clinical presentation may be similar.

Group 1: Pulmonary Arterial Hypertension

PAH was once regarded mainly as a disease of excess vasoconstriction, but this view was incomplete.[43] PAH is a proliferative vasculopathy, characterized not just by vasoconstriction, but also by cell proliferation, fibrosis, and thrombosis. Hyperplasia and hypertrophy occur in the intima, media, and adventitia of the pulmonary arteries that are <50 μm.[42] Characteristic histologic findings of PAH include remodeling of small pulmonary arteries and arterioles with varying degrees of endothelial cell proliferation, muscular hypertrophy, and intimal fibrosis, ultimately leading to an obliteration of precapillary vessels. See **Figure 17-13**. Morphologic hallmarks of severe PAH are **plexiform lesions (PLs)**. PLs, in some ways, resemble neoplastic disorders, and are glomeruloid-like vascular structures originating from the pulmonary arteries.[44]

PAH has a genetic component. A genetic predisposition to pulmonary vascular disease includes mutations of a variety of genes. See **Table 17-9**. In the context of a possible genetic predisposition to PAH, patients with PAH may be exposed to a "second hit" or additional factors that may augment the risk for the development of full-blown PAH. Modifying factors may include a specific type of genetic mutation, a second genetic mutation, drug exposure, increased flow secondary to a congenital left-to-right shunt, an infectious organism such as HIV, altered structure or function of a membrane ion channel, inflammatory mediators, or cytokines.[42] See **Box 17-5**.

Group 2: PH Due to Left Heart Disease

LHF leads to increased pressures in the pulmonary veins and capillaries, causing increased stress on the alveolar capillary walls. With persistent, significant



FIGURE 17-13 Normal healthy artery (left) compared to a diseased artery (right) due to PAH with hyperplasia and hypertrophy of the PA wall.

TABLE 17-9
Genetic Components of PAH

Genetic Component	Pathophysiologic Mechanism
BMPR2	• Induces apoptosis • Permits excessive endothelial growth and proliferation due to injury
Activin-like kinase Type 1 receptor (ALK1 or ACVRL1)	• Member of transforming growth factor-beta • Mutations identified in some patients with PAH
5-Hydroxytryptamine (serotonin) transporter (5HTT)	• Activity related to PA smooth muscle hypertrophy
Endoglin (ENG)	• Protein involved in differentiation of angioblasts into endothelial cells (vasculogenesis)
Caveolin 1 (CAV1)	• Scaffolding plasma membrane–associated protein involved in cell cycle progression
Mothers against decapentaplegic homologue 9 (SMAD9)	• Intracellular signaling molecule downstream of the TGF-beta receptor • Mutations identified in patients with IPAH
Potassium channel subfamily K member 3 (KCNK3)	• Encodes a potassium channel • Mutations identified in patients with familial and IPAH

BOX 17-5 Modifiers of PAH

Congenital heart disease
Decreased NO–mediating signaling
Drug exposure
- Amphetamines
- Aminorex
- Benfluorex
- Dasatinib
- Dexfenfluramine
- Fenfluramine
- L-tryptophan
- Methamphetamines
- Selective serotonin reuptake inhibitors (SSRIs)*

HIV
Potassium channel dysfunction

*Increased risk of persistent PH in the newborns of mothers with intake of SSRIs.

elevation in the left atrial and pulmonary venous pressure, pulmonary capillary endothelial cells develop basal laminar thickening. Initially, the damage is reversible, but if it persists, irreversible, structural changes and remodeling occur, causing the walls of the alveolar capillary membrane to thicken, resulting in reduced diffusion capacity in the lungs.[42,45] The vascular remodeling is characterized by medial hypertrophy, intimal hyperplasia, and fibrosis in both pulmonary arterioles and venules.[42] Two compensatory mechanisms alleviate pulmonary capillary congestion: first, distension of the pulmonary lymphatics, which clears the increased transudation of fluid induced by the elevated pulmonary venous pressure; second, increased PVR, which decreases blood flow to the pulmonary capillaries.[42]

Other causes of left atrial hypertension also lead to PH. These include mitral and aortic valve disease, left atrial myxoma, pulmonary venous obstruction, restrictive cardiomyopathy, and constrictive pericarditis.[42] There is no specific genetic linkage identifiable with PH due to LHD.[27]

Group 3: PH due to Lung Diseases and/or Hypoxemia

PH is associated with a worse prognosis for patients with advanced lung disease. Acute hypoxemic pulmonary vasoconstriction can be reversed with the administration of supplemental oxygen. Chronic hypoxemia is implicated as the most important stimulus for vascular remodeling in patients with PH and lung disease.[46] Chronic hypoxemia causes hypoxia-induced pulmonary vasoconstriction via a variety of mechanisms and is only partially reversible. See **Table 17-10**.

Pathologic changes are consistent with the clinical observation that hypoxic vasoconstriction is initially reversible but eventually becomes irreversible due to vascular remodeling.[42] The severe intimal proliferation and PL formation are not associated with PH due to lung diseases. Endothelial cell dysfunction is the predominant factor in this type of PH.[46]

Group 4: CTEPH or Other Pulmonary Arterial Obstructions

The pathophysiology of this PH classification is related to the increased resistance to flow through the pulmonary arteries, which results initially from obstruction of pulmonary arterial vessels (from main to subsegmental levels) by organized thromboembolic material.[47] See **Figure 17-14**. CTEPH is mainly associated with prominent obstructions in larger vessels. The pathophysiology of CTEPH remains unclear. The commonly accepted explanation (the embolic hypothesis) is that CTEPH is the result of a single or recurrent PE arising from sites of venous thrombosis.[48] Another theory for the pathophysiology of CTEPH describes in situ thrombosis in the lung due to primary arteriopathy and endothelial dysfunction similar to that seen in PAH.[48]



FIGURE 17-14 The pathophysiology of CTEPH.
Modified from Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. *Eur Respir Rev.* 2010;19(115):59–63 (Figure 2, p. 61). doi:10.1183/09059180.00007309.

TABLE 17-10
Pathophysiology of PH from Chronic Hypoxic Vasoconstriction

Vasoconstriction Component	Pathophysiologic Mechanism
NO (endogenous vasodilator)	• Decreased production of NO by endothelial nitric oxide synthase (eNOS) • Increased hemoglobin-mediated inactivation of NO
Voltage-gated potassium channel's alpha subunit	• Production and activity decreased • Changes in resting membrane potential • Increases intracellular free calcium • Contracts PA smooth muscle

Cytosolic phospholipase A2 (cPLA2)	• Increased activity releases arachidonic acid from phospholipid membranes
	• Arachidonic acid is metabolized by cyclooxygenases and lipoxygenases into vasoactive eicosanoids:
	  • Prostaglandins
	  • Thromboxanes
	  • Leukotrienes

Endothelin	Increases cause vasoconstriction

Group 5: PH with Unclear and/or Multifactorial Mechanisms

This classification includes several disorders with multiple pathoetiologies. A common feature of these diseases is that the mechanisms of PH are poorly understood and may include pulmonary vasoconstriction, proliferative vasculopathy, extrinsic compression, intrinsic occlusion, high-output cardiac failure, vascular obliteration, and LHF as causes.[27]

Risk Factors

Individuals who are at an increased risk for developing PH include those patients with systemic sclerosis,[49] chronic liver disease,[29] congenital heart disease,[29] and obstructive sleep apnea. Any factor or condition that is suspected to play a predisposing or facilitating role in PH development is a risk factor.

Individuals appearing to be at a higher risk for the development of PH include those who have a family history of the condition. Others at high risk include persons who have certain diseases or conditions, such as heart and lung diseases, HIV infection, or pulmonary emboli.[31] Individuals who use street drugs (such as cocaine) or certain diet medicines, as well as those taking certain medications, appear to be at greater risk.[27]



FIGURE 17-15 Diagnostic testing algorithm for PH.

Adapted with permission from Rubin LJ, Hopkins W. Clinical features and diagnosis of pulmonary hypertension in adults. In: UpToDate, Post TW, ed. *UpToDate*, Waltham, MA. Copyright © 2018 UpToDate, Inc. For more information visit www.uptodate.com.

Complications

The most relevant long-term complication from PH is RV dysfunction leading to right heart failure. PH caused by left heart disease can lead to a reduction of the diffusion capacity of the lungs, causing a reduction in oxygenation leading to respiratory failure. Other complications and sequelae of PH include tricuspid valve (TV) incompetence, pulmonary valve incompetence, hemoptysis, and right bundle branch block.[50]

Diagnostic Testing

The diagnosis of PH requires a clinical suspicion based on symptoms and physical examination and review of a comprehensive set of investigations to confirm that hemodynamic criteria are met and to describe the etiology and functional and hemodynamic severity of the condition. The interpretation of these investigations requires a multidisciplinary team, including cardiology, pulmonology, radiology, and others. This is particularly important for identifying patients who may have more than one cause of PH.[27] See **Figure 17-15**.

Echocardiography

Echocardiography is usually the first test to suggest a diagnosis of PH.[4] TTE will show the effects of PH on the heart and estimate PAP from continuous wave Doppler

measurements.[27] This technique takes advantage of the tricuspid regurgitation that usually exists.[30] The tricuspid regurgitation is not due to an intrinsic abnormality of the TV but a secondary manifestation of dilation of the tricuspid annulus and RV. Other valvular issues due to PH include pulmonic insufficiency and mid-systolic closure of the pulmonic valve. Findings indicative of PH include RV hypertrophy and an elevated RV systolic pressure.[30]

Electrocardiogram

An ECG may provide supportive evidence of PH, but a normal ECG does not exclude the diagnosis of PH.[27] The ECG may demonstrate specific signs of RV hypertrophy or strain, including right axis deviation, an R wave/S wave ratio greater than 1 in Lead V1, incomplete or complete right bundle branch block, or increased P-wave amplitude in Lead II (P pulmonale) due to right atrial enlargement. Most ECG signs are specific to but not sensitive for the detection of RV disease.[30] These ECG changes differ from typical ECG findings seen in COPD, which largely reflect the hyperinflation of the lungs, such as low voltage.

Supraventricular arrhythmias may occur in advanced disease; atrial flutter and atrial fibrillation have a cumulative incidence in 25% of patients after 5 years.[51] Atrial arrhythmias typically compromise CO and almost always lead to clinical deterioration. Ventricular arrhythmias are not common.[27]

Pulmonary Function Assessments

Pulmonary function testing (PFT) using spirometry can be very useful in evaluating patients with PH. The detection of severe obstructive (COPD) or severe restrictive (interstitial lung disease, neuromuscular weakness, or chest wall disease) impairment suggests that all or at least a large portion of the PH is due to an inherent lung disorder. In most circumstances, PH should not be attributed to lung disease if the PFT results are only mildly abnormal because PH itself can cause PFT abnormalities. The diffusing capacity for carbon monoxide (DL_{CO}) is usually decreased with PH. A DL_{CO} $<$45% of the predicted value is associated with a poor outcome.[52]

Arterial Blood Gas/Overnight Oximetry

ABG measurements and pulse oximetry findings at rest and with exercise can uncover complicating resting or exercise hypoxemia requiring supplemental oxygen. Hypercapnia is synonymous with disorders such as severe chronic airflow obstruction, sleep apnea, or restrictive chest wall disease.

Overnight oximetry can identify nocturnal oxyhemoglobin desaturation and indicate if supplemental oxygen is needed. Nocturnal hypoxemia is common in patients with PAH.[53]

Radiographic Imaging

The standard CXR can provide characteristic clues to the diagnosis and etiology of PH. Symmetric enlargement of the central pulmonary arteries with attenuation of the distal vessels (pruning) resulting in dark (oligemic) lung fields may usually be seen in later stages of the disorder. Enlargement of the right atrium and ventricle (characterized by a prominent right heart border and diminished retrosternal space) is usually found in later stages of the disorder.[30] Asymmetrical enlargement of the central pulmonary arteries can occur in patients with PH due to chronic thromboembolic disease. Radiographic findings that suggest the underlying cause of PH include pulmonary venous congestion (e.g., LV failure or pulmonary veno-occlusive disease), hyperinflation (COPD), and interstitial lung disease (e.g., interstitial pulmonary fibrosis).

Polysomnography

Polysomnography is the gold standard for the diagnosis of sleep-disordered breathing. Polysomnography is appropriate to test for sleep-disordered breathing as a cause of PH. PH in the setting of sleep apnea is typically mild and frequently due to concomitant left-sided heart disease. Approximately 20% of patients with obstructive sleep apnea have PH.

Ventilation/Perfusion Lung Scan

When CTEPH is suspected, a V/Q lung scan is appropriate. It is the preferred imaging study to evaluate patients with CTEPH.[54] A normal V/Q lung scan essentially rules out the presence of CTEPH, while a normal CTPA does not exclude the presence of CTEPH. Newer techniques, such as the three-dimensional magnetic resonance (MR) perfusion mapping, are as sensitive as the V/Q scan in screening for CTEPH.[55]

Laboratory Findings

There is no definitive laboratory test capable of identifying the presence of a specific pulmonary circulatory disorder. However, laboratory tests provide evaluative evidence for the etiology of some forms of PH. Blood tests also aid in the assessment of end-organ damage. Routine chemistry, hematology, and thyroid function tests are typically required for all patients. Liver function test may show abnormal results due to elevated hepatic venous pressure. Thyroid disease is common with PAH and may develop during the disease.

The diagnostic evaluation of PH may include testing for antinuclear antibodies (ANAs) to determine if PH is due to underlying connective tissue disease. Patients with systemic lupus erythematosus may have anticardiolipin antibodies. HIV serological testing can identify HIV-associated PH. In the appropriate clinical setting, laboratory studies looking for evidence of chronic

hemolytic anemia (e.g., sickle cell disease) or schistosomiasis are appropriate.[30]

NT-proBNP is the precursor of BNP. Both peptides are released from the myocardial tissue of the right and left ventricles when stretched. NT-proBNP and BNP are helpful in diagnosing heart failure. NT-proBNP may be elevated in patients with PH and is an independent risk predictor in these patients.[27]

ABG analysis is highly useful for determining whether hypoxemia or acidosis is playing a role in the pathogenesis of the patient's PH. Pulmonary vascular disease can cause mild decreases in arterial PO_2 due to the nonuniform distribution of the disease and a ventilation–perfusion mismatch.[4]

Right Heart Catheterization

Although estimates of PAP are made with echocardiography, the definitive diagnosis of all forms of PH requires a RHC.[27,28,30,31] Not only does the RHC confirm the PH diagnosis, but it also determines the severity of the hemodynamic derangements and can rule in or rule out congenital heart disease, left-sided heart disease, and other etiologies when noninvasive techniques are insufficient. RHC can determine potential vasoreactivity to trial vasodilator therapy in patients with IPAH, HPAH, and PAH associated with drugs.[27]

Treatment and Management

As with many disease states, the earlier the identification, the earlier the treatment can begin. This is especially true of PH because advanced PH (worsening FC) is less responsive to therapy.[27] The goals of treatment are listed in **Box 17-6**.

Treatment for PH, in general, focuses on the underlying cause. However, Group 1 PH, PAH, tends to be idiopathic and is incurable. The FC of the patient is an important tool in the management of patients with PH. A baseline FC is an important correlate and predictor of survival, as well. The WHO functional classification (WHO-FC) system is based on the New York Heart Association functional classification system. The WHO-FC is a simple, reproducible, and clinically important assessment tool and prognostic measure in PAH patients, both at the time of diagnosis and at follow-up during PAH treatment.[56] See **Table 17-11**.

TABLE 17-11
WHO Functional Classification of PH

Class	Description
I	Patients with PH but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope.
II	Patients with PH resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain, or near syncope.
III	Patients with PH resulting in marked limitation of physical activity. They are comfortable at rest. Less-than-ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope.
IV	Patients with PH with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.

Reproduced from The Criteria Committee of the New York Heart Association. (1994). *Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels* (9th ed.). Boston: Little, Brown & Co. pp. 253–256

The functional classification before the initiation of treatment permits therapy response to be more easily evaluated. Another functional assessment that is easy to perform, inexpensive, reproducible, and well tolerated by patients is the **six-minute walking test (6MWT)**.[56] The 6MWT provides exercise capacity. Its results must always be interpreted in the clinical context and are influenced by several factors, including gender, age, height, weight, comorbidities, need for supplemental oxygen, learning curve, and motivation. The Borg scale can be used at the end of the 6MWT to determine the level of effort.[27] **Cardiopulmonary exercise testing (CPET)** also provides exercise capacity but is more involved and costly. Several variables resulting from CPET provide prognostic information. However, it is the peak oxygen consumption results that are used for therapeutic decisions.[27,56]

The treatment priority for patients with PH due to left heart disease, lung disease, CTEPH, or multifactorial mechanisms is focused on their underlying disease (primary therapy). See **Table 17-12**. The focus for the Group 1 PH (PAH) patients is to lower their risk status. Specifically, this means bringing and keeping the patient in the WHO-FC II whenever possible.[27] In most patients, this is accompanied by a near-normal or normal 6MWT.[27]

The first step in the treatment strategy for patients in the Group 1 PH (PAH) clinical classification includes the general measures and supportive therapy. This

BOX 17-6 Treatment Goals for PH

- Treat the underlying etiology
- Reduce symptoms and improve quality of life
- Slow the growth of pulmonary smooth muscle cells (or thrombus)
- Decrease myocardial work
- Improve myocardial oxygenation

initial approach is provided in Table 17-13. An acute vasoreactivity test determines whether calcium channel blocker (CCB) therapy is appropriate for the patient.[57] If the patient response is favorable and the WHO-FC remains within Class I or II, the CCB therapy should continue.[27,58] The choice of CCB is based on the patient's heart rate at baseline, with a relative bradycardia favoring nifedipine and amlodipine and a relative tachycardia favoring diltiazem.[27]

If the acute vasoreactivity test demonstrates non-vasoreactivity or the patient fails CCB therapy, the next step is to initiate therapy with an approved PAH drug or combination therapy. Current drug therapy for PAH includes **endothelin receptor antagonists (ERAs)**, **guanylate cyclase stimulators**, **phosphodiesterase Type 5 inhibitors (PDE-5i)**, **prostacyclin analogues**, and **prostacyclin receptor agonists**. See Table 17-14.

For those patients who have an inadequate clinical response to monotherapy, sequential combination therapy is appropriate.[57,58] Combination therapy—using two or more classes of drugs simultaneously—has been used successfully in the treatment of heart failure and systemic hypertension. The three separate signaling pathways known to be involved in PH include the

TABLE 17-12
Therapy for Each Clinical Classification of PH

Clinical Classification	Treatment Strategy

PAH	• Specific therapy for PAH
	• Supportive therapy
	  • Oral anticoagulants
	  • Oxygen
	  • Diuretics
	  • Digoxin
	• Surgical intervention
	  • Lung transplant
	  • Atrial septostomy

PH due to left heart disease	• Primary therapy for underlying heart disease
	• Supportive therapy
	  • Diuretics
	  • Oxygen

PH due to lung diseases and/or hypoxia	• Primary therapy for underlying lung disease
	• Supportive therapy
	  • Diuretics
	  • Oxygen

CTEPH and other PA obstructions	• Primary therapy for recurrent PE • Oral anticoagulants • Specific therapy for PAH for selected patients (WHO functional Class III or IV) • Surgical intervention (thromboendarterectomy)
PH with unclear and/or multifactorial mechanisms	• Primary therapy for underlying cause • Supportive therapy • Oxygen

TABLE 17-13
General Measures and Supportive Therapy for Group 1 PH (PAH)

General Measures	Supportive Therapy
Avoidance of strenuous physical activity	Digoxin
Avoidance of pregnancy	Diuretics
Cardiopulmonary rehabilitation	Oral anticoagulants
Infection prevention (influenza and pneumococcal immunization)	Oxygen
Post-menopausal hormonal therapy	Referral to an expert center for acute vasoreactivity testing for the indication of CCB therapy
Psychosocial support	

TABLE 17-14
Monotherapy Drugs for the Treatment of Group 1 PH (PAH) (Specific Therapy)

Drug Type	Mechanism of Action	FDA-Approved Drugs
ERAs	Endothelin receptors mediate vasoconstriction, fibrosis, proliferation, hypertrophy, and inflammation. ERAs prevent binding of endothelin to the endothelin receptor sites promoting vasodilation.	Ambrisentan Bosentan Macitentan
Soluble guanylate cyclase stimulators (sGCS)	Stimulate soluble guanylate cyclase, an enzyme in the cardiopulmonary system and the receptor for NO.	Riociguat
PDE-5i	Prevent the breakdown of cGMP, which has vasodilatory and antiproliferative effects on the pulmonary vasculature.	Sildenafil Tadalafil Vardenafil
Prostacyclin analogues (Prostanoids)	Promote direct arterial vasodilation and inhibit platelet aggregation.	Epoprostenol Treprostinil Iloprost
Prostacyclin (IP) receptor agonists	Relax vascular smooth muscle, inhibit platelet aggregation, and have an antiproliferative effect on vascular smooth muscle.	Selexipag



FIGURE 17-16 Sequential combination therapy used with Group 1 PH (PAH). Begin with monotherapy, then add a second drug from another pathway. If there is inadequate clinical results or deterioration, add a third drug from the remaining pathway.

prostacyclin pathway (prostacyclin analogues and prostacyclin receptor agonists), the endothelin pathway (ERAs), and the NO pathway (PDE-5i and guanylate cyclase stimulators).[27] Sequential combination therapy is the most widely used strategy. From monotherapy, there is the addition of a second and then the third drug in cases of inadequate clinical results or cases of deterioration.[58] See **Figure 17-16**.

After inadequate clinical response to the initial monotherapy and inadequate clinical response to maximal combination therapy, the next step is to consider eligibility for lung transplantation. Both heart-lung and double-lung transplantation have been performed for PAH. Veno-arterial extracorporeal membrane oxygenation (ECMO) can be utilized in an awake end-stage PH patient awaiting lung transplantation.

Prognosis

The clinical course of PH is one of progressive deterioration interspersed with episodes of acute decompensation. It is difficult to predict when patients will die because death may come either suddenly or slowly because of progressive heart failure.[27] The prognosis of PH is highly variable and depends on the type and severity of PH. The prognosis of Group 1 PH (PAH) is better studied than that of Groups 2 through 5. Without therapy, patients with Group 1 PH (PAH) have a worse survival rate than that of Groups 2 through 5. The exceptions are those in Group 4 (CTEPH), who have a pulmonary thromboendarterectomy.[31]

The mean survival rate for symptomatic IPAH patients who do not receive treatment is 3 years. With treatment, the survival rates vary due to the variable responses to therapy. Patients with severe Group 1 PH (PAH) or right heart failure die sooner without treatment (usually within 1 year) than patients with mild PAH or no right heart failure. Increased age and male gender may be associated with a worse survival rate.[31]

The prognosis of Groups 2 through 5 PH varies with the prognosis of the underlying disease, the severity of the PH, and response to therapy.[31]

KNOWLEDGE CHECK QUESTIONS

1. True or False: A diagnosis of Group 1 PH (PAH) requires a PVR measurement of less than 3 WU.
2. True or False: The clinical classification for post-capillary PH includes Group 2 (PH due to left heart disease) and Group 5 (PH with unclear and/or multifactorial mechanism).
3. True or False: Arachidonic acid is metabolized into vasoactive eicosanoids that cause PH.
4. True or False: Supportive therapy for Group 1 PH (PAH) includes the use of digoxin.
5. True or False: PDE-5i promote arterial vasodilation and inhibit platelet aggregation.
6. True or False: Treatment for PH is always combination therapy.

Chapter Summary

PE is not a distinct disorder but a serious and often fatal complication of underlying venous thrombosis. Thromboembolic disease is a highly preventable as well as treatable disorder causing significant morbidity as well as mortality in the United States. Pulmonary thromboembolism represents a composite of disorders that is most commonly dependent on the risk of calf vein venous thrombosis. Diagnosis of PE begins with an assessment of CPTP based on the combination of individual symptoms, signs, and common tests evaluated using prediction rules or clinical judgment. The primary goal of diagnostic testing for PE is to identify patients who would benefit from treatment.

Without proper treatment, calf vein thrombi extend into deep popliteal and femoral veins, causing proximal DVT. Without treatment of venous thrombosis, more than half of patients with proximal DVT develop most of the total cases of pulmonary thromboembolism. An untreated PE is associated with significant reoccurrence as well as high mortality, whereas most patients who receive adequate anticoagulant therapy survive. Any suspected cases of PE require immediate diagnostic testing and risk assessment of clinical probability. Hospitals need to have a strategy in place for antithrombotic and thrombolytic therapy to prevent VTE.

PH is a pathophysiologic disorder of the pulmonary circulation that involves multiple clinical conditions and can complicate many cardiovascular and respiratory diseases. The different hemodynamic definitions of PH arise from various combinations of PAP, PAWP, CO, DPG, and PVR assessed in stable clinical conditions. A systematic approach to diagnosis begins with a clinical suspicion of PH followed by the employment of methods to detect PH, which leads to the identification of an appropriate clinical classification. The true prevalence of PH in the general population is unknown, because of the broad classification and multiple etiologies. The epidemiology of PH varies among the different etiologies of the five groups and even within each clinical classification.

The five PH classifications have different pathophysiologic mechanisms, although each clinical presentation may be similar. The diagnosis of PH requires a clinical suspicion based on symptoms and physical examination and review of a comprehensive set of investigations to confirm that hemodynamic criteria are met and to describe the etiology and the functional and hemodynamic severity of the condition. Treatment for PH, in general, focuses on the underlying cause. However, Group 1 PH, PAH, tends to be idiopathic and is incurable. The FC of the patient is an important tool in the management of patients with PH.

Key Points

1. PE is an occlusion of one or more branches of the PA by a substance, mostly blood clots, carried in the bloodstream. These clots primarily originate from venous thromboemboli, 90% of which originate in the legs.
2. Pulmonary emboli occur when formed blood clots embolize (break loose and travel) to occlude pulmonary blood vessels. The presence of one or more elements of Virchow triad, blood vessel endothelial wall damage, blood flow stasis, or increase coagulability, increases the risk of PE.
3. Diagnosis of PE may not occur promptly due to nonspecific clinical signs and symptoms. Leg swelling is suggestive of DVT, the leading cause of PE.
4. Individual symptoms, signs, and diagnostic testing are used to exclude PE from a patient's diagnosis. This limits the use of imaging tests that emit radiation.
5. Anticoagulation therapy is the foundation for successful treatment of both PE and DVT. Reduction of the risk factors is crucial in the prevention of DVT or PE.
6. PH is an increase in mPAP ≥25 mm Hg at rest as assessed by RHC. Various hemodynamic definitions of PH are based on the location of the pulmonary vasoconstriction.
7. PH has five classification groups based on pathophysiology and clinical-based similarities or differences. Each group has a distinct mechanism responsible for the elevation of PAP, a different natural history, and a different approach to treatment.
8. The clinical signs and symptoms of PH depend on its etiology. Common symptoms include exertional dyspnea, lethargy, and fatigue.
9. Clinical suspicion based on symptoms and physical examination and a review of a comprehensive set of investigations confirming hemodynamic criteria is needed to diagnose and determine the severity of PH.
10. Treatment for PH focuses on the underlying cause and the FC of the patient. Treatment for Group 1 PH (PAH) focuses on vasoreactivity and response to therapy. Several different classes of vasodilators are currently approved for use with PAH.

Chapter Questions

1. The primary endogenous endothelium-derived relaxing factor (EDRF) responsible for pulmonary vasculature homeostasis is _____.
   a. acetylcholine
   b. adenosine triphosphate
   c. nitric oxide
   d. serotonin
2. The pulmonary capillaries _____ _____.
   a. vasoconstrict in response to nitric oxide
   b. decrease in diameter in response to increased intrapleural pressure
   c. vasoconstrict in response to perivascular inflammation
   d. anastomose with mediastinal veins
3. Most pulmonary emboli originate in the _____.
   a. ankles
   b. right atrium
   c. upper extremities
   d. legs
4. The simplified Well's Prediction Rule is used to _____.
   a. identify the clinical probability of pulmonary embolism (PE) in a patient
   b. confirm the diagnosis of pulmonary arterial hypertension (PAH)
   c. limit the overdiagnosis of PE
   d. identify the clinical probability of pulmonary hypertension (PH)

5. PE is the _____ most common cause of death from cardiovascular disease in the United States.
   a. first
   b. second
   c. third
   d. fourth
6. Risk factors that cause microthrombi to grow and propagate include **all except** _____.
   a. blood vessel endothelial wall damage
   b. abnormal blood flow
   c. loss of nitric oxide bioavailability
   d. increase in coagulability
7. PE directly affects the function of the _____ by causing pressure overload.
   a. right atrium
   b. right ventricle
   c. left atrium
   d. left ventricle
8. The D-dimer test _____.
   a. is very sensitive, but not specific, for venous thromboembolism or PE
   b. is both sensitive and specific for venous thromboembolism or PE
   c. is used specifically to "rule out" PE
   d. is positive when the result is greater than 1500 μg/L
9. The method of choice for imaging the pulmonary vasculature in patients suspected of having a PE is _____.
   a. pulmonary angiography
   b. ventilation–perfusion scanning
   c. magnetic resonance pulmonary angiography
   d. computed tomographic pulmonary angiography
10. Fibrinolysis therapy is _____.
    a. used for all patients with PE
    b. appropriate for hemodynamically unstable patients with massive PE
    c. not recommended for patients who develop acute right heart strain
    d. similar in action to anticoagulation medications
11. The pulmonary circulation is a _____ blood flow circuit.
    a. high-pressure
    b. low-capacitance
    c. high-resistance
    d. high-capacitance
12. The following hemodynamics is associated with PAH:
    a. Pulmonary vascular resistance 1–2 Woods units
    b. Pulmonary vascular resistance greater than 3 Woods units
    c. Pulmonary artery wedge pressure greater than 15 mm Hg
    d. Mean PAP 15–20 mm Hg
13. Postcapillary PH is associated with the clinical classification of Group _____ PH.
    a. 1 (PAH)
    b. 2 (PH due to left heart disease)
    c. 3 (PH due to lung disease and/or hypoxia)
    d. 4 (PH due to chronic thromboembolic PE)
14. Plexiform lesions are the morphologic hallmarks found in _____.
    a. Group 1 PH
    b. Group 2 PH
    c. Group 3 PH
    d. Group 4 PH
15. The protein involved in the differentiation of angioblasts into endothelial cells in PAH is _____.
    a. caveolin 1 (CAV1)
    b. activin-like kinase (ALK)
    c. endoglin (ENG)
    d. mothers against decapentaplegic homologue 9 (SMAD9)
16. A reduced diffusion capacity in the lungs is found with Group 2 PH due to _____.
    a. decreased alveolar surface area
    b. vascular remodeling with pulmonary arteriole fibrosis
    c. thickening of the interstitium
    d. decreased ventilation of perfused areas
17. Chronic hypoxic pulmonary vasoconstriction is mediated by _____.
    a. increased production of nitric oxide
    b. increased activity of voltage-gated potassium channel's alpha subunit
    c. increased activity of cytosolic phospholipase A2 (cPLA2)
    d. decreased levels of endothelin
18. The first test that suggests a diagnosis of PH is _____.
    a. echocardiography
    b. electrocardiogram
    c. pulmonary function test
    d. ventilation–perfusion lung scan
19. The definitive diagnosis of all forms of PH is made with _____.
    a. echocardiography
    b. left heart catheterization
    c. right heart catheterization
    d. ventilation–perfusion lung scan
20. Which class of medication is used to identify acute vasoreactivity?
    a. Phosphodiesterase Type 5 inhibitor
    b. Endothelin receptor antagonist
    c. Prostacyclin analogue
    d. Calcium channel blocker

References

1. Levitzky M. *Pulmonary Physiology*. 6th ed. New York, NY: McGraw-Hill; 2002.
2. Coggins M, Bloch K. Nitric oxide in the pulmonary vasculature. *Arterioscler Thromb Vasc Biol*. 2007;27(9):1877–1885. doi:10.1161/atvbaha.107.142943.
3. Lapner S, Kearon C. Diagnosis and management of pulmonary embolism. *BMJ*. 2013;346:f757. doi:10.1136/bmj.f757.
4. Weinberger S, Cockrill B, Mandel J. *Principles of Pulmonary Medicine*. 6th ed. Philadelphia, PA: Elsevier Saunders; 2014:179–200.
5. Wilbur J, Shian B. Diagnosis of deep venous thrombosis and pulmonary embolism. *Am Fam Physician*. 2012;86(10):913–919.
6. Deng X, Li Y, Zhou L, et al. Gender differences in the symptoms, signs, disease history, lesion position and pathophysiology in patients with pulmonary embolism. *PLos One*. 2015;10(7):e0133993. doi:10.1371/journal.pone.0133993.
7. Goldhaber S. Deep venous thrombosis and pulmonary thromboembolism. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill; 2013:211–220.
8. Konstantinides SV, Torbicki A, Agnelli G, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. *Eur Heart J*. 2014;35(43):3033–3073. doi:10.1093/eurheartj/ehu283.
9. Ducharme J, Brenner J. Pulmonary embolism. In: Aghababian R, ed. *Essentials of Emergency Medicine*. 2nd ed. Sudbury, MA: Jones & Bartlett Learning; 2011:716–723.
10. van der Hulle T, Dronkers C, Klok F, Huisman M. Recent developments in the diagnosis and treatment of pulmonary embolism. *J Intern Med*. 2015;279(1):16–29. doi:10.1111/joim.12404.
11. Ouellette D. Pulmonary embolism: practice essentials, background, anatomy. *Medscape*. June 22, 2016. https://emedicine.medscape.com/article/300901-overview. Accessed January 25, 2017.
12. Horlander K, Mannino D, Leeper K. Pulmonary embolism mortality in the United States, 1979-1998. *Arch Intern Med*. 2003;163(14):1711. doi:10.1001/archinte.163.14.1711.
13. Heit J. The epidemiology of venous thromboembolism in the community. *Arterioscler Thromb Vasc Biol*. 2008;28(3):370–372. doi:10.1161/atvbaha.108.162545.
14. Goldhaber S, Bounameaux H. Pulmonary embolism and deep vein thrombosis. *Lancet*. 2012;379(9828):1835–1846.
15. Heit J, O'Fallon W, Petterson T, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. *Arch Intern Med*. 2002;162(11):1245. doi:10.1001/archinte.162.11.1245.
16. Abunasser J, Tejada J, Foley R. The diagnosis and management of pulmonary embolism. *Conn Med*. 2012;76(1):5–14.
17. Bajc M, Neilly J, Miniati M, Schuemichen C, Meignan M, Jonson B. EANM guidelines for ventilation/perfusion scintigraphy: Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. *Eur J Nucl Med Mol Imaging*. 2009;36(8):1356–1370. doi:10.1007/s00259-009-1170-5.
18. Anderson D, Barnes D. Computerized tomographic pulmonary angiography versus ventilation perfusion lung scanning for the diagnosis of pulmonary embolism. *Curr Opin Pulm Med*. 2009;15(5):425–429. doi:10.1097/mcp.0b013e32832d6b98.
19. Kalb B, Sharma P, Tigges S, et al. MR imaging of pulmonary embolism: diagnostic accuracy of contrast-enhanced 3D MR pulmonary angiography, contrast-enhanced low–flip angle 3D GRE, and nonenhanced free-induction FISP sequences. *Radiology*. 2012;263(1):271–278. doi:10.1148/radiol.12110224.
20. Stein P, Chenevert T, Fowler S, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism. *Ann Inter Med*. 2010;152(7):434–443. doi:10.7326/0003-4819-152-7-201004060-00008.
21. Zondag W, Mos I, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. *J Thromb Haemost*. 2011;9(8):1500–1507. doi:10.1111/j.1538-7836.2011.04388.x.
22. Zondag W, den Exter P, Crobach M, et al. Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. *Thromb Haemost*. 2012;109(1):47–52. doi:10.1160/th12-07-0466.
23. Harikrishnan P, Palaniswamy C, Aronow W. Update on pharmacologic therapy for pulmonary embolism. *J Cardiovasc Pharmacol Ther*. 2014;19(2):159–169. doi:10.1177/1074248413506612.
24. Jaff M, McMurtry M, Archer S, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation*. 2011;123(16):1788–1830. doi:10.1161/cir.0b013e318214914f.
25. Tapson V. Treatment, prognosis, and follow-up of acute pulmonary embolism in adults. In: Mandel J, Hockberger R, eds. *Uptodate*. Waltham, MA: Wolters Kluwer; 2017. http://www.uptodate.com. Accessed February 26, 2017.
26. Rounds S, Klinger J. Pulmonary hypertension: pathophysiology and clinical disorders. In: Crapo J, Glassroth J, Karlinsky J, King T Jr, eds. *Baum's Textbook of Pulmonary Diseases*. 7th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:697–729.
27. Galiè N, Humbert M, Vachiery J, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2015;37(1):67–119. doi:10.1093/eurheartj/ehv317.
28. Hoeper M, Bogaard H, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25):D42–D50. doi:10.1016/j.jacc.2013.10.032.
29. Simonneau G, Gatzoulis M, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25):D34–D41. doi:10.1016/j.jacc.2013.10.029.
30. Rubin LJ, Hopkins W. Clinical features and diagnosis of pulmonary hypertension in adults. In: Mandel J, ed. *UpToDate*. Waltham, MA: Wolters Kluwer; 2017. https://www.uptodate.com. Accessed March 10, 2017.
31. Rubin LJ, Hopkins W. Overview of pulmonary hypertension in adults. In: Mandel J, ed. *UpToDate*. Waltham, MA: Wolters Kluwer; 2017. https://www.uptodate.com. Accessed March 10, 2017.
32. George M, Schieb L, Ayala C, Talwalkar A, Levant S. Pulmonary hypertension surveillance. *Chest*. 2014;146(2):476–495. doi:10.1378/chest.14-0527.
33. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France. *Am J Respir Crit Care Med*. 2006;173(9):1023–1030. doi:10.1164/rccm.200510-1668oc.
34. Ling Y, Johnson M, Kiely D, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension. *Am J Respir Crit Care Med*. 2012;186(8):790–796. doi:10.1164/rccm.201203-0383oc.
35. Oudiz R. Pulmonary hypertension associated with left-sided heart disease. *Clin Chest Med*. 2007;28(1):233–241. doi:10.1016/j.ccm.2006.12.001.
36. Seeger W, Adir Y, Barberà J, et al. Pulmonary hypertension in chronic lung diseases. *J Am Coll Cardiol*. 2013;62(25):D109–D116. doi:10.1016/j.jacc.2013.10.036.
37. Andersen K, Iversen M, Kjaergaard J, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. *J Heart Lung Transplant*. 2012;31(4):373–380. doi:10.1016/j.healun.2011.11.020.
38. Guérin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. *Thromb Haemost*. 2014;112(3):598–605. doi:10.1160/th13-07-0538.
39. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. *N Engl J Med*. 2011;365(1):44–53. doi:10.1056/nejmoa1005565.
40. Baughman R, Engel P, Meyer C, Barrett A, Lower E. Pulmonary hypertension in sarcoidosis. *Sarcoidosis Vasc Diffuse Lung Dis*. 2006;23:108–116.
41. Ohms Law Tutorial and Power in Electrical Circuits. Basic Electronics Tutorials. 2017. http://www.electronics-tutorials.ws/dccircuits/dcp_2.html. Accessed March 16, 2017.

42. Rubin LJ, Hopkins W. Pathogenesis of pulmonary hypertension. In: Mandel J, ed. *UpToDate*. Waltham, MA: Wolters Kluwer; 2017. https://www.uptodate.com Accessed March 10, 2017.
43. Chopra S, Badyal D, Baby PC, Cherian D. Pulmonary arterial hypertension: advances in pathophysiology and management. *Indian J Pharmacol*. 2012;44(1):4–11.
44. Jonigk D, Golpon H, Bockmeyer C, et al. Plexiform lesions in pulmonary arterial hypertension. *Am J Pathol*. 2011;179(1):167–179. doi:10.1016/j.ajpath.2011.03.040.
45. Lundgren J, Rådegran G. Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure. *Acta Physiol*. 2014;211(2):314–333. doi:10.1111/apha.12295.
46. Presberg K, Dincer H. Pathophysiology of pulmonary hypertension due to lung disease. *Curr Opin Pulm Med*. 2003;9(2):131–138. doi:10.1097/00063198-200303000-00007.
47. McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). *Heart.* 2007;93(9):1152–1158. doi:10.1136/hrt.2004.053603.
48. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. *Eur Respir Rev*. 2010;19(115):59–63. doi:10.1183/09059180.00007309.
49. MacGregor A, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. *Rheumatology*. 2001;40(4):453–459. doi:10.1093/rheumatology/40.4.453.
50. Diseases Database. 2017. http://www.diseasesdatabase.com/content.asp. Accessed March 21, 2017.
51. Olsson K, Nickel N, Tongers J, Hoeper M. Atrial flutter and fibrillation in patients with pulmonary hypertension. *Int J Cardiol*. 2013;167(5):2300–2305. doi:10.1016/j.ijcard.2012.06.024.
52. Sun X, Hansen J, Oudiz R, Wasserman K. Pulmonary function in primary pulmonary hypertension. *J Am Coll Cardiol*. 2003;41(6):1028–1035. doi:10.1016/s0735-1097(02)02964-9.
53. Rafanan A, Golish J, Dinner D, Hague L, Arroliga A. Nocturnal hypoxemia is common in primary pulmonary hypertension. *Chest*. 2001;120(3):894–899. doi:10.1378/chest.120.3.894.
54. Tunariu N, Gibbs S, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. *J Nucl Med*. 2007;48(5):680–684. doi:10.2967/jnumed.106.039438.
55. Rajaram S, Swift A, Telfer A, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. *Thorax*. 2013;68(7):677–678. doi:10.1136/thoraxjnl-2012-203020.
56. McLaughlin V, Gaine S, Howard L, et al. Treatment goals of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25):D73–D81. doi:10.1016/j.jacc.2013.10.034.
57. Taichman D, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. *Chest*. 2014;146(2):449–475.
58. Galiè N, Corris P, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. *J Am Coll Cardiol*. 2013;62(25):D60–D72. doi:10.1016/j.jacc.2013.10.031.

CHAPTER

18

Shock

"Welcome to the world of the emergency department. Where time and pressure are monumentally against the considered diagnosis of shock, a diagnosis that requires thoughtful contemplation and the review of the patient over time."

—Michelle Johnston

OUTLINE

OBJECTIVES

1. State the working definitions for each type of shock.
2. Outline the incidence, prevalence, and risk factors of each type of shock.
3. Define and discuss the clinical manifestations associated with each type of shock.
4. Explain diagnostic testing used in diagnosing each type of shock.
5. Summarize the recommended management of patients with each type of shock.
6. Identify common complications associated with each type of shock.
7. Define the prognosis of each type of shock.

KEY TERMS

Anaphylactoid reaction
Anaphylaxis
Cardiogenic shock (CS)
Crystalloid solution
Distributive shock
Hemorrhagic shock
Hypovolemia
Hypovolemic shock
Neurogenic shock
Nonhemorrhagic shock
Nonimmune anaphylaxis
Nontraumatic hemorrhagic shock
Persistent hypotension
Quick Sequential (Sepsis-Related) Organ Failure Assessment Score (qSOFA)
Sepsis
Septic shock
Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) Score
Serum lactate
Shock
Systemic inflammatory response syndrome (SIRS)
Traumatic hemorrhagic shock

Case Study

A 62-year-old female is working at the yard, planting some new trees. She just finished filling the dirt around the last tree and notices some chest discomfort. She thinks she strained a muscle planting the last tree. She stands up to massage the muscle to help relieve the discomfort. As she stands, the discomfort intensifies, she becomes dizzy, and she feels like she is going to faint (**Figure 18-1**). She looks around to see if there is something to grab hold of to prevent herself from falling. Before she can grab something, she loses consciousness and falls. Her neck strikes the edge of a planter.

Her neighbor witnessed the entire episode. The neighbor immediately called emergency services and ran over to check on her. He was speaking with the emergency services operator explaining the situation when the lady started to move. He immediately told her not to move, and that help was on the way. When the ambulance arrived, the neighbor explained what he saw happen. The rescuers put a cervical collar on the lady and placed her on a backboard. Due to the nature of the fall, the paramedics immediately put on electrocardiogram (ECG) patches. The ECG showed ST segment elevations in the inferior leads with a heart rate of 42 beats/minute and a blood pressure of 70/50 (**Figure 18-2**). The paramedics notified the hospital, started an intravenous (IV) line with normal saline, and quickly transported the patient to the hospital. One liter of normal saline was infused during the transport.

FIGURE 18-1 Lady fainting.

In the emergency department (ED), the ED physician ordered a computer tomographic (CT) of the head and neck. The cardiac catheterization lab was alerted for a possible heart attack patient. The patient's vitals in the ED were heart rate 44 beats/minute, regular and weak, blood pressure 75/48 mm Hg. She appeared dyspneic at rest, fully conscious and oriented. She is pale, clammy, and cold to the touch, especially in her extremities. Her oxygen saturation with a 4 L/minute nasal cannula was 88%. At that time, the supplemental oxygen was changed to a high-flow nasal cannula at 15 L/minute. She received a vasopressor to increase her blood pressure, and she was transported to the cardiac catheter lab for a heart catheterization and possible pacemaker insertion.



FIGURE 18-2 Twelve-lead ECG of inferior wall myocardial infarction.

Introduction

Shock is a state of organ hypoperfusion, which can lead to cellular dysfunction and death. Shock includes several mechanisms. Cardiogenic shock (CS) from heart failure decreases cardiac output. **Hypovolemic shock** is due to internal or external blood or volume loss. **Distributive shock** occurs due to profound vasodilation, causing a reduction of blood returning to the heart, and includes anaphylactic shock, septic shock, and **neurogenic shock**.[1] **Box 18-1** shows a summary of the different types of shock.

Shock is a life-threatening condition of circulatory failure that most commonly presents with hypotension.[2] Any shock decreases the amount of blood reaching the capillary exchange beds. The basis for a diagnosis of shock includes clinical, hemodynamic, and biochemical signs. There are three categories of assessments. First, hypotension is present, but chronic hypertension can hide the magnitude of the hypotension. Tachycardia is usually present when the systolic arterial blood pressure is <90 mm Hg or the mean arterial pressure is <70 mm Hg. Second, clinical signs of hypoperfusion include cold and clammy skin, cyanosis (in low-flow states), decreased urine output (<0.5 mL/kg of body weight per hour), and altered mental state. Third, increased **serum lactate** is typically present, indicating abnormal cellular oxygen metabolism (> 1.5 mmol/L).[3] Typically, the effects of shock are initially reversible but can rapidly become irreversible, resulting in multiorgan system failure and death.[4]

Cardiogenic Shock

Cardiogenic shock (CS) occurs when the heart muscle is damaged enough that it is unable to pump enough sufficient blood to the vital organs. The decrease in cardiac output results in drop in blood pressure, hypoperfusion of organs, and death if not treated promptly.

Definition/Diagnosis

CS results from intracardiac causes of cardiac pump failure that result in reduced cardiac output.[4] These cardiac problems are a result of acute or chronic disorders. The most frequent cause of CS is acute myocardial infarction (AMI). Cardiac pump failure will cause a decrease in cardiac output, even with an adequate blood volume. Consequently, if cardiac output becomes too low, there will be evidence of organ and tissue hypoxia from hypoperfusion.

BOX 18-1 Types of Shock

Anaphylactic shock: A form of distributive shock resulting in low blood pressure (<90/60 mm Hg) due to an allergic reaction to a drug or other substance (e.g., insect stings, certain foods such as peanuts, shellfish, tree nuts, eggs, dairy products, or latex).

Cardiogenic shock: Low blood pressure (<90/60 mm Hg) due to lox cardiac output. Common causes include myocardial infraction, pericardial tamponade, cardiac arrhythmia (ventricular tachycardia, supraventricular tachycardia, ventricular fibrillation, bradycardia), and tear or rupture (myocardium, septum, valve tendons).

Hypovolemic shock: Low blood pressure (<90/60 mm Hg) due to decreased intravascular volume. Common causes include blood loss due to trauma or internal bleeding or loss of fluids due to vomiting, diarrhea, burns, or excessive sweating.

Neurogenic shock: A form of distributive shock resulting in low blood pressure (<90/60 mm Hg) and occasionally bradycardia. Causes include head trauma, brain injury, cervical or thoracic spinal cord injury (SCI) resulting in a loss of sympathetic stimulation, vasodilation, and a decrease in peripheral vascular resistance.

Obstructive shock: A form of shock sometimes grouped with CS resulting in low blood pressure (<90/60 mm Hg) due to obstruction of blood flow from the heart or major vessels. Causes include pulmonary embolus, cardiac tamponade, and narrowing of the aortic artery.

Septic shock: A form of distributive shock resulting in low blood pressure (<90/60 mm Hg) due to decreased systemic vascular resistance as a result of an overwhelming infection. Common causes include gram-negative sepsis, although other bacteria or fungi may cause septic shock. The resulting hypotension is due to inappropriate peripheral vasodilation caused by toxins released by the offending microorganism. With early septic shock, cardiac output may be elevated; it may be depressed with late septic shock.

Hemodynamic parameters help to define CS. Persistent hypotension (systolic blood pressure <80–90 mm Hg or mean arterial pressure 30 mm Hg lower than baseline) is one parameter. Second, there is a severe reduction in the cardiac index with adequate or elevated filling pressures (left ventricular end-diastolic pressure >18 mm Hg or right ventricular end-diastolic pressure >10–15 mm Hg).[5] Without aggressive care, CS due to AMI has a high mortality rate.[3]

Clinical Signs and Symptoms

Clinical findings vary depending on the etiology and the stage of presentation. CS in the presence of an AMI will have all the signs and symptoms associated with an AMI. AMI patients will present with an abrupt onset of chest pain, which may radiate to the left arm or neck. The chest pain may be atypical, especially for women, the location being epigastric or only in the neck or arm. The patient will appear pale, apprehensive, and diaphoretic. Mentation may be altered, with somnolence, confusion, and agitation. Other symptoms include nausea, vomiting, diaphoresis, exertional dyspnea, dyspnea at rest, pre-syncope, syncope, palpitations, generalized anxiety, and depression.[6] **Table 18-1** and **Figure 18-3** show the characteristics of patients with CS.

TABLE 18-1
Characteristics of Patients with CS

Characteristic	Description
Appearance	Ashen or cyanotic in color, jugular vein distension
Skin	Cool and clammy
Extremities	Mottled, peripheral edema
Peripheral pulses	Rapid, faint, irregular (with arrhythmias)
Pulse pressure	Low
Pulse	Tachycardia (weak and rapid) or severe bradycardia
Heart sounds	Distant, third and fourth heart sounds may be present
Breath sounds	Crackles
Mentation	Altered mental status
Urinary output	Low (<30 mL/hour)

Etiology

Table 18-2 shows the etiologies of CS. The myocardial infarction (MI) with left ventricular failure remains



FIGURE 18-3 Organs affected by CS include the heart, brain, lungs, kidneys, and skin.

TABLE 18-2
Etiologies of CS

Types of Dysfunction	Examples
Systolic dysfunction	AMI Acute severe left ventricular dysfunction Acute severe right ventricular dysfunction Acute myopericarditis Takotsubo cardiomyopathy
Diastolic dysfunction	Hypertrophic cardiomyopathy Restrictive cardiomyopathy Hemorrhage Pericardial tamponade
Valvular dysfunction	Acute valvular regurgitation (from endocarditis or chordal rupture) Valve or ventricular septal rupture Aortic stenosis with acute stress Mitral stenosis with acute stress
Cardiac arrhythmias	Atrial arrhythmias Ventricular arrhythmias
Coronary artery disease (CAD)	Acute coronary syndrome
Other causes	Aortic dissection Massive pulmonary embolism

the most common cause of CS.[5] However, any cause of acute, severe left ventricular or right ventricular dysfunction may lead to CS.[5]

Epidemiology

In the United States, the incidence rate of CS from an AMI ranges from 5% to 10%. In Europe, the rate is approximately 7%.[7] Patients arriving in the ED with ST-segment elevation MI (STEMI) have a 7.9% chance of developing CS.[7] Up to 3% of patients with non-ST-segment elevation acute coronary syndrome develop CS.[7] The literature has little data on CS in patients without ischemia.[6] Early treatment for shock, increased monitoring efforts, use of increasingly effective cardiac medications, and careful attention to the maintenance of desirable hemodynamic parameters in patients with AMI have decreased the prevalence of CS over the last 40 years.[8]

Pathology/Pathophysiology

CS results from reduced cardiac output. The decreased cardiac output can be a result of extensive left ventricular MI, development of a mechanical defect (such as a ventricular septal defect or papillary muscle rupture), or right ventricular infarction.[5] CS from a myocardial pathology is characterized by a systolic or a diastolic

dysfunction, most often a result of an AMI. **Figure 18-4** summarizes the pathophysiology of CS.

A systolic myocardial dysfunction causes a decrease in stroke volume because the myocardium is unable to contract as vigorously as necessary. In this case, cardiac output will also decrease, causing hypotension and a decrease in systemic perfusion. As the stroke volume decreases, additional blood remains in the left ventricle, increasing the left heart intracardiac pressure. This increase in pressure is transmitted back to the lung and causes pulmonary edema and congestive heart failure. Consequently, the myocardial filling pressures increase with a coronary perfusion reduction. The body compensates by increasing the heart rate and increasing myocardial oxygen demand with no increase in myocardial perfusion. The result is myocardial ischemia. The systemic vasculature constricts, to compensate for the decrease in systemic perfusion. The compensatory mechanisms become maladaptive and produce a worsening in hemodynamics.[9] Diastolic myocardial dysfunction leads to elevated left ventricular end-diastolic pressure and pulmonary capillary wedge pressure, as well as pulmonary congestion and hypoxemia. The result is also myocardial ischemia.

If an AMI causes the CS, it is usually due to multivessel CAD with limited coronary blood flow reserve. The limited coronary blood flow reserve affects both the systolic and the diastolic function. A **systemic inflammatory response syndrome (SIRS)** may accompany large infarctions and shock. Inflammatory mediators contribute to the genesis of CS as they do to that of other forms of shock. Lactic acidosis from anaerobic metabolism and strained cellular metabolism due to poor tissue perfusion and hypoxemia from pulmonary edema may result from pump failure and then contribute to the vicious cycle by worsening myocardial ischemia and hypotension.[9] If ischemia is severe and prolonged, myocardial cellular injury becomes irreversible and leads to myocardial tissue necrosis.[6] In some cases, the myocardial dysfunction is reversible. This potentially reversible dysfunction is myocardial stunning or hibernating myocardium. Both types can be present at the same time. Hibernating myocardium improves following revascularization (reperfusion). Myocardial stunning retains inotropic reserve and can respond to inotropic stimulation.[6] CS is a medical emergency, and it is important to assess the situation, find the cause, and correct it as quickly as possible. Approximately three-fourths of patients with CS complicating MI develop shock after hospital presentation.[6,10] The vicious cycle of deterioration that leads to death in patients with CS must be broken quickly. The therapeutic goal of interrupting the vicious cycle is based on the concept that myocardial function can be stabilized



FIGURE 18-4 Pathophysiology of CS.
Modified from Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. *Ann Internal Med.* 1999;131(1):47–59.

and eventually improved.[11] Some of the medications used to treat MI may contribute to the development of CS. These medications include beta-blockers, angiotensin-converting enzyme inhibitors, morphine, and diuretics.[5]

Risk Factors

Risk factors for the development of CS in the context of MI include older age, anterior MI, hypertension, diabetes mellitus, multivessel CAD, prior MI or angina, prior diagnosis of heart failure, STEMI, and left bundle-branch block.[5] The risk of CS increases if more than 40% of the left ventricle myocardium is lost.[6]

Because of the potentially serious consequences of CS, identification of subgroups of patients with acute coronary syndromes who are at high risk for developing shock is important. It may be equally important to identify the low-risk group of patients who may be spared any costly or invasive intervention aimed at preventing CS.[12]

Complications

Complications from CS appear in **Box 18-2**.

Diagnostic Testing

Due to the unstable condition of patients with CS, supportive therapy must be initiated simultaneously with diagnostic evaluation.[9] Diagnosing the cause of CS requires laboratory studies, ECG, chest radiography, echocardiography, angiography, and invasive hemodynamic monitoring.

A complete blood count typically shows an elevated white blood cell count with a left shift. Hypoperfusion may cause liver enzymes to be elevated. Poor tissue perfusion may result in a high anion gap metabolic acidosis and the presence of elevated serum lactate levels. Also, there is a marked increase in the cardiac enzymes (e.g., creatine kinase and its subclasses, troponin T, troponin I, myoglobin, and LDH). Before delivery of supplemental oxygen, arterial blood gasses demonstrate hypoxemia.

BOX 18-2 Complications of CS

- Cardiopulmonary arrest
- Death
- Dysrhythmia
- Multisystem organ failure
- Renal failure
- Stroke
- Thromboembolic sequelae
- Ventricular aneurysm

Using a 12-lead ECG immediately helps to diagnose an AMI and myocardial ischemia. In CS, due to AMI with left ventricular failure, Q waves with >2-mm ST elevation in multiple leads or left bundle-branch block are usually present. More than one-half of all infarcts associated with shock are anterior.[9] If evidence of an AMI and myocardial ischemia exists, then an emergency heart catheterization with revascularization is necessary.

A chest x-ray can be used to assess for aortic dissection, tension pneumothorax, or pneumomediastinum. The chest x-ray may show pulmonary vascular congestion or pulmonary edema.

A two-dimensional echocardiogram with color-flow Doppler helps identify the etiology of the CS. It can check the wall motion of the ventricles and determine the ejection fraction. An echo can identify structural problems, such as a ventricular septal defect, free myocardial wall rupture, pericardial tamponade, and atrioventricular valve regurgitation because of papillary muscle rupture.[6] If the echo demonstrates a hyperdynamic left ventricle, then other causes of the shock can be investigated (e.g., **sepsis** or anemia).

Treatment and Management

In addition to the usual treatment for AMI, initial therapy focuses on maintaining adequate systemic and coronary perfusion by raising systemic blood pressure and coronary perfusion.[9] IV access is needed immediately, preferably via a central line, for fluid and medication infusions to correct hypotension and **hypovolemia**. If pulmonary edema is present, careful monitoring is needed when giving fluids. An arterial line may also be necessary. Having venous and arterial access helps to monitor both pressures and blood gasses.[6] Oxygenation and airway protection are critical and applied when necessary. Caution is recommended with intubation; while positive-pressure ventilation may improve oxygenation, it may also compromise preload of the heart.

Various IV drugs may be used to augment blood pressure and cardiac output in patients with CS. All of them have important disadvantages, and none has been shown to change the outcome in patients with established shock.[9] Vasopressors are used to augment the coronary and cerebral blood flow. Sympathomimetic amines with both alpha- and beta-adrenergic effects may be used. Dopamine and dobutamine are the drugs of choice to improve cardiac contractility, with dopamine preferred for hypotension.[6] Diuretics decrease peripheral and pulmonary edema.

Reducing the workload of the heart can help correct and prevent CS. Two devices that make this possible are the intra-aortic balloon pump (IABP) (**Figure 18-5**) and the left ventricular assist device



The IABP rapidly shuttles helium gas in and out of the balloon, which is located in the descending aorta. The balloon is inflated at the onset of cardiac diastole and deflated at the onset of systole.

FIGURE 18-5 Intra-aortic balloon pump.

Weil K. On guard for intra-aortic balloon pump problems. *Nursing*. 2007;37(7):28. doi:10.1097/01.nurse.0000279412.31117.3a.



FIGURE 18-6 LVAD attached to the left ventricle of the heart and the aorta.

(LVAD) (**Figure 18-6**). A heart catheterization can place either of these devices. The use of an IABP helps increase coronary perfusion by increasing coronary perfusion pressure and reducing afterload leading to a reduction in the work of the left ventricle. The IABP is a temporary measure that gives clinicians additional time to find and treat the cause of the CS or to transfer the patient to a tertiary care center. The LVAD assists the left ventricle to increase cardiac output, sending oxygenated blood to the body and vital organs, increasing perfusion. A ventricle assist device (VAD) can be used for the left or right ventricle. If a heart



FIGURE 18-7 Algorithm for revascularization strategy in CS.

Reproduced with permission from Reynolds H. Hochman J. Cardiogenic shock: current concepts and improving outcomes. *Circulation.* 2008;117(5):686–697. http://dx.doi.org/10.1161/circulationaha.106.613596.

transplant is needed, the VADs can act as a bridge to surgery.[13]

Early revascularization is the most essential treatment of CS. As in AMI without shock, the earlier, the better. Revascularization with percutaneous cardiac intervention (PCI) or coronary artery bypass graft (CABG) is a Class I recommendation for patients age <75 with ST elevation or left bundle-branch block MI who develop CS within 36 hours of MI and who can be revascularized within 18 hours of the development of CS.[9] Presentation 0–6 hours after symptom onset is associated with the lowest mortality among CS patients.[5] Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, or tirofiban) post stent placement is used to prevent platelet adhesion. When mechanical revascularization is not possible, IABP and fibrinolytic therapy are recommended.[9] **Figure 18-7** shows the revascularization strategy for CS.

Prognosis

CS has a wide range of expected death rates based on age, severity of hemodynamic abnormalities, severity of the clinical manifestations of hypoperfusion, and the performance of early revascularization.[9]

The mortality rates for different races are provided in **Table 18-3**. These differences disappear with revascularization.[6] Men have a higher risk of developing CS than women; about 42% of all CS happen in women.[6] The mortality rate for CS by race appears in Table 18-3.

TABLE 18-3
Mortality from CS by Race

Race	CS Mortality Rate (%)
African American	74
Asian/other	41
Caucasian	56
Hispanic	74

KNOWLEDGE CHECK QUESTIONS

1. True or False: Persistent hypotension is a mean arterial pressure 15 mm Hg lower than the patient's baseline.
2. True or False: Multivessel CAD can cause CS.
3. True or False: Cardiac contractility is improved and hypotension relieved by dopamine.

Hypovolemic Shock

A significant reduction in the amount of circulating volume in the bloodstream results in hypovolemic shock. When this occurs, vital organs are deprived of oxygen, causing cellular hypoxia and organ failure.

Definition/Diagnosis

Hypovolemic shock is a potentially fatal medical emergency due to inadequate tissue perfusion caused by decreased intravascular circulating volume.[14] The intravascular volume drop leads to a disruption of homeostatic mechanisms, hypotension, cardiovascular collapse, and impaired end-organ perfusion. There are two categories for hypovolemic shock: hemorrhagic and **nonhemorrhagic shock**. **Hemorrhagic shock** has a further classification based on the amount of blood lost and whether the hemorrhage is traumatic or nontraumatic. Hemorrhagic shock occurs in the EDs, operating rooms, and intensive care units.

Shock due to hypovolemia may be confused with or confounded by shock from other causes. In some instances, there may be more than one type of shock in play.[15] Diagnosis is, therefore, very challenging.

Clinical Signs and Symptoms

The signs and symptoms of both types of hypovolemic shock are very similar. The main difference is that nonhemorrhagic shock may have a more insidious onset. The normal physiologic response to hypovolemia is to maintain perfusion of the brain and heart while attempting to restore an effective circulating blood volume. To maintain perfusion, the body increases sympathetic activity and ventilation, collapses venous capacitance vessels, releases stress hormones, and reduces urinary output.[16] The physiologic manifestations are directly related to the amount of blood volume loss. See **Table 18-4**.

Perfusion of the central nervous system is normal until shock becomes severe. Therefore, mental obtundation is an ominous clinical sign. The transition from mild to severe hypovolemic shock can be insidious or extremely rapid. If severe shock is not reversed quickly, death is imminent. There is a very narrow time frame that separates the reversibility with aggressive resuscitation from progressive decompensation and irreversible cell injury.[16]

Etiology

Nonhemorrhagic hypovolemic shock is due to reduced intravascular volume from fluid loss other than blood. This volume depletion from loss of sodium and water can occur from several anatomic sites.[4] Gastroenteritis and extensive burns result in a fluid loss that can lead to nonhemorrhagic hypovolemic shock. See **Table 18-5**.

Hemorrhagic hypovolemic shock can be a nontraumatic or traumatic shock. The most common causes of **nontraumatic hemorrhagic shock** include severe gastrointestinal (GI) bleeding or an abdominal aortic aneurysm. The etiology of **traumatic hemorrhagic shock** includes blunt or penetrating trauma. See Table 18-5.

Hemorrhagic hypovolemic shock is further broken down into a classification that depends on the quantity of blood loss. **Table 18-6** shows the four classes of hemorrhagic hypovolemic shock and the signs and symptoms of each. Class I is a nonshock state, such as occurs when donating a unit of blood, whereas Class IV is a preterminal event requiring immediate therapy. Massive hemorrhage is the loss of total estimated blood volume (EBV) (for a 70-kg person, it is approximately 5 L) within a 24-hour period or loss of half of the EBV in a 3-hour period.[16]

TABLE 18-4
Signs and Symptoms of Hypovolemic Shock

Systems	Mild Hypovolemia (≤20% Loss of Blood Volume)	Moderate Hypovolemia (~20–40% Loss of Blood Volume)	Severe Hypovolemia (>40% Loss of Blood Volume)
Cardiac	Mild tachycardia	Tachycardia	Marked tachycardia
Respiratory	Within normal limits	Tachypnea	Hemodynamic instability
Extremities	Cool extremities Increased capillary refill time	Cool extremities Increased capillary refill time	Cool extremities Increased capillary refill time
Fluid	Diaphoresis	Diaphoresis Oliguria	Oliguria
Cardiovascular	Collapsed veins	Postural hypotension	Hypotension
Mental	Anxiety	Anxiety	Agitation, confusion, coma

TABLE 18-5
Causes of Hypovolemic Shock

	Hemorrhagic Hypovolemic Shock	
Nonhemorrhagic Hypovolemic Shock	**Traumatic Hemorrhagic Shock**	**Nontraumatic Hemorrhagic Shock**
GI losses • Diarrhea • External drainage • Vomiting	Arterial lacerations	Aneurysm rupture
Renal losses • Excessive drug-induced diuresis • Hypoaldosteronism • Osmotic diuresis	Major vessel rupture	Arteriovenous malformations
Skin losses • Burns • Heat stroke • Stevens–Johnson syndrome	Pelvic and femoral fractures	Esophageal varices
Third space losses • Cirrhosis • Intestinal obstruction • Pancreatitis	Solid abdominal organ injury	Mallory–Weiss syndrome Peptic ulcers

TABLE 18-6
Classification of Hemorrhagic Hypovolemic Shock

Signs/Symptoms	Class I	Class II	Class III	Class IV
Blood loss (mL)	<750	750–1,500	1,500–2,000	>2,000
Blood loss (%)	<15	15–30	30–40	>40
Pulse (beats/minute)	<100	>100	>120	>140
Blood pressure	Normal	Decreased	Decreased	Decreased
Respiratory rate (breaths/minute)	12–20	20–30	30–40	>35
Urine output (mL/hour)	>30	20–30	5–15	Negligible
Central nervous system symptoms	Normal	Anxious	Confused	Lethargic

Reproduced from Gutierrez G, Reines H, Wulf-Gutierrez M. Clinical review: hemorrhagic shock. *Crit Care.* 2004;8(5):373–381. doi:10.1186/cc2851.

Epidemiology

Hypovolemic shock is the most common form of shock. More than 1 million patients present with hypovolemic shock or develop hypovolemic shock in U.S. hospitals each year. There is no know gender prevalence. Hypovolemic shock may occur at any age, depending upon the underlying etiology.[17]

Pathology/Pathophysiology

Hypovolemic shock causes a decrease in circulating volume (**Figure 18-8**). This volume loss reduces both preload and stroke volume and causes reduced cardiac output.[15] Regardless of the etiology, the body will compensate for fluid or blood loss by activating the hematologic, cardiovascular, renal, and neuroendocrine systems.[18] The hematologic system responds to hypovolemic shock by activating the clotting cascade and causing vasoconstriction in the blood vessel at the site of the injury. An immature clot forms quickly but takes approximately 24 hours to be considered mature. Both mechanisms help to decrease or stop the fluid or blood loss.[18]

When the body becomes hypovolemic, cardiac output decreases, resulting in organ and tissue hypoperfusion. The body attempts to compensate for the drop in



FIGURE 18-8 The vicious cycle of hypovolemic shock.

Reproduced with permission from Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York: McGraw-Hill Education; 2013.

cardiac output by increasing heart rate and myocardial contractility, constricting the peripheral blood vessels, and shunting the blood to a vital organ (e.g., brain, heart, and kidneys). These actions are designed to increase cardiac output and maintain the blood pressure to maintain organ and tissue perfusion.[19]

The renal system compensates for hypovolemia with an increase in renin secretion, resulting in an increase in angiotensin II. The angiotensin II causes vasoconstriction and the release of aldosterone by the adrenal cortex. Aldosterone induces increases in sodium reabsorption and water retention.[15,16] The neuroendocrine system responds to hypovolemia by increasing levels of antidiuretic hormone (ADH), which also increases reabsorption of water and sodium.[15,16]

Endothelial function is significantly altered following hypovolemic shock due to ischemia of the endothelial cells and by reperfusion due to resuscitation with fluids. Activation of endothelial cells leads to the release of vasoactive substances (nitric oxide [NO], endothelin, platelet-activating factor, prostacyclin, mitochondrial N-formyl peptide), inflammatory mediators (tumor necrosis factor-alpha [TNF-α], interleukins [IL], interferons), and thrombosis.[20] The hypoxemia from hypovolemic shock causes the death of endothelial cells. The compromise of the endothelial cells leads to increased permeability and leakage of fluids into the tissue, causing edema.[20]

The acid–base balance reflects the stages of shock. In compensated or mild-to-moderate shock, the most frequently observed acid–base abnormality is respiratory alkalosis. As the shock state progresses, anaerobic metabolism predominates, stimulating lactate production and subsequent metabolic acidosis. This metabolic acidosis further exacerbates the shock by decreasing sensitivity to catecholamines and stress hormones, resulting in decreased myocardial contractility, increasing the occurrence of cardiac arrhythmias.[15]

Risk Factors

Risk factors for hypovolemic shock resulting from blood loss include intra- and postpartum complications (e.g., ectopic pregnancy, placental abruption, placenta previa), trauma, pelvic and femoral fracture, liver injury, ruptured abdominal or thoracic aortic aneurysm, GI tract bleeding, and surgery. Fluid loss through vomiting, diarrhea, diuresis, and diabetes insipidus increases the risk of hypovolemic shock. Internal fluid shifts leading to hypovolemic shock can result from severe burns, ascites, peritonitis, and dehydration. Older adults are at risk for more severe hypovolemic shock and for developing complications, such as MI and stroke.[21]

Complications

If untreated, hypovolemic shock will lead to death. Otherwise, the complications associated with hypovolemic shock include acute respiratory distress syndrome (ARDS), multisystem organ failure, gangrene of the extremities, and MI.

Diagnostic Testing

The physical examination should always begin with an assessment of the airway, breathing, and circulation. Once these have been evaluated and stabilized, the circulatory system needs evaluation for signs and symptoms of shock. The body's compensatory mechanisms may prevent the systolic blood pressure from dropping until there is a 30% loss of blood volume.

Therefore, relying on the systolic blood pressure as an indication may result in a delayed diagnosis. The pulse rate, respiratory rate, and skin perfusion will be more beneficial.[18]

With female patients, hypovolemic shock may be secondary to an ectopic pregnancy. In these cases, a pregnancy test is done immediately and, if positive, a surgical consult and pelvic ultrasound are necessary.[18]

A high clinical suspicion for the presence of hypovolemic shock is critical for diagnosis. The easiest diagnosis for hypovolemic shock comes from obvious trauma. The priority, in this case, is to stop the bleeding and stabilize the patient. With nontraumatic hemorrhagic shock and nonhemorrhagic shock, the diagnosis is not as apparent. A targeted history from prehospital or hospital providers, the patient, their relatives, or the medical record can provide ample information on a patient's risk of shock, as well as the potential etiology.[2] It is important to distinguish between hypovolemic and CS because while both may respond to volume initially, definitive therapy differs significantly. The major difference in CS ongoing volume expansion is undesirable and may cause further organ dysfunction.[16]

Laboratory tests that assist in diagnosing hypovolemic shock appear in **Box 18-3**.

If no visible signs of trauma exist, point-of-care ultrasonography is necessary to check for an abdominal aortic aneurysm. Shock due to a suspected long-bone fracture is identified with radiography. In the case of a suspected GI bleed, a nasogastric tube placement and gastric lavage are necessary. An upright chest x-ray is useful to diagnose a perforated ulcer. When the upright chest x-ray indicates a thoracic dissection, one or more of the following tests are necessary: transesophageal echocardiography, aortography, or CT scan of the chest. When additional bleeding is suspected, an endoscopy is appropriate.[18]

A suspected traumatic thoracic or abdominal injury requires a point-of-care ultrasound whether the patient is stable or not. Stable patients with suspected traumatic abdominal injury will typically have a CT scan.[18]

Treatment and Management

Throughout every phase of trauma care, the priorities of circulation, airway, and breathing are paramount. Problems encountered in these areas must be addressed rapidly and sequentially. Sources of bleeding require continual assessment. Hemodynamic monitoring is also continuous.[15]

The three primary focuses of resuscitation for a patient with hypovolemic shock include controlling further blood loss, reexpansion of the circulating intravascular blood volume, and maximizing oxygen delivery. See **Table 18-7**.

Active bleeding and all sources of fluid loss must be identified and controlled. External bleeding is controlled by applying direct pressure or pressure dressings, Pneumatic antishock garments are also useful. The patient's legs can also be elevated about 12 inches to promote venous return. Pregnant patients need to be placed on the left side to decrease pressure, by the fetus, on the vena cava, increasing circulation. If the bleeding is internal, surgical intervention may be necessary. In the cases of long-bone fractures, traction can help to decrease blood loss.[18]

Reexpansion of the circulating volume is achieved with fluid infusions regardless of the etiology of the hypovolemic shock. This volume resuscitation begins with the rapid infusion of either isotonic saline or Ringer's lactate, **crystalloid solutions**, through large-bore IV lines.[16] Ringer's lactate solution may theoretically be preferable because of its ability to buffer metabolic

BOX 18-3 Laboratory Tests for Hypovolemic Shock

- Activated partial thromboplastin time
- Arterial blood gasses
- Blood urea nitrogen
- Complete blood count
- Electrolyte panel (sodium, potassium, chloride, and bicarbonate)
- Glucose
- Prothrombin time
- Serum lactate
- Type and cross-matched for blood transfusion urinalysis (in patients with trauma)
- Urine pregnancy test

TABLE 18-7
Resuscitation of Hypovolemic Shock

Control Further Blood Loss	Reexpand Volume	Maximize Oxygen Delivery
Direct pressure	Large-bore IV access, intraosseous (IO) access	Blood transfusion with rewarming techniques when necessary
Pneumatic antishock garment or elevate legs 12 inches	Rapid crystalloid infusion (isotonic saline or Ringer's lactate)	Supplemental high-flow oxygen
Surgical intervention	Maintain ventricular performance (norepinephrine, vasopressin, dopamine)	Intubation with mechanical ventilation

acidosis and prevent hyperchloremic acidosis associated with normal saline infusions.[14] The initial fluid bolus for an adult should be 1–2 L.[18] This infusion should restore normal hemodynamic parameters. Continued hemodynamic instability implies that shock has not been reversed or there are significant ongoing blood or other volume losses.[16]

The infusion of isotonic saline or Ringer's lactate resuscitate volume does little to increase the oxygen-carrying capacity of the blood. Continuing acute blood loss, with hemoglobin concentrations declining to <10 g/dL, indicates that a blood transfusion, with preferably fully crossed-matched recently banked blood (<14 days old), is necessary.[16] Blood products are the most readily available fluids to increase oxygen-carrying capacity and cardiac preload. The decision to transfuse is based on the assessment of ongoing blood loss, the patient's ability to compensate, and the availability of cross-matched blood products.[15]

If there is no type and cross-match for the patient, Type O blood is appropriate. If the patient is a female of childbearing age, Type O Rh-negative blood is appropriate to help to prevent sensitization and future complications.[18] In the case of a patient nearing death, Class IV shock, both crystalloids and Type O blood are appropriate to start initially. The condition of the patient is always considered when providing fluids therapy.[18] Other factors considered include hypothermia from massive blood product transfusion, coagulopathy or hypocoagulability due to major trauma or deficient clotting factors in crystalloids, and banked packed red blood cells.

Following severe or prolonged hypovolemia, inotropic support with norepinephrine, vasopressin, or dopamine may be required to maintain adequate ventricular performance, but only after blood volume is restored. Increases in peripheral vasoconstriction with inadequate resuscitation lead to tissue loss and organ failure. Following hemorrhage control and patient stabilization, blood is not transfused unless the hemoglobin is <7 g/dL.[16]

Resuscitation for a GI bleed may be accomplished using vasopressin and H2 blockers. However, caution is necessary, as vasopressin may cause adverse reactions (e.g., hypertension, arrhythmias, gangrene, and myocardial or splanchnic ischemia). The use of H2 blockers is safe but has not been proven to have benefits. When hypovolemic shock results from acute gynecologic bleeding, surgical intervention is required to stop the bleeding. Causes of acute gynecologic bleeding include ectopic pregnancy, placenta previa, abruptio placenta, ruptured cyst, or miscarriage.[18]

Even if IV or IO access is established in the prehospital setting, two large-bore IV lines are necessary so fluids can be given quickly. If severe hemorrhage is occurring, an intra-arterial (IA) line is appropriate. Having an IA line in place can also measure pressures and makes drawing arterial blood gasses easier.[18]

Successful resuscitation also requires the support of the respiratory function. Supplemental oxygen must always be provided usually via a high-flow, high-concentration device. Endotracheal intubation may be necessary to protect the airway and maintain ventilation and arterial oxygenation. Caution is necessary with positive-pressure ventilation, due to the possibility of reduced venous return, which could worsen cardiac output.

Prognosis

The prognosis of hypovolemic shock will depend on the amount of blood or fluid loss, the type of injury that caused the shock, and how quick the diagnoses is done and treatment begins.[18] Organ system failures commonly seen with hypovolemic shock include pulmonary, hepatic, and renal failure.[15] The more organ failures there are, the worse the prognosis is.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Nonhemorrhagic hypovolemic shock may be due to extensive cutaneous burns.
2. True or False: The most common acid–base abnormality in mild-to-moderate hypovolemic shock is metabolic acidosis.
3. True or False: The treatment of hypovolemic shock is the infusion of crystalloid solutions.

Anaphylactic Shock

Individuals with severe, immunoglobulin E (IgE)-mediated allergic reactions to food, drugs, latex, and insect bites are at risk for developing anaphylactic shock from an anaphylactic reaction. Anaphylactic shock is the result of the anaphylactic reaction causing a decrease in blood supply to vital organs.

Definition/Diagnosis

Anaphylaxis is a serious allergic reaction that is rapid on onset and may cause death.[22] **Anaphylactic shock** results from anaphylaxis depressing cardiac output due to coronary hypoperfusion from systemic vasodilation, leakage of plasma and volume loss due to increased vascular permeability, and reduced venous return.[23]

Anaphylaxis is a systemic, Type I hypersensitivity reaction that occurs in sensitized individuals, resulting in mucocutaneous, cardiovascular, respiratory, and GI manifestations.[24] Most cases of anaphylaxis

are IgE mediated. Antibodies exposed to a specific allergen attach to mast cells and basophils, resulting in their activation and degranulation.[25] The activation and degranulation of the mast cells and basophils release a variety of chemical mediators, including histamine, heparin, tryptase, kallikrein, platelet-activating factor, bradykinin, TNF, nitrous oxide, and several types of ILs.[26] An **anaphylactoid reaction**, **nonimmune anaphylaxis**, is an anaphylactic-like reaction triggered by direct activation of the mast cells and not by an IgE-mediated response. Radiocontrast media cause this type of reaction.

A rapid diagnosis of anaphylaxis is imperative for treatment to begin as soon as possible. Therefore, only a brief, direct history of present illness is obtained. This history should include questions regarding a past medical history of allergies, asthma, hypersensitivity, or prior anaphylaxis to anything. Also, inquire about exposure to new foods, medications, and insect bites or stings.

Clinical Signs and Symptoms

The clinical picture of anaphylaxis almost always involves the skin. One or more manifestations of pruritus, erythema, urticaria, or angioedema occur in more than 90% of patients. Mucosal edema and erythema of the nose, eyes, or mouth may also be seen with resultant tearing, itching, nasal congestion, and sneezing. The GI tract is also affected. Symptoms of abdominal pain, nausea, vomiting, and diarrhea are common.[27] See **Table 18-8**.

Anaphylaxis often produces signs and symptoms within minutes of exposure to an allergen, but some reactions might develop more than 30 minutes after exposure. The more rapidly anaphylaxis occurs after exposure to an offending stimulus, the more likely the reaction will be severe and potentially life threatening. It is imperative that the signs and symptoms of anaphylaxis be recognized promptly.[22]

Etiology

There are numerous causes for anaphylaxis. See **Table 18-9**. The most common include medications, foods, insect stings, and physical factors. Sometimes the etiology is not known or idiopathic.

Epidemiology

In the general population, the estimated prevalence of anaphylaxis is at least 1.6% and probably higher.[28] Mortality rates vary greatly among different age groups, with people 65 years or older having the highest rates and children 17 years or younger having the lowest rates.[29] The number of anaphylaxis episodes occurs more frequently from July through September, due to the increase in insect stings during the summer months.[30] Food-related reactions are most common in children up to age 4, and medication reactions are most common in patients older than 55 years.[31]

Although anaphylactic reactions are potentially life threatening, the probability of dying is very low for those cases that require ED or hospital attention. The likelihood of dying is low when all anaphylactic reactions are considered.[29]

Pathology/Pathophysiology

Anaphylaxis is a clinical syndrome resulting from several pathogenetic mechanisms with the presentation of identical clinical manifestations. These manifestations occur due to the degranulation of mast cells and basophils with subsequent release of chemical mediators inducing the anaphylactic symptomatology. See **Figure 18-9**. Other chemical mediators are derived from the metabolism of arachidonic acid and include leukotrienes and prostaglandins.

Anaphylaxis occurs when a person has reexposure to an antigen to which the person has produced a specific IgE antibody.[24] Reexposure to the antigen causes

TABLE 18-8
Signs and Symptoms of Anaphylactic Shock

Mucocutaneous	Respiratory	Cardiovascular	GI
Angioedema	Cough	Chest pain	Abdominal cramps
Flushing	Dyspnea	Hypotension	Diarrhea
Pruritus	Hoarseness	Syncope	Nausea
Swelling of lips	Rhinorrhea	Tachycardia	Vomiting
Urticaria	Stridor		
	Throat tightness (swelling of tongue)		
	Wheezing		

TABLE 18-9
Some Etiologies of Anaphylaxis and Anaphylactoid Reactions

Medications	Foods	Venoms and Saliva	Miscellaneous
Aspirin Antibiotics Analgesics Blood products Biologic agents General anesthetics Radiocontrast media Immunotherapy Nonsteroidal anti-inflammatory agents	Bananas Beets Buckwheat Chamomile tea Citrus fruits Cottonseeds Cow milk Egg whites Fish Peanuts Sesame seeds Shellfish Sunflower seeds Tree nuts	Bees Deer flies Fire ants Hornets Jellyfish Rattlesnakes Sawflies Wasps Yellowjackets	Blood products Cold temperatures Dialysis membranes Exercise Gelatin Latex Radiologic contrast media Seminal fluid



FIGURE 18-9 Anaphylactic reaction.

the degranulation of mast cells and basophils. Histamine is thought to be the primary mediator of anaphylactic shock, and most of the signs and symptoms of anaphylaxis are attributable to binding of histamine to its receptors (H_1 and H_2).[24] Numerous chemical mediators, from chymase to TNF-α, are responsible for the variety of clinical manifestations common to anaphylaxis.

Anaphylaxis has three grades: immune (IgE mediated), nonimmune (non-IgE mediated), and idiopathic (undetermined cause). Because the clinical manifestations and emergency treatment do not differ, the necessity to identify immunologically driven anaphylaxis from nonimmune and idiopathic reactions is not necessary for the initial management of the reaction.[32]

During anaphylactic shock, depression of cardiac output is due to coronary hypoperfusion from systemic vasodilation, leakage of plasma, and volume loss due to increased vascular permeability and reduced venous return. The shifting of intravascular fluid to extravascular spaces may decrease the circulating blood volume by as much as 35% within 10 minutes.[23]

Risk Factors

The risk factors for an anaphylaxis include having atopy (hay fever, eczema, and asthma), food allergies (peanut allergy, shellfish allergy), or latex allergy. Certain medications also make patients more susceptible to anaphylaxis and inhibit their response to treatment, an example being beta-blockers used to treat hypertension and, in certain cases, anxiety. Patients taking beta-blockers for whatever reason are more likely to experience anaphylaxis.[32]

Complications

Complications from anaphylaxis are rare, and most patients completely recover. When hypotension and

hypoxia occur in anaphylactic shock, there could be some myocardial ischemia, more so if there is underlying CAD. Myocardial ischemia and arrhythmias may occur if vasopressors are administered.[30] Airway obstruction, bronchospasm, cardiovascular effects, cutaneous reactions, or GI symptoms may occur singly or in any combination. Severe bronchospasm or laryngeal edema can occur with anaphylaxis, leading to hypercapnic respiratory failure and hypoxemic respiratory failure. Brain anoxia from hypoxia can cause irreversible brain injury. Syncope during anaphylactic shock can result in a fall injury.[30]

Diagnostic Testing

The diagnosis of anaphylaxis is clinical and based on the observation of the typical features. When these are associated with a history of exposure to a foreign substance, the diagnosis is virtually certain.[27] Diagnostic confusion may occur when cutaneous manifestations are not present. Anaphylaxis is possible when a patient presents in shock or syncope without any obvious cause.[27]

Because anaphylaxis is a clinical diagnosis, the value of blood testing is limited.[33] However, there are two tests that may be helpful in confirming anaphylaxis in the acute setting. These two blood tests are serum histamine and tryptase levels. Histamine levels must be obtained within 1 hour of symptom onset. Moreover, samples require special handling because histamine breaks down with any movement. Tryptase levels do not increase until 30 minutes after the onset of symptoms and peak at 1–2 hours. Therefore, serial levels of tryptase are drawn on presentation, 1–2 hours after presentation, and 24 hours after presentation to assess for a return to baseline.[33]

Treatment and Management

Immediate intervention for anaphylaxis includes focused examination and maintenance of circulation, airway, breathing, and level of consciousness, followed by epinephrine administration. A large-bore IV line with isotonic crystalloid solution is advisable, and hypotensive patients require vigorous fluid resuscitation with an initial bolus of 1 L.[27] Timely administration of epinephrine, at initial diagnosis and ideally before respiratory failure or cardiovascular compromise, is the most important treatment for anaphylaxis.[22,25,27,32,34] However, a delay in epinephrine administration is associated with poor outcomes.[34] Subcutaneous administration is recommended, except for patients in profound shock, in which case epinephrine is given intravenously. Sublingual injection is an alternative for patients in severe distress who lack IV access.[27] See **Table 18-10**.

About 20% of patients with anaphylactic shock experience a delayed second phase of the symptoms (biphasic reaction) after the initial episode. Therefore, these patients require a minimum of 4 hours of observation following the relief of the initial symptoms.[27,30] Approximately 90% of biphasic reactions will occur during this time.[30]

TABLE 18-10
Treatment of Anaphylactic Shock

Indication	Treatment
Airway compromise	• Bag-valve mask ventilation • Intubation
Apnea	• Bag-valve mask ventilation • Mechanical ventilation
Circulation compromise	• Cardiac compressions
Anaphylactic shock, angioedema, airway obstruction, bronchospasm, urticaria	• Epinephrine (up to 0.5 mg every 15 minutes subcutaneous, 0.1 mg slow IV) • Large-bore IV • Isotonic crystalloid solution
Hypotension, urticaria	• H_1-blocker antihistamine (diphenhydramine, cetirizine) • H_2-blocker antihistamine (cimetidine, ranitidine) • Dopamine (hypotension only)
Bronchospasm	• Albuterol (2.5 mg via small-volume nebulizer every 15 minutes) • Hydrocortisone or methylprednisolone
Shock, for patients with beta-blockade	• Glucagon

An important aspect of anaphylaxis treatment is the prevention of further events. The patient and family need education to avoid all known and potential anaphylaxis triggers. All individuals with a history of anaphylactic reactions need to wear a medical alert bracelet and carry an epinephrine auto-injector. Proper training on the administration of the auto-injector is extremely important. An anaphylaxis action plan is essential for each person at risk for anaphylaxis. This action plan includes a list of common signs and symptoms of anaphylaxis and emphasizes the importance of using the epinephrine auto-injector promptly and of calling 911 or emergency medical services promptly. If a reaction occurs, the patient should be instructed to seek medical attention, even after the self-administration of epinephrine.[22]

Prognosis

The more rapidly anaphylaxis occurs after exposure to an offending stimulus, the more likely the reaction will be severe and potentially life threatening.[22] Dying from anaphylactic shock is infrequent, but not rare. Cardiovascular collapse and respiratory compromise cause death due to anaphylaxis.[30]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Anaphylaxis can depress cardiac output due to coronary hypoperfusion.
2. True or False: Nonimmune anaphylaxis is triggered by direct activation of mast cells.
3. True or False: There are no blood tests to confirm anaphylactic shock.

Septic Shock

Sepsis is a systemic inflammatory response to infection, which when complicated by a persistent drop in blood pressure becomes septic shock. As with other forms of shock, septic shock can result in organ failure due to decreased oxygen delivery to the tissues.

Definition/Diagnosis

When microbes traverse the epithelial barriers and enter underlying tissues, they cause both local and



FIGURE 18-10 Septic shock.

systemic responses. Sepsis is a life-threatening organ dysfunction due to dysregulated host response to infection. **Septic shock** is the presence of sepsis with **persistent hypotension** requiring vasopressors to maintain a mean arterial pressure of 65 mm Hg or higher and a serum lactate level >18 mg/dL despite adequate volume resuscitation.[35]

The basis of sepsis is the presence of infection associated with a systemic inflammatory response that results in physiologic alterations at the capillary endothelial level. The term *systemic inflammatory response syndrome* (SIRS) describes the clinical manifestations that result from the systemic response to infection. However, a patient can have a severe infection without having SIRS, and SIRS can have noninfectious disease processes such as trauma or pancreatitis. Septic shock occurs in a subset of patients with sepsis and comprises an underlying circulatory and cellular/metabolic abnormality that increases mortality.[36] See **Figure 18-10**.

Clinical Signs and Symptoms

In septic shock, it is important to identify the potential source of infection. Physical signs can help to localize the source of an infection. See **Table 18-11**.

The clinical manifestations of the septic response are superimposed on the signs and symptoms of the patient's underlying illness and primary infection. The rate at which sepsis and septic shock develop may differ from patient to patient.[37] The hallmarks of septic shock are changes that occur at the microvascular and cellular level with diffuse activation of inflammatory and coagulation cascades, vasodilation and vascular maldistribution, capillary endothelial leakage, and dysfunctional utilization of oxygen and nutrients at the cellular level. The challenge for clinicians is to recognize that this process is under way when it may not be clearly manifested in the vital signs or clinical examination.[36] See **Table 18-12**.

For patients in septic shock, it is important to assess the patient's skin color and temperature. The skin can become pale, grayish, or mottled, and these are signs of poor tissue perfusion. Initially, in sepsis, the cardiac output stays the same, and there may even be an increase. Because of the vasodilation from the release of NO, the skin and extremities will be warm, and there will be normal capillary refill; this is the warm phase of septic shock. If the cause of the septic shock is not found and treated, stroke volume and cardiac output fall. As this happens, signs of poor perfusion occur, including cool skin, cool extremities, and delayed capillary refill; this is known as the cold phase of septic shock.[36]

If the sepsis patient has a fever, a determination of its onset (abrupt or gradual), duration, and maximal

TABLE 18-11
Physical Signs to Localize the Site of Infection

Site of Infection	Physical Signs
Head and neck infections	Inflamed tympanic membranes, sinus tenderness, nasal congestion, pharyngeal erythema, pharyngeal exudates, inspiratory stridor, cervical lymphadenopathy, severe headache
Chest and pulmonary infections	Dullness on percussion, bronchial breath sounds, localized crackles, evidence of consolidation
Cardiac infections	Any new murmur, especially in patients with a history of injection or IV drug use
Abdominal and GI infections	Abdominal distention, localized tenderness, diarrhea, vomiting
Pelvic and genitourinary infections	Pelvic or flank pain, adnexal tenderness or masses, vaginal or urethral discharge
Bone and soft-tissue infections	Localized limb pain or tenderness, focal erythema, edema, swollen joint
Skin infections	Petechiae, purpura, erythema, ulceration, bullous formation, fluctuance

TABLE 18-12
Signs of Septic Shock and Their Causes

Sign	Cause
Cool skin Cool extremities Delayed capillary refill	Poor perfusion from decreased cardiac output
Pallor Grayish-colored skin Mottled skin	Poor tissue perfusion is common with septic shock
Petechia Purpura	Disseminated intravascular coagulation (ominous sign)
Tachycardia	Compensation for decreased cardiac output Response to stress Hypothermia Along with narrow pulse pressure, the earliest signs of shock
Narrow pulse pressure	Along with tachycardia, the earliest signs of shock
Tachypnea	Pulmonary dysfunction due to pneumonia, ARDS Compensation for metabolic acidosis
Altered mental status	Cerebral hypoperfusion Altered amino acid metabolism

temperature needs investigation. Having this information helps determine the burden and severity of the infection. Fever, alone, is an insensitive indicator of sepsis. Hypothermia, however, is a better predictor of sepsis severity and the likelihood of death.[36]

A rapid assessment tool that provides simple bedside criteria to identify adult patients with suspected infection who are likely to have poor outcomes is the **Quick Sequential (Sepsis-Related) Organ Failure Assessment Score (qSOFA)**.[35] This assessment tool does not require laboratory tests, is quick, and can be repeated. The qSOFA can be used to prompt clinicians to investigate further for organ dysfunction, to initiate or escalate therapy as appropriate, and to consider referral to critical care or increase the frequency of monitoring.[35] See **Box 18-4**.

Etiology

Serious bacterial infections at any site in the body, with or without bacteremia, are usually associated with important changes in the function of every organ system in the body. These changes are mediated mostly by elements of the host immune system against infection. Shock is present when volume replacement fails to increase blood pressure to acceptable levels. Shock is also present when associated clinical evidence indicates inadequate perfusion of major organ systems, and with progressive organ function failure.[36] Table 18-11 identifies the sites of infections that may lead to septic shock. It is respiratory infections, however, that are the most common cause of septic shock.[38,39]

Epidemiology

The incidence of sepsis in the United States has grown recently. Cases of severe sepsis increased threefold between 1979 and 2000, from 83 cases per 100,000 population per year to 240 per 100,000. These increases are attributed to an increase in the elderly population, increased recognition of the disease, increases in surgeries, increased use of certain medications (e.g., immunosuppressive agents and chemotherapy), increased use of immunosuppressive agents and chemotherapy, increased use of indwelling lines and devices, and an increase in HIV.[36]

BOX 18-4 The Quick Sequential Organ Failure Assessment Score (qSOFA)

Respiratory rate ≥22 breaths/minute

Altered mental status

Systolic blood pressure ≤100 mm Hg

Reproduced with permission from Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801. doi:10.1001/jama.2016.0287.

As recently as 30 years ago, death from septic shock was more than 80%. However, with advances in training, better surveillance and monitoring, and prompt initiation of therapy to treat the underlying infection and support failing organs, mortality is now closer to 20–30%.[39]

Pathology/Pathophysiology

Septic shock causes three major pathophysiologic effects within the cardiovascular system: vasodilation, maldistribution of blood flow, and myocardial depression. In septic shock, the absolute intravascular volume may be normal; however, because of acute vasodilation, relative hypovolemia occurs.[40]

Localized infections cause the activation of neutrophils and monocytes, release of inflammatory mediators, local vasodilation, endothelial permeability, and activation of coagulation pathways. Septic shock causes these responses to occur systemically, leading to diffuse endothelial disruption, vascular permeability, vasodilation, and thrombosis or end-organ capillaries. Endothelial damage can further activate inflammatory and coagulation cascades, creating a positive feedback loop leading to further endothelial and end-organ damage.[36]

In septic shock, proinflammatory cytokines and other metabolites cause an increase in endothelial-derived NO.[40] Excessive NO has a detrimental effect on the vasculature and blood pressure, causing NO-mediated hypotension and vasorelaxation. The NO-mediated hypotension leads to severe hypoxia in peripheral vital organs, resulting in progressive organ failure.[41]

Some of the mediators released during septic shock cause various blood vessels to remain vasoconstricted, leading to maldistribution of blood flow. Vascular occlusion also leads to inadequate tissue perfusion. In septic shock, endothelial cells are stimulated by the proinflammatory mediators, TNF-α and IL-1β, and endotoxin, causing activation of the coagulation cascade, creation of microvascular plugs, and, subsequently, maldistribution of blood flow. The maldistribution contributes to tissue hypoxia.[40]

Proinflammatory mediators, along with cytokines and activated leukocytes, increase vascular permeability, allowing fluid and protein to leak out of the intravascular space into the interstitium, causing third spacing. This leakage further decreases the circulating blood volume and decreases diffusion of oxygen into the tissues.[40] In the lungs, the interaction between humoral and cellular mediators, inflammatory cytokines, and chemokines leads to the development of ARDS due to increased alveolar–capillary membrane permeability. The alveolar–capillary permeability leads to the inactivation of the type II pneumocytes causing decreases in pulmonary surfactant production. Plasma proteins in the alveolar fluid inactivate the surfactant previously

produced, causing atelectasis and increased surface tension.[36] ARDS develops in about 50% of patients with septic shock.[37]

Depression of myocardial function, manifested as increased end-diastolic and systolic ventricular volumes with a decreased ejection fraction, develops within 24 hours in most patients with sepsis.[37] Overt myocardial depression in septic shock occurs in a few patients and is characterized by reversible biventricular dilatation, decreased ejection fraction, altered myocardial compliance, and decreased contractile response to fluid resuscitation and catecholamines.[40] The myocardial depression is not caused by altered coronary perfusion or global ischemia, but by myocardial depressant molecular factors.[42] These myocardial depressant factors include endothelin-1, TNF-α, IL-1, and IL-6. Other factors that play a role in myocardial depression include calcium channels (reduce contractility and shorten repolarization time), NO (causes oxidative stress), reactive oxygen species (causes necrosis), and Toll-like receptors (mediators in the pathway of septic myocardial dysfunction).[42]

In the circulatory system, septic shock results in pathologic vasodilation, shunting blood from the vital organ to nonvital areas (e.g., skin or fat). Consequently, the vital organs are hypoperfused, causing global tissue hypoxia. Vasodilation drops blood pressure. The body's compensatory mechanism is to increase the heart rate. This increase may cause problems in people who have underlying CAD.[36]

Risk Factors

Risk factors for septic shock are related both to a patient's predisposition to infection and to the likelihood of acute organ dysfunction if infection develops. There are many well-known risk factors for the infections that most commonly precipitate septic shock.[39] These factors appear in **Table 18-13**.

TABLE 18-13
Risk Factors for Septic Shock

Category	Risk Factors
Demographics	• Extremes of age (<10 years and >70 years) • Males > females • Blacks > whites
Comorbidities	• Alcoholism • IV drug abuse • Diabetes mellitus • Cardiopulmonary diseases • Cancer
Immunosuppression	• Immunosuppressive agents • Neutropenia
Invasive procedures	• Catheter placement • Intravascular devices • Indwelling prosthetic devices
Medications	• Previous antibiotic treatment
Other factors	• Prolonged hospitalization • Underlying genetic susceptibility • Childbirth • Abortion • Malnutrition

Complications

The complications from septic shock appear in **Box 18-5**.

BOX 18-5 Complications from Septic Shock

- ARDS
- Acute kidney injury
- Chronic renal dysfunction
- Disseminated intravascular coagulation (occurs in 40% of patients with septic shock)
- Gangrene
- Liver failure
- Mesenteric ischemia
- Myocardial ischemia and dysfunction

Diagnostic Testing

For patients in septic shock, early recognition and management are the two most important factors. Patients with septic shock require close monitoring of their cardiac function, blood pressure, and oxygen saturation. Stabilization of the patient is a priority; diagnosis is secondary. qSOFA can be rapidly scored at the bedside without the need for blood tests and should identify an infection that poses a greater threat to life. If appropriate laboratory tests have not been done, this may prompt testing to identify biochemical organ dysfunction.[35] A positive qSOFA criteria, see Box 13-4, should prompt further investigation.

Further investigation to identify septic shock includes the full **Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) Score**. The diagnostic tests necessary to complete the SOFA score include an arterial blood gas, platelet count, bilirubin, arterial blood pressure, Glasgow Coma Score, creatinine, and urinary output. See **Table 18-14**. The SOFA score is not intended for use as a tool for patient management but for clinical characterization of a septic patient.[35]

The baseline SOFA score is assumed to be zero unless the patient is known to have preexisting (acute or chronic) organ dysfunction before the onset of infection. Patients with a SOFA score of 2 or more have a

TABLE 18-14
The Sequential (Sepsis-Related) Organ Failure Assessment Score

System	Score				
	0	1	2	3	4
Respiration Pao_2/Fio_2	≥400	<400	<300	<200 with respiratory support	<100 with respiratory support
Coagulation platelets, $\times 10^3/\mu L$	≥150	<150	<100	<50	<20
Liver bilirubin, mg/dL	<1.2	1.2–1.9	2.0–5.9	6.0–11.9	>12.0
Cardiovascular	MAP ≥70 mm Hg	MAP <70 mm Hg	Dopamine <5 or dobutamine (any dose)	Dopamine 5.1–15 or epinephrine ≤0.1 or norepinephrine ≤0.1	Dopamine >15 or epinephrine >0.1 or norepinephrine >0.1*
Central nervous system Glasgow Coma Score†	15	13–14	10–12	6–9	<6
Renal creatinine, mg/dL	<1.2	1.2–1.9	2.0–3.4	3.5–4.9	>5.0
Urinary output, mL/day				<500	<200

*Catecholamine doses are given as µg/kg/minute for at least 1 hour.
†Glasgow Coma Scores range from 3 to 15; a higher score indicates better neurologic function.

Reproduced with permission from Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801. doi:10.1001/jama.2016.0287.

2- to 25-fold increased risk of dying compared with patients with a SOFA score <2.[35] See **Figure 18-11**.

A complete blood count with differential identifies white blood cell count and neutrophil band count, important to the identification of a bacterial infection. It also assesses hemoglobin concentration. It is important to maintain the hemoglobin concentration above 7 g/dL to assure organ and tissue perfusion and oxygenation. A urine culture can identify a urinary tract infection, which is a common cause of septic shock. A blood culture can help to diagnose intravascular infections, such as endocarditis, and infections of indwelling intravascular devices.[36] Cultures of other sites, such as urine, cerebrospinal fluid, wounds, respiratory secretions, and other body fluids, need assessment before antimicrobial therapy begins. A Gram stain can be useful, for respiratory tract specimens, to determine if inflammatory cells are present and if culture results will be informative of lower respiratory pathogens.[43]

A chest x-ray can detect pneumonia and ARDS. If the suspect infection is in the abdomen, a supine, and upright or lateral decubitus (lying down), an abdominal x-ray is appropriate. If the physical exam reveals the possibility of a bowel obstruction or perforation, abdominal plain films are needed. Abdominal ultrasonography is helpful to identify cholecystitis.[36]

Using echocardiography provides a comprehensive cardiac assessment and should be considered for patients with hemodynamic instability. An echocardiogram can also evaluate sepsis-induced myocardial dysfunction, right heart failure, dynamic left ventricular obstruction, and cardiac tamponade. A CT scan assists with diagnosing an intra-abdominal abscess or a retroperitoneal source of infection.[36]

Treatment and Management

Establishing vascular access and initiating aggressive fluid resuscitation are the first priorities when managing patients with septic shock. Prompt infusion of antimicrobial agents should also be a priority and may require additional vascular access. In the presence of septic shock, each hour delay in achieving the administration of effective antibiotics causes a measurable increase in mortality. The initial empiric anti-infective therapy needs to include one or more drug that has activity against all likely pathogens and that penetrates in adequate concentrations into the tissues presumed to be the source of sepsis.[43] The overall goals of treatment for septic shock are provided in **Box 18-6**.

Crystalloid infusion is the fluid of choice for the resuscitation of patients with septic shock. When patients require substantial amounts of crystalloids for fluid resuscitation, albumin is an additional option.[43]

The target for vasopressor therapy initially is a mean arterial pressure of 65 mm Hg. The vasopressor drug



FIGURE 18-11 Identifying patients with sepsis and septic shock. The baseline SOFA score should be assumed to be 0 unless the patient is known to have preexisting (acute or chronic) organ dysfunction before the onset of infection.

Reproduced with permission from Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801. doi:10.1001/jama.2016.0287.

BOX 18-6 The Goals and Principles of Septic Shock Treatment

- Early infection source recognition and control
- Early hemodynamic resuscitation and continued support to correct hypotension, hypoperfusion, and hypoxia
- Early intervention with antimicrobial therapy (appropriate spectrum and dosage), or surgery, or both
- Maintenance of adequate organ system function to prevent progression to MODS
- Appropriate ventilator management using lung protective strategies

of choice is norepinephrine. Epinephrine can be added to and potentially substituted for norepinephrine when an additional agent is needed to maintain adequate blood pressure. Vasopressin can be added to norepinephrine to raise the MAP or lower the norepinephrine dose. Dopamine is an alternative vasopressor agent to norepinephrine only in patients with low risk of tachyarrhythmias and absolute or relative bradycardia. A trial of dobutamine infusion may be added to vasopressor in the presence of myocardial dysfunction or with ongoing signs of hypoperfusion, despite achieving adequate intravascular volume and adequate MAP.

Supplemental oxygen and mechanical ventilatory support may be necessary to support respiratory function because respiratory distress is common with septic shock. Lung protective strategies are necessary to prevent barotrauma or volutrauma. Urine output measurements will help to quantify the cardiac output and kidney perfusion. Other treatments that may be needed include removal or drainage of the infected foci, treatment for complications, and interventions to prevent and treat effects of harmful host responses. Source control is an essential component of sepsis management.[36]

Prognosis

Approximately 40–60% of patients with septic shock die within 30 days. Others die within the ensuing 6 months. Late deaths often result from poorly controlled infection, immunosuppression, complications of intensive care, failure of multiple organs, or the patient's underlying disease. See **Box 18-7**. The most commonly

BOX 18-7 Factors Affecting the Prognosis of Septic Shock

- Advanced age
- Infection with a resistant organism
- Impaired host immune status
- Poor prior functional status
- Continued need for vasopressors in the past 24 hours
- Development of sequential organ failure, despite adequate supportive measures and antimicrobial therapy

identified etiologic agents in patients who die are *Staphylococcus aureus*, *Streptococcus pyrogens*, *Streptococcus pneumoniae*, and *Neisseria meningitides*. Individuals with preexisting comorbidities are at greater risk of dying of septic shock at any age. The etiologic agents in these cases are likely to be *S. aureus, Pseudomonas aeruginosa*, various Enterobacteriaceae, enterococci, or fungi.[37]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Approximately 25% of patients with septic shock die within 30 days.
2. True or False: Septic shock can cause dysfunctional utilization of oxygen and nutrients at the cellular level.
3. True or False: Vasodilation occurs due to the release of endothelial-derived NO.

Neurogenic Shock

Injury to the spinal cord can result in a loss of sympathetic tone due to the disruption of the autonomic nervous system. The disruption reduces vascular resistance, dropping systemic blood pressure and reducing oxygen delivery to body tissues and organs.

Definition/Diagnosis

Neurogenic shock, the least common type of shock, occurs with a cervical or high thoracic SCI due to a loss or impairment of vascular tone. The disruption of the autonomic pathways within the spinal cord causes hypotension and bradycardia.[44] Disruption of the descending sympathetic pathways results in unopposed vagal tone in the vascular smooth muscle, causing decreased systemic vascular resistance and vasodilation. The hypotension that results from neurogenic shock places patients at an increased risk for secondary spinal cord ischemia due to impairment of autoregulation.[45] The precise circulatory mechanisms involved have not been well characterized, and clinically neurogenic shock is simply defined as hypotension and bradycardia with the exclusion of other causes of shock.[46]

Clinical Signs and Symptoms

Patients with neurogenic shock typically exhibit hypotension and relative bradycardia. Tracheobronchial suctioning, defecation, turning, and hypoxia exacerbate the bradycardia. The patient's skin is often warm and flushed initially in contrast to the usual sympathetic vasoconstriction-induced coolness found with hypovolemic or CS. Hypothermia may develop later because of profound vasodilation and heat loss. A decrease in systemic vascular resistance causes a low central venous pressure.[45]

Etiology

Neurogenic shock is typically considered a clinical diagnosis of exclusion in patients with SCI.[46] It most commonly occurs when the level of the SCI is above the sixth thoracic vertebrae (T6).[45] Neurogenic shock may occur any time after the onset of injury or illness, ranging from the time of presentation to several weeks after presentation.[45] Neurogenic shock differs from spinal shock in that spinal shock is characterized by a marked reduction or complete loss of motor and reflex function below the level of the injury. Blood pressure changes and autonomic nervous system control following a SCI characterize neurogenic shock.

Epidemiology

In the United States, neurogenic shock in children with SCI occurs in 1.99 per 100,000 children. New cases account for approximately 1,500 annual hospital admissions. It is estimated that 40–55% of SCIs in children are from a motor vehicle accident, and more than 65% of these children are not properly restrained. Some of the other causes of SCI are spinal anesthesia, Guillain–Barre syndrome, and autonomic nervous system toxins. Some of the causes of SCI that are unique to children are birth-related injuries, lap-belt injuries, and child abuse.[45]

Approximately 7–10% of all patients with trauma SCIs develop neurogenic shock.[44] The incidence is much higher with cervical injuries (24.4%).[44]

Pathology/Pathophysiology

Stimulation of the sympathetic nervous system (SNS) causes vasoconstriction and increases heart rate. Stimulation of the parasympathetic nervous system (PNS) causes vasodilatation and decreases heart rate. When the SNS is depressed, or the influence is lost, the PNS has unrestricted influence over the smooth muscles of

the blood vessels and the heart rate and its contractility. SNS depression causes massive systemic vasodilatation, down to the arterioles, resulting in hypotension and bradycardia. The higher the SCI, the greater the hypotension and bradycardia.[47]

There is no definitive diagnostic test for neurogenic shock. Disruption of the descendent pathways results in sympathetic hypoactivity and unopposed parasympathetic outflow through the intact vagal nerve. Sympathetic hypoactivity results in low resting blood pressure, loss of regular adaptability of blood pressure, and disturbed reflex control. Clinicians must identify the SCI patients with hypotension and bradycardia. In the early stages of neurogenic shock, the skin is often warm and flushed. Initially, hyperthermia may develop because of the vasodilation. As the blood pressure drops, hypothermia occurs along with an altered mental status due to poor perfusion of the tissues and organs. A high SCI usually results in apnea.[45,47]

Spinal shock is not neurogenic. Neurogenic shock describes the hemodynamic changes following SCI, whereas spinal shock is characterized by a reversible reduction of sensory, motor, or reflex function of the spinal cord below the level of injury.[45] These characteristics include sensory deficits, flaccid paralysis, the absence of deep tendon reflexes, abolishment of reflex somatic activity, and thermoregulatory disturbances below the level of injury. Spinal shock involves different aspects depending on the site of the cord injury.[48]

Risk Factors

There are no specific risk factors for neurogenic shock itself. However, there are several risk factors for SCI. See **Box 18-8**.

Complications

Complications of neurogenic shock include organ dysfunction due to profound vasodilation, secondary ischemia to the spinal cord, pulmonary embolism, and death. The types of complications from the SCI itself depend on the level of the injury.

Diagnostic Testing

There are no definitive diagnostic tests for neurogenic shock. Diagnosis is made by clinical manifestations with a history of a SCI above the level of the sixth thoracic vertebra. Hemorrhagic shock must be ruled out first. At that time, the presence of hypotension; relative bradycardia; initial warm, flushed skin; and then heat loss and vasodilation increase cardiac output. There may be an increase in serum vasopressin and random cortisol levels.[49]

Treatment and Management

The hypotension from neurogenic shock is not due to hypovolemia, but to the massive systemic vasodilatation, which increases venous capacity. The treatment for neurogenic shock implies the correction of the arterial hypotension and bradycardia. This treatment is individualized for each patient, depending on the severity of the blood pressure and heart rate dysfunctions.

Upon arrival in the ED, it is unclear whether the traumatic SCI patient has hypotension due to hypovolemic hemorrhagic shock or neurogenic shock. Therefore, infusion of crystalloid fluids is initiated to restore intravascular volume. Once hemorrhage is ruled out, norepinephrine or a pure alpha-adrenergic agent may be necessary to augment vascular resistance and maintain an adequate mean arterial pressure.[16]

The cervical spine needs to be stabilized to prevent additional damage. The patient may require intubation to assist with ventilation and oxygenation; however, caution must be to prevent further spinal cord damage when intubating a patient with a cervical spine injury.

Prognosis

The prognosis of neurogenic shock depends on the location of the SCI. The closer the SCI is to the cervical portion of the spine, the more likely a patient is to develop neurogenic shock. Many patients with thoracolumbar SCI do not commonly develop neurogenic shock. Neurogenic shock may delay the treatment of a patient, and could result in an unfavorable outcome. Some symptoms may persist, up to 1–6 weeks, even after the resolution of neurogenic shock. These symptoms include low resting blood pressure, orthostatic hypotension, episodic hypertension, flushing, diaphoresis, and tachycardia.[45]

BOX 18-8 Risk Factors for SCI

- Male
- Ages 16 through 30 years
- Older than 65 years
- Engaging in risky behavior
- Bone or joint disorder

KNOWLEDGE CHECK QUESTIONS

1. True or False: Neurogenic shock and spinal shock refer to the same syndrome.
2. True or False: Patients with neurogenic shock initially have warm and flushed skin.
3. True or False: Neurogenic shock occurs more commonly with lower spinal cord injuries.

Chapter Summary

Shock is a syndrome that can be life threatening if not diagnosed and treated quickly. The etiology of shock determines its classification. Shock may be due to cardiac failure causing CS, low or depleted intravascular volume causing hypovolemic shock, sepsis causing septic shock, severe IgE-mediated allergic reaction causing anaphylactic shock, and the interruption of autonomic pathways causing neurogenic shock. Regardless of the type of shock, the effects on the body are the same: the organs and tissue hypoperfusion and hypoxia, which result in death of the organ and tissue.

The persistence of inadequate oxygen delivery due to hypoperfusion leads to irreversible cell injury. Only rapid restoration of oxygen delivery can reverse the progression of the shock state. Therefore, the basic approach to shock management is to recognize overt and impending shock in a timely fashion and to intervene emergently to restore perfusion. Most often this requires expansion or reexpansion of intravascular blood volume. Control of any inciting pathologic process (e.g., impaired cardiac function, infection, continued hemorrhage) must occur simultaneously.[16]

Key Points

1. Shock is a life-threatening syndrome.
2. Rapid diagnosis and treatment of shock are imperative.
3. Shock can be a result of cardiac failure, fluid depletion, or massive vasodilatation (distributive shock).
4. Hypotension is a result in all types of shock.
5. The hypotension from shock causes hypoperfusion of organs and tissue and can lead to organ failure.
6. The priority in shock treatment is to stabilize the patient, then to identify the cause of the shock.
7. Aggressive fluid resuscitation is used initially to increase systemic pressure during shock.
8. Fluids are not effective with neurogenic shock; alpha-adrenergic agents are used to increase vascular resistance.
9. Risk factors for shock include ischemic heart disease, allergens, bacteria, viruses, external or internal injuries, or trauma.
10. Complications are varied and include organ dysfunction and death.

Chapter Questions

1. _____ shock is classified as distributive.
   a. Cardiogenic
   b. Septic
   c. Hypovolemic
   d. Respiratory
2. Cardiogenic shock (CS) is most commonly the result of a(an) _____.
   a. non-ST-segment elevation myocardial infarction (STEMI)
   b. STEMI
   c. atrial arrhythmia
   d. aortic dissection
3. In CS, which of the following is the result of left ventricular systolic dysfunction?
   a. Increased stroke volume
   b. Increased organ perfusion
   c. Decreased stroke volume
   d. Lower left ventricular end-diastolic volume
4. When the heart muscle is not perfused properly, _____ accumulates in the tissues.
   a. water
   b. carbon dioxide
   c. oxygen
   d. lactic acid
5. Which diagnostic test is used to diagnose CS?
   a. Echocardiography
   b. Lumbar puncture
   c. Computed tomographic scan of the chest
   d. Serum tryptase
6. A left ventricular assist device will help the heart by _____.
   a. decreasing the afterload
   b. increasing the preload
   c. decreasing the preload
   d. increasing the cardiac output
7. _____ is the cause of hemorrhagic shock.
   a. Fluid loss
   b. Blood loss
   c. Systemic vasodilatation
   d. Hypervolemia
8. What does the renal system do initially to compensate for hypovolemia?
   a. Decrease water and sodium retention
   b. Increase angiotensin I secretion
   c. Increase renin secretion
   d. Decrease angiotensin I secretion
9. Which of the symptoms is indicative of severe hypovolemia?
   a. Diaphoresis
   b. Mild tachycardia
   c. More than 40% blood loss
   d. Anxiety
10. Due to the body's compensatory mechanisms, _____ blood loss must occur before the systolic blood pressure drops.
    a. 30%
    b. 10%
    c. 50%
    d. 25%

11. Which classification of hemorrhagic hypovolemic shock is associated with 30–40% blood loss?
- **a.** Class I
- **b.** Class II
- **c.** Class III
- **d.** Class IV

12. If there are no visible signs of trauma, which test is appropriate to identify the cause of hypovolemic shock?
- **a.** Echocardiogram
- **b.** Ultrasound
- **c.** Angiogram
- **d.** Lumbar puncture

13. Which of the following is the most likely cause of nonimmune anaphylactic (anaphylactoid) shock?
- **a.** Shellfish
- **b.** Eggs
- **c.** Peanuts
- **d.** Latex

14. Anaphylactic reactions result from the mast cells releasing which of the following substances?
- **a.** Histamine
- **b.** Troponin
- **c.** Renin
- **d.** Potassium

15. What percentage of patients with anaphylactic shock experience a delayed second-phase reaction (biphasic reaction)?
- **a.** 5%
- **b.** 10%
- **c.** 15%
- **d.** 20%

16. Septic shock is a result of which of the following?
- **a.** Spinal cord injury
- **b.** Bacteria
- **c.** Dehydration
- **d.** Myocardial infarction

17. The hypotension in septic shock is caused by _____.
- **a.** fluid loss
- **b.** reduced renin secretion
- **c.** nitric oxide
- **d.** histamine

18. Mottled skin, found with septic shock, is a result of _____.
- **a.** a response to stress
- **b.** poor tissue perfusion
- **c.** hyperthermia
- **d.** altered amino acid metabolism

19. The factor that increases the chance of a poor prognosis in septic shock is _____.
- **a.** young age
- **b.** strong immune system
- **c.** organ failure
- **d.** persistent hypertension

20. Sympathetic hypoactivity and unopposed parasympathetic outflow is the pathogenesis of _____ shock.
- **a.** neurogenic
- **b.** anaphylactic
- **c.** septic
- **d.** cardiogenic

21. The hypotension associated with neurogenic shock is caused by _____.
- **a.** nitric oxide release
- **b.** systemic vasodilatation
- **c.** hypovolemia
- **d.** heart failure

22. Aggressive fluid resuscitation is not effective for _____ shock.
- **a.** anaphylactic
- **b.** nontraumatic hemorrhagic
- **c.** neurogenic
- **d.** septic

References

1. de Moya MA. Shock. *Merck Manuals Professional Edition*. 2016. http://www.merckmanuals.com/professional/critical-care-medicine/shock-and-fluid-resuscitation/shock. Accessed October 18, 2015.
2. Gaieski DF, Mikkelsen ME. Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock. In: Parsons PE, Hockberger MD, eds. *UpToDate*, Waltham, MA: UpToDate.
3. Finfer S, Vincent J, Vincent J, De Backer D. Circulatory shock. *N Engl J Med*. 2013;369(18):1726–1734. doi:10.1056/nejmra1208943.
4. Gaieski DF, Mikkelsen ME. Definition, classification, etiology, and pathophysiology of shock in adults. In: Parsons PE, ed. *UpToDate*. Waltham, MA: UpToDate.
5. Reynolds H, Hochman J. Cardiogenic shock: current concepts and improving outcomes. *Circulation*. 2008;117(5):686–697. doi:10.1161/circulationaha.106.613596.
6. Cardiogenic Shock Clinical Presentation: History, Physical Examination. 2016. http://emedicine.medscape.com/article/152191-clinical?src=refgatesrc1. Accessed November 18, 2016.
7. Kolte D, Khera S, Aronow W, et al. Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States. *J Am Heart Assoc*. 2014;3(1):e000590. doi:10.1161/jaha.113.000590.
8. Goldberg R, Spencer F, Gore J, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. *Circulation*. 2009;119(9):1211–1219. doi:10.1161/circulationaha.108.814947.
9. Hochman J, Ingbar D. Cardiogenic shock and pulmonary edema. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Medical; 2013:295–302.
10. Babaev A, Frederick P, Pasta D, et al. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. *JAMA*. 2005;294(4):448. doi:10.1001/jama.294.4.448.
11. Califf R, Bengtson J. Cardiogenic shock. *N Engl J Med*. 1994;330(24):1724–1730.
12. Hasdai D, Topol E, Califf R, Berger P, Holmes D. Cardiogenic shock complicating acute coronary syndromes. *Lancet*. 2000;356(9231):749–756. doi:10.1016/S0140-6736(00)02640-4.

13. Thiele H, Smalling R, Schuler G. Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock. *Eur Heart J*. 2007;28(17):2057–2063. doi:10.1093/eurheartj/ehm191.
14. Kobayashi L, Costantini T, Coimbra R. Hypovolemic shock resuscitation. *Surg Clin North Am*. 2012;92(6):1403–1423. doi:10.1016/j.suc.2012.08.006.
15. Kelley D. Hypovolemic shock. *Crit Care Nurs Q*. 2005;28(1):2–19. doi:10.1097/00002727-200501000-00002.
16. Maier R. Approach to the patient with shock. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Education; 2013:263–273.
17. Hypovolemic Shock Symptoms | Symptoma¯. *Symptoma.com*. 2016. https://www.symptoma.com/en/info/hypovolemic-shock. Accessed November 25, 2016.
18. Kolecki P. Hypovolemic shock. 2016. http://emedicine.medscape.com/article/760145-overview. Accessed November 25, 2016.
19. Gutierrez G, Reines H, Wulf-Gutierrez M. Clinical review: hemorrhagic shock. *Crit Care*. 2004;8(5):373–381. doi:10.1186/cc2851.
20. Gulati A. Vascular endothelium and hypovolemic shock. *Curr Vasc Pharmacol*. 2016;14(2):187–195. doi:10.2174/1570161114666151202210221.
21. Shub T, March P. Shock, hypovolemic. *CINAHL nursing guide*. 2016. http://www.cinahl.com. Accessed November 26, 2016.
22. Stoloff S. Optimizing the clinical identification and management of patients at risk for anaphylaxis. *J Fam Pract*. 2010;59(8):S1–S8.
23. Kounis N, Soufras G, Hahalis G. Anaphylactic shock: Kounis hypersensitivity-associated syndrome seems to be the primary cause. *N Am J Med Sci*. 2013;5(11):631–636. doi:10.4103/1947-2714.122304.
24. Johnson R, Peebles R. Anaphylactic shock: pathophysiology, recognition, and treatment. *Semin Respir Crit Care Med*. 2004;25(6):695–703. doi:10.1055/s-2004-860983.
25. Arnold J, Williams P. Anaphylaxis: recognition and management. *Am Fam Physician*. 2011;84(10):1111–1118.
26. Ben-Shoshan M, Clarke A. Anaphylaxis: past, present and future. *Allergy*. 2010;66(1):1–14. doi:10.1111/j.1398-9995.2010.02422.x.
27. Krause R. Hypersensitivity. In: Aghababian R, ed. *Essentials of Emergency Medicine*. 2nd ed. Sudbury, MA: Jones & Bartlett Learning; 2011:303–308.
28. Wood R, Camargo C, Lieberman P, et al. Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. *J Allergy Clin Immunol*. 2014;133(2):461–467. doi:10.1016/j.jaci.2013.08.016.
29. Ma L, Danoff T, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. *J Allergy Clin Immunol*. 2014;133(4):1075–1083. doi:10.1016/j.jaci.2013.10.029.
30. Mustafa S. Anaphylaxis: practice essentials, background, pathophysiology. 2016. http://emedicine.medscape.com/article/135065-overview#a5. Accessed December 7, 2016.
31. Tang M, Osborne N, Allen K. Epidemiology of anaphylaxis. *Curr Opin Allergy Clin Immunol*. 2009;9(4):351–356. doi:10.1097/aci.0b013e32832db95a.
32. Bethel J. Anaphylaxis: diagnosis and treatment. *Nurs Stand*. 2013;27(41):49–56.
33. Stone S, Cotterell C, Isbister G, Holdgate A, Brown S. Elevated serum cytokines during human anaphylaxis: identification of potential mediators of acute allergic reactions. *J Allergy Clin Immunol*. 2009;124(4):786–792.e4. doi:10.1016/j.jaci.2009.07.055.
34. Kemp S, Lockey R, Simons F. Epinephrine: the drug of choice for anaphylaxis—a statement of the World Allergy Organization. *World Allergy Organ J*. 2008;1(S2):S18–S26. doi:10.1186/1939-4551-1-s2-s18.
35. Singer M, Deutschman C, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801–810. doi:10.1001/jama.2016.0287.
36. Kalil A. Septic shock: practice essentials, background, pathophysiology. 2016. http://emedicine.medscape.com/article/168402-overview. Accessed December 8, 2016.
37. Munford R. Severe sepsis and septic shock. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Education; 2013:276–287.
38. Martin G, Mannino D, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med*. 2003;348(16):1546–1554. doi:10.1056/nejmoa022139.
39. Angus Dvan der Poll T. Severe sepsis and septic shock. *N Engl J Med*. 2013;369(9):840–851. doi:10.1056/nejmra1208623.
40. Bridges E, Dukes S. Cardiovascular aspects of septic shock—pathophysiology, monitoring, and treatment. *Crit Care Nurse*. 2005;25(2):14–42.
41. Cauwels A. Nitric oxide in shock. *Kidney Int*. 2007;72(5):557–565. doi:10.1038/sj.ki.5002340.
42. Antonucci E, Fiaccadori E, Donadello K, Taccone F, Franchi F, Scolletta S. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. *J Crit Care*. 2014;29(4):500–511. doi:10.1016/j.jcrc.2014.03.028.
43. Dellinger R, Levy M, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. *Intensive Care Med*. 2013;39(2):165–228. doi:10.1007/s00134-012-2769-8.
44. Mallek J, Inaba K, Branco B, et al. The incidence of neurogenic shock after spinal cord injury in patients admitted to a high-volume level I trauma center. *Am Surg*. 2012;78(5):623–626.
45. Mack E. Neurogenic shock. *Open Pediatr Med J*. 2013;7(1):16–18. doi:10.2174/1874309901307010016.
46. Summers R, Baker S, Sterling S, Porter J, Jones A. Characterization of the spectrum of hemodynamic profiles in trauma patients with acute neurogenic shock. *J Crit Care*. 2013;28(4):531.e1–531.e5. doi:10.1016/j.jcrc.2013.02.002.
47. Darovic G. *Handbook of Hemodynamic Monitoring*. 1st ed. St. Louis, MO: Saunders; 2004.
48. Popa C, Popa F, Grigorean V, et al. Vascular dysfunctions following spinal cord injury. *J Med Life*. 2010;3(3):275–285.
49. Muehlschlegel S, Greer D. Neurogenic shock. In: Gabrielli A, Layon A, Mihae Y, eds. *Civetta, Taylor, & Kirby's Critical Care*. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2009:925–940.

CHAPTER

19

Acute Respiratory Distress Syndrome

OUTLINE

OBJECTIVES

1. Describe the current definitions of acute respiratory distress syndrome (ARDS).
2. Identify the causes of ARDS.
3. Identify the clinical manifestations and anatomical changes in patients with ARDS.
4. Use diagnostic testing, chest radiographs, and arterial blood gas values to treat patients with ARDS.
5. Discuss the management of patients with ARDS, including lung protective strategy, and alternative therapies.

KEY TERMS

Acute respiratory distress syndrome (ARDS)
Air bronchograms
ARDSNet Protocol
Atelectasis
Canals of Lambert
Cardiogenic pulmonary edema
Channels of Martin
Cisatracurium
Continuous mandatory ventilation (CMV)
Disseminated intravascular coagulation (DIC)
Homogeneous
Hyaline membrane
Hypercarbia
Hypoxemia
Infiltrates
Inhaled prostaglandins
Low tidal volume ventilation
Mean airway pressure (mPaw)
Mechanical ventilation
Neuromuscular blockade (NMB)
Nitric oxide (NO)
Open-lung approach
P/F ratio
Peak expiratory flow rate (PEFR)
Plateau pressure
Pores of Kohn
Positive end-expiratory pressure (PEEP)
Proinflammatory cytokines
Prone positioning
Pulmonary artery wedge pressure (PAWP)
Pulmonary compliance
Pulmonary contusions
Pulmonary hypertension
Pulmonary vasoconstriction
Respiratory failure
Sepsis
Shunting
Squamous metaplasia
Supine position
Surfactant
Transpulmonary pressure
Ventilation/perfusion (V/Q) mismatch

Introduction

Acute respiratory distress syndrome (ARDS) is a severe disease of the pulmonary system, which causes diffuse alveolar damage and lung injury. ARDS affects approximately 150,000 patients in the United States alone, and even with advances in medical treatment, ARDS has a mortality rate of approximately 30–40%.

Definition/Diagnosis

Having a reliable definition for a disease process is essential in developing treatment strategies based on researched clinical evidence, in the form of clinical trials. Evidence collected helps determine how often the disease occurs, pathophysiology, diagnosis, treatment, and prognosis. As diseases such as ARDS become better understood, the definitions may be modified to better represent the disease. The following paragraphs describe the historical and current definitions of ARDS.

AECC Definition of ARDS

In 1967, Ashbaugh and colleagues formally recognized ARDS. Until 1994, no single definition of ARDS existed. In 1994, the American-European Consensus Conference (AECC) published a clear clinical definition of ARDS. The AECC definition of ARDS was widely used in the clinical setting until 2011 (**Table 19-1**).

Using the same criteria, the AECC also separated acute lung injury (ALI) from ARDS. According to the AECC, the degree of **hypoxemia** associated with ALI (Pa_{O_2}/F_{IO_2} ratio ≤300 mm Hg) was the only difference between ALI and ARDS. Only one criterion, the **P/F ratio** is what historically separated ALI from ARDS.

The Berlin Definition of ARDS

In 2011, an expert panel of clinicians from the European Society of Critical Care Medicine met in Berlin to revise and improve the ARDS definition. The result was the "Berlin definition" of ARDS published in 2012 (**Table 19-2**).

There are several differences between the AECC definition of ARDS and the Berlin definition of ARDS. The Berlin definition has a defined time for the onset of ARDS and acknowledges that positive end-expiratory pressure (PEEP) affects the Pa_{O_2}/F_{IO_2} ratio. The Berlin definition no longer takes the **pulmonary artery wedge pressure (PAWP)** into consideration, as patients with ARDS may also have an increase in PAWP due to fluid resuscitation and underlying causes, such as cardiogenic pulmonary edema. The term "acute lung injury (ALI)" is also no longer part of the Berlin definition of ARDS. ALI is viewed as a category rather than a degree of ARDS. **Table 19-3** describes the difference between the AECC definition and the Berlin definition.

Risk Factors for ARDS

Many risk factors predispose patients to develop ARDS in the clinical setting. The common clinical disorders responsible for the development of ARDS are placed into two categories, direct causes of ARDS and indirect causes of ARDS (**Table 19-4**). It is important that **cardiogenic pulmonary edema** is excluded as a causative factor, as cardiogenic pulmonary edema has a similar presentation as ARDS. The Berlin definition suggests that ruling out left heart failure using echocardiography be the gold standard. If the patient's presentation cannot be tied to either fluid overload or cardiogenic pulmonary edema, the patient probably has ARDS. The primary cause of ARDS in adults is related to **sepsis** (up to 46%). However, it is estimated that 18–33% of patients with sepsis will develop ARDS. Studies have shown that patients with trauma-associated ARDS have a decreased mortality rate and a milder illness than non-trauma-related ARDS. ARDS occurred in 35% of patients with severe trauma requiring multiple transfusions, 22% of patients with **pulmonary contusions**, and 11% of patients with long bone fracture. Aspiration of gastric contents was associated with an incidence of ARDS as high as 36%.

Increasing age appears to be associated with increased risk for developing ARDS in patients with

TABLE 19-1
The AECC Criteria for ARDS[1–4]

Acute onset of symptoms
Bilateral infiltrates on chest x-ray (CXR) that may have a ground glass appearance
PAWP ≤18 mm Hg (absence of left atrial hypertension)
Hypoxemia associated with a partial pressure of arterial oxygen to fraction of inspired oxygen (Pa_{O_2}/F_{IO_2} ratio of ≤200 mm Hg)

TABLE 19-2
The Berlin Definition of ARDS[1–4]

Onset of ARDS within 1 week of a known clinical insult, new, or worsening respiratory symptoms
Bilateral lung opacities, not caused by **atelectasis**, pleural effusions, or pulmonary nodules
Respiratory failure not explained by fluid overload or cardiac failure
Mild ARDS: Pa_{O_2}/F_{IO_2} ratio ≤300 mm Hg
Moderate ARDS: Pa_{O_2}/F_{IO_2} ratio ≤200 mm Hg
Severe ARDS: Pa_{O_2}/F_{IO_2} ratio ≤100 mm Hg with PEEP ≥5 mm Hg

TABLE 19-3
The AECC Definition and the Berlin Definition of ARDS (a Comparison)[1–4]

	The AECC Definition	The Berlin Definition		
Timing	Acute onset of symptoms	Within 1 week of a known clinical insult, new, or worsening respiratory symptoms		
CXR	Bilateral infiltrates	Bilateral lung opacities, not caused by atelectasis, pleural effusion, or pulmonary nodules		
Pao_2/Fio_2 ratio (hypoxemia)	ALI: Pao_2/Fio_2 ratio ≤300 mm Hg ARDS: Pao_2/Fio_2 ratio ≤200 mm Hg	Mild: Pao_2/Fio_2 ratio ≤300 mm Hg with PEEP ≥5 cm H_2O Moderate: Pao_2/Fio_2 ratio ≤200 mm Hg with PEEP ≥5 cm H_2O Severe: Pao_2/Fio_2 ratio ≤100 mm Hg with PEEP ≥5 cm H_2O		
Origin of edema	PAWP ≤18 mm Hg (absence of left atrial hypertension)	Respiratory failure not fully explained by fluid overload or cardiac failure		
Mortality rates	Not evaluated for predictive mortality	Mild 27%	Moderate 32%	Severe 45%

TABLE 19-4
Risk Factors for Developing ARDS[5–7]

Direct Causes of ARDS	Indirect Causes of ARDS
Pneumonia	Nonpulmonary sepsis
Pulmonary contusion	Severe trauma
Aspiration (gastric contents)	Multiple transfusions or transfusion-associated ALI (TRALI)
Fat emboli	Drug overdose
Near drowning	Pancreatitis
Inhalation injury	Cardiopulmonary bypass
Reperfusion pulmonary edema	**Disseminated intravascular coagulation (DIC)**



FIGURE 19-1 ARDS cycle from injury to resolution.

similar risk conditions. Gender does not appear to be a risk in the development of ARDS in patients with similar risk conditions. Patients with chronic alcoholism, however, do have an increased risk for developing ARDS, in the presence of similar risk conditions.

Pathology and Pathophysiology

It has been 50 years since Ashbaugh and colleagues first identified ARDS; since that time, much research has been devoted to understanding the pathology and pathophysiology. No matter the causative factors—indirect or direct—initiating the ARDS process, the anatomical changes remain consistent. Unfortunately, the process is not **homogenous** and affects the lungs differently throughout the stages of progression. See **Figure 19-1**.

Two primary pathophysiologic changes occurring with ARDS are increased capillary permeability and inflammation. Injury to the capillary endothelium and alveolar epithelium triggers an influx of protein-rich fluid into the alveoli, resulting in damage to alveolar Type 2 epithelial cells. Injury to the alveolar Type 2 epithelial cells significantly reduces **surfactant**, which increases alveolar surface tension that leads to alveolar collapse and decreasing pulmonary compliance. As ARDS progresses, the intravascular walls develop a **hyaline membrane** because of the coagulation cascade products, such as fibrin and thrombin. The second finding is the initiation of an inflammatory cascade due to neutrophil activation; some of the notable **proinflammatory cytokines** include tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6. A consequential effect resulting from the mediators is cell damage or death. The above pathophysiologic changes occur within three distinct stages—exudative, proliferative, and fibrotic—and its progression is critical to determining appropriate management (**Table 19-5**).[8]

TABLE 19-5
Three Stages of ARDS with Time of Onset and Particular Pathologic Alterations

Stage	Timeframe	Pathologic Changes
Exudative	Occurs within 24 hours Lasts 1–7 days	• Diffuse alveolar damage • Edema and alveolar hemorrhage • Type 1 pneumocytes destroyed • Surfactant deficiency
Proliferative	7–14 days	• Proliferation of inflammatory cells • **Squamous metaplasia**
Fibrotic	>14 days or sooner	• Collagen formation and hyalinization of alveolar walls

Modified from Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. *Thorax*. 1998;53:815–817. doi:10.1136/thx.53.10.815.

Clinical Manifestations

Certain clinical indicators should alert the clinician that a patient may be developing ARDS. Reviewing the Berlin definition presents three key findings that should always be evaluated: the timing of the injury, P/F ratio, and CXR interpretation. Not only will the previous key findings be discussed more thoroughly below, but changes with intracardiac pressures are another manifestation occurring during the various ARDS stages.

Oxygenation and Ventilation

As ARDS progressively worsens, so will arterial blood gases (ABGs), P/F ratio, and oxygen requirements. Each stage of ARDS will see an increase in oxygen requirements and elevation of carbon dioxide that initially shows impending **respiratory failure**. Hypoxemia and **hypercarbia** can be managed with supplemental oxygen therapy and increased spontaneous respiratory rates (RRs, tachypnea). However, over the course of time, F_{IO_2} requirements will begin to exceed 0.60, necessitating the use of positive pressure as the lungs begin to become overwhelmed by pulmonary capillary leakage and inflammation. Also, the rise in F_{IO_2} needs due to low P_{aO_2} will result in decreasing P/F ratios that assist with staging the severity—mild, moderate, or severe—of ARDS. In addition, pulmonary changes causing hypoxemia, as noted above, will also drastically reduce gas exchange, causing ventilatory failure ($pH \leq 7.25$ and $P_{aCO_2} > 50$ mm Hg) requiring **mechanical ventilation**. It is critical for a clinician to recognize the changes early and intervene with appropriate therapies.

TABLE 19-6
Hemodynamics

ARDS Severity	mPAP	PAWP	RAP	CI
Mild	Normal or ↑	Normal or ↑	Normal or ↑	Normal
Moderate	↑	↑	↑	Normal
Severe	↑↑	↑↑	↑↑	Normal

Modified from Calcaianu G, Calcaianu M, Gschwend A, Canuet M, Meziani F, Kessler R. Hemodynamic profile of pulmonary hypertension in ARDS. *Pulm Circ*. 2018;8(1):1–5. doi:10.1177/2045893217753415.

Hemodynamics

Multiple factors negatively affect hemodynamics with ARDS. A primary complication associated with ARDS is hypoxemia causing **pulmonary vasoconstriction**, resulting in changes to cardiac filling pressures—mean pulmonary artery pressure (mPAP), PAWP, and right atrial pressure (RAP) (Table 19-5). Not only is hypoxemia a direct provocateur for pulmonary vasoconstriction, but hypercapnia (permissive or nonpermissive) also causes vasoconstriction that potentially places more stress on the right ventricle, possibly leading to right ventricular failure. Calcaianu et al.[9] observed higher PAWP among severe ARDS possibly attributed to decreasing **pulmonary compliance** and a degree of diastolic heart failure. In addition, poorer pulmonary compliance across the different ARDS stages and increasing **positive end-expiratory pressure (PEEP)** levels will have unfavorable alterations to hemodynamics. Hemodynamic changes according to hypoxemic and hypercarbic induced **pulmonary hypertension** associated with ARDS severity (**Table 19-6**).

Radiographic Imaging

Radiographic imaging remains pivotal in the management of ARDS. In the early stages of ARDS, a CXR will appear normal without any overt indication of pathologic changes (**Figure 19-2**A). As ARDS progresses, bilateral patchy **infiltrates** will be viewable along with **air bronchograms** progressing outward beyond the cardiac silhouette. Severe ARDS, as shown with graphic D in Figure 19-2, displays bilateral opacities and loss of heart border that could be a combination of atelectasis, low lung volumes, and alveolar–capillary leakage. Various portions of the lung may be minimally affected, so it is important to realize that ARDS is a nonhomogenous process that is not clearly portrayed in Figure 19-2 because x-rays depict only images that are two dimensional.



FIGURE 19-2 ARDS chest radiograph changes over the course of 7 days. **(A)** No pathologic changes. **(B)** Bilateral pulmonary infiltrates in lower lobes. **(C)** Significant bilateral consolidation with notable air bronchograms. **(D)** Severe opacification of right and left lung ("white-out").

Treatment and Management

Although many clinical trials have been performed on patients with ARDS, the treatment for ARDS remains largely supportive. Early identification and reversal of causative factors such as pulmonary infection, intraabdominal sepsis, and extrapulmonary infections may improve survival rates. Clinician focus is on alveolar recruitment, stabilization, and the prevention of further insult to the lungs when mechanical ventilation is required. The following paragraphs discuss current treatment and management strategies, alternative therapies, and adjunct therapies that may be used in managing patients with ARDS.

Mechanical Ventilation/Lung Protective Strategy

Patients with ARDS often require ventilatory support during their disease process and have both healthy functioning alveoli and injured alveoli, which do not function properly. The result is varying degrees of **ventilation/perfusion (V/Q) mismatch** and **shunting**. During positive pressure ventilation, the tidal volume takes the path of least resistance and goes to regions of the lung that are most compliant. Historically, tidal volumes used to ventilate patients were between 10 and 15 mg/kg of ideal body weight (IBW). Research shows that tidal volumes in the range of 10–15 mL/kg of IBW cause high airway pressures and over-distension of healthy alveoli in patients with ARDS. This results in ventilator-induced lung injury (VILI), which exacerbates the ARDS disease process and increases mortality and morbidity in patients with ARDS. It is the high mortality and morbidity rates associated with ARDS that drove the medical community to develop alternative therapies in the management of patients with ARDS.

There have been many clinical studies on mechanical ventilation in patients with ARDS. The ARDS Network, from 1996 to 1999, performed the most promising study. The goal of the ARDS Network study was to decrease the mortality and morbidity associated with ARDS. The ARDS Network study used tidal volumes between 4 and 8 mL/kg of IBW to prevent over-distension while using PEEP to recruit and stabilize damaged alveoli. The ARDS Network was able to show a 22% reduction in mortality

and morbidity using low tidal volumes between 4 and 8 mL/kg of IBW when compared to conventional tidal volumes of 10–15 mL/kg of IBW. Because of their findings, the ARDS Network developed the "**ARDSNet Protocol**," a lung protective strategy to manage ventilated patients with ARDS. Although the clinical definition for ARDS has changed, the ventilator management remains the same. See **Tables 19-7** and **19-8**.

TABLE 19-7
Lung Protective Protocol[10–13]

IBW calculation	Women: [height (inches) − 60] 2.3 + 45.5													
	Men: [height (inches) − 60] 2.3 + 50													
Mode of ventilation	Any ventilator mode, such as volume control, pressure-regulated volume control, pressure control													
Tidal volumes	4–8 mL/kg of IBW													
RR	≤35 breaths/minute													
Inspiratory-to-expiratory ratio	1:1–1:3													
PEEP	Use a minimum PEEP of 5 cm H_2O. Consider use of incremental F_{IO_2}/PEEP combinations such as shown below:													
Lower-PEEP group														
F_{IO_2}	0.3	0.4	0.4	0.5	0.5	0.6	0.7	0.7	0.7	0.8	0.9	0.9	0.9	1.0
PEEP	5	5	8	8	10	10	10	12	14	14	14	16	18	18–24
Higher-PEEP group														
F_{IO_2}	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.5	0.5–0.8	0.8	0.9	1.0	
PEEP	5	8	10	12	14	14	16	16	18	20	22	22	22–24	
Higher-PEEP group (after protocol's change) Data from ARDS Network. *N Engl J Med* 2004;351;327-336.														
F_{IO_2}	0.3	0.3	0.4	0.4	0.5	0.5	0.5–0.8	0.8	0.9	1.0				
PEEP	12	14	14	16	16	18	20	22	22	22–24				
Monitoring Parameters:														
Arterial pH	pH GOAL: 7.30–7.45													
	pH 7.20–7.30: increase RR until pH >7.30 or $Paco_2$ <25 (maximum set RR = 35).													
	pH <7.20: increase RR to 35.													
	If pH remains <7.20, V_T may be increased in 1 mL/kg increments until pH >7.15 (P-plat target of 30 may be exceeded).													
Oxygen saturation	88–95%													
	Pao_2 55–80 mm Hg													
Plateau pressures	≤30 cm H_2O													
	If P-plat >30 cm H_2O, decrease V_T by 1 mL/kg increments (minimum = 4 mL/kg).													
	If P-plat <25 cm H_2O and V_T < 6 mL/kg, increase V_T by 1 mL/kg until P-plat > 25 cm H_2O or V_T = 6 mL/kg.													
	If P-plat <30 cm H_2O and breath stacking or dyssynchrony occurs: may increase V_T in 1 mL/kg increments up to 7 or 8 mL/kg if P-plat remains <30 cm H_2O.													

Data from Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. *N Engl J Med.* 2004:351:327–336.

Airway Pressure Release Ventilation

First described in 1987, airway pressure release ventilation (APRV) uses an **open-lung approach** to ventilation. APRV is a mode of ventilation that may be used by clinicians in patients with ARDS who continue to have refractory hypoxemia on **low tidal volume ventilation** or are intolerant to low tidal volume ventilation.

APRV is a type of time-cycled, pressure-limited, time-triggered, inverse ratio ventilation that uses two levels of continuous positive airway pressure (CPAP), with intermittent releases in airway pressure. Patients may breathe spontaneously throughout the breath cycle. APRV uses long inspiratory times and short expiratory times, with inspiratory-to-expiratory ratios (I:E) typically ≥4:1. Longer inspiratory times recruit collapsed alveoli via the **pores of Kohn**, **channels of Martin**, and the **canals of Lambert**, creating a greater surface area for gas exchange. Expiratory times have a twofold benefit: (1) They allow for CO_2 clearance. (2) Short expiratory times create purposeful air trapping/auto-PEEP, recruiting and stabilizing collapsed alveoli. Alveolar recruitment and stabilization can improve oxygenation in patients with ARDS, by improving V/Q mismatch. Patients may also be ventilated in the absence of spontaneous breathing. Spontaneous breathing is, however, encouraged, as it has many advantages: (1) leads to better gas distribution, resulting in improved V/Q mismatch, and shunting; (2) augments CO_2 removal; (3) maintains and strengthens the diaphragm; (4) reduces the need for sedative drips and neuromuscular blockades (NMBs); (5) lowers the peak airway pressures (P_{aw}) (**Tables 19-8** to **19-10** and **Figures 19-3** and **19-4**).

TABLE 19-8
Other Names Synonymous with APRV

• BiLevel ventilation
• BiVent ventilation
• DuoPAP ventilation
• BiPhasic ventilation

TABLE 19-9
APRV Terminology[14–16]

P_{High}	Pressure high	Upper CPAP level
P_{Low}	Pressure low	Lower CPAP level
T_{High}	Time high	Inspiratory time
T_{Low}	Time low	Expiratory time

TABLE 19-10
APRV Initial Settings[14–16]

P_{High}	P_{High} set at plateau pressure obtained on conventional ventilation.
	P_{High} typically set between 20 and 30 cm H_2O.
	P_{High} target maximum setting 35 cm H_2O. P_{High} settings >35 cm H_2O may cause over-distension of alveoli- and ventilator-induced lung injury.
	P_{High} settings >35 mm Hg may be required in patients with low thoracic and abdominal compliance (morbid obesity, abdominal distension).
P_{Low}	P_{Low} is set at 0 to decrease expiratory resistance.
	P_{Low} set above 0 may impede expiratory gas flow, increasing CO_2 levels, and work of breathing.
T_{High}	T_{High} is targeted at 4–6 seconds, or 8–12 breath cycles/minute (to maximize alveolar recruitment).
	T_{High} may need to be set at 1.0–3.0 seconds, to increase minute ventilation (V_E) and breath cycles/minute. Increasing V_E and breath cycles/minute may help eliminate CO_2 in patients with severe hypercapnia and a pH <7.20.
	T_{High} below 3.0 may affect oxygenation and alveolar recruitment
T_{Low}	T_{Low} is set to clip at 50% of the **peak expiratory flow rate (PEFR)**. See Figure 19-4. Generally remains a fixed number once the desired auto-PEEP is achieved.
	T_{Low} typically set between 0.5 and 0.8 seconds in patients with ARDS.
	T_{Low} settings in patients with the obstructive disease may be between 0.8 and 1.5 seconds to allow for adequate exhalation.
Pressure Support (PS) is available on some ventilators. Care should be taken when using PS in APRV. Adding PS above P_{High} creates variable pressure, which may increase **transpulmonary pressures** to unsafe levels causing lung injury.	



FIGURE 19-3 Spontaneous breath.



FIGURE 19-4 PEFR for setting T_{Low} in APRV.

High-Frequency Oscillatory Ventilation

High-frequency oscillatory ventilation (HFOV) may be an alternative mode of ventilation for patients with ARDS. It was introduced in the 1970s as an alternative to **continuous mandatory ventilation (CMV)**-type modes. Patients with moderate-to-severe ARDS may require high driving pressures in CMV-type ventilator modes in order to maintain adequate oxygenation and ventilation. These high airway pressures may cause over-distension of the lungs, exacerbating lung injury. HFOV like APRV uses an open-lung approach to ventilation. The goal of HFOV is to recruit and stabilize alveoli while preventing over-distension and atelectasis in patients with ARDS.

HFOV uses higher mean airway pressures (mPaws), RRs, and lower tidal volumes than conventional CMV-type modes. In adults, RRs typically range between 180 and 900 breaths/minute. Tidal volumes typically range between 150 and 250 cc, often closer to or lower than anatomical dead space. **Mean airway pressure (mPaw)** and the F_{IO_2} setting in HFOV are the primary determinates of oxygenation. When mPaw is appropriately set, the lungs receive a constant distending pressure. This constant distending pressure allows for recruitment and stabilization of alveoli in patients with ARDS.

HFOV Demystified

Perhaps it is easier for clinicians to understand HFOV if it is described as a concept of waves similar to water. For the purpose of this explanation, the power is a rock, the amplitude is the height of the wave, and the air in the lungs is water. If a small rock is dropped into the water (lower power), the shorter the wave created (amplitude) and the less the water displaced (air in the lungs). The opposite occurs with a larger rock (higher power). The higher the power, the taller the wave and the greater the displacement of gas in the lungs. This is how amplitude affects CO_2 removal. The taller the wave, the more the CO_2 removed. Tidal volumes



FIGURE 19-5 Comparison of high and low amplitude in HFOV. **(A)** High amplitude: diagram shows how taller waves displace more tidal volume, increased CO_2 removal. **(B)** Low amplitude: Diagram shows how shorter waves displace less tidal volume, decreased CO_2 removal compared with higher amplitudes.

achieved are less than or equal to anatomical dead space. It is also worth noting that the taller the wave (amplitude) is, the less lung protective the oscillator becomes. See **Figure 19-5**.

There is also a direct relationship between Hertz and frequency. The Hertz dictates the width of the wave and how many waves per minute are created (breaths/minute). A higher Hertz creates thinner waves, and more of them (frequency). A lower Hertz creates wider waves and less of them (frequency). The oscillator is capable of RRs between 60 and 900 breaths/minute. The lower the Hertz is, the less lung protective the oscillator becomes, but more CO_2 is removed. Therefore, the height and width of the wave dictate CO_2 removal. See **Figure 19-6**.

Oxygenation

In regard to oxygenation, the mPaw and the F_{IO_2} dictate oxygenation. The mPaw is the pressure applied to the lungs (distending pressure), and the F_{IO_2} is the amount of oxygen the patient receives. When mPaw is applied to the lungs, a volume of air is trapped in the lungs and is held in place, increasing the patients' functional residual capacity (FRC). The lower the mPaw, the lower the volume of air trapped, and the higher the mPaw, the higher the volume of air trapped. It is worth noting that mPaw

that is too low can result in alveolar collapse, while mPaw that is too high can result in over-distension of the alveoli, lung injury, and hemodynamic instability. See **Tables 19-11** and **19-12**, **Figure 19-7**.



FIGURE 19-6 Comparison of high and low frequency in HFOV. **(A)** High frequency: diagram shows how an increase in frequency increases waves per second, while the width of the wave is decreased, displacing less tidal volume. The result is a decrease in CO_2 removal compared to low Hertz. **(B)** Low frequency: diagram shows how wider waves displace more tidal volume, resulting in increased CO_2 removal.

Source: https://www.quora.com/What-are-low-pitch-sounds.

Prone Positioning

Prone positioning may be a valuable adjunct in mechanically ventilated patients with ARDS. Patients are normally kept in the **supine position** (face up–chest up) and are intermittently turned from side to side to prevent pressure ulcers. In patients with ARDS, pleural pressure exceeds intra-alveolar pressure, causing atelectasis and subsequent hypoxemia. This is primarily due to the weight of the heart, abdomen, and heavy beefy edematous lungs. The heart alone can add 3–5 cm H_2O



FIGURE 19-7 The art of HFOV relates to achieving and maintaining optimal lung inflation. Optimal oxygenation is achieved by gradual increases in mean airway pressure to recruit lung volume and monitoring the effects on arterial oxygenation. The aim is to achieve maximum alveolar recruitment without causing over-distension of the lungs.

Source: https://www.slhd.nsw.gov.au/rpa/neonatal/html/newprot/hfov.html.

TABLE 19-11
HFOV Definitions[17–20]

mPaw	3–55 cm H_2O range • Bias flow dependent	Primary role is oxygenation.
Power	Determines amplitude (Delta P) • Max power setting is 10.	Primary role is ventilation.
Amplitude (Delta P)	Amplitude = height of the wave • Determined by the power setting	Primary role is ventilation.
Hz/frequency	Hz = width of the wave • Frequency = 60–900 oscillations/breath/minute	Primary role is ventilation.
Bias flow	0–60 continuous L/minute • Bias flow affects mPaw. • Amplitude affects bias flow.	Primary role is to replenish oxygen and remove CO_2 from the circuit. • Eliminates circuit dead space.
% Inspiratory time	30–50% of the oscillatory cycle • Changes in % inspiratory time may affect mPaw or Delta P.	Primary role is oxygenation.

TABLE 19-12
HFOV Initial Settings[17–20]

mPaw	mPaw starting point is 5 cm H_2O above the mPaw on conventional CMV-type modes. • mPaw starting point of 2–3 cm H_2O above mPaw on conventional CMV-type modes may be required in patients with hemodynamic instability. • mPaw target maximum in adults is 45 cm H_2O. • mPaw 40 cm H_2O for 40 seconds (alveolar recruitment maneuver).
Power/amplitude (Delta P)	Power is set between 1 and 10 to achieve the desired amplitude (Delta P). • Power is adjusted until amplitude (Delta P) is 20–30 cm H_2O higher than the CO_2 on CMV-type modes, or until chest wiggle is observed in the patient's mid-thigh. (e.g., for a CO_2 of 70 mm Hg on CMV-type, modes the power would be adjusted to achieve an amplitude (Delta P) of 90–100 cm H_2O). • Increasing power/amplitude (Delta P) increases tidal volume (augments CO_2 removal/less lung protective). • Decreasing power/amplitude [Delta P] decreases tidal volume (when CO_2 retention is desired/more lung protective).
Frequency/Hz	Frequency is initially started at 5 Hz in adults. • Increasing frequency/Hz decreases tidal volume/more lung protective (when CO_2 retention is desired). • Decreasing frequency/Hz increases tidal volume/less lung protective (augments CO_2 removal).
Bias flow	Bias flow set range is between 20 and 40 L/minute. • A good starting point in adults is 30 L/minute. • Bias flow eliminates circuit dead space. • Continuous flow through the circuit replenishes O_2 and removes CO_2 from the circuit. • At high amplitudes, the oscillatory flow may exceed bias flow through circuit, decreasing ventilation (increasing CO_2). • Decreasing bias flow will decrease mPaw availability. Lower amplitudes = lower bias flow (20–30 L/minute). • Higher amplitudes = increase in bias flow (30–40 L/minute). • Change in bias flow creates change in mPaw. • Increasing bias flow will increase mPaw availability.
% Inspiratory time	% inspiratory time is set at 33% initially in adults. • % inspiratory time range is typically 30–50%. • Higher frequencies lean toward 30%. • Lower frequencies lean toward 50%. • % inspiratory time does not typically change. • Changes in % inspiratory time may change oscillator piston position affecting mPaw or Delta P. • Changes in % inspiratory time may affect mPaw.
F_{IO_2}/O_2 saturations	F_{IO_2} initially set at 100%. • F_{IO_2} goal ≤60% • Oxygen saturation ≥88% or within physician specified limits • P_{O_2} ≥60 mm Hg
Monitoring	ABG 60 minutes after initiation of HFOV • pH goals >7.20 or within physician specified limits • Every 2–4 hours for the first 24 hours • After setting changes, or as needed CXR within 4 hours of initiation of HFOV • Every 12 hours for the first 24 hours • Look for hyperinflation End-tidal CO_2 should be monitored continuously to alert clinicians of changes in ventilation.
Sedation/NMB	Patients on HFOV should have adequate sedation and pain management (not being able to exhale normally can be uncomfortable). • NMBs are used in patients on HFOV. Spontaneous breathing can cause large fluctuations in mPaw. • Clinicians should watch for fluctuations in mPaw, as this can be an indication of inadequate paralysis (look for signs of spontaneous breathing). Signs of inadequate sedation, pain medication: • A significant increase in blood pressure (BP) and heart rate (HR) can be signs that the patient may be awake while receiving a NMB.

of pressure to the lungs in the supine position. Patients in the prone position are placed (face down–chest down). Intra-alveolar pressures exceed pleural pressures in the prone position, due to off-loading of the weight of the abdomen, heart, and ventral portions of the lungs, resulting in improved alveolar ventilation, recruitment, and oxygenation (**Figures 19-8** to **19-10**).

It has been demonstrated for some time in randomized clinical trials that patients placed in the prone position have significant improvements in oxygenation when compared with the supine position. In 2013, the PROSEVA Study Group published the results of a multicenter, prospective, randomized, controlled trial on the use of prone positioning in severe ARDS. The study involved 466 patients, of which 237 patients were placed in a prone group and 229 patients were placed in a supine group. To meet criteria, patients had a minimum PEEP requirement of 5 cm H_2O, a minimum oxygen requirement of 60%, and a Pao_2/Fio_2 ratio <150 mm Hg. Both groups were ventilated using low tidal volume ventilation. Patients in the prone group remained in the prone position a minimum of 16 hours. The result was a 28-day mortality rate of 16% in the prone group and a 28-day mortality rate of 32% in the supine group (**Table 19-13**).

FIGURE 19-8 Patient in the supine position (face up, chest up).



FIGURE 19-9 Patient properly placed in the prone position (face down, chest down).

Extracorporeal Life Support

Extracorporeal life support (ECLS) is a temporary treatment strategy that may be used in patients with ARDS that continue to have severe refractory hypoxemia despite conventional treatment strategies. The



FIGURE 19-10 Cross section of the lungs. **(A)** Normal lung in the supine position. **(B)** ARDS lung in the supine position. **(C)** Normal lung in the prone position. **(D)** ARDS lung in the prone position. Circles represent alveoli. Shaded circles indicate alveoli with infiltrates.

TABLE 19-13
Complications Associated with Prone Positioning[21–24]

Endotracheal tube dislodgement
Airway obstruction
Increased need for paralytics and sedation
Hypotension
Cardiac dysrhythmias
Loss of intravenous access
Loss of tubes and catheters
Facial and airway edema
Transient oxygen desaturation
Aspiration of tube feeds (turn off minimum of 1 hour prior to prone positioning)

TABLE 19-14
Indications and Contraindications for ECLS[25–29]

Indications for ECLS	Contraindications for ECLS
Hypoxic respiratory failure: • Considered with a mortality risk of 50% or greater • Indicated with a mortality risk of 80% or greater	Mechanical ventilation with high settings for >7 days: • F_{IO_2} >90% • P-plat >30 cm H_2O
High P-plat (>30 cm H_2O) with CO_2 retention on mechanical ventilation	Significant pharmacologic immunosuppression: • Absolute neutrophil count <400/mm^3
Severe air leak syndromes	Recent or expanding central nervous system (CNS) hemorrhage
Patient on lung transplant list in need of intubation	Nonsurvivable comorbidity: • Terminal malignancy • CNS damage
Cardiac or respiratory collapse: • Pulmonary embolus • Airway obstruction • Unresponsive to optimal care	Consider increased risk with increased age

TABLE 19-15
Complications Related to ECLS[25–29]

Bleeding from cannula site, wounds, intracerebral
Clotting of the circuit
Air emboli
Infection
Trauma to major blood vessels

Extracorporeal Life Support Organization (ELSO) defines ECLS as "the use of mechanical devices to temporarily (days to months) support heart or lung function (partially or totally) during cardiopulmonary failure, leading to organ recovery or replacement." Extracorporeal membrane oxygenation (ECMO) is indicated in patients with a significant risk of death from either cardiopulmonary failure or cardiac failure (**Table 19-14** to **19-16**).

ECLS is essentially an artificial lung. The patient is cannulated, using large catheters, and blood flows from the body to the membrane lung, where oxygen is added to the blood and carbon dioxide is removed. Patients may also have CO_2 removal only. The blood is then pumped back to the body. The type of ECLS therapy used is dependent upon the organ in need of rest, the heart, and/or lungs. Patients are cannulated for ECLS using three different techniques, venoarterial (VA), venovenous (VV), and extracorporeal carbon dioxide removal ($ECCO_2R$), with the catheters placed in the large vessels of the neck or groin (**Figures 19-11** and **19-12**).

Pharmacologic Treatment

Although there is a considerable shift toward minimizing the use of paralytics in the ICU, a certain subset of ARDS patients could benefit from short-term use of a **neuromuscular blockade (NMB)**. During the extended clinical management of an ARDS patient, certain problems could persist while on mechanical ventilation—hypoxemia, hypercarbia, poor pulmonary compliance, and asynchrony—that prolong ventilation and ICU days. A 2018 study by Sottile et al.[30] identified that the use of NMB in moderate-to-severe ARDS patients who are receiving low tidal volume ventilation results in reduction in biomarkers of epithelial and endothelial lung injury and systemic inflammation.

TABLE 19-16
Three Types of ECLS[25–29]

	VA ECLS	VV ECLS	$ECCO_2R$
Strategy	To allow superprotective (4 mL/kg/IBW) mechanical ventilation settings in patients with severe ARDS who also need cardiac support	To allow superprotective (4 mL/kg/IBW) mechanical ventilation settings in patients with severe ARDS	To allow superprotective (4 mL/kg/IBW) mechanical ventilation settings in patients with moderate-to-severe ARDS
Cannulation site(s)	Internal jugular or femoral vein and femoral artery are preferred	Femoral and jugular veins with two cannulas or a double lumen cannula via the jugular vein	Jugular or femoral veins with a double lumen catheter
Therapeutic support	Heart and lungs	Lungs only	Lungs only
Gas exchange	Oxygenation and CO_2 removal	Oxygenation and CO_2 removal	CO_2 removal only
Hemodynamics support	Pump flow plus native cardiac output Severely depressed cardiac function	Native cardiac output, medications Adequately or moderately depressed cardiac function	Native cardiac output, medications
Blood flow	Up to 7 L/minute	Up to 7 L/minute	200–1,500 mL/minute



FIGURE 19-11 **(A)** VA ECLS used when patients require cardiac support and/or respiratory support. **(B)** VV ECLS used when patients require blood flow and gas exchange for respiratory failure, not for cardiac support.



FIGURE 19-12 $ECCO_2R$ is used for patients requiring CO_2 removal only.

A plausible reason for NMB reducing biomarkers is improvement in patient–ventilator synchrony that could lessen the pulmonary injury. Unfortunately, the above study did not associate any findings to improving patient outcomes. In 2010, a study using **cisatracurium** for 48 hours in severe ARDS patients noted an improvement with calculated 90-day mortality rates, increased number of ventilator-free days and days outside the ICU, and lowering pulmonary complications (i.e., pneumothorax).[31] Short-term use of NMB has the potential to lessen lung injury, which could lead to better overall outcomes for moderate-to-severe ARDS.

The use of **inhaled prostaglandins** is another pharmacologic agent being reviewed to reduce hypoxemia in ARDS. A primary goal is to promote local vasodilation to pulmonary vasculature adjacent to functional alveoli, thus improving ventilation–perfusion matching and reducing hypoxemia. A study by Kallet et al.[32] reviewed records of 208 ARDS subjects receiving aerosolized prostaglandin that showed a mean Pao_2/Fio_2 rising 33 mm Hg in 62% of the participants. However,



FIGURE 19-13 Ventilation and perfusion mismatch effects from INO and intravenous prostaglandins. **(A)** Exhibits normal V/Q matching. **(B)** V/Q matching negatively affected by hypoxic pulmonary vasoconstriction. **(C)** Introduction of INO causes local pulmonary vasodilation to adjacent vessels of patent alveolus. **(D)** Delivery of intravenous prostaglandin worsens V/Q matching and Pao_2/Fio_2 by vasodilating all pulmonary vasculature. **(E)** Inadequate vascular tone associated with such conditions as sepsis further leads to poorer oxygenation. **(F)** Leakage of INO through collateral ventilation between lung units counteracts the initial V/Q matching improvement.

subjects diagnosed with sepsis saw minimal improvement using aerosolized prostaglandin. A meta-analysis by Fuller et al.[33] also saw an increase with Pao_2/Fio_2 and a decrease in pulmonary artery pressure using inhaled prostaglandins (epoprostenol and alprostadil) but did not identify any change in mortality. The current studies involving aerosolized prostaglandins for ARDS show no benefit toward improving patient outcomes; thus, further studies are recommended to determine patient benefit.

Nitric oxide (NO) is a potent endogenous vasodilator that has been used as a therapeutic gas—inhaled nitric oxide (INO)—in patients affected by ARDS. The intent is to improve the V/Q mismatch by dilating the pulmonary vasculature lining the patent alveoli, thus improving Pao_2/Fio_2 (**Figure 19-13**). As noted with inhaled prostaglandin therapy, INO also had a positive impact with Pao_2/Fio_2 within the first 24 hours, and then no progression was made beyond 24 hours.[34] The ideology of implementing INO therapy to reduce high Fio_2 requirements (50% or higher) that cause pulmonary oxygen toxicity is noble; however, no long-term outcome benefit has been identified. The Cochrane Review by Gebistorf et al.[34] produced no strong evidence supporting the use of INO in adults or children with acute respiratory failure and hypoxemia when initiating short-term or long-term INO therapy. INO should not be a recommended therapy for ARDS.

Case Study

Subjective

A 5-foot 7-inch 22-year-old woman arrives at the emergency department complaining of shortness of breath. She has been battling an upper respiratory infection over the past 3 days—cough, runny nose, low-grade fever, and malaise. However, this afternoon she is experiencing dyspnea on exertion and moments of gasping for her next breath. She also notes a dull pain in her right lower chest.

Objective

Vitals

- BP, 114/71; HR, 116; RR, 24 mildly labored; T, 102.3°F; Spo_2, 86% on room air

Neuro

- The patient is awake, alert, and oriented.

Cardiovascular

- Normal S1 and S2, no gallops, no bruits

Pulmonary

- Dry, nonproductive cough
- Auscultation reveals bibasilar fine inspiratory crackles.
- Dullness on the right lower chest during percussion.

Laboratory

- ABG: pH, 7.36; $Paco_2$, 44; Pao_2, 52; HCO_3^-, 24; Sao_2, 85%
- CBC: WBC, 15.1 billion cells/L; RBC, 3.2 million cells/μL; Hgb, 13.0 g/L; Hct, 38%; platelets, 225 billion/L
- Electrolytes: Na^+, 146 mEq/L; K^+, 3.7 mEq/L; Cl^-, 105 mEq/L

Radiology

- CXR shows bilateral lower lobe infiltrates, greater on right than on the left

Assessment

- Hypoxic respiratory failure (moderate hypoxemia) secondary to community-acquired pneumonia
- Dehydration due to poor oral intake

Plan

- Admit to hospital for a 48- to 72-hour stay
- Place on oxygen to maintain Spo_2 >90%; currently on 3 L/minute with Spo_2 92%
- Start antibiotic therapy using levofloxacin
- IV fluids

Twelve hours after admission, a rapid response is initiated for respiratory distress. The patient is leaning forward in a tripod position with overt signs of respiratory distress—accessory muscle use and tachypnea. She is observed to have central cyanosis; her current vitals are RR, 28; BP, 132/78; HR, 128; Spo_2, 85% on 3 L/minute nasal cannula. A 15 L/minute non-rebreather is placed that raises her Spo_2 to 91%. An ABG is ordered: pH, 7.32; $Paco_2$, 49; Pao_2, 58; HCO_3^-, 25, Sao_2 89%. Noninvasive positive pressure ventilation (NPPV) is started with an inspiratory positive airway pressure (IPAP) of 14 cm H_2O, expiratory positive airway pressure (EPAP) of 6 cm H_2O, and FIo_2 1.0. She is transferred to the medical intensive care unit for closer monitoring. Sixty minutes after transferring to the ICU, she continues to decompensate, resulting in a follow-up ABG and CXR. The patient's ABG on NPPV is pH, 7.22; $Paco_2$, 59; Pao_2, 60; HCO_3^-, 25; Sao_2 88%. A CXR shows significant bilateral opacities and air bronchograms extending to the lung periphery that is consistent with ARDS. Following the diagnostic results, the patient is prepped for endotracheal intubation.

After successful intubation, she is placed on mechanical ventilation: PRVC, rate 14 breaths/minute, V_T, 490 mL (8 mL × 61.6 kg); PEEP, 10 cm H_2O; FIo_2, 1.0. A CXR completed following intubation showed the ETT to be 4 cm above the carina. An arterial line is inserted 15 minutes later; an ABG reveals pH, 7.30; $Paco_2$, 52 mm Hg; Pao_2, 68 mm Hg; HCO_3^-, 25 mEq/L. Tidal volume was reduced within 2 hours to 6 mL/kg of IBW, resulting in a delivered V_T of 370 mL that decreased the plateau pressure from 31 to 26 cm H_2O that follows ARDSNet guidelines. However, the reduction in V_T affected the Pao_2, which dropped to 50 torr; an optimal PEEP study was begun that raised baseline pressure from 10 to 20 cm H_2O. Upon completion of the PEEP study, the static compliance had improved from 20 to 31 mL/cm H_2O; plateau pressure rose from 26 to 28 cm H_2O.

Unfortunately, the successes detailed above did not last past 24 hours as the patient was eventually transitioned to HFOV and required a bedside video-assisted thoracoscopic surgery to remove thoracic blood clots that were complicating mechanical ventilation efforts. The care for this patient would continue for

(*Continues*)

Case Study (*Continued*)

another 72 hours before a transfer is requested for an ECMO center. She was ultimately placed on ECMO for 10 days; after 10 days, she was removed from ECMO secondary to an inability to safely maintain activated clotting times necessary for minimizing clotting or hemorrhaging complications associated with ECMO.

Although she encountered many complications, she would eventually overcome all the medical challenges by surviving an ordeal that still sees mortality rates ranging from 30% to 40% and possibly higher depending on studies (**Table 19-17**).

TABLE 19-17
Complications Associated with ARDS[35]

Complications	Causes
Barotrauma	Poor lung compliance, excessive ventilator pressures, inappropriate PEEP levels
Infections	Nosocomial from prolonged hospitalization, indwelling catheters (central or arterial lines, urinary), ventilator-associated pneumonia (VAP)
Lung scarring	Pulmonary infection, mechanical ventilation, ARDS cycle (exudative ⟹ proliferative ⟹ fibrotic)
Blood clots	Immobility, poor use of anticoagulants and compression socks
Hypotension	Excessive PEEP, overuse of diuretic therapy

Chapter Summary

Patients surviving in-hospital ARDS still must overcome challenges upon discharge. Evaluating outcomes and quality of life after surviving ARDS is pertinent to developing an overall health plan after patients leave the acute care setting. An article by Herridge et al.[36] evaluated ARDS survivors at 3, 6, and 12 months and at 2, 3, 4, and 5 years after discharge from an ICU. The findings included exercise limitation, physical and psychologic issues, and a decrease in quality of life that can extend up to 5 years post-discharge and possibly beyond within particular subgroups. Interestingly, ARDS survivors had normal or near-normal pulmonary function tests at 3 and 5 years, yet 6-minute walking distances were reduced.[36] Survivors who had a quicker resolution of lung injury achieved a greater distance in the 6-minute walk versus those having slower lung injury resolution—454 m versus 427 m.[36] During the ICU course, many of the patients will have prolonged ventilation days resulting in a variety of sedatives, analgesics, and possibly paralytics that directly influence physical and psychologic issues. Options such as limiting the usage of the above medication classes, undergoing early physical therapy while in the ICU, and developing an ARDS survivor discharge plan may lead to reducing the time of post-hospitalization sequela. ARDS survivors healthcare management does not end as identified obstacles persist post-discharge from the hospital.

Key Points

1. ARDS mortality remains between 30% and 40% depending on severity.
2. Berlin definition classifies ARDS severity according to Pao_2/Fio_2 ratio—severe (≤100 mm), moderate (101–200 mm Hg), and mild (201–300 mm Hg).
3. Sepsis remains the primary causative factor for developing ARDS.
4. ARDS occurs throughout three different stages—exudative, proliferative, and fibrotic—during the course of 14 days.
5. A secondary consequence of ARDS is pulmonary hypertension that will negatively affect hemodynamics, such as mPAP, PAWP, and RAP.
6. CXR still remain an integral diagnostic exam to evaluate ARDS progression or regression. An indicator for ARDS is bilateral infiltrates on a CXR.
7. Implementation of a lung protective mechanical ventilation strategy as proposed by ARDSNet has reduced mortality and morbidity by 22%. Other advance ventilation strategies for managing hypoxemia include APRV and HFOV.
8. APRV uses two pressures (P_{High} and P_{Low}) along with long inspiratory times and short expiratory times to improve V/Q mismatch and gas distribution as well as lessening the need for sedatives and NMBs.

9. HFOV is a decoupling ventilator that permits the clinician to control mPaw that augments pulmonary distending pressures to facilitate improvement in FRC.
10. Prone positioning is a safe and beneficial option for ARDS because it was demonstrated to reduce mortality.
11. The use of a NMB, cisatracurium, for 48 hours in severe ARDS saw an improvement with calculated 90-day mortality rates, increased number for ventilator-free days, and lowering pulmonary complications.
12. Incorporating inhaled prostaglandins or NO raises Pao_2 for short term, but has not shown to improve outcomes for ARDS.
13. Complications accompanied with ARDS are associated with the necessary interventions to manage its progression: mechanical ventilation, indwelling catheters, diuretics, and hospitalization.
14. ARDS survivors will have to overcome physical and psychologic issues once discharged from the hospital. Survivors having a quicker pulmonary resolution achieve greater walking distances than those who had a slower recovery time.

Chapter Questions

1. According to the Berlin definition, which of the following are clinical criteria for ARDS?
   I. Onset within 1 week of a known clinical insult
   II. Respiratory failure not explained by fluid overload
   III. Pulmonary artery wedge pressure ≤18 mm Hg
   IV. Bilateral infiltrates on chest x-ray
   Answer:
   a. All of the above
   b. I and II
   c. III and IV
   d. I, II, and III
2. Which of the following is not a direct cause of ARDS?
   a. Pulmonary contusion
   b. Near drowning
   c. Drug overdose
   d. Inhalation injury
3. True or false: Increased capillary permeability and inflammation are two primary pathophysiologic changes occurring with ARDS.
4. Using the ideal body weight (IBW) calculation, calculate the IBW for a 5-foot 8-inch tall female.
   a. 74 kg
   b. 64 kg
   c. 55 kg
   d. 48 kg
5. Which of the following may be advantages associated with airway pressure release ventilation?
   I. Improved V/Q mismatch
   II. Lower peak airway pressures
   III. Worsening gas distribution
   IV. Reduced need for neuromuscular blockades
   Answer:
   a. I, II, and III
   b. I, II, and IV
   c. III and IV
   d. All of the above
6. True or false: Patients being ventilated using high-frequency oscillatory ventilation should be allowed to spontaneously breathe, as spontaneous breathing is more comfortable for the patient.
7. Which of the following is not a complication associated with prone positioning?
   a. Endotracheal tube dislodgement
   b. Airway obstruction
   c. Improvement in oxygenation
   d. Facial and airway edema
8. Which of the following extracorporeal life support therapies is specifically for carbon dioxide removal?
   a. Venoarterial
   b. Venovenous
   c. $ECCO_2R$
   d. Venobrachial
9. Which of the following are complications associated with ARDS?
   I. Barotrauma
   II. Hypertension
   III. Blood clots
   IV. Infections
   Answer:
   a. All of the above
   b. I, III, and IV
   c. I, II, and III
   d. II and III

References

1. The ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition. *JAMA*. 2012;307:2526–2533. doi:10.1001/jama.2012.5669.
2. Ferguson N, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. *Intensive Care Med*. 2012;38(10):1573–1582. doi:10.1007/s00134-012-2682-1.
3. Fanelli V, Aikaterini V, Shirin G, et al. Acute respiratory distress syndrome: new definition, current and future therapeutic options. *J Thorac Dis*. 2013;5(3):326–334. doi:10.3978/j.issn.2072-1439.2013.04.05.
4. Pneumatikos I, Papaioannou VE. The new Berlin definition: what is, finally, the ARDS? *PNEUMON*. 2012;25(4):365–368.
5. Saguil A, Fargo M. Acute respiratory distress syndrome: diagnosis and management. *Am Fam Physician*. 2012;85(4):352–358.

6. Hudson L, Steinberg KP. Epidemiology of acute lung injury and ARDS. *Chest.* 1999;116(1):74S–85S.
7. Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med.* 2000;342(18):1334–1350.
8. Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. *Thorax.* 1998;53:815–817. doi:10.1136/thx.53.10.815.
9. Calcaianu G, Calcaianu M, Gschwend A, Canuet M, Meziani F, Kessler R. Hemodynamic profile of pulmonary hypertension in ARDS. *Pulm Circ.* 2018;8(1):1–5. doi:10.1177/2045893217753415.
10. Adsnet.org. NHLBI ARDS Network/About. 2018. http://www.ardsnet.org. Accessed April 11, 2018.
11. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. *Chest*. 2001;120(4):1347–1367.
12. Wright BJ. Lung-protective strategies and adjunctive treatments for the emergency medicine patient with acute respiratory failure. *Emerg Med Clin North Am.* 2014;32(4):871–887. doi:10.1016/j.emc.2014.07.012.
13. Girard TD, Bernard GR. Mechanical ventilation in ARDS: a state of the art review. *Chest*. 2007;131(3):921–929. doi:10.1378/chest.06-1515
14. Modrykamien A, Chatburn RL, Rendell AW. Airway pressure release ventilation: an alternative mode of mechanical ventilation in acute respiratory distress syndrome. *Cleve Clin J Med.* 2011;78(2):101–110.
15. Frawley MP, Habashi NM. Airway pressure release ventilation: theory and practice. *AACN Clin Issues.* 2001;12(2):234–246.
16. Daoud EG, Farag HL, Chatburn RL. Airway pressure release ventilation: what do we know? *Respir Care.* 2012;57(2):282–292. doi:10.4187/respcare.01238.
17. CareFusion. 2018. http://pages.carefusion.com/rs/carefusioncorporation/images/RC_3100B-pocket-guide.pdf. Accessed April 12, 2018.
18. Higgins J, Estetter B, Holland D, Smith B, Derdak S. High-frequency oscillatory ventilation in adults: respiratory therapy issues. *Crit Care Med*. 2005;33(3):196–203. doi:10.1097/01.CCM.0000155922.78943.2D.
19. Krishnan JA, Brower RG. High-frequency ventilation for acute lung injury and ARDS. *Chest.* 2000;118(3):795–807.
20. Chan KP, Stewart TE, Sangeeta M. High-frequency oscillatory ventilation for adult patients with ARDS. *Chest.* 2007;131(6):1907–1916. doi:10.1378/chest.06-1549.
21. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. *N Engl J Med.* 2013;368(23):2159–2168. doi:10.1056/NEJMoa1214103.
22. Scholten EL, Beitler JR, Prisk KG, Malhotra A. Treatment of ARDS with prone positioning. *Chest.* 2017;151(1):215–224. doi:10.1016/j.chest.2016.06.032.
23. Drahnak DM, Custer N. Prone positioning of patients with acute respiratory distress syndrome. *Crit Care Nurse*. 2015;35(6):29–37. doi:10.4037/ccn2015753.
24. Henderson WR, Griesdale DE, Dominelli P, Ronco JJ. Does prone positioning improve oxygenation and reduce mortality in patients with acute respiratory distress syndrome? *Can Respir J.* 2014;21(4):213–215.
25. Extracorporeal Life Support Organization. Guidelines for adult respiratory failure. [online]. 2017. https://www.elso.org/Portals/0/ELSO%20Guidelines%20For%20Adult%20Respiratory%20Failure%201_4.pdf. Accessed May 14, 2018.
26. Brodie D. The evolution of extracorporeal membrane oxygenation for adult respiratory failure. *Ann Am Thorac Soc.* 2018;15(suppl_1):S57–S60. doi:10.1513/AnnalsATS.201705-386KV.
27. Schulman CS, Bibro C, Downey DB, Lasich C. Transferring patients with refractory hypoxemia to a regional extracorporeal membrane oxygenation center: key considerations for clinicians. *AACN Adv Crit Care*. 2014;25(4):351–364. doi:10.1097/NCI.0000000000000054.
28. Williams KE. Extracorporeal membrane oxygenation for acute respiratory distress syndrome in adults. *AACN Adv Crit Care*. 2013;24(2):149–158. doi:10.1097/NCI.0b013e31828a09ff.
29. Combes A, Pesenti A, Ranieri MV. Is extracorporeal circulation the future of acute respiratory distress syndrome management? *Am J Respir Crit Care Med*. 2017;195(9):1161–1170. doi:10.1164/rccm.201701-0217CP.
30. Sottile PD, Albers D, Moss MM. Neuromuscular blockade is associated with the attenuation of biomarkers of epithelial and endothelial injury in patients with moderate-to-severe acute respiratory distress syndrome. *Crit Care.* 2018;22(1):63. doi:10.1186/s13054-018-1974-4.
31. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. *N Engl J Med.* 2010;363:1107–1116. doi:10.1056/NEJMoa1005372.
32. Kallet RH, Burns G, Zhuo H, et al. Severity of hypoxemia and other factors that influence the response to aerosolized prostacyclin in ARDS. *Respir Care.* 2017;62(8):1014–1022. doi:10.4187/respcare.05268.
33. Fuller BM, Mohr NM, Skrupky L, Fowler S, Kollef MH, Carpenter CR. The use of inhaled prostaglandins in patients with ARDS. *Chest.* 2015;147(6):1510–1522. doi:10.1378/chest.14-3161.
34. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database Syst Rev.* 2016;(6):CD002787. doi:10.1002/14651858.CD002787.pub3.
35. Stoppler MC. ARDS definition and facts. 2017. https://www.medicinenet.com/ards/article.htm#ards_acute_respiratory_syndrome_definition_and_facts
36. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. *N Engl J Med.* 2011;364(14):1293–1304. doi:10.1056/NEJMoa1011802.

CHAPTER

20

Drowning Injury

"An ounce of prevention is worth a pound of cure."

—Benjamin Franklin, *Pennsylvania Gazette*, February 4, 1735

OUTLINE

OBJECTIVES

1. Identify the common characteristics, manifestations, and diagnostic features of submersion injury.
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of submersion injuries.
3. Describe the underlying pathophysiologic mechanisms in submersion injury.
4. Utilize diagnostic testing to identify the severity of a submersion injury.
5. Discuss the recommended management for patients with submersion injury.
6. Identify common complications and risk factors of submersion injury.

KEY TERMS

Apneic time
Autonomic conflict
Cerebral hypoxia
Class 1 patient
Class 2 patient
Class 3 patient
Class 4 patient
Cold shock
Diving response
Drowning
DUBBS
Immersion
Laryngospasm
Mild hypothermia
Moderate hypothermia
Nonfatal drowning
Rhabdomyolysis
Severe hypothermia
Static apnea
Submersion
Time interval

Case Study

Jeremy Parton is a 21-month-old well-developed, well-nourished (14-kg) white male found with his face submerged and upper torso stuck in a bucket of water in his grandparents' laundry room. The boy apparently walked away from his family while they were eating in the kitchen and was missing for approximately 5 minutes. When found, the infant's mother removed him from the bucket and immediately began mouth-to-mouth resuscitation. After about five rescue breaths, the infant began breathing spontaneously, cried, and vomited a large amount of water. An ambulance took him to the local emergency department. In the emergency department, he was alert and crying. The infant's temperature was 36.8°C, pulse 156 beats/minute, respiratory rate 36 beats/minute, blood pressure 95/55. The child's neurologic assessment was within normal limits with a Glasgow Coma Score of 13. Chest auscultation revealed crackles anteriorly and posteriorly over the bilateral lower lung fields and scattered bilateral wheezing. His initial arterial blood gas (ABG) results on room air was pH 7.34, $PaCO_2$ 34 torr, PaO_2 51 torr, SaO_2 84%, and HCO_3^- 19 mEq/L. The patient received supplemental oxygen by nasal cannula at 4 L/minute. A follow-up ABG on 4 L/minute showed the pH 7.37, $PaCO_2$ 33 torr, PaO_2 72 torr, SaO_2 94%, and HCO_3^- 19 mEq/L. A 20 L/minute high-flow nasal cannula (HFNC) with 50% oxygen replaced the low-flow nasal cannula. His oxygenation improved at that time (**Figure 20-1**).

A chest radiograph revealed patchy opacifications in both lower lobes with the left clearer than the right, consistent with bibasilar subsegmental atelectasis. There were mild central pulmonary congestion and interstitial edema consistent with noncardiogenic interstitial pulmonary edema. The patient was under observation in the emergency department for 6 hours and admitted due to hypoxemia and atelectasis. He received supportive care, was weaned off the oxygen, and was discharged on Day 4 with no neurologic or pulmonary consequences.

FIGURE 20-1 The respiratory therapists discontinued the patient's supplemental oxygen 2 days later, but the child remained in the hospital for 10 days.

Introduction

As long as people have congregated around water, there has been injury and death. Paleolithic humans swam for the first time to escape enemies or from wild animals. The Greek civilization has thousands of years of naval history with many reports about swimming appearing in both historical and mythological accounts from ancient Greece.[1]

Drowning was a frequent hazard 275 years ago, and physicians knew that they could do almost nothing to revive an unconscious person pulled from the water. Few people knew how to swim—even anglers and seamen usually could not swim (**Figure 20-2**). In 1745, an English physician read a paper to the Royal Society about "a man dead in appearance" who recovered after his lungs were "distended with air."[2] The science and medical community did not follow up on this promising lead. In 1767, the medical climate was more receptive. At that time, a physician described several cases of resuscitation in Switzerland to the Academy of Sciences in Paris.[2]

FIGURE 20-2 The poor princess fell into the sea and nearly drowned.

Mouth-to-mouth resuscitation for drowning victims was officially recommended by the Paris Academy of Sciences in 1741.[3] Soon societies for the revival of the apparently drowned were created in the leading scientific

cities—Amsterdam, Milan, Venice, Hamburg, Paris, St. Petersburg, Berlin, and Boston, Massachusetts.[2]

Over 3,000 people die each year in the United States as a result of drowning.[4] Worldwide, about 372,000 people died from drowning in 2012, making drowning an important public health problem.[5] Despite well-recognized prevention strategies, knowledge of drowning pathophysiology, and advances in emergency medicine and critical care, each year many young, previously healthy people die or suffer from injury secondary to this dramatic clinical picture.[6]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The best method to resuscitate a drowning victim has always been cardiac compressions.
2. True or False: Drowning is a worldwide public health problem.

Definition/Diagnosis

In past years, much confusion surrounded the terminology utilized to describe persons who drowned. In 2005, Papa et al. published an article in *Resuscitation* that reviewed the drowning literature from 1966 to 2002. They found 20 different definitions for drowning, 13 different definitions for near drowning, and 13 related terms in the 43 articles they reviewed. They also identified 20 inconsistent outcome measures.[7] There was little consistency and lack of common language about drowning. The terminology used in the past attempted to align definitions of drowning with the pathophysiologic process of drowning and its clinical implications.[8] The terms included drowning, near drowning, secondary drowning, wet drowning, dry drowning, active drowning, passive drowning, and silent drowning. The lack of standardized definitions stood as a hindrance to population-based surveillance studies on drowning incidents and prospective clinical studies of prognostic factors and outcomes of drowning.[8] This means that studies could not be compared to evaluate prognosis or outcomes of drowning.

In June 2002, an international consensus conference on drowning convened to create uniform report standards for drowning data. This process also included formal discussions, expert panel review, endorsements from multiple organizations, and recommendations from other interested parties.[8] The conference was part of a larger comprehensive meeting called the World Congress on Drowning.[7] The uniform definitions, terminology, and datasets created are referred to as "Utstein style" guidelines, named for the location of the earlier international consensus conferences: the Utstein Abbey on the island of Mosterøy, Norway. Representatives from major organizations whose focus is resuscitation and epidemiology were present at these conferences. See **Table 20-1** for the names of these organizations.

TABLE 20-1
Organizations with Representatives on the Utstein Task Force on Drowning

Organization	Country
American Heart Association	United States
Dutch Society to Rescue People from Drowning	The Netherlands
European Resuscitation Council	European Countries
Centers for Disease Control and Prevention	United States
Australia and New Zealand Resuscitation Council	Australia and New Zealand
InterAmerican Heart Foundation	North and South American Countries
Heart and Stroke Foundation of Canada	Canada
Resuscitation Council of South Africa	South Africa

Data from Idris A, Berg R, Bierens J. Recommended guidelines for uniform reporting of data from drowning: the "Utstein Style". *Circulation.* 2003;108(20):2565–2574.

The World Health Organization (WHO) adopted the definitions agreed upon at the 2002 World Congress on Drowning that year. The conference findings determined that terms like "near drowning," "dry or wet drowning," "secondary drowning," "active and passive drowning," and "delayed onset of respiratory distress" should be avoided.[9] The two terms that appear in the accepted definition of drowning are submersion and immersion. **Submersion** refers to the entire body, including the airway, being within a liquid, usually water. A submersion usually occurs in a swimming pool or body of water. **Immersion** occurs when part of the body, specifically the face and airway, is within a liquid. Immersion typically occurs in a bucket of water or toilet. Therefore, **drowning** is the process of experiencing respiratory impairment from submersion/immersion in liquid.[9] The liquid/air interface at the entrance of the airway prevents the victim from breathing air.[10] See **Table 20-2**[11] for currently acceptable terminology. The World Congress on Drowning 2002 also defined three possible outcomes for drowning, as seen in **Figure 20-3**. The victim may live or die after the drowning process, but whatever the outcome, he or she was involved in a drowning incident.

The Drowning Process

Drowning is a continuous process that begins with the victim's inability to keep his or her airway clear of fluid. The conscious victim will either voluntarily spit out or

TABLE 20-2
WHO Accepted Terminology for Drowning

Term	Definition
Drowning	The process of experiencing respiratory impairment from submersion or immersion in liquid
Nonfatal drowning	Survival after drowning, further classified as nonfatal (survival) with morbidity or no morbidity
Fatal drowning	Death due to drowning
Submersion	The whole body is under water
Immersion	Part of the body is covered with water (for drowning to occur, the face and airway would have to be immersed)
Witnessed	Drowning episode observed from the onset of immersion or submersion
Unwitnessed	Victim found in water; no one saw the event
Time interval	The time between the initial airway compromise and return of ventilatory efforts

Data from Jones P, Moran K, Webber J. Drowning terminology: not what it used to be. *N Z Med J.* 2013;126(1386):114–116. http://journal.nzma.org.nz/journal126-1386. Accessed August 24, 2015.

swallow the liquid. Next, a conscious victim begins to breath-hold. When the inspiratory drive is too high to resist, aspiration occurs, and some amount of liquid moves into the airways and coughing occurs as a reflex response. An involuntary period of **laryngospasm**, closure of the larynx due to laryngeal muscle spasm, may follow secondary to the presence of liquid in the oropharynx or larynx. During the period of breath holding and laryngospasm, there is a depletion of oxygen and retention of carbon dioxide. The victim suffers hypercarbia, hypoxemia, and acidosis. Frequently, the victim also swallows large volumes of water during this time. The victim's respiratory movements may become active, but there is no exchange of air because of the obstruction at the level of the larynx. As the victim's arterial oxygen tension decreases further, laryngospasm stops, and the victim actively inhales liquid. The amount of liquid aspirated varies considerably from victim to victim. If no rescue occurs, aspiration continues and the hypoxemia leads to a loss of consciousness and apnea. Changes occur in the lungs, body fluids, oxygen tension, acid–base balance, and electrolyte concentrations, which are dependent on the composition and volume of the liquid aspirated and the duration of submersion (**time interval**).[9,12–14]



FIGURE 20-3 Three possible drowning outcomes.

KNOWLEDGE CHECK QUESTION

1. True or False: When part of the body is within the water, it is known as immersion.
2. True or False: The three possible drowning outcomes include aspiration, laryngospasm, and hypoxia.

Clinical Signs and Symptoms

Removal of victims from the body of water or liquid is crucial to decrease morbidity and mortality. Drowning victims can appear mottled and have minimal or no peripheral pulses despite a heartbeat. Rescuers may assume the victim is dead when, in fact, there is cardiac function. Assessment at this time is difficult, making it vital to begin cardiopulmonary resuscitation (CPR) immediately after the victim is out of the water. Successful on-scene resuscitation is the surest predictor of survival.[15] Delaying CPR until the arrival of emergency personnel lessens the likelihood of the victim's survival.[16]

Initial Assessment

Table 20-3 shows a summary of the initial on-the-scene assessment of a drowning victim. This table demonstrates that in addition to victim information,

TABLE 20-3
Initial Scene Assessment of Drowning Victims

History	Information
Victim information	Age, gender, medical history, allergies, drug history, precipitating events—trauma, drugs, alcohol
Scene information	Witnessed (submersion/immersion is observed) Body of water (bathtub, swimming pool, ocean, lake, river) Time of submersion (if known) Time of removal from liquid (if known) Water type (fresh, salt, chemical, other) Water temperature
Prehospital care	Conscious or unconscious when removed from water CPR—time started, any delay Neurologic status: ABC and Glasgow Coma Scale (GCS) Initial vital signs (spontaneous breathing, palpable pulse, temperature, blood pressure, pupillary reaction, oxygen saturation)

Data from Idris A, Berg R, Bierens J. Recommended guidelines for uniform reporting of data from drowning: the "Utstein Style". *Circulation.* 2003;108(20):2565–2574.

TABLE 20-4
Simplified Classification of Drowning Victims for Hospitalized Patients

Class	At-the-Scene Description	Type of Patient
1	No evidence of inhalation of liquid	Asymptomatic patient
2	Clinical evidence of inhalation of liquid with adequate ventilation	Asymptomatic patient or symptomatic patient
3	Clinical evidence of inhalation of liquid and inadequate ventilation	Symptomatic patient
4	Absent ventilation and circulation	Cardiopulmonary arrest

Data from Hasibeder WR. Drowning. *Curr Opin Anaesthesiol.* 2003:16:139–146.

knowledge of certain scene information is helpful in determining the extent of the drowning injury.

The degree of physiologic derangement experienced is determined by the timing of rescue and ranges from no evidence of harm to cardiopulmonary arrest. **Table 20-4** shows a simplified classification system for drowning victims used to treat patients in the emergency department and intensive care units (ICUs).[17]

The Asymptomatic Patient

A patient who was immersed or submerged in a liquid and suffered any respiratory event suffered a drowning. The respiratory compromise may have been subtle, such as coughing or aspirating a small amount of water. Simply being submerged and breath holding does not constitute a drowning event if no respiratory compromise occurred. Sometimes this subtle distinction between drowning and submersion without respiratory compromise is difficult or impossible for the patient or the provider to distinguish.[18]

An asymptomatic drowning patient has no cough or dyspnea. These patients may fit into Class 1 or 2 (Table 20-4). **Class 1 patients** present to the emergency department with GCS scores of >13 and oxygen saturations of ≥95%. Their vital signs, chest x-rays, and breath sounds are within normal limits, and there is no sign of any respiratory distress. These patients need observation for 4–6 hours. If at that time the pulmonary examination does not reveal crackles, rhonchi, wheezing, or retractions and arterial oxygen saturation on room air remains ≥95%, the patient can be discharged home. The patient should be told to return if fever, mental status changes, or pulmonary symptoms occur.[19]

The Symptomatic Patient

The **Class 2 patient** (Table 20-4) can have adequate ventilation and have mild symptoms with a cough or a sore throat. Without evidence of inadequate ventilation, these individuals need observation for 4–6 hours to ensure no additional signs or symptoms appear. If respiratory distress occurs, the patient needs supplemental oxygen at high concentrations. The course of events in the hospital determines the disposition of the patient. The patient may be either discharged home if breath sounds are clear and arterial oxygen saturation remains ≥95% on room air or admitted to the ICU if there are clinical signs of respiratory distress. If discharged, the patient also needs to know to return if fever or changes in mental or pulmonary status occur.

The **Class 3 patient** (Table 20-4) can present with mild-to-moderate symptoms, including a cough, sore throat, dyspnea, altered vital signs, arrhythmias, hypoxia, hypothermia, consciousness changes, or metabolic acidosis. Chest auscultation may reveal subtle wheezes from bronchospasm or foreign body obstruction, or crackles from atelectasis or pulmonary edema. For Class 3 patients, follow the standard Advanced Cardiac Life Support (ACLS) and Advanced Trauma Life Support (ATLS) protocols with a focus on airway, breathing, and circulation. Indications for spinal stabilization include cervical spine injuries or head trauma from diving into shallow water, surfing, water skiing, and jet skiing or another hazard. All vital signs need assessment. Oxygen should be given to maintain an oxygen saturation >92%. All wet clothing need to be removed and rewarming started on any hypothermic patient. These patients require placement on telemetry to monitor for cardiac arrhythmias. The patient may require a chest radiograph to look for evidence of aspiration, pneumonitis, atelectasis, pulmonary edema, and inhaled foreign bodies.[18] The mild to moderately symptomatic patients with abnormal vital signs, including low oxygen saturation, should be admitted for observation and supportive care for a *minimum* of 6–24 hours. The length of admission depends on the patient's clinical status. When symptoms have resolved, these patients may be discharged.[18]

The **Class 4 patient** (Table 20-4) is a severely symptomatic victim of drowning. Follow the ACLS, ATLS, and emergency stabilization guidelines with a focus on prompt correction of hypoxemia and acidosis for these patients. Attempts at spinal immobilization should *not* delay the removal of a patient from the water.[10] On scene, drowning victims can appear mottled and have minimal or no peripheral pulses, due to profound vasoconstriction, despite a heartbeat. Rescuers may assume the victim is dead when, in fact, there is cardiac function. Because the initial assessment in this situation is difficult, CPR needs to begin the moment the victim is out of the water.[20] Basic life support (BLS) is key to victim survival with on-scene resuscitation the surest predictor of survival.[15]

Some patients with prolonged submersion in cold water may appear "cold and dead." In these severely hypothermic patients, resuscitation and warming should be initiated and continued until the core temperature reaches 32–34°C.[14] If the patient is still in cardiopulmonary arrest following rewarming, resuscitation can be terminated.[18]

Cardiac arrest from drowning is due mostly to hypoxia. The sequence of CPR for drowning remains airway–breathing–circulation rather than circulation–airway–breathing because drowning victims need urgent replenishment of oxygen starting with rescue breaths as a result of severe asphyxia.[21] Mouth-to-mouth ventilation in the water may be helpful when administered by a trained rescuer.[22]

Table 20-5 shows a more sophisticated classification system based on data from 41,279 rescues.[13] This system not only stratifies risk but also helps guide prehospital interventions and predicts survival. This classification system has eight grades: Rescue, Grades 1 through 6, and Dead.[13] Patient evaluations and submersion time are the basis for the classification system. The initial assessment includes checking for verbal and tactile responses to stimuli. No response to these stimuli initiates opening the airway and checking for ventilation. Subsequent evaluations guide the recommendations for interventions and management, including checking for a pulse, breath sounds, cough, and blood pressure. This classification system allows for research concerning the treatment and progress of drowning victims.

TABLE 20-5
Severity Drowning Classification System for Prehospital Victims

Grade	Signs and Symptoms
Rescue	Alive with normal breath sounds • no cough • no evidence of pulmonary edema (no foam in mouth or nose) • no dyspnea • no cardiac arrest
1	Cough present • no evidence of pulmonary edema (no foam in mouth or nose)
2	Some crackles on auscultation • small amount of pulmonary edema (some foam in mouth or nose)
3	Acute pulmonary edema without hypotension or shock • large amounts of foam in mouth or nose • palpable radial pulse
4	Acute pulmonary edema with hypotension or shock • large quantities of foam in mouth or nose • no palpable radial pulse • carotid pulse present
5	Respiratory arrest • no breathing • pulse present
6	Cardiopulmonary arrest
Dead	Obvious physical evidence of death

Data from Szpilman D, Simcock A, and Graves S. Classifications of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment.* 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014: 689.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The target oxygen concentration for a drowning patient is ≥92%.
2. True or False: The presence of foam in the mouth or nose is an indicator of pulmonary edema.

Etiology

Witnesses rarely report the classic image of the drowning victim who is gasping for air and thrashing the water around. More often, witnesses describe the victim as suddenly motionless in the water or diving into the water and never resurfacing, swimming under water and appearing to "play possum," or quietly disappearing below the surface.[23] Drowning is mostly silent and rapid.

The primary reasons for drowning include the inability to swim, lack of barriers around swimming areas, lapses in supervision, and failure to utilize safety equipment. Drowning is often a secondary event and may be due to several factors. See Box 20-1. These factors include alcohol ingestion, cardiac arrhythmias, cervical spine injury, drug ingestion, head trauma, hyperventilation, hypoglycemia, hypothermia, myocardial infarction, poor neuromuscular control, seizures, suicide, and syncope.[24] Alcohol and drug use can impair judgment and swimming ability. Cardiac arrhythmias, myocardial infarction, seizures, and syncope can incapacitate a swimmer. Immersion in cold water can result in a loss of body heat and lead to hypothermia, resulting in

BOX 20-1 Primary and Secondary Causes of Drowning

Primary Causes of Drowning	Secondary Causes of Drowning
• Inability to swim • Lack of barriers around swimming areas • Lapses in supervision • Failure to utilize safety equipment • Forces of nature	• Alcohol use • Assault • Cardiac arrhythmias • Cervical spine injury • Drug ingestion • Head trauma • Hypoglycemia • Hypothermia • Intentional hyperventilation • Myocardial infarction • Poor neuromuscular control • Seizures • Suicide • Syncope

confusion, incoordination, and muscle rigidity. Head and cervical spine injury may prevent a person from resurfacing following a diving or boating accident. Hyperventilation prior to diving into water decreases the body's $Paco_2$, while not significantly increasing the Pao_2. The result of lower $Paco_2$ levels at the start of breath-hold is that it takes longer to reach the levels required to drive the urge to breathe. During underwater swimming, the Pao_2 can decrease to levels of 30–40 torr. The delay in the urge to breathe can result in loss of consciousness due to hypoxia with no warning.[23,25]

The behaviors that may lead to drowning injury include intentional hyperventilation, static apnea, and hypoxic training swimming. These behaviors have been designated as "dangerous underwater breath-holding behaviors" (**DUBBS**). **Static apnea** is pure breath holding underwater. Hypoxic training swimming entails underwater lap swimming and resistance to the urge to breathe. DUBBS can lead to the death or injury of otherwise strong, healthy swimmers.[26]

The cause of drowning tends to vary with the person's age.[24] Infants and children under the age of 5 years most often drown by falling into swimming pools or other bodies of water around the home (buckets and bathtubs).[27] It is not usually a complete lack of adult supervision that leads to these drownings. It is, rather, a momentary lapse in supervision, as in the chapter case study.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The drowning of infants and small children is often due to a momentary lapse in supervision.
2. True or False: Drowning victims typically thrash about in the water gasping for air.

Epidemiology

In 2014, the WHO reported that worldwide, drowning accounts for an estimated 372,000 deaths annually and is the third leading cause of unintentional injury death.[28] Overall, drowning death rates in the United States have declined in the past decade; however, drowning is the primary cause of injury death among children 1–4 years of age.[4,29] In all ages groups, unintentional drowning is the tenth leading cause of injury death. See **Table 20-6** for an age breakdown of unintentional drowning as a cause of injury deaths in the United States.

The site of drowning varies by age group, with bathtubs responsible for 51% of the drowning deaths of infants under age 1 year. Swimming pools account for 58% of drowning deaths among children ages 1–4 years, and natural bodies of water are the site of 55% of drowning among children 5–19 years.[30] **Figure 20-4** shows the percentage of deaths for all age groups that occur in the United States from drowning in the various sites. In the United States, during 1999–2006, three states had the highest number of unintentional drowning mortalities: California, Florida, and Texas.[31]

TABLE 20-6
Unintentional Drowning as a Leading Cause of Death by Age Group

Rank of Unintentional Drowning as Related to the Leading 10 Causes of Injury Deaths	Age Group
1	1–4 years
2	5–9 years
3	No age group
4	No age group
5	10–14 years
6	15–24 years
7	<1 year
8	25–34 years
9	35–44 years
10	45–54 years

Data from National Center for Injury Prevention and Control. CDC using WISQARSTM, 10 Leading Causes of Injury Deaths by Age Group Highlighting Unintentional Injury Deaths, United States; 2013.



FIGURE 20-4 Locations of unintentional drowning deaths—the United States, 2010.

Data from Baldwin G, Gilchrist J, Noonan R. The burden of drowning: issues in selected countries – The United States. In: Bierens J, ed. Drowning: Prevention, Rescue, Treatment. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:99–100.



FIGURE 20-5 Death rates from unintentional drowning, by age group: United States, 1999–2010.

From Xu JQ. *Unintentional Drowning Deaths in the United States*, 1999–2010. NCHS data brief no. 149. Hyattsville, MD: U.S. Department of Health and Human Services, CDC, National Center for Health Statistics; 2014.

The National Center for Health Statistics (NCHS) reported that drowning death rates decreased over time for all age groups.[29] The exception is adults aged 45–84 years.[23] Also, the average daily number of deaths from unintentional drownings on a weekend day was 48% higher than that on a weekday.[29] Furthermore, drowning occurs most often (a) in a bathtub for persons under 1 year of age and over 85 years of age, (b) in a swimming pool for children aged 1–4 years, and (c) in natural water for persons aged 5–84 years.[29] **Figure 20-5** shows the deaths per 100,000 in the United States by age group for the years 1999 through 2010.

The global burden of death from drowning is within all economies and regions. However, the WHO has found three exceptions. First, low- and middle-income countries account for 91% of unintentional drowning deaths. Second, over half of the world's drowning occurs in the WHO Western Pacific Region and WHO South-East Asia Region. Third, drowning death rates are highest in the WHO African Region and are 10–13 times greater than those seen in the United Kingdom or Germany, respectively.[28]

In the United States, the most economically active segment of the population suffers 45% of deaths from drowning. The mortality rate for males is higher than for females, and the death rate for blacks is significantly greater than the overall death rate. Males accounted for more than half of the **nonfatal drowning** patients in the emergency department.[4] The economic burden of drowning is tremendous. Coastal drowning in the United States alone accounts for $273 million each year in direct and indirect costs.[28]

KNOWLEDGE CHECK QUESTIONS

1. In the United States, the death rate is highest for the _____ age group.
   - **a.** <1 year
   - **b.** 1–4 years
   - **c.** 10–14 years
   - **d.** 15–24 years
2. The highest number of unintentional drowning mortalities occurs in _____.
   - **a.** Louisiana
   - **b.** North Carolina
   - **c.** Texas
   - **d.** Washington

Pathophysiology

Pathophysiologic events are only part of the cause of drowning. Several factors influence drowning, including the swimming ability of the victim; the time in or under the water; the water temperature; and water conditions such as clarity, waves, currents, and water pollution.[32] Each drowning scenario is different, and not all pathophysiologic mechanisms involved in drowning occur. Many of the mechanisms may be life threatening, and some may be life protective.[32]



FIGURE 20-6 The drowning process[9,13,18,33]—a victim can be rescued at any time during the drowning process.

The Drowning Process

The drowning process itself is a continuum (**Figure 20-6**) that starts when the victim's airway falls below the surface of a liquid medium, most often water. Before this occurs, while the victim's airway is above the water, a struggle may occur. Adults can struggle for about 60 seconds while children only for 20 seconds before they become submerged.[33]

Once the victim's airway is under the surface, voluntary breath holding occurs. During the panic, however, breath holding may be completely absent. The amount of time for this breath holding, **apneic time**, varies widely. These variabilities depend on water temperature, previous experience, training, psychologic factors, age, gender, vital capacity of the lungs, and glucose and progesterone levels.[32] Most individuals tolerate only about 1 minute of apnea, less if alcohol is involved. Hypoxia trained individuals may tolerate over 2 minutes of breath holding. The tolerance in these trained individuals is increased most of all for a higher $PaCO_2$ and to a lesser extent for a lower PaO_2.[32] The maximum amount of apneic time for a static dive is longer than 10 minutes.[34]

Gasping causes a small quantity of water to enter the lungs during the struggle or breath-hold. This amount is typically <30 mL.[33] During the apneic time, the oxygen level drops, and the carbon dioxide level builds within the blood. The victim suffers hypercarbia, hypoxemia, and acidosis. Involuntary laryngospasm may occur following the voluntary breath-hold. During this time, respiratory movement may occur but aspiration does not take place. Once the degree of hypoxia is sufficient, causing the victim to lose consciousness, the protective reflexes intact are lost and the laryngospasm releases. At this time, the victim aspirates water.[35] Unconsciousness may occur earlier in the drowning continuum if the victim hyperventilates prior to or during the drowning process. The loss of consciousness is from **cerebral hypoxia**, lack of oxygen in the brain, occurring prior to the hypercapnic drive to breathe.[23,25]

Involuntary respiratory drive or loss of consciousness leads to the aspiration of water. The amount of water that enters the lungs in human drowning is somewhere between 2 and 4 mL/kg.[14] Water ingestion happens most commonly during the initial struggle to stay above water and varies among victims. Water ingestion can lead to regurgitation and aspiration during the drowning process, spontaneous recovery, and resuscitation.[36]

Pulmonary Injury

Pulmonary injury from drowning initiates with the aspiration of water. As little as 1–3 mL/kg of water may be sufficient to affect the lung parenchyma.[18] The bottom line in pulmonary compromise from drowning is the same no matter what type of water is aspirated: ventilation–perfusion mismatch.

Fluid aspiration, salt water or fresh water, causes a disruption in the pulmonary surfactant, leading to alveolar collapse, ventilation–perfusion mismatch, and ultimately pulmonary shunting (**Figure 20-7**). The aspiration of salt water washes out pulmonary surfactant and draws capillary fluid into the pulmonary interstitium and alveoli. This causes a decrease in lung compliance, bronchospasm, and ventilation–perfusion mismatching. Freshwater aspiration destroys pulmonary surfactant and causes capillary permeability. This leads to a reduction in lung compliance, atelectasis, and ventilation–perfusion mismatching.

Whether the drowning event occurs in fresh water or salt water, the result is pulmonary edema, a decrease in pulmonary compliance, and an increase in the ventilation–perfusion mismatch. Immediately after aspiration of either type of liquid, a large alveolar–arterial oxygen gradient is seen, whether the subject is breathing room air or 100% oxygen. This suggests the hypoxia seen in drowning victims is due to ventilation–perfusion mismatch, which spans the spectrum from absolute intrapulmonary shunt to a simple imbalance in the ventilation–perfusion ratio.[14] The damage caused to the lung parenchyma and capillaries can lead to acute lung injury and ultimately acute respiratory distress syndrome (ARDS).[18]

Finally, the aspirated medium may carry debris and infectious organisms, which can promote lung infections.[38] When the aspiration is significant, there may be early evidence of intra-alveolar consolidation. See **Figure 20-8**. It may be tough to differentiate infection from aspiration pneumonitis in the acute setting.[18]

Cardiovascular Dysfunction

The cardiovascular effects of drowning result from hypoxia, acid–base disturbances, catecholamine release, and hypothermia. Initially, apnea leads to decreased oxygen saturation and precipitates tachycardia and hypertension. Bradycardia and hypotension follow. Blood shunts to vital organs, such as the brain, heart, and lungs.[39] Bradycardia is myocardial protection when present because myocardial oxygen consumption falls in response to the bradycardia.[10] See **Figure 20-9**. Bradycardia is also a response activated when there is cold-water immersion of the face. This is called the **diving response** and is one of the mechanisms proposed to explain why a few drowning victims survive underwater in cold water for as long as 66 minutes.[40]

Immersion in cold water speeds the above process and often leads to the impaired ability of the victim to swim (swimming failure) because of decreased perfusion of the extremities.[41] A sudden immersion in cold water produces a dynamic response in the body's



FIGURE 20-7 Pulmonary damage from drowning.[37] Profound alterations in oxygenation may occur when a victim aspirates as little as 1–2.2 mL/kg of water into the lungs.[14]



FIGURE 20-8 Chest radiograph of an 84-year-old post-drowning patient taken 1 hour after submersion shows multiple, confluent consolidations.

Case courtesy of Dr Jan Frank Gerstenmaier, Radiopaedia.org, rID: 24685.



FIGURE 20-9 Cardiovascular changes during drowning.

cutaneous thermoreceptors, located just below the surface of the skin. This response, called **cold shock**, causes a sympathetically mediated tachycardia, uncontrollable hyperventilation, hypertension, and increases in plasma catecholamine levels. Hypothermia increases the heart's vulnerability to ventricular fibrillation and makes it relatively unresponsive to both electrical and pharmacologic interventions.

Sinus bradycardia is the most common arrhythmia noted after submersion, but fatal arrhythmias such as ventricular fibrillation and asystole are also frequently encountered.[42] The interactions between the parasympathetic-mediated bradycardia by the diving response and sympathetic-mediated vasoconstriction by the cold shock response lead to autonomic arrhythmogenic co-activation of the heart. See Figure 20-9. Both sympathetic and parasympathetic stimulation of the heart can induce cardiac arrhythmias even in young, fit, and healthy individuals. The activation of both the sympathetic and parasympathetic nervous systems is called "**autonomic conflict**" (**Figure 20-10**). It produces a simultaneous and conflicting positive and negative chronotropic drives to the heart, causing supraventricular and junctional arrhythmias.[42] Death from autonomic conflict is most likely an underreported cause of mortality in drowning because arrhythmias are undetectable during autopsy.[42]

In drowning victims, who are in cardiac arrest, pulseless electrical activity (PEA) and asystole are the most common arrhythmias, owing to the hypoxic nature of the injury.[13] Hypoxic myocardial dysfunction, as well as immersion diuresis, can lead to systemic hypotension, further exacerbating cardiac and neurologic injury.[43]

Unlike victims with a primary cardiac arrest, almost all submersion victims have a health heart when they get into trouble. The course of cardiac events during drowning is much more complex and variable than the on–off mechanisms that occur during a cardiac arrest due to ventricular fibrillation. Drowning is a unique form of cardiopulmonary arrest.[44]

Hypothermia

Hypothermia is a core body temperature of <35°C. There are three categories: **mild hypothermia** (32–35°C), **moderate hypothermia** (30–32°C), and **severe hypothermia** (<30°C). The rate of change of core temperature in an immersed body is dependent on the interrelationship of several physical and physiologic factors. These factors include the water temperature, relative movement of water adjacent to the skin, body surface area to mass ratio, insulation, peripheral circulation, metabolism, or conditions that may cause any of these factors (e.g., injury, intoxication).[45] People cool 4–5 times faster in water than in air at the same temperature. In water below 25°C, the heat loss is greater than the metabolic heat production. This is why people rescued from water are often hypothermic, especially children because of their large surface area to body mass ratios.[46]

Hypothermia can play an important role in facilitating aspiration and poses a problem even if the victim's head remains out of the water (head-out immersion). As body temperature falls, shivering increases oxygen consumption and metabolic rate with contractions of small and large muscle groups, in an attempt to increase heat production. Below a core temperature of about 30°C, shivering stops, heart rate and blood pressure fall, and oxygen consumption and metabolic rate decrease.[6] Immersion times of 2–5 minutes seem to be well tolerated by young, healthy people. Total immersion of 25 minutes or more is associated with a very high mortality rate, although precise figures vary widely according to the associated factors mentioned earlier.[6] Hypothermia can lead to the drowning of head-out immersion victims. See **Table 20-7** for effects of hypothermia on body function.

There is considerable debate about whether hypothermia in drowning acts as a protective mechanism. For hypothermia to have a neurologic protective function, cooling must take place rapidly and ideally before any hypoxic insult.[20] The water would need to be <10°C (50°F) for this to occur.[47] One example is a 2-year-old girl who fell into iced water (<5°C) and recovered after being completely submerged for 66 minutes.[48] **Table 20-8** shows a time table with responses and hazards of immersion and submersion in cold water.



FIGURE 20-10 Autonomic conflict—cold-water immersion activates two powerful reflexes—the diving response (on facial immersion) and the cold shock response (on the activation of cutaneous cold receptors). The magnitudes of these responses can vary with a range of factors, including water temperature, clothing, and habituation. Individually, the diving response triggers a parasympathetic bradycardia, while cold shock activates a sympathetically driven tachycardia. Together these conflicting inputs to the heart can lead to arrhythmias—particularly during the breath-hold that increases parasympathetic tone that varies with breathing. The substrate for arrhythmias is enhanced by various predisposing factors, including the failure of the QT interval to match the rapid and transient changes in heart rate. In circumstances other than cold-water immersion, these may additionally include awakening, anger, stress, arousal, etc.

Reprinted with permission from Wagner C. Pediatric submersion injuries. *Air Med J.* 2009;28(3):116–119. doi:10.1016/j.amj.2009.02.009.

Blood Volume and Electrolyte Effects

Changes in blood volume and electrolytes depend directly on the amount of fluid aspirated. The amount of fluid typically aspirated by a drowning victim is only 2–4 mL/kg. It takes more than 11 mL/kg of hypotonic fluid to increase blood volume. If resuscitated, this type of victim develops hypovolemia due to redistribution of the liquid. Hypovolemia occurs following the aspiration of a significant amount of hypertonic fluid (salt water). However, most drowning victims do not aspirate enough fluid to cause life-threatening changes in blood volume.[14]

Significant electrolyte changes secondary to aspiration of large fluid volumes is rare.[10] An exception is drowning in extremely electrolyte-rich liquids, such as the Dead Sea, which has electrolyte concentrations 10-fold higher than sea water.[49]

TABLE 20-7
Grades of Hypothermia

Body Function	Mild Hypothermia (32–35°C)	Moderate Hypothermia (30–32°C)	Severe Hypothermia (<30°C)
Circulation	Tachycardia Vasoconstriction Acrocyanosis	Bradycardia Atrial arrhythmia Electrocardiogram (ECG) changes (J wave, prolonged QT time)	Ventricular arrhythmia Asystole PEA
Respiration	Tachypnea Hyperventilation	Bradypnea Hyperventilation	Apnea Pulmonary edema
Neurology	Apathy Ataxia Hyperreflexia Impaired speech Impaired cognition	Impaired consciousness Hyporeflexia Dilated pupils	Coma Unreactive pupils
Muscular symptoms	Shivering	Muscular rigor	Rhabdomyolysis
Other	Cold diuresis		

Reproduced from Schilling U, Bortonlin M. Drowning. *Minerva Anestesiol.* 2012;78(1):74.

TABLE 20-8
Responses and Hazards of Immersion and Submersion in Cold Water

Time Period	Tissue Cooled	Physiologic Responses	Hazards
Initial (0–3 minutes)	Skin	Cold shock Autonomic conflict	Drowning Cardiovascular problems
Short term (3–30 minutes)	Superficial nerves and muscles	Decreased: coordination, strength, dexterity, and swimming ability	Drowning Physical incapacitation
Long term (>30 minutes)	Deep body tissues	Deep body cooling	Drowning Hypothermia Unconsciousness Cardiac problems Collapse of arterial blood pressure

Reproduced with permission from Tipton M, Golden F. The physiology of cooling in cold water. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment.* 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014;848.

Neurologic Injury

Traditionally, drowning has been viewed as a process affecting the pulmonary system. However, a more accurate description of drowning includes effects on the brain.[43] During the first 5 minutes of submersion, the brain receives less and less oxygen due to cardiopulmonary compromise. As the cerebral blood flow falls, hypoxia occurs (cerebral anoxia). The brain has negligible metabolic reserves and cannot remain viable in the absence of a continuous delivery oxygenated blood. It is the intensity and duration of cerebral hypoxia that are the most important elements of brain demise in drowning.[50] This cerebral hypoxia causes a pathophysiologic cascade leading to neuronal damage and death. Irreversible acute neuronal injury and the resulting pathologic changes (demyelination, tissue death, edema, and hemorrhage) can result in chronic morbidity, ranging from mild cognitive impairment to a persistent vegetative state.[43]

Over the past 50 years, numerous clinicians and researchers have attempted to enhance cerebral perfusion in hopes of promoting favorable neurologic outcome after a drowning event. Even after creating an ideal environment for the brain to heal (normal arterial oxygen concentrations, normal glucose levels, normal intracranial pressures, sufficient cerebral perfusion pressures, permissive hypothermia for the first 20–24 hours post submersion), there is no improvement in outcomes.[18]



FIGURE 20-11 Simplified scheme of the complex pathophysiology in drowning. Other factors, not in this scheme, include hypercapnia, arrhythmia, hypothermia, and infection. Cerebral and pulmonary damage, primarily due to hypoxia, are the limiting prognostic factors.
Reproduced from Schilling U, Bortonlin M. Drowning. *Minerva Anestesiol.* 2012;78(1):69–77.

Renal Injury

Kidney failure frequently develops after prolonged submersion injury. Acute tubular necrosis can develop from hypoxia, lactic acidosis, hypoperfusion, hemoglobinuria, or muscle injury.[10,42]

Summary of Pathophysiology of Drowning

A summary of the pathophysiology of drowning is given in **Figure 20-11**. It shows a "simplified" schematic view of the pathophysiology of drowning, including initial submersion, aspiration, hypoxia, pulmonary damage, and cerebral damage.

KNOWLEDGE CHECK QUESTIONS

1. The amount of water that typically enters the lungs during drowning is _____.
   a. 1–3 mL/kg
   b. 2–4 mL/kg
   c. 4–6 mL/kg
   d. 6–8 mL/kg
2. True or False: The end result of drowning in salt water or fresh water is the same, pulmonary shunt.

Risk Factors

Identification of the risk factors leading to drowning is essential for the development of targeted, effective prevention strategies. Drowning is a multifaceted event with multiple risks varying by the type of body of water, age group, and activity involved.[25] There are two main risk factor categories: host risk factors and environmental risk factors. See **Box 20-2** for the risk factors for drowning by age group in the United States.

Host Risk Factors

Certain factors about the individuals who drown have been identified as risk factors for drowning. These are considered host risk factors and include gender, age, alcohol usage, seizure disorders, behavior, and swimming ability.

Gender

Males are especially at risk of drowning, with twice the overall mortality rate for females. Males are more likely to be hospitalized than females for nonfatal drowning. Studies suggest that the higher drowning rates among males are due to the increased exposure to water and riskier behavior. These behaviors include swimming alone, drinking alcohol before swimming alone, and boating.[28]

Age

Globally age is one of the major risk factors for drowning. In the United States, drowning is the first leading cause of unintentional injury in children aged 1–4 years.[51] This relationship is associated with a lapse in supervision. Children younger than the age of 1 year most often drown in bathtubs, buckets, and toilets. Children ages 1–4 are more likely to drown in

BOX 20-2 Various risk factors for drowning

Residential pools	https://www.shutterstock.com/image-photo/child-danger-drowning-pool-watch-your-762059431?src=ZmfDDN1MHjp1tvzURflP_w-1-1
Access to open bodies of water	https://www.shutterstock.com/image-photo/danger-drowning-warning-sign-330918137?src=ZmfDDN1MHjp1tvzURflP_w-1-6
Alcohol use	https://www.shutterstock.com/image-photo/sunset-boat-party-young-people-toasting-1066679024?src=MpxaxgjfiEFLN-6dNHVzag-1-12

From Nelson S, McCorvey S. *Submersion and drowning injuries.* AHC Media. 2015. http://www.ahcmedia.com/articles/135278-submersionand-drowning-injuries. Accessed September 7, 2015.

a residential pool.[18] The ratio of child to adult drowning in the United States is 3:1, a relatively high ratio.[25] Adolescent drownings in association with recreational water activities occur due to inexperience in boating or swimming.[25] Drowning among adults 65 and older is often due to comorbid medical conditions, such as cardiovascular disease or depression, and most often due to bathing alone at home.[52]

Alcohol

Alcohol is often used in association with recreational aquatic activity. Thirty to seventy percent of swimming and boating fatal drowning victims had a measurable blood alcohol concentration, and 10–30% of those deaths could be attributed specifically to alcohol use.[53] Alcohol intake impairs judgment and performance before submersion and impairs orientation and enhances hypothermia once submersion occurs.[54]

Seizure Disorders

The presence of seizure disorders in any age group increases the risk of drowning.[52] The bathtub is the highest risk site for drowning fatalities related to seizure disorder.[25]

Behavioral Risk Factors

Risk-taking behaviors include alcohol use, not using approved safety devices and swimming where there is no lifeguard or supervision. Greater alcohol use and increased risk taking while vacationing may explain increased drowning risk of tourists. Minority groups may avoid the use of safety devices because they do not want others to stigmatize them for not being able to swim or swim well.[55]

Swimming Ability

Poor minority children, specifically African American and Hispanic/Latino, are at a significant disadvantage concerning swimming ability. Females are more "at risk" regarding their swimming ability than their male counterparts. Age, race, and socioeconomic factors (lunch program and parental education) are associated with children who have low swimming ability.[56]

Environmental Risk Factors

Another risk factor for drowning is the environment within which a person drowns. A person could have none of the host factors but could drown because that person was in or from a high-risk environment. These factors include place of occurrence, socioeconomic status, parental supervision, and geographic and climate conditions.

Place of Occurrence

Access to swimming pools, especially residential, is a primary risk factor for childhood drowning. Risk also varies with the type of barrier used to prevent access to the water, with four-sided isolation fencing having the lowest risk. Containers of water in or around the home, such as five-gallon buckets, present a drowning risk for toddlers as it did in the chapter case study. Open bodies of water, such as lakes, ponds, rivers, and canals, are the sites where people drown most often.

Socioeconomic Status

Individuals and families of lower socioeconomic status often live in unsafe environments. Several factors common to low-income families may increase a child's risk for drowning, including single-parent households, lack of parental education, young maternal age, and multiple siblings.[57] Low-income families are less likely to use safety devices, due to lack of money, lack of transportation to obtain safety devices, lack of control over housing conditions, or all of these.[57]

Parental Supervision

Infant drowning is not always due to a complete lack of adult supervision but, rather, because of a momentary lapse in supervision.[54] It is during that momentary lapse that a child can fall into a pool, bucket, or any open body of water. What composes adequate supervision remains poorly defined. It includes multiple skills, such as being aware of hazards; shouldering responsibility to take on the role of supervision; providing close, constant, and unimpaired attention; and recognizing when someone is in distress.[25]

TABLE 20-9
Prevention Measures for Drowning[13,54,58]

Environmental Strategies	Individual Strategies
Adult supervision of young children	Swimming instruction
Pool fencing (four sided)	Water survival training
Pool alarms (water-entry alarms)	Use personal floatation devices (not inflatable arm bands)
Lifeguards	Avoid rip currents
CPR training	Swim in areas with lifeguards
	Do not drink and swim or boat
	Swim with others

Geographic and Climate Conditions

Adverse climate and water conditions, such as extreme heat or cold, storms or typhoons, or flooding, substantially increase the risk of fatal drownings. Unfamiliarity with easily changing weather is an important risk factor for drowning.[25]

Prevention

The most efficient intervention for drowning is prevention, with the prime targets being the environment and the individuals. Multiple "layers of protection" are best to prevent drowning, because no single strategy is likely to avoid all submersion deaths and injuries. These layers might include environmental changes, such as adult supervision, pool fencing, water-entry alarms, lifeguards, and CPR training. Individual focus prevention includes strategies such as swimming and survival skills training and the use of personal floatation devices.[54] **Table 20-9** summarizes preventative measures for drowning.

KNOWLEDGE CHECK QUESTIONS

1. _____ is a risk factor for drowning in children and adolescents in the United States.
   a. Alcohol use
   b. Being male
   c. Using a bath seat
   d. Swimming in residential pools
2. True or False: Multiple layers of protection are best to prevent drowning.

Complications Associated with Drowning

Drowning victims often develop aspiration (chemical) pneumonitis. Drowning-associated pneumonia is difficult to diagnose due to the pulmonary abnormalities that appear on the chest x-rays of drowning victims. Patients who had a drowning incident in grossly contaminated water, such as sewage or manure, should receive antibiotics to reduce the risk of bacterial lung infections. The use of prophylactic antibiotics does not influence patient outcomes and is not indicated.[20,49,59] **Table 20-10** shows other complications of drowning.

TABLE 20-10
Complications Associated with Drowning

ARDS	Pneumonia
Aspiration (water, sand, vomitus)	Pneumonitis
Cardiac arrhythmias	Pulmonary edema
Dehydration	Renal insufficiency
Electrolyte abnormalities	Rhabdomyolysis (muscle fiber death from extreme muscle strain)
Hypothermia	Trauma
Hypoxic encephalopathy	

Data from Moon R, Long R. Drowning and near-drowning. *Emerg Med.* 2002;14:377–386.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Drowning victims rarely develop pneumonitis.
2. True or False: Give prophylactic antibiotics to reduce the risk of bacterial infection during the post-drowning recovery period.

Diagnostic Testing

Diagnostic testing for drowning injury is based on the severity of the patient. Aspiration of water disrupts gas exchange by washing out surfactant and can precipitate ARDS.

Radiological Imaging

Chest radiography is an ancillary diagnostic test for drowning patients because imaging immediately after a drowning episode is most often normal. Chest x-rays are useful in the emergency department if trauma or symptoms dictate (respiratory distress or arrest or worsening mental status).[20,43] If pulmonary edema is present, a "batwing" pattern of pulmonary edema is seen.[60] **Figure 20-12** shows a chest radiograph of a post-resuscitation drowning patient.



FIGURE 20-12 Posterior–anterior chest radiograph of a post-resuscitation drowning patient.
Reproduced with permission from THE UNIVERSITY OF VIRGINIA.

Laboratory Studies

Patients with mild symptoms and normal oxygen saturation do not warrant specific laboratory testing. Obtaining ABG levels is unnecessary in well-appearing, normoxic asymptomatic patients.[43]

Patients displaying moderate to severe symptoms, or patients for whom a detailed history is unobtainable, may benefit from laboratory testing to evaluate continued altered mental status, cardiac disease, **rhabdomyolysis** (breakdown of muscle tissue that releases a damaging protein into the blood), and other conditions affected by or related to the drowning incident.[43] See **Table 20-11** for tests that may aid in further evaluation of sequelae from the drowning event.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A "batwing" pattern seen on the chest radiograph of a hospitalized drowning patient is evidence of pulmonary edema.
2. One of the lab tests recommended for a hospitalized drowning patient with evidence of altered mental status is _____.
   a. serum creatinine
   b. coagulation panel
   c. ABG
   d. ECG

TABLE 20-11
Diagnostic Workup for Post-drowning Patients with Moderate to Severe Symptoms

Symptoms	Diagnostic/Laboratory Testing
Altered mental status	• ABG • Blood glucose • Blood alcohol level • Basal metabolic panel (BMP) • Complete blood count (CBC) • Head computed tomography (CT) scan
Cardiac disease	• Cardiac enzymes • ECG
Rhabdomyolysis	• BMP • Creatine kinase (CK) • ECG • Potassium • Serum creatinine
Trauma (head/neck)	• BMP • Coagulation panel • CBC • CT scan of head and C-spine • Type and screen

Data from Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract.* 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.

Treatment and Management

The goal of resuscitation is immediate ventilation and oxygenation to interrupt the sequence of events leading to cerebral anoxia. To accomplish this goal, aggressive field and hospital resuscitation must be used.[23] Two categories for drowning treatment exist, prehospital (field) treatment and hospital treatment.

Prehospital Treatment

Depending on the distance involved, the best recommendation for drowning may be to bring the medical equipment to the victim to decrease the time to intervention.[61] Advanced medical treatment is given according to drowning classification. **Table 20-12** shows the drowning severity classification system, seen in Table 20-5, along with the prehospital treatment recommended for each classification.

Hospital Treatment

The basis for hospital treatment is the four-patient classification system seen in Table 20-4. The initial emergency department evaluation and treatment focuses on establishing and maintaining a patent airway, along with the delivery of oxygen with the goal to keep oxygen saturation at around 95%.[43]

Patients with submersion associated with EMS notification, amnesia for the event, loss or depressed consciousness, an observed period of apnea, and those who

TABLE 20-12
Prehospital (Field) Treatment for the Different Grades of Drowning Severity

Grade of Severity	Prehospital Treatment
Rescue	• Evaluate victim • Release from the accident site without further medical care
1. Coughing with normal lung auscultation	• Rest • Warm • Calm the victim • Advanced medical attention or oxygen is not required
2. Abnormal auscultation with crackles in some pulmonary fields	• Nasal cannula 5 L/minutes • Warm • Calm the victim • Recovery position if unconscious (lateral decubitus) • Hospitalization for 6–48 hours • Chest radiograph for suspected pulmonary edema • ABG
3. Acute pulmonary edema without hypotension	• High-flow oxygen (HFNC, nonrebreather mask) • Possibly noninvasive ventilatory support or intubation with mechanical ventilation • Recovery position (lateral decubitus position) if unconscious • Follow protocols for Grade 4
4. Acute pulmonary edema with hypotension	• Treatment for Grade 3 • Start crystalloid intravenously (IV) via peripheral vein (independent of type of water) until restoration of normal blood pressure • Inotropic or vasopressor drugs rarely needed.
5. Respiratory arrest	• Mouth-to-mouth ventilation immediately at 12–20 breaths/minute with 15 L of oxygen until restoration of breathing • Treatment for Grade 4
6. Cardiopulmonary arrest	• Initiate BLS • Intubate as early as possible • Defibrillate if necessary • Obtain venous access to give epinephrine each 3 minutes • After CPR, follow treatment for Grade 3 and 4 • If hypothermic, continue CPR
Dead	• Do not start resuscitation

Data from Szpilman D, Simcock A, Graves S. Classifications of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment.* 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014; 689.

require a period of artificial ventilation should be transported to an emergency department for evaluation, even if they are asymptomatic at the scene.[19] All patients need to be warmed, assessed for GCS score, and monitored for vital signs, and IV access needs to be established. **Figure 20-13** shows a general flow chart for the initial emergency department treatment of a drowning patient.

Class 1: No Evidence of Inhalation of Liquid

A significant number of victims who had to be rescued and received immediate care at the accident site have not inhaled water at all.[62] Asymptomatic patients who have suffered a drowning incident have no cough or dyspnea. Their vital signs are normal, without hypoxia or tachypnea, and their chest exam is normal, without crackles or wheezing. Management of these patients includes taking a complete set of vital signs, including temperature and pulse oximetry, doing a full physical exam, and looking for evidence of pulmonary or traumatic injury.[63] **Box 20-3** is a treatment summary for Class 1 patients. If 4–6 hours of observation reveals no abnormalities in oxygen status and pulmonary examination, the patient may be discharged home; see **Box 20-4**. Instructions to return if respiratory symptoms, fever, or mental status changes develop must be given.

Class 2: Clinical Evidence of Inhalation of Liquid with Adequate Ventilation

This category of patients has inhaled liquid but initial assessment shows the patient to have adequate ventilation. Assume these patients have hypoxemia until otherwise proven and require treatment with high-flow oxygen. Monitor their cardiorespiratory system closely. These patients may improve, but respiratory deterioration needs aggressive treatment. This treatment may include either continuous positive airway pressure



FIGURE 20-13 Initial drowning treatment flow chart for emergency department or ICU.

Redrawn from Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment.* 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:695.

BOX 20-3 Treatment Summary Class 1: Patients with No Evidence of Inhalation of Liquid

- Admit to emergency department for close observation
- Monitor oxygen saturation
- Assess for hypothermia
- If necessary, check electrolytes, glucose, CBC, and chest radiography
- Discharge after 6 hours

Data from Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:696.

BOX 20-4 Criteria for 6-Hour Discharge

- No fever, no cough, no respiratory symptoms
- No crackles, no rhonchi, no wheezing in lungs
- Normal oxygenation on room air (saturation ≥95%)

Data from Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:696.

(CPAP) or, when this fails, intubation and mechanical ventilation.[62] Hypothermia is a concern in all patients who were submerged in cold water. Assessing the patient for hypothermia is essential. If the findings of pulmonary examination and oxygen saturation on room air remain normal, discharge the patient home with explicit instructions to seek medical care for any respiratory, mental changes or fever. **Box 20-5** is a treatment summary for Class 2 patients.

BOX 20-5 Treatment Summary Class 2: Clinical Evidence of Inhalation of Liquid with Adequate Ventilation

- Admit for close observation
- Oxygen to maintain oxygen saturation at 90–95%, CPAP if necessary
- Assess for hypothermia and initiate rewarming if necessary
- Check electrolytes, glucose, CBC, and chest radiography
- Transfer to ICU wherever possible

Data from Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:697.

Class 3: Clinical Evidence of Inhalation of Liquid and Inadequate Ventilation

This category of patients has inhaled liquid and is showing progressive deterioration of respiratory function. Many of these patients have gasping respiration with a low respiratory rate.[62] Trials of noninvasive positive pressure ventilation (NIPPV) may overcome these challenges and should be considered.[14] In patients with poor persistent ventilation, poor oxygenation, or depressed mental status, intubation and positive end-expiratory pressure (PEEP) may be necessary.[14] Drowning victims can develop ARDS requiring ventilatory support and ICU admission. This class of patient requires continuous cardiopulmonary and neurologic monitoring and may require treatment for hypothermia. **Box 20-6** is a treatment summary for Class 3 patients.

Class 4: Absent Ventilation and Circulation

Class 4 patients need immediate intubation and mechanical ventilation with supplemental oxygen and PEEP. Asystole and ventricular fibrillation warrant aggressive CPR. The time to first resuscitation attempts is a critical factor that influences survival. Therefore, aggressive resuscitative measures, including reversal of hypoxia and cardiovascular stabilization, need urgent initiation in drowning victims regardless of initial clinical presentation.[13] ACLS and ATLS algorithms need follow-up with a focus on oxygenation, ventilation, volume support, and correction of acidosis. **Box 20-7** is the treatment summary for Class 4 patients.

BOX 20-6 Treatment Summary Class 3: Clinical Evidence of Inhalation of Liquid and Inadequate Ventilation

- Admit and transfer to ICU
- NIPPV trial or intubate and mechanically ventilate with supplemental oxygen and PEEP
- Monitor oxygenation and neurologic status
- IV infusion of warmed fluid
- Assess for hypothermia and metabolic acidosis
- Chest radiography, CBC, electrolytes, BMP, CK, ECG, serum creatinine

Data from Schmidt A, Sempsrott J. Drowning in the adult population: Emergency department resuscitation and treatment. *Emerg Med Pract*. 2015;17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015; Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:697.

BOX 20-7 Treatment Summary Class 4: Absent Ventilation and Circulation

- CPR
- Assess for hypothermia; initiate rewarming if necessary
- ECG
- Defibrillate ventricular fibrillation or ventricular tachycardia
- Intubation and mechanical ventilation with supplemental oxygen and PEEP
- Chest radiography, ABG, CBC, BMP, coagulation studies, electrolytes, CK, blood glucose
- Admit to ICU

Data from Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract*. 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.

There are no universally accepted standard ventilation strategies for drowning patients. Because drowning may lead to ARDS, utilizing lung protective ventilation strategies is recommended.[13,18,43] In some patients, pulmonary function deteriorates so dramatically that adequate oxygenation can be maintained only by extracorporeal membrane oxygenation (ECMO). Good evidence supporting the use of ECMO is lacking, and access to ECMO may be limited. Other treatments for these critically ill patients include the use of exogenous surfactant, inhaled nitric oxide, and partial liquid ventilation with perfluorocarbons.[13]

TABLE 20-13
Active Rewarming Methods for Hospitalized Patients

Active External Rewarming
• Forced-air warming blankets
• Radiant heaters
• Warm water bath
• Warming mattress
Active Internal Rewarming
• Warmed IV fluids
• Warmed inhaled oxygen
• Warmed bladder irrigation
• Peritoneal lavage
• Thoracic lavage
• Hemodialysis
• ECMO
• Cardiopulmonary bypass (CPB)

From Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract*. 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.

Hypothermia

There are numerous case studies reporting the normal neurologic outcome of hypothermic patients following prolonged submersion. These cases are most often children with rapid immersion in water <5°C, but these cases are rare.[43] Hypothermia usually reflects a prolonged submersion time and carries a poor prognosis.[13] Hypothermia triggers arrhythmias, thus hampering CPR. This may result in ventricular fibrillation that is impossible to defibrillate into sinus rhythm in gravely hypothermic patients.[64] The target temperature for a hypothermic patient receiving CPR is 34°C.[43,64] In the initial resuscitation of any hypothermic drowning patient, rewarming the core needs to begin early. For patients in cardiopulmonary arrest, active rewarming techniques require initiation during the resuscitation. **Table 20-13** shows active rewarming techniques used for hospitalized patients with hypothermia. **Table 20-14** displays the treatment strategies according to core temperature.

Summary of Hospital Treatment for Post-drowning Patients

Figure 20-14 shows an example of an emergency department clinical pathway for the resuscitation and treatment of patients involved in a drowning event. **Figure 20-15** is an emergency department clinical pathway for the resuscitation and treatment of patients in cardiac arrest after a drowning incident.



Abbreviations: ABCs - airway, breathing, and circulation; ABG - arterial blood gas; AMS - altered mental status; BMP - basal metabolic panel; CBC - complete blood count; Ca - calcium; CK - creatine kinase; CT - computed tomography; CXR - chest x-ray; ECG - electrocardiogram; EtOH - ethanol; CGS - Glasgow Coma Scale; ICU - intensive care unit; NC - nasal cannula; NIPPV - noninvasive positive-pressure ventilation; NRB - nonrebreather; Phos - phosphate; PPV - positive-pressure ventilation; PT - prothrombin time; PTT - partial thromboplastin time; SaO_2 - oxygen saturation; SOB - shortness of breath.

[a]Work up
- Hypoxia: CXR, ABG
- AMS: Head CT, Blood glucose, ABG, EtOH, BMP, CBC–
- Trauma (head/neck): CT head and C-spine, CBC, BMP, PT, PTT
- Hypothermia (mod-severe): CBC, BMP, Phos, Ca, PT, PTT, ECG
- Rhabdomyolysis: CK, BMP

FIGURE 20-14 Clinical pathway for emergency department resuscitation and treatment of patients involved in a drowning event.

Reproduced from Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract.* 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.



FIGURE 20-15 Clinical pathway for emergency department resuscitation and treatment of patients in cardiac arrest after a drowning incident.

Reproduced from Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract.* 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.

TABLE 20-14
Suggested Hypothermia Treatment Strategies According to Core Temperature

Core Temperature (°C)	Treatment Strategies
32–35	Warm environment Dress in warm clothing Give warm oral fluids Encourage movement
28–32	Warm IV fluids Apply heat packs Use forced-air warming blanket Warmed inhaled oxygen
24–28	Warmed IV fluids Warmed inhaled oxygen Warmed bladder irrigation Peritoneal lavage Thoracic lavage Hemodialysis
<24	ECMO CPB

Data from Engel S. Drowning episodes: prevention and resuscitation tips. *J Fam Pract.* 2015;64(2):E1–E6.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The recovery position for drowning victims is the lateral decubitus position.
2. The suggested method for rewarming a severely hypothermic (<24°C) drowning patient is _____.
   a. ECMO
   b. warm inhaled oxygen
   c. warm IV solutions
   d. peritoneal lavage

TABLE 20-15
Severity Classification with Percent Survival

Grade	Signs and Symptoms	Percent Survival
Rescue	Alive with normal breath sounds	100
1	Cough present	100
2	Some crackles on auscultation	99
3	Acute pulmonary edema without hypotension or shock	95–96
4	Acute pulmonary edema with hypotension or shock	78–81
5	Respiratory arrest	56–69
6	Cardiopulmonary arrest	7–12
Dead	Obvious physical evidence of death	0

Data from Szpilman D, Simcock A, Graves S. Classifications of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment.* 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:689.

TABLE 20-16
Prognostic Factors Used with Drowning Victims

Good Prognostic Indicators	Poor Prognostic Indicators
Submersion <5 minutes	Submersion >5 minutes
CPR in the field	No resuscitation for >10 minutes
CPR <25 minutes	Pupils fixed and dilated
Detectable pulse on arrival at emergency department	GCS <5 (comatose)
Age <14	pH <7.1

Data from Salomez F, Vincent J. Drowning: a review of epidemiology, pathophysiology, treatment and prevention. *Resuscitation.* 2004;63(3): 261–268. doi:10.1016/j.resuscitation.2004.06.007; Szpilman D, Bierens J, Handley A, Orlowski J. Drowning. *N Engl J Med.* 2012;366(22):2102–2110; Nelson S, McCorvey S. Submersion and drowning injuries. *AHC Media.* 2015. http://www.ahcmedia.com/articles/135278-submersionand-drowning-injuries. Accessed September 7, 2015.

Prognosis

The stratification of patients seen in Tables 20-5 and 20-12 has been used to predict mortality. The prediction of mortality, in this instance, is considered from the accident site until discharge from the hospital and is based on data from 41,279 rescues.[65] Table 20-15 shows the percent survival rate based on this information.

Considerable focus is placed on determining which historical, physical examination or laboratory findings determine patient prognosis. Unfortunately, despite decades of research on this topic, most studies have not proven that a single or combination of clinical or laboratory factors have adequate prognostic value.[43,62] The biggest determinants of outcome and long-term neurologic complications are the submersion time and the interval time between drowning and ventilation efforts.[18,66] The GCS scores and pupillary response used to determine cerebral and brainstem activity are thought to represent the extent of hypoxic brain injury.[43] However, it is the initial prompt resuscitation, including aggressive respiratory and cardiovascular treatment and avoidance of hyperthermia, that helps to prevent secondary neurologic injury and is the mainstay of central nervous system therapy for drowning victims. Table 20-16 shows some of the more common prognostic factors used with drowning victims.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The GCS score is used to assess a patient's cerebral and brainstem activity after a drowning incident.
2. True or False: Acute pulmonary edema without hypotension or shock has a 56–69% survival rate.

Chapter Summary

Most drownings are preventable and disproportionately affect children. Drowning remains a significant cause of unintentional mortality and morbidity around the world. Factors that help to reduce the number of drownings each year include public health interventions, such as pool fencing and public education campaigns. Drowning occurs when the victim aspirates liquid because the airway is below the surface of a fluid, usually water, and the victim is unable to breathe air. The pulmonary system undergoes tremendous changes, leading to alveolar collapse and hypoxemia. The primary mechanism of injury to the central nervous system is tissue hypoxia and ischemia. After a drowning victim is carefully rescued, aggressive early therapy directly relates to the final prognosis. Treatment in the hospital depends on the presentation of the patient and can range from vital sign monitoring for 4–6 hours through invasive mechanical ventilation and active rewarming for hypothermia. There is no single prognostic factor to predict the outcome for a victim of drowning. There is a direct relationship between mortality and the amount of time submerged.

Key Points

1. Over 3,000 people die each year in the United States because of drowning. Worldwide, about 372,000 people died from drowning in 2012, making drowning an important public health problem.
2. Drowning is the process of experiencing respiratory impairment from submersion/immersion in liquid. Submersion means the entire body is under water. Immersion means part of the body is under water. For drowning to occur due to immersion, the airway needs to be under water.
3. The initial scene assessment of a drowning victim includes victim information (gender, medical history, etc.), scene information (witnessed or unwitnessed, body of water, time of submersion, water temperature), and prehospital care (conscious or unconscious, neurologic status, when CPR began).
4. Asymptomatic drowning victims should remain in the emergency department for at least 4–6 hours for observation. Symptomatic drowning victims can range from having a cough to pulmonary edema with foam in the nose and mouth to respiratory arrest or cardiopulmonary arrest.
5. Primary causes of drowning include the inability to swim, lack of barriers around swimming areas, lapses in supervision, failure to utilize safety equipment, and forces of nature. Secondary causes of drowning include alcohol use, drug ingestion, hypothermia, poor neuromuscular control, seizures, and syncope.
6. The 1- to 4-year-old age group has the number one spot in leading causes of unintentional deaths. The number one location for unintentional drowning deaths in the United States is natural water, with more occurring on weekend days as opposed to weekdays.
7. The amount of water that enters the lungs during drowning is somewhere between 2 and 4 mL/kg. Water ingestion is common and can lead to regurgitation during drowning, spontaneous recovery, and resuscitation. As little as 1–3 mL/kg of water is sufficient to affect the lung parenchyma, leading to ventilation–perfusion mismatch and pulmonary shunt.
8. Cold shock and diving response cause autonomic conflict that causes supraventricular and junctional arrhythmias. Drowning leads to hypoxic myocardial dysfunction, a unique form of cardiopulmonary arrest.
9. Hypothermia, core body temperature of $<35°C$, is commonly found in drowning victims. It can be a consequence of drowning or a cause of drowning. Consider hypothermia with every drowning victim and the rewarming technique used depends on the severity of the hypothermia.
10. The pathophysiology of drowning includes the initial submersion, aspiration, hypoxia, and pulmonary and cerebral damage.
11. Drowning is a multifaceted event with multiple risks varying by the type of body of water, age group of the victim, and activity involved. The places that people drown differ according to age groups.
12. There are numerous complications associated with drowning, such as ARDS, aspiration, cardiac arrhythmias, dehydration, hypothermia, pneumonia, pulmonary edema, and rhabdomyolysis.
13. Laboratory and diagnostic tests for drowning patients depend on the patient's status. In the emergency department, chest radiographs are useful to identify pulmonary edema or trauma. Post-drowning patients who have altered mental status, cardiac disease, or rhabdomyolysis benefit from laboratory testing.
14. The overall goal of the treatment and management of drowning is immediate ventilation and

oxygenation. Base the treatment of drowning victims on the classification of signs and symptoms. Treat hypothermia with active rewarming to a target core temperature of 34°C.

15. The time submerged is indirectly related to the prognosis of the drowning victim. A longer submersion has a worse prognosis. Other prognostic factors include how soon resuscitation in the field began, the amount of time CPR was performed, GCS, age, and blood pH.

Chapter Questions

1. Profound alterations in gas exchange and decreased lung compliance occurs with as little as _____ fluid aspiration.
   - **a.** 1 mL/kg
   - **b.** 4 mL/kg
   - **c.** 11 mL/kg
   - **d.** 22 mL/kg
2. _____ infants and toddlers have a high-risk factor for drowning.
   - **a.** African American
   - **b.** Caucasian
   - **c.** Female
   - **d.** Male
3. Chest radiographs of drowning victims will usually show _____.
   - **a.** cardiogenic pulmonary edema
   - **b.** noncardiogenic pulmonary edema
   - **c.** flattened diaphragm
   - **d.** pulmonary infiltrates
4. Death from drowning is due to _____.
   - **a.** hemolysis
   - **b.** cerebral anoxia
   - **c.** pulmonary edema
   - **d.** electrolyte imbalance
5. The amount of fluid aspirated by most drowning victims is _____.
   - **a.** >15 mL/kg
   - **b.** 10–12 mL/kg
   - **c.** 5–10 mL/kg
   - **d.** 2–4 mL/kg
6. Toddlers (ages 1–4 years) are more likely to drown in _____.
   - **a.** the ocean
   - **b.** bath tubs
   - **c.** residential pools
   - **d.** lakes and streams
7. The most common dysrhythmia found in pulseless drowning patients is _____.
   - **a.** pulseless electrical activity and asystole
   - **b.** ventricular fibrillation
   - **c.** ventricular tachycardia
   - **d.** atrial flutter
8. The primary goal of acute treatment of a drowning patient in the emergency department is _____.
   - **a.** reversal of hypoxia
   - **b.** reversal of hypothermia
   - **c.** reversal of hypotension
   - **d.** reversal of hypokalemia
9. The most significant indicator of a poor prognosis in a drowning victim is _____.
   - **a.** the age of the victim
   - **b.** the length of submersion
   - **c.** reduced pupillary response
   - **d.** electrolyte imbalance
10. A drowning victim brought to the emergency department has a mild cough with a sore throat, is alert and oriented, and has normal vital signs, and oxygen saturation 97% without any supplemental oxygen. What is the best treatment plan for this patient?
    - **a.** Observe the patient in the emergency department for 4–6 hours and discharge home if there are no clinical changes.
    - **b.** Obtain an arterial blood gas, glucose level, and chest radiography.
    - **c.** Recommend admission to the hospital, oxygen via nasal cannula, and albuterol treatments every 4 hours.
    - **d.** Initiate active rewarming methods and oxygen via nonrebreather mask, and check the Glasgow Coma Scale score hourly.

References

1. Avramidis S. Drowning in ancient Greek history and mythology. *Int J Aquatic Res Educ.* 2009;3:422–431.
2. Exhibits.hsl.virginia.edu. A watery grave: discovering resuscitation | Claude Moore Health Sciences Library: Historical Collections Online Exhibit. 2015. http://exhibits.hsl.virginia.edu/water. Accessed August 26, 2015.
3. American Heart Association. About Cardiopulmonary Resuscitation (CPR). American Heart Association. http://www.heart.org/HEARTORG/CPRAndECC/WhatisCPR/CPRFactsandStats/History-of-CPR_UCM_307549_Article.jsp. Accessed August 20, 2015.
4. Centers for Disease Control and Prevention. *Drowning—United States, 2005–2009.* Atlanta, GA: Centers for Disease Control and Prevention; 2012:344–347.
5. World Health Organization. Drowning. World Health Organization. http://www.who.int/mediacentre/factsheets/fs347/en. Accessed August 10, 2015.
6. Salomez F, Vincent J. Drowning: a review of epidemiology, pathophysiology, treatment and prevention. *Resuscitation*. 2004;63(3):261–268. doi:10.1016/j.resuscitation.2004.06.007.
7. Papa L, Hoelle R, Idris A. Systematic review of definitions for drowning incidents. *Resuscitation*. 2005;65(3):255–264. doi:10.1016/j.resuscitation.2004.11.030.
8. Idris A, Berg R, Bierens J. Recommended guidelines for uniform reporting of data from drowning: the "Utstein Style". *Circulation*. 2003;108(20):2565–2574.
9. van Beeck E, Branche C, Szpilman D, Modell J, Bierens J. A new definition of drowning: towards documentation and prevention

of a global public health problem. *Bull World Health Organ*. 2005;83(11):853–856.
10. Carter E, Sinclair R. Drowning. *CEACCP*. 2011;11(6):210–213.
11. Jones P, Moran K, Webber J. Drowning terminology: not what it used to be. *N Z Med J*. 2013;126(1386):114–116. http://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2013/vol-126-no-1386. Accessed August 24, 2015.
12. Papadodima S, Athanaselis S, Skliros E, Spiliopoulou C. Forensic investigation of submersion deaths. *Int J Clin Pract*. 2010;64(1):75–83. doi:10.1111/j.1742-1241.2008.01890.x.
13. Szpilman D, Bierens J, Handley A, Orlowski J. Drowning. *N Engl J Med*. 2012;366(22):2102–2110.
14. Layon A, Modell J. Drowning Update 2009. *Anesthesiology*. 2009;110(6):1390–1401.
15. Venema A, Groothoff J, Bierens J. The role of bystanders during rescue and resuscitation of drowning victims. *Resuscitation*. 2010;81(4):434–439. doi:10.1016/j.resuscitation.2010.01.005.
16. Pepe PE. Wigginton JG, Mann DM, et al. Prospective, decade-long population-based study of pediatric drowning-related incidents. *Acad Emerg Med.* 2002;9:516–517.
17. Hasibeder WR. Drowning. *Curr Opin Anaesthesiol*. 2003:16:139–146.
18. Nelson S, McCorvey S. Submersion and drowning injuries. *AHC Media*. 2015. http://www.ahcmedia.com/articles/135278-submersion-and-drowning-injuries. Accessed September 7, 2015.
19. Causey A, Nichter M. Drowning. In: Tintinalli J, Stapczynski J, Ma O, Cline D, Cydulka R, Meckler G, eds. *Tintinalli's Emergency Medicine: A Comprehensive Study Guide*. 7th ed. New York, NY: McGraw-Hill; 2015. http://accessmedicine.mhmedical.com/content.aspx?bookid=348&Sectionid=40381691. Accessed August 4, 2015.
20. Engel S. Drowning episodes: prevention and resuscitation tips. *J Fam Pract*. 2015;64(2):E1–E6.
21. Travers A, Rea T, Bobrow B, et al. Part 4: CPR overview: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation*. 2010;122(18_suppl_3):S676–S684. doi:10.1161/circulationaha.110.970913.
22. Berg R, Hemphill R, Abella B, et al. Part 5: Adult basic life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation.* 2010;122(18_suppl_3):S685–S705. doi:10.1161/circulationaha.110.970939.
23. Bross M, Clark J. Near-drowning. *Am Fam Physician*. 1995;51(6):1545–1551.
24. Cantwell G, Verive M, Shoff W. Drowning: background, pathophysiology, etiology. Medscap. 2015. http://emedicine.medscape.com/article/772753-overview#a4. Accessed September 12, 2015.
25. Pollack N. Loss of consciousness in breath-holding swimmers. National Drowning Prevention Alliance. 2015. http://ndpa.org/loss-of-consciousness-in-breath-holding-swimmers. Accessed August 23, 2015.
26. Boyd C, Levy A, McProud T, Huang L, Raneses E, Olson C. Fatal and nonfatal drowning outcomes related to dangerous underwater breath-holding behaviors—New York State, 1988–2011. *MMWR Morb Mortal Wkly Rep*. 2015;64(19):518–521.
27. Gilchrist J, Parker E. Racial and ethnic disparities in fatal unintentional drowning among persons less than 30years of age—United States, 1999–2010. *J Safety Res*. 2014;50:139–142. doi:10.1016/j.jsr.2014.06.001.
28. Who.int. WHO | Drowning. 2015. http://www.who.int/mediacentre/factsheets/fs347/en. Accessed September 15, 2015.
29. Xu JQ. *Unintentional Drowning Deaths in the United States, 1999–2010*. NCHS data brief no. 149. Hyattsville, MD: U.S. Department of Health and Human Services, CDC, National Center for Health Statistics; 2014. http://www.cdc.gov/nchs/data/databriefs/db149.htm. Accessed September 8, 2015.
30. Centers for Disease Control and Prevention. *Unintentional Drowning Deaths in the United States, 1999–2010*. Atlanta, GA: National Center for Health Statistics; 2014.
31. Nasrullah M, Muazzam S. Drowning mortality in the United States, 1999–2006. *J Commun Health*. 2010;36(1):69–75.
32. Bierens J, Lunetta P, Tipton M. Pathophysiology of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:545–560.
33. Schmidt A. Drownings present as hypoxic events. *J Emerg Med Serv*. 2012; 32(7). http://www.jems.com/articles/print/volume-37/issue-7/patient-care/drownings-present-hypoxic-events.html. Accessed August 23, 2015.
34. Lindholm P, Lundgren C. The physiology and pathophysiology of human breath-hold diving. *J Appl Physiol*. 2008;106(1):284–292. doi:10.1152/japplphysiol.90991.2008.
35. Modell J. Aspiration. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:561–564.
36. Kibayashi K, Shimada R, Nakao K. Frequent detection of stomach contents in accidental drowning. *Med Sci Law*. 2011;51(3):161–163. doi:10.1258/msl.2011.010150.
37. Modell J, Pellis T, Weil MH, Lunetta P. Cardiovascular changes. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014.
38. Orlowski J, Szpilman D. Drowning. *Pediatr Clin North Am*. 2001;48(3):627–646. doi:10.1016/s0031-3955(05)70331-x.
39. Bierens J, Knape J, Gelissen H. Drowning. *Curr Opin Crit Care*. 2002;8(6):578–586.
40. Bierens J, Lunetta P, Tipton M. Pathophysiology of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014; 545–560.
41. DuCharme M. Self-rescue during accidental cold water immersion. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:409–412.
42. Wagner C. Pediatric submersion injuries. *Air Med J*. 2009;28(3):116–119. doi:10.1016/j.amj.2009.02.009.
43. Schmidt A, Sempsrott J. Drowning in the adult population: emergency department resuscitation and treatment. *Emerg Med Pract*. 2015; 17(5). http://www.slremeducation.org/wp-content/uploads/2015/02/Drowning-In-The-Adult-Population-Emergency-Department-Resuscitation-And-Treatment.pdf. Accessed September 20, 2015.
44. Wenzel V, Bierens J. Pre-hospital treatment: summary and recommendations. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:541–544.
45. Golden F, Tipton M, Scott R. Immersion, near-drowning and drowning. *Br J Anaesth*. 1997;79(2):214–225. doi:10.1093/bja/79.2.214.
46. Walpoth B, Daanen H. Immersion hypothermia: summary and recommendations. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:839–841.
47. Wollenek G, Honarwar N, Golej J, Marx M. Cold water submersion and cardiac arrest in treatment of severe hypothermia with cardiopulmonary bypass. *Resuscitation*. 2002;52(3):255–263. doi:10.1016/s0300-9572(01)00474-9.
48. Tipton M. Cold water immersion: sudden death and prolonged survival. *Lancet*. 2003;362:s12–s13. doi:10.1016/s0140-6736(03)15057-x.
49. Moon R, Long R. Drowning and near-drowning. *Emerg Med*. 2002;14:377–386.
50. Warmer D, Knape J. Brain resuscitation in the drowning victim. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014; 769–776.
51. Drowning Prevention | Child Safety and Injury Prevention| CDC Injury Center. (2016). https://www.cdc.gov/safechild/drowning/. Accessed September, 25, 2016.
52. Quan L. Characteristics of drowning by different age groups. *Inj Prev*. 2003;9(2):163–168. doi:10.1136/ip.9.2.163.
53. Driscoll T. Review of the role of alcohol in drowning associated with recreational aquatic activity. *Inj Prev*. 2004;10(2):107–113. doi:10.1136/ip.2003.004390.

54. Weiss J. Prevention of drowning. *Pediatrics*. 2010;126(1):e253–e262. doi:10.1542/peds.2010-1265.
55. Quan L. Review of risk factors. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:123–126.
56. Irwin C, Irwin R, Ryan T, Drayer J. Urban minority youth swimming (in)ability in the United States and associated demographic characteristics: toward a drowning prevention plan. *Inj Prev*. 2009;15(4):234–239. doi:10.1136/ip.2008.020461.
57. Safe Kids Worldwide. Facts about children at higher risk for accidental injuries. http://www.safekidskalamazoo.org. Accessed on September 28, 2015.
58. Bennett E, Linnan M. The prevention of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014:147–151.
59. Tadié J, Heming N, Serve E, et al. Drowning associated pneumonia: a descriptive cohort. *Resuscitation*. 2012;83(3):399–401. doi:10.1016/j.resuscitation.2011.08.023.
60. Med-ed.virginia.edu. Chest Radiology. 2015. https://www.med-ed.virginia.edu/courses/rad/cxr/pathology2Dchest.html. Accessed October 3, 2015.
61. Spilzman D, Hanley A, Bierens J, Quan L, Vasconcellos R. Drowning. In: Field J, Kudenchuk P, O'Connor R, et al., ed. *The Textbook of Cardiovascular Care and CPR*. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:483–486.
62. Wenzel V, Hasibeder W, Simcock A. Treatment protocols: emergency department and intensive care unit. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014: 693–704.
63. Causey A, Tilelli J, Swanson M. Predicting discharge in uncomplicated near-drowning. *Am J Emerg Med*. 2000;18(1):9–11. doi:10.1016/s0735-6757(00)90039-1.
64. Schilling U, Bortonlin M. Drowning. *Minerva Anestesiol*. 2012;78(1):69–77.
65. Szpilman D, Simcock A, Graves S. Classifications of drowning. In: Bierens J, ed. *Drowning: Prevention, Rescue, Treatment*. 2nd ed. Dordrecht, The Netherlands: Springer Heidelberg; 2014; 685–691.
66. Quan L, Mack C, Schiff M. Association of water temperature and submersion duration and drowning outcome. *Resuscitation*. 2014;85(6):790–794. doi:10.1016/j.resuscitation.2014.02.024.

CHAPTER

21

Interstitial Lung Disease

"Whenever I feel blue, I start breathing again."

—L. Frank Baum

OUTLINE

OBJECTIVES

1. Recognize common characteristics, manifestations, and diagnostic features of interstitial lung diseases (ILDs).
2. Review the classification system for ILDs.
3. Relate the importance of a thorough history in the evaluation of a patient for ILD.
4. Discuss the pathophysiology mechanisms that lead to ILD.
5. Identify the diagnostic steps to the evaluation of a patient with ILD.

KEY TERMS

Alveolar macrophages (AMs)
Apoptosis
Connective tissue diseases (CTDs)
Cryobiopsy
Extracellular matrix (ECM)
Fibroblastic foci
Fibroblasts
Honeycomb
Idiopathic pulmonary fibrosis (IPF)
Interstitial lung diseases (ILDs)
Interstitial macrophages (IMs)
Myofibroblasts
Organizing pneumonia
Reticular
Sarcoidosis
Surface marker expression
Usual interstitial pneumonia (UIP)

Case Study

A 70-year-old widowed plumber presented to his physician with a complaint of worsening exertional breathlessness over the past 6 months. The patient described himself as being active, exercising regularly at a local gym, until around a year ago. He recently noticed an inability to run up a flight of stairs or walk fast due to significant dyspnea. He also reported a sporadic nonproductive cough, which began several months ago. The patient denied a personal or family history of respiratory disease. He is a currently a nonsmoker; however, he admitted to smoking one to two packs of cigarettes for 3 or 4 years in his early 20s. The patient described poor ventilation in the workshop where he worked for the past 35 years and questioned whether this closed-exposure contributed to some type of lung disease. On review of systems, the patient reported occasional arthralgias, which seem worse with activity but denied Raynaud-like symptoms. He has frequent gastroesophageal reflux symptoms but denied any overt history of significant gastric aspiration. He currently takes no medications other than occasional acetaminophen for discomfort.

On physical examination, this asthenic gentleman appears in no obvious respiratory distress when at rest. His temperature is 98.7°F, pulse is 106 beats/minute, resting respiratory rate is 22 breaths/minute, blood pressure is 135/85, height is 67 inches, and weight is 123 lb. His nasal mucosa and turbinates are pink and moist. Chest auscultation reveals a few fine late inspiratory crackles at both bases with no wheezes, rhonchi, or other adventitious sounds. His heart rhythm is regular with a prominent split P_2 heart sound. Physical examination of the chest wall reveals limited excursion with normal thoracic anteroposterior diameter. Abdominal exam is noncontributory. Extremities are unremarkable, with no evidence of peripheral edema or signs of digital clubbing.

The patient's chest radiograph shows a normal heart shadow with increased interstitial markings and cystic-like changes within the mid-lung fields. A high-resolution computed tomography (HRCT) scan shows only minimal peripheral reticular opacities in the upper lung regions. Mid-lung regions, however, exhibited fine reticular changes at the pleural surface with minimal changes in the peripheral areas. The lower lung zones show asymmetric reticular changes found predominantly on the right with some cystic changes primarily in the mid-lung rather than on the periphery. **Honeycomb** changes are present. An electrocardiogram (ECG) reveals mild tachycardia with evidence of right heart strain. Pulmonary function studies pre- and post-bronchodilator reveal a mild restrictive ventilatory defect with the following results: forced expiratory volume in 1 second (FEV_1), 75% predicted; forced vital capacity (FVC), 77% predicted; total lung capacity (TLC), 75%; and diffusing capacity of the lung for carbon monoxide (DLCO), 68% (uncorrected for alveolar volume). Oxygen saturation on room air declined from 94% to 88% during a "modified" 6-minute walk test (6MWT) that included five flights of stairs.

Laboratory chemistries revealed a hemoglobin of 17.2 g/dL with normal white blood cell count. The erythrocyte sedimentation rate is 20 mm/hour, with a positive antinuclear antibody (ANA) titer of 1:40 and normal rheumatoid (RA) factor level. Tests for ribonucleoprotein (RNP) suggest coexisting dermatomyositis/polymyositis and scleroderma (SCL)-70 antibodies are negative. The histidyl-t-RNA synthetase (anti-Jo-1) antibody for mixed connective disease is also negative.

An open-lung biopsy is performed, and histologic findings reveal evidence of fibrosis with mild chronic inflammation adjacent to areas of fibrosis as well as microscopic honeycombing. Temporal and spatial heterogeneity are also shown, with fibrosis at the periphery and a transition to areas of normal lung. Fibroblastic foci are present. Normal lung tissue is also identified adjacent to pathologic parenchymal biopsy findings.

Introduction

Interstitial lung diseases (ILDs) represent a heterogeneous group of diffuse parenchymal lung diseases (DPLDs) with a variety of causes, both known and unknown. ILD is an extremely diverse group of both acute and chronic disorders that have common clinical, radiographic, and pathophysiologic features. The descriptive term "interstitial" reflects the pathologic appearance that the abnormality begins in the interstitium, but the term is misleading, as most of these disorders are also associated with extensive alteration of alveolar and airway architecture.[1] Although diverse, all ILDs are characterized by varying degrees of inflammation and fibrosis of the lung parenchyma, not only between the different diseases, but also among individuals with the same disease.[2] In clinical practice, determining whether the ILD is predominantly inflammatory or fibrotic defines the appropriate treatment choices. Those patients with

mostly inflammation may respond to immunosuppressive and modulatory therapy, while those with mostly fibrosis may respond to antifibrotic drugs.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The abnormality from ILD is primarily in the alveoli.
2. True or False: Fibrosis is the main problem with ILD.

Definition/Diagnosis

ILD is an umbrella term, synonymous with DPLD, for a large group of diseases affecting the tissue and space around the alveoli, causing progressive scarring of lung tissue through inflammation and fibrosis.[3] Establishing an exact diagnosis of ILD can be challenging for clinicians as there are more than 200 different subtypes.[4] **Sarcoidosis**, **idiopathic pulmonary fibrosis (IPF)**, and pulmonary fibrosis associated with **connective tissue diseases (CTDs)** are the most common ILDs of unknown etiology. The largest group of diseases with known etiologies include those caused by occupational and environmental exposures. These exposures include the inhalation of inorganic dusts, organic dusts, and various gases.

Many forms of ILD can be diagnosed clinically, especially when there is a history of occupational and environmental exposure. Diagnosis is often made using a combination of clinical, pathophysiologic, immunologic, and imaging (especially computed tomography [CT]) features. For a precise diagnosis, a surgical lung biopsy with histologic examination may be necessary; however, even this procedure does not always find a clear answer.[5]

KNOWLEDGE CHECK QUESTIONS

1. True or False: DPLD is different from ILD.
2. True or False: Occupational exposure can cause ILD.

Clinical Signs and Symptoms

Some forms of ILD can present acutely; however, the most common presentation of ILD is a slowly progressive onset of dyspnea and a nonproductive cough. At first, dyspnea occurs on exercise; later it progresses to breathlessness at rest. The duration of progressive dyspnea usually ranges from months to years. A dry cough mostly occurs on exertion and fatigue is often present. Fever, chills, and weight loss are the main symptoms of interstitial pulmonary infections but may also occur in collagen vascular disorders.[6]

The most critical step in the initial evaluation of a patient with suspected ILD is obtaining a complete history. This is important because the cause of the illness is often recognized from the patient's history. See **Box 21-1**. Also, a thorough review of past systemic conditions is particularly critical.

The age and gender of the patient are of concern because some ILDs are more common in specific age groups or have a male or female predominance. A thorough review of the home and work environments with a strict chronological listing of the patient's entire lifelong employment is necessary. The detailed job history can help identify occupational exposures and exposures to dust, fumes, and antigens associated with ILD. Hobbies can also be the cause of environmental exposures. Prior medication use may put the patient at risk for ILD, whether they be by prescription, over the counter, or illicit. In some cases, lung disease may occur weeks to years after the drug has been discontinued.[1] Therapeutic irradiation is also a cause for the development of ILD.

Collectively, the interstitial lung disorders widely vary in etiology, radiographic presentation, histopathologic features, and clinical course. Because several ILD have similar clinical signs and symptoms, they are often not easily identified by clinical examination. Most symptoms are limited to the respiratory tract unless the underlying lung pathology is secondary to a multisystem disorder. Predominate respiratory complaints include exertional breathlessness and nonproductive cough. Sputum production, hemoptysis, chest pain, or wheezing may sometimes also occur. Multisystem interstitial disorders, such as many connective tissue disorders often produce nonrespiratory symptoms, such as myalgia, arthralgia, or sclerodactyly (a musculoskeletal deformity that affects the hands of people

BOX 21-1 Clinical History of ILD

- Dyspnea on exertion or at rest
- Nonproductive cough
- Fever, chills, and night sweats
- Prior medications used and irradiation
- Family history of ILD
- Detailed work history
- Travel history
- Environmental exposures
- Hobbies
- Smoking history
- Past systemic conditions

with SCL). Physical examination findings typically reveal bilateral inspiratory fine crackles ("Velcro®-like") on lung auscultation at the lung bases in most affected individuals. Wheezing is uncommon unless the disorder also includes airway involvement (as in sarcoidosis) or a concurrent airway disease is also present, such as chronic obstructive pulmonary disorder or asthma. Occasionally, wheezing may offer a clue as to a diagnosis, such as sarcoidosis, which can involve the airways as well as the interstitium. Some interstitial lung disorders, on the other hand, may present with only diminished breath sounds despite noticeably abnormal chest radiographs. Late cardiac manifestations of interstitial lung disorders often include signs of pulmonary arterial hypertension with right ventricular dysfunction displaying lower-extremity edema or jugular venous distention. See **Table 21-1**.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The most critical step in the evaluation of a patient suspected of ILD is the physical examination.
2. True or False: The common lung sound with ILD is bilateral fine inspiratory crackles.
3. True or False: Digital clubbing does not occur with ILD.

Etiology

Because there are so many ILDs, it is difficult to review etiology without first reviewing the classification system. Over the past decade, ILDs were reclassified in

TABLE 21-1
Clues from the Initial Evaluation That Suggest ILD[7]

Physical Signs, Symptoms, History	Associated ILD
Dyspnea	All ILD
Nonproductive cough	Most ILD, productive cough is unusual
Fatigue	Most ILD, and is present with dyspnea
Fever/chills/weight loss	Interstitial pulmonary infections, collagen vascular disorders
Inspiratory crackles	Most ILD
Wheezing	Uncommon, mostly with hypersensitivity pneumonitis
Pleural rub	Rheumatoid arthritis, systemic lupus erythematosus
Digital clubbing	Interstitial pulmonary fibrosis, asbestosis
Tachypnea	15% of all interstitial pulmonary diseases
Arthralgias, arthritis	CTDs, sarcoidosis
Hemoptysis	Diffuse alveolar hemorrhage syndrome, LAM
Chest pain	Uncommon, pleuritic chest pain associated with rheumatoid arthritis, systemic lupus erythematosus, acute chest pain could be a pneumothorax
Abnormal gastroesophageal reflux, gastroesophageal reflux disorder, dysphagia	CTD (especially SCL), IPF
Cutaneous lesions	Sarcoidosis, tuberous sclerosis, necrotizing vasculitis, dermatomyositis, collagen vascular diseases
Eye symptoms	Sarcoidosis, CTD, polyangiitis with granulomatosis
Salivary gland enlargement	Sarcoidosis, Sjögren's disease
Peripheral lymph adenopathy	Sarcoidosis, lymphoid interstitial pneumonitis, ILD with connective tissue disorders
Hepatosplenomegaly	Sarcoidosis, amyloidosis, eosinophilic granuloma, chronic cor pulmonale
Neurologic manifestations	Tuberous sclerosis, systemic vasculitis, sarcoidosis, eosinophilic granuloma
Rapid onset and worsening	Acute interstitial pneumonia, acute hypersensitivity pneumonitis, cryptogenic organizing pneumonia, CTD, diffuse alveolar hemorrhage

comprehensive international consensus statements.[8–10] The major subgroups of ILD are now broadly defined as idiopathic interstitial pneumonias, granulomatous ILD (e.g., sarcoidosis, hypersensitivity pneumonitis), ILD with known associations (e.g., occupational and drug exposures, CTDs), and miscellaneous ILD (e.g., pulmonary Langerhans cell histiocytosis [PLCH]). See **Figure 21-1**.

Many of the known etiologies of ILD produce similar clinical features. The common known etiologies for ILD include those that are drug related or are due to environmental inhalants and CTDs. Other known etiologies of ILD are found at initial diagnosis and include occupational and environmental sources of exposure, such as inorganic dusts, specific toxins, exposure to radiation, oxygen toxicity, certain infectious agents, as well as pulmonary hypersensitivity reactions. Various infections, vasculitis lung disorders, as well as various "miscellaneous" disorders affecting the lung may present as an ILD. See **Table 21-2**. It is estimated that 30% of persons with interstitial disease have no clear-cut cause that is easily identifiable. These observations significantly affect the difficulty in distinguishing a specific diagnosis or finding a precise etiology for ILD.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Some medications can cause interstitial lung disease.
2. True or False: CTDs can be a cause of ILD.
3. True or False: All ILD have known causes.



FIGURE 21-1 ILD classification.

Source: Kreuter M, Herth F, Wacker M, et al. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry—The EXCITING-ILD Registry. *Biomed Res Int.* 2015;2015:1–9 (Figure 1). doi:10.1155/2015/123876.

TABLE 21-2
Causes of ILD[7,11,12]

Cause	Examples
Drugs	Selected list: angiotensin-converting enzyme (ACE) inhibitors, amiodarone, amphotericin B, beta-blockers, bevacizumab, bleomycin, erlotinib, methotrexate, nonsteroidal antiinflammatory drugs, penicillamine, rituximab, statins, supplemental oxygen, tocainide
Illicit drugs	Cocaine, heroin
Inorganic material	Selected list: aluminum powder, asbestos, beryllium, coal dust, cadmium, cobalt, silica, titanium oxide, talc, tungsten
Organic material	Selected list: bird droppings, coffee, farming material, hot tub, malt, maple bark, mushrooms, tea
Infections	Aspergillosis, histoplasmosis, parasitic infection, mycobacterial infection, viral infection
Connective tissue disorders	Autoimmune myositis, Goodpasture syndrome, IgG-4 related disease, mixed CTD, rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, system sclerosis, undifferentiated CTD
Vasculitis	Eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, microscopic polyangiitis
Miscellaneous causes	Amyloidosis, chronic aspiration, eosinophilic pneumonia, lipoid pneumonia, pulmonary alveolar proteinosis, PLCH, pulmonary lymphoma, sarcoidosis, tuberous sclerosis

Epidemiology

Most data on the epidemiology of ILDs come from prospective registries of data reported by pulmonologists. However, there are only a few ILD registries, and all have limitations due to the difficulties in accurately diagnosing these conditions.[13] Therefore, many may not be fully representative of the true populations of ILD patients.[13]

One study reported that 80.9 per 100,000 men and 67.2 per 100,000 women suffer from interstitial disease in the United States, with 31.5 new cases diagnosed per 100,000 men per year and 26.1 new cases diagnosed per 100,000 women per year.[14] In this study, the most prevalent interstitial diseases included pulmonary fibrosis, occupational- and environmental-associated disease, CTD–associated interstitial disease, and sarcoidosis.

ILD is predominantly an adult disease; however, it does occur in children. Certain ILDs, such as sarcoidosis, PLCH, and autoimmune-associated lung disease, develop in young adults. IPF most often occurs between the ages of 40 and 70.

The incidence for sarcoidosis in the United States ranges from 5 to 40 cases per 100,000 population with the age-adjusted incidence for whites at 11 cases per 100,000 population and that for African Americans at 34 cases per 100,000 population. The prevalence is 10 times greater for African Americans than for whites. The incidence for sarcoidosis peaks in persons between 25 and 35 years and again for women between ages 45 and 65 years.[15] Working on the World Trade Center debris pile is associated with an elevated risk of post-9/11 sarcoidosis.[16]

IPF occurs primarily in middle-aged to older adults. Its overall incidence and prevalence are unclear due to the updated classification system and International Classification of Disease codes.[17] The prevalence of IPF varies widely depending on case definitions and geographic areas in epidemiologic studies performed in the United States.[18] A review of some of the current studies does agree that the prevalence and incidence of IPF are higher in older age groups.[17] It also appears to be more common in men compared to women. However, some postulate this may be due to gender differences in historical smoking patterns rather than an inherent gender-related risk for IPF.[17]

KNOWLEDGE CHECK QUESTIONS

1. True or False: ILD does not occur in children.
2. True or False: IPF most often affects people older than 70 years.
3. True or False: Sarcoidosis is associated with working close to the 9/11 World Trade Center pile.

Pathogenesis

Most ILDs share the same type of structural remodeling of the distal airspaces leading to impaired gas exchange. However, the diverse range of ILDs arrive at that state with different levels of inflammation and fibrosis at the alveolar, distal airways, and septal interstitium of the lungs. In ILDs dominated by inflammation, the histology is that of **organizing pneumonia** (a pathologic presence of buds of granulation tissue in the distal air spaces that have progressed from fibrin exudates to loosely organized collagen-containing fibroblasts) or nonspecific interstitial pneumonitis, while fibrosis-dominant ILD is characterized by **fibroblastic foci** and only mild-to-moderate inflammation.[2] The difference between the two underlying causes determines whether an ILD will respond to treatment.

Infection or hypersensitivity initiates inflammation and can also lead to many forms of ILD. However, lung inflammation does not necessarily result in fibrotic remodeling, and fibrosis can occur in the absence of inflammation.[19] Therefore, inflammation has a prominent, but not an essential role in lung remodeling and fibrosis.[19]

The lung is susceptible to various forms of short- and long-term injuries, both airborne and blood-borne, that may result in fibrosis.[20] Some forms of fibrosis, such as acute lung injury or cryptogenic organizing pneumonia, are at least partially reversible, whereas others, particularly IPF, are progressive and fatal.[20] The injuries are caused by infection, radiation, environmental exposures, medications, and systemic diseases. The resulting damage affects the epithelial or endothelial layers and their associated basement membrane with **apoptosis** and necrosis of the alveolar epithelial cells (AECs) occurring early in the disease.[21] This is one of the vital initiating events in the pathogenesis of lung fibrosis.[22–24]

Lung fibrotic disorders are characterized by the accumulation of **fibroblasts**, **myofibroblasts**, and **extracellular matrix (ECM)** leading to chronic respiratory failure. The origins of the fibroblasts and their activation are probably multiple, but currently unknown.[20] Although there are more than 40 different cell types in the lungs, the type of cell that produces most of the ECM deposits in IPF is the activated myofibroblast in fibroblast foci. The activated myofibroblasts in fibroblast foci is the histopathologic hallmark of IPF.[21] These lesions consist of groups of activated fibroblasts that produce excessive levels of ECM within the alveolar space at the site of epithelial cell loss. See **Figure 21-2**. This does not occur in healthy lungs, and the number of activated fibroblasts correlates with survival, and large quantities of fibroblastic foci are the most discriminative feature for separating idiopathic from collagen vascular disease–associated ILD.



FIGURE 21-2 Comparison of the structure and function of the ECM in a healthy lung and that of an injured or fibrotic lung.
Data from Frantz C, Stewart K, Weaver V. The extracellular matrix at a glance. *J Cell Sci.* 2010;123(24):4195–4200. doi:10.1242/jcs.023820.

In healthy lung tissue, at least two types of macrophage populations are present: **alveolar macrophages (AMs)** and **interstitial macrophages (IMs)**. See **Figure 21-3**. These macrophages can be distinguished from each other by their cell **surface marker expression**, their location within the lung, and physical and behavioral traits (phenotype). Lung macrophages are long-lived cells, which are not replaced from the circulation and are shaped by their local environment.[21] AM functions include sensing immunologic stimuli, responding to antigens, and recycling surfactant. The healthy lung response to injury is for macrophages to acquire a phenotype that promotes fibroproliferation.[21] In patients with IPF, AMs release chemicals that attract neutrophils,[25] cytokines, growth factors, ECM proteins, and tissue inhibitors of metalloproteases, contributing to alveolar injury and aberrant lung repair.[25] Increased neutrophils and their products are associated with



FIGURE 21-3 Tissue localization of pulmonary macrophages during the development of lung fibrosis. **(A)** A schematic of a normal healthy lung tissue with normal lung architecture is depicted. AMs are in the airway space. IMs reside in the lung parenchyma. **(B)** A schematic of fibrotic lung tissue with normal or fibrotic regions and subepithelial fibroblastic foci consisting of fibroblasts and myofibroblasts is shown. Activated macrophages are ideally placed to influence these processes in the parenchyma and alveolar spaces. The bottom panel shows the legend key for the different cell types depicted in (A) and (B).

Reproduced from Byrne A, Maher T, Lloyd C. Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? *Trends Mol Med.* 2016;22(4):303–316 (Figure 1). doi:10.1016/j.molmed.2016.02.004.

lung fibrosis in both animal studies and human ILDs, whereby they correlate with increased mortality.[26–28] IMs acquire profibrotic characteristics with specific surface marker expression in mice bleomycin models.[21] Nonresident circulating macrophages derived from monocytes drive fibrosis by causing AEC-specific injury. Both circulating monocytes and resident lung macrophages play critical roles in the pathogenesis of lung fibrosis.[21]

The commonality among the numerous ILD is alveolar epithelium disruption and the response of different cells to this damage. Distinct cell populations seem to contribute to the complex and diverse pathogenesis of lung fibrosis leading to ILD.[20] See **Table 21-3**.

Identification of cells and their biomarkers assists in the diagnosis of ILD. Although the combination of history, physical examination, chest radiography, and other appropriate laboratory testing, including blood tests and pulmonary function testing (PFT), provides vital information, additional testing is usually needed to reach a confident diagnosis of a specific ILD. At times, a HRCT may provide invaluable information that strongly supports a specific diagnosis. However, when no diagnosis can be made from the HRCT, bronchoscopy, or bronchoalveolar lavage (BAL), a surgical lung biopsy is necessary. The specimen is analyzed for cell count, differential cell count, cell marker testing, cytology, and staining. Continued investigation into the cells and biomarkers involved in the pathogenesis of the various ILD and cellular response to medications will allow for cell-specific targets and support novel therapeutic strategies for ILD in the future.

TABLE 21-3
Cells Involved in the Development of ILD[20,21,24,25,29,30]

Cell	Possible Function
AECs	Type II cells replace damaged Type I cells and proliferate to protect the injured basement membrane. The Type II cells differentiate into Type I cells initiating the fibrotic process.
Capillary endothelial cells	Damage to the microvasculature in the lungs leads to repair by endothelial progenitor cells (EPCs). EPCs secrete cytokines and may give rise to fibroblasts. Possibly involved in the development of pulmonary hypertension (PH) in IPF.
Fibroblasts	Modulates ECM turnover by synthesizing and depositing large quantities of extracellular proteins.
Fibrocytes	Circulating precursors of fibroblasts.
Lymphocytes	B lymphocytes produce autoantibodies, secrete IL-6. IL-6 is an independent predictor of decline in the DLCO in some ILD.
	T lymphocytes accumulate in the lung when pulmonary inflammation and fibrosis occur. Secrete interleukin-2 (IL-2), macrophage migration inhibition factor, monocyte chemotactic factor, and neutrophil inhibitory factor, which regulate other effector cells. When activated T lymphocytes predominate, there is recruitment of mononuclear phagocytes and additional lymphocytes may result in granuloma formation.
Macrophages	Activation of macrophages causes them to take on a profibrotic phenotype.
Mast cells	Potential source of profibrotic factors, stimulator of fibroblast growth, and potentiates ECM production.
Myofibroblasts	The effector cells of fibrosis. Contribute to tissue repair and to the ECM deposition.
Natural killer cells	Produce various cytokines and are found in the mucus samples and blood of patients affected by certain ILD.
Neutrophils	Once activated, can release collagenase, elastase, neutral protease and various oxidants, which all markedly derange the alveolar structure.
Pericytes	These cells are involved in wound healing and collagen production.
Pleural mesothelial cells	These cells are thought to transform into myofibroblasts. An increase in these cells correlates with increased severity of IPF.
Polymorphonuclear cells	These cells are associated with the production of elastases and reactive oxygen species and the amplification of lung damage through production of profibrotic cytokines.

KNOWLEDGE CHECK QUESTIONS

1. True or False: ILD dominated by inflammation take on the histology of organizing pneumonia.
2. True or False: Inflammation is an essential part in lung remodeling and fibrosis in ILD.
3. True or False: AECs and the basement membrane are damaged early on in ILD.
4. True or False: Activated myofibroblasts produce most of the ECM deposits in IPF.
5. True or False: Circulating macrophages do not have a role in the pathogenesis of ILD.

Risk Factors

Cigarette smoking is a widespread and addictive habit and is well known for its harmful effects due to the high number of chemicals contained. Smoking increases the risk of many diseases, such as chronic obstructive pulmonary disease (COPD), lung cancer, and atherosclerosis. Additionally, three ILD are etiologically attributed to smoking. Therefore, smoking is a risk factor for respiratory bronchiolitis-associated ILD, desquamative interstitial pneumonia, and PLCH.[31] Individuals with COPD are at higher risk for the development of ILD. Older age and male gender are risk factors for ILD in patients with rheumatoid arthritis.[32] Exposure to radiation therapy increases the risk for ILD.

Most cases of IPF occur sporadically in people with no history of IPF in their family. Familial pulmonary fibrosis appears to have an autosomal dominant pattern of inheritance.[33] This inheritance pattern means that one copy of an altered gene in each cell is sufficient to cause the disease. However, some people who inherit the mutated gene never develop features of familial pulmonary fibrosis. It is unclear why some people develop the disease and others with the mutated gene do not.[33]

Other risk factors include hepatitis C or a history of tuberculosis or pneumonia. Individuals who are exposed to silica dust, asbestos fibers, grain dust, bird and animal droppings, and indoor hot tubs are at risk for ILD due to long-term exposure to toxins and pollutants. Exposure to certain drugs increases the risk of developing ILD. These drugs are listed in Table 21-2. Also, anyone with any of the causative diseases, such as rheumatoid arthritis, SCL, mixed CTD, sarcoidosis, Sjögren syndrome, dermatomyositis, and polymyositis is at risk for developing ILD.

The risk of developing ILD is increased with taking certain drugs. Systemic antineoplastic drugs are a common form of iatrogenic injury, with the lungs being a frequent target. Ten to twenty percent of all patients treated with an antineoplastic agent develop some form of lung toxicity. Chemotherapy regimens that include bleomycin, gemcitabine, paclitaxel, cyclophosphamide, or doxorubicin are associated with the development of ILD.[34]

Patients with subclinical ILD are at a significantly higher risk for developing symptomatic and severe radiation pneumonitis when being treated for Stage 1 non-small-cell lung cancer with stereotactic body radiation therapy (SBRT) alone.[35] These patients should be reviewed for evidence of ILD before the start of SBRT, and the therapy should not be performed if ILD or interstitial changes are identified.[36]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Cigarette smoking increases the risk for COPD and lung cancer, but not ILD.
2. True or False: Familial pulmonary fibrosis has an autosomal recessive pattern of inheritance.
3. True or False: Taking amiodarone continuously for the treatment of certain cardiac arrhythmias is a risk factor for the development of ILD.

Complications

PH is a significant complication of several ILDs and can adversely affect patient outcome.[37] PH is a complication of IPF, ILD associated with CTD, systemic sclerosis, lymphangioleiomyomatosis (LAM), pneumoconiosis, drug-related ILD, and PLCH. PH is a rare complication of sarcoidosis.[37] The pathogenesis of PH in ILD is multifactorial and incompletely understood.[38] The reported prevalence of ILD-associated PH ranges from 30% to 90% and is similar to that of patients with COPD. The rates of PH depend on the population studied. For IPF, PH is present in 8–15% at initial evaluation, 30–50% in advanced cases, and over 60% in end-stage IPF. The prevalence of PH with ILD associated with CTD varies widely among the CTDs.[1] Right ventricular failure (cor pulmonale) is the end point of all forms of PH and is associated with reduced survival in patients with ILD.[39]

Acute respiratory failure typically occurs in late-stage ILD, and the treatment is challenging. The only definitive therapy in pharmacologically refractory ILD is lung transplantation. Lung transplantation is mainly reserved for stable patients who are already on the transplant list. For patients not yet on the transplant list, prognosis following intensive care unit admission is typically very poor.[40–42]

KNOWLEDGE CHECK QUESTIONS

1. True or False: PH occurs in up to 90% of patients with ILD.
2. True or False: The definitive therapy for pharmacologic refractory ILD is lung transplantation.

Diagnostic Testing

Because ILD occurs with a broad range of diseases, exposures, and drugs, ascertaining the correct diagnosis is essential. Following a careful exploration of past medical history, medication use, potential exposures, and a thorough physical examination, routine laboratory tests, PFT, chest radiography, and HRCT are obtained. Some patients may need to have a bronchoscopy with BAL and a transbronchial lung biopsy and finally the open-lung biopsy to arrive at a diagnosis. See **Figure 21-4**.



FIGURE 21-4 Approach to the evaluation of a patient with ILD.

Laboratory Tests

These usually include biochemical testing for liver and renal function, complete blood test with differential cell counts, and urinalysis. See **Table 21-4** for clues for ILD from blood and urine tests.

Additional blood tests include those to detect the presence of autoantibodies (**Table 21-5**), precipitating immunoglobulins against organic antigens, and serum ACE. These tests do not usually confirm the diagnosis, and there is potential for both false positive (particularly autoantibodies in older patients) and false negative results; however, they can be useful in helping further direct diagnostics.[2]

Several serum biomarkers that are suggestive of ILD have been identified. These include surfactant protein A and B (SP-A, SP-B), monocyte chemoattractant protein-1 (MCP-1), and Kerbs von Lungren (KL)-6, a circulating, high-molecular-weight glycoprotein expressed by Type II pneumocytes.[43]

Lung Function Tests

PFTs can provide useful information but are not diagnostic by themselves. PFTs are a means of quantitatively assessing respiratory symptoms and are useful for monitoring the severity of lung involvement, disease

TABLE 21-4
Clues for Specific Diagnoses from Blood and Urine Testing

Laboratory Test	Abnormal Result	Suggested ILD
Complete blood count	Microcytic anemia (decreased mean corpuscular volume [MCV])	Occult pulmonary hemorrhage
	Normocytic anemia (normal MCV with decreased hemoglobin and hematocrit)	CTD
	Leukocytosis (elevated white blood cell count)	Infection, hematologic malignancy
	Eosinophilia (increased eosinophils in the blood)	Eosinophilic pneumonia, drug toxicity
	Thrombocytopenia (low platelet count)	CTD, sarcoidosis
Calcium	Hypercalcemia (elevated calcium level)	Sarcoidosis
Creatinine	Increased	CTD, pulmonary-renal syndrome (most often due to an autoimmune disorder), sarcoidosis, amyloidosis
Liver function	Increased gamma-glutamyl transpeptidase, alanine transaminase (ALT), and aspartate transaminase (AST)	Sarcoidosis, amyloidosis, CTD (polymyositis)
Urine	Abnormal sediment with red blood cell casts and/or dysmorphic red blood cells	Vasculitis (CTD, polyangiitis with granulomatosis, Goodpasture syndrome, microscopic polyangiitis)
Muscle enzymes	Increased creatine kinase, aldolase	Polymyositis, dermatomyositis
ACE	Increased	Sarcoidosis, other ILDs
Lymphocyte proliferation	Stimulated by beryllium	Chronic beryllium diseases

Data from Meyer K, Raghu G. Patient evaluation. In: Baughman R, du Bois R, ed. *Diffuse Lung Disease: A Practical Approach.* 2nd ed. New York, NY: Springer; 2012:3–16 (Table 1.4).

TABLE 21-5
Autoantibodies in Connective Tissue ILD

Antibody	Associated CTD
ANA (>1:320)	Many
RF (>60 IU/mL)	RA, Sjögren syndrome, SLE
Anti-CCP	RA
Anti-centromere	Systemic sclerosis
Antinuclear ANA	Systemic sclerosis
Anti-Ro (SS-A)	SLE, Sjögren syndrome, and others
Anti-La (SS-B)	SLE, Sjögren syndrome
Anti-RNP	SLE, MCTD
Anti-dsDNA	SLE
Anti-Smith	SLE
Anti-tRNA synthetase	Poly-/dermatomyositis (anti-synthetase syndrome)
Anti-PM-Sci	Systemic sclerosis/myositis overlap
Anti-Th/To	Systemic sclerosis
Antir-U3 RNP	Systemic sclerosis
ANCA panel	Vasculitides
Anti-topoisomerase (Sci-70)	Systemic sclerosis

Reproduced with permission from Mikolasch T, Garthwaite H, Porter J. Update in diagnosis and management of interstitial lung disease. *Clin Med*. 2017;17(2):146–153. doi:10.7861/clinmedicine.17-2-146.

progression, and responses to therapeutic interventions.[44] Most ILDs have a restrictive lung defect with reduced TLC, functional residual capacity, and residual volume. The FEV_1 and FVC are generally decreased proportionally with a normal or elevated FEV_1/FVC ratio.

A reduction diffusing capacity (DLCO) is a common finding, although nonspecific. The reduction in DLCO is due mostly to the extent of ventilation/perfusion mismatching in the alveoli. In some ILDs, notably sarcoidosis, there can be considerable reduction in lung volumes and/or severe hypoxemia but normal or slightly reduced DLCO.[43]

Early in ILD, resting arterial blood gas (ABG) results may be normal or may show mild resting hypoxemia and respiratory alkalosis. Hypercapnia is rare and usually manifests in end-stage ILD. Normal values for resting blood oxygen levels do not rule out significant hypoxemia during sleep or exercise. It is essential to include some form of exercise testing to assess for hypoxemia during exercise. The exercise tests include a 6MWT with pulse oximetry, or a cardiopulmonary exercise test and overnight pulse oximetry to assess for nocturnal hypoxemia. Patients with mild disease may have a normal 6MWT and resting ABG, and the only manifestation of their disease may be a widening of the alveolar–arterial gradient during formal cardiopulmonary exercise testing.[44]

Cardiac Assessment

A cardiac assessment is needed to rule out heart failure as a differential diagnosis of ILD. An ECG is usually obtained to evaluate for evidence of PH or concurrent cardiac disease. If heart failure or PH is suspected, a serum brain natriuretic peptide or N-terminal-proBNP level is measured.[43] Assessment for PH is needed because the presence of pulmonary hypertension may be a clue to the underlying ILD etiology and severity. In patients with IPF, the presence of PH is associated with increased disease severity and decreased survival.[43]

Radiography

Most patients are referred for a chest radiograph at the time they seek medical attention for breathlessness and cough. Chest radiographic patterns can be suggestive of ILD. Comparison with old chest radiographs can demonstrate chronicity. Most often at the time of presentation for symptoms, the chest radiographs show pulmonary changes. Although the chest radiography almost always shows interstitial changes when ILD is present, it may appear normal when lung involvement is mild. This situation can be encountered with hypersensitivity pneumonitis, sarcoidosis, cellular nonspecific interstitial pneumonia, bronchiolitis, respiratory bronchiolitis, ILD, or collagen vascular disease. The various radiologic patterns and their possible association with ILD appear in **Table 21-6**. **Figures 21-5** to **21-7** show some common radiologic patterns.

HRCT provides greater accuracy than plain chest radiography, with some minor inconsistencies. HRCT has become a central component of the diagnostic evaluation of patients with suspected ILD.[45] In general, a complete lack of pulmonary parenchymal changes on HRCT imaging virtually excludes a diagnosis of ILD. However, ILD may rarely be present with the lung having microscopic involvement that does not reach the threshold for the detection of an abnormality detectable by HRCT.[7]

HRCT is the most appropriate protocol for ILD, due to the specific radiation attenuation properties of the lung tissue. The imaging data are interpreted by assessing the extent and distribution of the various ILD textural patterns in the lung CT scan. Typical ILD patterns in CT images are reticulation, honeycombing, ground glass opacity, consolidation, and micronodules.[46] See **Table 21-7** and **Figures 21-8** to **21-10**.

Tissue Sampling

In some cases, the diagnosis of ILD cannot be confirmed radiologically. Although ILDs are a histologically

TABLE 21-6
Routine Chest Radiographic Patterns in ILD

Radiographic Pattern	Consistent with ILD Diagnosis, Mimics, or Is a Complication of ILD
Hilar lymphadenopathy	Sarcoidosis, silicosis, chronic beryllium disease, infection, malignancy
Septal thickening	Congestive heart failure malignancy, infection, pulmonary veno-occlusive disease
Lower lung zone predominance	Interstitial pulmonary fibrosis, asbestosis, desquamative interstitial pneumonia, collagen vascular disease, nonspecific interstitial pneumonia
Mid/upper lung zone predominance	Sarcoidosis, silicosis, acute hypersensitivity pneumonitis, Langerhans cell histiocytosis, chronic beryllium diseases, ankylosing spondylitis, chronic eosinophilic pneumonia
Peripheral lung zone predominance	Cryptogenic organizing pneumonia, chronic eosinophilic pneumonia, IPF
Honeycomb change	IPF, asbestosis, chronic hypersensitivity pneumonitis, sarcoidosis, fibrotic nonspecific interstitial pneumonia, collagen vascular disease
Small nodules	Sarcoidosis, hypersensitivity pneumonitis, infection
Cavitating nodules	Polyangiitis with granulomatosis, mycobacterium infection, cancer
Migratory or fluctuating opacities	Hypersensitivity pneumonitis, cryptogenic organizing pneumonia, desquamative interstitial pneumonia
Pneumothorax	Langerhans cell histiocytosis, LAM, tuberous sclerosis
Pleural involvement	Asbestosis, collagen vascular disease, acute hypersensitivity pneumonitis, malignancy, sarcoidosis, radiation fibrosis
Kerley B line prominence	Lymphangitic carcinomatosis, congestive heart failure

Data from Meyer K, Raghu G. Patient evaluation. In: Baughman R, du Bois R, eds. *Diffuse Lung Disease: A Practical Approach.* 2nd ed. New York, NY: Springer; 2012:3–16 (Table 1.3).



FIGURE 21-5 Chest radiograph demonstrating bilateral hilar lymphadenopathy.
Case courtesy of Dr Mohammad Taghi Niknejad, Radiopaedia.org, rID: 21198.



FIGURE 21-6 Pleural involvement with numerous pleural plaques. This patient has asbestos-related pleural disease.
Published with permission from LearningRadiology.com.

heterogeneous group of disease, they mostly have somewhat similar clinical manifestations with each other, or even with different lung disorders, so that differential diagnosis is difficult even for experienced practitioners.[46] Histologic specimens include endobronchial biopsies, transbronchial biopsies, **cryobiopsy**, video-assisted thoracic surgical biopsies, and traditional open biopsies. Depending on the specific disease, any of these biopsy techniques may allow a definitive diagnosis. However, the most likely method to obtain a specific tissue



FIGURE 21-7 Honeycomb pattern on chest radiograph. Honeycombing more pronounced with a HRCT.
Reproduced with permission from The Radiology Assistant.

TABLE 21-7
HRCT Patterns in ILD

Pattern	Consistent with ILD Diagnosis, Mimics of ILD, and/or Complications of ILD
Nodules	Sarcoidosis, hypersensitivity pneumonitis, chronic beryllium diseases, pneumoconiosis, rheumatoid arthritis, malignancy
Septal thickening	Edema, malignancy, infection, drug toxicity, pulmonary veno-occlusive disease
Cyst formation	LAM, Langerhans cell histiocytosis, lymphoid interstitial pneumonia, desquamative interstitial pneumonia, Sjögren syndrome
Reticular lines	IPF, asbestosis, chronic eosinophilic pneumonia, chronic hypersensitivity pneumonitis, CTD, nonspecific interstitial pneumonia
Traction bronchiectasis	IPF, other end-stage fibrosis
Honeycomb change	IPF, chronic eosinophilic pneumonia and hypersensitivity pneumonitis, asbestosis, sarcoidosis
Ground glass opacity	Acute interstitial pneumonia, acute eosinophilic pneumonia, pulmonary alveolar proteinosis, chronic eosinophilic pneumonia, cryptogenic organizing pneumonia, lymphoma, sarcoidosis, nonspecific interstitial pneumonia, infection, hemorrhage

Data from Meyer K, Raghu G. Patient evaluation. In: Baughman R, du Bois R, eds. *Diffuse Lung Disease: A Practical Approach*. 2nd ed. New York, NY: Springer; 2012:3–16 (Table 1.3).



FIGURE 21-8 HRCT scan demonstrating a usual interstitial pneumonia (UIP) pattern: the fibrotic changes predominate in the lung bases and subpleural regions and are associated with honeycombing and traction bronchiectasis. The latter is, as the name suggests, caused by the fibrotic lung pulling on the bronchi, causing irreversible dilation. The most common cause of UIP is IPF.
Case courtesy of Dr. David Cuete, Radiopaedia.org, rID: 33436.

diagnosis is with a surgical lung biopsy. In general, small endobronchial or transbronchial biopsies may be diagnostic in diseases in which the histologic changes are unique or sufficiently characteristic that they may be appreciated even in tiny specimens.[47]

BAL has gained widespread acceptance as a procedure that can be performed safely to retrieve respiratory secretions for the examination of cellular and acellular components for diagnostic purposes.[44] BAL is routinely



FIGURE 21-9 A HRCT scan demonstrating ground glass opacifications. This patient was diagnosed with ILD developed from amiodarone or amiodarone lung.
Case courtesy of A.Prof Frank Gaillard, Radiopaedia.org.



FIGURE 21-10 HRCT scan of a patient with the early nodular stage of PLCH.
Case courtesy of Dr Michael Sargent, Radiopaedia.org.

used as a tool to diagnose respiratory infections, evaluate patients with acute respiratory failure or evidence of DPLDs, and monitor the status of transplanted lung allografts.[44] Current application of BAL is limited but can be diagnostic in certain ILDs, such as pulmonary alveolar proteinosis and pneumoconiosis. Otherwise, the precise information is not obtained for most ILDs. Many patients with an acute onset of ILD will be evaluated with BAL to assess for acute eosinophilic pneumonia, alveolar hemorrhage, malignancy, and opportunistic or atypical infection, which can often be diagnosed based on BAL findings. BAL analysis alone has no diagnostic value; it must be put together with other clinical and radiologic features and reviewed by a multidisciplinary team.[44,48] The American Thoracic Society (ATS) statement has been clear and realistic about the use of BAL. When used in conjunction with comprehensive clinical information and adequate thoracic imaging, such as HRCT of the thorax, BAL cell patterns and other characteristics frequently provide useful information for the diagnostic evaluation of patients with suspected ILD.[49,50] BAL does not have an established role in the assessment of ILD progression or response to therapy.[43]

Transbronchial biopsy (TBB) can be helpful when primary lung neoplasm, infectious pneumonitis, or sarcoidosis is high on the list for differential diagnosis. TBB is often the biopsy procedure of choice when the suspected ILD is likely to have a centrilobular location and when a diagnosis can be made from small samples of lung tissue. Examples of centrilobular diseases include sarcoidosis, hypersensitivity pneumonitis, lymphangitic carcinomatosis, eosinophilic pneumonia, and alveolar proteinosis.[51]

Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be used to evaluate enlarged hilar and mediastinal lymph nodes. EBUS-TBNA has a yield of 90–96% for the diagnosis of sarcoidosis in the presence of hilar or mediastinal adenopathy.[51]

In a patient with characteristic clinical features, a confident diagnosis of IPF can be made after excluding alternative causes of ILD and demonstrating typical features on HRCT of the lungs. In patients with atypical features on imaging or other cause of diagnostic uncertainty, a surgical lung biopsy may be required to confirm the diagnosis.[52] This may be important for management because treatment options and prognosis differ significantly between the various types of ILD.[52]

When BAL and TBB are nondiagnostic, surgical lung biopsies are appropriate unless specific contraindications exist. A lung biopsy is the gold standard to determine the specific diagnosis for patients with ILD. There are several indications for surgical lung biopsy. See **Box 21-2**.

Examination of the tissue allows for confirmation of a specific ILD, affects the treatment plan development, predicts response to treatment, and provides prognostic information.[53] A lung biopsy is the most definitive way to diagnose different pathologic subtypes of ILD. Lung biopsy helps to distinguish treatable secondary causes

BOX 21-2 Indications for Surgical Lung Biopsy

Patient younger than 65 years
History of fever, weight loss, and sweats
History of hemoptysis
Family history of ILD
Symptoms and signs of peripheral vasculitis
History of pneumothorax
Normal chest radiograph despite clinical signs
Atypical radiographic features of IPF
Unexplained extrapulmonary manifestations
Unexplained PH
Unexplained cardiomegaly
Rapidly progressive disease

and steroid-responsive primary causes of interstitial lung disorders. Tissue samples from a TBB are often too small and are hampered by sampling variation. For these reasons, biopsy techniques using video-assisted thoracoscopic surgery or open thoracotomy are often preferred because they provide larger tissue sampling.

The optimal number, size, and location of lung biopsies depend upon the suspected diagnosis and the anatomic distribution of the disease process. The clinician should communicate with the thoracic surgeon any specific concerns and suggestions regarding these issues. HRCT imaging plays an essential role in selecting the best location(s) to biopsy.[54] The areas to avoid taking the biopsy from are those regions that appear completely normal and those areas of greatest involvement and honeycombing. These would be of little diagnostic value. Lung parenchyma with mild involvement or lung parenchyma adjacent to obviously abnormal areas should be biopsied.[43] See **Figure 21-11**.



FIGURE 21-11 **(A)** A possible UIP pattern. The CT scan shows subpleural and bibasal predominant reticular abnormality without honeycombing. Although the patient was highly likely to have IPF, surgical lung biopsy is needed to confirm the diagnosis. **(B)** The patient underwent open-lung biopsy, which shows fibrotic lung disease with heterogeneous spatial and temporal fibrosis consistent with a **usual interstitial pneumonia (UIP)** pattern. **(C)** Honeycomb change with enlarged subpleural alveolar spaces with bronchiolar metaplasia, mucus plugs, and mild chronic inflammatory infiltrate. Based on clinical, radiologic, and pathologic data, a diagnosis of IPF was made.

A pattern-based histopathologic approach to ILD provides a "map" to use with the aid of the clinical and radiologic patterns of presentation. Several patterns assist in narrowing down the diagnosis. See **Table 21-8**.

Recognizing the dominant pattern is essential for navigating the differential diagnosis and addressing the primary clinical concerns. Specific patterns should be considered dominant over others based on clinical concerns. Acute lung injury should always come first given the acuity of the clinical presentation when this pattern is present and the potentially lethal immediate consequences.[55] The characteristic findings on HRCT of UIP are **reticular** abnormality and honeycombing with basal predominance. Honeycombing is a strong predictor of UIP and is a significant predictor of mortality.[56] Because UIP carries the most adverse prognosis among the subtypes of idiopathic interstitial pneumonia, it is essential to be able to differentiate this entity from nonspecific interstitial pneumonia and desquamative interstitial pneumonia from UIP, because these patients may show similar clinical presentations.[56]

Taking into consideration the various investigations involved in ILD diagnosis, no single diagnostic test can provide a confident answer.[2] The use of a multidisciplinary diagnosis team (MDT) approach is the current gold standard in ILD diagnosis and comprises interdisciplinary discussions of multiple forms of information to provide diagnostic and management outputs.[57] Several studies report that MDT diagnosis is associated with higher levels of diagnostic confidence and better interobserver agreement when compared with the individual components of the MDT in isolation.[58] An MDT approach to the diagnosis of ILDs combines clinical data with serial lung function and disease behavior to establish an accurate expert diagnosis and decide on treatment options.[59]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Patients with connective tissue ILDs test positive for autoantibodies.
2. True or False: DLCO can determine the etiology of ILDs.
3. True or False: Small nodules found on chest radiography is common with IPF.
4. True or False: HRCT is the gold standard for the diagnosis of ILD.

Treatment and Management

Once there is a confident diagnosis, a plan to treat and monitor disease activity can begin. See **Box 21-3**. The MDT must develop a plan that answers several questions: (1) What pharmacologic agent(s) are appropriate,

TABLE 21-8
Six Histopathologic Patterns for ILD[55]

Pattern	Description
Acute lung injury	• Diffuse alveolar damage • Infections • Drug reactions • Related to rheumatic disease • Related to toxins, fumes, and gases • Acute eosinophilic pneumonia • Alveolar hemorrhage syndromes • Transplant rejection • Idiopathic forms (acute interstitial pneumonia and acute fibrinous and organizing pneumonia)
Fibrosis	• Pneumoconiosis • UIP • Chronic hypersensitivity pneumonitis • Related to rheumatic disease • Chronic drug reactions • Advanced sarcoidosis • Fibrotic nonspecific interstitial pneumonia • Chronic aspiration • Chronic radiation injury • Advanced Langerhans cell histiocytosis • Hermansky–Pudlak syndrome • Erdheim–Chester disease (non-Langerhans cell histiocytosis) • Idiopathic airway-centered fibrosis
Cellular infiltrates	• Hypersensitivity pneumonitis • Drug reactions • Related to rheumatic disease • Lymphoproliferative diseases • Nonspecific interstitial pneumonia • Certain infections (e.g., mycoplasma, HIV) • Lymphoid interstitial pneumonia
Alveolar filling	• Pulmonary edema • Granulomatous infection • Pneumoconioses, especially silica related • Aspiration • Nodular drug reaction (e.g., amiodarone) • Sarcoidosis/berylliosis • Langerhans cell histiocytosis • Wegener granulomatosis • Persistent organizing pneumonia • Pulmonary hyalinizing granuloma • Plasma cell granuloma • Lung infarct • Rosai–Dorfman disease
Minimal changes	• Pulmonary edema • A very subtle interstitial infiltrate • Pulmonary emboli (including fat emboli) • Constrictive bronchiolitis • Vasculopathic diseases • Cystic diseases • LAM • Langerhans cell histiocytosis • Sampling error

if any? (2) How will disease progression be monitored? (3) Should a lung transplantation referral be made? (4) Is the disease end stage? (5) Is the disease likely to respond to therapy? (6) Is supportive, palliative care for this patient the best approach?[7]

Because ILD refers to a broad category of lung diseases rather than a specific disease entity, many medications are used for its treatment and its various symptoms. Individual treatment should be highly dependent on the underlying disease and primary histologic classification. Medical treatment may consist of immunosuppressive drugs and avoidance of disease-inducing exposures. Careful questioning of current or recent contact with environmental mold, birds, tobacco smoke, and specific medications is essential. In many cases, just removing the inciting agent may be sufficient to bring about disease regression, without the need for immune suppression.[4]

In ILD, few diseases are amenable to specific treatments. However, most therapy is targeted at reducing inflammation, preventing fibrosis, and maintaining function. Corticosteroid-based regimens are standard, often with the addition of immunosuppressive agents, including azathioprine, mycophenolate, and cyclophosphamide.[4] Individually or in combinations, these are the basic medications used for the treatment of ILD.

New guidelines, by the American Thoracic Society/European Respiratory Society/Japanese Respiratory Society, and the Latin American Thoracic Association (ATS/ERS/JRS/ALAT), for the treatment of IPF were published in 2015.[9] The recommendations for the treatment of IPF now conditionally include the use of nintedanib and pirfenidone. Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases, including the platelet-derived growth factor receptor, fibroblast growth factor receptors, and vascular endothelial growth factor receptors.[60] These tyrosine kinases are involved in signaling pathways that have been implicated in the development and progression of fibrosis.[61] Pirfenidone has antifibrotic, antiinflammatory, and antioxidant effects.[62] Both drugs can significantly slow the rate of IPF progression. Until now IPF has no known effective treatment.

Despite its significant diversity, several other therapy modalities can be of benefit to most patients with ILD, including supplemental oxygen therapy. Oxygen is often prescribed because hypoxemia is a common finding with ILD. Pulmonary rehabilitation, though not as well studied in ILD patients compared to those with obstructive lung disease, is a valuable management tool for building aerobic fitness, maintaining physical activity, and improving quality of life. Vaccinations and infection avoidance are also important adjuncts in the care of persons with ILD. This is especially true in those patients that are treated with immunosuppressive medications known to cause

BOX 21-3 Management Strategies for Patients with ILD[7]

- Establish a partnership with the patient to provide a patient-centered, personalized care plan.
- Provide the patient with:
  - Information regarding the nature of the specific disease and its prognosis
  - Treatment options with appropriate counseling include:
    - Enrollment in clinical trials
    - Off-label therapy options
    - Lung transplantation
    - Best supportive care
- Use disease-specific monitoring (for prognosis and treatment decisions).
  - PFT
    - FVC
    - DLCO
    - 6MWT
  - Thoracic imaging
  - Dyspnea score
- Pulmonary rehabilitation
- Supplemental oxygen if indicated (keep Spo_2 ≥90%)
  - During exertion
  - During sleep
  - Continuous if indicated
- Detect and treat comorbidities and complications
  - Gastroesophageal reflux disease
  - Drug toxicity (if treated)
  - Sleep-disordered breathing
  - Secondary PH
  - Metabolic bone disease (osteopenia, osteoporosis)
  - Anemia
  - Anxiety and depression
- Maintain ideal body mass index (weight reduction if obese, improved nutrition if cachectic)
- Vaccinations (pneumococcal vaccine, seasonal influenza, others as indicated)

some increased risk for the development of infections. Patients should receive a pneumococcal vaccine per the Centers for Disease Control and Prevention (CDC) guidelines and a yearly influenza virus vaccine. Additionally, individuals treated with certain specific immunosuppressive regimens should also receive Pneumocystis prophylaxis.

Ultimately, the goals of treatment for any of the ILD disorders include the reduction of breathlessness and inflammation and the suppression of overactive immune systems. Regardless of the underlying cause of ILD, treatment needs to decrease inflammation and prevent further lung scarring, removing the source of the problem when possible, minimizing and managing potential complications, and attempting to improve or prevent a worsening in a person's quality of life. However, many ILDs have limited effective therapies and may require lung transplantation for ongoing survival. Lung transplantation is a potentially curative option for a select group of ILD sufferers. Timely transplant referral is critical, particularly for younger patients with treatment-refractory, aggressive fibrosis.[4] The rate of decline in FVC and DLCO is a predictor of the requirement for transplantation. Transplantation is the only option shown to prolong the survival rate of patients with advanced ILD, especially IPF. ILD is the second most common indication for lung transplantation.[63] Among the ILDs, IPF most commonly requires lung transplantations.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Sometimes just removing the causative agent can cause ILD regression.
2. True or False: Nintedanib and pirfenidone are two new antiinflammatory drugs for IPF.
3. True or False: Pulmonary rehabilitation is not indicated for ILD.
4. True or False: Lung transplantation is a potential curative option for a select group of patients with ILD.

Prognosis

The prognosis of ILD depends on the specific type of ILD and the response to therapy. Patients with IPF have a better chance of survival if they are female, are younger, have less dyspnea, and have a more significant response with lavage at the onset of symptoms. The overall prognosis for IPF is typically poor, and most patients have progressive loss of lung function and may suffer acute exacerbations with an acceleration of lung function loss that often leads to death.[7]

The radiographic and pathologic pattern that defines IPF is UIP. However, UIP is also associated with a few conditions, mainly CTDs and chronic hypersensitivity pneumonitis. The presence of a UIP pattern on HRCT with patients who have ILD with rheumatoid arthritis has a prognosis like IPF. Differentiation of UIP is important as it carries the worst prognosis and treatment varies widely from the other types of ILDs.[64,65] This is because in those with a UIP pattern, the areas of ground glass attenuation tend to progress to fibrosis despite treatment. In those patients with more active inflammation involving the pulmonary interstitium, there is a faster progression of honeycombing in long-term follow-up.[65]

BAL cell counts do not appear to be a reliable indicator of prognosis for some ILDs.[66–68] An increased proportion of neutrophils in BAL fluid was associated with more extensive lung disease on HRCT, a more significant reduction in DLCO, and early mortality (HR: 8.40, 95% CI: 1.91–36.95), but it did not predict the rate of functional deterioration or progression-free survival.[67] The rate of survival for patients with ILD is changing due to the introduction of new therapies in the past few years and will continue to change with the new therapies currently in clinical trials and research into molecular biomarkers.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The prognosis for ILD is dependent on the specific type of disease.
2. True or False: The UIP pattern on chest radiography carries a positive prognosis for patients with ILD.
3. True or False: BAL is a reliable indicator for ILD prognosis.

Chapter Summary

ILDs have a gradual onset but can also present as an acute exacerbation. A thorough history is essential when trying to identify the etiology of the disease. When the etiology is known, prevention and cessation of exposure is vital. PFT typically shows a restrictive-type defect. Hypoxemia is common especially during exertion and may progress to occur at rest. Diagnosis of ILD is usually made with a combination of clinical, immunologic, radiologic, and pathologic examinations and reviewed by a multidisciplinary team to determine the most likely diagnosis. There are times when there are no clear answers to the diagnosis. The prognosis of ILD varies with its cause and its severity.

Key Points

1. The most common presentation of ILD is a slowly progressive onset of dyspnea and a nonproductive cough.
2. A thorough history is crucial to the identification of the cause of ILD.
3. Many of the known etiologies of ILD produce similar clinical features.
4. Both inflammation and fibrosis occur with ILD, and their presence determines whether the ILD will respond to treatment.
5. Fibrosis is caused by damage to the epithelial or endothelial layers and their associated basement membranes, leading to apoptosis and necrosis of the AECs.
6. The fibrosis that occurs with IPF is not reversible, as it is at least partially reversible in some ILDs.
7. With IPF, epithelial damage causes AMs to release chemical markers that attract neutrophils, cytokines, growth factors, ECM proteins, and tissue inhibitors of metalloproteases. These all contribute to further alveolar injury and aberrant lung repair.
8. Cigarette smoking, occupational exposure, environmental exposure, and certain medications are risk factors for the development of ILD. Having certain CTDs are risk factors for the development of ILDs.
9. PH is a common complication of ILD, especially IPF. PH adversely affects patient outcome.
10. PFT serves as a guide to severity and to monitor patient progression. Radiologic and histopathologic patterns are used as a guide to diagnosis. The prognosis of the patient varies with the type of ILD and its severity.

Chapter Questions

1. One of the most common interstitial lung diseases of unknown etiology is _____.
   a. eosinophilic pneumonia
   b. sarcoidosis
   c. amyloidosis
   d. polymyositis
2. A patient presenting with progressive dyspnea, nonproductive cough, eye symptoms, salivary gland enlargement, hypercalcemia, and a chest radiography with hilar lymphadenopathy most likely has a diagnosis of _____.
   a. idiopathic pulmonary fibrosis (IPF)
   b. hypersensitivity pneumonitis
   c. asbestosis
   d. sarcoidosis
3. A patient presenting with a slow onset of breathlessness and dry cough, digital clubbing, and pleural involvement with a reticular line pattern on chest radiograph who was a construction worker in the 1970s may have _____.
   a. asbestosis
   b. sarcoidosis
   c. lymphangioleiomyomatosis
   d. cryptogenic organizing pneumonia
4. The most likely method of obtaining a specific tissue diagnosis is with _____.
   a. bronchoalveolar lavage
   b. cryobiopsy
   c. surgical biopsy
   d. high-resolution computed tomography (HRCT)
5. An endobronchial ultrasound transbronchial needle aspiration biopsy can be used to obtain histologic specimen in cases of _____.
   a. sarcoidosis
   b. asbestosis
   c. IPF
   d. chronic hypersensitivity pneumonitis
6. _____ may be diagnosed from typical features on HRCT scan of the lungs.
   a. Chronic hypersensitivity pneumonitis
   b. IPF
   c. Chronic eosinophilic pneumonia
   d. Sjögren syndrome
7. _____ can cause a predominant fibrosis pattern on radiologic images.
   a. Diffuse alveolar damage
   b. Transplant rejection
   c. Chronic drug reaction
   d. Wegner granulomatosis
8. A cellular infiltrate pattern is indicative of _____.
   a. persistent organizing pneumonia
   b. chronic radiation injury
   c. cystic disease
   d. hypersensitivity pneumonitis
9. _____ is one of two antifibrotic drugs used in the treatment of IPF.
   a. Cyclophosphamide
   b. Mycophenolate
   c. Nintedanib
   d. Azathioprine
10. The worst prognosis for interstitial lung disease is one with a demonstrated pattern of _____ on HRCT.
    a. acute lung injury
    b. usual interstitial pneumonia
    c. ground glass opacification
    d. nodules

References

1. King T Jr. Approach to the adult with interstitial lung disease: Clinical evaluation. In: Flaherty K, Hollingsworth H, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed July 6, 2018.
2. Mikolasch T, Garthwaite H, Porter J. Update in diagnosis and management of interstitial lung disease. *Clin Med*. 2017;17(2):146–153. doi:10.7861/clinmedicine.17-2-146
3. Zibrak JD, Price D. Interstitial lung disease: raising the index of suspicion in primary care. *NPJ Prim Care Respir Med*. 2014;24(1):14054. doi:10.1038/npjpcrm.2014.54
4. Troy L, Corte T. Interstitial lung disease in 2015: where are we now? *Aust Fam Physician*. 2015;44(8):546–552.
5. Interstitial lung diseases–ERS. Erswhitebook.org. https://www.erswhitebook.org/chapters/interstitial-lung-diseases. Published 2018. Accessed July 11, 2018.
6. Peros-Golubicic T. Diffuse parenchymal lung disease. *Rad 522 Med Sci*. 2015;41:35–45. https://hrcak.srce.hr/index.php?show=toc&id_broj=11253. Accessed July 6, 2018.
7. Meyer K. Diagnosis and management of interstitial lung disease. *Transl Respir Med*. 2014;2(1):4. doi:10.1186/2213-0802-2-4
8. Travis W, Costabel U, Hansell D, et al. An official American Thoracic Society/European Respiratory Society Statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013;188(6):733–748. doi:10.1164/rccm.201308-1483st
9. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir Crit Care Med*. 2015;192(2):e3–e19. doi:10.1164/rccm.201506-1063st
10. Fischer A, Antoniou K, Brown K, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *Eur Respir J*. 2015;46(4):976–987. doi:10.1183/13993003.00150-2015
11. Lee J. Overview of Interstitial Lung Disease—Pulmonary Disorders—MSD Manual Professional Edition. MSD Manual Professional Edition. https://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/overview-of-interstitial-lung-disease. Published 2018. Accessed July 11, 2018.
12. Schwaiblmair M, Behr W, Haeckel T, Märkl B, Foerg W, Berghaus T. Drug induced interstitial lung disease. *Open Respir Med J*. 2012;6(1):63–74. doi:10.2174/1874306401206010063
13. Kreuter M, Herth F, Wacker M, et al. Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registry—The EXCITING-ILD Registry. *Biomed Res Int*. 2015;2015:1–9. doi:10.1155/2015/123876
14. Thoracic.org. https://www.thoracic.org/patients/patient-resources/breathing-in-america/resources/chapter-10-interstitial-lung-disease.pdf. Published 2018. Accessed July 11, 2018.
15. English J, Patel P, Greer K. Sarcoidosis. *J Am Acad Dermatol*. 2001;44(5):725–746. doi:10.1067/mjd.2001.114596
16. Jordan H, Stellman S, Prezant D, Teirstein A, Osahan S, Cone J. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. *J Occup Environ Med*. 2011;53(9):966–974. doi:10.1097/jom.0b013e31822a3596
17. Ley B, Collard H. Epidemiology of idiopathic pulmonary fibrosis. *Clin Epidemiol*. 2013;5:483–492. doi:10.2147/clep.s54815
18. Harari S, Caminati A, Madotto F, Conti S, Cesana G. Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. *Eur Respir J*. 2017;49(1):1601504. doi:10.1183/13993003.01504-2016
19. Glasser S, Hardie W, Hagood J. Pathogenesis of interstitial lung disease in children and adults. *Pediatr Allergy Immunol Pulmonol*. 2010;23(1):9–14. doi:10.1089/ped.2010.0004
20. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. *Eur Respir Rev*. 2015;24(135):102–114. doi:10.1183/09059180.00003214
21. Byrne A, Maher T, Lloyd C. Pulmonary macrophages: a new therapeutic pathway in Fibrosing Lung Disease? *Trends Mol Med*. 2016;22(4):303–316. doi:10.1016/j.molmed.2016.02.004
22. Lappi-Blanco E. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. *Lung*. 1999;177:367–376.
23. Myers J, Katzenstein A. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. *Chest*. 1988;94(6):1309–1311. doi:10.1378/chest.94.6.1309
24. Uhal B. The role of apoptosis in pulmonary fibrosis. *Eur Respir Rev*. 2008;17(109):138–144. doi:10.1183/09059180.00010906
25. Bargagli E, Prasse A, Olivieri C, Muller-Quernheim J, Rottoli P. Macrophage-derived biomarkers of idiopathic pulmonary fibrosis. *Pulm Med*. 2011;2011:1–7. doi:10.1155/2011/717130
26. Obayashi Y, Yamadori I, Fujita J, Yoshinouchi T, Ueda N, Takahara J. The role of neutrophils in the pathogenesis of idiopathic pulmonary fibrosis. *Chest*. 1997;112(5):1338–1343. doi:10.1378/chest.112.5.1338
27. Kinder B, Brown K, Schwarz M, Ix J, Kervitsky A, King T. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. *Chest*. 2008;133(1):226–232. doi:10.1378/chest.07-1948
28. Kelly M, Leigh R, Gilpin S, et al. Cell-specific gene expression in patients with usual interstitial pneumonia. *Am J Respir Crit Care Med*. 2006;174(5):557–565. doi:10.1164/rccm.200510-1648oc
29. Kage H, Borok Z. EMT and interstitial lung disease. *Curr Opin Pulm Med*. 2012:18:517–523. doi:10.1097/mcp.0b013e3283566721
30. Rossi G, Cavazza A, Spagnolo P, et al. The role of macrophages in interstitial lung diseases: number 3 in the series "Pathology for the clinician" Edited by Peter Dorfmüller and Alberto Cavazza. *Eur Respir Rev*. 2017;26(145):170009. doi:10.1183/16000617.0009-2017
31. Hagmeyer L, Randerath W. Smoking-related interstitial lung disease. *Dtsch Arztebl Int*. 2015;112(4):43–50. doi:10.3238/arztebl.2015.0043
32. Kur-Zalewska J, Tlustochowicz M, Tlustochowicz W. THU0060 risk factors of interstitial lung disease in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2013;71(Suppl 3):173.1–173. doi:10.1136/annrheumdis-2012-eular.2025
33. Genetics Reference. Idiopathic pulmonary fibrosis. Genetics Home Reference. https://ghr.nlm.nih.gov/condition/idiopathic-pulmonary-fibrosis#inheritance. Published 2018. Accessed July 9, 2018.
34. Maldonado F, Limper A. Pulmonary toxicity associated with systemic antineoplastic therapy: clinical presentation, diagnosis, and treatment. In: Flaherty K, Hollingsworth H, Savarese D, eds. *Uptodate*. Waltham, MA: Uptodate; 2018. http://www.uptodate.com. Accessed July 8, 2018.
35. Glick D, Lyen S, Kandel S, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival in patients treated with lung stereotactic body radiation therapy (SBRT). *Clin Lung Cancer*. 2018;19(2):e219–e226. doi:10.1016/j.cllc.2017.06.021
36. Yoshitake T, Shioyama Y, Asai K, Nakamura K, Sasaki T. Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer. *Anticancer Res*. 2015;35:4909–4914. http://ar.iiarjournals.org/content/35/9/4909.full. Accessed July 8, 2018.
37. Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic interstitial lung diseases. *Eur Respir Rev*. 2013;22(129):292–301. doi:10.1183/09059180.00002713
38. Anklesaria Z, Saggar R, Derhovanessian A, Saggar R. Non-group 1 pulmonary hypertension associated with systemic sclerosis: an understudied patient population. *Adv Pulm Hypertens*. 2017;16(2):68–75. doi:10.21693/1933-088x-16.2.68
39. Zangiabadi A, De Pasquale C, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. *Biomed Res Int*. 2014;2014:1–13. doi:10.1155/2014/739674

40. Trudzinski F, Kaestner F, Schäfers H, et al. Outcome of patients with interstitial lung disease treated with extracorporeal membrane oxygenation for acute respiratory failure. *Am J Respir Crit Care Med*. 2016;193(5):527–533. doi:10.1164/rccm.201508-1701oc
41. Blivet S, Philit F, Sab J, et al. Outcome of patients with idiopathic pulmonary pibrosis admitted to the ICU for respiratory failure. *Chest*. 2001;120(1):209–212. doi:10.1378/chest.120.1.209
42. Bag R, Suleman N, Guntupalli K. Respiratory failure in interstitial lung disease. *Curr Opin Pulm Med*. 2004;10(5):412–418. doi:10.1097/01.mcp.0000136404.09581.41
43. King T Jr. Approach to the adult with interstitial lung disease: Diagnostic testing. In: Flaherty K, Hollingsworth J, eds. *Uptodate*. Waltham, MA: Uptodate; 2017. http://www.uptodate.com. Accessed July 8, 2018.
44. Meyer K, Raghu G. Patient evaluation. In: Baughman R, du Bois R, eds. *Diffuse Lung Disease: A Practical Approach*. 2nd ed. New York: Springer; 2012.
45. Lynch D, Godwin J, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med*. 2005;172(4):488–493. doi:10.1164/rccm.200412-1756oc
46. Anthimopoulos M, Christodoulidis S, Ebner L, Christe A, Mougiakakou S. Lung pattern classification for interstitial lung diseases using a deep convolutional neural network. *IEEE Trans Med Imaging*. 2016;35(5):1207–1216. doi:10.1109/tmi.2016.2535865
47. Colby T, Leslie K. Pathology of diffuse lung disease. In: Baughman R, du Bois R, eds. *Diffuse Lung Disease: A Practical Approach*. 2nd eds. New York, NY: Springer; 2012.
48. Efared B, Ebang-Atsame G, Rabiou S, et al. The diagnostic value of the bronchoalveolar lavage in interstitial lung diseases. *J Negat Results Biomed*. 2017;16(1). doi:10.1186/s12952-017-0069-0
49. Meyer K, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? *Eur Respir J*. 2011;38(4):761–769. doi:10.1183/09031936.00069509
50. Meyer K, Raghu G, Baughman R, et al. An official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. *Am J Respir Crit Care Med*. 2012;185(9):1004–1014. doi:10.1164/rccm.201202-0320st
51. King T Jr. Raj R. Role of lung biopsy in the diagnosis of interstitial lung disease. In: Flaherty K, Nicholson A, Hollingsworth H, eds. *Uptodate*. Waltham, MA: Uptodate; 2016. http://www.uptodate.com. Accessed July 8, 2018.
52. Hutchinson J, Fogarty A, McKeever T, Hubbard R. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. *Am J Respir Crit Care Med*. 2016;193(10):1161–1167. doi:10.1164/rccm.201508-1632oc
53. Fiddler C, Parfrey H. Diffuse parenchymal lung disease. *Medicine (Baltimore)*. 2016;44(6):359–366. doi:10.1016/j.mpmed.2016.03.014
54. Qureshi R, Ahmed T, Grayson A, Soorae A, Drakeley M, Page R. Does lung biopsy help patients with interstitial lung disease? *Eur J Cardiothorac Surg*. 2002;21(4):621–626. doi:10.1016/s1010-7940(02)00021-0
55. Leslie K. My approach to interstitial lung disease using clinical, radiological and histopathological patterns. *J Clin Pathol*. 2009;62(5):387–401. doi:10.1136/jcp.2008.059782
56. Misumi S. Idiopathic pulmonary fibrosis/usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, and temporal progression. *Proc Am Thorac Soc*. 2006;3(4):307–314. doi:10.1513/pats.200602-018tk
57. Jo H, Corte T, Moodley Y et al. Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. *BMC Pulm Med*. 2016;16(1). doi:10.1186/s12890-016-0179-3
58. Walsh S. Multidisciplinary evaluation of interstitial lung diseases: current insights. *Eur Respir Rev*. 2017;26(144):170002. doi:10.1183/16000617.0002-2017
59. Chaudhuri N, Spencer L, Greaves M, Bishop P, Chaturvedi A, Leonard C. A review of the multidisciplinary diagnosis of interstitial lung diseases: a retrospective analysis in a Single UK Specialist Centre. *J Clin Med*. 2016;5(8):66. doi:10.3390/jcm5080066
60. Hostettler K, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. *Respir Res*. 2014;15(1):157. doi:10.1186/s12931-014-0157-3
61. Grimminger F, Günther A, Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. *European Respiratory Journal*. 2015;45(5):1426–1433. doi:10.1183/09031936.00149614
62. Margaritopoulos G, Vasarmidi E, Antoniou K. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. *Core Evid*. 2016;11:11–22. doi:10.2147/ce.s76549
63. Yusen R, Edwards L, Dipchand A, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Lung and Heart–Lung Transplant Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. 2016;35(10):1170–1184. doi:10.1016/j.healun.2016.09.001
64. Tomassetti S, Ravaglia C, Poletti V. Diffuse parenchymal lung disease. *Eur Respir Rev*. 2017;26(144):170004. doi:10.1183/16000617.0004-2017
65. Niknejad M, Weerakkody Y. Usual interstitial pneumonia | Radiology Reference Article | Radiopaedia.org. Radiopaedia.org. https://radiopaedia.org/articles/usual-interstitial-pneumonia. Published 2018. Accessed July 10, 2018.
66. Bouros D, Wells A, Nicholson A, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med*. 2002;165(12):1581–1586. doi:10.1164/rccm.2106012
67. Goh N, Veeraraghavan S, Desai S, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progression. *Arthritis Rheum*. 2007;56(6):2005–2012. doi:10.1002/art.22696
68. Strange C, Bolster M, Roth M, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. *Am J Respir Crit Care Med*. 2008;177(1):91–98. doi:10.1164/rccm.200705-655oc

CHAPTER

22

Postoperative Pulmonary Complications

"An ounce of prevention is worth a pound of cure."

—Benjamin Franklin

OUTLINE

OBJECTIVES

1. Discuss the causes and treatment of postoperative atelectasis and hypoxemia.
2. Distinguish between patient-related and procedure-related risk factors for postoperative lung complications.
3. Discuss perioperative strategies in preventing patient and procedure-related postoperative respiratory complications.
4. Review preoperative testing evaluation in determining the risk of postoperative lung complications.
5. Discuss expected postoperative benefits of laparoscopic versus open surgery.

KEY TERMS

ARISCAT Risk Index
Arozullah Respiratory Failure Index
Atelectrauma
Barotrauma
Biofilm
Epidural anesthesia
General anesthesia
Gupta calculator for postoperative pneumonia
Gupta calculator for postoperative respiratory failure
Inspiratory muscle training
Nasogastric tube decompression
Nondepolarizing neuromuscular blocking agents (NMBAs)
Pack-year
Perioperative
Postoperative pulmonary complications (PPCs)
Spinal anesthesia
Subglottic suctioning
Volutrauma

Case Study

A 44-year-old white female schoolteacher was admitted to the hospital through the emergency department with complaints of severe right upper quadrant abdominal pain. Her previous medical history included some fatty food intolerance and dyspepsia. She smokes one pack of cigarettes per day since her freshman year of college (26 pack-years) and had childhood asthma until the age of 16. She described a recurrent "allergic cough" that is productive of clear sputum usually occurring through the spring until the late fall season. Her only significant medical history that she reported is hypercholesterolemia and "being overweight" due to "not getting around or exercising as much as I should." On physical examination, she seems to have a mild degree of labored breathing at rest. Her temperature was 100.7°F, pulse was 116/minute, resting respiratory rate was 26/minute and shallow, blood pressure was 136/92. She is 60 inches tall and weighs 205 lb (body mass index [BMI] = 40). Her nasal mucosa and turbinates are pink and moist. Chest examination reveals diminished breath sounds felt to be in part due to shallow breathing. Heart sounds are normal, and pulse is rapid. Abdominal exam reveals tenderness primarily over the right upper quadrant. Extremities are unremarkable with no signs of peripheral edema. A bedside spirometry screening before and following bronchodilator aerosol shows a mild airflow obstruction, which improved with aerosolized albuterol. Arterial blood gas on 2 L of oxygen shows a pH of 7.52, Pao_2 of 110 mm Hg, and $Paco_2$ of 36 mm Hg. Complete blood count shows a hemoglobin of 16.8 (12.1–16.3 g/dL) and a white blood cell count of 18,500 (4.1–10.5). Her serum amylase is mildly elevated with a normal lipase level. A chest radiograph shows a normal heart shadow and normally curved hemi-diaphragms. An electrocardiogram (ECG) revealed evidence of mild tachycardia but was otherwise unremarkable. Her diagnosis is suspected acute cholecystitis, and a surgical consultation and a decision for an exploratory laparotomy occurred the next morning. The patient was kept NPO following admission, began on inhaled bronchodilator therapy every 4 hours to avoid any potentially reversible airway obstruction before anesthesia induction, and received lung expansion maneuvers training.

Following an uncomplicated laparoscopic cholecystectomy, the patient was transferred to the intensive care unit (ICU), where she was later extubated. In the immediate postoperative period following extubation, she moved to the surgical wing and continued receiving 2 L of humidified supplemental nasal oxygen, which sustained the patient's oxygen saturation at more than 95%. She continued to receive aerosolized albuterol treatments as well as deep breathing exercises, incentive spirometry (IS), and respiratory therapist-assisted deep induced cough. On her third postoperative day, the patient became progressively short of breath. Pulse oximetry while receiving 3 L of supplemental oxygen via nasal cannula was 80%. Her breath sounds were diminished, and percussion was dull over the right middle and lower lobe regions of the chest with observed tracheal deviation to the right side. An arterial blood gas taken on 6 L via facial mask revealed a pH of 7.51, Pao_2 of 50 mm Hg, and $Paco_2$ of 36 mm Hg. A comparison portable chest radiograph confirmed suspected collapse of the right middle and lower lobes with obscuring of the right diaphragm and right heart border. Because of alleged airway obstruction, the patient underwent fiberoptic bronchoscopy, at which time a sizeable amount of mucous plugging occluded in both right middle and lower lobe airways.

Introduction

Postoperative pulmonary complications (PPCs) are broadly defined as abnormal occurrences affecting the respiratory tract producing identifiable disease, or dysfunction.[1] Postoperative adverse events are likely to be clinically significant and adversely influence the clinical course of patients following surgery, particularly in the first postoperative week. While there was considerable progress over the years in the management of **perioperative** patients, pulmonary complications remain a significant cause of postoperative morbidity and mortality.[2,3] Even mild PPCs are associated with increased early postoperative death, ICU admission, and length of stay (ICU and hospital).[4]

The etiology for PPCs is multifactorial and associated with preoperative, intraoperative, and postoperative risk factors.[5] In addition to perioperative risks, several postoperative complications are related to disrupted normal pulmonary physiology from preexisting lung disease. Residual effects of anesthesia and pharmacologic interventions cause reduced lung volumes creating

hypoventilation leading to atelectasis and pneumonia. PPCs occur at least as often as cardiac complications following noncardiac surgery and are a significant cause of morbidity and mortality.[1] While a PPC risk factor may exist as a solo issue, many risk factors are interrelated and commonly coexist in the same individual. Individual or combined PPCs are associated with increased morbidity, mortality, and hospital length of stay (LOS) and substantially increase consumption of healthcare resources.[5] Estimates suggest that more than 1 million PPCs occur annually in the United States, with 46,200 related deaths and 4.8 million additional hospitalization days.[4] PPCs are expensive and require longer hospital LOSs when compared with patients who experience no or only minor postoperative complications.[5] PPCs typically prolong a hospital LOS an additional 3–10 days in many cases.[6]

The type and duration of the surgery as well as the type and delivery mode of anesthesia administered directly influence the risk for postsurgical complications. While PPCs are anticipated to occur in 6–40% of patients undergoing upper abdominal and thoracic surgery,[2] they typically happen less often than other types of surgical procedures. The reported frequency of PPCs in the literature, however, varies as wide as from 2% to 70%. The wider range is due in part to patient selection and procedure-related risk factors, although differing definitions for postoperative complications account for much of the variability and make a comparison or reported incidences across different studies difficult.[7] The site of surgery is the most crucial factor in predicting the overall risk of PPCs. The rate of pulmonary complications is related to the surgical proximity to the diaphragm. The closer the surgery is to the diaphragm, the higher is the risk of PPC.[7,8] Surgical procedures lasting longer than 3 hours are also associated with higher risk of pulmonary complications. General anesthesia poses a higher risk of pulmonary complications than spinal or epidural anesthesia.[7] Regional nerve block is associated with lower risk and is a viable option for high-risk patients.[7] Anesthesia, sedatives, and opiates may worsen patients with obstructive sleep apnea (OSA) by decreasing pharyngeal muscle tone and blunting responses to hypercarbia and upper airway obstruction.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Clinically significant postoperative pulmonary adverse events typically occur within the second postoperative week.
2. True or False: The type and duration of anesthesia influence the risk for postsurgical complications.

Pulmonary Complication Risk Factors

Several independent risk factors are associated with PPCs. Circumstances that directly or indirectly affect preoperative pulmonary risk stratification are grouped into patient-related and procedure-related factors. See **Table 22-1**.

There is evidence that supports specific patient-related factors for developing perioperative pulmonary complications. The ASA physical status classification system (ASAPS) offers clinicians a simple categorization of a patient's physiologic status that can be helpful in predicting operative risk. This classification system assumes that age is unrelated to physiologic fitness, an assumption that is incorrect because neonates and the very elderly, even in the absence of disease, are far more "fragile" in their tolerance of anesthetics compared to young adults.[9] See **Table 22-2**.

The patient's ASA status predicts PPCs in those patients with an ASA or two or higher. Functional dependency and poor general health are significant predictors of PPCs. Total dependence (the inability to perform any activity of daily living) more than doubles the patient's likelihood of developing pneumonia.[1]

Evidence also exists that supports specific procedure-related factors, nature of the surgery and surgical site, as being a risk for PPCs.[1,2,4,7,10] Surgical sites such as aorta, thorax, abdomen and upper abdomen, head, neck, and vasculature pose the most significant risk.[1] Prolonged surgery and anesthesia change the body's immune defense and gas exchange capacity by depressing alveolar macrophage function, interfering with surfactant production, slowing mucociliary clearance, and increasing the permeability of the alveolar-capillary barrier. Anesthetic agents diminish respiratory drive and the body's response to

TABLE 22-1
Risk Factors for PPCs[1,7]

Patient-Related Factors	Procedure-Related Factors
Advanced age (>60 years) Asthma Poor general health status (American Society of Anesthesiologists [ASA] >2) Chronic obstructive pulmonary disease (COPD) Cigarette use Congestive heart failure (CHF) Metabolic and nutritional factors Nutritional status OSA Upper respiratory infection Pulmonary hypertension	Duration of surgery (>3 hours) Emergency surgery Surgical site (abdominal, thoracic, neurosurgery, vascular, head and neck surgery) Anesthetic factors (general anesthesia, neuromuscular block)

TABLE 22-2
ASA Physical Status Classification System[9]

ASA Classification	Description	Example
ASA 1	A normal healthy patient	Fit patient with a BMI <30, a nonsmoking patient with good exercise tolerance
ASA 2	A patient with mild systemic disease	Patient with no functional limitations and a well-controlled disease, such as treated hypertension, obesity with BMI <35, frequent social drinker or a cigarette smoker
ASA 3	A patient with a severe systemic disease that is not life threatening	Patient with some functional limitation because of a disease, such as poorly treated hypertension or diabetes, morbid obesity, chronic renal failure, a bronchospastic disease with intermittent exacerbation, stable angina, implanted pacemaker
ASA 4	A patient with a severe systemic disease that is a constant threat to life	Patient with functional limitation from severe, life-threatening disease, such as unstable angina, poorly controlled COPD, symptomatic CHF, MI <3 months ago, stroke <3 months ago
ASA 5	A moribund patient who is not expected to survive without the operation; the patient is not likely to survive beyond the next 24 hours without surgery	Ruptured aortic aneurysm, massive trauma, and extensive intracranial hemorrhage with mass effect
ASA 6	A brain-dead patient whose organs are being removed with the intention of transplanting them into another patient	
Addition of "E" to ASAPS	Emergency surgical procedure; "when the delay in treatment of the patient would lead to a significant increase in the threat to life or body part"	ASA 2E is a patient with a mild systemic disease who requires emergency surgery

hypoxia and hypercapnia, causing hypoventilation. In a spontaneously breathing patient, the closing capacity approaches functional residual capacity (FRC) and the small airways collapse, causing atelectasis in the dependent regions of the lung. Hypoxemia can result from ventilation–perfusion mismatching and increased shunt fraction. Prolonged periods of 100% oxygen may produce absorption atelectasis as all the oxygen is absorbed and the splinting effect of nitrogen in the alveoli is lost.[1] In patients undergoing laparotomy, FRC decreases to approximately 50% of baseline, returning toward normal in over 1–2 weeks.[8]

In contrast to patients who develop cardiac complications following noncardiac surgery, procedure-related factors are more predictive of pulmonary complications than are patient-related factors.[1] Even healthy patients undergoing high-risk surgery are at risk for pulmonary complications.

Age

Age is a nonmodifiable risk factor for PPCs and is a consistently reported predictor of PPCs.[2,8,11,12] Increasing age brings about a slow yet progressive decline in pulmonary function, such as decreases in forced expiratory flow rates, decrease in pulmonary elastic recoil, decrease in inspiratory capacity, fall in arterial oxygen pressure (Pa_{O_2}), and increase in alveolar-arterial oxygen tension difference ($A\text{-}aP_{O_2}$).[10,13] Elderly individuals are more susceptible to infection due to alterations in systemic immunity. In addition, advancing age is associated with a decrease in mucociliary clearance efficiency and a reduction in respiratory muscle function. Elderly patients experience more difficulty in clearing their airway secretions due to generalized muscle weakness.[13,14] The overall consequences of advanced age become particularly significant between the ages of 60 and 65 and escalate from there.[13,14]

Chronic Obstructive Pulmonary Disease

COPD is a major patient-related risk factor for PPCs.[15] The increased risk in patients with COPD is attributed to the airflow obstruction and the presence of other comorbidities commonly seen in smokers, such as CHF, obesity, and poor general health status.[16] Patients with COPD suffer exacerbations of bronchial inflammation following instrumentation of the airway. The combination of bacterial colonization of their airways, surgery-induced immunosuppression, and increased work of breathing may make COPD patients more susceptible.[1] Respiratory failure can result from fatigue, sepsis-induced alveolar–capillary membrane permeability, or fluid overload and heart failure.[1] The incidence

of PPCs parallels the severity of COPD, although the surgical site is the most important predictor and risk increases as the incision approaches the diaphragm.[16] Despite the increased risk of PPCs in patients with COPD, there appears to be no prohibitive level of pulmonary function below which surgery is absolutely contraindicated. However, the benefit of the surgery must be weighed against the known risks, even very high-risk patients may proceed to surgery if the indication is sufficiently compelling.[7]

Although COPD is a nonmodifiable risk factor, a patient's pulmonary status can be optimized prior to surgery to minimize the risk of PPCs.[17] The commonly used preoperative management strategy includes utilizing all the measures already established for stable COPD patients who are not going to have surgery. The presence of comorbid conditions, especially cardiac abnormalities, needs to be assessed and treated prior to any major surgical intervention.[16]

Asthma

It is relatively well established that patients with well-controlled asthma have a similar risk for PPCs as do patients without asthma.[7,17,18] On the other hand, poorly controlled asthma increases the risk of PPCs.[19,20] Surgical patients with emergency care for asthma in the preoperative 3 months had nearly doubled risk of postoperative mortality compared with controls.[18] Patients who were hospitalized for asthma in the 3 months preceding surgery had almost three times the risk of developing postoperative pneumonia (PP) compared with controls.[18] The presence of asthma in a patient undergoing elective surgery, therefore, warrants a thorough preoperative evaluation to assess whether a stepup in the patient's asthma therapy is needed before undergoing surgery. Patients with controlled asthma may require only a short-acting beta-2-agonist just prior to surgery. Patients with poorly controlled asthma may require a brief course of systemic glucocorticoids.[17,21] The perioperative use of systemic corticosteroids has not been found to increase respiratory infection or delay wound healing among patients with asthma.[22] Treatment options prior to surgery are, therefore, based on the patient's asthma severity and asthma control.

Nutritional Status

Extremes of nutritional status, malnutrition, and obesity have an influence on the risk of PPC development. In malnourished patients, low serum albumin is an established risk for PPC because it is associated with changes in pulmonary dynamics and functioning of the respiratory muscles, as it is related to higher rates of pneumonia.[10] Several studies show that a low serum albumin level (<35 g/L) is an important predictor of PPCs.[2,23] Preoperative nutritional supplements are advisable for the severely undernourished patient.[2] However, there is no proven advantage to total parenteral nutrition over no supplementation or total enteral nutrition in reducing PPCs.[23]

Obesity (BMI > 30 kg/m^2), especially morbid obesity, creates physiologic changes that cause decreased lung volumes, decreased FRC, ventilation/perfusion mismatch, increased alveolar–arterial oxygenation gradient ($A\text{-}aDO_2$), and hypoxemia. Despite this, obesity has not been found to be a risk factor for PPCs. The American College of Surgeons' National Surgical Quality Improvement Program study of the effect of BMI on perioperative outcomes after major surgery reviewed 141,802 patients and found that PPCs were no more common among obese adults than "normal" adults.[24] Most studies found the PPC rates to be almost identical for obese and nonobese patients.[15,23] However, there is an increased risk for PPCs in obese patients with OSA and obesity hypoventilation syndrome as opiate sensitivity contributes to the severity of nocturnal hypoxia.[25]

Obstructive Sleep Apnea

OSA syndrome is a common sleep-related breathing disorder occurring with an estimated prevalence of between 0.1% and 25% for mild-to-moderate OSA in the general population although this may even be greater in patients undergoing elective surgery.[26] Patients with OSA commonly present with difficulties in airway management in the perioperative period and therefore ideally should be identified in a timely fashion so that appropriate actions can be taken, yet OSA is often undiagnosed.[7,23,26] Procedure-related factors such as sedation and anesthesia in OSA patients can increase upper airway collapsibility, while anesthesia along with sleep may contribute to upper airway obstruction by diminishing pharyngeal dilator muscle activation and in resting lung volume. An analysis of 13 studies including 3,942 patients found that the incidence of postoperative desaturation, respiratory failure, and ICU transfers was higher in patients with OSA undergoing noncardiac surgery.[27] Because OSA is frequently associated with perioperative pulmonary complications, individuals with known or suspected OSA require careful postoperative management. It is particularly important when consciousness and arousal responses are impaired by sedation, analgesia, and anesthesia, causing significant compromise of mechanisms that usually protect individuals against asphyxiation during natural sleep.

The ASA adopted a set of guidelines with the purpose of improving the perioperative care and reducing the risk of adverse outcomes in patients with confirmed or suspected OSA who receive sedation, analgesia, or anesthesia. Part of these recommendations includes an example of a scoring system for perioperative risk from OSA. See **Table 22-3**.

If the OSA patient does not have a sleep study at the time of preoperative evaluation, there may not be

TABLE 22-3
Scoring System for Perioperative Risk form OSA: Example*

A. Severity of sleep apnea based on sleep study (or clinical indicators if sleep study is not available) Point score: (0–3)†,‡	
Severity of OSA	Points
None	0
Mild	1
Moderate	2
Severe	3
B. Invasiveness of surgery and anesthesia Point score: (0–3)	
Type of surgery and anesthesia	Points
Superficial surgery under local or peripheral nerve block anesthesia without sedation	0
Superficial surgery with moderate sedation or general anesthesia	1
Peripheral surgery with spinal or epidural anesthesia (with no more than moderate sedation)	1
Peripheral surgery with general anesthesia	2
Airway surgery with moderate sedation	2
Major surgery, general anesthesia	3
Airway surgery, general anesthesia	3
C. Requirement for postoperative opioids Point score: (0–3)	
Opioid requirement	Points
None	0
Low-dose oral opioids	1
High-dose oral opioids, parenteral or neuraxial opioids	3
D. Estimation of perioperative risk: Overall point score: the score for A plus the greater of the score for either B or C: (0–6)§	

*A scoring system similar to the above may be used to estimate whether a patient is at increased perioperative risk of complications from OSA. This example, which has not been clinically validated, is meant only as a guide, and clinical judgment should be used to assess the risk of an individual patient.

†One point may be subtracted if a patient has been on continuous positive airway pressure (CPAP) or nasal intermittent positive pressure ventilation before surgery and will be using his or her appliance consistently during the postoperative period.

‡One point should be added if a patient with mild or moderate OSA also has a resting $Paco_2$, >50 mm Hg.

§Patients with a score of 4 may be at an increased perioperative risk from OSA; patients with a score of 5 or 6 may be at significantly increased perioperative risk from OSA.

Practice Guidelines for the Perioperative Management of Patients with Obstructive Sleep Apnea. Anesthesiology. 2014;120(2):268-286. doi:10.1097/aln.0000000000000053.

enough time to complete the referral and study prior to the need for surgery. If the patient does not have a diagnosis of OSA but has a high risk of OSA, emergency surgery should be allowed. The decision to defer elective surgery for further evaluation is made on a case-by-case basis, based on the judgment that optimal management of OSA will improve patient outcome. When possible, deferring surgery in high-risk patients to allow optimization of the patient's condition is preferred.[26]

Smoking

Recent findings of patients undergoing elective surgery from the Veterans Administration Surgical Quality Improvement Program demonstrated current smokers had a dose-dependent increase in postsurgical pulmonary complications (especially PP) based on **pack-year** exposure.[28] A smoking history of ≥20 pack-years has an association with a fivefold increased risk of PPCs.[17] Preoperative smoking is associated with an increased risk for general morbidity, wound complications, general infections, neurological complications, as well as pulmonary complications.[12] Smokers produce more mucus and have slower mucus clearance, increased airway sensitivity, and increased pulmonary epithelial permeability and impaired macrophage and natural killer cytotoxic activity.[1] Smoking cessation prior to elective surgery appears to improve several outcomes, such as wound healing and postoperative pulmonary recovery. One study showed that 2 months of preoperative smoking cessation is necessary for intraoperative sputum volume to decrease to the baseline levels of nonsmokers.[15] A systematic review of 13 randomized controlled trials concluded that intensive smoking interventions initiated at least 4 weeks prior to surgery using multiple contacts for behavioral support and pharmacotherapy (**Box 22-1**) are beneficial for changing overall smoking behavior and reducing complications.[29] Because there are no well-established guidelines for the duration of abstinence from smoking necessary to reduce

BOX 22-1 Strategies for Smoking Cessation[31]

Ask, advise, assess, assist, and arrange (steps to intervention for tobacco addiction)
Behavioral counseling (to enhance motivation and abstinence)
Pharmacotherapy

- Nicotine replacement therapy (NRT)
  - Gum
  - Lozenge
  - Nasal spray
  - Inhaler
  - Sublingual tablet
  - Transdermal patch
- Bupropion hydrochloride (sustained release)
- Varenicline tartrate

pulmonary complications, more than 8 weeks may be preferable.[30]

Poor General Health (ASA Class >2)

A patient's overall health status is an essential determinant of pulmonary risk and the development of complications.[2,7] Higher ASA physical status is associated with PPCs following both thoracic and non-thoracic surgery.[32] An ASA classification of two or higher has an increased risk of PPCs when compared with an ASA classification of one.[22] Refer back to Table 22-1. In a recent multicenter study involving seven U.S. academic centers, one-third of all patients with severe systemic disease (ASA physical status 3) undergoing non-cardiothoracic surgery for 2 hours or more had PPCs.[4] Poor general health status, including impaired sensorium and functional dependency, also increases the risk of PPCs.[22] Total dependency (the ability to perform any activity of daily living) more than doubles the patient's likelihood of developing pneumonia.[1]

Congestive Heart Failure

The risk of PPCs is high with patients who have CHF. Good-quality evidence shows that CHF is a significant risk factor for PPCs.[15,23,33] Patients with preoperative CHF often have left atrial hypertension and pulmonary interstitial edema, which in turn resulted in a change in the pulmonary ventilation/blood flow ratio, thus causing postoperative hypoxemia and prolonged ventilation support.[34] Preoperative CHF also causes the lymph to back up, leading to pulmonary alveolar edema and decreasing pulmonary compliance, thus further aggravating respiratory dysfunction. Therefore, patients with preoperative CHF are prone to PPCs.[34]

KNOWLEDGE CHECK QUESTIONS

1. True or False: According to the ASA' Physical Status Classification System, a patient with a severe systemic disease that is not life threatening is in category ASA-2.
2. True or False: COPD is a modifiable risk factor for PPCs.
3. True or False: A fivefold increased risk of PPCs is present with a smoking history of ≥20 pack-years.
4. True or False: CHF is a significant risk factor for PPCs.

Preoperative Assessment for Pulmonary Risk

It is possible to reliably identify patients at the highest risk for postoperative mortality and pulmonary complications with information that is available before the surgical procedure. A detailed history and physical examination are the most critical elements of preoperative risk assessment.[7]

The preoperative evaluation, particularly before major intrathoracic or upper abdominal surgery, needs to include any significant history of smoking and cough, obesity, and known underlying pulmonary and cardiac disease. Important factors in the preoperative assessment include the presence and character of a cough and sputum production; history or presence of abnormal breath sounds, including wheezing; and history and/or presence of shortness of breath and exercise intolerance. Other known medical conditions such as neurologic events capable of impairing normal airway protection mechanisms require consideration in the preoperative evaluation. While such occurrences may be subtle, obtaining a history of swallowing difficulties or prior aspiration may trigger perioperative intervention strategies likely to reduce the risk of aspiration. Relevant physical findings include the presence of wheezing or other adventitious lung sounds, prolonged expiration, or any other manifestations of pulmonary disease.

Pulmonary Function Testing

The routine preoperative evaluation of pulmonary function testing (spirometry) is less useful in predicting postoperative pulmonary complication risk than a thorough clinical assessment including the history and physical examination and determination of functional status (ASA classification).[23] Spirometry is, however, appropriate for individuals suspected of having a significant underlying cardiopulmonary disease by history and/or physical examination.[23] See **Box 22-2**.

BOX 22-2 Criteria for Preoperative Pulmonary Function Testing[7]

- Assess current COPD or asthma control to identify the need for optimizing therapy
- Differential diagnosis for unexplained pulmonary issues after history and physical exam
- Not to be used as the primary factor to deny surgery
- Not to be used routinely prior to abdominal surgery or for other high-risk operations (except for lung resection surgery)

Chest Radiography

Preoperative chest radiographs add little to the clinical evaluation in identifying healthy patients at risk for perioperative complications.[7] A systematic review of the literature by Smetana, Lawrence, and Cornell concluded that clinicians might predict most abnormal preoperative chest radiographs based on the history and physical examination and that chest radiography only rarely provides unexpected information that influences preoperative management.[15] It is reasonable, however, to obtain a preoperative chest radiograph in patients with known cardiopulmonary disease and in those over age 50 years who are undergoing surgical procedures, including upper abdominal, aortic, esophageal, and thoracic surgery.

Chest radiography is especially useful when PPCs are clinically suspected as with the development of unexplained fever, unexpected significant hypoxemia, change in normal respiratory effort (development of tachypnea), alterations in breath sounds on lung auscultation, or change in the peripheral white blood cell count. A detailed review of the postoperative chest radiography may substantiate the presence of an infiltrate, signs of lung volume loss as with atelectasis or lung collapse, or the development of pleural effusion (PE) or pneumothorax. Other radiography findings include an increased density around atelectasis, the presence of air bronchograms, hemidiaphragm elevation on the affected side of atelectasis, and mediastinal shift with the significant collapse of lung tissue on the affected side.

Assessment of Oxygenation

Measurement of oxygenation via pulse oximetry is an essential factor in the prediction of PPCs. Pulse oxygen saturation (Spo_2) assessment is included in the ARISCAT Risk Index[3] and is helpful for stratifying risk, particularly prior to high-risk surgeries. Current data do not support the use of preoperative arterial blood gas analyses to stratify risk for PPCs.[7]

Risk Prediction Tools

Risk prediction tools use preoperative factors to estimate the risk of PPCs. These tools are for the stratification of risk when advising patients prior to surgery and, in some cases, to identify patients most likely to benefit from risk-reduction interventions. For example, patients predicted to be at high risk for PPCs may be scheduled for postoperative care in a more intensive care location.[7]

There are four indices available for PPC risk stratification. These include the **Gupta calculator for postoperative respiratory failure**, the **Gupta calculator for postoperative pneumonia**, the **Arozullah Respiratory Failure Index**, and the **ARISCAT Risk Index**. These tools are a useful starting point when estimating pulmonary risk before major noncardiac surgery, and they guide conversations between the surgeon and the patient.[7]

The Gupta calculator for postoperative respiratory failure utilizes numerous preoperative factors to predict the risk of failure to liberate a patient from mechanical ventilation within 48 hours of surgery or unplanned intubation within 30 days of surgery.[35] The Gupta calculator was developed to aid in the surgical decision making and informed consent process. It is in the form of an interactive spreadsheet and is available online as a free download.[35] The Gupta calculator for postoperative pneumonia is also available online for downloading.

The Arozullah Respiratory Failure Risk Index is a validated model for identifying patients at risk for developing postoperative respiratory failure and may be useful for guiding perioperative respiratory care.[36] This risk index is based on several factors, including laboratory results, type of surgery, history of COPD, age, and functional status. The index is too complicated for clinical practice and may be of value in research settings.[7]

The ARISCAT Risk Index is based on seven easily assessed factors. These factors include age, preoperative Spo_2, respiratory infection within the last month before surgery, preoperative anemia, surgical incision site, duration of operation, and whether the surgery is emergent.[3] Each factor is assigned a risk score that is weighted. The higher the risk, the higher the weight, based on the statistical findings of the research.[3] The ARISCAT Risk Index is useful for differentiating three levels of PPC risk.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Spirometry is performed only preoperatively on select patients who are suspected of having pulmonary disease.
2. True or False: Poor preoperative pulmonary function test results can cause a patient to be denied surgery.
3. True or False: Two indices are available for postoperative pulmonary complication risk strategy.

Common PPCs

The term PPC encompasses almost any complications that affect the lungs after anesthesia and surgery. These complications can have significant adverse effects on postoperative patients and are difficult to predict, even with prediction tools. **Table 22-4** shows six common PPCs and their definitions.

While these PPCs represent some of the common causes of overall perioperative morbidity and mortality in the patient undergoing surgery, other adverse events include acute upper airway obstruction, exacerbation of OSA, pulmonary edema, pulmonary embolism, abdominal compartment syndrome, and tracheal laceration or rupture.[3]

TABLE 22-4
Common PPCs and Definitions[1,3,37,38]

Complication	Definition
Atelectasis	Lung opacification with a shift of the mediastinum, hilum, or hemidiaphragm toward the affected area and compensatory over-inflation in the adjacent non-atelectatic lung
Bronchospasm	Newly detected expiratory wheezing treated with bronchodilators
Chemical pneumonitis (aspiration)	Acute lung injury after the inhalation of regurgitated gastric contents
Pleural effusion	Chest radiograph showing blunting of the costophrenic angle, loss of sharp silhouette of the ipsilateral hemidiaphragm in an upright position, evidence of displacement of adjacent anatomical structures, or (in supine position) a hazy opacity in one hemithorax with preserved vascular shadows
Pneumothorax	Air in the pleural space with no vascular bed surrounding the visceral pleura
Respiratory failure	Failure to wean from mechanical ventilation within 48 hours after surgery or unplanned intubation/reintubation intraoperatively or postoperatively
Respiratory infection (pneumonia)	Treatment with antibiotics for a suspected respiratory infection with one of the following criteria: new or changed sputum, new or altered lung opacities, fever, leukocyte count >12,000/mm^3

Anesthetic gas effects can also produce adverse effects that may lead to pulmonary complications, including a reduction in diaphragmatic function, impairment of mucociliary clearance for several days, and elimination of protective cough, and may inhibit hypoxic vasoconstriction in poorly ventilated areas of the lung. These mechanisms can foster consequences of atelectasis, reduction in FRC, and ventilation–perfusion mismatch.[39]

Atelectasis

As soon as the patient loses consciousness from general anesthesia, adverse respiratory effects begin. The anesthesia depresses the patient's central respiratory drive, causing prolonged apnea. Because the central nervous system (CNS) is affected, ventilatory responses to hypercapnia and hypoxemia are blunted. Although artificial ventilation maintains carbon dioxide removal and oxygenation, the cephalad diaphragm is displaced in the dependent areas, and there is a reduction in the cross-sectional area of the chest wall.[37] These changes in end-expiratory muscle tone lead to a decrease in FRC when compared with the patient's awake, supine volume.[37] See **Figure 22-1**.

While often clinically uneventful, atelectasis is one of the most common PPC, particularly following abdominal and thoracoabdominal procedures.[3] It is estimated that up to 15–20%[37,40] of the lung is regularly collapsed at its base during uncomplicated anesthesia prior to any surgery and can persist for several days following surgery.[3] See **Figure 22-2**.

Anesthesia-induced lung collapse commonly occurs with almost all anesthetics mainly from hyperoxygenation during induction,[40] anesthesia-related loss of muscle tone,[37] and reduction in FRC[40] resulting in absorption atelectasis behind closed airways. Other potential causes of atelectasis include lung tissue compression as well as the loss of surfactant or surfactant function. The administration of 100% oxygen following a vital capacity maneuver in lung tissue previously collapsed and subsequently attempted to be re-expanded will frequently result in rapid recurrence of atelectasis. This also occurs with the combination of oxygenation and airway suctioning. Given the likelihood of anesthetic agents and increased oxygen in contributing to the development of postoperative atelectasis, it has become common to utilize alveolar recruitment maneuvers prior to extubation followed by ventilation with moderate concentrations of F_{IO_2}.[1,41]

The underlying mechanisms responsible for the development of lung atelectasis include increases in bronchial secretion volume, increases in secretion viscosity, reduced tidal volume, as well as FRC and the inability to effectively cough.[3] Atelectasis resulting in the loss of functional alveolar units is recognized as a significant pathophysiologic mechanism responsible for postoperative hypoxemia.

The formation of atelectasis in high-risk patients may be prevented during invasive mechanical ventilation by the application of positive end-expiratory pressure (PEEP). Following extubation, however, this positive airway pressure is lost, and subsequent collapse of alveoli can occur immediately. When this effect occurs in combination with suboptimal postoperative coughing, lack of deep inspirations, PEs, and increased interstitial lung water, the formation of atelectasis can progress further, reducing oxygenation. CPAP can be continued in the spontaneously breathing patient following extubation from mechanical ventilation. CPAP is used either intermittently or continuously with patients who are unable to perform effort-dependent measures, which increase postoperative lung volumes.[30] Treatment with CPAP, theoretically, prevents further collapse of alveolar units, while it simultaneously acts to increase FRC and arterial oxygenation. CPAP also effectively reduces respiratory workload as well as cardiac preload.

The clinical presentation of postoperative atelectasis can range from subclinical or asymptomatic to manifesting overt clinical signs of increased work of breathing (respiratory distress) and hypoxemia.[3] Significant postoperative atelectasis is usually accompanied



FIGURE 22-1 Model showing how incoordination of respiratory muscles impairs lung function. The position of the midpoint of a horizontal bar, suspended between fixed surfaces by inspiratory and expiratory muscles, represents lung volume as denoted on a scale from low (residual volume, RV) to high (total lung capacity, TLC) volumes. During awake, coordinated inspiration (lower left), the bar remains horizontal (representing normal chest wall expansion), and lung volume changes efficiently. When anesthetized, muscle activity becomes uncoordinated, such that the bar tilts during inspiration (representing chest wall distortion), impairing lung expansion. Incoordination continues into the postoperative period after thoracic and abdominal surgery. Dashed lines in lower panels denote the end-expiratory position of the bar.

Reproduced with permission from Warner D. Preventing postoperative pulmonary complications. *Anesthesiology*. 2000;92(5):1467–1472 (Figure 1, p. 1468). doi:10.1097/00000542-200005000-00037.

by tachycardia, associated shallow and rapid breathing, increased late inspiratory crackles, or reduced breath sounds on chest auscultation accompanied by dullness on chest percussion over the area of sizeable collapse.[3] A fever can occur concurrently with the presence of an underlying infection. Chest radiography can substantiate the existence of consolidation and parenchymal collapse.

The onset of hypoxemia due to postoperative atelectasis tends to occur within the first 48 hours following most major surgeries (such as early after the patient has left the post-anesthesia care unit). Generally, hypoxemia becomes most severe during the second postoperative night and continues through the fourth or fifth postoperative night.[3] Hypoxemia that develops earlier perioperatively as in a patient who has not yet been discharged from the post-anesthesia care unit should prompt investigation into alternate postoperative complications such as hypoventilation due to residual anesthetic effects and upper airway obstruction due to airway tissue edema. The upper airway obstruction can result from the accumulation of pharyngeal secretions, prolapse of the tongue posteriorly, or either iatrogenic or allergic tongue edema. Early ambulation and the use of breathing exercises and expiratory maneuvers, such as positive expiratory pressure, are especially crucial following upper abdominal surgery in preventing atelectasis.[42,43]

Bronchospasm

Exacerbations of bronchospasm in the postoperative period can be caused by reflex constriction of bronchial smooth muscles due to tracheal stimulation by secretions, suctioning, endotracheal intubation, or other surgical stimulation. Additionally, postoperative bronchospasm can be triggered by aspiration, histamine release caused by certain medications such as opiates, tubocurarine, or atracurium, an allergic response to medications, or an exacerbation of a chronic pulmonary condition, such as asthma or COPD.[3]

The clinical manifestations of postoperative bronchospasm are identical to those of asthma or COPD.



FIGURE 22-2 Factors producing respiratory muscle dysfunction after surgical trauma. From left to right: (1) surgical trauma stimulates CNS reflexes mediated by both visceral and somatic nerves that produce reflex inhibition of the phrenic and other nerves innervating respiratory muscle; (2) mechanical disruption of respiratory muscles impairs efficiency; and (3) pain produces voluntary limitation of respiratory motion. These factors all tend to reduce lung volumes and can produce hypoventilation and atelectasis.

These manifestations include wheezing, chest tightness, tachypnea, prolonged expiratory time, dyspnea, small tidal volumes, and hypercapnia. Treatment includes the removal of the cause, if it is medication, and bronchodilator administration. The decision to use an inhaled beta-2-agonist alone or in combination with a short-acting muscarinic antagonist, ipratropium bromide, is made on a case-by-case basis, depending on the severity of the bronchospasm.[3]

Chemical Pneumonitis

Surgical patients are at risk for chemical pneumonitis resulting from the aspiration of acidic gastric contents during the perioperative period. Anesthetic agents depress the airway protective reflexes, which predispose patients to aspiration.[44] The increased risk for aspiration and chemical pneumonitis during the perioperative period is most likely to be related to the anesthetic-induced depression of airway protective reflexes and the use of muscle relaxants and pain medications.[3]

The incidence of aspiration is infrequent in healthy adults; it is more common in obstetric and pediatric patients.[3] Most aspirations occur during tracheal extubation or laryngoscopy. A high ASA classification and emergency surgery are associated with a higher risk of aspiration.[3]

Witnessed aspiration is treated with lateral head positioning and suctioning of the oropharynx. Patients with uncertain aspiration may development coughing, diffuse crackles on lung auscultation, abrupt onset of dyspnea, tachycardia, fever, bronchospasm, hypoxemia, and frothy pink sputum.[3,44] Patients who do not develop these signs and symptoms are unlikely to develop chemical pneumonitis.[3] However, some patients may develop a secondary bacterial infection (pneumonia) or acute respiratory distress syndrome (ARDS).[3]

Pleural Effusion

Pleural effusion (PE) occurs because of the deterioration of the balance of absorption and secretion in the pleura. It occurs most often within the first week following cardiac[45] and upper abdominal surgeries.[3] A PE is more common following abdominal surgery (especially upper abdominal surgery), among patients with postoperative atelectasis, and among patients with free abdominal fluid.

A postoperative patient with a significant amount of pleural fluid, particularly when associated with fever, needs a diagnostic thoracentesis to rule out pleural infection as a cause. If an effusion develops more than 72 hours after surgery, it is probably not related to the surgical procedure itself and alternative explanations require investigation, including conditions such as pulmonary embolization, intra-abdominal infection, and cardiac decompensation due to volume overload.

Most postoperative PEs resolve spontaneously within a few days and, therefore, do not require intervention. However, atypical characteristics of either the PE or the patient's clinical course warrant diagnostic evaluation of the effusion. Postoperative PEs are evaluated in the same way as other PEs.[3]

Pneumothorax

Tension pneumothorax is suspected in patients with chest pain, dyspnea, tachypnea, hypoxemia, hypotension, distended neck veins, tracheal deviation, or risk factors that include attempted or actual central line insertion, surgery in the neck or thorax, or chronic lung disease. A needle decompression can be performed immediately, followed by chest tube placement as soon as possible if the thoracotomy equipment is not immediately available.[44]

Respiratory Failure

Postoperative respiratory failure accounts for more than 20% of all patients receiving ventilatory support[3] and is one of the most serious pulmonary complications.[38] Prolonged mechanical ventilation is frequently a cause for delayed recovery following cardiac surgery.[46] Respiratory failure requiring unplanned reintubation in the postoperative period is associated with high morbidity, leading to a longer hospital stay, and increase in 30-day mortality to as high as 18-fold.[47–49] Older individuals have a higher incidence of unanticipated reintubation within the first 72 hours after surgery.[47,48] The first 6 hours post extubation have the highest risk of reintubation due to pulmonary edema, atelectasis, pneumonia, aspiration, impaired brain function, and airway obstruction.[3]

Postoperative respiratory failure can be caused by several factors. The loss of airway protection results from a variety of risk factors, including neurologic impairment, absent or ineffective cough, absent gag reflex, or laryngeal edema. Failure to oxygenate leading to hypoxemic respiratory failure (Type I respiratory failure) is another cause. Also, a failure to ventilate leads to hypercapnic respiratory failure (Type II respiratory failure).

Postoperative respiratory failure is considered by many to be an extremely morbid event and marker of ill health that reliably forecasts additional postsurgical complications. Fortunately, the occurrence of respiratory failure is uncommon in postoperative patients without preexisting cardiopulmonary disease, such as severe COPD or the presence of a neuromuscular disorder subjected to thoracic or upper abdominal surgery. Acute respiratory failure may, however, occur in patients without preexisting cardiopulmonary or neuromuscular disorders if circumstances of overwhelming pneumonia, PE, pneumothorax, or acute airway obstruction occur during the postoperative period. One study found postoperative patients who developed respiratory failure as a complication of surgery had a 26% mortality within 30 days of their surgery. In this study, 6% had a myocardial infarction, 35% developed pneumonia, 10% developed acute renal failure, and 3% developed deep vein thrombosis (DVT) or pulmonary embolism.[50] Incidence rates of these events were lower than 2% among patients without respiratory failure.[50]

ARDS is recognized as a leading cause of postoperative respiratory failure, associated with a mortality rate approaching 40% in the general population and 80% in the subset of patients undergoing cardiac surgery.[51] This represents a significant concern with profound economic implications.

Respiratory Infection

Postoperative pneumonia (PP), the third most common PPC, is a major cause of morbidity and high cost of care in the postsurgical patient.[52,53] A diagnosis of PP is clinically made in a patient who develops fever, increased secretions, purulent sputum, leukocytosis, and hypoxemia that is associated with a new or progressive infiltrate on chest x-ray. PP tends to occur within 5 postoperative

days.[3,40] The incidence of PP ranges from a rate of 3.0% to greater than 20% in high-risk groups, depending on the patient population and the diagnostic criteria utilized.[5] The incidence of PP abruptly increases among patients who undergo prolonged tracheal intubation for ≥48 hours.[5] Risk factors for PP after non-cardiothoracic surgery include smoking, age >70 years, ASA >2, preexisting COPD, and high-risk surgeries.[40] The occurrence of PP is consistently associated with increased ICU and hospital LOSs. PP is associated with a higher postoperative mortality rate in all risk groups depending on the severity of illness, comorbid disorders, and causative pathogens.[5]

PP, especially ventilator-associated pneumonia, is a result of the aspiration of microorganisms from the subglottic area.[40] See **Table 22-5**. Another cause of PP is the aspiration of regurgitated material from the digestive tract. PP is frequently caused by resistant organisms.[3]

Factors contributing to the development of PP following aspiration include the predominant organism(s), a large inoculum, and compromised host defenses.[5] Although aspiration that leads to pneumonia can occur at various times in the perioperative period, most aspirations occur during tracheal intubation. Bronchial airway contamination following intubation occurs from bacterial migration within or surrounding the endotracheal tube. Bacterial movement through the endotracheal tube can form a **biofilm**, which represents an aggregate of colonizing, adherent microorganisms that may exist on the inner surface of the tube as early as 6 hours after tracheal intubation.[5] When present, this collection of organic material eventually descends by gravity into the distal airways. Microaspiration from oropharyngeal secretions permits bacterial movement from around an endotracheal tube cuff because of improper cuff position or inflation, cuff deflation, tube manipulation, or patient movement. Secretions can also leak through channeled folds that develop despite a properly positioned and inflated high-volume, low-pressure cuff.[5] See **Figure 22-3**. Some endotracheal tubes have integrated **subglottic suctioning** ports to provide continuous suctioning of accumulated secretions around the cuff of the endotracheal tube. See **Figure 22-4**



FIGURE 22-3 (**A**) Biofilm on the inner wall of the endotracheal tube with distal migration of microorganisms through the lumen. (**B**) Microaspiration with distal migration of microorganisms around the inflated endotracheal tube cuff.

Reproduced with permission from Shander A, Fleisher LA, Barie BS, et al. Clinical and economic burden of postoperative pulmonary complications: Patient safety summit on definition, risk-reducing interventions, and preventive strategies. *Crit Care Med.* 2011; 39(9):2166 (Figure 1).

TABLE 22-5
Microorganisms That Cause PP[3,5]

Microorganism	Risk Factors
Haemophilus influenza *Streptococcus pneumoniae*	Traumatically injured patients are at higher risk, predominate in early infections
Methicillin-resistant *Staphylococcus aureus* (MSRA)	Previous antibiotic use, a positive nasal screen for MSRA, long operations (>5 hours) and emergency surgery, predominates in late infections
Staphylococcus aureus	Mechanically ventilated neurosurgical patients, victims of blunt trauma and coma, and patients with closed head injuries
Pseudomonas aeruginosa	Intubation >8 days, structural lung disease (e.g., bronchiectasis, cystic fibrosis, and COPD), corticosteroid therapy, malnutrition, and prolonged exposure to antibiotics, predominates in late infections
Acinetobacter species	Mechanical ventilation, predominates in late infections
Anaerobic species	Abdominal surgery



FIGURE 22-4 Endotracheal tube with subglottic suction.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Anesthetic gas can impair mucociliary clearance for several days.
2. True or False: Increasing the tidal volume during surgery helps in in reducing the development of atelectasis.
3. True or False: Hypoxemia due to postoperative atelectasis occurs within the first 48 hours following most major surgeries.
4. True or False: The greatest risk for postoperative chemical pneumonitis occurs with patients who have a low ASA classification.

Strategies to Reduce PPCs

Perioperative risk-modification strategies to reduce preventable patient and procedure surgery-related pulmonary complications should be routinely implemented, especially in higher-risk patients. Despite a robust enthusiasm to curb the adverse effects that can result from invasive surgery, a systematic review of strategies to reduce PPCs following surgery has identified very few evidence-based interventions that definitively impact reduction of these complications. Individuals presenting with symptoms of a cough or shortness of breath preoperatively need assessment to determine the underlying etiology of these symptoms and to stratify the risk for PPCs. Concurrent medical disorders need treatment when identified because chronic medical comorbidities are notably essential determinants of perioperative morbidity and mortality.

Preoperative Strategies

Treatment to decrease the risk of PPCs starts before surgery. These strategies include, but are not limited to, patient education, smoking cessation, preoperative exercises, pulmonary rehabilitation, and presurgical weight loss.

Patient Education

Preoperative education is vital in preparing the patients for what is expected as well as what they could potentially encounter following surgery. Information about the type of surgery planned, the degree of postoperative pain intensity for the specific operation, the possibility of PPCs after surgery, and the types of respiratory interventions used during the postoperative period is essential to this education. The best time to teach lung expansion maneuvers, such as coughing, IS, and voluntary deep breaths and inspiratory muscle training is before surgery. It is challenging to explain these strategies to patients with surgical pain. A systematic review of cardiac patients showed that preoperative

intervention intending to improve the patient's ability to cope with the surgery reduced PPCs.[54]

Smoking Cessation

Cigarette smoking is a known health risk, and current smokers have an increased risk for PPCs. The preoperative evaluation provides an opportunity to discuss the benefits of smoking cessation with the patient.[55] However, one concern about smoking cessation in the immediate preoperative period is that abrupt removal of the irritant effect of cigarette smoke can inhibit coughing and lead to retention of secretions and small airway obstruction. It takes several weeks for the improvement in ciliary action, small airway function, and decreased mucus production to occur.[56] An important clinical question is whether quitting smoking less than 8 weeks prior to surgery could, in fact, increase PPCs. Systemic reviews and meta-analyses, however, have not supported that concern.[30] A large retrospective cohort analysis of elective operations from 2002 to 2008 yielded 393,794 patients in the Veterans Affairs Surgical Quality Improvement Program for all surgical specialties and found that there is a dose-dependent increase in PPCs based on pack-year exposure. Those with more than 20 pack-years of cigarette smoking had significant increases in smoking-related surgical complications, including PPs and deaths.[57] A literature review of 25 studies comparing current smokers and the risk of respiratory complications found that at least 4 weeks of abstinence from smoking reduces respiratory complications. Short-term (<4 weeks) smoking cessation does not appear to increase or reduce the risk of PPCs.[58]

All patients anticipating elective surgery can avoid the increased risk of PPCs by cigarette abstinence. If time allows, a longer duration of abstinence is optimal. Most patients require either behavioral intervention or NRT or both.[30]

Preoperative Exercise and Pulmonary Rehabilitation

The effectiveness of postoperative lung expansion therapy with IS is controversial.[43] The effectiveness of IS postoperatively depends on the patient being attentive, not affected by sedatives or narcotic analgesics, the level of presurgical instruction, and encouragement and supervision.

Recent evidence demonstrates that combinations of different breathing exercises with and without equipment and early postoperative ambulation is effective at reducing the rate of PPCs, especially in those who are at high risk.[59–63] In the literature, these therapies are referred to as **inspiratory muscle training**, preoperative physical therapy, preoperative respiratory rehabilitation, preoperative physiotherapy, and perioperative pulmonary rehabilitation. See **Box 22-3**.

BOX 22-3 Preoperative Therapies to Reduce PPCs[59–63]

- Active cycle of breathing
- Aerobic exercises
- Forced expiratory technique
- Incentive spirometer
- Inspiratory muscle training (with variable resistance device)
- Inspiratory and expiratory breathing exercises
- Pulmonary rehabilitation

Presurgical Weight Reduction

Patients who are obese have an increased frequency of comorbid disease as well as a high incidence of postoperative wound complications. Physiologically, these individuals have higher rates of oxygen consumption and carbon dioxide production, which subsequently intensifies their work of breathing. Because those who are obese develop a large, stiff chest wall, they may also exhibit a concomitant restrictive pulmonary impairment. Obesity also results in a buildup of soft tissue in the oropharynx, which may cause upper airway obstruction during sleep. A significant number of morbidly obese patients consequently develop sleep-related breathing disorders, such as OSA and obesity hypoventilation syndrome associated with hypoxia, hypercapnia, elevation in blood pressure, nocturnal angina, and increased cardiac morbidity and mortality, including stroke and sudden death. There is a positive relationship between BMI and right ventricular dysfunction (a sequela of chronic pulmonary hypertension).[64] Because a multitude of disorders are associated with the obese state, a controlled preoperative weight loss program may be beneficial (though in reality is frequently unsuccessful) before elective procedures.

Intraoperative Strategies

General anesthesia and surgery both produce alterations in the lungs and are responsible, along with underlying conditions, for PPCs. Intraoperative techniques that can impact the incidence of PP include the choice of anesthesia, type of neuromuscular blockade, duration and type of surgery, and ventilation during surgery.

Neuroblocking Agents

Evidence shows that the use of short-acting **nondepolarizing neuromuscular blocking agents (NMBAs)** to facilitate laryngoscopy for endotracheal intubation is less likely to be associated with PPCs

than intermediate- or long-acting NMBAs. The use of intermediate-acting NMBAs is associated with an increased risk of SaO_2 levels to below 90% and with reintubation requiring unplanned admission to an ICU.[65] Complete reversal of neuromuscular blockade at the end of a surgical procedure is essential, especially in patients with underlying pulmonary disease. Residual postoperative neuromuscular blockade can cause hypoventilation, which increases the risk of PPCs.[30]

Type of Anesthesia

When comparing the use of the different types of anesthesia and their incidences of PPCs, studies show different results. However, when the weight of the evidence suggests that both general and spinal or epidural anesthesia are safe and appropriate for a specific procedure, **spinal anesthesia** or **epidural anesthesia** is favored over **general anesthesia** of patients who are at high risk for PPCs, such as patients with COPD.[30] Also, when a nerve block is appropriate, it may also reduce the risk in very high-risk patients.[66]

Duration of Surgery and Anesthesia

General anesthesia disrupts the CNS regulation of breathing, resulting in disordered neural messaging. The altered neural response leads to hypoventilation. Hypoventilation and positional dependence cause regional atelectasis to occur soon after anesthesia induction. This effect typically persists postoperatively and is compounded by ongoing disruption of respiratory muscle contraction, limited diaphragm excursion due to pain, and interference with neurally mediated diaphragmatic functions. These are expected to occur with general anesthesia. Analysis of a large national database demonstrated that patients with significantly increased anesthesia duration have increased risk of overall complications rate and increased LOS, and return to the operating room.[67] Surgical procedures performed using a general anesthetic technique lasting more than 3–4 hours are associated with a higher risk of pulmonary complications.[30] Decreasing the duration of surgery and anesthesia appears to reduce the risk of extended ICU stay in patients with severe COPD undergoing non-cardiothoracic operations.

Type of Surgery

Thoracic surgery impairs postoperative respiratory function, resulting in a relatively high risk of developing PPCs. The incidence of PPCs for thoracic surgery is 19–59%, the incidence for upper abdominal surgery is 16–17%, and the incidence for lower abdominal surgery is 0–5%.[32] Upper abdominal, open aortic aneurysm repair, open thoracotomy, and head and neck surgery carry the greatest risk of PPCs. Because upper abdominal and thoracic operations carry the greatest risk, a percutaneous (laparoscopic) procedure should be substituted for an open procedure, if possible.[56]

Lung Protective Strategies

Intraoperative ventilation is necessary during anesthesia in an estimated 234 million patients each year worldwide.[68] It is therefore important to reduce the impact of ventilation on the lungs during surgery. Anesthesiologists utilize some of the ventilator strategies used with mechanically ventilated patients in the ICUs to reverse atelectasis and protect the lungs from injury.

For patients undergoing abdominal surgery, a lung protective strategy of low tidal volume ventilation, including 6–8 mL/kg of predicted body weight, a PEEP of 6–8 cm of water, and recruitment maneuvers every 30 minutes, is associated with a reduction in adverse pulmonary events.[30] See **Box 22-4**. One multicenter, double-blind, parallel-group trial of 400 patients revealed that the use of a lung protective ventilation strategy in intermediate-risk and high-risk patients undergoing major abdominal surgery was associated with a decreased incidence of PPCs, improved clinical outcomes, and reduced healthcare utilization.[69] Use of these parameters with other types of surgeries may not have significant effects on the development of PPCs.

Clinical studies show that a PEEP of 10 cm of water is required to reduce or eliminate atelectasis, improve compliance without increasing dead space, and maintain end-expiratory lung volume during general anesthesia in both nonobese and obese patients.[41] Using ventilator graphics can help manage respiratory mechanics and reduce dynamic hyperinflation. The bottom line is that the ventilation settings used for each surgical patient must provide adequate oxygenation and ventilation and limit lung injury from **barotrauma**, **volutrauma**, and **atelectrauma**.[41]

Postoperative Strategies

Many PPCs are caused by the presence of the atelectasis created during and after the induction of general anesthesia. Pharmacologic treatment is obvious in the management of a pulmonary infection, but an even better strategy is to eliminate the causative factor.[39] Risk-reduction strategies continue into the postoperative period and include early mobilization of the patient, lung expansion techniques, adequate analgesia,

BOX 22-4 Example of Lung Protective Strategies Used during Surgery[30]

Tidal volume: 6–8 mL/kg predicted body weight

PEEP: 6–8 cm H_2O

Recruitment maneuvers every 30 minutes

restricted use of nasogastric tubes (NGTs), and, when necessary, respiratory support for inadequate ventilation and oxygenation.

Early Mobilization

The postoperative benefits of early mobilization and ambulation are the rule, rather than the exception despite the alternative supposition that the chief purpose of bed rest following abdominal surgery is to put the affected parts at rest "since inactivity is necessary for optimal wound healing." While this old concept had some limited merit, practitioners acknowledge the disadvantages of analgesia and prolonged bed rest include various pathophysiologic aspects. Anesthetics inherently interfere with the central regulation of breathing, resulting in uncoordinated neural messaging. Hypoventilation and positional dependence cause regional atelectasis following induction, and they continue postoperatively. Disordered respiratory musculature, limited respiratory excursion due to pain, and disruption of neurally mediated diaphragmatic functions after manipulation of abdominal viscera also occur. These events contribute to a setting conducive to respiratory dysfunction and subsequent complications.

The typical recumbent position assumed during most abdominal surgeries causes a reduction in lung volumes. A further lung volume reduction results from a decrease in diaphragmatic function and a relative fixation of the diaphragm in an elevated position. The higher horizontal positioning of the diaphragm dramatically decreases the efficiency of the cough reflex, invariably leading to atelectasis. Early postoperative turning, side to side, and repositioning of the patient in a high Fowler position or at least in a semi-Fowler position help to improve ventilation and oxygenation. Early ambulation may improve atelectasis by encouraging a distribution of ventilation to the nondependent regions of the lungs.[70] This action dependently lowers the diaphragm and increases the efficiency of the cough reflex to expel accumulated secretions and aerate the collapsed areas. Benefits of early mobilization include less pneumonia, delirium, pain, fatigue, DVT, and ventilator-dependent days.[71]

Lung Expansion Techniques

The postoperative period is characterized by decreased lung volumes and atelectasis due to surgery-related shallow breathing, bed rest, diaphragmatic dysfunction, pain, and impaired mucociliary clearance. Therefore, it is especially important for those individuals with underlying risk factors for PPCs to begin lung expansion techniques to modify the potential cascade of events leading to PPCs. A variety of lung expansion techniques reduce PPCs in selected patients, include chest physiotherapy, deep breathing exercises, cough, postural drainage, percussion and vibration, IS, and CPAP. These techniques increase lung volumes after surgery through inspiratory effort. All these interventions are more effective if patient teaching begins before surgery.[30]

Postoperative lung expansion interventions via deep breathing exercises and IS (particularly volume-oriented IS) improve diaphragm excursion and pulmonary function.[72] These therapies are safe and low cost, and are typically utilized following upper abdominal and thoracic surgery.[30] For those patients who are unable to perform these effort-dependent techniques, CPAP may be used intermittently. However, a systematic review of 10 randomized controlled trials with more than 5,000 patients shows a very low-quality evidence suggesting that routine CPAP initiated during the postoperative period might reduce postoperative atelectasis, pneumonia, and reintubation, and its effects on mortality, hypoxemia, or invasive ventilation are uncertain.[73]

Improvement in acute atelectasis caused by excessive secretion retention may be accomplished by effective deep breathing and assisted productive coughing using splinting of the surgical site. When atelectasis is more extensive, as in cases of lobar atelectasis, vigorous chest physiotherapy may be helpful in re-expanding the collapsed lung when performed just after nebulized bronchodilator therapy. Nasotracheal suctioning can also be effective in removing excessive retained secretions during the postoperative period following extubation.

Prevention and control of infection and airway secretions in perioperative settings assumes an even greater significance because of the vulnerability of patients who are already ill or injured. Surgery, anesthesia, and immediate postoperative recovery may expose patients to invasive procedures allowing more portals of entry for infection.

No single postoperative intervention can prevent all PPCs. Reduction of the incidence of PPCs requires a multifaceted approach involving many clinical disciplines. One such multifaceted approach is the I COUGH multidisciplinary program, which incorporates IS, coughing and deep breathing, oral care (brushing teeth and using mouthwash twice daily), patient and family education, mobilization out of bed at least three times daily, head-of-bed elevation, and postoperative pain control.[74]

Adequate Analgesia

Postoperative pain control provides a significant contribution to efficient pulmonary hygiene and prevention of atelectasis and pneumonia by enhancing the ability of a patient to be able to take deep breaths, adequately cough, and ambulate earlier.[68] Without sufficient postoperative upper abdominal and thoracic pain control (for upper abdominal and thoracic surgery),

inadequate lung expansion and an impaired cough mechanism result in greater risk of PPC. When excessive sedation occurs following administration of opioid analgesics, adequate ventilation can be achieved by delaying endotracheal extubation and continuing ventilatory support for 24–48 hours until the patient is more alert or by using noninvasive positive pressure ventilation continuously. While pain control is essential, the likelihood of successful extubation in a high-risk patient is optimized if awake and cooperative. Postoperative epidural and patient-controlled intravenous analgesia to achieve adequate pain control following surgery appear to be superior to on-demand delivery of opioids in preventing and potentially reducing PPCs.[75] In patients undergoing aortic aneurysm repair, coronary bypass surgery, and abdominal surgery, the use of postoperative thoracic epidural analgesia has shown reduced rates of pneumonia, respiratory failure, and pulmonary complications overall by approximately one-third to more than one-half.[50] Excessive use of narcotic analgesics, on the other hand, is well known to depress ventilatory drive and suppress the protective cough reflex.

Restricted Use of Nasogastric Tubes

Nasogastric tube decompression is the act of reducing gastric pressure using a large bore tube suction system inserted into the stomach, which aims to minimize abdominal distention, delays in early bowel return, nausea or vomiting, and aspiration.[75] Swallow physiology is altered by the presence of a NGT. The placement of a NGT is reserved only for patients who develop a need for decompression postoperatively because routine use of an NGT significantly increases PPCs, including pneumonia.[30]

Postoperative Respiratory Support

PPCs that occur may present early as arterial hypoxemia, develop later as pneumonia, and in rare cases manifest as acute respiratory failure or lung injury (ARDS). PPCs occurring following cardiac surgery have demonstrated improvement in arterial oxygenation as well as reduced the incidence of pulmonary complications, including pneumonia, decreased reintubation rate, and reduced readmission to the ICU with long-term administration of prophylactic nasal CPAP (nCPAP).[76] Therefore, for elective cardiac surgery, nCPAP may be a useful tool to reduce the rate of PPCs.

Bilevel positive airway pressure ventilatory support may benefit patients in the postoperative period with neurologic disorders significantly affected by anesthesia, such as myotonic dystrophy.[77] Thus, noninvasive respiratory support techniques appear useful in providing respiratory support without the need for an invasive airway and represent important tools in preventing (prophylactic treatment) or treating acute respiratory failure.

KNOWLEDGE CHECK QUESTIONS

1. True or False: There is a dose-dependent increase in PPCs based on the number of pack-years a patient smoked.
2. True or False: The single most effective preoperative strategy to reduce PPCs is with the use of IS.
3. True or False: Long-acting non-depolarizing NMBAs are associated with a decrease in the risk of PPCs.
4. True or False: Thoracic surgery carries the highest risk for the development of PPCs.
5. True or False: A recumbent position following abdominal surgery reduces the risk of atelectasis.
6. True or False: A multifaceted, multidisciplinary approach to postoperative lung expansion techniques is most effective at reducing the incidence of PPCs.

Chapter Summary

PPCs are common, associated with increased morbidity and mortality, and often significantly affect clinical and healthcare resources. The preoperative risk assessment helps identify and direct effective prophylactic interventions targeted to those individuals considered to be at high risk. Decreasing the incidence of PPCs require evidence-based strategies that modify causative factors. These strategies include reducing perioperative aspiration with proper patient repositioning, optimizing care of the endotracheal tube, using endotracheal tubes that minimize microaspiration, consideration of noninvasive ventilation in certain circumstances, shortening surgery and anesthesia duration, and developing effective protocols for the timely removal of endotracheal tubes. Predictors of PPC risk, including advanced age and evidence of poor health, need assessment and risk stratification by the ASA classification system to determine those at high risk for PPCs. Individualized patient modifiable risk factor efforts need to be directed toward smoking cessation, weight loss in the obese patient undergoing elective nonemergent surgery, perioperative optimization of reversible airway obstruction, and the preoperative treatment of bacterial evidence of infection (such as bronchitis or pneumonia) in nonemergent surgeries. Proven procedure-related factor strategies that should

be utilized to reduce risk include such methods as postoperative lung expansion techniques, preoperative inspiratory muscle training, postoperative thoracic epidural analgesia, selective rather than routine use of NGTs, regional rather than general anesthesia, and laparoscopic rather than open surgical procedures when feasible.

Key Points

1. Several independent risk factors are associated with PPCs, which can be grouped into patient-related and procedure-related factors.
2. The goal of preoperative medical evaluation is to identify predisposing medical conditions that increase PPC risk, potentially optimize these conditions, recommend appropriate preoperative strategies that can aid management, and assist in selecting postoperative strategies to minimize risk of complications.
3. PPCs occur as frequently as cardiac complications after noncardiac surgery and increase the morbidity and mortality of postoperative patients.
4. Surgical patients who are identified as high risk for pulmonary complications benefit from preoperative education, breathing exercises, inspiratory muscle training, IS, and other preoperative therapies to help attenuate the likelihood of postoperative complications.
5. Pneumonia is currently the third most common postoperative infection, most often occurs within the first 5 postoperative days, and is associated with increased ICU and hospital LOSs.
6. Because PPCs are associated with increased morbidity, mortality, and hospital and ICU lengths of stay due to conditions such as postoperative bronchospasm, pneumonia, PE, atelectasis, ARDS, pneumothorax, and respiratory failure, they substantially increase consumption of healthcare resources.
7. Effective postoperative pain management allows for early ambulation and deep breathing and coughing, whereas ineffective pain control can lead to serious pulmonary complications.
8. While malnutrition is associated with increased risk for PPCs, the routine administration of total parenteral or enteral nutrition does not reduce the risk of pulmonary complications. However, severely undernourished patients may benefit from preoperative nutritional supplements.
9. Postoperative risk-reduction strategies include early mobilization of the patient, lung expansion techniques, adequate analgesia, restricted use of NGTs, and, when necessary, respiratory support for inadequate ventilation and oxygenation.
10. Postoperative ventilatory support following general anesthesia for several hours may occasionally be necessary in patients with residual anesthetic respiratory depression.
11. Atelectasis, bronchospasm, chemical pneumonitis, PE, pneumothorax, respiratory failure, and pneumonia are common postoperative problems that can be significantly reduced with appropriate perioperative preventive strategies.

Chapter Questions

1. Surgery that lasts longer than _____ increases a patient's risk for postoperative pulmonary complications (PPCs).
   a. 30 minutes
   b. 1 hour
   c. 2 hours
   d. 3 hours
2. The overall consequences of advanced age become significant between the ages of _____.
   a. 50 and 55
   b. 55 and 60
   c. 60 and 65
   d. 65 and 70
3. A modifiable preoperative risk factor for the development of PPCs is _____.
   a. nutritional status
   b. chronic obstructive pulmonary disease
   c. asthma
   d. age
4. The most critical element of a preoperative risk assessment is _____.
   a. spirometry
   b. history and physical exam
   c. assessment of oxygenation
   d. chest radiograph
5. The most common postoperative pulmonary complication is _____.
   a. pneumonia
   b. pneumothorax
   c. atelectasis
   d. bronchospasm
6. Hypoxemia typically occurs within the first _____ after major surgery.
   a. 12 hours
   b. 24 hours
   c. 36 hours
   d. 48 hours
7. Postoperative pleural effusions occur most often during the first week after _____ surgery.
   a. thoracic
   b. upper abdominal
   c. orthopedic
   d. head and neck

8. Long operations, lasting more than 5 hours, and emergency surgery increase the risk for postoperative pneumonia caused by _____.
   a. Methicillin-resistant *Staphylococcus aureus*
   b. *Haemophilus influenza*
   c. *Pseudomonas aeruginosa*
   d. Acinetobacter species
9. The highest incidence for PPCs occurs with _____.
   a. lower abdominal surgery
   b. upper abdominal surgery
   c. head and neck surgery
   d. thoracic surgery
10. The most effective postoperative intervention to reduce PPCs uses _____.
   a. incentive spirometry
   b. early ambulation
   c. deep breathing exercises and coughing
   d. a combination of therapies

References

1. Davies O, Husain T, Stephens R. Postoperative pulmonary complications following non-cardiothoracic surgery. *BJA Educat*. 2017;17(9):295–300. doi:10.1093/bjaed/mkx012.
2. Canet J, Mazo V. Postoperative pulmonary complications. *Minerva Anestesiol*. 2010;76:138–143. doi:10.1097/aln.0b013e3181fc6e0a.
3. Conde M, Adams S. Overview of the management of postoperative pulmonary complications. In: Manaker S, Hines R, ed. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed March 25, 2018.
4. Fernandez-Bustamante A, Frendl G, Sprung J, et al. Postoperative pulmonary complications, early mortality, and hospital stay following noncardiothoracic surgery: a multicenter study by the Perioperative Research Network. *JAMA Surg*. 2017;152(2):157–166. doi:10.1001/jamasurg.2016.4065.
5. Shander A, Fleisher L, Barie P, Bigatello L, Sladen R, Watson C. Clinical and economic burden of postoperative pulmonary complications: patient safety summit on definition, risk-reducing interventions, and preventive strategies*. *Crit Care Med*. 2011;39(9):2163–2172. doi:10.1097/ccm.0b013e31821f0522.
6. Patel K, Hadian F, Ali A, et al. Postoperative pulmonary complications following major elective abdominal surgery: a cohort study. *Perioper Med*. 2016;5(1):10. doi:10.1186/s13741-016-0037-0.
7. Smetana G. Evaluation of preoperative pulmonary risk. In: King T, Auerbach A, Holt N, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed March 25, 2018.
8. Rudra A, Das S. Postoperative pulmonary complications. *Indian J Anesth*. 2006;50(2):89–98.
9. Doyle DJ, Garmon EH. American Society of Anesthesiologists classification (ASA Class) [Updated October 6, 2017]. In: *StatPearls* [Internet]. Treasure Island, FL: StatPearls Publishing; 2018. https://www.ncbi.nlm.nih.gov/books/NBK441940
10. de Ávila A, Fenili R. Incidence and risk factors for postoperative pulmonary complications in patients undergoing thoracic and abdominal surgeries. *Rev Col Bras Cir*. 2017;44(3):284–292. doi:10.1590/0100-69912017003011.
11. Kodra N, Shpata V, Ohri I. Risk factors for postoperative pulmonary complications after abdominal surgery. *Open Access Maced J Med Sci*. 2016;4(2):259–263. doi:10.3889/oamjms.2016.059.
12. Diaz-Fuentes G, Hashmi H, Venkatram S. Perioperative evaluation of patients with pulmonary conditions undergoing non-cardiothoracic surgery. *Health Serv Insights*. 2016;9(suppl 1):9–23. doi:10.4137/hsi.s40541.
13. Meyer K. Aging. *Proc Am Thorac Soc*. 2005;2(5):433–439. doi:10.1513/pats.200508-081js.
14. Occhipinti M, Larici A, Bonomo L, Incalzi R. Aging airways: between normal and disease. A multidimensional diagnostic approach by combining clinical, functional, and imaging data. *Aging Dis*. 2017;8(4):471–485. doi:10.14336/AD.2016.1215.
15. Smetana G, Lawrence V, Cornell J. Preoperative pulmonary risk stratification for noncardiothoracic surgery: systematic review for the American College of Physicians. *Ann Intern Med*. 2006;144(8):581–595. doi:10.7326/0003-4819-144-8-200604180-00009.
16. Global Initiative for Chronic Obstructive Lung Disease. *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*. Global Initiative for Chronic Obstructive Lung Disease; 2018. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. Accessed March 27, 2018.
17. Lin C, Chang C, Yeh C, Chung C, Chen T, Liao C. Postoperative adverse outcomes in patients with asthma. *Medicine (Baltimore)*. 2016;95(3):e2548. doi:10.1097/md.0000000000002548.
18. Numata T, Nakayama K, Fujii S, et al. Risk factors of postoperative pulmonary complications in patients with asthma and COPD. *BMC Pulm Med*. 2018;18(1):4. doi:10.1186/s12890-017-0570-8.
19. National Heart, Lung and Blood Institute. *Expert Panel Report 3 (EPR3): Guidelines for the Diagnosis and Management of Asthma*. Bethesda, MA: U.S. Department of Health and Human Services, National Institutes of Health; 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed March 28, 2018.
20. Woods B, Sladen R. Perioperative considerations for the patient with asthma and bronchospasm. *Br J Anaesth*. 2009;103(suppl 1):i57–i65. doi:10.1093/bja/aep271.
21. Applegate R, Lauer R, Lenart J, Gatling J, Vadi M. The perioperative management of asthma. *J Aller Ther*. 2013;01(S11):7. doi:10.4172/2155-6121.s11-007.
22. Lo I, Siu C, Tse H, Lau T, Leung F, Wong M. Pre-operative pulmonary assessment for patients with hip fracture. *Osteoporos Int*. 2010;21(S4):579–586. doi:10.1007/s00198-010-1427-7.
23. Qaseem A, Snow V, Fitterman N, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery: a guideline from the American College of Physicians. *Ann Intern Med*. 2006;144(8):575–580. doi:10.7326/0003-4819-144-8-200604180-00008.
24. Sood A, Abdollah F, Sammon J, et al. The effect of body mass index on perioperative outcomes after major surgery: results from the National Surgical Quality Improvement Program (ACS-NSQIP) 2005–2011. *World J Surg*. 2015;39(10):2376–2385. doi:10.1007/s00268-015-3112-7.
25. Hodgson L, Murphy P, Hart N. Respiratory management of the obese patient undergoing surgery. *J Thorac Dis*. 2015;7(5):943–952. doi:10.3978/j.issn.2072-1439.2015.03.08.
26. Olson E, Chung F, Seet E. Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea In: Jones SB, Collop N, Crowley M, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed March 29, 2018.
27. Kaw R, Chung F, Pasupuleti V, Mehta J, Gay P, Hernandez A. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. *Br J Anaesth*. 2012;109(6):897–906. doi:10.1093/bja/aes308.
28. Singh J, Hawn M, Campagna E, Henderson W, Richman J, Houston T. Mediation of smoking-associated postoperative mortality by perioperative complications in veterans undergoing elective surgery: data from Veterans Affairs Surgical Quality Improvement Program (VASQIP)—a cohort study. *BMJ Open*. 2013;3(4):e002157. doi:10.1136/bmjopen-2012-002157.

29. Thomsen T, Villebro N, Moller A. Interventions for preoperative smoking cessation (Review). *Cochrane Database Syst Rev*. 2014;3:CD002294. doi:10.1002/14651858.CD002294.pub4.
30. Smetana G. Strategies to reduce postoperative pulmonary complications in adults. In: King, Jr. T, Aronson M, Hines R, Hollingsworth H, eds. *UpToDate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed March 25, 2018.
31. Aubin H, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. *Br J Clin Pharmacol*. 2014;77(2):324–336. doi:10.1111/bcp.12116.
32. Agostini P, Cieslik H, Rathinam S, et al. Postoperative pulmonary complications following thoracic surgery: are there any modifiable risk factors? *Thorax*. 2010;65(9):815–818. doi:10.1136/thx.2009.123083.
33. Duarte A, Machado H. Postoperative pulmonary complications: an epidemiological, risk factors and prevention review. *J Anesth Clin Res*. 2016;7(1):600. doi:10.4172/2155-6148.1000600.
34. Ji Q, Mei Y, Wang X, Feng J, Cai J, Ding W. Risk factors for pulmonary complications following cardiac surgery with cardiopulmonary bypass. *Int J Med Sci*. 2013;10(11):1578–1583. doi:10.7150/ijms.6904.
35. Gupta H, Gupta P, Fang X, et al. Development and validation of a risk calculator predicting postoperative respiratory failure. *Chest*. 2011;140(5):1207–1215. doi:10.1378/chest.11-0466.
36. Arozullah A, Daley J, Henderson W, Khuri S. Multifactorial risk index for predicting postoperative respiratory failure in men after major noncardiac surgery. *Ann Surg*. 2000;232(2):242–253. doi:10.1097/00000658-200008000-00015.
37. Miskovic A, Lumb A. Postoperative pulmonary complications. *Br J Anaesth*. 2017;118(3):317–334. doi:10.1093/bja/aex002.
38. Gupta P, Gupta H, Natarajan B, et al. Postoperative respiratory failure after thyroid and parathyroid surgery: analysis of national surgical quality improvement program. *Head Neck*. 2011;34(3):321–327. doi:10.1002/hed.21723.
39. Hedenstierna G. Oxygen and anesthesia: what lung do we deliver to the post-operative ward? *Acta Anaesthesiol Scand*. 2012;56(6):675–685. doi:10.1111/j.1399-6576.2012.02689.x.
40. Kelkar K. Post-operative pulmonary complications after non-cardiothoracic surgery. *Indian J Anaesth*. 2015;59(9):599–605. doi:10.4103/0019-5049.165857.
41. Güldner A, Kiss T, Serpa Neto A, et al. Intraoperative protective mechanical ventilation for prevention of postoperative pulmonary complications. *Anesthesiology*. 2015;123(3):692–713. doi:10.1097/aln.0000000000000754.
42. Olsén M, Lönroth H, Bake B. Effects of breathing exercises on breathing patterns in obese and non-obese subjects. *Clin Physiol*. 1999;19(3):251–257. doi:10.1046/j.1365-2281.1999.00167.x.
43. Restrepo R, Wettstein R, Wittnebel L, Tracy M. Incentive spirometry: 2011. *Respir Care*. 2011;56(10):1600–1604. doi:10.4187/respcare.01471.
44. Bittner E. Respiratory problems in the post-anesthesia care unit (PACU). In: Holt N, Finlay G, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed March 25, 2018.
45. Imazio M, Brucato A, Rovere M, et al. Colchicine prevents early postoperative pericardial and pleural effusions. *Am Heart J*. 2011;162(3):527–532.e1. doi:10.1016/j.ahj.2011.05.017.
46. Herlihy J, Koch S, Jackson R, Nora H. Course of weaning from prolonged mechanical ventilation after cardiac surgery. *Tex Heart Inst J*. 2006;33(2):122–129.
47. Nafiu O, Ramachandran S, Ackwerh R, Tremper K, Campbell D, Stanley J. Factors associated with and consequences of unplanned post-operative intubation in elderly vascular and general surgery patients. *Eur J Anaesthesiol*. 2011;28(3):220–224. doi:10.1097/eja.0b013e328342659c.
48. Ramachandran S, Nafiu O, Ghaferi A, Tremper K, Shanks A, Kheterpal S. Independent predictors and outcomes of unanticipated early postoperative tracheal intubation after nonemergent, noncardiac surgery. *Anesthesiology*. 2011;115(1):44–53. doi:10.1097/aln.0b013e31821cf6de.
49. Brueckmann B, Villa-Uribe J, Bateman B, et al. Development and validation of a score for prediction of postoperative respiratory complications. *Anesthesiology*. 2013;118(6):1276–1285. doi:10.1097/aln.0b013e318293065c.
50. Smetana G. Postoperative pulmonary complications: an update on risk assessment and reduction. *Cleve Clin J Med*. 2009;76(Suppl_4):S60–S65. doi:10.3949/ccjm.76.s4.10.
51. Rong L, Di Franco A, Gaudino M. Acute respiratory distress syndrome after cardiac surgery. *J Thorac Dis*. 2016;8(10):E1177–E1186. doi:10.21037/jtd.2016.10.74.
52. Kazaure H, Martin M, Yoon J, Wren S. Long-term results of a postoperative pneumonia prevention program for the inpatient surgical ward. *JAMA Surg*. 2014;149(9):914–918. doi:10.1001/jamasurg.2014.1216.
53. Chughtai M, Gwam CU, Khlopas A, et al. The incidence of postoperative pneumonia in various surgical subspecialties: a dual database analysis. *Surg Technol Int*. 2017;25(30):45–51.
54. Snowdon D, Haines T, Skinner E. Preoperative intervention reduces postoperative pulmonary complications but not length of stay in cardiac surgical patients: a systematic review. *J Physiother*. 2014;60(2):66–77. doi:10.1016/j.jphys.2014.04.002.
55. Warner D. Preoperative smoking cessation: the role of the primary care provider. *Mayo Clin Proc*. 2005;80(2):252–258. doi:10.4065/80.2.252.
56. Yoder M. Perioperative pulmonary management: background, perioperative pulmonary physiology, patient- and procedure-related risk factors. 2015. https://emedicine.medscape.com/article/284983-overview#a6. Accessed April 5, 2018.
57. Hawn M, Houston T, Campagna E, et al. The attributable risk of smoking on surgical complications. *Ann Surg*. 2011;254(6):914–920. doi:10.1097/sla.0b013e31822d7f81.
58. Wong J, Lam D, Abrishami A, Chan M, Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. *Can J Anesth*. 2011;59(3):268–279. doi:10.1007/s12630-011-9652-x.
59. Hulzebos E, Helders P, Favié N, De Bie R, Brutel de la Riviere A, Van Meeteren N. Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery. *JAMA*. 2006;296(15):1851–1857. doi:10.1001/jama.296.15.1851.
60. Boden I, Skinner E, Browning L, et al. Preoperative physiotherapy for the prevention of respiratory complications after upper abdominal surgery: pragmatic, double blinded, multicentre randomised controlled trial. *BMJ*. 2018:j5916. doi:10.1136/bmj.j5916.
61. Vagvolgyi A, Rozgonyi Z, Kerti M, Vadasz P, Varga J. Effectiveness of perioperative pulmonary rehabilitation in thoracic surgery. *J Thorac Dis*. 2017;9(6):1584–1591. doi:10.21037/jtd.2017.05.49.
62. Inoue J, Ono R, Makiura D, et al. Prevention of postoperative pulmonary complications through intensive preoperative respiratory rehabilitation in patients with esophageal cancer. *Dis Esophagus*. 2012;26(1):68–74. doi:10.1111/j.1442-2050.2012.01336.x.
63. Hulzebos E, Smit Y, Helders P, van Meeteren N. Preoperative physical therapy for elective cardiac surgery patients. *Cochrane Database Syst Rev*. 2012;11:CD010118. doi:10.1002/14651858.cd010118.pub2.
64. Wong C, O'Moore-Sullivan T, Leano R, Hukins C, Jenkins C, Marwick T. Association of subclinical right ventricular dysfunction with obesity. *J Am Coll Cardiol*. 2006;47(3):611–616. doi:10.1016/j.jacc.2005.11.015.
65. Ruscic K, Grabitz S, Rudolph M, Eikermann M. Prevention of respiratory complications of the surgical patient. *Curr Opin Anaesthesiol*. 2017;30(3):399–408. doi:10.1097/aco.0000000000000465.
66. Hausman M, Jewell E, Engoren M. Regional versus general anesthesia in surgical patients with chronic obstructive pulmonary disease. *Anesth Analg*. 2015;120(6):1405–1412. doi:10.1213/ane.0000000000000574.
67. Phan K, Kim J, Kim J, et al. Anesthesia duration as an independent risk factor for early postoperative complications in adults

undergoing elective ACDF. *Global Spine J*. 2017;7(8):727–734. doi:10.1177/2192568217701105.
68. Mills G. Respiratory complications of anesthesia. *Anesthesia*. 2018;73:25–33. doi:10.1111/anae.14137.
69. Futier E, Constantin J, Paugam-Burtz C, et al. A trial of intraoperative low-tidal-volume ventilation in abdominal surgery. *N Engl J Med*. 2013;369(5):428–437. doi:10.1056/nejmoa1301082.
70. Zafiropoulos B, Alison J, McCarren B. Physiological responses to the early mobilisation of the intubated, ventilated abdominal surgery patient. *Aust J Physiother*. 2004;50(2):95–100. doi:10.1016/s0004-9514(14)60101-x.
71. Kalisch B, Lee S, Dabney B. Outcomes of inpatient mobilization: a literature review. *J Clin Nurs*. 2013;23(11–12):1486–1501. doi:10.1111/jocn.12315.
72. Alaparthi G, Augustine A, Anand R, Mahale A. Comparison of diaphragmatic breathing exercise, volume and flow incentive spirometry, on diaphragm excursion and pulmonary function in patients undergoing laparoscopic surgery: a randomized controlled trial. *Minim Invasive Surg*. 2016;2016:1–12. doi:10.1155/2016/1967532.
73. Ireland C, Chapman T, Mathew S, Herbison G, Zacharias M. Continuous positive airway pressure (CPAP) during the postoperative period for prevention of postoperative morbidity and mortality following major abdominal surgery. *Cochrane Database Syst Rev*. 2014;8:CD008930. doi:10.1002/14651858.cd008930.pub2.
74. Cassidy M, Rosenkranz P, McCabe K, Rosen J, McAneny D. I COUGH: reducing postoperative pulmonary complications with a multidisciplinary patient care program. *JAMA Surg*. 2013;148(8):740–745. doi:10.1001/jamasurg.2013.358.
75. Grooms D. Postoperative pulmonary complications. Clinical Foundations. 2012. http://www.clinicalfoundations.org/assets/foundations13.pdf. Accessed April 8, 2018.
76. Zarbock A, Mueller E, Netzer S, Gabriel A, Feindt P, Kindgen-Milles D. Prophylactic nasal continuous positive airway pressure following cardiac surgery protects from postoperative pulmonary complications. *Chest*. 2009;135(5):1252–1259. doi:10.1378/chest.08-1602.
77. Ioscovich A, Barth D, Briskin A. Biphasic Intermittent Positive Airway Pressure (BIPAP) ventilation support in the postoperative period for patients with myotonic dystrophy. *Internet J Anesthesiol*. 2006;10(2). doi:10.5580/1b36.

CHAPTER

23

Pulmonary Tuberculosis

The pure culture is the foundation for all research on infectious disease.

—Robert Koch, *A Life in Medicine and Bacteriology*. 1st ed. New York, NY: Science Tech Pub; 1988:94.

OUTLINE

OBJECTIVES

1. Identify the common characteristics, manifestations, and diagnostic features of pulmonary tuberculosis.
2. Discuss the incidence, prevalence, and risk factors as well as prognostic determinants of pulmonary tuberculosis.
3. Describe the underlying pathophysiologic mechanisms in pulmonary tuberculosis.
4. Utilize diagnostic testing to establish the diagnosis of pulmonary tuberculosis.
5. Discuss the recommended management for patients with pulmonary tuberculosis.
6. Identify common complications and risk factors of pulmonary tuberculosis.

KEY TERMS

Acid-fast bacilli (AFB)
Bacille Calmette–Guérin (BCG)
Booster phenomenon
Droplet nuclei
Gastric washing
Ghon focus
Granulomas
Interferon-γ release assays (IGRAs)
Latent tuberculosis infection (LTBI)
Multiple-drug-resistant TB (MDR-TB)
Mycobacterium tuberculosis
Nucleic acid amplification (NAA)
Primary TB
Pulmonary TB disease
Secondary TB
Sputum smears
Tuberculin skin testing (TST)
Tuberculoma

Case Study

A recently immigrated 28-year-old woman is in the hospital's pulmonary clinic today. Through an interpreter, the woman gives an 8-week history of a cough productive of clear mucus. Three weeks ago, the mucus began to turn green and had streaks of blood in it. The patient complains of night sweats, fevers, and 12-pound weight loss over the past 6 weeks. The patient's physical examination reveals a temperature of 100.8°F, pulse 88 beats/minute, respiratory rate 18, blood pressure 140/86. Her chest is dull to percussion over the right middle and upper lobes. Auscultation reveals rhonchi over the right middle and upper lobes. The patient is negative for cyanosis and clubbing. Her cardiac and neurologic exams are normal. The patient's chest radiograph is shown in **Figure 23-1**.

Due to the patient's history of present illness and chest radiograph findings, the patient is admitted to the hospital and placed in a negative pressure isolation room with TB airborne precautions. Three-morning sputum samples are ordered for sputum smears to detect acid-fast bacilli and sputum culture (usually takes 3–6 weeks). Blood for a QuantiFERON-TB Gold Test is drawn. The patient is started on a three-drug regimen of anti-tuberculosis drugs.



FIGURE 23-1 The chest radiograph showing consolidation in the right middle and upper lobes and air bronchograms.

Introduction

Tuberculosis (TB) is an airborne disease caused by the rod-shaped, non-spore-forming, aerobic bacterium ***Mycobacterium tuberculosis*** (*M. tuberculosis*). See **Figure 23-2**. *M. tuberculosis* and seven very closely related mycobacterial species (*M. bovis, M. africanum, M. microti, M. caprae, M. pinnipedii, M. canetti*, and *M. mungi*) together comprise what is known as the *M. tuberculosis* complex.[1] Most, but not all, of these species have been found to cause disease in humans. In the United States, most TB cases are caused by *M. tuberculosis*. *M. tuberculosis* organisms are also called tubercle bacilli.

M. tuberculosis is carried in airborne particles, called **droplet nuclei**, of 1–5 μm in diameter. TB is spread from person to person by way of infectious droplet nuclei that are generated when persons with pulmonary or laryngeal TB disease cough, sneeze, shout, or sing. Droplet nuclei may also be produced by aerosol treatments, sputum induction, aerosolization during bronchoscopy, and manipulation of lesions or processing of tissue or secretions in the hospital or laboratory.[2] *M. tuberculosis* is spread through the air, not by surface contact. The infectiousness of a person with TB disease is directly related to the number of tubercle bacilli expelled into the air. The more tubercle bacilli are expelled, the more infectious the person. Transmission occurs when the inhaled droplets containing *M. tuberculosis* are inhaled and reach the alveoli.



FIGURE 23-2 *M. tuberculosis* is a pathogenic bacterial species.

KNOWLEDGE CHECK QUESTIONS

1. True or False: *M. tuberculosis* can form spores.
2. True or False: *M. tuberculosis* droplet nuclei are between 1 and 5 μm in diameter.

Definition/Diagnosis

TB is one of the oldest known diseases, with evidence of TB in the skeletal remains of early humans.[3] Today, TB remains a major global health problem causing ill-health in millions of people each year. In 2015, TB was one of the top 10 causes of death worldwide, ranking above human immunodeficiency virus (HIV)/AIDS. This mortality occurs even though a timely diagnosis and correct treatment will cure most people who develop TB disease.[4]

TB disease most commonly affects the lungs and is referred to as **pulmonary TB disease**. TB disease can also occur in almost any anatomical site or as disseminated disease.[1] The diagnosis of TB requires the identification of *M. tuberculosis* in a culture of a diagnostic specimen. The most frequent sample for culture from a patient with a persistent and productive cough is sputum.[1] For patients who have difficulty generating sputum, inhalation of an aerosol of normal or hypertonic saline may be useful to induce a deep sputum-producing cough.[1,2] If necessary, a bronchoscopy with bronchial washings or a bronchoalveolar lavage can provide sputum for diagnosis.[1] Children may not be able to produce sputum when they cough with or without the inhalation of aerosol. In this situation, **gastric washing** may be utilized. In patients, with an involvement of intrathoracic lymph nodes, who have **sputum smears** negative for *M. tuberculosis*, a culture of specimens collected by transbronchial needle aspiration can be used to accurately and immediately diagnose the disease.[5] See **Box 23-1**.

Positive cultures for *M. tuberculosis* confirm the diagnosis of TB disease; however, in the absence of a positive culture, TB disease may also be diagnosed based on clinical signs and symptoms alone.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The best way to obtain specimens from children who cannot produce sputum is by bronchoscopy.
2. True or False: For patients who are unable to cough up sputum, aerosolized hypertonic saline can encourage deep coughing.

BOX 23-1 Methods of Obtaining a Sputum Specimen

- Spontaneous sputum sample
- Sputum induction
- Bronchoscopy/bronchoalveolar lavage
- Gastric washing

Clinical Signs and Symptoms

The clinical manifestations of TB vary widely and depend on several factors summarized in **Box 23-2**. The pulmonary presentation of TB has three distinctive presentations: **primary TB**, **secondary (reactivation) TB**, and military TB (widespread dissemination). Before the HIV infection epidemic, in the late 1980s, most TB cases were limited to the lungs with few nonpulmonary or combined cases.[6,7]

The most easily quantifiable systemic effect of pulmonary TB is a fever. The fever is usually low grade at the onset but becomes marked with the progression of the disease. It is classically diurnal, with an afebrile period early in the morning and a gradually rising temperature throughout the day, reaching a peak in the late afternoon or evening. Fever subsides during sleep, but night sweats may occur. Fever and night sweats are classic features of TB. However, the absence of fever does not exclude TB.

The most common symptom of pulmonary TB is a cough. A cough may be absent or mild initially and may be nonproductive or productive of only scant sputum. Initially, the cough may be present only in the morning, when accumulated secretions during sleep are expectorated. As the disease progresses, cough becomes more continuous

BOX 23-2 Factors Influencing the Clinical Features of TB

Organism Factors

- Virulence
- Predilection for specific tissues

Endogenous Factors

- Age
- Immune status
  - Specific immunodeficiency status
  - Nutritional status
  - Genetic factors
- Comorbidities
- Immunization with bacillus Calmette–Guérin (BCG)

Host–Organism Interaction

- Site of involvement
- Disease severity

Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J Respir Crit Care Med*. 2000;161(4 Pt 1):1376–1395.

throughout the day and productive of yellow or yellow-green sputum, which is rarely foul smelling. Hemoptysis may also develop.

Dyspnea can occur in the setting of extensive parenchymal involvement, pleural effusions, or a pneumothorax. Pleuritic chest pain is not common but, when present, signifies inflammation abutting or invading the pleura, with or without an effusion. Anorexia, wasting, and malaise are all common features of advanced disease and may be the only presenting features in some patients. Finger clubbing and pallor are also manifested in some patients with pulmonary TB.

The most common hematologic findings are mild anemia, leukocytosis, and thrombocytosis with a slightly elevated erythrocyte sedimentation rate and C-reactive protein level. None of these findings are consistent or sufficiently accurate for diagnostic purposes. Hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone has also been reported.[8]

In many patients, TB is associated with other serious disorders. These include HIV infection, alcoholism, chronic renal failure, diabetes mellitus, neoplastic diseases, and drug abuse. The signs and symptoms of these diseases and their complications can easily obscure especially in patients with HIV infection.[9]

KNOWLEDGE CHECK QUESTIONS

1. True or False: A patient with pulmonary TB will always be febrile.
2. True or False: Pleuritic chest pain is a common symptom of pulmonary TB.

Etiology

M. tuberculosis are classified as **acid-fast bacilli (AFB)** and have a unique cell wall structure crucial to their survival. The well-developed cell wall contains a considerable amount of a fatty acid, mycolic acid, covalently attached to the underlying peptidoglycan-bound polysaccharide arabinogalactan, providing an extraordinary lipid barrier. This barrier is responsible for many of the medically challenging physiological characteristics of TB, including resistance to antibiotics and host defense mechanisms.[5]

Humans are the only known reservoir for *M. tuberculosis*. The interaction of *M. tuberculosis* with the human host begins when droplet nuclei containing microorganisms from infectious individuals are inhaled.[8] The droplet nuclei aerosolized by coughing, sneezing, or speaking may number up to 3,000 and remain airborne for minutes to hours after expectoration. The most likely hosts to spread TB are those whose sputum contains AFB visible by microscopy.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Humans are the only known reservoir for *M. tuberculosis*.
2. True or False: The most infectious host is one with AFB visible by microscopy.

Close contact with these hosts increases the likelihood of transmission.

The introduction of *M. tuberculosis* into the lungs leads to infection of the respiratory system; however, the organisms can spread to other organs, such as the lymphatics, pleura, bones/joints, or meninges, and cause extrapulmonary TB.[5]

Epidemiology

The epidemiology of TB varies substantially around the world. Worldwide in 2015, there were an estimated 10.4 million incident TB cases. Approximately 62% of these cases were male, and 90% were adults. Six countries accounted for 60% of the global total: India, Indonesia, China, Nigeria, Pakistan, and South Africa.[4] In 2015 in the United States, the overall number of TB cases increased over the previous year after having declined yearly during 1993–2014. Despite a slight increase in case count, the TB incidence rate per 100,000 persons has remained relatively stable since 2013.[10] See **Table 23-1**.

Globally, the absolute number of TB deaths, excluding TB deaths among HIV-positive people, and the TB incidence rate have fallen since 2000. The number of TB deaths fell from 1.8 million in 2000 to 1.4 million in 2015. However, the global rate of decline in the TB incidence rate was only 1.5% from 2014 to 2015, and the case fatality ratio in 2015 was 17%. (Case fatality ratio is the proportion of cases that result in death). TB is one of the top 10 causes of death worldwide and caused more deaths than HIV in 2015.[4]

During 1993–2003, rates declined in both the U.S.-born and the foreign-born populations in the United States. However, the decline was substantially less among the foreign-born populations. In 2002, for the first time, TB cases among foreign-born persons accounted for the majority (51.2%) of TB cases in the United States. Overall, the number of cases in foreign-born persons has remained virtually level, with approximately 7,000–8,000 cases each year, until 2009, when the number dropped to 6,854. The number of cases in U.S.-born persons decreased from more than 17,000 in 1993 to 3,981 in 2011.[1]

There is a declining trend in TB rates by race/ethnicity in the United States. The 2011 TB case rate by race/ethnicity appears in **Table 23-2**.

Table 23-2 brings to light the disproportionate burden of TB in minorities. In certain circumstances, the TB infection may be acquired in the country of origin

TABLE 23-1
TB Incidence in the United States, 1993–2015

Year	Number of Cases	Rate per 100,000
2015	9,557	3.0
2014	9,406	2.9
2013	9,550	3.0
2012	9,942	3.2
2011	10,510	3.4
2010	11,159	3.6
2009	11,520	3.8
2008	12,893	4.2
2007	13,282	4.4
2006	13,728	4.6
2005	14,060	4.8
2004	14,499	5.0
2003	14,835	5.1
2002	15,055	5.2
2001	15,945	5.6
2000	16,308	5.8
1999	17,499	6.3
1998	18,286	6.6
1997	19,751	7.2
1996	21,210	7.9
1995	22,726	8.5
1994	24,206	9.2
1993	25,102	9.7

CDC | TB | Data and Statistics. 2017. https://www.cdc.gov/tb/statistics. Accessed May 9, 2017.

in foreign-born minorities. Also, socioeconomic status and overcrowding of living quarters play a large part in the higher rates.[1]

HIV-infected persons are at high risk for developing TB disease after infection with *M. tuberculosis*. In the United States, the percentage of HIV coinfection decreased from 15% in 1993 to 6% in 2011.[1] Worldwide, between 9% and 14% of the incident TB cases in 2015 were among people living with HIV. The proportion of TB cases coinfected with HIV was the highest in countries in the World Health Organization African Region and exceeded 50% in parts of southern Africa.[4]

TABLE 23-2
TB Rates by Race/Ethnicity in the United States in 2011

Race/Ethnicity	Cases per 100,000
African Americans	6.3
American Indians/Alaska Natives	5.6
Asians	20.9
Hispanics	5.8
Non-Hispanic whites	0.8
Native Hawaiian or Other Pacific Islanders	15.9

Data from *Core Curriculum on Tuberculosis: What the Clinician Should Know.* 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The incidence of TB has decreased or remained steady in the United States since 1993.
2. True or False: The proportion of TB cases coinfected with HIV is the highest in Asia.

Pathology/Pathophysiology

The pathogenesis of TB is well understood and has been for decades. Inhalation of aerosol droplets containing *M. tuberculosis* with subsequent deposition in the lungs leads to one of a variety of paths. See **Figure 23-3**. The host immune system may immediately clear the infection. The host immune system may suppress the infection into a **latent tuberculosis infection (LTBI)**. The LTBI may become active years later, causing secondary or reactivation disease. The infection may overwhelm the host immune system and lead to the onset of active disease (primary disease).

The risk of developing primary TB disease depends mostly on a person's innate immunologic and nonimmunologic defenses and the level of function of cell-mediated immunity. The initial physical defense, in most individuals, is the mucociliary escalator system. Bacteria that can bypass this system reach the alveoli, where they are engulfed by and may multiply within the alveolar macrophages.[2] The bacteria grow for 2–12 weeks until they reach 1,000–10,000 in number. At that time, there is a sufficient amount of organisms to elicit a cellular immune response to the tuberculin skin test.[11] The phagocytosis by the alveolar macrophages initiates



FIGURE 23-3 Progression of TB. People who are exposed to *M. tuberculosis* may or may not develop LTBI. People with LTBI may or may not develop TB disease.

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013 (Figure 2.4, p. 29). https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

an antigenic cascade of events that result in either successful control of the infection, followed by LTBI, or progression to active TB (primary disease).[11] Individuals with LTBI cannot spread TB.

Regardless of whether the infection becomes controlled or progresses, initial development involves the production of proteolytic enzymes and cytokines by the macrophages to try to kill the bacteria. In persons with intact immune systems, collections of activated T cells and macrophages form **granulomas** (nodular-like lesions) that limit multiplication and spread of the organism. Granulomas in persons with adequate immune systems undergo fibrosis and calcification, successfully controlling the infection so that the bacilli are contained in the dormant, healed lesions.[12] In persons with weaker immune systems, the granuloma walls lose integrity, and the bacilli can escape and spread to other alveoli or other organs (regional lymph nodes, the apex of the lung, kidneys, brain, and bone), via the lymphatic system.[1] See **Figure 23-4**. This situation leads to active TB. Individuals with active TB can spread TB.

Active pulmonary TB most often involves the middle and lower lung lobes. The lesion that forms after the initial infection is the **Ghon focus** or Ghon lesion. The Ghon focus is usually peripheral and in young children is almost invariably accompanied by a transient hilar to paratracheal lymphadenopathy. In most cases, the lesion heals spontaneously into a **tuberculoma** (calcified caseating granuloma). This "Ghon focus" with or without overlying pleural reaction is referred as the *Ghon complex*.[8]

Among individuals with LTBI and intact immune systems, secondary TB (reactivation) disease occurs in approximately 5–10% of cases.[1] The risk of reactivation is high in patients with HIV and other medical conditions. These outcomes are determined by the interplay of factors attributable to both the organism and the host. For persons whose immune system is weak, especially those with HIV infection, the risk of developing TB disease is much higher than for persons with a normal immune system. Reactivation most often involves the superior segments of the lower lung lobes. **Table 23-3** shows the differences between LTBI and TB disease.



Intact immune system: Macrophages and T lymphocytes form nodule-like lesions to contain bacilli. Fibrosis and calcification contain the bacilli.

Weakened immune system: Nodule-like lesion wall breaks down and the bacilli escape an spread to other alveoli or other organs.

FIGURE 23-4 Pathophysiology of TB.

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013 (Figure 2.3 parts 4 and 5, p. 27). https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

TABLE 23-3
Characteristics of LTBI versus TB Disease

Characteristics	LTBI	Active TB Disease
Number of bacilli in the body	Small number	Large number
State of bacilli in the body	Alive, inactive	Alive, active
Infectiousness	Cannot spread TB bacteria to others	May spread TB bacteria to others
Symptoms	Does not feel sick If bacteria activate, may become sick	May feel sick Symptoms: cough, fever, weight loss, night sweats
Radiograph	Normal	Abnormal
Sputum	Smears and cultures are negative	Smears and cultures are positive
Treatment required	To prevent TB disease	To treat TB disease
Isolation precautions	None	Respiratory isolation
Case consideration	Not a TB case	A TB case

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013 (From Reference 1, Table 2.5, p. 30). https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

Cavitation in the lungs occurs from the dissemination of the bacilli from the initial site of deposition in the middle and lower lung lobes. TB cavities most often occur in the apices of the lungs or the apical segments of the lower lobes. TB cavity formation is classically described as "post-primary," occurring later after the initial "primary" infection.[13]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Patients with LTBI can spread the disease.
2. True or False: Granulomas in patients with weak cellular immunity break down and release the bacilli.

Risk Factors

TB is a social disease with medical implications. It has always occurred disproportionately among disadvantaged populations such as the homeless, malnourished, and overcrowded. The spread of HIV infection and the immigration of persons from areas of high incidence have resulted in increased numbers of TB cases.[2]

TABLE 23-4
Risk Factors for TB Disease[14]

At Risk for Infection with TB Bacteria	Medical Conditions That Weaken the Immune System
Close contact with a person with infectious TB disease	HIV infection
Immigration from areas of the world with high TB rates	Substance abuse
Younger than 5 years with positive TB test	Silicosis
Homeless	Diabetes mellitus
Injection drug users	Severe kidney disease
HIV infection	Low body weight
Work with high-risk individuals in hospitals, homeless shelters, correctional facilities, nursing homes, residential homes for those with HIV	Organ transplants
	Gastrectomy or jejunoileal bypass
	Head and neck cancer
	Immunosuppressive therapy (such as systemic corticosteroids or tumor necrosis factor-alpha antagonists)
	Specialized treatment for rheumatoid arthritis or Crohn disease

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

There are two basic categories of high-risk factors for developing TB disease. One is individuals who have been recently infected with TB bacteria and the other is those with medical conditions that weaken the immune system. **Table 23-4** summarizes the TB risk factors. **Table 23-5** shows the overall risk over a lifetime for persons infected only with *M. tuberculosis*.

KNOWLEDGE CHECK QUESTIONS

1. True or False: All individuals have the same risk for the development of TB disease.
2. True or False: Individuals with untreated HIV infection and no LTBI treatment have the highest risk for developing TB disease during their lifetime.

TABLE 23-5
Lifetime Risk for Developing TB Disease

Risk Factor	Risk of Developing TB Disease	Description
TB infection and no risk factors	About 10% over a lifetime	For people with TB infection, no risk factors and no treatment; the risk is about 5% in the first 2 years after infection and about 10% over a lifetime.
TB infection and diabetes	About 30% over a lifetime	For people with TB infection and diabetes, and with no treatment, the risk is three times as high or about 30% over a lifetime.
TB infection and HIV infection	About 7–10% per year	For people with TB infection and untreated HIV infection with no LTBI treatment, the risk is about 7–10% per year, a very high risk over a lifetime.

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

Complications

Pulmonary complications of TB include hemoptysis, pneumothorax, bronchiectasis, extensive pulmonary destruction (including pulmonary gangrene), malignancy, and chronic pulmonary aspergillosis. Hemoptysis occurs most frequently in the setting of active TB or after completion of treatment.[1,15] Before the availability of antituberculous therapy, spontaneous pneumothorax was a frequent and dangerous complication of pulmonary TB.[16] Since the advent of antituberculous therapy, spontaneous pneumothorax associated with TB is reported in about 1% of hospitalized patients.[17,18]

Bronchiectasis may develop following primary or reactivation TB and can be associated with hemoptysis. Rarely, TB can cause progressive, extensive destruction of areas of one or both lungs.[18,19] In primary TB, occasionally lymph node obstruction of the bronchi together with distal collapse, necrosis, and bacterial superinfection can produce parenchymal destruction.[20] More commonly, destruction results from chronic reactivation TB, typically in the absence of effective chemotherapy. Symptoms include progressive dyspnea, hemoptysis, and weight loss. The causal relationship of malignancy is not clear, but mycobacterial cell wall components may induce production of nitric oxide and reactive oxygen species, which have been implicated in DNA damage leading to carcinogenesis.[21] Chronic pulmonary aspergillosis can be a sequela of pulmonary TB.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The most frequently occurring complication of active TB disease is hemoptysis.
2. True or False: The most common cause of lung destruction is chronic reactivation TB.

Diagnostic Testing

Targeted testing is a TB control strategy used to identify, evaluate, and treat individuals who are at high risk for LTBI or at high risk for developing TB disease once infected with the microorganism. One of the goals of TB control and elimination is to identify individuals with LTBI. This can stop further spread of TB by preventing infected people from developing TB disease.[1]

Testing for LTBI

There are two methods to test for LTBI. The original method of testing uses an active protein fraction known as tuberculin purified protein derivative (PPD) that is injected subcutaneously. Skin testing with tuberculin-PPD or **tuberculin skin testing (TST)** or Mantoux tuberculin skin test is widely used in screening for LTBI. However, this method has some drawbacks. PPD is not mycobacterial species specific due to a large number of proteins in the various species. The reaction interpretation is also open to subjectivity, there may be batch-to-batch variations, and the results are available 48–72 hours after placement. It takes approximately 2–8 weeks from exposure for the body's immune system to react to the tuberculin. Because TST has a relatively low sensitivity and specificity and is unable to discriminate between LTBI and active TB disease, it is of no value in the diagnosis of active TB disease.[8]

The TST result depends on the size of the raised, hard area or swelling. It also depends on the person's risk of TB infection and the risk of progression to TB disease. See **Figure 23-5**. A positive TST means the individual's body was infected with TB bacteria. Additional tests are needed to determine if the person has LTBI or TB disease. Treatment is as needed. A negative TST means the individual's body did not react to the test and that LTBI or TB disease is not likely.

The second method to test for LTBI uses **interferon-γ release assays (IGRAs)**. IGRAs require



FIGURE 23-5 Evaluation of individuals with LTBI based on the risk of infection, the risk of progression to TB, and benefit of therapy. The three groups are unlikely to be infected, likely to be infected with low-to-intermediate risk of progression, and likely to be infected with a high risk of progression. CXR, chest radiography; RR, respiratory rate.

Reproduced with permission from Lewinsohn D, Leonard M, LoBue P, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis.* 2017;64(2):111–115 (Figure 1, p. 113). doi:10.1093/cid/ciw778.

blood to be drawn for testing. The results can be available in 24 hours, and the laboratory test is not open to the subjectivity, as is the TST. Two IGRAs are available and approved by the U.S. Food and Drug Administration (FDA) for the diagnosis of TB infection. They are QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and T-Spot®.TB test. IGRAs identify the presence of *M. tuberculosis* infection by measuring the immune response to the TB proteins in whole blood. IGRAs cannot differentiate between LTBI and active TB disease. As with the TST, additional tests are needed to diagnose or rule out TB disease.[1]

A positive IGRA means that the person is infected with TB bacteria. A negative IGRA means that the individual's blood did not react to the test and that LTBI or TB disease is not likely. IGRAs are the preferred method of TB infection testing for people who have received **bacille Calmette–Guérin** (**BCG** is a vaccine for TB) and people who have a difficult time returning for a second appointment to look for a reaction to the TST. There is no problem with repeated IGRAs.[8,22]

The BCG vaccine is a live, attenuated (weakened) vaccine derived from a strain of *M. bovis.* The BCG vaccination is not recommended in the United States due to a combination of factors. These factors include the low risk of infection with *M. tuberculosis*, the variable efficacy of the BCG vaccine against pulmonary TB, the small risk of severe disseminated TB disease in young children in the United States, and the vaccine's interference with the ability to determine TST reactivity. Many highly TB-prevalent countries vaccinate infants with BCG as part of their TB control effort to prevent children from contracting severe disseminated TB or TB meningitis.[8]

The TST or IGRA is not contraindicated for persons who have been vaccinated with BCG. The TST or IGRA results are used to support decisions about the diagnosis of infection with *M. tuberculosis*. TST in persons vaccinated with BCG should be interpreted using the same criteria for those not BCG vaccinated. The booster phenomenon may occur among persons who have had a prior BCG vaccination.

The **booster phenomenon** occurs mainly in previously infected, older adults whose ability to react to tuberculin has waned over time. When these people are skin tested many years after infection with *M. tuberculosis*, they may have an initial negative reaction. However, if they are tested again within a year of the first test, they may have a positive result. This is because the first TST "triggered the memory" of the immune system, boosting its ability to react to the second TST. It may appear that these people were infected between the first and second tests (recent TB infection). The second, positive test reaction is a boosted reaction due to TB infection that occurred a long time ago. These people may still be considered for LTBI treatment if they fit into a high-risk category for progression to TB disease.

While both TST and IGRA testing provide evidence for infection with *M. tuberculosis*, they cannot distinguish active from latent TB. Therefore, the diagnosis of active TB must be excluded before embarking on treatment for LTBI. This is typically done by determining whether symptoms suggestive of TB disease are present, performing a chest radiograph, and, if radiographic signs of active TB disease are seen, then sputum sampling is performed and the patient managed accordingly.[23]

Testing for TB Disease

The key to the diagnosis of TB is a high index of suspicion. Diagnosis is not difficult with a high-risk patient with typical symptoms and a classic chest radiograph. On the other hand, the diagnosis can be easily missed in an elderly patient or a teenager with a focal infiltrate. The initial suspicion of pulmonary TB is often based on an abnormal chest x-ray in a patient with symptoms, although computed tomographic (CT) scanning is more sensitive than plain chest radiography for diagnosis, particularly for smaller lesions located in the apex of the lung.[8]

Radiographic Procedures

Some patterns of chest radiographic abnormalities are considered more "typical" of TB disease.[22] These "classic" patterns include upper lobe infiltrates and cavitary lesions. See **Figure 23-6**. However, virtually any radiographic pattern—from a normal film or a solitary pulmonary nodule to diffuse alveolar infiltrates in a patient with adult respiratory distress syndrome—may be seen.[8] Old, healed TB presents a different radiologic appearance from active TB. Dense pulmonary nodules, with or without visible calcification, may be found in the hilar area or upper lobes. Smaller nodules, with or without fibrotic scars, are often seen in the upper lobes, and upper lobe volume loss often accompanies these scars.[2] In patients with HIV infection, the nature of the radiographic findings depends, to an extent, on the degree of immunocompromise produced by the HIV infection. The more advanced the HIV disease, the more "atypical" the chest x-ray. Cavitation is uncommon in the case of advanced HIV, and lower lung zone or diffuse infiltrates and intrathoracic adenopathy are frequent.[2] See **Figure 23-7**. Thus, while certain chest x-ray findings can be indicative of TB, it remains an insensitive and nonspecific test.[22]

CT may be useful in interpreting questionable findings on plain chest radiography and may be helpful in diagnosing some forms of extrapulmonary TB.



FIGURE 23-6 Chest radiograph, PA view, of a 60-year-old female patient diagnosed with pulmonary TB, showing fibro-exudative infiltrates at the right apex and left middle lung zone.



FIGURE 23-7 Chest radiograph, PA view, of a 43-year-old male with HIV disease and TB disease.

Magnetic resonance imaging is useful in the diagnosis of intracranial TB.[8]

Bacteriologic Examination

A critical component for the diagnosis of TB disease is the bacteriological examination. The TB bacteriological examinations are done in a laboratory and identify *M. tuberculosis*, as well as other mycobacteria. There are five components to the bacteriologic examination: specimen collection, AFB smears, nucleic acid amplification, specimen culturing and identification, and drug susceptibility testing.

For diagnostic purposes, all persons suspected of having TB disease need to have sputum specimens collected for an AFB smear and culture, even those without respiratory symptoms. A minimum of three consecutive sputum specimens is required. Each of these specimens is collected in 8- to 24-hour intervals, with at least one being an early morning specimen.[1] Methods for obtaining a sputum specimen include a spontaneous sputum sample, sputum induction, bronchoscopy, and gastric washing. See **Table 23-6**. Smear examination is a quick procedure, the results of which are usually available within 24 hours of specimen collection. If AFB is found on a sputum smear, it is considered smear positive, and it often indicates TB disease. However, a positive smear does not confirm a diagnosis of TB because some stained mycobacteria are not *M. tuberculosis.* Additionally, smear-negative results do not exclude TB disease, because the AFB may not be seen.

Rapid identification of a microorganism is done via direct detection using **nucleic acid amplification (NAA)**. NAA tests amplify DNA and RNA segments of the mycobacterium. This testing permits the identification of *M. tuberculosis* in as little as several hours, with high specificity and sensitivity approaching that of culture.[1,8] It is recommended that the NAA testing be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities, such as contact investigations.[1,23]

The gold standard for the definitive diagnosis of TB disease is the isolation and identification of *M. tuberculosis* in cultures from a clinical specimen.[1,8,23] Culture examinations should be done on all diagnostic specimens, regardless of AFB smear or NAA results. Liquid and solid mycobacterial cultures are available, but at least the liquid culture needs to be done on all specimens.[23] Because most species of mycobacteria

TABLE 23-6
Methods of Obtaining a Sputum Specimen

Method	Description	Advantage	Disadvantage
Spontaneous sputum sample	• Patient coughs up sputum into a sterile container	• Inexpensive • Easy to do	• Patient may not be able to cough up sputum or cough up saliva instead of sputum • Coaching and supervision by a healthcare provider is necessary
Sputum induction	• Patient inhales aerosolized, hypertonic saline (between 3% and 10%) • Used when spontaneous coughing is nonproductive of sputum	• Easy to do	• Requires special equipment • May cause bronchospasm • Specimens may be watery and may be confused with saliva (label "induced specimen")
Bronchoscopy	• Bronchoscope is passed through the mouth or nose directly into the diseased portion of the lung, and sputum or lung tissue is removed • Used when sputum induction is not productive, or other diseases are being considered	• Direct removal of sputum from the lung. Will not have saliva • No active involvement by patient is required	• Expensive • Invasive • Requires special equipment • Performed in hospital or clinic • Requires anesthesia
Gastric washing	• Tube inserted through the patient's mouth or nose and passed into the stomach to obtain a sample of gastric secretions that contain sputum that has been coughed into the throat and then swallowed • Used to obtain a sputum sample from children who do not produce sputum when they cough	• No active involvement by the patient is required	• Can be uncomfortable for the patient • Must be done as soon as the patient wakes up in the morning • May require a hospital stay

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

grow slowly, 4–8 weeks are required before growth is detected. Positive cultures for *M. tuberculosis* confirm the diagnosis of TB disease; however, in the absence of a positive culture, TB disease may also be diagnosed based on clinical signs and symptoms alone.[1]

Once the growth of *M. tuberculosis* is detected, it can be sub-cultured onto media containing antibiotics.[22] Susceptibility to the first-line anti-TB drugs isoniazid, rifampin, ethambutol, and pyrazinamide is performed to identify **multiple-drug-resistant TB (MDR-TB)**.[1,8] The results of drug susceptibility tests direct clinicians to choose the appropriate drugs for treating each patient. Patients with TB disease who are treated with drugs to which their strain of TB is resistant may not be successfully cured. In fact, their strain of TB may become resistant to additional drugs.[1] A patient is diagnosed with MDR-TB disease if the organisms are resistant to at least isoniazid and rifampin, the two most potent first-line anti-TB drugs.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: TST in persons vaccinated with BCG should be interpreted using different criteria than for those not BCG vaccinated.
2. True or False: The best way to obtain specimens from children who are unable to produce sputum is by gastric washing.
3. True or False: Cultures should be done on all diagnostic specimens, regardless of the other bacteriologic examination results.
4. True or False: Resistance to isoniazid, rifampin, ethambutol, and pyrazinamide is required for a diagnosis of MDR-TB.

Treatment and Management

Currently, 10 drugs have been approved by the FDA for the treatment of TB disease. See **Table 23-7**. Also, the fluoroquinolones (levofloxacin, moxifloxacin, and gatifloxacin), although not approved by the FDA for TB disease, are commonly used to treat TB disease caused by drug-resistant organisms or for patients who are intolerant of some first-line drugs.[1] The goals of TB treatment are to interrupt transmission, make the patient noninfectious, and prevent morbidity and death by curing patient with TB while preventing the emergence of drug resistance.[8]

A few basic treatment regimens are recommended for treating adults with TB disease caused by organisms that are known or presumed to be susceptible to isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB). **Table 23-8** shows two of these regimens. Each treatment regimen consists of an initial 2-month treatment phase followed by a continuation phase of either 4 or 7 months.[1] See **Table 23-9**. The choice of treatment in the initial phase is usually empiric, as susceptibility data may not be available or become available at the end of the initial phase of treatment. The initial drug regimen is based on the knowledge of the likely drug susceptibility. Four drugs, INH, RIF, PZA, and EMB, are used in the initial phase of previously untreated TB because of concern for INH resistance.[1,11] These drugs are well absorbed after oral administration with peak serum levels at 2–4 hours and nearly complete elimination within 24 hours. The drugs are recommended based on their bactericidal activity to rapidly reduce the number of viable organisms and render the patients noninfectious. Sputum AFB smears and cultures need to be obtained at the time of completion of the initial phase of treatment (8 weeks) to identify patients at increased risk of relapse. Once the TB isolate is known to be fully susceptible, ethambutol can be discontinued. After 2 months of therapy, pyrazinamide can be stopped. The duration of therapy depends on the drugs used, the drug susceptibility test results of the isolate, and the patient's response to therapy. Many patients with untreated pulmonary TB disease can be managed with either a 6-month or a 9-month regimen, although the 6-month regimen is used for most patients.[1]

TABLE 23-7
FDA-Approved Anti-TB Drugs

Drug Class	Drug Name	Comments
First-line anti-TB drugs	Isoniazid (INH)	INH, RIF, PZA, and EMB form the core of initial treatment regimen. RPT may be used once weekly with INH in the continuation phase of treatment for HIV-negative patients with noncavitary, drug-susceptible pulmonary TB who have negative sputum smears at the completion of the initial phase of therapy.
	Rifampin (RIF)	
	Pyrazinamide (PZA)	
	Ethambutol (EMB)	
	Rifapentine (RPT)	
Second-line anti-TB drugs	Streptomycin (SM)	Increasing prevalence of resistance to SM in many parts of the world has decreased its overall usefulness. SM was formerly a first-line anti-TB drug. SM is still used in initial treatment.
	Cycloserine	
	Capreomycin	
	Para-aminosalicylic acid	
	Ethionamide	

Courtesy of U.S. Food and Drug Administration.

TABLE 23-8
Recommended Drug Regimens for Adults with Drug-Susceptible Organisms

Initial Phase			Continuation Phase		
Regimen	**Drugs**	**Duration**	**Regimen**	**Drugs**	**Duration**
1	INH, RIF, PZA, EMB	2 months*	1a	INH, RIF	4 months*
			1b	INH, RPT	4 months*
2	INH, RIF, EMB	2 months*	2	INH, RIF	7 months*

*There are several combinations of doses and days/week these medications may be administered. Patients on regimens given less than 7 days/week should receive direct observation therapy. Regimens given less than 3 times/week are not recommended for HIV-infected patients.

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

TABLE 23-9
Phases of TB Disease Treatment

Phase	Purpose	Treatment
Initial phase	• Kills most of the tubercle bacilli • Prevents the emergence of drug resistance • Determines the outcome of the regimen	• The duration is 2 months • Most often includes four drugs (INH, RIF, PZA, and EMB) • Multiple drugs are needed to prevent the development of drug-resistant TB disease

Continuation phase	• Kills remaining tubercle bacilli (after initial phase)
	• If continuation phase is not utilized, surviving bacilli may cause TB disease in the patient later on
		• Duration is either 4 or 7 months
		• 4 months is used for most patients
		• 7 months is recommended only for persons
		  • Who have drug-susceptible cavitary or extensive pulmonary TB disease and whose sputum culture obtained at the end of the initial phase is positive
		  • Whose initial phase of treatment did not include PZA
		  • Who are treated with once-weekly INH and RPT and whose sputum culture at the end of the initial phase is positive

Treatment completion	Defines the number of doses ingested within a specific time frame Duration depends on • Drugs used • Drug susceptibility test results of the isolate • Patient's response to therapy	Most patients with previously untreated pulmonary TB disease can be treated with either • 6-month regimen (preferred) containing INH, RIF, and initially PZA Or • 9-month regimen containing INH and RIF

Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.

The continuation phase of treatment for pulmonary TB is administered for 4 or 7 months and, in most cases, consists of INH and RIF. Treatment completion is defined primarily as the ingestion of the total number of doses prescribed within the specified time frame.[8] The duration of therapy depends on the drugs used, the drug susceptibility test results of the isolate, and the patient's response to therapy.[1,8,11]

Routine follow-up after treatment is not necessary for patients who have had a satisfactory response to a 6- or 9-month regimen with both INH and RIF. Patients whose organisms were fully susceptible to the drugs being used should be instructed to promptly report the development of any symptoms, particularly prolonged cough, fever, or weight loss.

State and local health departments have the primary responsibility for preventing and controlling TB. However, TB control is a complex undertaking and requires the collaborative efforts of a broad range of persons, organizations, and institutions both inside and outside the public health sector. These various persons and organizations have a role in improving the detection of TB cases, one of the most important responsibilities of TB control.[1]

Drug-resistant TB disease can develop in two different ways, known as primary and secondary resistance. Primary resistance occurs in persons who are initially exposed to and infected with resistant organisms. Secondary resistance, or acquired resistance, develops during TB therapy, either because the patient was treated with an inadequate regimen or because the patient did not adhere to the prescribed regimen appropriately or because of other conditions such as drug malabsorption or drug–drug interactions leading to low serum levels.[1]

When initiating treatment for MDR-TB, at least 3–5 previously unused drugs for which there is in vitro susceptibility are used. Levofloxacin, which is a fluoroquinolone, has been shown to be the best suited over a long term and should be included in the regimen.[11] Other drugs that are used, but not FDA approved for TB treatment, include amikacin, capreomycin, kanamycin, levofloxacin, ciprofloxacin, ofloxacin, prothionamide, terizidone, and bedaquiline.[11]

Any patients who have a clinically significant result on TST or a positive IGRA result should receive a course of therapy for latent TB, once active infection and disease are ruled out. Recommendations from the CDC include the use of INH individually for either 9 or 6 months, INH and RPT for 3 months, or RIF for 4 months. The duration of LTBI treatment depends on the patient. However, the preferred regimen is daily treatment with INH for 9 months.[1]

The efficacy of treatment and presence of adverse reactions to therapy require evaluation by clinicians. There are three methods to determine whether a patient is responding to therapy. These methods include clinical evaluation, bacteriological examination, and chest radiograph. During the initial therapy, patient symptoms should gradually improve and eventually go away. If not, the patient may have regimen adherence issues and develop drug resistance.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The initial treatment phase for TB disease consists of 6 months of treatment.
2. True or False: The initial treatment phase typically consists of four medications.
3. True or False: A LTBI requires the same treatment as active TB disease.
4. True or False: Treatment for MDR-TB includes using at least three to five previously unused anti-TB drugs.

Prognosis

TB disease now ranks alongside HIV as a leading cause of death worldwide.[4] There are several factors that directly affect the prognosis of a person with TB disease. These factors include alcohol abuse, age, HIV infection, comorbidities of malignancy, renal disease, and respiratory disorders and malnutrition.[24,25] Comorbidity has a significant effect on the survival of patients with TB disease, and it is a poor prognostic indicator that needs consideration regardless of sputum conversion.[26] Other important predictors of mortality include socioeconomic status, multidrug resistance, and delayed diagnosis.[27–29] The absence of respiratory symptoms, including a chronic cough and dyspnea, are significant factors associated with early mortality within 30 days, making early diagnosis and treatment important features in improving the outcome of TB disease.[30] With early diagnosis and adequate treatment, almost all patients will recover and be cured.[1]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Comorbidities have no influence on the outcome of TB disease treatment.
2. True or False: Given adequate treatment, almost all patients will recover and be cured.

Chapter Summary

TB is an airborne disease caused by *M. tuberculosis*. These bacteria are carried in droplet nuclei or airborne particles that are between 1 and 5 μm in diameter. People can handle the mycobacterium in one of three ways. A person's immune system can clear the infection. A person's immune system can suppress the organism into a dormant state called LTBI. Latent TB is not communicable. However, the microbes may be activated later on in life if the person's immune system becomes weak, causing secondary TB. A person's immune system can be overwhelmed on initial exposure, causing primary TB.

LTBI can be detected by either TST or IGRAs or both. TB disease is diagnosed using physical examination along with chest radiography and bacteriological examination. The organism is tested for susceptibility to at least two of the first-line medications. There are currently five first-line medications and five second-line medicines, approved by the FDA, for the treatment of TB disease. TB disease is always treated with multiple drugs. The number and types of drugs used depend on the organism's susceptibility, the patient's response to therapy, and the phase of treatment.

Key Points

1. TB is an airborne disease caused by the rod-shaped, non-spore-forming, acid-fast, aerobic bacterium *M. tuberculosis*.
2. *M. tuberculosis* is carried in airborne particles called droplet nuclei that are 1–5 μm in diameter.
3. TB most commonly affects the lungs but can also occur in almost any anatomical site.
4. Sputum specimen is obtained from spontaneous samples, sputum induction, bronchoscopy, bronchoalveolar lavage, or gastric washing to culture *M. tuberculosis* for the diagnosis of TB disease.

5. Factors that influence the clinical features of TB disease include host–organism interaction, host endogenous factors, and organism factors.
6. The most common symptom of pulmonary TB disease is a cough.
7. TB disease is one of the top 10 causes of death worldwide and in 2015 caused more deaths than HIV.
8. The host immune system can clear the TB infection, suppress the TB infection into latent TB (which may become active years later), or be overwhelmed by the infection and lead to the onset of active (primary) disease.
9. Risk factors for developing TB disease include recent infection with TB bacteria and those individuals with weakened immune systems.
10. Hemoptysis is the most frequently occurring complication of TB disease.
11. Testing for latent TB includes TST and IGRAs.
12. Diagnostic testing to identify TB disease in patients relies on the use of chest radiography, acid-fast smears of sputum specimen, NAA testing, culturing, and drug susceptibility testing.
13. The goals of TB treatment are to interrupt the transmission of the disease by rendering a patient non-infectious, prevent patient morbidity and mortality, and avoid the development of drug-resistant strains.
14. The three phases of TB therapy include the initial phase (2 months), the continuation phase (4–7 months), and treatment completion (depends on the drug used, organism susceptibility, and patient response).
15. Multiple drug therapy is always used to treat TB disease.
16. Comorbidity has a significant effect on the prognosis for TB disease.

Chapter Questions

1. *Mycobacterium tuberculosis* is _____.
   a. non-spore forming and anaerobic
   b. rod shaped and aerobic
   c. spore forming and aerobic
   d. spherical and anaerobic
2. The purpose of a sputum smear is to identify _____.
   a. leukocytes
   b. gram-negative bacilli
   c. acid-fast bacilli
   d. drug-resistant bacilli
3. The specimen collection process that best suits small children who cannot produce sputum is _____.
   a. transbronchial needle aspiration
   b. sputum induction
   c. bronchoalveolar lavage
   d. gastric washing
4. Endogenous factors that influence the clinical manifestations of tuberculosis disease include all of the following **except** _____.
   a. host immunocompetence
   b. the host country of origin
   c. immunization with bacillus Calmette–Guérin
   d. the presence of comorbidities
5. The most common symptom of tuberculosis (TB) disease is _____.
   a. cough
   b. night sweats
   c. foul-smelling sputum
   d. pleuritic chest pain
6. The most common hematologic findings of TB disease is _____.
   a. polycythemia
   b. hypernatremia
   c. leukocytosis
   d. reduced erythrocyte sedimentation
7. In 2011, the TB disease rate in the United States was the highest for which race/ethnicity?
   a. Non-Hispanic white
   b. African American
   c. Hispanic
   d. Asian
8. Once exposed, how long does it take *M. tuberculosis* to grow, within a host, until they reach 1,000 to 10,000 in number?
   a. 2–12 weeks
   b. 4–16 weeks
   c. 6–18 weeks
   d. 8–20 weeks
9. _____ is(are) the most common site for tuberculosis to affect the human body.
   a. Kidneys
   b. Liver
   c. Lungs
   d. Central nervous system
10. Which of the following statements about TB is true?
    a. Latent tuberculosis infection (LTBI) and TB disease both begin with macrophage production of proteolytic enzymes and cytokines.
    b. Tubercle bacilli are in the body only with tuberculosis disease.
    c. Granulomas are present with immunocompromised individuals exposed to TB.
    d. Individuals with LTBI can spread the tuberculosis TB disease.
11. The primary lesion in active pulmonary TB may spontaneously heal into a _____.
    a. Ghon lesion
    b. tuberculoma
    c. granuloma
    d. Ghon focus

12. Which of the following is true concerning the characteristics of LTBI?
- **a.** Smears and cultures are positive for LTBI.
- **b.** Isolation precautions are necessary for LTBI.
- **c.** The bacilli are alive but inactive with LTBI.
- **d.** There are a large number of bacilli in the body with LTBI.

13. Cavitation in the lungs from bacilli dissemination occurs most often in the _____.
- **a.** basal portion of the lower lobes
- **b.** middle lobes
- **c.** lower portion of the upper lobes
- **d.** apices of the upper lobes

14. A common complication of active pulmonary TB is _____.
- **a.** hemoptysis
- **b.** necrosis
- **c.** lymph obstruction
- **d.** pleural effusion

15. Following exposure to TB, it takes the body's immune system approximately _____ to react to the tuberculin skin test.
- **a.** 48–72 hours
- **b.** 2–8 weeks
- **c.** 8–12 days
- **d.** 4 months

16. The gold standard for the definitive (confirmation) diagnosis of active pulmonary tuberculosis disease is the _____.
- **a.** culture and examination of a clinical specimen
- **b.** tuberculin skin test
- **c.** acid-fast stain
- **d.** nucleic acid amplification tests

17. A patient is diagnosed with multiple-drug-resistant tuberculosis (MDR-TB) when the *M. tuberculosis* is resistant to at least _____.
- **a.** ethambutol and rifampin
- **b.** capreomycin and ethionamide
- **c.** streptomycin and isoniazid
- **d.** isoniazid and rifampin

18. The initial treatment phase for pulmonary TB disease is _____.
- **a.** 2 months
- **b.** 4 months
- **c.** 6 months
- **d.** 8 months

19. The continuation phase of treatment for pulmonary TB disease is _____.
- **a.** 1–3 months
- **b.** 4–7 months
- **c.** 5–6 months
- **d.** 6–12 months

20. The anti-TB drug that has been shown to be the best suited for a long-term MDR-TB regimen is _____.
- **a.** kanamycin
- **b.** prothionamide
- **c.** levofloxacin
- **d.** ciprofloxacin

References

1. *Core Curriculum on Tuberculosis: What the Clinician Should Know.* 6th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2013. https://www.cdc.gov/tb/education/corecurr/pdf/corecurr_all.pdf. Accessed April 25, 2017.
2. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. *Am J Respir Crit Care Med*. 2000; 161(4 Pt 1):1376–1395.
3. Hershkovitz I, Donoghue H, Minnikin D, et al. Detection and molecular characterization of 9000-year-old *M. tuberculosis* from a Neolithic settlement in the Eastern Mediterranean. *PLoS ONE*. 2008;3(10):e3426. doi:10.1371/journal.pone.0003426.
4. World Health Organization. *Global Tuberculosis Report 2016*. World Health Organization; 2016. http://www.who.int/tb/publications/global_report/en. Accessed March 12, 2017.
5. Knechel N. Tuberculosis: pathophysiology, clinical features, and diagnosis. *Crit Care Nurs*. 2009;29(2):34–43. doi:10.4037/ccn2009968.
6. Rieder H, Snider D, Cauthen G. Extrapulmonary tuberculosis in the United States. *Am Rev Respir Dis.* 1990;141(2):347–351. doi:10.1164/ajrccm/141.2.347.
7. Slutsker L, Castro K, Ward J, Dooley S. Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. *Clin Infect Dis*. 1993;16(4):513–518. doi:10.1093/clind/16.4.513.
8. Raviglione M, O'Brien R. Tuberculosis. In: Loscalzo J, ed. *Harrison's Pulmonary and Critical Care Medicine*. 2nd ed. New York, NY: McGraw-Hill Education; 2013:121–146.
9. Lee S, Meintjes G, Kamarulzaman A, Leung C. Management of tuberculosis and latent tuberculosis infection in human immunodeficiency virus-infected persons. *Respirology*. 2013;18(6):912–922. doi:10.1111/resp.12120.
10. CDC | TB | Data and Statistics. 2017. https://www.cdc.gov/tb/statistics. Accessed May 9, 2017.
11. Herchline T. Tuberculosis: practice essentials, background, pathophysiology. Medscape. 2016. http://emedicine.medscape.com/article/230802-overview. Accessed May 17, 2017.
12. Dheda K, Booth H, Huggett J, Johnson M, Zumla A, Rook G. Lung remodeling in pulmonary tuberculosis. *J Infect Dis*. 2005;192(7): 1201–1209. doi:10.1086/444545.
13. Ong C, Elkington P, Friedland J. Tuberculosis, pulmonary cavitation, and matrix metalloproteinases. *Am J Respir Crit Care Med*. 2014;190(1):9–18. doi:10.1164/rccm.201311-2106pp.
14. CDC | TB | Basic TB Facts | TB Risk Factors. 2017. https://www.cdc.gov/tb/topic/basics/risk.htm. Accessed May 24, 2017.
15. Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. *Arch Intern Med*. 1989;149:1666–1668.
16. Conlan AA, Hurwitz SS, Krige L, et al. Massive hemoptysis. Review of 123 cases. *J Thorac Cardiovasc Surg*. 1983;85:120–124.

17. Wilder RJ, Beacham EG, Ravitch MM. Spontaneous pneumothorax complicating cavitary tuberculosis. *J Thorac Cardiovasc Surg*. 1962;43:561–573.
18. Ihm HJ, Hankins JR, Miller JE, McLaughlin JS. Pneumothorax associated with pulmonary tuberculosis. *J Thorac Cardiovasc Surg*. 1972;64:211–219.
19. Aktoğu S, Yorgancioglu A, Cirak K, et al. Clinical spectrum of pulmonary and pleural tuberculosis: a report of 5,480 cases. *Eur Respir J*. 1996;9:2031–2035.
20. Bobrowitz ID, Rodescu D, Marcus H, Abeles H. The destroyed tuberculous lung. *Scand J Respir Dis*. 1974;55:82–88.
21. Palmer PE. Pulmonary tuberculosis—usual and unusual radiographic presentations. *Semin Roentgenol*. 1979;14:204–243.
22. Cudahy P, Shenoi S. Diagnostics for pulmonary tuberculosis. *Postgrad Med J*. 2016;92(1086):187–193. doi:10.1136/postgradmedj-2015-133278.
23. Lewinsohn D, Leonard M, LoBue P, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis*. 2017;64(2):111–115. doi:10.1093/cid/ciw778.
24. Sterling T, Zhao Z, Khan A, et al. Mortality in a large tuberculosis treatment trial: modifiable and non-modifiable risk factors. *Int J Tuberc Lung Dis*. 2006;10(5):542–548.
25. Kim H, Lee C, Shin S, et al. The impact of nutritional deficit on mortality of in-patients with pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2010;14(1):79–85.
26. Oursler K, Moore R, Bishai W, Harrington S, Pope D, Chaisson R. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. *Clin Infect Dis*. 2002;34(6):752–759. doi:10.1086/338784.
27. Kliiman K, Atraja A. Predictors and mortality associated with treatment default in pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2010;14(4):454–463.
28. Liu Y, Lin H, Chen Y, et al. Reduced health provider delay and tuberculosis mortality due to an improved hospital programme. *Int J Tuberc Lung Dis*. 2010;14(1):72–78.
29. Kawai V, Soto G, Gilman R, et al. Tuberculosis mortality, drug resistance, and infectiousness in patients with and without HIV infection in Peru. *Am J Trop Med Hyg*. 2006;75(6):1027–1033. doi:10.4269/ajtmh.2006.75.1027.
30. Feng J, Su W, Chiu Y, et al. Initial presentations predict mortality in pulmonary tuberculosis patients—a prospective observational study. *PLoS One*. 2011;6(9):e23715. doi:10.1371/journal.pone.0023715.

CHAPTER

24

Neonatal and Pediatric Pulmonary Disorders

"You treat a disease, you win, you lose.

You treat a person, I guarantee you, you'll win, no matter what the outcome."

—Patch Adams

OUTLINE

OBJECTIVES

1. Describe the abnormalities underlying neonatal and pediatric pulmonary disorders.
2. Review the development, etiology, and pathophysiology of the various pulmonary disorders in newborns, infants, and children.
3. Discuss the clinical manifestations associated with each type of neonatal and pediatric pulmonary disorder.
4. Explain diagnostic testing used in analyzing each type of pulmonary disorder seen in newborns, infants, and children.
5. Recognize and manage various neonatal and pediatric pulmonary disorders.
6. Identify clinical treatment options available for the various pulmonary disorders in newborns, infants, and children.
7. Define the complications and prognosis primarily associated with the various neonatal and pediatric pulmonary disorders.

KEY TERMS

Apgar scores
Apnea of prematurity (AOP)
Bronchiolitis
Bronchopulmonary dysplasia (BPD)
Central apnea
Congenital diaphragmatic hernia (CDH)
Congenital heart defect (CHD)
Croup
Epiglottitis
Extracorporeal membrane oxygenation (ECMO)
Fetal heart rate (FHR)
Fetal hypoxic stress
Fetal ultrasonography
Foreign body aspiration
Foreign body obstruction (FBO)
Golden minute
Heliox
Infant respiratory distress syndrome (IRDS)
Meconium
Meconium aspiration syndrome (MAS)
Mixed apnea
Persistent pulmonary hypertension of the newborn (PPHN)
Prematurity
Respiratory syncytial virus (RSV)
Scalp blood sampling
Surfactant
Surfactant replacement therapy
Transient tachypnea of the newborn (TTN)

Introduction

Cardiopulmonary diseases represent the most common cause of death in infants and children worldwide. Proper knowledge of the etiology and pathophysiology of various cardiopulmonary disorders in the neonate and pediatric patient is fundamental to effective patient care. Neonatal and pediatric airways are different than those of adults, and these patients are prone to rapid status changes. Recognizing, managing, and treating these disorders require an understanding of how a diagnosis presents, the predisposed condition, and treatment options available. This essential knowledge base can improve patient care and allow the child to thrive, especially in the medical field.

This chapter will focus on the etiologic and pathophysiologic characteristics of the most common neonatal and pediatric cardiopulmonary disorders of the respiratory system. It will focus on the clinician understanding the complexity of the diseases and engaging in potential management strategies to improve outcomes.

Neonatal

There are several differences between the respiratory system of the neonate and that of a pediatric patient. The following sections will focus on the neonatal aspects and will cover everything from what to expect in the delivery room to the numerous afflictions that can affect newborns.

Delivery Room Care

The birth of a baby in the delivery room is one of the most extraordinary moments in healthcare. In 2015, the number of babies born in the United States was just shy of 4 million.[1] Most of these newborns will need routine clinical attention; however, roughly 1% may require extensive postdelivery medical care. The outcomes of these challenging newborns can be enhanced through proper patient assessment and efficient neonatal resuscitation. Prior to delivery, it is important to check that all necessary equipment (e.g., intubation tray) is present and functioning properly. The delivery room setup is imperative. The room should be warm, the radiant warmer turned on, and warm towels available. Lastly, the maternal case notes should be viewed for any relevant information, specifically searching for risk factors associated with pulmonary disorders. Based on findings, clinicians should anticipate the need for potential resuscitation and gather the applicable personnel and equipment to ensure the patient care team responds in a suitable and successful manner. Various methods, including **fetal heart rate (FHR)** monitoring and **scalp blood sampling**, can be used to evaluate fetal health during labor and delivery.[2] FHR monitoring can help to detect irregularities in normal heart patterns.[2] Trends in FHR are used to estimate fetal tolerance, help prevent unnecessary treatments, and guide the patient care team in making clinical decisions.[2] Fetal scalp blood sampling is a monitoring practice that uses pH to verify whether fetal oxygenation is sufficient.[3,4] A low fetal scalp pH is considered abnormal and may mean that the baby is not tolerating labor very well.[3,4] Following delivery, the newborn should be assessed right away. If a neonate passes the initial assessment then the baby should remain with the mother. However, if a neonate is failing to thrive upon examination then a neonatal resuscitative algorithm should be initiated (**Figure 24-1**). Clinicians have approximately 60 seconds, the **golden minute**, to complete the preliminary evaluation and initiate the resuscitative interventions.[5] A brief physical exam, including Apgar scoring, vital signs, and other procedures, should be performed. It is the responsibility of the clinicians attending the delivery to ensure that the infant is provided proper care, immediately examined for problems, and given any resuscitation that may be needed. The first few minutes following delivery may determine the quality of life of a patient.[6] If neonatal breathing is not adequate, the ABCs (i.e., airway, breathing, circulation) of resuscitation should be followed. A patent airway is obtained through repositioning the infant's head and carefully suctioning to clear secretions.[7] If breathing efforts are shallow, gentle stimulation and supplemental oxygen therapy may be required. Clinicians must thoroughly understand the adverse effects of excessive and insufficient oxygen delivery to the newborn. Failure to establish spontaneous breathing indicates the need for positive pressure ventilation (via face mask) or even endotracheal intubation and assisted ventilation.[7] Clinicians should ventilate at an appropriate respiratory rate, observe chest movement, and listen for heart and breath sounds. Assessment of circulation is done through heart rate monitoring, palpation, and skin color check of the infant. Chest compressions, medications, and volume expanders may be started if the heart rate drops and remains below 60 beats/minute.[7] Newborns needing resuscitative measures in the delivery room should be transported to the neonatal intensive care unit (NICU) for close monitoring as well as for additional management and treatment.

Apnea of Prematurity

In recent years, the understanding of the anatomy and physiology of neonatal breathing has increased. In utero, breathing is intermittent but becomes continuous following birth.[8,9] After birth, **apnea of prematurity (AOP)** or the cessation of breathing efforts is a key concern of ICU nursery clinicians. This neonatal condition is the most common form of newborn apnea and causes significant increases in morbidity and mortality rates.[9] Clinicians must be able to properly differentiate the various clinical definitions



FIGURE 24-1 American Heart Association neonatal resuscitative algorithm. ETT, endotracheal tube; HR, heart rate; PPV, positive pressure ventilation.

Reproduced with permission from Wyckoff MH, et al. (2015). Part 13: Neonatal resuscitation: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation*, 132(18 suppl 2), S543–S560.

involved in this disorder. Apnea, in general, is defined as the cessation of breathing.[8,9] Remember that apnea can be classified into three subcategories: central, obstructive, or mixed apnea. **Central apnea** is a complete interruption in the effort to breathe.[8,10] Obstructive apnea is absent respiratory airflow in the presence of continued efforts.[8,10] **Mixed apnea** contains elements of both central and obstructive apnea symptoms.[8,10] AOP is a result of immature respiratory control developing into a disorder most commonly defined as the cessation

of respiratory airflow for more than 20 seconds or the cessation of respiratory airflow for less than 20 seconds if complemented by bradycardia or oxygen (O_2) desaturations[8] in neonates with less than 37 weeks' maturation.

Clinical Signs and Symptoms

It is the responsibility of the bedside clinician to identify the problem through a physical examination and thorough patient assessment. Clinical symptoms associated with apnea, including bradycardia and oxygen desaturations, must be documented.[11] Physical observation of the neonate's breathing patterns, sleeping positions, and lying postures should be noted. Further assessment of infant apnea should include identification of airway deformities (e.g., choanal atresia, jaw anomalies, or neck masses) as well as any distant organ disorders that potentially affect breathing (e.g., brain hemorrhages, seizures, or congenital heart disease).[11] Other clinical symptoms include choking, snoring, and mouth breathing; however, in some newborn cases, no additional respiratory distress signs may present.[11] Added fluctuations in skin color, breathing pattern, or muscle tone may result.[11] Monitoring of the infant's cardiac, neurologic, and respiratory statuses may reveal supplemental clinically significant findings.

Etiology

Over the years, several aspects of causation have been proposed because the etiology of AOP is not fully understood. As it stands, when all other causes of apnea have been eliminated, a premature infant may be considered to have AOP.[12,13] This clinical phenomenon is associated with unorganized, yet interconnected brain stem neurons and their responses to stimuli (e.g., respiratory system).[12,13] This immature respiratory control system is represented in abnormal breathing patterns seen during apnea episodes. There are two types of apnea related to this disorder at birth. An increased respiratory rate and depth indicates primary apnea.[12,13] During this primary stage, infants usually respond to stimulation measures.[12,13] When asphyxia is allowed to continue, the infant may suffer from a period of gasping respirations as well as a falling heart rate and blood pressure.[12,13] This secondary stage requires resuscitation. In some cases, it can be difficult to distinguish primary from secondary apnea, so many clinicians, therefore, assume any apnea at birth requires immediate artificial respiration.[12,13]

Epidemiology

AOP is the most common problem in premature infants. During their hospital stay, nearly 70% of infants born at 34 weeks gestational age or younger have clinically significant apnea episodes[14] (**Figure 24-2**). Simply put, the more premature the infant, the higher the risk of AOP. Research findings have shown that AOP may not resolve at full term and the condition may persist for some time following discharge.[15] Family members and other caregivers must be well trained in in-home monitoring, infant care, and cardiopulmonary resuscitation.



FIGURE 24-2 Apnea of prematurity. GA, gestational age.
Reproduced with permission from American Academy of Pediatrics.

Pathology/Pathophysiology

Premature infants with AOP are considered susceptible to impaired chemoreceptors, immature lung and airway receptors, as well as an inhibited central nervous system (CNS).[16,17] This depression of the central respiratory drive output mechanism to the muscles is depicted as the key element in the pathogenesis of AOP.[16,17] Sleep and sleep state are major contributing factors in apnea as well. When compared with full-term infants, preterm infants have more frequent REM sleep episodes, resulting in larger sleep cycles spent in respiratory depression.[18]

Risk Factors

There are numerous causes of apnea in premature infants. A mixture of inappropriate neural signaling and airway obstruction typically triggers apneic episodes in these patients; however, underlying pathologies, including sepsis, necrotizing enterocolitis (NEC), asphyxia, respiratory distress, infection, gastroesophageal reflux disease (GERD), and cardiovascular disorders, may also be causes of neonatal apnea.[19] AOP is specifically a developmental disorder. Risk factors significantly associated with AOP include a fetal birth weight of fewer than 1,500 g, hypotension, GERD, and the immediate need for postdelivery positive pressure ventilation.[19]

Complications

Regardless of past medical history, premature infants are at an increased risk for apnea episodes following

administration of anesthetics or sedatives.[12] As a result of this increased risk, allowing the infant's respiratory control system to mature before performing elective surgery is highly recommended.

Diagnostic Testing

Research has shown that highly trained clinicians miss nearly 50% of all AOP cases.[20] Due to this high prevalence, preterm infants with a 35-week or less gestational age should be monitored for apnea.[20] Clinicians must familiarize themselves with the benefits and drawbacks of sophisticated monitoring tools used to improve bedside detection of AOP. Neonates with frequent apnea episodes following birth should receive routine diagnostic tests, including a chest radiograph (CXR), electrocardiogram (ECG) monitoring, arterial blood gas (ABG) analysis, and complete blood count (CBC).[8] Cultures of blood, urine, and spinal fluid should be performed if a serious infection is suspected.[20] Cardiorespiratory monitors are essential for not only identifying AOP but furthermore for continuous monitoring of the infant's blood pressure and heart rate.[20] Pulse oximetry may be useful in revealing hypoxemia, but clinicians must be aware of the issues (e.g., potential recording delay) surrounding these diagnostic tools. Impedance pneumography is another commonly used instrument that monitors a patient's apneic events.[20] Through the use of electrodes, this device tracks respiratory volume and breathing rate. Impedance pneumography in combination with a nasal thermistor may be clinically used to distinguish types of apnea.[8,21] A nasal thermistor is a conventional respiratory airflow-recording device that measures temperature as an alternate of flow.[8,21] Obtaining a polysomnographic recording is the recommended diagnostic standard because it provides sufficient information on chest wall movement measurements, airflow changes, oxygen saturation, and heart rate trends.[8,21] The severity and duration of these apneic events through nasal airflow, thoracic impedance, oxygen saturation, and heart rate monitoring must be accurately noted. Patient care teams commonly rely heavily on documentation to make bedside management decisions. Through the use of standardized approaches, precise diagnosis of AOP can be improved.

Treatment and Management

Treatment goals should focus on addressing the underlying cause of the apnea, providing appropriate patient management, and preventing further occurrences. This begins with monitoring, identifying, and treating the primary disease process—ineffective breathing potentially resulting in apnea. Defining escalating treatment options can be an effective management strategy. Depending on the severity and frequency of AOP, common treatments include stimulation, assisted ventilation, or methylxanthine therapy.[22] Using high-flow nasal cannula (HFNC) oxygen therapy may alleviate airway occlusions enough to reduce obstructive apnea events.[23] Further research is still needed to determine the usefulness of this therapy method. Sometimes it is as simple as fetal tactile stimulation (i.e., rubbing the back); however, if the problem persists, more advanced therapies may be required. Bag-mask ventilation may be initiated when bradycardic or hypoxemic episodes require assistance. Assisted ventilation (e.g., nasal continuous positive airway pressure [CPAP] or invasive ventilation) to manage severe AOP can be life saving. To prevent hyperoxia and the associated risk of retinopathy of prematurity (ROP), Fio_2 levels should be limited to maintaining adequate fetal oxygenation statuses.[23] Following prolonged apneic episodes, a low dose of a methylxanthine compound, including caffeine, theophylline, or aminophylline, may be administered to promote respiratory stimulation.[22] Recently, safety concern questions have been raised regarding the use of methylxanthines in the treatment of AOP. Early reports indicate a potential risk for decreased cerebral blood flow in patients following medication administration.[22] Clinical trials related to the safety of methylxanthines in preterm infants with AOP are ongoing.[12,22]

Prognosis

Prognosis is excellent. In infants born prematurely, apnea episodes gradually decrease following the first few months of postpartum life.[23] In some cases, however, apnea events may continue until 44 weeks after conception.[23] If apneic episodes persist, the neonate should be evaluated for secondary causes of apnea, including neurologic issues or GERD.

Meconium Aspiration

Meconium aspiration or **meconium aspiration syndrome (MAS)** is the passage of stained bowel discharge before, during, or following birth.[24] **Meconium** is a dark-green substance composed mainly of water, amniotic fluid, mucus, and other intestinal debris.[24] Meconium itself is sterile and harmless; however, if inhaled into the lungs, it can cause serious distress to the newborn. Complications including airway obstruction or lung inflammation, leading to infections, can be life threatening.[24] Because meconium is rarely found in the amniotic fluid in infants less than 34 weeks' gestational age, MAS primarily affects the term or near-term infants and is associated with increased morbidity and mortality.[25] The longer a pregnancy continues, the higher the likelihood of the passage of meconium.

Clinical Signs and Symptoms

Patients with MAS are usually term or post-term infants delivered through meconium staining and who have already faced substantial **fetal hypoxic stress**.

Past medical history most likely includes prolonged labor, breech delivery, as well as inconsistent fetal heart tracings.[26,27] Following delivery, severe respiratory distress may be present. Thicker meconium usually correlates with more severe respiratory symptoms. Signs including cyanosis, end-expiratory grunting, nasal flaring, intercostal retractions, and tachypnea may also be observed.[26,27] Contingent on the degree of hypoxia, some infants may exhibit low **Apgar scores**. Physical examination symptoms may include a mature infant with yellow-green staining of skin (e.g., nails and umbilical cord), and green urine, and the umbilical cord may have limited Wharton jelly (i.e., gelatinous substance).[26,27] In some cases, auscultation of the chest reveals rhonchi, diminished aeration, as well as a barrel chest (i.e., increased anteroposterior [AP] diameter) due to the manifestation of air trapping.[26,27]

Etiology

Factors such as chronic maternal hypertension, placental insufficiency (i.e., inadequate supply of nutrients), preeclampsia (i.e., gestational hypertension), oligohydramnios (i.e., deficiency of amniotic fluid), infections, and ongoing maternal drug use can all potentially promote the passage of meconium in utero.[25]

Epidemiology

In the United States, meconium staining occurs in nearly 8–25% of all births, significantly increasing in pregnancies continuing past 42 weeks.[25,28] Approximately 10% of infants delivered through meconium staining develop MAS.[25,28] Additionally, 30% of MAS-diagnosed infants will require intubation and mechanical ventilation.[25,28] Changes in obstetric/neonatal approaches appear to be decreasing these numbers.

Pathology/Pathophysiology

Meconium passage results from fetal hypoxic stress in utero. Theoretically, as childbirth approaches, the gastrointestinal (GI) tract matures and vagal stimulation causes relaxed rectal sphincter tone, leading to the passage of meconium into the amniotic fluid.[29] The possibility of aspiration always exists, but odds increase with fetal hypoxic stress because of potential gasping breaths and greater respiratory efforts in utero.[29] The pathophysiologic effects of meconium staining include increased risk of infection and perinatal aspiration, resulting in four major pulmonary consequences: airway obstruction, surfactant dysfunction, chemical pneumonitis, and pulmonary hypertension.[25,30] The amount and consistency of meconium present may lead to significant degrees of airway obstruction. Large amounts of thick meconium may cause complete airway obstruction, resulting in atelectasis and subsequent alveolar collapse.[29] A smaller amount of meconium typically causes partial airway obstruction, resulting in alveolar hyperdistension, commonly called the ball-valve effect[30] (**Figure 24-3**). The term *ball-valve effect* describes the happening of gas being trapped in the lung and potentially rupturing into the pleura, mediastinum, or pericardium.[30] It has been suggested that meconium deactivates surfactant and may also compete with surfactant components, thereby inhibiting surfactant synthesis.[30] Research has shown that this surfactant hindrance may lead to diffuse atelectasis and decreased pulmonary compliance.[30] Following meconium aspiration, inflammation of the airways and a release of cytokines also occur, initiating a diffuse chemical pneumonitis.[29] To drastically complicate the clinical picture further, fetal hypoxic stress is suggested to contribute to pulmonary vascular restructuring, resulting in infants quickly developing pulmonary hypertension.[29] As one can see, the presence of meconium in the airways has detrimental effects on the newborn.



FIGURE 24-3 Ball-valve effect obstruction by meconium aspiration into the airway.
Modified from Koff PB, Eitzman DV, Neu J. Neonatal and Pediatric Care. ed 2. St Louis, MO: Mosby; 1993.

Risk Factors

Risk factors that increase the likelihood of the development of meconium staining include thicker meconium consistency, inconsistent fetal heart tracings, fetal acidosis, meconium below the cords, cesarean delivery, intubation requirements at birth, and low Apgar scores.[25,28] Additionally, research has shown that African American and Pacific Islander infants are at a higher risk for an MAS diagnosis.[25,28]

Complications

MAS complications are extensive and depend on the severity of the disorder as well as the duration and level of treatment required. Assisted ventilation always brings with it a risk of barotrauma or air leak syndrome, especially in situations where the ball-valve effect creates air trapping.[31] Increased intracranial pressure is another serious complication in MAS. Compromised infants with unstable vasculature must be regularly assessed for this high incidence complication. As a safety precaution, clinicians should always be closely monitoring high-risk infants for sudden deterioration.

Diagnostic Testing

The diagnosis of MAS requires the presence of meconium staining, respiratory distress, as well as radiographic abnormalities. CXR is essential for determining the extent of the disease and any further associated complications. Chest images typically show widespread involvement of acute atelectasis as well as air trapping and hyperexpansion.[28,32] Patchy opacities and pleural effusions may be present, especially when an infection develops[28,32] (**Figure 24-4**). Air leaks, including pneumothorax, pneumomediastinum, and pulmonary interstitial emphysema (PIE) are common.[28,32]



FIGURE 24-4 CXR of MAS.

Reproduced from Parenchymal lung disease. Auckland District Health Board. http://www.adhb.govt.nz/newborn/TeachingResources/Radiology/LungParenchyma.htm.

An echocardiogram is necessary to evaluate cardiac function in the setting of pulmonary hypertension or shunting.[28,32] ABG assessment of the infant's acid–base status is crucial in determining V/Q mismatch and hypoxic stress severity. A combination of metabolic acidosis from hypoxic stress and respiratory acidosis from pulmonary hypertension usually develops, resulting in respiratory failure and severe hypoxemia.[28,32] ABG measurements, as well as continuous pulse oximetry, are essential for proper patient management. Obtaining serum electrolyte concentrations and a CBC can help to ensure adequate selection of treatment modalities.[28,32]

Treatment and Management

Traditionally, national guidelines are provided regarding complicated delivery indications, MAS prevention tactics, and management strategies immediately following delivery. Prevention of MAS is vital: clinicians need to closely monitor neonates in an attempt to better detect distress. Amnioinfusion, an intrapartum intervention, is believed to dilute meconium and thereby minimize aspiration severity in infants identified as at risk for MAS.[33] However, a large multicenter study recently reported outcomes that the routine use of amnioinfusion did not reduce the risk of MAS in infants born with meconium staining.[33] Further research is still needed to resolve the uncertainties of this intervention. Routine intrapartum suctioning for infants born with meconium staining is no longer advised following current research recommendations.[34] Additionally, no clinical studies warrant suctioning on the basis of meconium consistency alone.[34] National evidence-based guidelines are continuously under review regarding the management of meconium-exposed infants. In regard to endotracheal suctioning in the delivery room, the most recent guidelines state that for a vigorous infant (i.e., normal respiratory effort and muscle tone), a bulb syringe may be used to clear secretions while receiving initial newborn care. For non-vigorous infants (i.e., depressed respiratory effort or muscle tone), place the infant on the radiant warmer, clear the secretions with a bulb syringe, and proceed with newborn resuscitation. Mechanical ventilation is required by nearly 30% of infants diagnosed with MAS.[35,36] Optimal ventilator parameters, including minimal mean airway pressure, short inspiratory times, and maintained oxygen saturations, are essential to provide acceptable oxygenation and ventilation.[35,36] Minimal stimulation handling, sedation, and ABG monitoring may be necessary for clinical improvement.[35,36] While conventional ventilation is typically used as an initial management technique, high-frequency ventilation (HFV) is an alternative effective therapy. HFV aimed at lessening barotrauma, increasing secretion mobilization, and maintaining respiratory alkalosis may be advantageous.[35,36] **Surfactant**

therapy can be considered a treatment therapy of MAS because it is used as a detergent to remove meconium.[37,38] Surfactant administration may reduce the severity of the disease, reduce the need for ECMO (i.e., extracorporeal membrane oxygenation) utilization, and decrease the length of hospital stay.[37,38] If all other therapy options have been attempted, ECMO may be used. Note that although ECMO is effective in treating MAS, it is also correlated with high occurrences of poor neurologic outcomes.[38] Clinical intervention selections should depend on the severity of the aspiration and the degree of hypoxia that presents.

Prognosis

The prognosis of infants with MAS has drastically improved over the past several years. In the United States, a retrospective analysis study revealed the overall mortality rate for MAS to be at a little over 1%.[29,39] Some infants experience an increased prevalence of respiratory infections as a result of lung recovery.[29,39] Survivors of MAS may develop chronic lung disease, including BPD, from clinical interventions.[29,39] Chronic hypoxia, owing to meconium staining, may cause long-term neurologic deficits, including CNS damage, seizures, mental retardation, and cerebral palsy.[29,39] New delivery room care techniques, as well as careful management of resuscitative measures, have allowed for a better quality of life outcomes.

Congenital Heart Defects

A **congenital heart defect (CHD)** is a health abnormality, present at birth, with the structure of the heart. Some defects can cause an array of difficulties in the care and management of the patient, while others are simple and do not need treatment. Many different structural defects can ultimately lead to the diagnosis of congenital heart disease. Heart defects can be divided into classes, acyanotic and cyanotic defects.[40,41] If a defect does not influence oxygen in the body, it is called acyanotic, whereas a defect that reduces the amount of oxygen in the body is called cyanotic. More specifically, acyanotic heart defects refer to heart problems that do not normally interfere with the amount of oxygen or blood that reaches the body's tissues.[40,41] Acyanotic heart defects do not usually cause cyanosis. Acyanotic heart defects include septal wall defects, aortic and pulmonic stenosis, double aortic arch, and coarctation of the aorta[40,42,43] (**Table 24-1** and **Figures 24-5** to **24-11**). Cyanotic heart defects refer to heart issues that allow for the mixture of oxygen-rich blood and oxygen-poor blood.[40,41] Cyanotic heart defects result in the development of cyanosis and include

TABLE 24-1
Acyanotic CHDs[40,42,43]

Type	Signs/Symptoms	Epidemiology	Pathophysiology	Risk Factors
Atrial septal defects[51,52]	• Shortness of breath • Fatigue • Heart palpitations/murmur • Swelling	• 10% of all CHDs • 2:1 female-to-male ratio	• Freshly oxygenated blood from left atrium mixes with deoxygenated blood of right atrium and is pumped to the lungs • Increases blood volume to the lungs • Overworks right side of the heart, enlarging and weakening	• Rubella infection • Drug/alcohol use • Maternal diabetes • Maternal obesity
Ventricular septal defects[53–55]	• Failure to thrive • Tachypnea • Fatigue	• 2–7% of live births • More common in females	• Septum between the ventricles fails to form • Oxygenated blood mixes with deoxygenated blood • Heart must work harder to provide oxygen to body tissues	• Genetics • Hereditary
Atrioventricular septal defects[56,57]	• Tachypnea • Wheezing • Tachycardia • Cyanosis • Lack of appetite; poor weight gain	• 3–5% prevalence • No variance in sex or race	• Oxygen-rich and oxygen-poor blood mix through the hole in the ventricles • Only one large valve between upper and lower heart chambers • Blood leaks into ventricles • Overworks and enlarges the heart	• Down syndrome • Smoking/drinking during pregnancy • Poorly controlled maternal diabetes • Rubella infection

Type	Signs/Symptoms	Epidemiology	Pathophysiology	Risk Factors
Aortic stenosis[58–60]	• Chest pain • Dyspnea • Syncope	• 6% of CHDs • Severe aortic stenosis rare • Obstruction at aortic valve most common	• Aortic valve cusps defective/too thick/ improper separation • Outflow obstruction	• Rheumatic fever • Older maternal age • Infections
Pulmonic stenosis[60,61]	• Heart murmur • Fatigue • Shortness of breath • Chest pain • Fainting	• 10% of CHDs • Female predominance	• Pulmonary valve cusps defective/too thick/ improper separation • Blood flow restricted	• Carcinoid syndrome • Rheumatic fever • Noonan syndrome • Pulmonary valve replacement
Double aortic arch[62,63]	• Stridor • Apneic episodes • Difficulty swallowing	• Unknown	• Multiple arches on aorta present at birth • Arches compress trachea and esophagus	• Genetics
Coarctation of the aorta[64,65]	• Cyanosis • Heavy sweating • Difficulty breathing • Difficulty eating	• 4–6% of CHDs • Male predominance	• Narrowing of the aorta • Heart must pump harder to force blood through narrowed part	• Bicuspid aortic valve • Patent ductus arteriosus • Septal wall defects • Valve stenosis • Valve regurgitation

Type	Complications	Diagnosis	Treatment	Prognosis
Atrial septal defects	• Pulmonary hypertension • Right-sided heart failure • Heart arrhythmias • Stroke	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Medical monitoring • Beta-blockers and anticoagulants • Open-heart surgery • Cardiac catheterization	• Excellent prognosis • Repair of atrial septal defect (ASD) improves prognosis
Ventricular septal defects	• Heart failure • Pulmonary hypertension Endocarditis	• Echocardiogram • CXR • ECG • Cardiac catheterization • Pulse oximetry	• Surgical repair • Cardiac catheterization • Lasix and beta-blockers	• Medical therapy shows decrease in shunting
Atrioventricular septal defects	• Heart enlargement • Pulmonary hypertension • Recurrent respiratory tract infections • Heart failure	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Surgery	• Develops more rapidly than other CHDs • Prognosis poor without surgery
Aortic stenosis	• Heart failure • Blood clots • Arrhythmias • Infections	• Echocardiogram • ECG • CXR • Cardiac catheterization	• Aortic valve repair • Balloon valvuloplasty • Aortic valve replacement	• Active, healthy following surgery
Pulmonic stenosis	• Infection • Right ventricular hypertrophy • Heart failure • Arrhythmias	• Echocardiogram • ECG • Cardiac catheterization	• Balloon valvuloplasty • Open-heart surgery	• Treatment highly successful
Double aortic arch	• Upper airway obstruction • Swallowing difficulties • Tracheal or esophageal damage	• Barium esophagography • Echocardiogram • ECG • CXR • Cardiac catheterization	• Supportive care • Surgical repair • Cardiac catheterization	• Excellent long-term prognosis • Persistent respiratory symptoms
Coarctation of the aorta	• Aortic stenosis • Hypertension • Aneurysm • Heart failure • Premature coronary artery disease	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Surgery • Balloon angioplasty and stenting • Medications	• Guarded prognosis • Follow-up monitoring/ care imperative



FIGURE 24-5 Atrial septal defect. AO, aorta; LA, left atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrium; RV, right ventricle.



FIGURE 24-6 Ventricular septal defect (VSD).



FIGURE 24-7 Atrioventricular septal defect.



FIGURE 24-8 Aortic stenosis.



FIGURE 24-9 Pulmonic stenosis.

total anomalous pulmonary venous return, truncus arteriosus, transposition of the great arteries, hypoplastic left heart syndrome, Ebstein anomaly, pulmonary atresia and tetralogy of Fallot[40,42,43] (Table 24-2 and Figures 24-12 to 24-18). A comprehension of fetal development is essential for properly detecting these abnormalities, understanding their pathophysiology, and planning treatment options.



FIGURE 24-10 Double aortic arch.



FIGURE 24-11 Coarctation of the aorta.

TABLE 24-2
Cyanotic CHDs[40,42,43]

Type	Signs/Symptoms	Epidemiology	Pathophysiology	Risk Factors
Total anomalous pulmonary venous return[66]	• Heart murmur • Cyanosis • Tachypnea	• 1% of CHDs • Male predominance (3:1)	• Pulmonary veins attach to the heart incorrectly • Oxygen-rich blood returns to the right atrium, mixing with oxygen-poor blood • Less oxygen-filled blood flows to the body, causing cyanosis	• Hereditary • Genetics
Truncus arteriosus[67,68]	• Cyanosis • Poor feeding/growth • Sleepiness • Dyspnea • Tachypnea	• 1–2% of CHDs • No variance in sex or race	• One large blood vessel leads out of the heart • Creates severe circulatory problems	• Viral illness during pregnancy • Poorly controlled diabetes • Chromosomal disorders • Smoking during pregnancy
Transposition of the great arteries[69,70]	• Cyanosis • Shortness of breath • Lack of appetite • Poor weight gain	• 5–7% of CHDs • 70% male predominance	• Position of the pulmonary artery and aorta are switched • Circulation of oxygen-poor blood through body; cyanosis	• Rubella • Poor maternal nutrition • Alcohol use during pregnancy • Down syndrome • Older maternal age
Hypoplastic left heart syndrome[71,72]	• Cyanosis • Tachypnea • Cold extremities • Fatigue • Poor feeding	• >1.5% of all CHDs • 70% male predominance	• Left ventricle is too small/may not exist • Left-sided heart valves do not work properly • Aorta smaller than normal	• Family history • Genetics

(Continues)

TABLE 24-2
Cyanotic CHDs[40,42,43] (*Continued*)

Type	Signs/Symptoms	Epidemiology	Pathophysiology	Risk Factors
Ebstein anomaly[73]	• Shortness of breath • Fatigue • Arrhythmias • Cyanosis	• 0.5% of CHDs • Misdiagnosis rate high	• Tricuspid valve sits lower than normal in right ventricle • Portion of right ventricle becomes atrialized, causing a larger-than-usual right atrium • Right ventricle does not work properly	• Maternal exposure to lithium • Family history • Genetics
Pulmonary atresia[74]	• Cyanosis • Tachypnea • Fatigue • Feeding problems • Clammy skin	• ~3% of CHDs • Male predominance	• Pulmonary valve does not form correctly • Solid sheet of tissue forms • Blood cannot travel normal route to lungs	• Rubella • Family history • Alcohol use/smoking during pregnancy • Down syndrome
Tetralogy of Fallot[75–77]	• Cyanosis • Dyspnea • Fainting • Clubbing • Poor weight gain • Fatigue • Heart murmur	• 10% of CHDs • More common in males	• Combination of four defects • Oxygen-poor blood flows to rest of the body; cyanosis	• Rubella • Alcoholism • Family history • Genetics • Poor maternal nutrition • Older maternal age

Type	Complications	Diagnosis	Treatment	Prognosis
Total anomalous pulmonary venous return	• Enlarged heart • Pulmonary hypertension • Respiratory failure • Heart failure • Enlarged liver	• Echocardiogram • ECG • CXR	• Surgery	• Following surgery, grow and develop normally
Truncus arteriosus	• Respiratory problems • Pulmonary hypertension • Cardiomegaly • Heart failure	• Echocardiogram • CXR	• Diuretics and inotropic agents • Surgical procedures • Cardiac catheterization	• Increasing survival rate
Transposition of the great arteries	• Hypoxia • Heart failure • Lung damage	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Vasodilators • Atrial septostomy • Surgery	• Prognosis depends on therapy used
Hypoplastic left heart syndrome	• Arrhythmias • Edema • Developmental problems • Pulmonary embolism/ stroke	• Echocardiogram	• Vasodilators • Fluid support • Atrial septostomy • Surgery • Heart transplant	• 60% 1-year survival
Ebstein anomaly	• Heart failure • Arrhythmias • Cardiac arrest	• Echocardiogram • ECG • CXR • Cardiac magnetic resonance imaging (MRI) • Cardiac catheterization	• Regular monitoring • Beta-blockers and diuretics • Surgery • Radiofrequency catheter ablation • Heart transplant	• Depends on severity of anomaly
Pulmonary atresia	• Infectious endocarditis • Death if untreated	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Vasodilators • Stent placement • Radiofrequency catheter ablation • Heart surgery	• Critical CHD • Varies per child • Worst prognosis of CHDs
Tetralogy of Fallot	• Infectious endocarditis • Disability • Death	• Echocardiogram • CXR • ECG • Cardiac catheterization	• Temporary surgery • Intracardiac repair	• Critical CHD • 50% 1-year survival • Worst prognosis of CHDs



FIGURE 24-12 Total anomalous pulmonary venous return. IVC, inferior vena cava; SVC, superior vena cava.



FIGURE 24-13 Truncus arteriosus.



FIGURE 24-14 Transposition of the great arteries.



FIGURE 24-15 Hypoplastic left heart syndrome.



FIGURE 24-16 Ebstein anomaly.



FIGURE 24-17 Pulmonary atresia.



FIGURE 24-18 Tetralogy of Fallot.

Clinical Signs and Symptoms

Severe CHDs are evident before birth or during the first few weeks of life. Signs and symptoms may include cyanosis, tachypnea, swelling in the legs, abdomen, or areas around the eyes, as well as dyspnea during feedings, resulting in minimal weight gain.[44] If the patient is asymptomatic at birth, less serious CHDs may not be diagnosed until later in childhood. Signs and symptoms apparent in older children could include easily dyspneic or fatigued during exercise, fainting spells, in addition to swelling in the hands, ankles, or feet.[44] Additional CHD signs that may be detected during a patient assessment or diagnostic test include arrhythmias, heart murmurs, or even a weak pulse.[44] Consider more conclusive diagnostic testing if any of these symptoms occur.

Etiology

CHDs are generally caused by an irregular formation of the heart during fetal growth.[45] Literature has shown that in most cases, there is no distinguishable cause for the development of a CHD.[45] However, there are several risk factors, usually genetic and environmental, that are generally considered to cause the condition (see the "Risk Factors" section).

Epidemiology

CHDs account for nearly one-third of all major congenital abnormalities.[46,47] CHDs are common in children, with approximately 8 cases per 1,000 live births every year.[46,47] See Tables 24-1 and 24-2 for statistics on specific CHDs.

Pathology/Pathophysiology

By the fourth week of development, the heart begins taking shape and starts efficiently pumping blood.[42,43,48] During this critical time, the major blood vessels begin to form. It is at this point that deviations in cardiac development occur leading to CHDs. There are many different types of CHDs, which are defined by specific clinical characteristics (Tables 24-1 and 24-2). In certain cases, septal wall defects (i.e., holes) can form between heart chambers or major blood vessels.[43] These holes allow the mixing of oxygenated and deoxygenated blood to occur, resulting in adverse effects to cardiac output or tissue oxygenation.[43] Depending on the severity of the hole, lack of sufficient oxygen can cause cyanosis or perhaps lead to congestive heart failure (CHF).[43] The three types of septal wall defects include ASDs, ventricular septal defects, and atrioventricular septal defects.[43] Atrial septal defects occur when there is an opening in the intra-atrial septum (i.e., upper heart chamber walls)[49,50] (Figure 24-5). A ventricular septal defect is a hole between the right and left ventricles (i.e., lower heart chamber walls)[51–53] (Figure 24-6). An atrioventricular septal defect is a condition in which there are holes between the heart chambers and the valves of the heart (i.e., hole in the center of the heart)[54,55] (Figure 24-7). Additionally, patent ductus arteriosus is an opening between two blood vessels (e.g., pulmonary artery and aorta) in the heart.[54,55] Another type of CHD is characterized by obstructed blood flow. Aortic and pulmonic stenosis is defined by a discrete narrowing of the heart valves or blood vessels, resulting in an increased exertion of the heart to pump blood[56–59] (Figures 24-8 and 24-9). Eventually, these obstructions can lead to cardiomegaly or cardiomyopathy.[56–59] Several CHDs occur due to abnormal blood vessels. A defect called double aortic arch takes place when an arch fails to remodel and two aortic arches form a complete vascular ring, causing compression of both the trachea and the esophagus[60,61] (Figure 24-10). Coarctation of the aorta is a discrete narrowing of the large blood vessel (i.e., descending aorta) leading from the heart[62,63] (Figure 24-11). Total anomalous pulmonary venous return is a CHD that occurs when the four pulmonary veins attach to incorrect areas of the heart[64] (Figure 24-12). In other words, there is no joining between the pulmonary vein confluence (i.e., coming together of the pulmonary veins) and the left atrium.[64] Truncus arteriosus is a condition in which a single blood vessel leaves the heart, instead of the normal two vessels (i.e., pulmonary artery and aorta), and supplies both the systemic and the pulmonary circulation[65,66] (Figure 24-13). Lastly, a CHD called transposition of the great arteries happens when the pulmonary artery and the aorta are on the wrong sides of the heart so that the pulmonary artery develops from the left ventricle and the aorta develops from the right ventricle[67,68] (Figure 24-14). An underdeveloped heart illustrates another type of CHD. In hypoplastic

left heart syndrome, the left side of the heart is too immature to effectively pump blood to the body[69,70] (Figure 24-15). An additional type of CHD is characterized by heart valve abnormalities. In Ebstein anomaly, the tricuspid valve is malformed, displaced, and oftentimes does not work properly[71] (Figure 24-16). Pulmonary atresia is also a heart valve disorder wherein the pulmonary valve is missing, triggering unusual blood flow to the lungs[72] (Figure 24-17). Finally, some infants are born with numerous heart defects. Tetralogy of Fallot is the most common cyanotic CHD and is a combination of a ventricular septal defect, pulmonic stenosis, a misplaced aorta, and right ventricular hypertrophy (i.e., thickened ventricular walls)[73–75] (Figure 24-18).

Risk Factors

Most CHDs are a result of in utero heart development complications, the cause of which is typically unknown. However, there are several environmental and genetic risk factors that may play a role. Environmental factors, including maternal rubella, gestational diabetes, certain medications, alcohol consumption, and maternal smoking, have all shown to adversely affect heart development.[47] Medications known to increase the risk of CHDs include thalidomide, angiotensin-converting enzyme (ACE) inhibitors, statins, antiseizure medicines, and lithium.[47] Family history can also play a role in producing a CHD. Some heart defects have autosomal-dominant inheritance, meaning that a parent with a defect has a 50% chance of passing the condition on to their newborn.[47] Research has also shown that some types of CHDs can be directly related to chromosome abnormalities or single gene disorders.[47] Genetic testing can help to detect these fetal development disorders that are associated with an increased risk for CHDs.

Complications

Specific complications depend on the type and severity of the particular CHD. There are several conditions that can develop as complications of CHDs, including endocarditis, developmental delays, pulmonary hypertension, CHF, and stroke.[76] Clinicians should discuss with family members ways to minimize the risk for complications due to CHDs.

Diagnostic Testing

The identification of CHDs is often made before birth and is commonly detected via **fetal ultrasonography.**[77] Prompt diagnosis of CHDs allows for thorough monitoring as well as proper planning prior to delivery. Delivery of these infants should ideally be performed at facilities with dedicated cardiac ICUs and experienced ECMO programs. For those infants not diagnosed in utero, many diagnostic techniques exist to clarify the type, location, and severity of the heart defect. These tools include ECGs, CXRs, cardiac catheterization, echocardiogram, cardiac auscultation, and Doppler ultrasound (US).[78]

Treatment and Management

Management of CHDs is mostly supportive; however, that does not diminish the significance of the clinician's role. Proper oxygenation and ventilation management can significantly impact the cardiovascular system and assist in avoiding further complications. Additionally, hemodynamic imbalances must be appropriately monitored as they can cause cardiac abnormalities, poor tissue perfusion, or even cardiac arrest and are detrimental to the infant's prognosis.[79,80] Recognition of patient deterioration and cautious clinical assessment can play a substantial role in proper CHD treatment and management. As mentioned previously, some CHDs have no long-term consequences and may safely go untreated. Certain defects may even correct themselves as the patient ages. However, others are very serious and require treatment soon after diagnosis. Treatment decisions will depend on the type and severity of the defect. Options may include cardiac catheterization, open-heart surgery, or heart transplant.[79,80] Procedures using catheterization allow repairs to be done (e.g., fix holes or increase areas of narrowing) without surgically opening the heart. For milder defects, especially those found later in life, certain medications could help to make the heart function more efficiently. ACE inhibitors, angiotensin II receptor blockers, and beta-blockers are drugs that alleviate strain on the heart by decreasing blood pressure, heart rate, and fluid retention.[79,80] Additionally, some medications can help with arrhythmias. In some cases, a combination of treatment modalities is required. Additionally, some procedures may need to be done in phases, over an extent of time, while others may need to be repeated as the patient ages.[79,80] Some infants with CHDs may require long-term treatment throughout their lifetime. While outcomes for infants with CHD have improved drastically, most patients will require lifelong monitoring and treatment. Follow-up cardiology appointments, exercise restrictions, and infection prevention will aid in letting infants with CHD grow up to lead healthy lives.[79,80]

Prognosis

Infants diagnosed with CHDs should continue to receive routine exams throughout their lifetime to reduce the risk of heart disease. Furthermore, undetectable CHD have the potential to cause disabilities later in life.

Infant Respiratory Distress Syndrome

Infant respiratory distress syndrome (IRDS), also known neonatal respiratory distress syndrome, and previously called hyaline membrane disease, almost exclusively affects premature infants with immature lung development[81–84] (**Figure 24-19**). It is a neonatal condition caused by an insufficient development of pulmonary surfactant and lung structure immaturity.[85] The occurrence and severity of IRDS are inversely related to the gestational age of the newborn.[84,86] Immense strides in research, clinical practice, and education have been made to better understand the pathophysiology and management of IRDS, leading to improvements in morbidity and mortality rates.

Clinical Signs and Symptoms

The clinical characteristics of IRDS are consistent with the infant's maturity. Signs of surfactant deficiency and increased chest wall compliance are highly depicted in this patient. Progressive symptoms of respiratory distress begin immediately after birth and include tachypnea, expiratory grunting, intercostal and subcostal retractions (i.e., "seesaw" pattern), cyanosis, and nasal flaring.[87,88] Extremely premature infants look distressed and may develop apnea events, causing eventual unresponsiveness.[87,88] Chest auscultation features decrease breath sounds.[87,88]

Etiology

IRDS develops in premature infants because of impaired surfactant synthesis, resulting in insufficient amounts of surfactant, leading to adverse effects, including atelectasis, V/Q mismatch, and hypoventilation.[89] Surfactant is a mixture of lipids and proteins that reduces surface tension at the alveolar interface in the lung. It is composed of phospholipids and four surfactant proteins, including A, B, C, and D.[89] Surfactant deficiency is one of the principal causes of respiratory distress in premature infants. Generally, alveolar type II cells synthesize and store surfactant starting at 16 weeks' gestation.[89] Between weeks 28 and 38 of gestation, surfactant is secreted into the alveoli and transfers into the amniotic fluid.[89] The genes involved in surfactant enhancement include surfactant protein B (SP-B) gene, surfactant protein C (SP-C) gene, and the ABCA3 gene.[90,91] All are critical for surfactant production and proper function of the infant lung.[90] Therefore, infants born prior to 28 weeks' gestation may potentially have underdeveloped lung structures with little or no surfactant production, leading to IRDS susceptibility.[91]

Epidemiology

Approximately 5,000 infants are born with IRDS each year.[86] The risk of developing IRDS depends on gestational age. That is, the closer to term a newborn is, the less likely the risk of IRDS. The incidence of IRDS is 10% in all-preterm infants, with 60% of those infants being less than 28 weeks' gestational age.[83] Despite clinical advancements, the mortality rates for infants with respiratory distress syndrome (RDS) is still reaching nearly 10%, making it the fifth leading cause of death in infants under 1 year of age.[83] IRDS does not affect sex and race equally. Males are more often affected than females.[92] Additionally, the Caucasian race historically has a higher incidence of RDS than others.[93]

Pathology/Pathophysiology

Poor gas exchange, increased chest wall compliance, thickened alveolar–capillary (A–C) membranes, inadequate vascular processes, and deprived lung fluid clearance are all pathophysiologic means that contribute to the clinical picture of an IRDS preterm infant.[89]



FIGURE 24-19 Characteristics of immature lung development.

The etiological significance of surfactant deficiency as well as the immature vascular development and abnormal surface tension components all impact IRDS disease progression[89] (**Figure 24-20**). This disturbance of normal surfactant transformation has been identified in the neonatal population as a cause of respiratory distress.[90] Surfactant dysfunction in the form of abnormal surfactant quantity, composition, metabolism, and inactivation of surfactant has been described in several infant acute lung injuries, including IRDS.[91] Decreases, increases, and no changes in surfactant quantity have all been described.[91] These inconsistent fluctuations in surfactant can lead to interstitial edema, hyaline membrane formation, and pulmonary hypertension as a result of both respiratory and metabolic acidosis.[90] Furthermore, the onset of pulmonary hypertension can lead to the shunting of blood (as much as 80% of the cardiac output), which can cause greater hypoxemia problems for the infant.[89] This vicious cycle can continue and may even lead to further pathophysiologic suppression. Clinicians must remember that not only these infants have immature lungs, but **prematurity** also puts them at risk for both metabolic and cardiac challenges.

Risk Factors

Prematurity is the greatest risk factor for IRDS. Additional risk factors include maternal diabetes, cesarean delivery, and asphyxia.[94]

Complications

Complications related to IRDS can significantly influence morbidity outcomes. Some of the complications impacting these premature infants include septicemia (i.e., blood poisoning), **bronchopulmonary dysplasia (BPD)**, pulmonary hemorrhage, hypertension, NEC, and susceptibility to other respiratory disorders.[95] An interruption in regular growth patterns, also known as failure to thrive, significantly impacts infants with RDS and is perhaps the leading contributor to worldwide childhood morbidity and mortality.[95] Increased work of breathing, decreased lung compliance, and recurring oxygen desaturations are also commonly seen in pulmonary tests (PFT) of premature infants surviving IRDS.[95] Future focuses on immunologic processes and chronic pathologies related to IRDS will assist in improving the outcomes of these patients.



FIGURE 24-20 Pathogenesis of IRDS versus BPD.
Modified from http://flipper.diff.org/app/items/info/6229.

Diagnostic Testing

IRDS may coexist with a multitude of conditions and therefore complicate diagnostic approach considerations. Clinicians should base their diagnosis on the history, patient assessment, CXR, and laboratory evaluation. Infants at risk for IRDS should be evaluated using fetal lung maturity tests. The amniotic fluid lecithin-to-sphingomyelin (L:S) ratio test is a marker of fetal lung maturity. Lecithin is the most common phospholipid in surfactant. Typically, there is twice as much lecithin as sphingomyelin; thus, an L:S ratio of greater than 2:1 depicts a mature lung.[96] Additionally, an increased level of phosphatidylglycerol (PG), the second most common phospholipid in surfactant, near term indicates a low risk for IRDS.[96] The presence of PG and an L:S ratio greater than 2:1 drop the risk of IRDS to nearly 0%.[96] Blood gas analysis typically shows moderate-to-severe hypoxemia, varying levels of hypercapnia, and mixed respiratory and metabolic acidosis.[86] Respiratory acidosis is primarily due to alveolar atelectasis and overdistension. On the other hand, metabolic acidosis occurs because of lactic acid accumulation (i.e., poor tissue perfusion and anaerobic metabolism). CXR of infants with IRDS reveal diffuse, bilateral, ground-glass appearances, air bronchograms, and reduced lung expansion[86] (**Figure 24-21**). Also, the heart may be normal or slightly enlarged.[86] Using radiographic findings, IRDS can be described as stages and is generally correlated with disease severity and progression. In the early stages (stage 1), air bronchograms are absent and alveolar atelectasis targets the dependent areas of the lungs.[86] In infants with mild-to-moderate IRDS (stages 2 and 3), the CXR reveals overdistension, the presence of air bronchograms, and an increase in dense opacities.[86] As IRDS progresses (stage 4), large areas of increased lung opacity (i.e., "white out"), uniform atelectasis, and air bronchograms can be seen on the radiograph.[86] When IRDS is characterized by excess fluid (e.g., pulmonary edema), fluid input and output must be closely monitored. While infrequently used to date, a recent study has reported the accurate and reliable use of lung US in diagnosing IRDS.[86] Ultrasonography can be used to find lung consolidations and even diagnose or exclude a coinciding pleural effusion.[86] Other monitoring devices, including end-tidal CO_2, cardiopulmonary displays, and Doppler flow studies, can be used to monitor patient progress.



FIGURE 24-21 CXR of IRDS.

Reproduced from Parenchymal lung disease. Auckland District Health Board. http://www.adhb.govt.nz/newborn/TeachingResources/Radiology/LungParenchyma.htm.

Treatment and Management

Due to the complexity of IRDS, the preferred treatment should always be prevention. If predictive tests (L:S ratio, PG levels) indicate a high IRDS risk, elective cesarean delivery should be stopped and premature delivery should be delayed.[96] The administration of antenatal corticosteroid therapy prior to delivery may accelerate lung development and reduce the risk of respiratory distress.[97] However, a recent study concluded that multiple courses of antenatal corticosteroids did not improve results and were associated with decreases in neonatal weight at birth.[97] Because research results remain unclear, clinical judgment must be used when deciding on repeat doses of administered corticosteroids for preterm delivery. The arrival of surfactant replacement therapy has reduced morbidity and mortality rates in infants with IRDS by nearly 50%.[98] Studies have found that early surfactant therapy reduces the occurrence of pulmonary air leaks as well as the severity of the chronic lung disease.[98] Another clinical trial targeting intubated IRDS patients showed that early surfactant therapy combined with rapid extubation to nasal CPAP (nCPAP) decreased the need for and duration of mechanical ventilation.[99] **Surfactant replacement therapy** has the ability to improve survival and lung development outcomes in these preterm infants. Oxygen therapy as a treatment modality for IRDS is administered via an oxygen hood, nasal cannula, or isolette to the infant.[99] Providing adequate oxygenation, preventing atelectasis, and reducing risk factors for IRDS are the main features of this therapy option. When applying oxygen therapy, substantial efforts must be made to minimize Fio_2 levels to no more than what is necessary to prevent potential lung damage. Oxygen therapy was the principal therapeutic modality for IRDS before the introduction of CPAP. If oxygenation fails to improve with basic oxygen therapy, CPAP should be started. CPAP has the ability to keep the alveoli open at the

end of expiration, therefore decreasing the opportunity for shunts.[99] Studies have shown that early nCPAP can reduce the need for mechanical ventilation later on.[99] With the ability of CPAP to stabilize the alveoli, surfactant production is allowed to continue without interference. Heated and humidified HFNC therapy is another respiratory support modality being used in infants with IRDS. This device allows for the delivery of 100% heated and humidified high-flow oxygen at body temperature.[100] Some research has suggested that HFNC therapy may be a more effective, better-tolerated treatment method for IRDS.[100] Evidence suggests fewer ventilator days, reduced nasal trauma, and improvements in weight gain when using HFNC therapy.[100] However, further research is still required to determine the best methods for weaning as well as the long-term effects of neonatal treatments. Endotracheal intubation and mechanical ventilation may be indicated for a variety of reasons. Mechanical ventilation should be initiated in infants with IRDS when Fio_2 or pressure requirements exceed safe thresholds, ABG results display increases in respiratory acidosis, or if prolonged apneic episodes persist.[101] In the very preterm infants, mechanical ventilation may be needed immediately following delivery. For these delivery room cases, clinicians should use their patient care protocols and physical assessment skills to guide decision making. Mechanical ventilation may also be indicated in full-term infants if presenting with severe respiratory distress or asphyxia.[101] Mechanical ventilation should be considered a physiologic support to the patient while they recover from IRDS. Additionally, HFV may be indicated in infants struggling while receiving conventional mechanical ventilation. An animal study demonstrated that HFV promoted uniformity in lung aeration, gas exchange improvements, and decreased lung inflammation in patients with IRDS.[101] Nevertheless, HFV clinical trials are still awaiting evaluation of short-term and long-term patient outcomes.[101] Hypothermia may further complicate IRDS. Clinicians must prevent hypothermia and care for these patients in a neutral thermal environment. Routine monitoring and consistent assessments are very useful in managing the daily abnormalities of these patients.

Prognosis

Prognosis of preterm infants with IRDS has steadily improved. In the last 50 years, the mortality rate for IRDS has significantly decreased by almost 13%.[102] If managed effectively, IRDS often gets worse following birth and will improve slowly over time. Acute clinical problems following diagnosis of IRDS include alveolar rupture, infections, AOP, and hemorrhaging.[102] Bronchopulmonary dysplasia (BPD), ROP, and neurologic impairments are possible long-term clinical issues following treatment and management of IRDS.[102] Despite improved survival rates, oftentimes therapies (e.g., mechanical ventilation) needed to treat IRDS are the very reasons responsible for prolonged symptoms and altered lung development. The major long-term respiratory complication of RDS is BPD. Forthcoming alterations in pulmonary function tests (PFT) suggest the development of reactive airway disease in these patients as a result of BPD diagnosis.[102] Fetal care improvements have led to better neonatal outcomes.

Bronchopulmonary Dysplasia

BPD is the most common cause of respiratory insufficiency and ventilator dependence in infants born prematurely. BPD affects nearly 10,000–15,000 infants every year in the United States.[103,104] It is a multifactorial syndrome that affects major organ systems within the body. BPD is defined as a clinical, radiographic, and pathologic disease process affecting premature infants with IRDS, exposed to aggressive ventilatory support and high levels of oxygen therapy.[103,104] This long-term mechanical ventilation and supplemental oxygen requirements cause severe lung derangement resulting in poor prognoses. Because of this, infants with BPD have an increased risk of pulmonary morbidity and mortality within the first 2 years of life.[103,104] Lung function impairment may persist throughout childhood and even into adulthood.[103,104] The validity and utility of a commonly used definition for BPD remains questionable. A recent study compared three diagnostic criteria for defining BPD: the original 36-week threshold, the National Institutes of Health workshop definition, and the physiologic definition requiring a room air challenge.[103,104] Conclusions stated that a contemporary definition of BPD, which correlates with respiratory morbidities in childhood, is still needed.[105] A diagnostic criterion that clearly defines the pulmonary abnormalities of BPD is important to identify infants who have different severities of this lung disease.

Clinical Signs and Symptoms

BPD usually presents with irregular findings on physical examination, CXR, PFT, and histopathologic exam. Infants born with BPD exhibit signs and symptoms similar to that of IRDS, including tachypnea, tachycardia, increased work of breathing (e.g., nasal flaring, retractions), and recurrent desaturations.[106] BPD patients are usually very premature, have very low birth weight, and require significant respiratory support to maintain oxygenation and ventilation.[106]

Etiology

BPD is often due to respiratory distress. As previously stated, IRDS is the result of lung development

complications. The insufficient production of surfactant occurs because of infant prematurity and prompts the need for ventilatory support in these patients.[107] Invasive mechanical ventilation has the likelihood of causing lung damage and may result in the infant requiring prolonged support, and a BPD diagnosis. BPD may also arise from other adverse medical conditions, including congenital lung malformations, pneumonia, or even other infections.[107] All of these BPD-associated illnesses can cause further lung inflammation and scarring to the patient. Genetic susceptibility has also recently been suggested to contribute to some cases of BPD; however, follow-up research is still needed to support these findings.[107]

Epidemiology

The epidemiology of BPD has transformed over the years following the introduction of new, advanced therapies as well as a better clinical understanding of the disease progression. Today, severe BPD is less frequent and has been replaced by milder, more frequent forms as the survival of premature infants has strikingly increased.[108] The most important determinant of BPD incidence is the degree of prematurity, with BPD largely occurring in infants less than 28 weeks' gestational age or below 1,000 g birth weight.[108] A recent report stated that the incidence of diagnosis of BPD had significantly decreased concurrently with improvements in BPD care protocols.[108] Nowadays, BPD rarely occurs in infants greater than 30 weeks' gestational age or with birth weights greater than 1,200 g.[108] African American infants generally have a lower occurrence of BPD compared with Caucasians.[108] Additionally, male premature infants with BPD tend to have worsening disease progression and outcomes. Noteworthy is the challenge in comparing BPD incidence as different patient classifications, criteria, and management strategies are frequently used.

Pathology/Pathophysiology

Four distinct pathologic findings of BPD are generally described: acute lung injury, exudative bronchiolitis, proliferative bronchiolitis, and obliterative fibroproliferative bronchiolitis.[109] The pathology of BPD is complex, and clinicians must be able to recognize the various factors that lead to lung injury in this patient population. Damage to alveolar, bronchial, or vascular development can result in significant dysfunction in infants with BPD. A thorough comprehension of the alveolar, bronchial, and vascular pathology will assist in providing optimal care to these preterm infants. Wilson-Mikity syndrome describes preterm infants presenting with respiratory distress soon after birth.[109] Initially, these infants have diffuse lung infiltrates, tachypnea, and cyanosis.[109] Over the course of weeks, some infants recover spontaneously while those who die exhibit hyperaeration and reduced A–C membrane density.[109] The classical description of BPD, defined by structural injury, is now commonly referred to as "old BPD." "Old BPD" was described as developing in four pathologic stages based on days of life (DOL). In stage one, the first through third DOL, the appearance of BPD is the same as IRDS with not enough surfactant in the lungs.[110–112] This stage of BPD involves the presence of widespread atelectasis, hyaline membranes, and air bronchograms.[110–112] In stage two, the 4th through 10th DOL, lung destruction occurs. Hyaline membranes persist and alveoli begin to merge in a similar manner as emphysema.[110–112] Stage three, the 10th through 20th DOL, involves progressive repair of the lung. Persistent injury results in air trapping, interstitial edema, and ciliary dysfunction.[110–112] In stage four, more than 1 month of age, the CXR depicts emphysematous alveoli. This chronic lung damage causes pulmonary hypertension, fibrosis, and prolonged atelectasis.[110–112] Recognizing any of these above stages could assist in the diagnosis of BPD. Presently, the "new BPD" defines BPD as a developmental delay. The key features of the "new BPD" pathology include alveolar hypoplasia, hindered A–C development, abnormal pulmonary vasculature, and increased interstitial fibrosis.[113] It is believed that these features manifest as a result of subsequent changes in lung development following birth. While there are no causative links to "new BPD," mechanical ventilation and oxygenation can still be justifying factors.

Risk Factors

Multiple risk factors exist for the development of BPD. Premature infants with very low birth weights are often exceptionally susceptible to BPD because of their immature structural and functional respiratory system. Premature birth and subsequent events, including long-term oxygen exposure, prolonged mechanical ventilation, and infection, are the leading causes of lung development abnormalities and loss of gas exchange in BPD.[114] Other risk factors include hypothermia or hypotension at admission, preeclampsia, or hypercarbia.[114] Certain risk factors may increase the degree of BPD severity, including prolonged acidosis, patent ductus arteriosus, oligohydramnios, or an Apgar score of less than 6.[114]

Complications

The complications associated with BPD are relatively unpredictable and can vary widely between individual patients. Acute complications include bronchiolitis, heart problems, and kidney difficulties.[115] Long-term complications may involve respiratory infections, delayed growth, neurologic dysfunction, and coordination problems.[115] Various degrees of obstructive lung disease may persist throughout the life span. For some, prolonged lung dysfunction will continue to be apparent in abnormalities, including airway hypersensitivity,

wheezing, and emphysematous symptoms.[115] Frequent rehospitalizations for respiratory exacerbations and infections may continue into adolescence and adulthood. These chronic health complications can also adversely impact the families of these babies.

Diagnostic Testing

ABG analysis in BPD patients may disclose acidosis, hypercapnia, and hypoxia with mounting oxygen therapy requirements.[116,117] End-tidal CO_2 monitoring may be advantageous in recognizing trends, especially when correlated with ABG results.[116,117] Continuous oxygenation monitoring may be required because of frequent desaturations. Changes in pulmonary mechanics, including increased airway resistance, decreased lung compliance, increases in functional residual capacity (FRC), and increased airway hyperresponsiveness, may all appear on PFT.[116,117] Infants with BPD can develop pulmonary hypertension, increased pulmonary vascular resistance, or right ventricular hypertrophy.[116,117] Echocardiograms are extremely valuable tools in diagnosing injury to the pulmonary circulation. BPD severity levels can be determined through the use of CXR. CXRs may show diminished lung volumes, atelectasis, pulmonary edema, or even PIE[118] (**Figure 24-22**). Today, high-resolution imaging (computed tomography or MRI tests) can help detect irregularities not commonly seen on CXRs.

Treatment and Management

In most cases of BPD, the focus of therapy is on prevention and routine treatment of IRDS. The foundation for treating IRDS includes minimal oxygen therapy use, surfactant replacement therapy, CPAP, and mechanical ventilation.[119] Supplemental oxygen therapy is necessary to prevent tissue hypoxia; however, oxygen toxicity should always be avoided. Premature infants have a relatively deficient antioxidant defense and therefore are at an increased risk of injury due to oxygen free radicals.[119] Ideal oxygen saturation strategies for infants at risk for BPD have not been clearly determined. However, many clinicians have adopted the consensus of targeting oxygen saturation ranges of 90–95% following the results of the Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT) trial.[119] Recall that surfactant dysfunction occurs in a high percentage of preterm infants requiring continued ventilatory support. While there is limited evidence regarding the usefulness of late surfactant therapy in infants with BPD, early surfactant administration has been associated with a lower incidence of disease progression.[120] The use of "gentler ventilation," described earlier as more aggressive CPAP and less-invasive techniques, may eliminate the need for advanced therapies and even decrease injury to the lungs.[121,122] While positive pressure ventilation is necessary to recruit alveoli and prevent atelectasis in the immature lung, this treatment option is a targeted marker for the development of BPD. Early extubation and favorable use of noninvasive positive pressure ventilation (NIPPV) have the potential to reduce BPD severity likelihood.[121] Many ventilator modes and strategies have been studied in the hopes of reducing impending lung injury. Some researchers have adopted the term *volutrauma*, suggesting the occurrence of lung injury in regard to low versus high tidal volume (V_T) approaches.[122] Results have been mixed when discussing which specific mode provides the most optimal use of conventional ventilation in regard to improved pulmonary outcomes.[122] However, minimizing oxygen and volume in the lungs is promised to reduce the lung injury in BPD diagnoses. Generally, when ventilating infants with chronic lung injury, using adequate positive end-expiratory pressure levels, stabilizing atelectatic alveoli, avoiding overdistension, and targeting reduced tidal volume (V_T) values have been shown to have clear benefits in managing BPD.[122] Though HFV is an applicable lung-protective ventilatory strategy, most trials have not had large enough sample sizes or sufficient evidence to support its use. Regardless of the ventilatory strategy used, an increase in alveolar recruitment, avoidance of hypocapnia, and a decrease in BPD risk factors need to be the main focus. While several of these interventions are individually effective, ventilator bundle strategies have been shown to positively improve management of patients with BPD.[122] BPD can be further complicated by pulmonary edema. Fluid restrictions and diuretics are often used to prevent excessive fluid administration and treat pulmonary edema.[122] Other therapies suggested to manage BPD involve permissive hypercapnia (ventilation strategy that allows for un-physiologically



FIGURE 24-22 CXR of a patient with BPD.

Reproduced from Semple T, Akhtar MR, Owens CM. (2017). Imaging bronchopulmonary dysplasia: a multimodality update. *Front. Med.* 4:88. doi: 10.3389/fmed.2017.00088.

high partial pressure of carbon dioxide (Pco_2) to permit lung-protective tidal volume values[123]), corticosteroids (group of hormones used to improve lung function and reduce inflammation[124]), mast cell stabilizers (block the release of mast cells, thereby preventing airway hyperreactivity[125]), antioxidants (enzymes that protect the lung and prevent deficiency of trace elements[126]), vitamin A (promotes gene regulation necessary for lung growth and increases surfactant production[127]), and inhaled nitric oxide (pulmonary vasodilator that improves gas exchange and reduces pulmonary vascular resistance); however, effectiveness varies and routine use is not commonly recommended[128]).

Prognosis

Survival rates of the most preterm infants have drastically improved since the introduction of surfactant therapy.[129,130] Advancements in technology and improved understanding of BPD pathophysiology have led to milder BPD disease progression today than in years past. Infants who develop severe BPD remain at risk for repeated hospital admissions throughout their life span.[129,130] Irregular neurologic effects, muscular development, and long-term respiratory morbidity are common in infants with BPD.[129,130]

Transient Tachypnea of the Newborn

Transient tachypnea of the newborn (TTN) is a lung condition seen in infants shortly after delivery. Others have termed it "wet lungs" or "type II respiratory distress syndrome."[131,132] It is a disorder that describes mild neonatal respiratory problems, which begin after birth and last roughly 3 days.[131,132] It is a self-limited illness (i.e., resolves spontaneously with or without treatment), typically correcting within 48–72 hours.[131,132] TTN is caused by excessive lung fluid due to compromised clearance mechanisms.[131,132] Signs of respiratory distress typically become evident within 6 hours of birth. At delivery, clinicians may have challenges distinguishing TTN from other causes of respiratory distress, including sepsis, aspiration, and pneumonia.[131,132]

Clinical Signs and Symptoms

Attaining a full history and clinical assessment are crucial to the proper management of these infants. The maternal history in TTN consists of cesarean delivery or extremely rapid labor.[133] Within the first few hours of life, tachypnea and signs of respiratory distress (e.g., nasal flaring, grunting, retractions, and cyanosis), increased oxygen requirements, and hypoxia without associated carbon dioxide retention characterize this disease.[133] It is important for clinicians to observe these infants for signs of clinical deterioration, which may suggest the development of respiratory fatigue or another diagnosis. This disorder is again transient, meaning clinical symptoms will usually resolve within 72 hours following birth.

Etiology

TTN results from complications during the prenatal to postnatal transition period. Delayed absorption of fetal lung fluid following delivery causes TTN. The subsequent pulmonary edema is a common cause for respiratory distress in the immediate newborn. This development of fluid accumulation may provoke tachypnea, increased work of breathing, or reduced pulmonary compliance, especially in neonates.[134,135]

Epidemiology

The exact incidence of TTN is weakly unknown, but publications have estimated that roughly 1% of newborns have some form of respiratory distress unrelated to infection.[136,137] Of this 1%, nearly 30–50% have TTN.[136,137] Despite being one of the most common causes of IRDS, many cases go underdiagnosed due to coexisting problems.[136,137] While TTN is generally a self-resolving disorder, it has been correlated with subsequent morbidity.

Pathology/Pathophysiology

TTN results in the admission of neonates to the NICU because of failure to clear fetal lung fluid prior to delivery. The ensuing respiratory distress is characterized by the retention of fluid in air spaces, resulting in alveolar hypoventilation.[138,139] Typically at birth, the mature lung switches from fluid secretion to fluid absorption in response to traveling catecholamines and other hormones.[138,139] The remaining fluid is routinely expelled during delivery. Reduced expression of chemical channels (e.g., Na^+, Cl^-) contributes to the inability of the immature fetal lung to switch from fluid secretion to fluid absorption.[138,139] Several studies have demonstrated the critical physiologic importance of Na^+ transport channels during delivery. Ineffective Na^+ channels have the potential to cause respiratory distress in at-risk patients. Disruption of this process can lead to liquid filling the alveoli and moving into the interstitium.[138,139] Mature newborns, especially infants delivered by cesarean section, are often deprived of these fluid clearance changes during labor, making the risk of excessive pulmonary fluid much more probable.[138,139] Research has also suggested that low lamellar body counts derived from infant secretions, consistent with surfactant abnormalities, may be associated with TTN.[138,139]

Risk Factors

The main risk factors for TTN include cesarean delivery, low gestational age, male gender, maternal history of asthma, macrosomia, and maternal diabetes.[131,140] As more babies are being delivered by elective cesarean

section before the onset of labor, the occurrence of respiratory distress due to failed transition has increased.[131,140] Studies have also shown that gestational age is inversely proportional to TTN occurrence due to the adverse effects of prematurity factors.[131,140] Likewise, research has found a potential connection between TTN and asthma, demonstrating that male infants of asthmatic mothers are more likely to develop TTN later in life.[131,140] Additionally, neonates with TTN are at a higher risk for subsequent development of asthma.[131,140] However, to date, no straightforward correlation with asthma and TTN can be made based on the existing literature.[131,140]

Complications

Few potential complications exist. One study found neonatal problems and prematurity difficulties to be significantly increased in infants with TTN.[141] Some infants may develop hypoxia, respiratory fatigue, and acidosis as a consequence of RDS.[141] In infants with an increased work of breathing, air leaks may be occasionally seen.[141] Careful monitoring for worsening respiratory distress should be performed.

Diagnostic Testing

Most often, infants with TTN are hemodynamically stable, but an ABG assessment is essential to establish the degree of gas exchange as well as acid–base balance. A rising carbon dioxide level may indicate respiratory fatigue, impending respiratory failure, or even a pneumothorax.[131] Clinicians should continuously monitor pulse oximetry for assessment of infant oxygenation. Pulse oximetry monitoring allows for oxygen-level adjustments needed to maintain adequate saturation in these patients. The diagnostic standard for TTN is CXR and is characterized by diffuse infiltrates, prominent perihilar streaking secondary to retained lung fluid, and small pleural effusions[131] (**Figure 24-23**). Follow-up CXRs may be needed if the respiratory status worsens. The definitive diagnosis of TTN is often based on the remedying of symptoms within a strict time frame (i.e., within 72 hours).[131] Misdiagnosis of TTN occurs if symptoms remain beyond the 72-hour period. Additional patient evaluation and diagnostic testing must be done to determine the true cause of the respiratory distress. An echocardiogram may be necessary for patients with more than 5–6 days of persistent tachypnea to help exclude congenital cardiac defects.[131]

Treatment and Management

Treatment and management of TTN is oftentimes in the form of supportive care in that the pulmonary system will improve as retained lung fluid is absorbed. Supportive care may include both intravenous fluids and NG feeding until the respiratory distress decreases enough to allow for oral feedings.[131] Supplemental oxygen therapy, a state of thermal balance, and minimal stimulation are necessary for these patients.[131] Repeat ABG assessments and CXRs should be performed if the infant's status decompensates. Therapeutic care should be given on an as-needed basis for developing hypoglycemia, hypothermia, or sepsis, all risk factors associated with TTN.[131] Additionally, several studies have evaluated the use of antenatal corticosteroids (e.g., dexamethasone) as a management option for fetal lung immaturity and reduced expression of chemical channels. Results demonstrate a decreased incidence of pulmonary adverse outcomes and the greatest impact of exposure in the reduction of respiratory morbidity in TTN.[142] Following resolution of TTN, the clinical focus needs to be on routine newborn management.

Prognosis

Prognosis is excellent for infants with TTN. Recall that TTN is a self-limiting disease and thus rarely causes long-term morbidity and mortality. One study looked at TTN characteristics as risk factors for childhood asthma. Conclusions revealed that infants with TTN are at an increased risk for asthma-related hospitalizations during the toddler years.[143,144] Additionally, infants with



FIGURE 24-23 CXR of TTN with perihilar streaking.

Reproduced with permission from Transient Tachypnea of the Newborn Lokesh Guglani, Satyan Lakshminrusimha, Rita M. Ryan. Pediatrics in Review. 2008; 29(11);e59-e65. doi: 10.1542/pir.29-11-e59.

TTN delivered by cesarean section may develop pulmonary hypertension owing to retained lung fluid.[143,144] A challenging clinical course, potentially requiring ECMO, may be required.

Congenital Diaphragmatic Hernia

Congenital diaphragmatic hernia (CDH) is a complex congenital disorder with high mortality. The incidence of CDH is roughly 1 in 2,500 births.[145–147] CDH is a major medical concern and is not well known outside the realm of neonatology. A primary characterization of CDH is a hole in the diaphragm that allows abdominal organs to move into the chest, thus hindering lung development[146,147] (**Figure 24-24**). As a result, CDH infants suffer a combination of various degrees of insufficient lung growth and pulmonary hypertension.[146,147]

Clinical Signs and Symptoms

The first clinical manifestations of CDH are usually seen in prenatal ultrasonography findings. A CDH diagnosis can be made as early as 15 weeks' gestation.[148,149] An earlier gestational diagnosis oftentimes leads to potentially worse outcomes because this discovery indicates a more severe defect or pulmonary dysfunction.[148,149] Prenatal US findings will usually show an improperly situated stomach as well as the intestines being located next to the heart.[148,149] "Liver-up," or the presence of the liver in the thorax, usually depicts a more severe form of CDH because it again indicates a larger defect or pulmonary dysfunction.[148,149] At delivery, infants most generally exhibit respiratory distress (e.g., retractions and grunting) and cyanosis, although a delayed presentation is possible.[148,149] During the neonatal assessment, CDH infants frequently present with a scaphoid abdomen (i.e., sucked inward) and barrel chest.[148,149] Continuing with auscultation of the lungs, the clinician will hear poor air entry (i.e., diminished breath sounds) on one side and bowel sounds on the affected side.[148,149] A shift in cardiac sounds may also be heard because of the incorrect anatomic location of the heart.[148,149] Furthermore, in patients with severe CDH, a pneumothorax may be found.[148,149] Hypoxemia is a commonly seen clinical characteristic of CDH. Multiple factors, including pulmonary vascular abnormalities, the extent of lung hypoplasia, and the compression of lung units, contribute to worsening hypoxemia.[148,149] Ongoing hypoxemia, along with right-to-left shunting, may cause tissue hypoxia and increases in metabolic acidosis.[148,149] Pulmonary hypertension is another common clinical symptom in patients with CDH. Moreover, these anatomic irregularities and pulmonary hypertension can both contribute to further cardiac insufficiency.

Etiology

During normal gestation, the diaphragm is fully formed by the 12th week. In CDH infants, a part of the diaphragm does not form correctly, resulting in a defect that causes the abdominal innards to enter the thoracic cavity.[146] Classification of CDH is based upon the anatomic location of the defect. CDH can be classified as a posterolateral, anterior, or central defect.[146] Posterolateral defects, also termed Bochdalek hernia, make up 90% of CDH cases, with the remaining 10% comprising anterolateral defects (Morgagni hernia) and relatively rare forms of total diaphragm absence.[150] The majority of CDH cases occur on the left side with less frequent incidences on the right side or bilaterally.[147,150]

Epidemiology

CDH occurs in 1 in every 2,000–3,000 newborns and accounts for 8% of all major congenital abnormalities.[145] The risk of recurrence in future siblings is approximately 2%.[145] Mortality and morbidity are traditionally difficult to calculate and sometimes underestimated



FIGURE 24-24 Congenital diaphragmatic hernia.
Printed with permission from Texas Children's Hospital.

because of the "hidden mortality" in CDH. Hidden mortality refers to fetuses with hernias that die in utero or shortly after birth.[151] Studies have found that hidden mortality significantly exists in this condition, with hidden CDH deaths at 45%.[151] The presence of other abnormalities and associations (e.g., prematurity, low birth weight, and pneumothorax) has been correlated with poor outcome in these patients.

Pathology/Pathophysiology

CDH has a very complex pathophysiology and remains weakly understood. Research experiments have demonstrated that incomplete growth of the lungs (pulmonary hypoplasia) occurs prior to diaphragm shortcomings.[146] Using this evidence, researchers were able to show that lung growth is already affected prior to the development of the diaphragmatic hernia.[152] This led to the "dual-hit hypothesis," which postulates CDH as the result of developmental compromises. The first hit or compromise affects both lungs and occurs before diaphragm development as a result of genetic and environmental factors.[152] The second hit affects only the ipsilateral lung and occurs after development of the defect, causing herniation of organs into the thorax.[152] Retinoid (compounds chemically related to vitamin A) signaling disturbances may play a significant role in the pathophysiology of CDH.[146] Additionally, studies have shown an increased risk for CDH associated with various maternal factors, including alcohol use, smoking, low intake of retinol, obesity, and antimicrobial drugs.[146] Genetics is also being associated with congenital abnormalities in CDH. Genetic syndromes, chromosome abnormalities, and congenital anomalies have all been identified in CDH infants.[146] Several cardiovascular malformations (CVMs) commonly coexist with CDH following the birth of these patients, including pulmonary hypoplasia, patent ductus arteriosus (i.e., an opening between two blood vessels leading from the heart), patent foramen ovale (i.e., a hole between the two atria in the heart), and intestinal malrotation.[152]

Risk Factors

Risk factors contributing to the onset of CDH remain unclear. Studies have found CDH to be associated with several demographic risk factors, including male fetal gender, higher maternal age, Caucasian race, and maternal smoking.[153,154] Additionally, maternal pre-gestational diabetes and alcohol use are related to the occurrence of CDH in infants.[153,154] Several of these risk factors are modifiable and significant attention should be given to patient and family education. There are also several clinical characteristics related to poor outcomes that have been identified as risk factors in infants with CDH, such as low birth weight, size of the diaphragmatic defect, a low Apgar score, prematurity, air leaks, as well as the presence of other structural defects or hereditary abnormalities.[153,154] In cases of isolated CDH (the only major health problem), pulmonary hypoplasia and PPHN are main causes of morbidity and mortality.[153,154] Further studies are needed to determine a clear etiology and established risk factors of CDH, especially to help with prevention efforts.

Complications

Neonatal research has documented that both pulmonary hyperplasia and **persistent pulmonary hypertension of the newborn (PPHN)** are chief complications following the repair of CDH.[157] Histologic research has shown increased musculature in the pulmonary vasculature.[152] Continued contraction of the vasculature can produce chronic constriction of the arterioles, resulting in pulmonary hypertension or PPHN.[152] Good patient assessment and strict follow-up is necessary for patients who develop postoperative complications. CDH babies are at risk for long-term morbidities, including pulmonary diseases, GI disorders, growth failure, neurologic impairment, and chest wall deformities.[146]

Diagnostic Testing

Prenatally, CDH is diagnosed by an US examination. Polyhydramnios is commonly present and is the main indicator in pregnancies complicated by CDH.[155] The diagnosis of CDH is confirmed by radiographic imaging. The CXRs may indicate abdominal organs in the thorax as well as an abnormal cardiac axis or mediastinal shift in the opposite direction[146,155] (**Figure 24-25**). Pulmonary hypoplasia can be measured by the severity



FIGURE 24-25 Chest and abdominal radiograph showing a CDH.

Reproduced with permission from James A. O'Neill Jr and The American Pediatric Surgical Association.

of fetal breathing movements.[155] Postnatal clinical symptoms soon after birth also help in the diagnosis and management of CDH. The onset of symptoms may differ depending on the volume of innards in the thorax and the severity of pulmonary hypoplasia present.[156] Undiagnosed patients may present with acute respiratory distress, a barrel-shaped chest, concave abdomen, the absence of breath sounds, shifted cardiac sounds, and bowel sounds in the chest.[146] Some CDH infants remain asymptomatic and present later in life with CI symptoms or some other ailment.[155] Prenatal diagnosis is advantageous as it can help in better management and intervention of the infant and mother, individualized patient education, and planned delivery in a skillful facility.[146,155]

Treatment and Management

One essential management component of all CDH cases is parental counseling. Parents need to properly understand the severity of the disorder, disease process expectations, and potential outcomes. Furthermore, prenatal management of CDH consists of routine US surveillance for potential prenatal complications.[146] Postnatal management has evolved to include lung-protective ventilation with possible permissive hypercapnia, infant stabilization prior to surgical repair, inhaled nitric oxide (iNO), HFV, or **extracorporeal membrane oxygenation (ECMO)** therapies.[146] In the delivery room, the aim is to achieve adequate oxygenation and ventilation. Infants should receive a nasogastric (NG) tube to prevent further bowel enlargement.[155] Severe CDH infants should be immediately intubated and placed on safe mechanical ventilation settings. Ventilatory strategies should consist of lung protection principles, maintaining an Spo_2 of at least 85%, allowing for comfortable permissive hypercapnia, and stimulating spontaneous breathing.[146] Bag-mask ventilation should be avoided as it can lead to bowel distension and further respiratory distress.[146,155] ABG values should be used as ventilatory management determinants in infants with CDH.[156] Once the cardiopulmonary functions are stabilized, usually in the first week of life, surgical repair can be accomplished. The operating approach consists of open or minimally invasive surgical techniques.[146] The transabdominal approach is preferred and the standard technique for repair.[157] If the abdominal cavity is inadequate, the transthoracic approach is used for good exposure to the defect.[157] Generally, the closure method depends on the size and severity of the defect. Smaller defects are repaired with permanent sutures, whereas larger defects require a patch.[146,155] In recent years, experimental surgical treatment approaches for CDH have been developed and used. Fetal tracheal occlusion therapy is an improved technique of fetal surgery.[146,158] Outcomes have varied, with some studies reporting reduced pulmonary hypoplasia while others failing to show improved survival.[146,158] HFV and ECMO can be used as rescue therapies when conventional ventilation fails. Some studies have reported improved survival rates with both HFV and ECMO; however, discrepancies exist.[146,155] Recent advancements in NICU protocols have significantly helped to reduce CDH mortality in hospital centers.[152]

Prognosis

Despite the continuous improvement in knowledge and management of this disease, CDH still carries over a 50% mortality rate.[155] Traditional therapies, including pulmonary vasodilators, pharmacologic paralysis, HFV, and ECMO, have all shown potential but made no noteworthy impact on the pulmonary hypertension issues facing these patients.[155] Presently, iNO therapy, a potent pulmonary vasodilator, is the most common treatment for pulmonary hypertension in CDH infants.[146] However, the benefits of blood pressure enhancement are debatable. The long-term outcomes and quality of life of CDH infants vary. Due to the high morbidity prevalence rates, the importance of close follow-up and long-term care among CDH survivors must be emphasized.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Cyanotic heart defects are more dangerous than acyanotic heart defects.
2. True or False: IRDS is caused by weakness or underdevelopment of the chest muscles.
3. True or False: Positive pressure ventilation support in infants can lead to BPD.

Pediatrics

The following sections will discuss the etiologic and pathophysiologic characteristics of several pediatric cardiopulmonary disorders of the respiratory system. These will include croup, epiglottitis, bronchiolitis, and **foreign body obstruction (FBO)**.

Croup

Croup, also known as acute laryngotracheitis or acute laryngotracheobronchitis, is a common pediatric viral inflammatory condition.[159,160] Croup generally affects the subglottic airway (i.e., larynx and trachea) but can extend as far as the bronchi.[159,160] With this area being the narrowest part of the pediatric airway, significant airway obstruction is very common in these patients.

This respiratory tract disorder is characterized by a hoarse voice, cough, acute onset of stridor, and a varying degree of respiratory distress.[159,160]

Clinical Signs and Symptoms

There tends to be a wide clinical spectrum of croup. Patients with croup initially present with nonspecific respiratory symptoms such as a sore throat, cough, and runny nose.[161,162] Over the course of a few days, characteristic signs include low-grade fever, hoarseness, a seal-like barking cough, inspiratory stridor, and a variable degree of respiratory distress.[161,162] Symptoms tend to worsen at night and usually resolve within 3–7 days but have been seen to last as long as 2 weeks.[161,162] The clinical presentation of stridor has wide variation. Some children have stridor only during physical activity, while others have stridor accompanied by respiratory distress at rest.[161,162] Substantial degrees of airway obstruction can even cause "quiet stridor" in certain patients.[161,162] Milder cases may present with normal respiratory sounds, but more severe cases can have inspiratory and expiratory stridor, retractions, or even poor air entry.[161,162] Fatigue and agitation occur and are due to respiratory distress, triggering hypoxemia and hypercarbia.[161,162] Additional signs of respiratory distress include tachypnea, tachycardia, cyanosis, and poor muscle tone. Additionally, during severe coughing fits, respiratory arrest has been known to occur.[161,162] Croup scoring systems have been created to assist clinicians in characterizing the severity of respiratory impairment in children with croup. The most widely used clinical score, demonstrated by its validity and reliability is the Westley croup score.[163] The Westley croup score evaluates the severity of croup by considering 5 common symptoms: level of consciousness, stridor, cyanosis, air entry, and retractions[163] (**Table 24-3**). The score for each of the symptoms is totaled. Children with a Westley croup score of 0–2 are considered to have mild croup.[163] Those corresponding to a Westley croup score of 3–5 indicate moderate croup.[163] Severe croup is denoted by a Westley croup score of 6–11.[163] A Westley croup score of greater than 11 signifies impending respiratory failure.[163]

Etiology

Croup is caused by viruses spread through direct inhalation from a cough/sneeze or by contamination of hands with consequent touching of the face.[164] Parainfluenza viruses (Types I, II, III) are the most common viral types causing croup outbreaks each year.[164] They account for nearly 80% of all croup cases.[164] Other etiologic agents include **respiratory syncytial virus (RSV)**, adenovirus, and influenza viruses A and B.[164] The chief entry points of the virus are the nose and nasopharynx.[164] The infection spreads and eventually reaches the larynx and trachea. In some cases, the lower airways may also be affected and could necessitate additional evaluation to address concerns of secondary bacterial infections.[164]

Epidemiology

Croup is the most common pediatric upper airway disorder, accounting for nearly 15% of the annual emergency department (ED) visits each year.[165] It typically affects infants and toddlers between the ages of 6 months and 3 years, with a peak incidence in the second year of life.[165] Croup occurs most often in early fall and winter but may present at any time.[165] The male-to-female ratio is roughly 1.4:1 for croup.[165] While infrequent, croup can also be a recurring disorder, with nearly 5% of patients experiencing more than 1 episode of croup.[165]

Pathology/Pathophysiology

Recall that the narrowest portion of the pediatric airway is the subglottis, just below the vocal cords. This anatomic distinction predisposes children to airway obstruction and to infectious diseases, such as croup.[166] Inflammation and edema of the subglottic airway are cause for concern. The infiltration of inflammatory cells

TABLE 24-3
Westley Croup Score[165]

	Score					
Symptom	**0**	**1**	**2**	**3**	**4**	**5**
Stridor	None	With agitation	At rest w/stethoscope	At rest w/o stethoscope	N/A	N/A
Retractions	None	Mild	Moderate	Severe	N/A	N/A
Air Entry	Normal	Decreased	Markedly decreased	N/A	N/A	N/A
Cyanosis on Room Air	None	N/A	N/A	N/A	With agitation	At rest
Level of Consciousness	Normal	N/A	N/A	N/A	N/A	Disoriented

Modified from Li S. The Westley croup score. *Acad Emerg Med.* 2003;10(3):289. doi:10.1197/aemj.10.3.289.

can trigger swelling, which can significantly reduce airflow.[166] Seal-like coughs, stridor, and chest wall retractions arise from the narrowing of the pediatric airway.[161,166] Associated hoarseness is due to the reduced mobility of the vocal cords secondary to edema.[161,166] In severe croup cases, hypoxemia may occur from the development of even greater airway obstruction, impaired alveolar ventilation, or V/Q mismatching.[166]

Risk Factors

Individuals most at risk of getting croup are children between the ages of 6 months and 3 years.[167] Preventing colds and the flu, frequent hand washing, and up-to-date vaccinations can help to stop the incidence of croup.[167] Other risk factors for developing croup include seasonal variation, prematurity, and other cases of viral infections.[167]

Complications

Complications due to croup are sporadic. In most cases, less than 5% of patients diagnosed with croup need in-patient hospitalization and less than 2% of those require intubation tactics.[159] Mortality from croup has occurred in as little as 0.5% of intubated patients, provided good airway management is carried out.[159] A secondary bacterial infection, such as pneumonia or tracheitis, may result from croup. Additionally, conditions including pulmonary edema, pneumothorax, pneumomediastinum, ear infections, and lymphadenitis (i.e., lymph node inflammation) have been reported.[159] Poor nutritional status and increased fluid loss can lead to patients requiring intravenous fluid hydration.[159]

Diagnostic Testing

Croup is a clinical diagnosis, with the past medical history and physical assessment findings presenting as clues. Laboratory tests rarely confirm the diagnosis; however, white blood cell (WBC) count and differential can help to identify the specific etiologic agent type.[164,168] Nasal washing can help to determine isolation precautions in the hospital setting and to decide whether antiviral therapies should be initiated.[164,168] Pulse oximetry is useful to assess decompensating respiratory status and the demand for supplemental oxygen therapy. ABGs are necessary only if respiratory failure arises. Fluid support may be required to maintain the needed fluid volume. Laryngoscopy is indicated only in unusual cases.[164,168] CXRs can help confirm a presumptive diagnosis or exclude other disorders. Lateral neck films detect haziness in the subglottic airway or a distended hypopharynx, which contrast epiglottitis findings.[169,170] The AP radiograph of the neck classically shows subglottic narrowing or the steeple sign[169,170] (**Figure 24-26**). While helpful, these radiographic findings are seen only in roughly 50% of clinical croup cases.[169,170]



FIGURE 24-26 Neck radiograph of croup showing steeple sign.
Reproduced with permission from American Academy of Family Physicians.

Treatment and Management

Treatment and management recommendations for croup are based on the severity of symptoms and any corresponding assessments. Most mild croup cases can be successfully treated at home using humidified mist, anti-fever medications, head elevation, and continued parental monitoring.[171–173] In the cases of severe respiratory distress, a thorough evaluation should be performed to determine airway patency and maintenance of oxygenation and ventilation.[171–173] Keeping children as comfortable as possible and avoiding painful interventions can prevent agitation, reduce respiratory distress, and decrease oxygen therapy requirements. Careful monitoring of vital signs and nutritional/hydration status is important. Due to their antiinflammatory capabilities, corticosteroids are beneficial in the treatment of croup. Corticosteroids are known to decrease laryngeal edema and reduce the inflammatory reaction.[174] Dexamethasone is the most common corticosteroid used for the treatment of croup. Studies have shown that if administered within the first 24 hours, a single dose of dexamethasone has been effective in reducing overall croup severity.[174] The route of administration (i.e., intravenously, intramuscularly, or orally) is patient dependent and has shown to have the same efficacy toward the presenting illness.[174] Nebulized racemic epinephrine is typically reserved for croup patients with moderate-to-severe respiratory distress. Epinephrine works by adrenergic stimulation, leading to improvements in laryngeal edema.[175] It takes effect immediately and has shown to have effective therapeutic benefits within the first 30 minutes, lasting up to 2 hours.[175] Due to the short half-life of epinephrine,

a single dose may relieve symptoms, but a repeat dose could be required. Clinicians should continue to monitor these patients for the possible return of symptoms, which include recurring bronchospasm, worsening respiratory distress, and tachycardia.[175] A system-wide study showed that patients who received corticosteroids and single-dose racemic epinephrine were managed differently than those who received multidose racemic epinephrine and corticosteroids.[174,175] Higher rates of hospital admission were seen in patients who received only single-dose racemic epinephrine treatments in the ED.[174,175] The administration of **heliox** can be a beneficial treatment option for select patients with croup. Heliox can be dispensed as 80:20, 70:30, or 60:40 mixtures; however, patients requiring less than 40% oxygen will not see the benefits of heliox therapy. By using heliox, turbulent airflow is transformed into a more laminar flow, thus bypassing obstructions and lessening airway resistance.[176] This lower density gas carries oxygen and medications through the narrowed airways, thereby decreasing the work of breathing and improving gas exchange.[176] High costs and delivery setup complexity are some limiting factors to heliox therapy. Some recent trials have demonstrated no advantageous benefits of heliox therapy over traditional modalities, while other studies have shown it to be equally effective to racemic epinephrine in the treatment of moderate-to-severe croup.[176] Heliox has also shown to improve symptoms in patients failing to improve with racemic epinephrine treatments.[176] Heliox serves as a therapeutic bridge until the underlying condition can be treated. Infants experiencing severe respiratory distress may require ventilatory support due to increasing respiratory fatigue and worsening hypercarbia.[176] Discharge can occur only if the patient demonstrates clinical stability.

Prognosis

The prognosis of croup is excellent. Advancements in treatment and management have altered this disorder from a once fatal upper airway disease to a somewhat self-limiting disorder. The majority of croup cases can be treated as outpatients. Patients younger than 6 months, an unusually long duration of symptoms, and those with recurring croup should be evaluated for congenital anomalies.[160]

Epiglottitis

Epiglottitis, also termed *supraglottitis*, is a bacterial inflammation of the structures above the insertion of the glottis (i.e., epiglottis, surrounding tissues, and the supraglottic larynx).[177,178] The epiglottis is the most common spot of swelling. As the edema increases, the epiglottis is repositioned posteriorly, causing gradual airway obstruction.[177,178] The anatomic features of the epiglottis are significantly different between children and adults. The epiglottis is located more anteriorly and superiorly, and it is at a greater angle to the trachea in children.[177,178] Acute epiglottitis and associated life-threatening airway obstruction have substantial morbidity and mortality consequences.[177,178]

Clinical Signs and Symptoms

An abrupt onset of severe respiratory symptoms characterizes epiglottitis. If not quickly recognized, symptoms can quickly progress to severe airway obstruction or respiratory arrest. Symptoms typically begin with fever, followed by stridor, labored breathing, dysphagia, hoarseness, refusal to eat, sore throat, and anxiety.[161] The onset of classic epiglottitis is easily identified using the clinical triad: drooling, dysphagia, and distress.[161] Upon physical examination, children appear restless, irritable, and extremely anxious.[161] Children may sit in the tripod position (i.e., chin hyperextended and body leaning forward), which maximizes airflow entry and improves diaphragmatic excursion.[161] During an examination of the oropharynx, a swollen, red epiglottis can be seen. Patients may present with stridor, but as the epiglottitis progresses, breath sounds may become diminished as a result of severe airway obstruction.[161] A clinician capable of obtaining an airway should attend to this patient at all times.

Etiology

Formerly, Haemophilus influenza type b (Hib) was the most common cause (>90%) of pediatric epiglottitis cases.[178] However, since the introduction of the Hib vaccine, the main contributing agent of epiglottitis has changed. Bacterial causes of epiglottitis include *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Haemophilus parainfluenzae*.[178] While viruses do not routinely cause epiglottitis, a previous viral infection can increase the chances of a bacterial infection occurring. Viral agents, including herpes simplex virus, parainfluenzae virus, human immunodeficiency virus, and varicella (i.e., chickenpox), can cause primary or secondary infections to occur.[178] Noninfectious etiologies such as trauma or thermal injury may also cause epiglottic inflammation.[178]

Epidemiology

Epiglottitis is a rare condition most commonly seen in children between 2 and 5 years old.[179] Studies have shown a seasonal variation in pediatric epiglottitis incidence.[179] A comparative study found a 10-fold decline in acute epiglottitis admissions in large U.S. children's hospitals.[179] Generally, studies have shown no racial predominance for epiglottitis; however, a recent report revealed higher incidence in black and Hispanic patients.[179] Epiglottitis is also a male-dominant disorder, which remains true even with changing epidemiology.[179]

Pathology/Pathophysiology

The pathophysiology of epiglottitis involves the respiratory transmission of bacteria through close contact. Infectious pathogens penetrate the mucosa and invade the bloodstream, leading to infections of the epiglottis and surrounding tissues.[180,181] Infection of the epiglottis results in acute swelling of the airways. Respiratory distress or ultimately arrest can occur due to severe airway obstruction, aspiration of secretions, or mucus plugging.[180,181]

Risk Factors

Several factors increase the risk of a child developing epiglottitis. Children younger than 1 year of age who have not completed the Hib vaccine series are at a higher risk for emerging epiglottitis.[178] While unclear, the male gender is more likely to develop epiglottitis than females.[178] Increased exposure to respiratory infections (e.g., schools or day care centers) heightens the risk of getting epiglottitis.[178] Furthermore, a weakened immune system can make it more challenging to combat infections, making it easier for epiglottitis to develop.[178]

Complications

During the progression of epiglottitis, other infections are possible. The most commonly associated infection is pneumonia.[182] The two most common complications are accidental extubation and respiratory arrest.[182] Additionally, complications related to an inflamed epiglottis include airway obstruction as well as aspiration, tracheal stenosis, pneumothorax, and epiglottic abscess.[182]

Diagnostic Testing

The diagnosis of epiglottitis requires a superior clinical inkling and careful recognition of the clues provided in the patient's presentation. Securing and maintaining the airway is of utmost importance. In patients with mild cases, visualization of the epiglottis may be performed via gentle compression of the tongue with a tongue depressor.[183,184] While laryngoscopy is the best way to confirm diagnosis via direct visualization of the epiglottis, it is not advised without first securing the airway.[183,184] Refrain from progressing with diagnostic testing until airway maintenance is performed. Laboratory test results show an elevated WBC count and positive blood cultures for the bacterial etiologic agent.[183,184] In highly suspected epiglottitis cases, radiography is not indicated. In less clear cases, radiologic images can establish the diagnosis and rule out other conditions (i.e., croup or FBO).[185] A lateral neck radiograph may demonstrate the thumb sign, indicating a swollen epiglottis protruding from the hypopharynx[185] (**Figure 24-27**).



FIGURE 24-27 Neck radiograph of the epiglottitis showing thumb sign.
Case courtesy of Dr Andrew Ho, Radiopaedia.org, rID: 22906.

Treatment and Management

The typical treatment and management of epiglottitis include treating potential hypoxemia, maintaining the airway, relieving the airway obstruction, and eradicating the infectious agent.[186,187] Oxygen therapy is used to treat hypoxemia in distressed patients while stabilizing the airway.[186,187] Clinicians should always be prepared to evaluate the ABCs (i.e., airway, breathing, and circulation). If epiglottitis is suspected, emergency airway management should be performed. Mortality rates for children who require, but do not receive, endotracheal intubation is as high as 10%.[186,187] Because there is no underlying lung disease, clinicians should place the patient on normal rest ventilator settings. Appropriate antibiotic therapy should be tailored to the cause of the bacterial infection. Patients recovering from epiglottitis may be extubated when an air leak around the endotracheal tube occurs at 24–48 hours.[186,187] Children should be placed on supplemental oxygen therapy and closely monitored. Clinicians must be prepared for emergent reintubation situations, as patients with epiglottitis have a substantial risk of decompensating following extubation.[186,187]

Prognosis

Patients with epiglottis, and whose airways have been properly secured, have a good prognosis. There is a less than 1% mortality rate in these patients.[186] There are no long-term complications associated with epiglottitis and discharge usually occurs within a week.[186]

Bronchiolitis

Bronchiolitis is an acute, viral inflammation of the bronchioles. It is typically a self-limiting disorder with a wide spectrum of clinical symptoms. Bronchiolitis is characterized by acute swelling, increased mucus production, and bronchoconstriction.[188,189] It is the most common cause of lower respiratory tract infection in infants younger than 1 year of age.[188,189] Although it occurs in children of all ages, severe bronchiolitis has a peak incidence in infants between 3 and 6 months of age.[188,189] Despite the published clinical practice guidelines, there are still inconsistencies in the management and treatment of patients with bronchiolitis. More standardized bronchiolitis care can lead to fewer patient hospitalizations and shorter length of stays.

Clinical Signs and Symptoms

The past medical history and clinical assessment form the finding of bronchiolitis. Initial clinical manifestations are subtle, including difficult feedings, tachypnea, expiratory wheezing, low-grade fever, and nasal congestion.[190,191] Feeding intolerance can lead to dehydration and trigger thickened secretions. Progression of bronchiolitis leads to the development of a cough, dyspnea, and profound inspiratory and expiratory wheezing.[190,191] Severe cases result in impending respiratory failure secondary to lower respiratory tract obstruction and inflammation.[190,191] Hypoxia is the best predictor to determine the severity of the disease. This V/Q mismatch occurs because of the collapse of the bronchioles and atelectasis. Typically, severity worsens over the first 72 hours, then plateaus, and rectifies over several weeks. Though several severity-scoring systems exist, none are widely used and few prove predictive validity. While rarely lasting longer than a few days, careful monitoring is required to detect apneic episodes in these patients. Additional clinical signs include retractions, nasal flaring, and cyanosis.[190,191]

Etiology

Most cases of bronchiolitis are caused by a variety of viral pathogens, but RSV is the most common.[191,192] RSV accounts for nearly 80% of all bronchiolitis cases in children younger than 2 years.[191,192] Other etiologic agents include rhinovirus, parainfluenza virus, adenovirus, and coronavirus.[191,192] Bronchiolitis is highly contagious and is spread via direct contact with nasal secretions or respiratory droplets.[191,192] Once contaminated, RSV can survive on the hands for a considerable amount of time, making good hand-washing technique and infection prevention imperative.

Epidemiology

In the United States, nearly 125,000 hospitalizations and 250 infant deaths due to bronchiolitis occur each year.[193] Of those patients hospitalized, roughly 2–5% require mechanical ventilation support.[193] Recall that RSV is the most common viral cause of bronchiolitis. Nearly all children are infected with RSV at least once by the age of 2, but peak numbers occur between 2 and 3 months following birth.[193] The highest RSV infections occur in winter months, with peak season happening from October to February.[193]

Pathology/Pathophysiology

Once viruses penetrate the bronchioles (i.e., small airways) and cause infection, bronchiolar injury and subsequent inflammation occur.[194,195] A complex inflammatory response develops in the epithelium, resulting in necrosis.[194,195] The release of cytokines amplifies the inflammatory response into the airways. Bronchiolar injury is caused by inflammation, edema, and debris in the respiratory tract.[194,195] Adverse effects of bronchiolar injury, including increased mucus production, airway obstruction, air trapping, and atelectasis, typically begin to appear about 24 hours following infection.[194,195] The extent of mucus plugging prompts various degrees of airway obstruction, the principal contributing factor to V/Q mismatching, hypoxemia, and, ultimately, respiratory failure.[194,195]

Risk Factors

Risk factors described with bronchiolitis include younger gestational age (i.e., <3 months), low birth weight, parental smoking, chronic lung disease, congenital heart disease, and airway anomalies.[196] Male gender, living in crowded environments, attending day care, and low socioeconomic status (SES) are additional risk factors for the development of bronchiolitis.[196] Age significantly impacts the severity of bronchiolitis. The younger the patient is, the more severe the respiratory tract infection seems to be. While the exact reason is unknown, severe bronchiolitis occurs more frequently in males than in females.[196] Lower SES may poorly affect outcomes and increase the probability of hospitalization.[196] Clinicians should consider hospitalization in questionable patients with a history of apnea, difficulty feeding, pronounced respiratory distress, and the need for supplemental oxygen.[196]

Complications

Various complications are possible with bronchiolitis. Bronchiolitis is most commonly a self-limiting disorder. However, the more severe cases can result in acute RDS, bronchiolitis obliterans, CHF, other infections, or chronic lung disease.[196] A quite dangerous complication associated with bronchiolitis is apnea, predominantly in the premature, low-birth-weight infant.[196] Neurologic complications, including seizures and encephalopathy, are experienced by both healthy children and previously impaired children with bronchiolitis.[196]

Diagnostic Testing

The most common diagnosis of bronchiolitis is based on clinical presentation and physical examination. Few laboratory tests are needed if the patient assessment is consistent with the suspected diagnosis of bronchiolitis. Diagnostic testing is usually used to exclude other diagnoses, verify viral etiology, and establish required infection controls for the hospital setting.[197,198] While diagnostic testing is common, the literature does not support routine use, largely due to costs and unnecessary hospitalizations.[197,198] Hospital-based protocols or guidelines can assist clinicians in better evaluating the proven benefit of diagnostic tests in bronchiolitis. The most common diagnostic tests used for bronchiolitis are viral testing of nasal secretions, pulse oximetry, ABG analysis (in severe patients), and CXR.[197,198] RSV is the most common pathogen found when viral testing is performed.[197,198] Though the nasal swab technique is the simpler, less traumatic option for sampling mucus, the more reliable technique is nasal washing.[197,198] Despite being generally good at detecting viruses, the test results rarely impact the clinical management or outcome of bronchiolitis. Lower limits of acceptable oxygen saturation levels for children with bronchiolitis have recently been supported by clinical management guidelines.[197,198] While CXR are not routinely required, if indicated, include both AP and lateral views. CXRs are most useful in identifying alternative conditions (e.g., pneumonia, CHF, or foreign body aspiration).[199] Radiographic findings of bronchiolitis are variable, but most acute cases present with at least one of the following: hyperinflation, lobar infiltrates, and atelectasis.[199] A CXR is warranted in children who appear ill, are clinically deteriorating, or are at high risk.

Treatment and Management

Recall that bronchiolitis is the most common cause of hospitalization in children. While management varies widely, the mainstay is directed toward maintenance care and symptomatic relief. The usual treatment interventions include supplemental oxygen therapy, pharmacologic remedies, chest physiotherapy, nasal suctioning, and positive pressure ventilation.[197,200,201] Initial management involves cardiorespiratory monitoring, pulse oximetry, and maintenance of adequate hydration status. The use of proper oxygenation administration has shown to be the primary indicator of the length of stay in bronchiolitis patients.[197,200,201] Reduced intubation rates and decreased escalation of care have been seen in infants with bronchiolitis treated using HFNC therapy.[197,200,201] Fever and tachypnea cause infants with bronchiolitis to become dehydrated.[197,200,201] It is vital to have fluid goal therapies in place to replace deficits and maintain adequate requirements. Pharmacology plays a restricted role in bronchiolitis management. Despite several drugs (e.g., bronchodilators, antivirals, corticosteroids, and hypertonic saline) being commonly used to treat bronchiolitis, none have shown conclusive evidence to support routine use.[202] Bronchodilators (e.g., B2-adrenergic and alpha-adrenergic) have been recommended only in infants who show documented positive clinical improvements; otherwise, discontinuation due to adverse side effects is encouraged.[202] While once a core therapeutic intervention for bronchiolitis, ribavirin (i.e., broad-spectrum antiviral medication) is no longer supported for routine use because of its inconsistent effects on RSV infections.[202] Nevertheless, some professional associations support the use of aerosolized ribavirin therapy for high-risk infants with RSV disease.[202] Corticosteroids were believed to reduce the edematous pathology; however, inconclusive benefits have been reported.[202] As a safety precaution, experts recommend avoiding their use in patients unless a clear clinical advantage is seen. Opinions vary when it comes to the beneficial use of hypertonic saline therapy. There is accumulating evidence against the routine practice of nebulized hypertonic saline; however, one trial did find that nebulized 3% hypertonic saline was safe, inexpensive, and effective in moderately ill infants with bronchiolitis.[203] Therefore, clinicians should make pharmacologic treatment decisions based on clinical presentation and disease state progression. Although considered useful for patients with severe plugging or atelectasis, chest physiotherapy cannot be endorsed for symptomatic treatment in patients with bronchiolitis either. Airway obstruction is the most recurrent complication in acute bronchiolitis. Infants with bronchiolitis may require frequent nasal suctioning to clear their passages; however, no clear evidence supports this therapy. Frequent suctioning has several risks, so equipment selection and regularity of therapy should be tailored toward maximal effectiveness.[203] Patients with bronchiolitis experiencing apnea or increased work of breathing may require positive pressure ventilation. Clinicians must supportively provide adequate oxygenation and ventilation via ventilator strategies. Patients must be monitored and assessed regularly and changes in respiratory status should regulate alterations in ventilatory management. CPAP can increase FRC and improve V/Q matching, leading to decreased respiratory distress.[204] NIPPV helps to splint the bronchioles, reduce airway resistance and gas trapping, and recruit underinflated lung units, resulting in improved V/Q matching.[204] In worsening cases, conventional ventilation, HFV, or ECMO may need to be initiated. Additionally, heliox therapy has shown to be successful in reducing respiratory distress in patients with airway compromise.[204]

Prognosis

Improved prognosis in pediatric bronchiolitis is a result of a better clinical understanding of the pathophysiology behind the viral infection. Bronchiolitis

causes mortality in less than 1% of cases.[205] Most infants with bronchiolitis recover within 2–5 days, but severe cases may be hospitalized or display symptoms for a few weeks.[205] An increased incidence of recurring wheezing is commonly seen in infants recovering from bronchiolitis.[205] Furthermore, while bronchiolitis is a risk factor for asthma, research has not yet confirmed its contributing impact in the development of asthma.[205]

Foreign Body Obstruction

Foreign body obstruction (FBO) is a common experience in children. It is defined as an aspirated solid lodging in the larynx or trachea.[206] While common, it can be a life-threatening emergency. If the aspirated solid is large enough to completely obstruct the airway, asphyxia and possibly death can occur rapidly. A milder degree of obstruction usually results in less severe clinical symptoms. The peak incidence age of obstruction is between 1 and 2 years, with the majority of incidences occurring before the age of 4 years.[206] Food is the most often aspirated object, but other items, including small toys, coins, and pins, have been observed.

Clinical Signs and Symptoms

In FBO cases, a quick assessment is necessary to allow for reversal of symptoms and prevention of complete airway obstruction as soon as possible. In nearly complete obstruction, respiratory distress, cyanosis, loss of consciousness, and impending death occur quickly, unless the object is dislodged.[207,208] When the degree of obstruction is less serious or the object falls into the lower airway, the clinical signs are less dramatic. In these milder cases, symptoms sometimes disappear until chronic wheezing or recurrent pneumonia brings patients to the ED.[207,208] Presenting clinical symptoms include a cough, dyspnea, fever, chest pain, and hemoptysis.[207,208] Upon physical examination, wheezing, stridor, or diminished breath sounds are normally heard.[207,208]

Etiology

Children are always at an increased risk for putting small toys, coins, or food pieces into their mouths. Children aged 1–4 years are easily distracted and are often not attentive during meals, thus increasing accidents. During eating, incomplete incisors cause food fragments to push posteriorly, triggering an impulse aspiration.[209] Oftentimes, children are just inquisitive and place objects in their mouths, not knowing the detrimental health consequences that can ensue.

Epidemiology

The true prevalence of **foreign body aspiration** is unknown because cases are suddenly discovered, unobserved, or misdiagnosed.[210,211] Literature puts choking as the fourth leading cause of unintentional death in the United States.[210,211] Morbidity increases with FBO cases the longer the object remains lodged.[210,211] Younger patients are at an increased risk for FBO because of their juvenile behavior and because of the way they chew.

Pathology/Pathophysiology

Anatomic and physiologic features increase the risk of foreign body aspiration in children. If the object descends into the lower airway, its whereabouts would depend on the patient's age and physical position at the time of aspiration.[210,212] Equal prevalence of foreign body location is seen in infants because the angle of the mainstem bronchi is identical until the age of 15.[210,212] Objects may continuously descend or reposition, especially following unsuccessful attempts at removal. The foreign object may cause inflammation, edema, and even bleeding to occur, resulting in more difficult obstructions. Swelling causes formation of a plug around the object, decreasing airflow to the distal airways. Air trapping, atelectasis, volume loss, and infection may occur distally to the obstruction.[210,212]

Risk Factors

Predisposing factors for FBO include access to unsuitable foods or objects, active behavior while eating, and small airway diameters (i.e., prone to easy obstruction).[213]

Complications

The prospect of complications increases the longer the airway remains obstructed, making hasty removal of the object crucial. Clinical complications include atelectasis and post-obstructive infection.[213] Recurrent infections can eventually lead to bronchiectasis, which should be treated after the removal of the foreign object.[213] Major complications seen following foreign body removal include pneumothorax, hemorrhage, and respiratory distress or arrest; however, these seldom occur.[213]

Diagnostic Testing

An ABG analysis to monitor the adequacy of ventilation should be performed in conjunction with a physical examination, vital sign monitoring, and pulse oximetry.[208,214] On a CXR, hyperinflation, atelectasis, and a mediastinal shift can be seen[208,214] (**Figure 24-28**). Most foreign objects are radiolucent. The presence of a foreign body, its location, shape, composition, position, size, and the extent of obstruction must be identified prior to removal procedures taking place.[208,214] Some foreign objects are missed on radiography if they disguise themselves or are completely immersed by surrounding tissues.[208,214]



FIGURE 24-28 CXR of a foreign body aspiration.
Reproduced with permission from Life in the Fast Lane (LITFL.com).

Treatment and Management

Recall that prompt removal of foreign objects is recommended. Bronchoscopy is both a diagnostic and a therapeutic tool used in FBO cases. Removal of the foreign body can be done with rigid or flexible bronchoscopy.[213] While rigid bronchoscopy usually requires sedation or general anesthesia, it is the procedure of choice in children, with success rates at more than 98%.[213] Regardless of which technique is used, it is essential to make sure that all fragments of the foreign object have been extracted. Removal using direct visualization is complicated but effective in children with partial FBO cases. In this treatment option, a laryngoscope and Magill forceps are used to remove the object.[213] Careful follow-up monitoring and a short course of antibiotics, bronchodilators, or steroid therapy may be suggested.[213]

Prognosis

Prognosis is good for patients who experience FBOs, as long as it is treated expeditiously. Almost all FBOs are reversible using bronchoscopy. Clinicians should monitor these patients post-procedurally for signs of airway irritation, respiratory distress, or the development of scar carcinoma.[215]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Treatment for bronchiolitis almost always involves surgery.
2. True or False: The cause of most cases of croup is viral.
3. True or False: The type of obstruction typically involved with acute epiglottitis is supraglottic.

Chapter Summary

Precise and timely recognition of pulmonary disorders can often make the difference between a neonatal or pediatric patient's survival and death. These respiratory system deficiencies illustrate the importance of why clinicians must carefully choose appropriate diagnostic modalities and properly assess symptoms to effectually and appropriately arrive at a positive diagnosis and a management care plan.

Key Points

1. Widespread physiologic changes accompany the birth process, sometimes exposing neonatal pulmonary conditions that require proper clinical reasoning and decision making to manage.
2. The anticipatory preparation of clinicians in delivery room care ensures excellent short- and long-term outcomes in neonates.
3. In most cases, AOP will resolve itself with no lasting complications; however, some infants require pharmacologic or ventilatory support to maintain respiratory functionality.
4. Neonates with MAS may have tachypnea, nasal flaring, desaturations, abnormal breath sounds, retractions, cyanosis, or visible meconium staining in the oropharynx.
5. Infants with CHDs are often at lasting risk for other medical troubles and developmental complications.
6. The main causes of IRDS are lung structure immaturity and a lack of surfactant in the lungs.
7. BPD most commonly develops in neonates who require prolonged ventilator support or long-term supplemental oxygen therapy, which interrupts typical lung development.
8. Once transient TTN resolves, infants recover quickly and have no minimal risk for additional respiratory or chronic health problems.
9. The progression of a CDH allows abdominal contents to enter the chest cavity, compressing the infant's lung and triggering respiratory distress.
10. Clinicians must have powerful problem-solving skills to appropriately diagnose, treat, and manage pediatric pulmonary disorders.
11. Croup is an acute, viral pediatric respiratory tract infection that is usually identified clinically, but a neck radiographic film typically shows a classic steeple sign, supporting the diagnosis.
12. If epiglottitis is suspected, securing a child's compromised airway is of greatest importance.
13. Indications for bronchiolitis include advancing respiratory distress, lethargy, history of apneic episodes, hypoxemia, and inadequate feedings.
14. FBO occurs very acutely and causes asphyxia in children; thus, rapid clinical recognition is the key to successful patient outcomes.

Chapter Questions

1. True or False: Apnea is a symptom of any number of different etiologies.
2. Croup affects what three anatomical areas of the infant?
   - **a.** Larynx, trachea, and bronchi
   - **b.** Larynx, trachea, and esophagus
   - **c.** Trachea, esophagus, and bronchi
   - **d.** It affects only two anatomical areas: larynx and trachea
3. True or False: Acute bronchiolitis is usually bacterial in nature.
4. What are the major factors involved in the pathophysiology of infant respiratory distress syndrome (IRDS)?
   - I. Surfactant deficiency
   - II. Increased alveolar surface area
   - III. Shunting of blood
   - IV. Deprived lung fluid clearance
     - **a.** I, II, III
     - **b.** I, III, IV
     - **c.** II, III, IV
     - **d.** I, II, III, IV
5. What is associated with the ball-valve effect in meconium aspiration syndrome?
   - **a.** Barotrauma
   - **b.** Atelectrauma
   - **c.** Volutrauma
   - **d.** Biotrauma
6. Which of the following defects is NOT associated with tetralogy of Fallot?
   - **a.** Ventricular septal defect
   - **b.** Pulmonic stenosis
   - **c.** Misplaced aorta
   - **d.** Right ventricular hypoplasia
7. The most common radiographic finding that suggests the presence of epiglottitis is (the) _____.
   - **a.** steeple sign
   - **b.** atelectasis
   - **c.** thumb sign
   - **d.** perihilar streaking
8. The cause of transient tachypnea of the newborn (TTN) is believed to be _____.
   - **a.** delayed clearance of fetal lung fluid
   - **b.** pre-eclampsia
   - **c.** irregular formation of the heart
   - **d.** impaired surfactant production
9. What is the best strategy in the management/treatment of bronchopulmonary dysplasia (BPD)?
   - **a.** Extracorporeal membrane oxygenation
   - **b.** Prevention
   - **c.** HFNC therapy
   - **d.** Antibiotics
10. The standard diagnostic tool to confirm the presence of a congenital diaphragmatic hernia is _____.
    - **a.** magnetic resonance imaging
    - **b.** echocardiogram
    - **c.** ABG analysis test
    - **d.** chest radiography (CXR)
11. All of the following are included in the clinical presentation of foreign body obstruction in children, EXCEPT _____.
    - **a.** cyanosis
    - **b.** increased mucus production
    - **c.** wheezing
    - **d.** respiratory distress
12. True or False: Most congenital heart defects are caused by genetics.
13. If a neonate is failing to thrive upon delivery examination, clinicians have approximately _____ to complete the preliminary evaluation and initiate resuscitative interventions.
    - **a.** 30 seconds
    - **b.** 60 seconds
    - **c.** 2 minutes
    - **d.** 5 minutes
14. What is another name for TTN?
    - **a.** Fetal asphyxia
    - **b.** Fetal hypoxic stress syndrome
    - **c.** Wet lungs
    - **d.** Hyaline membrane disease
15. What breath sounds are heard in congenital diaphragmatic hernia?
    - **a.** Diminished with wheezing sounds on the affected side
    - **b.** Rhonchi sounds on the affected side
    - **c.** Diminished with bowel sounds in the chest cavity
    - **d.** Rhonchi with bowel sounds in the chest cavity
16. Which information would be most helpful during patient/caregiver education about the primary prevention of foreign body aspiration?
    - **a.** Most common objects that infants aspirate
    - **b.** Signs and symptoms of foreign body aspiration
    - **c.** Therapeutic management of foreign body aspiration
    - **d.** Risks associated with foreign body aspiration
17. True or False: Thinner meconium usually correlates with more severe respiratory symptoms.
18. If neonatal breathing is not adequate, the ABCs of resuscitation should be followed. What do the ABCs stand for?
    - **a.** Airway, breathing, and circulation
    - **b.** Airway, blood sampling, and CXR
    - **c.** ABG analysis, breathing, and corticosteroids
    - **d.** Apgar score, bronchodilators, and circulation

19. Lower gestational age _____ the incidence of apnea.
- **a.** increases
- **b.** decreases
- **c.** does not affect

20. The position of the pulmonary artery and aorta being switched describes the pathophysiology of which congenital heart defect?
- **a.** Truncus arteriosus
- **b.** Coarctation of the aorta
- **c.** Ebstein anomaly
- **d.** Transposition of the great arteries

References

1. Martin JA, Hamilton BE, Osterman JK, Driscoll AK, Drake P. Births: final data for 2016 [Report]. *National Vital Statistics Report.* 2018;67(1):1–54. https://www.cdc.gov/nchs/fastats/births.htm
2. Haverkamp A, Thompson H, McFee J, Cetrulo C. The evaluation of continuous fetal heart rate monitoring in high-risk pregnancy. *Am J Obstet Gynecol.* 1976;125(3):310–320. doi:10.1016/0002-9378(76)90565-2.
3. Clark S, Paul R. Intrapartum fetal surveillance: the role of fetal scalp blood sampling. *Am J Obstet Gynecol.* 1985;153(7):717–720. doi:10.1016/0002-9378(85)90330-8.
4. Chandraharan E, Wiberg N. Fetal scalp blood sampling during labor: an appraisal of the physiological basis and scientific evidence. *Acta Obstet Gynecol Scand.* 2014;93(6):544–547. doi:10.1111/aogs.12416.
5. Choudhury P. Neonatal resuscitation program: first golden minute. *Indian Pediatr.* 2009;46(1):7–9.
6. Tomek S. Newborn resuscitation: the golden minute. *EMS World.* 2011;40(6):45–50.
7. Hamilton P. ABC of labour care: care of the newborn in the delivery room. *BMJ.* 1999;318(7195):1403–1406. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1115782/
8. Eichenwald EC. Apnea of prematurity. *Pediatrics.* 2016;137(1). doi:10.1542/peds.2015-3757.
9. Thach BT. Apnea and the sudden infant death syndrome. In: Saunders NA, Sullivan CE. eds. *Sleep and Breathing.* 2nd ed. New York, NY: Marcel Dekker; 1994:649–671.
10. Mathew O. Apnea of prematurity: pathogenesis and management strategies. *J Perinatol.* 2011;31(5):302–310. doi:10.1038/jp.2010.126.
11. Moriette G, Lescure S, Ayoubi M, Lopez E. Apnea of prematurity: what's new? *Arch Pediatr.* 2010;17(2):186–190.
12. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. *Eur J Pediatr.* 2011;170(9):1097–1105. doi:10.1007/s00431-011-1409-6.
13. Darnall R, Ariagno R, Kinney H. The late preterm infant and the control of breathing, sleep, and brainstem development: a review. *Clin Perinatol.* 2006;33(4):883–914. doi:10.1016/j.clp.2006.10.004.
14. Lorch S, Srinivasan L, Escobar G. Epidemiology of apnea and bradycardia resolution in premature infants. *Pediatrics.* 2011;128(2):e366–e373. doi:10.1542/peds.2010-1567.
15. Blackmon L, Batton D, Bell E, et al. Apnea, sudden infant death syndrome, and home monitoring. *Pediatrics.* 2003;111(4):914–917. doi:10.1542/peds.111.4.914.
16. Poets C. Apnea of prematurity: what can observational studies tell us about pathophysiology? *Sleep Med.* 2010;11(7):701–707. doi:10.1016/j.sleep.2009.11.016.
17. Di Fiore J, Martin R, Gauda E. Apnea of prematurity—perfect storm. *Respir Physiol Neurobiol.* 2013;189(2):213–222. doi:10.1016/j.resp.2013.05.026.
18. Holditch-Davis D. Development of sleep and sleep problems in preterm infants. In: *Encyclopedia of Early Childhood Development.* 2nd ed. Chapel Hill, NC: Encyclopedia of Early Childhood Development; 2010.
19. Ducrocq S, Biran-Mucignat V, Boelle P, Lebas F, Baudon J, Gold F. Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate.(Report). *Arch Pediatr.* 2006;13(10):1299–1304. doi:10.1016/j.arcped.2006.06.016.
20. Atkinson E, Fenton A. Management of apnea and bradycardia in neonates. *Paediatr Child Health.* 2009;19(12):550–554. doi:10.1016/j.paed.2009.06.008.
21. Stokowski L. A primer on apnea of prematurity. *Adv Neonatal Care.* 2005;5(3):155–170. doi:10.1016/j.adnc.2005.02.010.
22. Bancalari E. Caffeine therapy for apnea of prematurity [Editorial]. *N Engl J Med.* 2006;354(20):2179–2181. doi:10.1056/NEJMoa054065.
23. Pantalitschka T, Sievers J, Urschitz M, Herberts T, Reher C, Poets C. Randomised crossover trial of four nasal respiratory support systems for apnoea of prematurity in very low birthweight infants. *Arch Dis Child Fetal Neonatal Ed.* 2009;94(4):F245–F248. doi:10.1136/adc.2008.148981.
24. Lee J, Romero R, Lee K, et al. Meconium aspiration syndrome: a role for fetal systemic inflammation. *Am J Obstet Gynecol.* 2016;214(3):366.e1–366.e9. doi:10.1016/j.ajog.2015.10.009.
25. Swarnam K, Soraisham A, Sivanandan S. Advances in the management of meconium aspiration syndrome. *Int J Pediatr.* 2012;2012:359571. doi:10.1155/2012/359571.
26. Committee opinion no.689 summary: delivery of a newborn with meconium-stained amniotic fluid. *Obstet Gynecol.* 2017;129(3):593–594. doi:10.1097/AOG.0000000000001946
27. Ince DA, Takci S, Altintas B. Risk factors and clinical follow-up features of meconium aspiration syndrome. *J Turgut Ozal Med Cent.* 2015;22(2):158–164. doi:10.7247/jtomc.2014.2256.
28. Dargaville P, Copnell B. The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. *Pediatrics.* 2006;117(5):1712–1721. doi:10.1542/peds.2005-2215.
29. Singh BS, Clark RH, Powers RJ, Spitzer AR. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. *J Perinatol.* 2009;29(7):497–503. doi:10.1038/jp.2008.241.
30. Janssen D, Carnielli V, Cogo P, et al. Surfactant phosphatidylcholine metabolism in neonates with meconium aspiration syndrome. *J Pediatr.* 2006;149(5):634–639. doi:10.1016/j.jpeds.2006.07.027.
31. Wiswell T, Tuggle J, Turner B. Meconium aspiration syndrome: have we made a difference? *Pediatrics.* 1990;85(5):715–721. doi:10.1038/345009b0.
32. Walsh-Sukys M, Tyson J, Wright L, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. *Pediatrics.* 2000;105(1):14–20. doi:10.1542/peds.105.1.14.
33. Fraser W, Hofmeyr J, Lede R, et al. Amnioinfusion for the prevention of the meconium aspiration syndrome. *N Engl J Med.* 2005;353(9):909–917. doi:10.1056/NEJMoa050223.
34. Vain NE, Szyld E, Prudent LM, Hodnett E. Intrapartum suctioning of the mouth and nose did not reduce the incidence of meconium aspiration syndrome. *Evidence-based Obstet Gynecol.* 2005;7(3):125–126. doi:10.1016/j.ebobgyn.2005.05.013.
35. Mammel M, Gordon M, Connett J, Boros S. Comparison of high-frequency jet ventilation and conventional mechanical ventilation in a meconium aspiration model. *J Pediatr.* 1983;103(4):630–634. doi:10.1016/S0022-3476(83)80603-9.
36. Goldsmith J. Continuous positive airway pressure and conventional mechanical ventilation in the treatment of meconium aspiration syndrome. *J Perinatol.* 2008;28(Suppl 3):S49–S55. doi:10.1038/jp.2008.156.
37. Kopincová J, Mokrá D, Mikolka P, Kolomazník M, Čalkovská A. N-acetylcysteine advancement of surfactant therapy in experimental meconium aspiration syndrome: possible mechanisms. *Physiol Res.* 2014;63:S629–S642.

38. Marks S, Nicholl R. The reduction in the need for ECMO by using surfactant in meconium aspiration syndrome. *J Pediatr.* 1999;135(2):267–268. doi:10.1016/S0022-3476(99)70040-5.
39. Macfarlane P, Heaf D. Pulmonary function in children after neonatal meconium aspiration syndrome. *Arch Dis Child.* 1988;63(4):368–372. doi:10.1136/adc.63.4.368.
40. Garne E, Olsen M, Johnsen S, et al. How do we define congenital heart defects for scientific studies? *Congenit Heart Dis.* 2012;7(1):46–49. doi:10.1111/j.1747-0803.2011.00581.x.
41. Nichols DG, Cameron DE, Ungerleider RM, et al. *Critical Heart Disease in Infants and Children.* 2nd ed. Philadelphia, PA: Elsevier Mosby; 2006.
42. Westmoreland D. Critical congenital cardiac defects in the newborn. *J Perinat Neonatal Nurs.* 1999;12(4):67–87. doi:10.1097/00005237-199903000-00007.
43. Britannica, Educational Publishing. Types of congenital heart diseases. In: Rogers K, ed. *Cardiovascular System*. Edinburgh: Britannica Educational Publishing; 2011.
44. Chandramouli B. The neonate with congenital heart disease: diagnosis and management. *Indian J Pediatr.* 1991;58(4):453–469. doi:10.1007/BF02750929.
45. Shi H, Yang S, Liu Y, et al. Study on environmental causes and SNPs of MTHFR, MS and CBS genes related to congenital heart disease. *PLoS One.* 2015;10(6):e0128646. doi:10.1371/journal.pone.0128646
46. Laas E, Lelong N, Thieulin A, et al. Preterm birth and congenital heart defects: a population-based study. *Pediatrics.* 2012;130(4):e829–e837. doi:10.1542/peds.2011-3279.
47. Saperova EV, Vahlova IV. Congenital heart diseases in children: incidence, risk factors, mortality. *Voprosy Sovremennoj Pediatrii.* 2017;16(2):126–133. doi:10.15690/vsp.v16i2.1713.
48. Chowdhury D. Pathophysiology of congenital heart diseases. *Ann Card Anaesth.* 2007;10(1):19–26. doi:10.4103/0971-9784.37920.
49. Mainwaring R, Pastuszko P, Lamberti, J. Atrial septal defects. In: Kaiser L, Kron IL, Spray TL, eds. *Mastery of Cardiothoracic Surgery*. Philadelphia, PA: Wolters Kluwer; 2014.
50. Geva T, Martins J, Wald R. Atrial septal defects. *Lancet.* 2014;383(9932):1921–1932.
51. Fuller S. Ventricular septal defects. In: Kaiser L, Kron IL, Spray TL, eds. *Mastery of Cardiothoracic Surgery*. Philadelphia, PA: Wolters Kluwer; 2014.
52. Bonello B, Fouilloux V, Bel S, Fraisse A, Kreitmann B, Metras D. Ventricular septal defects. In: *Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care*. London, UK: Springer-Verlag; 2014:1455–1478. doi:10.1007/978-1-4471-4619-3_15.
53. Rubio A, Lewin M. Ventricular septal defects. In: *Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult.* 8th ed. (Vols. 1–2). Philadelphia, PA: Wolters Kluwer Health Adis (ESP); 2013.
54. Berger S, Bartz PJ, Saudek DE, Hambrook JT, Tweddell JS. Atrioventricular septal defects. In: Moller JH, Hoffman JIE, eds. *Pediatric Cardiovascular Medicine.* Oxford, UK: Wiley-Blackwell; 2012:308–327. doi:10.1002/9781444398786.ch22.
55. Cetta F, Minich L, Maleszewski J, Dearani J, Burkhart H. Atrioventricular septal defects. In: *Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult.* 8th ed. (Vols. 1–2). Philadelphia, PA: Wolters Kluwer Health Adis (ESP); 2013.
56. Brudney C. Aortic stenosis. In: Vincent J-L, Hall JB, eds. *Encyclopedia of Intensive Care Medicine*. Berlin, Germany: Springer-Verlag; 2012.
57. Sun J, Felner J. Aortic stenosis. In: Sun J, Felner J, Merlino J, eds. *Practical Handbook of Echocardiography: 101 Case Studies*. Oxford, UK: Wiley-Blackwell; 2010:24–26. doi:10.1002/9781444320367.ch7.
58. Rigby M. Severe aortic or pulmonary valve stenosis in premature infants. *Early Hum Dev.* 2012;88(5):291–294. doi:10.1016/j.earlhumdev.2012.02.011.
59. Dye FJ. Pulmonary stenosis. In: Dye FJ, ed. *Dictionary of Developmental Biology and Embryology*. Boston, MA: Wiley; 2012.
60. Lee M, Kumar T, Paudel G. Double aortic arch presenting as neonatal respiratory failure in the delivery room. *Cardiol Young.* 2017;28(3):476–478. doi:10.1017/S1047951117002335.
61. Kaldararova M, Simkova I, Varga I, et al. Double aortic arch anomalies in children: a systematic 20-year single center study. *Clin Anat.* 2017;30(7):929–939. doi:10.1002/ca.22955.
62. Gross R. Coarctation of the aorta. *Circulation.* 1953;7(5):757–768. doi:10.1161/01.CIR.7.5.757.
63. Sudarshan C, Cochrane A, Jun Z, Soto R, Brizard C. Repair of coarctation of the aorta in infants weighing less than 2 kilograms. *Ann Thorac Surg.* 2006;82(1):158–163. doi:10.1016/j.athoracsur.2006.03.007.
64. Epifânio P, Emanuel Amaral M, Moreira Â, Rodrigues D, Pires A, Castela E. Total anomalous pulmonary venous return. *Rev Port Cardiol* (English Ed.). 2016;35(4):243–244. doi:10.1016/j.repce.2015.10.023.
65. Bibevski S, Friedland-Little J, Ohye R, Thor T, Gaies M. Truncus arteriosus. In: Da Cruz E, Ivy D, Jaggers J, eds. *Pediatric and Congenital Cardiology, Cardiac Surgery and Intensive Care.* London, UK: Springer-Verlag; 2014:1983–2001. doi:10.1007/978-1-4471-4619-3_48.
66. Mavroudis C, Backer C. Truncus arteriosus. In: Mavroudis C, Backer C, eds. *Pediatric Cardiac Surgery.* 4th ed. Oxford, UK: Blackwell Publishing Ltd; 2013:361–375. doi:10.1002/9781118320754.ch19.
67. Warnes C. Transposition of the great arteries. *Circulation.* 2006;114(24):2699–2709. doi:10.1161/CIRCULATIONAHA.105.592352.
68. Wernovsky G. Transposition of the great arteries. In: *Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult.* 8th ed., Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2013.
69. Barron D, Kilby M, Davies B, Wright J, Jones T, Brawn W. Hypoplastic left heart syndrome. *Lancet.* 2009;374(9689), 551–564. doi:10.1016/S0140-6736(09)60563-8.
70. Mussa S, Barron D. Hypoplastic left heart syndrome. *Paediatr Child Health.* 2017;27(2):75–82. doi:10.1016/j.paed.2016.12.002.
71. Yuan S. Ebstein's anomaly: genetics, clinical manifestations, and management. *Pediatr Neonatol.* 2017;58(3):211–215. doi:10.1016/j.pedneo.2016.08.004.
72. Kozik DJ, Plunkett D. Pulmonary stenosis and pulmonary atresia with intact septum. In: Kaiser L, Kron IL, Spray TL, eds. *Mastery of Cardiothoracic Surgery*. Philadelphia, PA: Wolters Kluwer; 2014.
73. Fraser C, Bacha E, Comas J, Sano S, Sarris G, Tsang V. Tetralogy of Fallot. *Semin Thorac Cardiovasc Surg.* 2015;27(2):189–204. doi:10.1053/j.semtcvs.2015.08.006.
74. Sharkey A, Sharma A. Tetralogy of fallot. *Semin Cardiothorac Vasc Anesth.* 2012;16(2):88–96. doi:10.1177/1089253211434566.
75. Apitz C, Webb GD, Redington AN. Tetralogy of fallot. *Lancet.* 2009;374(9699):1462–1471.
76. Szlam S, Dejanovich B, Ramirez R, Rice S, McMorrow-Jones S. Congenital heart disease: complications before and after surgical repair. *Clin Pediatr Emerg Med* 2012;13(2):65–80. doi:10.1016/j.cpem.2012.04.005.
77. Hamadah M, Kabbani M, Faraji M. Ultrasonography assessment of congenital renal anomalies in children with congenital heart diseases. *J Saudi Heart Assoc.* 2016;28(3):219. doi:10.1016/j.jsha.2016.04.078.
78. Sholler G, Kasparian N, Pye V, Cole A, Winlaw D. Fetal and postnatal diagnosis of major congenital heart disease: implications for medical and psychological care in the current era. *J Paediatr Child Health.* 2011;47(10):717–722. doi:10.1111/j.1440-1754.2011.02039.x.
79. Bute M. Congenital heart disease and treatment options. *Case Manager.* 2004;15(2):56–58. doi:10.1016/j.casemgr.2004.02.006.
80. Miera O, Potapov E, Berger F. End-stage heart failure in children or patients suffering from congenital heart disease: are new treatment options emerging? *Eur J Cardiothorac Surg.* 2013;43(5):886–887. doi:10.1093/ejcts/ezt090.
81. Ley D, Wide-Swensson D, Lindroth M, Svenningsen N, Marsal K. Respiratory distress syndrome in infants with impaired intrauterine growth. *Acta Pædiatr.* 1997;86(10):1090–1096. doi:10.1111/j.1651-2227.1997.tb14814.x.

82. Garvey J. Infant respiratory distress syndrome. *Am J Nurs.* 1975;75(4):614–617. doi:10.1097/00000446-197504000-00028.
83. Simone L, Fischer J. Newborn infant with respiratory distress. *Ann Emerg Med.* 2016;67(3):e7–e8. doi:10.1016/j.annemergmed.2015.08.026.
84. Gill P, Campbell D. A newborn infant with respiratory distress: more than meets the eye. *J Paediatr Child Health.* 2018;54(3):327–329. doi:10.1111/jpc.13750.
85. Lyra PPR, Diniz EMA. The importance of surfactant on the development of neonatal pulmonary diseases [Síndrome da angustia respiratória aguda e proteinose alveolar congênita]. *Clinics.* 2007;62(2):181–190. doi:10.1590/S1807-59322007000200014.
86. Miranda J, Collins B, Wydro G, Gar M. Infant with acute respiratory distress. *Ann Emerg Med.* 2017;69(2):166–191. doi:10.1016/j.annemergmed.2016.07.011.
87. American College of Obstetricians and Gynecologists. *Clinical Management Guidelines for Obstetrician-Gynecology: Fetal Lung Maturity.* Washington, DC: ACOG; 2008.
88. Agrons GA, Courtney SE, Stocker JT, et al. From the archives of the AFIP: lung disease in premature neonates: radiologic-pathologic correlation. *Radiographics.* 2005;25(4):1047–1073.
89. Williams GD, Christodoulou J, Stack J, et al. Surfactant protein B deficiency: clinical, histological and molecular evaluation. *J Paediatr Child Health.* 1999;35(2):214–220.
90. Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. *Pediatr Dev Pathol.* 2009;12(4):253–274.
91. Jobe AH, Ikegami M. Surfactant and acute lung injury. *Proc Assoc Am Physicians.* 1998;110(6):489–495.
92. Mage D, Donner E. The fifty percent male excess of infant respiratory mortality. *Acta Pædiatr.* 2004;93(9):1210–1215. doi:10.1111/j.1651-2227.2004.tb02751.x.
93. Frisbie W, Song S, Powers D, Street J. The increasing racial disparity in infant mortality: respiratory distress syndrome and other causes. *Demography.* 2004;41(4):773–800. doi:10.1353/dem.2004.0030.
94. Davey M, Watson L, Rayner J, Rowlands S. Risk scoring systems for predicting preterm birth with the aim of reducing associated adverse outcomes. *Cochrane Database Syst Rev*. 2011;(11):CD004902.
95. Dimitriou G, Fouzas S, Giannakopoulos I, Papadopoulos V, Decavalas G, Mantagos S. Prediction of respiratory failure in late-preterm infants with respiratory distress at birth. *Eur J Pediatr.* 2011;170(1):45–50. doi:10.1007/s00431-010-1264-x.
96. Cruz A, Buhi W, Birk S, Spellacy W. Respiratory Distress Syndrome with mature lecithin/sphingomyelin ratios: diabetes mellitus and low Apgar scores. *Am J Obstet Gynecol.* 1976;126(1):78–82. doi:10.1016/0002-9378(76)90468-3.
97. Murphy K, Hannah M, Willan A, et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. *Lancet.* 2008;372(9656):2143–2151. doi:10.1016/S0140-6736(08)61929-7.
98. Polin R, Carlo W. Surfactant replacement therapy for preterm and term neonates with respiratory distress. *Pediatrics.* 2014;133(1):156–163. doi:10.1542/peds.2013-3443.
99. Aly H, Massaro A, Patel K, El-Mohandes A. Is it safer to intubate premature infants in the delivery room? *Pediatrics.* 2005;115(6):1660–1665. doi:10.1542/peds.2004-2493.
100. Murki S, Singh J, Khant C, et al. High-flow nasal cannula versus nasal continuous positive airway pressure for primary respiratory support in preterm infants with respiratory distress: a randomized controlled trial. *Neonatology.* 2018;113(3):235–241. doi:10.1159/000484400.
101. Jaegere A, Deurloo E, Rijn R, Offringa M, Kaam A. Individualized lung recruitment during high-frequency ventilation in preterm infants is not associated with lung hyperinflation and air leaks. *Eur J Pediatr.* 2016;175(8):1085–1090. doi:10.1007/s00431-016-2744-4.
102. De Kleine M, Den Ouden A, Kollée L, et al. Lower mortality but higher neonatal morbidity over a decade in very preterm infants. *Paediatr Perinat Epidemiol.* 2007;21(1):15–25. doi:10.1111/j.1365-3016.2007.00780.x.
103. Javaid A, Morris I. Bronchopulmonary dysplasia. *Paediatr Child Health.* 2018;28(1):22–27. doi:10.1016/j.paed.2017.10.004.
104. Gappa M, Pillow J, Allen J, Mayer O, Stocks J. Lung function tests in neonates and infants with chronic lung disease: lung and chest-wall mechanics. *Pediatr Pulmonol.* 2006;41(4):291–317. doi:10.1002/ppul.20380.
105. Poindexter B, Feng R, Schmidt B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. *Ann Am Thorac Soc.* 2015;12(12):1822–1830. doi:10.1513/AnnalsATS.201504-218OC.
106. Nickerson BG. Bronchopulmonary dysplasia. Chronic pulmonary disease following neonatal respiratory failure. *Chest.* 1985;87(4):528–535.
107. Zeitlin P, Nogee L. Etiology of bronchopulmonary dysplasia: before birth. *Pediatr Allergy Immunol Pulmonol.* 2011;24(1):21–25. doi:10.1089/ped.2011.0074.
108. Jensen E, Schmidt B. Epidemiology of bronchopulmonary dysplasia. *Birth Defects Res A Clin Mol Teratol.* 2014;100(3):145–157. doi:10.1002/bdra.23235.
109. Hwang J, Rehan V. Recent advances in bronchopulmonary dysplasia: pathophysiology, prevention, and treatment. *Lung.* 2018;196(2):129–138. doi:10.1007/s00408-018-0084-z.
110. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the national institute of health consensus definition of bronchopulmonary dysplasia. *Pediatrics.* 2005;116(6):1353–1360.
111. Baraldi E, Fillippone M. Chronic lung disease after premature birth. *N Engl J Med.* 2007;357:1946–1955.
112. Walsh MC, Szefler S, Davis J, et al. Summary proceedings from the bronchopulmonary dysplasia group. *Pediatrics.* 2006;117(3):S52–S56.
113. Voynow J. "New" bronchopulmonary dysplasia and chronic lung disease. *Paediatr Respir Rev.* 2017;24:17–18. doi:10.1016/j.prrv.2017.06.006.
114. Klinger G, Sokolover N, Boyko V, et al. Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of very-low-birthweight infants. *Am J Obstet Gynecol.* 2013;208(2):115.e1–115.e9. doi:10.1016/j.ajog.2012.11.026.
115. Torchin H, Ancel P, Goffinet F, et al. Placental complications and bronchopulmonary dysplasia: epipage-2 cohort study. (Report). *Pediatrics*. 2016;137(3):e20152163.
116. May C, Kennedy C, Milner A, Rafferty G, Peacock J, Greenough A. Lung function abnormalities in infants developing bronchopulmonary dysplasia (Report). *Arch Dis Child.* 2011;96(11):1014. doi:10.1136/adc.2011.212332.
117. Jobe AJ. The New BPD: an arrest of lung development. *Pediatr Res.* 1999;46(6):641–643. doi:10.1203/00006450-199912000-00007.
118. Moya M, Bisset III G, Auten Jr. R, Miller C, Hollingworth C, Frush D. Reliability of CXR for the diagnosis of bronchopulmonary dysplasia. *Pediatr Radiol.* 2001;31(5):339–342. doi:10.1007/s002470000420.
119. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Target ranges of oxygen saturation in extremely preterm infants. (Clinical report). *N Engl J Med.* 2010;362(21):1959–1969. doi:10.1056/NEJMoa0911781.
120. Jasani B, Kabra N, Nanavati R. Surfactant replacement therapy beyond respiratory distress syndrome in neonates. *Indian Pediatr.* 2016;53(3):229–234. doi:10.1007/s13312-016-0826-z.
121. Millar D, Kirpalani H, Lemyre B, Yoder B, Chiu A, Roberts R. 171 Nippv does not reduce Bronchopulmonary Dysplasia (Bpd) or death in extremely low birth weight infants—a randomised trial. *Arch Dis Child.* 2012;97(suppl 2):A49. doi:10.1136/archdischild-2012-302724.0171.
122. Mariann HB, Trond M, Thomas H. Ventilator flow data predict bronchopulmonary dysplasia in extremely premature neonates. *ERJ Open Res.* 2018;4(1). pii: 00099-2017. doi:10.1183/23120541.00099-2017.
123. Fuchs H, Rossmann N, Schmid M, et al. Permissive hypercapnia for severe acute respiratory distress syndrome in immunocompromised children: a single center experience.(Research Article)(Report). *PLoS One.* 2017;12(6):e0179974. doi:10.1371/journal.pone.0179974.
124. Jobe A. Postnatal corticosteroids for preterm infants—do what we say, not what we do. *N Engl J Med.* 2004;350(13):1349–1351. doi:10.1056/NEJMe048031.

125. Buonocore G, Bracci R, Weindling M. *Neonatology: A Practical Approach to Neonatal Diseases*. Milan, Italy: Springer-Verlag; 2012: 1–1348. doi:10.1007/978-88-470-–1405-3.
126. Welty S. Is there a role for antioxidant therapy in bronchopulmonary dysplasia? *J Nutr.* 2001;131(3):947S–950S. doi:10.1093/jn/131.3.947S.
127. Schwart E, Zelig R, Parker A, Johnson S. Vitamin A supplementation for the prevention of bronchopulmonary dysplasia in preterm infants: an update. *Nutr Clin Pract.* 2017;32(3):346–353. doi:10.1177/0884533616673613.
128. Hoehn T, Krause M, Krueger M, Hentschel R. Treatment of respiratory failure with inhaled nitric oxide and high-frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia. *Respiration.* 1998;65(6):477–480. doi:10.1159/000029317.
129. Hakulinen A, Lansimies E, Heinonen K. Pulmonary function and respiratory morbidity in school-aged prematurely-born children ventilated for neonatal respiratory insufficiency. *Pediatr Res.* 1989;26(5):517. doi:10.1203/00006450-198911000-00109.
130. Blayney M, Kerem E, Whyte H, Brodovich H. Bronchopulmonary dysplasia: Improvement in lung function between 7 and 10 years of age. *J Pediatr.* 1991;118(2):201–206. doi:10.1016/S0022-3476(05)80483-4.
131. Sutton, A. *Respiratory disorders sourcebook.* Basic consumer health information about the risk factors, symptoms, diagnosis, and treatment of lung and respiratory disorders, including asthma, bronchitis, chronic obstructive pulmonary disease (COPD), influenza, lung cancer, pneumonia, and other infectious and inflammatory pulmonary diseases; along with information about pediatric respiratory disorders, tips on preventing respiratory problems and living with chronic lung disease, a glossary of related terms, and a directory of resources for additional help and information. 3rd ed. Detroit, MI: Omnigraphics Inc; 2014.
132. Hagen E, Chu A, Lew C. Transient tachypnea of the newborn. *NeoReviews.* 2017;18(3):e141–e148.
133. Dehdashtian M, Aletayeb M, Malakian A, Aramesh M, Malvandi H. Clinical course in infants diagnosed with transient tachypnea of newborn: a clinical trial assessing the role of conservative versus conventional management. *J Chin Med Assoc.* 2018;81(2):183–186. doi:10.1016/j.jcma.2017.06.016.
134. Kasap B, Duman N, Özer E, Tatli M, Kumral A, Özkan H. Transient tachypnea of the newborn: predictive factor for prolonged tachypnea. *Pediatr Int.* 2008;50(1):81–84. doi:10.1111/j.1442-200X.2007.02535.x.
135. Reuter S, Moser C, Baack M. Respiratory distress in the newborn. *Pediatr Rev.* 2014;35(10):417–428.
136. Yurdakok M, Ozek E. Transient tachypnea of the newborn: the treatment strategies. *Curr Pharm Des.* 2012;18(21):3046–3049.
137. Yurdakok M. Transient tachypnea of the newborn: what is new? *J Matern Fetal Neonatal Med.* 2010;23(suppl 3):24–26.
138. Hooper S, Siew M, Kitchen M, Te Pas A. Establishing functional residual capacity in the non-breathing infant. *Semin Fetal Neonatal Med.* 2013;18(6):336–343. doi:10.1016/j.siny.2013.08.011.
139. Machado L, Fiori H, Baldisserotto M, Ramos Garcia P, Vieira A, Fiori R. Surfactant deficiency in transient tachypnea of the newborn. *J Pediatr.* 2011;159(5):750–754. doi:10.1016/j.jpeds.2011.04.023.
140. Guglani L, Ryan R, Lakshminrusimha S. Risk factors and management of transient tachypnea of the newborn. *Pediatr Health.* 2009;3(3):251–260. doi:10.2217/phe.09.24.
141. Liem J, Huq S, Ekuma O, Becker A, Kozyrskyj A. Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms. *J Pediatr.* 2007;151(1):29–33. doi:10.1016/j.jpeds.2007.02.021.
142. Ramadan M, Hussein G, Saheb W, Rajab M, Mirza F. Antenatal corticosteroids in the late preterm period: a prospective cohort study. *J Neonatal Perinatal Med.* 2016;9(1):15–22. doi:10.3233/NPM-16915086.
143. Okulu E, Kahvecioğlu D, Kılıç A, et al. 1781 The predictive factors in the progress of transient tachypnea of the newborn. *Arch Dis Child.* 2012;97(suppl 2):A504. doi:10.1136/archdischild-2012-302724.1781.
144. Guglani L, Lakshminrusimha S, Ryan RM. Transient tachypnea of the newborn. *Pediatr Rev.* 2008;29(11):e59–e65.
145. Lin A, Pober B, Adatia I. Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management. *Am J Med Genet C Semin Med Genet.* 2007;145(2):201–216. doi:10.1002/ajmg.c.30131.
146. Leeuwen L, Fitzgerald DA. Congenital diaphragmatic hernia. *J Paediatr Child Health.* 2014;50(9):667–673.
147. Greer JJ. Current concepts on the pathogenesis and etiology of congenital diaphragmatic hernia. *Respir Physiol Neurobiol.* 2013;189(2):232–240.
148. Skarsgard ED, Harrison MR. Congenital diaphragmatic hernia: the surgeon's perspective. *Pediatric Rev.* 1999;20:e71-e78.
149. Mohseni-Bod H, Bohn D. Pulmonary hypertension in congenital diaphragmatic hernia. *Semin Pediatr Surg.* 2007;16:126–133.
150. McHoney M. Congenital diaphragmatic hernia. *Early Hum Dev.* 2014;90(12):941–946.
151. Burgos C, Frenckner B. Addressing the hidden mortality in CDH: a population-based study. *J Pediatr Surg.* 2017;52(4):522–525. doi:10.1016/j.jpedsurg.2016.09.061.
152. Keijzer R, Puri P. Congenital diaphragmatic hernia. *Semin Pediatr Surg.* 2010;19(3):180–185.
153. McAteer J, Hecht A, De Roos A, Goldin A. Maternal medical and behavioral risk factors for congenital diaphragmatic hernia. *J Pediatr Surg.* 2014;49(1):34–38. doi:10.1016/j.jpedsurg.2013.09.025
154. García A, Machicado S, Gracia G, Zarante I. Risk factors for congenital diaphragmatic hernia in the Bogota birth defects surveillance and follow-up program, Colombia. *Pediatr Surg Int.* 2016;32(3):227–234. doi:10.1007/s00383-015-3832-7.
155. Arora M, Bajpai M, Soni TR, Sai Prasad TR. Congenital diaphragmatic hernia. *Indian J Pediatr.* 2000;67(9):665–670.
156. Kumar A, Bhatnagar V. Respiratory distress in neonates. *Indian J Pediatr.* 2005;72(5):425–428.
157. Sakai H, Tamura M, Hosokawa Y, et al. Effect of surgical repair on respiratory mechanics in congenital diaphragmatic hernia. *J Pediatr.* 1987;111:432–438.
158. Tsao K, Lally KP. Congenital diaphragmatic hernia and eventration. In: Holcomb GW III, Murphy JP, eds. *Pediatric Surgery*. 5th ed. Philadelphia, PA: Saunders; 2010:304–321.
159. Johnson D. Croup. *BMJ Clin Evid.* 2014;0321.
160. Bjornson C, Johnson D. Croup in children. *CMAJ.* 2013;185(15): 1317–1323. doi:10.1503/cmaj.121645.
161. Tibballs J, Watson T. Symptoms and signs differentiating croup and epiglottitis. *J Paediatr Child Health.* 2011;47(3):77. doi:10.1111/j.1440-1754.2010.01892.x.
162. Dykes J. Managing children with croup in emergency departments. *Emerg Nurse* (through 2013). 2005;13(6):14–19. doi:10.7748/en2005.10.13.6.14.c1217.
163. Li S. The Westley croup score. *Acad Emerg Med.* 2003;10(3):289. doi:10.1197/aemj.10.3.289.
164. Wald E. Croup: common syndromes and therapy. *Pediatr Ann.* 2010;39(1):15–21. doi:10.3928/00904481-20091210-04.
165. Shah S, Sharieff G. Pediatric respiratory infections. *Emerg Med Clin North Am.* 2007;25(4):961–979. doi:10.1016/j.emc.2007.07.006.
166. Roth DE, Caulfield LE, Ezzati M, Black RE. Acute lower respiratory infections in childhood: opportunities for reducing the global burden through nutritional interventions. *Bull World Health Organ.* 2008;86(5):356–364.
167. Pruikkonen H, Dunder T, Renko M, Pokka T, Uhari M. Risk factors for croup in children with recurrent respiratory infections: a case-control study. *Paediatr Perinat Epidemiol.* 2009;23(2):153–159. doi:10.1111/j.1365-3016.2008.00986.x.
168. Petrocheilou A, Tanou K, Kalampouka E, Malakasioti G, Giannios C, Kaditis A. Viral croup: diagnosis and a treatment algorithm. *Pediatric Pulmonol.* 2014;49(5):421–429. doi:10.1002/ppul.22993.
169. Hankins J. Practical pediatric imaging: diagnostic radiology of infants and children. *Mil Med.* 1993;158(3):A11–A12. doi:10.1093/milmed/158.3.A11b.
170. Huang C, Shih S. Images in clinical medicine. Steeple sign of croup. *N Engl J Med*. 2012;367(1):66. doi:10.1056/NEJMicm1113937.

171. Ortiz-Alvarez O. Acute management of croup in the emergency department. *Paediatr Child Health (Canada).* 2017;22(3):166–169. doi:10.1093/pch/pxx019.
172. Smith DK, McDermott AJ, Sullivan JF. Croup: diagnosis and management. *Am Fam Physician.* 2018;97(9):575–580.
173. Pitluk J, Uman H, Safranek S. Clinical inquiries. What's best for croup? *J Fam Pract.* 2011;60(11):680.
174. Thabet A, Greenfield T, Cantor RM, Wilson B. Corticosteroid use in management of pediatric emergency conditions [digest]. *Pediatr Emerg Med Pract.* 2018;15(3 suppl):1–2.
175. Bjornson C, Russell K, Vandermeer B, Klassen T, Johnson D. Nebulized epinephrine for croup in children. *Cochrane Database Syst Rev.* 2013;2013(10):CD006619. doi:10.1002/14651858.CD006619.pub3.
176. Moraa I, Sturman N, McGuire T, van Driel M. Heliox for croup in children. *Cochrane Database Syst Rev.* 2013;12(12):CD006822. doi:10.1002/14651858.CD006822.pub4.
177. Liang R. Epiglottitis. *J Paediatr Child Health.* 2010;46(7–8):446. doi:10.1111/j.1440-1754.2010.01824_1.x.
178. Adil E, Adil A, Shah R. Epiglottitis. *Clin Pediatr Emerg Med.* 2015;16(3):149–153. doi:10.1016/j.cpem.2015.07.005.
179. Hopkins A, Lahiri T, Salerno R, Heath B. Changing epidemiology of life-threatening upper airway infections: the reemergence of bacterial tracheitis. *Pediatrics.* 2006;118(4):1418–1421. doi:10.1542/peds.2006-0692.
180. Rafei K, Lichenstein R. Airway infectious disease emergencies. *Pediatr Clin North Am.* 2006;53(2):215–242. doi:10.1016/j.pcl.2005.10.001.
181. Savenkova MS, Balyasinskaya GL, Bychkov VA, Voronyuk GM, Korobko LM, Anin AN. Acute epiglottitis in children (etiopathogenesis, diagnosis, treatment). *Voprosy Sovremennoj Pediatrii.* 2008;7(5):91–97. https://doaj.org/article/bd26def8bc5847f3a04b6f415494acd6
182. Tanner K, Fitzsimmons G, Carrol E, Flood T, Clark J. Lesson of the week: Haemophilus influenzae type b epiglottitis as a cause of acute upper airways obstruction in children. *BMJ.* 2002;325(7372):1099–1100. doi:10.1136/bmj.325.7372.1099
183. Shah R, Roberson D, Jones D. Epiglottitis in the hemophilus influenzae type B vaccine era: changing trends. *Laryngoscope.* 2004;114(3), 557–560. doi:10.1097/00005537-200403000-00031.
184. Sobol S, Zapata S. Epiglottitis and croup. *Otolaryngol Clin North Am.* 2008;41(3):551–566. doi:10.1016/j.otc.2008.01.012.
185. Schamp S, Pokieser P, Danzer M, Marks B, Denk D. Radiological findings in acute adult epiglottitis. *Eur Radiol.* 1999;9(8):1629–1631. doi:10.1007/s003300050898.
186. Tebruegge M, Pantazidou A, Thorburn K, et al. Bacterial tracheitis: a multi-centre perspective. *Scand J Infect Dis.* 2009;41(8):548–557. doi:10.1080/00365540902913478.
187. Shargorodsky J, Whittemore K, Lee G. Bacterial tracheitis: a therapeutic approach. *Laryngoscope.* 2010;120(12):2498–2501. doi:10.1002/lary.21105.
188. Meissner H. Viral bronchiolitis in children. *N Engl J Med.* 2016;374(1):62–72s. doi:10.1056/NEJMra1413456.
189. Florin T, Plint A, Zorc J. Viral bronchiolitis. *Lancet.* 2017;389(10065):211–224. doi:10.1016/S0140-6736(16)30951-5.
190. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. *Pediatr Pulmonol.* 2011;46(4):324–347. doi:10.1002/ppul.21377.
191. Gökçe Ş, Kurugöl Z, Koturoğlu G, Çiçek C, Aslan A. Etiology, seasonality, and clinical features of viral respiratory tract infections in children hospitalized with acute bronchiolitis: a single-center study. *Glob Pediatr Health.* 2017;4:2333794X17714378. doi:10.1177/2333794X17714378.
192. Papadopoulos N, Gourgiotis D, Javadyan A, et al. Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants? *Respir Med.* 2004;98(9):879–882. doi:10.1016/j.rmed.2004.01.009.
193. Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. *Pediatr Rev.* 2014;35(12):519–530. doi:10.1542/pir.35-12-519.
194. McNamara P, Flanagan B, Hart C, Smyth R. Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis. *J Infect Dis.* 2005;191(8):1225–1232. doi:10.1086/428855.
195. Marguet C, Bocquel N, Benichou J, et al. Neutrophil but not eosinophil inflammation is related to the severity of a first acute epidemic bronchiolitis in young infants. *Pediatr Allergy Immunol.* 2008;19(2):157–165. doi:10.1111/j.1399-3038.2007.00600.x.
196. Wainwright C. Acute viral bronchiolitis in children—a very common condition with few therapeutic options. *Paediatr Respir Rev.* 2010;11(1):39–45. doi:10.1016/j.prrv.2009.10.001.
197. Eiland L. Respiratory syncytial virus: diagnosis, treatment and prevention. *J Pediatr Pharmacol Ther.* 2009;14(2):75–85. doi:10.5863/1551-6776-14.2.75.
198. Macfarlane P, Denham J, Assous J, Hughes C. RSV testing in bronchiolitis: which nasal sampling method is best? *Arch Dis Child.* 2005;90(6):634–635. doi:10.1136/adc.2004.065144.
199. Schuh S, Lalani A, Allen U, et al. Evaluation of the utility of radiography in acute bronchiolitis. *J Pediatr.* 2007;150(4):429–433. doi:10.1016/j.jpeds.2007.01.005.
200. Iqbal S. Management of acute viral bronchiolitis in children: evidence beyond guidelines. *Sudan J Paediatr.* 2012;12(1):40–48.
201. Wohl M, Chernick V. Treatment of acute bronchiolitis. *N Engl J Med.* 2003;349(1):82–83. doi:10.1056/NEJMe030052.
202. Wright M, Mullett C, Piedimonte G. Pharmacological management of acute bronchiolitis. *Ther Clin Risk Manag.* 2008;4(5):895–903. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621418/
203. Zhang L, Mendoza-Sassi R, Klassen T, Wainwright C. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. *Pediatrics.* 2015;136(4):687–701. doi:10.1542/peds.2015-1914.
204. Verma N, Lodha R, Kabra S. Recent advances in management of bronchiolitis. *Indian Pediatr.* 2013;50(10):939–949. doi:10.1007/s13312-013-0265-z.
205. Hall C, Weinberg G, Iwane M, et al. The burden of respiratory syncytial virus infection in young children. *N Engl J Med.* 2009;360(6):588–598. doi:10.1056/NEJMoa0804877.
206. Lowe D, Vasquez R, Maniaci V. Foreign body aspiration in children. *Clin Pediatr Emerg Med.* 2015;16(3):140–148. doi:10.1016/j.cpem.2015.07.002.
207. Orji F, Akpeh J. Tracheobronchial foreign body aspiration in children: how reliable are clinical and radiological signs in the diagnosis? *Clin Otolaryngol.* 2010;35(6):479–485. doi:10.1111/j.1749-4486.2010.02214.x.
208. Tenjović D, Petrović S, Dautović G, Lovrenski J, Rodić B. Clinical and radiological characteristics of unrecognised foreign body aspiration into respiratory tract in children. *Medicinski pregled.* 2013;66(5–6):214–219. doi:10.2298/MPNS1306214T.
209. Daines C, Wood R, Boesch R. Foreign body aspiration: an important etiology of respiratory symptoms in children. *J Allergy Clin Immunol.* 2008;121(5):1297–1298. doi:10.1016/j.jaci.2008.03.014.
210. Burton E, Brick W, Hall J, Riggs Jr. W, Houston C. Tracheobronchial foreign body aspiration in children. *South Med J.* 1996;89(2):195–198. doi:10.1097/00007611-199602000-00007.
211. Boufersaoui A, Smati L, Benhalla K, et al. Foreign body aspiration in children: experience from 2624 patients. *Int J Pediatr Otorhinolaryngol.* 2013;77(10):1683–1688. doi:10.1016/j.ijporl.2013.07.026.
212. Singh H, Parakh A. Tracheobronchial foreign body aspiration in children. *Clin Pediatr.* 2014;53(5):415–419. doi:10.1177/0009922813506259.
213. Sultan T, van As A. Review of tracheobronchial foreign body aspiration in the South African paediatric age group. *J Thorac Dis.* 2016;8(12):3787–3796. doi:10.21037/jtd.2016.12.90.
214. Tseng H, Hanna T, Shuaib W, Aized M, Khosa F, Linnau K. Imaging foreign bodies: ingested, aspirated, and inserted. *Ann Emerg Med.* 2015;66(6):570–582.e5. doi:10.1016/j.annemergmed.2015.07.499.
215. Aydogdu K. Foreign body aspiration involved with bronchial carcinoma: two cases. *J Clin Anal Med.* 2016;6(150):216–218. doi:10.4328/JCAM.1475.

CHAPTER

25

Lung Transplantation

OUTLINE

OBJECTIVES

1. Explain differences between the pre-2005 and current U.S. lung transplantation allocation system.
2. Discuss primary graft dysfunction (PGD) and its implications in lung transplantation.
3. Discuss lung allograft rejection, including the diagnosis and management.
4. Review all non-rejection complications following lung transplantation.
5. Discuss current prognosis and quality of life (QOL) in patients following lung transplantation.

KEY TERMS

Acute cellular rejection (ACR)
Allograft
Allograft rejection
Anastomosis
Antibody-mediated rejection (AMR)
Bilateral lung transplantation (BLT)
Brain-dead donors (BDDs)
Bronchial anastomotic dehiscence
Bronchiolitis obliterans syndrome (BOS)
Chronic allograft rejection
Chronic lung allograft dysfunction (CLAD)
Donation after cardiac death (DCD)
Ex vivo lung perfusion (EVLP)
Expanded criteria donors
Extracorporeal photopheresis
Heart-lung transplantation (HLT)
Hyperacute allograft rejection (HAR)
Living donor lobar lung transplantation
Lung allocation score (LAS)
Primary graft dysfunction (PGD)
Restrictive allograft syndrome (RAS)
Single lung transplantation (SLT)

Case Study

A 42-year-old male and former 10 pack-year smoker with severe chronic obstructive pulmonary disease (COPD) due to emphysema and alpha-1-antitrypsin deficiency returned to his primary care provider's office for follow-up. He was recently hospitalized in the intensive care unit (ICU) for 3 days with an exacerbation of COPD, requiring the use of intravenous steroids and antibiotics, nebulized bronchodilators, and noninvasive positive pressure support (NIPPV). He had been admitted to the hospital several times over the past year. Following a brief 3-day stay in the ICU, he is transferred to a step-down unit, where he remained for 3 additional days. While in the respiratory step-down unit, the hospitalist caring for him asked him if he was ever asked about having a lung transplant, to which he denied. An arterial blood gas analysis taken before his hospital discharge showed a pH of 7.37, Pco_2 of 48, and Po_2 of 63 mm Hg.

During a follow-up office visit 10 days following hospital discharge, he reported compliance with his medical therapy, which included nebulized albuterol every 4 hours while awake, inhaled tiotropium four times daily, and inhaled salmeterol-fluticasone twice daily. He continues to wear supplemental nasal oxygen at 3 L around the clock. On physical exam, the patient appeared cachectic and has mild respiratory distress while at rest. With portable nasal oxygen, at 3 L/minute, he can walk into the exam room very slowly. His height is 5 feet 5 inches; weight is 106 pounds; blood pressure is 100/65; pulse is 110; and the oral temperature is 98.0°F. His respiratory rate is 28 and he appeared visibly labored and shallow. Pulse oximetry taken in his physician's office measured 91% on 3 L oxygen. HEENT examination displays no significant abnormal findings other than a slightly deviated nasal septum. His neck is supple with no jugular vein distension or thyroid gland enlargement. Lungs reveal markedly decreased bilateral breath sounds. Cardiac examination reveals distant heart sounds with a right ventricular heave noted but no audible murmur. The patient's abdomen is scaphoid and without masses or organomegaly. Extremity examination reveals diminished distal pulses bilaterally. Neurologic examination reveals no focal deficits.

Complete pulmonary function testing performed as an outpatient before the physician office visit reveals an forced expiratory volume in one second (FEV_1) of <30% predicted with significant elevation of static lung volumes and calculated airway resistance. He scored 3 on the Modified Medical Research Council (MMRC) Dyspnea Scale. See **Table 25-1**. He is able to walk only 100 m during a 6-minute walk test (6MWT). His body mass index (BMI) measured 17.6 kg/m^2.

During his follow-up office visit, the patient inquires as to any other treatment options that might be available to him, including whether he might be a candidate for a lung transplant.

TABLE 25-1
MMRC Dyspnea Scale

MMRC Grade	Degree of Breathlessness Related to the Following Activities
0	I get breathless only with strenuous exercise.
1	I get short of breath when hurrying on the level or walking up a slight hill.
2	I walk slower than people of the same age on the level because of breathlessness, or I have to stop for a breath when walking on my own pace on the level.
3	I stop for breath after walking about 100 m or after a few minutes on the level.
4	I am too breathless to leave the house, or I am breathless when dressing or undressing.

Data from Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for The Diagnosis, Management, And Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease; 2018. http://goldcopd.org.

Introduction

In 1963, the first human lung transplantation was attempted, but it was not until 1986 that Dr. Joel Cooper reported the first successful single lung transplant extending survival at the University of Toronto. In 1968, Dr. Denton Cooley and associates were first to attempt heart-lung transplantation (HLT) to correct an atrioventricular canal defect and pulmonary hypertension in a 2-year-old girl although the patient died 14 hours postoperatively.[1] It was not until 1981 that the first successful heart-lung transplant was performed at Stanford in a 45-year-old woman, with primary pulmonary hypertension, who survived more than 5 years following the procedure (due mostly to the advent and use of cyclosporine).[2] In 1988, Dr. Alexander Patterson described en bloc double-lung transplantation associated with tracheal anastomotic complications because of poor vascularity, which led to the development of bilateral-sequential single lung transplantation (SLT) becoming the standard of care for patients requiring bilateral lung replacement.[2] Knowledge gained from early lung transplantations resulted in refinements in patient selection, surgical techniques, immunosuppression, and postoperative care, which have made successful application of lung transplantation possible to a wide

variety of advanced lung disorders. Through June 2014, the Registry of the International Society for Heart and Lung Transplantation has data from 51,440 adult lung transplants and 3,820 adult heart-lung transplants.[3] This offers the prospect of improved functional status and QOL for the patients. Despite the growing demand for lung transplantation, serious problems persist that limit the utility of this procedure. Among those patients who make it to the waiting list in the United States, an average of 300 patients die annually while waiting for lung transplants.[4] Lung transplantation is severely limited by a shortage of donor organs, and furthermore, only 20% of potential donor lungs are used.[5]

Unfortunately, under current lung donor selection standards, many potential donors are considered incapable of meeting the demands of the many desperately ill patients awaiting transplantation. In the United States, an average of 300 patients die annually while waiting for lung transplants.[4] Some estimates suggest that as many as 80% of lungs available for transplantation are not usable because of injury imposed by the inflammatory response to brain death and complications associated with treatment in the ICU, such as barotrauma, neurogenic, and hydrostatic pulmonary edema.[6] Transplant recipients are also predisposed to numerous potential complications arising from the surgical procedure, innate transplant immunology, lifelong immunosuppressive medications, and the increased risks of developing both common and uncommon infections. Immunosuppressive therapy produces several troubling side effects, such as the significant risk of infection and malignancy. Despite the intended therapeutic use of immunosuppressive agents, allograft rejection occurs frequently and continually threatens organ function. Long-term survival utilizing current techniques continues to be an arduous goal because only about half of lung transplant recipients live beyond 5 years.[7] Optimizing outcomes in the face of these drawbacks mandates the judicious selection of candidates and meticulous care of recipients by clinicians competent in dealing with the vulnerabilities of posttransplant life.

Lung transplantation (LTx) is a well-established therapy for selected patients with end-stage pulmonary disease.[8] Transplantation is now included as a treatment option in selected patients for a diverse range of advanced pulmonary disorders that affect the airways, parenchyma, and pulmonary vasculature. Although COPD exclusive of alpha-1 antitrypsin deficiency was initially the most common indication worldwide, currently the number of transplants performed for idiopathic pulmonary fibrosis (IPF) is equal to the number of lung transplants for COPD.[8] Cystic fibrosis (CF) is the third most common indication for lung transplantation, with less common indications including emphysema due to alpha-1 antitrypsin deficiency, sarcoidosis, non-CF bronchiectasis, nontransplant obliterative bronchiolitis, and lymphangioleiomyomatosis. Idiopathic pulmonary arterial hypertension (IPAH), which at one time was considered a significant indication for lung transplantation, currently comprises only about 2% of the total number of lung transplantations performed.[9] This change has occurred as the result of major advances in the medical management of these patients. Severe lung disorders that are controversial for transplant consideration include conditions involving underlying collagen vascular disease because extrapulmonary manifestations of the systemic disease involving esophageal motility and gastrointestinal reflux may compromise posttransplant outcomes by potentially increasing the risk of aspiration and graft loss. Lung transplantation for locally advanced bronchoalveolar carcinoma results in a high rate of cancer recurrence, leading most transplant centers to abandon this as a realistic option for definitive cure.[9]

Extending the current long-term survival rate following lung transplantation is dependent upon the reduction of several common complications. These complications continue to be encountered despite vigorous attempts to identify them early and modify or extinguish their effects. **Primary graft dysfunction (PGD)**, airway complications, acute rejection, **chronic lung allograft dysfunction (CLAD)**, and respiratory infection can significantly impact immediate as well as long-term survival. PGD typically takes place in the first few weeks following transplantation, whereas acute rejection and airway complications primarily occur within the first posttransplantation year. CLAD, on the other hand, usually happens later in the posttransplant period. Infections by a wide variety of bacteria, fungi, viruses, as well as several opportunistic pathogens pose a significant risk of morbidity and mortality at all stages following transplantation.

It is vital that advances in pre- and posttransplantation care continue to evolve and have a positive impact on lung transplantation's overall success. Improving lung donor availability by utilizing extended criteria has increased the number of acceptable lungs for donation. Ex vivo lung perfusion serves to "recondition" lungs that previously might have been unacceptable and discarded.[10] Other developments include the use of gene therapy to help repair damaged donor lungs previously found unfit for transplant. These developments continue to increase the number of lungs deemed suitable for transplantation. The introduction of newer or modified immunosuppressive agents as they become available and are capable of improved immunotherapy induction, maintenance, or rescue efficacy will be welcome additions.

The Transplantation System

In 1984, the U.S. Congress passed the National Organ Transplant Act, which established the Organ Procurement and Transplantation Network (OPTN) to maintain a national registry for organ matching.[11] The U.S. organ transplantation system is composed of three distinct yet linked divisional sections. The United Network for Organ Sharing (UNOS) administers the OPTN and is under

KNOWLEDGE CHECK QUESTIONS

1. True or False: In the United States, an average of 100 patients die every year while waiting for lung transplants.
2. True or False: The number of lung transplants for IPF equals the amount for COPD.
3. True or False: Donor lungs cannot be re-conditioned to make them acceptable for transplantation.

contract with the Health Resources and Services Administration of the U.S. Department of Health and Human Services. The Organ Procurement Organizations (OPOs) are nongovernmental and have two significant roles in their service areas, to increase the number of registered donors and to coordinate the donation process. There are currently 58 OPOs in the United States, each with its designated service area.[12] Transplant centers represent the third arm of the U.S. transplantation system and are the focal point within the system where the transplantation procedures are performed.

Worldwide, organ distribution policies are influenced by medical, ethical, geographic, and political factors that vary from country to country. With many of the allocation systems in current use, however, potential recipients are placed on a waiting list and must be matched for blood group compatibility and lung size with an acceptable donor. Most lungs are procured from deceased donors after brain death, although studies of **donation after cardiac death (DCD)** suggest using DCD donors to expand the available pool.[13] Until 2005, patients in the United States were transplanted in the order they were placed on the waiting list without regard to the severity of illness. Earlier-listed patients were prioritized higher based on the length of time they had accrued on the waiting list. The rules governing the allocation of organs vary between different countries but typically involve a time-based or need-based ranking of candidates on the waiting list, or some combination of the two.[9] Experience with other solid organ transplantation made it evident that the existing time-based system was inequitable. A more valid and consistent priority system could result in lower mortality for patients with more significant need and the likelihood of not surviving prolonged waiting times.

In May 2005, the United States implemented a lung allocation scoring (LAS) system that is based on the need for transplant and the likelihood of success. The LAS system is predicated on an analysis of the comprehensive UNOS national database, which identifies a dozen factors independently predictive of 1-year survival without and with transplantation.[4] See **Box 25-1**. These factors are then used to calculate an individual's **lung allocation score (LAS)**, which can range from 0 to 100. The higher the score, the higher the preference for transplantation. Because survival without transplantation is factored into both net transplant benefit and medical urgency measures, it has a more significant impact on the LAS than posttransplant survival.[9] With the LAS system, wait time has decreased from 2 to 3 years to less than 6 months, and one-quarter of patients are waiting less than 35 days. Also, there was a significant reduction in the waiting list death rate, one of the primary objectives of the new system.[9]

BOX 25-1 LAS Data

Age
Height
Weight
Lung diagnosis code
Functional status
Diabetes
Assisted ventilation
Required supplemental oxygen
Predicted forced vital capacity (FVC) percentage
6MWT
Pulmonary artery systolic pressure
Mean pulmonary artery pressure
Cardiac index
Central venous pressure
$Paco_2$: current, highest, lowest
Serum creatinine: current, highest, lowest
Total bilirubin: current, highest, lowest

Data from the Organ Procurement and Transplantation Network Lung Allocation Score Calculator at https://optn.transplant.hrsa.gov/resources/allocation-calculators/las-calculator/.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The current lung allocation system in the United States considers both the need for transplantation and the likelihood of success.
2. True or False: Before 2005, the lung transplantation list did not consider need or success.
3. True or False: The LAS decreased the waiting time from 3 years to 1 year.

Candidate (Recipient) Selection

Referral for transplant and placement on the waiting list are two distinct processes, but there is general agreement that referral to a lung transplant program should occur early in patients who have a pulmonary disease that is amenable to transplant.[14] Ideal candidates for lung transplantation are free of comorbidities,

committed to the procedure, and have strong psychosocial support. Given the potential risks, LTx candidates should have refractory end-stage lung disease with advanced functional limitations and a limited expected survival.[15]

The pulmonary diseases amenable to lung transplantation include a broad spectrum of chronic and severely debilitating illnesses involving the airways, lung parenchyma, or pulmonary vasculature. The most common of these diseases include interstitial lung disease, most specifically IPF; CF; COPD, including both non-alpha-1 antitrypsin deficiency and alpha-1 antitrypsin deficiency; and pulmonary vascular diseases.[14] **Table 25-2** is a summary of internationally accepted disease-specific candidate selection criteria from the International Society for Heart and Lung Transplantation (ISHLT). If a patient is referred to a transplant center, it is not an automatic endorsement of listing that individual. Referral implies that a patient meets the minimum clinical characteristics that might warrant transplant consideration.[14] Listing for transplantation occurs when the pulmonary disease has advanced to a disabling and potentially life-threatening stage, such that survival with transplantation is deemed to be more likely than survival without transplantation.[9]

Patients with advanced cardiac and pulmonary disease not amenable to either isolated heart or lung transplant may be candidates for combined HLT. Most commonly, patients with irreversible myocardial dysfunction or congenital defects with irreparable defects of the valves or chambers in conjunction with intrinsic lung disease or severe pulmonary artery hypertension are considered for HLT.[14] While these more common indications for invasive transplantation procedures are life-limiting conditions, candidates for lung transplantation despite having a severe chronic lung disease that is

TABLE 25-2
Lung Transplantation Guidelines for Disease-Specific Candidate Selection

Disease	Time of Referral for Lung Transplant	Time of Placement on Wait List
IPF	At the time of diagnosis	• FVC <65% predicted • DLCO <40% predicted • 6 MWD <250 m • ≥10% decline in FVC over 6 m • ≥15% decline in DLCO over 6 m • 50 m decline in 6MVD over 6 m • Spo_2 <88% during 6MWT • Extensive and/or worsening fibrosis on HRCT • Presence of significant pulmonary hypertension • Moderate-to-severe and/or worsening dyspnea • History of respiratory hospitalization
COPD	Presence of ≥1: • BODE index ≥5 • Pao_2 <60 mm Hg and/or $Paco_2$ >50 mm Hg • FEV_1 <25% predicted • Progressive disease despite optimal medical therapy, including pulmonary rehabilitation	Presence of ≥1: • BODE ≥7 • FEV_1 <15–20% predicted • Frequent exacerbations • Episode of acute hypercapnic respiratory failure • Moderate-to-severe pulmonary hypertension
CF	• FEV_1 <30% predicted or rapid decline in FEV_1, particularly in females • Increasing frequency of exacerbations • Exacerbations requiring NIV • Recurrent or refractory pneumothorax or massive hemoptysis • Worsening nutritional status despite supplementation • 6 MWD <400 m	• $Paco_2$ >50 mm Hg • Pao_2 <60 mm Hg • Advanced functional limitation • Pulmonary hypertension
Pulmonary vascular diseases	• NYHA Functional Class III or IV with symptoms during escalating therapy • Rapidly progressive disease • Use of parenteral targeted PAH therapy regardless of symptoms or NYHA Functional Class • Known or suspected PVOD or pulmonary capillary hemangiomatosis	• Persistent NYHA Class III or IV despite maximal medical therapy • CI <2 L/minute/m^2 • Mean right atrial pressure >15 mm Hg • 6 MWD <350 m • Development of significant hemoptysis, pericardial effusion, or signs of progressive right heart failure (renal insufficiency, increasing bilirubin, brain natriuretic peptide, or recurrent ascites)

Data from Weill D, Benden C, Corris P, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant.* 2015;34(1):1-15. doi:10.1016/j.healun.2014.06.014; Girgis R, Khaghani A. A global perspective of lung transplantation: part 1—recipient selection and choice of procedure. *HYPERLINK "https://www.ncbi.nlm.nih.gov/pubmed/29043255"Glob Cardiol Sci Pract.* 2016;2016(1). doi:10.21542/gcsp.2016.5.

unresponsive to medical or surgical therapy should ideally be otherwise in reasonably good health.

Older patients have a significantly worse survival rate compared with younger patients who have similar risk factors. However, a study by Hayanga et al. suggests that, contrary to findings from previous studies, being older than 70 years of age is not an independent predictor of death at 1-year post-LTx.[16] This study, of over 6,500 patients, showed that more recently (2006–2012) survival rates for the age group 70–79 years are higher at 3- and 5-year post-LTx than in previous years (2000–2005).[16] Age needs to be considered on a case-by-case basis and in conjunction with other factors when assessing a recipient's candidacy. However, comorbidities often associated with aging, such as diabetes, coronary artery disease, and hypertension, increase risk.[15]

Patients with critical illness resulting from their severe lung disease often have major coexistent organ dysfunction or malignancy, persistent infection, obstinate behavioral nonadherence, psychiatric impairments, poor nutritional status, or other contraindications to transplantation. Each transplant center requires specific evaluation requirements that potential lung transplant recipients must undergo before a candidate is considered suitable for placement on the UNOS national waiting list. While all patients considered for transplantation undergo a standard assessment of their disease determined by each transplant center's own set of guidelines, transplant centers include a meticulous, systematic evaluation to

BOX 25-2 Testing Components of Lung Transplant Evaluation

Pulmonary Evaluation

1. PA and lateral chest radiograph
2. Spiral CT of the chest with contrast
3. Pulmonary function test with DLCO
4. Arterial blood gases on room air
5. 6MWT with pre- and post-oxygen saturation
6. Ventilation/perfusion scan with differential quantitation for single lung transplant cases
7. Diaphragmatic sniff test: ultrasound or fluoroscopy
8. Quantiferon test/T-spot test

Cardiovascular Evaluation

1. ECG
2. Echocardiogram
3. Right heart catheterization
4. Left heart catheterization with coronary angiography for patients over age 50 or age 45 with strong family history or clinical suspicion.
5. If known coronary artery disease, consider stress testing (dobutamine ECHO)
6. Carotid Doppler for high-risk patients over age 60, history of a neurologic event, and patients found to have coronary artery disease.
7. Lower extremity ankle-brachial index for high risk over age 60 or exam suggestive of peripheral vascular disease, diabetes, and patients found to have coronary artery disease.

Gastrointestinal Evaluation

1. Spiral CT of abdomen and pelvis with contrast
2. Colonoscopy or CT colonography for patients over age 50
3. Cine-esophagogram on all patients

Other Testing

1. 24-hour urine for creatinine clearance if the calculated glomerular filtration rate is less than 40
2. Bone mineral density
3. Mammogram for women over age 40
4. PAP smear annually
5. Dental clearance

Laboratory Tests

1. Full chemistry panel, CBC with differential, uric acid, lipid panel, thyroid function, iron, TIBC, ferritin, vitamin D level, PT/PTT, pre-albumin, Hgb A_1C
2. Urine drug screen
3. Blood cotinine level
4. Urinalysis, with micro
5. Urine-albumin-to-creatinine ratio, if diabetic
6. Hypercoagulable workup if there is a personal or family history of venous and/or arterial thrombosis
7. Stool for occult blood, if no colonoscopy
8. PSA in males over the age of 40 or younger if family history of prostate cancer
9. Sputum Gram stain and culture (routine, fungal, and AFB) if productive cough present and in all CF/bronchiectasis patients
10. MRSA nasal swab
11. Anti-human leukocyte antigens (HLA) antibodies (PRA)
12. Blood type, tissue typing (before listing)
13. Serology: cytomegalovirus (CMV) IgG, HIV, viral hepatitis, Epstein-Barr virus (EBV), RPR, HSV, varicella-zoster virus (VZV), MMR, toxoplasmosis

Data from Girgis R, Khaghani A. A global perspective of lung transplantation: part 1—recipient selection and choice of procedure. *Glob Cardiol Sci Pract*. 2016;2016(1). doi:10.21542/gcsp.2016.5.

BOX 25-3 Contraindications to Lung Transplantation

Absolute Contraindications

- Recent history of malignancy of ≤5 years (except non-melanoma localized skin cancer treated appropriately)
- Untreatable significant dysfunction of another major organ system unless combined organ transplantation can be performed:
  - Heart
  - Liver
  - Kidney
  - Brain
- Uncorrected atherosclerotic disease and/or coronary artery disease not amenable to revascularization
- Acute medical instability, including, but not limited to, acute sepsis, myocardial infarction, and liver failure
- Uncorrectable bleeding diathesis
- Chronic infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant
- Evidence of active *Mycobacterium tuberculosis* infection
- Class II or III obesity (BMI ≥35.0 kg/m^2)
- Current nonadherence to medical therapy or a history of repeated or prolonged episodes of nonadherence to medical therapy that are perceived to increase the risk of nonadherence posttransplantation
- Psychiatric or psychologic conditions associated with the inability to cooperate with the medical/healthcare team and/or adhere to complex medical therapy
- Severely limited functional status with poor rehabilitation potential
- Substance abuse or dependence on alcohol, tobacco, marijuana, or other illicit substances

Relative Contraindications

- Age over 65–70 years; case-by-case analysis for older patients
- Class I obesity (BMI 30.0–34.9 kg/m^2)
- Progressive or severe malnutrition
- Severe, symptomatic osteoporosis
- Extensive prior chest surgery with lung resection
- Chronic mechanical ventilation and/or extracorporeal life support; case-by-case evaluation
- Colonization or infection with highly resistant or highly virulent bacteria, fungi, and certain strains of mycobacteria
- Uncontrolled HIV
- Atherosclerotic disease burden is sufficient to put the candidate at risk for end-organ disease after lung transplantation
- Other medical conditions not resulting in end-stage organ damage must be optimally managed:
  - Diabetes mellitus
  - Systemic hypertension
  - Epilepsy
  - Central venous obstruction
  - Peptic ulcer disease
  - Gastroesophageal reflux

Data from Weill D, Benden C, Corris P, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2015;34(1):1–15. doi:10.1016/j.healun.2014.06.014.

assess the severity of the disease and detect potential risks for a poor outcome.[15] See **Box 25-2**.

Evidence of significant renal, hepatic, or left ventricular dysfunction precludes lung transplantation although multiorgan transplantation such as heart-lung or lung-liver may be considered in highly select patients. Because lung transplantation is a complex therapy with a significant risk of perioperative morbidity and mortality, it is essential to consider the overall sum of contraindications and comorbidities.[14] See **Box 25-3** for absolute (inadvisable) and relative (may be done with caution if benefits outweigh risk) contraindications for lung transplantation.

Controversy continues to exist among transplant centers regarding the eligibility of ventilator-dependent patients before transplantation in the ICU. This situation was recognized as a risk factor for heightened short-term posttransplant mortality in the past, but it does not appear to adversely impact outcomes beyond the first posttransplantation year.[9] Mechanical ventilation is associated with increased posttransplant mortality; the risk is not prohibitive and should be factored into the entire assessment. These patients should already be on a waiting list or have nearly completed their evaluation. Long-term ventilator dependency causes respiratory muscle weakness and infections that are likely to complicate the situation. To improve their posttransplant survival rate, these patients must have early tracheostomies and minimal sedation, and must participate in aggressive physical therapy pre-transplant.[15]

Some transplant centers chose to restrict transplant eligibility to select patients early in respiratory failure before the onset of profound debility or intercurrent complications of critical illness. Patients receiving noninvasive ventilatory support in contrast to those requiring invasive ventilation who meet all other criteria are eligible to receive lung transplantation. Issues that face individual transplant centers in decision making regarding eligibility for lung transplant selection are those candidates with prior cardiopulmonary bypass and those individuals who received pleurodesis, which increases the risk of intraoperative bleeding. Similarly, pleural thickening associated with aspergillomas complicates native lung removal and carries the additional risk of contaminating the pleural space with fungal organisms.

KNOWLEDGE CHECK QUESTIONS

1. True or False: All transplant centers utilize a standard set of guidelines for pre-transplantation assessment.
2. True or False: Patients with untreatable, significant multiorgan disease may not be considered for a lung transplant.
3. True or False: Patients over the age of 65 are never considered for lung transplantation.

Donor Selection

Conventional experience dictates that thoughtful determination of lung donor selection and meticulous organ preservation be essential to transplant success. As a result, it was traditional and considered crucial that strict selection criteria be applied when selecting lung donors. Mounting evidence, however, has suggested that these standard criteria may, in fact, be too stringent, leading to unnecessary wastage of suitable lungs. Given the limited lung resources available, lung donor criteria have become progressively more relaxed. Many centers advocate the use of **expanded criteria donors** to increase the donor pool with similar transplant outcomes.[13]

The first lung transplantation, in 1963, used a cardiac-arrested donor. Since then most of the donated lung came from **brain-dead donors (BDDs)**. BDD lungs harvested are exceptionally fragile and frequently compromised by volume overload, contusion, aspiration of gastric contents, pneumonia, and prior smoking.[9] To avoid the use of compromised lungs, selection criteria were established around 30 years ago that define the standard lung donor. These criteria lead to the lowest recovery rates of all the major transplantable organs.[9] Today there are little data showing that any of the historical criteria for defining the ideal lung transplant donor impact either short- or long-term outcomes.[13,17] The number of lungs harvested has increased slightly with the use of "extended criteria" donors, with posttransplant outcomes approximating those achieved with the use of donors meeting standard lung transplant criteria. Current studies suggest the benefit of using DCD donors to expand the available donor pool.[13] Therefore, most centers have judiciously relaxed these requirements to expand the donor pool.[7] See **Table 25-3**. The decision whether the organ is suitable for transplantation or not is determined after retrieval, interventions to improve donor lung function, and close inspection of the parenchyma and hilar structures.[18] The acceptance of the extended donor criteria coupled with improvements in donor management has contributed to an increase in lung transplantation procedures over the past decade.[7] See **Box 25-4**.

TABLE 25-3
Traditional versus Extended Criteria for Acceptability of Donor Lungs

Traditional Donor Criteria	Extended Donor Criteria
• Age <50 years • Minimal tobacco exposure • Normal chest radiograph • Pao_2 >300 mm Hg with PEEP 5 cm H_2O and FIO_2 100% • No evidence of aspiration	• Age up to 65 years • Smoking up to 20 pack-years • Unilateral chest trauma or infiltrate • Mechanical ventilation >4 days • Positive Gram stain on tracheobronchial washing and/or bronchoalveolar lavage

Data from Spahr J, Meyer K. Lung transplantation. In: Hricik D, ed. *Primer on Transplantation*. 3rd ed. Hoboken, NH: Wiley-Blackwell; 2011 (Table 9.4, p. 214). https://doi.org/10.1002/9781444391770.ch9. Accessed April 16, 2018.

BOX 25-4 Interventions to Improve Donor Lung Function

- Frequent suctioning to remove secretions
- Ventilatory manipulation to promote lung expansion and reverse atelectasis (inspiratory pressures of 25 cm H_2O and positive end-expiratory pressure of 15 cm H_2O for 2 hours)
- Reverse fluid overload with diuresis and fluid restriction
- Absolute criteria when donor lungs with extended criteria are utilized:
  - Pao_2/FIO_2 >300 mm Hg
  - No persistent radiographic infiltrates
  - No copious purulent secretions
  - No bronchoscopic evidence of aspiration

Data from Spahr J, Meyer K. Lung transplantation. In: Hricik D, ed. *Primer on Transplantation*. 3rd ed. Hoboken, NH: Wiley-Blackwell; 2011 (Table 9.4, p. 214). https://doi.org/10.1002/9781444391770.ch9. Accessed April 16, 2018.

Another procedure that helps extend the lung donor pool, in addition to DCD donor lungs and expanded criteria, is the implementation of **ex vivo lung perfusion (EVLP)**. EVLP serves to "recondition" lungs that were previously unacceptable and discarded.[10] General indications for EVLP include (1) low oxygenation rates (Pa_{O_2}/Fi_{O_2} or P/F <300); (2) signs of pulmonary edema on chest radiograph or during procurement at lung examination; (3) poor lung compliance at procurement; (4) high-risk clinical history, such as history for aspiration or pneumonia of contra-lateral donor lung; and (5) cardiac death with >60 minutes between withdrawal of life-sustaining therapies and arrest.[19] Advantages for using EVLP include avoiding exposure to the damaging effects of cytokine, which accompanies brain death. Also, EVLP allows for re-expansion of atelectasis, clearance of secretions vial serial bronchoscopies, clot removal with the ex vivo perfusate, maintenance of normothermic metabolic function, and closer monitoring of the status of the lung through serial evaluations of radiographs, blood gases, and lung mechanics.[10] See **Figure 25-1**.

The foundations for EVLP include the gradual warming up to normothermia, gradual increase in vascular flow as the lungs are rewarmed, targeting 49% of the donor predicted cardiac output, protective lung ventilation, and acellular perfusate with increased colloid osmotic pressure.[6] Criteria for lung acceptance or declination for transplantation after EVLP appear in **Table 25-4**.

By the hyper-oncotic withdrawal of fluid out of the extravascular space leading to the removal of lung edema, EVLP significantly improves oxygenation and permits successful transplantation of lungs initially deemed unsuitable.[19] EVLP also holds promise for pharmacologic manipulation of the lung, not only using antibiotics but also with agents to enhance fluid clearance, as well as gene therapy to promote lung repair.[10]



FIGURE 25-1 Photo depicting the early stages of EVLP. After the acellular perfusate is pumped through the pulmonary artery (yellow) and out through the left atrium (green), the lungs are warmed to 32°C, the endotracheal tube is unclamped, and protective ventilation begins.

Reproduced with permission from Nathan S. The future of lung transplantation. *Chest.* 2015; 147(2):309–316. doi:10.1378/chest.14-1748.

TABLE 25-4
Acceptance and Exclusion Criteria after 4–6 hours of EVLP

Acceptance Criteria after EVLP	Exclusion Criteria after EVLP
P/F ratio >400	P/F ratio <400
Stable or improving pulmonary artery pressure	>15% deterioration in pulmonary artery pressure
Stable or improving airway pressure	>15% deterioration in airway pressure
Stable or improving lung compliance	>15% deterioration in lung compliance

Data from Machuca T, Cypel M. Ex vivo lung perfusion. *J Thorac Dis.* 2014;6(8):1054–1062.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Extended criteria allow donor lungs to be mechanically ventilated for more than 4 days before harvesting.
2. True or False: EVLP is acceptable for donor's lungs with P/F <300.
3. True or False: Donor lungs with a P/F <400 is adequate for transplant after EVLP.

Lung Transplant Procedures

There are three prominent lung transplant surgical techniques currently utilized to varying degrees, including single lung, bilateral-sequential, and living donor bi-lobar transplantation. HLT is sometimes considered a fourth form of lung transplantation. Historically, HLT was the first surgical lung transplant procedure to achieve a successful outcome yet presently accounts for less than 3% of all current procedures.[9] The choice of surgical procedure is dictated by certain factors, such as the underlying lung disease; associated conditions, such as previous thoracic or pleural surgeries; the age of the patient, survival, and functional advantages; and institutional practice-specific preferences.

Single lung transplantation (SLT) and **bilateral lung transplantation (BLT)** currently comprise at least 97% of all procedures performed worldwide.[9] SLT offers more efficient use of the limited donor pool and is preferred when feasible because frail patients better tolerate it, technically represents the simplest surgical procedure, and usually can be performed without cardiopulmonary

bypass. On the downside, SLT provides less functional reserve than BLT in the setting of allograft dysfunction. Results in SLT may also be hindered by complications if the native remaining diseased lung in single lung transplants is not removed in patients with bilaterally infected lungs (such as in patients with CF or non-CF extensive bronchiectasis). Most patients now receive BLT with IPAH as well as those with severe secondary pulmonary hypertension, although SLT has been performed successfully in carefully selected patients. The shift away from single lung transplant use has occurred because SLT poses an increased risk of perioperative allograft edema resulting from the transplanted lung assuming the entire cardiac output. Although SLT has been the primary surgical procedure for the treatment of end-stage COPD and IPF awaiting lung transplant, BLT currently accounts for two-thirds of all procedures for COPD and more than one-half of procedures performed for IPF.[9]

The **living donor lobar lung transplantation** represents a technique established to expedite transplantation and relieve some of the stress on the UNOS donor pool.[7] The procedure involves transplantation of lower lobes from each of two living, blood group–compatible donors. One donor lower lobe is implanted into each hemithorax of the recipient in a manner like BLT. The donors must be larger than the recipient to allow adequate matching of the donor lobe to the dimensions of the recipient thoracic cage.[7] Despite an overall low risk posed to the donors, living bilateral-lobar transplantation has not gained widespread acceptance, accounting for only 3.5% of annual transplant volume at its peak.

Heart-lung transplantation (HLT), on the other hand, is principally restricted to patients with Eisenmenger syndrome with surgically uncorrectable cardiac conditions, as well as for coexistent end-stage lung and heart disease.[20] Interestingly, heart replacement is frequently not necessary for cor pulmonale because right ventricular function tends to recover when pulmonary vascular afterload is normalized by lung transplantation. Other indications for HLT is in conditions in which there is end-stage disease in one organ with poor function in the other prohibiting single-organ transplantation, such as in primary pulmonary hypertension, congenital heart disease with Eisenmenger physiology, fibrotic lung disease, and CF.[20]

KNOWLEDGE CHECK QUESTIONS

1. True or False: SLT is better tolerated by frail patients.
2. True or False: Living lung donation uses the upper lobes of the donor.
3. True or False: An indication for a heart-lung transplant is recipient cor pulmonale.

Posttransplant Management

Routine posttransplant management is concentrated on periodic monitoring of the **allograft**, by modifying immunosuppressive therapy as needed and by identifying problems or complications promptly. Customary frequent contact with a transplant coordinator, consistent physician follow-up, and periodic chest radiographs, blood tests, and spirometry especially during the first year following transplantation are routine. Surveillance bronchoscopies are employed in many transplant programs. Uncomplicated transplantation typically shows rapid improvement in lung function that stabilizes within 3–6 months. A sustained FEV_1 decline of 10–15%, on the other hand, signals a potentially significant problem.

Immunosuppression

Optimal immunosuppression remains paramount in maintaining long-term graft survival and preserving a fragile balance between infection and rejection. Immunosuppression therapy strategies target multiple immune pathways to decrease both acute and chronic allograft rejection. The relatively high required burden of immunosuppressant agents adds a cumulative risk of nephrotoxicity, bone marrow depression, and malignancy. Induction immunosuppressive agents deplete the recipient immune system in the immediate posttransplant period to decrease early interaction between recipient immune cells and donor allograft antigens to prevent acute rejection. Data from the ISHLT registry indicate that about 51% of lung transplant patients receive some type of induction therapy.[21] Induction therapy is administered in the early postoperative period when the risk of rejection is the highest. The aim is to decrease the incidence of acute rejections, which in lung transplantation is one of the highest among the solid organ transplantations.[18]

Despite a shift toward more potent immunosuppressive regimens, the occurrence of **chronic allograft rejection** continues to impact long-term survival of lung transplant recipients negatively. Newer and more potent therapies have continued to emerge as alternative therapeutic options with some success.

Maintenance immunosuppressive therapy (**Box 25-5**) is initiated immediately at the time of transplantation. Immunosuppressive treatment is lifelong. This therapy consists of a three-drug protocol composed of a calcineurin inhibitor (cyclosporine or tacrolimus), an antimetabolite purine synthesis inhibitor (azathioprine or mycophenolate), and corticosteroids (prednisone). The calcineurin inhibitor decreases IL-2 production and reduces T-cell activation and proliferation. Dosages of the calcineurin inhibitor agents are adjusted by blood-level monitoring. The antimetabolite purine synthesis inhibitor depletes the number of lymphocytes. Corticosteroids are known to suppress prostaglandin

BOX 25-5 Posttransplantation Immunotherapy

Induction Agents

- Basiliximab/daclizumab
- Alemtuzumab
- Anti-Thymocyte Globulin
- Muromonab-CD3

Maintenance Agents

- Glucocorticoids
- Calcineurin inhibitors
  - Cyclosporine
  - Tacrolimus
- Nucleotide-blocking agents
  - Mycophenolate mofetil
  - Azathioprine
- mTOR inhibitors
  - Sirolimus
  - Everolimus

Data from Bhorade S, Kotloff R. Maintenance immunosuppression following lung transplantation. In: Trulock E, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www/uptodate.com. Accessed April 20, 2018.

synthesis, minimize histamine/bradykinin release, decrease vascular permeability, and downgrade cytokines. These agents metabolized by the hepatic cytochrome P450 system are known to interact with other medications that affect this pathway, which can significantly alter the clearance and blood level of these agents. Sirolimus, an inhibitor of IL-2-stimulated T-cell proliferation, is the newest immunosuppressive agent to be introduced into clinical transplant practice. Because this IL-2 receptor antagonist lacks the inherent nephrotoxicity of the calcineurin inhibitors, sirolimus has been successfully substituted for cyclosporine or tacrolimus in patients with renal insufficiency, leading to the recovery of renal function without undue risk of rejection. Sirolimus, however, should not be initiated until complete healing of the bronchial **anastomosis** has been documented because this drug impairs wound healing and has been associated with life-threatening **bronchial anastomotic dehiscence** when used immediately following transplantation.

Decision making in the care of transplant recipients requires considerable familiarity with the administration, side effects, and drug interactions of these immunosuppressive agents. Although functioning as a basis for current transplant therapeutic immunosuppression, the use of calcineurin inhibitors is particularly problematic, necessitating recurrent monitoring of blood levels to ensure appropriate dosing. Adverse effects of calcineurin inhibitor agents, as well as of the other drugs commonly utilized, are significant and substantially contribute to the morbidity associated with transplantation. Antibody-based induction therapy remains relatively common, yet there has been a movement away from T-cell-depleting agents, such as anti-thymocyte globulin toward anti-IL-2 receptor monoclonal antibodies. Newer immunosuppressive agents have also recently been introduced within the past few years. Two such immunosuppressive agents are sirolimus and everolimus which function by blocking growth factor–driven cell proliferation. Much remains to be determined in the process of optimizing immunosuppressive therapy.

Infection Prophylaxis

Infectious complications substantially affect morbidity and mortality following lung transplantation and account for up to 25% of all posttransplant deaths.[3] Despite significant advances in the overall management of lung transplant recipients, these patients remain at an increased risk for infections and infectious complications. The high rate of infection is due to high level of immunosuppression required to prevent acute and chronic rejection, adverse effects of transplantation on local pulmonary host defenses (including loss of lymphatics, reduced mucociliary clearance, and decreased cough), and continuous environmental exposure allowing various infectious pathogens direct access into the allograft. The likelihood and type of infection vary with the degree of recipient immunosuppression, duration of time since transplantation, type and duration of antimicrobial prophylaxis, and environmental microbiology. Laboratory testing, history, and physical exam in the pre-transplant period pay particular attention to previous infection or exposure to HIV, hepatitis B, hepatitis C, toxoplasmosis, VZV, CMV, and EBV. Coinfection with viruses such as EBV, CMV, HIV, and hepatitis C virus predisposes transplant patients to bacterial and fungal infections.

In the immediate postoperative period in lung transplant, recipients are at high risk of bacterial infections. Most of these infections occur in the lower respiratory tract (bronchitis and pneumonia). Subsequent occurrences of bacterial infections tend to re-emerge as a late complication of lung transplantation among patients in whom bronchiolitis obliterans develops. Transplant centers typically establish their own routine antibiotic prophylaxis protocol based on organisms usually recovered at their center. The protocol may be modified to the individual patient based on pre-transplant culture sensitivities of colonizing organisms acquired from the donor lungs and subsequent recipient respiratory cultures. Because patterns of bacterial resistance often vary from institution to institution, susceptibility testing is typically very helpful in designing treatment strategies. Primary immunization should be instituted in the

pre-transplant period, unless otherwise contraindicated, for influenza, *Streptococcus pneumonia*, tetanus, and hepatitis B. Live vaccines should be avoided following transplant.

Fungal infections are a frequent complication in lung transplant recipients, with a 1-year cumulative incidence of 8.6%.[22] Because fungal pathogens can pose a substantial risk to their lung transplant recipients, most transplant centers utilize either universal or targeted antifungal prophylaxis. Although the use of antifungal prevention has resulted in a decreased mortality and incidence of fungal disease, the approach to achieving this strategy has not been a uniform. Antifungal prophylaxis in the form of aerosolized Amphotericin B in the immediate postoperative period and azole antifungals such as itraconazole or voriconazole for 1–12 months are commonly employed. Treatment of invasive mycoses is dependent on the site of infection and the specific organism causing disease.

CMV is the second most common infection among lung transplant recipients, after bacterial pneumonia.[23] CMV prophylaxis is essential because CMV causes considerable morbidity and mortality and has been identified as a risk factor for chronic rejection in lung transplant recipients.[24] There are two strategies for CMV prophylaxis—universal prophylaxis and preemptive prophylaxis; LTx patients at high risk for CMV infection are candidates for universal prophylaxis with either intravenous ganciclovir or oral valganciclovir. Benefits of antiviral CMV prophylaxis not only reduce the incidence of CMV disease but also lessen the effects of CMV on allograft and patient survival. Pre-emptive prophylaxis approach uses frequent (e.g., weekly) monitoring for CMV. If viral replication has reached a certain threshold, defined by each institution, the patient receives either valganciclovir orally or ganciclovir intravenously until the viral load becomes undetectable.[24]

Trimethoprim-sulfamethoxazole (TMP-SMX) is given routinely to all transplant recipients who do not have sulfa allergies, to prevent *Pneumocystis jiroveci* pneumonia (PCP). Before the generalized use of prophylaxis, the risk of *Pneumocystis* infection in solid organ transplant recipients was the highest between the second and the sixth month posttransplantation, during periods of intensified immunosuppression. Since the establishment of routine prophylaxis with TMP-SMX, PCP within the first year posttransplantation has virtually been eliminated.[25] Also, TMP-SMX also provides effective prevention against opportunistic pathogens such as *Listeria monocytogenes*, *Toxoplasma gondii*, and Nocardia. TMP-SMX represents the first-line agent for PCP prophylaxis because it is better tolerated, has fewer adverse effects, and can potentially treat a wide range of infections. Dapsone, pentamidine, and atovaquone may be substituted when necessary as second-line alternatives. While some controversy exists regarding the duration of time for PCP prophylaxis, most transplant centers use between 6 and 12 months as their routine.[25]

Specific treatment options for most community-acquired respiratory viruses are not available except for influenza virus and possibly respiratory syncytial virus (RSV). Therefore, appropriate infection control strategies are especially important in the healthcare setting because transplant recipients appear to have prolonged viral shedding following community-acquired viral infection. As with most infections that are acquired during the posttransplant period, supportive care and reduction of immunosuppression, when possible, remain basic strategies in community-acquired respiratory virus treatment. While the use of antimicrobial prophylaxis has been effective in decreasing the incidence of both common and opportunistic infections following transplantation, this strategy has not reduced the need for ongoing vigilance in identifying infections.

Surveillance

A lung transplant patient must be carefully monitored to ensure that the lung allograft is functioning properly, immunosuppressive medications are properly administered and tolerated, and complications are detected early and addressed quickly. Transplant programs call for patients to return regularly and often for follow-up office visits, blood tests (including routine surveillance with serial CMV antigenemia testing, and CMV DNA polymerase chain reaction), and chest radiographs especially during the initial 2–3 months following transplantation. Most centers provide and encourage participation in an intensive pulmonary rehabilitation program during this time. Frequently, posttransplant patients monitor and chart their pulmonary function daily with portable spirometers. A drop of more than 10% in their FEV_1 or FVC requires they contact the transplant center. Fiberoptic bronchoscopy with transbronchial biopsy (TBB) helps determine the status of posttransplant allograft histopathologic events over time. Bronchoalveolar lavage (BAL), which is typically performed in conjunction with TBB, is useful for diagnosing subclinical and overt active infection.

Some transplant centers rely on the use of mandatory bronchoscopy when clinical manifestations of lung allograft rejection or infection are suspected. There is a consensus among transplant centers that clinically mandated transbronchial lung biopsies enhance diagnostic complication precision while providing an acceptable risk–benefit analysis in experienced hands. Many transplant programs employ frequent surveillance bronchoscopies in their lung transplant population utilizing inspection, particularly of anastomotic sites as well as transbronchial lung biopsies and BAL, within the first posttransplant year as a means of monitoring the allograft. Use of fiberoptic bronchoscopy also allows for the

identification and management of mechanical complications of lung transplantation (such as airway stenosis or tracheomalacia) with interventional procedures, such as stent placement, balloon dilatation, and laser treatment. Utilizing a surveillance bronchoscopy (SB) can frequently detect clinically significant infection and rejection with very low complication rates.[26] SB is also gaining prominence in the management of post-transplant airway complications.[27] SB reduces healthcare costs and improve QOL due to lower hospital admission rates in stable lung transplant recipients.

KNOWLEDGE CHECK QUESTIONS

1. True or False: A decline of ≥10–15% in FEV_1 signals a potentially significant problem with the transplanted lungs.
2. True or False: Immunosuppressive therapy with sirolimus begins immediately following the transplant surgery.
3. True or False: CMV is the most common cause of infection among lung transplant recipients.

Common Complications of Lung Transplantation

The complications following lung transplantation include, but are limited to, immediate graft failure, pulmonary edema, diaphragmatic paralysis, pulmonary edema, acute bacterial infection, bleeding, anastomotic stenosis, renal failure, and stroke. See **Table 25-5**. Only the most common of the pulmonary complications of lung transplantation are included in this section.

Primary Graft Dysfunction

PGD, infection, and late graft failure account for most of the deaths in the first year following lung transplant. PGD after lung transplantation represents a multifactorial injury to the newly transplanted lung that develops within the first 72 hours after transplantation.[9] PGD reflects the summation of injury inflicted on the donor's lung by the transplant process (retrieval, preservation, implantation, and reperfusion) and by other recipient factors, such as acid aspiration, pneumonia, and microtrauma from mechanical ventilation.[28] PGD affecting 11–25%[29] of early transplant recipients is a significant cause of early morbidity and is associated with a 30-day mortality of nearly 50%[30] and inferior long-term survival.[3] Despite its usual early appearance shortly following lung transplantation, the risk of death remains excessive even beyond the first year suggesting that PGD has enduring life-threatening consequences well after resolution of the acute event.[9] Those individuals that

TABLE 25-5
Posttransplant Complications

Type of Complication	Examples
PGD	
Allograft rejection	• Hyperacute allograft rejection • Acute allograft rejection • CLAD
Infections	• Bacterial • Viral • Fungal • Mycobacterial • Pneumocystis species
Coagulation/ thrombotic events	• Hemorrhage • Hypercoagulability • Thrombosis of venous anastomoses • Venous thromboembolism • Axillary vein thrombosis • Heparin-induced thrombocytopenia with thrombosis
Multisystem organ failure	
Airway complications	• Bronchial stenosis • Bronchial dehiscence • Bronchial necrosis • Excessive exophytic granulation tissue • Tracheo-bronchomalacia • Bronchial fistula • Vocal fold paralysis

Other pulmonary complications	• Pleural effusion
	• Phrenic nerve injury
	• SLT complications
	  • Native lung hyperinflation
	  • Native lung infection
	  • Native lung pneumothorax

Cardiovascular	• Systemic hypertension • Cardiac rhythm disturbances • Hyperlipidemia
Neurologic complications	• Central nervous system dysfunction • Tremor
Diabetes mellitus	• New onset • Worsened control of established disease

Gastrointestinal complications	• Impaired motility
	  • Diarrhea
	  • Bezoar
	• Colon complications
	  • Diverticulitis
	  • Perforation
	  • Colitis

Musculoskeletal complications	• Impaired bone metabolism
	  • Osteoporosis
	  • Compression fractures
	  • Avascular necrosis
	• Myopathy
	• Myelosuppression

(*Continues*)

TABLE 25-5
Posttransplant Complications (*Continued*)

Type of Complication	Examples

Other complications	• Malignancies/lymphoproliferative disease
	  • Posttransplantation lymphoproliferative disease
	  • Primary lung cancer
	• Menstrual irregularities
	• Hemolytic-uremic syndrome

Data from Spahr J, Meyer K. Lung transplantation. In: Hricik D, ed. *Primer on Transplantation.* 3rd ed. Hoboken, NH: Wiley-Blackwell; 2011 (Table 9.5, p. 219). https://doi.org/10.1002/9781444391770.ch9. Accessed April 16, 2018.

TABLE 25-6
Classification of PGD

PGD Grade	Infiltrates on Chest Radiography	Pao_2/Fio_2 Ratio
0	None	≥300
1	Present	≥300
2	Present	200–300
3	Present	<200

Data from Spahr J, Meyer K. Lung transplantation. In: Hricik D, ed. *Primer on Transplantation.* 3rd ed. Hoboken, NH: Wiley-Blackwell (Key Points 9.3, p. 218). https://doi.org/10.1002/9781444391770.ch9. Accessed April 16, 2018.



FIGURE 25-2 Bilateral airspace disease with a normal-sized heart, clinically correlating with PGD as seen at day 1, with significant worsening by day 3 and remarkable improvement by day 8. PGD, however, is a diagnosis of exclusion, and other etiologies such as pulmonary edema hemorrhage, need to be ruled out before making this diagnosis.

Reproduced with permission from Tejwani V, Panchabhai T, Kotloff R, Mehta A. Complications of lung transplantation. *Chest.* 2016;149(6):1535–1545 (Figure 1; p. 1536). doi:10.1016/j.chest.2015.12.019.

survive PGD tend to experience a prolonged and incomplete recovery, longer duration of mechanical ventilation, more prolonged hospital stay, decrease in long-term pulmonary function, and an increased risk of developing **bronchiolitis obliterans syndrome (BOS)**. PGD is characterized by the early development of severe hypoxemia manifested by a reduced Pao_2/Fio_2 ratio; noncardiogenic pulmonary edema; the radiographic appearance of diffuse pulmonary opacities or parenchymal infiltrates resembling acute respiratory distress syndrome (ARDS) without other identifiable cause; and the absence of hyperacute rejection, pulmonary venous anastomotic obstruction, or infection. PGD is graded based on the severity of gas exchange impairment. See **Table 25-6**.

Histologically, the pathologic pattern of PGD manifests in diffuse alveolar damage believed to occur secondary to ischemia/reperfusion injury with damage to the pulmonary endothelium and epithelium. Chest radiographs are typically nonspecific, showing consolidation or interstitial opacities in the perihilar or basilar regions.[31] See **Figure 25-2**. Several risk factors associated with the development of PGD may be both donor and recipient related. See **Box 25-6**.

Preventive strategies used to avert the development of PGD are primarily focused on improving lung preservation techniques, avoiding donor lung trauma, modifying organ preservation solutions, and minimizing organ ischemic times. While no consistently effective therapy has been found to date, treatment of PGD remains largely supportive. Patients are managed similarly to patients with ARDS with low tidal volume ventilation and maintenance of patients' extravascular volume status on the "dry" side with diuresis. Inhaled nitric oxide (iNO) may improve oxygenation and lower mean pulmonary artery pressure. Extracorporeal membrane oxygenation is reserved for patients with severe, life-threatening PGD who do not respond to iNO therapy.[36]

Allograft Rejection

Despite advances in immunosuppression, the life expectancy of lung transplant recipients remains limited by the occurrence of organ rejection.[8] **Allograft rejection** includes **hyperacute allograft rejection (HAR)**, **acute cellular rejection (ACR)**, **antibody-mediated rejection (AMR)**, and CLAD.

BOX 25-6 Risk Factors for the Development of PGD[30,32–35]

Donor Risk Factors

- Smoking history
- Probable contributors
  - Aspiration
  - Chest trauma/lung contusion
  - Undersized donor lungs compared to recipient
  - Heavy alcohol use
- Possible contributors
  - Age >65
  - Oxygenation
  - Chest radiographic abnormalities
  - Purulent secretions at bronchoscopy
  - Thromboembolism/fat embolism
  - Traumatic brain injury
  - Prolonged mechanical ventilation
  - Consequences of neurologic injury
  - Consequences of brain death

Recipient Risk Factors

- Female
- African American descent
- BMI ≥25 kg/m^2
- Disease before lung transplant
  - IPF
  - Sarcoidosis
  - Pulmonary arterial hypertension
- Pre-transplant inflammatory state

Operative Event Risk Factors

- Cardiopulmonary bypass
- Prior cardiothoracic surgery
- Transfusion
- Ischemic time
- FIO_2 during reperfusion (≥40%)
- Delayed chest closure

Hyperacute Allograft Rejection

HAR is a highly lethal rejection that occurs within the first 24 hours after transplantation as a response to preformed antibodies of recipient origin directed against HLA contained on donor tissue (alloantigen). The major target of this humoral immune response affecting the lung primarily involves the pulmonary microvascular epithelium where complement-mediated along with neutrophil-mediated destruction occurs. Also, extensive deposition of platelet/fibrin thrombi and hemorrhage is taking place, resulting in acute loss of vascular integrity. In clinical practice, the occurrence of HAR is encountered only when a solid organ graft is inadvertently transplanted across an ABO blood group barrier. HAR also occurs when the recipient was previously sensitized to an alloantigen from previous exposures to blood product transfusions, previous multiple pregnancies, or a failed transplant. Any of these causes is likely to expose the potential transplant recipient to foreign HLA proteins, which naturally stimulate the production of anti-HLA antibodies.

Because HAR is driven by preformed antibodies, the rejection process involving the lung allograft occurs within minutes of reperfusion and becomes clinically manifest within minutes to hours of establishing perfusion to the freshly implanted lung. Following HAR, the allograft often becomes grossly edematous and densely opacified on chest x-ray resulting from edema produced by the allograft and requiring the initiation of frequent suctioning from the endotracheal tube. Additional clinical manifestations include profound graft dysfunction with the development of severe hypoxemia along with hemodynamic instability often resulting in death.

The current clinical approach to HAR relies on prevention though appropriate cross-matching between donor and recipient hyperacute rejection is extremely rare.[18]

Acute Cellular Rejection

ACR is the predominant type of acute lung transplant rejection and is mediated by T lymphocyte recognition of foreign major histocompatibility complexes, also known as HLA, or other antigens.[37] Acute rejection occurs when targeted donor antigens are trapped within recipient macrophages and cannot be cleared by the reticuloendothelial (RE) system. T cells constitute the focal constituent responsible for ACR. ACR is often accompanied by an acquired antibody response resulting in the process sometimes called T cell–mediated rejection (TCMR). Multiple TBBs are the gold standard for ACR diagnosis. To definitively diagnose ACR, the TBBs must show histologic identification of perivascular or airway lymphocytic variable-emerging infiltrates. Perivascular mononuclear infiltrates with or without lymphocytic bronchitis/bronchiolitis in the absence of infection are the histologic hallmark of ACR.[7] The diagnosis of ACR relies on the histologic identification of perivascular and airway lymphocyte-predominant inflammatory changes that receive grades from A0 (normal) to A4 (severe).

ACR has both short-term and long-term implications. Short-term implications include an increased need for immunosuppressive therapy with consequent morbidity and increased cost of care for monitoring and treating subsequent acute rejection episodes. ACR has an adverse impact on the long-term outcome as an immunologic predictor of CLAD.

Following the initial posttransplant year, the incidence of ACR declines considerably. For most of the cases, ACR typically occurs within the first few weeks to months of allograft transplantation but can happen at any time. ACR following lung transplantation was 35% between 2004 and 2012 for adults within the first year of lung transplantation but does not have a high mortality rate (4% within the first month of transplant and less at later time points).[31]

The clinical manifestations of ACR are often indistinguishable from other disorders, such as infectious pneumonia, resulting in a relatively low clinical diagnostic accuracy. Many incidences of ACR are asymptomatic. Clinical manifestations that do arise from ACR are usually nonspecific and include malaise, low-grade fever, dyspnea, cough, leukocytosis, and crackles or rhonchi on chest auscultation. Radiographic ground-glass opacities, septal thickening, and pleural effusions on CT scans are suggestive of ACR, although study sensitivity is estimated to be as low as 35% with limited capability of excluding other processes.[38] Other critical clinical findings suggesting the possible presence of ACR include a decline in arterial oxygenation at rest or with exercise and a precipitous fall of greater than 10% in spirometric values on pulmonary function testing. While clinical manifestations may be suggestive of ACR, similar findings accompany bouts of infection. Reliance on clinical and radiographic criteria without histologic confirmation with transbronchial lung biopsy runs the risk of misdiagnosis and the needless augmentation of immunosuppression.

Early and frequent surveillance of the allograft by some transplant centers utilizing multiple TBB samplings and BAL demonstrated that most transplant recipients experience at least one episode of ACR in the first year. Induction therapy can prevent ACR during the initial posttransplantation stages. Often antibody therapies serve to extensively deplete or inactivate T cells during the immediate postoperative period of engraftment, during which time reperfusion injury is most likely to secure immune recognition. Immunosuppressive regimens are frequently scheduled initially to promote a concentrated course of therapy in the immediate postoperative period and then tapered to lower, less toxic levels over time. Treating established ACR consists of increased immunosuppression with corticosteroids. Most transplant centers will treat ACR Grade 2 and more severe.[38] With the development of increasingly more effective immunosuppression, allograft loss from ACR is becoming progressively rarer.

Antibody-Mediated Rejection

A less common type of rejection is the AMR or humoral rejection. It is mediated by antibodies directed against donor HLA. These antibodies may have been present in the recipient at a low level before transplant and rise in titer with an anamnestic response after transplantation or may develop afterward. About 10–15% of lung transplant recipients are presensitized to HLA antigens.[38] If HLA antibodies are identified in the potential recipient, the corresponding HLA antigens are avoided in a donor.

The diagnosis and grading of AMR in lung transplantation is challenging due to the lack of specific diagnostic features. AMR is defined as either clinical or subclinical. Clinical AMR demonstrates alterations in pulmonary physiology, gas exchange properties, radiologic features, or deteriorating functional performance, whereas in subclinical AMR the lung function is normal. However, clinical AMR may also be asymptomatic with small, but significant changes in pulmonary physiology. Clinical AMR is then subclassified into definite, probable, and possible AMR.[39] The diagnosis of definitive AMR requires allograft dysfunction in the presence of donor-specific HLA antibodies plus positive histology suggestive of AMR, sub-endothelial C4d deposition (deposition of C4d on vascular endothelium is consistent with AMR) in alveolar capillaries, and exclusion of other potential causes of allograft dysfunction.[40] Both ACR and AMR can occur at the same time.

Plasmapheresis can reduce the circulating antibodies from the pulmonary capillaries in lung transplant recipients who do not respond to corticosteroid therapy or intravenous immunoglobulin. Other treatments include drugs such as rituximab, bortezomib, and carfilzomib.[38] Acute AMR can be a fatal form of lung transplant rejection, with the survivors having an increased risk of developing CLAD.

Chronic Lung Allograft Dysfunction

Progress in surgical techniques and perioperative management have improved the short-term survival rate for lung transplant recipients. However, the long-term survival rate for lung transplantation is the poorest among all the solid organ transplants. The 10-year survival rate for kidney transplantation is 58%, liver transplantation is 56%, pancreas transplant is 77%, and the intestine is 44%. However, lung transplantation survival at 10 years is only 27%.[41] CLAD develops in approximately 50% of lung transplant recipients by 5 years posttransplant representing the critical factor limiting the long-term survival of these patients.[42] CLAD is an overarching term that embraces all forms of chronic lung dysfunction after transplant and encompasses a range of pathologies that cause a transplanted lung not to achieve or maintain normal function. CLAD manifests as airflow restriction or obstruction and is predominantly a result of chronic rejection.[43] CLAD results in one of three phenotypes: BOS, restrictive allograft syndrome (RAS), and neutrophilic reversible allograft dysfunction (NRAD). Each of these phenotypes is mostly unresponsive to changes in immunosuppression.[43]

Although the term "chronic" connotes a long duration of time, a minimum of 3 weeks posttransplantation is sufficient to label allograft dysfunction as "chronic."[44] The overall pathologic process is

usually insidious and gradually manifests over a period of years. The constant exposure to the external environment (pathogens, allergens, or pollutants), the potential for aspiration, susceptibility to ischemia-reperfusion injury-mediated graft dysfunction, and the lung's propensity to contain abundant lymphoid tissue in concert with allo- and autoimmune responses are thought to contribute to CLAD.[43]

The most common form of CLAD is BOS, with a chronic rejection rate of 65–75%.[45] BOS is characterized by irreversible, progressive airflow obstruction and air trapping caused by the presence of obliterative bronchiolitis.[31] After a diagnosis of BOS, median survival is 3–5 years with early onset (<2 years posttransplant) or high-grade onset (FEV_1 decline >35%) having the lowest survival rate.[45]

BOS has a clinically nonspecific presentation, typically with dyspnea on exertion and a nonproductive cough. Symptoms develop insidiously. Chest radiographs are usually unchanged; however, high-resolution CT scan may reveal bronchiectasis and air trapping. See **Figure 25-3**. **Table 25-7** summarizes the early and late clinical presentation of posttransplant patients with BOS. BOS classification of severity is based on spirometry. The baseline spirometry is the average of the two highest, not necessarily consecutive measurements, obtained at least 3 weeks apart.[18] See **Table 25-8**.

Potential therapies for BOS include adding long-term azithromycin, changing the maintenance immunosuppressive medications, **extracorporeal photopheresis**, total lymphoid irradiation, plasmapheresis, treatments that target antibodies to the allograft (immune globulin, rituximab, proteasome inhibitors), and inhaled cyclosporine.[37] Extracorporeal photopheresis is a cell-based immunomodulatory therapy that involves collecting leukocytes from peripheral blood. These cells are



FIGURE 25-3 CT scan of a chest showing bronchiectasis **(A)** and air trapping **(B)** in a lung transplant recipient, suggestive of CLAD due to BOS. Confirmation of the diagnosis requires a pulmonary function test showing airflow obstruction.

Reproduced with permission from Tejwani V, Panchabhai T, Kotloff R, Mehta A. Complications of lung transplantation. *Chest*. 2016;149(6):1535–1545 (Figure 12, p. 1541). doi:10.1016/j.chest.2015.12.019.

TABLE 25-7
Clinical Presentation of BOS Post Lung Transplantation

	Early BOS	Late BOS
Symptoms	Nonproductive cough; dyspnea on exertion	Productive cough; dyspnea at rest
Physical examination	Breath sounds clear on auscultation	Wheezing
Chest radiograph	Clear	Bronchiectasis, hyperinflation
Pulmonary function test	Obstruction; shown mostly in mid-flows (forced expiratory flow over the middle half of the FVC, FEF_{25-75}%)	Severe obstruction
Sputum culture	Negative	Pseudomonas

Data from Pilewski J. Chronic lung transplant: bronchiolitis obliterans. In: Trulock E, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed April 24, 2018.

TABLE 25-8
Classification of BOS

Classification	Spirometry Measurement
BOS 0	FEV_1 >90% of baseline and FEF_{25-75}% >75% of baseline
BOS 0-potential	FEV_1 81–90% of baseline and/or FEF_{25-75}% <75% of baseline
BOS 1	FEV_1 66–80% of baseline
BOS 2	FEV_1 51–65% of baseline
BOS 3	FEV_1 <50% of baseline

Data from Aigner C, Klepetko W. Lung transplantation. In: Ziemer G, Haverich A, eds. *Cardiac Surgery*. New York, NY: Springer; 2017:1061 -1077 (Table 26.3, p. 1073).

exposed to a photosensitizing agent, 8-methoxypsoralen, and are then treated with ultraviolet radiation, after which they are re-infused.[46] Response to therapy is assessed with ongoing spirometry. Treatment usually slows but does not stop the functional decline of the transplant recipient and re-transplantation may be considered.

Restrictive allograft syndrome (RAS), sometimes called restrictive CLAD (rCLAD), presents as a restrictive pulmonary disorder with pulmonary function testing and is supported by consistent radiographic infiltrates, such as pleural/septal thickening, or predominant histopathologic findings of parenchymal fibrosis and pleural thickening.[47] RAS affects 25–35% of CLAD patients.[45] Pulmonary function testing shows a persistent decline in vital capacity and total lung capacity that is accompanied by a decrease in FEV_1 of more than 20%. Two pulmonary function measurements at least 3 weeks apart showing this decline with other causes ruled out clinically identified RAS. High-resolution CT scans can be an alternative tool to diagnose RAS when pulmonary function testing is inconclusive. On thoracic CT scans RAS appears as persistent infiltrates with ground-glass opacities, interstitial infiltrates, and possibly honeycombing, with fibrotic changes predominantly in the upper lung zone.[44] There are also patients with diffuse or basal-dominated infiltrates on CT. These patients have a worse outcome compared with patients with apical dominated fibrosis.[45]

As with BOS, RAS causes a persistent pattern of decline in pulmonary function. The reduction is initiated by the acute phase, characterized by acute lung injury (diffuse alveolar damage) and followed by a resolution stage, during which fibrosis further develops.[48] Episodes of acute exacerbations in RAS share multiple features with ARDS in pathologic and radiographic findings.[48] See **Figure 25-4**.

There is limited experience in treating RAS patients; however, successful case reports demonstrate that the use of pirfenidone[43] and nintedanib[45] helps stabilizes the disease. Extracorporeal photopheresis therapy does not show promise in slowing the progression of RAS. Plasmapheresis, intravenous immunoglobulins, and rituximab may be useful in reducing the antibody titer.[45] RAS is a relatively new identified complication of lung transplantation with no animal studies to date and little experience with treatment.[43] Clinical trials are needed to identify appropriate treatment.



FIGURE 25-4 A representative case of RAS after lung transplantation of a 28-year-old man with CF who received cadaveric BLT. **(A)** Posttransplant day 215, when the patient was stable. **(B)** Posttransplant day 374, when the patient underwent the first episode of acute exacerbation. CT scan showed extensive bilateral ground-glass opacities, bilateral pneumothorax, and pneumomediastinum. TBBs demonstrated diffuse alveolar damage, without apparent rejection or infection. **(C)** Posttransplant day 535, when the patient was recovering from the first episode of acute exacerbation. After steroid pulse and increased prednisone, function partially recovered with clearance of ground-glass opacities, although interlobular septal thickening, interstitial reticular shadow, and consolidation remained. **(D)** Posttransplant day 817, when the patient had the second episode of acute exacerbation. CT scan showed reappearance of diffuse ground-glass opacities with worsening interstitial shadows. **(E)** Posttransplant day 1,131, when the patient was recovering from the second exacerbation. Although his condition was relatively stable for 2 years after the second episode, the patient's CT scan showed gradual increases in interlobular septal thickening, interstitial reticular shadow, and consolidation. He was listed for re-transplantation. **(F)** Posttransplant day 1,333, when the patient had the third episode of acute exacerbation. CT scan shows further volume loss in the transplanted lungs, extensive ground-glass opacities, and worsening consolidation and interlobular septal thickening.

Reproduced with permission from Sato M, Hwang D, Waddell T, Singer L, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. *J Heart Lung Transplant.* 2013;32(1):23–30 (Figure 5B -5G, p. 28). doi:10.1016/j.healun.2012.09.026. Erratum: https://vdocuments.site/erratum-58668dd94b057.html.

The third phenotype and most recent addition to the CLAD family of diseases is NRAD. This form of chronic rejection is characterized by active inflammation and neutrophilic infiltration that responds to azithromycin, which suppresses inflammation both directly and indirectly.[43] Currently, no exact clinical definition exists, and although NRAD responds positively to azithromycin therapy, multiple studies demonstrate that NRAD is associated with worse overall survival.[43]

Infectious Complications

Of all solid organ transplants, lung transplants are the most prone to infection. Infectious complications remain one of the most important causes of morbidity and mortality in lung transplant recipients. There are several reasons for the transplanted lung's heightened predisposition to infection. See **Box 25-7**.

Lung transplant recipients are at high risk for bacterial, viral, fungal, and protozoal infections, which are the leading causes of death during the early posttransplantation period. Pneumonia, particularly bacterial pneumonia, is the most common type of infection in lung transplant recipients, although bloodstream, pleural space, and wound infections are also common.[49] Despite antibiotic prophylaxis, the incidence of bacterial pneumonia is approximately 10–20% in the first 30 days following lung transplantation and infectious.[50] Early posttransplant pneumonias are typically caused by hospital-acquired bacteria, including multidrug-resistant *Pseudomonas aeruginosa*, Enterobacteriaceae, and methicillin-resistant *Staphylococcus aureus*.[50] Research findings have demonstrated that coinfection with viruses such as EBV, CMV, HIV, and hepatitis C virus can predispose transplant patients to bacterial and fungal infections. Infection poses an ever-present threat to the lung transplant recipient as a leading cause of morbidity and both early and late death despite attempts to curb this tendency with the use of prophylactic antibiotics. Airway colonization and recurrent lower respiratory tract infection with *Pseudomonas aeruginosa* are prevalent among lung transplant recipients and may have a significant impact on posttransplant follow-up because it is often seen presenting in patients with chronic rejection. CMV is the second most frequent cause of infectious complications following lung transplantation.[24] Fungal infections are more common in recipients of lung transplants than of most other solid organs and are predominantly due to Candida species or Aspergillus, and less commonly *Cryptococcus neoformans*. Aspergillus remains a predominant cause of pulmonary fungal infection in lung transplant recipients.[8] Numerous pathogens cause infectious complications after lung transplantation. See **Table 25-9**. For this reason, routine posttransplantation prophylactic antimicrobial protocols are common.

Sequential measurements of procalcitonin (PCT) have been shown to improve the diagnosis of early infectious complications following lung transplantation compared with other commonly used markers such as serum C-reactive protein (CRP) and leukocyte count. Patients with infectious complications present with significantly higher levels of PCT as early as the first day following transplantation and during subsequent days. In contrast, CRP levels and leukocyte counts are unable to discriminate between the patients with and without infections at any time. It has therefore been suggested that measurement of PCT is a useful diagnostic tool in detecting early infectious complications in lung transplant patients.

BOX 25-7 Reasons for Pulmonary Infections Following Lung Transplantation

- Abnormal mucociliary clearance from denervation of the allograft
- Continuous and direct exposure to microbial organisms in outside environment via inhaled air
- Complications associated with the anastomosis site
- Donor lung predisposed to aspiration
- Donor lung predisposed to ventilator-associated pneumonias
- Higher levels of immunosuppression needed due to an increased propensity for humoral or cellular-mediated immune responses
- Impaired cough reflex from denervation of the allograft
- Impaired lymphatic drainage
- Infection from the native lung in SLT
- Passive transfer of occult infection from the donor organ
- Recipient comorbidities (diabetes, renal insufficiency, malnutrition)

Data from Remund K, Best M, Egan J. Infections relevant to lung transplantation. *Proc Am Thorac Soc*. 2009;6(1):94–100. doi:10.1513/pats.200809-113go.

Airway Complications

Airway complications following lung transplantation are local structural or infectious alterations of the airways, which occur early or several months posttransplant. After infectious diseases, airway complications are another major contributor to the morbidity and mortality of lung transplant recipients. The incidence of airway complications ranges widely between 2% and 33%[51] with a mortality rate between

TABLE 25-9
Most Common Pathogens Relevant to Lung Transplantation[25,49,50]

Infection Type	Specific Pathogens	Comments
Bacterial infections	*Pseudomonas aeruginosa*	Commonly colonizes the lungs of patients with CF
	Burkholderia cepacia	Commonly colonizes the lungs of patients with CF
	Staphylococcus aureus	Includes methicillin-resistant *S. aureus*
	Streptococcus pneumoniae	Community-acquired pneumonia typically occurs in late in the posttransplant period (>6 months)
	Chlamydia pneumoniae	Causes upper and lower respiratory tract infections
	Nocardia spp.	Considered when pneumonia does not respond to empiric therapy
	Clostridium difficile	Frequently occurs in the early posttransplantation period in patients requiring prolonged hospitalization
	Mycobacterium tuberculosis	May occur due to reactivation
Viral infections	CMV	Can develop a lifelong latency
	EBV	Associated with the posttransplant lymphoproliferative disease
	Community-acquired viruses	Influenza, RSV, parainfluenza virus, and human metapneumovirus
Fungal infections	*Aspergillus fumigatus*	Occurs at bronchial anastomosis and in the tracheobronchial tree
	Candida spp.	Most invasive infections appear during the first month posttransplant
	Pneumocystis jirovecii	A frequent cause of pneumonia among immunocompromised patients

2% and 5%.[52,53] In the early era of lung transplantation, disruption of the airway anastomosis was one of the major causes of death among patients who survived at least 2 weeks after transplantation. Lung transplantation creates a unique environment that is prone to anastomotic airway complications.[54] These complications are classified according to either the time of development or the nature of the structural deformities. Airway complications that develop within 3 months posttransplant are early complications; after 3 months they are considered late complications. The anastomotic airway complications that most frequently occur include stenosis, necrosis and dehiscence (unraveling of sutures at the site of anastomosis), exophytic granulation tissue development (obstructive granulation tissue), bronchomalacia, fistula formation, and infection of the anastomosis.[54] When these complications are significant, they require interventional procedures, such as debridement, dilatation, or stent placement. The most significant factors responsible for the development of these posttransplant complications include airway ischemia, airway colonization and local infections, surgical techniques, and immunosuppressive treatment. These factors significantly impair healing of the anastomotic site. See **Table 25-10**.

TABLE 25-10
Anastomotic Healing Classification[52]

Grade	Description
1	Complete circumferential primary mucosal healing
2A	Complete circumferential primary healing of the airway wall without necrosis and with partial primary mucosal healing
2B	Complete circumferential primary healing of the airway wall without necrosis but with no primary mucosal healing
3A	Limited focal necrosis, extending less than 5 mm from the anastomotic line
3B	Extensive necrosis

Data from Anile M, Diso D, Rendina E, Venuta F. Airway anastomosis for lung transplantation. *J Thorac Dis*. 2016;8(Suppl 2):S197–S203. doi:10.3978/j.issn.2072-1439.2016.01.67.

Management of posttransplant airway complications typically often requires a dedicated multispecialty team approach, See **Table 25-11**. Early diagnosis of anastomosis complications and correct management are vital to gain satisfactory results and a better survival following lung transplantation.[52]

TABLE 25-11
Overview of Posttransplantation Airway Complications[51,52,54]

Airway Complication	Possible Cause	Treatments
Bronchial stenosis	Related to ischemia and impaired local microcirculation or cellular rejection	Mechanical dilation, balloon bronchoplasty, and airway stenting
Bronchomalacia	Related to ischemia, infection, or altered response of the bronchial wall to immunosuppression	Airway stenting
Bronchial dehiscence	Initiation of sirolimus in the immediate postoperative period and extreme mucosal necrosis	Airway stenting for scaffolding, reduction in corticosteroid dosing, chest tube for associated pneumothorax
Bronchial necrosis	Related to ischemia	Causes dehiscence
Exophytic granulation tissue	Exacerbated by the presence of Aspergillus infection at the surgical anastomosis	Airway debridement of granulation tissue at the surgical anastomosis
Anastomotic infection	Immunosuppression with constant exposure to the external environment; devascularization, immunosuppression, disruption of lymphatic drainage, and altered alveolar phagocyte function make anastomosis susceptible to saprophytic infections	Antifungal prophylaxis, broad-spectrum therapy
Bronchopleural fistula	Prolonged or profound ischemia	Drainage of associated empyema, broad-spectrum antibiotics, surgical closure

KNOWLEDGE CHECK QUESTIONS

1. True or False: Most lung transplant recipients are presensitized to donor HLA.
2. True or False: CLAD has three phenotypes, of which BOS is the most common.
3. True or False: RAS is characterized by diffuse alveolar damage and the development of fibrosis.
4. True or False: The lungs are less prone to infection than any of the other solid organs transplanted.
5. True or False: Bronchial dehiscence is treated with airway stenting and a reduction in corticosteroid therapy.
6. True or False: The presence of Aspergillus infection increases the risk of bronchopleural fistula.

Lung Transplantation Prognosis

The median survival following lung transplantation had steadily improved from 4.0 years in the 1988–1994 era to 6.0 years in 2007, and the bilateral lung recipients appear to have a better median survival than single lung recipients.[55] Since the first human lung transplant procedure in 1963, improvements have been made in surgical techniques, immunosuppressive therapy, postoperative management, and donor selection. Lung transplantation is now a viable option for individuals with various end-stage lung diseases. However, the presence of allograft rejection negatively impacts the long-term survival rate. The demand for lung transplantation continues to rise as the current 1-year survival rate following lung transplantation approaches 80%. Unfortunately, the 5-year survival rate has remained essentially unchanged at approximately 50% over the last 15 years primarily due to lung allograft rejection, and the 10-year survival rate is around 27%. PGD, infection, and allograft failure account for most of the deaths in the first year following lung transplant. Factors suggesting an increased risk of death occurring early following lung transplantation include ventilator dependence or inotropic support of the recipient before transplantation, a primary diagnosis of pulmonary fibrosis or IPAH, elevated bilirubin, and advanced recipient or donor age. The development of CLAD is responsible for causing most deaths beyond the first year of lung transplantation with the lethal consequences of progressive respiratory failure and increased susceptibility to infection.

Quality of life (QOL) measures following successful lung transplantation have significantly improved, achieving satisfaction levels approximating that of the general population. In a randomized controlled trial, supervised exercise training initiated immediately following hospital posttransplant discharge increased participation in daily activity while improving functional recovery and cardiopulmonary morbidity.[56] Although several QOL measures and performance status appear to improve from pre-transplant status, less than

one-half of lung transplant recipients return to the workforce.[57,58] Several important limitations affecting the QOL that have been observed include persistently increased levels of depression and anxiety as well as a diminished perception of body image.[59] Other troubling QOL issues arise from the adverse effects of immunosuppressive medications as well as the development of BOS, which is associated with a significant deterioration in the QOL measures. QOL measures about essential caregivers of lung recipient patients may also be affected. Recent studies by Lefaiver and others found these individuals often experience fatigue, depression, and the financial impact of the transplant, as well as may be adversely affected by a lack of patient family support.[60]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The median survival rate following lung transplantation is approximately 9 years.
2. True or False: Single lung recipients have a better median survival rate than bilateral lung recipients.
3. True or False: Less than half of lung transplant recipients return to the workforce.

Chapter Summary

Advances in surgical transplantation techniques, immunosuppressive therapy, and postoperative management have resulted in lung transplantation becoming an established therapeutic option for individuals with a variety of end-stage lung diseases. While current 1-year survival rates following LTx have risen, the 5-year survival rate has remained virtually constant at approximately 50% over the last 15 years because of acute and chronic lung allograft rejection. Although an assortment of immunosuppressive agents are currently available to suppress graft rejection, insufficient immunosuppression results in graft loss due to rejection, excess immune suppression usually results in increased morbidity and mortality from opportunistic infections and malignancies.

Unfortunately, individuals with life-threatening lung conditions awaiting lung transplantation have surpassed the availability of organs based on selection criteria established in the 1980s that define lung donor standards to the present day. Historically, most lung organ donors fail to meet these criteria, leading to lung recovery rates of only 15–25%, the lowest of all the major transplantable organs. Recent evidence demonstrates that adherence to standard criteria is in fact too stringent, resulting in significant underuse of viable lungs. Reasonably easing donor selection criteria, accepting "marginal" lungs, and utilizing EVLP may help to address this problem. Expanding living donor procedures, use of artificial lungs or xenotransplantation (the transplantation of an organ or a tissue from an animal of one species to an animal of a different species), and gene repair of previously damaged lungs are modalities that may address the significant organ shortage in the future.

Key Points

1. The lung allocation system identifies a dozen factors independently predictive of 1-year survival without and with transplantation. These factors are then used to calculate an individual's LAS, which can range from 0 to 100. The higher the score, the higher the preference for transplantation.
2. Lung transplantation is a viable therapeutic option for a broad spectrum of end-stage nonmalignant disorders of the airways, lung parenchyma, and pulmonary vasculature. Key issues that continue to hamper progress in transplantation include donor shortage and PGD, which increases both short- and long-term mortality.
3. PGD is a devastating form of acute lung injury occurring in patients within the first hours following lung transplantation, presumed to be a consequence of ischemia-reperfusion injury, mimics adult respiratory distress syndrome, and is often initially fatal. PGD represents a significant risk for the development of CLAD in those who initially recover.
4. Pulmonary infections are a leading cause of morbidity and mortality in lung transplantation even with the use of prophylactic antibiotics. Because posttransplant patients tolerate established infection poorly, strategies aimed at prevention primarily in the healthcare setting are of paramount importance.
5. The two significant hurdles that currently limit the clinical usefulness of lung transplantation for life-threatening lung disorders are the scarcity of suitable donor organs and current immunosuppressive strategies that unfortunately fail to ensure long-term allograft function.
6. ACR is characterized by perivascular lymphocytic infiltration that develops in many recipients within the first year following transplant. While this disorder usually will successfully respond to high-dose corticosteroid therapy, its reoccurrence represents a significant risk factor for subsequent development of chronic lung allograft rejection.
7. CLAD develops in approximately 50% of lung transplant recipients by 5 years post-transplant and is a major limitation to long-term survival. CLAD includes all forms of chronic lung dysfunction occurring after transplant. CLAD manifests as airflow restriction or obstruction and presents as one of three phenotypes: BOS, RAS, and NRAD.
8. Infection continues to remain a significant cause of morbidity and mortality in the lung transplant recipient. Strategies used in preventing infectious

complications may not only decrease the direct consequences of infection but also reduce subsequent causes of ultimate allograft failure, including both acute and chronic rejection.

9. The 5-year survival associated with lung transplantation has slowly improved over the past several years primarily due to the development of CLAD. Half of lung transplant recipients surviving to 5 years develop biopsy-proven CLAD.

Chapter Questions

1. Priority for lung transplantation depends on _____ _____.
   - **a.** time of diagnosis and severity of the disease
   - **b.** severity of the disease and need for transplant
   - **c.** likelihood of transplant success and need for transplant
   - **d.** severity of the disease and likelihood of success
2. A patient diagnosed with _____ _____ is referred for lung transplant at the time of diagnosis.
   - **a.** cystic fibrosis
   - **b.** idiopathic pulmonary fibrosis
   - **c.** pulmonary vascular disease
   - **d.** chronic obstructive pulmonary disease (COPD)
3. During ex vivo lung perfusion, the lungs are _____ _____.
   - **a.** gradually warmed to increase vascular blood flow
   - **b.** ventilated with high tidal volumes and pressure
   - **c.** gradually cooled to preserve the lung tissue
   - **d.** quickly warmed to body temperature
4. The first-line pharmacologic agent to prevent pneumocystis pneumonia is _____.
   - **a.** a calcineurin inhibitor
   - **b.** vaccination
   - **c.** anti-thymocyte globulin
   - **d.** trimethoprim-sulfamethoxazole
5. _____ may develop within the first 72-hours after lung transplantation.
   - **a.** Acute allograft rejection
   - **b.** Chronic lung allograft dysfunction (CLAD)
   - **c.** Pneumocystis pneumonia
   - **d.** Primary graft dysfunction (PGD)
6. Classification of PGD is based on _____.
   - **a.** chest radiography
   - **b.** Pao_2/Fio_2 ratio
   - **c.** bronchoscopic findings
   - **d.** histologic findings
7. Risk for the development of PGD is increased with _____ recipients.
   - **a.** female
   - **b.** tobacco smoking
   - **c.** cystic fibrosis
   - **d.** COPD
8. The type of rejection that occurs within 24 hours of lung transplantation is _____.
   - **a.** acute cellular rejection
   - **b.** hyperacute allograft rejection
   - **c.** PGD
   - **d.** antibody-mediated rejection
9. Bronchiolitis obliterans syndrome and restrictive allograft syndrome are two types of _____ _____.
   - **a.** acute cellular rejection
   - **b.** antibody-mediated rejection
   - **c.** CLAD
   - **d.** PGD
10. Ground-glass opacities and an FEV_1 decrease of more than 20% are indicative of _____ _____.
    - **a.** bronchiolitis obliterans syndrome
    - **b.** PGD
    - **c.** restrictive allograft syndrome
    - **d.** hyperacute allograft rejection

References

1. Venuta F, Van Raemdonck D. History of lung transplantation. *J Thorac Dis*. 2017;9(12):5458–5471. doi:10.21037/jtd.2017.11.84.
2. Whitson B. Lung transplantation: practice essentials, history of the procedure, indications. Medscape. 2017. https://emedicine.medscape.com/article/429499-overview#a1. Accessed April 15, 2018.
3. Yusen R, Edwards L, Kucheryavaya A, et al. The registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report—2015; Focus Theme: Early Graft Failure. *J Heart Lung Transplant*. 2015;34(10):1264–1277. doi:10.1016/j.healun.2015.08.014.
4. Egan T, Edwards L. Effect of the lung allocation score on lung transplantation in the United States. *J Heart Lung Transplant*. 2016;35(4):433–439. doi:10.1016/j.healun.2016.01.010.
5. Fildes J, Archer L, Blaikley J, et al. Clinical outcome of patients transplanted with marginal donor lungs via ex vivo lung perfusion compared to standard lung transplantation. *Transplantation*. 2015;99(5):1078–1083. doi:10.1097/tp.0000000000000462.
6. Machuca T, Cypel M. Ex vivo lung perfusion. *J Thorac Dis*. 2014;6(8):1054–1062.
7. Spahr J, Meyer K. Lung transplantation. In: Hricik D, ed. *Primer on Transplantation*. 3rd ed. Hoboken, NH: Wiley-Blackwell; 2011. https://doi.org/10.1002/9781444391770.ch9. Accessed April 16, 2018.
8. Adegunsoye A, Strek M, Garrity E, Guzy R, Bag R. Comprehensive care of the lung transplant patient. *Chest*. 2017;152(1):150–164. doi:10.1016/j.chest.2016.10.001.
9. Kotloff R, Thabut G. Lung transplantation. *Am J Respir Crit Care Med*. 2011;184(2):159–171. doi:10.1164/rccm.201101-0134ci.
10. Nathan S. The future of lung transplantation. *Chest*. 2015;147(2):309–316. doi:10.1378/chest.14-1748.
11. Organ Donation Laws, Legislation, Policy | organdonor.gov. 2018. https://organdonor.gov/about-dot/laws.html. Accessed April 16, 2018.
12. Organ Procurement Organization (OPO) List | organdonor.gov. 2018. https://organdonor.gov/awareness/organizations/local-opo.html. Accessed April 16, 2018.
13. Chaney J, Suzuki Y, Cantu III E, van Berkel V. Lung donor selection criteria. *J Thorac Dis*. 2014;6(8):1032–1038. doi:10.3978/j.issn.2072-1439.2014.03.24.
14. Weill D, Benden C, Corris P, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society

for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2015;34(1):1–15. doi:10.1016/j.healun.2014.06.014.
15. Girgis R, Khaghani A. A global perspective of lung transplantation: part 1—recipient selection and choice of procedure. *Glob Cardiol Sci Pract*. 2016;2016(1). doi:10.21542/gcsp.2016.5.
16. Hayanga A, Aboagye J, Hayanga H, et al. Contemporary analysis of early outcomes after lung transplantation in the elderly using a national registry. *J Heart Lung Transplant*. 2015;34(2):182–188. doi:10.1016/j.healun.2014.09.028.
17. Kotecha S, Hobson J, Fuller J, et al. Continued successful evolution of extended criteria donor lungs for transplantation. *Ann Thorac Surg*. 2017;104(5):1702–1709. doi:10.1016/j.athoracsur.2017.05.042.
18. Aigner C, Klepetko W. Lung transplantation. In: Ziemer G, Haverich A, eds. *Cardiac Surgery*. New York, NY: Springer; 2017:1061–1077.
19. Cypel M, Keshavjee S. Ex vivo lung perfusion. *Oper Tech Thorac Cardiovasc Surg*. 2014;19(4):433–442.
20. Mancini M. Heart-Lung Transplantation: Background, Indications, Contraindications. Medscape. 2017. https://emedicine.medscape.com/article/429188-overview#a3. Accessed April 20, 2018.
21. Lund L, Edwards L, Kucheryavaya A, et al. The registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation. *J Heart Lung Transplant*. 2014;33(10):996–1008. doi:10.1016/j.healun.2014.08.003.
22. Palmer S, Zaas A, Wolfe C. Fungal infections following lung transplantation. In: Trulock E, Kauffman C, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://uptodate.com. Accessed April 20, 2018.
23. Zamora M. Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients. In: Marr KA, Hirsch MS, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://uptodate.com. Accessed April 20, 2018.
24. Zamora M. Prevention of cytomegalovirus infection in lung transplant recipients. In: Marr KA, Hirsch MS, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://uptodate.com. Accessed April 20, 2018.
25. Iriart X, Challan Belval T, Fillaux J, et al. Risk factors of pneumocystis pneumonia in solid organ recipients in the era of the common use of posttransplantation prophylaxis. *Am J Transplant*. 2014;15(1):190–199. doi:10.1111/ajt.12947.
26. McWilliams T, Williams T, Whitford H, Snell G. surveillance bronchoscopy in lung transplant recipients: risk versus benefit. *J Heart Lung Transplant*. 2008;27(11):1203–1209. doi:10.1016/j.healun.2008.08.004.
27. Rademacher J, Suhling H, Greer M, et al. Safety and efficacy of outpatient bronchoscopy in lung transplant recipients—a single centre analysis of 3,197 procedures. *Transplant Res*. 2014;3(1):11. doi:10.1186/2047-1440-3-11.
28. Snell G, Yusen R, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2017;36(10):1097–1103. doi:10.1016/j.healun.2017.07.021.
29. Mariscal A, Cypel M, Keshavjee S. Ex vivo lung perfusion. *Curr Transplant Rep*. 2017;4(2):149–158. doi:10.1007/s40472-017-0145-x.
30. Shah R, Diamond J, Cantu E, et al. Objective estimates improve risk stratification for primary graft dysfunction after lung transplantation. *Am J Transplant*. 2015;15(8):2188–2196. doi:10.1111/ajt.13262.
31. Tejwani V, Panchabhai T, Kotloff R, Mehta A. Complications of lung transplantation. *Chest*. 2016;149(6):1535–1545. doi:10.1016/j.chest.2015.12.019.
32. Liu Y, Liu Y, Su L, Jiang S. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. *PLoS One*. 2014;9(3):e92773. doi:10.1371/journal.pone.0092773.
33. Diamond J, Lee J, Kawut S, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. *Am J Respir Crit Care Med*. 2013;187(5):527–534. doi:10.1164/rccm.201210-1865oc.
34. Diamond J, Arcasoy S, Kennedy C, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes—A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2017;36(10):1104–1113. doi:10.1016/j.healun.2017.07.020.
35. Shigemura N, Bhama J, Gries C, et al. Lung transplantation in patients with prior cardiothoracic surgical procedures. *Am J Transplant*. 2012;12(5):1249–1255. doi:10.1111/j.1600-6143.2011.03946.x.
36. Hartwig M, Walczak R, Lin S, Davis R. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. *Ann Thorac Surg*. 2012;93(2):366–371.
37. Pilewski J. Chronic lung transplant: bronchiolitis obliterans. In: Trulock E, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed April 24, 2018.
38. Martinu T, Pavlisko E, Chen D, Palmer S. Acute allograft rejection: cellular and humoral processes. *Clin Chest Med*. 2011;32(2):295–310. doi:10.1016/j.ccm.2011.02.008.
39. Benzimra M, Calligaro G, Glanville A. Acute rejection. *J Thorac Dis*. 2017;9(12):5440–5457. doi:10.21037/jtd.2017.11.83.
40. Levine D, Glanville A, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2016;35(4):397–406. doi:10.1016/j.healun.2016.01.1223.
41. Royer P, Olivera-Botello G, Koutsokera A, et al. Chronic lung allograft dysfunction. *Transplantation*. 2016;100(9):1803–1814. doi:10.1097/tp.0000000000001215.
42. Yusen R, Edwards L, Kucheryavaya A, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heart–Lung Transplant Report—2014; Focus Theme: retransplantation. *J Heart Lung Transplant*. 2014;33(10):1009–1024. doi:10.1016/j.healun.2014.08.004.
43. Gauthier J, Hachem R, Kreisel D. Update on chronic lung allograft dysfunction. *Curr Transplant Rep*. 2016;3(3):185–191. doi:10.1007/s40472-016-0112-y.
44. Verleden G, Raghu G, Meyer K, Glanville A, Corris P. A new classification system for chronic lung allograft dysfunction. *J Heart Lung Transplant*. 2014;33(2):127–133. doi:10.1016/j.healun.2013.10.022.
45. Verleden S, Vos R, Vanaudenaerde B, Verleden G. Chronic lung allograft dysfunction phenotypes and treatment. *J Thorac Dis*. 2017;9(8):2650–2659. doi:10.21037/jtd.2017.07.81.
46. Klassen J. The role of photopheresis in the treatment of graftversus-host disease. *Curr Oncol*. 2010;17(2):55–58. doi:10.3747/co.v17i2.565.
47. Verleden S, Todd J, Sato M, et al. Impact of clad phenotype on survival after lung retransplantation: a multicenter study. *Am J Transplant*. 2015;15(8):2223–2230. doi:10.1111/ajt.13281.
48. Sato M, Hwang D, Waddell T, Singer L, Keshavjee S. Progression pattern of restrictive allograft syndrome after lung transplantation. *J Heart Lung Transplant*. 2013;32(1):23–30. doi:10.1016/j.healun.2012.09.026.
49. Remund K, Best M, Egan J. Infections relevant to lung transplantation. *Proc Am Thorac Soc*. 2009;6(1):94–100. doi:10.1513/pats.200809-113go.
50. Mohamedaly O, Zaas A, Wolfe C, Palmer SM. Bacterial infections following lung transplantation. In: Trulock E, Marr KA, Bond S, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://www.uptodate.com. Accessed April 25, 2018.
51. Mahajan A, Folch E, Khandhar S, et al. The diagnosis and management of airway complications following lung transplantation. *Chest*. 2017;152(3):627–638. doi:10.1016/j.chest.2017.02.021.
52. Anile M, Diso D, Rendina E, Venuta F. Airway anastomosis for lung transplantation. *J Thorac Dis*. 2016;8(suppl 2):S197–S203. doi:10.3978/j.issn.2072-1439.2016.01.67.
53. Lari S, Gonin F, Colchen A. The management of bronchus intermedius complications after lung transplantation: a retrospective study. *J Cardiothorac Surg*. 2012;7(1):8. doi:10.1186/1749-8090-7-8.

54. Cho E, Haam S, Kim S, Chang Y, Paik H. Anastomotic airway complications after lung transplantation. *Yonsei Med J*. 2015;56(5):1372–1378. doi:10.3349/ymj.2015.56.5.1372.
55. Hachem RR. Lung transplantation: an overview. In: Trulock EP, Hollingsworth H, eds. *Uptodate*. Waltham, MA: UpToDate; 2018. http://uptodate.com. Accessed April 26, 2018.
56. Langer D. Rehabilitation in patients before and after lung transplantation. *Respiration*. 2015;89(5):353–362. doi:10.1159/000430451.
57. Petrucci L, Ricotti S, Michelini I, et al. Return to work after thoracic organ transplantation in a clinically-stable population. *Eur J Heart Fail*. 2007;9(11):1112–1119. doi:10.1016/j.ejheart.2007.08.002.
58. Suhling H, Knuth C, Haverich A, Lingner H, Welte T, Gottlieb J. Employment after lung transplantation—a single-center cross-sectional study. *Dtsch Arztebl Int*. 2015;112:213–219. doi:10.3238/arztebl.2015.0213.
59. Singer L, Singer J. Quality of life in lung transplantation. *Semin Respir Crit Care Med*. 2013;34(03):421–430. doi:10.1055/s-0033-1348470.
60. Lefaiver C, Keough V, Letizia M, Lanuza D. Quality of life in caregivers providing care for lung transplant candidates. *Prog Transplant*. 2009;19(2):142–152. doi:10.7182/prtr.19.2.g226182714730n07.

CHAPTER

26

Palliative of the Respiratory Patient

"After we die we hover for a while at treetop level with the mourners beneath us, but we are not separate from them nor they from us. They are singing but the words don't mean anything in our new language." —Jim Harrison

OUTLINE

OBJECTIVES

1. Discuss differences between curative (or restorative) traditional health care and palliative care.
2. Discuss components of effective comprehensive palliative care management.
3. Discuss differences between patient autonomy and medical paternalism in palliative care decision making.
4. Review palliative care versus hospice care.
5. Discuss differences between palliative sedation therapy (PST) and euthanasia (physician-assisted suicide).

KEY TERMS

Adjuvant drugs
Allodynia
Anorexia–cachexia syndrome
Autonomy
Delirium
Hospice
Hyperalgesia
Intractable dyspnea
Karnofsky index
Life-extending treatments
Life-limiting disorder
Medical paternalism
Myoclonus
Nonnarcotic analgesics
Opioid-induced delirium
Opioid-induced pruritus
Palliative care medicine
Palliative sedation therapy (PST)
Percutaneous endoscopic gastrotomy (PEG) tube
Physician Orders for Life-Sustaining Treatment (POLST)
Principle of double effect
Surgical palliative care

Case Study

A 76-year-old woman with previously diagnosed GOLD standard Stage IV chronic obstructive pulmonary disease (COPD), pulmonary hypertension, congestive heart failure, and coronary artery disease presents to the emergency room with complaints of worsening shortness of breath, increasing weakness and fatigue, pain, and lower-extremity swelling. She does not improve with bronchodilator therapy, steroids, and diuretics and is subsequently admitted. She states that her COPD has progressed steadily over the last 15 years, leaving her dependent on continuous oxygen and bronchodilator therapy over the last 5 years and on oral steroids for the last year. She also suffers from symptoms of angina treated with nitrates. A recent pathologic rib fracture from coughing has caused her pain and dyspnea to become even more difficult to control. She describes becoming considerably much weaker and is barely ambulatory. She requires help with all activities of daily living. Constipation, anorexia, and anxiety are active concerns. Although her physician has determined that she continues to remain mentally competent, both she and her family agree that her health has significantly declined in the last few weeks.

On physical examination, her temperature was 99.1°F, pulse was 118, and the respiratory rate was 26, visibly labored with the use of accessory, muscles, tripod positioning, and pursed-lip breathing. Her weight was 95 lb, height was 5 feet 1 inch, and blood pressure was 100/75 mm Hg. On physical examination, the patient appeared somewhat malnourished. Examination of her head and neck was essentially normal. Auscultation of the heart revealed a mild tachycardia of 118 beats/minute. Chest examination revealed obvious barrel chest, while lung auscultation revealed overall diminished breath sounds bilaterally. Tenderness was noted over the anterior fifth right rib cage. Abdominal examination was noncontributory as was examination of the lower extremities. A posterioranterior and lateral chest radiograph taken in the emergency department displayed flattened diaphragms with increased hyperlucency in bilateral lung fields and a nondisplaced fracture of the anterior right fifth rib. The cardiac size on portable chest x-ray was considered to be mildly enlarged. Arterial blood gases on 4 L of supplemental nasal oxygen reveal a pH of 7.41, P_{CO_2} of 74, P_{O_2} of 58, and HCO_3 of 49.

Introduction

Palliative care medicine is a specialized discipline of health care that distinctively addresses the needs of individuals who have serious life-threatening illnesses that often rapidly terminate in death. This medical discipline does not focus on the acute treatment of the patient's underlying disease process but is a patient-centered focus on the relief of distressing symptoms while preserving the greatest possible quality of life (QOL) for the patient and family members.[1] It is also specifically intended to simultaneously support the patient's family before and after the death of the patient. Ideally, the concept of palliative care is introduced to patients and their families when it becomes apparent that curative or restorative attempts at treating a serious life-threatening condition are no longer possible, inappropriate, or desired by the patient.[1] See **Figure 26-1**. It is during the course of a potentially life-threatening respiratory or other life-limiting illness that patients and their families often face emotional and spiritual issues that are regularly addressed as part of the palliative care practice.

Palliative medicine is a recognized dynamic healthcare specialty with an inherent interdisciplinary nature, including medicine, nursing, social work, psychology, nutrition, and rehabilitation. This specialty calls for skilled practitioners to use their advanced knowledge of the pathophysiology of serious illnesses to medically manage advanced disease in seriously ill patients and is generally considered to be optimally delivered through a dedicated interdisciplinary "palliative care team" approach.[2] A major characteristic of palliative care is its ability to coordinate and partner with **hospice** programs as each involved patient traverses across the trajectory of disease. While its fundamental principles based on multiple national and international guidelines are sound, the depth of support available from each discipline varies from institution to institution.

The goals of palliative care are endorsed by several medical organizations and related healthcare organizations that view palliative care as seeking ways to prevent and relieve suffering, as well as support the best possible QOL for patients and their families, regardless of the stage of disease or the need for other therapies. Palliative care treatment may begin at any stage of a patient's illness and with or without simultaneous life-prolonging therapies. It is well established that palliative care can appropriately be delivered concurrently with life-prolonging (disease-modifying) care or as the focus of care, rather than reserving palliative care for patients deemed at the "end of life."



FIGURE 26-1 Palliative care's place in the course of illness.
Data from Grant M, Elk R, Ferrell B, et al. Current status of palliative l29:l32.

The current meaning and scope of palliative care medical practice reflects a significant change from its original conception. Initially, the idea of palliative care was focused on end-of-life care or the terminal phase of a life-limiting disease process when it origins in the UK began in the 1960s.[3] Since then, a more broad and updated definition clarifies the goal of comprehensive palliative care as maintaining and improving the QOL of all patients and their families during any stage of illness, whether acute, chronic, or terminal. The key domains of palliative care include symptom management, psychosocial-spiritual support, and facilitation of medical decision making, commonly referred to as goal setting.[4] Palliative care services should be available and offered to appropriate patients during and after life-prolonging treatments, as well as for the family both before and following the patient's death. Because several aspects of palliative care are justifiably applicable earlier in the course of the illness in conjunction with other treatments, palliative care is applicable to respiratory patients with life-limiting conditions such as lung cancer as well as to patients with advanced lung conditions, such as progressive COPD, granulomatous disease, or interstitial lung processes.[5]

Seriously ill patients tend to enter palliative care programs when faced with advanced-stage malignancies. In the United States, the leading primary organ-system sites causing cancer deaths include lung, colon-rectal, breast, and pancreas.[6] Individuals faced with advanced cancer confront their own unique difficult decisions regarding their treatment, including complex choices about end-of-life care. Although cancer-directed therapies have become increasingly more available, only a small number of promising new treatments provide a cure. Optimal cancer treatment and management includes access to palliative care throughout the cancer care continuum. Early enrollment and implementation of palliative care has proven beneficial in increasing the QOL for patients dying from cancer.[7] For this reason, palliative care providers require the skills necessary to recognize patients who are hospice-eligible by aptly utilizing prognostication and communication skills.[8] This is done in conjunction with appropriate provider–patient dialogue concerning individual end-of-life preferences.

Individuals who face life-limiting nonmalignant disorders in addition to advanced pulmonary disease experience conditions such as congestive heart failure, renal failure, liver failure, dementia, stroke, and HIV/AIDS.[9] Because patients who receive palliative care due to a life-limiting disorder share a similar prognosis of ultimate death, the focus of care is different from that in patients who receive anticipated "curative or restorative care" in the typical acute care settings. New symptoms arising during the key life-limiting process may indicate a secondary disease process that should be investigated and treated when appropriate. Unfortunately, the focus of the palliative visit is directed at the relief of long-standing symptoms that are considered progressive manifestations of the primary disease process or simply poorly controlled. It is therefore important that seemingly atypical manifestations occurring within the course of the primary illness prompt a review of the patient's medical history as well as consultation with previous treating physicians and consultants when feasible. In situations in which the cause of symptoms is not obvious, the importance of providing a multidisciplinary team approach is crucial to objectively address symptom origins. Difficult symptom manifestations affecting not only physical but also the psychologic, social, and spiritual sequelae can have a significant impact on a patient's QOL.

Palliative and hospice care services, though considered distinct, are closely related because their specific roles are often included in the course of a serious life-limiting illness typically leading to ultimate death. These distinctive categories within palliative medical care are not synonymous but represent separate portions of a disease course continuum in patients extending from acute as well as chronic serious illnesses and hospice care for those individuals with serious conditions considered near the end of life.[10] Therefore, palliative care as a component of palliative medicine should not be a service reserved for patients considered to be nearing the end of life who are imminently dying, but focuses on consultative services addressing goals of care that include symptom management, QOL, and family support of care in patients with serious illness and their families.[11] Ordinarily, interdisciplinary counseling provides the additional resources to aid the palliative care team in addressing the patient's needs, including the continuation of **life-extending treatments**.

Hospice as a distinct category within the palliative medicine continuum provides team-based support services to patient, family, and caregivers in the home or an institution when the patient has become

terminally ill. The Centers for Medicare and Medicaid Services define hospice as a specific patient plan of care that is "a comprehensive set of services identified and coordinated by an interdisciplinary group to provide for the physical, psychosocial, spiritual, and emotional needs of a terminally ill patient and/or family members."[10]

Hospice care services characteristically occupy the terminal phase of palliative care medicine, focusing specifically on patient- and family-centered needs to relieve suffering and promote comfort specifically during the end-of-life transition phase when curative therapy is no longer desired and/or a foreseeable option. As a distinct portion of the palliative care continuum, hospice care is considered more consistent with end-of-life care by primarily concentrating on enhancing a dying patient's QOL by providing adequate pain relief, managing physical symptoms, and providing emotional support to both the patient and the family.[12] Current support recommends that palliative care should be incorporated into the daily clinical management of the seriously ill patient regardless of the underlying illness or stage of disease, whereas hospice care should be considered when patients with life-threatening illness face an anticipated survival of 6 months or less.[11]

Coordination and partnerships between palliative care and hospice programs are essential components across the trajectory of serious disease as an interdisciplinary endeavor, including medicine, nursing, social work, psychology, nutrition, and rehabilitation.[3] Unfortunately, primary caregivers are often reluctant to discuss or recommend hospice because of their lack of training in communicating to patients near death or because they are unaware of hospice availability for noncancer patients.[13] Patients agreeing to initiate or transition to hospice care (unlike those receiving benefits from a palliative care program) are required to give up insurance for life-prolonging treatment. While the importance of each of palliative and hospice care has steadily progressed since their early beginnings, the depth of involvement available from each discipline continues to vary from institution to institution. Nevertheless, it is essential that all patients with serious illnesses receiving palliative medicine services, including hospice care, have clearly defined goals for care that are periodically reevaluated and that their symptoms are appropriately managed.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Palliative medicine is interdisciplinary.
2. True or False: The focus of hospice care is to prevent and relieve suffering during life-prolonging therapy.
3. True or False: Palliative care may be given during life-extending treatments.

Barriers to Effective Palliative Care

In cases in which treatment of a serious **life-limiting disorder** is successful, remission followed by recurrence and additional treatment may occur with many of these patients. When this occurs, there is usually multiple physician involvement that introduces fragmentation of care as the patient progresses through the course of the disease process. Coordination of care across these many disciplines is limited and difficult. One approach to this problem has been the use of familiar lay persons in assisting patients as they progress through diagnosis, treatment, and follow-up care of life-limiting and/or terminal illnesses.[14] Examples of such persons are nurses, social workers, or case managers.

Despite the increasing availability of comprehensive palliative care, including hospice services, there are numerous barriers that remain that pose obstacles to their timely use. Several studies demonstrate how transitioning from curative to palliative care is fraught with impeding roadblocks, including poor communication demonstrated between healthcare givers with their patients as well as the limited ability of staff to make difficult management decisions. Difficulty and discomfort that many caregivers have with candid discussions about end-of-life care with their patients may delay timely initiation of palliative care.[15] Some of the difficulty experienced by healthcare professionals may be related to the apprehension they have that discussing "palliative or supportive" in their patient's care and management will suggest to their patients that they have given up on them or that there are no further treatment options available. While this anxiety barrier may be present, honest communication with the patient should help to instill comfort and trust. Knowing that effective palliative care works in synchrony with more active therapeutic options, including active steps in preventing frequent and multiple hospital admissions that many patients with chronic lung disease experience, should be relayed to each patient.[15]

One of the most troubling causes of impaired discussions between caregivers and patients is the misconstrued, yet persistent, association of palliative and hospice care with imminent death. For patients with cancer of the respiratory system who are seeking cure or life prolongation and for physicians attempting to meet their patients' needs, this perception can limit acceptance of appropriate palliative care interventions. Fortunately, the acquisition of early consultation with a palliative care consultant or team can greatly facilitate communication. It is important to convey that palliative care can be delivered concurrently with anticancer

treatments.[16] In fact, the National Comprehensive Cancer Network (NCCN) guidelines have defined palliative care as "an organized, highly structured system for delivering care to persons with life-threatening or debilitating illnesses. Palliative care is patient and family centered care . . . . The goal of palliative care is to prevent and relieve suffering and to support the best possible QOL for patients and their families, regardless of the stage of disease or the need for other therapies.."[17] In many instances, comprehensive palliative medical care is delivered in tandem with life-prolonging care or even as the main focus of care by providing aggressive pain and symptom management, psychosocial support, spiritual care, nutritional support, music or art therapy, as well as additional services desired by the patient.[14] Care can be provided in hospitals, outpatient settings, as well as many other healthcare settings because currently there are no point-of-care criteria that restrict specific access to palliative care services.[18] Moreover, national and international organizations, including the Institute of Medicine, the American Society of Clinical Oncology, and the NCCN, have recommended the addition of palliative care practices into the cancer care continuum beginning at initial diagnosis.

Another potential impediment facing the healthcare provider in initiating early palliative care is the limited scope of some palliative medical services in some healthcare settings that may not provide access to hospice care. Hospice services within the complete continuum of palliative medicine should be available to patients with a prognosis of 6 months or less who are willing to relinquish insurance coverage for curative or life-prolonging treatments for focused supportive care.[11] Healthcare professionals also often fear that by mentioning the words "palliative or supportive care," they may unintentionally mislead their patients into sensing that they have nothing more to offer them or that no further treatment options will be available. The art of skillfully discussing how effective palliative or supportive care works in synchrony with more active therapeutic options must be developed through specific training and/or experience.[19] Explaining that one of the primary purposes of this form of specialized care is to prevent the frequent and multiple hospital admissions that many patients with chronic lung disease experience should help lessen this trepidation. Unfortunately, prognosticating the anticipated survival of patients with advanced lung diseases other than cancer as well as most patients admitted to the ICU is characteristically unreliable, perhaps adding more difficulty to a caregiver's ability to initiate early referral. The U.S. reimbursement criteria for hospice are subject to Medicare regulations over 80% of the time. If a patient's prognosis is indeterminate or if the patient wishes to pursue life-prolonging therapies, the patient becomes ineligible for hospice care reimbursement.[20] Such requirements can place the primary caregiver under additional pressures to make decisions they may not be able to make in good conscience.

Inconsistent and widely varying payment coverage by different insurers of patients with terminal illness adds to troublesome reimbursement issues. This introduces added burdens to providers due to complicated eligibility requirements, approved length of covered stay, and other time-consuming issues.[12] Nonpaid services by insurers of treatments, including outpatient managed care, include such expenses as co-pays and deductibles, and nearly all prescription medications (e.g., oral analgesics) can present significant financial obstacles to effective palliative care services.[12] Multifaceted professional staff as well as family-member caregiver stress and burnout can also contribute to suboptimal care. Even patients' attitudes regarding the appropriateness of treating symptoms associated with their serious illness or their fear and unwillingness to confront the acceptance of terminal disease may hinder effective delivery of palliative care.

Ineffective Communication

The most common and largest barrier to effective palliative care is ineffective communication and misconception of what palliative care is, by both healthcare professionals and patients.[21] Unfortunately, many healthcare providers lack the sufficient skills needed to implement meaningful discussions concerning goals, preferences, and end-of-life care with seriously ill patients. The inability to communicate effectively has been identified in several studies and institutional reports, including those of the Institute of Medicine. Not appropriately identifying patient and family concerns and wishes leads to persistent gaps in care for persons with serious and advanced illness. Specific care deficiencies ultimately arise in symptom control and continuity of care, and result in unmet spiritual, psychologic, and specific informational needs for the dying and their loved ones.[22]

Communication in health care is not a simple, naturally occurring process, but rather a complex endeavor. Proper communication requires intense education and practice. The need for expert communication skills is universal in health care but takes on special importance during intense times, such as serious illness and end-of-life care.[23] The ability to communicate well is important to good patient care and has been associated with greater patient satisfaction, better patient outcomes, less patient anxiety, better adherence to treatments, and better care at the end of life.[8]

When specifically asked, patients state their preferences as to the type of care they wish to receive when serious and life-threatening disease occurs typically include pain and symptom control, avoidance of an extended dying process, the capability of maintaining a sense of self-control, concerns regarding added hardships that their illness may have on their family, as well as a desire

to strengthen certain personal relationships.[24] Such communication interactions are often prolonged and may require several encounters to sufficiently address multiple critical and sensitive issues, such as preferences regarding life-sustaining treatments, the use of supportive technologies, and desire for home versus hospital care. While these topics of personal care seem entirely reasonable, the majority of research studies into patient goals and requests fail to demonstrate that their preferences are adequately met. Research findings suggest approximately 90% of patients specify a preference to die at home, yet significant numbers of terminal patients die in the hospital (including the ICU, where patients in this technology-rich environment are often faced with even greater difficulty communicating with their families), and 24% die in a skilled nursing facility.[25] A change in the healthcare approach from disease-centered care to patient-centered palliative care early in the course of serious illnesses can begin to familiarize the patient as well as family with palliative care services, permit dialogue to begin earlier in the course of palliative treatment regarding sensitive topics such as death, and provide for a window of opportunities for discussion of goals of care between the physician, patient, and family.

Empathetic and honest dialogue involving the patient and the palliative care team (including the primary treating physician and the patient's family) is an important factor in diminishing psychologic distress, enhancing patient compliance, developing patient and family realistic expectations, and promoting patient and family satisfaction. This is especially important at critical transition points in the patient's illness, which involve delivering bad news at points of transition in the disease course.[26] Physician availability to the patient and family is important, as well as responding to a patient's and family's feelings with attentive empathy. An appropriate physical location should be sought for the purpose of uninterrupted discussions. Time spent with the patient should also include the presence of appropriate family members so that informed choice and autonomy are possible.[27] Advance planning of care, continuity, and clinical guidance can positively impact the patient and family throughout this process. Yet, despite the combined efforts of a dedicated palliative care team, communication remains a significant problem in an estimated 20% of cases while analogous problems exist between the patient and family members in approximately 30–40% of cases.

Topics of conversation expressed by patients that are consistently absent or receive inadequate discussion in many studies include asking about religious beliefs, feelings regarding becoming increasingly more ill, suspected uncertainties regarding the dying process, and length of time remaining they might be expected to live.[23] Because of the inherent ambiguity regarding prognosis and chronicity of life-limiting lung disorders, effective communication skills regarding advance care planning remain challenging. This is especially true when caregivers begin discussions in response to an acute deterioration in the primary disease process or secondary exacerbating condition. Although the American Thoracic Society/European Respiratory Society guidelines for respiratory patients with advanced disease recommend beginning discussions regarding end-of-life care while patients are clinically stable, it is estimated that less than one-third of these patients have discussed their feelings with their healthcare provider or family members.[28] If patients with advanced lung disease such as COPD or pulmonary fibrosis choose to decline aggressive care in the terminal phase of their disease, they need to be repeatedly assured by all caregivers that those discussions are not intended to imply that they will, in any way, be medically or emotionally abandoned. Communication between caregivers and the patient should convey that "hope" is relative to one's current situation and should be preserved by setting reasonable expectations and goals based on straightforward prognostic information.[20] Successful early discussion before periods of crisis between caregivers and their patients and families provides an opportunity to better plan the use of time to make informed choices regarding specific goals such as hospitalization as well as procedures and treatments.[29] While these principles hold true, it is important to remember that with each individual case, there is no one path, no one speed, no one approach that will work for everyone.

KNOWLEDGE CHECK QUESTIONS

1. True or False: The U.S. reimbursement criteria for hospice care are subject to Medicare regulations.
2. True or False: The main barrier to palliative care is communication.
3. True or False: Most patients discuss their feelings regarding end-of-life care with their healthcare providers and their family.

Palliative Management Concerns

A key role assumed by a dedicated comprehensive palliative care team is the integration of a patient's unique detailed assessment and subsequent development of an often complex treatment plan consistent with the patient's and family's goals of care. Palliative care in the seriously ill typically involves multiple symptom management. Because such care is by its nature multifaceted and progressively more difficult, primary care clinicians are often encouraged to seek expert advice from a palliative care specialist and his or her team.[30]

The appropriateness of laboratory testing in patients receiving early palliative care is usually predicted on the suspicion of a concurrent acute disease process that will warrant additional treatment measures if discovered.

Although a patient receiving palliative care may have a high probability of coexisting morbidity, laboratory testing may not be necessary or appropriate. A patient with end-stage renal disease who presents with a seemingly unrelated symptom, such as a minor soft tissue infection, would likely not benefit from confirming the presence of an elevated serum creatinine level. It may become necessary to recheck renal functions if the need arises to subsequently treat requiring the adjustment of antibiotic dosing based on current renal function. Radiographic imaging, as with laboratory studies, are typically reserved for the identification of conditions that will change treatment when present. Substantiating the presence of a lung mass in a patient with lung cancer who presents with complaints unrelated to the chest is unnecessary. A patient who presents with a new cough associated with an elevated fever may warrant a chest radiograph if pneumonia is strongly suspected and the patient has indicated that he or she would receive antibiotic treatment for pneumonia, if established.

Commonly acceptable procedures for patients receiving palliative care include intravenous fluid administration for dehydration, thoracentesis for symptomatic relief of pleural effusion, paracentesis for symptomatic ascites, and urinary catheter placement to maintain hygiene or to prevent obstruction. The use of nasogastric (NG) tubes can temporarily supplement oral intake although they are usually uncomfortable and may significantly increase the risk of aspiration. In those cases where patients have indicated their desire for nutritional support, placement of a **percutaneous endoscopic gastrotomy (PEG) tube** may be a reasonable consideration.[31] Use of thromboprophylaxis with anticoagulant therapy involving patients with advanced life-threatening conditions such as cancer may be utilized in accordance with an acceptable estimate of risks and benefits.[32] Determination of potential anticoagulant usage is usually predicated on the presence of an adequate individual performance status determined by the **Karnofsky index**. Current studies suggest that low-molecular-weight heparin be employed in patients with an adequate performance status who is temporarily at an increased risk of venous thromboembolism (VTE) and has no substantial contraindications.[33]

The concept and practice of **surgical palliative care** has also evolved over time. Originally considered primarily a theoretical deliberation, it has become a more serious consideration in specific conditions. What was initially a limited practice consisting of a poorly defined set of invasive procedures has evolved to the level of an evidence-based approach of utilizing surgical means of relieving suffering and promoting QOL that may include cure or remission of the underlying disease. Thus, the fundamental principles guiding the application of surgical palliative care are deeply entrenched in surgical tradition.[34] Successful palliative surgery intervention, though generally not curative, is most likely to provide symptomatic benefit in a patient who has pain, ulceration, or bleeding or suffers complications of obstruction.[35] A careful patient selection process reflecting a clear understanding of expressed patient goals is necessary, given the desired outcome of lasting symptom control without operative morbidity. The American College of Surgeons Surgical Palliative Care Task Force defines palliative surgery as "any invasive procedure used for treatment when the major goal of treatment is _relief or the prevention of symptoms to improve QOL for patients with incurable illness. This treatment may or may not prolong life, but that is not the primary goal of the procedure"[34] (https://www.journalacs.org/article/S1072-7515(04)01340-7/fulltext).

KNOWLEDGE CHECK QUESTIONS

1. True or False: The placement of a PEG tube, for feeding purposes, is appropriate during palliative care.
2. True or False: Surgical palliative care is generally curative.

Management of Common Symptoms

There are numerous respiratory symptoms that are encountered with patients who are in the end-of-life phase. These include, but are not limited to, cough, dyspnea, pain, the adverse effects of opioid treatment, constipation, anxiety, depression, fatigue, anorexia, **delirium**, nausea and vomiting, psychological distress, and spiritual distress.

Cough

Cough and shortness of breath are among the most commonly encountered respiratory symptoms and often may become debilitating and result in profound reduction in QOL.[36] An unrelenting cough may not only cause debilitating manifestations in itself, but also exacerbate associated symptoms of shortness of breath, urinary and fecal incontinence, chest discomfort, and insomnia. Because cough receptors are located within the small or large airways, cough frequently occurs as the result of primary lung malignancy involving these locations as well as with any extrathoracic malignancy causing pulmonary metastasis.[36] In cases involving cough due to lung cancer, standard antineoplastic treatment, such as external beam radiotherapy (EBRT) or chemotherapy, has been found to be quite effective in reducing or halting cancer-induced cough.[37]

Dyspnea

Intractable dyspnea or breathlessness is a common devastating symptom of advanced-stage cancer as well as nonmalignant progressive lung disease. It may be defined as a subjective experience of difficult, labored,

and uncomfortable breathing.[38] Dyspnea as a symptom disorder is considered by many to be the most troubling and debilitating of pulmonary complications causing both distress and isolation for patients and their families. Controlling dyspnea, therefore, is considered fundamental in the palliative care of respiratory patients.[39] As with other distressing symptoms, it is important that the underlying cause of dyspnea is identified. Although bronchospasm and/or hypoxemia are commonly associated with symptoms of dyspnea in advanced lung disease, a less frequent cause and subsequent form of treatment may be required (as in thoracentesis for pleural effusion or diuresis for pulmonary edema). This is especially true in the elderly population who may present with unique challenges, such as hypothyroidism, anemia, and deconditioning, which can exacerbate dyspnea.[40] Symptom-directed management should be focused toward optimal disease-specific treatment.

Unfortunately, efforts to eliminate dyspnea are apt to be suboptimal because there is no completely effective palliative intervention. It is therefore important that patients are encouraged early to participate in pulmonary rehabilitation programs to hopefully learn ways to control their dyspnea and alleviate anxiety.[41] Integrating regular assessment with use of opioids and anxiolytics as well as management counseling may provide considerable relief. The physiologic component of dyspnea resulting from hypoxia may be significantly relieved with supplemental oxygen, whereas noninvasive positive-pressure ventilation can be helpful for hypercapnic adult patients.[42] Reversible cause of dyspnea should be identified and treated, such as pneumonia, symptomatic pleural effusion, severe anemia, and ascites. In the case of advanced-stage cancer, however, persistent breathlessness is significantly more complex because its cause is typically multifactorial.[43] Severity is generally unrelated to measurable pulmonary function or disease status and correlates poorly with respiratory rate, accessory muscle use, arterial blood gas analysis, and oxyhemoglobin saturation. Optimum palliative management should be focused on the patient's needs and goals and not be predicated simply on patient endurance.[41] Most often, management involves pharmacologic treatment with opioids given by oral route as a first-line therapy for symptomatic control of dyspnea in patients with advanced lung disorders. Effective dosages necessary for relief of dyspnea are often lower than doses necessary to control pain.[38] The majority of adverse effects associated with opioid therapy used for the relief of intractable breathlessness are nausea/vomiting and constipation, whereas respiratory depression is very rare and does not occur when opioids are titrated against pain, increased slowly, and dosed according to renal and hepatic function.[44] In fact, several studies have shown that opioid treatment for dyspnea does not lead to evidence of decreased respiratory rate, increased carbon dioxide retention, or earlier death. Less evidence of opioid effectiveness, however, is observed in patients with dyspnea caused by cancer.[45]

Nonpharmacologic interventions, such as the use of a directed fan or cool ambient airflow stimulation of receptors in the face and nasal passages, may be quite helpful for some patients.[46] Occasionally, oxygen therapy may benefit patients who do not meet Medicare reimbursement criteria for home oxygen therapy. In such cases, the Medicare Hospice Benefit covers the oxygen therapy costs with patients enrolled in a palliative care program. The use of benzodiazepines is particularly beneficial in dyspnea worsened by anxiety. The use of parenteral opioids and **palliative sedation therapy (PST)** may ultimately be necessary at the end of life when appropriate.

While the use of supplemental oxygen therapy can reverse hypoxemia, it may not necessarily relieve the sensation of dyspnea.[39] Although administering oxygen to cancer patients with and without hypoxemia can result in improved oxygen saturation, rarely does a reduction in dyspnea occur when cancer patients are placed on oxygen versus remaining on room air. Despite theoretical physiologic benefits associated with oxygen therapy, no additional symptomatic relief is likely to result when supplemental oxygen compared with room air is given to patients with refractory dyspnea due to most life-limiting illnesses.[47] In nonhypoxemic cancer patients, studies reflect no significant difference between oxygen-administered patients and those administered room air in reducing dyspnea during exercise. Evidence to support the use of oxygen therapy for dyspnea in advanced cancer patients remains weak because no consistent beneficial effect in relieving the symptom of dyspnea is observed in individuals with end-stage malignancies or congestive heart failure. Strong evidence exists, however, that does support oxygen therapy for dyspnea during exercise in hypoxemic patients with COPD, while merely blowing air across the face can also improve the sensation of dyspnea.[39] Nonpharmacologic interventions, such as pulmonary rehabilitation training that includes breathing training during exercise, combined with low-impact aerobics and strength training, can be effective in relieving breathlessness in advanced stages of chronic lung disease.[41]

Pain

A major area of palliative care concentration involves optimizing comfort and reducing physical suffering through management of bothersome symptoms, including pain.[48] While most respiratory disorders are more likely to produce respiratory-related symptoms, such as a cough or shortness of breath, cancer-related respiratory disorders and complications secondary to advanced respiratory disorders often result in pain. Control of pain normally begins with patient routine screening and assessment. Self-described pain assessment scales are used to subjectively quantitate levels

or degrees of pain, such as the familiar numeric 0–10 verbal pain scale. In the elderly, a three-component, descriptive scale utilizing mild–moderate–severe levels may be more appropriate for describing various intensities or degrees of pain. Another pain assessment tool includes a visual analog scale. The guiding principle with assessment scales is matching a suitable scale to the individual and using the tool consistently for serial assessment. By consecutively using the same scale over time, the level of pain control can be assessed, and reasonable goals can be established.[49] As with any distressing symptom, potentially reversible causes of pain should be investigated.

Nonnarcotic analgesics, including medications such as aspirin, acetaminophen, or nonsteroidal antiinflammatory drugs (NSAIDs), are used for mild pain (score of 1–3 on the 0–10 pain intensity scale).[49] Nonopioid adjuvant analgesics (which include agents such as NSAIDs, corticosteroids, antiepileptics, antidepressants, anticonvulsants, and local anesthetics) may be used in combination with opioids to treat moderate-to-severe pain (*moderate pain score of 4–6 and severe pain score of 7–10 on the 0–10 pain intensity scale*).[49] These agents are used to potentially minimize opioid adverse effects while maintaining pain control (especially in patients with cancer). **Adjuvant drugs** are particularly useful in the management of neuropathic pain (arising from injury to or abnormal stimulation of nerves).[50] Agents with the lowest adverse-effect profiles should be selected initially beginning with the lowest dose recommended and progressively increased until the desired relief effect is achieved without unfavorable effect. Other adjuvant analgesic therapies used for the palliation of painful cancer bone metastasis include bisphosphonates as well as radiation therapy and radioisotopes (such as strontium 89). Tricyclic antidepressants (TCAs) are typically reserved as initial treatment of neuropathic pain.[49,50] Nortriptyline and desipramine are typically preferred over antidepressant drugs such as amitriptyline because of their lower adverse effects. Other effective treatments of neuropathic pain include serotonin–norepinephrine reuptake inhibitors, anticonvulsants (e.g., gabapentin, carbamazepine),[49,50] and local anesthetics.

Opioids are considered the cornerstone of therapy for patients with moderate-to-severe cancer pain and/or intolerable dyspnea. Evidence also exists that opioids are also effective for nonmalignant sources of pain originating from painful somatic and visceral stimuli (nociceptive) as well as pain originating in the nervous system (neuropathic pain).[51] The optimal dosage of opioid that may be used is the dose that controls the patient's pain with the least amount of adverse effects. Based on the "**principle of double effect**," the relief of suffering adequately justifies using the premise that there is "no maximum dose of opioid" that supersedes the need to control dyspnea or pain suffering.[44] While no one form of opioid has been shown to have superior analgesic efficacy, oral morphine is the most preferred opioid for treating moderate-to-severe pain because of its convenience, stable blood levels, overall physician familiarity, and relative low cost, and because it has been studied the most. Various forms and types of opioids that are available include immediate and sustained or controlled-release oral preparations as well as parenteral morphine (given either subcutaneously or by the intravenous route). Transdermal or rectal suppository administration routes of specific opioid categories can be used for those individuals unable to take medications by mouth.[52] Because the active metabolites of opioids are primarily cleared by the kidneys and accumulation of these byproducts can therefore occur in renal dysfunction leading to oversedation with respiratory depression, hydromorphone and transdermal fentanyl are considered safer choices in patients with renal failure.[44] Meperidine is one opioid generally avoided because of its variable oral bioavailability, short duration of action, and neurotoxic metabolites. The metabolite normeperidine can accumulate with prolonged meperidine use at high doses or in cases of renal failure causing dysphoria, agitation, nervousness, and seizures.[44]

Adverse Effects of Opioid Treatment

Unfortunately, opioid therapy representing the foremost pharmacologic treatment of severe pain as well as intractable symptoms of dyspnea often produces predictable disturbing complications. Previous evidence has clearly shown that low-dose oral morphine has the best proven efficacy in patients with chronic progressive pulmonary disease and remains the gold standard as the pharmacologic agent of choice. Despite its proven efficacy, concerns regarding respiratory depression continue to be common especially when dosage is rapidly increased in opioid-naive patients.[44] Several studies have demonstrated, nevertheless, that the discomfort of dyspnea can be palliated safely without adversely depressing the respiratory rate, increasing carbon dioxide arterial levels, or causing premature death. Even when mild respiratory depression is encountered, individual tolerance to respiratory depression develops over time. Temporarily withholding the opioid and lowering the dose may alleviate mild cases of respiratory depression. If respiratory depression becomes more severe, diluted naloxone can be titrated to produce the desired respiratory response.[52]

Other predictable opioid adverse side effects include opioid-induced constipation with scheduled use typically requiring concurrent preventative as well as active treatment with scheduled stimulant or osmotic laxatives. The use of stool softeners is typically ineffective when exclusively used by themselves.[51] Nausea and vomiting associated with opioid use is felt to be mediated largely by dopamine and is generally temporary. Tolerance to opioid-induced nausea commonly

develops within a few days of its use. Because pain as well as dyspnea relief is often dependent on this medication, anti-dopaminergic antiemetics, such as metoclopramide or prochlorperazine, may be given because of their effectiveness in opioid-induced nausea. Delirium is defined as a group of symptoms caused by a disturbance in the normal functioning of the brain manifested by a state of mental confusion. Delirium typically develops quickly and usually fluctuates in intensity with opioid therapy in contrast to individuals with dementia.[52] Tolerance to opioid-induced delirium usually develops within 3–7 days of beginning treatment. Other reasonable measures to combat adverse effects include opioid agent rotation or using a sustained-release or transdermal steady-release opioid agent. Reducing the opioid dose while simultaneously combining the use of adjuvant analgesics may also decrease symptoms of delirium. The pharmacologic use of low-dose haloperidol has also been found to be effective in **opioid-induced delirium**.[52] Sedation commonly occurs with opioid agents yet decreases with tolerance. Sedation usually occurs within a few days of use and may be reversible with dose reduction or use of a different opioid preparation.[44] Psychostimulants such as methylphenidate can sometimes be used to offset persistent opioid-induced sedation. **Opioid-induced pruritus**, though rare, results from histamine release. It may be treated by switching to a different opioid agent or by adding low doses of non-sedating antihistamines to counteract symptoms.[44] Opioid-induced **hyperalgesia** results in a patient becoming paradoxically more sensitive to pain despite opioid use, and especially in those individuals requiring high-dose therapy. Likewise, **allodynia** (referring to pain evoked by a stimulus that is not normally painful, such as in the soft touch of a bed sheet) may occur in patients receiving high doses of opioid agents. Resolution of either hyperalgesia or allodynia symptoms may respond to a reduction in opioid dose, by rotating the specific type of opioid or by using adjuvant analgesics. **Myoclonus** (consisting of involuntary spastic contractions of a muscle or group of muscles) is uncommon yet a potential adverse effect of opioid therapy, which may respond to low-dose benzodiazepines. Other known adverse effects of opioid therapy include urinary retention, which is often self-limited but may require intermittent straight catheterizations or the temporary placement of a Foley catheter in more extreme cases,[4] and dry mouth normally treated with good-quality oral hygiene and saliva substitutes.

It has been suggested that palliative care pain management should follow several fundamental guiding principles. See **Box 26-1** and **Figure 26-2**.

BOX 26-1 Fundamental Guiding Principles for Palliative Care Pain Management

- Pain medications need to be dispensed on a regularly scheduled basis.
- As needed (PRN) or rescue doses need to be available for breakthrough pain or pain not controlled by the standing regimen.
- Palliative care patients beginning opioid therapy need to be routinely started on a prophylactic bowel regimen.
- The World Health Organization (WHO) analgesic stepladder approach to the use of analgesic drugs should be used as a guide for most pain syndromes.



FIGURE 26-2 The WHO pain relief ladder.
Reproduced with permission from WHO Analgesic Step Ladder. http://www.who.int/cancer/palliative/painladder/en.

Constipation

Constipation may be defined as the passage of hard, dry stools less frequently than the patient's usual bowel-habit pattern, rather than simply the decrease in the number of stools per day or week. While not normally a symptom that is necessarily associated with respiratory disease, constipation is common in advanced progressive illness and prevalence usually increases with age and reduced activity.[53] The consequences of constipation can be substantial, ranging from considerable annoyance to nausea and abdominal pain to fecal impaction and even death from colon perforation. In patients with terminal disease, this disturbing symptom almost routinely results when medications such as opioids are employed. While the use of opioids represents the most common iatrogenic cause of constipation, many other medication types may also contribute, such as anticholinergic agents, calcium, and iron. Therefore, when the addition of these types of agents is considered necessary, the minimum effective dose should be employed to lessen their pharmacologic contribution to constipation.[44] Management is often successful when a stimulant laxative, such as senna, with or without

a stool softener as an adjunct is part of prophylactic bowel regime.

The addition of a different laxative class, such as an osmotic laxative, should be considered if a prophylactic management regime alone is not effective. Laxative dosing ideally should be adjusted to maintain a patient's usual normal bowel habits. Recent evidence suggests that gastrointestinal mu-opioid receptor antagonists, such as methylnaltrexone, may effectively treat opioid-induced constipation that is unsuccessful with usual laxative therapy. This agent works by selectively blockading peripheral opioid receptors to relieve constipation without precipitating opioid withdrawal.[53,54] A bulk-forming laxative in palliative care is usually not recommended because it may exacerbate constipation in those individuals who are dehydrated or less mobile. Use of laxatives may also cause additional adverse side effects, including bloating, abdominal cramping, nausea, and diarrhea. Bisacodyl suppositories or enemas may be used in more refractory cases of uncomplicated symptomatic constipation. While constipation is a predictable side effect associated with opioids or other pain analgesics in patients with advanced illness, constipation may be multifactorial, prompting investigation into other potentially coexisting reversible causes.[53] Responsible medications should be potentially discontinued or reduced, toilet facilities made accessible, a bowel routine established utilizing the gastrocolic reflex, and fluid intake as well as activity encouraged if feasibly appropriate.

Anxiety

Anxiety is common in patients with respiratory disorders, especially when facing a life-limiting illness and potential premature end of life. Anxiety may occasionally occur as a primary psychiatric disorder, such as depression, or more frequently may represent a heightened reaction to stress and apprehension.[55] While anxiety can be significantly problematic for patients, other potential contributors to distress should be investigated before considering pharmacotherapy treatment. Anxiety may be exaggerated by certain medications such as corticosteroids, psychostimulants, caffeine, alcohol, beta-agonists, or theophylline, as well as drug and/or alcohol withdrawal, delirium, depression, and insomnia. Approximately 70% of terminally ill patients have anxiety.[55]Although dyspnea is considered a cause for anxiety and panic attacks, the opposite is also true that anxiety causes dyspnea. Whichever occurs, compromises a patients' QOL, decreases how well a patient responds to emergency therapies during acute exacerbations, and subsequently leads to more frequent hospitalizations. Anxiety disorders are likely to increase requirements for opioids used in the management of acute as well as chronic pain. Anxiolytics such as short-acting benzodiazepines are often considered a useful addition in these patients although adverse effects can occur, including paradoxical agitation, sedation, and respiratory depression. Other neuroleptic agents that may prove beneficial in treatment include antidepressants, antipsychotics, and buspirone.[28]

Depression

Physicians need to be attentive and responsive to the fact that patients dealing with life-threatening disorders in up to approximately 30% of advanced cases become depressed.[56] Medications such as chemotherapy, corticosteroids, or interferon can also affect depression as well as physiologic factors, including pain. Examples of psychological factors influencing the development of depression include spiritual issues, loss of personal control, and/or weak social support. In addition to their patients, clinicians should also carefully monitor caregivers for signs of depression, discuss their potential vulnerability, and offer support and referral resources when needed. A briefly depressed mood or transient depression lasting a few days to a few weeks can be normally expected in individuals confronted by serious, life-threatening illness. Most experts agree, however, that symptoms that endure for several weeks are neither normal nor expected.[57] Assessment for major depression should follow persistent warning signs, such as sadness, irritability, and distress; withdrawal from daily activities; unexplained worsening of physical symptoms or disproportionate to the apparent extent of disease; feelings of hopelessness or inappropriate guilt; and suicidal behavior or refusal of care. Treatment of depression with selective serotonin reuptake inhibitors is usually considered safe in most patients presenting with persistent symptoms. While psychostimulants, such as methylphenidate, are effective in individuals without major contraindications, use of these agents may require several weeks to achieve a therapeutic effect.[58] A depressed patient exhibiting active suicidal ideation should be assessed immediately and referred to an appropriate mental health or palliative care professional.

Fatigue

Fatigue may be defined as a persistent sense of tiredness that is not relieved by sleep or rest. It is an extremely common problem among palliative care patients occurring in an estimated 75–90% of patients with cancer, causing significant distress.[59] The prevalence of fatigue is similar to that of patients with other progressive chronic diseases, including advanced lung disease. Fatigue negatively impacts the QOL of patients as well as their caregivers as a multidimensional problem causing physical, emotional, and cognitive difficulties. While fatigue may be caused by commonly associated factors, such as stress, lack or disruption of sleep, poor diet, or excessive workload, palliative care patients are more likely to have fatigue from the illness itself, adverse

effects of treatment, and/or trying to cope with the huge number of issues surrounding the end of life.[59]

Specific factors that may intensify or aggravate fatigue in palliative care patients include severe dyspnea, pain, anemia, nutritional and metabolic deficiencies, diminished activity and deconditioning, and the adverse effects of various therapies, including radiotherapy. Fatigue can also be exacerbated by medications such as chemotherapy, corticosteroids, interferon, anticholinergics, sedative-hypnotics, opioids, and antihistamines.[60] Pharmacologic therapies used for the treatment of fatigue, such as psychostimulant agents and corticosteroids, have shown only modest benefits, whereas hematopoietic growth factors can improve fatigue in anemic cancer patients undergoing chemotherapy.[60] Nonpharmacologic interventions that may be worth attempting in patients in whom a specific reversible mechanism remains elusive include various coping strategies, music therapy, reflexology, cognitive therapies, behavioral therapies, psychotherapy, and exercise.[59]

Anorexia

The **anorexia–cachexia syndrome** involving the loss of appetite and unintentional weight loss occurs frequently in severe advanced respiratory diseases but is most commonly described in patients with cancer who often lose a desire to eat or drink at the end of life.[61] Some adult patients, however, deliberately choose to stop eating and drinking to control and/or accelerate the dying process. If an individual with a life-limiting illness who retains the capacity to make decisions chooses to forego nutrition and hydration, caregivers need to respect the decision and support the patient and family by continuing to provide palliative care. Support for this inaction is legally and morally justified because there is no compelling evidence that dehydration or foregoing nutrition in the dying patient leads to significant suffering.[62] If the wishes of the patient are known that nutrition and hydration are desired to be continued, efforts should be made to identify potentially reversible causes of anorexia.

Nonpharmacologic intervention to promote nutrition and hydration may be warranted when the overall survival prognosis remains uncertain and death is not imminent, though typically results in only marginal success. Such measures include offering nutritional supplements, such as liquids, puddings, and textures; using natural supplements and herbs; and avoiding noxious odors. Other techniques include offering small and frequent meals; avoiding forced eating; practicing breath control while eating; and controlling pain. Efforts that may also be beneficial in some cases include addressing accompanying social, psychologic, and spiritual issues.[63] Pharmaceutic agents that have some success in anorexia–cachexia syndrome are progestins and corticosteroids. Progestins such as megestrol and corticosteroids such as medroxyprogesterone are equally effective in temporarily stimulating appetite and increasing weight in patients with cancer, although use of megestrol in older nursing home patients has been associated with increased mortality without a significant increase in weight. These medications have not, however, shown a beneficial effect on QOL.[64] In fact, several adverse effects may occur with the use of progestins, such as lower-extremity edema, venous thromboembolic disease, and gastrointestinal intolerance. Adverse effects that are associated with corticosteroids include gastrointestinal disturbances, edema, anxiety, steroid psychosis, hyperglycemia, and hypertension.[53]

Delirium

Delirium is described as a mental state of acute confusion and inattention that normally follows a fluctuating course pattern. It is accompanied by either disorganized thinking or an altered level of consciousness.[65] In palliative care patients facing end of life, delirium is distressing and should be recognized early and treated. While commonly encountered in palliative care, an attempt should be made to identify any potentially reversible causes of delirium, such as the treatment of underlying pain or other symptoms like urinary obstruction, bowel impaction, or factors affecting sensory deprivation that may be contributing to delirium. While several factors can play a role, medications account for the most common cause of delirium, and therefore, all nonessential medications should be eliminated. If possible, reorientation should be gently encouraged with minimization of excessive environmental stimuli. Efforts should also be focused at avoiding sleep deprivation to minimize the risk of delirium.[65]

While there is currently little evidence regarding the role of pharmacotherapy in the management of delirium in the terminally ill, patients can generally be treated with low-dose haloperidol as first-line therapy. Agitation and restlessness not responsive to haloperidol are likely to respond to the more sedating chlorpromazine. Benzodiazepines are typically reserved as second-line agents because they are less effective than neuroleptic agents and associated with a greater occurrence of paradoxical reactions, such as agitation, sedation, worsening delirium, and respiratory depression. Respiratory patients with advanced cancer who experience hypoactive delirium may benefit from methylphenidate.[66]

Nausea and Vomiting

Nausea is a subjective, unpleasant awareness of the urge to vomit. The action of vomiting represents a neuromuscular reflex most often reversibly caused by bowel distension from constipation that results in the forceful oral expulsion of stomach contents.[67] The next most frequent reversible cause of nausea and vomiting is narcotic medications primarily occurring when treatment is initiated.[68] An attempt should always be made to

identify other potentially reversible causes of nausea. It is estimated that approximately 60% of individuals with a life-limiting illness such as cancer, congestive heart failure, end-stage renal disease, and AIDS will experience nausea, and 30% will display vomiting.[68] Before treating, it is important to identify the likely cause because symptoms of nausea and vomiting are commonly multifactorial, which may include the disease process itself and/or various therapies. Identifying a likely physiologic mechanism substantially increases the likelihood of choosing an effective antiemetic regimen (consisting of one or more medications). Vomiting is mediated via neurotransmitter signals (*including serotonin, dopamine, acetylcholine, and histamine*), as well as other stimuli communicated from the chemoreceptor trigger zone, the vestibular apparatus, the cerebral cortex, and the gut to the brain's vomiting center.[67]

A mechanism-based pharmacologic approach utilizing neurotransmitter-focused treatment can effectively relieve nausea and vomiting in up to 90% of patients faced with terminal illness. Neurotransmitters, including serotonin, dopamine, and substance P, appear to be particularly important in mediating acute chemotherapy-induced nausea. Symptoms may be effectively treated with combination therapy, including a serotonin antagonist, dexamethasone, and aprepitant (an adjunctive antiemetic).[69] Opioid-induced nausea mediated primarily by the neurotransmitter dopamine, on the other hand, is usually most effectively treated with medications such as metoclopramide, prochlorperazine, or haloperidol, although dopamine receptor antagonists can be associated with extrapyramidal symptoms and akathisia (a feeling or sensation of restlessness and anxiety).[51] Those individuals experiencing refractory nausea should be scheduled for treatment around the clock with multiple agents that target diverse neurotransmitter receptors.

Psychologic and Spiritual Distress

Psychologic as well as spiritual distress is generally common in individuals with lung cancer as well as advanced respiratory diseases, particularly as life-sustaining interventions become increasingly more limited. Although serious illness can raise deep-seated spiritual issues for patients, spirituality can also often become a significant source of comfort. An assessment of patients' spiritual beliefs can be closely evaluated by using a spiritual history assessment tool, such as the FICA or SPIRIT acronym. See **Figure 26-3**. A physician's role in dealing with these disturbances is to recognize the patient's concerns, determine the extent to which the patient is able to cope, and provide appropriate resources that might be of help.[70] At the same time, clinicians should carefully monitor caregivers for similar difficulties and depression, discuss their vulnerability with them, and if needed, suggest support and referral resources to them.



FIGURE 26-3 Useful acronyms for obtaining a spiritual history. **(A)** FICA where F = faith and beliefs, I = importance of spirituality in the patient's life, C = Spiritual community of support, and A = how does the patient wish spiritual issues to be addressed in his or her care? **(B)** SPIRIT where S = spiritual belief system, P = personal spirituality, I = integration with a spiritual community, R = ritualized practices and restrictions, I = implications for medical care, and T = terminal events planning.

Addressing the psychosocial and spiritual needs of patients and families is a core element of palliative care as mental suffering may become unbearable to some. Often, these disturbances lead to subsequent worsening of physical symptoms, such as pain and anxiety.[70] It is common that spouses demonstrating profound emotional and psychologic distress exhibit increased morbidity and mortality, especially those who have assumed an active caregiver role. While sometimes not obvious, spiritual and religious beliefs may play a significant role in shaping treatment decisions among critically ill patients and their families particularly regarding the initiation and continuation of life-sustaining therapies.[71] Physician-initiated discussion regarding spiritual or religious beliefs that displays respectful listening and meaningful compassion is usually appreciated and welcomed by most seriously ill patients and their families.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Cancer-induced cough can be alleviated via external beam radiotherapy.
2. True or False: Dyspnea due to hypoxemia is not treatable during palliative care.
3. True or False: Dyspnea worsened by anxiety may be treated with benzodiazepines.
4. True or False: Fatigue causes significant distress in cancer patients.

Palliative Care in Chronic Progressive Lung Disorders

The American Thoracic Society (ATS) End-of-Life Care Task Force has issued practical guidelines for integrating palliative with standard care for individuals with

chronic respiratory disease. An official ATS Clinical Policy Statement subsequently recognized the WHO position on palliative care that aims to prevent and relieve suffering by early identification, assessment, and treatment of pain and other types of physical, psychologic, emotional, and spiritual distress symptoms.[28]

Because most patients have decision-making capacity early in a chronic progressive disease, it is important to sensitively determine their immediate and long-term goals of care and identify whom they want to make decisions on their behalf when they are unable to do so.[8] Candid communication regarding palliative care services should be guided by patients' articulated goals, expressed preferences, and questions. In contrast to the acute care setting, such as during ICU care, decision making may occur only after several visits in the outpatient setting. By managing distressing symptoms facing a chronic significantly ill respiratory patient with a terminal disease process, palliative care can improve QOL by offering other support services to patients and their families.[72] The task force further expands palliative care goals originally discussed to ideally include "all patients receiving curative or restorative health care should receive palliative care concurrently, the elements and intensity of which are individualized to meet the patient's and family's needs and preferences."[28] The policy executive summary emphasizes the need to include patients at all stages of illness whether terminal or not terminal that may benefit from palliative care. This is despite an acknowledgment that this specialized service was originally conceived and practiced as end-of-life care before evolving to its present position.

Decision making involving patients with advanced lung diseases may include several discussions regarding realistic continued active care options, including mechanical ventilation, lung transplantation, and Phase I or II clinical trials.[73] These options need to be thoughtfully addressed with clear, honest, and realistic descriptions of their benefits as well as drawbacks, including the potential for reducing time spent with family and other loved ones. Individuals with non-neoplastic advanced lung disease, such as advanced COPD or interstitial pulmonary fibrosis, confront several complexities in getting appropriate referral to hospice.[73] Unfortunately, palliative care, including hospice services, remains underused in patients with advanced pulmonary diseases other than cancer. Because the only curative option for selected patients with advanced lung diseases is lung transplantation, if transplantation is not a viable option, palliation of symptoms and hospice care may offer those individuals relief from intolerable symptoms and an opportunity to die with dignity and comfort.[73]

Most patients with lung cancer who are subsequently referred to hospice typically die within a 6-month period. Prognostication involving noncancer patients with advanced lung diseases, however, is significantly more difficult to determine because of the lack of reliable predictive survival models for these individuals. Primary care givers more comfortable with providing predominately preventative medical care frequently fail to recommend hospice care at home or in another setting for nonmalignant patients with terminal disease because they are unfamiliar with its availability or eligibility criteria for noncancer patients. Because there has been increasing support by home care organizations to embrace palliative and hospice care, obstacles to referral of patients with life-limiting respiratory disorders have at least been partially offset.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Palliative care may be given concurrently with restorative health care.
2. True or False: Hospice care is routinely recommended to noncancer advanced lung disease patients.

Advanced Directives

Studies done regarding accurate and detailed prognostic information on end-of-life options indicate that most patients who face life-limiting illness prefer their physician initiate discussions about whether they wish to know their length of survival prognosis and in what level of detail.[20] Approximately one in five seriously ill patients, however, would rather not personally discuss end-of-life options with their health provider despite maintaining obvious self-preferences or wishes. This usually necessitates the designation of an appropriate proxy (such as a family member) to accomplish this task. If feasible, it is important to determine the patients' immediate and long-term goals of care as well as whom they want to make decisions on their behalf if they become incapable of doing so. Utilizing advance directives, the patient or designated surrogate on behalf of the patient specifies the patients' desires as to whether/when to discontinue life-prolonging interventions and the types/amount of palliative care they wish to receive. Although logic would suggest that advance directives are vital in maintaining autonomy (patients' control over one's self well-being), most patients do not have advance directives or do not update them.[74] Most adult patients who do create advance directives, however, rarely if ever change their affirmed initial preferences over time, permitting the desired and coordinated provision of palliative care to preferably begin in an effective way to meet all of the needs of the patient and family.[74] While critical decisions are ideally addressed in an advance directive, physicians as well as patients should be aware that specific limitations of advance directives are inherent in actual situations.

All 50 of the United States and the District of Columbia have enacted legislation to recognize the legal right of competent adults to responsibly designate advance directives. The purpose of these directives is to provide guidance for healthcare decision making near the end of life should illness, disease, or injury eliminate a patient's ability to decide for themselves.[1] Although there is much common ground among state laws, specific legal provisions may vary from state to state, particularly regarding default surrogate decision makers if one was not previously specified by the patient.[75] Usually providing an advance directive appointing a durable healthcare power of attorney or healthcare proxy may prevent later conflict or confusion. The intent of providing a legal representative of the patient is not to appoint someone to choose or determine the patient's outcome but rather for a representative to embody the patient's expressed wishes when he or she can no longer do so if the patient's condition suddenly deteriorates. If possible, discussions regarding interventions that no longer achieve the patient's goals should take place when the patient's functional status and QOL are still intact yet may be declining, but before the patient loses the ability to express his or her desired preferences.[24] It is only relatively recently that societal pressures have encouraged patients to choose healthcare surrogates or proxies as well as to establish advanced care planning documents. These are exemplified by the expanded use of living wills or personally signed do-not-attempt-resuscitation (DNAR) or DNR orders. While the overall intention of instituting these types of documents is to protect patients against unwanted treatments and to ensure that their wishes are followed as they approach death, few studies support that these documents alter practice. Yet it has been suggested that caregiver and family discussions regarding such documents concerning the patient's end-of-life care decisions may help provide comfort to the family that they are respecting their loved one's wishes.

Advanced care planning, including advance directive documents such as living wills, are theoretically based on the ethical principle of patient autonomy. They are generally viewed as an opportunity for patients to self-direct their care at a future time when illness could otherwise render them incapable of speaking on their own behalf.[24] Unfortunately, as a rule, they are characteristically ambiguous. Frequently, such efforts in planning cannot reliably predict all eventualities and unforeseen options and may be additionally limited by inadequate communication and misunderstanding.[74] Even the most ardent efforts at following the content of written advance directives in a precise manner are not often medically feasible. They, therefore, may fail because such advanced planning encompasses a huge range of available objective data, provider skills, and available technologies, and involves considerable individual subjective judgments and values. Even though the more recently introduced patient autonomy model regarding medical decision making starts from the premise that the patient knows what treatment decision is in line with his or her true sense of well-being, physician judgment and combined cultural values of the palliative care team will often indirectly drive the actions taken with or without advance directives.[75] It is therefore important to remember that despite seemingly exercised autonomy with the perceived merits of having self-directed goals and preferences delineated in the form of written advance directives, patients and their families often make their decisions based on what is said, by whom, what is seemingly being offered, and what they have come to subsequently understand and believe.[24,75] Therefore, it may be argued that in reality medical paternalism based on the classic beneficence model, although indirect, remains at least a part of modern medical decision making.

Several efforts have been made to improve desired outcomes from advance directives fraught with potential hazards of ambiguity and limitations despite their completion in accordance with state law; patient preferences for care at the end of life are not consistently followed by healthcare professionals especially in emergency situations. **Physician Orders for Life-Sustaining Treatment (POLST)** is a relatively recent program developed that is similar yet does not replace an Advance Health Care Directive. It is recommended that a seriously ill patient have both a signed POLST form and an advance directive for implementing shared, informed medical decision making. POLST is designed to effectively translate a patient's goals for care at the end of life into medical orders that follow the patient as they move from one residential or medical setting to another. Thus, POLST can supersede several inherent limitations of traditional advance directives, providing a means to assess and transmit the wishes of patients with serious life-limiting illness who may have a life expectancy of less than 1 year or anyone of advanced age or chronic illness as to their wishes for end-of-life care.[76] See **Table 26-1**.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Most patients wish to discuss end-of-life options with their healthcare providers.
2. True or False: Patients' wishes for end-of-life care can be specified in advance directives.
3. True or False: Advanced care planning is based on the ethical principle of paternalism.
4. True or False: Advance directives is another name for POLST.

TABLE 26-1
Differences between POLST and Advance Directives

Characteristics	POLST	Advance Directives
Population	For the seriously ill	All adults
Time frame	Current care	Future care
Who completes the form	Healthcare professionals	Patients
Resulting from	Medical orders (POLST)	Advance directive
Healthcare agent of surrogate role	Can engage in discussion if patient lacks capacity	Cannot complete
Portability	Provider responsibility	Patient/family responsibility
Periodic review	Provider responsibility	Patient/family responsibility

Reproduced with permission from Bomba PA, Kemp M, Black JS. POLST: an improvement over traditional advance directives. *Cleve Clin J Med.* 2012;79(7): 457–464, p. 458.

Palliative Care in Advanced-Stage Lung Cancer

Pulmonary symptoms necessitating palliation in more advanced stages of lung cancer patients typically include those caused by a primary cancer itself. Symptoms may include one or several respiratory manifestations of disease, including cough, dyspnea, wheezing, hemoptysis, chest pain, or symptoms related to regionally localized metastases.[40,43,77] Complications resulting from lung cancer treatment or from comorbid conditions can also contribute to adverse respiratory symptoms. Nonspecific (constitutional) symptoms such as anorexia, weight loss, weakness, and increased fatigability commonly occur and subsequently require attention and care as well as symptoms attributable to distant metastases that necessitate a specific response for optimal symptom control.

In 2018, it is estimated that 234,030 new cases of respiratory system cancer will occur in the United States along with approximately 154,050 respiratory cancer-related deaths.[78] While many life-prolonging treatments continue to become available to patients with primary as well as metastatic lung cancer, unfortunately most cases cannot be cured. It is therefore essential that healthcare providers support these patients and their families from the time of cancer diagnosis through the dying process by integrating palliative care and hospice services into the cancer care continuum. Lung cancer as a leading cause of death from cancer worldwide is a debilitating disease that typically results in a high symptom burden and poor QOL.[43] It affects literally all aspects of daily living for both patients and their family members and causes one of the lowest survival outcomes of any cancer. Despite its devastating effects, many distressing symptoms are inadequately palliated or are not referred to palliative care services until very late during their illness, if at all.

Data obtained from several Phase III randomized controlled trials have recently demonstrated substantial evidence of the benefits of palliative care in patients with metastatic non-small-cell lung cancer and/or high symptom burden receiving standard oncology care, including symptom improvement, QOL, patient satisfaction, and a decrease in caregiver tasks.[79] Findings from these studies also strongly suggest that earlier involvement of palliative care also promotes the more fitting use of hospice as well as the reduced application of ineffectual intensive care.[40] This has prompted an expert panel of the American Society of Clinical Oncology to issue a provisional clinical opinion strongly supporting concurrent palliative care and standard oncologic care at initial diagnosis of patients with metastatic non-small-cell lung cancer.[80]

Despite the increasing availability of palliative care and hospice services in the United States, numerous barriers remain limiting their timely use. One of the most troubling of these is the persistent misconstrued association of palliative care with imminent death. For patients with cancer who are seeking cure or life prolongation and for physicians who seek to meet their patients' needs, this perception can limit the acceptance of appropriate palliative care interventions because of this fundamental misunderstanding. Palliative care may be administered in tandem with life-prolonging care or as the main focus of care.[79] Palliative care programs in the United States are not specifically designed or restricted to those patients who are imminently dying. For instance, palliative care can and when appropriate should be delivered concurrently with life-prolonging anticancer treatments.[43] The NCCN guidelines define palliative care as:

> "An organized, highly structured system for delivering care to persons with life-threatening or debilitating illnesses. Palliative care is patient and family centered care . . . . The goal of palliative care is to prevent and relieve suffering and to support the best possible QOL for patients and their families, regardless of the stage of disease or the need for other therapies"[17] (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573467/).

KNOWLEDGE CHECK QUESTIONS

1. True or False: Most cancers are still not curable.
2. True or False: Concurrent standard oncologic care and palliative care are recommended at the initial diagnosis of metastatic non-small-cell lung cancer.

The ICU and Palliative Care

Palliative and end-of-life care continues to emerge as a comprehensive area of expertise in the ICU that demands a similar level of expertise and competence as all other areas of ICU practice. Care involving the terminally ill includes the prevention or treatment of pain, anxiety, and physical symptoms in addition to the potential of withholding and withdrawing of life support in certain circumstances by either the non-initiation of specific interventional technologies or the withdrawal of such various modalities of life-sustaining treatment, respectively.[81,82] Palliative services to patients normally involve the use of sedatives, analgesics, and nonpharmacologic approaches to easing the suffering of the dying process.

While it is estimated that approximately 20% of deaths follow admission to an ICU in the United States,[82,83] ICU management has clearly improved survival in appropriately selected patients. Yet despite advances occurring in the treatment of patients admitted to the intensive care in recent years, end-of-life decision making foregoing life support has become a key issue facing critical care practice, especially because patients unlikely to benefit from aggressive life-sustaining care are still often admitted to an ICU, leading to needless suffering and wasted resources.[83] ICU restriction of admission utilizing systems such as rationing (the allocation of healthcare resources in the face of limited availability) and triage of patients (prioritizing based on their underlying conditions) is uncommon in the United States, including patients with end-stage illness.[83]

Admission to the ICU can still occur despite factors such as a patient's wishes to decline extraordinary measures if medically determined to be terminally ill or in a state of permanent unconsciousness. Studies suggest that clinicians often display widely dissimilar treatments when faced with seriously ill patients ranging from aggressive care to palliation.[1] The explanation for this variability in treatment is unknown but probably affected by dissimilarities in individual practice style, access to care, and local cultural and religious traditions. Palliative along with end-of-life care practice, which can differ dramatically among physicians as well as hospitals, adds to the apprehension that external factors besides a patient's illness and preferences will determine treatment and ultimately whether patients will live or die. Despite the presence of knowledgeable trained staff, it is also well known that inadequate treatment of pain and dyspnea is common.[84]

Problematic consequences to palliative care patients can result from mistaken assumptions regarding prognosis and functional status. ICU and its interventional technologies may be appropriate for some, but not for others. Similarly, even though a patient has prepared advance directives or has decided to forego resuscitation efforts should a cardiopulmonary arrest occur, it says little about their overall preferences.[81] Finally, agreement between families and physicians does not necessarily ensure that appropriate decisions are made. Every major decision requires careful deliberation to maximize the likelihood that critical choices are consistent with the patients' fundamental wishes.[85] Including a palliative care team into the care of a seriously ill patient admitted to the ICU is one strategy that at least theoretically can improve overall communication in conflict resolution as well as provide greater opportunities for goal setting, advanced care planning, and spiritual, cultural, and bereavement support at the end of life.[82,85]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Once advance directives are in place, admission to the ICU is inappropriate.
2. True or False: Inclusion of the palliative care team in end-of-life decisions improves overall communication among all involved in the decision-making process.

Withdrawing Life Support

Individuals suffering from acute, chronic, or acute-on-chronic respiratory failure often experience symptoms such as pain and dyspnea along with a high incidence of morbidity and mortality. These patients are typically treated aggressively when they, their families, and their physicians believe that health and QOL can be reasonably restored. Treatment goal emphasis typically changes from restorative to palliative care or "the transition from cure to comfort" among those patients determined to have reached the end of life.[86] Aggressive therapeutic interventions, such as mechanical ventilation, which can be effective in reversing respiratory failure in patients with acute decompensation, are usually not considered a sustainable option for the terminally ill. Discussions with patients and their families should obligate caregivers to provide sufficient reassurance, however, that a limitation of life-sustaining treatment does not automatically equate with acceptance

of certain death, complacent surrender, or patient abandonment.[81] When clinically appropriate, as with patients in the final process of dying from their underlying illness, withholding as well as the voluntary action of withdrawing life-sustaining therapy and medical technology, including mechanical ventilatory support, is supported as ethically neutral and legally allowable.

Adult patients who sustain their decision-making capacity and choose without coercion may voluntarily refuse all medical treatments, including life-support interventions, as a function of their individual **autonomy** and the right to make their own independent decisions regarding control over their own bodily integrity.[85,86] The ethical principle of autonomy is counterbalanced against a previously customary philosophy of **medical paternalism** in which health decisions were not self-resolved but "best left in the hands of those providing health care" for physicians to decide on the behalf of their patients in their presumed best interest.[87] Because concern may arise as to whether patients have sufficient understanding regarding their medical circumstances and treatment options as well as the probable consequences of their decisions, medical practitioners have been empowered by the law to decide whether a patient has appropriate decision-making capacity. It has also become a generally well-accepted ethical as well as legal opinion that a physician who subsequently limits or removes life support in response to a dying patient's directive is fulfilling an ethical duty in respecting that patient's autonomy. It is generally acknowledged that the underlying life-limiting disease process rather than the limitation of life support is considered the direct cause of death.[87]

Discussions regarding the decision to withdraw mechanical ventilatory support or other extraordinary life-support interventions, such as dialysis, should be initiated when a patient or their surrogate(s) mention the concern, when primary caregivers believe that continued life-sustaining provisions are no longer satisfying the patient's expressed goals, and when such necessary modalities as mechanical ventilation become more problematical than beneficial to the patient.[87] Once a decision has been made to stop a life-extending intervention, a consensus should be reached on when and how this will occur. Withdrawal of mechanical ventilation is certainly more common in the ICU setting but may sometimes occur outside the ICU environment, such as in a long-term ventilator facility or even at home.[82,87] As the situation occurs in many instances, when a patient lacks decision-making capacity, either the patient's prior desired advance directives or the wishes of appointed decision makers identified by the patient should be utilized to guide the decision-making process. In any case, the family should be realistically made aware that it is difficult to predict how long a patient will continue to breathe after ventilator withdrawal and should also be advised as to what to expect and hear during the dying process. When a life-ending situation does not involve an advance directive, decision making is usually a joint process between the patient's family and medical team.[87,88] In all potential settings following the withdrawal of mechanical ventilatory support, caregivers should continue to administer opioids and benzodiazepines to the patient to maintain satisfactory control of any signs of discomfort or suffering.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Invasive mechanical ventilation is not considered an aggressive therapeutic intervention.
2. True or False: Removal of life support, including mechanical ventilation, is legal and is considered ethically neutral.
3. True or False: It is the healthcare practitioner's ethical duty to respect patient autonomy.

Hospice and End-of-Life Care

As discussed earlier, hospice care typically occupies the terminal stage or end-of-life phase of palliative care medicine as the patient with life-limiting disease transitions along the lifespan timeline. Eligibility requirements for hospice services currently require that the patient's expected death will occur in less than 6 months and that the patient agrees to relinquish Medicare-reimbursed services for therapies focused on cure or life-prolonging treatment.[3,11] Consultative palliative care (in contrast to hospice services) allows for the assessment and treatment of patients anywhere along the disease trajectory, regardless of prognosis. Because of added requirements for hospice eligibility versus palliative services under Medicare and other insurers, individuals with non-neoplastic advanced lung disease often face added difficulty in meeting hospice eligibility requirements. This is primarily because accurately prognosticating a 6-month mortality timeline in patients with progressive lung disorders is inherently inaccurate. Also, potentially impeding hospice eligibility is the fact that standard predictive survival instruments such as the BODE (body mass index [BMI], airflow obstruction, dyspnea, and exercise capacity) index provide prognostic information from 12 to 52 months but are not capable of determining a risk of mortality greater than 50% at a 6-month period necessary to qualify for hospice care.[28]

Hospice care program criteria for admission of adult patients with nonmalignant advanced lung disease were initially published in 1996. Since that time, Medicare and other insurers have integrated these recommendations into their own hospice enrollment eligibility criteria. See **Box 26-2**. Consideration for

BOX 26-2 Medicare Criteria for Hospice Eligibility of Patients with Advanced Lung Disease

Patients are considered to be in the terminal stage of pulmonary disease (life expectancy of 6 months or less) if they meet the following criteria. The criteria refer to patients with various forms of advanced pulmonary disease who eventually follow a final common pathway for end-stage pulmonary disease (Criteria 1 and 2 should be present. Criteria 3, 4, and 5 will lend supporting documentation):

Criteria 1. Severe chronic lung disease including (a) as well as (b):

- **a.** Disabling dyspnea at rest, poorly responsive or unresponsive to bronchodilators, resulting in decreased functional capacity (e.g., bed-to-chair existence), fatigue, and cough. (Documentation of FEV_1, after bronchodilator, less than 30% of predicted is objective evidence for disabling dyspnea but is not necessary to obtain.)
- **b.** Progression of end-stage pulmonary disease, as evidenced by increasing visits to the emergency department or hospitalizations for pulmonary infections and/or respiratory failure or increasing physician home visits before initial certification. (Documentation of serial decrease of $FEV_1 > 40$ mL/year is objective evidence for disease progression but is not necessary to obtain.)

Criteria 2. Hypoxemia at rest on ambient air, as evidenced by Po_2 less than or equal to 55 mm Hg or oxygen saturation less than or equal to 88% on supplemental oxygen determined either by arterial blood gases or by oxygen saturation monitors; *or* hypercapnia, as evidenced by $Pco_2 >$ 50 mm Hg. These values may be obtained from recent (within 3 months) hospital records.

Criteria 3. Right heart failure secondary to pulmonary disease (cor pulmonale) (e.g., not secondary to left heart disease or valvulopathy).

Criteria 4. Unintentional progressive weight loss of greater than 10% of body weight over the preceding 6 months.

Criteria 5. Resting tachycardia > 100/minute.

Lankin PN, Terry PB, DeLisser HM, et al. on behalf of the ATS End-of-Life Care Task Force. An Official American Thoracic Society Clinical Policy Statement: Palliative care for patients with respiratory diseases and critical illnesses. *Am J Respir Crit Care Med*. 2008; 177(8):912–927, p 916.

hospice eligibility in addition to those satisfying predictive survival instrument specifications includes the presence of comorbidities and a rapidly declining course. Other criteria that have been proposed as justification for advanced lung disease hospice admission include conditions in which

1. "despite optimal treatment, a chronic respiratory disease has progressed to the point that the patient may die at any time because of a common intercurrent illness such as bronchitis;
2. [t]he patient has severely distressing symptoms or limited performance status that can be most humanely and reasonably managed by hospice care; or
3. [t]he patient accepts that death is near and wants to avoid needless prolongation of suffering. There are no comparable criteria suggested for enrollment of children with advanced respiratory diseases into hospice."[10]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Patients who enter hospice care are generally expected to die in less than 6 months.
2. True or False: Resting tachycardia is required for Medicare to cover patients with advanced lung disease who wish to enter hospice care.

Palliative Homecare

Fortunately, there are no criteria that currently exist that restrict access to palliative care services. This permits these services to be provided in many healthcare settings, including within the patient's home environment.[19] There is, however, significant variability in the kinds of services that outpatient home palliative care may be provided to patients who qualify. Interdisciplinary palliative care team extenders may provide home visits about once per week to address physical, psychologic, social, and spiritual needs involved with a patient's disease process. Recommendations for management are then communicated to the patient's primary care physician.[11] Palliative home care services aim to facilitate patient autonomy, access to information, and choice by eliciting the patient's goals of care, focusing on improving the QOL, and promoting comfort by therapies that are in line with the patient's goals.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Palliative care is available only within a hospital or nursing home setting.
2. True or False: Interdisciplinary palliative care team extenders may provide home visits once per week.

Hospice Homecare

Compared to outpatient home palliative care services, home-based hospice services provide comprehensive patient care through Hospice Medicare Benefit coverage. This program provides for interdisciplinary team services, including physician and nursing participation. Many home hospice programs will provide up to 1–4 hours/day of nursing/certified nursing-assistant care up to 5 days a week, depending upon the patient's needs. Home care programs suggest and/or require patients to obtain an additional care provider, such as a family member and/or friend who can be available to provide supplemental home hospice care. Hospice Medicare Benefit coverage includes durable medical equipment as well as medications related to hospice services, including pain and symptom control. While home care hospice coverage is not normally extended to provide 24 hours a day care, the Medicare Hospice Benefit includes a continuous-care option that is available during periods of crisis and acute symptom control to assist maintaining the patient at home. Inpatient hospice services for acute symptom control, on the other hand, normally provide 24-hour-a-day personal care as well as interdisciplinary services.[3,11,17]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Home hospice care is exactly like home palliative care.
2. True or False: Family members may be involved in home hospice care.

Palliative Sedation Therapy

PST (Table 26-2), which is also known as terminal or total sedation, is commonly defined as treatment employed to "produce relief of otherwise intractable pain, dyspnea, delirium, cough, or existential distress by the use of medications that intentionally cause sedation."[89] Professional support for PST has evolved for those patients with severe, intolerable physical symptoms in the final stages of the dying process that possess a completed DNAR order and the patient (or surrogate if the patient lacks decision-making capacity) has given informed consent. Appropriate

TABLE 26-2
PST Classifications

Type of Sedation	Explanation
Ordinary sedation	The ordinary use of sedative medications for the treatment of anxiety, agitated depression, insomnia, or related disorders, in which the goal of treatment is the relief of the symptom without reducing the patient's level of consciousness.
Palliative sedation (PS)	The use of sedative medication at least in part to reduce patient awareness of distressing symptoms that are insufficiently controlled by symptom-specific therapies. The level of sedation is proportionate to the patient's level of distress, and alertness is preserved as much as possible.
PS to unconsciousness	The administration of sedatives to the point of unconsciousness when less extreme sedation has not achieved sufficient relief of distressing symptoms. This practice is used only for the most severe, intractable suffering at the very end of life.

Data from American Academy of Hospice and Palliative Medicine Position Statement on Palliative Sedation. http://www.aahpm.org/positions/sedation.html.

symptomatology is considered to be refractory to aggressive symptom-specific interventions in providing relief, associated with unacceptable morbidity, and/or are unlikely to provide relief within a reasonable period. Despite the development and availability of aggressive, high-quality palliative-symptom management, some patients protract symptoms, such as agitated delirium, dyspnea, pain, and nausea/vomiting that remain refractory to standard therapies. PST is typically reserved as an option for those terminally ill patients at the very end of life whose intolerable symptoms persist in causing intractable suffering.[90] Sedative medications are specifically and carefully titrated to the patient's comfort for the intent of producing a cessation of symptoms by reducing consciousness, and not for euthanasia. See Box 26-3.

The fundamental basis of PST is supported by the principle of double effect, which justifies the use of drugs given explicitly to relieve intolerable distress in the setting of terminal illness, even when they may hasten death.[90] PST use is generally contingent upon evidence of other standard interventions being tried and shown to be ineffective. When used appropriately, PST is morally justified despite potentially undesired side effects, including the unintentional hastening of death.[89] The concept of double effect provides a distinction between the intention with which an action is performed and the potential serious consequence it may produce, characterizing a difference between an intended (good) effect and an unintended (bad) effect

BOX 26-3 Ethical Features Involving PS

1. The clinician's intent is to relieve suffering.
2. The degree of sedation must be proportionate to the severity of suffering.
3. The patient should give informed consent; if the patient is not capable of decision making, the surrogate decision maker should give informed consent consistent with the goals of care and values previously stated by the patient.

Data from American Academy of Hospice and Palliative Medicine Position Statement on Palliative Sedation. http://www.aahpm.org/positions/sedation.html.

KNOWLEDGE CHECK QUESTIONS

1. True or False: PST is typically reserved as an option for those terminally ill patients at the very end of life whose intolerable symptoms persist in causing intractable suffering.
2. True or False: The principle of double effect justifies the use of drugs given explicitly to relieve intolerable distress in the setting of terminal illness, even when they may hasten death.
3. True or False: Midazolam is currently the most frequently used sedative medication for PST.

of an intervention. Under the concept or doctrine of double effect, an action that has foreseen harmful effects that may be virtually inseparable from the good effect is justifiable if "the nature of the act is itself good, or at least morally neutral; the agent intends the good effect and not the bad either as a means to the good or as an end itself; the good effect outweighs the bad effect in circumstances sufficiently grave to justify causing the bad effect and the agent exercises due diligence to minimize the harm"[91]

Because sedative effects include additional anxiolytic benefits as well as antiepileptic, muscle-relaxant, and amnesic properties, midazolam is currently the most frequently used sedative medication for PST. Other sedatives used include various neuroleptic agents, such as chlorpromazine, barbiturates, and general anesthetics such as propofol. Because no evidence exists that giving an appropriate sedation dosage shortens life, administration of sedative agents may selectively be done intermittently (which may allow for periods of consciousness) or continuously (providing constant sedation).[92] Given that the intent of palliative sedative therapy is to relieve unbearable suffering rather than hasten the process of death, the dosage of therapy used is individually titrated to achieve patient's comfort. This may be achieved with only mild sedation in some patients because deep and continuous sedation is not always necessary for symptom relief, while another person may require greater sedation to relieve suffering.[93] The objective of PS clearly differs from euthanasia or assisted suicide, which is unequivocally intended to cause the patient's death.

Bereavement Counseling

Another essential component of palliative care includes bereavement care, which should begin before and continue after the death of the patient. This includes "care for the caregivers" whether they are family members, lay caregivers, or healthcare providers.[94] It is extremely important that palliative care practitioners learn and be able to describe to families the normal grieving process experience and complex period of mourning following the loss of a beloved person. Palliative care providers should therefore be familiar with appropriate resources for bereavement counseling as sources of support.[22] These may include referrals to religious clergy, healthcare professionals with specialized training and skills such as social workers, nurses, bereavement counselors, and hospice-sponsored grief recovery support groups that can spend significant amounts of time with families to assist in this process when clinically indicated.

The majority of those bereaving a loved one's death will normally transition through several stages of the normal grief process within several months to 2 years depending on the length and closeness of the relationship. Most people affected do not require formal treatment for bereavement though they may choose to participate in support groups for recently bereaved people or hospice follow-up programs.[29] More serious forms of bereavement, such as traumatic grief (typically resulting from a specific type of event during a traumatic situation) and complicated grief (referring to an abnormally intense and prolonged response to bereavement), may, on the other hand, take several years to resolve even with appropriate treatment.[94] While it is probably accurate that no two people respond similarly to their individual loss associated with the death of a loved one, their personal experience may be influenced by factors such as ethnic or religious traditions; individual viewpoints about life after death; the nature of the relationship that ended with death; the cause of death; the age of the person at the time of death; whether the death was sudden or anticipated; as well as many other dynamics. Because emotional complexity and a diversity of issues may shape how a death will affect a family member or a close loved one, caregivers often advise those mourning to trust their own feelings about bereavement, and it is important to grieve in the way that seems most helpful to them. If the bereavement response to a death becomes abnormally intense and likely to represent

suffering from traumatic or complicated grief, various psychologic inventories or questionnaires may be necessary to determine whether the condition meets the criteria for posttraumatic stress disorder (PTSD), major depression, or recognized form of acute stress disorder.[95]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Bereavement counseling should begin at the time of death.
2. True or False: The death of a loved one may cause PTSD.

Chapter Summary

While prevention of morbidity and death has always been a primary goal of medicine, it is only within the past few decades that the capability of providing a comfortable and peaceful death has been largely acknowledged as an important end in itself. Even with widespread professional acknowledgment of the importance of palliative care, many patients with respiratory disease are profoundly affected by poor QOL, often inappropriately undergo unnecessary interventions, have pervasive gaps in symptom control and continuity of care, develop avoidable side effects, and die in moderate or severe pain. Poorly prepared caregivers are frequently unaware of the patients' unmet desires regarding their treatment and end-of-life care, including spiritual and psychologic needs. Providing relief from seemingly intractable suffering and a reasonably high-quality end-of-life care is a difficult and complex process. The provision of this level of expertise normally requires a diverse healthcare provider skill set necessary to provide such care as derived from the perspectives of patients with acute as well as chronic life-limiting illnesses, their family members, and team of caregivers.

The ATS policy statement adopted by the ATS Board of Directors in 2007 endorses the currently held concept that palliative care should be available to patients at all stages of chronic respiratory illness and that care should be individualized based on the needs and preferences of the patient and the patient's family. It also supports the recommendation that caretakers of patients with chronic or advanced respiratory diseases and/or critical illnesses should be trained in and capable of providing several recommended fundamental competencies in palliative and end-of-life care. The policy further endorses and supplies criteria for enrollment into hospice care in the United States as an appropriate multidisciplinary phase of palliative care to patients at the terminal phase of their life available to the patients and their families.

Studies regarding the use of palliative care have been shown to improve patient outcomes, provide lower cost of care, and decrease intensive care utilization. Outpatient palliative care services provided to patients with advanced respiratory disorders receiving standard care have improved QOL and mood compared with patients receiving only standard care, despite a lack of effect on survival. Recent findings, however, involving patients with newly diagnosed metastatic non-small-cell lung cancer who received palliative care in addition to standard care show better QOL and mood in addition to longer survival than patients receiving only standard care.

Key Points

1. The percentage of hospice admissions by primary diagnosis is predominately due to nonmalignant disorders with lung disease accounting for the fourth most common noncancer diagnosis.
2. The goal of palliative care is patient-centered relief of symptom burdens and providing the best possible QOL within the limitations of the illness. Burdens may include physical, psychologic, spiritual, or social problems that typically require a multidisciplinary approach.
3. Palliative care represents a continuum of palliative medicine intended to support patients of all ages with debilitating and life-threatening illness and their families through the full duration of illness until cure or death as well as through the bereavement period.
4. Palliative care planning should optimally begin early in the care of patients with progressive, debilitating respiratory illnesses such as COPD and pulmonary fibrosis.
5. Patients with advanced respiratory disorders require palliative care management of dyspnea involving the treatment of underlying disease process as well as coexisting morbidities such as anemia, pleural effusion, congestive heart failure, reversible airway obstruction, main stem bronchial compression or obstruction.
6. Psychosocial factors worsening dyspnea should be treated with relaxation techniques, distraction, activity modifications, behavioral modifications, and treatment for anxiety, and/or cognitive therapy, antidepressants, or a combination of both for depression.
7. Pain management necessitating opioids requires use of a sufficient amount and dosage interval to relieve suffering without intolerable adverse effects. Individualized dosage titrations are typically higher in those individuals who have previously received opioids.
8. While advance directives can be useful, they are by nature ambiguous, causing serious limitations.

Such efforts in planning cannot reliably predict all eventualities and unforeseen options as well as often being additionally limited by inadequate communication and misunderstanding.

9. PST is a recognized therapeutic procedure in which sedative medications are given to reduce consciousness in a gravely ill patient to relieve intolerable pain, dyspnea, agitated delirium, and/or nausea/vomiting during the terminal phase of the dying process.
10. Approximately 70% of terminally ill patients enrolled in palliative care hospice programs eventually die in their place of residence, with the majority dying at their private residence followed by nursing home or residential facilities.

Chapter Questions

1. Palliative care focuses on _____.
   a. moving quickly to the end-of-life phase
   b. relief of distressing symptoms
   c. curing the patient of disease
   d. end-of-life care only
2. Patients receiving palliative care who develop secondary manifestations _____.
   a. are transferred immediately to a skilled nursing facility
   b. typically receive consultations and medical record reviews
   c. are automatically transferred to hospice care
   d. receive no additional care
3. Initiation of palliative care is usually delayed due to _____.
   a. poor communication between provider and patient/family
   b. reduced staffing at the acute care hospital
   c. lack of medical coverage
   d. refusal by the patient
4. About _____% of chronically ill patients wish to die at home.
   a. 35
   b. 50
   c. 75
   d. 90
5. _____ is a procedure that is **not** acceptable for patients receiving palliative care.
   a. PEG tube placement
   b. Thoracentesis for pleural effusion
   c. Bronchoscopy for biopsy
   d. Paracentesis for symptomatic ascites
6. The most common and debilitating symptom encountered by end-of-life patients is _____.
   a. anxiety
   b. pain
   c. cough
   d. depression
7. Most patients with lung cancer who are referred to hospice typically die within _____.
   a. 3 months
   b. 6 months
   c. 9 months
   d. 1 year
8. Advance directives are based on the ethical principle of _____.
   a. beneficence
   b. veracity
   c. paternalism
   d. autonomy
9. Hospice home care programs typically provide up to _____ hours per day of care.
   a. 1–4
   b. 4–6
   c. 6–8
   d. 12
10. Palliative sedation therapy is based on the principle of _____.
    a. paternalism
    b. double effect
    c. autonomy
    d. placebo effect

References

1. Truog RD, Campbell ML, Curtis JR, et al. Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American Academy of Critical Care Medicine. *Crit Care Med*. 2008;36(3):953–963.
2. Zimmerman C, Riechelmann R, Krzyanowska M, et al. Effectiveness of specialized palliative care: a systematic review. *JAMA*. 2008;299(14):698–1709.
3. Lutz S. The history of hospice and palliative care. *Curr Probl Cancer*. 2011;35(6):304–309.
4. Kelley AS, Morrison RS. Palliative care for the seriously ill. *New Engl J Med*. 2015;373:747–755. doi: 10.1056/NEJMra1404684.
5. Narsavage GL, Chen YJ, Korn B, et al. The potential of palliative care for patients with respiratory diseases. *Breathe*. 2017;13:278–289.
6. Sigel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7–30.
7. Walling AM, Asch SM, Lorenz CP, et al. The quality of care provided to hospitalized patients at the end of life. *Arch Intern Med*. 2010;170(12):1057–1063.
8. Clayton JM, Hancock KM, Butow PN, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. *Med J Aust*. 2007;18(186)(12 Suppl):S77, S79, and S83–S108.
9. Kuebler KK, Heidrich DE, Esper P. *Palliative and End of Life Care: Clinical Practice Guide*. 2nd ed. St. Louis, MO: Saunders/Elsevier; 2007. ISBN: 9781416030799.
10. Epocrates Online. (2018). End-of-life care Overview. Retrieved from https://online.epocrates.com/diseases/102011/End-of-life-care/Overview
11. Buss MK, Rock LK, McCarthy EP. Understanding palliative care and hospice: a review for primary care providers. *Mayo Clin Proc*. 2017;92(2):280–286.
12. Hughes MT, Smith TJ. The growth of palliative care in the United States. *Annu Rev Public Health*. 2014;35:459–475.
13. Shanawani S, Wenrich MD, Tonelli MR, Curtis JR. Meeting physicians' responsibilities in providing end-of-life care. *Chest*. 2008;133(3):775–786.
14. Ramchandrank K, Von Roenn JH. Palliative care always. *Oncology*. 2013;13–36.

15. Stephen N, Skirton H, Woodward V, Prigmore S, Endacott R. End-of-life care discussions with nonmalignant respiratory disease patients: a systematic review. *J Palliat Med*. 2013;16(5):555–565.
16. Collins A, McLachlan S, Philip C. How should we talk about palliative care, death and dying? A qualitative study exploring perspectives from caregivers of people with advanced cancer. *Palliat Med*. 2018;32(4):864–869.
17. Dans M, Smith T, Back A, et al. NCCN guidelines insights: palliative care, version 2.2017. *J Natl Compr Canc Netw*. 2017;15:989–997. doi:10.6004/jnccn.2017.0132.
18. Kamal AH, Currow DC, Ritchie CS, Bull J, Abernethy AP. Community-based palliative care: the natural evolution for palliative care delivery in the U.S. *J Pain Symptom Manage*. 2013;46(2):254–263.
19. Meier DE, Bowman B. The changing landscape of palliative care. *J Am Soc Aging*. 2017;41(1):74–80.
20. Glare PA, Sinclair CT. Palliative medicine review: prognostication. *J Palliat Med*. 2008;11(1):84–103.
21. Pinkowish RD. End-of-life care: communication and a stable patient-physician relationship lead to better decisions. *CA Cancer J Clin*. 2009;59(4):217–219.
22. Wright AA, Baohui Zhang B, Ray A, et al. Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. *JAMA*. 2008; 300(14):1665–1673.
23. Malloy P, Virani R, Kelly K, Mune'var C. Beyond bad news: communication skills of nurses in palliative care. *J Hosp Palliat Nurs*. 2010;12(3):166–174.
24. Will JF. A brief historical and theoretical perspective on patient autonomy and medical decision making. Part II: the autonomy model. *Chest*. 2011;139(6):1491–1497.
25. Agar M, Currow DC, Shelby-James TM, Plummer J, Sanderson C, Abernethy AP. Preference for place of care and place of death in palliative care: are these different questions? *Palliat Med*. 2008;22(7):787–795.
26. Finlay E, Casarett D. Making difficult discussions easier. Using prognosis to facilitate transitions to hospice. *CA Cancer J Clin*. 2009;59(4):250–263.
27. Mack JW, Cronin A, Taback N, et al. End-of-life care discussions among patients with advanced cancer: a cohort study. *Ann Int Med*. 2012;156(3):204–210.
28. Lanken PN, Terry PB, DeLissar HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. *Am J Respir Crit Care Med*. 2008;177(8):912–927.
29. Holtslander L, Baxter S, Mills K, et al. Honoring the voices of bereaved caregivers: a metasummary of qualitative research. *BMC Palliat Care*. 2017;16:48.
30. Quill TE, Abernethy AP. Generalist plus specialist palliative care—creating a more sustainable model. *New Engl J Med*. 2013; 368(13):1173–1175.
31. Bradley CT, Brasel KJ. Developing guidelines that identify patients who would benefit from palliative care services in the surgical intensive care unit. *Crit Care Med*. 2009;37(3):946–950.
32. Ansell JE. Prophylaxis and treatment of venous thromboembolism in cancer patients: a review. *Am J Clin Oncol*. 2009;32(4 Suppl):S8–S12.
33. McLean S, Ryan K, O'Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. *Palliat Med*. 2010;24(4):386–395.
34. Dunn, GP. Surgery, palliative care, and the American College of Surgeons. *Ann Palliat Med*. 2015;4(1):5–9.
35. Dunn, GP. Surgical palliative care: recent trends and developments. *Anesthesiol Clin*. 2012;30(1):13–28. doi:10.1016/j.anclin.2011.11.001.
36. Morice A, Shanks G. Pharmacology of cough in palliative care. *Curr Opin Support Palliat Care*. 2017;11(3):147–151.
37. Haas AR. Recent advances in the palliative management of respiratory symptoms in advanced-stage oncology patients. *Am J Palliat Care*. 2007;24(2):144–151.
38. Booth S, Moosavi SH, Higginson IJ. The etiology and management of intractable breathlessness in patients with advanced cancer: a systematic review of pharmacological therapy. *Nat Clin Pract Oncol*. 2008;5(2):90–100.
39. Horton R, Rocker G. Contemporary issues in refractory dyspnoea in advanced chronic obstructive pulmonary disease. *Curr Opin Support Palliat Care*. 2010;4(2):56–62.
40. Stapleton RD, Curtis JR. End-of-life considerations in older patients who have lung disease. *Clin Chest Med*. 2007;28(4):801–811.
41. Reticker AL, Nici L, ZuWallack R. Pulmonary rehabilitation and palliative care in COPD: Two sides of the same coin? *Chron Respir Dis*. 2012;9(2):107–116.
42. Sinuff Y, Cook DJ, Keeenan SP, et al. Noninvasive ventilation for acute respiratory failure near end of life. *Crit Care Med*. 2008; 36(3):789–794.
43. Freedman OC, Zimmermann C. The role of palliative care in the lung cancer patient: can we improve quality while limiting futile care? *Curr Opin Pulm Med*. 2009;15(4):321–326.
44. Hall EJ, Sykes NP. Analgesia for patients with advanced disease: I. *Postgrad Med J*. 2004;80(941):148–154. doi:10.1136/pgmj.2003.015511.
45. Oaseem A, Snow V, Shekelle P, Casey DE, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life: a clinical practice guideline from the American College of Physicians, *Ann Intern Med*. 2008;148(2):141–146.
46. Booth S, Moffat C, Burkin J, Galbraith S, Bausewein C. Nonpharmacological interventions for breathlessness. *Curr Opin Support Palliat Care*. 2011;5(2):77–86.
47. Uronis HE, Abernathy AP. Oxygen for relief of dyspnea: what is the evidence? *Curr Opin Support Palliat Care*. 2008;2(2):89–94.
48. Wilkie, DJ, Ezenwa, MO. Pain and symptom management in palliative care and at end of life. *Nurs Outlook*. 2012;60(6):357–364. doi:10.1016/j.outlook.2012.08.002.
49. Krause R, Stanford J. Advances in pain control in palliative care: pain in palliative care needs to be carefully assessed before treatment. *CME: Your SA Journal of CPD*. 2011;29(7):270.
50. Hall EJ, Sykes, NP. Analgesia for patients with advanced disease: 2. *Postgrad Med J*. 2004;80(942):190.
51. Star A, Boland JW. Updates in palliative care—recent advancements in the pharmacological management of symptoms. *Clin Med*. 2018;18(1):11–16. doi:10.7861/clinmedicine.18-1-11.
52. Masman, AD, van Dijk M, Tibboel D, Baar FPM, Mathôt RAA. Medication use during end-of-life care in a palliative care centre. *Int J Clin Pharm*. 2015;37(5):767–775. doi:10.1007/s11096-015-0094-3.
53. Matsuo N, Morita T, Matsuda Y, et al. Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study. *Support Care Cancer*. 2017; 25(1):41–50. doi:10.1007/s00520-016-3383-z.
54. Librach SL, Bouvette M, De Angelis C, et al. Consensus recommendations for the management of constipation in patients with advanced, progressive illness. *J Pain Symptom Manage*. 2010; 40(5):761–773.
55. Kolva E, Rosenfeld B, Pessin H, Breitbart W, Brescia R. Anxiety in terminally ill cancer patients. *J Pain Symptom Manage*. 2011; 42(5):691–701.
56. Lloyd-Williams M, Shiels C, Taylor F, Dennis M. Depression–an independent predictor of early death in patients with advanced cancer. *J Affect Disord*. 2009;113(1–2):127–132.
57. Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. *J Pain Symptom Manage*. 2007;133(2):118–129.
58. Rayner L, Price A, Valsraj K, Hotopf M, Higgins IJ. Antidepressants for the treatment of depression in palliative care: systemic review and meta-analysis. *Palliat Med*. 2011;25(1):36–51.
59. Harris JD. Fatigue in chronically ill patients. *Curr Opin Support Palliat Care*. 2008;2(3):180–186.
60. Yennurajalingam S, Bruera E. Palliative management of fatigue at the close of life: "It feels like my body is just worn out." *JAMA*. 2007;297(3):295–304.
61. Acreman S. Nutrition in palliative care. *Br J Community Nurs*. 2009;14(10):427–428.

62. Brody H, Hermer LD, Scott LD, Grumbles LL, Kutac JE, McCammon SD. Artificial nutrition and hydration: the evolution of ethics, evidence, and policy. *J Gen Intern Med.* 2011;26(9):1053–1058.
63. Furman P. Nutrition support at the end of life: a critical decision. *Today's Dietician*. 2008;10(9):68.
64. Zhang F, Shen A, Jin Y, Qiang W. The management strategies of cancer-associated anorexia: a critical appraisal of systematic reviews. *BMC Complement Altern Med*. 2018;18(1):1–9. doi:10.1186/s12906-018-2304-8.
65. Gagnon PR. Treatment of delirium in supportive and palliative care. *Curr Opin Support Palliat Care*. 2008;2(1):60–66.
66. Grassi L, Caraceni A, Mitchell AJ, Nanni MG, Berardi MA, Caruso R, Riba M. Management of delirium in palliative care: a review. *Curr Psychiatry Rep*. 2015;17(13):11.
67. Neoh K, Adkinson L, Montgomery V, Hurlow A. Management of nausea and vomiting in palliative care. *Br J Hosp Med*. 2014;75(7):391–396. doi:10.12968/hmed.2014.75.7.391.
68. Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. *Am J Hosp Palliat Med*. 2010;27(3):219–225.
69. Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. *Clin Interv Aging*. 2011;6:243–259. doi:10.2147/CIA.S13109.
70. Broeckaert B. Spirituality and palliative care. *Indian J Palliat Care*. 2011;17:S39–S41.
71. Sulmasy DP. Spirituality, religion, and clinical care. *Chest*. 2009;135(6):1634–1642.
72. Au DH, Udris EM, Engelberg RA, et al. A randomized trial to improve communication about end-of-life care among patients with COPD. *Chest*. 2012;141(3):726–735.
73. Gilbert CR, Smith CM. Advanced parenchymal lung disease: quality of life and role of palliative care. *Mt Sinai J Med*. 2009;76(1):63–70.
74. Sudore RL, Fried TR. Redefining the "planning" in advance care planning: preparing for end-of-life decision making. *Ann Intern Med*. 2010;153(4):256–261.
75. Liantonio J, Liquori M, Lakhtman L, Parks S. Advanced care planning: making it easier for patients (and you). *J Fam Pract.* 2017;66(8):487–491.
76. Bomba PA, Kemp M, Black JS. POLST: an improvement over traditional advance directives. *Cleve Clin J Med*. 2012;79(7):457–464.
77. Kvale PA. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest.* 2007;132(3 Suppl):368S–403S.
78. American Cancer Society. *Cancer Facts & Figures 2018*. Atlanta, GA: American Cancer Society; 2018.
79. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non–small-cell lung cancer. *N Engl J Med.* 2010;363(8):733–742.
80. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology Provisional Clinical Opinion: the integration of palliative care into standard oncology care. *J Clin Oncol.* 2012;30(8):880–888.
81. Graw JA, Spies CD, Wernecke KD, Braun JP. Managing end-of-life decision making in intensive care medicine—a perspective from Charité Hospital, Germany. *PLoS ONE*. 2012;7(10):e46446. doi:10.1371/journal.pone.0046446.
82. Mercadante S, Gregoretti C, Cortegiani A. Palliative care in intensive care units: why, where, what, who, when, how. *BMC Anesthesiol*. 2018;18:106. doi:10.1186/s12871-018-0574-9.
83. Siegel MD. End of life decision making in the ICU. *Clin Chest Med*. 2009;30(1):181–194.
84. Mularski RA, Puntillo K, Varkey B. Pain management within the palliative and end-of-life care experience in the ICU. *Chest.* 2009;135(5):1360–1369.
85. O'Mahony S, McHenry J, Blank AE, et al. Preliminary report of the integration of a palliative care team into an intensive care unit. *Palliat Med*. 2009;24(2):154–165.
86. Kostakou E, Rovina N, Kyriakopoulou M, Koulouris NG, Koutsoukou A. Critically ill cancer patient in intensive care unit: issues that arise. *J Criti Care*. 2014;29(5):817–822. doi:10.1016/j.jcrc.2014.04.007.
87. Szalados JE. Discontinuation of mechanical ventilation at end-of-life: the ethical and legal boundaries of physician conduct in termination of life support. *Crit Care Clin*. 2007;22(2):317–337.
88. Robert R, Le Gouge A, Kentish-Barnes N, et al. Terminal weaning or immediate extubation for withdrawing mechanical ventilation in critically ill patients (the ARREVE observational study). *Intensive Care Med*. 2017;43(12):1793–1807. doi:10.1007/s00134-017-4891-011.
89. Quill TE, Lo B, Brock DW, Meisel A. Last-resort options for palliative sedation. *Ann Int Med*. 2009;151(6):421–424.
90. Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G. Palliative pharmacological sedation for terminally ill adults. *Cochrane Database Syst Rev*. 2015;(1).
91. Cerminara KL. The law and its interaction with medical ethics in end-of-life decision making. *Chest*. 2011;140(3):775–780.
92. Olsen ML, Swetz KM, Mueller PS. Ethical decision making with end-of-life care: palliative sedation and withholding or withdrawing life-sustaining treatments. *Mayo Clin Proc*. 2010;85(10):949–954.
93. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. *J Clin Oncol*. 2012;30(12):1378–1383.
94. Holtslander LF. Caring for bereaved family caregivers: analyzing the context of care. *Clin J Oncol Nurs*. 2008;12(3):501–506.
95. Siegel MD, Hayes E, Vanderwerker LC, et al. Psychiatric illness in the next of kin of patients who die in the intensive care unit. *Crit Care Med*. 2008;36(6):1722–1728.

CHAPTER

27

Disease Management

"It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has."

—William Osler, MD

OUTLINE

OBJECTIVES

1. State the working definition of disease management (DM).
2. Explain the meaning of a chronic illness and provide two cardiopulmonary examples.
3. Describe terms associated with DM.

KEY TERMS

Acute disease
Ask-tell-ask
Care management
Case management
Center for Medicare and Medicaid Service (CMS)
Chronic care model (CCM)
Chronic disease
Comorbidity
Continuum of care
Demand management
Disease management (DM)
Integrated health care
Multiple chronic conditions
Patient navigator
Self-care
Self-management

Case Study

Mrs. Taylor is a 61-year-old female who has had eight visits to the emergency department and three hospital admissions in the past 6 months, all due to acute exacerbations of her chronic obstructive pulmonary disease (COPD). She received the COPD diagnosis 8 years ago and currently is in Global Initiative for Chronic Obstructive Lung Disease (GOLD) Stage III. During each of her admissions, Mrs. Taylor was treated with standard pharmacotherapeutics in the hospital and discharged home with prescriptions for albuterol and an antibiotic after 2 days. Mrs. Taylor did not receive any other services at home. However, in addition to managing this patient's acute exacerbations, she requires ongoing treatment to prevent future exacerbations. After the last hospitalization, Mrs. Taylor was enrolled in a COPD disease management (DM) program and received prescriptions for a long-acting beta-agonist and a long-acting muscarinic antagonist. The patient's modified Medical Research Council (mMRC) dyspnea score , GOLD stage, exacerbation occurrences, and risk factors put her into GOLD Category D. In the COPD DM program (DMP), Mrs. Taylor receives a review of her therapy. She also receives self-management education, a recommendation for influenza and pneumococcal vaccination, a referral for pulmonary rehabilitation, a smoking cessation program referral, and a support group referral.

Introduction

The number of people with chronic conditions is rapidly rising. Between 2000 and 2030, the number of Americans with one or more chronic diseases will increase 37%, which is an increase of 46 million people.[1] Currently, about half of the U.S. population has one or more chronic conditions, which account for 86% of our nation's healthcare cost. Patients with chronic disease account for 81% of hospital admissions, 91% of all prescriptions filled, and 76% of all physician visits.[2] The U.S. Center for Disease Control and Prevention (CDC) reports chronic illnesses account for approximately 75% of the national aggregate healthcare spending or an estimated $5,300 per person in the United States each year. Healthcare costs for individuals with a chronic condition average $6,032 annually, which is five times higher than those without a chronic condition. Chronic disease is the primary cause of premature death and the most common costly health problem and among the most preventable, and most can be adequately controlled.

Although **chronic disease** is most common in the adult and elderly population, the rate of chronic disease in children has increased steadily over the past three decades. Research suggests as many as 1 out of 4 children in the United States or 15–18 million children age 17 years and younger suffer from a chronic disease.[3,4] Chronic diseases that occur in children are a result of prematurity, congenital anomalies, or acquired. More than half of children, ages 8–14, have a chronic disease ranging from asthma to ventilator dependence. Some sources refer to this group of children as medically fragile and maybe technology dependent. Advances in medical technology have impacted many of these children's lives, who many years ago would not have survived.

These chronic conditions require consistent and dedicated **self-management** and later place unique challenges for the child, their parents, families' healthcare providers, and communities. The economic and quality-of-life costs of chronic illness and disability in children are equally burdensome and costly. Teaching self-management techniques may prevent or deter complications and costs as the child transitions to adulthood.

Many children live with chronic disease. Examples of chronic childhood diseases include asthma, obesity, diabetes, cystic fibrosis, and cancer. Chronic childhood diseases vary based on the etiology, symptoms, and treatment plans. Children and families are affected by the chronic illness and challenges placed upon them. As a result, it may be difficult for the child, parents, siblings, and other family members. Self-management for chronic diseases that affect children must be active, and address psychosocial and environmental aspects of the child's life to include the cultural norms, values, and practices.

Healthcare System

Health care focuses on the acute, episodic model that no longer meets the needs of patients with chronic diseases. In the past, the acute disease was the primary cause of illness, and patients were the passive recipients of care. Currently, the approach to healthcare cost containment involves controlling individual components of care, such as drug, hospitalization, or laboratory testing costs. This has been the primary method for delivering health care since the 1980s. This model focuses on controlling costs by limiting the use of resources or services. This model results in low quality of care and poor clinical outcomes and does not control costs. Each aspect of care requires separate management with no coordination of services. The lack of coordinated services results in higher costs and more acute care or physician

office visits. This type of care focuses on reactive care instead of proactive or preventive care.

Increased collaboration among different healthcare systems to prevent and manage chronic disease is the current trend. The Institute of Medicine published a national report called "Primary Care and Public Health: Exploring Integration to Improve Population Health." This report recognized the need and identified opportunities for health care to improve population health.[5] The Patient Protection and Affordable Care Act emerged in the report as an essential vehicle for health systems to achieve increased collaboration.

Now chronic diseases have become a major medical issue, and the patient must be a partner in managing their disease by contributing to their care and decisions. Healthcare systems must maximize resources for these patients with chronic diseases. Health care is delivered more efficiently when patients are part of the process. Today, chronic illness is the primary reason people seek medical care and consume about 70% of the healthcare spending.[6] This means communication must take place across settings and health providers and across time from the initial diagnosis to the current time being seen by a healthcare provider. Coordinating care across different healthcare settings and community resources and providing methods for self-management will leverage healthcare services. The outcomes of this type of care improve health and patient experiences.

TABLE 27-1
Acute versus Chronic Diseases

Characteristic	Acute Disease	Chronic Disease
Onset	Abrupt	Gradual and often subtle
Appearance of symptoms	Sudden	Usually progressive
Duration of symptoms	Limited, short, a few days to a week or two	Lengthy or indefinite, extended period of months to years
Cause	Typically, a single cause	Typically, multiple causes with changes over time
Diagnosis and prognosis	Accurate	Uncertain in early stages
Technological intervention	Usual effective	Often indecisive, adverse effects are common
Outcome	Cure is possible	No cure
Uncertainty	Minimal	Pervasive
Knowledge	Professionals are knowledgeable; patients are inexperienced	Practitioners and patients have complementary knowledge and experience

Modified from Holman H, Lorig K. Patients as partners in managing chronic disease partnership is a prerequisite for effective and efficient health care. *BMJ.* 2000;320(7234):526–527. doi:10.1136/bmj.320.7234.526.

KNOWLEDGE CHECK QUESTIONS

1. True or False: Higher healthcare cost is directly related to lack of coordinated care.
2. True or False: Patient health improves when patients contribute to their care coordination.

Etiology of Chronic Disease

A chronic disease is a condition that lasts 12 months or longer and requires ongoing medical attention and limits a person's daily activities. Racial, ethnic, and geographic disparities exist with chronic disease. The likelihood of having a chronic disease increases with age. However, some chronic diseases begin in childhood or adolescence, such as asthma or cystic fibrosis. There are numerous people with multiple chronic diseases; these are comorbidities. Being able to describe the difference between acute and chronic disease is essential for respiratory therapists (RTs). See **Table 27-1**.

An **acute disease** usually has a treatment that returns the person to a healthy state, whereas with a chronic illness, there is a permanent change in the patients' life. The chronic illness has patterns that require continuous and complex DM plans. The change in the patterns of the illness and its treatments lead to uncertain outcomes that create uncertainty in the prognosis. The key to managing the chronic disease is understanding the trends of the illness, the goal being maintenance, not cure.

With chronic disease, patients know the trends of the disease better than the healthcare practitioner and can provide information and preferences that will complement the healthcare providers' knowledge. Together they are necessary to manage the chronic disease.

Approximately 1.2 billion people in the United States live in extreme poverty and are less healthy, exposed to risks associated with illness than their peers. Individuals who are poor are at an increased risk of experiencing chronic disease. Once a diagnosis is made, the economically disadvantaged experience barriers to care and lack a source of health care. They often have a vicious cycle that spirals down to poor health. Factors that impact health in the socioeconomically disadvantaged include prenatal factors, socioeconomic status, and lack of education, unemployment, and the living environment. These impact access to care, which exacerbates the chronic diseases.

Many chronic diseases are linked to lifestyle choices. Some of the most common chronic conditions include heart disease, hypertension, stroke, cancer, COPDs, diabetes, asthma, and arthritis. Many of these chronic

diseases are attributable to common risk factors, and most U.S. adults have more than one risk factors.[2] See **Box 27-1**.

Some chronic diseases can be prevented or lessened by many of the same interventions and strategies. The risk factors for chronic disease must need addressing at both the individual level and the population level. The CDC leads U.S. efforts to prevent and control chronic disease and associated risk factors through the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). NCCDPHP focuses on four key domains.[2] See **Box 27-2**.

Many chronic diseases are genetic or idiopathic and cannot be avoided by similar interventions. These include cystic fibrosis, asthma, amyotrophic lateral sclerosis, Alzheimer disease, arthritis, and cancer.

Regardless of the cause of the chronic disease, the patterns of illness and care are consistent. Because the chronic disease does not have a cure, the goal is to control the disease as best as possible to prevent it from worsening. Therefore, individuals with chronic diseases need to be proactive, not reactive, toward their disease. This prevents exacerbations of disease, resulting in emergency room or hospital stays. Patients with chronic diseases must understand their disease. They must recognize signs and symptoms of potential exacerbations, develop problem-solving skills to identify and act promptly to symptoms and signs of worsening of the condition, seek health care when it is needed, and develop abilities to communicate with the healthcare providers and to stay healthy as long as possible.

BOX 27-1 Multiple Risk Factors for U.S. Adults

- High blood pressure
- Tobacco use and second-hand exposure
- Obesity (high body mass index)
- Physical inactivity
- Excessive alcohol use
- Diets low in fruits and vegetables
- Diets high in sodium and saturated fats

BOX 27-2 National Center for Chronic Disease Prevention and Health Promotion Key Domains

I. Epidemiology and surveillance to monitor trends and track progress
II. Environmental approaches to promote health and support healthy behaviors
III. Healthcare system interventions that help doctors diagnose health threats earlier and manage them better
IV. Community programs linked to clinical services that help people prevent and manage their chronic disease and improve their quality of life

KNOWLEDGE CHECK QUESTIONS

1. True or False: The goal of chronic DM is to cure the disease.
2. True or False: Lack of education is a factor that affects health negatively.

Disease Management

Once a person receives a diagnosis of a chronic condition, that person requires ongoing management over a period of years or decades. Regardless of the chronic disease, COPD or cardiovascular disease, while different, are persistent and require some level of healthcare management across time. One of the greatest challenges facing health care today is meeting the complex needs of patients with chronic disease. Chronic diseases require a change in healthcare delivery, which must be proactive and patient centered. Therefore, everyone on the interdisciplinary healthcare team requires skills to work with patients to change behavior.

People with chronic disease may think they are free from the chronic illness when they have no symptoms. Having no symptoms does not mean that chronic illness has disappeared. It may mean the chronic disease is under control via various ways, such as controller medications, exercise, and proper nutrition.

One of the solutions is the development of DMP. High-quality coordinated care enhances the patients' health, reduce hospitalization rates, and lower treatment costs.[7] **Disease management (DM)** is the concept of reducing healthcare costs and improving the quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care.

What Is DM?

DM grew out of the 1990s as a means to deal with the rising healthcare costs of people with chronic disease and to improve the quality of care. Years ago people referred to the term *disease management* loosely to refer to general public health campaigns to promote exercise or vaccinations or to case management programs tailored to individual patients. Primary prevention and health promotion are not covered in this chapter.

DMP focus on specific groups of patients who all have the same chronic condition, use evidence-based intervention with the goal to enhance the patients' health and quality of life, reduce hospitalizations, and lower healthcare spending. A DMP is designed to identify and treat the chronic conditions more quickly, thus slowing the progression of the disease. A DMP coordinates healthcare interventions and communications for defined patient populations with conditions where implementation of self-care efforts are possible. DMPs empower individuals to manage their disease and prevent complications.[8]

DM concentrates on people with chronic conditions who require long-term care and close monitoring to prevent complications or acute exacerbations of the chronic disease. Health insurance companies and large self-ensured employers can use DM to deal with the spiraling costs of health care. DM is a multidisciplinary effort to improve the quality and cost-effectiveness of care for patients suffering from one or more chronic conditions using evidence-based guidelines and treatment plans.[9]

The Population Health Alliance, formerly the Disease Management Association of America, defines DM as a system of coordinated healthcare interventions and communication for populations with conditions in which patient self-care efforts are significant.[10] This definition has gained widespread acceptance and has contributed to increased standardization of the terminology and has been used by CMS and other payers. Currently, there is no DM certification. Many disease managers take the case management exam given by the Commission on Case Management Certification.

DM supports the healthcare practitioner–patient relationship and plan of care. It emphasizes prevention of exacerbations and complications utilizing evidence-based practice guidelines and patient empowerment strategies. It also evaluates clinical humanistic and economic outcomes on an ongoing basis with the goal of improving overall health.

Some investigators and literature searches use all closely related terms when discussing DM. See **Box 27-3**. Collaboration among health professionals results in problem solving and decision making and achieves better patient care by working together than if working alone. Multidisciplinary teams include individuals from different disciplines who contribute specialized knowledge on hierarchical relationships and who act according to situational demands. The continuity of care or care transition occurs when there is effective information exchange within a patient–clinician relationship.

Interprofessional Collaboration

The basis for health professional collaborative interactions is shared power and authority with mutual respect for the unique abilities of each member. The relationships result in cooperative problem solving and decision making, where participants achieve better patient care by working together than would have been possible individually.[11]

BOX 27-3 Terminology Related to DM

- Care coordination
- Care management programs
- Case management
- Chronic DM
- Comprehensive health care
- Continuity of patient care
- Continuous healthcare improvement
- Critical pathways
- Disease state management
- Interprofessional collaboration
- Multidisciplinary teams
- Patient care navigator
- Patient care planning
- Patient care team
- Population-based care

Case Management

The Case Management Society of America defines case management as "a collaborative process of assessment, planning, facilitation and advocacy for options and services to meet an individual's health needs through communication and available resources to promote quality cost-effective outcomes."[12] **Case management** is a collaborative process of assessment, planning, facilitation, and advocacy for options and services to meet individuals' health care through communication and resources to promote quality cost-effective outcomes.

Care Management

This term is used interchangeably with care coordination. The aim of **care management** is to manage the needs of the whole person across a range of health and social settings from home to hospital to acute care. Care management programs apply systems, science, incentives, and information to improve medical practice and help patients manage medical conditions more effectively. Evidence demonstrates that care management improves outcomes for the patient with chronic disease. The goal of care management is to improve patient health status and reduce the need for expensive medical services.[13]

Demand Management

The **Center for Medicare and Medicaid Service (CMS)** will penalize hospitals for high readmission rates for

patients who return within 30 days of discharge. Patients with chronic disease are frequent consumers of health care. These patients can make decisions about their care. This mode would reduce the use of costly, unnecessary medical services and interventions. The **demand management** model uses protocols or pathways to enable the healthcare provider to achieve better outcomes. Patients can have care when they need it based on the protocol and to reduce unnecessary medical spending.

Integrated Care

Integrated health care means different things to different people, and the World Health Organization (WHO) defines one working definition that provides the right care in the right place and defines integrated care as "the organization and management of health services so the people get the care they need, when they need it in ways that are user-friendly, achieve the desired results and provide value for the money."[14]

Continuum of Care

A **continuum of care** is linking healthcare services across the delivery setting and sites of care. The continuum of care for chronic disease includes prevention, long-term maintenance treatment, and management of acute symptom exacerbation, rehabilitation, and palliative or hospice care. Some patients require ongoing social services in the community. This is important not to duplicate services. These patients with chronic diseases use healthcare services on a regular and expected basis, as compared to unpredictable needs of patients with acute problems.

KNOWLEDGE CHECK QUESTIONS

1. True or False: DM and case management have the same goals.
2. True or False: The goal of care management is to improve patient health and reduce the need for expensive medical services.
3. True or False: The reduction of unnecessary medical spending utilizing protocols or clinical pathways is demand management.

The Chronic Care Model

The **Chronic Care Model (CCM)** was created by Wagner et al. as a model for managing chronic disease.[15] This model takes the proactive approach to managing the chronic disease. Instead of managing sickness, the model attempts to keep people well and moves the healthcare provider from focusing on those who are sick to a proactive approach that works with the patient to keep him/her healthy for as long as possible.

Chronic disease can be effectively prevented and managed using the community as well as having the patient to be involved in the management of their disease. Addressing the causes of the chronic disease is central to attempt to prevent the future epidemics. A decreased exposure to the risk factors, such as tobacco use and unhealthy diet, leads to a reduction in blood pressure and body weight. Interventions are required to address the underlying causes of chronic disease. Interventions that focus on people at high risk for chronic disease reduce the risk of developing chronic disease, reduce complications, and improve the quality of life.[15]

The model states effective chronic illness care requires an appropriately organized delivery system linked with complementary community resources available outside the organization and is sustained by interactions between multidisciplinary primary care teams and activates patients to participate. The team is responsible for organizing and coordinating care through activities that include patient assessment, setting goals with patients, solving problems for improved self-management, and applying clinical and behavioral interventions that prevent complications and optimize disease control and patient well-being. To achieve effective patient management, the CCM promotes comprehensive system change encompassing six areas: community resource links, the healthcare organization systems, self-management support, delivery system redesign, decision support, and clinical information systems.[16] The more recent updates include patient safety, cultural competency, care coordination, community policies, and case management for the CCM. Improved patient outcomes are the ultimate goal of the model (**Figure 27-1**).[16]

Patient or Care Navigator

The **patient navigator** does not have a standard definition yet is "someone who helps assist patients to



FIGURE 27-1 The CCM supports patients in the self-management of their condition by enhancing their skills. This requires engaging a broader team that includes links with community care agencies, tracking systems to monitor patient progress, and delegation of the central organizational role from physician to a case manager.

Reproduced with permission from Wagner E. Chronic disease management: what will it take to improve care for chronic illness? *Eff Clin Pract.* 1998;1:2–4.

overcome barriers to care."[14] The patient navigator offers assistance to patients to navigate through the complex healthcare system to overcome the obstacles to accessing care and treatment. The patient navigator is a patient-centered model of care, and the navigator is someone who understands the patient's fears and hopes, removes the barriers to care by coordinating services, and increase the quality of life. The patient navigator is useful for the underserved patient with **multiple chronic conditions**.

It is important to note that a person who will be a disease manager must have knowledge of the disease process, treatment, expected outcomes, and self-care skills needed. The disease manager needs to be an excellent communicator, have the ability to call patients, conduct telephonic interviews and assessments, identify the patients at risk, and be able to coach or counsel the patient. The disease manager must be able to participate in the decision making regarding interventions, behavior modification, outcome identification, and goal achievement.

Mary Hart created an asthma navigator program that identified the patients who were high healthcare utilizers with repeat emergency and hospitalizations. Most of the patients in this program are minorities. This program identified some barriers to accessing health care. The physicians within the hospital in the emergency room were champions of this program. The respiratory therapist was an RRT, with the AE-C, and was able to follow the patient from the entrance to the ER to home. The patients received the self-management tools to manage asthma. This, in turn, led to a decrease in healthcare utilization and increased quality of life and goal attainment.[17]

KNOWLEDGE CHECK QUESTIONS

1. True or False: The team approach to DM is embodied in the CCM.
2. True or False: The patient navigator is most useful in assisting chronically ill patients with no comorbidities.

Disease Management Programs

DMPs vary based on the focus, population, location, and other factors. Some are clinic focused or prevention oriented or broad based. Therefore, it is hard to determine a true "model" or common elements of a program. The best practices of successful DMP have objective data that demonstrate health improvement/behavior change, cost savings or cost neutrality and achievement of program goals, duration of the program exceeds 3 years and the ability to replicate the program is possible. See **Table 27-2**.

TABLE 27-2
Elements of a Successful DMP

Essential Element	Explanation
Define problem and program objective	Identify and clearly describe the problem, program objective, and target population using relevant, reputable data. Success is defined at inception and measures included in plans.
Tailor program to the target population	Program and its resources are tailored to achieve objectives within the target population. Program materials and approach must reflect cultural sensitivity and health literacy level and be relevant to the target population.
Engage leadership	An individual group is responsible for the program and its success. Leaders promote participation, shepherd resources, and provide ongoing support.
Coordinate among stakeholders and across settings	Engages the target population and those who can help achieve program goals and success. Collaboration, communication, transparency of program processes, data, and goals.
Integrate throughout the organization or community	Program is part of the culture, messages, activities, and the target population.
Empower target population	Program engages with the target population to develop the knowledge needed to achieve the desired results.
Motivate target population	Program engages regularly, encourages, assists, rewards, recognizes, and equips the target population to foster their involvement. Encourages participation by managing resistance to change, building individual accountability, regular communication, achievement, and success.
Sustain and institutionalize program	Program is sustainable and continues over time and change to policy is achieved.
Measure, evaluate, and refine program	The program includes ongoing evaluation, assessment of gaps between outcomes, and goals. Evolves to improve outcomes, achieve goals, and needs.

DMP require certain components to be successful. See **Box 27-4**.

DM is a proactive multidisciplinary, systematic approach to healthcare delivery. The DMP includes all members with chronic disease and supports the provider–patient relationship and plan of care. The DMP optimizes patient care through prevention and proactive interventions based on evidence-based guidelines. A successful DMP incorporates patient self-management and contiguously evaluates each patient's health status.

BOX 27-4 DM Components

- Evidence-based practice guidelines
- Population identification process
- Collaborative practice models to include physician support service providers
- Patient self-management education (may include primary prevention, behavior modification, and compliance surveillance)
- Process and outcome measurement, evaluation and management
- Routine reporting/feedback loop

Outcomes are carefully measured to improve overall health and the quality of life and lower the cost of care.

Identify the Target Population

To begin a DMP, the director needs to use data to identify a health issue, target population, and program plan. The director develops measurable objectives and goals to define success at the beginning of the program. The director determines milestones to track the progress of achieving the goals and methods to measure them. Therefore, define What? Why? Who? How/When? Poof!

For example, a county determines there is an issue with school-age children and uncontrolled asthma. The children missed more school and were behind in classes. The DMP defined uncontrolled asthma based on the National Asthma Education and Prevention Program guidelines. The population was defined as the elementary children between the ages of 5 and 12 years who were diagnosed with asthma and majority of the district had families living below the federal poverty level. The family and child were invited to participate in the asthma program. The program was designed to identify indoor asthma triggers such as dust, pests, indoor tobacco use, and humidity. The RT made a home assessment that utilized a questionnaire, conducted visual inspection of the home, and measured environmental measurements. The RT provided education to the family to identify the asthma triggers, remove the triggers, and use proper medication. Over the school year, the RT measures progress to reduce asthma triggers, and the families that participated in the program had fewer urgent health services and fewer days with asthma symptoms.

Program Materials and Approach

The successful programs tailor the education program and materials to the cultural preferences and needs of the target population. The DMP may vary based on age, sex, race, and geographic location. Also, the program needs to address health literacy of the participants.

The educational materials, for the program mentioned earlier, were made available in Spanish; at least one person in the group assessing the home was bilingual. The cultural norms were addressed as part of the education based on the responses of the family. For example, candles are used as part of the Hispanic culture on a weekly basis. Many candles exude a scent, and the smoke is an asthma trigger. Therefore, wickless battery-operated candles were a solution to continue with the culture yet with an asthma-friendly solution.

Commitment by the Leadership

Having a strong leader who can make the connections with the community stakeholders creates networks, mobilizes resources, and sustains the DMP. Join forces with other programs with similar goals. The program, being discussed, did not initially have a pharmacist. The group partnered with a pharmacy school that provided pharmacy faculty and students. This group was able to make house assessment, ensure medications were available, and, if there was a **comorbidity**, share the information about multiple medications.

Program Coordination

Being able to coordinate groups of stakeholders across the community expands the program. It allows the circle of influence to grow and decrease barriers to reach the goals. The DMP is integrated into the community, health plan, physician offices, and workplaces. The integration reinforces the message and goals to reach success. The program is a part of all the activities of the target population.

Engaging and Motivating the Target Population

The DMP engages the people to assume responsibility for their chronic disease and the behaviors associated with the disease. People are educated about consequences of the disease and methods to manage the illness to prevent exacerbations. This teaches the person the methods to remove the barriers to achieving the best health. The DMP incorporates technology to monitor the progress of the participants using cell phone apps or follow-up phone calls or telemedicine. The technology facilitates the use of evidence-based guidelines for the chronic disease. Using a secure email, web-based interactions, or online surveys allow communication to take place.

DMPs motivate participants by recognizing the willingness to change and incentivize people to make the change. For example, some health plans will provide gift certificates for completing certain screening and vaccinations. Also, some plans will provide a reduced copayment to the insured or a rebate.

Sustaining the DM Program

A plan for sustainability needs to be used for a DMP to be successful. The DMP must not be a one-time shot and no follow-up. Therefore, ensuring the population is engaged and the plans are involved will follow the sustainability.

Evaluating the DM Program

The DMP outcomes must be identified at the beginning of the program. These outcomes/goals and objectives must be established at the beginning and then measured again over the course of the program at various intervals and again at the end of the program. This could be looking at health claims, healthcare utilization, pharmacy renewals, and quality-of-life measures.[18]

The Patient and the Caregiver

Chronic diseases require patients take a role for the responsibility in managing their health. This requires more time in the healthcare provider's office. This group of patients must make behavior and lifestyle changes, develop new skills, increase compliance with therapies, and learn to interact with the healthcare system to successfully manage their chronic disease. This means the patient must participate in the care and the healthcare provider must support the patient's efforts. The literature demonstrates patients with chronic conditions who participate in interventions that promote patient engagement are associated with improved health outcomes. When patients take an active role in their chronic disease on a daily basis (e.g., medication management and adherence, tobacco cessation, and proper eating, sleep, and exercise), it influences their health.

In 2010, the American Association for Respiratory Care published an expert panel reference-based clinical practical guideline that suggests that RTs take an active role in educating the patient, family, and caregivers in the management of their cardiopulmonary disease state. This guideline demonstrates that RTs can provide patient-centered care and information to and elicit input from the patient and caregiver to improve the patient understanding of the chronic disease. The RT impacts a positive change in the patient's and caregiver's behavior and better manages the disease.[19]

Also, the RT can assess the learning needs of a patient who can benefit from self-management. Self-management education needs to be documented and reassessed on a frequent basis. See **Table 27-3**.

TABLE 27-3
Excerpts from Providing Patient and Caregiver Training, 2010

Indications	• Patients with the need to increase knowledge and understanding of health status • Patients with the need to improve skills needed for performing therapy • Patients with the need to improve adherence to therapy and know the answers to the "ask me 3." (1. What is my main problem? 2. What do I need to do? 3. Why is it important for me to do this?)
Contraindications	None
Complications	• Omission of essential steps in care, inconsistency in the information presented • Failure to validate the learning process can lead to poor results • Lack of cultural sensitivity, lack of information appropriate for the language needs of the patient • Lack of trust by the patient or caregiver of the medical team
Limitation of method	Patient limitations: Lack of motivation, impairment, inability to understand instruction, literacy, language barriers, religious, and/or cultural beliefs are at odds with the education materials.
	Respiratory therapist limitations: Lack of positive attitude, limited knowledge of skills being taught, inadequate assessment of patient's readiness to learn, cultural or religious practices may affect learning, the inability to personalize the material, insufficient time, inadequate communication skills, and inadequate knowledge of cultural or religious practice
	System limitations: Hospital stays too brief, the absence of interdisciplinary cooperation and communication, inconsistent information, lack of community-based interpreters
	Other limitations: Lack of patient support system; reimbursement issues; interruptions, distractions, or noise; inadequate lighting, heat, or space; poorly chosen resources, including inappropriate reading level and vocabulary
Assessment of need	Determine patient's knowledge base and the gap between what the patient knows and what the patient needs to know. Apply this to all learning domains.
Assessment of outcome	Evaluate the knowledge gained and skills mastered. The patient should return demonstration without assistance. Reassess patient outlook, attitude, and lifestyle changes.
Resources	• Access to trained interpreters • Written material at fifth to sixth grade level in a variety of formats • Utilize demonstration models for hands-on training and practice
Monitoring	• Patient verbal and nonverbal responses to material • Document instruction and outcome • Track adherence • Ability to demonstrate and participate frequently

Reproduced with permission from AARC Clinical Practice Guideline. Providing patient and caregiver training 2010. *Respir Care*. 2010;55(6):765–769.

Promoting healthy behaviors through education is important. The healthcare professionals should model the healthy behaviors and be active in the promotion of disease prevention and wellness. RTs are well positioned to provide DM for a range of chronic lung disease patients, including those who have asthma, COPD, emphysema, bronchitis, pulmonary hypertension, cystic fibrosis, and pulmonary fibrosis.[17]

The potential for success is highest when patients are informed and equipped to manage their disease. This patient population consumes significant acute care resources because of poor disease control. Patient education and intervention result in better understanding of the disease and greater rapport with the healthcare provider and maximize the ability of the patient to care for himself/herself.[19]

Self-care

The WHO defines **self-care** as "the activities individuals, families and communities undertake with the intention of enhancing health, preventing disease, limiting illness and restoring health."[20] This means taking action for oneself, one's children, or family to stay fit and maintain good physical and mental health, meet social and psychologic needs, prevent illness or accidents, care for minor ailments and long-term conditions, and maintain health. Self-care skills and knowledge is part of daily living that include behavior change to encompass the chronic disease.

KNOWLEDGE CHECK QUESTIONS

1. True or False: DMP use evidence-based practice guidelines.
2. True or False: A DMP usually does not exceed a duration of 3 years.

Self-Management

Patients with chronic disease need to become effective managers of their health. It is essential they have an understanding of the skills to manage the disease, ongoing support, and information about the disease. Self-management involves information giving and collaborative partnership between patient and healthcare providers. The self-management education takes place with patient education and includes a plan that provides the patient with problem-solving skills to address changes in the disease. The patient is the expert about their lives, and the healthcare provider is the expert about the disease and treatment plans.

The patient is empowered to accept the responsibility to manage their chronic disease and encouraged to solve their problems with the information from the healthcare professional.

There is internal motivation, which is more effective to assist with lifestyle change than external motivation and create a better outcome. This is more of a collaborative care model. **Table 27-4** compares traditional and collaborative care in chronic disease.

TABLE 27-4
Comparison of Traditional and Collaborative Care in Chronic Disease

Issue	Traditional Care	Self-Management Collaborative Care
What is the relationship between patient and health professionals?	Professionals are the experts who tell patients what to do. Patients are passive.	Shared expertise with active patients. Professionals are experts about the disease, and patients are experts about their lives.
Who is the principal caregiver? Who is the problem solver? Who is responsible for outcomes?	The healthcare professional	The patient and professionals are the principal caregivers; they share responsibility for solving problems and for outcomes.
What is the goal?	Compliance with instructions, noncompliance, is a personal deficit of the patient.	The patient sets goals, and the professional helps the patient make informed choices. Lack of goal achievement is a problem to be solved by modifying strategies.
How is behavior changed?	External motivation	Internal motivation. Patients gain understanding and confidence to accomplish new behaviors.
How are problems identified?	By the professional, for example, changing unhealthy behaviors	By the patient, for example, pain or inability to function, and by the professional.
How are problems solved?	Professionals solve problems for patients.	Professionals teach the problem-solving skills and help patients in solving problems.

Data from Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. *JAMA*. 2002;288(19):2469. doi:10.1001/jama.288.19.2469.

TABLE 27-5
Self-Management Education

What is taught?	Skills on how to act on problems.
How are problems formulated?	The patient identifies problems he/she experiences that may or may not be related to the disease.
Relation of education to the disease	Education provides problem-solving skills that are relevant to the consequences of chronic conditions in general.
What is the theory underlying the education?	Greater patient confidence in his/her capacity to make life-improving changes (self-efficacy) yields better clinical outcomes.
What is the goal?	Increased self-efficacy to improve clinical outcomes.
Who is the educator?	A health professional peer leader or other patients often in group settings.

Data from Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. *JAMA*. 2002;288(19): 2469. doi:10.1001/jama.288.19.2469.

BOX 27-5 The Five Self-Management Skills for All Populations with Chronic Disease

1. Problem solving
2. Decision making
3. Accessing appropriate resources
4. Forming a partnership with the healthcare provider
5. Taking action toward health goals

Self-management education teaches the patient problem-solving skills and allows the patient to identify the problems and provides techniques to help the patient make decisions and take appropriate actions; later these actions encounter changes in circumstances or disease. See **Table 27-5**. People with chronic disease face three issues that need to be addressed: (1) medical management of the chronic condition, including taking medications, modifying diet, or self-monitoring; (2) creating and maintaining new meaningful life roles regarding the person's job, family, and friends; and (3) coping with anger, fear, frustration, and sadness of having a chronic disease.[21]

Self-management for children with chronic disease requires the patient/family take an active role in their care. The education supports the needs, concerns, and problems identified by the patient and family.[21] **Box 27-5** shows self-management skills necessary for all chronic disease populations.

The goal of self-management includes optimizing health status and quality of life. The CCM may serve as a framework for organizing and delivering the care across the continuum of care.

One of the important pieces of self-management education is the patient-generated action plan. The action plan should be realistic, proposing behavior change the patient is confident in accomplishing. **Figure 27-2** is an example of an asthma action plan for schools and families. To be effective, a written chronic disease action plan must be embedded in the total healthcare package. Fundamental to an action plan is the ability of the patient to recognize early warning signs of the deterioration of disease control and the knowledge of when to seek medical advice. Objective measurements are important because patients are often unable to recognize and interpret subjective symptoms.

A confidence scale can be used to measure the patient's confidence to make behavior changes based on a scale of 1–10. When the answer is 7, or higher, the action plan is likely to be accomplished; however, if the answer is less than 7, the action plan should be modified to be realistic and avoid failure. See **Figure 27-3** and **Box 27-6**.

Confidence is necessary for a patient to be able to carry out a behavior necessary to reach a set goal. Action plans, developed by the patients and health practitioners, document these goals and these goals are necessary to keep the chronic disease manageable.

Any chronic disease requires a long-term management strategy, of which self-management is a key component. The literature demonstrates asthma self-management education improves outcomes, especially in those with severe asthma.[22–27] Asthma self-management skills are more effective than providing information only in improving clinical outcomes and reducing costs for asthma.

Strategies for teaching chronic disease self-management include the establishment of the agenda "**Ask-Tell-Ask**" collaborative communication, assessment of readiness to change, goal setting, and closing the loop.[28] See **Table 27-6**.

The first three strategies set the stage for collaborative communication. A shared agenda can be set by simply asking the patient, "What would you like to discuss today?" Then a collaborative decision can be made about what concerns take priority. This reassures the patient that the practitioner is listening to them.[29] The "ask-tell-ask" strategy is a way of shifting the educational message from a directive to a collaborative partnership. It also provides a way for the practitioner to structure the information to the patient's needs. This entails asking



School Information

Asthma Action Plan for Schools and Families

Health Care Provider Information

Last Name: _____ First Name: _____

Date of Birth (mm/dd/yyyy): _____ Medical Record #: _____

School Name: _____ School Contact Phone #: _____

Parent/Guardian Name: _____ Parent/Guardian Phone #: _____

Emergency Contact: _____ Emergency Phone #: _____

Health Care Provider Name: _____ Health Care Provider Phone #: _____

To be completed by health care provider: **Asthma Severity:** ☐ Intermittent ☐ Mild Persistent ☐ Moderate Persistent ☐ Severe Persistent

Attention Parent/Guardian/School Personnel: ANY student with asthma (of any severity) can have a severe asthma attack.

Asthma symptoms are triggered by: ☐ Exercise ☐ Dust ☐ Animal dander ☐ Strong Odors or Fumes ☐ Mold ☐ _____

Green Zone **Personal Best Peak Flow (PF)** _____ **Date:** _____

Peak flow is between _____ (80% of personal best) and _____ (100% of personal best)

1. Take CONTROLLER medication(s) (at home) EVERY DAY:

Take _____ (Name of Medicine) inhaler _____ (How much) puffs _____ (How often) times/day.

Take _____ (Name of Medicine) inhaler _____ (How much) puffs _____ (How often) times/day.

If asthma is triggered by exercise (at school or home), take ☐ Albuterol or _____ (Name of Medicine) inhaler _____ (How much) puffs at least _____ minutes before exercise. Restrictions or activity limitations: _____

Yellow Zone-Caution! DO NOT LEAVE STUDENT ALONE!

Peak flow is between _____ (50% of personal best) and _____ (80% of personal best).

1. Begin QUICK RELIEF medication (at school or home) right NOW:

Take ☐ Albuterol or _____ (Name of Medicine) inhaler _____ (How much) puffs **OR** _____ (Name of Medicine) solution _____ (How much) ml by nebulizer.

- If symptoms are better or if the peak flow is improved within ☐ 15 minutes/_____ minutes, **THEN** repeat QUICK RELIEF MEDICATION (as listed above in 1) every _____ (Number) hours for _____ (Number) days.
- If symptoms are **NOT** better or if the peak flow is **NOT** improved, go to Red Zone.

☐ **Attention School: Call Parent/Guardian when quick relief medication has been administered by student and/or staff.**

2. Attention Parent/Guardian (Home Instructions):

☐ Call your child's Health Care Provider

☐ Continue to take CONTROLLER medication (at home) everyday as written above in *Green Zone* instructions.

☐ Increase CONTROLLER medication:

Take _____ (Name of Medicine) inhaler _____ (How much) puffs _____ (How often) times/day for _____ (Number) days.

Red Zone-Medical Alert! Get Help! DO NOT LEAVE STUDENT ALONE! Peak flow is below _____ (50% of personal best).

1. Take QUICK RELIEF medication (at school or home) right NOW:

Take ☐ Albuterol or _____ (Name of Medicine) inhaler _____ (How much) puffs **OR** _____ (Name of Medicine) solution _____ (How much) ml by nebulizer and **REPEAT EVERY 20 MINUTES UNTIL PARAMEDICS ARRIVE!**

- **Call 9-1-1 immediately and call Parent/Guardian**

2. Attention Parent/Guardian (Home Instructions):

☐ Call your child's Health Care Provider. ☐ Continue CONTROLLER medication (at home):

Take _____ (Name of Medicine) inhaler _____ (How much) puffs _____ (How often) times/day for _____ (Number) days.

☐ And ADD _____ (Name of Medicine) _____ (How much) mg orally once daily for _____ (Number) days.

Authorization and Disclaimer from Parent/Guardian: I request that the school assist my child with the above asthma medications and the Asthma Action Plan in accordance with state laws and regulations. Yes ☐ No ☐

My child may carry and self-administer asthma medications and I agree to release the school district and school personnel from all claims of liability if my child suffers any adverse reactions from self-administration of asthma medications: Yes ☐ No ☐

_____ (Parent/Guardian Signature) _____ (Date)

Health Care Provider: My signature provides authorization for the above written orders. I understand that all procedures will be implemented in accordance with state laws and regulations. Student may carry and self-administer asthma medications: Yes ☐ No ☐ (This authorization is for a maximum of one year from signature date.) _____ (Healthcare Provider Signature) _____ (Date)

1-24-07 California Asthma Public Health Initiative, California Department of Health Services

FIGURE 27-2 Asthma action plan for schools and families.

Reproduced from California Asthma Public Health Initiative. Asthma Action Plan for Schools and Families. Available at: http://www.betterasthmacare.org. Courtesy of the California Asthma Public Health Initiative.



FIGURE 27-3 Confidence scale. See text for explanation.

the patient what is already known or what they want to know about the illness. Then tell the patient what he or she wants to know and ask to restate the information. This keeps the patient involved in the conversation.[29]

To assess the patient's readiness to change, the practitioner can ask two simple questions. The first is "How important is it to you to make this change, on a scale of 0–10, with 10 being extremely important?" This puts the practitioner and the patient on the same page concerning goals.[29] The second question is to ask about the patient's confidence about making a change. See Figure 27-3.

The next step is collaborative goal setting. This can be done using the transtheoretical model, which is based on stages of change. These stages include pre-contemplation, where the patient is not thinking

BOX 27-6 Examples of Possible Dialogue for Addressing Importance of Confidence

1. If you were to decide to begin dieting now, how confident are you that you would succeed?
2. On a scale of 0–10, with 0 being not at all confident and 10 being extremely confident, how confident are you that you could change your eating habits?
3. Tell me why you are at a (use client's chosen score) and not a 10? Encourage change talk, rather than resistance where the person must defend his/her current behavior or position.
4. Listen carefully at this point as one will begin to identify strengths on which to build and possible motivating factors that might influence behavior change.
5. What would need to happen for you to go from a chosen number to a higher number?
6. How can we help you go from a chosen number to a higher number?

Miller W, Rollnick S. ***Motivational Interviewing***. 3rd ed. New York, NY: Guilford Publ.; 2012:225.

TABLE 27-6
Five Communication Strategies for Teaching Self-Management

Setting the stage	Taking action
Set a shared agenda	Set self-management goals
Ask-tell-ask	Close the loop
Assess readiness to change	

Reproduced with permission from Boxer H, Snyder S. Five communication strategies to promote self-management of chronic illness. *Fam Pract Manag*. 2009;16(5):12–16. https://www.aafp.org/fpm/2009/0900/p12.html. Accessed September 28, 2016.

about changing the behavior. The contemplation stage is where the patient is thinking about changing the behavior but has not taken any action steps. The preparation stage is where the patient is committed to changing the behavior and may have made an attempt in the recent past. In the action stage, the patient is in the process of making an overt lifestyle change. The maintenance stage is where the patient has established the new habit and the focus is on maintaining the behavior changes.[29] Goals need to follow the SMART acronym (**Box 27-7**).

Closing the loop means to have the patient repeat the important points and instructions to ensure correct understanding. Verbalization of key instructions allows the practitioner to correct any misunderstandings before they become errors.[29]

BOX 27-7 Setting SMART Goals

S	Specific, significant
M	Measurable, meaningful, motivational
A	Achievable, attainable, agreed upon
R	Realistic, relevant, reasonable
T	Timely, tangible

KNOWLEDGE CHECK QUESTIONS

1. True or False: Patients play a passive role in their care in a self-management program.
2. True or False: Learning problem-solving skills is part of a self-management program.

Evaluation of the DM Process

Health outcomes affect the quality of life and healthcare services. DMPs are evaluated based on defined outcome measures. Evaluation measures for DM interventions vary. Some of these are included in **Table 27-7**. Evaluation reviews, baseline data, performance indicators, and outcome measures analyze them to determine if the program achieved its goal or provided quality improvement. The performance indicators assess the performance compared to predefined indicators. Outcome measures determine the result of an action or intervention. Meaningful outcomes improve the quality of the program. These outcomes include clinical outcomes, healthcare utilization, and humanistic or quality of life. Patient assessment of program impact on physical, social, and emotional well-being is measured. Also, the economic outcome is calculated as the cost of the intervention less any savings from the health improvement.[8]

KNOWLEDGE CHECK QUESTIONS

1. True or False: Caseload and staffing ratios are used to evaluate patient-related process measures of a DM intervention.
2. True or False: Long-term patient outcome measures for a DMP include assessing patient quality of life and well-being.

TABLE 27-7
Evaluation Measures for DM Interventions

Evaluation Measure	Variable	Example
Input Measures		
Structure of DMP		Caseload size; staffing ratios; staff qualifications; hours of training; organizational supports
Process Measures		
Patient related	• Reach of program • Patient education • Patient coaching	• Initial contact rate; enrollment rate; referral rate; targeted populationEducation sessions; content covered • Contact frequency; call duration; call content; written action plan; smoking cessation counseling
Organization related		Frequency of disease-specific diagnostic testing and/or follow-up (e.g., AbA1c tests; blood pressure tests); procedures performed (e.g., bronchoscopy, perfusion imaging); adherence to clinical practice guidelines; prescription rates
Organizational Output Measures		
Utilization	Utilization	Hospital admissions; emergency department visits; primary care practitioner visits; urgent care visits; length of stay; scheduled primary care practitioner visits; readmission rate; number of insurance claims for medication; waiting times; discharge rates
Patient Outcome Measures		
Immediate	Knowledge	Participant knowledge (general and disease specific); beliefs (general and disease specific)
Intermediate	1. Self-care behavior 2. Self-efficacy	1. Administration of medication; adherence to diet/exercise; peak flow self-monitoring; symptom self-monitoring; glucose self-monitoring 2. Self-efficacy; health locus of control; psychosocial adaption and coping skills
Post-intermediate	1. Clinical 2. Satisfaction	1. Physiologic measures (e.g., FEV1/FVC; FEV1; blood pressure, HbA1c); weight; self-reported severity of symptoms; shortness of breath; smoking rate; quantity and frequency of exercise; adherence to medication 2. Program satisfaction; perceptions of DM; participant satisfaction with care
Long term		Quality of life and well-being; health status; functional ability (emotional well-being, daily work, social and physical activities); self-reported health; fatigue; pain; disability; mortality
Impacts		
Financial		Overall healthcare costs (direct and/or indirect); project cost savings; detailed financial performance measures; return on investment, cost-effectiveness; cost-benefit; and cost-consequences.
Socioeconomic		Absenteeism rate; return to work; productivity; (corporate) "image."

Reproduced with permission from Conklin A & Nolte E. (2011). Disease management evaluation: A comprehensive review of current state of the art. *Rand health quarterly*:1(1).

Chapter Summary

DM is an approach to patient care that seeks to limit preventable events by maximizing patient adherence to prescribed treatment and health promotion behaviors. DM plans produce significant clinical improvements, as well as financial savings. The DM process provides opportunities to improve patient outcomes. True DM can be achieved only with the complete commitment of the healthcare team.[8]

As the number of people with chronic disease continues to increase, healthcare providers with knowledge of the disease, methods for teaching self-management, assessment, and follow-up are essential. RTs are in a unique situation to take on respiratory DM. RTs already work on ensuring appropriate therapy and follow the evidence-based guidelines. They collaborate with the patient and family to ensure needs are met and communication

is taking place. RTs are patient advocates and able to serve on various leadership committees that impact chronic disease. RTs can educate the community, primary care practitioners, and insurance plans about the unique needs of patients with chronic respiratory disease.

Key Points

1. DM is a philosophy of caring for patients from the first day of being diagnosed with a chronic disease.
2. Chronic disease is one that lasts longer than 1 year and requires a medical management. Examples of a chronic respiratory disease include asthma, COPD, or cystic fibrosis.

Chapter Questions

1. A chronic disease is characterized by _____.
   a. a sudden appearance of symptoms
   b. an abrupt onset of illness
   c. multiple causes that change over time
   d. a short, limited duration of symptoms
2. The concept of reducing healthcare costs and improving quality of life through prevention and minimizing the effects of a chronic disease describes _____.
   a. case management
   b. disease management
   c. patient care planning
   d. critical pathways
3. Quality, cost-effective outcomes obtained through a collaborative process of assessment, planning, facilitation, and advocacy for individual patients is _____.
   a. case management
   b. disease management
   c. demand management
   d. patient navigation
4. The Center for Medicare and Medicaid Service (CMS) advocates _____ to lower 30-day readmission rates by using protocols and critical pathways.
   a. case management
   b. care management
   c. integrated care
   d. demand management
5. Complications of providing patient and caregiver training include _____.
   a. lack of motivation
   b. insufficient time
   c. lack of cultural sensitivity
   d. inadequate communication skills
6. Taking action for oneself or one's children with the intention of enhancing health, preventing disease, limiting illness, and restoring health is _____.
   a. case management
   b. self-care
   c. care management
   d. demand management
7. Learning problem-solving skills is a key part of _____.
   a. care management
   b. self-management
   c. demand management
   d. case management
8. An asthma action plan helps patients to _____.
   a. identify early warning signs of deterioration
   b. measure the patient's confidence
   c. know how to speak to their physician
   d. remember long-term management strategy
9. The "ask-tell-ask" strategy _____.
   a. assesses a patient's readiness to change
   b. creates a collaborative partnership for learning
   c. sets up the goal setting process
   d. allows patients to take a passive role in their care
10. An organizational output measure that assesses disease management program utilization includes _____.
    a. the number of procedures performed
    b. prescription rates
    c. case load size
    d. number of emergency department visits

References

1. Anderson G. Chronic care: making the case for ongoing care. Princeton, NJ: Robert Wood Johnson Foundation; 2010. http://www.rwjf.org/content/dam/farm/reports/reports/2010/rwjf54583. Accessed October 9, 2016.
2. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion | At a glance reports | Publications | Chronic disease prevention and health promotion | CDC. Cdcgov. 2016. http://www.cdc.gov/chronicdisease/resources/publications/aag/nccdphp.htm. Accessed October 9, 2016.
3. Van Cleave J. Dynamics of obesity and chronic health conditions among children and youth. *JAMA*. 2010;303(7):623. doi:10.1001/jama.2010.104.
4. van der Lee J, Mokkink L, Grootenhuis M, Heymans H, Offringa M. Definitions and measurement of chronic health conditions in childhood. *JAMA*. 2007;297(24):2741. doi:10.1001/jama.297.24.2741.
5. Committee on Quality of Health Care in America; Institute of Medicine. *Crossing the Quality Chasm: A New Health System for the 21st Century*. Washington, DC: National Academy Press; 2001.
6. Holman H, Lorig K. Patients as partners in managing chronic disease partnership is a prerequisite for effective and efficient health care. *BMJ*. 2000;320(7234):526–527. doi:10.1136/bmj.320.7234.526.
7. Brandt S, Hartmann J, Hebner S. How to design a successful disease-management program. McKinsey & Company. 2010. http://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/how-to-design-a-successful-disease-management-program. Accessed October 9, 2016.

8. Academy of Managed Care Pharmacy. Concept series paper on disease management. 2016. http://www.amcp.org/WorkArea/DownloadAsset.aspx?id=9295. Accessed October 9, 2016.
9. Faxon DP, Schwamm LH, Pasternak RC, et al. Improving quality of care through disease management: principles and recommendations from the American Heart Association's Expert Panel on Disease Management. *Circulation*. 2004;109(21):2651–2654. doi:10.1161/01.cir.0000128373.90851.7b.
10. Howe R. *The Disease Manager's Handbook*. Sudbury, MA: Jones and Bartlett Publishers; 2005.
11. Zillich A, Doucette W, Carter B, Kreiter C. Development and initial validation of an instrument to measure physician–pharmacist collaboration from the physician perspective. *Value Health*. 2005;8(1):59–66. doi:10.1111/j.1524-4733.2005.03093.x.
12. Case Management Society of America. Definition of case management. 2016. http://www.cmsa.org/who-we-are/what-is-a-case-manager/Accessed November 28, 2015.
13. Mechanic R. Will care management improve the value of U.S. health care? In: *11th Annual Princeton Conference*. Waltham, MA: Schneider Institute for Health Policy, Brandeis University; 2004:2–15. http://healthforum.brandeis.edu/research/pdfs/CareManagementPrincetonConference.pdf. Accessed October 9, 2016.
14. World Health Organization. World health organization report 2006: preventing chronic diseases: a vital investment. 2006. http://www.who.int/chp/chronic_disease_report/en.
15. Wagner EH, Glasgow RE, Davis C, et al. Quality improvement in chronic illness care: a collaborative approach. *Jt Comm J Qual Improv*. 2001;27(2):63–80.
16. Waddinton C, Egger D. Integrated health services—what and why? Geneva, Switzerland: World Health Organization; 2008. http://www.who.int/healthsystems/technical_brief_final.pdf. Accessed October 9, 2016.
17. Hart M. Asthma navigator: an added value RT's can provide. *AARC Times*. 2014;38(7):22.
18. Dohan D, Schrag D. Using navigators to improve care of underserved patients. *Cancer*. 2005;104(4):848–855. doi:10.1002/cncr.21214.
19. AARC Clinical Practice Guideline. Providing patient and caregiver training 2010. *Respir Care*. 2010;55(6):765–769.
20. World Health Organization. Health education in self-care possibilities and limitations. Geneva, Switzerland: World Health Organization; 1984. https://extranet.who.int/iris/restricted/bitstream/10665/70092/1/HED_84.1.pdf. Accessed October 9, 2016.
21. Gurnee MD, Da Silva R. Constructing disease management programs. Managed Care. 1997. http://www.managedcaremag.com/archives/1997/6/constructing-disease-management-programs. Accessed October 9, 2016.
22. Knieper V, Meldrum C, Bria W. Impact of innovative model of inpatient asthma disease management program on patient outcomes. *Chest*. 2003;124(4):95S. doi:10.1378/chest.124.4_meetingabstracts.95s.
23. McCarty K. Inpatient asthma education program. *Pediatr Nurs*. 2012;38(5):257–269.
24. Shelledy D, Legrand T, Gardner D, Peters J. A randomized, controlled study to evaluate the role of an in-home asthma disease management program provided by respiratory therapists in improving outcomes and reducing the cost of care. *J Asthma*. 2009;46(2):194–201. doi:10.1080/02770900802610068.
25. Mancuso C, Sayles W, Allegrante J. Knowledge, attitude, and self-efficacy in asthma self-management and quality of life. *J Asthma*. 2010;47(8):883–888. doi:10.3109/02770903.2010.492540.
26. Jones M. Asthma self-management patient education. *Respir Care*. 2008;53(6):778–784.
27. Poureslami I, Nimmon L, Doyle-Waters M, et al. Effectiveness of educational interventions on asthma self-management in Punjabi and Chinese asthma patients: a randomized controlled trial. *J Asthma*. 2012;49(5):542–551. doi:10.3109/02770903.2012.682125.
28. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. *JAMA*. 2002;288(19):2469. doi:10.1001/jama.288.19.2469.
29. Boxer H, Snyder S. Five communication strategies to promote self-management of chronic illness. *Fam Pract Manag*. 2009;16(5):12–16. https://www.aafp.org/fpm/2009/0900/p12.html. Accessed September 28, 2016.

Glossary

A

abdominal paradox Opposite to normal movement of the abdomen as related to the chest. On inspiration the abdomen moves inward and on expiration the abdomen moves outward as a compensatory mechanism for the use of accessory inspiratory muscles.

acid-fast bacilli (AFB) A bacterium that holds the acid-fast stain.

acinus Any small, saclike structure. Refers to the functional unit of the lung.

active cycle of breathing A breathing technique that includes abdominal breathing, thoracic expansion exercises, and forced expiratory technique to promote airway clearance in individuals' copious amounts of secretions.

acute cellular rejection (ACR) Lung transplant rejection mediated by T-lymphocyte recognition of human leukocyte antigens.

acute disease A medical condition that occurs suddenly.

acute hypercapnic respiratory failure Life-threatening abnormalities in ventilation, ventilatory failure, and Type II respiratory failure.

acute hypoxemic respiratory failure Life-threatening abnormalities in oxygenation, oxygenation failure, and Type I respiratory failure.

acute pericarditis A rapidly developing inflammation of the pericardium.

acute respiratory distress syndrome Respiratory failure of sudden onset in adults or children that follows injury to the endothelium of the lung and results in accumulation of protein-rich fluid and the collapse of alveoli, leading to difficult, rapid breathing and very low oxygen levels in the blood.

acute-on-chronic respiratory failure (ACRF) Chronic respiratory failure complicated by an acute respiratory acidosis and worsening hypoxemia.

adaptive servo-ventilation (ASV) A type of PAP therapy that adjusts the airflow to maintain a preset minute ventilation.

adenocarcinoma A type of non-small-cell lung carcinoma that arises from secretory cells in the peripheral bronchi and is gland-like in appearance. It is commonly found in never smokers.

adenosine triphosphate binding cassette (ABC) A type of cellular pump that uses energy released by adenosine triphosphate hydrolysis to move ions across membranes.

adjuvant chemotherapy Chemotherapy used after the initial treatment, usually surgery, for cancer.

adjuvant drugs Drugs helpful in the management of a certain illness that are not primarily used for that particular illness, such as antidepressants used for the treatment of pain.

adventitious breath sounds Abnormal lung sounds due to pulmonary pathologies.

aerobic Bacteria that require oxygen to exist.

aerobic metabolism Using oxygen to produce energy.

afterload The amount of resistance the heart needs to overcome to open the aortic valve and pump blood volume into the systemic circulation.

air bronchograms A tubular outline of an airway made visible by filling of the surrounding alveoli by fluid or inflammatory exudates.

airflow limitation Decrease in the volume of exhaled air.

alcohol septal ablation (ASA) The injection of 1–3 mL of desiccated ethanol into the artery feeding a hypertrophied septum. This will cause localized muscle death and shrink the hypertrophied septum.

alcoholic dilated cardiomyopathy An abnormally enlarged heart muscle caused by alcohol abuse.

allele One of two or more versions of a gene.

allodynia Extreme pain sensations caused by something that is ordinarily painless.

allograft Tissue taken from a donor and given to a recipient. Allografts can be bone, ligament, cartilage, tendon, tissue, or skin.

allograft rejection Rejection of the donor tissue by the recipient.

alpha-1-antitrypsin (AAT) A protein that protects the lungs from damage by neutrophil elastase.

alpha-1-antitrypsin (AAT) deficiency (AATD) Deficiency in a specific protein called alpha-1 antitrypsin, which inactivates neutrophil elastase.

alveolar dead space Refers to the volume of ventilation received by the alveoli that are ventilated but receive no perfusion.

alveolar macrophages (AMs) A cell located within the alveoli of the lungs that phagocytizes foreign bodies that enter the lung. It is part of the respiratory tract defense mechanism.

alveolar-to-arterial oxygen tension gradient [$P_{(A\text{-}a)}O_2$] An oxygen evaluation tool that looks at the difference between

the alveolar oxygen partial pressure and the arterial oxygen partial pressure. [$F_{IO_2} \times (PB - 47) - (P_{aCO_2} \times 1.25)$] – P_{aO_2}

American Heart Association/American College of Cardiology Foundation classification system A classification system for heart failure that uses risk factors.

amyotrophic lateral sclerosis (ALS) Disease process that involves progressive degeneration of nerve cells that control muscle movements.

anaerobic Bacteria that can exist only without oxygen. These organisms are also called obligate anaerobes.

anaerobic metabolism Producing energy without the use of oxygen.

anaphylactoid reaction A serious, life-threatening allergic reaction from a non-immunoglobulin E.

anaphylaxis A serious, life-threatening allergic reaction from an immunoglobulin E.

anastomosis A surgical connection.

anatomic dead space Refers to the volume of gas in the conducting airways.

anatomic shunt A normal bypassing of the ventilated alveoli that occurs due to anatomic structures, such as the bronchial veins, Thebesian veins, and pleural veins.

anemia Low hemoglobin level.

anemic hypoxia P_{aO_2} is normal; however, insufficient oxygen is delivered to the tissue because there is less hemoglobin available to carry O_2.

angina pectoris Chest pain that is most often the first sign of a myocardial ischemia.

angioedema Localized swelling in the dermis, subcutaneous tissue, mucosa, and/or submucosa due to vascular permeability and leakage.

anion gap A measurement of the difference between the sum of the positive electrolytes and the sum of the negative electrolytes routinely measured by clinical chemistry.

ankylosing spondylitis (AS) A chronic inflammatory rheumatic disease that can affect the axial skeleton.

anorexia–cachexia syndrome A syndrome that includes loss of appetite, weight loss, and nutritional deficiencies.

anterior–posterior (A–P) diameter Measurement of the distance between the anterior thorax and the posterior thorax.

antibody-mediated rejection (AMR) A type of tissue rejection caused by antibodies focused against human lymphocyte antigens.

anticholinergic bronchodilator A drug that blocks the effects of the parasympathetic nervous system, causing bronchodilation.

antidromic Refers to a type of atrioventricular re-entrant tachycardia in which impulses are conducted anterogradely down the accessory tract and retrogradely up the AV node.

aortic insufficiency (AI) The inability of the aortic valve to close properly, allowing the blood to regurgitate back into the left ventricle during diastole.

aortic stenosis (AS) The opening between the left ventricle and the aorta is narrow.

Apgar score A newborn assessment used to report the status of a newborn. It is done after delivery and scores are recorded 1–5 minutes after birth. A = appearance, P = pulse, G = Grimace, A = activity, R = respirations. Each is scored on a scale of 0–2, with 2 being the best score.

apnea Cessation of breathing.

apnea of prematurity (AOP) Cessation of breathing in a premature newborn. The more premature an infant is, the more likely the infant will have apnea.

apnea threshold The P_{aCO_2} level below which respiratory output ceases, primarily resulting in a central apneic event.

apneic time The amount of time for breath holding during the drowning process.

apoptosis Programmed cell death that occurs in multicellular organisms.

ARDSNet protocol An evidence-based guide to the mechanical ventilation management of ARDS, which uses low-tidal-volume ventilation.

ARISCAT risk index Assess Respiratory Risk in Surgical Patients in Catalonia risk index predicts the overall incidence of postoperative pulmonary complications (of any severity), by assigning a weighted point score to seven independent risk factors.

Arozullah respiratory failure index An assessment index used to identify patients at risk for developing postoperative respiratory failure and for guiding perioperative respiratory care.

arrhythmia An abnormal heart rhythm.

arterial blood oxygen content (C_{aO_2}) An oxygen evaluation tool that assesses the total amount of oxygen that is carried by the hemoglobin and in the plasma. $(Hb \times 1.34 \times S_{aO_2}) + (P_{aO_2} \times 0.003)$

arterial oxygen tension to oxygen concentration ratio (P/F ratio) An oxygen evaluation tool that compares the arterial oxygen partial pressure with the oxygen concentration being breathed.

arterial to alveolar oxygen tension ratio (P_{aO_2}/PA_{O_2} or a/A ratio) An oxygen evaluation tool that compares the arterial oxygen partial pressure with the alveolar oxygen partial pressure.

ask-tell-ask A motivational interviewing technique that ensures the patient understands the information given.

asthma-COPD overlap syndrome (ACOS) A syndrome that has the clinical features of both asthma and chronic obstructive pulmonary disease.

asystole No electrical activity in the heart.

atelectasis Collapse of the expanded lung; also: defective expansion of the pulmonary alveoli at birth.

atelectrauma Alveolar injury due to shearing forces as adjacent alveoli collapse and re-expand during mechanical ventilation.

atherosclerosis A build-up of plaque in the coronary arteries.

atrial fibrillation (AF) A cardiac arrhythmia characterized by disorganized electrical activity in the atria, resulting in a loss of coordinated atrial contractions.

atrial flutter A cardiac arrhythmia characterized by rapid, regular atrial activity due to an ectopic pacemaker that results in a heart rate of 250–350 beats/minute.

atrial gallop The S4 heart sound that occurs when atrial contraction forces blood into a noncompliant left ventricle.

atrial septal defects (ASD) Persistent openings in the heart between the left and the right atria.

Atrioventricular nodal re-entrant tachycardia (AVRT) A re-entry cardiac arrhythmia caused by an alternate pathway within the atrioventricular node.

atrioventricular node A collection of specialized cells that function to slow down electrical conduction from the atria to the ventricles to allow for atrial contraction.

atrioventricular re-entrant tachycardia (AVRT) A reentry cardiac arrhythmia caused by an accessory pathway in the left or right atrioventricular septum or lateral walls of the right or left atrium. The pathway allows the electrical signal to bypass the AV node.

atypical pneumonia Pneumonia caused by bacteria not normally associated with pneumonia. This type of pneumonia occurs most often in people with comorbidities.

autonomic conflict The activation of both sympathetic and parasympathetic nervous systems due to cold water immersion.

autonomy The right of a patient to make their decisions about their own medical care.

auto-titrating positive airway pressure (APAP) A newer mode of positive airway pressure delivery designed to act in response to changes in upper airway resistance by making automatic pressure changes within a set parameter.

average volume-assured pressure support (AVAPS) A type of pressure support mode that automatically changes pressure support level to guarantee a set tidal volume.

B

Bacille Calmette–Guérin (BCG) A vaccine for tuberculosis that uses a live, attenuated strain of *Mycobacterium bovis*.

bacteremia Bacteria in the blood.

bacteremic septicemia A bacterial infection in the blood causing sepsis.

bare-metal stent (BMS) A stent made of metal that contains no coating or medication.

barotrauma Trauma to the lungs due to invasive mechanical ventilation pressures rupturing alveoli and causing air leaks, resulting in conditions including pneumothorax, pneumomediastinum, pneumoperitoneum, and subcutaneous emphysema.

basic metabolic panel (BMP) A clinical chemistry panel of measurements that include calcium, creatinine, electrolytes, and glucose in the blood.

Beck triad Three physical signs that are indicative of cardiac tamponade. They are venous pressure elevation, decline in arterial pressure, and muffled heart tones.

Becker muscular dystrophy A neuromuscular disease caused by progressive muscle wasting and weakness due to the degeneration of skeletal, smooth, and cardiac muscle.

benign Noncancerous.

Berlin Questionnaire A survey instrument used to identify risk factors associated with sleep apnea.

beta-adrenergic agonists A drug that stimulates the sympathetic nervous system, causing bronchodilation.

bilateral lung transplantation Transplantation of both lungs.

bi-level positive airway pressure (BPAP) A noninvasive ventilator mode that provides two different pressures: inspiratory positive airway pressure and expiratory positive airway pressure.

biofilm A group of microorganisms that stick to one another and often also to a surface.

biomass fuel The burning of substances like wood for cooking and heating.

Biot respiration A breathing pattern characterized by a short burst of uniform, large tidal volume breaths followed by periods of apnea.

blunt force trauma Non-penetrating trauma, typically due to an acceleration or deceleration injury, to the chest (or any body part) caused by an impact.

BODE index An assessment tool used to predict survival in COPD patients.

body mass index (BMI) A measurement of a person's weight as it relates to the person's height. It is used to identify obesity.

booster phenomenon Initially negative TST turns positive in an individual who was infected many years before because the TST triggered the memory of the immune system causing a reaction.

botulism A neuromuscular disease process that occurs when a patient is affected by one of the neurotoxins A-G.

bradycardia Slower than normal heart rate, less than 60 beats/minute.

bradypnea Slower than normal respiratory rate, less than 10 breaths/minute.

brain-dead donors (BDDs) Donors who have lost all brain function and are being maintained by mechanical ventilation and medications so their organs may be recovered for donation.

bronchial anastomotic dehiscence A rupture of the surgical connection between the donor bronchus and the recipient bronchus.

bronchial challenge A test that utilizes a provocations substance, such as methacholine, to assess bronchial hyperresponsiveness.

bronchial hyperresponsiveness (BHR) An increased sensitivity to stimuli that cause bronchospasm.

bronchial thermoplasty A procedure that utilizes thermal energy to decrease the airway smooth muscles that spasm. It is used for patients with severe chronic asthma to improve quality of life and reduce asthma exacerbations.

bronchiectasis severity index A method of determining the severity of bronchiectasis by assigning points to several clinical, radiologic, and microbiologic features. It is also used to predict mortality, hospital admissions, exacerbations, and quality of life.

bronchiolitis Inflammation of the bronchioles that typically occurs with infants and is usually caused by a viral infection, most commonly respiratory syncytial virus.

bronchiolitis obliterans syndrome (BOS) An irreversible, progressive obstructive disease that is the most common form of chronic lung allograft dysfunction.

bronchoalveolar carcinoma A unique type of adenocarcinoma that has no invasive component and presents as an interstitial lung disease on chest radiography.

bronchoalveolar lavage A technique used to obtain cells and fluid from the bronchioles and alveoli using a saline wash using either a bronchoscope or a specialized catheter. Specimens are sent for cytologic analysis.

bronchogenic carcinoma Malignant neoplasms that originate in the airways or lung parenchyma.

bronchoplasty Endoscopic airway dilation with a rigid or flexible bronchoscope. A rigid bronchoscope can be advanced through the stenotic airway opening, which has a "coring" effect instead of balloon dilation.

bronchopneumonia A multifocal pneumonia (lobular pneumonia) that involves both airways and lung parenchyma, caused by aspiration of secretions from a colonized trachea seen typically in hospital-acquired pneumonia.

bronchopulmonary dysplasia (BPD) A form of chronic lung disease that develops in premature neonates who are treated with positive pressure ventilation and supplemental oxygen.

bronchoscopy Therapeutic or diagnostic examination of the airways using a bronchoscope.

bronchovesicular breath sound A combination of tracheal and vesicular breath sounds heart over the upper part of the sternum between the first and second intercostal spaces.

Bruce protocol A common type of exercise stress test using a treadmill.

bundle of His A bundle of specialized cardiac muscle cells that connect the atrioventricular node to the right and left bundle branches.

burn shock A unique type of shock that is a combination of distributive and hypovolemic shock, which occurs in burn patients.

C

cachectic Loss of weight and muscle mass due to disease.

cachexia Generalized weakness and malnutrition caused by a chronic disease such as lung cancer.

canals of Lambert Accessory connections between bronchioles and adjacent alveoli, which facilitate collateral ventilation within the smallest parts of the lung.

capillary refill time The amount of time required for the return of color to a nail bed after the application of blanching pressure.

capnography A noninvasive technique to measure end-tidal carbon dioxide.

carbonaceous particles Burnt matter, often called soot, that is a by-product of combustion.

carboxyhemoglobin (COHb) Carbon monoxide attached to the hemoglobin in red blood cells.

carboxymyoglobin Carbon monoxide attached to myoglobin.

carcinoma A cancer that begins in the tissues that cover body organs.

cardiac catheterization The process of inserting a catheter into the heart to evaluate the heart structure, patency of the coronary arteries, and cardiac function.

cardiac enzymes A group of proteins that are found in myocardial tissue and are released in the serum when cardiac cells are injured, as in myocardial infarction.

cardiac tamponade A lift-threatening condition caused by the accumulation of pericardial fluid under pressure, compressing the heart and severely limiting the filling of its chambers.

cardiac troponins Include troponin I (cTnI) and troponin T (cTnT), which are released into the blood after cardiac damage.

cardiogenic pulmonary edema The accumulation of fluid with a low protein content in the lung interstitium and alveoli as a result of cardiac dysfunction.

cardiogenic shock (CS) Shock that results from pump failure (heart), and is classified as a circulatory shock.

cardiopulmonary exercise testing (CPET) A full range of testing that provides exercise capacity and prognostic information and is used for therapeutic decisions.

care management A type of interdisciplinary management system that assists patients in managing medical conditions and coordinating care activities.

carotid bruit A sound caused by turbulent blood flow in the carotid artery resulting from stenosis of the artery.

case management A collaborative process that plans, implements, coordinates, monitors, assesses, and evaluates healthcare options to meet patients' needs, using communication and available resources to promote positive patient outcomes.

Center for Medicare and Medicaid Service (CMS) The branch of the U.S. Department of Health and Human Services that administers Medicare and Medicaid programs.

central airway obstruction (CAO) Obstruction of the airflow through the trachea and the mainstem bronchi.

central apnea Cessation of breathing caused by a lack of signaling from the respiratory center in the brain.

central nervous system The part of the nervous system that in vertebrates consists of the brain and spinal cord, to which sensory impulses are transmitted and from which motor impulses pass out, and which coordinates the activity of the entire nervous system.

central sleep apnea (CSA) Cessation of breathing due to failure of stimulation of the respiratory system by medullary respiratory centers, characterized by lack of effort.

central venous pressure (CVP) The pressure exerted by blood in the right atrium.

centrilobular emphysema Emphysema that affects the proximal respiratory bronchioles mostly in the upper portions of the lungs and is the most common form of emphysema.

cerebral hypoxia Lack of oxygen in the brain.

channels of Martin Interbronchiolar pathways that facilitate collateral ventilation in the lungs.

Cheyne–Stokes respirations A repeating pattern of breathing in which the rate and depth of breathing increases to a peak, followed by a decrease in the rate and depth of breathing, followed by a period of apnea.

chief complaint (CC) The problem or group of symptoms that brings a patient to the practitioner or hospital for health care.

chronic care model (CCM) A proactive approach to chronic disease care that promotes comprehensive system change to achieve improved patient outcomes.

chronic disease A medical condition that has developed over a long period of time.

chronic lung allograft dysfunction (CLAD) A type of lung rejection that manifests as either airflow obstruction or restriction and includes bronchiolitis obliterans syndrome, restrictive allograft syndrome, and neutrophilic reversible allograft dysfunction.

chronic obstructive pulmonary disease (COPD) Two long-term lung diseases—chronic bronchitis and emphysema—that often occur together.

chronic respiratory failure (CRF) Long-term respiratory failure involving inappropriate levels of minute ventilation or increases in dead space, also known as chronic ventilatory failure.

circadian rhythm A person's 24-hour internal clock.

cisatracurium A nondepolarizing skeletal muscle relaxant/paralyzing agent.

class 1 patient Asymptomatic drowning victim showing no evidence of inhalation of liquid.

class 2 patient Asymptomatic or symptomatic drowning victim showing clinical evidence of liquid aspiration with adequate ventilation.

class 3 patient Symptomatic drowning victim showing clinical evidence of liquid aspiration with inadequate ventilation.

class 4 patient Drowning victim in both ventilatory and cardiac arrest.

clinical chemistry An analysis of the noncellular components of the blood present in the plasma. It includes bilirubin, calcium, creatinine, electrolytes, glucose, liver enzymes, proteins, and urea nitrogen.

Cobb angle The angle between the upper and lower portions of a spinal curvature used to quantify the severity of scoliosis.

cold shock A sympathetically mediated response to sudden immersion in cold water, causing tachycardia, uncontrollable hyperventilation, hypertension, and increases in plasma catecholamine levels.

community-acquired pneumonia (CAP) Pneumonia that develops while the person is not in a hospital or other healthcare setting with the onset of symptoms in the community.

comorbidity More than one disease in an individual.

complete blood count (CBC) An overall assessment of the kinds and numbers of cells in the blood. It includes WBC count and differential, RBC count, hematocrit, hemoglobin, platelet count, and mean platelet volume.

complete heart block A cardiac arrhythmia characterized by a complete failure of electrical conduction between the atria and ventricles of the heart. Also known as third-degree atrioventricular block.

comprehensive metabolic panel (CMP) A clinical chemistry panel of measurements that include bilirubin, calcium, creatinine, electrolytes, glucose, liver enzymes, and proteins in the blood.

computed tomographic pulmonary angiography (CTPA) A diagnostic test that uses computed tomography to obtain an image of the pulmonary arteries. It is the method of choice for imaging the pulmonary vasculature in patients with suspected pulmonary embolism.

computed tomography (CT) A radiographic technique that produces a film representing detailed cross sections of tissues in 1- to 2-mm thickness.

concentric hypertrophy A thickening of myocytes causing increased ventricular wall thickness.

congenital central hypoventilation syndrome (CCHS) A syndrome that causes very decreased ventilatory response during sleep, but is normal during wakefulness.

congenital diaphragmatic hernia (CDH) A birth defect that causes a malformation (hole) of the diaphragm allowing the contents of the abdomen to migrate into the chest area.

congenital heart defect (CHD) An abnormality of the heart that develops in utero. The defect can involve the walls of the heart, the arteries and veins going to and from the heart, or the valves of the heart.

connective tissue diseases (CTDs) A group of autoimmune diseases affecting the connective tissue of the body.

consolidation A radiologic sign showing lung tissue filled with dense material or liquid.

constrictive pericarditis A rigid pericardium, caused by marked inflammation, that does not allow the heart to stretch and fill appropriately during diastole.

continuous mandatory ventilation (CMV) A mode of positive pressure mechanical ventilation that provides both mandatory breaths and assisted breaths at a set respiratory rate and tidal volume. The set tidal volume is applied for both the set respiratory rate and the patient's spontaneous respiratory rate.

continuous positive airway pressure (CPAP) A noninvasive mode where the expiratory pressure is maintained at above atmospheric pressure and the patient breathes spontaneously.

continuum of care Healthcare services of chronic disease that includes prevention, long-term maintenance treatment, management of acute symptom exacerbation, rehabilitation, and palliative care.

contractility The internal strength of the ventricle to squeeze the blood out of its chamber.

co-oximetry A technique (a type of blood gas analyzer) that measures the actual oxygen saturation of blood and all types of hemoglobin (i.e., concentrations of deoxyhemoglobin, oxyhemoglobin, methemoglobin, and carboxyhemoglobin).

COPD Assessment Test (CAT) An eight-item survey to assess the health status impairment of COPD.

coronary artery bypass grafting (CABG) A surgical procedure to bypass a closed-off coronary artery with either the left internal mammary artery or the saphenous vein as the graft.

coronary artery disease (CAD) Another name for ischemic heart disease or coronary heart disease.

coronary heart disease Another name for ischemic heart disease or coronary artery disease.

crackles Adventitious breath sound due to popping open of alveoli, air passing through fluid-containing bronchi, or air passing through fluid in the small airways and alveoli.

C-reactive protein (CRP) A substance that is produced by the liver in response to inflammation within the body.

creatine kinase (CK-MB) The standard chemical marker for evaluating myocardial injury.

croup Also known as laryngotracheobronchitis. It is an upper airway infection affecting the trachea by causing swelling below the vocal cords, making it difficult to breathe.

cryobiopsy A procedure, done through a flexible bronchoscope, that uses a freeze–thaw cycle to extract pieces of tissue from the lung. It is used as a less invasive form of lung tissue biopsy.

cryotherapy Local ablation using repeated freeze/thaw cycles via bronchoscopy.

crystalloid solution A fluid used to replenish body fluid loss caused by shock. The most common solutions are isotonic saline and Ringer's lactate.

CT pulmonary angiography A radiographic technique that uses a combination of CT scans and intravenous contrast media to detect pulmonary emboli.

CURB-65 An index used to stratify patients into mortality risk groups based on the presence of five factors: confusion, urea, respiratory rate, blood pressure, and age 65 or more.

cyanosis A bluish discoloration of the skin and mucous membranes due to desaturated hemoglobin of 5 g or more.

ciliary dyskinesia A disease that impairs the cilia lining the airways and makes them unable to move mucus up the mucociliary escalator.

cystic fibrosis transmembrane conductance regulator (CFTR) CFTR is a protein that helps to balance salt and water in the lungs and other organs. When CFTR does not work, chloride remains trapped in the cells and water cannot hydrate the lining of the airways, making the layer of mucus thick and tenacious.

cytokines Cellular signaling molecules that stimulate the movement of different cells toward sites of inflammation, infection, and trauma. It is also an inflammatory mediator released by various cells in the asthma inflammatory cascade.

D

D-dimer A degradation product of cross-linked fibrin. Plasma levels of D-dimer increase in the setting of venous thrombosis and various other conditions, including myocardial infarction, pneumonia, sepsis, and inflammation.

dead space V/Q = ∞, ventilation without perfusion.

decerebrate posturing An abnormal neurologic response to painful stimuli that causes internal rotation and extension of the arms, with the wrists pronated, fingers flexed, and the legs extended.

decorticate posturing An abnormal neurologic response to painful stimuli that causes arms to adduct and elbows, wrists, and fingers to flex toward the chest with stiffly extended legs rotated internally.

deep vein thrombosis (DVT) A blood clot that develops in deep vein, usually in a leg.

deglutition muscles Muscles used for swallowing.

delirium A disturbance of mental abilities that results in confused thinking and a reduction in awareness of the environment.

demand management A program designed to guide healthcare consumers to the most appropriate care by involving the patient.

dermis The thickest of the three layers that makes up skin. It contains capillaries, nerves, sweat glands, hair follicles, and other structures.

diastolic blood pressure The amount of pressure remaining in the arteries during ventricular relaxation.

diffusion The movement of oxygen and carbon dioxide across the alveolar air sac and capillary wall.

dilated cardiomyopathy (DCM) Heart enlargement caused by myocyte damage due to a variety of causes.

disease management (DM) A proactive, patient-centered program that aids in the management of high-risk, high-cost patients with chronic conditions

disseminated intravascular coagulation (DIC) Excessive bleeding due to increased clotting within the bloodstream, which depletes both platelets and clotting factors.

disseminated intravascular coagulation A condition in which small blood clots develop throughout the bloodstream, blocking small blood vessels, which ultimately depletes platelets, thus causing excessive bleeding.

distributive shock A category of shock that is a result of massive systemic vasodilatation.

Dittrich plugs Sputum that contains masses of foul-smelling bacteria and fatty acid crystals that are yellow to gray in color.

diving response A parasympathetically mediated response to cold water on the face, causing bradycardia.

donation after cardiac death (DCD) Donation of an organ by a deceased person who died from cardiac arrest.

driver mutations The type of mutation that pushes cell toward becoming cancerous.

droplet nuclei An airborne pathogenic particle of 1–5 μm that carry *Mycobacterium tuberculosis*.

drowning The process of experiencing respiratory impairment from submersion/immersion in liquid.

drug-eluting stent (DES) A stent made with a metal platform, a polymer, and an anti-restenotic drug.

Dual antiplatelet therapy (DAPT) Therapy with two blood thinners used following stent deployment to reduce the risk of clot formation.

DUBBS Dangerous underwater breath-holding behaviors like static apnea or intentional hyperventilation.

Duchenne muscular dystrophy (DMD) A severe form of muscular dystrophy due to the absence of dystrophin protein; is more likely to occur in boys.

dyshemoglobins Hemoglobin molecules that are saturated with carbon monoxide (carboxyhemoglobin) or have oxidized iron (Fe^{3+}) (methemoglobin).

dyslipidemia A disorder of lipoprotein metabolism, either overproduction or deficiency.

dyspnea A term used to describe the uncomfortable awareness of difficult or labored breathing associated with feeling short of breath.

E

eccentric hypertrophy Elongation of myocytes, leading to enlargement of the ventricle chamber and thickening of its walls.

ECG telemetry Wireless continuous electrocardiogram monitoring.

echocardiography A specific type of ultrasonography that uses sound waves to assess the heart structures.

eFAST (extended focused assessment with sonography for trauma) Ultrasonography used to assess a trauma patient for life-threatening injuries.

endobronchial electrocautery Contact electrical thermal injury administered via flexible bronchoscope.

electroencephalogram (EEG) A method of monitoring and recording brain electrical activity. This method is also used to measure brain wave activity through the scalp during polysomnography.

electromyogram (EMG) A method of monitoring and recording skeletal muscle electrical activity and muscle activity used during polysomnography.

electrooculogram (EOG) A method of monitoring and recording eye movement during sleep to identify the difference between nonrapid eye movement and rapid eye movement sleep stages. This method is used during polysomnography to indicate REM or NREM sleep.

electrophysiologic studies (EPS) A group of minimally invasive tests performed to evaluate abnormal electrical activity of the heart.

electrophysiologic test (EP) A study of the heart's electrical system to recognize the nature of cardiac arrhythmias.

embolus A piece of a thrombus that breaks off and travels through blood vessels.

empirical antimicrobial treatment Use of certain antibiotics, typically based on local microbiology and antimicrobial resistance patterns, without knowing the causative organism (while the results of bacterial culture and other tests are pending).

empyema A collection of pus in the pleural space.

empyema necessitans A spontaneous abscess caused by an empyema.

end-tidal carbon dioxide ($ETCO_2$) The measurement of exhaled carbon dioxide made at the end of exhalation used to assess the adequacy of ventilation and the effectiveness of cardiopulmonary resuscitation.

endemic Pertains to a certain area, common to a certain region.

endobronchial laser therapy Thermally ablative noncontact technique performed using a rigid or flexible bronchoscope.

endobronchial ultrasound (EBUS) An ultrasound that uses a flexible bronchoscope to evaluate endobronchial lesions and airway wall and adjacent structures.

endothelin receptor antagonists (ERAs) A type of drug used in the treatment of pulmonary arterial hypertension. They prevent binding of endothelin to the endothelin receptor sites promoting vasodilation.

endothelium-derived relaxing factors (EDRF) A group of vasoactive compounds that are responsible for maintaining the tone of the pulmonary vasculature. Includes acetylcholine, bradykinin, histamine, thrombin, serotonin, adenosine triphosphate, and nitric oxide.

eosinophils A type of white blood cell that, when stimulated in the asthma inflammatory cascade, release cytokines, toxic oxygen radicals, and chemotactic factors contributing to inflammation.

epidermis The outermost layer of skin.

epidural anesthesia An injection of local anesthetic into the epidural space to anesthetize the spinal nerve roots, most commonly used for abdominal, pelvic, and lower extremity procedures and, less commonly, thoracic procedures.

epiglottis A swelling of the epiglottis, typically caused by a rapidly progressive bacterial infection, which can lead to a potentially life-threatening upper airway obstruction.

epistaxis Nose bleed.

Epworth Sleepiness Scale (ESS) A self-administered eight-item subjective sleep questionnaire used to assess daytime sleepiness.

erythrocytes The name for red blood cells.

eschar A thick coagulated crust cover an area of skin that was burned.

escharectomy A surgical procedure to remove eschar.

escharotomy An incision into the inelastic burned tissue to relieve underlying pressure, increase perfusion, and allow movement.

ex vivo lung perfusion (EVLP) A procedure used to recondition lungs so as to make them suitable for donation.

exacerbation A flare-up of symptoms.

excessive daytime sleepiness (EDS) A feeling of sleepiness and lack of energy during daytime hours.

excessive daytime sleepiness (EDS) Daytime lethargy, usually due to sleep-disordered breathing.

expanded criteria donors More relaxed guidelines that include organ donors who may not meet the strict guidelines in order to increase the donor pool.

extracellular matrix (ECM) A collection of molecules that are secreted by cells that provide support.

extracorporeal membrane oxygenation (ECMO) A technique, similar to heart–lung bypass, in which blood oxygenation and cardiac function are performed by a mechanical pump and oxygenator outside the body.

extracorporeal photopheresis A cell-based immunomodulatory therapy that involves collecting leukocytes from peripheral blood used to treat bronchiolitis obliterans syndrome.

extrathoracic airways Those airways that are outside of the thoracic cage and superior to the thoracic inlet.

exudative Fluid that contains fibrin and white blood cells. In the case of a pleural effusion, it is caused by an inflammatory process.

F

FACED FEV1; Age; Colonization; Extent; Dyspnea.

facultative anaerobes Bacteria that can exist with or without oxygen and have the capacity to use fermentation.

fatty streak The atherosclerotic lesion developed from macrophage ingestion of modified LDL.

fetal heart rate (FHR) A measurement of heart rate of a baby in utero.

fetal hypoxic stress In utero reduction in the supply of oxygen to the fetus caused by several factors such as maternal smoking, prolapsed umbilical cord, and placental infarction.

fetal ultrasonography High-frequency sound waves used to produce an image of the fetus.

fibrillation A type of cardiac arrhythmia that causes the heart muscle, either the atria or the ventricles, to quiver and not contract.

fibrinolysis The enzymatic breakdown of the fibrin in blood clots.

fibroblastic foci Dense collections of myofibroblasts and scar tissue.

fibroblasts The cells that are responsible for synthesizing the extracellular matrix and collagen.

Fick method A method of determining cardiac output using analysis of both arterial and mixed venous blood withdrawn from a pulmonary artery catheter and oxygen consumption measured via indirect calorimetry.

fine needle aspiration A biopsy sampling technique that uses a fine needle inserted into an area of abnormally appearing tissue.

first-degree atrioventricular block A cardiac arrhythmia caused by the prolongation of the normal delay of electrical signal within the atrioventricular node, causing an increase in the PR interval.

first heart sound (S_1) The heart sound produced when the mitral and tricuspid valves snap shut simultaneously at the beginning of systole.

fixed obstruction An airway obstruction that is minimally affected by the airway pressure changes during inspiration and expiration.

flail chest Two or more ribs broken in two or more places, creating a separate piece of chest wall that does not ventilate physiologically.

flow-directed pulmonary artery catheter A pulmonary artery catheter that is used to measure pulmonary artery pressure and pulmonary capillary wedge pressure and sample blood from the pulmonary artery. It is also known as a Swan-Ganz catheter.

fluid resuscitation The parenteral replacement of lost volume.

forced expiratory volume in 1 second (FEV1) A spirometry test that shows the presence of airflow limitation. It is used to assess for asthma severity and the amount of reversibility following administration of a short-acting beta-agonist medication. Also measure of volume expired over the first 1 second of an FVC maneuver.

forced vital capacity (FVC) The maximum volume of gas that can be expired when a patient exhales as forcefully and rapidly as possible after a maximal inspiration.

foreign body aspiration The inhalation of a foreign body into the lungs, which can obstruct the airway.

foreign body obstruction (FBO) A blockage of the upper airway that leads to respiratory distress and has the potential to be life threatening.

fractional exhaled nitric oxide (FE_{NO}) A test that measures the amount of nitric oxide exhaled, which is a biomarker of airway inflammation.

fractional flow reserve (FFR) The calculation of blood flow across a stenosis in the coronary arteries, used to guide treatment.

fremitus Vibration.

full-thickness graft A graft of skin, both epidermal and dermal layers, that contains all the elements contained in the dermis.

fungi A kingdom of eukaryotic microorganisms, comprised of hyphae, except for yeast, that live by decomposing and absorbing organic material on which they live.

G

gallops Abnormal heart sounds, S3 and S4.

gamma globulin A portion of the blood made up of immunoglobulin antibodies that are secreted by the plasma cells in response to an antigen.

gastric washing A sample taken from the stomach used for the identification of *Mycobacterium tuberculosis* in children who are unable to produce a sputum sample.

general anesthesia Anesthesia delivered either intravenously or by gas to medically induce a coma, not sleep, during a surgical procedure. These drugs keep a patient unresponsive, unconscious, and unable to feel pain.

Ghon focus A primary lesion in the lungs caused by *Mycobacterium tuberculosis*.

Glasgow Coma Scale A scoring system that assesses a patient's neurologic state. The scores range between 3, the worst, and 15, the best using three parameters: best eye response, best verbal response, and best motor response

Global Initiative for Chronic Obstructive Lung Disease (GOLD) Works with healthcare professionals and public health officials to raise awareness about chronic obstructive pulmonary disease (COPD) and to improve prevention and treatment.

glottis The space or opening between the vocal cords.

golden minute The first 60 seconds after birth within which a baby should be breathing or should be ventilated with a bag and mask.

graduated compression stockings (GCS) Stockings that exert compression at the ankle and gradually decrease compression up the garment.

Gram staining A microbiologic staining technique used to distinguish distinct differences in the cell wall structure of various bacteria.

gram-negative Bacteria that are gram-negative appear pink, under microscopy, because their thin peptidoglycan cell wall layer is covered by a lipopolysaccharide and protein layer that does not retain the crystal violet stain.

gram-negative pneumonia A pneumonia caused by gram-negative bacteria predominantly in individuals who are debilitated, immunocompromised, or recently hospitalized.

gram-positive Bacteria that are gram-positive appear purple, under microscopy, due to their thick peptidoglycan cell wall that retains the crystal violet dye in the stain.

granulomas Nodular-like lesions formed by collections of activated T cells and macrophages that limit the multiplication and spread of an organism, such as *Mycobacterium tuberculosis*. Also small masses of inflamed tissue that are typically a result of inflammation.

grunting An adventitious breath sound heard when a newborn exhales against a partially closed glottis.

guanylate cyclase stimulators A type of drug used in the treatment of pulmonary arterial hypertension. Stimulates soluble guanylate cyclase, an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO).

Guillain–Barre syndrome A peripheral motor nerve disorder in which the immune system mistakenly attacks the peripheral motor neurons. The syndrome includes several pathologic subtypes, of which the most common is a multifocal demyelinating disorder of the peripheral nerves in close association with macrophages.

Gupta calculator for postoperative pneumonia An assessment index that provides a risk estimate for postoperative pneumonia and aids in surgical decision making and informed consent.

H

Hampton hump A radiologic sign that shows a wedge-shaped or rounded pleural-based infiltrate with the apex pointed toward the hilum. It is frequently located adjacent to the diaphragm and typically seen with a pulmonary infarction.

heart block A block in the heart's normal conduction pathway.

heart disease Any condition that affects the heart and prevents it from functioning properly.

heart failure (HF) The inability of the heart to pump enough blood to support the body's needs.

heart murmurs The "whooshing" sounds created when blood travels backward through a leaky valve.

heart-lung transplantation Transplantation of both heart and lungs from donor to recipient.

Heimlich maneuver An abdominal thrust given in an effort to clear a foreign body from the upper airway.

heliox A mixture of helium and oxygen that can be administered to patients during an acute exacerbation to help decrease the work of breathing and improve ventilation. The mixture is typically either 70% helium and 30% oxygen or 80% helium and 20% oxygen.

hematology The study of blood in health and disease.

hemodynamics A branch of physiology dealing with the study of the circulation of blood through the body.

hemopneumothorax A combination of air and blood in the pleural space.

hemoptysis The presence of frank blood in the sputum.

hemorrhagic shock Shock due to intravascular blood loss.

hemothorax A collection of blood in the pleural space, usually due to trauma.

heterogeneous Varying clinical manifestations or presentations.

high-density cholesterol (HDL) Is considered the "good cholesterol," and when elevated appears to protect against atherosclerosis.

high-frequency chest wall compression An airway clearance modality that externally compresses the chest wall, using a vest or wrap, to deliver short expiratory flow pulses.

high-density lipoprotein (HDL) The "good" cholesterol.

histamine An inflammatory mediator released by various cells in the asthma inflammatory cascade.

history of present illness (HPI) Detailed information pertinent to the chief complaint of a patient.

histotoxic hypoxia Oxygen is received at the cellular level but the cells are unable to utilize the oxygen.

holosystolic murmur A heart sound that is caused by the "swishing" through a hole. It is indicative of a septal defect.

home sleep apnea testing (HSAT) Testing for sleep-disordered breathing at home using a portable system to record airflow, respiratory effort, and pulse oximetry.

homeostatic sleep regulation An internal body function that generates the drive to sleep and regulates sleep intensity.

homogeneous Uniform structure or composition throughout.

homozygous A genetic term that pertains to two copies of the same allele for a particular trait located at similar positions on paired chromosomes.

honeycomb The characteristic appearance of different sized cysts in the background of fibrotic lung tissue.

Horner syndrome A neurologic syndrome consisting of miosis, ptosis, and anhidrosis of the eyes. It can be a complication of regional lung carcinoma spread.

hospice A specialized type of care for patients with life-limiting illnesses, their families, and caregivers.

hospital-acquired pneumonia (HAP) A pneumonia that occurs at least 48 hours after a hospital admission and is not associated with mechanical ventilation.

hyaline membrane A membrane composed of dead cells and proteins lining the alveoli, which makes gas exchange difficult.

hyperacute allograft rejection (HAR) A highly lethal rejection that occurs within the first 24 hours after transplantation as a response to pre-formed antibodies of recipient origin directed against human leukocyte antigens (HLA) contained on donor tissue (alloantigen).

hyperacute phase The early phase of an acute myocardial infarction that may not be visible on ECG.

hyperalgesia Increased sensation of pain.

hyperbaric oxygen therapy Therapy used to treat carbon monoxide poisoning by using increased atmospheric pressure with 100% oxygen.

hypercarbia Abnormally elevated levels of carbon dioxide in the blood.

hyperemia An increase in blood flow in the coronary arteries.

hyperpnea A fast and deep breathing pattern.

hypertension A state of sustained elevated blood pressure.

hyperthermia Elevated body temperature due to excessive heat production or inadequate heat dissipation from heavy exertion in a hot, humid environment.

hypertonic saline (HTS) A solution that contains more than 0.9% sodium chloride, or the salinity of body fluids.

hypertrophic cardiomyopathy A genetic cardiac disease that causes the hypertrophy of the left ventricle of more than 1.5 cm.

hypertrophic obstructive cardiomyopathy (HOCM) A genetic cardiac disease that causes the asymmetric hypertrophy of the upper interventricular septum, which causes a transient obstruction of the left outflow tract during systole.

hypodermis The layer of skin that is directly below the dermis, connecting the skin to the fibrous tissue of the bones and muscles.

hypopnea Slow or shallow breathing.

hypothermia A body temperature below normal.

hypovolemia Low fluid and blood volume.

hypovolemic shock Shock as a result of fluid or blood loss.

hypoxemia Deficient oxygen of the blood.

hypoxemic hypoxia Insufficient oxygen at the tissue level due to low Pao_2.

I

idiopathic dilated cardiomyopathy An abnormally enlarged heart muscle of unknown etiology.

idiopathic pulmonary fibrosis (IPF) A lung disease of unknown origin that causes scarring in the lung parenchyma.

immersion When part of the body is within a liquid.

immunoglobulin E (IgE) A type of immunoglobulin or antibody produced in response to an allergen.

immunomodulator A drug that helps regulate the immune system response in asthma.

immunoreactive trypsinogen (IRT) test A screening test for cystic fibrosis that is given to all neonates.

immunosenescence Age-related decline of a person's immune system.

implantable cardioverter defibrillator An internally placed device that is capable of delivering electrical shocks to the heart to stop life-threatening arrhythmias.

indeflator The device that is used to inflate the balloon during an angioplasty or a stent deployment.

infant respiratory distress syndrome (IRDS) A breathing disorder of premature newborns caused by insufficient amounts of pulmonary surfactant. It is also known as hyaline membrane disease.

infiltrates A substance denser than air, such as pus, blood, or protein, present in the parenchyma of the lung.

infraglottic That portion of the larynx inferior to the glottis.

inhalation injury Refers to damage to the respiratory tract or parenchyma caused by heat, smoke, or chemical irritants brought into the airways during inspiration.

inhaled corticosteroid (ICS) An inhaled antiinflammatory drug that is used to control asthma.

inhaled prostaglandins Promote pulmonary vasodilation in patients with pulmonary hypertension via cyclic adenosine monophosphate-mediated release of intracellular calcium. The result is pulmonary vasodilation, and improved ventilation and perfusion mismatch.

inoculum A small amount of microorganism containing material from a pure culture that is used to begin a new culture or to inject into a person to induce immunity to the disease that the microorganism causes.

inspiratory muscle training The use of inspiratory resistance via flow-resistive loading or threshold loading to provide breathing exercise.

integrated health care The organization and management of health care so that patients receive the care they need in a user-friendly manner, so that the desired results are achieved while providing value for the money.

interferon-γ release assays (IGRAs) A type of blood test that identifies the presence of *Mycobacteria tuberculosis* by measuring the immune response to the tuberculosis proteins in whole blood.

interstitial lung diseases (ILDs) A heterogeneous group of diffuse parenchymal lung diseases that have various causes both known and unknown that are caused by various degrees of inflammation and fibrosis.

interstitial macrophages (IMs) Phagocytes that are located in the interstitium of the lung.

interstitial pneumonia Pneumonia commonly caused by viruses.

intima Inside layer of the artery.

intractable dyspnea Breathlessness that is unrelated to measurable pulmonary function and not relieved by traditional management.

intrapulmonary shunt Unoxygenated blood returns to the arterial system after perfusing non-ventilated alveoli. Also known as physiologic shunt.

intrathoracic airways All the conducting airways from the trachea, at the thoracic inlet, to the terminal bronchioles.

ischemic Lack of oxygen to a body tissue.

Ischemic dilated cardiomyopathy An abnormally enlarged heart muscle caused by ischemia due to coronary artery disease.

ischemic heart disease (IHD) A heart disease caused by a lack of sufficient blood (not getting enough oxygen) to the heart muscle.

IVUS A procedure that uses a special catheter to perform an ultrasound of the inside of a coronary artery.

J

jugular vein distension Bulging of the jugular veins of the neck.

K

Karnofsky index A scale used to determine the functional status of a patient, including needs, abilities, and prognosis.

keratin pearls Fibrous protein "balls" found deep in cancerous clusters of squamous cell lung carcinoma seen with histologic staining.

Kussmaul sign The distension of the jugular veins that increases with inspiration.

kyphoscoliosis A combination of anteroposterior curvature of the thoracic spine (kyphosis) and lateral curvature of the lumbar spine (scoliosis).

kyphosis Also known as "dowager hump or hyperkyphosis," it is an anteroposterior curvature of the thoracic spine (abnormal forward curvature of the spine).

L

large cell lung carcinoma (LCLC) A type of non-small-cell lung carcinoma that appears larger than normal cells and lack the classic glandular or squamous morphology.

laryngeal reinnervation A surgical procedure that brings a new nerve supply to the injured vocal cord.

laryngopharynx The area that extends below the epiglottis to the level of the cricoid cartilage.

laryngospasm Closure of the larynx due to laryngeal muscle spasm.

latent tuberculosis infection (LTBI) Suppression of the *Mycobacterium tuberculosis* infection into an inactive state.

lateral decubitus A chest radiographic view in which the patient is lying on either the right or the left side.

left heart catheterization An invasive diagnostic test that uses a catheter to inject contrast directly into the coronary arteries of the left side of the heart.

left heart failure Failure of the left ventricle to pump properly.

left shift Referring to white blood cell count, it is a phrase that means there are a high number of young, immature white blood cells present in the blood. This corresponds to infection or inflammation.

left ventricular ejection fraction (LVEF) The percentage of blood pumped out of the left ventricle with each contraction.

left ventricular hypertrophy (LVH) Thickening of the walls of the left ventricle due to chronic pressure or volume overload.

left ventricular outflow tract (LVOT) The portion of the left ventricle through which blood passes to enter the aorta.

leukocytes The name for white blood cells.

leukotriene receptor antagonist (LTRA) A drug that inhibits the leukotriene pathway to inflammation.

leukotrienes An inflammatory mediator released by mask cells in the asthma inflammatory cascade.

life-extending treatments Medical care administered to prolong life, not cure the illness.

life-limiting disorder An illness where the patient is expected to die as a direct consequence of the specific disorder.

living donor lobar lung transplantation A technique that involves transplantation of lower lobes from each of two living, blood group–compatible donors.

lobar pneumonia Also called alveolar pneumonia, it involves one or more of the five major lobes of the lungs.

long-acting beta-agonist (LABA) A type of beta-agonist drugs that are secondary asthma maintenance medications. They are not to be used alone for maintenance, nor are they used for acute bronchospasm.

loop gain An engineering concept used to understand the chemoreceptor feedback system between the brain and the lungs.

lordosis Abnormal posterior curvature of the spine.

low-density cholesterol (LDL) Is considered the "bad cholesterol" and, when elevated, correlates with an increased incidence of atherosclerosis and coronary artery disease.

low-tidal-volume ventilation A ventilatory strategy that uses tidal volumes between 4 and 8 mL/kg/IBW as a method of protecting the lungs from volutrauma.

low-density lipoprotein (LDL) The bad cholesterol that is responsible for atherosclerosis.

lung allocation score (LAS) A method used to prioritize lung transplant candidates, based on urgency and post-transplant survival, for the waiting list.

lung volume reduction surgery (LVRS) Surgical removal of damaged parts of the lung, so the healthier portion can expand to improve gas exchange.

M

magnetic resonance imaging (MRI) A radiographic technique that uses a powerful magnetic field to align the nuclear magnetization of hydrogen atoms in the water of the body to produce images.

mainstream capnograph sensor A type of capnograph sensor that measures CO_2 at the patient interface and sends an electronic signal to the capnograph.

malignant Cancerous.

mandibular advancement devices (MADs) A device that is placed in the mouth to reposition the lower jaw forward and downward to reduce upper airway obstruction during sleep.

massive pulmonary embolism A pulmonary embolism that is accompanied by hypotension or shock, severe hypoxemic respiratory failure, acute right-sided heart dysfunction, and/or a pulmonary vasculature obstruction exceeding 50%.

mast cells A type of cells that, when stimulated in the asthma inflammatory cascade, release histamine, cytokines, prostaglandins, and leukotrienes.

maximum oxygen uptake (Vo_2max) The primary parameter for evaluating cardiorespiratory fitness, representing the functional limitation of the cardiovascular system and a measure of aerobic fitness.

mean airway pressure (mPaw) The average airway pressure applied during mechanical ventilation.

mean arterial pressure The pressure that drives the blood through the systemic vascular system.

mechanical ventilation An artificial device connected to a patient via artificial airway, which moves ambient air and/or oxygen to the lungs.

meconium A dark green stool of newborns composed of materials ingested during gestation.

meconium aspiration syndrome (MAS) The aspiration of meconium stained amniotic fluid, which can occur prior to, during, or immediately following birth, causing airway obstruction, surfactant dysfunction, chemical pneumonitis, and pulmonary hypertension.

medialization laryngoplasty A procedure that moves the paralyzed vocal cord to the middle to meet the nonparalyzed vocal cord and restore vocal quality.

mediastinoscopy An invasive procedure to examine the mediastinum through an endoscope inserted through an incision above the sternum.

medical paternalism Physician-directed care without the patient's consent.

meshing Creating a matrix of small holes in a skin graft, which allows it to be stretched.

mesothelium A layer of flat cells that covers the surface of the pleura.

metabolic equivalent (MET) The standard workload measure for exercise testing. One MET is defined as the average resting oxygen uptake of 3.5 mL/kg/minute.

metastasize Spread beyond the original or primary tumor lesion.

methacholine One type of drug used in the bronchial challenge test to stimulate bronchospasm.

methylxanthine A class of medications that may be used as an alternative therapy in the treatment of asthma. This class of medications has mild-to-moderate bronchodilator and mild antiinflammatory effects.

microaspiration The inhaling of small volumes of oropharyngeal secretions or gastric fluid into the lungs.

microbiome An ecosystem of nonpathogenic bacteria that exists in the human body.

microbiota Another term for microbiome.

mild hypothermia Core body temperature between 32 and 35°C.

mitral regurgitation (insufficiency) A common valve problem resulting in the backward movement of blood between the left ventricle and the left atrium during systole.

mitral stenosis (MS) The opening between the left atrium and left ventricle is narrow.

mixed apnea Cessation of breathing cause by obstruction and central sleep apneas.

Mobitz I A second-degree atrioventricular block characterized by a progressive lengthening of the PR interval until a QRS complex fails to appear following a P wave (dropped beat). It is also known as Wenckebach.

Mobitz II A second-degree atrioventricular block characterized by a complete block of electrical conduction in one bundle branch and an intermittent block in the other, producing AV conduction ratios of 4:3 or 3:2.

moderate hypothermia Core body temperature between 30 and 32°C.

Modified Medical Research Council (mMRC) Dyspnea Scale Is best used to establish baseline functional impairment due to dyspnea attributable to respiratory disease.

mucociliary escalator A physiologic process that continuously moves a thin layer of mucus toward the airway opening to clear foreign particles from the airways.

mucolytics A type of drug that works to loosen and thin mucus, which can make it easier to eliminate the mucus.

mucopurulent Refers to secretions that contain mucus and pus.

multidrug-resistant organism (MDRO) Bacteria that are resistant to several antibiotics, such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococcus (VRE), and resistant *Acinetobacter*.

multiple chronic conditions Having more than one chronic condition.

multiple drug–resistant tuberculosis (MDR-TB) A strain of *Mycobacterium tuberculosis* that is not susceptible to at least isoniazid and rifampin.

multiple organ dysfunction syndrome A failure of multiple organs due to an uncontrolled inflammatory state.

muscular dystrophy (MD) Defined as one of a group of genetic diseases characterized by progressive weakness and degeneration of the skeletal or voluntary muscles that control movement.

myasthenia gravis (MG) Disease characterized by progressive weakness and exhaustibility of voluntary muscles without atrophy or sensory disturbance and caused by an autoimmune attack on acetylcholine receptors at the neuromuscular junction.

mycobacterium tuberculosis (MDR-TB) Rod-shaped, non-spore-forming, aerobic bacterium that causes tuberculosis.

myoclonus A sudden, involuntary muscle jerk, shake, or spasm.

myofibroblasts Cells that are primarily involved in the process of fibrosis or scaring.

N

nasal flaring The flaring outward of the external nares during inhalation.

nasogastric tube decompression A nasogastric tube is connected to suction to removing stomach contents and thereby decompress it.

nasopharynx The space that occupies that portion below the nasal passage and above the soft palate of the mouth.

necrosis Tissue or organ death.

neoplasm A mass of abnormal tissue that is proliferated due to rapid division into the tissue surrounding it. Neoplasms are either benign or malignant.

neuroendocrine cells Cells located in the lungs, and other organs, that release hormones to regulate numerous physiologic processes.

neuroendocrine markers A type of biomarker that is secreted by small-cell lung carcinoma cells.

neuroendocrine progenitors A cell that will become a neuroendocrine cell when mature.

neurogenic shock Shock due to cervical or high thoracic spinal cord injury that causes profound vasodilation.

neuromuscular blockade The blockade of transmission through the myoneural junction at nicotine receptors, decreasing skeletal muscle tone and resulting in muscle weakness and/or paralysis.

neuropathy Described as an abnormal and usually degenerative state of the nervous system or nerves.

neutrophil elastase (NE) An enzyme secreted by neutrophils in response to infection or irritants that digests damaged tissue in the lungs.

neutrophil proteases Enzymes that play a role in the migration of neutrophils toward a site of inflammation and degradation of proteins from invading microorganisms or other substances from an inflammatory response.

New York Heart Association (NYHA) Functional Classification A classification system for heart failure that uses symptoms.

nitric oxide (NO) A potent inhaled pulmonary vasodilator currently approved for use in babies with pulmonary hypertension of the newborn. It is also the predominant endothelium-derived relaxing factors in the pulmonary vasculature.

nondepolarizing neuromuscular blocking agents (NMBAs) A pharmacologic agent used to induce prolonged paralysis in patients in the intensive-care unit to facilitate optimal oxygenation and ventilation via mechanical ventilation.

nonfatal drowning Survival after drowning, further classified as nonfatal (survival) with morbidity or no morbidity.

non-hemorrhagic shock Hypovolemic shock due to loss of intravascular volume due to gastroenteritis or extensive cutaneous burns.

nonimmune anaphylaxis An anaphylactic-like reaction triggered by direct activation of the mast cells and not by an IgE-mediated response.

nonnarcotic analgesics Nonprescription medications used to control pain, such as acetaminophen, aspirin and ibuprofen.

nonrapid eye movement (NREM) sleep A sleep stage during which there is no eye movement, a slower heart rate, and reduced respiratory rate. It is the stage of sleep characterized by slow-wave, restorative sleep.

nonrestrictive VSD A large ventricular septal defect that does not cause resistance to blood flow.

non-small-cell lung carcinoma (NSCLC) A major histologic type of lung cancer of which all types behave similarly. Non-small-cell lung carcinoma includes adenocarcinoma, squamous cell lung carcinoma, and large cell lung carcinoma.

nonsteroidal anti-inflammatory drug (NSAID) A class of medications that are used to decrease fever and reduce pain and inflammation.

non-traumatic hemorrhagic shock Shock due to internal blood loss, for example, from gastrointestinal bleeding or an abdominal aortic aneurysm.

normal sinus rhythm (NSR) The normal rhythm of the heart.

nosocomial Originating in a hospital setting.

nucleic acid amplification (NAA) A test that amplifies the DNA and RNA segments of mycobacterium, thereby allowing for the rapid identification of *Mycobacterium tuberculosis*.

O

obstructive sleep apnea (OSA) An abnormal sleep condition characterized by recurrent episodes of complete or partial interruption of airflow resulting from upper airway collapse and obstruction during sleep despite continued efforts in breathing.

OCT A procedure that uses a special catheter to perform an optical view of the inside of a coronary artery.

open lung approach A mechanical ventilatory strategy that uses low tidal volumes and applied PEEP to recruit and stabilize alveoli.

open pneumothorax Also known as a "sucking chest wound," it occurs when an object penetrates the chest wall leaving a hole that communicates with the atmosphere.

opioid-induced delirium Mental disturbances caused by opioids.

opioid-induced pruritus Itching caused by opioids. A common side effect of opioids.

opportunistic Refers to an organism that is normally nonpathogenic, but when the host's resistance is reduced, it will cause disease. An opportunistic infection is caused by an organism that takes advantage of a weakened immune system to cause a disease.

organizing pneumonia A pathologic presence of granulation tissue in the distal air spaces progressing from fibrin exudates to loose collagen-containing fibroblasts.

oropharynx The area between the soft palate and the epiglottis,

orthodromic Refers to a type of atrioventricular re-entrant tachycardia in which impulses are conducted anterogradely down the AV node and retrogradely up the accessory pathway.

orthopnea Difficulty breathing in the lying-down position.

ostium An opening.

ostium primum defect An atrial septal defect caused by an opening in the lower right portion of the interatrial septum.

ostium secundum defect An atrial septal defect caused by an opening in the area of the foramen ovale.

oxygenation index (OI) A comprehensive indicator of oxygenation status used for patients receiving invasive mechanical ventilation.

P

P/F ratio The ratio of arterial oxygen partial pressure to fractional inspired oxygen.

pack-year A unit used to express a person's cumulative exposure to cigarette smoking. One pack-year is equivalent to smoking one pack per day for one year.

palliative care medicine A branch of medicine that specializes in providing relief from the symptoms and stress of serious illness. Palliative care may be provided at the same time as curative treatments.

palliative sedation therapy (PST) The use of pharmacologic agents to treat intolerable and refractory symptoms for those diagnosed with an advanced progressive illness.

Pancoast syndrome A tumor in the superior pulmonary sulcus adjacent to the subclavian vessels commonly caused by non-small-cell lung carcinoma.

panlobular emphysema Emphysema that affects the bases of the lungs. It is common with alpha-1 antitrypsin deficiency.

papillomatosis Nonmalignant tumors in the airway or digestive tract.

paradoxical breathing The chest wall moving inward during inspiration and outward during expiration.

paradoxical chest movement During inspiration the chest moves inward and during expiration the chest moves outward.

parapneumonic effusion A pleural effusion associated with a pneumonia.

parietal pleura The outer layer of the pleura that is just inside the thoracic wall.

pathogens A disease-producing microorganism.

pathologic Q wave A permanent or deeper Q wave seen on ECG resulting from cardiac tissue death.

patient navigator A person that assists patients in coordinating healthcare services for the diagnosis or treatment of chronic disease.

peak expiratory flow rate (PEFR) The maximum flow rate generated during a forceful expiration, starting from full lung

inflation. It is used to monitor airway obstruction and response to therapy in asthma. On a mechanical ventilator it is used to establish the set time-low in airway pressure release ventilation.

pectus carinatum (PC) Also known as pigeon chest, it is the abnormal protrusion of the sternum and adjacent costal cartilages.

pectus excavatum (PE) Also known as funnel chest, it is a posterior depression in the sternum and lower costal cartilage.

pedal edema Swelling of the ankles due to fluid accumulation in the interstitial space.

percutaneous coronary angioplasty Insertion of a special catheter into a coronary artery to perform an angioplasty to reduce the size of a lesion.

percutaneous coronary intervention (PCI) A cardiac catheterization of the left heart used to guide angioplasty and/or stenting of coronary arteries.

percutaneous endoscopic gastrostomy (PEG) tube A feeding tube placed directly into the stomach through the skin (percutaneously) using an endoscope.

pericardial effusion Fluid accumulation in the pericardial sac.

pericarditis Inflammation of the pericardium.

perioperative The term that refers to all three phases of surgery: preoperative, intraoperative, and postoperative.

peripheral nervous system Consists of various parts of the nervous system that is outside the brain and the spinal cord system.

persistent hypotension Systolic blood pressure less than 80–90 mm Hg or mean arterial pressure 30 mm Hg lower than baseline.

persistent pulmonary hypertension (PPHN) Failure of the circulatory transition that occurs after birth, characterized by marked pulmonary hypertension that causes hypoxemia due to a right-to-left shunting of blood through the ductus arteriosus and foramen ovale.

phenotype The expression of a specific trait or disease process that has the potential to cause asthma exacerbations.

phosphodiesterase Type 5 inhibitors (PDE-5i) A type of drug used in the treatment of pulmonary arterial hypertension. Prevent the breakdown of cGMP, which has vasodilatory and antiproliferative effects on the pulmonary vasculature.

photodynamic therapy Non-thermal light modality administered via bronchoscope following intravenous administration of a photosensitizing agent.

Physician Orders for Life-Sustaining Treatment (POLST) A medical order for the specific medical treatments a patients wants during a medical emergency.

physiologic dead space Refers to the total functional dead space and consists of the alveolar dead space plus the anatomic dead space.

plasmapheresis Process that directly removes AChR from the circulation and shows quick improvement for the patient.

plateau pressure The pressure applied to the small airways and alveoli during positive pressure mechanical ventilation. Also known as an inspiratory hold/pause.

platypnea Difficulty breathing in the upright position, which improves by lying down.

pleural effusion Fluid accumulated in the pleural space that can be caused by various disorders.

pleural space The potential space created by the two layers of the pleura that contain a minute amount of fluid to allow for lung movement.

pleurodesis A surgical procedure that is used to cause the visceral and parietal pleura to adhere to each other. It is used to treat and prevent pleural effusions.

plexiform lesions (PLs) Complex vascular formations that originate from the remodeling of pulmonary arteries.

pneumatic compression devices (PCD) A therapeutic device that uses an air pump and inflatable limb sleeve, designed to intermittently compress the limb to improve venous circulation.

pneumatocele A cavity in the lung tissue that is filled with air. An air-filled cyst.

pneumomediastinum Air in the mediastinal area of the chest.

pneumonia An acute infection of the lung tissue caused by one or more pathogens.

pneumonia severity index (PSI) An index used to predict the severity of pneumonia utilizing certain physical findings, patient characteristics, and lab values.

pneumothorax Air in the pleural space.

point of maximal impulse The apex of the heart beating against the chest wall.

polycythemia Elevated hemoglobin level.

polymicrobial infection An infection caused by more than one microorganism.

polymorphic ventricular tachycardia A ventricular cardiac arrhythmia characterized by continually changing QRS complex shape and ventricular rate due to multiple ectopic foci or a continually changing reentry pathway.

polysomnography (PSG) A sleep study used to identify various sleep disorders by monitoring brain waves, eye movement, leg movement, breathing, oxygen level in blood, and heart rate.

polysomnography (PSG) The technique creating a continuous record of physiologic variables, including respiratory, cardiac, brain, and muscle activity, during sleep.

pores of Kohn Also known as alveolar connections, these are discrete holes of the walls of adjacent alveoli that allow for collateral ventilation.

positive airway pressure (PAP) therapy Positive pressure applied to the upper airways to prevent the collapse of the upper airway during sleep.

positive end-expiratory pressure (PEEP) A pressure applied during mechanical ventilation at the end of expiration,

which increases functional residual capacity. The ideal result is alveolar recruitment and stabilization.

positron emission tomography (PET) A type of nuclear medicine imaging that uses a radioactive tracer injected into the bloodstream. The tracer material accumulates in areas of cancerous cells due to the high metabolic rate of those cells. This technique produces a three-dimensional image showing anatomic structure and metabolic activity of the tissues and organs scanned.

postoperative pulmonary complication (PPC) Pulmonary complications that develop after surgery that are common and costly, and increase patient morbidity and mortality.

postthrombotic syndrome A delayed complication that causes the venous valves of the leg to become incompetent and exude interstitial fluid, causing chronic leg pain, swelling, and heaviness. Also known as chronic venous insufficiency.

preload The amount of ventricular stretch at the end of diastole, just prior to ventricular contraction. It is measured using left ventricular end-diastolic pressure.

prematurity A baby born at less than 37 weeks of gestation.

primary graft dysfunction (PGD) A multifactorial injury to newly transplanted lung that develops within the first 72 hours post-transplant.

primary spontaneous pneumothorax Air in the pleural space that typically occurs with tall, thin individuals who smoke and are between the ages of 18 and 40.

primary survey The initial observation of a trauma patient, which typically follows the ABCDE of trauma to assure that the patient has no critical or life-threatening injuries.

primary tuberculosis TB disease that occurs just after the initial infection with *Mycobacteria tuberculosis*. It occurs most often in immunocompromised individuals or children.

principle of double effect An ethical criterion that permits an action that causes serious harm as a side effect of promoting some good end.

Prinzmetal angina Angina caused by coronary artery spasms. Also called variant angina.

procalcitonin (PCT or ProCT) A biomarker used in the diagnosis of bacterial infections and sepsis. Demonstrates specificity for proinflammatory markers such as cytokines.

proinflammatory cytokines A type of signaling molecule secreted from immune cells, macrophages, and other cell types, which increase inflammation in the face of infection, inflammation, trauma, and immune response.

prone position A position in which a person is horizontal, with the head and torso facing down and the back/dorsal region facing upward.

prostacyclin analogues A type of drug used in the treatment of pulmonary arterial hypertension. Promote direct arterial vasodilation and inhibit platelet aggregation.

prostacyclin receptor agonists A type of drug used in the treatment of pulmonary arterial hypertension. Relax vascular smooth muscle, inhibit platelet aggregation, and have an antiproliferative effect on vascular smooth muscle.

prostaglandin D2 An inflammatory mediator released by mast cells in the asthma inflammatory cascade.

ptosis Drooping of one or both eyelids.

pulmonary arterial hypertension (PAH) A subset of pulmonary hypertension requiring a mean pulmonary artery pressure ≥25 mm Hg, a pulmonary artery wedge pressure ≤15 mm Hg, and a pulmonary vascular resistance >3 Wood units.

pulmonary artery pressure (PAP) Blood pressure from within the pulmonary artery reflecting the pulmonary vascular resistance.

pulmonary artery wedge pressure (PAWP) An indirect estimate of left atrial pressure using a pulmonary artery catheter.

pulmonary capillary wedge pressure (PCWP) A pressure measurement from a pulmonary artery catheter that provides an estimate of left atrial and left ventricular end-diastolic pressure.

pulmonary compliance A measure of the lung's ability to stretch and expand.

pulmonary contusion Bruising of the lung that results in the release of inflammatory mediator and at times can lead to acute respiratory distress syndrome.

pulmonary embolism (pulmonary thromboembolism) Occlusion of one or more branches of the pulmonary artery by a substance, mostly blood clots, carried in the bloodstream.

pulmonary function tests (PFTs) The primary diagnostic tool for evaluating patients with respiratory symptoms and for guiding the management of such patients' diagnosed lung disease.

pulmonary hypertension (PH) An increase in mean pulmonary artery pressure ≥25 mm Hg as assessed by right heart catheterization.

pulmonary shunt A condition in which the alveoli receive blood flow, but no ventilation, such as in alveolar collapse.

pulmonary stenosis (PS) A narrowing of the opening between the right ventricle and the pulmonary artery.

pulmonary tuberculosis disease Active TB disease of the lungs.

pulmonary vascular resistance (PVR) The resistance to flow that must be overcome to push blood through the pulmonary vascular.

pulmonary vasoconstriction A reflex contraction of vascular smooth muscle in the pulmonary circulation in response to low regional partial pressure of oxygen.

pulmonic regurgitation (insufficiency) (PI) A leaky valve between the right ventricle and the pulmonary artery causing backward flow into the right ventricle.

pulse oximetry A noninvasive technique using optical sensor (spectrophotometry) to estimate the functional arterial oxygen saturation (Spo_2).

pulse pressure The difference between the systolic and diastolic blood pressure.

pulseless electrical activity (PEA) Cardiac electrical activity is present, but cardiac contractions are weak, resulting in no systolic pulse.

pulsus paradoxus A pulse that weakens abnormally during inspiration due to an abnormally large decrease in systolic blood pressure during inspiration. It occurs in moderate to severe asthma exacerbations.

Purkinje fibers Fibers within the ventricle endocardium that initiate the ventricular depolarization cycle.

pursed-lips breathing A pattern of exhaling through puckered lips to create resistance to exhalation adopted by individuals with COPD.

pyrexia Elevated body temperature above normal.

Q

Quick Sequential Organ Failure Assessment Score A rapid assessment tool used to identify adult patients with suspected infection who may develop septic shock.

R

radio frequency catheter ablation (RFCA) A minimally invasive technique using a specialized catheter to burn the myocardium that is causing a cardiac arrhythmia.

radiolucent The black areas on a radiograph produced by low-density tissue, such as air-filled structures.

radiopaque The white areas on a radiograph produced by high-density tissue, such as bones or the heart.

rapid eye movement (REM) sleep A stage of sleep characterized by increased brain activity, rapid eye movements, dreaming, increased heart and respiratory rates, and partial paralysis of skeletal muscles.

renin-angiotensin-aldosterone system (RAAS) A system that plays an important part in regulating blood volume and systemic vascular resistance, increasing or decreasing cardiac output and arterial blood pressure.

resonance The natural frequencies of vibration through normal, air-filled lungs.

respiration A rapid and deep breathing associated with metabolic acidosis, usually diabetic ketoacidosis.

respiratory events Breathing events indicative of sleep-disordered breathing, including apnea and hypopnea.

respiratory failure Inadequate gas exchange by the pulmonary system, resulting in abnormal blood oxygen levels and/or carbon dioxide levels.

respiratory syncytial virus (RSV) A virus that is responsible for bronchiolitis and pneumonia in children.

restenosis The recurrence of narrowing of an coronary artery after a corrective procedure.

resting scan The radiologic scan of the heart done at rest.

restrictive allograft syndrome (RAS) A form of chronic lung allograft rejection that is predominantly restrictive and is characterized by diffuse alveolar damage causing fibrosis.

restrictive cardiomyopathy (RCM) Abnormally rigid ventricles caused by fibrosis or scarring of the endo-myocardium or infiltration of the myocardium resulting in diastolic failure.

reticular A type of radiologic pattern that is seen as a network of curvy and straight opacities seen with interstitial lung diseases.

review of systems A review of all of the patient symptoms categorized by body systems.

rhabdomyolysis A breakdown of muscle tissue that releases a damaging protein into the blood.

rhonchi A deep rumbling adventitious breath sound produced by air passing through partially obstructed airways.

right heart failure Failure of the right ventricle to pump properly.

rotational atherectomy A procedure that uses an oval shaped burr tip catheter to grind hard plaque down.

round pneumonia Pneumonia that appears as a rounded opacity on chest radiograph.

rule of nines A method for estimating burn size by percentage of total body surface area, necessary for determining the amount of fluid resuscitation required and whether the patient needs to be transferred to a burn center.

S

saddle pulmonary embolus A large embolism that has lodged at the bifurcation of the main pulmonary artery.

sarcoidosis A rare inflammatory disease in which clumps of inflammatory cells, known as granulomas, collect in various organs, including the lungs.

scalp blood sampling Sampling of blood taken from the scalp of a fetus during labor to assess oxygenation and ventilation.

sclerotherapy Instillation of pharmaceutical agents, such as bleomycin, into the pleural space to relieve malignant pleural effusions.

scoliosis Abnormal lateral curvature of the spine.

second heart sound (S_2) The heart sound produced when the aortic and pulmonic valves close during ventricular relaxation.

secondary spontaneous pneumothorax Air in the pleural space due to parenchymal lung diseases.

secondary survey A second inspection of the trauma patient that looks for critical issues not found in the primary survey.

secondary tuberculosis Reactivation of a previous infection that usually occurs when an individual's health declines.

second-degree atrioventricular block A group of cardiac arrhythmias that are characterized by a delay or interruption of

atrial impulse conduction to the ventricles through the atrioventricular node.

self-care The activities individuals, families, and communities do to enhance health, prevent disease, limit illness, and restore health.

self-management Includes information giving and a collaborative partnership between patients and healthcare providers.

sepsis A life-threatening organ dysfunction due to dysregulated host response to infection.

septal myomectomy A surgical intervention that removes the septal wall to open the left ventricular outflow tract.

septic shock The presence of sepsis with persistent hypotension requiring vasopressors to maintain mean arterial pressure of 65 mm Hg or higher and a serum lactate level >18 mg/dL despite adequate volume resuscitation.

Sequential (Sepsis-Related) Organ Failure Assessment Score A series of diagnostic tests completed to identify septic shock. The tests include arterial blood gas, platelet count, bilirubin, arterial blood pressure, Glasgow coma score, creatinine, and urinary output.

serum lactate A measure of the amount of lactic acid in the blood. It is a marker of strained cellular metabolism and is used to identify shock.

severe hypothermia Core body temperature less than 30°C.

shock A critical condition that is brought on by a sudden drop in blood flow through the body.

Short-acting beta-adrenergic agonists (SABAs) A fast-acting drug that stimulates the activity of the beta receptors within the smooth muscles of the bronchioles.

shunt V/Q = 0, perfusion without ventilation.

shunting The process of developing perfusion without ventilation.

side-stream capnograph sensor A type of capnograph sensor that aspirates exhaled gases through a small sampling tube and brings the gas to the capnograph for measurement.

silent heart attack A heart attack that occurs without the typical anginal symptoms.

simple pneumothorax A collection of air in the pleural space that is trapped and not expanding.

single-fiber electromyography (SFEMG) Selective EMG recording technique that allows identification of action potentials (APs) from individual muscle fiber.

single lung transplantation Transplantation of a single lung, which is better tolerated by frail patients.

sinoatrial (SA) node The heart's normal pacemaker.

sinus bradycardia (SB) A cardiac arrhythmia characterized by normal sinus rhythm with a heart rate of <60 beats/minute.

sinus tachycardia (ST) A type of cardiac arrhythmia that originates in the sinoatrial node, and has normal P waves and QRS complexes with a heart rate typically between 100 and 180 beats/minute.

sinus venosus defect An atrial septal defect caused by an opening high in the atrial septal wall.

six-minute walk test (6MWT) A simple exercise test for functional limitation that measures the distance a patient can walk on a flat, hard surface in a period of 6 minutes. This technique is used to assess exercise tolerance, response to therapy, and provide prognosis for a wide range of chronic cardiopulmonary conditions.

sleep-disordered breathing (SDB) A sleep disorder that is characterized by snoring due to periods of apnea or hypopnea.

sleep-related breathing disorders (SRBDs) A sleep disorder that causes respiratory events to occur during sleep.

small-cell lung carcinoma (SCLC) A major histologic type of lung cancer that is aggressive and is commonly associated with smoking.

smoking history Number of packs smoked per day multiplied by the number of years of smoking, expressed as pack-years.

spinal anesthesia Anesthetic medicine injected directly in the cerebrospinal fluid that surrounds the spinal cord to numb the body below and sometimes above the site of the injection.

spirometry A part of a pulmonary function testing that measures how an individual inhales or exhales volumes of air as a function of time.

split-thickness graft A piece of skin shaved to contain epidermis and various layers of dermis, typically between 0.15 and 0.45 mm thick. It does not contain all the elements of the dermis.

spontaneous coronary artery dissection (SCAD) A rare type of CAD that causes sudden death or MI.

spontaneous pneumothorax Air in the pleural space not caused by trauma or underlying lung disease.

sputum cytologic studies The diagnostic testing of lung secretions to observe, under microscopy, for cancerous cells.

sputum smear A sample of thick fluid brought up from the lungs, usually by coughing, to be stained and viewed under microscopy for acid fast bacilli.

squamous cell lung carcinoma (SQCLC) A type of non-small-cell lung carcinoma that arises in the main bronchi and has a flat appearance.

squamous metaplasia Is characterized by the replacement of Type I and Type II pneumocytes by squamous epithelium.

stable angina Chest pain (angina) that occurs during exertion and subsides at rest.

stage N1 of NREM The initial stage of "light sleep."

stagnant hypoxia Blood flow is inadequate to maintain oxygenation to the tissues.

static apnea Breath holding underwater with no swimming.

stenosis Abnormal narrowing.

sternal retractions The inward movement of intercostal spaces during inspiration.

stress scan The radiologic scan of the heart done as soon as the stress test is ended.

stridor A high-pitched loud sound typically caused by an upper airway obstruction. It is produced by high velocity airflow through a narrowed larynx and trachea.

subacute pericarditis A prolonged inflammation of the pericardial sac. Usually, a prolongation of acute pericarditis.

subglottic suctioning Removal of subglottic secretions pooling around the artificial airway cuff using a syringe or wall suction.

subglottic Pertaining to the part of the larynx just below the vocal cords and above the upper part of the trachea.

submersion The entire body, including the airway, is within a liquid.

supine position A position in which a person is horizontal with the head and torso facing up and the back/dorsal region facing downward.

supraglottic Pertaining to a part of the larynx above the vocal cords.

supraventricular tachycardias (SVTs) A group of cardiac arrhythmias that result either from an ectopic focus above the bundle of His or from a reentry circuit.

surface marker expression Proteins secreted by and on the surface of specific cell types that identify them.

surfactant A surface active agent, a mixture of proteins and lipids secreted by Type II alveolar cells that reduces surface tension of the air/liquid interface within the alveoli of the lung.

surfactant replacement therapy Administration of exogenous surfactant directly into the trachea of a neonate to treat or prevent infant respiratory distress syndrome.

surgical palliative care Surgery used to relieve suffering and improve quality of life of the patient with an advanced disease.

sweat chloride test A test used to diagnose cystic fibrosis by measuring the amount of chloride in sweat.

synchronized direct-current (DC) cardioversion The delivery of an electrical shock on the "R" wave of an ECG in an effort to convert an arrhythmia to normal sinus rhythm.

systemic corticosteroid A type of antiinflammatory drug given by mouth or parentarally.

systemic inflammatory response syndrome (SIRS) Clinical manifestations that result from the systemic response to infection, trauma, or pancreatitis.

systemic vascular resistance (SVR) Resistance in the systemic vascular bed, which provides a measure of left heart afterload.

systole Pressure generated by the force of the left ventricle required to move blood forward in the systemic vascular system.

systolic blood pressure Pressure in the arteries caused by ventricular contraction.

T

T lymphocytes A type of white blood cell that, when stimulated, in the asthma inflammatory cascade, release cytokines contributing to inflammation.

tachycardia A rapid heart rate, greater than 100 beats/minute.

tachypnea A rapid respiratory rate, greater than 20 breaths/minute.

tenacious Referring to mucus; it means thick and sticky.

tension pneumothorax Life-threatening positive pressure in the pleural space accumulating from an air leak out of the lung parenchyma, requiring immediate decompression. If not treated, a tension pneumothorax will compress the underlying lung and shift the mediastinum to the opposite side, causing shock.

tetanus Caused by *Clostridium tetani*, which is a gram-positive bacillus bacterium that can result in respiratory paralysis and tonic clonic spasms and rigidity of the voluntary muscles.

thermodilution method A method of determining cardiac output that uses a special thermistor-tipped pulmonary artery catheter.

third-degree atrioventricular block A cardiac arrhythmia characterized by a complete failure of electrical conduction between the atria and ventricles of the heart. Also known as complete heart block.

thoracentesis A procedure used to remove fluid from the pleural space.

thoracoscopy An invasive procedure to examine the lungs through an endoscope inserted through an incision in the chest wall.

thrombocytes The name for platelets.

thrombocythemia An excessive amount of platelets.

thrombocytopenia A decreased platelet count that may lead to excessive bleeding.

thrombus A solid mass of platelets, fibrin, and other blood components that is located in the vessel within which it formed.

thymectomy removal of the thymus gland surgically.

time interval The time between the initial airway compromise and return of ventilatory efforts.

tongue-retaining devices (TRDs) A device used to keep the tongue in place, thereby preventing the occlusion of the upper airway by the tongue.

torsades de pointes Literally means the twisting of points, and is a form of polymorphic ventricular tachycardia that presents as varying amplitudes of the QRS complexes.

total body surface area (TBSA) The total amount of surface area of a human, estimated to determine the percentage of body surface that is burned.

tracheal (bronchial) breath sound A high-pitched, loud-intensity sound made by bulk air movement through the trachea and mainstem bronchi.

tracheal deviation A trachea that is not midline in the neck. This can be caused by a life-threatening tension pneumothorax, atelectasis, cervical tumors, etc.

tracheal stenosis A decrease in the diameter of the trachea due to scarring caused by tracheal wall damage.

tracheomalacia (TM) An upper airway obstructive disorder that is characterized by weakness of the supporting structures of the trachea.

transbronchial needle aspiration A biopsy sampling technique that is performed using endobronchial ultrasound to remove cancerous cells from within the lungs through a bronchoscope.

transesophageal echocardiography (TEE) A type of echocardiography that looks at the heart from within the esophagus, which sits just behind the left atrium.

transient tachypnea of the newborn (TTN) It is a common self-limited disease of term newborns that results from the newborn's inability to expel or absorb amniotic fluid during and following delivery.

translesional pressure The difference in pressure across a lesion in a coronary artery used to calculate the fractional flow reserve.

transpulmonary pressure The difference between airway pressure and pleural pressure. Separates the pressure to the lung from the pressure acting on the chest wall and abdomen.

transthoracic echocardiography (TTE) A type of echocardiography that looks at the heart through the anterior chest. The sound waves must pass through bones, muscles, and the lungs, which may alter the quality of the image.

transthoracic needle aspiration (TTNA) A biopsy sampling technique that is performed with imaging guidance (computed tomography or fluoroscopy) to remove cancerous cells from inside the body using a needle inserted through the thoracic wall.

transudative Fluid that has low protein content. In the case of a pleural effusion, it is caused by fluid leaking into the pleural space.

traumatic hemorrhagic shock A traumatic cause of hemorrhagic shock that includes blunt or penetrating trauma leading to massive blood loss.

traumatic pneumothorax A traumatic injury (penetrating or blunt trauma) to the chest that causes a partial or complete lung collapse.

treatment-emergent central sleep apnea A form of central sleep apnea that becomes apparent during the titration of CPAP in patients with obstructive sleep apnea.

tricuspid regurgitation (TR) A malfunction of the tricuspid valve that allows blood to flow backward from the right ventricle into the right atrium.

tricuspid stenosis (TS) A narrowing of the opening between the right atrium and the right ventricle, obstructing blood flow during diastole.

trigger Stimuli that initiate asthma symptoms, such as allergens, strong odors, exercise, and cold air.

trypsin The activated form of trypsinogen that is necessary for the breakdown of proteins in the digestive tract.

tuberculin skin test (TST) Done to identify individuals exposed to *Mycobacterium tuberculosis*.

tuberculoma A calcified caseating granuloma.

Type I atrioventricular block See Mobitz I.

Type I LM A collapse of the bodies of the arytenoid cartilages over the laryngeal inlet.

Type I respiratory failure Failure of the lungs to provide oxygen to the blood, Pao_2 <60 torr or a Sao_2 <90%.

Type II atrioventricular block See Mobitz II.

Type II LM Short aryepiglottic folds cause the anteroposterior dimension of the airway to be significantly reduced.

Type II respiratory failure Failure of the lungs to remove carbon dioxide from the blood.

Type III LM Pronounced narrowing of the laryngeal lumen caused by abnormal degrees of posterior deflection of the epiglottis during inspiration.

U

ultrasonography A type of diagnostic imaging that produces images using the echoes of an ultrasound beam from interfaces between tissues with differing acoustic properties.

unstable angina Chest pain (angina) that occurs during rest and does not subside.

upper airway obstruction (UAO) Obstruction of the airflow between the mouth and the trachea at the level of the carina.

urinothorax Leakage of urine into the pleural space.

urticaria A dermatologic disorder known as hives, associated with angioedema.

usual interstitial pneumonia (UIP) A type of interstitial lung disease that is characterized by progressive scarring of both lungs.

uvulopalatopharyngoplasty (UPPP, or U3P) A common surgical procedure used to treat obstructive sleep apnea in certain patients.

V

variable extrathoracic obstruction An obstruction that occurs in the extrathoracic airway that causes reduced flow rates during forced inspiration.

variable intrathoracic obstruction An obstruction in the airways within the thoracic cage that collapses during a forced expiration.

variant angina Chest pain caused by coronary artery spasms, often due to exertion or emotional stress.

venous thromboembolism (VTE) A blood clot that develops in a vein.

ventilation/perfusion (V/Q) mismatch A condition in which one or more areas of the lungs receive oxygen but no blood flow, or the lungs receive blood flow and no oxygen.

ventilation/perfusion ratio (V/Q) The ratio of pulmonary alveolar ventilation to pulmonary capillary perfusion.

ventilation–perfusion scanning (V/Q scan) A nuclear-medical scan that uses tiny amounts of radioactive material gas to examine ventilation and blood flow in the lungs.

ventilator-associated pneumonia (VAP) Pneumonia that becomes symptomatic more than 48–73 hours after endotracheal intubation.

ventricular fibrillation (VF) A life-threatening cardiac arrhythmia characterized by a lack of organized ventricular contraction.

ventricular septal defect (VSD) An abnormal opening in the intraventricular septal wall.

ventricular tachycardia (VTach) A cardiac arrhythmia originating from an ectopic pacemaker below the level of the bundle of His creating a heart rate between 100 and 200 beats/minute and a series of three or more premature ventricular beats.

vesicular breath sound A low-pitched, soft sound heard over most of the lungs.

video-assisted thoracoscopy (VAT) An invasive procedure to examine the lungs with a video camera through and endoscope inserted through an incision in the chest wall. This technique is also used to perform minimally invasive surgery.

video-laryngostroboscopy A diagnostic test that visualizes and documents the vocal cord movement.

Virchow triad The three risk factors that all cause microthrombi to grow and propagate, blood vessel endothelial wall damage, abnormal blood flow in the form of stasis, and a state of increased coagulability.

virulence The ability of a microorganism to cause disease.

virus A submicroscopic infectious organism that contains a core of either RNA or DNA surrounded by a coat of antigenic protein.

visceral pleura The inner layer of the pleura that is next to the lungs.

volutrauma Lung injury due to excessive tidal volumes used during invasive mechanical ventilation.

W

Wenckebach See Mobitz I.

wheeze A musical breath sound heard over lungs with narrowed airways.

Wolff–Parkinson–White The most common type of atrioventricular reentry tachycardia caused by an accessory pathway called the bundle of Kent.

X

xenograft A temporary, non-vascularizing, wound covering usually for partial-thickness burns after superficial debridement.

Z

zone of coagulation The center of the burn wound within which no viable cells exist.

zone of hyperemia The outermost area of a burn that contains viable cells and vasodilation caused by inflammatory mediators. This zone typically recovers fully unless complicated by infection or severe hypoperfusion.

zone of stasis A zone of tissue surrounding the center of a burn that contains both viable and nonviable cells with capillary vasoconstriction and ischemia. This zone can convert to an area of necrosis without proper wound care management.

Index

Note: Page numbers followed by *b*, *f*, or *t* indicate material in boxes, figures, or tables, respectively.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Z